ID,tags,text,tokens,ner_tags
NCT02105766,"8:16:chronic_disease,20:32:treatment",portal fibrosis by liver biopsy,['portal' 'fibrosis' 'by' 'liver' 'biopsy'],[0. 2. 0. 1. 1.]
NCT03008070,22:34:treatment,Contra-indication to liver biopsy,['Contra-indication' 'to' 'liver' 'biopsy'],[0. 0. 1. 1.]
NCT03008070,",32:44:treatment,,",Have a stable weight since the liver biopsy was performed defined by no more than a 5 % loss of initial body weight,"['Have' 'a' 'stable' 'weight' 'since' 'the' 'liver' 'biopsy' 'was'
 'performed' 'defined' 'by' 'no' 'more' 'than' 'a' '5' '%' 'loss' 'of'
 'initial' 'body' 'weight']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03008070,"26:38:treatment,",Subject agrees to have a liver biopsy performed after 24 weeks of treatment,"['Subject' 'agrees' 'to' 'have' 'a' 'liver' 'biopsy' 'performed' 'after'
 '24' 'weeks' 'of' 'treatment']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02515708,",43:55:treatment,",Liver steatosis (on visual estimate or on liver biopsy) > 30%,"['Liver' 'steatosis' '(' 'on' 'visual' 'estimate' 'or' 'on' 'liver'
 'biopsy' ')' '>' '30' '%']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0.]
NCT02474199,"85:97:treatment,,","For subjects with elevated liver tests as defined above, local pathology reading of liver biopsy 6-10 days after darTregs infusion is without AR according to Banff criteria","['For' 'subjects' 'with' 'elevated' 'liver' 'tests' 'as' 'defined' 'above'
 ',' 'local' 'pathology' 'reading' 'of' 'liver' 'biopsy' '6-10' 'days'
 'after' 'darTregs' 'infusion' 'is' 'without' 'AR' 'according' 'to'
 'Banff' 'criteria']","[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02474199,11:23:treatment,"Screening liver biopsy with any of the following histological criteria, as determined by the reading of a central pathologist","['Screening' 'liver' 'biopsy' 'with' 'any' 'of' 'the' 'following'
 'histological' 'criteria' ',' 'as' 'determined' 'by' 'the' 'reading' 'of'
 'a' 'central' 'pathologist']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02412540,",,42:54:treatment,","Weight reduction of >5% between baseline liver biopsy and enrollment, as weight loss >5% may change NASH severity","['Weight' 'reduction' 'of' '>' '5' '%' 'between' 'baseline' 'liver'
 'biopsy' 'and' 'enrollment' ',' 'as' 'weight' 'loss' '>' '5' '%' 'may'
 'change' 'NASH' 'severity']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02094794,"1:22:treatment,26:61:treatment,,",Echocardiogram (ECHO) or multi gated acquisition scan (MUGA): ejection fraction of >= 50%,"['Echocardiogram' '(' 'ECHO' ')' 'or' 'multi' 'gated' 'acquisition' 'scan'
 '(' 'MUGA' ')' ':' 'ejection' 'fraction' 'of' '>' '=' '50' '%']",[1. 1. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02257138,"85:98:treatment,116:138:treatment",patients with newly diagnosed or previously treated disease are eligible as long as prior therapy does not include hypomethylating agents,"['patients' 'with' 'newly' 'diagnosed' 'or' 'previously' 'treated'
 'disease' 'are' 'eligible' 'as' 'long' 'as' 'prior' 'therapy' 'does'
 'not' 'include' 'hypomethylating' 'agents']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 1.]
NCT03126110,",54:67:treatment",Has not recovered to ≤ Grade 1 from toxic effects of prior therapy,"['Has' 'not' 'recovered' 'to' '≤' 'Grade' '1' 'from' 'toxic' 'effects'
 'of' 'prior' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT03104699,"32:45:treatment,,",Persisting toxicity related to prior therapy of NCI CTCAE grade >1 severity,"['Persisting' 'toxicity' 'related' 'to' 'prior' 'therapy' 'of' 'NCI'
 'CTCAE' 'grade' '>' '1' 'severity']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT03007030,13:26:treatment,Any line of prior therapy,['Any' 'line' 'of' 'prior' 'therapy'],[0. 0. 0. 1. 1.]
NCT02942095,"28:41:treatment,,",Patient who were receiving prior therapy will require wash out period of either more than 2 weeks or more than 5 half-lives whichever shorter,"['Patient' 'who' 'were' 'receiving' 'prior' 'therapy' 'will' 'require'
 'wash' 'out' 'period' 'of' 'either' 'more' 'than' '2' 'weeks' 'or' 'more'
 'than' '5' 'half-lives' 'whichever' 'shorter']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02932280,"52:65:treatment,",have recovered from the acute toxic effects of all prior therapy to ≤ grade 1 before entering this study,"['have' 'recovered' 'from' 'the' 'acute' 'toxic' 'effects' 'of' 'all'
 'prior' 'therapy' 'to' '≤' 'grade' '1' 'before' 'entering' 'this' 'study']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02912572,",,42:55:treatment",Persisting Grade >=2 toxicity related to prior therapy,['Persisting' 'Grade' '>' '=2' 'toxicity' 'related' 'to' 'prior' 'therapy'],[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02584647,11:24:treatment,Allowable prior therapy,['Allowable' 'prior' 'therapy'],[0. 1. 1.]
NCT02553460,9:22:treatment,Limited prior therapy,['Limited' 'prior' 'therapy'],[0. 1. 1.]
NCT02425904,49:62:treatment,There is no limitation of amount or the type of prior therapy or drugs,"['There' 'is' 'no' 'limitation' 'of' 'amount' 'or' 'the' 'type' 'of'
 'prior' 'therapy' 'or' 'drugs']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.]
NCT02392572,"51:64:treatment,",Persistent clinically significant toxicities from prior therapy must not be greater than grade 1,"['Persistent' 'clinically' 'significant' 'toxicities' 'from' 'prior'
 'therapy' 'must' 'not' 'be' 'greater' 'than' 'grade' '1']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02383927,34:47:treatment,has relapsed or is refractory to prior therapy,['has' 'relapsed' 'or' 'is' 'refractory' 'to' 'prior' 'therapy'],[0. 0. 0. 0. 0. 0. 1. 1.]
NCT02370693,",,,,58:71:treatment",Fall in FVC > 10% over 6 months on at least 12 months of prior therapy,"['Fall' 'in' 'FVC' '>' '10' '%' 'over' '6' 'months' 'on' 'at' 'least' '12'
 'months' 'of' 'prior' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02340156,61:74:treatment,Radiographic demonstration of disease progression following prior therapy,"['Radiographic' 'demonstration' 'of' 'disease' 'progression' 'following'
 'prior' 'therapy']",[0. 0. 0. 0. 0. 0. 1. 1.]
NCT02315612,67:80:treatment,"Subjects must have recovered from the acute side effects of their prior therapy, such that eligibility criteria are met","['Subjects' 'must' 'have' 'recovered' 'from' 'the' 'acute' 'side'
 'effects' 'of' 'their' 'prior' 'therapy' ',' 'such' 'that' 'eligibility'
 'criteria' 'are' 'met']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02302235,",,62:75:treatment",Failure to recover from <CTCAE grade 2 toxicities related to prior therapy,"['Failure' 'to' 'recover' 'from' '<' 'CTCAE' 'grade' '2' 'toxicities'
 'related' 'to' 'prior' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02192359,42:55:treatment,Any clinically significant toxicity from prior therapy must have improved to grade 0 or grade 1,"['Any' 'clinically' 'significant' 'toxicity' 'from' 'prior' 'therapy'
 'must' 'have' 'improved' 'to' 'grade' '0' 'or' 'grade' '1']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02159495,"39:52:treatment,","Non hematological toxicity related to prior therapy must either have returned to =< grade 2, baseline, or deemed irreversible","['Non' 'hematological' 'toxicity' 'related' 'to' 'prior' 'therapy' 'must'
 'either' 'have' 'returned' 'to' '=' '<' 'grade' '2' ',' 'baseline' ','
 'or' 'deemed' 'irreversible']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02146924,"39:52:treatment,","Non-hematological toxicity related to prior therapy must either have returned to =< grade 3, baseline, or deemed irreversible","['Non-hematological' 'toxicity' 'related' 'to' 'prior' 'therapy' 'must'
 'either' 'have' 'returned' 'to' '=' '<' 'grade' '3' ',' 'baseline' ','
 'or' 'deemed' 'irreversible']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02101034,",49:62:treatment",Minimum of 14 days elapsed since the end of any prior therapy,"['Minimum' 'of' '14' 'days' 'elapsed' 'since' 'the' 'end' 'of' 'any'
 'prior' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02013336,27:40:treatment,Disease progression after prior therapy in locally advanced or metastatic setting,"['Disease' 'progression' 'after' 'prior' 'therapy' 'in' 'locally'
 'advanced' 'or' 'metastatic' 'setting']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT01954576,"36:49:treatment,,","Recovery from the toxic effects of prior therapy to not more than grade 1 or >3 weeks from prior therapy to registration, whichever is later","['Recovery' 'from' 'the' 'toxic' 'effects' 'of' 'prior' 'therapy' 'to'
 'not' 'more' 'than' 'grade' '1' 'or' '>' '3' 'weeks' 'from' 'prior'
 'therapy' 'to' 'registration' ',' 'whichever' 'is' 'later']","[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT01906385,"30:43:treatment,,",Recovered from toxicities of prior therapy to grade 0 or 1,"['Recovered' 'from' 'toxicities' 'of' 'prior' 'therapy' 'to' 'grade' '0'
 'or' '1']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT01896999,"5:18:treatment,",All prior therapy must have been completed at least 21 days prior to enrollment,"['All' 'prior' 'therapy' 'must' 'have' 'been' 'completed' 'at' 'least'
 '21' 'days' 'prior' 'to' 'enrollment']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01865162,",,62:75:treatment",Failure to recover from <CTCAE grade 2 toxicities related to prior therapy,"['Failure' 'to' 'recover' 'from' '<' 'CTCAE' 'grade' '2' 'toxicities'
 'related' 'to' 'prior' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01849146,35:48:treatment,recovered from severe toxicity of prior therapy,['recovered' 'from' 'severe' 'toxicity' 'of' 'prior' 'therapy'],[0. 0. 0. 0. 0. 1. 1.]
NCT01553071,49:62:treatment,Patients must have recovered from toxicities of prior therapy,"['Patients' 'must' 'have' 'recovered' 'from' 'toxicities' 'of' 'prior'
 'therapy']",[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01430390,67:80:treatment,"Subjects must have recovered from the acute side effects of their prior therapy, such that eligibility criteria are met","['Subjects' 'must' 'have' 'recovered' 'from' 'the' 'acute' 'side'
 'effects' 'of' 'their' 'prior' 'therapy' ',' 'such' 'that' 'eligibility'
 'criteria' 'are' 'met']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT01371630,9:22:treatment,minimal prior therapy,['minimal' 'prior' 'therapy'],[0. 1. 1.]
NCT01037790,"74:87:treatment,","The subject has not recovered from clinically-meaningful toxicity due to prior therapy (i.e., back to baseline or Grade ≤ 1)","['The' 'subject' 'has' 'not' 'recovered' 'from' 'clinically-meaningful'
 'toxicity' 'due' 'to' 'prior' 'therapy' '(' 'i.e.' ',' 'back' 'to'
 'baseline' 'or' 'Grade' '≤' '1' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00412594,79:92:treatment,Patients with relapsed disease are eligible if they have had no more than one prior therapy,"['Patients' 'with' 'relapsed' 'disease' 'are' 'eligible' 'if' 'they'
 'have' 'had' 'no' 'more' 'than' 'one' 'prior' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT00004317,",25:38:treatment",No more than 1 month of prior therapy,['No' 'more' 'than' '1' 'month' 'of' 'prior' 'therapy'],[0. 0. 0. 0. 0. 0. 1. 1.]
NCT02542202,"18:21:chronic_disease,69:128:treatment,,,","patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration","['patients' 'who' 'are' 'HIV' 'positive' 'are' 'eligible' ',' 'provided'
 'they' 'are' 'under' 'treatment' 'with' 'highly' 'active'
 'antiretroviral' 'therapy' '(' 'HAART' ')' 'and' 'have' 'a' 'CD4' 'count'
 '>' '=' '200' 'cells/microliter' 'within' '30' 'days' 'prior' 'to'
 'registration']","[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02346253,"1:4:chronic_disease,61:120:treatment,,,","HIV-positive patients are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter no more than 30 days prior to registration","['HIV-positive' 'patients' 'are' 'eligible' ',' 'provided' 'they' 'are'
 'under' 'treatment' 'with' 'highly' 'active' 'antiretroviral' 'therapy'
 '(' 'HAART' ')' 'and' 'have' 'a' 'CD4' 'count' '>' '=' '200'
 'cells/microliter' 'no' 'more' 'than' '30' 'days' 'prior' 'to'
 'registration']","[2. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03175159,1:4:chronic_disease,HIV-uninfected,['HIV-uninfected'],[2.]
NCT03175159,26:29:chronic_disease,Involvement in any other HIV Prevention study that may interfere with the ability to test major study outcomes,"['Involvement' 'in' 'any' 'other' 'HIV' 'Prevention' 'study' 'that' 'may'
 'interfere' 'with' 'the' 'ability' 'to' 'test' 'major' 'study' 'outcomes']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03167606,1:4:chronic_disease,HIV+,['HIV+'],[2.]
NCT03167606,13:16:chronic_disease,Self-report HIV-negative or unknown status,['Self-report' 'HIV-negative' 'or' 'unknown' 'status'],[0. 2. 0. 0. 0.]
NCT03157167,16:19:chronic_disease,The subject is HIV positive,['The' 'subject' 'is' 'HIV' 'positive'],[0. 0. 0. 2. 0.]
NCT03135886,17:20:chronic_disease,are offered any HIV and/or HCV tests,['are' 'offered' 'any' 'HIV' 'and/or' 'HCV' 'tests'],[0. 0. 0. 2. 0. 0. 0.]
NCT03132415,1:4:chronic_disease,HIV-positive,['HIV-positive'],[2.]
NCT03132415,16:19:chronic_disease,Self-report as HIV-negative or sero-status unaware,['Self-report' 'as' 'HIV-negative' 'or' 'sero-status' 'unaware'],[0. 0. 2. 0. 0. 0.]
NCT03109431,23:26:chronic_disease,Acutely infected with HIV,['Acutely' 'infected' 'with' 'HIV'],[0. 0. 0. 2.]
NCT03109431,1:4:chronic_disease,HIV-negative (high-risk HIV-negative youth will be invited to participate in another study),"['HIV-negative' '(' 'high-risk' 'HIV-negative' 'youth' 'will' 'be'
 'invited' 'to' 'participate' 'in' 'another' 'study' ')']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03109431,1:4:chronic_disease,HIV-positive serostatus,['HIV-positive' 'serostatus'],[2. 0.]
NCT03088709,14:17:chronic_disease,Positive for HIV,['Positive' 'for' 'HIV'],[0. 0. 2.]
NCT03086057,1:4:chronic_disease,HIV Positive at baseline,['HIV' 'Positive' 'at' 'baseline'],[2. 0. 0. 0.]
NCT03081559,38:41:chronic_disease,"Evidence of suboptimal engagement in HIV care, as indicated by one or more","['Evidence' 'of' 'suboptimal' 'engagement' 'in' 'HIV' 'care' ',' 'as'
 'indicated' 'by' 'one' 'or' 'more']",[0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03081559,1:4:chronic_disease,HIV+ confirmed via antibody testing,['HIV+' 'confirmed' 'via' 'antibody' 'testing'],[2. 0. 0. 0. 0.]
NCT03081559,"14:17:chronic_disease,",Reporting no HIV primary care appointments in the prior 6 months,"['Reporting' 'no' 'HIV' 'primary' 'care' 'appointments' 'in' 'the' 'prior'
 '6' 'months']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03078153,1:4:chronic_disease,HIV negative,['HIV' 'negative'],[2. 0.]
NCT03078153,1:4:chronic_disease,HIV positive,['HIV' 'positive'],[2. 0.]
NCT03078153,27:30:chronic_disease,Not enrolled in any other HIV prevention trial,['Not' 'enrolled' 'in' 'any' 'other' 'HIV' 'prevention' 'trial'],[0. 0. 0. 0. 0. 2. 0. 0.]
NCT03060772,1:4:chronic_disease,HIV-positive,['HIV-positive'],[2.]
NCT03059355,23:26:chronic_disease,Be serum positive for HIV,['Be' 'serum' 'positive' 'for' 'HIV'],[0. 0. 0. 0. 2.]
NCT03056339,29:32:chronic_disease,Known positive serology for HIV,['Known' 'positive' 'serology' 'for' 'HIV'],[0. 0. 0. 0. 2.]
NCT03004170,"96:99:chronic_disease,",Report engaging in one or more occasions of condomless anal and/or vaginal intercourse with an HIV-negative or unknown HIV serostatus sex partner in the 3 months prior to study enrollment,"['Report' 'engaging' 'in' 'one' 'or' 'more' 'occasions' 'of' 'condomless'
 'anal' 'and/or' 'vaginal' 'intercourse' 'with' 'an' 'HIV-negative' 'or'
 'unknown' 'HIV' 'serostatus' 'sex' 'partner' 'in' 'the' '3' 'months'
 'prior' 'to' 'study' 'enrollment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02979366,12:15:chronic_disease,arriers of HIV antibodies,['arriers' 'of' 'HIV' 'antibodies'],[0. 0. 2. 0.]
NCT02953509,1:4:chronic_disease,HIV,['HIV'],[2.]
NCT02944578,"1:4:chronic_disease,",HIV negative women,['HIV' 'negative' 'women'],[2. 0. 0.]
NCT02944578,"1:4:chronic_disease,",HIV positive women,['HIV' 'positive' 'women'],[2. 0. 0.]
NCT02929069,"1:4:chronic_disease,,","HIV sexual risk (≥1 act of condomless anal with a male partner of unknown status or HIV+ status, unless with HIV+ partner with known undetectable viral load)","['HIV' 'sexual' 'risk' '(' '≥1' 'act' 'of' 'condomless' 'anal' 'with' 'a'
 'male' 'partner' 'of' 'unknown' 'status' 'or' 'HIV+' 'status' ','
 'unless' 'with' 'HIV+' 'partner' 'with' 'known' 'undetectable' 'viral'
 'load' ')']","[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02929069,1:4:chronic_disease,HIV-negative status,['HIV-negative' 'status'],[2. 0.]
NCT02929069,1:4:chronic_disease,HIV-positive status,['HIV-positive' 'status'],[2. 0.]
NCT02915744,1:4:chronic_disease,HIV,['HIV'],[2.]
NCT02907944,"27:30:chronic_disease,",Employed at participating HIV clinic for at least 6 months,"['Employed' 'at' 'participating' 'HIV' 'clinic' 'for' 'at' 'least' '6'
 'months']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT02907944,1:4:chronic_disease,HIV-infected,['HIV-infected'],[2.]
NCT02907944,11:14:chronic_disease,Receiving HIV care in the index clinic,['Receiving' 'HIV' 'care' 'in' 'the' 'index' 'clinic'],[0. 2. 0. 0. 0. 0. 0.]
NCT02895945,"1:4:chronic_disease,,",HIV+ with stable disease and CD4+ count ≥ 200 cells/mm^3 at screening,"['HIV+' 'with' 'stable' 'disease' 'and' 'CD4+' 'count' '≥' '200'
 'cells/mm^3' 'at' 'screening']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02848417,1:4:chronic_disease,HIV,['HIV'],[2.]
NCT02835729,7:10:chronic_disease,Known HIV-infected patients,['Known' 'HIV-infected' 'patients'],[0. 2. 0.]
NCT02833805,1:4:chronic_disease,HIV seropositivity,['HIV' 'seropositivity'],[2. 0.]
NCT02820350,1:4:chronic_disease,HIV,['HIV'],[2.]
NCT02801747,"27:30:chronic_disease,,,","Sub-optimal engagement in HIV care (assessed from the medical record, defined as less than 1 visit in every 4-mo. period in the past year [two of them at least 90 days apart], pro-rated for those diagnosed less than a year ago) or > 2 missed visits (without prior cancellation) in the past year","['Sub-optimal' 'engagement' 'in' 'HIV' 'care' '(' 'assessed' 'from' 'the'
 'medical' 'record' ',' 'defined' 'as' 'less' 'than' '1' 'visit' 'in'
 'every' '4-mo' '.' 'period' 'in' 'the' 'past' 'year' '[' 'two' 'of'
 'them' 'at' 'least' '90' 'days' 'apart' ']' ',' 'pro-rated' 'for' 'those'
 'diagnosed' 'less' 'than' 'a' 'year' 'ago' ')' 'or' '>' '2' 'missed'
 'visits' '(' 'without' 'prior' 'cancellation' ')' 'in' 'the' 'past'
 'year']","[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02797262,1:4:chronic_disease,HIV-infected individuals in HIV care,['HIV-infected' 'individuals' 'in' 'HIV' 'care'],[2. 0. 0. 0. 0.]
NCT02796027,23:26:chronic_disease,positive confirmatory HIV test,['positive' 'confirmatory' 'HIV' 'test'],[0. 0. 2. 0.]
NCT02772562,51:54:chronic_disease,"immunocompromised individuals, such as those with HIV","['immunocompromised' 'individuals' ',' 'such' 'as' 'those' 'with' 'HIV']",[0. 0. 0. 0. 0. 0. 0. 2.]
NCT02770547,1:4:chronic_disease,HIV positive,['HIV' 'positive'],[2. 0.]
NCT02770326,"1:4:chronic_disease,,",HIV infection with CD4 count <240,['HIV' 'infection' 'with' 'CD4' 'count' '<' '240'],[2. 0. 0. 0. 0. 0. 0.]
NCT02766998,1:4:chronic_disease,HIV positive mothers,['HIV' 'positive' 'mothers'],[2. 0. 0.]
NCT02764853,1:4:chronic_disease,HIV-positive,['HIV-positive'],[2.]
NCT02759575,1:4:chronic_disease,HIV,['HIV'],[2.]
NCT02734771,24:27:chronic_disease,Patient is known to be HIV positive (test result not required for enrollment),"['Patient' 'is' 'known' 'to' 'be' 'HIV' 'positive' '(' 'test' 'result'
 'not' 'required' 'for' 'enrollment' ')']",[0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02660528,1:4:chronic_disease,HIV,['HIV'],[2.]
NCT02641093,1:4:chronic_disease,HIV,['HIV'],[2.]
NCT02635360,18:21:chronic_disease,Known history of HIV,['Known' 'history' 'of' 'HIV'],[0. 0. 0. 2.]
NCT02629120,1:4:chronic_disease,HIV positive,['HIV' 'positive'],[2. 0.]
NCT02629120,9:12:chronic_disease,Must be HIV negative,['Must' 'be' 'HIV' 'negative'],[0. 0. 2. 0.]
NCT02610374,1:4:chronic_disease,HIV-infected cohort (Cohort A),['HIV-infected' 'cohort' '(' 'Cohort' 'A' ')'],[2. 0. 0. 0. 0. 0.]
NCT02610374,1:4:chronic_disease,HIV-negative cohorts (Cohort B and C),['HIV-negative' 'cohorts' '(' 'Cohort' 'B' 'and' 'C' ')'],[2. 0. 0. 0. 0. 0. 0. 0.]
NCT02600273,10:13:chronic_disease,"Unstable HIV or associated comorbidities, as determined by a licensed medical professional","['Unstable' 'HIV' 'or' 'associated' 'comorbidities' ',' 'as' 'determined'
 'by' 'a' 'licensed' 'medical' 'professional']",[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02593123,23:26:chronic_disease,Negative serology for HIV,['Negative' 'serology' 'for' 'HIV'],[0. 0. 0. 2.]
NCT02578641,1:4:chronic_disease,HIV Positive,['HIV' 'Positive'],[2. 0.]
NCT02578641,"11:14:chronic_disease,",Status of HIV must be confirmed via a HIV antibody test or other confirmatory tests available within 12 months before screening or at screening,"['Status' 'of' 'HIV' 'must' 'be' 'confirmed' 'via' 'a' 'HIV' 'antibody'
 'test' 'or' 'other' 'confirmatory' 'tests' 'available' 'within' '12'
 'months' 'before' 'screening' 'or' 'at' 'screening']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02567422,33:36:chronic_disease,patients with poorly controlled HIV,['patients' 'with' 'poorly' 'controlled' 'HIV'],[0. 0. 0. 0. 2.]
NCT02566395,1:4:chronic_disease,HIV positive,['HIV' 'positive'],[2. 0.]
NCT02566304,1:4:chronic_disease,HIV positive,['HIV' 'positive'],[2. 0.]
NCT02552953,13:16:chronic_disease,Known to be HIV-positive,['Known' 'to' 'be' 'HIV-positive'],[0. 0. 0. 2.]
NCT02543983,10:13:chronic_disease,Positive HIV test,['Positive' 'HIV' 'test'],[0. 2. 0.]
NCT02542202,1:4:chronic_disease,HIV testing is not required for eligibility for this protocol,"['HIV' 'testing' 'is' 'not' 'required' 'for' 'eligibility' 'for' 'this'
 'protocol']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02541903,7:10:chronic_disease,known HIV carrier,['known' 'HIV' 'carrier'],[0. 2. 0.]
NCT02531932,20:23:chronic_disease,A known history of HIV seropositivity,['A' 'known' 'history' 'of' 'HIV' 'seropositivity'],[0. 0. 0. 0. 2. 0.]
NCT02531880,19:22:chronic_disease,Positive test for HIV,['Positive' 'test' 'for' 'HIV'],[0. 0. 0. 2.]
NCT02531295,",,37:40:chronic_disease",Pre-ART viral load <2000 copies/ml (HIV controllers),"['Pre-ART' 'viral' 'load' '<' '2000' 'copies/ml' '(' 'HIV' 'controllers'
 ')']",[0. 0. 0. 0. 0. 0. 0. 2. 0. 0.]
NCT02529644,",143:146:chronic_disease",Minors 18 and under are intentionally excluded since the intervention study has been designed specifically for adults with information of how HIV affects the African American adult population,"['Minors' '18' 'and' 'under' 'are' 'intentionally' 'excluded' 'since'
 'the' 'intervention' 'study' 'has' 'been' 'designed' 'specifically' 'for'
 'adults' 'with' 'information' 'of' 'how' 'HIV' 'affects' 'the' 'African'
 'American' 'adult' 'population']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0.
 0. 0. 0. 0.]"
NCT02520427,24:27:chronic_disease,Known positiv test for HIV,['Known' 'positiv' 'test' 'for' 'HIV'],[0. 0. 0. 0. 2.]
NCT02515708,1:4:chronic_disease,HIV positive patient,['HIV' 'positive' 'patient'],[2. 0. 0.]
NCT02508038,1:4:chronic_disease,HIV infection,['HIV' 'infection'],[2. 0.]
NCT02472834,1:4:chronic_disease,HIV positive,['HIV' 'positive'],[2. 0.]
NCT02457845,7:10:chronic_disease,Known HIV seropositivity,['Known' 'HIV' 'seropositivity'],[0. 2. 0.]
NCT02453113,12:15:chronic_disease,History of HIV,['History' 'of' 'HIV'],[0. 0. 2.]
NCT02452268,1:4:chronic_disease,HIV positive patients,['HIV' 'positive' 'patients'],[2. 0. 0.]
NCT02446093,13:16:chronic_disease,Known to be HIV+,['Known' 'to' 'be' 'HIV+'],[0. 0. 0. 2.]
NCT02442297,7:10:chronic_disease,Known HIV positivity,['Known' 'HIV' 'positivity'],[0. 2. 0.]
NCT02430077,7:10:chronic_disease,Known HIV-infected patient,['Known' 'HIV-infected' 'patient'],[0. 2. 0.]
NCT02408861,"1:4:chronic_disease,,","HIV viral load should be well suppressed, defined as below the limit of detection of the local assay or below 75 copies/mL by Food and Drug Administration (FDA)-approved assays, within 4 weeks prior to registration","['HIV' 'viral' 'load' 'should' 'be' 'well' 'suppressed' ',' 'defined' 'as'
 'below' 'the' 'limit' 'of' 'detection' 'of' 'the' 'local' 'assay' 'or'
 'below' '75' 'copies/mL' 'by' 'Food' 'and' 'Drug' 'Administration' '('
 'FDA' ')' '-approved' 'assays' ',' 'within' '4' 'weeks' 'prior' 'to'
 'registration']","[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02400463,7:10:chronic_disease,known HIV infection,['known' 'HIV' 'infection'],[0. 2. 0.]
NCT02393690,22:25:chronic_disease,"patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial","['patients' 'known' 'to' 'be' 'HIV' 'positive' ',' 'but' 'without'
 'clinical' 'evidence' 'of' 'an' 'immunocompromised' 'state' ',' 'are'
 'eligible' 'for' 'this' 'trial']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02384954,5:8:chronic_disease,Not HIV positive,['Not' 'HIV' 'positive'],[0. 2. 0.]
NCT02379520,7:10:chronic_disease,Known HIV positivity,['Known' 'HIV' 'positivity'],[0. 2. 0.]
NCT02374333,1:4:chronic_disease,HIV infection,['HIV' 'infection'],[2. 0.]
NCT02374021,1:4:chronic_disease,HIV,['HIV'],[2.]
NCT02369406,",,39:42:chronic_disease,,,",57-365 days after birth if infant was HIV-negative based on testing performed within 96 hours after birth (or if unknown HIV status < 96 hours from birth) and then found to be HIV-positive based on testing performed between 96 hours and 42 days after birth,"['57-365' 'days' 'after' 'birth' 'if' 'infant' 'was' 'HIV-negative'
 'based' 'on' 'testing' 'performed' 'within' '96' 'hours' 'after' 'birth'
 '(' 'or' 'if' 'unknown' 'HIV' 'status' '<' '96' 'hours' 'from' 'birth'
 ')' 'and' 'then' 'found' 'to' 'be' 'HIV-positive' 'based' 'on' 'testing'
 'performed' 'between' '96' 'hours' 'and' '42' 'days' 'after' 'birth']","[0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02369406,"1:4:chronic_disease,",HIV-infection identified by testing conducted within 96 hours after birth,"['HIV-infection' 'identified' 'by' 'testing' 'conducted' 'within' '96'
 'hours' 'after' 'birth']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02369406,"1:4:chronic_disease,",HIV-negative within 96 hours after birth,['HIV-negative' 'within' '96' 'hours' 'after' 'birth'],[2. 0. 0. 0. 0. 0.]
NCT02369406,"1:4:chronic_disease,,",HIV-positive between 96 hours and 42 days after birth,['HIV-positive' 'between' '96' 'hours' 'and' '42' 'days' 'after' 'birth'],[2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02362997,1:4:chronic_disease,HIV-positive,['HIV-positive'],[2.]
NCT02358187,1:4:chronic_disease,HIV-positive patients,['HIV-positive' 'patients'],[2. 0.]
NCT02350764,23:26:chronic_disease,Any positive test for HIV,['Any' 'positive' 'test' 'for' 'HIV'],[0. 0. 0. 0. 2.]
NCT02347891,30:33:chronic_disease,Have a historically positive HIV test or test positive at screening for HIV,"['Have' 'a' 'historically' 'positive' 'HIV' 'test' 'or' 'test' 'positive'
 'at' 'screening' 'for' 'HIV']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02344355,7:10:chronic_disease,Known HIV-positive individuals,['Known' 'HIV-positive' 'individuals'],[0. 2. 0.]
NCT02340156,23:26:chronic_disease,"Positive results from HIV serology testing, if any available","['Positive' 'results' 'from' 'HIV' 'serology' 'testing' ',' 'if' 'any'
 'available']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT02335138,48:51:chronic_disease,Either partner expresses unwillingness to have HIV test kits delivered to a home address,"['Either' 'partner' 'expresses' 'unwillingness' 'to' 'have' 'HIV' 'test'
 'kits' 'delivered' 'to' 'a' 'home' 'address']",[0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02335138,52:55:chronic_disease,Either partner expresses unwillingness to test for HIV together with his male sexual partner,"['Either' 'partner' 'expresses' 'unwillingness' 'to' 'test' 'for' 'HIV'
 'together' 'with' 'his' 'male' 'sexual' 'partner']",[0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT02335138,"21:24:chronic_disease,,","Negative or unknown HIV status and not having tested in the last 6 months, with a partner meeting the same criteria OR in a sero-discordant with the negative/unknown partner reporting not having tested in the past 6 months","['Negative' 'or' 'unknown' 'HIV' 'status' 'and' 'not' 'having' 'tested'
 'in' 'the' 'last' '6' 'months' ',' 'with' 'a' 'partner' 'meeting' 'the'
 'same' 'criteria' 'OR' 'in' 'a' 'sero-discordant' 'with' 'the'
 'negative/unknown' 'partner' 'reporting' 'not' 'having' 'tested' 'in'
 'the' 'past' '6' 'months']","[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02335138,"30:33:chronic_disease,",Willingness to be tested for HIV with one's male sexual partner,"['Willingness' 'to' 'be' 'tested' 'for' 'HIV' 'with' 'one' ""'s"" 'male'
 'sexual' 'partner']",[0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT02335138,21:24:chronic_disease,Willingness to have HIV test kits delivered to a home address they provide,"['Willingness' 'to' 'have' 'HIV' 'test' 'kits' 'delivered' 'to' 'a' 'home'
 'address' 'they' 'provide']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02332850,7:10:chronic_disease,Known HIV seropositivity,['Known' 'HIV' 'seropositivity'],[0. 2. 0.]
NCT02329652,1:4:chronic_disease,HIV,['HIV'],[2.]
NCT02321501,18:21:chronic_disease,Known history of HIV seropositivity,['Known' 'history' 'of' 'HIV' 'seropositivity'],[0. 0. 0. 2. 0.]
NCT02312596,1:4:chronic_disease,HIV,['HIV'],[2.]
NCT02296684,18:21:chronic_disease,Known history of HIV (HIV 1/2 antibodies),['Known' 'history' 'of' 'HIV' '(' 'HIV' '1/2' 'antibodies' ')'],[0. 0. 0. 2. 0. 0. 0. 0. 0.]
NCT02256631,"22:25:chronic_disease,",At increased risk of HIV acquisition defined as documentation of one or more of the following risk factors,"['At' 'increased' 'risk' 'of' 'HIV' 'acquisition' 'defined' 'as'
 'documentation' 'of' 'one' 'or' 'more' 'of' 'the' 'following' 'risk'
 'factors']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02256631,"47:50:chronic_disease,,",Mother with any detectable viral replication (HIV RNA above the limit of detection) at last measurement prior to delivery determined within 30 days of delivery,"['Mother' 'with' 'any' 'detectable' 'viral' 'replication' '(' 'HIV' 'RNA'
 'above' 'the' 'limit' 'of' 'detection' ')' 'at' 'last' 'measurement'
 'prior' 'to' 'delivery' 'determined' 'within' '30' 'days' 'of' 'delivery']","[0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02233868,17:20:chronic_disease,"Have a positive HIV test (clinical laboratory results, medical history)","['Have' 'a' 'positive' 'HIV' 'test' '(' 'clinical' 'laboratory' 'results'
 ',' 'medical' 'history' ')']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02213913,7:10:chronic_disease,Known HIV positive status,['Known' 'HIV' 'positive' 'status'],[0. 2. 0. 0.]
NCT02204098,7:10:chronic_disease,Known HIV-positive status,['Known' 'HIV-positive' 'status'],[0. 2. 0.]
NCT02203903,15:18:chronic_disease,Patients with HIV infection,['Patients' 'with' 'HIV' 'infection'],[0. 0. 2. 0.]
NCT02203513,"1:4:chronic_disease,,,",HIV- positive patients who are not on HAART and have CD4 counts > 500 will be considered on an individual basis,"['HIV-' 'positive' 'patients' 'who' 'are' 'not' 'on' 'HAART' 'and' 'have'
 'CD4' 'counts' '>' '500' 'will' 'be' 'considered' 'on' 'an' 'individual'
 'basis']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02186418,21:24:chronic_disease,Sero-positivity for HIV,['Sero-positivity' 'for' 'HIV'],[0. 0. 2.]
NCT02179359,1:4:chronic_disease,HIV positive,['HIV' 'positive'],[2. 0.]
NCT02164422,45:48:chronic_disease,other unstable medical conditions including HIV,['other' 'unstable' 'medical' 'conditions' 'including' 'HIV'],[0. 0. 0. 0. 0. 2.]
NCT02159027,",,125:128:chronic_disease",score of < -0.5 OR a neurocognitive abnormality (< -0.5) in at least one cognitive domain known to be typically affected by HIV,"['score' 'of' '<' '-0.5' 'OR' 'a' 'neurocognitive' 'abnormality' '(' '<'
 '-0.5' ')' 'in' 'at' 'least' 'one' 'cognitive' 'domain' 'known' 'to' 'be'
 'typically' 'affected' 'by' 'HIV']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 2.]"
NCT02140255,11:14:chronic_disease,Confirmed HIV infection defined as positive results from two samples collected at different time points,"['Confirmed' 'HIV' 'infection' 'defined' 'as' 'positive' 'results' 'from'
 'two' 'samples' 'collected' 'at' 'different' 'time' 'points']",[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02140255,"21:24:chronic_disease,",No confirmed plasma HIV RNA greater than or equal to 200 copies/mL at Step 2 Week 24 and up to but excluding Step 2 Week 48 (see the study protocol for procedural guidance related to this criterion),"['No' 'confirmed' 'plasma' 'HIV' 'RNA' 'greater' 'than' 'or' 'equal' 'to'
 '200' 'copies/mL' 'at' 'Step' '2' 'Week' '24' 'and' 'up' 'to' 'but'
 'excluding' 'Step' '2' 'Week' '48' '(' 'see' 'the' 'study' 'protocol'
 'for' 'procedural' 'guidance' 'related' 'to' 'this' 'criterion' ')']","[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02140255,11:14:chronic_disease,No plasma HIV RNA detected at Step 2 Week 48 and thereafter,"['No' 'plasma' 'HIV' 'RNA' 'detected' 'at' 'Step' '2' 'Week' '48' 'and'
 'thereafter']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02140255,11:14:chronic_disease,No plasma HIV RNA detected at the time of the second consecutive negative HIV DNA test (based on testing performed in the study's designated VQA-certified central laboratory),"['No' 'plasma' 'HIV' 'RNA' 'detected' 'at' 'the' 'time' 'of' 'the'
 'second' 'consecutive' 'negative' 'HIV' 'DNA' 'test' '(' 'based' 'on'
 'testing' 'performed' 'in' 'the' 'study' ""'s"" 'designated'
 'VQA-certified' 'central' 'laboratory' ')']","[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02140255,"11:14:chronic_disease,","No plasma HIV RNA detected by testing performed at the local CLIA-certified (US sites) or VQA-certified (non-US sites) laboratory, after criteria above have been confirmed, with specimen collection for the assay within 14 days prior to Step 3 Entry","['No' 'plasma' 'HIV' 'RNA' 'detected' 'by' 'testing' 'performed' 'at'
 'the' 'local' 'CLIA-certified' '(' 'US' 'sites' ')' 'or' 'VQA-certified'
 '(' 'non-US' 'sites' ')' 'laboratory' ',' 'after' 'criteria' 'above'
 'have' 'been' 'confirmed' ',' 'with' 'specimen' 'collection' 'for' 'the'
 'assay' 'within' '14' 'days' 'prior' 'to' 'Step' '3' 'Entry']","[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02140255,8:11:chronic_disease,Plasma HIV RNA greater than or equal to LOD based on standard quantitative testing performed at the local CLIA-certified (US sites) or VQA-certified (non-US sites) laboratory after ART cessation (see the study protocol for procedural guidance related to this criterion),"['Plasma' 'HIV' 'RNA' 'greater' 'than' 'or' 'equal' 'to' 'LOD' 'based'
 'on' 'standard' 'quantitative' 'testing' 'performed' 'at' 'the' 'local'
 'CLIA-certified' '(' 'US' 'sites' ')' 'or' 'VQA-certified' '(' 'non-US'
 'sites' ')' 'laboratory' 'after' 'ART' 'cessation' '(' 'see' 'the'
 'study' 'protocol' 'for' 'procedural' 'guidance' 'related' 'to' 'this'
 'criterion' ')']","[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02140255,10:13:chronic_disease,Presumed HIV infection defined as greater than or equal to one positive rapid HIV antibody test obtained in the peripartum period,"['Presumed' 'HIV' 'infection' 'defined' 'as' 'greater' 'than' 'or' 'equal'
 'to' 'one' 'positive' 'rapid' 'HIV' 'antibody' 'test' 'obtained' 'in'
 'the' 'peripartum' 'period']",[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02140255,"17:20:chronic_disease,,","Two consecutive HIV DNA tests with no DNA detected in at least 850,000 PBMCs assayed (performed in the study's designated central laboratory) at least 8 weeks apart","['Two' 'consecutive' 'HIV' 'DNA' 'tests' 'with' 'no' 'DNA' 'detected' 'in'
 'at' 'least' '850,000' 'PBMCs' 'assayed' '(' 'performed' 'in' 'the'
 'study' ""'s"" 'designated' 'central' 'laboratory' ')' 'at' 'least' '8'
 'weeks' 'apart']","[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02140255,"26:29:chronic_disease,",Two consecutive negative HIV antibody tests by fourth generation enzyme-linked immunosorbent assay (ELISA) (performed in the study's designated central laboratory) at least 8 weeks apart,"['Two' 'consecutive' 'negative' 'HIV' 'antibody' 'tests' 'by' 'fourth'
 'generation' 'enzyme-linked' 'immunosorbent' 'assay' '(' 'ELISA' ')' '('
 'performed' 'in' 'the' 'study' ""'s"" 'designated' 'central' 'laboratory'
 ')' 'at' 'least' '8' 'weeks' 'apart']","[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02133196,18:21:chronic_disease,Seronegative for HIV antibody,['Seronegative' 'for' 'HIV' 'antibody'],[0. 0. 2. 0.]
NCT02128906,1:4:chronic_disease,HIV testing is not required for entry into this protocol,"['HIV' 'testing' 'is' 'not' 'required' 'for' 'entry' 'into' 'this'
 'protocol']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02128100,1:4:chronic_disease,HIV testing is not manditory for this protocol,['HIV' 'testing' 'is' 'not' 'manditory' 'for' 'this' 'protocol'],[2. 0. 0. 0. 0. 0. 0. 0.]
NCT02124902,7:10:chronic_disease,Known HIV-positivity,['Known' 'HIV-positivity'],[0. 2.]
NCT02106988,13:16:chronic_disease,known to be HIV positive,['known' 'to' 'be' 'HIV' 'positive'],[0. 0. 0. 2. 0.]
NCT02105766,1:4:chronic_disease,HIV positive,['HIV' 'positive'],[2. 0.]
NCT02101736,1:4:chronic_disease,"HIV testing will not be required as part of this trial, unless HIV is clinically suspected","['HIV' 'testing' 'will' 'not' 'be' 'required' 'as' 'part' 'of' 'this'
 'trial' ',' 'unless' 'HIV' 'is' 'clinically' 'suspected']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02100891,1:4:chronic_disease,HIV seropositive patients,['HIV' 'seropositive' 'patients'],[2. 0. 0.]
NCT02100891,1:4:chronic_disease,HIV-positive donors,['HIV-positive' 'donors'],[2. 0.]
NCT02081404,15:18:chronic_disease,Patients with HIV,['Patients' 'with' 'HIV'],[0. 0. 2.]
NCT02078102,31:34:chronic_disease,Patients must be negative for HIV,['Patients' 'must' 'be' 'negative' 'for' 'HIV'],[0. 0. 0. 0. 0. 2.]
NCT02075710,10:13:chronic_disease,positive HIV antibody test or hepatitis serologies,['positive' 'HIV' 'antibody' 'test' 'or' 'hepatitis' 'serologies'],[0. 2. 0. 0. 0. 0. 0.]
NCT02059239,26:29:chronic_disease,Known to be positive for HIV,['Known' 'to' 'be' 'positive' 'for' 'HIV'],[0. 0. 0. 0. 0. 2.]
NCT01976169,10:13:chronic_disease,Baseline HIV screening,['Baseline' 'HIV' 'screening'],[0. 2. 0.]
NCT01962415,1:4:chronic_disease,HIV negative,['HIV' 'negative'],[2. 0.]
NCT01956084,7:10:chronic_disease,Donor HIV negative,['Donor' 'HIV' 'negative'],[0. 2. 0.]
NCT01956084,16:19:chronic_disease,Donors who are HIV positive,['Donors' 'who' 'are' 'HIV' 'positive'],[0. 0. 0. 2. 0.]
NCT01953900,1:4:chronic_disease,HIV positivity,['HIV' 'positivity'],[2. 0.]
NCT01928576,1:4:chronic_disease,HIV-positive patients are excluded,['HIV-positive' 'patients' 'are' 'excluded'],[2. 0. 0. 0.]
NCT01925378,"31:34:chronic_disease,",Patients must have a negative HIV test within 14 days of starting the NFV,"['Patients' 'must' 'have' 'a' 'negative' 'HIV' 'test' 'within' '14' 'days'
 'of' 'starting' 'the' 'NFV']",[0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01920737,7:10:chronic_disease,Known HIV positive status,['Known' 'HIV' 'positive' 'status'],[0. 2. 0. 0.]
NCT01913106,1:4:chronic_disease,HIV + patients,['HIV' '+' 'patients'],[2. 0. 0.]
NCT01896999,1:4:chronic_disease,HIV viral loads undetectable by standard clinical HIV testing,"['HIV' 'viral' 'loads' 'undetectable' 'by' 'standard' 'clinical' 'HIV'
 'testing']",[2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01807611,1:4:chronic_disease,HIV negative,['HIV' 'negative'],[2. 0.]
NCT01804634,1:4:chronic_disease,HIV-positive,['HIV-positive'],[2.]
NCT01760655,1:4:chronic_disease,HIV positive,['HIV' 'positive'],[2. 0.]
NCT01734512,20:23:chronic_disease,A known history of HIV seropositivity,['A' 'known' 'history' 'of' 'HIV' 'seropositivity'],[0. 0. 0. 0. 2. 0.]
NCT01730937,"1:4:chronic_disease,,",HIV positive with CD4 count < (350) cells/microliter,"['HIV' 'positive' 'with' 'CD4' 'count' '<' '(' '350' ')'
 'cells/microliter']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01720836,7:10:chronic_disease,known HIV-positive patients,['known' 'HIV-positive' 'patients'],[0. 2. 0.]
NCT01666080,1:4:chronic_disease,HIV positive,['HIV' 'positive'],[2. 0.]
NCT01660607,1:4:chronic_disease,HIV ab,['HIV' 'ab'],[2. 0.]
NCT01660607,1:4:chronic_disease,HIV positive,['HIV' 'positive'],[2. 0.]
NCT01660607,18:21:chronic_disease,Seronegative for HIV 1 RNA (polymerase chair reaction (PCR),"['Seronegative' 'for' 'HIV' '1' 'RNA' '(' 'polymerase' 'chair' 'reaction'
 '(' 'PCR' ')']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01631617,1:4:chronic_disease,HIV seropositiviy,['HIV' 'seropositiviy'],[2. 0.]
NCT01599559,7:10:chronic_disease,Known HIV-positive serology,['Known' 'HIV-positive' 'serology'],[0. 2. 0.]
NCT01553942,7:10:chronic_disease,known HIV carrier,['known' 'HIV' 'carrier'],[0. 2. 0.]
NCT01522768,7:10:chronic_disease,Known HIV carrier,['Known' 'HIV' 'carrier'],[0. 2. 0.]
NCT01481974,1:4:chronic_disease,HIV positive,['HIV' 'positive'],[2. 0.]
NCT01473628,21:24:chronic_disease,Patients with known HIV infection,['Patients' 'with' 'known' 'HIV' 'infection'],[0. 0. 0. 2. 0.]
NCT01459107,1:4:chronic_disease,HIV (active or seropositive),['HIV' '(' 'active' 'or' 'seropositive' ')'],[2. 0. 0. 0. 0. 0.]
NCT01445821,1:4:chronic_disease,HIV positive,['HIV' 'positive'],[2. 0.]
NCT01436968,1:4:chronic_disease,HIV+ patients,['HIV+' 'patients'],[2. 0.]
NCT01419561,5:8:chronic_disease,Any HIV status,['Any' 'HIV' 'status'],[0. 2. 0.]
NCT01419561,87:90:chronic_disease,"Any abnormality that would be scored as NCI CTC Grade 4 toxicity that is unrelated to HIV, its treatment","['Any' 'abnormality' 'that' 'would' 'be' 'scored' 'as' 'NCI' 'CTC' 'Grade'
 '4' 'toxicity' 'that' 'is' 'unrelated' 'to' 'HIV' ',' 'its' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0.]
NCT01364363,1:4:chronic_disease,HIV seronegativity,['HIV' 'seronegativity'],[2. 0.]
NCT01189786,7:10:chronic_disease,Known HIV Positivity,['Known' 'HIV' 'Positivity'],[0. 2. 0.]
NCT01174121,18:21:chronic_disease,Seronegative for HIV antibody,['Seronegative' 'for' 'HIV' 'antibody'],[0. 0. 2. 0.]
NCT01140087,1:4:chronic_disease,HIV positive,['HIV' 'positive'],[2. 0.]
NCT00967577,18:21:chronic_disease,Known history of HIV,['Known' 'history' 'of' 'HIV'],[0. 0. 0. 2.]
NCT00959140,1:4:chronic_disease,HIV positive patients,['HIV' 'positive' 'patients'],[2. 0. 0.]
NCT00896493,15:18:chronic_disease,Those who are HIV-positive,['Those' 'who' 'are' 'HIV-positive'],[0. 0. 0. 2.]
NCT00887146,22:25:chronic_disease,"patients known to be HIV positive, but without clinical evidence of an immunocompromised state","['patients' 'known' 'to' 'be' 'HIV' 'positive' ',' 'but' 'without'
 'clinical' 'evidence' 'of' 'an' 'immunocompromised' 'state']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00799864,"11:14:chronic_disease,",Must have HIV-1 plasma viral load at screening greater than equal to 500 HIV-1 ribonucleic acid (RNA) copies/mL,"['Must' 'have' 'HIV-1' 'plasma' 'viral' 'load' 'at' 'screening' 'greater'
 'than' 'equal' 'to' '500' 'HIV-1' 'ribonucleic' 'acid' '(' 'RNA' ')'
 'copies/mL']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00788164,4:7:chronic_disease,No HIV seropositivity,['No' 'HIV' 'seropositivity'],[0. 2. 0.]
NCT00720785,1:4:chronic_disease,HIV-positive patients,['HIV-positive' 'patients'],[2. 0.]
NCT00670358,10:13:chronic_disease,No known HIV positivity,['No' 'known' 'HIV' 'positivity'],[0. 0. 2. 0.]
NCT00472329,18:21:chronic_disease,Patients who are HIV positive,['Patients' 'who' 'are' 'HIV' 'positive'],[0. 0. 0. 2. 0.]
NCT00368355,26:29:chronic_disease,Patients with documented HIV positivity,['Patients' 'with' 'documented' 'HIV' 'positivity'],[0. 0. 0. 2. 0.]
NCT00001337,1:4:chronic_disease,HIV negative,['HIV' 'negative'],[2. 0.]
NCT03136029,"1:7:chronic_disease,,,20:46:chronic_disease,,",Anemia (Hgb<9) and Severe Renal Insufficiency (individuals with creatinine clearance <30 by the Cockcroft-Gault formula),"['Anemia' '(' 'Hgb' '<' '9' ')' 'and' 'Severe' 'Renal' 'Insufficiency' '('
 'individuals' 'with' 'creatinine' 'clearance' '<' '30' 'by' 'the'
 'Cockcroft-Gault' 'formula' ')']",[2. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03095118,"1:7:chronic_disease,,",Anemia with Hgb < 8.5 g/dL,['Anemia' 'with' 'Hgb' '<' '8.5' 'g/dL'],[2. 0. 0. 0. 0. 0.]
NCT02851472,"1:7:chronic_disease,,",Anemia with hematocrit (Hct) less than 28 %,['Anemia' 'with' 'hematocrit' '(' 'Hct' ')' 'less' 'than' '28' '%'],[2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02844907,"1:7:chronic_disease,,",Anemia (hematocrit < 34%) as measured at screening visit,"['Anemia' '(' 'hematocrit' '<' '34' '%' ')' 'as' 'measured' 'at'
 'screening' 'visit']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02551679,1:7:chronic_disease,Anemia,['Anemia'],[2.]
NCT02457702,"1:7:chronic_disease,,",Anemia (hematocrit < 32%),['Anemia' '(' 'hematocrit' '<' '32' '%' ')'],[2. 0. 0. 0. 0. 0. 0.]
NCT02415387,1:7:chronic_disease,Anemia,['Anemia'],[2.]
NCT02234934,"1:7:chronic_disease,,",Anemia (hemoglobin < 8 g/dl),['Anemia' '(' 'hemoglobin' '<' '8' 'g/dl' ')'],[2. 0. 0. 0. 0. 0. 0.]
NCT02157974,1:7:chronic_disease,Anemia,['Anemia'],[2.]
NCT02134392,"1:7:chronic_disease,",Anemia on complete blood count,['Anemia' 'on' 'complete' 'blood' 'count'],[2. 0. 0. 0. 0.]
NCT02101944,"1:7:chronic_disease,,,",Anemia > 2 g/dL below the lower limit of normal or a hemoglobin value < 10 g/dL,"['Anemia' '>' '2' 'g/dL' 'below' 'the' 'lower' 'limit' 'of' 'normal' 'or'
 'a' 'hemoglobin' 'value' '<' '10' 'g/dL']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01895777,"1:7:chronic_disease,,",Anemia (hemoglobin < 80g/L),['Anemia' '(' 'hemoglobin' '<' '80g/L' ')'],[2. 0. 0. 0. 0. 0.]
NCT01419561,"1:7:chronic_disease,,",Anemia (hemoglobin<12.0g/dL),['Anemia' '(' 'hemoglobin' '<' '12.0g/dL' ')'],[2. 0. 0. 0. 0. 0.]
NCT01059786,"1:7:chronic_disease,,",Anemia (Hgb less than 10g/dL),['Anemia' '(' 'Hgb' 'less' 'than' '10g/dL' ')'],[2. 0. 0. 0. 0. 0. 0.]
NCT00904046,1:7:chronic_disease,Anemia,['Anemia'],[2.]
NCT00862433,1:7:chronic_disease,Anemia,['Anemia'],[2.]
NCT02349867,"24:35:chronic_disease,43:57:chronic_disease",Correct any identified hypokalemia and/or hypomagnesemia and repeat ECG to confirm exclusion of patient due to QTc,"['Correct' 'any' 'identified' 'hypokalemia' 'and/or' 'hypomagnesemia'
 'and' 'repeat' 'ECG' 'to' 'confirm' 'exclusion' 'of' 'patient' 'due' 'to'
 'QTc']",[0. 0. 0. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02236013,"13:24:chronic_disease,29:43:chronic_disease",Subject has hypokalemia and hypomagnesemia at Screening (defined as values below institutional lower limit of normal [LLN]),"['Subject' 'has' 'hypokalemia' 'and' 'hypomagnesemia' 'at' 'Screening' '('
 'defined' 'as' 'values' 'below' 'institutional' 'lower' 'limit' 'of'
 'normal' '[' 'LLN' ']' ')']",[0. 0. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02465060,23:34:chronic_disease,Patient must not have hypokalemia (value < institutional lower limit of normal),"['Patient' 'must' 'not' 'have' 'hypokalemia' '(' 'value' '<'
 'institutional' 'lower' 'limit' 'of' 'normal' ')']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02465268,"7:23:chronic_disease,27:52:chronic_disease",Known active infection or immunosuppressive disease,['Known' 'active' 'infection' 'or' 'immunosuppressive' 'disease'],[0. 2. 2. 0. 2. 2.]
NCT03149549,59:75:chronic_disease,"Serious concurrent illness, including clinically relevant active infection","['Serious' 'concurrent' 'illness' ',' 'including' 'clinically' 'relevant'
 'active' 'infection']",[0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT03143153,49:65:chronic_disease,Any serious or uncontrolled medical disorder or active infection,"['Any' 'serious' 'or' 'uncontrolled' 'medical' 'disorder' 'or' 'active'
 'infection']",[0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT03060564,1:17:chronic_disease,active infection,['active' 'infection'],[2. 2.]
NCT03035890,12:28:chronic_disease,ongoing or active infection,['ongoing' 'or' 'active' 'infection'],[0. 0. 2. 2.]
NCT03016871,72:88:chronic_disease,Patients should not have any uncontrolled illness including ongoing or active infection,"['Patients' 'should' 'not' 'have' 'any' 'uncontrolled' 'illness'
 'including' 'ongoing' 'or' 'active' 'infection']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02991651,12:28:chronic_disease,ongoing or active infection,['ongoing' 'or' 'active' 'infection'],[0. 0. 2. 2.]
NCT02985554,"15:31:chronic_disease,","Patients with active infection, un-resolving more than grade 2 transplant-related toxicities","['Patients' 'with' 'active' 'infection' ',' 'un-resolving' 'more' 'than'
 'grade' '2' 'transplant-related' 'toxicities']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02950337,12:28:chronic_disease,ongoing or active infection,['ongoing' 'or' 'active' 'infection'],[0. 0. 2. 2.]
NCT02945800,12:28:chronic_disease,ongoing or active infection,['ongoing' 'or' 'active' 'infection'],[0. 0. 2. 2.]
NCT02890979,12:28:chronic_disease,ongoing or active infection,['ongoing' 'or' 'active' 'infection'],[0. 0. 2. 2.]
NCT02857218,12:28:chronic_disease,ongoing or active infection,['ongoing' 'or' 'active' 'infection'],[0. 0. 2. 2.]
NCT02843568,12:28:chronic_disease,ongoing or active infection,['ongoing' 'or' 'active' 'infection'],[0. 0. 2. 2.]
NCT02694029,12:28:chronic_disease,ongoing or active infection,['ongoing' 'or' 'active' 'infection'],[0. 0. 2. 2.]
NCT02656550,17:33:chronic_disease,Subject with an active infection,['Subject' 'with' 'an' 'active' 'infection'],[0. 0. 0. 2. 2.]
NCT02624804,7:23:chronic_disease,Known active infection,['Known' 'active' 'infection'],[0. 2. 2.]
NCT02624258,14:30:chronic_disease,Uncontrolled active infection,['Uncontrolled' 'active' 'infection'],[0. 2. 2.]
NCT02581215,12:28:chronic_disease,Ongoing or active infection,['Ongoing' 'or' 'active' 'infection'],[0. 0. 2. 2.]
NCT02464878,38:54:chronic_disease,Subjects with laboratory evidence of active infection are excluded even in the absence of clinical evidence of active infection,"['Subjects' 'with' 'laboratory' 'evidence' 'of' 'active' 'infection' 'are'
 'excluded' 'even' 'in' 'the' 'absence' 'of' 'clinical' 'evidence' 'of'
 'active' 'infection']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02419560,16:32:chronic_disease,Subject has an active infection,['Subject' 'has' 'an' 'active' 'infection'],[0. 0. 0. 2. 2.]
NCT02374333,14:30:chronic_disease,Uncontrolled active infection,['Uncontrolled' 'active' 'infection'],[0. 2. 2.]
NCT02320292,39:55:chronic_disease,Serious non-malignant disease such as active infection or other condition which in the opinion of the investigator would compromise other protocol objectives,"['Serious' 'non-malignant' 'disease' 'such' 'as' 'active' 'infection' 'or'
 'other' 'condition' 'which' 'in' 'the' 'opinion' 'of' 'the'
 'investigator' 'would' 'compromise' 'other' 'protocol' 'objectives']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02291848,22:38:chronic_disease,Patients with severe active infection,['Patients' 'with' 'severe' 'active' 'infection'],[0. 0. 0. 2. 2.]
NCT02272998,16:32:chronic_disease,Symptomatic or active infection,['Symptomatic' 'or' 'active' 'infection'],[0. 0. 2. 2.]
NCT02232516,12:28:chronic_disease,Ongoing or active infection,['Ongoing' 'or' 'active' 'infection'],[0. 0. 2. 2.]
NCT02227199,1:17:chronic_disease,active infection,['active' 'infection'],[2. 2.]
NCT02226159,1:17:chronic_disease,active infection,['active' 'infection'],[2. 2.]
NCT02193191,12:28:chronic_disease,Ongoing or active infection,['Ongoing' 'or' 'active' 'infection'],[0. 0. 2. 2.]
NCT02120222,14:30:chronic_disease,Uncontrolled active infection within one week prior to first dose,"['Uncontrolled' 'active' 'infection' 'within' 'one' 'week' 'prior' 'to'
 'first' 'dose']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02037048,37:53:chronic_disease,"Patients with a clinically apparent active infection will not be eligible (please note, an isolated elevation in the white blood cell count, by itself, does not constitute evidence of an infection)","['Patients' 'with' 'a' 'clinically' 'apparent' 'active' 'infection' 'will'
 'not' 'be' 'eligible' '(' 'please' 'note' ',' 'an' 'isolated' 'elevation'
 'in' 'the' 'white' 'blood' 'cell' 'count' ',' 'by' 'itself' ',' 'does'
 'not' 'constitute' 'evidence' 'of' 'an' 'infection' ')']","[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02031250,15:31:chronic_disease,Patients with active infection,['Patients' 'with' 'active' 'infection'],[0. 0. 2. 2.]
NCT01976585,15:31:chronic_disease,Patients with active infection,['Patients' 'with' 'active' 'infection'],[0. 0. 2. 2.]
NCT01952730,14:30:chronic_disease,Uncontrolled active infection,['Uncontrolled' 'active' 'infection'],[0. 2. 2.]
NCT01919619,4:20:chronic_disease,No active infection,['No' 'active' 'infection'],[0. 2. 2.]
NCT01773707,9:25:chronic_disease,Have an active infection at time of randomization,['Have' 'an' 'active' 'infection' 'at' 'time' 'of' 'randomization'],[0. 0. 2. 2. 0. 0. 0. 0.]
NCT01037790,12:28:chronic_disease,ongoing or active infection,['ongoing' 'or' 'active' 'infection'],[0. 0. 2. 2.]
NCT00896493,14:30:chronic_disease,Uncontrolled active infection,['Uncontrolled' 'active' 'infection'],[0. 2. 2.]
NCT00412594,13:29:chronic_disease,Presence of active infection,['Presence' 'of' 'active' 'infection'],[0. 0. 2. 2.]
NCT01802346,"1:16:cancer,65:92:treatment",Prostate cancer subjects may have received prior treatment with metronomic cyclophosphamide as this is considered anti-angiogenic/immunomodulatory and not cytotoxic,"['Prostate' 'cancer' 'subjects' 'may' 'have' 'received' 'prior'
 'treatment' 'with' 'metronomic' 'cyclophosphamide' 'as' 'this' 'is'
 'considered' 'anti-angiogenic/immunomodulatory' 'and' 'not' 'cytotoxic']",[3. 3. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01734512,"1:12:cancer,25:47:cancer","Astrocytoma, Low Grade (Fibrillary astrocytoma, WHO Grade 2) - 10065886","['Astrocytoma' ',' 'Low' 'Grade' '(' 'Fibrillary' 'astrocytoma' ',' 'WHO'
 'Grade' '2' ')' '-' '10065886']",[3. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT02347111,"17:27:treatment,73:83:chronic_disease",Previous use of amiodarone other than short-term use (e.g. for an acute arrhythmia in hospital),"['Previous' 'use' 'of' 'amiodarone' 'other' 'than' 'short-term' 'use' '('
 'e.g' '.' 'for' 'an' 'acute' 'arrhythmia' 'in' 'hospital' ')']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0.]
NCT02933034,12:22:chronic_disease,develop an arrhythmia prior to or during either of the exercise tests; SeeMore should not be administered,"['develop' 'an' 'arrhythmia' 'prior' 'to' 'or' 'during' 'either' 'of'
 'the' 'exercise' 'tests' ';' 'SeeMore' 'should' 'not' 'be' 'administered']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02875301,14:24:chronic_disease,uncontrolled arrhythmia,['uncontrolled' 'arrhythmia'],[0. 2.]
NCT02793921,14:24:chronic_disease,uncontrolled arrhythmia,['uncontrolled' 'arrhythmia'],[0. 2.]
NCT02578641,14:24:chronic_disease,uncontrolled arrhythmia,['uncontrolled' 'arrhythmia'],[0. 2.]
NCT02421341,25:35:chronic_disease,No history of dangerous arrhythmia's,"['No' 'history' 'of' 'dangerous' 'arrhythmia' ""'s""]",[0. 0. 0. 0. 2. 0.]
NCT02227199,14:24:chronic_disease,uncontrolled arrhythmia,['uncontrolled' 'arrhythmia'],[0. 2.]
NCT01850355,",69:79:chronic_disease","Clinically significant abnormalities on ECG (e.g., QT prolongation, arrhythmia)","['Clinically' 'significant' 'abnormalities' 'on' 'ECG' '(' 'e.g.' ',' 'QT'
 'prolongation' ',' 'arrhythmia' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0.]
NCT01676259,10:20:chronic_disease,unstable arrhythmia,['unstable' 'arrhythmia'],[0. 2.]
NCT01445821,28:38:chronic_disease,Untreated life-threatening arrhythmia,['Untreated' 'life-threatening' 'arrhythmia'],[0. 0. 2.]
NCT00788164,13:23:chronic_disease,Symptomatic arrhythmia not controlled by medication,['Symptomatic' 'arrhythmia' 'not' 'controlled' 'by' 'medication'],[0. 2. 0. 0. 0. 0.]
NCT00432094,1:11:chronic_disease,arrhythmia,['arrhythmia'],[2.]
NCT02085941,"36:51:cancer,60:70:cancer",must have histologically confirmed malignant tumor that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective,"['must' 'have' 'histologically' 'confirmed' 'malignant' 'tumor' 'that'
 'is' 'metastatic' 'or' 'unresectable' 'and' 'for' 'which' 'standard'
 'curative' 'or' 'palliative' 'measures' 'do' 'not' 'exist' 'or' 'are'
 'no' 'longer' 'effective']","[0. 0. 0. 0. 3. 3. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02015390,35:50:cancer,Disseminated and/or nonresectable malignant tumor involving bone,"['Disseminated' 'and/or' 'nonresectable' 'malignant' 'tumor' 'involving'
 'bone']",[0. 0. 0. 3. 3. 0. 0.]
NCT03121352,46:56:cancer,willing to undergo a preliminary biopsy of a metastatic focus for research purposes,"['willing' 'to' 'undergo' 'a' 'preliminary' 'biopsy' 'of' 'a' 'metastatic'
 'focus' 'for' 'research' 'purposes']",[0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0.]
NCT03109041,13:23:cancer,Patient has metastatic disease,['Patient' 'has' 'metastatic' 'disease'],[0. 0. 3. 0.]
NCT02496208,39:49:cancer,Histologically confirmed diagnosis of metastatic,['Histologically' 'confirmed' 'diagnosis' 'of' 'metastatic'],[0. 0. 0. 0. 3.]
NCT02166190,1:11:cancer,metastatic disease,['metastatic' 'disease'],[3. 0.]
NCT02143726,6:16:cancer,have metastatic disease or locally advanced unresectable disease,"['have' 'metastatic' 'disease' 'or' 'locally' 'advanced' 'unresectable'
 'disease']",[0. 3. 0. 0. 0. 0. 0. 0.]
NCT02064673,26:36:cancer,no sign of lymph node or metastatic disease,['no' 'sign' 'of' 'lymph' 'node' 'or' 'metastatic' 'disease'],[0. 0. 0. 0. 0. 0. 3. 0.]
NCT01954173,15:25:cancer,Patients with metastatic disease outside of the pelvis,['Patients' 'with' 'metastatic' 'disease' 'outside' 'of' 'the' 'pelvis'],[0. 0. 3. 0. 0. 0. 0. 0.]
NCT02754544,"14:29:treatment,108:141:cancer",undergoing a tumor resection at the University of Texas M. D. Anderson Cancer Center for a newly diagnosed primary or metastatic brain tumor located in or adjacent to motor brain areas,"['undergoing' 'a' 'tumor' 'resection' 'at' 'the' 'University' 'of' 'Texas'
 'M.' 'D.' 'Anderson' 'Cancer' 'Center' 'for' 'a' 'newly' 'diagnosed'
 'primary' 'or' 'metastatic' 'brain' 'tumor' 'located' 'in' 'or'
 'adjacent' 'to' 'motor' 'brain' 'areas']","[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02442297,19:34:treatment,Subjects having a tumor resection if medically feasible,['Subjects' 'having' 'a' 'tumor' 'resection' 'if' 'medically' 'feasible'],[0. 0. 0. 1. 1. 0. 0. 0.]
NCT00924027,"1:21:cancer,64:76:treatment",gynecological cancer patients who may have received concurrent chemotherapy as a component of their treatment regimen,"['gynecological' 'cancer' 'patients' 'who' 'may' 'have' 'received'
 'concurrent' 'chemotherapy' 'as' 'a' 'component' 'of' 'their' 'treatment'
 'regimen']",[3. 3. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT03181126,",73:85:treatment",Refractory is defined as persistent disease after at least 2 courses of chemotherapy,"['Refractory' 'is' 'defined' 'as' 'persistent' 'disease' 'after' 'at'
 'least' '2' 'courses' 'of' 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT03153410,"33:45:treatment,",Must have received last dose of chemotherapy at least 14 days or longer prior to entry into the study,"['Must' 'have' 'received' 'last' 'dose' 'of' 'chemotherapy' 'at' 'least'
 '14' 'days' 'or' 'longer' 'prior' 'to' 'entry' 'into' 'the' 'study']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03139227,",,47:59:treatment","Must be > 1 year from pregnancy, lactation or chemotherapy","['Must' 'be' '>' '1' 'year' 'from' 'pregnancy' ',' 'lactation' 'or'
 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT03088709,",78:90:treatment",Less than twenty-one days have elapsed since the subject's last radiation or chemotherapy prior to conditioning,"['Less' 'than' 'twenty-one' 'days' 'have' 'elapsed' 'since' 'the'
 'subject' ""'s"" 'last' 'radiation' 'or' 'chemotherapy' 'prior' 'to'
 'conditioning']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT03082612,42:54:treatment,Have completed surgery with no plans for chemotherapy,['Have' 'completed' 'surgery' 'with' 'no' 'plans' 'for' 'chemotherapy'],[0. 0. 0. 0. 0. 0. 0. 1.]
NCT03082612,46:58:treatment,Treatment plans to include weekly outpatient chemotherapy,['Treatment' 'plans' 'to' 'include' 'weekly' 'outpatient' 'chemotherapy'],[0. 0. 0. 0. 0. 0. 1.]
NCT03051321,8:20:treatment,Active chemotherapy,['Active' 'chemotherapy'],[0. 1.]
NCT03011684,19:31:treatment,Has not yet begun chemotherapy,['Has' 'not' 'yet' 'begun' 'chemotherapy'],[0. 0. 0. 0. 1.]
NCT02913430,29:41:treatment,More than one prior line of chemotherapy in the metastatic setting,"['More' 'than' 'one' 'prior' 'line' 'of' 'chemotherapy' 'in' 'the'
 'metastatic' 'setting']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02912572,33:45:treatment,patients who have only received chemotherapy in the adjuvant setting,"['patients' 'who' 'have' 'only' 'received' 'chemotherapy' 'in' 'the'
 'adjuvant' 'setting']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02862938,19:31:treatment,Participant is on chemotherapy,['Participant' 'is' 'on' 'chemotherapy'],[0. 0. 0. 1.]
NCT02793583,1:13:treatment,chemotherapy,['chemotherapy'],[1.]
NCT02774421,28:40:treatment,who have been treated with chemotherapy at time of recurrence,"['who' 'have' 'been' 'treated' 'with' 'chemotherapy' 'at' 'time' 'of'
 'recurrence']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02759146,12:24:treatment,Undergoing chemotherapy,['Undergoing' 'chemotherapy'],[0. 1.]
NCT02758847,1:13:treatment,chemotherapy,['chemotherapy'],[1.]
NCT02658565,23:35:treatment,Patients who received chemotherapy directed at the present disease,"['Patients' 'who' 'received' 'chemotherapy' 'directed' 'at' 'the'
 'present' 'disease']",[0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02639208,79:91:treatment,either in the context of standard treatment or a clinical trial and including chemotherapy,"['either' 'in' 'the' 'context' 'of' 'standard' 'treatment' 'or' 'a'
 'clinical' 'trial' 'and' 'including' 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02635360,1:13:treatment,chemotherapy,['chemotherapy'],[1.]
NCT02603757,29:41:treatment,Patients who do not undergo chemotherapy,['Patients' 'who' 'do' 'not' 'undergo' 'chemotherapy'],[0. 0. 0. 0. 0. 1.]
NCT02589938,11:23:treatment,Receiving chemotherapy during study period,['Receiving' 'chemotherapy' 'during' 'study' 'period'],[0. 1. 0. 0. 0.]
NCT02565498,9:21:treatment,Planned chemotherapy for (neo)adjuvant treatment,['Planned' 'chemotherapy' 'for' '(' 'neo' ')' 'adjuvant' 'treatment'],[0. 1. 0. 0. 0. 0. 0. 0.]
NCT02562716,",,,151:163:treatment",women/men of reproductive potential must have agreed to use an effective contraceptive method for up to 3 months after the final administered dose of chemotherapy,"['women/men' 'of' 'reproductive' 'potential' 'must' 'have' 'agreed' 'to'
 'use' 'an' 'effective' 'contraceptive' 'method' 'for' 'up' 'to' '3'
 'months' 'after' 'the' 'final' 'administered' 'dose' 'of' 'chemotherapy']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1.]"
NCT02536794,23:35:treatment,Patients who have had chemotherapy,['Patients' 'who' 'have' 'had' 'chemotherapy'],[0. 0. 0. 0. 1.]
NCT02536794,",36:48:treatment",have received at least one line of chemotherapy in the metastatic setting,"['have' 'received' 'at' 'least' 'one' 'line' 'of' 'chemotherapy' 'in'
 'the' 'metastatic' 'setting']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02492867,37:49:treatment,Patients cannot tolerate concurrent chemotherapy,['Patients' 'can' 'not' 'tolerate' 'concurrent' 'chemotherapy'],[0. 0. 0. 0. 0. 1.]
NCT02481765,66:78:treatment,"Intensive medical treatment means that the subject is undergoing chemotherapy for a hematologic/oncologic condition, is carrying a pacemaker or has been diagnosed with a cardiac anomaly which causes cardiac insufficiency not compensated with medications","['Intensive' 'medical' 'treatment' 'means' 'that' 'the' 'subject' 'is'
 'undergoing' 'chemotherapy' 'for' 'a' 'hematologic/oncologic' 'condition'
 ',' 'is' 'carrying' 'a' 'pacemaker' 'or' 'has' 'been' 'diagnosed' 'with'
 'a' 'cardiac' 'anomaly' 'which' 'causes' 'cardiac' 'insufficiency' 'not'
 'compensated' 'with' 'medications']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02427841,",,,,156:168:treatment,,,","Women of child-bearing potential and men must be willing to use adequate contraception during the entire study and for 8 weeks following completion of all chemotherapy on study; this includes hormonal or barrier method, or abstinence","['Women' 'of' 'child-bearing' 'potential' 'and' 'men' 'must' 'be'
 'willing' 'to' 'use' 'adequate' 'contraception' 'during' 'the' 'entire'
 'study' 'and' 'for' '8' 'weeks' 'following' 'completion' 'of' 'all'
 'chemotherapy' 'on' 'study' ';' 'this' 'includes' 'hormonal' 'or'
 'barrier' 'method' ',' 'or' 'abstinence']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02416206,",43:55:treatment",Within 9 months of the start of induction chemotherapy and no evidence of relapse or progression,"['Within' '9' 'months' 'of' 'the' 'start' 'of' 'induction' 'chemotherapy'
 'and' 'no' 'evidence' 'of' 'relapse' 'or' 'progression']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02359825,12:24:treatment,undergoing chemotherapy,['undergoing' 'chemotherapy'],[0. 1.]
NCT02320292,19:31:treatment,No indication for chemotherapy,['No' 'indication' 'for' 'chemotherapy'],[0. 0. 0. 1.]
NCT02315196,",81:93:treatment",imaging must have been performed no greater than 30 days prior to initiation of chemotherapy,"['imaging' 'must' 'have' 'been' 'performed' 'no' 'greater' 'than' '30'
 'days' 'prior' 'to' 'initiation' 'of' 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02309892,10:22:treatment,Previous chemotherapy,['Previous' 'chemotherapy'],[0. 1.]
NCT02308709,12:24:treatment,"Concurrent chemotherapy is allowed, but not required","['Concurrent' 'chemotherapy' 'is' 'allowed' ',' 'but' 'not' 'required']",[0. 1. 0. 0. 0. 0. 0. 0.]
NCT02303977,",41:53:treatment","Pregnant or breast-feeding patients, as chemotherapy is thought to present substantial risk to the fetus/infant","['Pregnant' 'or' 'breast-feeding' 'patients' ',' 'as' 'chemotherapy' 'is'
 'thought' 'to' 'present' 'substantial' 'risk' 'to' 'the' 'fetus/infant']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02227199,54:66:treatment,Patients must be anticipated to complete 2 cycles of chemotherapy,"['Patients' 'must' 'be' 'anticipated' 'to' 'complete' '2' 'cycles' 'of'
 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02203513,",147:159:treatment","Patients should have recurrent platinum-resistant, defined as disease recurrence by imaging within 6 months of the last receipt of platinum-based chemotherapy","['Patients' 'should' 'have' 'recurrent' 'platinum-resistant' ',' 'defined'
 'as' 'disease' 'recurrence' 'by' 'imaging' 'within' '6' 'months' 'of'
 'the' 'last' 'receipt' 'of' 'platinum-based' 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02159703,"7:19:treatment,",Prior chemotherapy within the past 5 years,['Prior' 'chemotherapy' 'within' 'the' 'past' '5' 'years'],[0. 1. 0. 0. 0. 0. 0.]
NCT02153229,",62:74:treatment",Subjects who have received more than 2 doses of neo-adjuvant chemotherapy,"['Subjects' 'who' 'have' 'received' 'more' 'than' '2' 'doses' 'of'
 'neo-adjuvant' 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02135588,",40:52:treatment",At least 2 days from administration of chemotherapy,['At' 'least' '2' 'days' 'from' 'administration' 'of' 'chemotherapy'],[0. 0. 0. 0. 0. 0. 0. 1.]
NCT02128906,",,53:65:treatment",Pregnant women are excluded from this study because chemotherapy,"['Pregnant' 'women' 'are' 'excluded' 'from' 'this' 'study' 'because'
 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02128906,24:36:treatment,breast feeding because chemotherapy,['breast' 'feeding' 'because' 'chemotherapy'],[0. 0. 0. 1.]
NCT02115295,74:86:treatment,Patient with documented hypersensitivity to any of the components of the chemotherapy program,"['Patient' 'with' 'documented' 'hypersensitivity' 'to' 'any' 'of' 'the'
 'components' 'of' 'the' 'chemotherapy' 'program']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02101736,"21:33:treatment,",No myelosuppressive chemotherapy within 4 weeks of study entry,"['No' 'myelosuppressive' 'chemotherapy' 'within' '4' 'weeks' 'of' 'study'
 'entry']",[0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT02099591,49:61:treatment,Patients currently receiving the first cycle of chemotherapy,"['Patients' 'currently' 'receiving' 'the' 'first' 'cycle' 'of'
 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 1.]
NCT02091999,1:13:treatment,chemotherapy,['chemotherapy'],[1.]
NCT02037048,",40:52:treatment",for 90 days following the last dose of chemotherapy,['for' '90' 'days' 'following' 'the' 'last' 'dose' 'of' 'chemotherapy'],[0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02031250,43:55:treatment,Patients must be able to receive protocol chemotherapy in the judgment of the treating Medical Oncologist,"['Patients' 'must' 'be' 'able' 'to' 'receive' 'protocol' 'chemotherapy'
 'in' 'the' 'judgment' 'of' 'the' 'treating' 'Medical' 'Oncologist']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01953900,53:65:treatment,Recovered from the acute toxic effects of all prior chemotherapy,"['Recovered' 'from' 'the' 'acute' 'toxic' 'effects' 'of' 'all' 'prior'
 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01928589,73:85:treatment,Patient must have a Medical Oncology consult with the recommendation of chemotherapy,"['Patient' 'must' 'have' 'a' 'Medical' 'Oncology' 'consult' 'with' 'the'
 'recommendation' 'of' 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01925573,58:70:treatment,6 weeks since the completion of a nitrosourea-containing chemotherapy regimen,"['6' 'weeks' 'since' 'the' 'completion' 'of' 'a' 'nitrosourea-containing'
 'chemotherapy' 'regimen']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT01919619,",,,,128:140:treatment,",diffusing capacity of the lung for carbon monoxide (DLCO) >= 40% within 3 months of study entry (or within 1 month if received chemotherapy within the past 3 months),"['diffusing' 'capacity' 'of' 'the' 'lung' 'for' 'carbon' 'monoxide' '('
 'DLCO' ')' '>' '=' '40' '%' 'within' '3' 'months' 'of' 'study' 'entry'
 '(' 'or' 'within' '1' 'month' 'if' 'received' 'chemotherapy' 'within'
 'the' 'past' '3' 'months' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]"
NCT01901562,"15:27:treatment,",Have received chemotherapy in the last 12 months,['Have' 'received' 'chemotherapy' 'in' 'the' 'last' '12' 'months'],[0. 0. 1. 0. 0. 0. 0. 0.]
NCT01896999,46:58:treatment,Patients must have relapsed after first line chemotherapy,['Patients' 'must' 'have' 'relapsed' 'after' 'first' 'line' 'chemotherapy'],[0. 0. 0. 0. 0. 0. 0. 1.]
NCT01871766,",189:201:treatment",Participants treated on this protocol in the low or intermediate risk arm who experience disease progression prior to week 13 will transfer to the high risk arm and proceed with high risk chemotherapy starting at week 1 of the protocol,"['Participants' 'treated' 'on' 'this' 'protocol' 'in' 'the' 'low' 'or'
 'intermediate' 'risk' 'arm' 'who' 'experience' 'disease' 'progression'
 'prior' 'to' 'week' '13' 'will' 'transfer' 'to' 'the' 'high' 'risk' 'arm'
 'and' 'proceed' 'with' 'high' 'risk' 'chemotherapy' 'starting' 'at'
 'week' '1' 'of' 'the' 'protocol']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]"
NCT01859819,13:25:treatment,No previous chemotherapy,['No' 'previous' 'chemotherapy'],[0. 0. 1.]
NCT01807091,",,,87:99:treatment",Treatment-related mortality (TRM) score < 9.21 corresponding to a TRM rate of 3% when chemotherapy of similar intensity as proposed here is administered to inpatients,"['Treatment-related' 'mortality' '(' 'TRM' ')' 'score' '<' '9.21'
 'corresponding' 'to' 'a' 'TRM' 'rate' 'of' '3' '%' 'when' 'chemotherapy'
 'of' 'similar' 'intensity' 'as' 'proposed' 'here' 'is' 'administered'
 'to' 'inpatients']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT01754298,1:13:treatment,chemotherapy treatment,['chemotherapy' 'treatment'],[1. 0.]
NCT01730794,37:49:treatment,Immunosuppressed patients receiving chemotherapy,['Immunosuppressed' 'patients' 'receiving' 'chemotherapy'],[0. 0. 0. 1.]
NCT01703949,",63:75:treatment",Patients must be anticipated to complete at least 2 cycles of chemotherapy on study,"['Patients' 'must' 'be' 'anticipated' 'to' 'complete' 'at' 'least' '2'
 'cycles' 'of' 'chemotherapy' 'on' 'study']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.]
NCT01690468,31:43:treatment,"At least one prior regimen of chemotherapy, with no maximum number of chemotherapy cycles","['At' 'least' 'one' 'prior' 'regimen' 'of' 'chemotherapy' ',' 'with' 'no'
 'maximum' 'number' 'of' 'chemotherapy' 'cycles']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01676259,1:13:treatment,chemotherapy,['chemotherapy'],[1.]
NCT01620216,105:117:treatment,certain agents that prolong the corrected QT interval may be allowed but only after discussion with the chemotherapy pharmacist,"['certain' 'agents' 'that' 'prolong' 'the' 'corrected' 'QT' 'interval'
 'may' 'be' 'allowed' 'but' 'only' 'after' 'discussion' 'with' 'the'
 'chemotherapy' 'pharmacist']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT01614990,38:50:treatment,subjects may otherwise be undergoing chemotherapy,['subjects' 'may' 'otherwise' 'be' 'undergoing' 'chemotherapy'],[0. 0. 0. 0. 0. 1.]
NCT01526603,"43:55:treatment,",Patients who are delayed in consolidation chemotherapy beyond 8 weeks,"['Patients' 'who' 'are' 'delayed' 'in' 'consolidation' 'chemotherapy'
 'beyond' '8' 'weeks']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT01526603,40:52:treatment,Recovery from last induction course of chemotherapy,['Recovery' 'from' 'last' 'induction' 'course' 'of' 'chemotherapy'],[0. 0. 0. 0. 0. 0. 1.]
NCT01515527,74:86:treatment,Patient with documented hypersensitivity to any of the components of the chemotherapy program,"['Patient' 'with' 'documented' 'hypersensitivity' 'to' 'any' 'of' 'the'
 'components' 'of' 'the' 'chemotherapy' 'program']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT01505569,48:60:treatment,Timing: Recovery from last induction course of chemotherapy,"['Timing' ':' 'Recovery' 'from' 'last' 'induction' 'course' 'of'
 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01434316,7:19:treatment,Prior chemotherapy,['Prior' 'chemotherapy'],[0. 1.]
NCT01238120,63:75:treatment,Patients with a neutropenic episode during the first cycle of chemotherapy or at high risk for a neutropenic episode during future chemotherapy cycles at the treating physicians discretion,"['Patients' 'with' 'a' 'neutropenic' 'episode' 'during' 'the' 'first'
 'cycle' 'of' 'chemotherapy' 'or' 'at' 'high' 'risk' 'for' 'a'
 'neutropenic' 'episode' 'during' 'future' 'chemotherapy' 'cycles' 'at'
 'the' 'treating' 'physicians' 'discretion']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT01061515,41:53:treatment,All patients must be consented prior to chemotherapy,['All' 'patients' 'must' 'be' 'consented' 'prior' 'to' 'chemotherapy'],[0. 0. 0. 0. 0. 0. 0. 1.]
NCT01061515,"53:65:treatment,,,,",Patients must have adequate renal function prior to chemotherapy defined as serum creatinine ≤ 2.0 mg/dl or creatinine clearance ≥60 ml.min/1.73 m² for patients with creatinine levels above 2.0 mg/dl,"['Patients' 'must' 'have' 'adequate' 'renal' 'function' 'prior' 'to'
 'chemotherapy' 'defined' 'as' 'serum' 'creatinine' '≤' '2.0' 'mg/dl' 'or'
 'creatinine' 'clearance' '≥60' 'ml.min/1.73' 'm²' 'for' 'patients' 'with'
 'creatinine' 'levels' 'above' '2.0' 'mg/dl']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT01061515,21:33:treatment,have received prior chemotherapy,['have' 'received' 'prior' 'chemotherapy'],[0. 0. 0. 1.]
NCT01061515,105:117:treatment,must undergo a peritoneal scan documenting at least one working intraperitoneal port prior to receiving chemotherapy,"['must' 'undergo' 'a' 'peritoneal' 'scan' 'documenting' 'at' 'least' 'one'
 'working' 'intraperitoneal' 'port' 'prior' 'to' 'receiving'
 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT00911560,",,178:190:treatment","stage 4 with (any age) or without (>18 months old) MYCN amplification, MYCN-amplified stage 3 (unresectable; any age), MYCN-amplified stage 4S, or disease resistant to standard chemotherapy","['stage' '4' 'with' '(' 'any' 'age' ')' 'or' 'without' '(' '>' '18'
 'months' 'old' ')' 'MYCN' 'amplification' ',' 'MYCN-amplified' 'stage'
 '3' '(' 'unresectable' ';' 'any' 'age' ')' ',' 'MYCN-amplified' 'stage'
 '4S' ',' 'or' 'disease' 'resistant' 'to' 'standard' 'chemotherapy']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT00902720,1:13:treatment,chemotherapy,['chemotherapy'],[1.]
NCT00819208,63:75:treatment,"patients who are pre-planned to receive a shorter duration of chemotherapy, including as part of a research study","['patients' 'who' 'are' 'pre-planned' 'to' 'receive' 'a' 'shorter'
 'duration' 'of' 'chemotherapy' ',' 'including' 'as' 'part' 'of' 'a'
 'research' 'study']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00719888,",,97:109:treatment",ligible with (M2 marrow) with =< 25% blasts in marrow after having failed one or more cycles of chemotherapy,"['ligible' 'with' '(' 'M2' 'marrow' ')' 'with' '=' '<' '25' '%' 'blasts'
 'in' 'marrow' 'after' 'having' 'failed' 'one' 'or' 'more' 'cycles' 'of'
 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT00719888,",81:93:treatment",patients persistently aplastic for greater than one month since completing last chemotherapy are also eligible with PI approval,"['patients' 'persistently' 'aplastic' 'for' 'greater' 'than' 'one' 'month'
 'since' 'completing' 'last' 'chemotherapy' 'are' 'also' 'eligible' 'with'
 'PI' 'approval']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT00632853,1:13:treatment,chemotherapy,['chemotherapy'],[1.]
NCT00632853,115:127:treatment,patients also must have met all of the eligibility criteria in the protocol prior to receiving the first cycle of chemotherapy,"['patients' 'also' 'must' 'have' 'met' 'all' 'of' 'the' 'eligibility'
 'criteria' 'in' 'the' 'protocol' 'prior' 'to' 'receiving' 'the' 'first'
 'cycle' 'of' 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT00501826,36:48:treatment,failure to one induction course of chemotherapy are eligible,"['failure' 'to' 'one' 'induction' 'course' 'of' 'chemotherapy' 'are'
 'eligible']",[0. 0. 0. 0. 0. 0. 1. 0. 0.]
NCT00492778,23:35:treatment,Patients who received chemotherapy directed at the present recurrence,"['Patients' 'who' 'received' 'chemotherapy' 'directed' 'at' 'the'
 'present' 'recurrence']",[0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT00107289,52:64:treatment,Three weeks should have elapsed since last dose of chemotherapy,"['Three' 'weeks' 'should' 'have' 'elapsed' 'since' 'last' 'dose' 'of'
 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02140554,"22:32:cancer,36:61:chronic_disease",Any prior or current malignancy or immunodeficiency disorder,"['Any' 'prior' 'or' 'current' 'malignancy' 'or' 'immunodeficiency'
 'disorder']",[0. 0. 0. 0. 3. 0. 2. 2.]
NCT03171493,31:41:cancer,Patients with any other prior malignancy are not allowed,"['Patients' 'with' 'any' 'other' 'prior' 'malignancy' 'are' 'not'
 'allowed']",[0. 0. 0. 0. 0. 3. 0. 0. 0.]
NCT03158974,"28:38:cancer,",Have evidence of an active malignancy or have been immunocompromised within the 60 days prior to Screening,"['Have' 'evidence' 'of' 'an' 'active' 'malignancy' 'or' 'have' 'been'
 'immunocompromised' 'within' 'the' '60' 'days' 'prior' 'to' 'Screening']",[0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03158519,27:37:cancer,Diagnosis of other active malignancy,['Diagnosis' 'of' 'other' 'active' 'malignancy'],[0. 0. 0. 0. 3.]
NCT03145298,"12:22:cancer,",History of malignancy within the last 5 years,['History' 'of' 'malignancy' 'within' 'the' 'last' '5' 'years'],[0. 0. 3. 0. 0. 0. 0. 0.]
NCT03141359,"16:26:cancer,",Prior invasive malignancy unless disease free for a minimum of 3 years from enrollment,"['Prior' 'invasive' 'malignancy' 'unless' 'disease' 'free' 'for' 'a'
 'minimum' 'of' '3' 'years' 'from' 'enrollment']",[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03123068,8:18:cancer,Active malignancy,['Active' 'malignancy'],[0. 3.]
NCT03113760,32:42:cancer,current or previous history of malignancy,['current' 'or' 'previous' 'history' 'of' 'malignancy'],[0. 0. 0. 0. 0. 3.]
NCT03113695,17:27:cancer,"Patients with a malignancy that has been treated, but not with curative intent","['Patients' 'with' 'a' 'malignancy' 'that' 'has' 'been' 'treated' ','
 'but' 'not' 'with' 'curative' 'intent']",[0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03113695,"1:11:cancer,",malignancy has been in remission without treatment for 2 years prior to enrollment,"['malignancy' 'has' 'been' 'in' 'remission' 'without' 'treatment' 'for'
 '2' 'years' 'prior' 'to' 'enrollment']",[3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03086369,"25:35:cancer,",Have a known additional malignancy that is progressing or required active treatment within the past 1 year,"['Have' 'a' 'known' 'additional' 'malignancy' 'that' 'is' 'progressing'
 'or' 'required' 'active' 'treatment' 'within' 'the' 'past' '1' 'year']",[0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03076333,"20:30:cancer,",History of a prior malignancy within past 5 years,['History' 'of' 'a' 'prior' 'malignancy' 'within' 'past' '5' 'years'],[0. 0. 0. 0. 3. 0. 0. 0. 0.]
NCT03075826,43:53:cancer,Individuals with a history of a different malignancy,['Individuals' 'with' 'a' 'history' 'of' 'a' 'different' 'malignancy'],[0. 0. 0. 0. 0. 0. 0. 3.]
NCT03059355,"28:38:cancer,",Have a clinical history of malignancy within 3 years,['Have' 'a' 'clinical' 'history' 'of' 'malignancy' 'within' '3' 'years'],[0. 0. 0. 0. 0. 3. 0. 0. 0.]
NCT03043742,61:71:cancer,Any condition that may adversely affect bone marrow such as malignancy or prior irradiation to the pelvic bone,"['Any' 'condition' 'that' 'may' 'adversely' 'affect' 'bone' 'marrow'
 'such' 'as' 'malignancy' 'or' 'prior' 'irradiation' 'to' 'the' 'pelvic'
 'bone']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT03008070,8:18:cancer,Active malignancy,['Active' 'malignancy'],[0. 3.]
NCT03006770,8:18:cancer,Active malignancy,['Active' 'malignancy'],[0. 3.]
NCT03006770,"12:22:cancer,",history of malignancy within 5 years prior to study entry,"['history' 'of' 'malignancy' 'within' '5' 'years' 'prior' 'to' 'study'
 'entry']",[0. 0. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT03002519,"12:22:cancer,",History of malignancy (other than the disease that required the HCT) within 5 years prior to screening,"['History' 'of' 'malignancy' '(' 'other' 'than' 'the' 'disease' 'that'
 'required' 'the' 'HCT' ')' 'within' '5' 'years' 'prior' 'to' 'screening']",[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03001830,1:11:cancer,malignancy,['malignancy'],[3.]
NCT02961114,",,69:79:cancer",Prostate Specific Antigen (PSA) > 4 ng/mL with documentation of non-malignancy,"['Prostate' 'Specific' 'Antigen' '(' 'PSA' ')' '>' '4' 'ng/mL' 'with'
 'documentation' 'of' 'non-malignancy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT02950337,"34:44:cancer,",Patients with a known history of malignancy with a disease-free interval <3 years prior to enrollment,"['Patients' 'with' 'a' 'known' 'history' 'of' 'malignancy' 'with' 'a'
 'disease-free' 'interval' '<' '3' 'years' 'prior' 'to' 'enrollment']",[0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02942095,"34:44:cancer,",Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease,"['Diagnosed' 'or' 'treated' 'for' 'another' 'malignancy' 'within' '2'
 'years' 'before' 'study' 'enrollment' 'or' 'previously' 'diagnosed'
 'with' 'another' 'malignancy' 'and' 'have' 'any' 'evidence' 'of'
 'residual' 'disease']","[0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02924402,111:121:cancer,"History or evidence of a clinically unstable/uncontrollable disorder, condition or disease other than primary malignancy, that in the opinion of the Investigator would pose a risk to the patient safety or interfere with the study evaluation, procedures or completion","['History' 'or' 'evidence' 'of' 'a' 'clinically' 'unstable/uncontrollable'
 'disorder' ',' 'condition' 'or' 'disease' 'other' 'than' 'primary'
 'malignancy' ',' 'that' 'in' 'the' 'opinion' 'of' 'the' 'Investigator'
 'would' 'pose' 'a' 'risk' 'to' 'the' 'patient' 'safety' 'or' 'interfere'
 'with' 'the' 'study' 'evaluation' ',' 'procedures' 'or' 'completion']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02920710,12:22:cancer,History of malignancy,['History' 'of' 'malignancy'],[0. 0. 3.]
NCT02912572,43:53:cancer,Individuals with a history of a different malignancy,['Individuals' 'with' 'a' 'history' 'of' 'a' 'different' 'malignancy'],[0. 0. 0. 0. 0. 0. 0. 3.]
NCT02876302,43:53:cancer,Individuals with a history of a different malignancy are ineligible,"['Individuals' 'with' 'a' 'history' 'of' 'a' 'different' 'malignancy'
 'are' 'ineligible']",[0. 0. 0. 0. 0. 0. 0. 3. 0. 0.]
NCT02857218,"18:28:cancer,",History of other malignancy in the past 2 years,['History' 'of' 'other' 'malignancy' 'in' 'the' 'past' '2' 'years'],[0. 0. 0. 3. 0. 0. 0. 0. 0.]
NCT02803164,21:31:cancer,Proven or suspected malignancy in the wound,['Proven' 'or' 'suspected' 'malignancy' 'in' 'the' 'wound'],[0. 0. 0. 3. 0. 0. 0.]
NCT02719847,10:20:cancer,Patients malignancy is consistent with well differentiated neuroendocrine (carcinoid) histology,"['Patients' 'malignancy' 'is' 'consistent' 'with' 'well' 'differentiated'
 'neuroendocrine' '(' 'carcinoid' ')' 'histology']",[0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02706353,7:17:cancer,Prior malignancy,['Prior' 'malignancy'],[0. 3.]
NCT02693990,43:53:cancer,Individuals with a history of a different malignancy are ineligible except for the following circumstances,"['Individuals' 'with' 'a' 'history' 'of' 'a' 'different' 'malignancy'
 'are' 'ineligible' 'except' 'for' 'the' 'following' 'circumstances']",[0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT02687464,23:33:cancer,current treatment for malignancy,['current' 'treatment' 'for' 'malignancy'],[0. 0. 0. 3.]
NCT02682407,8:18:cancer,Have a malignancy,['Have' 'a' 'malignancy'],[0. 0. 3.]
NCT02678910,29:39:cancer,have a medical condition or malignancy that requires removal of all or part of one or both ovaries,"['have' 'a' 'medical' 'condition' 'or' 'malignancy' 'that' 'requires'
 'removal' 'of' 'all' 'or' 'part' 'of' 'one' 'or' 'both' 'ovaries']",[0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02594111,8:18:cancer,Active malignancy,['Active' 'malignancy'],[0. 3.]
NCT02593123,24:34:cancer,Determination that the malignancy is high risk will be made by the investigator,"['Determination' 'that' 'the' 'malignancy' 'is' 'high' 'risk' 'will' 'be'
 'made' 'by' 'the' 'investigator']",[0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02592707,"20:30:cancer,,",Current history of malignancy; patients with a secondary tumor in remission of > 5 years can be included,"['Current' 'history' 'of' 'malignancy' ';' 'patients' 'with' 'a'
 'secondary' 'tumor' 'in' 'remission' 'of' '>' '5' 'years' 'can' 'be'
 'included']",[0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02588612,51:61:cancer,Subjects must be in complete remission from prior malignancy in order to be eligible to enter the study,"['Subjects' 'must' 'be' 'in' 'complete' 'remission' 'from' 'prior'
 'malignancy' 'in' 'order' 'to' 'be' 'eligible' 'to' 'enter' 'the' 'study']",[0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02588326,"12:22:cancer,",History of malignancy within the past five years,['History' 'of' 'malignancy' 'within' 'the' 'past' 'five' 'years'],[0. 0. 3. 0. 0. 0. 0. 0.]
NCT02587962,32:42:cancer,Histologically confirmed solid malignancy that is metastatic or unresectable for which standard curative or palliative measures do not exist or are no longer effective (Dose Escalation phase only),"['Histologically' 'confirmed' 'solid' 'malignancy' 'that' 'is'
 'metastatic' 'or' 'unresectable' 'for' 'which' 'standard' 'curative' 'or'
 'palliative' 'measures' 'do' 'not' 'exist' 'or' 'are' 'no' 'longer'
 'effective' '(' 'Dose' 'Escalation' 'phase' 'only' ')']","[0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02585973,41:51:cancer,Patients with a currently active second malignancy,['Patients' 'with' 'a' 'currently' 'active' 'second' 'malignancy'],[0. 0. 0. 0. 0. 0. 3.]
NCT02584647,18:28:cancer,Active secondary malignancy unless the malignancy is not expected to interfere with the evaluation of safety and is approved by the Sponsor,"['Active' 'secondary' 'malignancy' 'unless' 'the' 'malignancy' 'is' 'not'
 'expected' 'to' 'interfere' 'with' 'the' 'evaluation' 'of' 'safety' 'and'
 'is' 'approved' 'by' 'the' 'Sponsor']",[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02584647,"42:52:cancer,",Subjects with a completely treated prior malignancy and no evidence of disease for ≥ 2 years are eligible,"['Subjects' 'with' 'a' 'completely' 'treated' 'prior' 'malignancy' 'and'
 'no' 'evidence' 'of' 'disease' 'for' '≥' '2' 'years' 'are' 'eligible']",[0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02574910,20:30:cancer,Evidence of active malignancy,['Evidence' 'of' 'active' 'malignancy'],[0. 0. 0. 3.]
NCT02574728,57:67:cancer,Participants must have had a histologic verification of malignancy at original diagnosis or relapse,"['Participants' 'must' 'have' 'had' 'a' 'histologic' 'verification' 'of'
 'malignancy' 'at' 'original' 'diagnosis' 'or' 'relapse']",[0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0.]
NCT02566304,55:65:cancer,Active involvement of the central nervous system with malignancy,"['Active' 'involvement' 'of' 'the' 'central' 'nervous' 'system' 'with'
 'malignancy']",[0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT02565901,10:20:cancer,No prior malignancy,['No' 'prior' 'malignancy'],[0. 0. 3.]
NCT02565901,"26:36:cancer,",Other adequately treated malignancy for which the patient is currently disease free for at least one year,"['Other' 'adequately' 'treated' 'malignancy' 'for' 'which' 'the' 'patient'
 'is' 'currently' 'disease' 'free' 'for' 'at' 'least' 'one' 'year']",[0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02565498,"7:17:cancer,",Prior malignancy within the previous five years,['Prior' 'malignancy' 'within' 'the' 'previous' 'five' 'years'],[0. 3. 0. 0. 0. 0. 0.]
NCT02555189,"26:36:cancer,",Patient has a concurrent malignancy or malignancy within 3 years of enrollment,"['Patient' 'has' 'a' 'concurrent' 'malignancy' 'or' 'malignancy' 'within'
 '3' 'years' 'of' 'enrollment']",[0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT02551679,14:24:cancer,Diagnosis of malignancy,['Diagnosis' 'of' 'malignancy'],[0. 0. 3.]
NCT02541903,"21:31:cancer,",effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured,"['effectively' 'treated' 'malignancy' 'that' 'has' 'been' 'in' 'remission'
 'for' 'more' 'than' '3' 'years' 'and' 'is' 'considered' 'to' 'be' 'cured']",[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02539160,12:22:cancer,Any active malignancy,['Any' 'active' 'malignancy'],[0. 0. 3.]
NCT02538198,"34:44:cancer,",Diagnosed or treated for another malignancy within 3 years prior to study enrollment,"['Diagnosed' 'or' 'treated' 'for' 'another' 'malignancy' 'within' '3'
 'years' 'prior' 'to' 'study' 'enrollment']",[0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT02532452,25:35:cancer,Uncontrolled relapse of malignancy,['Uncontrolled' 'relapse' 'of' 'malignancy'],[0. 0. 0. 3.]
NCT02525029,13:23:cancer,Progressive malignancy,['Progressive' 'malignancy'],[0. 3.]
NCT02514083,7:17:cancer,Prior malignancy,['Prior' 'malignancy'],[0. 3.]
NCT02510417,36:46:cancer,Active and uncontrolled relapse of malignancy,['Active' 'and' 'uncontrolled' 'relapse' 'of' 'malignancy'],[0. 0. 0. 0. 0. 3.]
NCT02505165,57:67:cancer,The diagnosis is determined to be a relapse or a second malignancy,"['The' 'diagnosis' 'is' 'determined' 'to' 'be' 'a' 'relapse' 'or' 'a'
 'second' 'malignancy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT02501954,"20:30:cancer,",evidence of active malignancy within the last five years,"['evidence' 'of' 'active' 'malignancy' 'within' 'the' 'last' 'five'
 'years']",[0. 0. 0. 3. 0. 0. 0. 0. 0.]
NCT02498951,18:28:cancer,History of other malignancy that could affect compliance with the protocol or interpretation of results,"['History' 'of' 'other' 'malignancy' 'that' 'could' 'affect' 'compliance'
 'with' 'the' 'protocol' 'or' 'interpretation' 'of' 'results']",[0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02481310,"57:67:cancer,",Patients who have been diagnosed or treated for another malignancy within 2 years before study enrollment,"['Patients' 'who' 'have' 'been' 'diagnosed' 'or' 'treated' 'for' 'another'
 'malignancy' 'within' '2' 'years' 'before' 'study' 'enrollment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0.]
NCT02481310,35:45:cancer,previously diagnosed with another malignancy and have any evidence of residual disease,"['previously' 'diagnosed' 'with' 'another' 'malignancy' 'and' 'have' 'any'
 'evidence' 'of' 'residual' 'disease']",[0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT02474199,"12:22:cancer,",History of malignancy within 5 years of enrollment,['History' 'of' 'malignancy' 'within' '5' 'years' 'of' 'enrollment'],[0. 0. 3. 0. 0. 0. 0. 0.]
NCT02473250,1:11:cancer,malignancy,['malignancy'],[3.]
NCT02471430,"12:22:cancer,",History of malignancy of any organ system within the past 5 years,"['History' 'of' 'malignancy' 'of' 'any' 'organ' 'system' 'within' 'the'
 'past' '5' 'years']",[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02466009,"25:35:cancer,",History of other active malignancy within past 2 years,['History' 'of' 'other' 'active' 'malignancy' 'within' 'past' '2' 'years'],[0. 0. 0. 0. 3. 0. 0. 0. 0.]
NCT02464696,18:28:cancer,Have a diagnosed malignancy,['Have' 'a' 'diagnosed' 'malignancy'],[0. 0. 0. 3.]
NCT02458014,26:36:cancer,No active or co-existing malignancy,['No' 'active' 'or' 'co-existing' 'malignancy'],[0. 0. 0. 0. 3.]
NCT02438995,"11:21:cancer,",Unrelated malignancy within 3 years,['Unrelated' 'malignancy' 'within' '3' 'years'],[0. 3. 0. 0. 0.]
NCT02437851,49:59:cancer,Participants must not have any other concurrent malignancy,"['Participants' 'must' 'not' 'have' 'any' 'other' 'concurrent'
 'malignancy']",[0. 0. 0. 0. 0. 0. 0. 3.]
NCT02437812,"27:37:cancer,",Subjects with concomitant malignancy or a previous malignancy within the past three years,"['Subjects' 'with' 'concomitant' 'malignancy' 'or' 'a' 'previous'
 'malignancy' 'within' 'the' 'past' 'three' 'years']",[0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02424968,67:77:cancer,Active central nervous system (CNS) involvement of the underlying malignancy,"['Active' 'central' 'nervous' 'system' '(' 'CNS' ')' 'involvement' 'of'
 'the' 'underlying' 'malignancy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT02424968,7:17:cancer,Prior malignancy,['Prior' 'malignancy'],[0. 3.]
NCT02424968,",,157:167:cancer","diagnosed > 5 years ago without evidence of disease, OR treated =< 5 years ago but have a greater than 50% chance of life expectancy of >= 5 years for that malignancy","['diagnosed' '>' '5' 'years' 'ago' 'without' 'evidence' 'of' 'disease' ','
 'OR' 'treated' '=' '<' '5' 'years' 'ago' 'but' 'have' 'a' 'greater'
 'than' '50' '%' 'chance' 'of' 'life' 'expectancy' 'of' '>' '=' '5'
 'years' 'for' 'that' 'malignancy']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.]"
NCT02403193,"7:17:cancer,",Prior malignancy in past 2 years or as identified in Section 7.2 of this protocol,"['Prior' 'malignancy' 'in' 'past' '2' 'years' 'or' 'as' 'identified' 'in'
 'Section' '7.2' 'of' 'this' 'protocol']",[0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02401035,8:18:cancer,"Active malignancy of any type, or history of a malignancy","['Active' 'malignancy' 'of' 'any' 'type' ',' 'or' 'history' 'of' 'a'
 'malignancy']",[0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02393794,26:36:cancer,Subject has a concurrent malignancy,['Subject' 'has' 'a' 'concurrent' 'malignancy'],[0. 0. 0. 0. 3.]
NCT02393794,"1:11:treatment,",malignancy within 3 years of study enrollment,['malignancy' 'within' '3' 'years' 'of' 'study' 'enrollment'],[1. 0. 0. 0. 0. 0. 0.]
NCT02392572,"51:61:cancer,",Subject has been diagnosed or treated for another malignancy within 3 years of enrolment,"['Subject' 'has' 'been' 'diagnosed' 'or' 'treated' 'for' 'another'
 'malignancy' 'within' '3' 'years' 'of' 'enrolment']",[0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0.]
NCT02358850,24:34:cancer,Indications: Suspected malignancy,['Indications' ':' 'Suspected' 'malignancy'],[0. 0. 0. 3.]
NCT02354547,51:61:cancer,Patients must have had histologic verification of malignancy at original diagnosis or relapse,"['Patients' 'must' 'have' 'had' 'histologic' 'verification' 'of'
 'malignancy' 'at' 'original' 'diagnosis' 'or' 'relapse']",[0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0.]
NCT02353819,"16:26:cancer,",Prior invasive malignancy unless disease free for a minimum of 3 years,"['Prior' 'invasive' 'malignancy' 'unless' 'disease' 'free' 'for' 'a'
 'minimum' 'of' '3' 'years']",[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02353728,"27:37:cancer,",History of another active malignancy within 5 years prior to study entry,"['History' 'of' 'another' 'active' 'malignancy' 'within' '5' 'years'
 'prior' 'to' 'study' 'entry']",[0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT02352480,5:15:cancer,any malignancy in the wound area,['any' 'malignancy' 'in' 'the' 'wound' 'area'],[0. 3. 0. 0. 0. 0.]
NCT02350764,14:24:cancer,Other active malignancy requiring concurrent intervention,['Other' 'active' 'malignancy' 'requiring' 'concurrent' 'intervention'],[0. 0. 3. 0. 0. 0.]
NCT02346526,"7:17:cancer,",Other malignancy treated within the last 3 years,['Other' 'malignancy' 'treated' 'within' 'the' 'last' '3' 'years'],[0. 3. 0. 0. 0. 0. 0. 0.]
NCT02344355,25:35:cancer,"Known active concurrent malignancy, as determined by treating physicians","['Known' 'active' 'concurrent' 'malignancy' ',' 'as' 'determined' 'by'
 'treating' 'physicians']",[0. 0. 0. 3. 0. 0. 0. 0. 0. 0.]
NCT02343549,11:21:cancer,Any other malignancy,['Any' 'other' 'malignancy'],[0. 0. 3.]
NCT02342782,53:63:cancer,Research participants with presence of other active malignancy,"['Research' 'participants' 'with' 'presence' 'of' 'other' 'active'
 'malignancy']",[0. 0. 0. 0. 0. 0. 0. 3.]
NCT02332850,"34:44:cancer,",Diagnosed or treated for another malignancy within 3 years of enrollment,"['Diagnosed' 'or' 'treated' 'for' 'another' 'malignancy' 'within' '3'
 'years' 'of' 'enrollment']",[0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0.]
NCT02323880,51:61:cancer,patients must have had histologic verification of malignancy at original diagnosis or relapse,"['patients' 'must' 'have' 'had' 'histologic' 'verification' 'of'
 'malignancy' 'at' 'original' 'diagnosis' 'or' 'relapse']",[0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0.]
NCT02321501,"48:58:cancer,",Patients who have a history of another primary malignancy unless the patient has been disease free for >/= 3 years,"['Patients' 'who' 'have' 'a' 'history' 'of' 'another' 'primary'
 'malignancy' 'unless' 'the' 'patient' 'has' 'been' 'disease' 'free' 'for'
 '>' '/=' '3' 'years']",[0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02319369,7:17:cancer,"Has a malignancy that is known to contain a non synonymous mutation, insertion, or deletion in the TP53 gene determined previously or at screening","['Has' 'a' 'malignancy' 'that' 'is' 'known' 'to' 'contain' 'a' 'non'
 'synonymous' 'mutation' ',' 'insertion' ',' 'or' 'deletion' 'in' 'the'
 'TP53' 'gene' 'determined' 'previously' 'or' 'at' 'screening']","[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02304458,51:61:cancer,Patients must have had histologic verification of malignancy at original diagnosis or relapse,"['Patients' 'must' 'have' 'had' 'histologic' 'verification' 'of'
 'malignancy' 'at' 'original' 'diagnosis' 'or' 'relapse']",[0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0.]
NCT02296684,"20:30:cancer,",A history of other malignancy ≤ 3 years previous,['A' 'history' 'of' 'other' 'malignancy' '≤' '3' 'years' 'previous'],[0. 0. 0. 0. 3. 0. 0. 0. 0.]
NCT02276456,240:250:cancer,"Examples include transition of care goals to comfort care, transition of care to inpatient or outpatient hospice, or the development of complications during the hospitalization that require early follow up appointments (e.g., diagnosis of malignancy)","['Examples' 'include' 'transition' 'of' 'care' 'goals' 'to' 'comfort'
 'care' ',' 'transition' 'of' 'care' 'to' 'inpatient' 'or' 'outpatient'
 'hospice' ',' 'or' 'the' 'development' 'of' 'complications' 'during'
 'the' 'hospitalization' 'that' 'require' 'early' 'follow' 'up'
 'appointments' '(' 'e.g.' ',' 'diagnosis' 'of' 'malignancy' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0.]"
NCT02266745,10:20:chronic_disease,Previous malignancy,['Previous' 'malignancy'],[0. 2.]
NCT02257424,"12:22:cancer,",History of malignancy other than disease under study within 3 years of study enrollment,"['History' 'of' 'malignancy' 'other' 'than' 'disease' 'under' 'study'
 'within' '3' 'years' 'of' 'study' 'enrollment']",[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02257424,12:22:cancer,History of malignancy with confirmed activating RAS mutation at any time,"['History' 'of' 'malignancy' 'with' 'confirmed' 'activating' 'RAS'
 'mutation' 'at' 'any' 'time']",[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02254863,19:29:cancer,Active concurrent malignancy,['Active' 'concurrent' 'malignancy'],[0. 0. 3.]
NCT02213289,28:38:cancer,No currently active second malignancy,['No' 'currently' 'active' 'second' 'malignancy'],[0. 0. 0. 0. 3.]
NCT02210078,36:46:cancer,Active and uncontrolled relapse of malignancy,['Active' 'and' 'uncontrolled' 'relapse' 'of' 'malignancy'],[0. 0. 0. 0. 0. 3.]
NCT02210078,28:38:cancer,Patients with or without a malignancy,['Patients' 'with' 'or' 'without' 'a' 'malignancy'],[0. 0. 0. 0. 0. 3.]
NCT02203695,25:35:cancer,Currently active second malignancy,['Currently' 'active' 'second' 'malignancy'],[0. 0. 0. 3.]
NCT02195232,49:59:cancer,Participants must have histologically confirmed malignancy that is metastatic or currently unresectable,"['Participants' 'must' 'have' 'histologically' 'confirmed' 'malignancy'
 'that' 'is' 'metastatic' 'or' 'currently' 'unresectable']",[0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0.]
NCT02192359,18:28:cancer,Any other active malignancy,['Any' 'other' 'active' 'malignancy'],[0. 0. 0. 3.]
NCT02159495,53:63:cancer,Research participants with presence of other active malignancy,"['Research' 'participants' 'with' 'presence' 'of' 'other' 'active'
 'malignancy']",[0. 0. 0. 0. 0. 0. 0. 3.]
NCT02159027,9:19:cancer,Current malignancy,['Current' 'malignancy'],[0. 3.]
NCT02152995,20:30:cancer,History of another malignancy,['History' 'of' 'another' 'malignancy'],[0. 0. 0. 3.]
NCT02146924,53:63:cancer,Research participants with presence of other active malignancy,"['Research' 'participants' 'with' 'presence' 'of' 'other' 'active'
 'malignancy']",[0. 0. 0. 0. 0. 0. 0. 3.]
NCT02138214,19:29:cancer,Concurrent active malignancy of another type,['Concurrent' 'active' 'malignancy' 'of' 'another' 'type'],[0. 0. 3. 0. 0. 0.]
NCT02134392,12:22:cancer,History of malignancy,['History' 'of' 'malignancy'],[0. 0. 3.]
NCT02131597,16:26:cancer,Any concurrent malignancy,['Any' 'concurrent' 'malignancy'],[0. 0. 3.]
NCT02128230,30:40:cancer,Patients must not have prior malignancy,['Patients' 'must' 'not' 'have' 'prior' 'malignancy'],[0. 0. 0. 0. 0. 3.]
NCT02128100,71:81:cancer,A reasonable attempt should be made to make a pathologic diagnosis of malignancy,"['A' 'reasonable' 'attempt' 'should' 'be' 'made' 'to' 'make' 'a'
 'pathologic' 'diagnosis' 'of' 'malignancy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT02128100,"7:17:cancer,",Prior malignancy within the last 3 years,['Prior' 'malignancy' 'within' 'the' 'last' '3' 'years'],[0. 3. 0. 0. 0. 0. 0.]
NCT02124772,20:30:cancer,History of another malignancy including resected non-melanomatous skin cancer,"['History' 'of' 'another' 'malignancy' 'including' 'resected'
 'non-melanomatous' 'skin' 'cancer']",[0. 0. 0. 3. 0. 0. 0. 0. 0.]
NCT02122185,"28:38:cancer,,",concurrent active invasive malignancy or one previously diagnosed with a greater than 30% chance of recurrence in the next two years,"['concurrent' 'active' 'invasive' 'malignancy' 'or' 'one' 'previously'
 'diagnosed' 'with' 'a' 'greater' 'than' '30' '%' 'chance' 'of'
 'recurrence' 'in' 'the' 'next' 'two' 'years']",[0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02100891,",57:67:cancer",Life expectancy severely limited by diseases other than malignancy,"['Life' 'expectancy' 'severely' 'limited' 'by' 'diseases' 'other' 'than'
 'malignancy']",[0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT02094625,48:58:cancer,(inclusive) at time of diagnosis of underlying malignancy,"['(' 'inclusive' ')' 'at' 'time' 'of' 'diagnosis' 'of' 'underlying'
 'malignancy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT02070549,20:30:cancer,History of another malignancy,['History' 'of' 'another' 'malignancy'],[0. 0. 0. 3.]
NCT02068092,11:21:cancer,Any prior malignancy,['Any' 'prior' 'malignancy'],[0. 0. 3.]
NCT02050113,20:30:cancer,Patient has active malignancy,['Patient' 'has' 'active' 'malignancy'],[0. 0. 0. 3.]
NCT02048332,25:35:cancer,Uncontrolled relapse of malignancy,['Uncontrolled' 'relapse' 'of' 'malignancy'],[0. 0. 0. 3.]
NCT02047474,"10:20:cancer,",No other malignancy within past five years,['No' 'other' 'malignancy' 'within' 'past' 'five' 'years'],[0. 0. 3. 0. 0. 0. 0.]
NCT02047474,36:46:cancer,There is no evidence of the second malignancy at the time of study entry,"['There' 'is' 'no' 'evidence' 'of' 'the' 'second' 'malignancy' 'at' 'the'
 'time' 'of' 'study' 'entry']",[0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0.]
NCT02020707,"14:24:cancer,",Other active malignancy =< 3 years prior to registration,"['Other' 'active' 'malignancy' '=' '<' '3' 'years' 'prior' 'to'
 'registration']",[0. 0. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT02008656,"36:46:cancer,",Patients with a history of a prior malignancy within the past 5 years,"['Patients' 'with' 'a' 'history' 'of' 'a' 'prior' 'malignancy' 'within'
 'the' 'past' '5' 'years']",[0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0.]
NCT01996449,12:22:cancer,History of malignancy,['History' 'of' 'malignancy'],[0. 0. 3.]
NCT01993810,"16:26:cancer,",Prior invasive malignancy unless disease free for a minimum of 3 years,"['Prior' 'invasive' 'malignancy' 'unless' 'disease' 'free' 'for' 'a'
 'minimum' 'of' '3' 'years']",[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01976585,"7:17:cancer,",Prior malignancy (active within 5 years of screening),"['Prior' 'malignancy' '(' 'active' 'within' '5' 'years' 'of' 'screening'
 ')']",[0. 3. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01947140,9:19:cancer,"Current malignancy or history of a prior malignancy, as outlined in the protocol","['Current' 'malignancy' 'or' 'history' 'of' 'a' 'prior' 'malignancy' ','
 'as' 'outlined' 'in' 'the' 'protocol']",[0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01945814,36:46:cancer,Active and uncontrolled relapse of malignancy,['Active' 'and' 'uncontrolled' 'relapse' 'of' 'malignancy'],[0. 0. 0. 0. 0. 3.]
NCT01941316,86:96:cancer,have histologically or cytologically-confirmed diagnosis of progressive or recurrent malignancy,"['have' 'histologically' 'or' 'cytologically-confirmed' 'diagnosis' 'of'
 'progressive' 'or' 'recurrent' 'malignancy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT01905046,"14:24:cancer,",Other active malignancy =< 5 years prior to pre-registration,"['Other' 'active' 'malignancy' '=' '<' '5' 'years' 'prior' 'to'
 'pre-registration']",[0. 0. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT01901562,20:30:cancer,Have suspicious of malignancy in ultrasound,['Have' 'suspicious' 'of' 'malignancy' 'in' 'ultrasound'],[0. 0. 0. 3. 0. 0.]
NCT01865162,"3:13:cancer,,",A malignancy diagnosed ≥2 years ago if the subject has had no evidence of disease for 2 years prior to screening,"['A' 'malignancy' 'diagnosed' '≥2' 'years' 'ago' 'if' 'the' 'subject'
 'has' 'had' 'no' 'evidence' 'of' 'disease' 'for' '2' 'years' 'prior' 'to'
 'screening']",[0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01823198,",,85:95:cancer",Serum glutamate pyruvate transaminase (SGPT) =< 200 IU/ml unless related to patient malignancy,"['Serum' 'glutamate' 'pyruvate' 'transaminase' '(' 'SGPT' ')' '=' '<'
 '200' 'IU/ml' 'unless' 'related' 'to' 'patient' 'malignancy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT01815359,73:83:cancer,"Subjects with other concurrent severe medical problems unrelated to the malignancy that would significantly limit full compliance with the study, or places them at an unacceptable risk for participation in the study","['Subjects' 'with' 'other' 'concurrent' 'severe' 'medical' 'problems'
 'unrelated' 'to' 'the' 'malignancy' 'that' 'would' 'significantly'
 'limit' 'full' 'compliance' 'with' 'the' 'study' ',' 'or' 'places' 'them'
 'at' 'an' 'unacceptable' 'risk' 'for' 'participation' 'in' 'the' 'study']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01804465,21:31:cancer,Concurrent or prior malignancy,['Concurrent' 'or' 'prior' 'malignancy'],[0. 0. 0. 3.]
NCT01766297,14:24:cancer,negative for malignancy on pathology,['negative' 'for' 'malignancy' 'on' 'pathology'],[0. 0. 3. 0. 0.]
NCT01760655,55:65:cancer,Active involvement of the central nervous system with malignancy,"['Active' 'involvement' 'of' 'the' 'central' 'nervous' 'system' 'with'
 'malignancy']",[0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT01737502,14:24:cancer,Other active malignancy,['Other' 'active' 'malignancy'],[0. 0. 3.]
NCT01716806,"20:30:cancer,",History of another malignancy within 1 year before first dose of study drug (Parts E and F only),"['History' 'of' 'another' 'malignancy' 'within' '1' 'year' 'before'
 'first' 'dose' 'of' 'study' 'drug' '(' 'Parts' 'E' 'and' 'F' 'only' ')']",[0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01676259,7:17:cancer,Other malignancy that would interfere with the current intervention,"['Other' 'malignancy' 'that' 'would' 'interfere' 'with' 'the' 'current'
 'intervention']",[0. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT01600040,"24:34:cancer,",History of a different malignancy except if disease-free for at least 5 years and are deemed by the investigator ro be at low risk for recurrence of that malignancy,"['History' 'of' 'a' 'different' 'malignancy' 'except' 'if' 'disease-free'
 'for' 'at' 'least' '5' 'years' 'and' 'are' 'deemed' 'by' 'the'
 'investigator' 'ro' 'be' 'at' 'low' 'risk' 'for' 'recurrence' 'of' 'that'
 'malignancy']","[0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT01532687,7:17:cancer,Prior malignancy,['Prior' 'malignancy'],[0. 3.]
NCT01532687,31:41:cancer,subjects who have had another malignancy and have been disease-free,"['subjects' 'who' 'have' 'had' 'another' 'malignancy' 'and' 'have' 'been'
 'disease-free']",[0. 0. 0. 0. 0. 3. 0. 0. 0. 0.]
NCT01505569,53:63:cancer,All patients must have histological verification of malignancy at original diagnosis,"['All' 'patients' 'must' 'have' 'histological' 'verification' 'of'
 'malignancy' 'at' 'original' 'diagnosis']",[0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0.]
NCT01505062,"12:22:cancer,",History of malignancy within a five year period,['History' 'of' 'malignancy' 'within' 'a' 'five' 'year' 'period'],[0. 0. 3. 0. 0. 0. 0. 0.]
NCT01494662,50:60:cancer,Individuals with a history of a different active malignancy,"['Individuals' 'with' 'a' 'history' 'of' 'a' 'different' 'active'
 'malignancy']",[0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT01465100,20:30:cancer,Subject has active malignancy,['Subject' 'has' 'active' 'malignancy'],[0. 0. 0. 3.]
NCT01459107,"14:24:cancer,",Negative for malignancy for past 5 years,['Negative' 'for' 'malignancy' 'for' 'past' '5' 'years'],[0. 0. 3. 0. 0. 0. 0.]
NCT01445821,18:28:cancer,Prior history of malignancy,['Prior' 'history' 'of' 'malignancy'],[0. 0. 0. 3.]
NCT01384513,55:65:cancer,Active involvement of the central nervous system with malignancy,"['Active' 'involvement' 'of' 'the' 'central' 'nervous' 'system' 'with'
 'malignancy']",[0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT01366612,"34:44:cancer,",Diagnosed or treated for another malignancy within 3 years of enrollment,"['Diagnosed' 'or' 'treated' 'for' 'another' 'malignancy' 'within' '3'
 'years' 'of' 'enrollment']",[0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0.]
NCT01312857,18:28:cancer,History of other malignancy,['History' 'of' 'other' 'malignancy'],[0. 0. 0. 3.]
NCT01293214,24:34:cancer,High risk of return of malignancy,['High' 'risk' 'of' 'return' 'of' 'malignancy'],[0. 0. 0. 0. 0. 3.]
NCT01087294,",,90:100:cancer","Platelet count less than 30,000/microL unless low platelet count is thought to be due to malignancy in the bone marrow and malignancy is documented in the bone marrow","['Platelet' 'count' 'less' 'than' '30,000/microL' 'unless' 'low'
 'platelet' 'count' 'is' 'thought' 'to' 'be' 'due' 'to' 'malignancy' 'in'
 'the' 'bone' 'marrow' 'and' 'malignancy' 'is' 'documented' 'in' 'the'
 'bone' 'marrow']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT00896493,"23:33:cancer,,,",Patients with a prior malignancy treated < 5 years ago but have a life expectancy of > 5 years for that malignancy,"['Patients' 'with' 'a' 'prior' 'malignancy' 'treated' '<' '5' 'years'
 'ago' 'but' 'have' 'a' 'life' 'expectancy' 'of' '>' '5' 'years' 'for'
 'that' 'malignancy']",[0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00887146,"14:24:cancer,",Other active malignancy within 5 years of registration,['Other' 'active' 'malignancy' 'within' '5' 'years' 'of' 'registration'],[0. 0. 3. 0. 0. 0. 0. 0.]
NCT00788164,15:25:cancer,No concurrent malignancy,['No' 'concurrent' 'malignancy'],[0. 0. 3.]
NCT00734877,10:20:cancer,No prior malignancy is allowed,['No' 'prior' 'malignancy' 'is' 'allowed'],[0. 0. 3. 0. 0.]
NCT00734877,"7:17:cancer,",Prior malignancy is acceptable provided there has been no evidence of disease within the three-year interval,"['Prior' 'malignancy' 'is' 'acceptable' 'provided' 'there' 'has' 'been'
 'no' 'evidence' 'of' 'disease' 'within' 'the' 'three-year' 'interval']",[0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03167359,"20:37:treatment,58:68:chronic_disease",Requiring regional nodal irradiation without evidence of N3 disease,"['Requiring' 'regional' 'nodal' 'irradiation' 'without' 'evidence' 'of'
 'N3' 'disease']",[0. 0. 1. 1. 0. 0. 0. 2. 2.]
NCT02585973,"47:74:treatment,57:74:treatment",Unable or unwilling to discontinue use of any sensitive CYP3A4 substrates and CYP3A4 substrates with a narrow therapeutic window,"['Unable' 'or' 'unwilling' 'to' 'discontinue' 'use' 'of' 'any' 'sensitive'
 'CYP3A4' 'substrates' 'and' 'CYP3A4' 'substrates' 'with' 'a' 'narrow'
 'therapeutic' 'window']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02518594,"32:45:cancer,110:120:treatment","Known, suspected or history of breast cancer because breast cancer is a contraindication to the active study medication","['Known' ',' 'suspected' 'or' 'history' 'of' 'breast' 'cancer' 'because'
 'breast' 'cancer' 'is' 'a' 'contraindication' 'to' 'the' 'active' 'study'
 'medication']",[0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT03186937,10:23:chronic_disease,Operable breast cancer,['Operable' 'breast' 'cancer'],[0. 2. 2.]
NCT03176979,17:30:cancer,Newly diagnosed breast cancer patients,['Newly' 'diagnosed' 'breast' 'cancer' 'patients'],[0. 0. 3. 3. 0.]
NCT03143894,23:36:cancer,Evidence of recurrent breast cancer at the time of enrollment,"['Evidence' 'of' 'recurrent' 'breast' 'cancer' 'at' 'the' 'time' 'of'
 'enrollment']",[0. 0. 0. 3. 3. 0. 0. 0. 0. 0.]
NCT03120728,28:41:cancer,current or past history of breast cancer,['current' 'or' 'past' 'history' 'of' 'breast' 'cancer'],[0. 0. 0. 0. 0. 3. 3.]
NCT03096418,",40:53:cancer",Women with pathologically demonstrated breast cancer,['Women' 'with' 'pathologically' 'demonstrated' 'breast' 'cancer'],[0. 0. 0. 0. 3. 3.]
NCT03096418,177:190:cancer,"studies (window studies, for example) that are deemed non-therapeutic, including those that utilize agents that are not FDA approved for the treatment of the patient's current breast cancer, are permitted","['studies' '(' 'window' 'studies' ',' 'for' 'example' ')' 'that' 'are'
 'deemed' 'non-therapeutic' ',' 'including' 'those' 'that' 'utilize'
 'agents' 'that' 'are' 'not' 'FDA' 'approved' 'for' 'the' 'treatment' 'of'
 'the' 'patient' ""'s"" 'current' 'breast' 'cancer' ',' 'are' 'permitted']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0.]"
NCT03025139,",,46:59:cancer,,,,","Women diagnosed with early stage, resectable breast cancer (Stage 0, I, II, or III) prior to age 50, and are within 5 years of diagnosis","['Women' 'diagnosed' 'with' 'early' 'stage' ',' 'resectable' 'breast'
 'cancer' '(' 'Stage' '0' ',' 'I' ',' 'II' ',' 'or' 'III' ')' 'prior' 'to'
 'age' '50' ',' 'and' 'are' 'within' '5' 'years' 'of' 'diagnosis']","[0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03011684,5:18:cancer,New breast cancer diagnosis,['New' 'breast' 'cancer' 'diagnosis'],[0. 3. 3. 0.]
NCT02982564,"18:31:cancer,,",Be classified in breast cancer stage grouping 0 to III according to the American Joint Committee on Cancer Classification of Malignant Tumors (TNM) Staging System (2013),"['Be' 'classified' 'in' 'breast' 'cancer' 'stage' 'grouping' '0' 'to'
 'III' 'according' 'to' 'the' 'American' 'Joint' 'Committee' 'on' 'Cancer'
 'Classification' 'of' 'Malignant' 'Tumors' '(' 'TNM' ')' 'Staging'
 'System' '(' '2013' ')']","[0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02982564,16:29:cancer,Diagnosed with breast cancer,['Diagnosed' 'with' 'breast' 'cancer'],[0. 0. 3. 3.]
NCT02926729,46:59:cancer,Involvement in another therapeutic trial for breast cancer,"['Involvement' 'in' 'another' 'therapeutic' 'trial' 'for' 'breast'
 'cancer']",[0. 0. 0. 0. 0. 0. 3. 3.]
NCT02924441,30:43:cancer,Must not have had history of breast cancer,['Must' 'not' 'have' 'had' 'history' 'of' 'breast' 'cancer'],[0. 0. 0. 0. 0. 0. 3. 3.]
NCT02876302,58:71:cancer,Participants must have histologically confirmed invasive breast cancer,"['Participants' 'must' 'have' 'histologically' 'confirmed' 'invasive'
 'breast' 'cancer']",[0. 0. 0. 0. 0. 0. 3. 3.]
NCT02860000,66:79:cancer,"Histologic proof of metastatic or locally advanced, unresectable breast cancer","['Histologic' 'proof' 'of' 'metastatic' 'or' 'locally' 'advanced' ','
 'unresectable' 'breast' 'cancer']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT02842658,49:62:cancer,Subjects will have been recently diagnosed with breast cancer,"['Subjects' 'will' 'have' 'been' 'recently' 'diagnosed' 'with' 'breast'
 'cancer']",[0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT02793921,28:41:cancer,Medical clearance by their breast cancer surgeon,['Medical' 'clearance' 'by' 'their' 'breast' 'cancer' 'surgeon'],[0. 0. 0. 0. 3. 3. 0.]
NCT02791646,"14:27:cancer,",diagnosis of breast cancer (initial or recurrence) within the last two years,"['diagnosis' 'of' 'breast' 'cancer' '(' 'initial' 'or' 'recurrence' ')'
 'within' 'the' 'last' 'two' 'years']",[0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02763228,26:39:cancer,Pathologically confirmed breast cancer,['Pathologically' 'confirmed' 'breast' 'cancer'],[0. 0. 3. 3.]
NCT02754752,",,39:52:cancer","Have a history of stage I, II, or III breast cancer","['Have' 'a' 'history' 'of' 'stage' 'I' ',' 'II' ',' 'or' 'III' 'breast'
 'cancer']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT02690116,"16:29:cancer,,","Diagnosed with breast cancer, stage 0-III","['Diagnosed' 'with' 'breast' 'cancer' ',' 'stage' '0-III']",[0. 0. 3. 3. 0. 0. 0.]
NCT02637349,24:37:cancer,Confirmed diagnosis of breast cancer (not metastatic),['Confirmed' 'diagnosis' 'of' 'breast' 'cancer' '(' 'not' 'metastatic' ')'],[0. 0. 0. 3. 3. 0. 0. 0. 0.]
NCT02608216,"54:67:cancer,,,,","History of histologically or cytologically confirmed breast cancer, any ER, PR or HER2 status is allowed as long as it expresses the Rb protein","['History' 'of' 'histologically' 'or' 'cytologically' 'confirmed' 'breast'
 'cancer' ',' 'any' 'ER' ',' 'PR' 'or' 'HER2' 'status' 'is' 'allowed' 'as'
 'long' 'as' 'it' 'expresses' 'the' 'Rb' 'protein']","[0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02538484,28:41:cancer,Estrogen receptor positive breast cancer,['Estrogen' 'receptor' 'positive' 'breast' 'cancer'],[0. 0. 0. 3. 3.]
NCT02536794,"97:110:cancer,,,","Patients must have a histologically documented (either primary or metastatic site) diagnosis of breast cancer that is HER2 non-overexpressing by immunohistochemistry, namely 0 or 1","['Patients' 'must' 'have' 'a' 'histologically' 'documented' '(' 'either'
 'primary' 'or' 'metastatic' 'site' ')' 'diagnosis' 'of' 'breast' 'cancer'
 'that' 'is' 'HER2' 'non-overexpressing' 'by' 'immunohistochemistry' ','
 'namely' '0' 'or' '1']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02522468,7:20:cancer,Prior breast cancer on ipsilateral side,['Prior' 'breast' 'cancer' 'on' 'ipsilateral' 'side'],[0. 3. 3. 0. 0. 0.]
NCT02494869,"27:40:cancer,",Predicted 10-year risk of breast cancer of ≥ 2.31%,['Predicted' '10-year' 'risk' 'of' 'breast' 'cancer' 'of' '≥' '2.31' '%'],[0. 0. 0. 0. 3. 3. 0. 0. 0. 0.]
NCT02494869,"28:41:cancer,",Predicted lifetime risk of breast cancer >20% based on family history),"['Predicted' 'lifetime' 'risk' 'of' 'breast' 'cancer' '>' '20' '%' 'based'
 'on' 'family' 'history' ')']",[0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02479230,26:39:cancer,Histologically confirmed breast cancer,['Histologically' 'confirmed' 'breast' 'cancer'],[0. 0. 3. 3.]
NCT02427581,"25:38:cancer,",Evidence of progressive breast cancer within the last 30 days,"['Evidence' 'of' 'progressive' 'breast' 'cancer' 'within' 'the' 'last'
 '30' 'days']",[0. 0. 0. 3. 3. 0. 0. 0. 0. 0.]
NCT02393794,70:83:cancer,"Confirmed germline BRCA1 or BRCA2 mutation, regardless of subtype of breast cancer","['Confirmed' 'germline' 'BRCA1' 'or' 'BRCA2' 'mutation' ',' 'regardless'
 'of' 'subtype' 'of' 'breast' 'cancer']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT02352025,21:34:cancer,"A prior, unrelated, breast cancer","['A' 'prior' ',' 'unrelated' ',' 'breast' 'cancer']",[0. 0. 0. 0. 0. 3. 3.]
NCT02352025,15:28:cancer,All stages of breast cancer,['All' 'stages' 'of' 'breast' 'cancer'],[0. 0. 0. 3. 3.]
NCT02352025,54:67:cancer,"Any prior treatment for the current, newly diagnosed breast cancer","['Any' 'prior' 'treatment' 'for' 'the' 'current' ',' 'newly' 'diagnosed'
 'breast' 'cancer']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT02341235,"10:23:cancer,",Report a breast cancer diagnosis no more than 10 years prior to enrollmen,"['Report' 'a' 'breast' 'cancer' 'diagnosis' 'no' 'more' 'than' '10'
 'years' 'prior' 'to' 'enrollmen']",[0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02328313,",,45:58:cancer,","Histologically confirmed Stage I, II or III breast cancer (if the patient has had more than one breast cancer, then the most recent diagnosis)","['Histologically' 'confirmed' 'Stage' 'I' ',' 'II' 'or' 'III' 'breast'
 'cancer' '(' 'if' 'the' 'patient' 'has' 'had' 'more' 'than' 'one'
 'breast' 'cancer' ',' 'then' 'the' 'most' 'recent' 'diagnosis' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02315196,",,58:71:cancer",Life expectancy >= 52 weeks excluding their diagnosis of breast cancer,"['Life' 'expectancy' '>' '=' '52' 'weeks' 'excluding' 'their' 'diagnosis'
 'of' 'breast' 'cancer']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT02204098,51:64:cancer,Newly diagnosed histologically confirmed invasive breast cancer,"['Newly' 'diagnosed' 'histologically' 'confirmed' 'invasive' 'breast'
 'cancer']",[0. 0. 0. 0. 0. 3. 3.]
NCT02106598,1:14:cancer,breast cancer patients in whom SLN mapping is indicated,['breast' 'cancer' 'patients' 'in' 'whom' 'SLN' 'mapping' 'is' 'indicated'],[3. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT02095184,"21:34:cancer,,,,",Unresected operable breast cancer stage I-III with primary tumor ≥ 2.0 cm,"['Unresected' 'operable' 'breast' 'cancer' 'stage' 'I-III' 'with'
 'primary' 'tumor' '≥' '2.0' 'cm']",[0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02068092,183:196:cancer,"A known deleterious mutation in BRCA1, BRCA2, PTEN, or TP53. (Note: The participant must be a documented carrier to meet this criterion. If there is a known mutation in a hereditary breast cancer susceptibility gene in a participant's family member, the participant herself must have undergone genetic testing as per National Comprehensive Cancer Network guidelines to be eligible per this criterion.)","['A' 'known' 'deleterious' 'mutation' 'in' 'BRCA1' ',' 'BRCA2' ',' 'PTEN'
 ',' 'or' 'TP53' '.' '(' 'Note' ':' 'The' 'participant' 'must' 'be' 'a'
 'documented' 'carrier' 'to' 'meet' 'this' 'criterion' '.' 'If' 'there'
 'is' 'a' 'known' 'mutation' 'in' 'a' 'hereditary' 'breast' 'cancer'
 'susceptibility' 'gene' 'in' 'a' 'participant' ""'s"" 'family' 'member' ','
 'the' 'participant' 'herself' 'must' 'have' 'undergone' 'genetic'
 'testing' 'as' 'per' 'National' 'Comprehensive' 'Cancer' 'Network'
 'guidelines' 'to' 'be' 'eligible' 'per' 'this' 'criterion' '.' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01953588,"10:23:cancer,,,,,,","Invasive breast cancer is estrogen receptor positive with an Allred score of 6, 7 or 8 by local institution standard protocol. If an Allred Score is not reported on the diagnostic pathology report, ER positivity in > 66% cells","['Invasive' 'breast' 'cancer' 'is' 'estrogen' 'receptor' 'positive' 'with'
 'an' 'Allred' 'score' 'of' '6' ',' '7' 'or' '8' 'by' 'local'
 'institution' 'standard' 'protocol' '.' 'If' 'an' 'Allred' 'Score' 'is'
 'not' 'reported' 'on' 'the' 'diagnostic' 'pathology' 'report' ',' 'ER'
 'positivity' 'in' '>' '66' '%' 'cells']","[0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01912612,",,26:39:cancer,",Diagnosis of stage 0-III breast cancer within 12 years prior to enrollment,"['Diagnosis' 'of' 'stage' '0-III' 'breast' 'cancer' 'within' '12' 'years'
 'prior' 'to' 'enrollment']",[0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0.]
NCT01912612,39:52:cancer,Pain that developed or worsened since breast cancer diagnosis and is not due to identifiable traumatic event or fracture,"['Pain' 'that' 'developed' 'or' 'worsened' 'since' 'breast' 'cancer'
 'diagnosis' 'and' 'is' 'not' 'due' 'to' 'identifiable' 'traumatic'
 'event' 'or' 'fracture']",[0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01905046,31:44:cancer,Must be at increased risk for breast cancer,['Must' 'be' 'at' 'increased' 'risk' 'for' 'breast' 'cancer'],[0. 0. 0. 0. 0. 0. 3. 3.]
NCT01755208,"22:35:cancer,,,",Participants who are breast cancer free (mammogram negative within 1 month of testing) with the absence of clinical suspicion of breast cancer on physical exam or with clinical stage II or stage III breast cancer,"['Participants' 'who' 'are' 'breast' 'cancer' 'free' '(' 'mammogram'
 'negative' 'within' '1' 'month' 'of' 'testing' ')' 'with' 'the' 'absence'
 'of' 'clinical' 'suspicion' 'of' 'breast' 'cancer' 'on' 'physical' 'exam'
 'or' 'with' 'clinical' 'stage' 'II' 'or' 'stage' 'III' 'breast' 'cancer']","[0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01622868,79:92:cancer,Pathologically (histologically or cytologically) proven diagnosis of invasive breast cancer,"['Pathologically' '(' 'histologically' 'or' 'cytologically' ')' 'proven'
 'diagnosis' 'of' 'invasive' 'breast' 'cancer']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT01591356,1:14:cancer,breast cancer are not exclusionary,['breast' 'cancer' 'are' 'not' 'exclusionary'],[3. 3. 0. 0. 0.]
NCT01570998,30:43:cancer,Axillary lymph node positive breast cancer,['Axillary' 'lymph' 'node' 'positive' 'breast' 'cancer'],[0. 0. 0. 0. 3. 3.]
NCT00948285,17:30:cancer,Newly diagnosed breast cancer patients,['Newly' 'diagnosed' 'breast' 'cancer' 'patients'],[0. 0. 3. 3. 0.]
NCT00948285,"15:28:cancer,,,",Patients with breast cancer diagnosis during pregnancy (women who could bear children must have a negative pregnancy test before beginning this study),"['Patients' 'with' 'breast' 'cancer' 'diagnosis' 'during' 'pregnancy' '('
 'women' 'who' 'could' 'bear' 'children' 'must' 'have' 'a' 'negative'
 'pregnancy' 'test' 'before' 'beginning' 'this' 'study' ')']",[0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00924027,",20:33:cancer",male patients with breast cancer,['male' 'patients' 'with' 'breast' 'cancer'],[0. 0. 0. 3. 3.]
NCT00909909,26:39:cancer,Histologically confirmed breast cancer,['Histologically' 'confirmed' 'breast' 'cancer'],[0. 0. 3. 3.]
NCT02977468,",,,176:186:treatment",Female subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication,"['Female' 'subjects' 'of' 'childbearing' 'potential' 'must' 'be' 'willing'
 'to' 'use' 'an' 'adequate' 'method' 'of' 'contraception' 'for' 'the'
 'course' 'of' 'the' 'study' 'through' '120' 'days' 'after' 'the' 'last'
 'dose' 'of' 'study' 'medication']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1.]"
NCT02581982,",,,233:243:treatment,","Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication; subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year","['Female' 'subjects' 'of' 'childbearing' 'potential' 'should' 'be'
 'willing' 'to' 'use' '2' 'methods' 'of' 'birth' 'control' 'or' 'be'
 'surgically' 'sterile' ',' 'or' 'abstain' 'from' 'heterosexual'
 'activity' 'for' 'the' 'course' 'of' 'the' 'study' 'through' '120' 'days'
 'after' 'the' 'last' 'dose' 'of' 'study' 'medication' ';' 'subjects' 'of'
 'childbearing' 'potential' 'are' 'those' 'who' 'have' 'not' 'been'
 'surgically' 'sterilized' 'or' 'have' 'not' 'been' 'free' 'from' 'menses'
 'for' '>' '1' 'year']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02541565,",,,149:159:treatment",Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication,"['Female' 'subject' 'of' 'childbearing' 'potential' 'should' 'have' 'a'
 'negative' 'urine' 'or' 'serum' 'pregnancy' 'within' '72' 'hours' 'prior'
 'to' 'receiving' 'the' 'first' 'dose' 'of' 'study' 'medication']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1.]"
NCT02541565,",,,,,233:243:treatment","Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication","['Female' 'subjects' 'of' 'childbearing' 'potential' 'should' 'be'
 'willing' 'to' 'use' '2' 'methods' 'of' 'birth' 'control' 'or' 'be'
 'surgically' 'sterile' ',' 'or' 'abstain' 'from' 'heterosexual'
 'activity' 'for' 'the' 'course' 'of' 'the' 'study' 'through' '120' 'days'
 'after' 'the' 'last' 'dose' 'of' 'study' 'medication']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02535533,",,71:81:treatment",Pre-existing uncontrolled hypertension defined as > 150/90 mm Hg with medication,"['Pre-existing' 'uncontrolled' 'hypertension' 'defined' 'as' '>' '150/90'
 'mm' 'Hg' 'with' 'medication']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02532543,25:35:treatment,Use of any substance or medication that will influence bone metabolism,"['Use' 'of' 'any' 'substance' 'or' 'medication' 'that' 'will' 'influence'
 'bone' 'metabolism']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02527265,32:42:treatment,"Any disease or exposure to any medication which, in the judgment of the principal Investigator, may impact glucose metabolism","['Any' 'disease' 'or' 'exposure' 'to' 'any' 'medication' 'which' ',' 'in'
 'the' 'judgment' 'of' 'the' 'principal' 'Investigator' ',' 'may' 'impact'
 'glucose' 'metabolism']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02502253,87:97:treatment,Deemed too unstable medically or neurologically to safely enroll in trial of research medication,"['Deemed' 'too' 'unstable' 'medically' 'or' 'neurologically' 'to' 'safely'
 'enroll' 'in' 'trial' 'of' 'research' 'medication']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02446457,",,106:116:treatment",have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication,"['have' 'a' 'negative' 'urine' 'or' 'serum' 'pregnancy' 'test' 'within'
 '72' 'hours' 'prior' 'to' 'receiving' 'the' 'first' 'dose' 'of' 'study'
 'medication']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02440815,42:52:treatment,Acute or uncontrolled medical illness or medication use impacting cognitive function,"['Acute' 'or' 'uncontrolled' 'medical' 'illness' 'or' 'medication' 'use'
 'impacting' 'cognitive' 'function']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02437773,16:26:treatment,"Not taking any medication, prescription or non-prescription, with psychotropic effects","['Not' 'taking' 'any' 'medication' ',' 'prescription' 'or'
 'non-prescription' ',' 'with' 'psychotropic' 'effects']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02437370,",,,,149:159:treatment","Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required","['Female' 'subject' 'of' 'childbearing' 'potential' 'should' 'have' 'a'
 'negative' 'urine' 'or' 'serum' 'pregnancy' 'within' '72' 'hours' 'prior'
 'to' 'receiving' 'the' 'first' 'dose' 'of' 'study' 'medication' ';' 'if'
 'the' 'urine' 'test' 'is' 'positive' 'or' 'can' 'not' 'be' 'confirmed'
 'as' 'negative' ',' 'a' 'serum' 'pregnancy' 'test' 'will' 'be' 'required']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02437370,",,,233:243:treatment,","Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication; subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year","['Female' 'subjects' 'of' 'childbearing' 'potential' 'should' 'be'
 'willing' 'to' 'use' '2' 'methods' 'of' 'birth' 'control' 'or' 'be'
 'surgically' 'sterile' ',' 'or' 'abstain' 'from' 'heterosexual'
 'activity' 'for' 'the' 'course' 'of' 'the' 'study' 'through' '120' 'days'
 'after' 'the' 'last' 'dose' 'of' 'study' 'medication' ';' 'subjects' 'of'
 'childbearing' 'potential' 'are' 'those' 'who' 'have' 'not' 'been'
 'surgically' 'sterilized' 'or' 'have' 'not' 'been' 'free' 'from' 'menses'
 'for' '>' '1' 'year']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02433977,138:148:treatment,"Any other condition and/or situation that causes the investigator to deem a subject unsuitable for the study (e.g. due to expected study medication non-compliance, inability to medically tolerate the study procedures, or a subject's unwillingness to comply with study-related procedures","['Any' 'other' 'condition' 'and/or' 'situation' 'that' 'causes' 'the'
 'investigator' 'to' 'deem' 'a' 'subject' 'unsuitable' 'for' 'the' 'study'
 '(' 'e.g' '.' 'due' 'to' 'expected' 'study' 'medication' 'non-compliance'
 ',' 'inability' 'to' 'medically' 'tolerate' 'the' 'study' 'procedures'
 ',' 'or' 'a' 'subject' ""'s"" 'unwillingness' 'to' 'comply' 'with'
 'study-related' 'procedures']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02427997,1:11:treatment,medication regime is likely to change during the course of the study,"['medication' 'regime' 'is' 'likely' 'to' 'change' 'during' 'the' 'course'
 'of' 'the' 'study']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02407171,",,131:141:treatment",childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication,"['childbearing' 'potential' 'should' 'have' 'a' 'negative' 'urine' 'or'
 'serum' 'pregnancy' 'within' '72' 'hours' 'prior' 'to' 'receiving' 'the'
 'first' 'dose' 'of' 'study' 'medication']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02391402,71:81:treatment,Participants could be reconsidered for eligibility after stability on medication was achieved,"['Participants' 'could' 'be' 'reconsidered' 'for' 'eligibility' 'after'
 'stability' 'on' 'medication' 'was' 'achieved']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.]
NCT02378714,",,171:181:treatment,",women of childbearing potential must agree to use a medically acceptable method of birth control or abstain from sexual intercourse during the time they are taking study medication and for at least one month after the medication period ends,"['women' 'of' 'childbearing' 'potential' 'must' 'agree' 'to' 'use' 'a'
 'medically' 'acceptable' 'method' 'of' 'birth' 'control' 'or' 'abstain'
 'from' 'sexual' 'intercourse' 'during' 'the' 'time' 'they' 'are' 'taking'
 'study' 'medication' 'and' 'for' 'at' 'least' 'one' 'month' 'after' 'the'
 'medication' 'period' 'ends']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02349867,19:29:treatment,Unable to swallow medication,['Unable' 'to' 'swallow' 'medication'],[0. 0. 0. 1.]
NCT02346201,3:13:treatment,"A medication for apathy is appropriate, in the opinion of the study physician","['A' 'medication' 'for' 'apathy' 'is' 'appropriate' ',' 'in' 'the'
 'opinion' 'of' 'the' 'study' 'physician']",[0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02340156,",,73:83:treatment",Have diastolic blood pressure of > 90 mm Hg resting at baseline despite medication,"['Have' 'diastolic' 'blood' 'pressure' 'of' '>' '90' 'mm' 'Hg' 'resting'
 'at' 'baseline' 'despite' 'medication']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02338999,67:77:treatment,"History of poor compliance with medical care, study visits and/or medication use","['History' 'of' 'poor' 'compliance' 'with' 'medical' 'care' ',' 'study'
 'visits' 'and/or' 'medication' 'use']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02332850,24:34:treatment,inability to take oral medication,['inability' 'to' 'take' 'oral' 'medication'],[0. 0. 0. 0. 1.]
NCT02332668,",110:120:treatment",abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication,"['abstain' 'from' 'heterosexual' 'activity' 'for' 'the' 'course' 'of'
 'the' 'study' 'through' '120' 'days' 'after' 'the' 'last' 'dose' 'of'
 'study' 'medication']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02332668,",60:70:treatment",within 72 hours prior to receiving the first dose of study medication,"['within' '72' 'hours' 'prior' 'to' 'receiving' 'the' 'first' 'dose' 'of'
 'study' 'medication']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02321501,",,,143:153:treatment,,",Negative serum or urine pregnancy test beta-Human Chorionic Gonadotropin (beta hCG) within 2 weeks prior to receiving the first dose of study medication for women of childbearing age,"['Negative' 'serum' 'or' 'urine' 'pregnancy' 'test' 'beta-Human'
 'Chorionic' 'Gonadotropin' '(' 'beta' 'hCG' ')' 'within' '2' 'weeks'
 'prior' 'to' 'receiving' 'the' 'first' 'dose' 'of' 'study' 'medication'
 'for' 'women' 'of' 'childbearing' 'age']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 0. 0. 0. 0. 0.]"
NCT02302976,20:30:treatment,current use of any medication (prescription or over-the-counter) determined to cause potential drug interactions by the study physicians,"['current' 'use' 'of' 'any' 'medication' '(' 'prescription' 'or'
 'over-the-counter' ')' 'determined' 'to' 'cause' 'potential' 'drug'
 'interactions' 'by' 'the' 'study' 'physicians']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02266004,8:18:treatment,Stable medication regimen,['Stable' 'medication' 'regimen'],[0. 1. 0.]
NCT02234934,53:63:treatment,Contraindication for administration of conditioning medication,"['Contraindication' 'for' 'administration' 'of' 'conditioning'
 'medication']",[0. 0. 0. 0. 0. 1.]
NCT02234934,54:64:treatment,patients with a correctable deficiency controlled on medication,"['patients' 'with' 'a' 'correctable' 'deficiency' 'controlled' 'on'
 'medication']",[0. 0. 0. 0. 0. 0. 0. 1.]
NCT02231073,19:29:treatment,Recent changes in medication,['Recent' 'changes' 'in' 'medication'],[0. 0. 0. 1.]
NCT02193490,",,94:104:treatment",negative urine pregnancy test is required within 14 days of receiving her first dose of test medication (placebo/ study drug) along with definite evidence of contraceptive use during the duration of the study,"['negative' 'urine' 'pregnancy' 'test' 'is' 'required' 'within' '14'
 'days' 'of' 'receiving' 'her' 'first' 'dose' 'of' 'test' 'medication' '('
 'placebo/' 'study' 'drug' ')' 'along' 'with' 'definite' 'evidence' 'of'
 'contraceptive' 'use' 'during' 'the' 'duration' 'of' 'the' 'study']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02178566,",,,125:135:treatment",Women of childbearing potential must use a reliable method of contraception from screening until 1 month after end of study medication,"['Women' 'of' 'childbearing' 'potential' 'must' 'use' 'a' 'reliable'
 'method' 'of' 'contraception' 'from' 'screening' 'until' '1' 'month'
 'after' 'end' 'of' 'study' 'medication']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02166905,40:50:treatment,The ability to swallow and retain oral medication,['The' 'ability' 'to' 'swallow' 'and' 'retain' 'oral' 'medication'],[0. 0. 0. 0. 0. 0. 0. 1.]
NCT02124772,98:108:treatment,Able to swallow and retain enterally (per oral [PO] or nasogastric or gastric tube) administered medication,"['Able' 'to' 'swallow' 'and' 'retain' 'enterally' '(' 'per' 'oral' '['
 'PO' ']' 'or' 'nasogastric' 'or' 'gastric' 'tube' ')' 'administered'
 'medication']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02070549,29:39:treatment,Current use of a prohibited medication,['Current' 'use' 'of' 'a' 'prohibited' 'medication'],[0. 0. 0. 0. 0. 1.]
NCT02044120,",,,191:201:treatment",Females of childbearing potential as well as males and their partners must agree to use an effective form of contraception during the study and for 6 months following the last dose of study medication,"['Females' 'of' 'childbearing' 'potential' 'as' 'well' 'as' 'males' 'and'
 'their' 'partners' 'must' 'agree' 'to' 'use' 'an' 'effective' 'form' 'of'
 'contraception' 'during' 'the' 'study' 'and' 'for' '6' 'months'
 'following' 'the' 'last' 'dose' 'of' 'study' 'medication']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02003222,64:74:treatment,"Patients must be considered reliable enough to comply with the medication regimen and follow-up, and have social support necessary to allow this compliance","['Patients' 'must' 'be' 'considered' 'reliable' 'enough' 'to' 'comply'
 'with' 'the' 'medication' 'regimen' 'and' 'follow-up' ',' 'and' 'have'
 'social' 'support' 'necessary' 'to' 'allow' 'this' 'compliance']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01954316,",,,194:204:treatment","Women and men of child producing potential must agree to use highly effective means of contraception during study participation, and for at least 30 days after the last administration of study medication","['Women' 'and' 'men' 'of' 'child' 'producing' 'potential' 'must' 'agree'
 'to' 'use' 'highly' 'effective' 'means' 'of' 'contraception' 'during'
 'study' 'participation' ',' 'and' 'for' 'at' 'least' '30' 'days' 'after'
 'the' 'last' 'administration' 'of' 'study' 'medication']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT01943851,",,,102:112:treatment",Female subjects must agree to use contraception until at least 7 months after the last dose of study medication,"['Female' 'subjects' 'must' 'agree' 'to' 'use' 'contraception' 'until'
 'at' 'least' '7' 'months' 'after' 'the' 'last' 'dose' 'of' 'study'
 'medication']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01943851,67:77:treatment,This method must be used from the time of the first dose of study medication until 16 weeks after the last dose of study medication,"['This' 'method' 'must' 'be' 'used' 'from' 'the' 'time' 'of' 'the' 'first'
 'dose' 'of' 'study' 'medication' 'until' '16' 'weeks' 'after' 'the'
 'last' 'dose' 'of' 'study' 'medication']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT01943851,",56:66:treatment",any subject who is expected to require a QT prolonging medication while on trial should not be enrolled,"['any' 'subject' 'who' 'is' 'expected' 'to' 'require' 'a' 'QT'
 'prolonging' 'medication' 'while' 'on' 'trial' 'should' 'not' 'be'
 'enrolled']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT01684397,36:46:treatment,Ability to swallow and retain oral medication,['Ability' 'to' 'swallow' 'and' 'retain' 'oral' 'medication'],[0. 0. 0. 0. 0. 0. 1.]
NCT01676753,",,,176:186:treatment",Female subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication,"['Female' 'subjects' 'of' 'childbearing' 'potential' 'must' 'be' 'willing'
 'to' 'use' 'an' 'adequate' 'method' 'of' 'contraception' 'for' 'the'
 'course' 'of' 'the' 'study' 'through' '120' 'days' 'after' 'the' 'last'
 'dose' 'of' 'study' 'medication']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1.]"
NCT01438073,17:27:treatment,no history of a medication reaction requiring emergency medical care,"['no' 'history' 'of' 'a' 'medication' 'reaction' 'requiring' 'emergency'
 'medical' 'care']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT00914823,17:27:treatment,no history of a medication reaction requiring emergency medical care,"['no' 'history' 'of' 'a' 'medication' 'reaction' 'requiring' 'emergency'
 'medical' 'care']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT00147056,",,23:33:treatment",diastolic BP > 100 on medication,['diastolic' 'BP' '>' '100' 'on' 'medication'],[0. 0. 0. 0. 0. 1.]
NCT02169739,"1:33:treatment,,112:120:chronic_disease",Diffusion-weighted imaging (DWI) lesion < 2.0cm in size at largest dimension and corresponding to the clinical syndrome,"['Diffusion-weighted' 'imaging' '(' 'DWI' ')' 'lesion' '<' '2.0cm' 'in'
 'size' 'at' 'largest' 'dimension' 'and' 'corresponding' 'to' 'the'
 'clinical' 'syndrome']",[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02110992,"1:8:treatment,12:24:treatment,",Surgery or chemotherapy within 4 weeks,['Surgery' 'or' 'chemotherapy' 'within' '4' 'weeks'],[1. 0. 1. 0. 0. 0.]
NCT03038620,1:8:treatment,Surgery scheduled for the trial duration period,['Surgery' 'scheduled' 'for' 'the' 'trial' 'duration' 'period'],[1. 0. 0. 0. 0. 0. 0.]
NCT02700178,1:8:treatment,Surgery,['Surgery'],[1.]
NCT02638454,"1:8:treatment,",Surgery in previous 6 months,['Surgery' 'in' 'previous' '6' 'months'],[1. 0. 0. 0. 0.]
NCT02606045,"1:8:treatment,",Surgery within the past 8 weeks,['Surgery' 'within' 'the' 'past' '8' 'weeks'],[1. 0. 0. 0. 0. 0.]
NCT02341235,"1:8:treatment,",Surgery in the past six months,['Surgery' 'in' 'the' 'past' 'six' 'months'],[1. 0. 0. 0. 0. 0.]
NCT02204098,1:8:treatment,Surgery,['Surgery'],[1.]
NCT02053792,1:8:treatment,Surgery substudy,['Surgery' 'substudy'],[1. 0.]
NCT01774019,"1:8:treatment,",Surgery intent within 4 weeks,['Surgery' 'intent' 'within' '4' 'weeks'],[1. 0. 0. 0. 0.]
NCT03181126,",73:85:treatment",Refractory is defined as persistent disease after at least 2 courses of chemotherapy,"['Refractory' 'is' 'defined' 'as' 'persistent' 'disease' 'after' 'at'
 'least' '2' 'courses' 'of' 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT03153410,"33:45:treatment,",Must have received last dose of chemotherapy at least 14 days or longer prior to entry into the study,"['Must' 'have' 'received' 'last' 'dose' 'of' 'chemotherapy' 'at' 'least'
 '14' 'days' 'or' 'longer' 'prior' 'to' 'entry' 'into' 'the' 'study']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03139227,",,47:59:treatment","Must be > 1 year from pregnancy, lactation or chemotherapy","['Must' 'be' '>' '1' 'year' 'from' 'pregnancy' ',' 'lactation' 'or'
 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT03088709,",78:90:treatment",Less than twenty-one days have elapsed since the subject's last radiation or chemotherapy prior to conditioning,"['Less' 'than' 'twenty-one' 'days' 'have' 'elapsed' 'since' 'the'
 'subject' ""'s"" 'last' 'radiation' 'or' 'chemotherapy' 'prior' 'to'
 'conditioning']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT03082612,42:54:treatment,Have completed surgery with no plans for chemotherapy,['Have' 'completed' 'surgery' 'with' 'no' 'plans' 'for' 'chemotherapy'],[0. 0. 0. 0. 0. 0. 0. 1.]
NCT03082612,46:58:treatment,Treatment plans to include weekly outpatient chemotherapy,['Treatment' 'plans' 'to' 'include' 'weekly' 'outpatient' 'chemotherapy'],[0. 0. 0. 0. 0. 0. 1.]
NCT03051321,8:20:treatment,Active chemotherapy,['Active' 'chemotherapy'],[0. 1.]
NCT03011684,19:31:treatment,Has not yet begun chemotherapy,['Has' 'not' 'yet' 'begun' 'chemotherapy'],[0. 0. 0. 0. 1.]
NCT02913430,29:41:treatment,More than one prior line of chemotherapy in the metastatic setting,"['More' 'than' 'one' 'prior' 'line' 'of' 'chemotherapy' 'in' 'the'
 'metastatic' 'setting']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02912572,33:45:treatment,patients who have only received chemotherapy in the adjuvant setting,"['patients' 'who' 'have' 'only' 'received' 'chemotherapy' 'in' 'the'
 'adjuvant' 'setting']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02862938,19:31:treatment,Participant is on chemotherapy,['Participant' 'is' 'on' 'chemotherapy'],[0. 0. 0. 1.]
NCT02793583,1:13:treatment,chemotherapy,['chemotherapy'],[1.]
NCT02774421,28:40:treatment,who have been treated with chemotherapy at time of recurrence,"['who' 'have' 'been' 'treated' 'with' 'chemotherapy' 'at' 'time' 'of'
 'recurrence']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02759146,12:24:treatment,Undergoing chemotherapy,['Undergoing' 'chemotherapy'],[0. 1.]
NCT02758847,1:13:treatment,chemotherapy,['chemotherapy'],[1.]
NCT02658565,23:35:treatment,Patients who received chemotherapy directed at the present disease,"['Patients' 'who' 'received' 'chemotherapy' 'directed' 'at' 'the'
 'present' 'disease']",[0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02639208,79:91:treatment,either in the context of standard treatment or a clinical trial and including chemotherapy,"['either' 'in' 'the' 'context' 'of' 'standard' 'treatment' 'or' 'a'
 'clinical' 'trial' 'and' 'including' 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02635360,1:13:treatment,chemotherapy,['chemotherapy'],[1.]
NCT02603757,29:41:treatment,Patients who do not undergo chemotherapy,['Patients' 'who' 'do' 'not' 'undergo' 'chemotherapy'],[0. 0. 0. 0. 0. 1.]
NCT02589938,11:23:treatment,Receiving chemotherapy during study period,['Receiving' 'chemotherapy' 'during' 'study' 'period'],[0. 1. 0. 0. 0.]
NCT02565498,9:21:treatment,Planned chemotherapy for (neo)adjuvant treatment,['Planned' 'chemotherapy' 'for' '(' 'neo' ')' 'adjuvant' 'treatment'],[0. 1. 0. 0. 0. 0. 0. 0.]
NCT02562716,",,,151:163:treatment",women/men of reproductive potential must have agreed to use an effective contraceptive method for up to 3 months after the final administered dose of chemotherapy,"['women/men' 'of' 'reproductive' 'potential' 'must' 'have' 'agreed' 'to'
 'use' 'an' 'effective' 'contraceptive' 'method' 'for' 'up' 'to' '3'
 'months' 'after' 'the' 'final' 'administered' 'dose' 'of' 'chemotherapy']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1.]"
NCT02536794,23:35:treatment,Patients who have had chemotherapy,['Patients' 'who' 'have' 'had' 'chemotherapy'],[0. 0. 0. 0. 1.]
NCT02536794,",36:48:treatment",have received at least one line of chemotherapy in the metastatic setting,"['have' 'received' 'at' 'least' 'one' 'line' 'of' 'chemotherapy' 'in'
 'the' 'metastatic' 'setting']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02492867,37:49:treatment,Patients cannot tolerate concurrent chemotherapy,['Patients' 'can' 'not' 'tolerate' 'concurrent' 'chemotherapy'],[0. 0. 0. 0. 0. 1.]
NCT02481765,66:78:treatment,"Intensive medical treatment means that the subject is undergoing chemotherapy for a hematologic/oncologic condition, is carrying a pacemaker or has been diagnosed with a cardiac anomaly which causes cardiac insufficiency not compensated with medications","['Intensive' 'medical' 'treatment' 'means' 'that' 'the' 'subject' 'is'
 'undergoing' 'chemotherapy' 'for' 'a' 'hematologic/oncologic' 'condition'
 ',' 'is' 'carrying' 'a' 'pacemaker' 'or' 'has' 'been' 'diagnosed' 'with'
 'a' 'cardiac' 'anomaly' 'which' 'causes' 'cardiac' 'insufficiency' 'not'
 'compensated' 'with' 'medications']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02427841,",,,,156:168:treatment,,,","Women of child-bearing potential and men must be willing to use adequate contraception during the entire study and for 8 weeks following completion of all chemotherapy on study; this includes hormonal or barrier method, or abstinence","['Women' 'of' 'child-bearing' 'potential' 'and' 'men' 'must' 'be'
 'willing' 'to' 'use' 'adequate' 'contraception' 'during' 'the' 'entire'
 'study' 'and' 'for' '8' 'weeks' 'following' 'completion' 'of' 'all'
 'chemotherapy' 'on' 'study' ';' 'this' 'includes' 'hormonal' 'or'
 'barrier' 'method' ',' 'or' 'abstinence']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02416206,",43:55:treatment",Within 9 months of the start of induction chemotherapy and no evidence of relapse or progression,"['Within' '9' 'months' 'of' 'the' 'start' 'of' 'induction' 'chemotherapy'
 'and' 'no' 'evidence' 'of' 'relapse' 'or' 'progression']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02359825,12:24:treatment,undergoing chemotherapy,['undergoing' 'chemotherapy'],[0. 1.]
NCT02320292,19:31:treatment,No indication for chemotherapy,['No' 'indication' 'for' 'chemotherapy'],[0. 0. 0. 1.]
NCT02315196,",81:93:treatment",imaging must have been performed no greater than 30 days prior to initiation of chemotherapy,"['imaging' 'must' 'have' 'been' 'performed' 'no' 'greater' 'than' '30'
 'days' 'prior' 'to' 'initiation' 'of' 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02309892,10:22:treatment,Previous chemotherapy,['Previous' 'chemotherapy'],[0. 1.]
NCT02308709,12:24:treatment,"Concurrent chemotherapy is allowed, but not required","['Concurrent' 'chemotherapy' 'is' 'allowed' ',' 'but' 'not' 'required']",[0. 1. 0. 0. 0. 0. 0. 0.]
NCT02303977,",41:53:treatment","Pregnant or breast-feeding patients, as chemotherapy is thought to present substantial risk to the fetus/infant","['Pregnant' 'or' 'breast-feeding' 'patients' ',' 'as' 'chemotherapy' 'is'
 'thought' 'to' 'present' 'substantial' 'risk' 'to' 'the' 'fetus/infant']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02227199,54:66:treatment,Patients must be anticipated to complete 2 cycles of chemotherapy,"['Patients' 'must' 'be' 'anticipated' 'to' 'complete' '2' 'cycles' 'of'
 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02203513,",147:159:treatment","Patients should have recurrent platinum-resistant, defined as disease recurrence by imaging within 6 months of the last receipt of platinum-based chemotherapy","['Patients' 'should' 'have' 'recurrent' 'platinum-resistant' ',' 'defined'
 'as' 'disease' 'recurrence' 'by' 'imaging' 'within' '6' 'months' 'of'
 'the' 'last' 'receipt' 'of' 'platinum-based' 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02159703,"7:19:treatment,",Prior chemotherapy within the past 5 years,['Prior' 'chemotherapy' 'within' 'the' 'past' '5' 'years'],[0. 1. 0. 0. 0. 0. 0.]
NCT02153229,",62:74:treatment",Subjects who have received more than 2 doses of neo-adjuvant chemotherapy,"['Subjects' 'who' 'have' 'received' 'more' 'than' '2' 'doses' 'of'
 'neo-adjuvant' 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02135588,",40:52:treatment",At least 2 days from administration of chemotherapy,['At' 'least' '2' 'days' 'from' 'administration' 'of' 'chemotherapy'],[0. 0. 0. 0. 0. 0. 0. 1.]
NCT02128906,",,53:65:treatment",Pregnant women are excluded from this study because chemotherapy,"['Pregnant' 'women' 'are' 'excluded' 'from' 'this' 'study' 'because'
 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02128906,24:36:treatment,breast feeding because chemotherapy,['breast' 'feeding' 'because' 'chemotherapy'],[0. 0. 0. 1.]
NCT02115295,74:86:treatment,Patient with documented hypersensitivity to any of the components of the chemotherapy program,"['Patient' 'with' 'documented' 'hypersensitivity' 'to' 'any' 'of' 'the'
 'components' 'of' 'the' 'chemotherapy' 'program']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02101736,"21:33:treatment,",No myelosuppressive chemotherapy within 4 weeks of study entry,"['No' 'myelosuppressive' 'chemotherapy' 'within' '4' 'weeks' 'of' 'study'
 'entry']",[0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT02099591,49:61:treatment,Patients currently receiving the first cycle of chemotherapy,"['Patients' 'currently' 'receiving' 'the' 'first' 'cycle' 'of'
 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 1.]
NCT02091999,1:13:treatment,chemotherapy,['chemotherapy'],[1.]
NCT02037048,",40:52:treatment",for 90 days following the last dose of chemotherapy,['for' '90' 'days' 'following' 'the' 'last' 'dose' 'of' 'chemotherapy'],[0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02031250,43:55:treatment,Patients must be able to receive protocol chemotherapy in the judgment of the treating Medical Oncologist,"['Patients' 'must' 'be' 'able' 'to' 'receive' 'protocol' 'chemotherapy'
 'in' 'the' 'judgment' 'of' 'the' 'treating' 'Medical' 'Oncologist']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01953900,53:65:treatment,Recovered from the acute toxic effects of all prior chemotherapy,"['Recovered' 'from' 'the' 'acute' 'toxic' 'effects' 'of' 'all' 'prior'
 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01928589,73:85:treatment,Patient must have a Medical Oncology consult with the recommendation of chemotherapy,"['Patient' 'must' 'have' 'a' 'Medical' 'Oncology' 'consult' 'with' 'the'
 'recommendation' 'of' 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01925573,58:70:treatment,6 weeks since the completion of a nitrosourea-containing chemotherapy regimen,"['6' 'weeks' 'since' 'the' 'completion' 'of' 'a' 'nitrosourea-containing'
 'chemotherapy' 'regimen']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT01919619,",,,,128:140:treatment,",diffusing capacity of the lung for carbon monoxide (DLCO) >= 40% within 3 months of study entry (or within 1 month if received chemotherapy within the past 3 months),"['diffusing' 'capacity' 'of' 'the' 'lung' 'for' 'carbon' 'monoxide' '('
 'DLCO' ')' '>' '=' '40' '%' 'within' '3' 'months' 'of' 'study' 'entry'
 '(' 'or' 'within' '1' 'month' 'if' 'received' 'chemotherapy' 'within'
 'the' 'past' '3' 'months' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]"
NCT01901562,"15:27:treatment,",Have received chemotherapy in the last 12 months,['Have' 'received' 'chemotherapy' 'in' 'the' 'last' '12' 'months'],[0. 0. 1. 0. 0. 0. 0. 0.]
NCT01896999,46:58:treatment,Patients must have relapsed after first line chemotherapy,['Patients' 'must' 'have' 'relapsed' 'after' 'first' 'line' 'chemotherapy'],[0. 0. 0. 0. 0. 0. 0. 1.]
NCT01871766,",189:201:treatment",Participants treated on this protocol in the low or intermediate risk arm who experience disease progression prior to week 13 will transfer to the high risk arm and proceed with high risk chemotherapy starting at week 1 of the protocol,"['Participants' 'treated' 'on' 'this' 'protocol' 'in' 'the' 'low' 'or'
 'intermediate' 'risk' 'arm' 'who' 'experience' 'disease' 'progression'
 'prior' 'to' 'week' '13' 'will' 'transfer' 'to' 'the' 'high' 'risk' 'arm'
 'and' 'proceed' 'with' 'high' 'risk' 'chemotherapy' 'starting' 'at'
 'week' '1' 'of' 'the' 'protocol']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]"
NCT01859819,13:25:treatment,No previous chemotherapy,['No' 'previous' 'chemotherapy'],[0. 0. 1.]
NCT01807091,",,,87:99:treatment",Treatment-related mortality (TRM) score < 9.21 corresponding to a TRM rate of 3% when chemotherapy of similar intensity as proposed here is administered to inpatients,"['Treatment-related' 'mortality' '(' 'TRM' ')' 'score' '<' '9.21'
 'corresponding' 'to' 'a' 'TRM' 'rate' 'of' '3' '%' 'when' 'chemotherapy'
 'of' 'similar' 'intensity' 'as' 'proposed' 'here' 'is' 'administered'
 'to' 'inpatients']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT01754298,1:13:treatment,chemotherapy treatment,['chemotherapy' 'treatment'],[1. 0.]
NCT01730794,37:49:treatment,Immunosuppressed patients receiving chemotherapy,['Immunosuppressed' 'patients' 'receiving' 'chemotherapy'],[0. 0. 0. 1.]
NCT01703949,",63:75:treatment",Patients must be anticipated to complete at least 2 cycles of chemotherapy on study,"['Patients' 'must' 'be' 'anticipated' 'to' 'complete' 'at' 'least' '2'
 'cycles' 'of' 'chemotherapy' 'on' 'study']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.]
NCT01690468,31:43:treatment,"At least one prior regimen of chemotherapy, with no maximum number of chemotherapy cycles","['At' 'least' 'one' 'prior' 'regimen' 'of' 'chemotherapy' ',' 'with' 'no'
 'maximum' 'number' 'of' 'chemotherapy' 'cycles']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01676259,1:13:treatment,chemotherapy,['chemotherapy'],[1.]
NCT01620216,105:117:treatment,certain agents that prolong the corrected QT interval may be allowed but only after discussion with the chemotherapy pharmacist,"['certain' 'agents' 'that' 'prolong' 'the' 'corrected' 'QT' 'interval'
 'may' 'be' 'allowed' 'but' 'only' 'after' 'discussion' 'with' 'the'
 'chemotherapy' 'pharmacist']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT01614990,38:50:treatment,subjects may otherwise be undergoing chemotherapy,['subjects' 'may' 'otherwise' 'be' 'undergoing' 'chemotherapy'],[0. 0. 0. 0. 0. 1.]
NCT01526603,"43:55:treatment,",Patients who are delayed in consolidation chemotherapy beyond 8 weeks,"['Patients' 'who' 'are' 'delayed' 'in' 'consolidation' 'chemotherapy'
 'beyond' '8' 'weeks']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT01526603,40:52:treatment,Recovery from last induction course of chemotherapy,['Recovery' 'from' 'last' 'induction' 'course' 'of' 'chemotherapy'],[0. 0. 0. 0. 0. 0. 1.]
NCT01515527,74:86:treatment,Patient with documented hypersensitivity to any of the components of the chemotherapy program,"['Patient' 'with' 'documented' 'hypersensitivity' 'to' 'any' 'of' 'the'
 'components' 'of' 'the' 'chemotherapy' 'program']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT01505569,48:60:treatment,Timing: Recovery from last induction course of chemotherapy,"['Timing' ':' 'Recovery' 'from' 'last' 'induction' 'course' 'of'
 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01434316,7:19:treatment,Prior chemotherapy,['Prior' 'chemotherapy'],[0. 1.]
NCT01238120,63:75:treatment,Patients with a neutropenic episode during the first cycle of chemotherapy or at high risk for a neutropenic episode during future chemotherapy cycles at the treating physicians discretion,"['Patients' 'with' 'a' 'neutropenic' 'episode' 'during' 'the' 'first'
 'cycle' 'of' 'chemotherapy' 'or' 'at' 'high' 'risk' 'for' 'a'
 'neutropenic' 'episode' 'during' 'future' 'chemotherapy' 'cycles' 'at'
 'the' 'treating' 'physicians' 'discretion']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT01061515,41:53:treatment,All patients must be consented prior to chemotherapy,['All' 'patients' 'must' 'be' 'consented' 'prior' 'to' 'chemotherapy'],[0. 0. 0. 0. 0. 0. 0. 1.]
NCT01061515,"53:65:treatment,,,,",Patients must have adequate renal function prior to chemotherapy defined as serum creatinine ≤ 2.0 mg/dl or creatinine clearance ≥60 ml.min/1.73 m² for patients with creatinine levels above 2.0 mg/dl,"['Patients' 'must' 'have' 'adequate' 'renal' 'function' 'prior' 'to'
 'chemotherapy' 'defined' 'as' 'serum' 'creatinine' '≤' '2.0' 'mg/dl' 'or'
 'creatinine' 'clearance' '≥60' 'ml.min/1.73' 'm²' 'for' 'patients' 'with'
 'creatinine' 'levels' 'above' '2.0' 'mg/dl']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT01061515,21:33:treatment,have received prior chemotherapy,['have' 'received' 'prior' 'chemotherapy'],[0. 0. 0. 1.]
NCT01061515,105:117:treatment,must undergo a peritoneal scan documenting at least one working intraperitoneal port prior to receiving chemotherapy,"['must' 'undergo' 'a' 'peritoneal' 'scan' 'documenting' 'at' 'least' 'one'
 'working' 'intraperitoneal' 'port' 'prior' 'to' 'receiving'
 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT00911560,",,178:190:treatment","stage 4 with (any age) or without (>18 months old) MYCN amplification, MYCN-amplified stage 3 (unresectable; any age), MYCN-amplified stage 4S, or disease resistant to standard chemotherapy","['stage' '4' 'with' '(' 'any' 'age' ')' 'or' 'without' '(' '>' '18'
 'months' 'old' ')' 'MYCN' 'amplification' ',' 'MYCN-amplified' 'stage'
 '3' '(' 'unresectable' ';' 'any' 'age' ')' ',' 'MYCN-amplified' 'stage'
 '4S' ',' 'or' 'disease' 'resistant' 'to' 'standard' 'chemotherapy']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT00902720,1:13:treatment,chemotherapy,['chemotherapy'],[1.]
NCT00819208,63:75:treatment,"patients who are pre-planned to receive a shorter duration of chemotherapy, including as part of a research study","['patients' 'who' 'are' 'pre-planned' 'to' 'receive' 'a' 'shorter'
 'duration' 'of' 'chemotherapy' ',' 'including' 'as' 'part' 'of' 'a'
 'research' 'study']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00719888,",,97:109:treatment",ligible with (M2 marrow) with =< 25% blasts in marrow after having failed one or more cycles of chemotherapy,"['ligible' 'with' '(' 'M2' 'marrow' ')' 'with' '=' '<' '25' '%' 'blasts'
 'in' 'marrow' 'after' 'having' 'failed' 'one' 'or' 'more' 'cycles' 'of'
 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT00719888,",81:93:treatment",patients persistently aplastic for greater than one month since completing last chemotherapy are also eligible with PI approval,"['patients' 'persistently' 'aplastic' 'for' 'greater' 'than' 'one' 'month'
 'since' 'completing' 'last' 'chemotherapy' 'are' 'also' 'eligible' 'with'
 'PI' 'approval']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT00632853,1:13:treatment,chemotherapy,['chemotherapy'],[1.]
NCT00632853,115:127:treatment,patients also must have met all of the eligibility criteria in the protocol prior to receiving the first cycle of chemotherapy,"['patients' 'also' 'must' 'have' 'met' 'all' 'of' 'the' 'eligibility'
 'criteria' 'in' 'the' 'protocol' 'prior' 'to' 'receiving' 'the' 'first'
 'cycle' 'of' 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT00501826,36:48:treatment,failure to one induction course of chemotherapy are eligible,"['failure' 'to' 'one' 'induction' 'course' 'of' 'chemotherapy' 'are'
 'eligible']",[0. 0. 0. 0. 0. 0. 1. 0. 0.]
NCT00492778,23:35:treatment,Patients who received chemotherapy directed at the present recurrence,"['Patients' 'who' 'received' 'chemotherapy' 'directed' 'at' 'the'
 'present' 'recurrence']",[0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT00107289,52:64:treatment,Three weeks should have elapsed since last dose of chemotherapy,"['Three' 'weeks' 'should' 'have' 'elapsed' 'since' 'last' 'dose' 'of'
 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT00896493,"14:38:chronic_disease,42:48:chronic_disease",Uncontrolled congestive heart failure or angina,['Uncontrolled' 'congestive' 'heart' 'failure' 'or' 'angina'],[0. 2. 2. 2. 0. 2.]
NCT03075761,1:25:chronic_disease,congestive heart failure,['congestive' 'heart' 'failure'],[2. 2. 2.]
NCT03060473,"8:32:chronic_disease,,",Active congestive heart failure (EF<45%),['Active' 'congestive' 'heart' 'failure' '(' 'EF' '<' '45' '%' ')'],[0. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT03035890,13:37:chronic_disease,symptomatic congestive heart failure,['symptomatic' 'congestive' 'heart' 'failure'],[0. 2. 2. 2.]
NCT03030859,1:25:chronic_disease,congestive heart failure,['congestive' 'heart' 'failure'],[2. 2. 2.]
NCT03028012,14:38:chronic_disease,Pre-existing congestive heart failure,['Pre-existing' 'congestive' 'heart' 'failure'],[0. 2. 2. 2.]
NCT03008408,"23:47:chronic_disease,,,",History of documented congestive heart failure (New York Heart Association functional classification III-IV),"['History' 'of' 'documented' 'congestive' 'heart' 'failure' '(' 'New'
 'York' 'Heart' 'Association' 'functional' 'classification' 'III-IV' ')']",[0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03007745,1:25:chronic_disease,congestive heart failure,['congestive' 'heart' 'failure'],[2. 2. 2.]
NCT02991651,13:37:chronic_disease,symptomatic congestive heart failure,['symptomatic' 'congestive' 'heart' 'failure'],[0. 2. 2. 2.]
NCT02986815,23:47:chronic_disease,NYHA class III and IV congestive heart failure,['NYHA' 'class' 'III' 'and' 'IV' 'congestive' 'heart' 'failure'],[0. 0. 0. 0. 0. 2. 2. 2.]
NCT02931110,",,,41:65:chronic_disease",New York Heart Association Class 3 or 4 congestive heart failure,"['New' 'York' 'Heart' 'Association' 'Class' '3' 'or' '4' 'congestive'
 'heart' 'failure']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT02908906,"13:37:chronic_disease,,,",symptomatic congestive heart failure (New York Heart Association class III-IV),"['symptomatic' 'congestive' 'heart' 'failure' '(' 'New' 'York' 'Heart'
 'Association' 'class' 'III-IV' ')']",[0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02807272,49:73:chronic_disease,New York Heart Association grade III or greater congestive heart failure,"['New' 'York' 'Heart' 'Association' 'grade' 'III' 'or' 'greater'
 'congestive' 'heart' 'failure']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT02793921,1:25:chronic_disease,congestive heart failure,['congestive' 'heart' 'failure'],[2. 2. 2.]
NCT02755116,54:78:chronic_disease,New York Heart Association (NYHA) Class II or higher congestive heart failure,"['New' 'York' 'Heart' 'Association' '(' 'NYHA' ')' 'Class' 'II' 'or'
 'higher' 'congestive' 'heart' 'failure']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT02694029,13:37:chronic_disease,symptomatic congestive heart failure,['symptomatic' 'congestive' 'heart' 'failure'],[0. 2. 2. 2.]
NCT02596776,1:25:chronic_disease,congestive heart failure,['congestive' 'heart' 'failure'],[2. 2. 2.]
NCT02595866,"1:25:chronic_disease,,,",congestive heart failure (New York Heart Association class III or IV),"['congestive' 'heart' 'failure' '(' 'New' 'York' 'Heart' 'Association'
 'class' 'III' 'or' 'IV' ')']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02583893,13:37:chronic_disease,symptomatic congestive heart failure,['symptomatic' 'congestive' 'heart' 'failure'],[0. 2. 2. 2.]
NCT02576301,13:37:chronic_disease,Symptomatic congestive heart failure,['Symptomatic' 'congestive' 'heart' 'failure'],[0. 2. 2. 2.]
NCT02567422,"13:37:chronic_disease,",Symptomatic congestive heart failure (requiring hospital stay within the last 6 months),"['Symptomatic' 'congestive' 'heart' 'failure' '(' 'requiring' 'hospital'
 'stay' 'within' 'the' 'last' '6' 'months' ')']",[0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02562755,"1:25:chronic_disease,",congestive heart failure within the preceding 12 months,['congestive' 'heart' 'failure' 'within' 'the' 'preceding' '12' 'months'],[2. 2. 2. 0. 0. 0. 0. 0.]
NCT02541903,1:25:chronic_disease,congestive heart failure New York Heart Association (NYHA) classification of 3,"['congestive' 'heart' 'failure' 'New' 'York' 'Heart' 'Association' '('
 'NYHA' ')' 'classification' 'of' '3']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02531932,"13:37:chronic_disease,,,",Symptomatic congestive heart failure of New York heart Association Class III or IV,"['Symptomatic' 'congestive' 'heart' 'failure' 'of' 'New' 'York' 'heart'
 'Association' 'Class' 'III' 'or' 'IV']",[0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02525861,"44:68:chronic_disease,,,",The participant has clinically significant congestive heart failure with New York Heart Association (NYHA) Class III/IV symptoms,"['The' 'participant' 'has' 'clinically' 'significant' 'congestive' 'heart'
 'failure' 'with' 'New' 'York' 'Heart' 'Association' '(' 'NYHA' ')'
 'Class' 'III/IV' 'symptoms']",[0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02489045,"28:52:chronic_disease,",Patients with uncontrolled congestive heart failure (NYHA Class IV),"['Patients' 'with' 'uncontrolled' 'congestive' 'heart' 'failure' '('
 'NYHA' 'Class' 'IV' ')']",[0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT02465060,"13:37:chronic_disease,,,",Symptomatic congestive heart failure (New York Heart Association [NYHA] classification of III/IV),"['Symptomatic' 'congestive' 'heart' 'failure' '(' 'New' 'York' 'Heart'
 'Association' '[' 'NYHA' ']' 'classification' 'of' 'III/IV' ')']",[0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02446236,29:53:chronic_disease,Uncontrolled or symptomatic congestive heart failure,['Uncontrolled' 'or' 'symptomatic' 'congestive' 'heart' 'failure'],[0. 0. 0. 2. 2. 2.]
NCT02442635,",,53:77:chronic_disease",Have New York Heart Association class II or greater congestive heart failure,"['Have' 'New' 'York' 'Heart' 'Association' 'class' 'II' 'or' 'greater'
 'congestive' 'heart' 'failure']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT02426476,1:25:chronic_disease,congestive heart failure,['congestive' 'heart' 'failure'],[2. 2. 2.]
NCT02417701,13:37:chronic_disease,symptomatic congestive heart failure,['symptomatic' 'congestive' 'heart' 'failure'],[0. 2. 2. 2.]
NCT02411773,"22:46:chronic_disease,,",Clinical evidence of congestive heart failure or ejection fraction below 35%,"['Clinical' 'evidence' 'of' 'congestive' 'heart' 'failure' 'or' 'ejection'
 'fraction' 'below' '35' '%']",[0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02405078,13:37:chronic_disease,Symptomatic congestive heart failure,['Symptomatic' 'congestive' 'heart' 'failure'],[0. 2. 2. 2.]
NCT02392572,"14:38:chronic_disease,,,",uncontrolled congestive heart failure (New York Heart Association class III and IV),"['uncontrolled' 'congestive' 'heart' 'failure' '(' 'New' 'York' 'Heart'
 'Association' 'class' 'III' 'and' 'IV' ')']",[0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02383927,",,27:51:chronic_disease",NYHA Grade III or greater congestive heart failure,['NYHA' 'Grade' 'III' 'or' 'greater' 'congestive' 'heart' 'failure'],[0. 0. 0. 0. 0. 2. 2. 2.]
NCT02353728,1:25:chronic_disease,congestive heart failure,['congestive' 'heart' 'failure'],[2. 2. 2.]
NCT02343549,",55:79:chronic_disease",New York Heart Association (NYHA) Grade II or greater congestive heart failure,"['New' 'York' 'Heart' 'Association' '(' 'NYHA' ')' 'Grade' 'II' 'or'
 'greater' 'congestive' 'heart' 'failure']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT02321501,"23:47:chronic_disease,,,",history of documented congestive heart failure (New York Heart Association functional classification III-IV),"['history' 'of' 'documented' 'congestive' 'heart' 'failure' '(' 'New'
 'York' 'Heart' 'Association' 'functional' 'classification' 'III-IV' ')']",[0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02314377,",,71:95:chronic_disease",Patients must not have New York Heart Association Grade II or greater congestive heart failure,"['Patients' 'must' 'not' 'have' 'New' 'York' 'Heart' 'Association' 'Grade'
 'II' 'or' 'greater' 'congestive' 'heart' 'failure']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT02272998,26:50:chronic_disease,Patients with history of congestive heart failure are excluded,"['Patients' 'with' 'history' 'of' 'congestive' 'heart' 'failure' 'are'
 'excluded']",[0. 0. 0. 0. 2. 2. 2. 0. 0.]
NCT02257424,",20:44:chronic_disease,",Current ≥ Class II congestive heart failure as defined by New York Heart Association,"['Current' '≥' 'Class' 'II' 'congestive' 'heart' 'failure' 'as' 'defined'
 'by' 'New' 'York' 'Heart' 'Association']",[0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02253316,",,,33:57:chronic_disease",uncompensated NYHA Class 3 or 4 congestive heart failure,"['uncompensated' 'NYHA' 'Class' '3' 'or' '4' 'congestive' 'heart'
 'failure']",[0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT02232516,13:37:chronic_disease,Symptomatic congestive heart failure,['Symptomatic' 'congestive' 'heart' 'failure'],[0. 2. 2. 2.]
NCT02227199,1:25:chronic_disease,congestive heart failure,['congestive' 'heart' 'failure'],[2. 2. 2.]
NCT02209636,"12:36:chronic_disease,,",History of congestive heart failure (EF < 35%),['History' 'of' 'congestive' 'heart' 'failure' '(' 'EF' '<' '35' '%' ')'],[0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02188745,1:25:chronic_disease,congestive heart failure,['congestive' 'heart' 'failure'],[2. 2. 2.]
NCT02152995,"44:68:chronic_disease,",History or evidence of current >= class II congestive heart failure as defined by the New York Heart Association (NYHA) functional classification system,"['History' 'or' 'evidence' 'of' 'current' '>' '=' 'class' 'II'
 'congestive' 'heart' 'failure' 'as' 'defined' 'by' 'the' 'New' 'York'
 'Heart' 'Association' '(' 'NYHA' ')' 'functional' 'classification'
 'system']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02143726,",,49:73:chronic_disease",New York Heart Association grade III or greater congestive heart failure,"['New' 'York' 'Heart' 'Association' 'grade' 'III' 'or' 'greater'
 'congestive' 'heart' 'failure']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT02128906,16:40:chronic_disease,no symptomatic congestive heart failure,['no' 'symptomatic' 'congestive' 'heart' 'failure'],[0. 0. 2. 2. 2.]
NCT02124772,"45:69:chronic_disease,",a history or evidence of current >=Class II congestive heart failure as defined by the New York Heart Association (NYHA) guidelines,"['a' 'history' 'or' 'evidence' 'of' 'current' '>' '=Class' 'II'
 'congestive' 'heart' 'failure' 'as' 'defined' 'by' 'the' 'New' 'York'
 'Heart' 'Association' '(' 'NYHA' ')' 'guidelines']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02106650,"1:25:chronic_disease,,,",congestive heart failure Class III/IV according to the New York Heart Association (NYHA) Functional Classification,"['congestive' 'heart' 'failure' 'Class' 'III/IV' 'according' 'to' 'the'
 'New' 'York' 'Heart' 'Association' '(' 'NYHA' ')' 'Functional'
 'Classification']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02094118,11:35:chronic_disease,Prevalent congestive heart failure prior to randomization,['Prevalent' 'congestive' 'heart' 'failure' 'prior' 'to' 'randomization'],[0. 2. 2. 2. 0. 0. 0.]
NCT02081404,",,,22:46:chronic_disease",NYHA class III or IV congestive heart failure,['NYHA' 'class' 'III' 'or' 'IV' 'congestive' 'heart' 'failure'],[0. 0. 0. 0. 0. 2. 2. 2.]
NCT02070549,",44:68:chronic_disease,",History or evidence of current >= class II congestive heart failure as defined by the New York Heart Association (NYHA) functional classification system,"['History' 'or' 'evidence' 'of' 'current' '>' '=' 'class' 'II'
 'congestive' 'heart' 'failure' 'as' 'defined' 'by' 'the' 'New' 'York'
 'Heart' 'Association' '(' 'NYHA' ')' 'functional' 'classification'
 'system']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02058095,34:58:chronic_disease,no clinical signs or symptoms of congestive heart failure,"['no' 'clinical' 'signs' 'or' 'symptoms' 'of' 'congestive' 'heart'
 'failure']",[0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT01989585,",44:68:chronic_disease,",History or evidence of current >= class II congestive heart failure as defined by the New York Heart Association (NYHA) functional classification system,"['History' 'or' 'evidence' 'of' 'current' '>' '=' 'class' 'II'
 'congestive' 'heart' 'failure' 'as' 'defined' 'by' 'the' 'New' 'York'
 'Heart' 'Association' '(' 'NYHA' ')' 'functional' 'classification'
 'system']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT01954316,"27:51:chronic_disease,,,",Have clinical symptomatic congestive heart failure defined at >= Class II of the New York Heart Association functional classification system or LVEF < 50% at baseline,"['Have' 'clinical' 'symptomatic' 'congestive' 'heart' 'failure' 'defined'
 'at' '>' '=' 'Class' 'II' 'of' 'the' 'New' 'York' 'Heart' 'Association'
 'functional' 'classification' 'system' 'or' 'LVEF' '<' '50' '%' 'at'
 'baseline']","[0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT01947673,22:46:chronic_disease,clinical evidence of congestive heart failure,['clinical' 'evidence' 'of' 'congestive' 'heart' 'failure'],[0. 0. 0. 2. 2. 2.]
NCT01943851,",43:67:chronic_disease",History or evidence of current >=Class II congestive heart failure as defined by New York Heart Association (NYHA),"['History' 'or' 'evidence' 'of' 'current' '>' '=Class' 'II' 'congestive'
 'heart' 'failure' 'as' 'defined' 'by' 'New' 'York' 'Heart' 'Association'
 '(' 'NYHA' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01919619,8:32:chronic_disease,Active congestive heart failure (New York Heart Association [NYHA] class III to IV),"['Active' 'congestive' 'heart' 'failure' '(' 'New' 'York' 'Heart'
 'Association' '[' 'NYHA' ']' 'class' 'III' 'to' 'IV' ')']",[0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01842399,7:31:chronic_disease,Known congestive heart failure now or in the past,['Known' 'congestive' 'heart' 'failure' 'now' 'or' 'in' 'the' 'past'],[0. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT01811368,14:38:chronic_disease,uncontrolled congestive heart failure,['uncontrolled' 'congestive' 'heart' 'failure'],[0. 2. 2. 2.]
NCT01750567,"12:36:chronic_disease,,,",History of congestive heart failure defined as NYHA class III or IV,"['History' 'of' 'congestive' 'heart' 'failure' 'defined' 'as' 'NYHA'
 'class' 'III' 'or' 'IV']",[0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT01670877,",122:146:chronic_disease","Testing for LVEF is not required for pre-registration, but patient must not have a recent LVEF < LLN or have symptoms of congestive heart failure","['Testing' 'for' 'LVEF' 'is' 'not' 'required' 'for' 'pre-registration' ','
 'but' 'patient' 'must' 'not' 'have' 'a' 'recent' 'LVEF' '<' 'LLN' 'or'
 'have' 'symptoms' 'of' 'congestive' 'heart' 'failure']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.
 2. 2.]"
NCT01568177,14:38:chronic_disease,uncontrolled congestive heart failure,['uncontrolled' 'congestive' 'heart' 'failure'],[0. 2. 2. 2.]
NCT01532687,",,17:41:chronic_disease,","Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA)","['Class' 'III' 'or' 'IV' 'congestive' 'heart' 'failure' ',' 'as' 'defined'
 'by' 'the' 'New' 'York' 'Heart' 'Association' '(' 'NYHA' ')']",[0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01526603,",,,,67:91:chronic_disease","shortening fraction ≥ 27% or ejection fraction ≥ 50%, no clinical congestive heart failure","['shortening' 'fraction' '≥' '27' '%' 'or' 'ejection' 'fraction' '≥' '50'
 '%' ',' 'no' 'clinical' 'congestive' 'heart' 'failure']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT01515527,13:37:chronic_disease,symptomatic congestive heart failure,['symptomatic' 'congestive' 'heart' 'failure'],[0. 2. 2. 2.]
NCT01430390,",,,51:75:chronic_disease",New York Heart Association (NYHA) stage III or IV congestive heart failure,"['New' 'York' 'Heart' 'Association' '(' 'NYHA' ')' 'stage' 'III' 'or' 'IV'
 'congestive' 'heart' 'failure']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT01306045,38:62:chronic_disease,"Ongoing or uncontrolled, symptomatic congestive heart failure (Class III or IV as defined by the NYHA functional classification system","['Ongoing' 'or' 'uncontrolled' ',' 'symptomatic' 'congestive' 'heart'
 'failure' '(' 'Class' 'III' 'or' 'IV' 'as' 'defined' 'by' 'the' 'NYHA'
 'functional' 'classification' 'system']",[0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01239160,14:38:chronic_disease,Diagnosis of congestive heart failure (uncontrolled),['Diagnosis' 'of' 'congestive' 'heart' 'failure' '(' 'uncontrolled' ')'],[0. 0. 2. 2. 2. 0. 0. 0.]
NCT00904046,12:36:chronic_disease,history of congestive heart failure NYHA class III or IV,"['history' 'of' 'congestive' 'heart' 'failure' 'NYHA' 'class' 'III' 'or'
 'IV']",[0. 0. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT00715611,10:34:chronic_disease,No acute congestive heart failure,['No' 'acute' 'congestive' 'heart' 'failure'],[0. 0. 2. 2. 2.]
NCT00540761,1:25:chronic_disease,congestive heart failure,['congestive' 'heart' 'failure'],[2. 2. 2.]
NCT00432094,15:39:chronic_disease,decompensated congestive heart failure,['decompensated' 'congestive' 'heart' 'failure'],[0. 2. 2. 2.]
NCT00075387,",114:138:chronic_disease",Subjects with uncontrolled (over the last 30 days) clinically significant confounding medical conditions such as congestive heart failure,"['Subjects' 'with' 'uncontrolled' '(' 'over' 'the' 'last' '30' 'days' ')'
 'clinically' 'significant' 'confounding' 'medical' 'conditions' 'such'
 'as' 'congestive' 'heart' 'failure']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT00065676,1:25:chronic_disease,congestive heart failure,['congestive' 'heart' 'failure'],[2. 2. 2.]
NCT00001379,12:36:chronic_disease,history of congestive heart failure will not be eligible to receive,"['history' 'of' 'congestive' 'heart' 'failure' 'will' 'not' 'be'
 'eligible' 'to' 'receive']",[0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02891850,"1:19:chronic_disease,21:56:chronic_disease","orthopedic disease, peripheral artery occlusive disease, which affects the patient's ability to walk","['orthopedic' 'disease' ',' 'peripheral' 'artery' 'occlusive' 'disease'
 ',' 'which' 'affects' 'the' 'patient' ""'s"" 'ability' 'to' 'walk']",[2. 2. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02388685,"1:12:treatment,16:36:treatment,",angioplasty or lumbar sympathectomy within 3 months of enrollment,"['angioplasty' 'or' 'lumbar' 'sympathectomy' 'within' '3' 'months' 'of'
 'enrollment']",[1. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02544880,"1:16:treatment,25:37:treatment",Prior radiation and any chemotherapy,['Prior' 'radiation' 'and' 'any' 'chemotherapy'],[1. 1. 0. 0. 1.]
NCT03181126,",73:85:treatment",Refractory is defined as persistent disease after at least 2 courses of chemotherapy,"['Refractory' 'is' 'defined' 'as' 'persistent' 'disease' 'after' 'at'
 'least' '2' 'courses' 'of' 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT03153410,"33:45:treatment,",Must have received last dose of chemotherapy at least 14 days or longer prior to entry into the study,"['Must' 'have' 'received' 'last' 'dose' 'of' 'chemotherapy' 'at' 'least'
 '14' 'days' 'or' 'longer' 'prior' 'to' 'entry' 'into' 'the' 'study']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03139227,",,47:59:treatment","Must be > 1 year from pregnancy, lactation or chemotherapy","['Must' 'be' '>' '1' 'year' 'from' 'pregnancy' ',' 'lactation' 'or'
 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT03088709,",78:90:treatment",Less than twenty-one days have elapsed since the subject's last radiation or chemotherapy prior to conditioning,"['Less' 'than' 'twenty-one' 'days' 'have' 'elapsed' 'since' 'the'
 'subject' ""'s"" 'last' 'radiation' 'or' 'chemotherapy' 'prior' 'to'
 'conditioning']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT03082612,42:54:treatment,Have completed surgery with no plans for chemotherapy,['Have' 'completed' 'surgery' 'with' 'no' 'plans' 'for' 'chemotherapy'],[0. 0. 0. 0. 0. 0. 0. 1.]
NCT03082612,46:58:treatment,Treatment plans to include weekly outpatient chemotherapy,['Treatment' 'plans' 'to' 'include' 'weekly' 'outpatient' 'chemotherapy'],[0. 0. 0. 0. 0. 0. 1.]
NCT03051321,8:20:treatment,Active chemotherapy,['Active' 'chemotherapy'],[0. 1.]
NCT03011684,19:31:treatment,Has not yet begun chemotherapy,['Has' 'not' 'yet' 'begun' 'chemotherapy'],[0. 0. 0. 0. 1.]
NCT02913430,29:41:treatment,More than one prior line of chemotherapy in the metastatic setting,"['More' 'than' 'one' 'prior' 'line' 'of' 'chemotherapy' 'in' 'the'
 'metastatic' 'setting']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02912572,33:45:treatment,patients who have only received chemotherapy in the adjuvant setting,"['patients' 'who' 'have' 'only' 'received' 'chemotherapy' 'in' 'the'
 'adjuvant' 'setting']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02862938,19:31:treatment,Participant is on chemotherapy,['Participant' 'is' 'on' 'chemotherapy'],[0. 0. 0. 1.]
NCT02793583,1:13:treatment,chemotherapy,['chemotherapy'],[1.]
NCT02774421,28:40:treatment,who have been treated with chemotherapy at time of recurrence,"['who' 'have' 'been' 'treated' 'with' 'chemotherapy' 'at' 'time' 'of'
 'recurrence']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02759146,12:24:treatment,Undergoing chemotherapy,['Undergoing' 'chemotherapy'],[0. 1.]
NCT02758847,1:13:treatment,chemotherapy,['chemotherapy'],[1.]
NCT02658565,23:35:treatment,Patients who received chemotherapy directed at the present disease,"['Patients' 'who' 'received' 'chemotherapy' 'directed' 'at' 'the'
 'present' 'disease']",[0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02639208,79:91:treatment,either in the context of standard treatment or a clinical trial and including chemotherapy,"['either' 'in' 'the' 'context' 'of' 'standard' 'treatment' 'or' 'a'
 'clinical' 'trial' 'and' 'including' 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02635360,1:13:treatment,chemotherapy,['chemotherapy'],[1.]
NCT02603757,29:41:treatment,Patients who do not undergo chemotherapy,['Patients' 'who' 'do' 'not' 'undergo' 'chemotherapy'],[0. 0. 0. 0. 0. 1.]
NCT02589938,11:23:treatment,Receiving chemotherapy during study period,['Receiving' 'chemotherapy' 'during' 'study' 'period'],[0. 1. 0. 0. 0.]
NCT02565498,9:21:treatment,Planned chemotherapy for (neo)adjuvant treatment,['Planned' 'chemotherapy' 'for' '(' 'neo' ')' 'adjuvant' 'treatment'],[0. 1. 0. 0. 0. 0. 0. 0.]
NCT02562716,",,,151:163:treatment",women/men of reproductive potential must have agreed to use an effective contraceptive method for up to 3 months after the final administered dose of chemotherapy,"['women/men' 'of' 'reproductive' 'potential' 'must' 'have' 'agreed' 'to'
 'use' 'an' 'effective' 'contraceptive' 'method' 'for' 'up' 'to' '3'
 'months' 'after' 'the' 'final' 'administered' 'dose' 'of' 'chemotherapy']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1.]"
NCT02536794,23:35:treatment,Patients who have had chemotherapy,['Patients' 'who' 'have' 'had' 'chemotherapy'],[0. 0. 0. 0. 1.]
NCT02536794,",36:48:treatment",have received at least one line of chemotherapy in the metastatic setting,"['have' 'received' 'at' 'least' 'one' 'line' 'of' 'chemotherapy' 'in'
 'the' 'metastatic' 'setting']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02492867,37:49:treatment,Patients cannot tolerate concurrent chemotherapy,['Patients' 'can' 'not' 'tolerate' 'concurrent' 'chemotherapy'],[0. 0. 0. 0. 0. 1.]
NCT02481765,66:78:treatment,"Intensive medical treatment means that the subject is undergoing chemotherapy for a hematologic/oncologic condition, is carrying a pacemaker or has been diagnosed with a cardiac anomaly which causes cardiac insufficiency not compensated with medications","['Intensive' 'medical' 'treatment' 'means' 'that' 'the' 'subject' 'is'
 'undergoing' 'chemotherapy' 'for' 'a' 'hematologic/oncologic' 'condition'
 ',' 'is' 'carrying' 'a' 'pacemaker' 'or' 'has' 'been' 'diagnosed' 'with'
 'a' 'cardiac' 'anomaly' 'which' 'causes' 'cardiac' 'insufficiency' 'not'
 'compensated' 'with' 'medications']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02427841,",,,,156:168:treatment,,,","Women of child-bearing potential and men must be willing to use adequate contraception during the entire study and for 8 weeks following completion of all chemotherapy on study; this includes hormonal or barrier method, or abstinence","['Women' 'of' 'child-bearing' 'potential' 'and' 'men' 'must' 'be'
 'willing' 'to' 'use' 'adequate' 'contraception' 'during' 'the' 'entire'
 'study' 'and' 'for' '8' 'weeks' 'following' 'completion' 'of' 'all'
 'chemotherapy' 'on' 'study' ';' 'this' 'includes' 'hormonal' 'or'
 'barrier' 'method' ',' 'or' 'abstinence']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02416206,",43:55:treatment",Within 9 months of the start of induction chemotherapy and no evidence of relapse or progression,"['Within' '9' 'months' 'of' 'the' 'start' 'of' 'induction' 'chemotherapy'
 'and' 'no' 'evidence' 'of' 'relapse' 'or' 'progression']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02359825,12:24:treatment,undergoing chemotherapy,['undergoing' 'chemotherapy'],[0. 1.]
NCT02320292,19:31:treatment,No indication for chemotherapy,['No' 'indication' 'for' 'chemotherapy'],[0. 0. 0. 1.]
NCT02315196,",81:93:treatment",imaging must have been performed no greater than 30 days prior to initiation of chemotherapy,"['imaging' 'must' 'have' 'been' 'performed' 'no' 'greater' 'than' '30'
 'days' 'prior' 'to' 'initiation' 'of' 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02309892,10:22:treatment,Previous chemotherapy,['Previous' 'chemotherapy'],[0. 1.]
NCT02308709,12:24:treatment,"Concurrent chemotherapy is allowed, but not required","['Concurrent' 'chemotherapy' 'is' 'allowed' ',' 'but' 'not' 'required']",[0. 1. 0. 0. 0. 0. 0. 0.]
NCT02303977,",41:53:treatment","Pregnant or breast-feeding patients, as chemotherapy is thought to present substantial risk to the fetus/infant","['Pregnant' 'or' 'breast-feeding' 'patients' ',' 'as' 'chemotherapy' 'is'
 'thought' 'to' 'present' 'substantial' 'risk' 'to' 'the' 'fetus/infant']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02227199,54:66:treatment,Patients must be anticipated to complete 2 cycles of chemotherapy,"['Patients' 'must' 'be' 'anticipated' 'to' 'complete' '2' 'cycles' 'of'
 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02203513,",147:159:treatment","Patients should have recurrent platinum-resistant, defined as disease recurrence by imaging within 6 months of the last receipt of platinum-based chemotherapy","['Patients' 'should' 'have' 'recurrent' 'platinum-resistant' ',' 'defined'
 'as' 'disease' 'recurrence' 'by' 'imaging' 'within' '6' 'months' 'of'
 'the' 'last' 'receipt' 'of' 'platinum-based' 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02159703,"7:19:treatment,",Prior chemotherapy within the past 5 years,['Prior' 'chemotherapy' 'within' 'the' 'past' '5' 'years'],[0. 1. 0. 0. 0. 0. 0.]
NCT02153229,",62:74:treatment",Subjects who have received more than 2 doses of neo-adjuvant chemotherapy,"['Subjects' 'who' 'have' 'received' 'more' 'than' '2' 'doses' 'of'
 'neo-adjuvant' 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02135588,",40:52:treatment",At least 2 days from administration of chemotherapy,['At' 'least' '2' 'days' 'from' 'administration' 'of' 'chemotherapy'],[0. 0. 0. 0. 0. 0. 0. 1.]
NCT02128906,",,53:65:treatment",Pregnant women are excluded from this study because chemotherapy,"['Pregnant' 'women' 'are' 'excluded' 'from' 'this' 'study' 'because'
 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02128906,24:36:treatment,breast feeding because chemotherapy,['breast' 'feeding' 'because' 'chemotherapy'],[0. 0. 0. 1.]
NCT02115295,74:86:treatment,Patient with documented hypersensitivity to any of the components of the chemotherapy program,"['Patient' 'with' 'documented' 'hypersensitivity' 'to' 'any' 'of' 'the'
 'components' 'of' 'the' 'chemotherapy' 'program']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02101736,"21:33:treatment,",No myelosuppressive chemotherapy within 4 weeks of study entry,"['No' 'myelosuppressive' 'chemotherapy' 'within' '4' 'weeks' 'of' 'study'
 'entry']",[0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT02099591,49:61:treatment,Patients currently receiving the first cycle of chemotherapy,"['Patients' 'currently' 'receiving' 'the' 'first' 'cycle' 'of'
 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 1.]
NCT02091999,1:13:treatment,chemotherapy,['chemotherapy'],[1.]
NCT02037048,",40:52:treatment",for 90 days following the last dose of chemotherapy,['for' '90' 'days' 'following' 'the' 'last' 'dose' 'of' 'chemotherapy'],[0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02031250,43:55:treatment,Patients must be able to receive protocol chemotherapy in the judgment of the treating Medical Oncologist,"['Patients' 'must' 'be' 'able' 'to' 'receive' 'protocol' 'chemotherapy'
 'in' 'the' 'judgment' 'of' 'the' 'treating' 'Medical' 'Oncologist']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01953900,53:65:treatment,Recovered from the acute toxic effects of all prior chemotherapy,"['Recovered' 'from' 'the' 'acute' 'toxic' 'effects' 'of' 'all' 'prior'
 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01928589,73:85:treatment,Patient must have a Medical Oncology consult with the recommendation of chemotherapy,"['Patient' 'must' 'have' 'a' 'Medical' 'Oncology' 'consult' 'with' 'the'
 'recommendation' 'of' 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01925573,58:70:treatment,6 weeks since the completion of a nitrosourea-containing chemotherapy regimen,"['6' 'weeks' 'since' 'the' 'completion' 'of' 'a' 'nitrosourea-containing'
 'chemotherapy' 'regimen']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT01919619,",,,,128:140:treatment,",diffusing capacity of the lung for carbon monoxide (DLCO) >= 40% within 3 months of study entry (or within 1 month if received chemotherapy within the past 3 months),"['diffusing' 'capacity' 'of' 'the' 'lung' 'for' 'carbon' 'monoxide' '('
 'DLCO' ')' '>' '=' '40' '%' 'within' '3' 'months' 'of' 'study' 'entry'
 '(' 'or' 'within' '1' 'month' 'if' 'received' 'chemotherapy' 'within'
 'the' 'past' '3' 'months' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]"
NCT01901562,"15:27:treatment,",Have received chemotherapy in the last 12 months,['Have' 'received' 'chemotherapy' 'in' 'the' 'last' '12' 'months'],[0. 0. 1. 0. 0. 0. 0. 0.]
NCT01896999,46:58:treatment,Patients must have relapsed after first line chemotherapy,['Patients' 'must' 'have' 'relapsed' 'after' 'first' 'line' 'chemotherapy'],[0. 0. 0. 0. 0. 0. 0. 1.]
NCT01871766,",189:201:treatment",Participants treated on this protocol in the low or intermediate risk arm who experience disease progression prior to week 13 will transfer to the high risk arm and proceed with high risk chemotherapy starting at week 1 of the protocol,"['Participants' 'treated' 'on' 'this' 'protocol' 'in' 'the' 'low' 'or'
 'intermediate' 'risk' 'arm' 'who' 'experience' 'disease' 'progression'
 'prior' 'to' 'week' '13' 'will' 'transfer' 'to' 'the' 'high' 'risk' 'arm'
 'and' 'proceed' 'with' 'high' 'risk' 'chemotherapy' 'starting' 'at'
 'week' '1' 'of' 'the' 'protocol']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]"
NCT01859819,13:25:treatment,No previous chemotherapy,['No' 'previous' 'chemotherapy'],[0. 0. 1.]
NCT01807091,",,,87:99:treatment",Treatment-related mortality (TRM) score < 9.21 corresponding to a TRM rate of 3% when chemotherapy of similar intensity as proposed here is administered to inpatients,"['Treatment-related' 'mortality' '(' 'TRM' ')' 'score' '<' '9.21'
 'corresponding' 'to' 'a' 'TRM' 'rate' 'of' '3' '%' 'when' 'chemotherapy'
 'of' 'similar' 'intensity' 'as' 'proposed' 'here' 'is' 'administered'
 'to' 'inpatients']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT01754298,1:13:treatment,chemotherapy treatment,['chemotherapy' 'treatment'],[1. 0.]
NCT01730794,37:49:treatment,Immunosuppressed patients receiving chemotherapy,['Immunosuppressed' 'patients' 'receiving' 'chemotherapy'],[0. 0. 0. 1.]
NCT01703949,",63:75:treatment",Patients must be anticipated to complete at least 2 cycles of chemotherapy on study,"['Patients' 'must' 'be' 'anticipated' 'to' 'complete' 'at' 'least' '2'
 'cycles' 'of' 'chemotherapy' 'on' 'study']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.]
NCT01690468,31:43:treatment,"At least one prior regimen of chemotherapy, with no maximum number of chemotherapy cycles","['At' 'least' 'one' 'prior' 'regimen' 'of' 'chemotherapy' ',' 'with' 'no'
 'maximum' 'number' 'of' 'chemotherapy' 'cycles']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01676259,1:13:treatment,chemotherapy,['chemotherapy'],[1.]
NCT01620216,105:117:treatment,certain agents that prolong the corrected QT interval may be allowed but only after discussion with the chemotherapy pharmacist,"['certain' 'agents' 'that' 'prolong' 'the' 'corrected' 'QT' 'interval'
 'may' 'be' 'allowed' 'but' 'only' 'after' 'discussion' 'with' 'the'
 'chemotherapy' 'pharmacist']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT01614990,38:50:treatment,subjects may otherwise be undergoing chemotherapy,['subjects' 'may' 'otherwise' 'be' 'undergoing' 'chemotherapy'],[0. 0. 0. 0. 0. 1.]
NCT01526603,"43:55:treatment,",Patients who are delayed in consolidation chemotherapy beyond 8 weeks,"['Patients' 'who' 'are' 'delayed' 'in' 'consolidation' 'chemotherapy'
 'beyond' '8' 'weeks']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT01526603,40:52:treatment,Recovery from last induction course of chemotherapy,['Recovery' 'from' 'last' 'induction' 'course' 'of' 'chemotherapy'],[0. 0. 0. 0. 0. 0. 1.]
NCT01515527,74:86:treatment,Patient with documented hypersensitivity to any of the components of the chemotherapy program,"['Patient' 'with' 'documented' 'hypersensitivity' 'to' 'any' 'of' 'the'
 'components' 'of' 'the' 'chemotherapy' 'program']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT01505569,48:60:treatment,Timing: Recovery from last induction course of chemotherapy,"['Timing' ':' 'Recovery' 'from' 'last' 'induction' 'course' 'of'
 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01434316,7:19:treatment,Prior chemotherapy,['Prior' 'chemotherapy'],[0. 1.]
NCT01238120,63:75:treatment,Patients with a neutropenic episode during the first cycle of chemotherapy or at high risk for a neutropenic episode during future chemotherapy cycles at the treating physicians discretion,"['Patients' 'with' 'a' 'neutropenic' 'episode' 'during' 'the' 'first'
 'cycle' 'of' 'chemotherapy' 'or' 'at' 'high' 'risk' 'for' 'a'
 'neutropenic' 'episode' 'during' 'future' 'chemotherapy' 'cycles' 'at'
 'the' 'treating' 'physicians' 'discretion']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT01061515,41:53:treatment,All patients must be consented prior to chemotherapy,['All' 'patients' 'must' 'be' 'consented' 'prior' 'to' 'chemotherapy'],[0. 0. 0. 0. 0. 0. 0. 1.]
NCT01061515,"53:65:treatment,,,,",Patients must have adequate renal function prior to chemotherapy defined as serum creatinine ≤ 2.0 mg/dl or creatinine clearance ≥60 ml.min/1.73 m² for patients with creatinine levels above 2.0 mg/dl,"['Patients' 'must' 'have' 'adequate' 'renal' 'function' 'prior' 'to'
 'chemotherapy' 'defined' 'as' 'serum' 'creatinine' '≤' '2.0' 'mg/dl' 'or'
 'creatinine' 'clearance' '≥60' 'ml.min/1.73' 'm²' 'for' 'patients' 'with'
 'creatinine' 'levels' 'above' '2.0' 'mg/dl']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT01061515,21:33:treatment,have received prior chemotherapy,['have' 'received' 'prior' 'chemotherapy'],[0. 0. 0. 1.]
NCT01061515,105:117:treatment,must undergo a peritoneal scan documenting at least one working intraperitoneal port prior to receiving chemotherapy,"['must' 'undergo' 'a' 'peritoneal' 'scan' 'documenting' 'at' 'least' 'one'
 'working' 'intraperitoneal' 'port' 'prior' 'to' 'receiving'
 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT00911560,",,178:190:treatment","stage 4 with (any age) or without (>18 months old) MYCN amplification, MYCN-amplified stage 3 (unresectable; any age), MYCN-amplified stage 4S, or disease resistant to standard chemotherapy","['stage' '4' 'with' '(' 'any' 'age' ')' 'or' 'without' '(' '>' '18'
 'months' 'old' ')' 'MYCN' 'amplification' ',' 'MYCN-amplified' 'stage'
 '3' '(' 'unresectable' ';' 'any' 'age' ')' ',' 'MYCN-amplified' 'stage'
 '4S' ',' 'or' 'disease' 'resistant' 'to' 'standard' 'chemotherapy']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT00902720,1:13:treatment,chemotherapy,['chemotherapy'],[1.]
NCT00819208,63:75:treatment,"patients who are pre-planned to receive a shorter duration of chemotherapy, including as part of a research study","['patients' 'who' 'are' 'pre-planned' 'to' 'receive' 'a' 'shorter'
 'duration' 'of' 'chemotherapy' ',' 'including' 'as' 'part' 'of' 'a'
 'research' 'study']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00719888,",,97:109:treatment",ligible with (M2 marrow) with =< 25% blasts in marrow after having failed one or more cycles of chemotherapy,"['ligible' 'with' '(' 'M2' 'marrow' ')' 'with' '=' '<' '25' '%' 'blasts'
 'in' 'marrow' 'after' 'having' 'failed' 'one' 'or' 'more' 'cycles' 'of'
 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT00719888,",81:93:treatment",patients persistently aplastic for greater than one month since completing last chemotherapy are also eligible with PI approval,"['patients' 'persistently' 'aplastic' 'for' 'greater' 'than' 'one' 'month'
 'since' 'completing' 'last' 'chemotherapy' 'are' 'also' 'eligible' 'with'
 'PI' 'approval']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT00632853,1:13:treatment,chemotherapy,['chemotherapy'],[1.]
NCT00632853,115:127:treatment,patients also must have met all of the eligibility criteria in the protocol prior to receiving the first cycle of chemotherapy,"['patients' 'also' 'must' 'have' 'met' 'all' 'of' 'the' 'eligibility'
 'criteria' 'in' 'the' 'protocol' 'prior' 'to' 'receiving' 'the' 'first'
 'cycle' 'of' 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT00501826,36:48:treatment,failure to one induction course of chemotherapy are eligible,"['failure' 'to' 'one' 'induction' 'course' 'of' 'chemotherapy' 'are'
 'eligible']",[0. 0. 0. 0. 0. 0. 1. 0. 0.]
NCT00492778,23:35:treatment,Patients who received chemotherapy directed at the present recurrence,"['Patients' 'who' 'received' 'chemotherapy' 'directed' 'at' 'the'
 'present' 'recurrence']",[0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT00107289,52:64:treatment,Three weeks should have elapsed since last dose of chemotherapy,"['Three' 'weeks' 'should' 'have' 'elapsed' 'since' 'last' 'dose' 'of'
 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT03171493,",,98:107:treatment",Men or women of childbearing potential who are unwilling to employ adequate contraception during treatment and 8 weeks following the completion of study drug treatment,"['Men' 'or' 'women' 'of' 'childbearing' 'potential' 'who' 'are'
 'unwilling' 'to' 'employ' 'adequate' 'contraception' 'during' 'treatment'
 'and' '8' 'weeks' 'following' 'the' 'completion' 'of' 'study' 'drug'
 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT03158974,",,102:111:treatment,","If female of childbearing potential, must have a negative urine pregnancy test result prior to study treatment and must be willing to use a barrier method of birth control while enrolled in the study","['If' 'female' 'of' 'childbearing' 'potential' ',' 'must' 'have' 'a'
 'negative' 'urine' 'pregnancy' 'test' 'result' 'prior' 'to' 'study'
 'treatment' 'and' 'must' 'be' 'willing' 'to' 'use' 'a' 'barrier' 'method'
 'of' 'birth' 'control' 'while' 'enrolled' 'in' 'the' 'study']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03158974,"14:23:treatment,,",Received any treatment for their EGW within 60 days of planned study enrollment,"['Received' 'any' 'treatment' 'for' 'their' 'EGW' 'within' '60' 'days'
 'of' 'planned' 'study' 'enrollment']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03154567,144:153:treatment,Candidates must meet DSM-5 criteria for Mild-to-Moderate Cannabis Use Disorder (CUD) and be willing to participate in research but not seeking treatment,"['Candidates' 'must' 'meet' 'DSM-5' 'criteria' 'for' 'Mild-to-Moderate'
 'Cannabis' 'Use' 'Disorder' '(' 'CUD' ')' 'and' 'be' 'willing' 'to'
 'participate' 'in' 'research' 'but' 'not' 'seeking' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT03153982,86:95:treatment,"Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious) illness","['Prisoners' 'or' 'subjects' 'who' 'are' 'compulsorily' 'detained' '('
 'involuntarily' 'incarcerated' ')' 'for' 'treatment' 'of' 'either' 'a'
 'psychiatric' 'or' 'physical' '(' 'e.g.' ',' 'infectious' ')' 'illness']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT03137771,",,133:142:treatment,",willing and able to use medically acceptable forms of contraception during the trial and for up to 180 days after completion of all treatment to prevent pregnancy or fathering a child,"['willing' 'and' 'able' 'to' 'use' 'medically' 'acceptable' 'forms' 'of'
 'contraception' 'during' 'the' 'trial' 'and' 'for' 'up' 'to' '180' 'days'
 'after' 'completion' 'of' 'all' 'treatment' 'to' 'prevent' 'pregnancy'
 'or' 'fathering' 'a' 'child']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 0. 0. 0. 0. 0. 0. 0.]"
NCT03127826,19:28:treatment,Already receiving treatment (other than primary care) for this episode of LBP,"['Already' 'receiving' 'treatment' '(' 'other' 'than' 'primary' 'care' ')'
 'for' 'this' 'episode' 'of' 'LBP']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03115398,",65:74:treatment,",Agree to utilize an adequate method of contraception throughout treatment and for at least 4 weeks after study therapy is completed,"['Agree' 'to' 'utilize' 'an' 'adequate' 'method' 'of' 'contraception'
 'throughout' 'treatment' 'and' 'for' 'at' 'least' '4' 'weeks' 'after'
 'study' 'therapy' 'is' 'completed']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03085784,",,,131:140:treatment,","Sexually active men* or women of childbearing potential** who are unwilling to practice adequate contraception start of the first treatment, during the study, and for at least 3 months after the last dose","['Sexually' 'active' 'men' '*' 'or' 'women' 'of' 'childbearing'
 'potential' '*' '*' 'who' 'are' 'unwilling' 'to' 'practice' 'adequate'
 'contraception' 'start' 'of' 'the' 'first' 'treatment' ',' 'during' 'the'
 'study' ',' 'and' 'for' 'at' 'least' '3' 'months' 'after' 'the' 'last'
 'dose']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03077243,",61:70:treatment",Adequate renal and hepatic function within 4 weeks prior to treatment,"['Adequate' 'renal' 'and' 'hepatic' 'function' 'within' '4' 'weeks'
 'prior' 'to' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT03077243,",,51:60:treatment","CBC/differential obtained within 8 weeks prior to treatment, with adequate bone marrow","['CBC/differential' 'obtained' 'within' '8' 'weeks' 'prior' 'to'
 'treatment' ',' 'with' 'adequate' 'bone' 'marrow']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT03070899,",49:58:treatment",planning a pregnancy within the duration of the treatment period of the study,"['planning' 'a' 'pregnancy' 'within' 'the' 'duration' 'of' 'the'
 'treatment' 'period' 'of' 'the' 'study']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT03045341,35:44:treatment,Available for the duration of the treatment and follow-up (20 months),"['Available' 'for' 'the' 'duration' 'of' 'the' 'treatment' 'and'
 'follow-up' '(' '20' 'months' ')']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT03042689,24:33:treatment,Previous assignment to treatment during this study,['Previous' 'assignment' 'to' 'treatment' 'during' 'this' 'study'],[0. 0. 0. 1. 0. 0. 0.]
NCT03033212,",42:51:treatment",Failed at least 3 months of conservative treatment,['Failed' 'at' 'least' '3' 'months' 'of' 'conservative' 'treatment'],[0. 0. 0. 0. 0. 0. 0. 1.]
NCT03025828,",26:35:treatment",More than three previous treatment regiments,['More' 'than' 'three' 'previous' 'treatment' 'regiments'],[0. 0. 0. 0. 1. 0.]
NCT03013543,44:53:treatment,"Patient completes the initial ~3 months of treatment period without evidence of severe or clinically relevant adverse events, changes in vital signs, or changes in safety laboratories or ECGs","['Patient' 'completes' 'the' 'initial' '~3' 'months' 'of' 'treatment'
 'period' 'without' 'evidence' 'of' 'severe' 'or' 'clinically' 'relevant'
 'adverse' 'events' ',' 'changes' 'in' 'vital' 'signs' ',' 'or' 'changes'
 'in' 'safety' 'laboratories' 'or' 'ECGs']","[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02932280,",,87:96:treatment,",Male patients must agree and commit to use a barrier method of contraception while on treatment and for 3 months after the last dose of the investigational product,"['Male' 'patients' 'must' 'agree' 'and' 'commit' 'to' 'use' 'a' 'barrier'
 'method' 'of' 'contraception' 'while' 'on' 'treatment' 'and' 'for' '3'
 'months' 'after' 'the' 'last' 'dose' 'of' 'the' 'investigational'
 'product']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02907944,108:117:treatment,"Meets criteria for lifetime or current tobacco, alcohol and/or opioid use disorder regardless of addiction treatment status","['Meets' 'criteria' 'for' 'lifetime' 'or' 'current' 'tobacco' ','
 'alcohol' 'and/or' 'opioid' 'use' 'disorder' 'regardless' 'of'
 'addiction' 'treatment' 'status']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02863991,",,,82:91:treatment","Absolute neutrophil count ≥1,000/mm3 without growth factor use ≤ 7 days prior to treatment (cycle 1 day 1, C1D1)","['Absolute' 'neutrophil' 'count' '≥1,000/mm3' 'without' 'growth' 'factor'
 'use' '≤' '7' 'days' 'prior' 'to' 'treatment' '(' 'cycle' '1' 'day' '1'
 ',' 'C1D1' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02863991,",,,187:196:treatment","Female patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of the trial and for at least 90 days after completion of treatment","['Female' 'patients' 'must' 'be' 'surgically' 'sterile' 'or' 'be'
 'postmenopausal' ',' 'or' 'must' 'agree' 'to' 'use' 'effective'
 'contraception' 'during' 'the' 'period' 'of' 'the' 'trial' 'and' 'for'
 'at' 'least' '90' 'days' 'after' 'completion' 'of' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02836574,"8:17:treatment,,",Stable treatment is defined as dose adjustment to no less than one half of the current dosage or to no more than 2 times the current dosage,"['Stable' 'treatment' 'is' 'defined' 'as' 'dose' 'adjustment' 'to' 'no'
 'less' 'than' 'one' 'half' 'of' 'the' 'current' 'dosage' 'or' 'to' 'no'
 'more' 'than' '2' 'times' 'the' 'current' 'dosage']","[0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02799095,",,,101:110:treatment",Females of childbearing potential must have a negative pregnancy test within 7 days of the start of treatment and on Day 1 before the first dose is administered,"['Females' 'of' 'childbearing' 'potential' 'must' 'have' 'a' 'negative'
 'pregnancy' 'test' 'within' '7' 'days' 'of' 'the' 'start' 'of'
 'treatment' 'and' 'on' 'Day' '1' 'before' 'the' 'first' 'dose' 'is'
 'administered']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02780401,"59:68:treatment,",History of autoimmunity that has not been controlled with treatment in the last 12 months,"['History' 'of' 'autoimmunity' 'that' 'has' 'not' 'been' 'controlled'
 'with' 'treatment' 'in' 'the' 'last' '12' 'months']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02762266,",,37:46:treatment",with score =< 9 ((within 4 weeks of treatment),"['with' 'score' '=' '<' '9' '(' '(' 'within' '4' 'weeks' 'of' 'treatment'
 ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02753283,62:71:treatment,Those with a history of hypocalcemia or contraindication for treatment,"['Those' 'with' 'a' 'history' 'of' 'hypocalcemia' 'or' 'contraindication'
 'for' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02725177,",,,,,,,,,,,326:335:treatment","Women of childbearing potential must be using adequate birth control measures (abstinence, hormonal contraceptives, intrauterine device, barrier method with spermicide, or surgical sterilization) and must agree to continue such precautions, and not become pregnant or plan a pregnancy for 6 months after receiving their last treatment with study agent","['Women' 'of' 'childbearing' 'potential' 'must' 'be' 'using' 'adequate'
 'birth' 'control' 'measures' '(' 'abstinence' ',' 'hormonal'
 'contraceptives' ',' 'intrauterine' 'device' ',' 'barrier' 'method'
 'with' 'spermicide' ',' 'or' 'surgical' 'sterilization' ')' 'and' 'must'
 'agree' 'to' 'continue' 'such' 'precautions' ',' 'and' 'not' 'become'
 'pregnant' 'or' 'plan' 'a' 'pregnancy' 'for' '6' 'months' 'after'
 'receiving' 'their' 'last' 'treatment' 'with' 'study' 'agent']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 0. 0. 0.]"
NCT02656706,",,122:131:treatment",must agree to use adequate barrier birth control measures during the course of the study and up to 2 months after end of treatment,"['must' 'agree' 'to' 'use' 'adequate' 'barrier' 'birth' 'control'
 'measures' 'during' 'the' 'course' 'of' 'the' 'study' 'and' 'up' 'to' '2'
 'months' 'after' 'end' 'of' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02654236,",,93:102:treatment",Women of child bearing potential should be willing to practice contraception throughout the treatment period,"['Women' 'of' 'child' 'bearing' 'potential' 'should' 'be' 'willing' 'to'
 'practice' 'contraception' 'throughout' 'the' 'treatment' 'period']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02639065,99:108:treatment,"Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding should be discontinued","['Because' 'there' 'is' 'an' 'unknown' 'but' 'potential' 'risk' 'for'
 'adverse' 'events' 'in' 'nursing' 'infants' 'secondary' 'to' 'treatment'
 'of' 'the' 'mother' ',' 'breastfeeding' 'should' 'be' 'discontinued']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02639065,",,,,216:225:treatment",Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 12 weeks after treatment discontinuation,"['Females' 'of' 'childbearing' 'potential' 'and' 'males' 'must' 'be'
 'willing' 'to' 'use' 'an' 'effective' 'method' 'of' 'contraception' '('
 'hormonal' 'or' 'barrier' 'method' 'of' 'birth' 'control' ';'
 'abstinence' ')' 'from' 'the' 'time' 'consent' 'is' 'signed' 'until' '12'
 'weeks' 'after' 'treatment' 'discontinuation']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]"
NCT02593526,30:39:treatment,History of poor adherence to treatment,['History' 'of' 'poor' 'adherence' 'to' 'treatment'],[0. 0. 0. 0. 0. 1.]
NCT02592551,106:115:treatment,"Any condition that, in the opinion of the investigator, would interfere with the evaluation of the study treatment or interpretation of subject safety or study results","['Any' 'condition' 'that' ',' 'in' 'the' 'opinion' 'of' 'the'
 'investigator' ',' 'would' 'interfere' 'with' 'the' 'evaluation' 'of'
 'the' 'study' 'treatment' 'or' 'interpretation' 'of' 'subject' 'safety'
 'or' 'study' 'results']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02589522,",,73:82:treatment",Life expectance of greater than two months to allow completion of study treatment and assessment of dose-limiting toxicity,"['Life' 'expectance' 'of' 'greater' 'than' 'two' 'months' 'to' 'allow'
 'completion' 'of' 'study' 'treatment' 'and' 'assessment' 'of'
 'dose-limiting' 'toxicity']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02587312,"30:39:treatment,",Participants who are seeking treatment for their smoking or who report that they intend to quit smoking within the next 30 days and have made a 24-hour quit attempt in the past year,"['Participants' 'who' 'are' 'seeking' 'treatment' 'for' 'their' 'smoking'
 'or' 'who' 'report' 'that' 'they' 'intend' 'to' 'quit' 'smoking' 'within'
 'the' 'next' '30' 'days' 'and' 'have' 'made' 'a' '24-hour' 'quit'
 'attempt' 'in' 'the' 'past' 'year']","[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02585973,4:13:treatment,Co-treatment with weak inhibitors of CYP3A4,['Co-treatment' 'with' 'weak' 'inhibitors' 'of' 'CYP3A4'],[1. 0. 0. 0. 0. 0.]
NCT02585973,",,,106:115:treatment",Women of childbearing potential (WOCBP) must have negative pregnancy test within 72 hours prior to D1 of treatment,"['Women' 'of' 'childbearing' 'potential' '(' 'WOCBP' ')' 'must' 'have'
 'negative' 'pregnancy' 'test' 'within' '72' 'hours' 'prior' 'to' 'D1'
 'of' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02584647,",,,,,,150:159:treatment",Creatinine ≤ 1.5 x ULN or calculated creatinine clearance (CrCl) > 60 mL/min using the Cockcroft-Gault formula less than eight days pior to start of treatment,"['Creatinine' '≤' '1.5' 'x' 'ULN' 'or' 'calculated' 'creatinine'
 'clearance' '(' 'CrCl' ')' '>' '60' 'mL/min' 'using' 'the'
 'Cockcroft-Gault' 'formula' 'less' 'than' 'eight' 'days' 'pior' 'to'
 'start' 'of' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1.]"
NCT02582775,",,104:113:treatment","Available donor per section 5: targeted MFI < 1,000 (MFI exceeding 1000 must be approved by the PI and treatment team.)","['Available' 'donor' 'per' 'section' '5' ':' 'targeted' 'MFI' '<' '1,000'
 '(' 'MFI' 'exceeding' '1000' 'must' 'be' 'approved' 'by' 'the' 'PI' 'and'
 'treatment' 'team' '.' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.
 0.]"
NCT02582775,112:121:treatment,"adult or parent (with information sheet for minors, if applicable) prior to any research related procedures or treatment","['adult' 'or' 'parent' '(' 'with' 'information' 'sheet' 'for' 'minors' ','
 'if' 'applicable' ')' 'prior' 'to' 'any' 'research' 'related'
 'procedures' 'or' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02581215,29:38:treatment,Known allergy to any of the treatment components,['Known' 'allergy' 'to' 'any' 'of' 'the' 'treatment' 'components'],[0. 0. 0. 0. 0. 0. 1. 0.]
NCT02579044,",,169:178:treatment",Sexually active male and female subjects of reproductive potential must agree to use a medically accepted form of birth control while on study and up to 10 weeks after treatment,"['Sexually' 'active' 'male' 'and' 'female' 'subjects' 'of' 'reproductive'
 'potential' 'must' 'agree' 'to' 'use' 'a' 'medically' 'accepted' 'form'
 'of' 'birth' 'control' 'while' 'on' 'study' 'and' 'up' 'to' '10' 'weeks'
 'after' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1.]"
NCT02578901,50:59:treatment,"Able to provide informed consent and comply with treatment and monitoring, or having a Legally Authorized Representative (LAR)","['Able' 'to' 'provide' 'informed' 'consent' 'and' 'comply' 'with'
 'treatment' 'and' 'monitoring' ',' 'or' 'having' 'a' 'Legally'
 'Authorized' 'Representative' '(' 'LAR' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02578901,71:80:treatment,Having been previously randomized in this study at any stage of their treatment,"['Having' 'been' 'previously' 'randomized' 'in' 'this' 'study' 'at' 'any'
 'stage' 'of' 'their' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02578732,",,,,,178:187:treatment",Women of child bearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 7 days prior to beginning of treatment,"['Women' 'of' 'child' 'bearing' 'potential' 'must' 'have' 'a' 'negative'
 'serum' 'or' 'urine' 'pregnancy' 'test' '(' 'minimum' 'sensitivity' '25'
 'IU/L' 'or' 'equivalent' 'units' 'of' 'HCG' ')' 'within' '7' 'days'
 'prior' 'to' 'beginning' 'of' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02577406,",,,61:70:treatment",at least 5% leukemic blasts in bone marrow after at least 2 treatment cycles,"['at' 'least' '5' '%' 'leukemic' 'blasts' 'in' 'bone' 'marrow' 'after'
 'at' 'least' '2' 'treatment' 'cycles']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02576444,",67:76:treatment",Inadequate bone marrow reserve within past 28 days prior to study treatment,"['Inadequate' 'bone' 'marrow' 'reserve' 'within' 'past' '28' 'days'
 'prior' 'to' 'study' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02576444,108:117:treatment,Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up,"['Patient' 'is' 'willing' 'and' 'able' 'to' 'comply' 'with' 'the'
 'protocol' 'for' 'the' 'duration' 'of' 'the' 'study' 'including'
 'undergoing' 'treatment' 'and' 'scheduled' 'visits' 'and' 'examinations'
 'including' 'follow' 'up']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02576444,103:112:treatment,"Patient must not have a co-morbid condition(s) that, in the opinion of the investigator, prevent safe treatment","['Patient' 'must' 'not' 'have' 'a' 'co-morbid' 'condition' '(' 's' ')'
 'that' ',' 'in' 'the' 'opinion' 'of' 'the' 'investigator' ',' 'prevent'
 'safe' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02576431,",44:53:treatment",Subjects who received less than 28 days of treatment and discontinued because of intolerance or toxicity are eligible,"['Subjects' 'who' 'received' 'less' 'than' '28' 'days' 'of' 'treatment'
 'and' 'discontinued' 'because' 'of' 'intolerance' 'or' 'toxicity' 'are'
 'eligible']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02575404,",,33:42:treatment","Pregnant or lactating women, as treatment involves unforeseeable risks to the embryo or fetus","['Pregnant' 'or' 'lactating' 'women' ',' 'as' 'treatment' 'involves'
 'unforeseeable' 'risks' 'to' 'the' 'embryo' 'or' 'fetus']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02575404,",,,132:141:treatment",Women of childbearing potential must have a serum or urine pregnancy test performed within 72 hours prior to the start of protocol treatment,"['Women' 'of' 'childbearing' 'potential' 'must' 'have' 'a' 'serum' 'or'
 'urine' 'pregnancy' 'test' 'performed' 'within' '72' 'hours' 'prior' 'to'
 'the' 'start' 'of' 'protocol' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02573493,",,,,,,,237:246:treatment","Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry, for the duration of study participation, and for 3 months after completing treatment","['Women' 'of' 'childbearing' 'potential' 'and' 'men' 'must' 'agree' 'to'
 'use' 'adequate' 'contraception' '(' 'hormonal' 'or' 'barrier' 'method'
 'of' 'birth' 'control' ',' 'abstinence' ')' 'prior' 'to' 'study' 'entry'
 ',' 'for' 'the' 'duration' 'of' 'study' 'participation' ',' 'and' 'for'
 '3' 'months' 'after' 'completing' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02560766,",,,,,,,,308:317:treatment,","Sexually active patients must agree to use 2 medically accepted methods of contraception, 1 of which is a highly effective method (e.g., hormonal or intrauterine device [IUD]) [the second may be a barrier method (e.g., male condom, female condom, diaphragm or cervical cap)], during the course of the study treatment and for 4 weeks after the last dose of study treatment","['Sexually' 'active' 'patients' 'must' 'agree' 'to' 'use' '2' 'medically'
 'accepted' 'methods' 'of' 'contraception' ',' '1' 'of' 'which' 'is' 'a'
 'highly' 'effective' 'method' '(' 'e.g.' ',' 'hormonal' 'or'
 'intrauterine' 'device' '[' 'IUD' ']' ')' '[' 'the' 'second' 'may' 'be'
 'a' 'barrier' 'method' '(' 'e.g.' ',' 'male' 'condom' ',' 'female'
 'condom' ',' 'diaphragm' 'or' 'cervical' 'cap' ')' ']' ',' 'during' 'the'
 'course' 'of' 'the' 'study' 'treatment' 'and' 'for' '4' 'weeks' 'after'
 'the' 'last' 'dose' 'of' 'study' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02555280,27:36:treatment,Appropriate candidate for treatment using posterior surgical approach,"['Appropriate' 'candidate' 'for' 'treatment' 'using' 'posterior'
 'surgical' 'approach']",[0. 0. 0. 1. 0. 0. 0. 0.]
NCT02555280,123:132:treatment,"Psychosocially, mentally, and physically able to fully comply with this protocol, including adhering to scheduled visits, treatment plan, completing forms, and other study procedures","['Psychosocially' ',' 'mentally' ',' 'and' 'physically' 'able' 'to'
 'fully' 'comply' 'with' 'this' 'protocol' ',' 'including' 'adhering' 'to'
 'scheduled' 'visits' ',' 'treatment' 'plan' ',' 'completing' 'forms' ','
 'and' 'other' 'study' 'procedures']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02555189,",,,120:129:treatment,",Sexually active males unless they use a condom during intercourse while taking the drug and for 30 days after stopping treatment and should not father a child in this period. A condom is required to be used by vasectomized men in order to prevent delivery of the drug via seminal fluid,"['Sexually' 'active' 'males' 'unless' 'they' 'use' 'a' 'condom' 'during'
 'intercourse' 'while' 'taking' 'the' 'drug' 'and' 'for' '30' 'days'
 'after' 'stopping' 'treatment' 'and' 'should' 'not' 'father' 'a' 'child'
 'in' 'this' 'period' '.' 'A' 'condom' 'is' 'required' 'to' 'be' 'used'
 'by' 'vasectomized' 'men' 'in' 'order' 'to' 'prevent' 'delivery' 'of'
 'the' 'drug' 'via' 'seminal' 'fluid']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02554903,",,101:110:treatment",Agreement to undertake monthly serum pregnancy tests during the study and up to 30 days after study treatment discontinuation,"['Agreement' 'to' 'undertake' 'monthly' 'serum' 'pregnancy' 'tests'
 'during' 'the' 'study' 'and' 'up' 'to' '30' 'days' 'after' 'study'
 'treatment' 'discontinuation']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02553447,111:120:treatment,Patients must have histologically confirmed newly diagnosed or previously untreated (patients may be under no treatment,"['Patients' 'must' 'have' 'histologically' 'confirmed' 'newly' 'diagnosed'
 'or' 'previously' 'untreated' '(' 'patients' 'may' 'be' 'under' 'no'
 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02542202,",,,158:167:treatment,",Pregnancy or women of childbearing potential who are sexually active and not willing/able to use medically acceptable forms of contraception during protocol treatment or for at least 6 months following treatment,"['Pregnancy' 'or' 'women' 'of' 'childbearing' 'potential' 'who' 'are'
 'sexually' 'active' 'and' 'not' 'willing/able' 'to' 'use' 'medically'
 'acceptable' 'forms' 'of' 'contraception' 'during' 'protocol' 'treatment'
 'or' 'for' 'at' 'least' '6' 'months' 'following' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02535923,103:112:treatment,"Current problematic drug or alcohol use that impacts functioning and study engagement, as deemed by a treatment provider","['Current' 'problematic' 'drug' 'or' 'alcohol' 'use' 'that' 'impacts'
 'functioning' 'and' 'study' 'engagement' ',' 'as' 'deemed' 'by' 'a'
 'treatment' 'provider']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02535923,61:70:treatment,Sufficient clinical stability to participate as deemed by a treatment provider,"['Sufficient' 'clinical' 'stability' 'to' 'participate' 'as' 'deemed' 'by'
 'a' 'treatment' 'provider']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02533674,56:65:treatment,Limitation of the patient's ability to comply with the treatment or follow-up protocol,"['Limitation' 'of' 'the' 'patient' ""'s"" 'ability' 'to' 'comply' 'with'
 'the' 'treatment' 'or' 'follow-up' 'protocol']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02532621,",59:68:treatment",The patient has had >2 previous arteriovenous accesses in treatment arm,"['The' 'patient' 'has' 'had' '>' '2' 'previous' 'arteriovenous' 'accesses'
 'in' 'treatment' 'arm']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02532543,41:50:treatment,Previous enrollment or randomization of treatment in the present study,"['Previous' 'enrollment' 'or' 'randomization' 'of' 'treatment' 'in' 'the'
 'present' 'study']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02531932,",,63:72:treatment",Negative serum pregnancy test within 7 days prior to starting treatment,"['Negative' 'serum' 'pregnancy' 'test' 'within' '7' 'days' 'prior' 'to'
 'starting' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02530034,",,,,,,,,,305:314:treatment","Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use acceptable contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive or double barrier device), and must have a negative urine pregnancy test within 2 weeks prior to beginning treatment on this trial","['Women' 'of' 'child-bearing' 'potential' '(' 'i.e.' ',' 'women' 'who'
 'are' 'pre-menopausal' 'or' 'not' 'surgically' 'sterile' ')' 'must' 'use'
 'acceptable' 'contraceptive' 'methods' '(' 'abstinence' ','
 'intrauterine' 'device' '[' 'IUD' ']' ',' 'oral' 'contraceptive' 'or'
 'double' 'barrier' 'device' ')' ',' 'and' 'must' 'have' 'a' 'negative'
 'urine' 'pregnancy' 'test' 'within' '2' 'weeks' 'prior' 'to' 'beginning'
 'treatment' 'on' 'this' 'trial']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 0. 0. 0.]"
NCT02527200,14:23:treatment,"No change in treatment plan with growth hormone (GH) from randomisation to the end of the open-label period patients on growth hormone to stay on, patients off GH to stay off during this period. Adjustments in doses of growth hormone will be permitted)","['No' 'change' 'in' 'treatment' 'plan' 'with' 'growth' 'hormone' '(' 'GH'
 ')' 'from' 'randomisation' 'to' 'the' 'end' 'of' 'the' 'open-label'
 'period' 'patients' 'on' 'growth' 'hormone' 'to' 'stay' 'on' ','
 'patients' 'off' 'GH' 'to' 'stay' 'off' 'during' 'this' 'period' '.'
 'Adjustments' 'in' 'doses' 'of' 'growth' 'hormone' 'will' 'be'
 'permitted' ')']","[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02524275,",,,,194:203:treatment",Women of reproductive potential must be non-pregnant and non-nursing and must agree to employ an effective barrier method of birth control throughout the study and for up to 6 months following treatment,"['Women' 'of' 'reproductive' 'potential' 'must' 'be' 'non-pregnant' 'and'
 'non-nursing' 'and' 'must' 'agree' 'to' 'employ' 'an' 'effective'
 'barrier' 'method' 'of' 'birth' 'control' 'throughout' 'the' 'study'
 'and' 'for' 'up' 'to' '6' 'months' 'following' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02519322,",,,52:61:treatment",Albumin >= 2.5 g/dL (within 28 days of first study treatment),"['Albumin' '>' '=' '2.5' 'g/dL' '(' 'within' '28' 'days' 'of' 'first'
 'study' 'treatment' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02519322,",,,52:61:treatment",Amylase < 1.5 X ULN (within 28 days of first study treatment),"['Amylase' '<' '1.5' 'X' 'ULN' '(' 'within' '28' 'days' 'of' 'first'
 'study' 'treatment' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02519322,",,,55:64:treatment",Hemoglobin >= 8.5 g/dL (within 28 days of first study treatment),"['Hemoglobin' '>' '=' '8.5' 'g/dL' '(' 'within' '28' 'days' 'of' 'first'
 'study' 'treatment' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02519322,",,,51:60:treatment",Lipase < 1.5 X ULN (within 28 days of first study treatment),"['Lipase' '<' '1.5' 'X' 'ULN' '(' 'within' '28' 'days' 'of' 'first'
 'study' 'treatment' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02519322,",,,,166:175:treatment",Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< 1.5 X upper limit of normal (ULN) (within 28 days of first study treatment),"['Prothrombin' 'time' '(' 'PT' ')' '/international' 'normalized' 'ratio'
 '(' 'INR' ')' 'and' 'partial' 'thromboplastin' 'time' '(' 'PTT' ')' '='
 '<' '1.5' 'X' 'upper' 'limit' 'of' 'normal' '(' 'ULN' ')' '(' 'within'
 '28' 'days' 'of' 'first' 'study' 'treatment' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]"
NCT02519322,",,,72:81:treatment",White blood cells (WBC) >= 2.0 X 10^9/L (within 28 days of first study treatment),"['White' 'blood' 'cells' '(' 'WBC' ')' '>' '=' '2.0' 'X' '10^9/L' '('
 'within' '28' 'days' 'of' 'first' 'study' 'treatment' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02519322,",39:48:treatment",Within 2 weeks prior to time of study treatment,['Within' '2' 'weeks' 'prior' 'to' 'time' 'of' 'study' 'treatment'],[0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02519322,",,,,,248:257:treatment","subjects with TnT or TnI levels between > 1 to 2 x ULN will be permitted if repeat levels within 24 hours are </= 1 x ULN; if TnT or TnI levels are > 1 to 2 x ULN within 24 hours, the subject may undergo a cardiac evaluation and be considered for treatment, following a discussion with the investigator or designee","['subjects' 'with' 'TnT' 'or' 'TnI' 'levels' 'between' '>' '1' 'to' '2'
 'x' 'ULN' 'will' 'be' 'permitted' 'if' 'repeat' 'levels' 'within' '24'
 'hours' 'are' '<' '/=' '1' 'x' 'ULN' ';' 'if' 'TnT' 'or' 'TnI' 'levels'
 'are' '>' '1' 'to' '2' 'x' 'ULN' 'within' '24' 'hours' ',' 'the'
 'subject' 'may' 'undergo' 'a' 'cardiac' 'evaluation' 'and' 'be'
 'considered' 'for' 'treatment' ',' 'following' 'a' 'discussion' 'with'
 'the' 'investigator' 'or' 'designee']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02515110,",,135:144:treatment",Women of child-bearing potential (WCBP) must agree to use a medically accepted form of pregnancy prevention for the duration of study treatment,"['Women' 'of' 'child-bearing' 'potential' '(' 'WCBP' ')' 'must' 'agree'
 'to' 'use' 'a' 'medically' 'accepted' 'form' 'of' 'pregnancy'
 'prevention' 'for' 'the' 'duration' 'of' 'study' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02512926,",,,,196:205:treatment",Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study and for a minimum of 3 months after study treatment,"['Male' 'and' 'female' 'patients' 'of' 'child-bearing' 'potential' 'must'
 'agree' 'to' 'use' 'an' 'effective' 'method' 'of' 'contraception'
 'approved' 'by' 'the' 'investigator' 'during' 'the' 'study' 'and' 'for'
 'a' 'minimum' 'of' '3' 'months' 'after' 'study' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02510417,7:16:treatment,"Early treatment for single or multiple infections with EBV, CMV and/or adenovirus","['Early' 'treatment' 'for' 'single' 'or' 'multiple' 'infections' 'with'
 'EBV' ',' 'CMV' 'and/or' 'adenovirus']",[0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02503358,21:30:treatment,Conception while on treatment must be avoided,['Conception' 'while' 'on' 'treatment' 'must' 'be' 'avoided'],[0. 0. 0. 1. 0. 0. 0.]
NCT02503358,",94:103:treatment,","Estimated life expectancy, in the judgment of the investigator, which will permit receipt of treatment of 12 weeks or more","['Estimated' 'life' 'expectancy' ',' 'in' 'the' 'judgment' 'of' 'the'
 'investigator' ',' 'which' 'will' 'permit' 'receipt' 'of' 'treatment'
 'of' '12' 'weeks' 'or' 'more']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02503358,",,,86:95:treatment","Known actionable mutations (e.g., EGFR, ALK, ROS1), against which there is available treatment","['Known' 'actionable' 'mutations' '(' 'e.g.' ',' 'EGFR' ',' 'ALK' ','
 'ROS1' ')' ',' 'against' 'which' 'there' 'is' 'available' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02503358,33:42:treatment,"Patients who progressed on such treatment, i.e., have developed acquired resistance and are no longer reasonably expected to derive therapeutic benefit are eligible for the trial","['Patients' 'who' 'progressed' 'on' 'such' 'treatment' ',' 'i.e.' ','
 'have' 'developed' 'acquired' 'resistance' 'and' 'are' 'no' 'longer'
 'reasonably' 'expected' 'to' 'derive' 'therapeutic' 'benefit' 'are'
 'eligible' 'for' 'the' 'trial']","[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02500602,30:39:treatment,Must consent to complete all treatment and follow-up visits,"['Must' 'consent' 'to' 'complete' 'all' 'treatment' 'and' 'follow-up'
 'visits']",[0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02498613,",74:83:treatment",A New York Heart Association (NYHA) classification of II controlled with treatment,"['A' 'New' 'York' 'Heart' 'Association' '(' 'NYHA' ')' 'classification'
 'of' 'II' 'controlled' 'with' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02498535,37:46:treatment,Willing and able to comply with the treatment schedule and procedures,"['Willing' 'and' 'able' 'to' 'comply' 'with' 'the' 'treatment' 'schedule'
 'and' 'procedures']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02496663,",,,112:121:treatment",Women of childbearing potential must have a negative urine pregnancy test within 7 days prior to initiation of treatment,"['Women' 'of' 'childbearing' 'potential' 'must' 'have' 'a' 'negative'
 'urine' 'pregnancy' 'test' 'within' '7' 'days' 'prior' 'to' 'initiation'
 'of' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02496663,23:32:treatment,patients must also be treatment naive to EGFR-monoclonal antibody,"['patients' 'must' 'also' 'be' 'treatment' 'naive' 'to' 'EGFR-monoclonal'
 'antibody']",[0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02496611,12:21:treatment,History of treatment with growth hormone,['History' 'of' 'treatment' 'with' 'growth' 'hormone'],[0. 0. 1. 0. 0. 0.]
NCT02496208,",91:100:treatment",Any of the following that have not resolved within 28 days before the first dose of study treatment,"['Any' 'of' 'the' 'following' 'that' 'have' 'not' 'resolved' 'within' '28'
 'days' 'before' 'the' 'first' 'dose' 'of' 'study' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02496208,",,,100:109:treatment",Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment,"['Hemoptysis' 'of' '>' '=' '0.5' 'teaspoon' '(' '2.5' 'mL' ')' 'of' 'red'
 'blood' 'within' '3' 'months' 'before' 'the' 'first' 'dose' 'of' 'study'
 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02496208,",,,,,191:200:treatment",The subject has prothrombin time (PT)/international normalized ratio (INR) or partial thromboplastin time (PTT) test >= 1.5 x the laboratory ULN within 7 days before the first dose of study treatment,"['The' 'subject' 'has' 'prothrombin' 'time' '(' 'PT' ')' '/international'
 'normalized' 'ratio' '(' 'INR' ')' 'or' 'partial' 'thromboplastin' 'time'
 '(' 'PTT' ')' 'test' '>' '=' '1.5' 'x' 'the' 'laboratory' 'ULN' 'within'
 '7' 'days' 'before' 'the' 'first' 'dose' 'of' 'study' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02496208,",68:77:treatment",To any other site(s) within 28 days before the first dose of study treatment,"['To' 'any' 'other' 'site' '(' 's' ')' 'within' '28' 'days' 'before' 'the'
 'first' 'dose' 'of' 'study' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02495415,54:63:treatment,patient who tested positive subsequent to their last treatment regimen,"['patient' 'who' 'tested' 'positive' 'subsequent' 'to' 'their' 'last'
 'treatment' 'regimen']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02495168,21:30:treatment,on the first day of treatment (prior to randomization at Visit 2),"['on' 'the' 'first' 'day' 'of' 'treatment' '(' 'prior' 'to'
 'randomization' 'at' 'Visit' '2' ')']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02494258,",100:109:treatment","She must agree to ongoing pregnancy testing during the course of the study, and after end of study treatment. This applies even if the subject practices true abstinence from heterosexual contact","['She' 'must' 'agree' 'to' 'ongoing' 'pregnancy' 'testing' 'during' 'the'
 'course' 'of' 'the' 'study' ',' 'and' 'after' 'end' 'of' 'study'
 'treatment' '.' 'This' 'applies' 'even' 'if' 'the' 'subject' 'practices'
 'true' 'abstinence' 'from' 'heterosexual' 'contact']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02483910,"69:78:treatment,",Stable educational plan with no planned changes in the intensity of treatment for 6 months,"['Stable' 'educational' 'plan' 'with' 'no' 'planned' 'changes' 'in' 'the'
 'intensity' 'of' 'treatment' 'for' '6' 'months']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02482376,34:43:treatment,Subjects unable to receive study treatment planning secondary to body habitus or inability to lie flat on the stomach at length,"['Subjects' 'unable' 'to' 'receive' 'study' 'treatment' 'planning'
 'secondary' 'to' 'body' 'habitus' 'or' 'inability' 'to' 'lie' 'flat' 'on'
 'the' 'stomach' 'at' 'length']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02481245,24:33:treatment,"History of significant treatment non-adherence or situations where the subjects is unlikely to adhere to treatment, in the opinion of the investigator","['History' 'of' 'significant' 'treatment' 'non-adherence' 'or'
 'situations' 'where' 'the' 'subjects' 'is' 'unlikely' 'to' 'adhere' 'to'
 'treatment' ',' 'in' 'the' 'opinion' 'of' 'the' 'investigator']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02479906,34:43:treatment,Subject is able to adhere to the treatment schedule,['Subject' 'is' 'able' 'to' 'adhere' 'to' 'the' 'treatment' 'schedule'],[0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02479230,9:18:treatment,Current treatment on another clinical trial,['Current' 'treatment' 'on' 'another' 'clinical' 'trial'],[0. 1. 0. 0. 0. 0.]
NCT02471430,",,76:85:treatment",Willingness to continue to use contraceptives for 90 days after completing treatment,"['Willingness' 'to' 'continue' 'to' 'use' 'contraceptives' 'for' '90'
 'days' 'after' 'completing' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02466750,",,,88:97:treatment",Females must agree to not become pregnant for 3 months after receipt of the last study treatment (vaccination),"['Females' 'must' 'agree' 'to' 'not' 'become' 'pregnant' 'for' '3'
 'months' 'after' 'receipt' 'of' 'the' 'last' 'study' 'treatment' '('
 'vaccination' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02466009,24:33:treatment,Previous assignment to treatment during this study. Subjects permanently withdrawn from study participation will not be allowed to re-enter study,"['Previous' 'assignment' 'to' 'treatment' 'during' 'this' 'study' '.'
 'Subjects' 'permanently' 'withdrawn' 'from' 'study' 'participation'
 'will' 'not' 'be' 'allowed' 'to' 're-enter' 'study']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02465060,",,,,121:130:treatment","Absolute neutrophil count >= 1,500/mcL (within 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration)","['Absolute' 'neutrophil' 'count' '>' '=' '1,500/mcL' '(' 'within' '2'
 'weeks' 'prior' 'to' 'screening' 'step' 'registration' 'and' 'within' '4'
 'weeks' 'prior' 'to' 'treatment' 'step' 'registration' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.
 0.]"
NCT02465060,",,,,107:116:treatment","Platelets >= 100,000/mcL (within 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration)","['Platelets' '>' '=' '100,000/mcL' '(' 'within' '2' 'weeks' 'prior' 'to'
 'screening' 'step' 'registration' 'and' 'within' '4' 'weeks' 'prior' 'to'
 'treatment' 'step' 'registration' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02465060,",85:94:treatment","patient must be off the drug for at least 5 half-lives prior to registration to the treatment step (Step 1, 3, 5, 7)","['patient' 'must' 'be' 'off' 'the' 'drug' 'for' 'at' 'least' '5'
 'half-lives' 'prior' 'to' 'registration' 'to' 'the' 'treatment' 'step'
 '(' 'Step' '1' ',' '3' ',' '5' ',' '7' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02465060,",,81:90:treatment",within 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration,"['within' '2' 'weeks' 'prior' 'to' 'screening' 'step' 'registration' 'and'
 'within' '4' 'weeks' 'prior' 'to' 'treatment' 'step' 'registration']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.]
NCT02465060,",42:51:treatment",within 4 weeks following notification of treatment assignment,"['within' '4' 'weeks' 'following' 'notification' 'of' 'treatment'
 'assignment']",[0. 0. 0. 0. 0. 0. 1. 0.]
NCT02459119,",,107:116:treatment",Fertile patients must use effective contraception during and for up to 3 months after completion of study treatment,"['Fertile' 'patients' 'must' 'use' 'effective' 'contraception' 'during'
 'and' 'for' 'up' 'to' '3' 'months' 'after' 'completion' 'of' 'study'
 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02459119,24:33:treatment,Previous assignment to treatment during this study,['Previous' 'assignment' 'to' 'treatment' 'during' 'this' 'study'],[0. 0. 0. 1. 0. 0. 0.]
NCT02456857,",,,150:159:treatment","Male patients whose sexual partner(s) are WOCBP who are not willing to use adequate contraception, during the study and for 8 weeks after the end of treatment","['Male' 'patients' 'whose' 'sexual' 'partner' '(' 's' ')' 'are' 'WOCBP'
 'who' 'are' 'not' 'willing' 'to' 'use' 'adequate' 'contraception' ','
 'during' 'the' 'study' 'and' 'for' '8' 'weeks' 'after' 'the' 'end' 'of'
 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1.]"
NCT02452268,",,,116:125:treatment,","Women of child-bearing potential and men must agree to use adequate contraception prior to study entry, during the treatment portion of the study and for 4 months after completion of hetIL-15 administration","['Women' 'of' 'child-bearing' 'potential' 'and' 'men' 'must' 'agree' 'to'
 'use' 'adequate' 'contraception' 'prior' 'to' 'study' 'entry' ','
 'during' 'the' 'treatment' 'portion' 'of' 'the' 'study' 'and' 'for' '4'
 'months' 'after' 'completion' 'of' 'hetIL-15' 'administration']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02446457,",,,78:87:treatment","Absolute neutrophil count (ANC) >= 1.0 x 10^9/L, performed within 28 days of treatment initiation","['Absolute' 'neutrophil' 'count' '(' 'ANC' ')' '>' '=' '1.0' 'x' '10^9/L'
 ',' 'performed' 'within' '28' 'days' 'of' 'treatment' 'initiation']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02446457,",,,53:62:treatment","Hemoglobin >= 8.0 g/dL, performed within 28 days of treatment initiation","['Hemoglobin' '>' '=' '8.0' 'g/dL' ',' 'performed' 'within' '28' 'days'
 'of' 'treatment' 'initiation']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02446457,",,,55:64:treatment","Platelets >= 75 x 10^9/L, performed within 28 days of treatment initiation","['Platelets' '>' '=' '75' 'x' '10^9/L' ',' 'performed' 'within' '28'
 'days' 'of' 'treatment' 'initiation']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02446457,",,,,,,,,,,,,,396:405:treatment","Serum creatinine OR measured or calculated creatinine clearance (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) (creatinine clearance will be calculated per institutional standard) =< 1.5 x upper limit of normal (ULN) OR >= 60 mL/min GFR or CrCl for subjects with creatinine levels > 1.5 x institutional ULN, performed within 28 days of treatment initiation","['Serum' 'creatinine' 'OR' 'measured' 'or' 'calculated' 'creatinine'
 'clearance' '(' 'glomerular' 'filtration' 'rate' '[' 'GFR' ']' 'can'
 'also' 'be' 'used' 'in' 'place' 'of' 'creatinine' 'or' 'creatinine'
 'clearance' '[' 'CrCl' ']' ')' '(' 'creatinine' 'clearance' 'will' 'be'
 'calculated' 'per' 'institutional' 'standard' ')' '=' '<' '1.5' 'x'
 'upper' 'limit' 'of' 'normal' '(' 'ULN' ')' 'OR' '>' '=' '60' 'mL/min'
 'GFR' 'or' 'CrCl' 'for' 'subjects' 'with' 'creatinine' 'levels' '>' '1.5'
 'x' 'institutional' 'ULN' ',' 'performed' 'within' '28' 'days' 'of'
 'treatment' 'initiation']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 0.]"
NCT02446457,",,,,,,143:152:treatment","Serum total bilirubin =< 1.5 x ULN OR direct bilirubin =< ULN for subjects with total bilirubin levels > 1.5 ULN, performed within 28 days of treatment initiation","['Serum' 'total' 'bilirubin' '=' '<' '1.5' 'x' 'ULN' 'OR' 'direct'
 'bilirubin' '=' '<' 'ULN' 'for' 'subjects' 'with' 'total' 'bilirubin'
 'levels' '>' '1.5' 'ULN' ',' 'performed' 'within' '28' 'days' 'of'
 'treatment' 'initiation']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 0.]"
NCT02446093,71:80:treatment,Patients with biliary obstruction must be stented prior to initiating treatment,"['Patients' 'with' 'biliary' 'obstruction' 'must' 'be' 'stented' 'prior'
 'to' 'initiating' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02438995,",,124:133:treatment,,",Patients must agree to use a medically effective method of contraception during and for a period of three months after the treatment period. A pregnancy test will be performed on each premenopausal female of childbearing potential immediately prior to entry into the research study,"['Patients' 'must' 'agree' 'to' 'use' 'a' 'medically' 'effective' 'method'
 'of' 'contraception' 'during' 'and' 'for' 'a' 'period' 'of' 'three'
 'months' 'after' 'the' 'treatment' 'period' '.' 'A' 'pregnancy' 'test'
 'will' 'be' 'performed' 'on' 'each' 'premenopausal' 'female' 'of'
 'childbearing' 'potential' 'immediately' 'prior' 'to' 'entry' 'into'
 'the' 'research' 'study']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02438995,",,214:223:treatment",will be informed as to the potential risk of procreation while participating in this research trial and will be advised that they must use effective contraception during and for a period of three months after the treatment period,"['will' 'be' 'informed' 'as' 'to' 'the' 'potential' 'risk' 'of'
 'procreation' 'while' 'participating' 'in' 'this' 'research' 'trial'
 'and' 'will' 'be' 'advised' 'that' 'they' 'must' 'use' 'effective'
 'contraception' 'during' 'and' 'for' 'a' 'period' 'of' 'three' 'months'
 'after' 'the' 'treatment' 'period']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]"
NCT02437851,",,,,,,,,,,395:404:treatment","all women of childbearing potential must agree to use a reliable birth control method (oral contraceptive pills, intrauterine device, Nexplanon, DepoProvera, or permanent sterilization, etc., or another acceptable method as determined by the investigator) during the entire period of the trial (3 years), and must not intend to become pregnant during study participation and for 3 months after treatment is discontinued","['all' 'women' 'of' 'childbearing' 'potential' 'must' 'agree' 'to' 'use'
 'a' 'reliable' 'birth' 'control' 'method' '(' 'oral' 'contraceptive'
 'pills' ',' 'intrauterine' 'device' ',' 'Nexplanon' ',' 'DepoProvera' ','
 'or' 'permanent' 'sterilization' ',' 'etc.' ',' 'or' 'another'
 'acceptable' 'method' 'as' 'determined' 'by' 'the' 'investigator' ')'
 'during' 'the' 'entire' 'period' 'of' 'the' 'trial' '(' '3' 'years' ')'
 ',' 'and' 'must' 'not' 'intend' 'to' 'become' 'pregnant' 'during' 'study'
 'participation' 'and' 'for' '3' 'months' 'after' 'treatment' 'is'
 'discontinued']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.]"
NCT02436408,",53:62:treatment,",Male patients must agree to not donate sperm during treatment and for 3 months after last dose,"['Male' 'patients' 'must' 'agree' 'to' 'not' 'donate' 'sperm' 'during'
 'treatment' 'and' 'for' '3' 'months' 'after' 'last' 'dose']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02436408,",,48:57:treatment,",Male patients must agree to use condoms during treatment and for 3 months after last dose,"['Male' 'patients' 'must' 'agree' 'to' 'use' 'condoms' 'during'
 'treatment' 'and' 'for' '3' 'months' 'after' 'last' 'dose']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02429830,59:68:treatment,Subject has been informed of the study procedures and the treatment and has signed an informed consent form,"['Subject' 'has' 'been' 'informed' 'of' 'the' 'study' 'procedures' 'and'
 'the' 'treatment' 'and' 'has' 'signed' 'an' 'informed' 'consent' 'form']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02425904,",,,,,,,248:257:treatment",Female patients of childbearing potential must have a negative serum pregnancy test within 14 days prior to enrollment. Male and female patients must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment,"['Female' 'patients' 'of' 'childbearing' 'potential' 'must' 'have' 'a'
 'negative' 'serum' 'pregnancy' 'test' 'within' '14' 'days' 'prior' 'to'
 'enrollment' '.' 'Male' 'and' 'female' 'patients' 'must' 'use' 'an'
 'effective' 'contraceptive' 'method' 'during' 'the' 'study' 'and' 'for'
 'a' 'minimum' 'of' '6' 'months' 'after' 'study' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02423863,115:124:treatment,"Serious concurrent infection or medical illness, which would jeopardize the ability of the patient to receive the treatment outlined in this protocol with reasonable safety","['Serious' 'concurrent' 'infection' 'or' 'medical' 'illness' ',' 'which'
 'would' 'jeopardize' 'the' 'ability' 'of' 'the' 'patient' 'to' 'receive'
 'the' 'treatment' 'outlined' 'in' 'this' 'protocol' 'with' 'reasonable'
 'safety']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02419495,",,,97:106:treatment,,",Negative serum pregnancy test in women of childbearing potential within 7 days of first dose of treatment and patients of child-bearing potential must agree to use effective contraception during/after 3 months post dose,"['Negative' 'serum' 'pregnancy' 'test' 'in' 'women' 'of' 'childbearing'
 'potential' 'within' '7' 'days' 'of' 'first' 'dose' 'of' 'treatment'
 'and' 'patients' 'of' 'child-bearing' 'potential' 'must' 'agree' 'to'
 'use' 'effective' 'contraception' 'during/after' '3' 'months' 'post'
 'dose']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02415660,"112:121:treatment,,,,","Able to make one initial appointment at the Army Medical Department Center and School at Fort Sam Houston, one treatment visit approximately 2-3 days after the initial visit, and then a final outcome visit approximately 5-7 days after 2nd visit","['Able' 'to' 'make' 'one' 'initial' 'appointment' 'at' 'the' 'Army'
 'Medical' 'Department' 'Center' 'and' 'School' 'at' 'Fort' 'Sam'
 'Houston' ',' 'one' 'treatment' 'visit' 'approximately' '2-3' 'days'
 'after' 'the' 'initial' 'visit' ',' 'and' 'then' 'a' 'final' 'outcome'
 'visit' 'approximately' '5-7' 'days' 'after' '2nd' 'visit']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02409888,63:72:treatment,agree not to seek additional alcohol or other substance abuse treatment during the study period,"['agree' 'not' 'to' 'seek' 'additional' 'alcohol' 'or' 'other' 'substance'
 'abuse' 'treatment' 'during' 'the' 'study' 'period']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02409888,29:38:treatment,mandated to substance abuse treatment by a court order,['mandated' 'to' 'substance' 'abuse' 'treatment' 'by' 'a' 'court' 'order'],[0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02407171,",126:135:treatment","Demonstrate adequate organ function as defined in Table 1, all screening labs should be performed within 28 days of protocol treatment","['Demonstrate' 'adequate' 'organ' 'function' 'as' 'defined' 'in' 'Table'
 '1' ',' 'all' 'screening' 'labs' 'should' 'be' 'performed' 'within' '28'
 'days' 'of' 'protocol' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02403193,108:117:treatment,Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up,"['Subject' 'is' 'willing' 'and' 'able' 'to' 'comply' 'with' 'the'
 'protocol' 'for' 'the' 'duration' 'of' 'the' 'study' 'including'
 'undergoing' 'treatment' 'and' 'scheduled' 'visits' 'and' 'examinations'
 'including' 'follow' 'up']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02403193,",,,,174:183:treatment,","Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, must use 2 highly effective methods of contraception while taking study treatment and for 90 days after the last dose of study treatment","['Women' 'of' 'child-bearing' 'potential' ',' 'defined' 'as' 'all' 'women'
 'physiologically' 'capable' 'of' 'becoming' 'pregnant' ',' 'must' 'use'
 '2' 'highly' 'effective' 'methods' 'of' 'contraception' 'while' 'taking'
 'study' 'treatment' 'and' 'for' '90' 'days' 'after' 'the' 'last' 'dose'
 'of' 'study' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02400463,",,,99:108:treatment",all females of child-bearing potential must have a negative serum pregnancy test within 7 days of treatment,"['all' 'females' 'of' 'child-bearing' 'potential' 'must' 'have' 'a'
 'negative' 'serum' 'pregnancy' 'test' 'within' '7' 'days' 'of'
 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02393794,",,91:100:treatment","their partners must use contraception prior to study entry, continuing for 5 months after treatment","['their' 'partners' 'must' 'use' 'contraception' 'prior' 'to' 'study'
 'entry' ',' 'continuing' 'for' '5' 'months' 'after' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02393794,56:65:treatment,who have not fully recovered from side effects of such treatment,"['who' 'have' 'not' 'fully' 'recovered' 'from' 'side' 'effects' 'of'
 'such' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02392572,",,85:94:treatment",must have a negative serum or urine pregnancy test within 1 week prior to beginning treatment on this trial,"['must' 'have' 'a' 'negative' 'serum' 'or' 'urine' 'pregnancy' 'test'
 'within' '1' 'week' 'prior' 'to' 'beginning' 'treatment' 'on' 'this'
 'trial']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02389023,",58:67:treatment",Any groin incision on index leg within 12 weeks prior to treatment initiation,"['Any' 'groin' 'incision' 'on' 'index' 'leg' 'within' '12' 'weeks' 'prior'
 'to' 'treatment' 'initiation']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02369653,",78:87:treatment",Subjects scheduled to have > 3 Lumbar Punctures over the course of the study treatment period,"['Subjects' 'scheduled' 'to' 'have' '>' '3' 'Lumbar' 'Punctures' 'over'
 'the' 'course' 'of' 'the' 'study' 'treatment' 'period']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02369458,",,,,,,,236:245:treatment,,","Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry, for the duration of study participation, and for 1 month after completing treatment. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately","['Women' 'of' 'childbearing' 'potential' 'and' 'men' 'must' 'agree' 'to'
 'use' 'adequate' 'contraception' '(' 'hormonal' 'or' 'barrier' 'method'
 'of' 'birth' 'control' ',' 'abstinence' ')' 'prior' 'to' 'study' 'entry'
 ',' 'for' 'the' 'duration' 'of' 'study' 'participation' ',' 'and' 'for'
 '1' 'month' 'after' 'completing' 'treatment' '.' 'Should' 'a' 'woman'
 'become' 'pregnant' 'or' 'suspect' 'she' 'is' 'pregnant' 'while'
 'participating' 'in' 'this' 'study' ',' 'she' 'must' 'inform' 'her'
 'treating' 'physician' 'immediately']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02367040,",89:98:treatment",Adequate baseline laboratory values collected no more than 7 days before starting study treatment,"['Adequate' 'baseline' 'laboratory' 'values' 'collected' 'no' 'more'
 'than' '7' 'days' 'before' 'starting' 'study' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02366819,",,,,,,,242:251:treatment","Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation, up until 30 days after final study treatment","['Women' 'of' 'child-bearing' 'potential' 'and' 'men' 'must' 'agree' 'to'
 'use' 'adequate' 'contraception' '(' 'hormonal' 'or' 'barrier' 'method'
 'of' 'birth' 'control' ';' 'abstinence' ')' 'prior' 'to' 'study' 'entry'
 'and' 'for' 'the' 'duration' 'of' 'study' 'participation' ',' 'up'
 'until' '30' 'days' 'after' 'final' 'study' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02359825,"43:52:treatment,",willing to comply with all aspects of the treatment and evaluation schedule over a 12 months period,"['willing' 'to' 'comply' 'with' 'all' 'aspects' 'of' 'the' 'treatment'
 'and' 'evaluation' 'schedule' 'over' 'a' '12' 'months' 'period']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02354703,79:88:treatment,"Prior to Randomization, the subject is compelled to participate in an alcohol treatment program to maintain his/her liberty","['Prior' 'to' 'Randomization' ',' 'the' 'subject' 'is' 'compelled' 'to'
 'participate' 'in' 'an' 'alcohol' 'treatment' 'program' 'to' 'maintain'
 'his/her' 'liberty']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02349867,",,,100:109:treatment",Any other hemorrhage/bleeding event >= grade 3 (CTCAE v4.0) within 12 weeks prior to initiation of treatment,"['Any' 'other' 'hemorrhage/bleeding' 'event' '>' '=' 'grade' '3' '('
 'CTCAE' 'v4.0' ')' 'within' '12' 'weeks' 'prior' 'to' 'initiation' 'of'
 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02349867,",,,145:154:treatment",Bronchopulmonary hemorrhage/bleeding event >= grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] v4.0) within 12 weeks prior to of treatment,"['Bronchopulmonary' 'hemorrhage/bleeding' 'event' '>' '=' 'grade' '2' '('
 'Common' 'Terminology' 'Criteria' 'for' 'Adverse' 'Events' '[' 'CTCAE'
 ']' 'v4.0' ')' 'within' '12' 'weeks' 'prior' 'to' 'of' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1.]"
NCT02349867,",,,113:122:treatment",Women of childbearing potential and men must agree to use a medically accepted form of birth control during the treatment,"['Women' 'of' 'childbearing' 'potential' 'and' 'men' 'must' 'agree' 'to'
 'use' 'a' 'medically' 'accepted' 'form' 'of' 'birth' 'control' 'during'
 'the' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02349867,",,,121:130:treatment",Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment,"['Women' 'of' 'childbearing' 'potential' 'must' 'have' 'a' 'negative'
 'serum' 'pregnancy' 'test' 'performed' 'within' '7' 'days' 'prior' 'to'
 'the' 'start' 'of' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02343549,",,,113:122:treatment",Participants of childbearing age must use effective contraception for at least 6 months following completion of treatment,"['Participants' 'of' 'childbearing' 'age' 'must' 'use' 'effective'
 'contraception' 'for' 'at' 'least' '6' 'months' 'following' 'completion'
 'of' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02340156,",,,,217:226:treatment","Males not naturally or surgically sterile, who have a female partner of childbearing potential, must agree to use two reliable methods of contraception from screening and up to 30 days after discontinuation of study treatment","['Males' 'not' 'naturally' 'or' 'surgically' 'sterile' ',' 'who' 'have'
 'a' 'female' 'partner' 'of' 'childbearing' 'potential' ',' 'must' 'agree'
 'to' 'use' 'two' 'reliable' 'methods' 'of' 'contraception' 'from'
 'screening' 'and' 'up' 'to' '30' 'days' 'after' 'discontinuation' 'of'
 'study' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02335905,",,153:162:treatment,",Female subjects who have reached menarche and are sexually active must be willing to practice sexual abstinence or dual methods of birth control during treatment and for at least 28 days after the last dose of any study drug,"['Female' 'subjects' 'who' 'have' 'reached' 'menarche' 'and' 'are'
 'sexually' 'active' 'must' 'be' 'willing' 'to' 'practice' 'sexual'
 'abstinence' 'or' 'dual' 'methods' 'of' 'birth' 'control' 'during'
 'treatment' 'and' 'for' 'at' 'least' '28' 'days' 'after' 'the' 'last'
 'dose' 'of' 'any' 'study' 'drug']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02332928,",67:76:treatment,",willing to use an acceptable method of birth control during study treatment and for 3 months afterwards,"['willing' 'to' 'use' 'an' 'acceptable' 'method' 'of' 'birth' 'control'
 'during' 'study' 'treatment' 'and' 'for' '3' 'months' 'afterwards']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02332850,",75:84:treatment",The following laboratory results must be met within 7 days of study drug (treatment) administration,"['The' 'following' 'laboratory' 'results' 'must' 'be' 'met' 'within' '7'
 'days' 'of' 'study' 'drug' '(' 'treatment' ')' 'administration']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.]
NCT02323191,",,60:69:treatment,,",Negative serum pregnancy test within 7 days prior to study treatment in premenopausal women and women less than or equal to (<=) 12 months post-menopause,"['Negative' 'serum' 'pregnancy' 'test' 'within' '7' 'days' 'prior' 'to'
 'study' 'treatment' 'in' 'premenopausal' 'women' 'and' 'women' 'less'
 'than' 'or' 'equal' 'to' '(' '<' '=' ')' '12' 'months' 'post-menopause']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02321501,",,,,151:160:treatment,","Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment","['Female' 'sterilization' '(' 'have' 'had' 'surgical' 'bilateral'
 'oophorectomy' 'with' 'or' 'without' 'hysterectomy' ')' 'or' 'tubal'
 'ligation' 'at' 'least' 'six' 'weeks' 'before' 'taking' 'study'
 'treatment' '.' 'In' 'case' 'of' 'oophorectomy' 'alone' ',' 'only' 'when'
 'the' 'reproductive' 'status' 'of' 'the' 'woman' 'has' 'been' 'confirmed'
 'by' 'follow' 'up' 'hormone' 'level' 'assessment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02321501,",,,,,131:140:treatment,,,,",Sexually active males unless they use a condom during intercourse while taking drug and for 3 months after the last dose of study treatment. Male patients for 3 months should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid. Also male patients whose sexual partner(s) are WOCBP who are not willing to use adequate contraception during the study and for 3 months after the end of enrollment,"['Sexually' 'active' 'males' 'unless' 'they' 'use' 'a' 'condom' 'during'
 'intercourse' 'while' 'taking' 'drug' 'and' 'for' '3' 'months' 'after'
 'the' 'last' 'dose' 'of' 'study' 'treatment' '.' 'Male' 'patients' 'for'
 '3' 'months' 'should' 'not' 'father' 'a' 'child' 'in' 'this' 'period' '.'
 'A' 'condom' 'is' 'required' 'to' 'be' 'used' 'also' 'by' 'vasectomized'
 'men' 'in' 'order' 'to' 'prevent' 'delivery' 'of' 'the' 'drug' 'via'
 'seminal' 'fluid' '.' 'Also' 'male' 'patients' 'whose' 'sexual' 'partner'
 '(' 's' ')' 'are' 'WOCBP' 'who' 'are' 'not' 'willing' 'to' 'use'
 'adequate' 'contraception' 'during' 'the' 'study' 'and' 'for' '3'
 'months' 'after' 'the' 'end' 'of' 'enrollment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02320292,",,127:136:treatment",of childbearing potential who are unwilling to employ adequate contraception for at least three months after completing study treatment,"['of' 'childbearing' 'potential' 'who' 'are' 'unwilling' 'to' 'employ'
 'adequate' 'contraception' 'for' 'at' 'least' 'three' 'months' 'after'
 'completing' 'study' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02316574,30:39:treatment,Agree to not seek additional treatment,['Agree' 'to' 'not' 'seek' 'additional' 'treatment'],[0. 0. 0. 0. 0. 1.]
NCT02316574,29:38:treatment,Legally mandated to receive treatment,['Legally' 'mandated' 'to' 'receive' 'treatment'],[0. 0. 0. 0. 1.]
NCT02316574,9:18:treatment,Seeking treatment for Alcohol Use Disorder,['Seeking' 'treatment' 'for' 'Alcohol' 'Use' 'Disorder'],[0. 1. 0. 0. 0. 0.]
NCT02315196,",,,,,,205:214:treatment,","Patients with reproductive potential must use an adequate contraceptive method (e.g. abstinence, intrauterine device, oral contraceptives, barrier device with spermicide or surgical sterilization) during treatment and for three months after completing treatment","['Patients' 'with' 'reproductive' 'potential' 'must' 'use' 'an' 'adequate'
 'contraceptive' 'method' '(' 'e.g' '.' 'abstinence' ',' 'intrauterine'
 'device' ',' 'oral' 'contraceptives' ',' 'barrier' 'device' 'with'
 'spermicide' 'or' 'surgical' 'sterilization' ')' 'during' 'treatment'
 'and' 'for' 'three' 'months' 'after' 'completing' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]"
NCT02314377,",,,109:118:treatment",Women of childbearing potential are required to obtain a negative pregnancy test within 14 days of starting treatment,"['Women' 'of' 'childbearing' 'potential' 'are' 'required' 'to' 'obtain'
 'a' 'negative' 'pregnancy' 'test' 'within' '14' 'days' 'of' 'starting'
 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02312596,51:60:treatment,"Alcohol or drug abuse, defined as current medical treatment for substance abuse","['Alcohol' 'or' 'drug' 'abuse' ',' 'defined' 'as' 'current' 'medical'
 'treatment' 'for' 'substance' 'abuse']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02312596,",,88:97:treatment",Greater than 30% reduction in wound size during the first two weeks of observation and treatment by the investigator,"['Greater' 'than' '30' '%' 'reduction' 'in' 'wound' 'size' 'during' 'the'
 'first' 'two' 'weeks' 'of' 'observation' 'and' 'treatment' 'by' 'the'
 'investigator']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02312570,",88:97:treatment",Greater than 30% reduction in wound size during the first two weeks of observation and treatment by the investigator,"['Greater' 'than' '30' '%' 'reduction' 'in' 'wound' 'size' 'during' 'the'
 'first' 'two' 'weeks' 'of' 'observation' 'and' 'treatment' 'by' 'the'
 'investigator']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02312518,",,88:97:treatment",Greater than 30% reduction in wound size during the first two weeks of observation and treatment by the investigator,"['Greater' 'than' '30' '%' 'reduction' 'in' 'wound' 'size' 'during' 'the'
 'first' 'two' 'weeks' 'of' 'observation' 'and' 'treatment' 'by' 'the'
 'investigator']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02312518,81:90:treatment,Presence of another wound that is concurrently treated and might interfere with treatment of index wound,"['Presence' 'of' 'another' 'wound' 'that' 'is' 'concurrently' 'treated'
 'and' 'might' 'interfere' 'with' 'treatment' 'of' 'index' 'wound']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02311361,",,,,,,255:264:treatment","Enrolled patients must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, the duration of study participation and 180 days (female patients) or 90 days (male patients) after the end of the treatment","['Enrolled' 'patients' 'must' 'agree' 'to' 'use' 'adequate'
 'contraception' '(' 'hormonal' 'or' 'barrier' 'method' 'of' 'birth'
 'control' ';' 'abstinence' ')' 'prior' 'to' 'study' 'entry' ',' 'the'
 'duration' 'of' 'study' 'participation' 'and' '180' 'days' '(' 'female'
 'patients' ')' 'or' '90' 'days' '(' 'male' 'patients' ')' 'after' 'the'
 'end' 'of' 'the' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1.]"
NCT02310464,",95:104:treatment",Subjects of child-bearing potential must agree to use acceptable contraceptive methods during treatment and until the end of the study,"['Subjects' 'of' 'child-bearing' 'potential' 'must' 'agree' 'to' 'use'
 'acceptable' 'contraceptive' 'methods' 'during' 'treatment' 'and' 'until'
 'the' 'end' 'of' 'the' 'study']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02308709,",22:31:treatment,",Life expectancy with treatment should be ≥6 months in the estimation of the treating physicians,"['Life' 'expectancy' 'with' 'treatment' 'should' 'be' '≥6' 'months' 'in'
 'the' 'estimation' 'of' 'the' 'treating' 'physicians']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02305537,29:38:treatment,Patients ineligible for the treatment program,['Patients' 'ineligible' 'for' 'the' 'treatment' 'program'],[0. 0. 0. 0. 1. 0.]
NCT02305537,107:116:treatment,those who report that they are unwilling to refrain from self-injurious behaviors during the waitlist and treatment periods,"['those' 'who' 'report' 'that' 'they' 'are' 'unwilling' 'to' 'refrain'
 'from' 'self-injurious' 'behaviors' 'during' 'the' 'waitlist' 'and'
 'treatment' 'periods']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02303977,110:119:treatment,"Patients must be capable of giving informed consent and be willing and able to comply with scheduled visits, treatment plan and laboratory testing","['Patients' 'must' 'be' 'capable' 'of' 'giving' 'informed' 'consent' 'and'
 'be' 'willing' 'and' 'able' 'to' 'comply' 'with' 'scheduled' 'visits' ','
 'treatment' 'plan' 'and' 'laboratory' 'testing']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02303977,",,109:118:treatment",Women of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatment,"['Women' 'of' 'childbearing' 'potential' 'and' 'sexually' 'active' 'males'
 'must' 'use' 'an' 'effective' 'contraception' 'method' 'during'
 'treatment' 'and' 'for' 'three' 'months' 'after' 'completing' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02302976,9:18:treatment,seeking treatment for drug abuse/dependence (for experimental cocaine component),"['seeking' 'treatment' 'for' 'drug' 'abuse/dependence' '(' 'for'
 'experimental' 'cocaine' 'component' ')']",[0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02293057,43:52:treatment,"Determined to be in need of substance use treatment by the court intake worker, probation officer, presiding judge or magistrate, and/or school counselor","['Determined' 'to' 'be' 'in' 'need' 'of' 'substance' 'use' 'treatment'
 'by' 'the' 'court' 'intake' 'worker' ',' 'probation' 'officer' ','
 'presiding' 'judge' 'or' 'magistrate' ',' 'and/or' 'school' 'counselor']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02293057,26:35:treatment,already in substance use treatment (residential or outpatient) and wish to remain with outside provider (as determined through referral partner),"['already' 'in' 'substance' 'use' 'treatment' '(' 'residential' 'or'
 'outpatient' ')' 'and' 'wish' 'to' 'remain' 'with' 'outside' 'provider'
 '(' 'as' 'determined' 'through' 'referral' 'partner' ')']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02291978,"103:112:treatment,",Individuals who are not able or willing to tolerate the required prolonged stationary position during treatment (can be up to 5 hrs of total table time),"['Individuals' 'who' 'are' 'not' 'able' 'or' 'willing' 'to' 'tolerate'
 'the' 'required' 'prolonged' 'stationary' 'position' 'during' 'treatment'
 '(' 'can' 'be' 'up' 'to' '5' 'hrs' 'of' 'total' 'table' 'time' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02287337,26:35:treatment,Inability to comply with treatment and follow-up schedule,['Inability' 'to' 'comply' 'with' 'treatment' 'and' 'follow-up' 'schedule'],[0. 0. 0. 0. 1. 0. 0. 0.]
NCT02273375,128:137:treatment,"Investigators must assure themselves the patients randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-up","['Investigators' 'must' 'assure' 'themselves' 'the' 'patients'
 'randomized' 'on' 'this' 'trial' 'will' 'be' 'available' 'for' 'complete'
 'documentation' 'of' 'the' 'treatment' ',' 'adverse' 'events' ',' 'and'
 'follow-up']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.
 0.]"
NCT02273375,33:42:treatment,Patients must be accessible for treatment and follow-up,['Patients' 'must' 'be' 'accessible' 'for' 'treatment' 'and' 'follow-up'],[0. 0. 0. 0. 0. 1. 0. 0.]
NCT02273375,"10:19:treatment,",Protocol treatment is to begin within 2 working days of patient randomization,"['Protocol' 'treatment' 'is' 'to' 'begin' 'within' '2' 'working' 'days'
 'of' 'patient' 'randomization']",[0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02272998,",35:44:treatment",through 4 months after the end of treatment,['through' '4' 'months' 'after' 'the' 'end' 'of' 'treatment'],[0. 0. 0. 0. 0. 0. 0. 1.]
NCT02271919,15:24:treatment,Interested in treatment that might change smoking behavior,"['Interested' 'in' 'treatment' 'that' 'might' 'change' 'smoking'
 'behavior']",[0. 0. 1. 0. 0. 0. 0. 0.]
NCT02268253,85:94:treatment,has signed informed consent prior to initiation of any study-specific procedures or treatment,"['has' 'signed' 'informed' 'consent' 'prior' 'to' 'initiation' 'of' 'any'
 'study-specific' 'procedures' 'or' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02266719,36:45:treatment,Patients that are not eligible for treatment with commercially available endografts,"['Patients' 'that' 'are' 'not' 'eligible' 'for' 'treatment' 'with'
 'commercially' 'available' 'endografts']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02261519,179:188:treatment,"The identified caregiver should be considered reliable by the Investigator and per the local regulations in providing support to the subject to help ensure compliance with study treatment, study visits and protocol procedures who preferably is also able to provide input helpful for completing study rating scales","['The' 'identified' 'caregiver' 'should' 'be' 'considered' 'reliable' 'by'
 'the' 'Investigator' 'and' 'per' 'the' 'local' 'regulations' 'in'
 'providing' 'support' 'to' 'the' 'subject' 'to' 'help' 'ensure'
 'compliance' 'with' 'study' 'treatment' ',' 'study' 'visits' 'and'
 'protocol' 'procedures' 'who' 'preferably' 'is' 'also' 'able' 'to'
 'provide' 'input' 'helpful' 'for' 'completing' 'study' 'rating' 'scales']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02259504,79:88:treatment,"Subject with social, medical, or psychological conditions that interfere with treatment and follow-up evaluation","['Subject' 'with' 'social' ',' 'medical' ',' 'or' 'psychological'
 'conditions' 'that' 'interfere' 'with' 'treatment' 'and' 'follow-up'
 'evaluation']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02236013,76:85:treatment,Subject agrees not to participate in another interventional study while on treatment,"['Subject' 'agrees' 'not' 'to' 'participate' 'in' 'another'
 'interventional' 'study' 'while' 'on' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02234193,34:43:treatment,"Subject is unable to comply with treatment, home care or follow-up visits","['Subject' 'is' 'unable' 'to' 'comply' 'with' 'treatment' ',' 'home'
 'care' 'or' 'follow-up' 'visits']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT02208362,126:135:treatment,"Research participants with any non-malignant intercurrent illness which is either poorly controlled with currently available treatment, or which is of such severity that the investigators deem it unwise to enter the research participant on protocol","['Research' 'participants' 'with' 'any' 'non-malignant' 'intercurrent'
 'illness' 'which' 'is' 'either' 'poorly' 'controlled' 'with' 'currently'
 'available' 'treatment' ',' 'or' 'which' 'is' 'of' 'such' 'severity'
 'that' 'the' 'investigators' 'deem' 'it' 'unwise' 'to' 'enter' 'the'
 'research' 'participant' 'on' 'protocol']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02207439,116:125:treatment,Patients must sign an informed consent document that indicates they are aware of the investigational nature of the treatment in this protocol as well as the potential risks and benefits,"['Patients' 'must' 'sign' 'an' 'informed' 'consent' 'document' 'that'
 'indicates' 'they' 'are' 'aware' 'of' 'the' 'investigational' 'nature'
 'of' 'the' 'treatment' 'in' 'this' 'protocol' 'as' 'well' 'as' 'the'
 'potential' 'risks' 'and' 'benefits']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02200445,",,,104:113:treatment,",Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for six months after completion of treatment,"['Men' 'and' 'women' 'of' 'reproductive' 'potential' 'must' 'agree' 'to'
 'use' 'an' 'acceptable' 'method' 'of' 'birth' 'control' 'during'
 'treatment' 'and' 'for' 'six' 'months' 'after' 'completion' 'of'
 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02188121,"62:71:treatment,,,",defined as entering one of the two-year First Episode Clinic treatment programs as a de novo patient (new disease) or having been diagnosed >2 years ago and had at least six visits in the past 12 months (prevalent disease),"['defined' 'as' 'entering' 'one' 'of' 'the' 'two-year' 'First' 'Episode'
 'Clinic' 'treatment' 'programs' 'as' 'a' 'de' 'novo' 'patient' '(' 'new'
 'disease' ')' 'or' 'having' 'been' 'diagnosed' '>' '2' 'years' 'ago'
 'and' 'had' 'at' 'least' 'six' 'visits' 'in' 'the' 'past' '12' 'months'
 '(' 'prevalent' 'disease' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02184520,10:19:treatment,Requires treatment of more than two vertebral levels,['Requires' 'treatment' 'of' 'more' 'than' 'two' 'vertebral' 'levels'],[0. 1. 0. 0. 0. 0. 0. 0.]
NCT02181478,6:15:treatment,such treatment may continue until the planned course is completed,"['such' 'treatment' 'may' 'continue' 'until' 'the' 'planned' 'course' 'is'
 'completed']",[0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02178709,",,,149:158:treatment","WOCBP and men must agree to use adequate contraception prior, to study entry, for the duration of study participation, and 8 weeks after the end of treatment","['WOCBP' 'and' 'men' 'must' 'agree' 'to' 'use' 'adequate' 'contraception'
 'prior' ',' 'to' 'study' 'entry' ',' 'for' 'the' 'duration' 'of' 'study'
 'participation' ',' 'and' '8' 'weeks' 'after' 'the' 'end' 'of'
 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1.]"
NCT02176967,58:67:treatment,"Patients must meet the specified criteria for one of the treatment groups defined below; genomic features include MYCN gene amplification, segmental chromosome aberrations (somatic copy number loss at 1p, 3p, 4p, or 11q or somatic copy number gain at 1q, 2p, or 17q) and deoxyribonucleic acid (DNA) index","['Patients' 'must' 'meet' 'the' 'specified' 'criteria' 'for' 'one' 'of'
 'the' 'treatment' 'groups' 'defined' 'below' ';' 'genomic' 'features'
 'include' 'MYCN' 'gene' 'amplification' ',' 'segmental' 'chromosome'
 'aberrations' '(' 'somatic' 'copy' 'number' 'loss' 'at' '1p' ',' '3p' ','
 '4p' ',' 'or' '11q' 'or' 'somatic' 'copy' 'number' 'gain' 'at' '1q' ','
 '2p' ',' 'or' '17q' ')' 'and' 'deoxyribonucleic' 'acid' '(' 'DNA' ')'
 'index']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02171104,",,,97:106:treatment",menstruating females must have a negative serum or urine pregnancy test within 14 days of study treatment start,"['menstruating' 'females' 'must' 'have' 'a' 'negative' 'serum' 'or'
 'urine' 'pregnancy' 'test' 'within' '14' 'days' 'of' 'study' 'treatment'
 'start']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02166905,29:38:treatment,Have been informed of other treatment options,['Have' 'been' 'informed' 'of' 'other' 'treatment' 'options'],[0. 0. 0. 0. 0. 1. 0.]
NCT02166905,",,118:127:treatment","Patients of child-bearing potential must agree to use acceptable contraceptive methods (e.g., double barrier) during treatment","['Patients' 'of' 'child-bearing' 'potential' 'must' 'agree' 'to' 'use'
 'acceptable' 'contraceptive' 'methods' '(' 'e.g.' ',' 'double' 'barrier'
 ')' 'during' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02161211,11:20:treatment,inpatient treatment at Lodging Plus primarily for alcohol (vs. other drug) dependence,"['inpatient' 'treatment' 'at' 'Lodging' 'Plus' 'primarily' 'for' 'alcohol'
 '(' 'vs.' 'other' 'drug' ')' 'dependence']",[0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02159027,10:19:treatment,"Adequate treatment is defined as meeting the current recommendations of the Centers of Disease Control and Prevention (CDC), National Institutes of Health (NIH) and the HIV Medicine Association of the Infectious Diseases Society of America (IDSA) guidelines33","['Adequate' 'treatment' 'is' 'defined' 'as' 'meeting' 'the' 'current'
 'recommendations' 'of' 'the' 'Centers' 'of' 'Disease' 'Control' 'and'
 'Prevention' '(' 'CDC' ')' ',' 'National' 'Institutes' 'of' 'Health' '('
 'NIH' ')' 'and' 'the' 'HIV' 'Medicine' 'Association' 'of' 'the'
 'Infectious' 'Diseases' 'Society' 'of' 'America' '(' 'IDSA' ')'
 'guidelines33']","[0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02159027,123:132:treatment,non-heterosexually active or have a an exclusive vasectomized partner from screening throughout the duration of the study treatment,"['non-heterosexually' 'active' 'or' 'have' 'a' 'an' 'exclusive'
 'vasectomized' 'partner' 'from' 'screening' 'throughout' 'the' 'duration'
 'of' 'the' 'study' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02158793,64:73:treatment,willing and able to return to follow-up visits as described in treatment plan,"['willing' 'and' 'able' 'to' 'return' 'to' 'follow-up' 'visits' 'as'
 'described' 'in' 'treatment' 'plan']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02158234,",,,143:152:treatment",Women of childbearing potential or sexually active males must be willing to use effective contraception throughout their participation in the treatment phase of the study,"['Women' 'of' 'childbearing' 'potential' 'or' 'sexually' 'active' 'males'
 'must' 'be' 'willing' 'to' 'use' 'effective' 'contraception' 'throughout'
 'their' 'participation' 'in' 'the' 'treatment' 'phase' 'of' 'the' 'study']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.
 0.]"
NCT02153229,101:110:treatment,"Patients must sign a document that indicates that they are aware of the investigative nature of the treatment of this protocol, and the potential benefits and risks","['Patients' 'must' 'sign' 'a' 'document' 'that' 'indicates' 'that' 'they'
 'are' 'aware' 'of' 'the' 'investigative' 'nature' 'of' 'the' 'treatment'
 'of' 'this' 'protocol' ',' 'and' 'the' 'potential' 'benefits' 'and'
 'risks']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02152995,"11:20:treatment,,",All prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v 4.0) grade =< 1,"['All' 'prior' 'treatment-related' 'toxicities' 'must' 'be' 'Common'
 'Terminology' 'Criteria' 'for' 'Adverse' 'Events' 'version' '4.0' '('
 'CTCAE' 'v' '4.0' ')' 'grade' '=' '<' '1']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02143050,",,70:79:treatment,","Fertile males should use an effective method of contraception during treatment and for at least 3 months after completion of treatment, as directed by their physician","['Fertile' 'males' 'should' 'use' 'an' 'effective' 'method' 'of'
 'contraception' 'during' 'treatment' 'and' 'for' 'at' 'least' '3'
 'months' 'after' 'completion' 'of' 'treatment' ',' 'as' 'directed' 'by'
 'their' 'physician']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02140255,159:168:treatment,"Otherwise assessed by the site investigator or designee, in consultation with the Clinical Management Committee (CMC), as having an indication to re-initiate treatment","['Otherwise' 'assessed' 'by' 'the' 'site' 'investigator' 'or' 'designee'
 ',' 'in' 'consultation' 'with' 'the' 'Clinical' 'Management' 'Committee'
 '(' 'CMC' ')' ',' 'as' 'having' 'an' 'indication' 'to' 're-initiate'
 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1.]"
NCT02135588,",,86:95:treatment",must have a negative urine or serum pregnancy test within 2 weeks prior to beginning treatment on this trial,"['must' 'have' 'a' 'negative' 'urine' 'or' 'serum' 'pregnancy' 'test'
 'within' '2' 'weeks' 'prior' 'to' 'beginning' 'treatment' 'on' 'this'
 'trial']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02133196,",,136:145:treatment",Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for four months after treatment,"['Patients' 'of' 'both' 'genders' 'must' 'be' 'willing' 'to' 'practice'
 'birth' 'control' 'from' 'the' 'time' 'of' 'enrollment' 'on' 'this'
 'study' 'and' 'for' 'four' 'months' 'after' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1.]"
NCT02132598,",69:78:treatment",Any of the following within 6 months before the first dose of study treatment,"['Any' 'of' 'the' 'following' 'within' '6' 'months' 'before' 'the' 'first'
 'dose' 'of' 'study' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02132598,",99:108:treatment",Patients must have normal organ and marrow function as defined below: (within 4 days of beginning treatment unless noted otherwise),"['Patients' 'must' 'have' 'normal' 'organ' 'and' 'marrow' 'function' 'as'
 'defined' 'below' ':' '(' 'within' '4' 'days' 'of' 'beginning'
 'treatment' 'unless' 'noted' 'otherwise' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02132598,",,,,191:200:treatment",The subject has prothrombin time (PT)/ International Normalized Ratio (INR) or partial thromboplastin time (PTT) test ≥ 1.3 x the laboratory ULN within 7 days before the first dose of study treatment,"['The' 'subject' 'has' 'prothrombin' 'time' '(' 'PT' ')' '/'
 'International' 'Normalized' 'Ratio' '(' 'INR' ')' 'or' 'partial'
 'thromboplastin' 'time' '(' 'PTT' ')' 'test' '≥' '1.3' 'x' 'the'
 'laboratory' 'ULN' 'within' '7' 'days' 'before' 'the' 'first' 'dose' 'of'
 'study' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02128230,107:116:treatment,Patients must have signed an IRB-approved informed consent indicating their understanding of the proposed treatment and understanding that the protocol has been approved by the IRB,"['Patients' 'must' 'have' 'signed' 'an' 'IRB-approved' 'informed'
 'consent' 'indicating' 'their' 'understanding' 'of' 'the' 'proposed'
 'treatment' 'and' 'understanding' 'that' 'the' 'protocol' 'has' 'been'
 'approved' 'by' 'the' 'IRB']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02122081,",,,100:109:treatment",Fertile men and women unwilling to use contraceptive techniques during and for 12 months following treatment,"['Fertile' 'men' 'and' 'women' 'unwilling' 'to' 'use' 'contraceptive'
 'techniques' 'during' 'and' 'for' '12' 'months' 'following' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02122081,"116:125:treatment,,","If the patient has an intra-abdominal chloroma on presentation, and has a partial response or complete response to treatment (size reduction of chloroma and marrow blast < 10%), the patient is eligible","['If' 'the' 'patient' 'has' 'an' 'intra-abdominal' 'chloroma' 'on'
 'presentation' ',' 'and' 'has' 'a' 'partial' 'response' 'or' 'complete'
 'response' 'to' 'treatment' '(' 'size' 'reduction' 'of' 'chloroma' 'and'
 'marrow' 'blast' '<' '10' '%' ')' ',' 'the' 'patient' 'is' 'eligible']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02111850,",,142:151:treatment",Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatment,"['Patients' 'of' 'both' 'genders' 'must' 'be' 'willing' 'to' 'practice'
 'birth' 'control' 'from' 'the' 'time' 'of' 'enrollment' 'on' 'this'
 'study' 'and' 'for' 'up' 'to' 'four' 'months' 'after' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1.]"
NCT02111850,",,122:131:treatment",Women of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the treatment on the fetus,"['Women' 'of' 'child-bearing' 'potential' 'must' 'have' 'a' 'negative'
 'pregnancy' 'test' 'because' 'of' 'the' 'potentially' 'dangerous'
 'effects' 'of' 'the' 'treatment' 'on' 'the' 'fetus']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02111850,",,120:129:treatment",Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant,"['Women' 'of' 'child-bearing' 'potential' 'who' 'are' 'pregnant' 'or'
 'breastfeeding' 'because' 'of' 'the' 'potentially' 'dangerous' 'effects'
 'of' 'the' 'treatment' 'on' 'the' 'fetus' 'or' 'infant']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02108860,",,95:104:treatment",Both women and men must be willing to use an effective means of birth control while receiving treatment through this study,"['Both' 'women' 'and' 'men' 'must' 'be' 'willing' 'to' 'use' 'an'
 'effective' 'means' 'of' 'birth' 'control' 'while' 'receiving'
 'treatment' 'through' 'this' 'study']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02108860,33:42:treatment,Willing and able to comply with treatment and follow-up procedures,"['Willing' 'and' 'able' 'to' 'comply' 'with' 'treatment' 'and' 'follow-up'
 'procedures']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02106650,",,80:89:treatment,",Male patients are to agree to use a barrier method of contraception from study treatment initiation until at least 90 days after the last administration of Folotyn,"['Male' 'patients' 'are' 'to' 'agree' 'to' 'use' 'a' 'barrier' 'method'
 'of' 'contraception' 'from' 'study' 'treatment' 'initiation' 'until' 'at'
 'least' '90' 'days' 'after' 'the' 'last' 'administration' 'of' 'Folotyn']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02102113,21:30:treatment,Current or lifetime treatment,['Current' 'or' 'lifetime' 'treatment'],[0. 0. 0. 1.]
NCT02101736,",,,98:107:treatment",Hemoptysis of ≥0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment,"['Hemoptysis' 'of' '≥0.5' 'teaspoon' '(' '2.5' 'mL' ')' 'of' 'red' 'blood'
 'within' '3' 'months' 'before' 'the' 'first' 'dose' 'of' 'study'
 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02101034,",,,187:196:treatment","Female patients must be surgically sterile or be postmenopausal, or must agree to use effective contraceptive during the period of the trial and for at least 90 days after completion of treatment","['Female' 'patients' 'must' 'be' 'surgically' 'sterile' 'or' 'be'
 'postmenopausal' ',' 'or' 'must' 'agree' 'to' 'use' 'effective'
 'contraceptive' 'during' 'the' 'period' 'of' 'the' 'trial' 'and' 'for'
 'at' 'least' '90' 'days' 'after' 'completion' 'of' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02100891,",,,110:119:treatment,","Fertile females who are unwilling to use contraceptive techniques during and for the twelve months following treatment, as well as females who are pregnant or actively breast feeding","['Fertile' 'females' 'who' 'are' 'unwilling' 'to' 'use' 'contraceptive'
 'techniques' 'during' 'and' 'for' 'the' 'twelve' 'months' 'following'
 'treatment' ',' 'as' 'well' 'as' 'females' 'who' 'are' 'pregnant' 'or'
 'actively' 'breast' 'feeding']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02100891,",,,108:117:treatment",Fertile males who are unwilling to use contraceptive techniques during and for the twelve months following treatment,"['Fertile' 'males' 'who' 'are' 'unwilling' 'to' 'use' 'contraceptive'
 'techniques' 'during' 'and' 'for' 'the' 'twelve' 'months' 'following'
 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02100891,86:95:treatment,"Patients, who in the opinion of the investigator, may not be able to comply with the treatment plan or safety monitoring requirements of the study Page 16 of 86 Children's Hospital of Wisconsin Medical College of Wisconsin","['Patients' ',' 'who' 'in' 'the' 'opinion' 'of' 'the' 'investigator' ','
 'may' 'not' 'be' 'able' 'to' 'comply' 'with' 'the' 'treatment' 'plan'
 'or' 'safety' 'monitoring' 'requirements' 'of' 'the' 'study' 'Page' '16'
 'of' '86' 'Children' ""'s"" 'Hospital' 'of' 'Wisconsin' 'Medical' 'College'
 'of' 'Wisconsin']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02099058,",,,113:122:treatment",Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment,"['Women' 'of' 'childbearing' 'potential' 'must' 'have' 'a' 'negative'
 'serum' 'pregnancy' 'test' 'within' '14' 'days' 'prior' 'to' 'initiation'
 'of' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02098161,198:207:treatment,Any concurrent severe and/or uncontrolled medical conditions that could increase the patient's risk for toxicity while in the study or that could confound discrimination between disease- and study treatment-related toxicities,"['Any' 'concurrent' 'severe' 'and/or' 'uncontrolled' 'medical'
 'conditions' 'that' 'could' 'increase' 'the' 'patient' ""'s"" 'risk' 'for'
 'toxicity' 'while' 'in' 'the' 'study' 'or' 'that' 'could' 'confound'
 'discrimination' 'between' 'disease-' 'and' 'study' 'treatment-related'
 'toxicities']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 0.]"
NCT02098161,51:60:treatment,"Willing and able to comply with scheduled visits, treatment plan and laboratory tests","['Willing' 'and' 'able' 'to' 'comply' 'with' 'scheduled' 'visits' ','
 'treatment' 'plan' 'and' 'laboratory' 'tests']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02094794,",,149:158:treatment","The time from the end last induction, re-induction, or consolidation regimen should be greater than or equal to 14 days from planned start of study treatment","['The' 'time' 'from' 'the' 'end' 'last' 'induction' ',' 're-induction' ','
 'or' 'consolidation' 'regimen' 'should' 'be' 'greater' 'than' 'or'
 'equal' 'to' '14' 'days' 'from' 'planned' 'start' 'of' 'study'
 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1.]"
NCT02080221,",,,,,178:187:treatment",Women of child bearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 7 days prior to beginning of treatment,"['Women' 'of' 'child' 'bearing' 'potential' 'must' 'have' 'a' 'negative'
 'serum' 'or' 'urine' 'pregnancy' 'test' '(' 'minimum' 'sensitivity' '25'
 'IU/L' 'or' 'equivalent' 'units' 'of' 'HCG' ')' 'within' '7' 'days'
 'prior' 'to' 'beginning' 'of' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02075671,",,,,,,257:266:treatment","They will also be required to be on at least one reliable form of effective birth control [examples: barrier method (condoms, diaphragm), oral, injectable, implant birth control or abstinence] during the course of this study and 30 days following the last treatment period","['They' 'will' 'also' 'be' 'required' 'to' 'be' 'on' 'at' 'least' 'one'
 'reliable' 'form' 'of' 'effective' 'birth' 'control' '[' 'examples' ':'
 'barrier' 'method' '(' 'condoms' ',' 'diaphragm' ')' ',' 'oral' ','
 'injectable' ',' 'implant' 'birth' 'control' 'or' 'abstinence' ']'
 'during' 'the' 'course' 'of' 'this' 'study' 'and' '30' 'days' 'following'
 'the' 'last' 'treatment' 'period']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 0.]"
NCT02072356,",,117:126:treatment",Evidence of potential delivery of greater than 16.5 mCi (30 Gy absorbed dose) of radiation to the lungs in a single treatment,"['Evidence' 'of' 'potential' 'delivery' 'of' 'greater' 'than' '16.5' 'mCi'
 '(' '30' 'Gy' 'absorbed' 'dose' ')' 'of' 'radiation' 'to' 'the' 'lungs'
 'in' 'a' 'single' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02059239,",,,,128:137:treatment",Male and female subjects must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment,"['Male' 'and' 'female' 'subjects' 'must' 'use' 'an' 'effective'
 'contraceptive' 'method' 'during' 'the' 'study' 'and' 'for' 'a' 'minimum'
 'of' '6' 'months' 'after' 'study' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02056873,41:50:treatment,"(If the subject chooses not to have the treatment, they cannot participate in the study","['(' 'If' 'the' 'subject' 'chooses' 'not' 'to' 'have' 'the' 'treatment'
 ',' 'they' 'can' 'not' 'participate' 'in' 'the' 'study']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02055053,36:45:treatment,History of Chronic pain or ongoing treatment for chronic pain,"['History' 'of' 'Chronic' 'pain' 'or' 'ongoing' 'treatment' 'for'
 'chronic' 'pain']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02048371,76:85:treatment,Patients who progress on placebo are specifically allowed to enroll on the treatment arm of the study if they meet all other entry criteria,"['Patients' 'who' 'progress' 'on' 'placebo' 'are' 'specifically' 'allowed'
 'to' 'enroll' 'on' 'the' 'treatment' 'arm' 'of' 'the' 'study' 'if' 'they'
 'meet' 'all' 'other' 'entry' 'criteria']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02048371,24:33:treatment,Previous assignment to treatment during this study,['Previous' 'assignment' 'to' 'treatment' 'during' 'this' 'study'],[0. 0. 0. 1. 0. 0. 0.]
NCT02043548,",,,104:113:treatment,",Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for twelve months after completion of treatment,"['Men' 'and' 'women' 'of' 'reproductive' 'potential' 'must' 'agree' 'to'
 'use' 'an' 'acceptable' 'method' 'of' 'birth' 'control' 'during'
 'treatment' 'and' 'for' 'twelve' 'months' 'after' 'completion' 'of'
 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02020707,",,74:83:treatment",Willing to return to enrolling institution for follow-up 2-4 weeks after treatment discontinuation,"['Willing' 'to' 'return' 'to' 'enrolling' 'institution' 'for' 'follow-up'
 '2-4' 'weeks' 'after' 'treatment' 'discontinuation']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02016924,",,111:120:treatment",females of childbearing potential must agree to utilize highly effective contraception methods while on study treatment or agree to abstain from heterosexual intercourse throughout the study period,"['females' 'of' 'childbearing' 'potential' 'must' 'agree' 'to' 'utilize'
 'highly' 'effective' 'contraception' 'methods' 'while' 'on' 'study'
 'treatment' 'or' 'agree' 'to' 'abstain' 'from' 'heterosexual'
 'intercourse' 'throughout' 'the' 'study' 'period']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02013778,37:46:treatment,Participation in another concurrent treatment protocol,['Participation' 'in' 'another' 'concurrent' 'treatment' 'protocol'],[0. 0. 0. 0. 1. 0.]
NCT02004275,",65:74:treatment",Must agree to not become pregnant or breast feed a child during treatment on this protocol,"['Must' 'agree' 'to' 'not' 'become' 'pregnant' 'or' 'breast' 'feed' 'a'
 'child' 'during' 'treatment' 'on' 'this' 'protocol']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02004275,65:74:treatment,Previous hypersensitivity to any of the components of the study treatment,"['Previous' 'hypersensitivity' 'to' 'any' 'of' 'the' 'components' 'of'
 'the' 'study' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01993719,",,142:151:treatment",Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatment,"['Patients' 'of' 'both' 'genders' 'must' 'be' 'willing' 'to' 'practice'
 'birth' 'control' 'from' 'the' 'time' 'of' 'enrollment' 'on' 'this'
 'study' 'and' 'for' 'up' 'to' 'four' 'months' 'after' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1.]"
NCT01993719,",,122:131:treatment",Women of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the treatment on the fetus,"['Women' 'of' 'child-bearing' 'potential' 'must' 'have' 'a' 'negative'
 'pregnancy' 'test' 'because' 'of' 'the' 'potentially' 'dangerous'
 'effects' 'of' 'the' 'treatment' 'on' 'the' 'fetus']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT01993719,",,120:129:treatment",Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant,"['Women' 'of' 'child-bearing' 'potential' 'who' 'are' 'pregnant' 'or'
 'breastfeeding' 'because' 'of' 'the' 'potentially' 'dangerous' 'effects'
 'of' 'the' 'treatment' 'on' 'the' 'fetus' 'or' 'infant']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT01990209,",,,163:172:treatment,",Male patients (even those post vasectomy) who are willing to use adequate contraceptive measures or abstain from heterosexual intercourse during the entire study treatment period and for 4 months after the last dose of study drug,"['Male' 'patients' '(' 'even' 'those' 'post' 'vasectomy' ')' 'who' 'are'
 'willing' 'to' 'use' 'adequate' 'contraceptive' 'measures' 'or' 'abstain'
 'from' 'heterosexual' 'intercourse' 'during' 'the' 'entire' 'study'
 'treatment' 'period' 'and' 'for' '4' 'months' 'after' 'the' 'last' 'dose'
 'of' 'study' 'drug']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01989546,81:90:treatment,"for the duration of study participation, and for 30 days after completing study treatment","['for' 'the' 'duration' 'of' 'study' 'participation' ',' 'and' 'for' '30'
 'days' 'after' 'completing' 'study' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01983462,84:93:treatment,"Any condition that, in the view of the PI, places the subject at high risk of poor treatment compliance or of not completing the study","['Any' 'condition' 'that' ',' 'in' 'the' 'view' 'of' 'the' 'PI' ','
 'places' 'the' 'subject' 'at' 'high' 'risk' 'of' 'poor' 'treatment'
 'compliance' 'or' 'of' 'not' 'completing' 'the' 'study']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.
 0. 0. 0.]"
NCT01976585,25:34:treatment,Able to comply with the treatment schedule,['Able' 'to' 'comply' 'with' 'the' 'treatment' 'schedule'],[0. 0. 0. 0. 0. 1. 0.]
NCT01972919,35:44:treatment,Participation in another clinical treatment trial while on study,"['Participation' 'in' 'another' 'clinical' 'treatment' 'trial' 'while'
 'on' 'study']",[0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT01967823,",,136:145:treatment",Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for four months after treatment,"['Patients' 'of' 'both' 'genders' 'must' 'be' 'willing' 'to' 'practice'
 'birth' 'control' 'from' 'the' 'time' 'of' 'enrollment' 'on' 'this'
 'study' 'and' 'for' 'four' 'months' 'after' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1.]"
NCT01967823,",,122:131:treatment",Women of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the treatment on the fetus,"['Women' 'of' 'child-bearing' 'potential' 'must' 'have' 'a' 'negative'
 'pregnancy' 'test' 'because' 'of' 'the' 'potentially' 'dangerous'
 'effects' 'of' 'the' 'treatment' 'on' 'the' 'fetus']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT01967823,",,120:129:treatment",Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant,"['Women' 'of' 'child-bearing' 'potential' 'who' 'are' 'pregnant' 'or'
 'breastfeeding' 'because' 'of' 'the' 'potentially' 'dangerous' 'effects'
 'of' 'the' 'treatment' 'on' 'the' 'fetus' 'or' 'infant']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT01966367,30:39:treatment,"Approval for the use of this treatment protocol by the individual institution's Human Rights Committee must be obtained, in accordance with the institutional assurance policies of the U. S. Department of Health and Human Services","['Approval' 'for' 'the' 'use' 'of' 'this' 'treatment' 'protocol' 'by'
 'the' 'individual' 'institution' ""'s"" 'Human' 'Rights' 'Committee' 'must'
 'be' 'obtained' ',' 'in' 'accordance' 'with' 'the' 'institutional'
 'assurance' 'policies' 'of' 'the' 'U.' 'S.' 'Department' 'of' 'Health'
 'and' 'Human' 'Services']","[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01959698,",,157:166:treatment","HBV DNA is negative, the subject may be included but must undergo at least every 2 months HBV DNA polymerase chain reaction (PCR) testing from the start of treatment throughout the duration the treatment course","['HBV' 'DNA' 'is' 'negative' ',' 'the' 'subject' 'may' 'be' 'included'
 'but' 'must' 'undergo' 'at' 'least' 'every' '2' 'months' 'HBV' 'DNA'
 'polymerase' 'chain' 'reaction' '(' 'PCR' ')' 'testing' 'from' 'the'
 'start' 'of' 'treatment' 'throughout' 'the' 'duration' 'the' 'treatment'
 'course']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]"
NCT01959698,",,,,,125:134:treatment",Serum creatinine of =< 1.5 mg/dL; if creatinine > 1.5 mg/dL creatinine clearance must be > 60 mL/min within 7 days prior to treatment either measured or calculated using a standard Cockcroft and Gault formula,"['Serum' 'creatinine' 'of' '=' '<' '1.5' 'mg/dL' ';' 'if' 'creatinine' '>'
 '1.5' 'mg/dL' 'creatinine' 'clearance' 'must' 'be' '>' '60' 'mL/min'
 'within' '7' 'days' 'prior' 'to' 'treatment' 'either' 'measured' 'or'
 'calculated' 'using' 'a' 'standard' 'Cockcroft' 'and' 'Gault' 'formula']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01943851,",73:82:treatment",at least 28 days (whichever is longer) following the last dose of study treatment,"['at' 'least' '28' 'days' '(' 'whichever' 'is' 'longer' ')' 'following'
 'the' 'last' 'dose' 'of' 'study' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01920737,",,113:122:treatment,",Men and women of childbearing potential must be willing to practice an effective method of birth control during treatment and at least 4 months after treatment is finished,"['Men' 'and' 'women' 'of' 'childbearing' 'potential' 'must' 'be' 'willing'
 'to' 'practice' 'an' 'effective' 'method' 'of' 'birth' 'control' 'during'
 'treatment' 'and' 'at' 'least' '4' 'months' 'after' 'treatment' 'is'
 'finished']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT01896999,",,113:122:treatment","vaccines are not prohibited on study, but must be given at least 6 weeks after cycle 1 and not within 7 days of treatment","['vaccines' 'are' 'not' 'prohibited' 'on' 'study' ',' 'but' 'must' 'be'
 'given' 'at' 'least' '6' 'weeks' 'after' 'cycle' '1' 'and' 'not' 'within'
 '7' 'days' 'of' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1.]"
NCT01893554,75:84:treatment,Subjects with clinically insignificant cardiac abnormalities requiring no treatment may be enrolled,"['Subjects' 'with' 'clinically' 'insignificant' 'cardiac' 'abnormalities'
 'requiring' 'no' 'treatment' 'may' 'be' 'enrolled']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT01884740,",,,144:153:treatment",Patients of reproductive age must agree to use a medically effective method of contraception during and for a period of three months after the treatment period,"['Patients' 'of' 'reproductive' 'age' 'must' 'agree' 'to' 'use' 'a'
 'medically' 'effective' 'method' 'of' 'contraception' 'during' 'and'
 'for' 'a' 'period' 'of' 'three' 'months' 'after' 'the' 'treatment'
 'period']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 0.]"
NCT01877382,23:32:treatment,for which no standard treatment is available,['for' 'which' 'no' 'standard' 'treatment' 'is' 'available'],[0. 0. 0. 0. 1. 0. 0.]
NCT01877382,"1:10:treatment,",treatment with small-molecule targeted agents within 2 weeks before study drug treatment,"['treatment' 'with' 'small-molecule' 'targeted' 'agents' 'within' '2'
 'weeks' 'before' 'study' 'drug' 'treatment']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01873131,46:55:treatment,Willingness of parent/guardian to follow the treatment schedule and post treatment care requirements,"['Willingness' 'of' 'parent/guardian' 'to' 'follow' 'the' 'treatment'
 'schedule' 'and' 'post' 'treatment' 'care' 'requirements']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT01873131,56:65:treatment,Willingness of parent/guardian to receive EXPERIMENTAL treatment,"['Willingness' 'of' 'parent/guardian' 'to' 'receive' 'EXPERIMENTAL'
 'treatment']",[0. 0. 0. 0. 0. 0. 1.]
NCT01873131,48:57:treatment,"whose parent/guardian is unable to comply with treatment, home care or follow-up visits","['whose' 'parent/guardian' 'is' 'unable' 'to' 'comply' 'with' 'treatment'
 ',' 'home' 'care' 'or' 'follow-up' 'visits']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT01871766,",,,,,,143:152:treatment",Female participants ≥ 10 years of age or post-menarchal must have a negative serum or urine pregnancy test within 24 hours prior to beginning treatment,"['Female' 'participants' '≥' '10' 'years' 'of' 'age' 'or' 'post-menarchal'
 'must' 'have' 'a' 'negative' 'serum' 'or' 'urine' 'pregnancy' 'test'
 'within' '24' 'hours' 'prior' 'to' 'beginning' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1.]"
NCT01869114,96:105:treatment,"Patients must be able to sign consent and be willing and able to comply with scheduled visits, treatment plan and laboratory testing","['Patients' 'must' 'be' 'able' 'to' 'sign' 'consent' 'and' 'be' 'willing'
 'and' 'able' 'to' 'comply' 'with' 'scheduled' 'visits' ',' 'treatment'
 'plan' 'and' 'laboratory' 'testing']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT01861106,174:183:treatment,"Should a patient have progressive disease, or a donor becomes not available after enrollment, the patient will be referred back to their primary hematologist-oncologist for treatment","['Should' 'a' 'patient' 'have' 'progressive' 'disease' ',' 'or' 'a'
 'donor' 'becomes' 'not' 'available' 'after' 'enrollment' ',' 'the'
 'patient' 'will' 'be' 'referred' 'back' 'to' 'their' 'primary'
 'hematologist-oncologist' 'for' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1.]"
NCT01841333,",,,138:147:treatment",Serum/urine pregnancy test (for females of childbearing potential) that is negative within 72 hours prior to initiation of first dose of treatment,"['Serum/urine' 'pregnancy' 'test' '(' 'for' 'females' 'of' 'childbearing'
 'potential' ')' 'that' 'is' 'negative' 'within' '72' 'hours' 'prior' 'to'
 'initiation' 'of' 'first' 'dose' 'of' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01829958,38:47:treatment,Must meet criteria for initiation of treatment,['Must' 'meet' 'criteria' 'for' 'initiation' 'of' 'treatment'],[0. 0. 0. 0. 0. 0. 1.]
NCT01827384,89:98:treatment,patients on other trials will be eligible as long as they are no longer receiving study treatment,"['patients' 'on' 'other' 'trials' 'will' 'be' 'eligible' 'as' 'long' 'as'
 'they' 'are' 'no' 'longer' 'receiving' 'study' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01827384,",,99:108:treatment",radiofrequency ablation (RFA) of localized lesions should have been performed >= 2 weeks prior to treatment,"['radiofrequency' 'ablation' '(' 'RFA' ')' 'of' 'localized' 'lesions'
 'should' 'have' 'been' 'performed' '>' '=' '2' 'weeks' 'prior' 'to'
 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01822522,",68:77:treatment",Any of the following within 28 days before the first dose of study treatment,"['Any' 'of' 'the' 'following' 'within' '28' 'days' 'before' 'the' 'first'
 'dose' 'of' 'study' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01822522,",,,100:109:treatment",Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment,"['Hemoptysis' 'of' '>' '=' '0.5' 'teaspoon' '(' '2.5' 'mL' ')' 'of' 'red'
 'blood' 'within' '3' 'months' 'before' 'the' 'first' 'dose' 'of' 'study'
 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01822522,",,,,,195:204:treatment",The participant has prothrombin time (PT)/international normalized ratio (INR) or partial thromboplastin time (PTT) test >= 1.3 x the laboratory ULN within 7 days before the first dose of study treatment,"['The' 'participant' 'has' 'prothrombin' 'time' '(' 'PT' ')'
 '/international' 'normalized' 'ratio' '(' 'INR' ')' 'or' 'partial'
 'thromboplastin' 'time' '(' 'PTT' ')' 'test' '>' '=' '1.3' 'x' 'the'
 'laboratory' 'ULN' 'within' '7' 'days' 'before' 'the' 'first' 'dose' 'of'
 'study' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT01817751,",,,117:126:treatment",Any other hemorrhage/bleeding event >= grade 3 (NCI CTCAE v4.0) within 4 weeks or less prior to first dose of study treatment,"['Any' 'other' 'hemorrhage/bleeding' 'event' '>' '=' 'grade' '3' '(' 'NCI'
 'CTCAE' 'v4.0' ')' 'within' '4' 'weeks' 'or' 'less' 'prior' 'to' 'first'
 'dose' 'of' 'study' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1.]"
NCT01817751,",,,121:130:treatment",Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment,"['Women' 'of' 'childbearing' 'potential' 'must' 'have' 'a' 'negative'
 'serum' 'pregnancy' 'test' 'performed' 'within' '7' 'days' 'prior' 'to'
 'the' 'start' 'of' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01811498,",,124:133:treatment",Patients must agree to use a medically effective method of contraception during and for a period of three months after the treatment period,"['Patients' 'must' 'agree' 'to' 'use' 'a' 'medically' 'effective' 'method'
 'of' 'contraception' 'during' 'and' 'for' 'a' 'period' 'of' 'three'
 'months' 'after' 'the' 'treatment' 'period']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT01804634,58:67:treatment,Patients must be willing to participate in all stages of treatment,"['Patients' 'must' 'be' 'willing' 'to' 'participate' 'in' 'all' 'stages'
 'of' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01794793,",,,131:140:treatment",In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment,"['In' 'case' 'of' 'use' 'of' 'oral' 'contraception' 'women' 'should'
 'have' 'been' 'stable' 'on' 'the' 'same' 'pill' 'for' 'a' 'minimum' 'of'
 '3' 'months' 'before' 'taking' 'study' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1.]"
NCT01794793,58:67:treatment,"Willingness and ability to comply with scheduled visits, treatment plans and any other study procedures","['Willingness' 'and' 'ability' 'to' 'comply' 'with' 'scheduled' 'visits'
 ',' 'treatment' 'plans' 'and' 'any' 'other' 'study' 'procedures']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT01787409,61:70:treatment,"During the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up","['During' 'the' 'Active' 'Monitoring' 'Phase' 'of' 'a' 'study' '(' 'i.e.'
 ',' 'active' 'treatment' 'and' 'observation' ')' ',' 'participants'
 'must' 'be' 'willing' 'to' 'return' 'to' 'the' 'consenting' 'institution'
 'for' 'follow-up']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT01776190,"49:58:treatment,",You are unable to come in three days a week for treatment for a 10-week period,"['You' 'are' 'unable' 'to' 'come' 'in' 'three' 'days' 'a' 'week' 'for'
 'treatment' 'for' 'a' '10-week' 'period']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT01763970,",,79:88:treatment",refusal of women of child bearing potential to take a pregnancy test prior to treatment,"['refusal' 'of' 'women' 'of' 'child' 'bearing' 'potential' 'to' 'take' 'a'
 'pregnancy' 'test' 'prior' 'to' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01742299,58:67:treatment,"Willingness and ability to comply with scheduled visits, treatment plans and any other study procedures","['Willingness' 'and' 'ability' 'to' 'comply' 'with' 'scheduled' 'visits'
 ',' 'treatment' 'plans' 'and' 'any' 'other' 'study' 'procedures']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT01720836,",,59:68:treatment",Subjects must be within 4 to 12 weeks of standard of care treatment for their particular stage of disease,"['Subjects' 'must' 'be' 'within' '4' 'to' '12' 'weeks' 'of' 'standard'
 'of' 'care' 'treatment' 'for' 'their' 'particular' 'stage' 'of' 'disease']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT01720836,",63:72:treatment",Subjects must not be more than 12 weeks from standard of care treatment for their particular stage of disease,"['Subjects' 'must' 'not' 'be' 'more' 'than' '12' 'weeks' 'from' 'standard'
 'of' 'care' 'treatment' 'for' 'their' 'particular' 'stage' 'of' 'disease']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT01670877,",,77:86:treatment,",Men must agree and commit to use a barrier method of contraception while on treatment and for 3 months after the last dose of the investigational product,"['Men' 'must' 'agree' 'and' 'commit' 'to' 'use' 'a' 'barrier' 'method'
 'of' 'contraception' 'while' 'on' 'treatment' 'and' 'for' '3' 'months'
 'after' 'the' 'last' 'dose' 'of' 'the' 'investigational' 'product']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT01620216,",,175:184:treatment",Female and male patients who are fertile must agree to use an effective form of contraception with their sexual partners from randomization through 4 months after the end of treatment,"['Female' 'and' 'male' 'patients' 'who' 'are' 'fertile' 'must' 'agree'
 'to' 'use' 'an' 'effective' 'form' 'of' 'contraception' 'with' 'their'
 'sexual' 'partners' 'from' 'randomization' 'through' '4' 'months' 'after'
 'the' 'end' 'of' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1.]"
NCT01620216,",100:109:treatment",Persons of reproductive potential must agree to use an adequate method of contraception throughout treatment,"['Persons' 'of' 'reproductive' 'potential' 'must' 'agree' 'to' 'use' 'an'
 'adequate' 'method' 'of' 'contraception' 'throughout' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01581749,58:67:treatment,implanted hardware or other material that would prohibit treatment planning or delivery,"['implanted' 'hardware' 'or' 'other' 'material' 'that' 'would' 'prohibit'
 'treatment' 'planning' 'or' 'delivery']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT01562626,",,,82:91:treatment",women must have a negative serum or urine pregnancy test 1 week before beginning treatment on this trial,"['women' 'must' 'have' 'a' 'negative' 'serum' 'or' 'urine' 'pregnancy'
 'test' '1' 'week' 'before' 'beginning' 'treatment' 'on' 'this' 'trial']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT01532687,32:41:treatment,must be willing to comply with treatment and follow-up,['must' 'be' 'willing' 'to' 'comply' 'with' 'treatment' 'and' 'follow-up'],[0. 0. 0. 0. 0. 0. 1. 0. 0.]
NCT01495637,20:29:treatment,Persistence (after treatment) of any of the following in the PICU before enrollment:,"['Persistence' '(' 'after' 'treatment' ')' 'of' 'any' 'of' 'the'
 'following' 'in' 'the' 'PICU' 'before' 'enrollment' ':']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01367444,33:42:treatment,Enrolment in any other clinical treatment study throughout the duration of the SAR422459 study,"['Enrolment' 'in' 'any' 'other' 'clinical' 'treatment' 'study'
 'throughout' 'the' 'duration' 'of' 'the' 'SAR422459' 'study']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01366612,",,,,90:99:treatment",unwilling to use acceptable birth control methods (men or women) for twelve months after treatment,"['unwilling' 'to' 'use' 'acceptable' 'birth' 'control' 'methods' '(' 'men'
 'or' 'women' ')' 'for' 'twelve' 'months' 'after' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01312857,",,54:63:treatment",Calcium ≥ lower limit of normal (≤ 48 hours prior to treatment start.),"['Calcium' '≥' 'lower' 'limit' 'of' 'normal' '(' '≤' '48' 'hours' 'prior'
 'to' 'treatment' 'start' '.' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT01312857,",,31:40:treatment",Lab values ≤ 14 days prior to treatment start:,['Lab' 'values' '≤' '14' 'days' 'prior' 'to' 'treatment' 'start' ':'],[0. 0. 0. 0. 0. 0. 0. 1. 0. 0.]
NCT01312857,",,56:65:treatment",Magnesium ≥ lower limit of normal (≤ 48 hours prior to treatment start.),"['Magnesium' '≥' 'lower' 'limit' 'of' 'normal' '(' '≤' '48' 'hours'
 'prior' 'to' 'treatment' 'start' '.' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT01312857,",36:45:treatment",Renal function (≤ 14 days prior to treatment start),"['Renal' 'function' '(' '≤' '14' 'days' 'prior' 'to' 'treatment' 'start'
 ')']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.]
NCT01306045,",222:231:treatment",Individuals who meet the eligibility criteria for EGFR germline mutation testing but who do not have advanced cancer as defined in 3.1.1 may enroll for EGFR germline mutation testing only and will not be eligible for the treatment or NOS arms,"['Individuals' 'who' 'meet' 'the' 'eligibility' 'criteria' 'for' 'EGFR'
 'germline' 'mutation' 'testing' 'but' 'who' 'do' 'not' 'have' 'advanced'
 'cancer' 'as' 'defined' 'in' '3.1.1' 'may' 'enroll' 'for' 'EGFR'
 'germline' 'mutation' 'testing' 'only' 'and' 'will' 'not' 'be' 'eligible'
 'for' 'the' 'treatment' 'or' 'NOS' 'arms']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]"
NCT01280669,18:27:treatment,are receiving no treatment,['are' 'receiving' 'no' 'treatment'],[0. 0. 0. 1.]
NCT01269853,",,124:133:treatment",Patients must agree to use a medically effective method of contraception during and for a period of three months after the treatment period,"['Patients' 'must' 'agree' 'to' 'use' 'a' 'medically' 'effective' 'method'
 'of' 'contraception' 'during' 'and' 'for' 'a' 'period' 'of' 'three'
 'months' 'after' 'the' 'treatment' 'period']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT01261728,31:40:treatment,"Supportive care trials or non-treatment trials, e.g. QOL","['Supportive' 'care' 'trials' 'or' 'non-treatment' 'trials' ',' 'e.g' '.'
 'QOL']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT01220583,",,,123:132:treatment,",Women of childbearing potential and male participants who are sexually active must practice adequate contraception during treatment and for 6 weeks following treatment,"['Women' 'of' 'childbearing' 'potential' 'and' 'male' 'participants' 'who'
 'are' 'sexually' 'active' 'must' 'practice' 'adequate' 'contraception'
 'during' 'treatment' 'and' 'for' '6' 'weeks' 'following' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT01174121,",,136:145:treatment",Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for four months after treatment,"['Patients' 'of' 'both' 'genders' 'must' 'be' 'willing' 'to' 'practice'
 'birth' 'control' 'from' 'the' 'time' 'of' 'enrollment' 'on' 'this'
 'study' 'and' 'for' 'four' 'months' 'after' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1.]"
NCT01174121,18:27:treatment,The experimental treatment being evaluated in this protocol depends on an intact immune system,"['The' 'experimental' 'treatment' 'being' 'evaluated' 'in' 'this'
 'protocol' 'depends' 'on' 'an' 'intact' 'immune' 'system']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01174121,",,122:131:treatment",Women of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the treatment on the fetus,"['Women' 'of' 'child-bearing' 'potential' 'must' 'have' 'a' 'negative'
 'pregnancy' 'test' 'because' 'of' 'the' 'potentially' 'dangerous'
 'effects' 'of' 'the' 'treatment' 'on' 'the' 'fetus']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT01174121,",,120:129:treatment",Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant,"['Women' 'of' 'child-bearing' 'potential' 'who' 'are' 'pregnant' 'or'
 'breastfeeding' 'because' 'of' 'the' 'potentially' 'dangerous' 'effects'
 'of' 'the' 'treatment' 'on' 'the' 'fetus' 'or' 'infant']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT01059786,",59:68:treatment",agree to use an acceptable method of birth control during treatment and for twelve months after completion of treatment,"['agree' 'to' 'use' 'an' 'acceptable' 'method' 'of' 'birth' 'control'
 'during' 'treatment' 'and' 'for' 'twelve' 'months' 'after' 'completion'
 'of' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00906984,",19:28:treatment",within 15 days of treatment demonstrating,['within' '15' 'days' 'of' 'treatment' 'demonstrating'],[0. 0. 0. 0. 1. 0.]
NCT00739362,31:40:treatment,Right-handedness (because the treatment will be given to the left dorsolateral prefrontal cortex and the evidence accumulated in this region was only in right-handed individuals),"['Right-handedness' '(' 'because' 'the' 'treatment' 'will' 'be' 'given'
 'to' 'the' 'left' 'dorsolateral' 'prefrontal' 'cortex' 'and' 'the'
 'evidence' 'accumulated' 'in' 'this' 'region' 'was' 'only' 'in'
 'right-handed' 'individuals' ')']","[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT00472329,",,,,99:108:treatment",Fertile men or women unwilling to use contraceptive techniques during and for 12 months following treatment,"['Fertile' 'men' 'or' 'women' 'unwilling' 'to' 'use' 'contraceptive'
 'techniques' 'during' 'and' 'for' '12' 'months' 'following' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT00338377,",,60:69:treatment",Pregnancy testing will be performed within 7 days prior to treatment. (Turnstile II),"['Pregnancy' 'testing' 'will' 'be' 'performed' 'within' '7' 'days' 'prior'
 'to' 'treatment' '.' '(' 'Turnstile' 'II' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT00004317,"4:13:treatment,",No treatment within the first year of life,['No' 'treatment' 'within' 'the' 'first' 'year' 'of' 'life'],[0. 1. 0. 0. 0. 0. 0. 0.]
NCT03179163,1:9:chronic_disease,diabetes,['diabetes'],[2.]
NCT03099590,24:32:chronic_disease,laboratory evidence of diabetes,['laboratory' 'evidence' 'of' 'diabetes'],[0. 0. 0. 2.]
NCT03060772,12:20:chronic_disease,History of diabetes,['History' 'of' 'diabetes'],[0. 0. 2.]
NCT03058146,12:20:chronic_disease,History of diabetes,['History' 'of' 'diabetes'],[0. 0. 2.]
NCT03041844,81:89:chronic_disease,DUs must be present on the ankle or foot and be secondary to complications from diabetes,"['DUs' 'must' 'be' 'present' 'on' 'the' 'ankle' 'or' 'foot' 'and' 'be'
 'secondary' 'to' 'complications' 'from' 'diabetes']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT03034213,"14:22:chronic_disease,,,",Uncontrolled diabetes (i.e. known HbA1C value > 7% within the prior 6 weeks of the Screening Visit),"['Uncontrolled' 'diabetes' '(' 'i.e' '.' 'known' 'HbA1C' 'value' '>' '7'
 '%' 'within' 'the' 'prior' '6' 'weeks' 'of' 'the' 'Screening' 'Visit' ')']",[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03003689,1:9:chronic_disease,diabetes,['diabetes'],[2.]
NCT02975986,1:9:chronic_disease,diabetes status,['diabetes' 'status'],[2. 0.]
NCT02967315,15:23:chronic_disease,Patients with diabetes,['Patients' 'with' 'diabetes'],[0. 0. 2.]
NCT02964039,14:22:chronic_disease,"Uncontrolled diabetes with recent weight loss, diabetic coma, or frequent insulin reactions","['Uncontrolled' 'diabetes' 'with' 'recent' 'weight' 'loss' ',' 'diabetic'
 'coma' ',' 'or' 'frequent' 'insulin' 'reactions']",[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02927639,"19:27:chronic_disease,",Have been seen in diabetes clinic in the last 6 months,"['Have' 'been' 'seen' 'in' 'diabetes' 'clinic' 'in' 'the' 'last' '6'
 'months']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT02881515,12:20:chronic_disease,history of diabetes,['history' 'of' 'diabetes'],[0. 0. 2.]
NCT02857283,1:9:chronic_disease,diabetes requiring medication,['diabetes' 'requiring' 'medication'],[2. 0. 0.]
NCT02838797,1:9:chronic_disease,diabetes,['diabetes'],[2.]
NCT02836574,14:22:chronic_disease,uncontrolled diabetes (defined as metabolically unstable by the Investigator),"['uncontrolled' 'diabetes' '(' 'defined' 'as' 'metabolically' 'unstable'
 'by' 'the' 'Investigator' ')']",[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02823665,59:67:chronic_disease,Healthy non-surgical patients with no personal history of diabetes,"['Healthy' 'non-surgical' 'patients' 'with' 'no' 'personal' 'history' 'of'
 'diabetes']",[0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02823665,56:64:chronic_disease,Healthy non-surgical patients with personal history of diabetes,"['Healthy' 'non-surgical' 'patients' 'with' 'personal' 'history' 'of'
 'diabetes']",[0. 0. 0. 0. 0. 0. 0. 2.]
NCT02798458,"14:22:chronic_disease,,",Uncontrolled diabetes with a hemoglobin A1C greater than 10,"['Uncontrolled' 'diabetes' 'with' 'a' 'hemoglobin' 'A1C' 'greater' 'than'
 '10']",[0. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02772562,14:22:chronic_disease,Uncontrolled diabetes,['Uncontrolled' 'diabetes'],[0. 2.]
NCT02751866,1:9:chronic_disease,diabetes,['diabetes'],[2.]
NCT02723266,23:31:chronic_disease,signs and symptoms of diabetes,['signs' 'and' 'symptoms' 'of' 'diabetes'],[0. 0. 0. 0. 2.]
NCT02690116,14:22:chronic_disease,Uncontrolled diabetes (fatigue-related factor),['Uncontrolled' 'diabetes' '(' 'fatigue-related' 'factor' ')'],[0. 2. 0. 0. 0. 0.]
NCT02682147,1:9:chronic_disease,diabetes,['diabetes'],[2.]
NCT02578732,14:22:chronic_disease,"Uncontrolled diabetes. If patient has diabetes, confirmation on status (controlled or uncontrolled) required at registration","['Uncontrolled' 'diabetes' '.' 'If' 'patient' 'has' 'diabetes' ','
 'confirmation' 'on' 'status' '(' 'controlled' 'or' 'uncontrolled' ')'
 'required' 'at' 'registration']",[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02555280,14:22:chronic_disease,Uncontrolled diabetes,['Uncontrolled' 'diabetes'],[0. 2.]
NCT02531932,"14:22:chronic_disease,,",uncontrolled diabetes as defined by fasting serum glucose >1.5 x ULN,"['uncontrolled' 'diabetes' 'as' 'defined' 'by' 'fasting' 'serum' 'glucose'
 '>' '1.5' 'x' 'ULN']",[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02522494,14:22:chronic_disease,Drug-induced diabetes,['Drug-induced' 'diabetes'],[0. 2.]
NCT02462161,13:21:chronic_disease,Preexisting diabetes,['Preexisting' 'diabetes'],[0. 2.]
NCT02430077,"32:40:chronic_disease,,,,",Previous clinical diagnosis of diabetes mellitus or fasting blood glucose ≥ 126 mg/dL or hemoglobin A1c ≥ 6.5%,"['Previous' 'clinical' 'diagnosis' 'of' 'diabetes' 'mellitus' 'or'
 'fasting' 'blood' 'glucose' '≥' '126' 'mg/dL' 'or' 'hemoglobin' 'A1c' '≥'
 '6.5' '%']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02425566,1:9:chronic_disease,diabetes,['diabetes'],[2.]
NCT02417701,"26:34:chronic_disease,,",Patients with controlled diabetes are allowed on study; controlled diabetes is defined as fetal bovine serum (FBS) =< 130 mg/dL in the context of this study,"['Patients' 'with' 'controlled' 'diabetes' 'are' 'allowed' 'on' 'study'
 ';' 'controlled' 'diabetes' 'is' 'defined' 'as' 'fetal' 'bovine' 'serum'
 '(' 'FBS' ')' '=' '<' '130' 'mg/dL' 'in' 'the' 'context' 'of' 'this'
 'study']","[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02408120,36:44:chronic_disease,Hyperglycemia without a history of diabetes,['Hyperglycemia' 'without' 'a' 'history' 'of' 'diabetes'],[0. 0. 0. 0. 0. 2.]
NCT02373644,1:9:chronic_disease,diabetes,['diabetes'],[2.]
NCT02347995,"38:46:chronic_disease,,,,",untreated and / or poorly controlled diabetes with fasting blood glucose of greater than 170 and HbA1c greater than 10.0,"['untreated' 'and' '/' 'or' 'poorly' 'controlled' 'diabetes' 'with'
 'fasting' 'blood' 'glucose' 'of' 'greater' 'than' '170' 'and' 'HbA1c'
 'greater' 'than' '10.0']",[0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02329652,1:9:chronic_disease,diabetes or any condition which requires frequent blood pressure monitoring or frequent venipuncture,"['diabetes' 'or' 'any' 'condition' 'which' 'requires' 'frequent' 'blood'
 'pressure' 'monitoring' 'or' 'frequent' 'venipuncture']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02307565,1:9:chronic_disease,diabetes,['diabetes'],[2.]
NCT02253368,1:9:chronic_disease,diabetes,['diabetes'],[2.]
NCT02245841,28:36:chronic_disease,Patients with uncontrolled diabetes,['Patients' 'with' 'uncontrolled' 'diabetes'],[0. 0. 0. 2.]
NCT02244814,23:31:chronic_disease,suspected preexisting diabetes,['suspected' 'preexisting' 'diabetes'],[0. 0. 2.]
NCT02226159,"1:9:chronic_disease,,",diabetes (type I or type II),['diabetes' '(' 'type' 'I' 'or' 'type' 'II' ')'],[2. 0. 0. 0. 0. 0. 0. 0.]
NCT02219581,15:23:chronic_disease,Patients with diabetes,['Patients' 'with' 'diabetes'],[0. 0. 2.]
NCT02169037,1:9:chronic_disease,diabetes (1 point),['diabetes' '(' '1' 'point' ')'],[2. 0. 0. 0. 0.]
NCT02139436,1:9:chronic_disease,diabetes,['diabetes'],[2.]
NCT02095808,19:27:chronic_disease,Poorly controlled diabetes,['Poorly' 'controlled' 'diabetes'],[0. 0. 2.]
NCT02087826,60:68:chronic_disease,Currently taking any medications used for the treatment of diabetes,"['Currently' 'taking' 'any' 'medications' 'used' 'for' 'the' 'treatment'
 'of' 'diabetes']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT01954966,1:9:chronic_disease,diabetes,['diabetes'],[2.]
NCT01905046,",,74:82:chronic_disease",Patients with hemoglobin a1c > 6.3 or who are being actively treated for diabetes,"['Patients' 'with' 'hemoglobin' 'a1c' '>' '6.3' 'or' 'who' 'are' 'being'
 'actively' 'treated' 'for' 'diabetes']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT01883258,12:20:chronic_disease,history of diabetes,['history' 'of' 'diabetes'],[0. 0. 2.]
NCT01807897,"19:27:chronic_disease,,",Poorly controlled diabetes (HbA1c > 9.0),['Poorly' 'controlled' 'diabetes' '(' 'HbA1c' '>' '9.0' ')'],[0. 0. 2. 0. 0. 0. 0. 0.]
NCT01803451,25:33:chronic_disease,healthy control without diabetes,['healthy' 'control' 'without' 'diabetes'],[0. 0. 0. 2.]
NCT01653080,12:20:chronic_disease,History of diabetes,['History' 'of' 'diabetes'],[0. 0. 2.]
NCT01627301,1:9:chronic_disease,diabetes,['diabetes'],[2.]
NCT01573429,14:22:chronic_disease,Uncontrolled diabetes,['Uncontrolled' 'diabetes'],[0. 2.]
NCT01422746,"23:31:chronic_disease,,,,","Previous diagnosis of diabetes, fasting glucose ≥126 mg/dL, or a hemoglobin A1c ≥6.5%","['Previous' 'diagnosis' 'of' 'diabetes' ',' 'fasting' 'glucose' '≥126'
 'mg/dL' ',' 'or' 'a' 'hemoglobin' 'A1c' '≥6.5' '%']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01421810,"23:31:chronic_disease,,,,","Previous diagnosis of diabetes, fasting glucose ≥126 mg/dL, or a hemoglobin A1c >6.5%","['Previous' 'diagnosis' 'of' 'diabetes' ',' 'fasting' 'glucose' '≥126'
 'mg/dL' ',' 'or' 'a' 'hemoglobin' 'A1c' '>' '6.5' '%']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01269034,1:9:chronic_disease,diabetes,['diabetes'],[2.]
NCT01028846,22:30:chronic_disease,No family history of diabetes,['No' 'family' 'history' 'of' 'diabetes'],[0. 0. 0. 0. 2.]
NCT00930228,25:33:chronic_disease,A previous diagnosis of diabetes,['A' 'previous' 'diagnosis' 'of' 'diabetes'],[0. 0. 0. 0. 2.]
NCT00929006,"23:31:chronic_disease,,,,","Previous diagnosis of diabetes, fasting glucose > or = 126 mg/dl, or a hemoglobin A1c > or = 6.5%","['Previous' 'diagnosis' 'of' 'diabetes' ',' 'fasting' 'glucose' '>' 'or'
 '=' '126' 'mg/dl' ',' 'or' 'a' 'hemoglobin' 'A1c' '>' 'or' '=' '6.5' '%']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00862433,",,51:59:chronic_disease",Nonobese (BMI less than or equal to 29.9) without diabetes,"['Nonobese' '(' 'BMI' 'less' 'than' 'or' 'equal' 'to' '29.9' ')' 'without'
 'diabetes']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT00862433,",,54:62:chronic_disease",Overweight (BMI greater than or equal to 27) without diabetes,"['Overweight' '(' 'BMI' 'greater' 'than' 'or' 'equal' 'to' '27' ')'
 'without' 'diabetes']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT00678145,27:35:chronic_disease,1st degree relatives with diabetes,['1st' 'degree' 'relatives' 'with' 'diabetes'],[0. 0. 0. 0. 2.]
NCT00678145,30:38:chronic_disease,No 1st degree relatives with diabetes,['No' '1st' 'degree' 'relatives' 'with' 'diabetes'],[0. 0. 0. 0. 0. 2.]
NCT00594217,"25:33:chronic_disease,,,,","A previous diagnosis of diabetes, a fasting glucose ≥ 126 mg/dl, or a hemoglobin A1c > 6.5%","['A' 'previous' 'diagnosis' 'of' 'diabetes' ',' 'a' 'fasting' 'glucose'
 '≥' '126' 'mg/dl' ',' 'or' 'a' 'hemoglobin' 'A1c' '>' '6.5' '%']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00085982,13:21:chronic_disease,Presence of diabetes as defined by the 2006 ADA criteria,"['Presence' 'of' 'diabetes' 'as' 'defined' 'by' 'the' '2006' 'ADA'
 'criteria']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT03177265,20:28:chronic_disease,ICD 9 diagnosis of dementia (excluded during data abstraction process),"['ICD' '9' 'diagnosis' 'of' 'dementia' '(' 'excluded' 'during' 'data'
 'abstraction' 'process' ')']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT03166371,9:17:chronic_disease,Current dementia,['Current' 'dementia'],[0. 2.]
NCT03134274,6:14:chronic_disease,Have dementia,['Have' 'dementia'],[0. 2.]
NCT03116464,"44:52:chronic_disease,",Be involved in the care of the person with dementia (at least 4 hours of care per day),"['Be' 'involved' 'in' 'the' 'care' 'of' 'the' 'person' 'with' 'dementia'
 '(' 'at' 'least' '4' 'hours' 'of' 'care' 'per' 'day' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03116464,81:89:chronic_disease,Be the primary unpaid family or friend who helps or supports an individual with dementia,"['Be' 'the' 'primary' 'unpaid' 'family' 'or' 'friend' 'who' 'helps' 'or'
 'supports' 'an' 'individual' 'with' 'dementia']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT03070535,12:20:chronic_disease,"Be free of dementia, and able to cognitively and physically give informed consent","['Be' 'free' 'of' 'dementia' ',' 'and' 'able' 'to' 'cognitively' 'and'
 'physically' 'give' 'informed' 'consent']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03054519,",,52:60:chronic_disease",Mini-Mental Status Examination (MMSE) score <23 or dementia,"['Mini-Mental' 'Status' 'Examination' '(' 'MMSE' ')' 'score' '<' '23' 'or'
 'dementia']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT03053908,",,74:82:chronic_disease",History of a first-degree family member with early onset (age <60 years) dementia,"['History' 'of' 'a' 'first-degree' 'family' 'member' 'with' 'early'
 'onset' '(' 'age' '<' '60' 'years' ')' 'dementia']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT03046121,"21:29:chronic_disease,,,,","screen positive for dementia on well-validated scales (Montreal Cognitive Assessment {MoCA} ≤ 25 123-127 and AD8 >2 128,129)","['screen' 'positive' 'for' 'dementia' 'on' 'well-validated' 'scales' '('
 'Montreal' 'Cognitive' 'Assessment' '{' 'MoCA' '}' '≤' '25' '123-127'
 'and' 'AD8' '>' '2' '128,129' ')']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03037879,",,44:52:chronic_disease",Pre-screen MoCA score of < 22 (to rule out dementia),"['Pre-screen' 'MoCA' 'score' 'of' '<' '22' '(' 'to' 'rule' 'out'
 'dementia' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0.]
NCT02982759,63:71:chronic_disease,Exclusion criteria include children with clinically-diagnosed dementia,"['Exclusion' 'criteria' 'include' 'children' 'with' 'clinically-diagnosed'
 'dementia']",[0. 0. 0. 0. 0. 0. 2.]
NCT02955537,117:125:chronic_disease,Patients with other serious medical conditions that may affect their ability to self-monitor blood pressure (such a dementia),"['Patients' 'with' 'other' 'serious' 'medical' 'conditions' 'that' 'may'
 'affect' 'their' 'ability' 'to' 'self-monitor' 'blood' 'pressure' '('
 'such' 'a' 'dementia' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0.]
NCT02901041,1:9:chronic_disease,dementia,['dementia'],[2.]
NCT02872857,12:20:chronic_disease,History of dementia,['History' 'of' 'dementia'],[0. 0. 2.]
NCT02839759,13:21:chronic_disease,No signs of dementia,['No' 'signs' 'of' 'dementia'],[0. 0. 0. 2.]
NCT02833792,"33:41:chronic_disease,","Diagnosed with mild to moderate dementia for at least 3 months prior to enrollment, based on the National Institute of Neurological and Communicative","['Diagnosed' 'with' 'mild' 'to' 'moderate' 'dementia' 'for' 'at' 'least'
 '3' 'months' 'prior' 'to' 'enrollment' ',' 'based' 'on' 'the' 'National'
 'Institute' 'of' 'Neurological' 'and' 'Communicative']",[0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02830074,64:72:chronic_disease,"unable to provide self-consent for participation (e.g., due to dementia)","['unable' 'to' 'provide' 'self-consent' 'for' 'participation' '(' 'e.g.'
 ',' 'due' 'to' 'dementia' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0.]
NCT02778282,20:28:chronic_disease,DSM-V diagnosis of dementia,['DSM-V' 'diagnosis' 'of' 'dementia'],[0. 0. 0. 2.]
NCT02762604,"13:21:chronic_disease,,,,",Presence of dementia (telephone-based memory impairment screen < 5 or Ascertain Dementia 8-item Informant Questionnaire score > 1),"['Presence' 'of' 'dementia' '(' 'telephone-based' 'memory' 'impairment'
 'screen' '<' '5' 'or' 'Ascertain' 'Dementia' '8-item' 'Informant'
 'Questionnaire' 'score' '>' '1' ')']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02726906,12:20:chronic_disease,Absence of dementia,['Absence' 'of' 'dementia'],[0. 0. 2.]
NCT02726906,10:18:chronic_disease,Baseline dementia,['Baseline' 'dementia'],[0. 2.]
NCT02724930,1:9:chronic_disease,dementia,['dementia'],[2.]
NCT02698722,18:26:chronic_disease,Known history of dementia,['Known' 'history' 'of' 'dementia'],[0. 0. 0. 2.]
NCT02663934,13:21:chronic_disease,presence of dementia,['presence' 'of' 'dementia'],[0. 0. 2.]
NCT02614365,",,35:43:chronic_disease",Scored below 24 on the MMSE (have dementia),['Scored' 'below' '24' 'on' 'the' 'MMSE' '(' 'have' 'dementia' ')'],[0. 0. 0. 0. 0. 0. 0. 0. 2. 0.]
NCT02600754,10:18:chronic_disease,probable dementia,['probable' 'dementia'],[0. 2.]
NCT02567227,13:21:chronic_disease,Presence of dementia,['Presence' 'of' 'dementia'],[0. 0. 2.]
NCT02567227,1:9:chronic_disease,dementia diagnosed by baseline cognitive assessment,['dementia' 'diagnosed' 'by' 'baseline' 'cognitive' 'assessment'],[2. 0. 0. 0. 0. 0.]
NCT02563574,13:21:chronic_disease,Evidence of dementia,['Evidence' 'of' 'dementia'],[0. 0. 2.]
NCT02465034,"10:18:chronic_disease,",Signs of dementia (score < 24 on the Montreal Cognitive Assessment),"['Signs' 'of' 'dementia' '(' 'score' '<' '24' 'on' 'the' 'Montreal'
 'Cognitive' 'Assessment' ')']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02461927,9:17:chronic_disease,Current dementia,['Current' 'dementia'],[0. 2.]
NCT02460900,"20:28:chronic_disease,,",Meets criteria for dementia by scoring below 10 on the Hopkins HIV Dementia Scale,"['Meets' 'criteria' 'for' 'dementia' 'by' 'scoring' 'below' '10' 'on'
 'the' 'Hopkins' 'HIV' 'Dementia' 'Scale']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02457832,12:20:chronic_disease,Absence of dementia,['Absence' 'of' 'dementia'],[0. 0. 2.]
NCT02427997,"11:19:chronic_disease,,",free from dementia as determined using the Mini Mental State Exam (MMSE>=24),"['free' 'from' 'dementia' 'as' 'determined' 'using' 'the' 'Mini' 'Mental'
 'State' 'Exam' '(' 'MMSE' '>' '=24' ')']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02414178,34:42:chronic_disease,"Cognitively normal, or with mild dementia, as assessed clinically","['Cognitively' 'normal' ',' 'or' 'with' 'mild' 'dementia' ',' 'as'
 'assessed' 'clinically']",[0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0.]
NCT02389465,21:29:chronic_disease,Absence of clinical dementia,['Absence' 'of' 'clinical' 'dementia'],[0. 0. 0. 2.]
NCT02366611,13:21:chronic_disease,Substantial dementia,['Substantial' 'dementia'],[0. 2.]
NCT02347995,1:9:chronic_disease,dementia by clinical evaluation,['dementia' 'by' 'clinical' 'evaluation'],[2. 0. 0. 0.]
NCT02347202,71:79:chronic_disease,caregivers who participate must be spouses or partners of people with dementia living with them at home when they enter the study,"['caregivers' 'who' 'participate' 'must' 'be' 'spouses' 'or' 'partners'
 'of' 'people' 'with' 'dementia' 'living' 'with' 'them' 'at' 'home' 'when'
 'they' 'enter' 'the' 'study']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02347202,86:94:chronic_disease,not having a family member with whom they are in communication about the person with dementia,"['not' 'having' 'a' 'family' 'member' 'with' 'whom' 'they' 'are' 'in'
 'communication' 'about' 'the' 'person' 'with' 'dementia']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02346929,1:9:chronic_disease,dementia,['dementia'],[2.]
NCT02332291,1:9:chronic_disease,dementia,['dementia'],[2.]
NCT02317523,41:49:chronic_disease,Providing in-home care to a spouse with dementia,['Providing' 'in-home' 'care' 'to' 'a' 'spouse' 'with' 'dementia'],[0. 0. 0. 0. 0. 0. 0. 2.]
NCT02266004,1:9:chronic_disease,dementia,['dementia'],[2.]
NCT02260258,14:22:chronic_disease,Pre-existing dementia,['Pre-existing' 'dementia'],[0. 2.]
NCT02219555,81:89:chronic_disease,"someone who could be considered a vulnerable person, such as an individual with dementia","['someone' 'who' 'could' 'be' 'considered' 'a' 'vulnerable' 'person' ','
 'such' 'as' 'an' 'individual' 'with' 'dementia']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02204956,22:30:chronic_disease,current diagnosis of dementia,['current' 'diagnosis' 'of' 'dementia'],[0. 0. 0. 2.]
NCT02165449,14:22:chronic_disease,Diagnosis of dementia of any type,['Diagnosis' 'of' 'dementia' 'of' 'any' 'type'],[0. 0. 2. 0. 0. 0.]
NCT02137122,"13:21:chronic_disease,,",Evidence of dementia (MMSE < 20),['Evidence' 'of' 'dementia' '(' 'MMSE' '<' '20' ')'],[0. 0. 2. 0. 0. 0. 0. 0.]
NCT01973283,",,41:49:chronic_disease",Mini Mental Exam < 24 or a diagnosis of dementia,['Mini' 'Mental' 'Exam' '<' '24' 'or' 'a' 'diagnosis' 'of' 'dementia'],[0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT01811381,14:22:chronic_disease,diagnosis of dementia,['diagnosis' 'of' 'dementia'],[0. 0. 2.]
NCT01530958,11:19:chronic_disease,prevalent dementia,['prevalent' 'dementia'],[0. 2.]
NCT03178552,7:41:chronic_disease,Known human immunodeficiency virus (HIV) positivity,['Known' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')' 'positivity'],[0. 2. 2. 2. 2. 0. 0. 0.]
NCT03137771,"7:41:chronic_disease,,",Known human immunodeficiency virus (HIV) positive with cluster of differentiation 4 (CD4) count < 200 cells/microliter,"['Known' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')' 'positive'
 'with' 'cluster' 'of' 'differentiation' '4' '(' 'CD4' ')' 'count' '<'
 '200' 'cells/microliter']",[0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03125902,10:44:chronic_disease,Negative human immunodeficiency virus (HIV) test at screening,"['Negative' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')' 'test' 'at'
 'screening']",[0. 2. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT03000257,37:71:chronic_disease,Confirmed positive test results for human immunodeficiency virus (HIV),"['Confirmed' 'positive' 'test' 'results' 'for' 'human' 'immunodeficiency'
 'virus' '(' 'HIV' ')']",[0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT02845596,16:50:chronic_disease,Infection with human immunodeficiency virus (HIV),['Infection' 'with' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')'],[0. 0. 2. 2. 2. 2. 0. 0.]
NCT02799095,41:75:chronic_disease,The subject is known to be positive for human immunodeficiency virus (HIV),"['The' 'subject' 'is' 'known' 'to' 'be' 'positive' 'for' 'human'
 'immunodeficiency' 'virus' '(' 'HIV' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT02682407,21:55:chronic_disease,Have a diagnosis of human immunodeficiency virus (HIV),"['Have' 'a' 'diagnosis' 'of' 'human' 'immunodeficiency' 'virus' '(' 'HIV'
 ')']",[0. 0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT02663622,47:81:chronic_disease,Patients seropositive or PCR positive for the human immunodeficiency virus (HIV),"['Patients' 'seropositive' 'or' 'PCR' 'positive' 'for' 'the' 'human'
 'immunodeficiency' 'virus' '(' 'HIV' ')']",[0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT02547662,7:41:chronic_disease,Known human immunodeficiency virus (HIV) positive,['Known' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')' 'positive'],[0. 2. 2. 2. 2. 0. 0. 0.]
NCT02536794,1:35:chronic_disease,human immunodeficiency virus (HIV),['human' 'immunodeficiency' 'virus' '(' 'HIV' ')'],[2. 2. 2. 2. 0. 0.]
NCT02495415,47:81:chronic_disease,"Known history of, or positive test result for human immunodeficiency virus (HIV) infection","['Known' 'history' 'of' ',' 'or' 'positive' 'test' 'result' 'for' 'human'
 'immunodeficiency' 'virus' '(' 'HIV' ')' 'infection']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0.]
NCT02493530,18:52:chronic_disease,Known history of human immunodeficiency virus (HIV),['Known' 'history' 'of' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')'],[0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT02456857,18:52:chronic_disease,Known history of human immunodeficiency virus (HIV) seropositivity,"['Known' 'history' 'of' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')'
 'seropositivity']",[0. 0. 0. 2. 2. 2. 2. 0. 0. 0.]
NCT02417701,7:41:chronic_disease,Known human immunodeficiency virus (HIV) positive patients who meet the following criteria,"['Known' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')' 'positive'
 'patients' 'who' 'meet' 'the' 'following' 'criteria']",[0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02411656,24:58:chronic_disease,Has a known history of human immunodeficiency virus (HIV),"['Has' 'a' 'known' 'history' 'of' 'human' 'immunodeficiency' 'virus' '('
 'HIV' ')']",[0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT02397083,38:72:chronic_disease,Patients who have a known history of human immunodeficiency virus (HIV) seropositivity,"['Patients' 'who' 'have' 'a' 'known' 'history' 'of' 'human'
 'immunodeficiency' 'virus' '(' 'HIV' ')' 'seropositivity']",[0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0.]
NCT02394028,1:35:chronic_disease,human immunodeficiency virus (HIV),['human' 'immunodeficiency' 'virus' '(' 'HIV' ')'],[2. 2. 2. 2. 0. 0.]
NCT02389309,21:55:chronic_disease,Patients with known human immunodeficiency virus (HIV),"['Patients' 'with' 'known' 'human' 'immunodeficiency' 'virus' '(' 'HIV'
 ')']",[0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT02323191,12:46:chronic_disease,History of human immunodeficiency virus (HIV),['History' 'of' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')'],[0. 0. 2. 2. 2. 2. 0. 0.]
NCT02273362,40:74:chronic_disease,Participants with a known diagnosis of human immunodeficiency virus (HIV),"['Participants' 'with' 'a' 'known' 'diagnosis' 'of' 'human'
 'immunodeficiency' 'virus' '(' 'HIV' ')']",[0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT02268253,11:45:chronic_disease,has known human immunodeficiency virus (HIV),['has' 'known' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')'],[0. 0. 2. 2. 2. 2. 0. 0.]
NCT02227199,35:69:chronic_disease,Patients known to be positive for human immunodeficiency virus (HIV),"['Patients' 'known' 'to' 'be' 'positive' 'for' 'human' 'immunodeficiency'
 'virus' '(' 'HIV' ')']",[0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT02215096,21:55:chronic_disease,A positive test for human immunodeficiency virus (HIV) antibody (testing at time of screening is not required),"['A' 'positive' 'test' 'for' 'human' 'immunodeficiency' 'virus' '(' 'HIV'
 ')' 'antibody' '(' 'testing' 'at' 'time' 'of' 'screening' 'is' 'not'
 'required' ')']",[0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02177838,15:49:chronic_disease,"Patients with human immunodeficiency virus (HIV) infection are not automatically excluded, but must meet the following criteria","['Patients' 'with' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')'
 'infection' 'are' 'not' 'automatically' 'excluded' ',' 'but' 'must'
 'meet' 'the' 'following' 'criteria']",[0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02165007,31:65:chronic_disease,Patients seropositive for the human immunodeficiency virus (HIV),"['Patients' 'seropositive' 'for' 'the' 'human' 'immunodeficiency' 'virus'
 '(' 'HIV' ')']",[0. 0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT02163317,1:35:chronic_disease,human immunodeficiency virus (HIV) testing,['human' 'immunodeficiency' 'virus' '(' 'HIV' ')' 'testing'],[2. 2. 2. 2. 0. 0. 0.]
NCT02146924,"31:65:chronic_disease,",research participants who are human immunodeficiency virus (HIV) positive based on testing performed within 4 weeks of enrollment,"['research' 'participants' 'who' 'are' 'human' 'immunodeficiency' 'virus'
 '(' 'HIV' ')' 'positive' 'based' 'on' 'testing' 'performed' 'within' '4'
 'weeks' 'of' 'enrollment']",[0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02122081,31:65:chronic_disease,Patients seropositive for the human immunodeficiency virus (HIV),"['Patients' 'seropositive' 'for' 'the' 'human' 'immunodeficiency' 'virus'
 '(' 'HIV' ')']",[0. 0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT02120222,13:47:chronic_disease,Known to be human immunodeficiency virus (HIV) seropositive,"['Known' 'to' 'be' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')'
 'seropositive']",[0. 0. 0. 2. 2. 2. 2. 0. 0. 0.]
NCT02106650,21:55:chronic_disease,"known, uncontrolled human immunodeficiency virus (HIV)-positive diagnosis","['known' ',' 'uncontrolled' 'human' 'immunodeficiency' 'virus' '(' 'HIV'
 ')' '-positive' 'diagnosis']",[0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0.]
NCT02003222,21:55:chronic_disease,Patients with known human immunodeficiency virus (HIV) infection,"['Patients' 'with' 'known' 'human' 'immunodeficiency' 'virus' '(' 'HIV'
 ')' 'infection']",[0. 0. 0. 2. 2. 2. 2. 0. 0. 0.]
NCT01976585,18:52:chronic_disease,Known history of human immunodeficiency virus (HIV),['Known' 'history' 'of' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')'],[0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT01976169,20:54:chronic_disease,Known positive for human immunodeficiency virus (HIV),['Known' 'positive' 'for' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')'],[0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT01951885,35:69:chronic_disease,Patients who are seropositive for human immunodeficiency virus (HIV),"['Patients' 'who' 'are' 'seropositive' 'for' 'human' 'immunodeficiency'
 'virus' '(' 'HIV' ')']",[0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT01925131,"30:64:chronic_disease,",Patients who are known to be human immunodeficiency virus (HIV)+ are eligible providing they meet all of the following additional criteria within 28 days prior to registration,"['Patients' 'who' 'are' 'known' 'to' 'be' 'human' 'immunodeficiency'
 'virus' '(' 'HIV' ')' '+' 'are' 'eligible' 'providing' 'they' 'meet'
 'all' 'of' 'the' 'following' 'additional' 'criteria' 'within' '28' 'days'
 'prior' 'to' 'registration']","[0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT01919619,7:41:chronic_disease,Known human immunodeficiency virus (HIV) seropositive,['Known' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')' 'seropositive'],[0. 2. 2. 2. 2. 0. 0. 0.]
NCT01823198,30:64:chronic_disease,Patients who are known to be human immunodeficiency virus (HIV)-seropositive,"['Patients' 'who' 'are' 'known' 'to' 'be' 'human' 'immunodeficiency'
 'virus' '(' 'HIV' ')' '-seropositive']",[0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0.]
NCT01817751,7:41:chronic_disease,Known human immunodeficiency virus (HIV) positivity,['Known' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')' 'positivity'],[0. 2. 2. 2. 2. 0. 0. 0.]
NCT01620216,7:41:chronic_disease,Known human immunodeficiency virus (HIV)-positive patient,"['Known' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')' '-positive'
 'patient']",[0. 2. 2. 2. 2. 0. 0. 0. 0.]
NCT01415882,7:41:chronic_disease,Known human immunodeficiency virus (HIV) positive,['Known' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')' 'positive'],[0. 2. 2. 2. 2. 0. 0. 0.]
NCT01037790,45:79:chronic_disease,The subject is known to be positive for the human immunodeficiency virus (HIV),"['The' 'subject' 'is' 'known' 'to' 'be' 'positive' 'for' 'the' 'human'
 'immunodeficiency' 'virus' '(' 'HIV' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT00919503,31:65:chronic_disease,Patients who are positive for human immunodeficiency virus (HIV),"['Patients' 'who' 'are' 'positive' 'for' 'human' 'immunodeficiency'
 'virus' '(' 'HIV' ')']",[0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT00716066,45:79:chronic_disease,Patients who are serologically positive for human immunodeficiency virus (HIV),"['Patients' 'who' 'are' 'serologically' 'positive' 'for' 'human'
 'immunodeficiency' 'virus' '(' 'HIV' ')']",[0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT00358657,14:48:chronic_disease,Positive for human immunodeficiency virus (HIV),['Positive' 'for' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')'],[0. 0. 2. 2. 2. 2. 0. 0.]
NCT03135171,"10:27:treatment,",The last radiation therapy must have occurred ≥3 weeks prior to study registration,"['The' 'last' 'radiation' 'therapy' 'must' 'have' 'occurred' '≥3' 'weeks'
 'prior' 'to' 'study' 'registration']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03113825,7:24:treatment,Prior radiation therapy to the chest [Period 2],['Prior' 'radiation' 'therapy' 'to' 'the' 'chest' '[' 'Period' '2' ']'],[0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT03077243,18:35:treatment,Prior history of radiation therapy to the head and neck,"['Prior' 'history' 'of' 'radiation' 'therapy' 'to' 'the' 'head' 'and'
 'neck']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT03076333,40:57:treatment,Previous radiation exposure precluding radiation therapy,['Previous' 'radiation' 'exposure' 'precluding' 'radiation' 'therapy'],[0. 1. 1. 0. 0. 0.]
NCT02982226,12:29:treatment,History of radiation therapy of the affected foot,['History' 'of' 'radiation' 'therapy' 'of' 'the' 'affected' 'foot'],[0. 0. 1. 1. 0. 0. 0. 0.]
NCT02774421,37:54:treatment,Patients who have already undergone radiation therapy for current recurrence,"['Patients' 'who' 'have' 'already' 'undergone' 'radiation' 'therapy' 'for'
 'current' 'recurrence']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0.]
NCT02501473,20:37:treatment,"For Parts 4 and 5, radiation therapy is omitted","['For' 'Parts' '4' 'and' '5' ',' 'radiation' 'therapy' 'is' 'omitted']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 0.]
NCT02496208,26:43:treatment,The subject has received radiation therapy,['The' 'subject' 'has' 'received' 'radiation' 'therapy'],[0. 0. 0. 0. 1. 1.]
NCT02442635,11:28:treatment,Receiving radiation therapy,['Receiving' 'radiation' 'therapy'],[0. 1. 1.]
NCT02434809,32:49:treatment,Patient is planning to undergo radiation therapy for primary,"['Patient' 'is' 'planning' 'to' 'undergo' 'radiation' 'therapy' 'for'
 'primary']",[0. 0. 0. 0. 0. 1. 1. 0. 0.]
NCT02359825,1:18:treatment,radiation therapy,['radiation' 'therapy'],[1. 1.]
NCT02315612,"1:18:treatment,",radiation therapy 3 weeks prior to apheresis,['radiation' 'therapy' '3' 'weeks' 'prior' 'to' 'apheresis'],[1. 1. 0. 0. 0. 0. 0.]
NCT02291848,",,72:89:treatment",Pulse oximetry of >93% on room air in patients who previously received radiation therapy,"['Pulse' 'oximetry' 'of' '>' '93' '%' 'on' 'room' 'air' 'in' 'patients'
 'who' 'previously' 'received' 'radiation' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02277548,33:50:treatment,Patients anticipated to receive radiation therapy with Protons,"['Patients' 'anticipated' 'to' 'receive' 'radiation' 'therapy' 'with'
 'Protons']",[0. 0. 0. 0. 1. 1. 0. 0.]
NCT02236013,"13:30:treatment,",Subject has radiation therapy within 4 weeks prior to the first study dose,"['Subject' 'has' 'radiation' 'therapy' 'within' '4' 'weeks' 'prior' 'to'
 'the' 'first' 'study' 'dose']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02217709,50:67:treatment,Patients should not be considered candidates for radiation therapy,"['Patients' 'should' 'not' 'be' 'considered' 'candidates' 'for'
 'radiation' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02208362,",123:140:treatment",Radiographic evidence of progression/recurrence of the measurable disease more than 12 weeks after the end of the initial radiation therapy,"['Radiographic' 'evidence' 'of' 'progression/recurrence' 'of' 'the'
 'measurable' 'disease' 'more' 'than' '12' 'weeks' 'after' 'the' 'end'
 'of' 'the' 'initial' 'radiation' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02163317,",,139:156:treatment","willing and able to complete the Expanded Prostate Cancer Index Composite (EPIC) questionnaire (baseline, 6, 12 and 24 months post end of radiation therapy)","['willing' 'and' 'able' 'to' 'complete' 'the' 'Expanded' 'Prostate'
 'Cancer' 'Index' 'Composite' '(' 'EPIC' ')' 'questionnaire' '('
 'baseline' ',' '6' ',' '12' 'and' '24' 'months' 'post' 'end' 'of'
 'radiation' 'therapy' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 1. 0.]"
NCT02160288,10:27:treatment,Previous radiation therapy to the anal canal and rectum,['Previous' 'radiation' 'therapy' 'to' 'the' 'anal' 'canal' 'and' 'rectum'],[0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02132598,26:43:treatment,The subject has received radiation therapy,['The' 'subject' 'has' 'received' 'radiation' 'therapy'],[0. 0. 0. 0. 1. 1.]
NCT02125786,"32:49:treatment,",Interval from start of initial radiation therapy to enrollment > 9 months,"['Interval' 'from' 'start' 'of' 'initial' 'radiation' 'therapy' 'to'
 'enrollment' '>' '9' 'months']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02125786,",,67:84:treatment",Pregnant women are excluded from enrollment on this study because radiation therapy is an agent with the potential for teratogenic or abortifacient effects,"['Pregnant' 'women' 'are' 'excluded' 'from' 'enrollment' 'on' 'this'
 'study' 'because' 'radiation' 'therapy' 'is' 'an' 'agent' 'with' 'the'
 'potential' 'for' 'teratogenic' 'or' 'abortifacient' 'effects']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02112617,83:100:treatment,Participants or their legal guardian must sign consent prior to the initiation of radiation therapy,"['Participants' 'or' 'their' 'legal' 'guardian' 'must' 'sign' 'consent'
 'prior' 'to' 'the' 'initiation' 'of' 'radiation' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02112617,"54:71:treatment,",Patients will be ineligible if any prior therapeutic radiation therapy > 500 cGy has been delivered,"['Patients' 'will' 'be' 'ineligible' 'if' 'any' 'prior' 'therapeutic'
 'radiation' 'therapy' '>' '500' 'cGy' 'has' 'been' 'delivered']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02112617,",,,99:116:treatment",Women of childbearing age/menstruating must have a negative pregnancy test prior to initiation of radiation therapy,"['Women' 'of' 'childbearing' 'age/menstruating' 'must' 'have' 'a'
 'negative' 'pregnancy' 'test' 'prior' 'to' 'initiation' 'of' 'radiation'
 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02110992,31:48:treatment,Original pathology report and radiation therapy records not available,"['Original' 'pathology' 'report' 'and' 'radiation' 'therapy' 'records'
 'not' 'available']",[0. 0. 0. 0. 1. 1. 0. 0. 0.]
NCT02078102,"33:50:treatment,",Patients must not have received radiation therapy within the past 4 weeks,"['Patients' 'must' 'not' 'have' 'received' 'radiation' 'therapy' 'within'
 'the' 'past' '4' 'weeks']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT01992861,24:41:treatment,Patients with no prior radiation therapy to the pelvis,['Patients' 'with' 'no' 'prior' 'radiation' 'therapy' 'to' 'the' 'pelvis'],[0. 0. 0. 0. 1. 1. 0. 0. 0.]
NCT01941316,"37:54:treatment,","Patients may have received previous radiation therapy, but it must have been completed at least 21 days prior to enrollment and the patient should have recovered from all associated toxicities","['Patients' 'may' 'have' 'received' 'previous' 'radiation' 'therapy' ','
 'but' 'it' 'must' 'have' 'been' 'completed' 'at' 'least' '21' 'days'
 'prior' 'to' 'enrollment' 'and' 'the' 'patient' 'should' 'have'
 'recovered' 'from' 'all' 'associated' 'toxicities']","[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT01878617,29:46:treatment,Completed protocol-directed radiation therapy,['Completed' 'protocol-directed' 'radiation' 'therapy'],[0. 0. 1. 1.]
NCT01871766,30:47:treatment,Patients requiring emergency radiation therapy are eligible for enrollment on this study,"['Patients' 'requiring' 'emergency' 'radiation' 'therapy' 'are' 'eligible'
 'for' 'enrollment' 'on' 'this' 'study']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT01817751,",43:60:treatment,",At least 12 weeks since the completion of radiation therapy to a total of >=50Gy,"['At' 'least' '12' 'weeks' 'since' 'the' 'completion' 'of' 'radiation'
 'therapy' 'to' 'a' 'total' 'of' '>' '=50Gy']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT01659203,27:44:allergy_name,History of sensitivity to radiation therapy,['History' 'of' 'sensitivity' 'to' 'radiation' 'therapy'],[0. 0. 0. 0. 4. 4.]
NCT01333046,",,88:105:treatment",Pulse oximetry of more than 95 percent on room air in patients who previously received radiation therapy,"['Pulse' 'oximetry' 'of' 'more' 'than' '95' 'percent' 'on' 'room' 'air'
 'in' 'patients' 'who' 'previously' 'received' 'radiation' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT03138512,35:53:chronic_disease,with an active known or suspected autoimmune disease,['with' 'an' 'active' 'known' 'or' 'suspected' 'autoimmune' 'disease'],[0. 0. 0. 0. 0. 0. 2. 2.]
NCT03123783,28:46:chronic_disease,"Active, known or suspected autoimmune disease","['Active' ',' 'known' 'or' 'suspected' 'autoimmune' 'disease']",[0. 0. 0. 0. 0. 2. 2.]
NCT03104699,26:44:chronic_disease,Active or history of any autoimmune disease,['Active' 'or' 'history' 'of' 'any' 'autoimmune' 'disease'],[0. 0. 0. 0. 0. 2. 2.]
NCT03001882,46:64:chronic_disease,"Participants with active, known or suspected autoimmune disease","['Participants' 'with' 'active' ',' 'known' 'or' 'suspected' 'autoimmune'
 'disease']",[0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02988960,"57:75:chronic_disease,",Participant must not have an active or prior documented autoimmune disease in the last 2 years,"['Participant' 'must' 'not' 'have' 'an' 'active' 'or' 'prior' 'documented'
 'autoimmune' 'disease' 'in' 'the' 'last' '2' 'years']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02955251,"28:46:chronic_disease,",Active or prior documented autoimmune disease in the last 2 years,"['Active' 'or' 'prior' 'documented' 'autoimmune' 'disease' 'in' 'the'
 'last' '2' 'years']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02947165,42:60:chronic_disease,"Patients with active, known or suspected autoimmune disease","['Patients' 'with' 'active' ',' 'known' 'or' 'suspected' 'autoimmune'
 'disease']",[0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02912572,8:26:chronic_disease,Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent,"['Active' 'autoimmune' 'disease' 'that' 'might' 'deteriorate' 'when'
 'receiving' 'an' 'immunostimulatory' 'agent']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02910700,98:116:chronic_disease,inhaled or topical steroids and adrenal replacement doses are permitted in the absence of active autoimmune disease,"['inhaled' 'or' 'topical' 'steroids' 'and' 'adrenal' 'replacement' 'doses'
 'are' 'permitted' 'in' 'the' 'absence' 'of' 'active' 'autoimmune'
 'disease']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02900794,1:19:chronic_disease,autoimmune disease,['autoimmune' 'disease'],[2. 2.]
NCT02869789,27:45:chronic_disease,"ctive, known or suspected autoimmune disease","['ctive' ',' 'known' 'or' 'suspected' 'autoimmune' 'disease']",[0. 0. 0. 0. 0. 2. 2.]
NCT02832167,46:64:chronic_disease,"Subjects with an active, known, or suspected autoimmune disease","['Subjects' 'with' 'an' 'active' ',' 'known' ',' 'or' 'suspected'
 'autoimmune' 'disease']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02762006,"28:46:chronic_disease,",Active or prior documented autoimmune disease within the past 2 years,"['Active' 'or' 'prior' 'documented' 'autoimmune' 'disease' 'within' 'the'
 'past' '2' 'years']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02759575,1:19:chronic_disease,autoimmune disease,['autoimmune' 'disease'],[2. 2.]
NCT02656706,42:60:chronic_disease,"Subjects with active, known or suspected autoimmune disease","['Subjects' 'with' 'active' ',' 'known' 'or' 'suspected' 'autoimmune'
 'disease']",[0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02635360,"23:41:chronic_disease,",Subject has an active autoimmune disease in the past 2 years,"['Subject' 'has' 'an' 'active' 'autoimmune' 'disease' 'in' 'the' 'past'
 '2' 'years']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02592551,"28:46:chronic_disease,",Active or prior documented autoimmune disease within the past 2 years,"['Active' 'or' 'prior' 'documented' 'autoimmune' 'disease' 'within' 'the'
 'past' '2' 'years']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02553642,22:40:chronic_disease,"Subjects with active autoimmune disease, symptoms or conditions","['Subjects' 'with' 'active' 'autoimmune' 'disease' ',' 'symptoms' 'or'
 'conditions']",[0. 0. 0. 2. 2. 0. 0. 0. 0.]
NCT02536794,38:56:chronic_disease,Patients with a history of or active autoimmune disease,['Patients' 'with' 'a' 'history' 'of' 'or' 'active' 'autoimmune' 'disease'],[0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02520791,43:61:chronic_disease,"Patients with active, known, or suspected autoimmune disease","['Patients' 'with' 'active' ',' 'known' ',' 'or' 'suspected' 'autoimmune'
 'disease']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02519322,42:60:chronic_disease,"Subjects with active, known or suspected autoimmune disease","['Subjects' 'with' 'active' ',' 'known' 'or' 'suspected' 'autoimmune'
 'disease']",[0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02502708,8:26:chronic_disease,Active autoimmune disease,['Active' 'autoimmune' 'disease'],[0. 2. 2.]
NCT02477826,45:63:chronic_disease,"Subjects with an active, known or suspected autoimmune disease","['Subjects' 'with' 'an' 'active' ',' 'known' 'or' 'suspected' 'autoimmune'
 'disease']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02454010,1:19:chronic_disease,autoimmune disease,['autoimmune' 'disease'],[2. 2.]
NCT02452268,12:30:chronic_disease,History of autoimmune disease,['History' 'of' 'autoimmune' 'disease'],[0. 0. 2. 2.]
NCT02439450,28:46:chronic_disease,"Active, known or suspected autoimmune disease","['Active' ',' 'known' 'or' 'suspected' 'autoimmune' 'disease']",[0. 0. 0. 0. 0. 2. 2.]
NCT02419495,45:63:chronic_disease,"subjects with an active, known or suspected autoimmune disease","['subjects' 'with' 'an' 'active' ',' 'known' 'or' 'suspected' 'autoimmune'
 'disease']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02401074,1:19:chronic_disease,autoimmune disease,['autoimmune' 'disease'],[2. 2.]
NCT02350764,45:63:chronic_disease,Patients with known or suspected history of autoimmune disease,"['Patients' 'with' 'known' 'or' 'suspected' 'history' 'of' 'autoimmune'
 'disease']",[0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02323126,53:71:chronic_disease,"any known or suspected, current or past history of, autoimmune disease","['any' 'known' 'or' 'suspected' ',' 'current' 'or' 'past' 'history' 'of'
 ',' 'autoimmune' 'disease']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02259621,66:84:chronic_disease,"Subjects are excluded if they have an active, known or suspected autoimmune disease","['Subjects' 'are' 'excluded' 'if' 'they' 'have' 'an' 'active' ',' 'known'
 'or' 'suspected' 'autoimmune' 'disease']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT01928576,31:49:chronic_disease,Any active history of a known autoimmune disease,['Any' 'active' 'history' 'of' 'a' 'known' 'autoimmune' 'disease'],[0. 0. 0. 0. 0. 0. 2. 2.]
NCT01174121,24:42:chronic_disease,History of major organ autoimmune disease,['History' 'of' 'major' 'organ' 'autoimmune' 'disease'],[0. 0. 0. 0. 2. 2.]
NCT03169543,9:19:chronic_disease,Current depression as assessed on the HDRS-17 (for depressed group only),"['Current' 'depression' 'as' 'assessed' 'on' 'the' 'HDRS-17' '(' 'for'
 'depressed' 'group' 'only' ')']",[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03107039,14:24:chronic_disease,Experiencing depression symptoms and generally healthy,['Experiencing' 'depression' 'symptoms' 'and' 'generally' 'healthy'],[0. 2. 0. 0. 0. 0.]
NCT03088592,"47:57:chronic_disease,,",Currently uncontrolled clinically significant depression (BDI>20),"['Currently' 'uncontrolled' 'clinically' 'significant' 'depression' '('
 'BDI' '>' '20' ')']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 0.]
NCT03034564,19:29:chronic_disease,Poorly controlled depression,['Poorly' 'controlled' 'depression'],[0. 0. 2.]
NCT02979327,1:11:chronic_disease,depression,['depression'],[2.]
NCT02964182,30:40:chronic_disease,Certain medications to treat depression,['Certain' 'medications' 'to' 'treat' 'depression'],[0. 0. 0. 0. 2.]
NCT02880215,21:31:chronic_disease,moderate or greater depression symptoms,['moderate' 'or' 'greater' 'depression' 'symptoms'],[0. 0. 0. 2. 0.]
NCT02809677,9:19:chronic_disease,current depression secondary to substances or general medical condition,"['current' 'depression' 'secondary' 'to' 'substances' 'or' 'general'
 'medical' 'condition']",[0. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02721537,12:22:chronic_disease,History of depression preceding a concussion,['History' 'of' 'depression' 'preceding' 'a' 'concussion'],[0. 0. 2. 0. 0. 0.]
NCT02674529,22:32:chronic_disease,history of resistant depression,['history' 'of' 'resistant' 'depression'],[0. 0. 0. 2.]
NCT02627495,"23:33:chronic_disease,,",Suffering from severe depression (as defined by a score of >30 in the Beck Depression Inventory),"['Suffering' 'from' 'severe' 'depression' '(' 'as' 'defined' 'by' 'a'
 'score' 'of' '>' '30' 'in' 'the' 'Beck' 'Depression' 'Inventory' ')']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02615353,11:21:chronic_disease,Diagnosed depression or other condition that may impact QoL,"['Diagnosed' 'depression' 'or' 'other' 'condition' 'that' 'may' 'impact'
 'QoL']",[0. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02570672,"11:21:chronic_disease,,",Untreated depression or Geriatric Depression Scale score on 15-item scale >7,"['Untreated' 'depression' 'or' 'Geriatric' 'Depression' 'Scale' 'score'
 'on' '15-item' 'scale' '>' '7']",[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02565199,"9:19:chronic_disease,,",Current depression (score more than 7 on the Hamilton Depression Rating Scale (HDRS)),"['Current' 'depression' '(' 'score' 'more' 'than' '7' 'on' 'the'
 'Hamilton' 'Depression' 'Rating' 'Scale' '(' 'HDRS' ')' ')']",[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02565199,"12:22:chronic_disease,,",No current depression (score less than 7 on the Hamilton Depression Rating Scale (HDRS)),"['No' 'current' 'depression' '(' 'score' 'less' 'than' '7' 'on' 'the'
 'Hamilton' 'Depression' 'Rating' 'Scale' '(' 'HDRS' ')' ')']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02565199,"12:22:chronic_disease,,",No current depression (score less than a 7 on the Hamilton Depression Rating Scale (HDRS)),"['No' 'current' 'depression' '(' 'score' 'less' 'than' 'a' '7' 'on' 'the'
 'Hamilton' 'Depression' 'Rating' 'Scale' '(' 'HDRS' ')' ')']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02466126,46:56:chronic_disease,must have clinically significant symptoms of depression,['must' 'have' 'clinically' 'significant' 'symptoms' 'of' 'depression'],[0. 0. 0. 0. 0. 0. 2.]
NCT02440815,22:32:chronic_disease,Moderate severity of depression using the Hamilton Depression Rating Scale,"['Moderate' 'severity' 'of' 'depression' 'using' 'the' 'Hamilton'
 'Depression' 'Rating' 'Scale']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT02339233,27:37:chronic_disease,no clinically significant depression,['no' 'clinically' 'significant' 'depression'],[0. 0. 0. 2.]
NCT02230605,"8:18:chronic_disease,,",Active depression as indicated by Geriatric Depression Scale screening test (score ≥ 10),"['Active' 'depression' 'as' 'indicated' 'by' 'Geriatric' 'Depression'
 'Scale' 'screening' 'test' '(' 'score' '≥' '10' ')']",[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02131467,8:18:chronic_disease,Active depression,['Active' 'depression'],[0. 2.]
NCT02104349,15:25:chronic_disease,Patients with depression (established during the screening questionnaire),"['Patients' 'with' 'depression' '(' 'established' 'during' 'the'
 'screening' 'questionnaire' ')']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02013492,25:35:chronic_disease,Patients with worsening depression that has not been addressed clinically,"['Patients' 'with' 'worsening' 'depression' 'that' 'has' 'not' 'been'
 'addressed' 'clinically']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT01948739,11:21:chronic_disease,Untreated depression that may affect motivation to participate in the study,"['Untreated' 'depression' 'that' 'may' 'affect' 'motivation' 'to'
 'participate' 'in' 'the' 'study']",[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01770587,14:24:chronic_disease,Diagnosis of depression,['Diagnosis' 'of' 'depression'],[0. 0. 2.]
NCT01742182,"13:23:chronic_disease,,",Presence of depression defined as the Beck Depression Inventory (BDI) score >14,"['Presence' 'of' 'depression' 'defined' 'as' 'the' 'Beck' 'Depression'
 'Inventory' '(' 'BDI' ')' 'score' '>' '14']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01614990,8:18:chronic_disease,Severe depression as determined by the investigator,['Severe' 'depression' 'as' 'determined' 'by' 'the' 'investigator'],[0. 2. 0. 0. 0. 0. 0.]
NCT01433315,21:31:chronic_disease,Those found to have depression on a depression screening tool (BDI-II),"['Those' 'found' 'to' 'have' 'depression' 'on' 'a' 'depression'
 'screening' 'tool' '(' 'BDI-II' ')']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00183482,53:63:chronic_disease,Families with at least one parent with a history of depression during the life of his or her child,"['Families' 'with' 'at' 'least' 'one' 'parent' 'with' 'a' 'history' 'of'
 'depression' 'during' 'the' 'life' 'of' 'his' 'or' 'her' 'child']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03181893,61:76:treatment,"failed at least 1 standard of care systemic treatment, (eg, corticosteroids)","['failed' 'at' 'least' '1' 'standard' 'of' 'care' 'systemic' 'treatment'
 ',' '(' 'eg' ',' 'corticosteroids' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT03113760,36:51:treatment,Patients receiving stable doses of corticosteroids,['Patients' 'receiving' 'stable' 'doses' 'of' 'corticosteroids'],[0. 0. 0. 0. 0. 1.]
NCT03067571,"35:50:treatment,,","has received a cumulative dose of corticosteroids more than the equivalent of >= 140 mg of prednisone within the 2 week period before cycle 1, day 1","['has' 'received' 'a' 'cumulative' 'dose' 'of' 'corticosteroids' 'more'
 'than' 'the' 'equivalent' 'of' '>' '=' '140' 'mg' 'of' 'prednisone'
 'within' 'the' '2' 'week' 'period' 'before' 'cycle' '1' ',' 'day' '1']","[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02918981,1:16:treatment,corticosteroids,['corticosteroids'],[1.]
NCT02819635,1:16:treatment,corticosteroids,['corticosteroids'],[1.]
NCT02811679,"22:37:treatment,",Therapeutic doses of corticosteroids within 14 days prior to study entry,"['Therapeutic' 'doses' 'of' 'corticosteroids' 'within' '14' 'days' 'prior'
 'to' 'study' 'entry']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02776761,"5:20:treatment,,","For corticosteroids, this will mean prednisone, or equivalent, greater than or equal to 0.5 mg/kg/day","['For' 'corticosteroids' ',' 'this' 'will' 'mean' 'prednisone' ',' 'or'
 'equivalent' ',' 'greater' 'than' 'or' 'equal' 'to' '0.5' 'mg/kg/day']",[0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02682407,"54:69:treatment,","For subjects in Cohort 2 and Cohort 3, have received corticosteroids within the 3 months prior to screening","['For' 'subjects' 'in' 'Cohort' '2' 'and' 'Cohort' '3' ',' 'have'
 'received' 'corticosteroids' 'within' 'the' '3' 'months' 'prior' 'to'
 'screening']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02527421,",75:90:treatment",Use within 30 days prior to the Screening Visit of any product containing corticosteroids,"['Use' 'within' '30' 'days' 'prior' 'to' 'the' 'Screening' 'Visit' 'of'
 'any' 'product' 'containing' 'corticosteroids']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02508311,18:33:treatment,Currently taking corticosteroids,['Currently' 'taking' 'corticosteroids'],[0. 0. 1.]
NCT02488967,50:65:treatment,Conditions that would prohibit administration of corticosteroids,"['Conditions' 'that' 'would' 'prohibit' 'administration' 'of'
 'corticosteroids']",[0. 0. 0. 0. 0. 0. 1.]
NCT02469519,19:34:treatment,Already receiving corticosteroids for another condition,['Already' 'receiving' 'corticosteroids' 'for' 'another' 'condition'],[0. 0. 1. 0. 0. 0.]
NCT02469519,46:61:treatment,Any contraindications to the maternal use of corticosteroids,"['Any' 'contraindications' 'to' 'the' 'maternal' 'use' 'of'
 'corticosteroids']",[0. 0. 0. 0. 0. 0. 0. 1.]
NCT02340169,27:42:allergy_name,Allergy or sensitivity to corticosteroids or any drug hypersensitivity or intolerance that would compromise patient safety or study results,"['Allergy' 'or' 'sensitivity' 'to' 'corticosteroids' 'or' 'any' 'drug'
 'hypersensitivity' 'or' 'intolerance' 'that' 'would' 'compromise'
 'patient' 'safety' 'or' 'study' 'results']",[0. 0. 0. 0. 4. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02336451,54:69:treatment,Patient is receiving unstable or increasing doses of corticosteroids,"['Patient' 'is' 'receiving' 'unstable' 'or' 'increasing' 'doses' 'of'
 'corticosteroids']",[0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02321501,33:48:treatment,Unstable or increasing doses of corticosteroids,['Unstable' 'or' 'increasing' 'doses' 'of' 'corticosteroids'],[0. 0. 0. 0. 0. 1.]
NCT02304458,35:50:treatment,Patients requiring daily systemic corticosteroids,['Patients' 'requiring' 'daily' 'systemic' 'corticosteroids'],[0. 0. 0. 0. 1.]
NCT02272218,"40:55:treatment,",any clinical disorder requiring use of corticosteroids within one week of visit,"['any' 'clinical' 'disorder' 'requiring' 'use' 'of' 'corticosteroids'
 'within' 'one' 'week' 'of' 'visit']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02236000,63:78:treatment,Conditions that would prohibit intermittent administration of corticosteroids for T-DM1 premedication,"['Conditions' 'that' 'would' 'prohibit' 'intermittent' 'administration'
 'of' 'corticosteroids' 'for' 'T-DM1' 'premedication']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02146924,15:30:treatment,Dependence on corticosteroids,['Dependence' 'on' 'corticosteroids'],[0. 0. 1.]
NCT02057133,48:63:treatment,Participants may be receiving a stable dose of corticosteroids,"['Participants' 'may' 'be' 'receiving' 'a' 'stable' 'dose' 'of'
 'corticosteroids']",[0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02043548,121:136:treatment,"there are complications or circumstances that, in the clinical site investigator's opinion, necessitate the tapering of corticosteroids","['there' 'are' 'complications' 'or' 'circumstances' 'that' ',' 'in' 'the'
 'clinical' 'site' 'investigator' ""'s"" 'opinion' ',' 'necessitate' 'the'
 'tapering' 'of' 'corticosteroids']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01851694,"13:28:treatment,",intravenous corticosteroids within 6 weeks of study,['intravenous' 'corticosteroids' 'within' '6' 'weeks' 'of' 'study'],[0. 1. 0. 0. 0. 0. 0.]
NCT01817751,"29:44:treatment,",Fixed or decreasing dose of corticosteroids (or no corticosteroids) for at least 1 week prior to cycle 1 day 1,"['Fixed' 'or' 'decreasing' 'dose' 'of' 'corticosteroids' '(' 'or' 'no'
 'corticosteroids' ')' 'for' 'at' 'least' '1' 'week' 'prior' 'to' 'cycle'
 '1' 'day' '1']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01793519,"43:58:treatment,",Treated with intramuscular or intravenous corticosteroids in the last 6 months for RA activity,"['Treated' 'with' 'intramuscular' 'or' 'intravenous' 'corticosteroids'
 'in' 'the' 'last' '6' 'months' 'for' 'RA' 'activity']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01631617,"16:31:treatment,","Use of topical corticosteroids on all intended sampling sites within 7 days, prior to baseline sampling","['Use' 'of' 'topical' 'corticosteroids' 'on' 'all' 'intended' 'sampling'
 'sites' 'within' '7' 'days' ',' 'prior' 'to' 'baseline' 'sampling']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00720785,19:34:treatment,Concurrent use of corticosteroids,['Concurrent' 'use' 'of' 'corticosteroids'],[0. 0. 0. 1.]
NCT03148795,24:46:chronic_disease,Clinically significant cardiovascular disease,['Clinically' 'significant' 'cardiovascular' 'disease'],[0. 0. 2. 2.]
NCT03104699,39:61:chronic_disease,"Clinically significant (i.e., active) cardiovascular disease","['Clinically' 'significant' '(' 'i.e.' ',' 'active' ')' 'cardiovascular'
 'disease']",[0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT03071393,1:23:chronic_disease,cardiovascular disease,['cardiovascular' 'disease'],[2. 2.]
NCT03037385,39:61:chronic_disease,"Clinically significant, uncontrolled, cardiovascular disease","['Clinically' 'significant' ',' 'uncontrolled' ',' 'cardiovascular'
 'disease']",[0. 0. 0. 0. 0. 2. 2.]
NCT02937272,25:47:chronic_disease,Have moderate or severe cardiovascular disease,['Have' 'moderate' 'or' 'severe' 'cardiovascular' 'disease'],[0. 0. 0. 0. 2. 2.]
NCT02913612,29:51:chronic_disease,"Hemodynamically significant cardiovascular disease, as determined by the investigator","['Hemodynamically' 'significant' 'cardiovascular' 'disease' ',' 'as'
 'determined' 'by' 'the' 'investigator']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02881515,12:34:chronic_disease,history of cardiovascular disease,['history' 'of' 'cardiovascular' 'disease'],[0. 0. 2. 2.]
NCT02881242,24:46:chronic_disease,Clinically significant cardiovascular disease,['Clinically' 'significant' 'cardiovascular' 'disease'],[0. 0. 2. 2.]
NCT02857283,23:45:chronic_disease,including significant cardiovascular disease,['including' 'significant' 'cardiovascular' 'disease'],[0. 0. 2. 2.]
NCT02741180,18:40:chronic_disease,History of prior cardiovascular disease or significant risk factors,"['History' 'of' 'prior' 'cardiovascular' 'disease' 'or' 'significant'
 'risk' 'factors']",[0. 0. 0. 2. 2. 0. 0. 0. 0.]
NCT02728336,16:38:chronic_disease,No significant cardiovascular disease or risk factors,['No' 'significant' 'cardiovascular' 'disease' 'or' 'risk' 'factors'],[0. 0. 2. 2. 0. 0. 0.]
NCT02663908,12:34:chronic_disease,Predefined cardiovascular disease,['Predefined' 'cardiovascular' 'disease'],[0. 2. 2.]
NCT02607917,12:34:chronic_disease,History of cardiovascular disease,['History' 'of' 'cardiovascular' 'disease'],[0. 0. 2. 2.]
NCT02562755,13:35:chronic_disease,Symptomatic cardiovascular disease,['Symptomatic' 'cardiovascular' 'disease'],[0. 2. 2.]
NCT02519322,29:51:chronic_disease,Uncontrolled or significant cardiovascular disease,['Uncontrolled' 'or' 'significant' 'cardiovascular' 'disease'],[0. 0. 0. 2. 2.]
NCT02514070,51:73:chronic_disease,"Subject must be healthy, with no known history of cardiovascular disease","['Subject' 'must' 'be' 'healthy' ',' 'with' 'no' 'known' 'history' 'of'
 'cardiovascular' 'disease']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02488057,1:23:chronic_disease,cardiovascular disease,['cardiovascular' 'disease'],[2. 2.]
NCT02452008,25:47:chronic_disease,Have moderate or severe cardiovascular disease,['Have' 'moderate' 'or' 'severe' 'cardiovascular' 'disease'],[0. 0. 0. 0. 2. 2.]
NCT02425566,1:23:chronic_disease,cardiovascular disease,['cardiovascular' 'disease'],[2. 2.]
NCT02278198,12:34:chronic_disease,History of cardiovascular disease that may adversely affect patient participation at the discretion of the primary investigator,"['History' 'of' 'cardiovascular' 'disease' 'that' 'may' 'adversely'
 'affect' 'patient' 'participation' 'at' 'the' 'discretion' 'of' 'the'
 'primary' 'investigator']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02203695,24:46:chronic_disease,Clinically significant cardiovascular disease,['Clinically' 'significant' 'cardiovascular' 'disease'],[0. 0. 2. 2.]
NCT02061761,29:51:chronic_disease,Uncontrolled or significant cardiovascular disease,['Uncontrolled' 'or' 'significant' 'cardiovascular' 'disease'],[0. 0. 0. 2. 2.]
NCT02048852,12:34:chronic_disease,history of cardiovascular disease,['history' 'of' 'cardiovascular' 'disease'],[0. 0. 2. 2.]
NCT01920061,29:51:chronic_disease,Uncontrolled or significant cardiovascular disease,['Uncontrolled' 'or' 'significant' 'cardiovascular' 'disease'],[0. 0. 0. 2. 2.]
NCT01625234,24:46:chronic_disease,Clinically significant cardiovascular disease,['Clinically' 'significant' 'cardiovascular' 'disease'],[0. 0. 2. 2.]
NCT03102320,1:6:cancer,Tumor type specific exclusion criteria,['Tumor' 'type' 'specific' 'exclusion' 'criteria'],[3. 0. 0. 0. 0.]
NCT02885649,"1:6:cancer,,",Tumor with androgen receptor (AR) expressed >= 4580 copies/ug ribonucleic acid (RNA),"['Tumor' 'with' 'androgen' 'receptor' '(' 'AR' ')' 'expressed' '>' '='
 '4580' 'copies/ug' 'ribonucleic' 'acid' '(' 'RNA' ')']",[3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02724540,1:6:cancer,Tumor burden dominant in the liver,['Tumor' 'burden' 'dominant' 'in' 'the' 'liver'],[3. 0. 0. 0. 0. 0.]
NCT02639546,1:6:cancer,Tumor with known or expected RAS/RAF/MEK/ERK pathway involvement,"['Tumor' 'with' 'known' 'or' 'expected' 'RAS/RAF/MEK/ERK' 'pathway'
 'involvement']",[3. 0. 0. 0. 0. 0. 0. 0.]
NCT02510456,"1:6:cancer,","Tumor size ≥ 2cm, measured on imaging or estimated by physical exam","['Tumor' 'size' '≥' '2cm' ',' 'measured' 'on' 'imaging' 'or' 'estimated'
 'by' 'physical' 'exam']",[3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02507232,1:6:cancer,Tumor is supratentorially located and measureable,['Tumor' 'is' 'supratentorially' 'located' 'and' 'measureable'],[3. 0. 0. 0. 0. 0.]
NCT02468024,1:6:cancer,Tumor located peripherally within the lung,['Tumor' 'located' 'peripherally' 'within' 'the' 'lung'],[3. 0. 0. 0. 0. 0.]
NCT02465060,1:6:cancer,"Tumor tissue for the confirmation of rare variant by the MATCH assay is to be submitted, preferably from the same time of collection as that evaluated by the designated outside laboratory","['Tumor' 'tissue' 'for' 'the' 'confirmation' 'of' 'rare' 'variant' 'by'
 'the' 'MATCH' 'assay' 'is' 'to' 'be' 'submitted' ',' 'preferably' 'from'
 'the' 'same' 'time' 'of' 'collection' 'as' 'that' 'evaluated' 'by' 'the'
 'designated' 'outside' 'laboratory']","[3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02438995,1:6:cancer,Tumor Recurrence which is surgically unresectable,['Tumor' 'Recurrence' 'which' 'is' 'surgically' 'unresectable'],[3. 0. 0. 0. 0. 0.]
NCT02427841,1:6:cancer,Tumor-associated deformity of the SMV (superior mesenteric vein) or PV (portal vein),"['Tumor-associated' 'deformity' 'of' 'the' 'SMV' '(' 'superior'
 'mesenteric' 'vein' ')' 'or' 'PV' '(' 'portal' 'vein' ')']",[3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02379377,1:6:cancer,Tumor confirmed by arteriography,['Tumor' 'confirmed' 'by' 'arteriography'],[3. 0. 0. 0.]
NCT02340156,1:6:cancer,Tumor foci detected below the tentorium or beyond the cranial vault,"['Tumor' 'foci' 'detected' 'below' 'the' 'tentorium' 'or' 'beyond' 'the'
 'cranial' 'vault']",[3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02207465,"1:6:cancer,",Tumor abutment to SMA but not to exceed greater than 180 degrees of circumferential vessel wall,"['Tumor' 'abutment' 'to' 'SMA' 'but' 'not' 'to' 'exceed' 'greater' 'than'
 '180' 'degrees' 'of' 'circumferential' 'vessel' 'wall']",[3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02158234,"1:6:cancer,",Tumor within 1 cm of the spinal cord,['Tumor' 'within' '1' 'cm' 'of' 'the' 'spinal' 'cord'],[3. 0. 0. 0. 0. 0. 0. 0.]
NCT02124772,1:6:cancer,Tumor tissue (archived or fresh) is required and must be available to be shipped to GSK or site specific laboratory,"['Tumor' 'tissue' '(' 'archived' 'or' 'fresh' ')' 'is' 'required' 'and'
 'must' 'be' 'available' 'to' 'be' 'shipped' 'to' 'GSK' 'or' 'site'
 'specific' 'laboratory']",[3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02085941,1:6:cancer,Tumor displacement from nerves may be required and will be performed as deemed appropriate to avoid nerve injury,"['Tumor' 'displacement' 'from' 'nerves' 'may' 'be' 'required' 'and' 'will'
 'be' 'performed' 'as' 'deemed' 'appropriate' 'to' 'avoid' 'nerve'
 'injury']",[3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02048722,1:6:cancer,Tumor deemed unresectable or metastatic,['Tumor' 'deemed' 'unresectable' 'or' 'metastatic'],[3. 0. 0. 0. 0.]
NCT02041936,1:6:cancer,Tumor size not measurable,['Tumor' 'size' 'not' 'measurable'],[3. 0. 0. 0.]
NCT02013154,1:6:cancer,Tumor tissue for mandatory evaluation,['Tumor' 'tissue' 'for' 'mandatory' 'evaluation'],[3. 0. 0. 0. 0.]
NCT01985087,"1:6:cancer,",Tumor o6-methylguanine-DNA-methyltransferase promoter methylation status must be determined,"['Tumor' 'o6-methylguanine-DNA-methyltransferase' 'promoter' 'methylation'
 'status' 'must' 'be' 'determined']",[3. 0. 0. 0. 0. 0. 0. 0.]
NCT01891318,1:6:cancer,Tumor located in the brainstem,['Tumor' 'located' 'in' 'the' 'brainstem'],[3. 0. 0. 0. 0.]
NCT01799135,"1:6:cancer,,",Tumor between 1 cm and 6 cm,['Tumor' 'between' '1' 'cm' 'and' '6' 'cm'],[3. 0. 0. 0. 0. 0. 0.]
NCT01505569,14:19:cancer,Arm A: Solid Tumor,['Arm' 'A' ':' 'Solid' 'Tumor'],[0. 0. 0. 0. 3.]
NCT01505569,1:6:cancer,Tumor may have originated in any primary site,['Tumor' 'may' 'have' 'originated' 'in' 'any' 'primary' 'site'],[3. 0. 0. 0. 0. 0. 0. 0.]
NCT02939183,"14:24:treatment,",received the transplant within 6 months prior to study day 1,"['received' 'the' 'transplant' 'within' '6' 'months' 'prior' 'to' 'study'
 'day' '1']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02582775,",,93:103:treatment","Cardiac: left ventricular ejection fraction ≥ 45%, normal EKG or approved by Cardiology for transplant","['Cardiac' ':' 'left' 'ventricular' 'ejection' 'fraction' '≥' '45' '%' ','
 'normal' 'EKG' 'or' 'approved' 'by' 'Cardiology' 'for' 'transplant']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02474199,",27:37:treatment",Be 36 months or more post-transplant,['Be' '36' 'months' 'or' 'more' 'post-transplant'],[0. 0. 0. 0. 0. 1.]
NCT02474199,",,55:65:treatment",α-fetoprotein (AFP) less than 100 μg/L at the time of transplant,"['α-fetoprotein' '(' 'AFP' ')' 'less' 'than' '100' 'μg/L' 'at' 'the'
 'time' 'of' 'transplant']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02440581,11:21:treatment,On active transplant list,['On' 'active' 'transplant' 'list'],[0. 0. 1. 0.]
NCT02424968,72:82:treatment,Must be an HLA-matched or single allele mismatched sibling of enrolled transplant patient,"['Must' 'be' 'an' 'HLA-matched' 'or' 'single' 'allele' 'mismatched'
 'sibling' 'of' 'enrolled' 'transplant' 'patient']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02416674,"19:29:treatment,,",Elapsed injury-to-transplant time of more than 6 months and less than 15 years,"['Elapsed' 'injury-to-transplant' 'time' 'of' 'more' 'than' '6' 'months'
 'and' 'less' 'than' '15' 'years']",[0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02342782,67:77:treatment,Bone marrow (BM) harvest required to reach adequate cell dose for transplant,"['Bone' 'marrow' '(' 'BM' ')' 'harvest' 'required' 'to' 'reach' 'adequate'
 'cell' 'dose' 'for' 'transplant']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02158793,",,41:51:treatment,,,,",Negative pregnancy test within 48hrs of transplant for women of childbearing age and who agree to use a reliable form of contraception for one year following transplant,"['Negative' 'pregnancy' 'test' 'within' '48hrs' 'of' 'transplant' 'for'
 'women' 'of' 'childbearing' 'age' 'and' 'who' 'agree' 'to' 'use' 'a'
 'reliable' 'form' 'of' 'contraception' 'for' 'one' 'year' 'following'
 'transplant']","[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02143830,",,60:70:treatment,",Women must be willing to undergo a pregnancy test prior to transplant and avoid becoming pregnant while on study,"['Women' 'must' 'be' 'willing' 'to' 'undergo' 'a' 'pregnancy' 'test'
 'prior' 'to' 'transplant' 'and' 'avoid' 'becoming' 'pregnant' 'while'
 'on' 'study']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02094794,32:42:treatment,"the patient, family member and transplant staff physician (physician, nurse, and social worker) meet at least once prior to starting the transplant procedure","['the' 'patient' ',' 'family' 'member' 'and' 'transplant' 'staff'
 'physician' '(' 'physician' ',' 'nurse' ',' 'and' 'social' 'worker' ')'
 'meet' 'at' 'least' 'once' 'prior' 'to' 'starting' 'the' 'transplant'
 'procedure']","[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02050347,85:95:treatment,An immune globulin rearrangement known to be a disease marker for this patient post transplant,"['An' 'immune' 'globulin' 'rearrangement' 'known' 'to' 'be' 'a' 'disease'
 'marker' 'for' 'this' 'patient' 'post' 'transplant']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02037048,57:67:treatment,Patients with any history of solid organ or bone marrow transplant will not be eligible,"['Patients' 'with' 'any' 'history' 'of' 'solid' 'organ' 'or' 'bone'
 'marrow' 'transplant' 'will' 'not' 'be' 'eligible']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT01943851,",48:58:treatment",At least 3 months has elapsed from the time of transplant,"['At' 'least' '3' 'months' 'has' 'elapsed' 'from' 'the' 'time' 'of'
 'transplant']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01908777,24:34:treatment,progressive disease at transplant work-up,['progressive' 'disease' 'at' 'transplant' 'work-up'],[0. 0. 0. 1. 0.]
NCT01908777,29:39:treatment,who are deemed eligible for transplant by their treating physician Disease status: CR or PR required,"['who' 'are' 'deemed' 'eligible' 'for' 'transplant' 'by' 'their'
 'treating' 'physician' 'Disease' 'status' ':' 'CR' 'or' 'PR' 'required']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01660607,79:89:treatment,Psychosocial circumstances that preclude the patient being able to go through transplant or participate responsibly in follow up care,"['Psychosocial' 'circumstances' 'that' 'preclude' 'the' 'patient' 'being'
 'able' 'to' 'go' 'through' 'transplant' 'or' 'participate' 'responsibly'
 'in' 'follow' 'up' 'care']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT01505569,",97:107:treatment",Minimum frozen PBSC of 4 x 106 CD34 cells/kg as 2 aliquots; i.e. 2 x 106 CD34 cells/kg for each transplant are mandatory,"['Minimum' 'frozen' 'PBSC' 'of' '4' 'x' '106' 'CD34' 'cells/kg' 'as' '2'
 'aliquots' ';' 'i.e' '.' '2' 'x' '106' 'CD34' 'cells/kg' 'for' 'each'
 'transplant' 'are' 'mandatory']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.
 0.]"
NCT01459107,82:92:treatment,"USA citizen or equivalent, or foreigner with documentation of ability to pay for transplant and required follow-up care","['USA' 'citizen' 'or' 'equivalent' ',' 'or' 'foreigner' 'with'
 'documentation' 'of' 'ability' 'to' 'pay' 'for' 'transplant' 'and'
 'required' 'follow-up' 'care']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT00711373,",,,124:134:treatment,",Women who are of child bearing potential must have a negative pregnancy test (urine test is acceptable) within 48 hours of transplant and agree to use reliable contraception for one year following transplant,"['Women' 'who' 'are' 'of' 'child' 'bearing' 'potential' 'must' 'have' 'a'
 'negative' 'pregnancy' 'test' '(' 'urine' 'test' 'is' 'acceptable' ')'
 'within' '48' 'hours' 'of' 'transplant' 'and' 'agree' 'to' 'use'
 'reliable' 'contraception' 'for' 'one' 'year' 'following' 'transplant']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT00630565,46:56:treatment,Patients can also be deemed not eligible for transplant because of specific organ toxicity,"['Patients' 'can' 'also' 'be' 'deemed' 'not' 'eligible' 'for' 'transplant'
 'because' 'of' 'specific' 'organ' 'toxicity']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT00432094,",165:175:treatment",Patients with progressive disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria by imaging techniques are not eligible to proceed to the second transplant,"['Patients' 'with' 'progressive' 'disease' 'by' 'Response' 'Evaluation'
 'Criteria' 'in' 'Solid' 'Tumors' '(' 'RECIST' ')' 'criteria' 'by'
 'imaging' 'techniques' 'are' 'not' 'eligible' 'to' 'proceed' 'to' 'the'
 'second' 'transplant']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1.]"
NCT00432094,",,55:65:treatment",Total Collection of ≥ 4 x 10^6 CD34 cells/kg prior to transplant one,"['Total' 'Collection' 'of' '≥' '4' 'x' '10^6' 'CD34' 'cells/kg' 'prior'
 'to' 'transplant' 'one']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT03186872,35:44:chronic_disease,evidence of active suicidality or psychosis (brief screen conducted by SWer in clinic using DSM-V cross cutting symptom inventory) to assess for psychosis,"['evidence' 'of' 'active' 'suicidality' 'or' 'psychosis' '(' 'brief'
 'screen' 'conducted' 'by' 'SWer' 'in' 'clinic' 'using' 'DSM-V' 'cross'
 'cutting' 'symptom' 'inventory' ')' 'to' 'assess' 'for' 'psychosis']","[0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT03157713,13:22:chronic_disease,have active psychosis,['have' 'active' 'psychosis'],[0. 0. 2.]
NCT03108950,32:41:chronic_disease,Current use of medications for psychosis,['Current' 'use' 'of' 'medications' 'for' 'psychosis'],[0. 0. 0. 0. 0. 2.]
NCT03034863,27:36:chronic_disease,untreated or un-medicated psychosis,['untreated' 'or' 'un-medicated' 'psychosis'],[0. 0. 0. 2.]
NCT02841956,"13:22:chronic_disease,",Duration of psychosis > 2 years,['Duration' 'of' 'psychosis' '>' '2' 'years'],[0. 0. 2. 0. 0. 0.]
NCT02808468,17:26:chronic_disease,Exhibit current psychosis,['Exhibit' 'current' 'psychosis'],[0. 0. 2.]
NCT02660528,12:21:chronic_disease,History of psychosis,['History' 'of' 'psychosis'],[0. 0. 2.]
NCT02640950,"29:38:chronic_disease,",have no previous history of psychosis or substance dependence or abuse within the six months prior to Screening,"['have' 'no' 'previous' 'history' 'of' 'psychosis' 'or' 'substance'
 'dependence' 'or' 'abuse' 'within' 'the' 'six' 'months' 'prior' 'to'
 'Screening']",[0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02613936,12:21:chronic_disease,history of psychosis,['history' 'of' 'psychosis'],[0. 0. 2.]
NCT02577666,24:33:chronic_disease,Evidence of unremitted psychosis or other condition which would impair mother's ability to understand or participate in the intervention or consent to the research,"['Evidence' 'of' 'unremitted' 'psychosis' 'or' 'other' 'condition' 'which'
 'would' 'impair' 'mother' ""'s"" 'ability' 'to' 'understand' 'or'
 'participate' 'in' 'the' 'intervention' 'or' 'consent' 'to' 'the'
 'research']","[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02533882,32:41:chronic_disease,Current use of medications for psychosis,['Current' 'use' 'of' 'medications' 'for' 'psychosis'],[0. 0. 0. 0. 0. 2.]
NCT02527564,9:18:chronic_disease,Current psychosis,['Current' 'psychosis'],[0. 2.]
NCT02404194,",13:22:chronic_disease",One or more psychosis-risk syndromes as defined by the Structured Interview for Psychosis-Risk Syndromes (SIPS),"['One' 'or' 'more' 'psychosis-risk' 'syndromes' 'as' 'defined' 'by' 'the'
 'Structured' 'Interview' 'for' 'Psychosis-Risk' 'Syndromes' '(' 'SIPS'
 ')']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02394704,1:10:chronic_disease,psychosis,['psychosis'],[2.]
NCT02357849,9:18:chronic_disease,"current psychosis (any positive symptom SOPS score of 6, i.e., extreme)","['current' 'psychosis' '(' 'any' 'positive' 'symptom' 'SOPS' 'score' 'of'
 '6' ',' 'i.e.' ',' 'extreme' ')']",[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02332291,17:26:chronic_disease,Current or past psychosis,['Current' 'or' 'past' 'psychosis'],[0. 0. 0. 2.]
NCT02293057,56:65:treatment,"observable cognitive or developmental delays or active psychosis that would interfere with completing consent, assessment or intervention","['observable' 'cognitive' 'or' 'developmental' 'delays' 'or' 'active'
 'psychosis' 'that' 'would' 'interfere' 'with' 'completing' 'consent' ','
 'assessment' 'or' 'intervention']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02131467,8:17:chronic_disease,Active psychosis,['Active' 'psychosis'],[0. 2.]
NCT02102113,29:38:chronic_disease,Having a family member with psychosis,['Having' 'a' 'family' 'member' 'with' 'psychosis'],[0. 0. 0. 0. 0. 2.]
NCT01989507,8:17:chronic_disease,active psychosis as evidenced by hallucinations or delusions,"['active' 'psychosis' 'as' 'evidenced' 'by' 'hallucinations' 'or'
 'delusions']",[0. 2. 0. 0. 0. 0. 0. 0.]
NCT01964404,"22:31:chronic_disease,,",Positive symptoms of psychosis (> 4 [moderate]) on any item of the Positive and Negative Syndrome Scale psychosis subscale (once abstinent) except for the hallucination item,"['Positive' 'symptoms' 'of' 'psychosis' '(' '>' '4' '[' 'moderate' ']' ')'
 'on' 'any' 'item' 'of' 'the' 'Positive' 'and' 'Negative' 'Syndrome'
 'Scale' 'psychosis' 'subscale' '(' 'once' 'abstinent' ')' 'except' 'for'
 'the' 'hallucination' 'item']","[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03041441,1:13:chronic_disease,coagulopathy,['coagulopathy'],[2.]
NCT03008603,26:38:chronic_disease,Subject with significant coagulopathy,['Subject' 'with' 'significant' 'coagulopathy'],[0. 0. 0. 2.]
NCT02973139,15:27:chronic_disease,Non corrected coagulopathy,['Non' 'corrected' 'coagulopathy'],[0. 0. 2.]
NCT02798458,27:39:chronic_disease,Untreated or unmanageable coagulopathy,['Untreated' 'or' 'unmanageable' 'coagulopathy'],[0. 0. 0. 2.]
NCT02706249,"13:25:chronic_disease,,,",Presence of coagulopathy (PT or PTT> 1.2 x upper limit of normal),"['Presence' 'of' 'coagulopathy' '(' 'PT' 'or' 'PTT' '>' '1.2' 'x' 'upper'
 'limit' 'of' 'normal' ')']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02548104,1:13:chronic_disease,coagulopathy (as diagnosed by history or laboratory evaluation),"['coagulopathy' '(' 'as' 'diagnosed' 'by' 'history' 'or' 'laboratory'
 'evaluation' ')']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02464904,",,23:35:chronic_disease,,","Platelet count < 50K, coagulopathy defined as an International Normalized Ratio (INR) > 1.5","['Platelet' 'count' '<' '50K' ',' 'coagulopathy' 'defined' 'as' 'an'
 'International' 'Normalized' 'Ratio' '(' 'INR' ')' '>' '1.5']",[0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02453373,"19:31:chronic_disease,,,,","Known preexisting coagulopathy, (INR > 1.3, PTT >1.5 x control)","['Known' 'preexisting' 'coagulopathy' ',' '(' 'INR' '>' '1.3' ',' 'PTT'
 '>' '1.5' 'x' 'control' ')']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02407028,7:19:chronic_disease,Fixed coagulopathy,['Fixed' 'coagulopathy'],[0. 2.]
NCT02394535,"30:42:chronic_disease,,","Known, existing uncontrolled coagulopathy, international normalized ratio (INR) > 1.5","['Known' ',' 'existing' 'uncontrolled' 'coagulopathy' ',' 'international'
 'normalized' 'ratio' '(' 'INR' ')' '>' '1.5']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02329652,12:24:chronic_disease,History of coagulopathy,['History' 'of' 'coagulopathy'],[0. 0. 2.]
NCT02323581,15:27:chronic_disease,Uncorrectable coagulopathy,['Uncorrectable' 'coagulopathy'],[0. 2.]
NCT02240498,15:27:chronic_disease,Uncorrectable coagulopathy,['Uncorrectable' 'coagulopathy'],[0. 2.]
NCT02166190,13:25:chronic_disease,Uncorrected coagulopathy,['Uncorrected' 'coagulopathy'],[0. 2.]
NCT02073292,11:23:chronic_disease,Untreated coagulopathy,['Untreated' 'coagulopathy'],[0. 2.]
NCT01975597,36:48:chronic_disease,"Patients with active, uncontrolled coagulopathy","['Patients' 'with' 'active' ',' 'uncontrolled' 'coagulopathy']",[0. 0. 0. 0. 0. 2.]
NCT01940757,"26:38:chronic_disease,,,,",Laboratory evidence of a coagulopathy (PTT or PT INR greater than 1.1-times the upper reference limit),"['Laboratory' 'evidence' 'of' 'a' 'coagulopathy' '(' 'PTT' 'or' 'PT' 'INR'
 'greater' 'than' '1.1-times' 'the' 'upper' 'reference' 'limit' ')']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01676259,35:47:chronic_disease,History of clinically significant coagulopathy,['History' 'of' 'clinically' 'significant' 'coagulopathy'],[0. 0. 0. 0. 2.]
NCT00862433,7:19:chronic_disease,Known coagulopathy,['Known' 'coagulopathy'],[0. 2.]
NCT00483249,15:27:chronic_disease,Uncorrectable coagulopathy,['Uncorrectable' 'coagulopathy'],[0. 2.]
NCT00167219,1:13:chronic_disease,coagulopathy,['coagulopathy'],[2.]
NCT02776891,12:20:cancer,Double hit lymphoma,['Double' 'hit' 'lymphoma'],[0. 0. 3.]
NCT02541565,",,88:96:cancer","Absolute neutrophil count (ANC) >= 1,500/mcL except in cases of marrow infiltration by lymphoma","['Absolute' 'neutrophil' 'count' '(' 'ANC' ')' '>' '=' '1,500/mcL'
 'except' 'in' 'cases' 'of' 'marrow' 'infiltration' 'by' 'lymphoma']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT02541565,",,68:76:cancer","Platelets >= 100,000/mcL except in cases of marrow infiltration by lymphoma","['Platelets' '>' '=' '100,000/mcL' 'except' 'in' 'cases' 'of' 'marrow'
 'infiltration' 'by' 'lymphoma']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT02541565,",,,80:88:cancer",emoglobin >= 9 g/dL or >= 5.6 mmol/L except in cases of marrow infiltration by lymphoma,"['emoglobin' '>' '=' '9' 'g/dL' 'or' '>' '=' '5.6' 'mmol/L' 'except' 'in'
 'cases' 'of' 'marrow' 'infiltration' 'by' 'lymphoma']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT02520713,1:9:cancer,lymphoma,['lymphoma'],[3.]
NCT02471911,59:67:cancer,Patients with known central nervous system involvement by lymphoma,"['Patients' 'with' 'known' 'central' 'nervous' 'system' 'involvement' 'by'
 'lymphoma']",[0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT02419560,11:19:cancer,Known CNS lymphoma,['Known' 'CNS' 'lymphoma'],[0. 0. 3.]
NCT02408861,",,81:89:cancer,,","Platelets: >= 75,000/mm^3, unless decreased due to bone marrow involvement with lymphoma (within 2 weeks prior to enrollment) (participants may receive GCSF and transfusions to meet these parameters)","['Platelets' ':' '>' '=' '75,000/mm^3' ',' 'unless' 'decreased' 'due' 'to'
 'bone' 'marrow' 'involvement' 'with' 'lymphoma' '(' 'within' '2' 'weeks'
 'prior' 'to' 'enrollment' ')' '(' 'participants' 'may' 'receive' 'GCSF'
 'and' 'transfusions' 'to' 'meet' 'these' 'parameters' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02384954,32:40:cancer,No active CNS involvement with lymphoma,['No' 'active' 'CNS' 'involvement' 'with' 'lymphoma'],[0. 0. 0. 0. 0. 3.]
NCT02374333,1:9:cancer,lymphoma,['lymphoma'],[3.]
NCT02341209,",,65:73:cancer","platelet count > 50,000 cells/mL unless felt to be secondary to lymphoma at which any count is permissible","['platelet' 'count' '>' '50,000' 'cells/mL' 'unless' 'felt' 'to' 'be'
 'secondary' 'to' 'lymphoma' 'at' 'which' 'any' 'count' 'is' 'permissible']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0.]
NCT02232516,69:77:cancer,Patients who have known central nervous system (CNS) involvement of lymphoma,"['Patients' 'who' 'have' 'known' 'central' 'nervous' 'system' '(' 'CNS'
 ')' 'involvement' 'of' 'lymphoma']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT02106650,",,,,,,,,283:291:cancer","Aspartate aminotransferase/serum glutamic-oxaloacetic transaminase (AST/SGOT), alanine aminotransferase/serum glutamic-pyruvic transaminase (ALT/SGPT), and gamma-glutamyltransferase (GGT) ≤2.5 xupper limit of normal (ULN) (AST/ALT/GGT ≤5 xULN if documented hepatic involvement with lymphoma)","['Aspartate' 'aminotransferase/serum' 'glutamic-oxaloacetic'
 'transaminase' '(' 'AST/SGOT' ')' ',' 'alanine' 'aminotransferase/serum'
 'glutamic-pyruvic' 'transaminase' '(' 'ALT/SGPT' ')' ',' 'and'
 'gamma-glutamyltransferase' '(' 'GGT' ')' '≤2.5' 'xupper' 'limit' 'of'
 'normal' '(' 'ULN' ')' '(' 'AST/ALT/GGT' '≤5' 'xULN' 'if' 'documented'
 'hepatic' 'involvement' 'with' 'lymphoma' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0.]"
NCT02078102,13:21:cancer,Transformed lymphoma,['Transformed' 'lymphoma'],[0. 3.]
NCT01996865,62:70:cancer,Presence or history of central nervous system involvement by lymphoma,"['Presence' 'or' 'history' 'of' 'central' 'nervous' 'system' 'involvement'
 'by' 'lymphoma']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT01891318,1:9:cancer,lymphoma,['lymphoma'],[3.]
NCT01859819,50:58:cancer,Patients with newly diagnosed Group A (low risk) lymphoma,"['Patients' 'with' 'newly' 'diagnosed' 'Group' 'A' '(' 'low' 'risk' ')'
 'lymphoma']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT00670358,",,,,63:71:cancer",AST ≤ 3 times ULN (5 times ULN if direct liver involvement by lymphoma),"['AST' '≤' '3' 'times' 'ULN' '(' '5' 'times' 'ULN' 'if' 'direct' 'liver'
 'involvement' 'by' 'lymphoma' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0.]
NCT00670358,",,,,80:88:cancer",Alkaline phosphatase ≤ 3 times ULN (5 times ULN if direct liver involvement by lymphoma),"['Alkaline' 'phosphatase' '≤' '3' 'times' 'ULN' '(' '5' 'times' 'ULN' 'if'
 'direct' 'liver' 'involvement' 'by' 'lymphoma' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0.]
NCT00001337,",,,105:113:cancer","greater than 1,000 and platelets greater than 100,000) unless impairment is due to organ involvement by lymphoma or immune-mediated mechanism caused by lymphoma","['greater' 'than' '1,000' 'and' 'platelets' 'greater' 'than' '100,000' ')'
 'unless' 'impairment' 'is' 'due' 'to' 'organ' 'involvement' 'by'
 'lymphoma' 'or' 'immune-mediated' 'mechanism' 'caused' 'by' 'lymphoma']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0.]
NCT03114891,7:25:chronic_disease,other psychotic disorder,['other' 'psychotic' 'disorder'],[0. 2. 2.]
NCT03058952,9:27:chronic_disease,Current psychotic disorder,['Current' 'psychotic' 'disorder'],[0. 2. 2.]
NCT03011307,18:36:chronic_disease,Suffering from a psychotic disorder,['Suffering' 'from' 'a' 'psychotic' 'disorder'],[0. 0. 0. 2. 2.]
NCT02851914,12:30:chronic_disease,History of psychotic disorder,['History' 'of' 'psychotic' 'disorder'],[0. 0. 2. 2.]
NCT02826577,1:19:chronic_disease,psychotic disorder,['psychotic' 'disorder'],[2. 2.]
NCT02734602,45:63:chronic_disease,First degree relative with a diagnosis of a psychotic disorder,"['First' 'degree' 'relative' 'with' 'a' 'diagnosis' 'of' 'a' 'psychotic'
 'disorder']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02709980,1:19:chronic_disease,psychotic disorder requiring admission,['psychotic' 'disorder' 'requiring' 'admission'],[2. 2. 0. 0.]
NCT02709317,16:34:chronic_disease,have a current psychotic disorder severe enough to require inpatient treatment,"['have' 'a' 'current' 'psychotic' 'disorder' 'severe' 'enough' 'to'
 'require' 'inpatient' 'treatment']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02556606,25:43:chronic_disease,Documented history of a psychotic disorder in a first-degree relative,"['Documented' 'history' 'of' 'a' 'psychotic' 'disorder' 'in' 'a'
 'first-degree' 'relative']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 0.]
NCT02536846,22:40:chronic_disease,"Without history of a psychotic disorder among parents, siblings, or children","['Without' 'history' 'of' 'a' 'psychotic' 'disorder' 'among' 'parents' ','
 'siblings' ',' 'or' 'children']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02481713,14:32:chronic_disease,diagnosis of psychotic disorder,['diagnosis' 'of' 'psychotic' 'disorder'],[0. 0. 2. 2.]
NCT02421315,30:48:chronic_disease,DSM-IV lifetime diagnosis of psychotic disorder,['DSM-IV' 'lifetime' 'diagnosis' 'of' 'psychotic' 'disorder'],[0. 0. 0. 0. 2. 2.]
NCT02418195,23:41:chronic_disease,A lifetime history of psychotic disorder,['A' 'lifetime' 'history' 'of' 'psychotic' 'disorder'],[0. 0. 0. 0. 2. 2.]
NCT02402647,1:19:chronic_disease,psychotic disorder,['psychotic' 'disorder'],[2. 2.]
NCT02214667,7:25:chronic_disease,brief psychotic disorder,['brief' 'psychotic' 'disorder'],[0. 2. 2.]
NCT02214667,1:19:chronic_disease,psychotic disorder NOS,['psychotic' 'disorder' 'NOS'],[2. 2. 0.]
NCT02155699,8:26:chronic_disease,have a psychotic disorder (at study entry) and/or have exhibited serious self-harm behaviors,"['have' 'a' 'psychotic' 'disorder' '(' 'at' 'study' 'entry' ')' 'and/or'
 'have' 'exhibited' 'serious' 'self-harm' 'behaviors']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02102113,38:56:chronic_disease,Having one relative with a confirmed psychotic disorder,['Having' 'one' 'relative' 'with' 'a' 'confirmed' 'psychotic' 'disorder'],[0. 0. 0. 0. 0. 0. 2. 2.]
NCT01794559,16:34:chronic_disease,Diagnosis of a psychotic disorder,['Diagnosis' 'of' 'a' 'psychotic' 'disorder'],[0. 0. 0. 2. 2.]
NCT02828618,1:17:cancer,liver metastasis or bulky lymph-nodes in the mediastinum in CT chest and abdomen/pelvis,"['liver' 'metastasis' 'or' 'bulky' 'lymph-nodes' 'in' 'the' 'mediastinum'
 'in' 'CT' 'chest' 'and' 'abdomen/pelvis']",[3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02730481,",,,106:122:cancer",Adequate liver function as demonstrated by:Total bilirubin of ≤1.5 mg/dL or ≤2.0 mg/dL for subjects with liver metastasis,"['Adequate' 'liver' 'function' 'as' 'demonstrated' 'by' ':' 'Total'
 'bilirubin' 'of' '≤1.5' 'mg/dL' 'or' '≤2.0' 'mg/dL' 'for' 'subjects'
 'with' 'liver' 'metastasis']",[0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02730481,",,,74:90:cancer",Alanine aminotransferase ≤3 x upper limit of normal (ULN) or ≤5 x ULN if liver metastasis is present,"['Alanine' 'aminotransferase' '≤3' 'x' 'upper' 'limit' 'of' 'normal' '('
 'ULN' ')' 'or' '≤5' 'x' 'ULN' 'if' 'liver' 'metastasis' 'is' 'present']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0.]
NCT02592551,",,,,,,,,,,,,,,,,,,334:350:cancer","Hemoglobin ≥ 9.0 g/dL Absolute neutrophil count (ANC) ≥ 1.5 × 109/L (> 1500 per mm3) Platelet count ≥ 100 × 109/L (>100,000 per mm3) Serum bilirubin ≤ 1.5× institutional upper limit of normal (ULN)AST<3.0 Creatinine clearance >50mL/miN Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 × ULN (≤ 5 × ULN if documented liver metastasis are present)","['Hemoglobin' '≥' '9.0' 'g/dL' 'Absolute' 'neutrophil' 'count' '(' 'ANC'
 ')' '≥' '1.5' '×' '109/L' '(' '>' '1500' 'per' 'mm3' ')' 'Platelet'
 'count' '≥' '100' '×' '109/L' '(' '>' '100,000' 'per' 'mm3' ')' 'Serum'
 'bilirubin' '≤' '1.5×' 'institutional' 'upper' 'limit' 'of' 'normal' '('
 'ULN' ')' 'AST' '<' '3.0' 'Creatinine' 'clearance' '>' '50mL/miN'
 'Aspartate' 'transaminase' '(' 'AST' ')' 'and' 'alanine' 'transaminase'
 '(' 'ALT' ')' '≤' '2.5' '×' 'ULN' '(' '≤' '5' '×' 'ULN' 'if' 'documented'
 'liver' 'metastasis' 'are' 'present' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 3. 3. 0. 0. 0.]"
NCT02536794,",27:43:cancer",#ERROR!,['#' 'ERROR' '!'],[0. 3. 0.]
NCT02536794,",27:43:cancer",#ERROR!,['#' 'ERROR' '!'],[0. 3. 0.]
NCT02422641,",,,67:83:cancer",Alkaline phosphatase <2.5x the ULN or <5x the ULN if secondary to liver metastasis,"['Alkaline' 'phosphatase' '<' '2.5x' 'the' 'ULN' 'or' '<' '5x' 'the' 'ULN'
 'if' 'secondary' 'to' 'liver' 'metastasis']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT02321501,",,,,,,,,,,,,,,,371:387:cancer","Absolute Neutrophil Count (ANC) >/= 1,500/microliter; Platelets >/= 100,000/microliter; Hemoglobin (Hgb) >/= 9 g/dL; Creatinine </= 1.5 X upper limit of normal (ULN); Prothrombin Time (PT), Partial Thromboplastin Time(PTT) </= 1.5 X ULN; Total bilirubin </= 1.5X ULN; Alanine Transaminase (ALT) and Aspartate Aminotransferase (AST) < 1.5 X ULN (< 5 X ULN if patient has liver metastasis)","['Absolute' 'Neutrophil' 'Count' '(' 'ANC' ')' '>' '/=' '1,500/microliter'
 ';' 'Platelets' '>' '/=' '100,000/microliter' ';' 'Hemoglobin' '(' 'Hgb'
 ')' '>' '/=' '9' 'g/dL' ';' 'Creatinine' '<' '/=' '1.5' 'X' 'upper'
 'limit' 'of' 'normal' '(' 'ULN' ')' ';' 'Prothrombin' 'Time' '(' 'PT' ')'
 ',' 'Partial' 'Thromboplastin' 'Time' '(' 'PTT' ')' '<' '/=' '1.5' 'X'
 'ULN' ';' 'Total' 'bilirubin' '<' '/=' '1.5X' 'ULN' ';' 'Alanine'
 'Transaminase' '(' 'ALT' ')' 'and' 'Aspartate' 'Aminotransferase' '('
 'AST' ')' '<' '1.5' 'X' 'ULN' '(' '<' '5' 'X' 'ULN' 'if' 'patient' 'has'
 'liver' 'metastasis' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0.]"
NCT02310464,",,,,76:92:cancer,,,,,,,,","AST/ALT ≤ 3X ULN (upper limit of normal) AST/ALT ≤ 5X ULN [with underlying liver metastasis] Total bilirubin ≤ 2.0 X ULN Serum creatinine ≤ 1.5X ULN ANC ≥ 1500 /µL Platelets > 100,000/µL","['AST/ALT' '≤' '3X' 'ULN' '(' 'upper' 'limit' 'of' 'normal' ')' 'AST/ALT'
 '≤' '5X' 'ULN' '[' 'with' 'underlying' 'liver' 'metastasis' ']' 'Total'
 'bilirubin' '≤' '2.0' 'X' 'ULN' 'Serum' 'creatinine' '≤' '1.5X' 'ULN'
 'ANC' '≥' '1500' '/µL' 'Platelets' '>' '100,000/µL']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02250157,",,,65:81:cancer",Total bilirubin of ≤ 1.5 mg/dL or ≤ 2.0 mg/dL for subjects with liver metastasis,"['Total' 'bilirubin' 'of' '≤' '1.5' 'mg/dL' 'or' '≤' '2.0' 'mg/dL' 'for'
 'subjects' 'with' 'liver' 'metastasis']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT02236000,",,,,157:173:cancer",aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be less than or equal to 1.5 x ULN for the lab or less than or equal to 5 x ULN if liver metastasis,"['aspartate' 'aminotransferase' '(' 'AST' ')' 'and' 'alanine'
 'aminotransferase' '(' 'ALT' ')' 'must' 'be' 'less' 'than' 'or' 'equal'
 'to' '1.5' 'x' 'ULN' 'for' 'the' 'lab' 'or' 'less' 'than' 'or' 'equal'
 'to' '5' 'x' 'ULN' 'if' 'liver' 'metastasis']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3.]"
NCT02188745,",,68:84:cancer,",ALT and AST ≤ 3.0 x upper limits of normal (ULN) For patients with liver metastasis: < 5 x upper limits of normal (ULN),"['ALT' 'and' 'AST' '≤' '3.0' 'x' 'upper' 'limits' 'of' 'normal' '(' 'ULN'
 ')' 'For' 'patients' 'with' 'liver' 'metastasis' ':' '<' '5' 'x' 'upper'
 'limits' 'of' 'normal' '(' 'ULN' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02112565,",,,,,,101:117:cancer",Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN; AST/ALT =< 5 x ULN if liver metastasis is present,"['Aspartate' 'aminotransferase' '(' 'AST' ')' '/alanine'
 'aminotransferase' '(' 'ALT' ')' '=' '<' '2.5' 'x' 'ULN' ';' 'AST/ALT'
 '=' '<' '5' 'x' 'ULN' 'if' 'liver' 'metastasis' 'is' 'present']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.
 3. 0. 0.]"
NCT01952730,",41:57:cancer",Greater than 1 month since resection of liver metastasis for vaccine production,"['Greater' 'than' '1' 'month' 'since' 'resection' 'of' 'liver'
 'metastasis' 'for' 'vaccine' 'production']",[0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0.]
NCT01676753,",,,,,,107:123:cancer","Aspartate aminotransferase (AST) (SGOT) and alanine aminotransferase ALT (SGPT) ≤ 2.5 x ULN, ≤ 5 x ULN if liver metastasis","['Aspartate' 'aminotransferase' '(' 'AST' ')' '(' 'SGOT' ')' 'and'
 'alanine' 'aminotransferase' 'ALT' '(' 'SGPT' ')' '≤' '2.5' 'x' 'ULN' ','
 '≤' '5' 'x' 'ULN' 'if' 'liver' 'metastasis']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 3. 3.]"
NCT01622868,",,,134:150:cancer,",Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 times institutional upper limit of normal with or without liver metastasis (within 21 days prior to study entry),"['Aspartate' 'aminotransferase' '(' 'AST' ')' 'and' 'alanine'
 'aminotransferase' '(' 'ALT' ')' '=' '<' '3.0' 'times' 'institutional'
 'upper' 'limit' 'of' 'normal' 'with' 'or' 'without' 'liver' 'metastasis'
 '(' 'within' '21' 'days' 'prior' 'to' 'study' 'entry' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.
 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01618357,",,,41:57:cancer",Bilirubin ≤ 1.5 mg/dL (≤ 3.0 mg/dL with liver metastasis),"['Bilirubin' '≤' '1.5' 'mg/dL' '(' '≤' '3.0' 'mg/dL' 'with' 'liver'
 'metastasis' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0.]
NCT01618357,",,,,78:94:cancer",Serum Glutamic-Oxaloacetic Transaminase (SGOT) ≤ 2.5 × ULN (≤ 5.0 × ULN with liver metastasis),"['Serum' 'Glutamic-Oxaloacetic' 'Transaminase' '(' 'SGOT' ')' '≤' '2.5'
 '×' 'ULN' '(' '≤' '5.0' '×' 'ULN' 'with' 'liver' 'metastasis' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0.]
NCT01618357,",,,74:90:cancer,",Serum Glutamic-Pyruvic Transaminase (SGPT) ≤ 2.5 × ULN (≤ 5.0 × ULN with liver metastasis) ULN = Upper normal limit of institution's normal range,"['Serum' 'Glutamic-Pyruvic' 'Transaminase' '(' 'SGPT' ')' '≤' '2.5' '×'
 'ULN' '(' '≤' '5.0' '×' 'ULN' 'with' 'liver' 'metastasis' ')' 'ULN' '='
 'Upper' 'normal' 'limit' 'of' 'institution' ""'s"" 'normal' 'range']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT03011684,1:13:treatment,Chemotherapy has already commenced or been completed,['Chemotherapy' 'has' 'already' 'commenced' 'or' 'been' 'completed'],[1. 0. 0. 0. 0. 0. 0.]
NCT02860000,"1:13:treatment,",Chemotherapy =< 21 days,['Chemotherapy' '=' '<' '21' 'days'],[1. 0. 0. 0. 0.]
NCT02843945,"1:13:treatment,,",Chemotherapy was administered for 2-6 cycles with any combination,"['Chemotherapy' 'was' 'administered' 'for' '2-6' 'cycles' 'with' 'any'
 'combination']",[1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02592707,"1:13:treatment,",Chemotherapy ≤ 3 months before enrolment,['Chemotherapy' '≤' '3' 'months' 'before' 'enrolment'],[1. 0. 0. 0. 0. 0.]
NCT02442635,11:23:treatment,Receiving Chemotherapy,['Receiving' 'Chemotherapy'],[0. 1.]
NCT02418195,1:13:treatment,Chemotherapy,['Chemotherapy'],[1.]
NCT02360579,1:13:treatment,Chemotherapy,['Chemotherapy'],[1.]
NCT02204098,1:13:treatment,Chemotherapy,['Chemotherapy'],[1.]
NCT02176161,1:13:treatment,Chemotherapy,['Chemotherapy'],[1.]
NCT02167958,1:13:treatment,Chemotherapy-sensitive (complete or partial response,['Chemotherapy-sensitive' '(' 'complete' 'or' 'partial' 'response'],[1. 0. 0. 0. 0. 0.]
NCT02130388,"1:13:treatment,,,",Chemotherapy within past 4 weeks or Absolute Neutrophil Count<500,"['Chemotherapy' 'within' 'past' '4' 'weeks' 'or' 'Absolute' 'Neutrophil'
 'Count' '<' '500']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02094794,"1:13:treatment,",Chemotherapy given within 14 days of planned study enrollment for the purpose of controlling counts is permitted,"['Chemotherapy' 'given' 'within' '14' 'days' 'of' 'planned' 'study'
 'enrollment' 'for' 'the' 'purpose' 'of' 'controlling' 'counts' 'is'
 'permitted']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01893307,12:24:treatment,Concurrent Chemotherapy,['Concurrent' 'Chemotherapy'],[0. 1.]
NCT01659203,"1:13:treatment,",Chemotherapy within 4 weeks prior to entering study,['Chemotherapy' 'within' '4' 'weeks' 'prior' 'to' 'entering' 'study'],[1. 0. 0. 0. 0. 0. 0. 0.]
NCT01625234,"1:13:treatment,",Chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity within the last 2 weeks,"['Chemotherapy' 'regimens' 'given' 'continuously' 'or' 'on' 'a' 'weekly'
 'basis' 'with' 'limited' 'potential' 'for' 'delayed' 'toxicity' 'within'
 'the' 'last' '2' 'weeks']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01625234,"1:13:treatment,",Chemotherapy regimens with delayed toxicity within the last 4 weeks,"['Chemotherapy' 'regimens' 'with' 'delayed' 'toxicity' 'within' 'the'
 'last' '4' 'weeks']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00909909,1:13:treatment,Chemotherapy allowed,['Chemotherapy' 'allowed'],[1. 0.]
NCT00819208,"1:13:treatment,,",Chemotherapy must have been completed (i.e. last dose received) a minimum of 60 days and a maximum of 180 days prior to registration,"['Chemotherapy' 'must' 'have' 'been' 'completed' '(' 'i.e' '.' 'last'
 'dose' 'received' ')' 'a' 'minimum' 'of' '60' 'days' 'and' 'a' 'maximum'
 'of' '180' 'days' 'prior' 'to' 'registration']","[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT03162731,8:19:chronic_disease,"active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive)","['active' 'hepatitis' 'B' '(' 'e.g.' ',' 'hepatitis' 'B' 'surface'
 'antigen' '[' 'HBsAg' ']' 'reactive' ')']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02682407,1:12:chronic_disease,hepatitis B,['hepatitis' 'B'],[2. 2.]
NCT02578641,10:21:chronic_disease,Positive hepatitis B surface antigen (HBsAg) results,['Positive' 'hepatitis' 'B' 'surface' 'antigen' '(' 'HBsAg' ')' 'results'],[0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02493530,"1:12:chronic_disease,",hepatitis B carriers with normal LFTs and undetectable viral loads,"['hepatitis' 'B' 'carriers' 'with' 'normal' 'LFTs' 'and' 'undetectable'
 'viral' 'loads']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02424968,24:35:chronic_disease,donors with a positive hepatitis B PCR test,['donors' 'with' 'a' 'positive' 'hepatitis' 'B' 'PCR' 'test'],[0. 0. 0. 0. 2. 2. 0. 0.]
NCT02412540,1:12:chronic_disease,hepatitis B,['hepatitis' 'B'],[2. 2.]
NCT02320292,22:33:chronic_disease,"HBsAg negative, anti-hepatitis B surface antibody (HBs) positive and/or anti-hepatitis B core antibody (HBc) positive and detectable viral deoxyribonucleic acid (DNA","['HBsAg' 'negative' ',' 'anti-hepatitis' 'B' 'surface' 'antibody' '('
 'HBs' ')' 'positive' 'and/or' 'anti-hepatitis' 'B' 'core' 'antibody' '('
 'HBc' ')' 'positive' 'and' 'detectable' 'viral' 'deoxyribonucleic' 'acid'
 '(' 'DNA']","[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02273375,34:45:chronic_disease,Patients with a past or resolved hepatitis B infection (defined as presence of hepatitis B core antibody (anti-HBc) and absence of HBSAg) are eligible,"['Patients' 'with' 'a' 'past' 'or' 'resolved' 'hepatitis' 'B' 'infection'
 '(' 'defined' 'as' 'presence' 'of' 'hepatitis' 'B' 'core' 'antibody' '('
 'anti-HBc' ')' 'and' 'absence' 'of' 'HBSAg' ')' 'are' 'eligible']","[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02109627,15:26:chronic_disease,patients with hepatitis B on antivirals and low viral load,"['patients' 'with' 'hepatitis' 'B' 'on' 'antivirals' 'and' 'low' 'viral'
 'load']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02004275,7:18:chronic_disease,Known hepatitis B surface antigen positivity,['Known' 'hepatitis' 'B' 'surface' 'antigen' 'positivity'],[0. 2. 2. 0. 0. 0.]
NCT01959698,",96:107:chronic_disease",Specific guidelines will be followed regarding inclusion of relapsed/refractory DLBCL based on hepatitis B serological testing,"['Specific' 'guidelines' 'will' 'be' 'followed' 'regarding' 'inclusion'
 'of' 'relapsed/refractory' 'DLBCL' 'based' 'on' 'hepatitis' 'B'
 'serological' 'testing']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0.]
NCT01919619,41:52:chronic_disease,antiviral (except antiviral directed at hepatitis B),['antiviral' '(' 'except' 'antiviral' 'directed' 'at' 'hepatitis' 'B' ')'],[0. 0. 0. 0. 0. 0. 2. 2. 0.]
NCT01919619,1:12:chronic_disease,hepatitis B,['hepatitis' 'B'],[2. 2.]
NCT01880567,22:33:chronic_disease,patients with active hepatitis B infection,['patients' 'with' 'active' 'hepatitis' 'B' 'infection'],[0. 0. 0. 2. 2. 0.]
NCT01880567,16:27:chronic_disease,positive serum hepatitis B antibody,['positive' 'serum' 'hepatitis' 'B' 'antibody'],[0. 0. 2. 2. 0.]
NCT01660607,31:42:chronic_disease,PCR+ or sAg (surface antigen) hepatitis B,['PCR+' 'or' 'sAg' '(' 'surface' 'antigen' ')' 'hepatitis' 'B'],[0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT01660607,1:12:chronic_disease,hepatitis B sAg,['hepatitis' 'B' 'sAg'],[2. 2. 0.]
NCT03070535,",,108:120:treatment","Women must be post-menopausal for at least 1 year before enrolling in the study, or be one year out from a hysterectomy","['Women' 'must' 'be' 'post-menopausal' 'for' 'at' 'least' '1' 'year'
 'before' 'enrolling' 'in' 'the' 'study' ',' 'or' 'be' 'one' 'year' 'out'
 'from' 'a' 'hysterectomy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT03042897,30:42:treatment,"Is a candidate for immediate hysterectomy, following evaluation by a physician","['Is' 'a' 'candidate' 'for' 'immediate' 'hysterectomy' ',' 'following'
 'evaluation' 'by' 'a' 'physician']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT03042897,34:46:treatment,"Is not a candidate for immediate hysterectomy, following evaluation by a physician, due to desire to preserve fertility, due to degree of obesity, due to comorbidities, or due to patient refusal of hysterectomy","['Is' 'not' 'a' 'candidate' 'for' 'immediate' 'hysterectomy' ','
 'following' 'evaluation' 'by' 'a' 'physician' ',' 'due' 'to' 'desire'
 'to' 'preserve' 'fertility' ',' 'due' 'to' 'degree' 'of' 'obesity' ','
 'due' 'to' 'comorbidities' ',' 'or' 'due' 'to' 'patient' 'refusal' 'of'
 'hysterectomy']","[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03033888,17:29:treatment,Had undergone a hysterectomy,['Had' 'undergone' 'a' 'hysterectomy'],[0. 0. 0. 1.]
NCT03018704,20:32:treatment,who have not had a hysterectomy,['who' 'have' 'not' 'had' 'a' 'hysterectomy'],[0. 0. 0. 0. 0. 1.]
NCT03008408,"88:100:treatment,,","Patients in whom ovaries are present and were not previously menopausal at the time of hysterectomy, should have a serum estradiol <10 pm/mL to confirm ovarian senescence","['Patients' 'in' 'whom' 'ovaries' 'are' 'present' 'and' 'were' 'not'
 'previously' 'menopausal' 'at' 'the' 'time' 'of' 'hysterectomy' ','
 'should' 'have' 'a' 'serum' 'estradiol' '<' '10' 'pm/mL' 'to' 'confirm'
 'ovarian' 'senescence']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02969187,1:13:treatment,hysterectomy,['hysterectomy'],[1.]
NCT02593123,",56:68:treatment,",Women who are not postmenopausal or have not undergone hysterectomy must have a documented negative serum pregnancy test per standard MCC-VCUHS BMT Program guidelines,"['Women' 'who' 'are' 'not' 'postmenopausal' 'or' 'have' 'not' 'undergone'
 'hysterectomy' 'must' 'have' 'a' 'documented' 'negative' 'serum'
 'pregnancy' 'test' 'per' 'standard' 'MCC-VCUHS' 'BMT' 'Program'
 'guidelines']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02592551,12:24:treatment,history of hysterectomy,['history' 'of' 'hysterectomy'],[0. 0. 1.]
NCT02536794,21:33:treatment,Has not undergone a hysterectomy,['Has' 'not' 'undergone' 'a' 'hysterectomy'],[0. 0. 0. 0. 1.]
NCT02515110,",56:68:treatment,,",Women who are not postmenopausal or have not undergone hysterectomy must have a documented negative pregnancy test within 14 days prior to study registration,"['Women' 'who' 'are' 'not' 'postmenopausal' 'or' 'have' 'not' 'undergone'
 'hysterectomy' 'must' 'have' 'a' 'documented' 'negative' 'pregnancy'
 'test' 'within' '14' 'days' 'prior' 'to' 'study' 'registration']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02514083,12:24:treatment,history of hysterectomy,['history' 'of' 'hysterectomy'],[0. 0. 1.]
NCT02466750,"23:35:treatment,",Exception: documented hysterectomy or ≥ 3 years of menopause,"['Exception' ':' 'documented' 'hysterectomy' 'or' '≥' '3' 'years' 'of'
 'menopause']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT02403193,21:33:treatment,history of complete hysterectomy,['history' 'of' 'complete' 'hysterectomy'],[0. 0. 0. 1.]
NCT02400255,",,102:114:treatment,",Women of childbearing potential is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 consecutive months,"['Women' 'of' 'childbearing' 'potential' 'is' 'defined' 'as' 'a'
 'sexually' 'active' 'mature' 'woman' 'who' 'has' 'not' 'undergone' 'a'
 'hysterectomy' 'or' 'who' 'has' 'had' 'menses' 'at' 'any' 'time' 'in'
 'the' 'preceding' '24' 'consecutive' 'months']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02236013,"46:58:treatment,",documented surgically sterile or status post hysterectomy (at least 1 month prior to Screening),"['documented' 'surgically' 'sterile' 'or' 'status' 'post' 'hysterectomy'
 '(' 'at' 'least' '1' 'month' 'prior' 'to' 'Screening' ')']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01532687,3:15:treatment,A hysterectomy,['A' 'hysterectomy'],[0. 1.]
NCT03135522,12:24:chronic_disease,History of pancreatitis,['History' 'of' 'pancreatitis'],[0. 0. 2.]
NCT03058029,"12:24:chronic_disease,",History of pancreatitis within the past 12 months,['History' 'of' 'pancreatitis' 'within' 'the' 'past' '12' 'months'],[0. 0. 2. 0. 0. 0. 0. 0.]
NCT02527200,12:24:chronic_disease,History of pancreatitis (acute or chronic),['History' 'of' 'pancreatitis' '(' 'acute' 'or' 'chronic' ')'],[0. 0. 2. 0. 0. 0. 0. 0.]
NCT02521818,12:24:chronic_disease,history of pancreatitis,['history' 'of' 'pancreatitis'],[0. 0. 2.]
NCT02496611,12:24:chronic_disease,History of pancreatitis,['History' 'of' 'pancreatitis'],[0. 0. 2.]
NCT02496208,",,75:87:chronic_disease",Lipase and amylase =< 2.0 x ULN and no radiologic or clinical evidence of pancreatitis,"['Lipase' 'and' 'amylase' '=' '<' '2.0' 'x' 'ULN' 'and' 'no' 'radiologic'
 'or' 'clinical' 'evidence' 'of' 'pancreatitis']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02467478,12:24:chronic_disease,History of pancreatitis,['History' 'of' 'pancreatitis'],[0. 0. 2.]
NCT02446093,36:48:chronic_disease,Evidence of clinically significant pancreatitis as determined by the investigator,"['Evidence' 'of' 'clinically' 'significant' 'pancreatitis' 'as'
 'determined' 'by' 'the' 'investigator']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 0.]
NCT02408861,56:68:chronic_disease,Participants with clinical or radiographic evidence of pancreatitis,"['Participants' 'with' 'clinical' 'or' 'radiographic' 'evidence' 'of'
 'pancreatitis']",[0. 0. 0. 0. 0. 0. 0. 2.]
NCT02262806,25:37:chronic_disease,Decrease in episodes of pancreatitis,['Decrease' 'in' 'episodes' 'of' 'pancreatitis'],[0. 0. 0. 0. 2.]
NCT02251431,7:19:chronic_disease,Prior pancreatitis,['Prior' 'pancreatitis'],[0. 2.]
NCT02244814,12:24:chronic_disease,History of pancreatitis,['History' 'of' 'pancreatitis'],[0. 0. 2.]
NCT02132598,",47:59:chronic_disease,",Lipase (no radiologic or clinical evidence of pancreatitis) < 2.0 x ULN,"['Lipase' '(' 'no' 'radiologic' 'or' 'clinical' 'evidence' 'of'
 'pancreatitis' ')' '<' '2.0' 'x' 'ULN']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0.]
NCT01906385,"33:45:chronic_disease,",History or clinical evidence of pancreatitis within 2 years,"['History' 'or' 'clinical' 'evidence' 'of' 'pancreatitis' 'within' '2'
 'years']",[0. 0. 0. 0. 0. 2. 0. 0. 0.]
NCT01822522,",,62:74:chronic_disease,",Lipase < 2.0 x ULN and no radiologic or clinical evidence of pancreatitis (within 1 week of study entry),"['Lipase' '<' '2.0' 'x' 'ULN' 'and' 'no' 'radiologic' 'or' 'clinical'
 'evidence' 'of' 'pancreatitis' '(' 'within' '1' 'week' 'of' 'study'
 'entry' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01722240,12:24:chronic_disease,history of pancreatitis,['history' 'of' 'pancreatitis'],[0. 0. 2.]
NCT03145298,8:30:chronic_disease,Active uncontrolled infection,['Active' 'uncontrolled' 'infection'],[0. 2. 2.]
NCT02566395,8:30:chronic_disease,Active uncontrolled infection,['Active' 'uncontrolled' 'infection'],[0. 2. 2.]
NCT02541903,15:37:chronic_disease,Any active or uncontrolled infection,['Any' 'active' 'or' 'uncontrolled' 'infection'],[0. 0. 0. 2. 2.]
NCT02354547,22:44:chronic_disease,Patients who have an uncontrolled infection,['Patients' 'who' 'have' 'an' 'uncontrolled' 'infection'],[0. 0. 0. 0. 2. 2.]
NCT02353728,1:23:chronic_disease,uncontrolled infection,['uncontrolled' 'infection'],[2. 2.]
NCT02323880,22:44:chronic_disease,Patients who have an uncontrolled infection,['Patients' 'who' 'have' 'an' 'uncontrolled' 'infection'],[0. 0. 0. 0. 2. 2.]
NCT02257138,31:53:chronic_disease,Active clinically serious and uncontrolled infection,['Active' 'clinically' 'serious' 'and' 'uncontrolled' 'infection'],[0. 0. 0. 0. 2. 2.]
NCT02158793,16:38:chronic_disease,Subject has an uncontrolled infection,['Subject' 'has' 'an' 'uncontrolled' 'infection'],[0. 0. 0. 2. 2.]
NCT02143050,16:38:chronic_disease,Have any other uncontrolled infection,['Have' 'any' 'other' 'uncontrolled' 'infection'],[0. 0. 0. 2. 2.]
NCT02114229,24:46:chronic_disease,"Presence of an active, uncontrolled infection","['Presence' 'of' 'an' 'active' ',' 'uncontrolled' 'infection']",[0. 0. 0. 0. 0. 2. 2.]
NCT02003222,33:55:chronic_disease,Patient must not have an active uncontrolled infection,['Patient' 'must' 'not' 'have' 'an' 'active' 'uncontrolled' 'infection'],[0. 0. 0. 0. 0. 0. 2. 2.]
NCT01943851,23:45:chronic_disease,Evidence of severe of uncontrolled infection,['Evidence' 'of' 'severe' 'of' 'uncontrolled' 'infection'],[0. 0. 0. 0. 2. 2.]
NCT01666080,9:31:chronic_disease,"Active, uncontrolled infection","['Active' ',' 'uncontrolled' 'infection']",[0. 0. 2. 2.]
NCT01532687,13:35:chronic_disease,Presence of uncontrolled infection,['Presence' 'of' 'uncontrolled' 'infection'],[0. 0. 2. 2.]
NCT01515527,19:41:chronic_disease,ongoing or active uncontrolled infection,['ongoing' 'or' 'active' 'uncontrolled' 'infection'],[0. 0. 0. 2. 2.]
NCT03042689,1:16:chronic_disease,Unstable angina (anginal symptoms at rest),['Unstable' 'angina' '(' 'anginal' 'symptoms' 'at' 'rest' ')'],[2. 2. 0. 0. 0. 0. 0. 0.]
NCT02986815,1:16:chronic_disease,Unstable angina,['Unstable' 'angina'],[2. 2.]
NCT02842658,1:16:chronic_disease,Unstable angina,['Unstable' 'angina'],[2. 2.]
NCT02780401,"1:16:chronic_disease,",Unstable angina within 4 months prior to enrollment,['Unstable' 'angina' 'within' '4' 'months' 'prior' 'to' 'enrollment'],[2. 2. 0. 0. 0. 0. 0. 0.]
NCT02516332,1:16:chronic_disease,Unstable angina,['Unstable' 'angina'],[2. 2.]
NCT02494869,1:16:chronic_disease,Unstable angina,['Unstable' 'angina'],[2. 2.]
NCT02484404,1:16:chronic_disease,Unstable angina,['Unstable' 'angina'],[2. 2.]
NCT02418195,1:16:chronic_disease,Unstable angina,['Unstable' 'angina'],[2. 2.]
NCT02095808,1:16:chronic_disease,Unstable angina,['Unstable' 'angina'],[2. 2.]
NCT02074436,1:16:chronic_disease,Unstable angina,['Unstable' 'angina'],[2. 2.]
NCT01959425,1:16:chronic_disease,Unstable angina,['Unstable' 'angina'],[2. 2.]
NCT01684397,1:16:chronic_disease,Unstable angina,['Unstable' 'angina'],[2. 2.]
NCT01668082,1:16:chronic_disease,Unstable angina,['Unstable' 'angina'],[2. 2.]
NCT01532687,1:16:chronic_disease,Unstable angina,['Unstable' 'angina'],[2. 2.]
NCT00788164,1:16:chronic_disease,Unstable angina,['Unstable' 'angina'],[2. 2.]
NCT03179163,1:28:chronic_disease,peripheral vascular disease,['peripheral' 'vascular' 'disease'],[2. 2. 2.]
NCT03158519,13:40:chronic_disease,symptomatic peripheral vascular disease,['symptomatic' 'peripheral' 'vascular' 'disease'],[0. 2. 2. 2.]
NCT03093272,"13:40:chronic_disease,",symptomatic peripheral vascular disease within 6 months prior to randomization,"['symptomatic' 'peripheral' 'vascular' 'disease' 'within' '6' 'months'
 'prior' 'to' 'randomization']",[0. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02833207,26:53:chronic_disease,Self-reported history of peripheral vascular disease,['Self-reported' 'history' 'of' 'peripheral' 'vascular' 'disease'],[0. 0. 0. 2. 2. 2.]
NCT02555280,13:40:chronic_disease,"Significant peripheral vascular disease (e.g., with diminished dorsalis pedis or posterior tibial pulses)","['Significant' 'peripheral' 'vascular' 'disease' '(' 'e.g.' ',' 'with'
 'diminished' 'dorsalis' 'pedis' 'or' 'posterior' 'tibial' 'pulses' ')']",[0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02473250,1:28:chronic_disease,peripheral vascular disease,['peripheral' 'vascular' 'disease'],[2. 2. 2.]
NCT02469857,21:48:chronic_disease,Patients with overt peripheral vascular disease in the involved area,"['Patients' 'with' 'overt' 'peripheral' 'vascular' 'disease' 'in' 'the'
 'involved' 'area']",[0. 0. 0. 2. 2. 2. 0. 0. 0. 0.]
NCT02315196,13:40:chronic_disease,Symptomatic peripheral vascular disease,['Symptomatic' 'peripheral' 'vascular' 'disease'],[0. 2. 2. 2.]
NCT02314377,36:63:chronic_disease,Patients must not have symptomatic peripheral vascular disease,"['Patients' 'must' 'not' 'have' 'symptomatic' 'peripheral' 'vascular'
 'disease']",[0. 0. 0. 0. 0. 2. 2. 2.]
NCT02020707,24:51:chronic_disease,Clinically significant peripheral vascular disease,['Clinically' 'significant' 'peripheral' 'vascular' 'disease'],[0. 0. 2. 2. 2.]
NCT02019641,128:155:chronic_disease,"Other medical conditions that may pose a risk to exercise testing or training as determined by the investigators (for example, peripheral vascular disease)","['Other' 'medical' 'conditions' 'that' 'may' 'pose' 'a' 'risk' 'to'
 'exercise' 'testing' 'or' 'training' 'as' 'determined' 'by' 'the'
 'investigators' '(' 'for' 'example' ',' 'peripheral' 'vascular' 'disease'
 ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.
 2. 0.]"
NCT01532687,13:40:chronic_disease,Symptomatic peripheral vascular disease,['Symptomatic' 'peripheral' 'vascular' 'disease'],[0. 2. 2. 2.]
NCT00540761,8:35:chronic_disease,severe peripheral vascular disease,['severe' 'peripheral' 'vascular' 'disease'],[0. 2. 2. 2.]
NCT00065676,1:28:chronic_disease,peripheral vascular disease,['peripheral' 'vascular' 'disease'],[2. 2. 2.]
NCT02834403,",25:35:chronic_disease",Patients with > Grade 2 neuropathy,['Patients' 'with' '>' 'Grade' '2' 'neuropathy'],[0. 0. 0. 0. 0. 2.]
NCT02710396,",25:35:chronic_disease",Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may qualify for the study,"['Subjects' 'with' '≤' 'Grade' '2' 'neuropathy' 'are' 'an' 'exception'
 'to' 'this' 'criterion' 'and' 'may' 'qualify' 'for' 'the' 'study']",[0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02578732,13:23:chronic_disease,Preexisting neuropathy is not allowed from any cause,['Preexisting' 'neuropathy' 'is' 'not' 'allowed' 'from' 'any' 'cause'],[0. 2. 0. 0. 0. 0. 0. 0.]
NCT02574455,",,83:93:chronic_disease",all toxicity at study entry < Grade 1 by NCI CTCAE v4.00 (Patients with ≤ Grade 2 neuropathy are eligible),"['all' 'toxicity' 'at' 'study' 'entry' '<' 'Grade' '1' 'by' 'NCI' 'CTCAE'
 'v4.00' '(' 'Patients' 'with' '≤' 'Grade' '2' 'neuropathy' 'are'
 'eligible' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0.]
NCT02538198,"13:23:chronic_disease,",Significant neuropathy ≥Grade 3 at baseline,['Significant' 'neuropathy' '≥Grade' '3' 'at' 'baseline'],[0. 2. 0. 0. 0. 0.]
NCT02451423,",,16:26:chronic_disease",CTCAE Gr >/= 2 neuropathy,['CTCAE' 'Gr' '>' '/=' '2' 'neuropathy'],[0. 0. 0. 0. 0. 2.]
NCT02383927,",,25:35:chronic_disease",Non-tolerable > Grade 2 neuropathy,['Non-tolerable' '>' 'Grade' '2' 'neuropathy'],[0. 0. 0. 0. 2.]
NCT02343042,",43:53:chronic_disease,,","In the SVd (Arm 2) only: Prior history of neuropathy Grade > 2, or Grade 2 neuropathy with pain at screening (within 21 days prior to C1D1)","['In' 'the' 'SVd' '(' 'Arm' '2' ')' 'only' ':' 'Prior' 'history' 'of'
 'neuropathy' 'Grade' '>' '2' ',' 'or' 'Grade' '2' 'neuropathy' 'with'
 'pain' 'at' 'screening' '(' 'within' '21' 'days' 'prior' 'to' 'C1D1' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02187848,34:44:chronic_disease,Unresolved signs and symptoms of neuropathy,['Unresolved' 'signs' 'and' 'symptoms' 'of' 'neuropathy'],[0. 0. 0. 0. 0. 2.]
NCT02091999,"21:31:chronic_disease,,",Preexisting sensory neuropathy Grade ≥ 2,['Preexisting' 'sensory' 'neuropathy' 'Grade' '≥' '2'],[0. 0. 2. 0. 0. 0.]
NCT02080221,13:23:chronic_disease,Preexisting neuropathy,['Preexisting' 'neuropathy'],[0. 2.]
NCT01941316,"31:41:chronic_disease,,,","Must not have any significant neuropathy (Grades 3-4, or Grade 2 with pain) within 14 days prior to enrollment","['Must' 'not' 'have' 'any' 'significant' 'neuropathy' '(' 'Grades' '3-4'
 ',' 'or' 'Grade' '2' 'with' 'pain' ')' 'within' '14' 'days' 'prior' 'to'
 'enrollment']",[0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01919619,"13:23:chronic_disease,,",Significant neuropathy (grades 3 to 4 or grade 2 pain),"['Significant' 'neuropathy' '(' 'grades' '3' 'to' '4' 'or' 'grade' '2'
 'pain' ')']",[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01220583,",24:34:chronic_disease",Pre-existing ≥ grade 2 neuropathy,['Pre-existing' '≥' 'grade' '2' 'neuropathy'],[0. 0. 0. 0. 2.]
NCT03158116,12:24:chronic_disease,History of tuberculosis,['History' 'of' 'tuberculosis'],[0. 0. 2.]
NCT03152058,12:24:chronic_disease,History of tuberculosis or untreated positive PPD,['History' 'of' 'tuberculosis' 'or' 'untreated' 'positive' 'PPD'],[0. 0. 2. 0. 0. 0. 0.]
NCT03059888,24:36:chronic_disease,Subject is at risk for tuberculosis,['Subject' 'is' 'at' 'risk' 'for' 'tuberculosis'],[0. 0. 0. 0. 0. 2.]
NCT02915744,1:13:chronic_disease,tuberculosis,['tuberculosis'],[2.]
NCT02639065,49:61:chronic_disease,Known history of previous clinical diagnosis of tuberculosis,"['Known' 'history' 'of' 'previous' 'clinical' 'diagnosis' 'of'
 'tuberculosis']",[0. 0. 0. 0. 0. 0. 0. 2.]
NCT02592551,49:61:chronic_disease,Known history of previous clinical diagnosis of tuberculosis,"['Known' 'history' 'of' 'previous' 'clinical' 'diagnosis' 'of'
 'tuberculosis']",[0. 0. 0. 0. 0. 0. 0. 2.]
NCT02570984,12:24:chronic_disease,history of tuberculosis,['history' 'of' 'tuberculosis'],[0. 0. 2.]
NCT02536794,1:13:chronic_disease,tuberculosis,['tuberculosis'],[2.]
NCT02484404,59:71:chronic_disease,Patients with a history of previous clinical diagnosis of tuberculosis are not eligible,"['Patients' 'with' 'a' 'history' 'of' 'previous' 'clinical' 'diagnosis'
 'of' 'tuberculosis' 'are' 'not' 'eligible']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0.]
NCT02273375,29:41:chronic_disease,known clinical diagnosis of tuberculosis,['known' 'clinical' 'diagnosis' 'of' 'tuberculosis'],[0. 0. 0. 0. 2.]
NCT02148796,1:13:chronic_disease,tuberculosis,['tuberculosis'],[2.]
NCT02043548,"22:34:chronic_disease,",Patients treated for tuberculosis with no recurrence in 3 years are permitted,"['Patients' 'treated' 'for' 'tuberculosis' 'with' 'no' 'recurrence' 'in'
 '3' 'years' 'are' 'permitted']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02007239,18:30:chronic_disease,Known history of tuberculosis,['Known' 'history' 'of' 'tuberculosis'],[0. 0. 0. 2.]
NCT03116997,",,35:49:treatment",INR > 1.5 (except for patients on anticoagulants),['INR' '>' '1.5' '(' 'except' 'for' 'patients' 'on' 'anticoagulants' ')'],[0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT03040778,22:36:treatment,Patients taking oral anticoagulants,['Patients' 'taking' 'oral' 'anticoagulants'],[0. 0. 0. 1.]
NCT02786251,142:156:treatment,"Use of medications that are judged by the investigators to affect the study outcome measures or increase the risk of study procedures (e.g., anticoagulants) and that cannot be temporarily discontinued for this study","['Use' 'of' 'medications' 'that' 'are' 'judged' 'by' 'the' 'investigators'
 'to' 'affect' 'the' 'study' 'outcome' 'measures' 'or' 'increase' 'the'
 'risk' 'of' 'study' 'procedures' '(' 'e.g.' ',' 'anticoagulants' ')'
 'and' 'that' 'can' 'not' 'be' 'temporarily' 'discontinued' 'for' 'this'
 'study']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02719327,16:30:treatment,Current use of anticoagulants,['Current' 'use' 'of' 'anticoagulants'],[0. 0. 0. 1.]
NCT02706288,46:60:treatment,"increase the risk of study procedures (e.g., anticoagulants) and that cannot be temporarily discontinued for this study","['increase' 'the' 'risk' 'of' 'study' 'procedures' '(' 'e.g.' ','
 'anticoagulants' ')' 'and' 'that' 'can' 'not' 'be' 'temporarily'
 'discontinued' 'for' 'this' 'study']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02669173,23:37:treatment,Patients on full-dose anticoagulants,['Patients' 'on' 'full-dose' 'anticoagulants'],[0. 0. 0. 1.]
NCT02656706,20:34:treatment,Therapeutic use of anticoagulants,['Therapeutic' 'use' 'of' 'anticoagulants'],[0. 0. 0. 1.]
NCT02541565,69:83:treatment,"as long as PT or PTT is within therapeutic range of intended use of anticoagulants, or subject is shown to have an antiphospholipid antibody on workup","['as' 'long' 'as' 'PT' 'or' 'PTT' 'is' 'within' 'therapeutic' 'range' 'of'
 'intended' 'use' 'of' 'anticoagulants' ',' 'or' 'subject' 'is' 'shown'
 'to' 'have' 'an' 'antiphospholipid' 'antibody' 'on' 'workup']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02524275,",,,,161:175:treatment","Prothrombin time (PT) or international normalized ratio (INR), and partial thromboplastin time (PTT) =< 1.5 x upper limit of normal unless subject is receiving anticoagulants","['Prothrombin' 'time' '(' 'PT' ')' 'or' 'international' 'normalized'
 'ratio' '(' 'INR' ')' ',' 'and' 'partial' 'thromboplastin' 'time' '('
 'PTT' ')' '=' '<' '1.5' 'x' 'upper' 'limit' 'of' 'normal' 'unless'
 'subject' 'is' 'receiving' 'anticoagulants']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02233868,1:15:treatment,anticoagulants,['anticoagulants'],[1.]
NCT02140554,35:49:treatment,patients on prophylactic doses of anticoagulants,['patients' 'on' 'prophylactic' 'doses' 'of' 'anticoagulants'],[0. 0. 0. 0. 0. 1.]
NCT02130687,16:30:treatment,Treatment with anticoagulants,['Treatment' 'with' 'anticoagulants'],[0. 0. 1.]
NCT02101736,18:32:treatment,Subject requires anticoagulants,['Subject' 'requires' 'anticoagulants'],[0. 0. 1.]
NCT03068442,"79:92:chronic_disease,,","MRI contraindications per ACR guidelines, including patients with pacemakers, renal failure with eGFR<30 ml/min/1.73m2, and contrast allergy","['MRI' 'contraindications' 'per' 'ACR' 'guidelines' ',' 'including'
 'patients' 'with' 'pacemakers' ',' 'renal' 'failure' 'with' 'eGFR' '<'
 '30' 'ml/min/1.73m2' ',' 'and' 'contrast' 'allergy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03030859,1:14:chronic_disease,renal failure,['renal' 'failure'],[2. 2.]
NCT02911831,"21:34:chronic_disease,,,",Patients with known renal failure and/or Cr > 5 within the last 6 months,"['Patients' 'with' 'known' 'renal' 'failure' 'and/or' 'Cr' '>' '5'
 'within' 'the' 'last' '6' 'months']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02473250,1:14:chronic_disease,renal failure,['renal' 'failure'],[2. 2.]
NCT02342444,13:26:chronic_disease,Presence of renal failure requiring non-standard dosing regimen,"['Presence' 'of' 'renal' 'failure' 'requiring' 'non-standard' 'dosing'
 'regimen']",[0. 0. 2. 2. 0. 0. 0. 0.]
NCT02312596,"7:20:chronic_disease,,",Known renal failure as determined by a Creatinine > 2.5 mg/dl,"['Known' 'renal' 'failure' 'as' 'determined' 'by' 'a' 'Creatinine' '>'
 '2.5' 'mg/dl']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02219555,1:14:chronic_disease,renal failure,['renal' 'failure'],[2. 2.]
NCT02095678,"12:25:chronic_disease,",Late stage renal failure with estimated glomerular filtration rate (eGFR),"['Late' 'stage' 'renal' 'failure' 'with' 'estimated' 'glomerular'
 'filtration' 'rate' '(' 'eGFR' ')']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01807897,"8:21:chronic_disease,,",Severe renal failure with estimated glomerular filtration rate <30 ml/min,"['Severe' 'renal' 'failure' 'with' 'estimated' 'glomerular' 'filtration'
 'rate' '<' '30' 'ml/min']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01666665,35:48:chronic_disease,Previous diagnosis (pre -burn) of renal failure,['Previous' 'diagnosis' '(' 'pre' '-burn' ')' 'of' 'renal' 'failure'],[0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT01666665,1:14:chronic_disease,renal failure,['renal' 'failure'],[2. 2.]
NCT01614990,"1:14:chronic_disease,,",renal failure (creatinine >1.5 mg/dL),['renal' 'failure' '(' 'creatinine' '>' '1.5' 'mg/dL' ')'],[2. 2. 0. 0. 0. 0. 0. 0.]
NCT01572480,12:25:chronic_disease,Absence of renal failure,['Absence' 'of' 'renal' 'failure'],[0. 0. 2. 2.]
NCT03186872,"4:17:treatment,",No psychotherapy within PCMH within past 6 months including with the psychologist,"['No' 'psychotherapy' 'within' 'PCMH' 'within' 'past' '6' 'months'
 'including' 'with' 'the' 'psychologist']",[0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03114891,"17:30:treatment,",Newly initiated psychotherapy (less than 6 weeks),['Newly' 'initiated' 'psychotherapy' '(' 'less' 'than' '6' 'weeks' ')'],[0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT03060096,"9:22:treatment,","Current psychotherapy [regular appointment(s) with a psychologist, counselor, or therapist within the last 30 days]","['Current' 'psychotherapy' '[' 'regular' 'appointment' '(' 's' ')' 'with'
 'a' 'psychologist' ',' 'counselor' ',' 'or' 'therapist' 'within' 'the'
 'last' '30' 'days' ']']",[0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03043573,77:90:treatment,Deemed too psychiatrically unstable to safely enroll in randomized trial of psychotherapy. Requiring psychiatric hospitalization at baseline for safety,"['Deemed' 'too' 'psychiatrically' 'unstable' 'to' 'safely' 'enroll' 'in'
 'randomized' 'trial' 'of' 'psychotherapy' '.' 'Requiring' 'psychiatric'
 'hospitalization' 'at' 'baseline' 'for' 'safety']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02901041,32:45:treatment,Must be willing to discontinue psychotherapy for substance use disorder (except A.A.),"['Must' 'be' 'willing' 'to' 'discontinue' 'psychotherapy' 'for'
 'substance' 'use' 'disorder' '(' 'except' 'A.A' '.' ')']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02567266,63:76:treatment,Adolescents will be excluded if they are receiving concurrent psychotherapy,"['Adolescents' 'will' 'be' 'excluded' 'if' 'they' 'are' 'receiving'
 'concurrent' 'psychotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02466126,30:43:treatment,Veterans currently receiving psychotherapy WILL be excluded,['Veterans' 'currently' 'receiving' 'psychotherapy' 'WILL' 'be' 'excluded'],[0. 0. 0. 1. 0. 0. 0.]
NCT02397889,34:47:treatment,Use of evidence-based individual psychotherapy (such as prolonged exposure) during the study,"['Use' 'of' 'evidence-based' 'individual' 'psychotherapy' '(' 'such' 'as'
 'prolonged' 'exposure' ')' 'during' 'the' 'study']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02332291,20:33:treatment,Current or planned psychotherapy,['Current' 'or' 'planned' 'psychotherapy'],[0. 0. 0. 1.]
NCT02317523,64:77:treatment,Caregivers enrolled in another intervention study or receiving psychotherapy to improve well-being or reduce distress,"['Caregivers' 'enrolled' 'in' 'another' 'intervention' 'study' 'or'
 'receiving' 'psychotherapy' 'to' 'improve' 'well-being' 'or' 'reduce'
 'distress']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT02061553,52:65:treatment,Concurrent involvement in one-to-one counseling or psychotherapy for emotional issues,"['Concurrent' 'involvement' 'in' 'one-to-one' 'counseling' 'or'
 'psychotherapy' 'for' 'emotional' 'issues']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02046330,"33:46:treatment,",An adequate trial of individual psychotherapy (>20 sessions with an experienced psychotherapist),"['An' 'adequate' 'trial' 'of' 'individual' 'psychotherapy' '(' '>' '20'
 'sessions' 'with' 'an' 'experienced' 'psychotherapist' ')']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03113695,",109:118:treatment",Males must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy,"['Males' 'must' 'agree' 'to' 'use' 'a' 'latex' 'condom' 'during' 'sexual'
 'contact' 'with' 'a' 'FCBP' 'even' 'if' 'they' 'have' 'had' 'a'
 'successful' 'vasectomy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT03067571,",,87:96:treatment,,","A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control eg, either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, and all men must also not donate sperm during the study and for 3 months after receiving the last dose of study drug","['A' 'man' 'who' 'is' 'sexually' 'active' 'with' 'a' 'woman' 'of'
 'childbearing' 'potential' 'and' 'has' 'not' 'had' 'a' 'vasectomy' 'must'
 'agree' 'to' 'use' 'a' 'barrier' 'method' 'of' 'birth' 'control' 'eg' ','
 'either' 'condom' 'with' 'spermicidal' 'foam/gel/film/cream/suppository'
 'or' 'partner' 'with' 'occlusive' 'cap' '(' 'diaphragm' 'or'
 'cervical/vault' 'caps' ')' 'with' 'spermicidal'
 'foam/gel/film/cream/suppository' ',' 'and' 'all' 'men' 'must' 'also'
 'not' 'donate' 'sperm' 'during' 'the' 'study' 'and' 'for' '3' 'months'
 'after' 'receiving' 'the' 'last' 'dose' 'of' 'study' 'drug']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02688647,",,146:155:treatment","Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm); or (d) vasectomy","['Effective' 'barrier' 'methods' 'are' 'male' 'or' 'female' 'condoms' ','
 'diaphragms' ',' 'and' 'spermicides' '(' 'creams' 'or' 'gels' 'that'
 'contain' 'a' 'chemical' 'to' 'kill' 'sperm' ')' ';' 'or' '(' 'd' ')'
 'vasectomy']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1.]"
NCT02629120,",41:50:treatment",Male partner has previously undergone a vasectomy,['Male' 'partner' 'has' 'previously' 'undergone' 'a' 'vasectomy'],[0. 0. 0. 0. 0. 0. 1.]
NCT02538198,",,,135:144:treatment",Men must agree to use a latex condom during sexual contact with a female of childbearing potential even if they have had a successful vasectomy,"['Men' 'must' 'agree' 'to' 'use' 'a' 'latex' 'condom' 'during' 'sexual'
 'contact' 'with' 'a' 'female' 'of' 'childbearing' 'potential' 'even' 'if'
 'they' 'have' 'had' 'a' 'successful' 'vasectomy']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1.]"
NCT02382419,",,,,398:407:treatment",Using an adequate method of contraception for at least 3 months with no changes and will remain on the contraception for the duration of the trial; an adequate method of contraception is defined as either a hormonal based method (except vaginal rings); an intrauterine device (IUD) (inserted at least 30 days prior to enrollment); female sterilization; or sexual activity with a partner who had a vasectomy,"['Using' 'an' 'adequate' 'method' 'of' 'contraception' 'for' 'at' 'least'
 '3' 'months' 'with' 'no' 'changes' 'and' 'will' 'remain' 'on' 'the'
 'contraception' 'for' 'the' 'duration' 'of' 'the' 'trial' ';' 'an'
 'adequate' 'method' 'of' 'contraception' 'is' 'defined' 'as' 'either' 'a'
 'hormonal' 'based' 'method' '(' 'except' 'vaginal' 'rings' ')' ';' 'an'
 'intrauterine' 'device' '(' 'IUD' ')' '(' 'inserted' 'at' 'least' '30'
 'days' 'prior' 'to' 'enrollment' ')' ';' 'female' 'sterilization' ';'
 'or' 'sexual' 'activity' 'with' 'a' 'partner' 'who' 'had' 'a' 'vasectomy']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1.]"
NCT02339922,",65:74:treatment","Male patients, even if surgically sterilized (i.e., status post-vasectomy), must agree to one of the following","['Male' 'patients' ',' 'even' 'if' 'surgically' 'sterilized' '(' 'i.e.'
 ',' 'status' 'post-vasectomy' ')' ',' 'must' 'agree' 'to' 'one' 'of'
 'the' 'following']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01754857,",,,,158:167:treatment",FCBP must also agree to ongoing pregnancy testing; men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy,"['FCBP' 'must' 'also' 'agree' 'to' 'ongoing' 'pregnancy' 'testing' ';'
 'men' 'must' 'agree' 'to' 'use' 'a' 'latex' 'condom' 'during' 'sexual'
 'contact' 'with' 'a' 'FCBP' 'even' 'if' 'they' 'have' 'had' 'a'
 'successful' 'vasectomy']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1.]"
NCT01543490,40:49:treatment,provide documentation for having had a vasectomy (with documented infertility),"['provide' 'documentation' 'for' 'having' 'had' 'a' 'vasectomy' '(' 'with'
 'documented' 'infertility' ')']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT01415752,",,,137:146:treatment","Men must agree to use a latex condom during sexual contact with a female of child-bearing potential, even if they have had a successful vasectomy","['Men' 'must' 'agree' 'to' 'use' 'a' 'latex' 'condom' 'during' 'sexual'
 'contact' 'with' 'a' 'female' 'of' 'child-bearing' 'potential' ',' 'even'
 'if' 'they' 'have' 'had' 'a' 'successful' 'vasectomy']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1.]"
NCT01054196,",,,107:116:treatment",Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy,"['Men' 'must' 'agree' 'to' 'use' 'a' 'latex' 'condom' 'during' 'sexual'
 'contact' 'with' 'a' 'FCBP' 'even' 'if' 'they' 'have' 'had' 'a'
 'successful' 'vasectomy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT00967785,",41:50:treatment",Male partner has previously undergone a vasectomy for which there is documentation of aspermatogenic sterility,"['Male' 'partner' 'has' 'previously' 'undergone' 'a' 'vasectomy' 'for'
 'which' 'there' 'is' 'documentation' 'of' 'aspermatogenic' 'sterility']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02950337,1:38:chronic_disease,psychiatric illness/social situations that could limit compliance with study requirements,"['psychiatric' 'illness/social' 'situations' 'that' 'could' 'limit'
 'compliance' 'with' 'study' 'requirements']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02945800,1:38:chronic_disease,psychiatric illness/social situations that would limit compliance with study requirements,"['psychiatric' 'illness/social' 'situations' 'that' 'would' 'limit'
 'compliance' 'with' 'study' 'requirements']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02890979,1:38:chronic_disease,psychiatric illness/social situations that would limit compliance with study requirements,"['psychiatric' 'illness/social' 'situations' 'that' 'would' 'limit'
 'compliance' 'with' 'study' 'requirements']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02857218,1:38:chronic_disease,psychiatric illness/social situations that would limit compliance with study requirements,"['psychiatric' 'illness/social' 'situations' 'that' 'would' 'limit'
 'compliance' 'with' 'study' 'requirements']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02843568,1:38:chronic_disease,psychiatric illness/social situations that would limit compliance with study requirements,"['psychiatric' 'illness/social' 'situations' 'that' 'would' 'limit'
 'compliance' 'with' 'study' 'requirements']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02811679,1:38:chronic_disease,psychiatric illness/social situations that would limit compliance with study requirements,"['psychiatric' 'illness/social' 'situations' 'that' 'would' 'limit'
 'compliance' 'with' 'study' 'requirements']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02694029,1:38:chronic_disease,psychiatric illness/social situations that would limit compliance with study requirements,"['psychiatric' 'illness/social' 'situations' 'that' 'would' 'limit'
 'compliance' 'with' 'study' 'requirements']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02639065,12:49:chronic_disease,History of psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent,"['History' 'of' 'psychiatric' 'illness/social' 'situations' 'that' 'would'
 'limit' 'compliance' 'with' 'study' 'requirements' 'or' 'compromise'
 'the' 'ability' 'of' 'the' 'subject' 'to' 'give' 'written' 'informed'
 'consent']",[0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02337465,1:38:chronic_disease,psychiatric illness/social situations that would limit compliance with study requirements,"['psychiatric' 'illness/social' 'situations' 'that' 'would' 'limit'
 'compliance' 'with' 'study' 'requirements']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02109627,38:75:chronic_disease,Uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements,"['Uncontrolled' 'intercurrent' 'illness' 'or' 'psychiatric'
 'illness/social' 'situations' 'that' 'would' 'limit' 'compliance' 'with'
 'study' 'requirements']",[0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02012296,8:45:chronic_disease,Active psychiatric illness/social situations that would limit compliance with protocol requirements,"['Active' 'psychiatric' 'illness/social' 'situations' 'that' 'would'
 'limit' 'compliance' 'with' 'protocol' 'requirements']",[0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT01515527,1:38:chronic_disease,psychiatric illness/social situations,['psychiatric' 'illness/social' 'situations'],[2. 2. 2.]
NCT03188042,30:38:chronic_disease,Other optic comorbidity than glaucoma,['Other' 'optic' 'comorbidity' 'than' 'glaucoma'],[0. 0. 0. 0. 2.]
NCT03129542,1:9:chronic_disease,glaucoma,['glaucoma'],[2.]
NCT03018704,12:20:chronic_disease,history of glaucoma,['history' 'of' 'glaucoma'],[0. 0. 2.]
NCT02823665,12:20:chronic_disease,History of glaucoma,['History' 'of' 'glaucoma'],[0. 0. 2.]
NCT02785042,21:29:chronic_disease,Negative history of glaucoma (not including family history),"['Negative' 'history' 'of' 'glaucoma' '(' 'not' 'including' 'family'
 'history' ')']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT02561104,10:18:chronic_disease,advanced glaucoma,['advanced' 'glaucoma'],[0. 2.]
NCT02503358,",,50:58:chronic_disease","Intra-ocular pressure > 21 mmHg, or uncontrolled glaucoma (irrespective of intra-ocular pressure)","['Intra-ocular' 'pressure' '>' '21' 'mmHg' ',' 'or' 'uncontrolled'
 'glaucoma' '(' 'irrespective' 'of' 'intra-ocular' 'pressure' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT02402660,1:9:chronic_disease,glaucoma,['glaucoma'],[2.]
NCT02252432,49:57:chronic_disease,"Increased intraocular pressure (e.g., untreated glaucoma)","['Increased' 'intraocular' 'pressure' '(' 'e.g.' ',' 'untreated'
 'glaucoma' ')']",[0. 0. 0. 0. 0. 0. 0. 2. 0.]
NCT02030990,"13:21:chronic_disease,,",Evidence of glaucoma or an intraocular pressure greater than 22 mm Hg at baseline,"['Evidence' 'of' 'glaucoma' 'or' 'an' 'intraocular' 'pressure' 'greater'
 'than' '22' 'mm' 'Hg' 'at' 'baseline']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01547429,28:36:chronic_disease,Patients with uncontrolled glaucoma,['Patients' 'with' 'uncontrolled' 'glaucoma'],[0. 0. 0. 2.]
NCT03110107,43:54:cancer,"histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent and/or unresectable)","['histologic' 'or' 'cytologic' 'confirmation' 'of' 'a' 'solid' 'tumor'
 'that' 'is' 'advanced' '(' 'metastatic' ',' 'recurrent' 'and/or'
 'unresectable' ')']",[0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03007030,",,13:24:cancer",stage I-III solid tumor,['stage' 'I-III' 'solid' 'tumor'],[0. 0. 3. 3.]
NCT02799095,59:70:cancer,the subject has histological or cytological evidence of a solid tumor,"['the' 'subject' 'has' 'histological' 'or' 'cytological' 'evidence' 'of'
 'a' 'solid' 'tumor']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT02730481,43:54:cancer,Histologically or cytologically confirmed solid tumor that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective,"['Histologically' 'or' 'cytologically' 'confirmed' 'solid' 'tumor' 'that'
 'is' 'metastatic' 'or' 'unresectable' 'and' 'for' 'which' 'standard'
 'curative' 'or' 'palliative' 'measures' 'do' 'not' 'exist' 'or' 'are'
 'no' 'longer' 'effective']","[0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02608125,58:69:cancer,Histological or cytological documentation of an advanced solid tumor,"['Histological' 'or' 'cytological' 'documentation' 'of' 'an' 'advanced'
 'solid' 'tumor']",[0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT02520713,",,46:57:cancer",Age ≤ 30 years at time of initial qualifying solid tumor diagnosis,"['Age' '≤' '30' 'years' 'at' 'time' 'of' 'initial' 'qualifying' 'solid'
 'tumor' 'diagnosis']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0.]
NCT02451553,26:37:cancer,Histologically confirmed solid tumor malignancy,['Histologically' 'confirmed' 'solid' 'tumor' 'malignancy'],[0. 0. 3. 3. 0.]
NCT02112565,126:137:cancer,"Patients must have histologically or cytologically confirmed (at original diagnosis or subsequent recurrence or progression) solid tumor that is metastatic, unresectable, progressive, or recurrent, and for which standard curative or palliative measures do not exist or are no longer effective","['Patients' 'must' 'have' 'histologically' 'or' 'cytologically'
 'confirmed' '(' 'at' 'original' 'diagnosis' 'or' 'subsequent'
 'recurrence' 'or' 'progression' ')' 'solid' 'tumor' 'that' 'is'
 'metastatic' ',' 'unresectable' ',' 'progressive' ',' 'or' 'recurrent'
 ',' 'and' 'for' 'which' 'standard' 'curative' 'or' 'palliative'
 'measures' 'do' 'not' 'exist' 'or' 'are' 'no' 'longer' 'effective']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02076906,42:53:cancer,Radiographically evaluable or measurable solid tumor target lesion(s),"['Radiographically' 'evaluable' 'or' 'measurable' 'solid' 'tumor' 'target'
 'lesion' '(' 's' ')']",[0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0.]
NCT00720785,52:63:cancer,Diagnosed with histologically confirmed metastatic solid tumor,"['Diagnosed' 'with' 'histologically' 'confirmed' 'metastatic' 'solid'
 'tumor']",[0. 0. 0. 0. 0. 3. 3.]
NCT00720785,52:63:cancer,Disease not evaluable radiographically (applies to solid tumor patients only),"['Disease' 'not' 'evaluable' 'radiographically' '(' 'applies' 'to' 'solid'
 'tumor' 'patients' 'only' ')']",[0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0.]
NCT02624258,"21:32:chronic_disease,",Patients with prior CNS disease that has been effectively treated will be eligible providing treatment was >4 weeks before enrollment,"['Patients' 'with' 'prior' 'CNS' 'disease' 'that' 'has' 'been'
 'effectively' 'treated' 'will' 'be' 'eligible' 'providing' 'treatment'
 'was' '>' '4' 'weeks' 'before' 'enrollment']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02512497,21:32:chronic_disease,Patient with active CNS disease,['Patient' 'with' 'active' 'CNS' 'disease'],[0. 0. 0. 2. 2.]
NCT02429934,22:33:chronic_disease,Subjects with active CNS disease,['Subjects' 'with' 'active' 'CNS' 'disease'],[0. 0. 0. 2. 2.]
NCT02315612,15:26:chronic_disease,Subjects with CNS disease,['Subjects' 'with' 'CNS' 'disease'],[0. 0. 2. 2.]
NCT02191098,39:50:chronic_disease,History or evidence of uncontrollable CNS disease,['History' 'or' 'evidence' 'of' 'uncontrollable' 'CNS' 'disease'],[0. 0. 0. 0. 0. 2. 2.]
NCT02188745,"7:18:chronic_disease,","Known CNS disease, unless clinically stable for ≥ 3 months","['Known' 'CNS' 'disease' ',' 'unless' 'clinically' 'stable' 'for' '≥' '3'
 'months']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02122081,8:19:chronic_disease,Active CNS disease as identified by positive CSF cytospin at time of enrollment,"['Active' 'CNS' 'disease' 'as' 'identified' 'by' 'positive' 'CSF'
 'cytospin' 'at' 'time' 'of' 'enrollment']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01554371,51:62:chronic_disease,Patients with stable and clinically insignificant CNS disease,"['Patients' 'with' 'stable' 'and' 'clinically' 'insignificant' 'CNS'
 'disease']",[0. 0. 0. 0. 0. 0. 2. 2.]
NCT01494662,"44:55:chronic_disease,,,","In cohort 1, patients must have measurable CNS disease, defined as at least one parenchymal brain lesion that can be accurately measured in at least one dimension with longest dimension ≥10 mm by local radiology review","['In' 'cohort' '1' ',' 'patients' 'must' 'have' 'measurable' 'CNS'
 'disease' ',' 'defined' 'as' 'at' 'least' 'one' 'parenchymal' 'brain'
 'lesion' 'that' 'can' 'be' 'accurately' 'measured' 'in' 'at' 'least'
 'one' 'dimension' 'with' 'longest' 'dimension' '≥10' 'mm' 'by' 'local'
 'radiology' 'review']","[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01059786,13:24:chronic_disease,Presence of CNS disease,['Presence' 'of' 'CNS' 'disease'],[0. 0. 2. 2.]
NCT00914628,22:33:chronic_disease,Patients with active CNS disease,['Patients' 'with' 'active' 'CNS' 'disease'],[0. 0. 0. 2. 2.]
NCT03181542,32:42:treatment,Emergency procedures requiring anesthesia,['Emergency' 'procedures' 'requiring' 'anesthesia'],[0. 0. 0. 1.]
NCT03151434,18:28:treatment,Desires Regional anesthesia for postoperative pain control,['Desires' 'Regional' 'anesthesia' 'for' 'postoperative' 'pain' 'control'],[0. 0. 1. 0. 0. 0. 0.]
NCT02770326,22:32:allergy_name,Contraindications to anesthesia for procedure,['Contraindications' 'to' 'anesthesia' 'for' 'procedure'],[0. 0. 4. 0. 0.]
NCT02148796,74:84:treatment,received mechanical ventilation with the exclusion of ventilation during anesthesia for a minor surgical procedure,"['received' 'mechanical' 'ventilation' 'with' 'the' 'exclusion' 'of'
 'ventilation' 'during' 'anesthesia' 'for' 'a' 'minor' 'surgical'
 'procedure']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02132130,34:44:treatment,Past serious adverse reaction to anesthesia,['Past' 'serious' 'adverse' 'reaction' 'to' 'anesthesia'],[0. 0. 0. 0. 0. 1.]
NCT01554410,19:29:treatment,Examination under anesthesia (if indicated),['Examination' 'under' 'anesthesia' '(' 'if' 'indicated' ')'],[0. 0. 1. 0. 0. 0. 0.]
NCT01505062,29:39:allergy_name,"Contraindications to use of anesthesia (local or general, as appropriate)","['Contraindications' 'to' 'use' 'of' 'anesthesia' '(' 'local' 'or'
 'general' ',' 'as' 'appropriate' ')']",[0. 0. 0. 0. 4. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01367444,29:39:treatment,"Contraindications to use of anesthesia (local or general, as appropriate)","['Contraindications' 'to' 'use' 'of' 'anesthesia' '(' 'local' 'or'
 'general' ',' 'as' 'appropriate' ')']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01011777,30:40:allergy_name,Previous adverse reaction to anesthesia,['Previous' 'adverse' 'reaction' 'to' 'anesthesia'],[0. 0. 0. 0. 4.]
NCT00618683,55:65:treatment,Electrophysiology study performed without sedation or anesthesia,"['Electrophysiology' 'study' 'performed' 'without' 'sedation' 'or'
 'anesthesia']",[0. 0. 0. 0. 0. 0. 1.]
NCT03160547,"49:59:treatment,",Expected death or withdrawal of life-sustaining treatments within 7 days from screening,"['Expected' 'death' 'or' 'withdrawal' 'of' 'life-sustaining' 'treatments'
 'within' '7' 'days' 'from' 'screening']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT03143985,",169:179:treatment",Any > grade 1 (according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTC AE) v.4.03) adverse reaction unresolved from previous treatments or not readily managed and controlled with supportive care,"['Any' '>' 'grade' '1' '(' 'according' 'to' 'the' 'National' 'Cancer'
 'Institute' 'Common' 'Terminology' 'Criteria' 'for' 'Adverse' 'Events'
 '(' 'NCI' 'CTC' 'AE' ')' 'v.4.03' ')' 'adverse' 'reaction' 'unresolved'
 'from' 'previous' 'treatments' 'or' 'not' 'readily' 'managed' 'and'
 'controlled' 'with' 'supportive' 'care']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02636530,"15:25:treatment,","initiation of treatments that could impact bone metabolism (diuretics, hormones, bine anabolic agents) in the prior 6 months","['initiation' 'of' 'treatments' 'that' 'could' 'impact' 'bone'
 'metabolism' '(' 'diuretics' ',' 'hormones' ',' 'bine' 'anabolic'
 'agents' ')' 'in' 'the' 'prior' '6' 'months']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02382549,"61:71:treatment,",Participants who have received the following medications or treatments at any time within 4 weeks of registration,"['Participants' 'who' 'have' 'received' 'the' 'following' 'medications'
 'or' 'treatments' 'at' 'any' 'time' 'within' '4' 'weeks' 'of'
 'registration']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02359825,7:17:treatment,other treatments known to affect the growth of the neural and vascular system,"['other' 'treatments' 'known' 'to' 'affect' 'the' 'growth' 'of' 'the'
 'neural' 'and' 'vascular' 'system']",[0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02354703,56:66:treatment,Willingness to participate in behavioral and medicinal treatments for Alcohol Use Disorder,"['Willingness' 'to' 'participate' 'in' 'behavioral' 'and' 'medicinal'
 'treatments' 'for' 'Alcohol' 'Use' 'Disorder']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02343042,32:42:treatment,Hypersensitivity to any of the treatments for the Arm in which the patient is enrolled,"['Hypersensitivity' 'to' 'any' 'of' 'the' 'treatments' 'for' 'the' 'Arm'
 'in' 'which' 'the' 'patient' 'is' 'enrolled']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02286154,68:78:treatment,Family unwillingness to sign informed consent or comply with study treatments,"['Family' 'unwillingness' 'to' 'sign' 'informed' 'consent' 'or' 'comply'
 'with' 'study' 'treatments']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01967823,60:70:treatment,Recurrent disease/progression after receiving all standard treatments,"['Recurrent' 'disease/progression' 'after' 'receiving' 'all' 'standard'
 'treatments']",[0. 0. 0. 0. 0. 0. 1.]
NCT00929006,39:49:treatment,Restrictions on use of other drugs or treatments,['Restrictions' 'on' 'use' 'of' 'other' 'drugs' 'or' 'treatments'],[0. 0. 0. 0. 0. 0. 0. 1.]
NCT03114020,"39:63:treatment,",Exacerbation requiring treatment with systemic corticosteroids within the last 3 months,"['Exacerbation' 'requiring' 'treatment' 'with' 'systemic'
 'corticosteroids' 'within' 'the' 'last' '3' 'months']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02574455,",35:59:treatment,,","At least 2 weeks beyond high dose systemic corticosteroids (however, low dose corticosteroids < 20 mg prednisone or equivalent daily are permitted)","['At' 'least' '2' 'weeks' 'beyond' 'high' 'dose' 'systemic'
 'corticosteroids' '(' 'however' ',' 'low' 'dose' 'corticosteroids' '<'
 '20' 'mg' 'prednisone' 'or' 'equivalent' 'daily' 'are' 'permitted' ')']","[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02495168,23:47:treatment,Patients who required systemic corticosteroids (for any reason),"['Patients' 'who' 'required' 'systemic' 'corticosteroids' '(' 'for' 'any'
 'reason' ')']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02460783,16:40:treatment,Current use of systemic corticosteroids,['Current' 'use' 'of' 'systemic' 'corticosteroids'],[0. 0. 0. 1. 1.]
NCT02446093,13:37:treatment,Patients on systemic corticosteroids,['Patients' 'on' 'systemic' 'corticosteroids'],[0. 0. 1. 1.]
NCT02393794,48:72:treatment,Subject is currently receiving or has received systemic corticosteroids,"['Subject' 'is' 'currently' 'receiving' 'or' 'has' 'received' 'systemic'
 'corticosteroids']",[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02311621,"4:28:treatment,",No systemic corticosteroids (unless physiologic replacement dosing) within 7 days of enrollment,"['No' 'systemic' 'corticosteroids' '(' 'unless' 'physiologic'
 'replacement' 'dosing' ')' 'within' '7' 'days' 'of' 'enrollment']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02304458,"33:57:treatment,",patients must not have received systemic corticosteroids within 7 days prior to enrollment,"['patients' 'must' 'not' 'have' 'received' 'systemic' 'corticosteroids'
 'within' '7' 'days' 'prior' 'to' 'enrollment']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02075671,"8:32:treatment,",Use of systemic corticosteroids 3 months prior to Visit 1,"['Use' 'of' 'systemic' 'corticosteroids' '3' 'months' 'prior' 'to' 'Visit'
 '1']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT01333046,20:44:treatment,Patients receiving systemic corticosteroids,['Patients' 'receiving' 'systemic' 'corticosteroids'],[0. 0. 1. 1.]
NCT03059888,"35:64:treatment,",Subject has undergone a change in immunosuppressive medications within the last three months prior to enrollment,"['Subject' 'has' 'undergone' 'a' 'change' 'in' 'immunosuppressive'
 'medications' 'within' 'the' 'last' 'three' 'months' 'prior' 'to'
 'enrollment']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02920710,17:46:treatment,Stable baseline immunosuppressive medications,['Stable' 'baseline' 'immunosuppressive' 'medications'],[0. 0. 1. 1.]
NCT02910700,"7:36:treatment,",other immunosuppressive medications within 14 days of study drug administration,"['other' 'immunosuppressive' 'medications' 'within' '14' 'days' 'of'
 'study' 'drug' 'administration']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02864147,8:37:treatment,taking immunosuppressive medications,['taking' 'immunosuppressive' 'medications'],[0. 1. 1.]
NCT02738749,17:46:treatment,Patients taking immunosuppressive medications,['Patients' 'taking' 'immunosuppressive' 'medications'],[0. 0. 1. 1.]
NCT02725177,15:44:treatment,Escalation of immunosuppressive medications between screening and initiation of the study medication,"['Escalation' 'of' 'immunosuppressive' 'medications' 'between' 'screening'
 'and' 'initiation' 'of' 'the' 'study' 'medication']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02707692,11:40:treatment,Receiving immunosuppressive medications,['Receiving' 'immunosuppressive' 'medications'],[0. 1. 1.]
NCT02490631,1:30:treatment,immunosuppressive medications,['immunosuppressive' 'medications'],[1. 1.]
NCT02353819,17:46:treatment,Not actively on immunosuppressive medications,['Not' 'actively' 'on' 'immunosuppressive' 'medications'],[0. 0. 0. 1. 1.]
NCT02259621,"7:36:treatment,",other immunosuppressive medications within 14 days of study drug administration,"['other' 'immunosuppressive' 'medications' 'within' '14' 'days' 'of'
 'study' 'drug' 'administration']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT03029806,8:15:treatment,"Recent steroid use (injected, inhaled, oral)","['Recent' 'steroid' 'use' '(' 'injected' ',' 'inhaled' ',' 'oral' ')']",[0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02914834,8:15:treatment,use of steroid medications,['use' 'of' 'steroid' 'medications'],[0. 0. 1. 0.]
NCT02536794,36:43:treatment,must have completed any prescribed steroid taper,['must' 'have' 'completed' 'any' 'prescribed' 'steroid' 'taper'],[0. 0. 0. 0. 0. 1. 0.]
NCT02465060,10:17:treatment,Low dose steroid use for appetite,['Low' 'dose' 'steroid' 'use' 'for' 'appetite'],[0. 0. 1. 0. 0. 0.]
NCT02451982,27:34:treatment,Using systemically active steroid use,['Using' 'systemically' 'active' 'steroid' 'use'],[0. 0. 0. 1. 0.]
NCT02272556,"19:26:treatment,",Current or recent steroid use in last 3 months,['Current' 'or' 'recent' 'steroid' 'use' 'in' 'last' '3' 'months'],[0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02219581,17:24:treatment,Current chronic steroid use,['Current' 'chronic' 'steroid' 'use'],[0. 0. 1. 0.]
NCT01896999,53:60:treatment,a history of occasional (but not continuous) use of steroid inhalers is allowed,"['a' 'history' 'of' 'occasional' '(' 'but' 'not' 'continuous' ')' 'use'
 'of' 'steroid' 'inhalers' 'is' 'allowed']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT01876511,21:28:treatment,Systemically active steroid use,['Systemically' 'active' 'steroid' 'use'],[0. 0. 1. 0.]
NCT01524536,34:41:treatment,Willingness to perform the timed steroid challenge,['Willingness' 'to' 'perform' 'the' 'timed' 'steroid' 'challenge'],[0. 0. 0. 0. 0. 1. 0.]
NCT02920788,36:39:chronic_disease,No history of any (mild to severe) TBI (as defined by DOD / VA; confirmed by medical records and in person Ohio State University TBI Instrument),"['No' 'history' 'of' 'any' '(' 'mild' 'to' 'severe' ')' 'TBI' '(' 'as'
 'defined' 'by' 'DOD' '/' 'VA' ';' 'confirmed' 'by' 'medical' 'records'
 'and' 'in' 'person' 'Ohio' 'State' 'University' 'TBI' 'Instrument' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02719964,13:16:chronic_disease,Penetrating TBI,['Penetrating' 'TBI'],[0. 2.]
NCT02709980,",61:64:chronic_disease",Report sleep problems for >1 month that developed after the TBI,"['Report' 'sleep' 'problems' 'for' '>' '1' 'month' 'that' 'developed'
 'after' 'the' 'TBI']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02695043,76:79:chronic_disease,"medically documented (e.g., EMS report, hospital record, physician record) TBI as a result of a blow to the head requiring admission to an acute inpatient rehabilitation unit","['medically' 'documented' '(' 'e.g.' ',' 'EMS' 'report' ',' 'hospital'
 'record' ',' 'physician' 'record' ')' 'TBI' 'as' 'a' 'result' 'of' 'a'
 'blow' 'to' 'the' 'head' 'requiring' 'admission' 'to' 'an' 'acute'
 'inpatient' 'rehabilitation' 'unit']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02504866,30:33:chronic_disease,Diagnosis of non-penetrating TBI,['Diagnosis' 'of' 'non-penetrating' 'TBI'],[0. 0. 0. 2.]
NCT02407028,"21:24:chronic_disease,,,","Present with severe TBI, defined as GCS of 3 to 8","['Present' 'with' 'severe' 'TBI' ',' 'defined' 'as' 'GCS' 'of' '3' 'to'
 '8']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02391402,"111:114:chronic_disease,,,,","Veterans with a history indicated by medical record review of a diagnosis of moderate, severe, or penetrating TBI, or self-reported history on the Structured Interview for Collecting Head Trauma Event Characteristics of TBI with Post-Traumatic Amnesia (PTA) greater than 24 hours or loss of consciousness (LOC) greater than 30 minutes","['Veterans' 'with' 'a' 'history' 'indicated' 'by' 'medical' 'record'
 'review' 'of' 'a' 'diagnosis' 'of' 'moderate' ',' 'severe' ',' 'or'
 'penetrating' 'TBI' ',' 'or' 'self-reported' 'history' 'on' 'the'
 'Structured' 'Interview' 'for' 'Collecting' 'Head' 'Trauma' 'Event'
 'Characteristics' 'of' 'TBI' 'with' 'Post-Traumatic' 'Amnesia' '(' 'PTA'
 ')' 'greater' 'than' '24' 'hours' 'or' 'loss' 'of' 'consciousness' '('
 'LOC' ')' 'greater' 'than' '30' 'minutes']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02377089,"18:21:chronic_disease,,",report of severe TBI with coma duration (30 minutes or more) during the screening interview and/or duration of post,"['report' 'of' 'severe' 'TBI' 'with' 'coma' 'duration' '(' '30' 'minutes'
 'or' 'more' ')' 'during' 'the' 'screening' 'interview' 'and/or'
 'duration' 'of' 'post']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02310633,42:45:chronic_disease,who meet criteria for moderate or severe TBI during deployment,"['who' 'meet' 'criteria' 'for' 'moderate' 'or' 'severe' 'TBI' 'during'
 'deployment']",[0. 0. 0. 0. 0. 0. 0. 2. 0. 0.]
NCT02266329,12:15:chronic_disease,History of TBI more severe than that classified as mild by DVBIC criteria,"['History' 'of' 'TBI' 'more' 'severe' 'than' 'that' 'classified' 'as'
 'mild' 'by' 'DVBIC' 'criteria']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03182907,16:23:treatment,has received a vaccine directed against C,['has' 'received' 'a' 'vaccine' 'directed' 'against' 'C'],[0. 0. 0. 1. 0. 0. 0.]
NCT03153319,22:29:treatment,Requirement for live vaccine exposure that would be expected to occur during the time frame of the study,"['Requirement' 'for' 'live' 'vaccine' 'exposure' 'that' 'would' 'be'
 'expected' 'to' 'occur' 'during' 'the' 'time' 'frame' 'of' 'the' 'study']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02865135,18:25:allergy_name,"Allergies to any vaccine, that after discussion with Immunovaccine","['Allergies' 'to' 'any' 'vaccine' ',' 'that' 'after' 'discussion' 'with'
 'Immunovaccine']",[0. 0. 0. 4. 0. 0. 0. 0. 0. 0.]
NCT02466750,",87:94:treatment","Agree to defer blood, bone marrow, and organ donation for 1 year after receipt of the vaccine","['Agree' 'to' 'defer' 'blood' ',' 'bone' 'marrow' ',' 'and' 'organ'
 'donation' 'for' '1' 'year' 'after' 'receipt' 'of' 'the' 'vaccine']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01893554,90:97:treatment,whose parent/guardian understands and signs the study informed consent and who agrees to vaccine administration following a detailed explanation of the study,"['whose' 'parent/guardian' 'understands' 'and' 'signs' 'the' 'study'
 'informed' 'consent' 'and' 'who' 'agrees' 'to' 'vaccine' 'administration'
 'following' 'a' 'detailed' 'explanation' 'of' 'the' 'study']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01893554,87:94:treatment,whose parents/guardians can understand and sign the informed consent and who agree to vaccine administration following detailed explanation of the study,"['whose' 'parents/guardians' 'can' 'understand' 'and' 'sign' 'the'
 'informed' 'consent' 'and' 'who' 'agree' 'to' 'vaccine' 'administration'
 'following' 'detailed' 'explanation' 'of' 'the' 'study']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT01795313,48:55:treatment,willing to travel to Pittsburgh to receive the vaccine,['willing' 'to' 'travel' 'to' 'Pittsburgh' 'to' 'receive' 'the' 'vaccine'],[0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01595529,1:8:treatment,vaccine,['vaccine'],[1.]
NCT00186927,22:29:treatment,prior to evidence of vaccine clearance,['prior' 'to' 'evidence' 'of' 'vaccine' 'clearance'],[0. 0. 0. 0. 1. 0.]
NCT03144245,52:63:treatment,patients with excessive blasts may be treated with hydroxyurea to bring counts down,"['patients' 'with' 'excessive' 'blasts' 'may' 'be' 'treated' 'with'
 'hydroxyurea' 'to' 'bring' 'counts' 'down']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT03088709,13:24:treatment,(except for hydroxyurea),['(' 'except' 'for' 'hydroxyurea' ')'],[0. 0. 0. 1. 0.]
NCT02981329,"7:18:treatment,,","If on hydroxyurea, fetal hemoglobin less than 20% at maximum tolerated dose","['If' 'on' 'hydroxyurea' ',' 'fetal' 'hemoglobin' 'less' 'than' '20' '%'
 'at' 'maximum' 'tolerated' 'dose']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02728050,12:23:treatment,The use of hydroxyurea prior to study registration,['The' 'use' 'of' 'hydroxyurea' 'prior' 'to' 'study' 'registration'],[0. 0. 0. 1. 0. 0. 0. 0.]
NCT02577406,1:12:treatment,hydroxyurea,['hydroxyurea'],[1.]
NCT02520011,",,55:66:treatment","Have a peripheral blast count of >30,000/mm3 (may use hydroxyurea as in #5 above)","['Have' 'a' 'peripheral' 'blast' 'count' 'of' '>' '30,000/mm3' '(' 'may'
 'use' 'hydroxyurea' 'as' 'in' '#' '5' 'above' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT02186418,33:44:treatment,Patients who are unable to take hydroxyurea due to financial or safety monitoring constraints,"['Patients' 'who' 'are' 'unable' 'to' 'take' 'hydroxyurea' 'due' 'to'
 'financial' 'or' 'safety' 'monitoring' 'constraints']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02105766,28:39:treatment,Complication/ Eligible for hydroxyurea,['Complication/' 'Eligible' 'for' 'hydroxyurea'],[0. 0. 0. 1.]
NCT01389024,33:44:allergy_name,Known allergy or intolerance of hydroxyurea,['Known' 'allergy' 'or' 'intolerance' 'of' 'hydroxyurea'],[0. 0. 0. 0. 0. 4.]
NCT03129061,"12:24:treatment,",Received a live vaccine within 30 days of planned PD-1 start date,"['Received' 'a' 'live' 'vaccine' 'within' '30' 'days' 'of' 'planned'
 'PD-1' 'start' 'date']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03113695,"20:32:treatment,",Vaccination with a live vaccine a minimum of 28 days prior to the start of treatment,"['Vaccination' 'with' 'a' 'live' 'vaccine' 'a' 'minimum' 'of' '28' 'days'
 'prior' 'to' 'the' 'start' 'of' 'treatment']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03101566,"26:38:treatment,",Must not have received a live vaccine within 30 days of planned start of the study therapy,"['Must' 'not' 'have' 'received' 'a' 'live' 'vaccine' 'within' '30' 'days'
 'of' 'planned' 'start' 'of' 'the' 'study' 'therapy']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03059888,"26:38:treatment,",Subject has received any live vaccine within 3 months of screening,"['Subject' 'has' 'received' 'any' 'live' 'vaccine' 'within' '3' 'months'
 'of' 'screening']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02977468,"16:28:treatment,",Has received a live vaccine within 30 days of planned start of study therapy,"['Has' 'received' 'a' 'live' 'vaccine' 'within' '30' 'days' 'of' 'planned'
 'start' 'of' 'study' 'therapy']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02567422,22:34:treatment,Patient who requires live vaccine administration,['Patient' 'who' 'requires' 'live' 'vaccine' 'administration'],[0. 0. 0. 1. 1. 0.]
NCT02324582,"12:24:treatment,",received a live vaccine within 30 days,['received' 'a' 'live' 'vaccine' 'within' '30' 'days'],[0. 0. 1. 1. 0. 0. 0.]
NCT02311361,"43:55:treatment,","Subjects, if enrolled, should not receive live vaccine during the study and 180 days after the last dose of both drugs","['Subjects' ',' 'if' 'enrolled' ',' 'should' 'not' 'receive' 'live'
 'vaccine' 'during' 'the' 'study' 'and' '180' 'days' 'after' 'the' 'last'
 'dose' 'of' 'both' 'drugs']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01059786,"14:26:treatment,",Receipt of a live vaccine within 4 weeks prior to randomization,"['Receipt' 'of' 'a' 'live' 'vaccine' 'within' '4' 'weeks' 'prior' 'to'
 'randomization']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT03120728,24:46:treatment,history of complicated solid organ transplant,['history' 'of' 'complicated' 'solid' 'organ' 'transplant'],[0. 0. 0. 1. 1. 1.]
NCT02974686,36:58:treatment,Dual organ or kidney after another solid organ transplant,"['Dual' 'organ' 'or' 'kidney' 'after' 'another' 'solid' 'organ'
 'transplant']",[0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02927769,3:25:treatment,a solid organ transplant,['a' 'solid' 'organ' 'transplant'],[0. 1. 1. 1.]
NCT02760498,28:50:treatment,Patients with a history of solid organ transplant,['Patients' 'with' 'a' 'history' 'of' 'solid' 'organ' 'transplant'],[0. 0. 0. 0. 0. 1. 1. 1.]
NCT02751151,43:65:treatment,The patient has been the recipient of any solid organ transplant,"['The' 'patient' 'has' 'been' 'the' 'recipient' 'of' 'any' 'solid' 'organ'
 'transplant']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02564198,12:34:treatment,History of solid organ transplant,['History' 'of' 'solid' 'organ' 'transplant'],[0. 0. 1. 1. 1.]
NCT02479698,12:34:treatment,history of solid organ transplant,['history' 'of' 'solid' 'organ' 'transplant'],[0. 0. 1. 1. 1.]
NCT02332668,15:37:treatment,Has undergone solid organ transplant at any time,['Has' 'undergone' 'solid' 'organ' 'transplant' 'at' 'any' 'time'],[0. 0. 1. 1. 1. 0. 0. 0.]
NCT02277613,10:32:treatment,Previous solid organ transplant,['Previous' 'solid' 'organ' 'transplant'],[0. 1. 1. 1.]
NCT03084640,"35:48:treatment,",who have had SD must have been on pembrolizumab for at least 12 weeks,"['who' 'have' 'had' 'SD' 'must' 'have' 'been' 'on' 'pembrolizumab' 'for'
 'at' 'least' '12' 'weeks']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02977468,21:34:allergy_name,Hypersensitivity to pembrolizumab or any of its excipients,"['Hypersensitivity' 'to' 'pembrolizumab' 'or' 'any' 'of' 'its'
 'excipients']",[0. 0. 4. 0. 0. 0. 0. 0.]
NCT02799095,59:72:allergy_name,Subjects with known hypersensitivity to any components of pembrolizumab (for patients in combination arm only),"['Subjects' 'with' 'known' 'hypersensitivity' 'to' 'any' 'components' 'of'
 'pembrolizumab' '(' 'for' 'patients' 'in' 'combination' 'arm' 'only' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 4. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02635360,21:34:allergy_name,Hypersensitivity to pembrolizumab or similar drugs,['Hypersensitivity' 'to' 'pembrolizumab' 'or' 'similar' 'drugs'],[0. 0. 4. 0. 0. 0.]
NCT02575404,117:130:treatment,Patients who have radiographic progression using Response Evaluation Criteria In Solid Tumors (RECIST) currently on pembrolizumab are also eligible,"['Patients' 'who' 'have' 'radiographic' 'progression' 'using' 'Response'
 'Evaluation' 'Criteria' 'In' 'Solid' 'Tumors' '(' 'RECIST' ')'
 'currently' 'on' 'pembrolizumab' 'are' 'also' 'eligible']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02509507,",,131:144:treatment",must be willing to use acceptable methods of effective contraception during treatment and through 4 months after the last dose of pembrolizumab,"['must' 'be' 'willing' 'to' 'use' 'acceptable' 'methods' 'of' 'effective'
 'contraception' 'during' 'treatment' 'and' 'through' '4' 'months' 'after'
 'the' 'last' 'dose' 'of' 'pembrolizumab']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02501473,73:86:treatment,For patients enrolled in Part 2 or Part 4 with the potential to receive pembrolizumab,"['For' 'patients' 'enrolled' 'in' 'Part' '2' 'or' 'Part' '4' 'with' 'the'
 'potential' 'to' 'receive' 'pembrolizumab']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02437370,40:53:allergy_name,Has known hypersensitivity to MK-3475 (pembrolizumab) or any of its incipients,"['Has' 'known' 'hypersensitivity' 'to' 'MK-3475' '(' 'pembrolizumab' ')'
 'or' 'any' 'of' 'its' 'incipients']",[0. 0. 0. 0. 0. 0. 4. 0. 0. 0. 0. 0. 0.]
NCT02362997,102:115:allergy_name,History of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab,"['History' 'of' 'allergic' 'reactions' 'attributed' 'to' 'compounds' 'of'
 'similar' 'chemical' 'or' 'biologic' 'composition' 'to' 'pembrolizumab']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4.]
NCT03038620,27:42:chronic_disease,Any lifetime history of a suicide attempt,['Any' 'lifetime' 'history' 'of' 'a' 'suicide' 'attempt'],[0. 0. 0. 0. 0. 2. 2.]
NCT03034863,",,,170:185:chronic_disease,","plan or intent on the Columbia Suicide Severity Rating Scale (C-SSRS), but scoring less than or equal to 4 on the C-SSRS Behavior Scale, and without history of a lethal suicide attempt in the last 3 months","['plan' 'or' 'intent' 'on' 'the' 'Columbia' 'Suicide' 'Severity' 'Rating'
 'Scale' '(' 'C-SSRS' ')' ',' 'but' 'scoring' 'less' 'than' 'or' 'equal'
 'to' '4' 'on' 'the' 'C-SSRS' 'Behavior' 'Scale' ',' 'and' 'without'
 'history' 'of' 'a' 'lethal' 'suicide' 'attempt' 'in' 'the' 'last' '3'
 'months']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0.]"
NCT02924194,26:41:chronic_disease,Subjects who have made a suicide attempt within the prior year,"['Subjects' 'who' 'have' 'made' 'a' 'suicide' 'attempt' 'within' 'the'
 'prior' 'year']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0.]
NCT02685358,"1:16:chronic_disease,",suicide attempt in the last two months,['suicide' 'attempt' 'in' 'the' 'last' 'two' 'months'],[2. 2. 0. 0. 0. 0. 0.]
NCT02543983,60:75:chronic_disease,"For participants who still experience the effects of their suicide attempt, i.e. someone who overdosed is significantly drowsy or confused, the consenting process will occur after the patient has improved from the effects","['For' 'participants' 'who' 'still' 'experience' 'the' 'effects' 'of'
 'their' 'suicide' 'attempt' ',' 'i.e' '.' 'someone' 'who' 'overdosed'
 'is' 'significantly' 'drowsy' 'or' 'confused' ',' 'the' 'consenting'
 'process' 'will' 'occur' 'after' 'the' 'patient' 'has' 'improved' 'from'
 'the' 'effects']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02513225,"32:47:chronic_disease,","Severe risk for suicide (i.e., suicide attempt within past 6 months)","['Severe' 'risk' 'for' 'suicide' '(' 'i.e.' ',' 'suicide' 'attempt'
 'within' 'past' '6' 'months' ')']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02496611,12:27:chronic_disease,History of suicide attempt,['History' 'of' 'suicide' 'attempt'],[0. 0. 2. 2.]
NCT02460692,17:32:chronic_disease,Past history of suicide attempt,['Past' 'history' 'of' 'suicide' 'attempt'],[0. 0. 0. 2. 2.]
NCT02377089,"1:16:chronic_disease,",suicide attempt within six months,['suicide' 'attempt' 'within' 'six' 'months'],[2. 2. 0. 0. 0.]
NCT02960555,7:51:chronic_disease,Known human immunodeficiency virus (HIV) infection,['Known' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')' 'infection'],[0. 2. 2. 2. 2. 2. 0. 0.]
NCT02819843,7:51:chronic_disease,Known human immunodeficiency virus (HIV) infection,['Known' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')' 'infection'],[0. 2. 2. 2. 2. 2. 0. 0.]
NCT02780401,18:62:chronic_disease,Known history of human immunodeficiency virus (HIV) infection,"['Known' 'history' 'of' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')'
 'infection']",[0. 0. 0. 2. 2. 2. 2. 2. 0. 0.]
NCT02533674,7:51:chronic_disease,Known human immunodeficiency virus (HIV) infection,['Known' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')' 'infection'],[0. 2. 2. 2. 2. 2. 0. 0.]
NCT02532231,12:56:chronic_disease,with known human immunodeficiency virus (HIV) infection,"['with' 'known' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')'
 'infection']",[0. 0. 2. 2. 2. 2. 2. 0. 0.]
NCT02367040,18:62:chronic_disease,Known history of human immunodeficiency virus (HIV) infection,"['Known' 'history' 'of' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')'
 'infection']",[0. 0. 0. 2. 2. 2. 2. 2. 0. 0.]
NCT01903330,1:45:chronic_disease,human immunodeficiency virus (HIV) infection,['human' 'immunodeficiency' 'virus' '(' 'HIV' ')' 'infection'],[2. 2. 2. 2. 2. 0. 0.]
NCT01389024,7:51:chronic_disease,Known human immunodeficiency virus (HIV) infection,['Known' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')' 'infection'],[0. 2. 2. 2. 2. 2. 0. 0.]
NCT00719888,12:56:chronic_disease,History of human immunodeficiency virus (HIV) infection,"['History' 'of' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')'
 'infection']",[0. 0. 2. 2. 2. 2. 2. 0. 0.]
NCT02905591,11:37:cancer,Recurrent non-small cell lung cancer,['Recurrent' 'non-small' 'cell' 'lung' 'cancer'],[0. 3. 3. 3. 3.]
NCT02588612,"79:105:cancer,,",Subject has a diagnosis of histologically or cytologically confirmed advanced non-small cell lung cancer (Stage IIIB or IV) or recurrent disease,"['Subject' 'has' 'a' 'diagnosis' 'of' 'histologically' 'or'
 'cytologically' 'confirmed' 'advanced' 'non-small' 'cell' 'lung' 'cancer'
 '(' 'Stage' 'IIIB' 'or' 'IV' ')' 'or' 'recurrent' 'disease']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02492867,",,70:96:cancer",Patients must have FDG-avid and pathologically proven Stage IIA-IIIB non-small cell lung cancer,"['Patients' 'must' 'have' 'FDG-avid' 'and' 'pathologically' 'proven'
 'Stage' 'IIA-IIIB' 'non-small' 'cell' 'lung' 'cancer']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3.]
NCT02468024,"39:65:cancer,","Radiographic findings consistent with non-small cell lung cancer, including lesions with ground glass opacities with a solid component of 50% or greater","['Radiographic' 'findings' 'consistent' 'with' 'non-small' 'cell' 'lung'
 'cancer' ',' 'including' 'lesions' 'with' 'ground' 'glass' 'opacities'
 'with' 'a' 'solid' 'component' 'of' '50' '%' 'or' 'greater']",[0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02264678,34:60:cancer,advanced recurrent or metastatic non-small cell lung cancer,"['advanced' 'recurrent' 'or' 'metastatic' 'non-small' 'cell' 'lung'
 'cancer']",[0. 0. 0. 0. 3. 3. 3. 3.]
NCT02194738,21:47:cancer,Completely resected non-small cell lung cancer with negative margins (R0),"['Completely' 'resected' 'non-small' 'cell' 'lung' 'cancer' 'with'
 'negative' 'margins' '(' 'R0' ')']",[0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0.]
NCT02194738,35:61:cancer,Suspected diagnosis of resectable non-small cell lung cancer,"['Suspected' 'diagnosis' 'of' 'resectable' 'non-small' 'cell' 'lung'
 'cancer']",[0. 0. 0. 0. 3. 3. 3. 3.]
NCT01993810,53:79:cancer,Histologically or cytologically proven diagnosis of non-small cell lung cancer,"['Histologically' 'or' 'cytologically' 'proven' 'diagnosis' 'of'
 'non-small' 'cell' 'lung' 'cancer']",[0. 0. 0. 0. 0. 0. 3. 3. 3. 3.]
NCT01799135,26:52:cancer,Histologically confirmed non-small cell lung cancer,['Histologically' 'confirmed' 'non-small' 'cell' 'lung' 'cancer'],[0. 0. 3. 3. 3. 3.]
NCT02759120,38:55:chronic_disease,"If the enrolling physician feels the renal dysfunction has resolved, documentation to that effect must be provided","['If' 'the' 'enrolling' 'physician' 'feels' 'the' 'renal' 'dysfunction'
 'has' 'resolved' ',' 'documentation' 'to' 'that' 'effect' 'must' 'be'
 'provided']",[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02620761,"16:33:chronic_disease,,,,,","No preexisting renal dysfunction, defined as serum creatinine > 1.0 mg/dl, or urine output <1.0 ml/kg/hour over the previous 24 hours","['No' 'preexisting' 'renal' 'dysfunction' ',' 'defined' 'as' 'serum'
 'creatinine' '>' '1.0' 'mg/dl' ',' 'or' 'urine' 'output' '<' '1.0'
 'ml/kg/hour' 'over' 'the' 'previous' '24' 'hours']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02554253,"15:32:chronic_disease,,",pre-operative renal dysfunction including a baseline creatinine equal to or greater than 1.5 mg/dL or requiring dialysis,"['pre-operative' 'renal' 'dysfunction' 'including' 'a' 'baseline'
 'creatinine' 'equal' 'to' 'or' 'greater' 'than' '1.5' 'mg/dL' 'or'
 'requiring' 'dialysis']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02243631,"13:30:chronic_disease,,",Significant renal dysfunction (CKD >stage 2),['Significant' 'renal' 'dysfunction' '(' 'CKD' '>' 'stage' '2' ')'],[0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02131467,13:30:chronic_disease,Significant renal dysfunction,['Significant' 'renal' 'dysfunction'],[0. 2. 2.]
NCT02058095,",,,,206:223:chronic_disease,","a minimal distance on 6-minute walk of equal or >450 meters will be recruited and calculated creatinine clearance of equal or less than 90 ml/min and greater than 30 ml/min, using the (MDRD-measurement of renal dysfunction, formula) assessed within the past 36 months","['a' 'minimal' 'distance' 'on' '6-minute' 'walk' 'of' 'equal' 'or' '>'
 '450' 'meters' 'will' 'be' 'recruited' 'and' 'calculated' 'creatinine'
 'clearance' 'of' 'equal' 'or' 'less' 'than' '90' 'ml/min' 'and' 'greater'
 'than' '30' 'ml/min' ',' 'using' 'the' '(' 'MDRD-measurement' 'of'
 'renal' 'dysfunction' ',' 'formula' ')' 'assessed' 'within' 'the' 'past'
 '36' 'months']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01757418,33:50:chronic_disease,known condition associated with renal dysfunction,['known' 'condition' 'associated' 'with' 'renal' 'dysfunction'],[0. 0. 0. 0. 2. 2.]
NCT01716806,",55:72:chronic_disease",have depressed ejection fraction or moderately severe renal dysfunction (Parts E and F only),"['have' 'depressed' 'ejection' 'fraction' 'or' 'moderately' 'severe'
 'renal' 'dysfunction' '(' 'Parts' 'E' 'and' 'F' 'only' ')']",[0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT01625923,12:29:chronic_disease,History of renal dysfunction,['History' 'of' 'renal' 'dysfunction'],[0. 0. 2. 2.]
NCT02560766,"13:36:treatment,",Received an investigational product within 6 months prior to dosing,"['Received' 'an' 'investigational' 'product' 'within' '6' 'months' 'prior'
 'to' 'dosing']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02551679,43:66:treatment,Participation at the same time in another investigational product or device study,"['Participation' 'at' 'the' 'same' 'time' 'in' 'another' 'investigational'
 'product' 'or' 'device' 'study']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.]
NCT02519322,",,,,184:207:treatment",WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of investigational product,"['WOCBP' 'must' 'have' 'a' 'negative' 'serum' 'or' 'urine' 'pregnancy'
 'test' '(' 'minimum' 'sensitivity' '25' 'IU/L' 'or' 'equivalent' 'units'
 'of' 'human' 'chorionic' 'gonadotropin' '[' 'HCG' ']' ')' 'within' '24'
 'hours' 'prior' 'to' 'the' 'start' 'of' 'investigational' 'product']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]"
NCT02498613,104:127:treatment,"Any condition that, in the opinion of the treating investigator would interfere with evaluation of the investigational product or interpretation of subject safety or study results","['Any' 'condition' 'that' ',' 'in' 'the' 'opinion' 'of' 'the' 'treating'
 'investigator' 'would' 'interfere' 'with' 'evaluation' 'of' 'the'
 'investigational' 'product' 'or' 'interpretation' 'of' 'subject' 'safety'
 'or' 'study' 'results']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02441062,",,103:126:treatment","≥60 years old,or of childbearing potential for whom a pregnancy test (with the results known prior to investigational product administration) is negative","['≥60' 'years' 'old' ',' 'or' 'of' 'childbearing' 'potential' 'for' 'whom'
 'a' 'pregnancy' 'test' '(' 'with' 'the' 'results' 'known' 'prior' 'to'
 'investigational' 'product' 'administration' ')' 'is' 'negative']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.
 0. 0.]"
NCT02401035,156:179:treatment,"Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study","['Other' 'severe' 'acute' 'or' 'chronic' 'medical' 'or' 'psychiatric'
 'condition' 'or' 'laboratory' 'abnormality' 'that' 'may' 'increase' 'the'
 'risk' 'associated' 'with' 'study' 'participation' 'or' 'investigational'
 'product' 'administration' 'or' 'may' 'interfere' 'with' 'the'
 'interpretation' 'of' 'study' 'results' 'and' ',' 'in' 'the' 'judgment'
 'of' 'the' 'investigator' ',' 'would' 'make' 'the' 'subject'
 'inappropriate' 'for' 'entry' 'into' 'this' 'study']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02311361,96:119:treatment,"Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results","['Any' 'condition' 'that' ',' 'in' 'the' 'opinion' 'of' 'the'
 'investigator' ',' 'would' 'interfere' 'with' 'evaluation' 'of' 'the'
 'investigational' 'product' 'or' 'interpretation' 'of' 'subject' 'safety'
 'or' 'study' 'results']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT01532687,",32:55:treatment","for 14 days before exposure to investigational product, through the dosing period","['for' '14' 'days' 'before' 'exposure' 'to' 'investigational' 'product'
 ',' 'through' 'the' 'dosing' 'period']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT01532687,",45:68:treatment",for at least 21 days after the last dose of investigational product,"['for' 'at' 'least' '21' 'days' 'after' 'the' 'last' 'dose' 'of'
 'investigational' 'product']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT03180398,26:49:cancer,Histologically confirmed prostate adenocarcinoma,['Histologically' 'confirmed' 'prostate' 'adenocarcinoma'],[0. 0. 3. 3.]
NCT03087903,26:49:cancer,Histologically confirmed prostate adenocarcinoma,['Histologically' 'confirmed' 'prostate' 'adenocarcinoma'],[0. 0. 3. 3.]
NCT03009981,26:49:cancer,Histologically confirmed prostate adenocarcinoma,['Histologically' 'confirmed' 'prostate' 'adenocarcinoma'],[0. 0. 3. 3.]
NCT02857218,10:33:cancer,low-risk prostate adenocarcinoma,['low-risk' 'prostate' 'adenocarcinoma'],[0. 3. 3.]
NCT02346253,39:62:cancer,Documented pathologic confirmation of prostate adenocarcinoma,['Documented' 'pathologic' 'confirmation' 'of' 'prostate' 'adenocarcinoma'],[0. 0. 0. 0. 3. 3.]
NCT02334579,23:46:cancer,Histologically proven prostate adenocarcinoma,['Histologically' 'proven' 'prostate' 'adenocarcinoma'],[0. 0. 3. 3.]
NCT01868386,14:37:cancer,diagnosis of prostate adenocarcinoma,['diagnosis' 'of' 'prostate' 'adenocarcinoma'],[0. 0. 3. 3.]
NCT01581749,"23:46:cancer,",histologically proven prostate adenocarcinoma within 1 year of enrollment,"['histologically' 'proven' 'prostate' 'adenocarcinoma' 'within' '1' 'year'
 'of' 'enrollment']",[0. 0. 3. 3. 0. 0. 0. 0. 0.]
NCT03152409,22:47:chronic_disease,Current diagnosis of major depressive disorder,['Current' 'diagnosis' 'of' 'major' 'depressive' 'disorder'],[0. 0. 0. 2. 2. 2.]
NCT03056287,1:26:chronic_disease,major depressive disorder,['major' 'depressive' 'disorder'],[2. 2. 2.]
NCT02943408,1:26:chronic_disease,"major depressive disorder (296.20-296.23, 296.30-296.33)","['major' 'depressive' 'disorder' '(' '296.20-296.23' ',' '296.30-296.33'
 ')']",[2. 2. 2. 0. 0. 0. 0. 0.]
NCT02826577,47:72:chronic_disease,Meet MINI criteria for anything but untreated major depressive disorder,"['Meet' 'MINI' 'criteria' 'for' 'anything' 'but' 'untreated' 'major'
 'depressive' 'disorder']",[0. 0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT02769000,36:61:chronic_disease,"Evidence of clinically significant major depressive disorder identified in a psychological diagnostic interview according to the criteria of the Diagnostic and Statistical Manual of Mental Disorder, Fifth Edition (DSM-V)","['Evidence' 'of' 'clinically' 'significant' 'major' 'depressive'
 'disorder' 'identified' 'in' 'a' 'psychological' 'diagnostic' 'interview'
 'according' 'to' 'the' 'criteria' 'of' 'the' 'Diagnostic' 'and'
 'Statistical' 'Manual' 'of' 'Mental' 'Disorder' ',' 'Fifth' 'Edition' '('
 'DSM-V' ')']","[0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02709980,1:26:chronic_disease,major depressive disorder,['major' 'depressive' 'disorder'],[2. 2. 2.]
NCT02332291,22:47:chronic_disease,"Current diagnosis of major depressive disorder (DSM-IV-TR), single episode, recurrent or chronic, without psychotic features, as detected by MINI and clinical exam","['Current' 'diagnosis' 'of' 'major' 'depressive' 'disorder' '('
 'DSM-IV-TR' ')' ',' 'single' 'episode' ',' 'recurrent' 'or' 'chronic' ','
 'without' 'psychotic' 'features' ',' 'as' 'detected' 'by' 'MINI' 'and'
 'clinical' 'exam']","[0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02214667,1:26:chronic_disease,major depressive disorder,['major' 'depressive' 'disorder'],[2. 2. 2.]
NCT03125226,",,72:91:treatment",Unable to have TraceIT hydrogel placement < 8 weeks prior to beginning radiation treatment,"['Unable' 'to' 'have' 'TraceIT' 'hydrogel' 'placement' '<' '8' 'weeks'
 'prior' 'to' 'beginning' 'radiation' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02843165,",,,82:101:treatment",Patient is a pregnant woman (pregnant women are excluded from this study because radiation treatment has known potential for teratogenic or abortifacient effects),"['Patient' 'is' 'a' 'pregnant' 'woman' '(' 'pregnant' 'women' 'are'
 'excluded' 'from' 'this' 'study' 'because' 'radiation' 'treatment' 'has'
 'known' 'potential' 'for' 'teratogenic' 'or' 'abortifacient' 'effects'
 ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02496585,38:57:treatment,Reduction of any acute toxicity from radiation treatment to grade 1,"['Reduction' 'of' 'any' 'acute' 'toxicity' 'from' 'radiation' 'treatment'
 'to' 'grade' '1']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.]
NCT02313428,18:37:treatment,Ulcer in area of radiation treatment,['Ulcer' 'in' 'area' 'of' 'radiation' 'treatment'],[0. 0. 0. 0. 1. 1.]
NCT01894061,"38:57:treatment,",Minimum interval since completion of radiation treatment is 12 weeks,"['Minimum' 'interval' 'since' 'completion' 'of' 'radiation' 'treatment'
 'is' '12' 'weeks']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0.]
NCT01766297,40:59:treatment,Breasts technically unsatisfactory for radiation treatment upon the discretion of the treating physician,"['Breasts' 'technically' 'unsatisfactory' 'for' 'radiation' 'treatment'
 'upon' 'the' 'discretion' 'of' 'the' 'treating' 'physician']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT01737502,37:56:treatment,Recovered from the toxic effects of radiation treatment before study entry,"['Recovered' 'from' 'the' 'toxic' 'effects' 'of' 'radiation' 'treatment'
 'before' 'study' 'entry']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.]
NCT00075387,",39:58:treatment",least 14 days must have elapsed since radiation treatment,"['least' '14' 'days' 'must' 'have' 'elapsed' 'since' 'radiation'
 'treatment']",[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT03085485,"1:10:chronic_disease,,",Cirrhosis or elevated liver transaminases > 3X ULN,['Cirrhosis' 'or' 'elevated' 'liver' 'transaminases' '>' '3X' 'ULN'],[2. 0. 0. 0. 0. 0. 0. 0.]
NCT03014687,1:10:chronic_disease,Cirrhosis,['Cirrhosis'],[2.]
NCT02955537,1:10:chronic_disease,Cirrhosis,['Cirrhosis'],[2.]
NCT02595866,1:10:chronic_disease,Cirrhosis with Child-Pugh score of B or C,['Cirrhosis' 'with' 'Child-Pugh' 'score' 'of' 'B' 'or' 'C'],[2. 0. 0. 0. 0. 0. 0. 0.]
NCT02323945,1:10:chronic_disease,Cirrhosis,['Cirrhosis'],[2.]
NCT02323698,1:10:chronic_disease,Cirrhosis,['Cirrhosis'],[2.]
NCT02128802,1:10:chronic_disease,Cirrhosis,['Cirrhosis'],[2.]
NCT01184547,1:10:chronic_disease,Cirrhosis,['Cirrhosis'],[2.]
NCT03067571,61:79:chronic_disease,"has any concurrent medical condition or disease (eg, active systemic infection, laboratory abnormalities) that is likely to interfere with study procedures or results, or that in the opinion of the investigator would constitute a hazard for participating in this study","['has' 'any' 'concurrent' 'medical' 'condition' 'or' 'disease' '(' 'eg'
 ',' 'active' 'systemic' 'infection' ',' 'laboratory' 'abnormalities' ')'
 'that' 'is' 'likely' 'to' 'interfere' 'with' 'study' 'procedures' 'or'
 'results' ',' 'or' 'that' 'in' 'the' 'opinion' 'of' 'the' 'investigator'
 'would' 'constitute' 'a' 'hazard' 'for' 'participating' 'in' 'this'
 'study']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02549833,17:35:chronic_disease,Must be free of systemic infection,['Must' 'be' 'free' 'of' 'systemic' 'infection'],[0. 0. 0. 0. 2. 2.]
NCT02515708,29:47:chronic_disease,Patient with current severe systemic infection,['Patient' 'with' 'current' 'severe' 'systemic' 'infection'],[0. 0. 0. 0. 2. 2.]
NCT02391987,8:26:chronic_disease,Active systemic infection,['Active' 'systemic' 'infection'],[0. 2. 2.]
NCT02334865,17:35:chronic_disease,Must be free of systemic infection,['Must' 'be' 'free' 'of' 'systemic' 'infection'],[0. 0. 0. 0. 2. 2.]
NCT02281409,"17:35:chronic_disease,",Any significant systemic infection within 4 weeks prior to dosing,"['Any' 'significant' 'systemic' 'infection' 'within' '4' 'weeks' 'prior'
 'to' 'dosing']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02131389,104:122:chronic_disease,"Infection, or history of infection, acute or chronic, in the hip joint, or acute or chronic unresolved systemic infection","['Infection' ',' 'or' 'history' 'of' 'infection' ',' 'acute' 'or'
 'chronic' ',' 'in' 'the' 'hip' 'joint' ',' 'or' 'acute' 'or' 'chronic'
 'unresolved' 'systemic' 'infection']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT01130077,26:44:chronic_disease,Patients must be free of systemic infection,['Patients' 'must' 'be' 'free' 'of' 'systemic' 'infection'],[0. 0. 0. 0. 0. 2. 2.]
NCT02993406,1:22:chronic_disease,uncontrolled diabetes,['uncontrolled' 'diabetes'],[2. 2.]
NCT02901041,35:56:chronic_disease,Significant medical problem (e.g. uncontrolled diabetes),"['Significant' 'medical' 'problem' '(' 'e.g' '.' 'uncontrolled' 'diabetes'
 ')']",[0. 0. 0. 0. 0. 0. 2. 2. 0.]
NCT02504866,12:33:chronic_disease,History of uncontrolled diabetes,['History' 'of' 'uncontrolled' 'diabetes'],[0. 0. 2. 2.]
NCT02382549,"19:40:chronic_disease,,","Participants with uncontrolled diabetes, defined as having a HgB-A1c greater than 7.5%","['Participants' 'with' 'uncontrolled' 'diabetes' ',' 'defined' 'as'
 'having' 'a' 'HgB-A1c' 'greater' 'than' '7.5' '%']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02353728,1:22:chronic_disease,uncontrolled diabetes,['uncontrolled' 'diabetes'],[2. 2.]
NCT01964859,16:37:chronic_disease,A diagnosis of uncontrolled diabetes,['A' 'diagnosis' 'of' 'uncontrolled' 'diabetes'],[0. 0. 0. 2. 2.]
NCT01925378,"15:36:chronic_disease,,",Patients with uncontrolled diabetes; as defined by hemoglobin A1C ≥ 7.1%,"['Patients' 'with' 'uncontrolled' 'diabetes' ';' 'as' 'defined' 'by'
 'hemoglobin' 'A1C' '≥' '7.1' '%']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01570816,1:22:chronic_disease,uncontrolled diabetes,['uncontrolled' 'diabetes'],[2. 2.]
NCT02920710,14:25:chronic_disease,Patient with sarcoidosis as defined by ATS/ERS/WASOG (American Thoracic Society/European Thoracic Society/World Association for Sarcoidosis and Other Granulomatous Disorders),"['Patient' 'with' 'sarcoidosis' 'as' 'defined' 'by' 'ATS/ERS/WASOG' '('
 'American' 'Thoracic' 'Society/European' 'Thoracic' 'Society/World'
 'Association' 'for' 'Sarcoidosis' 'and' 'Other' 'Granulomatous'
 'Disorders' ')']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02725177,"53:64:chronic_disease,","Administration of an investigational medication for sarcoidosis within 3 months, or 5 half-lives, whichever is longer","['Administration' 'of' 'an' 'investigational' 'medication' 'for'
 'sarcoidosis' 'within' '3' 'months' ',' 'or' '5' 'half-lives' ','
 'whichever' 'is' 'longer']",[0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02725177,14:25:chronic_disease,Patient with sarcoidosis,['Patient' 'with' 'sarcoidosis'],[0. 0. 2.]
NCT02311361,12:23:chronic_disease,History of sarcoidosis syndrome,['History' 'of' 'sarcoidosis' 'syndrome'],[0. 0. 2. 0.]
NCT02298491,32:43:chronic_disease,"A highly probable diagnosis of sarcoidosis, as determined using the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) Sarcoidosis Organ Assessment Instrument (Judson et al., 2014), with involvement not limited to the central nervous system","['A' 'highly' 'probable' 'diagnosis' 'of' 'sarcoidosis' ',' 'as'
 'determined' 'using' 'the' 'World' 'Association' 'for' 'Sarcoidosis'
 'and' 'Other' 'Granulomatous' 'Disorders' '(' 'WASOG' ')' 'Sarcoidosis'
 'Organ' 'Assessment' 'Instrument' '(' 'Judson' 'et' 'al.' ',' '2014' ')'
 ',' 'with' 'involvement' 'not' 'limited' 'to' 'the' 'central' 'nervous'
 'system']","[0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02265874,"57:68:chronic_disease,","Eligible adult patients will have histologically proven sarcoidosis, diagnosed at least 6 months before screening","['Eligible' 'adult' 'patients' 'will' 'have' 'histologically' 'proven'
 'sarcoidosis' ',' 'diagnosed' 'at' 'least' '6' 'months' 'before'
 'screening']",[0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02219555,1:12:chronic_disease,sarcoidosis,['sarcoidosis'],[2.]
NCT02210650,1:12:chronic_disease,sarcoidosis,['sarcoidosis'],[2.]
NCT02581215,83:95:cancer,Measurable disease determined using guidelines of Response Evaluation Criteria In Solid Tumors (RECIST 1.1),"['Measurable' 'disease' 'determined' 'using' 'guidelines' 'of' 'Response'
 'Evaluation' 'Criteria' 'In' 'Solid' 'Tumors' '(' 'RECIST' '1.1' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0.]
NCT02536794,74:86:cancer,Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria,"['Patients' 'must' 'have' 'measurable' 'disease' 'by' 'Response'
 'Evaluation' 'Criteria' 'in' 'Solid' 'Tumors' '(' 'RECIST' ')' 'criteria']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0.]
NCT02503722,74:86:cancer,Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors,"['Patients' 'must' 'have' 'measurable' 'disease' 'by' 'Response'
 'Evaluation' 'Criteria' 'in' 'Solid' 'Tumors']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT02498613,74:86:cancer,Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1,"['Patients' 'must' 'have' 'measurable' 'disease' 'by' 'Response'
 'Evaluation' 'Criteria' 'in' 'Solid' 'Tumors' '(' 'RECIST' ')' 'version'
 '(' 'v' ')' '1.1']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02309892,",75:87:cancer",At least 1 site of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1,"['At' 'least' '1' 'site' 'of' 'measurable' 'disease' 'per' 'Response'
 'Evaluation' 'Criteria' 'in' 'Solid' 'Tumors' '(' 'RECIST' ')' 'v1.1']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0.]
NCT02266745,44:56:cancer,"imaging by Response Evaluation Criteria in Solid Tumors (RECIST v1.1, Appendix 2)","['imaging' 'by' 'Response' 'Evaluation' 'Criteria' 'in' 'Solid' 'Tumors'
 '(' 'RECIST' 'v1.1' ',' 'Appendix' '2' ')']",[0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT01990209,102:114:cancer,Patients must have MBC that is measurable or evaluable as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria,"['Patients' 'must' 'have' 'MBC' 'that' 'is' 'measurable' 'or' 'evaluable'
 'as' 'defined' 'by' 'Response' 'Evaluation' 'Criteria' 'in' 'Solid'
 'Tumors' '(' 'RECIST' ')' 'v1.1' 'criteria']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0.]
NCT01946074,74:86:cancer,Subject must have measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1,"['Subject' 'must' 'have' 'measurable' 'disease' 'per' 'Response'
 'Evaluation' 'Criteria' 'In' 'Solid' 'Tumors' '(' 'RECIST' ')' 'version'
 '1.1']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0.]
NCT02433210,28:43:allergy_name,Problem with or allergy to anticoagulation,['Problem' 'with' 'or' 'allergy' 'to' 'anticoagulation'],[0. 0. 0. 0. 0. 4.]
NCT02423863,",,,,128:143:treatment","Transaminases ≤ 2 times above the upper limits of the institutional normal, - INR<2 (international normalized ratio) if off of anticoagulation","['Transaminases' '≤' '2' 'times' 'above' 'the' 'upper' 'limits' 'of' 'the'
 'institutional' 'normal' ',' '-' 'INR' '<' '2' '(' 'international'
 'normalized' 'ratio' ')' 'if' 'off' 'of' 'anticoagulation']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1.]"
NCT02342444,26:41:treatment,Receiving other forms of anticoagulation,['Receiving' 'other' 'forms' 'of' 'anticoagulation'],[0. 0. 0. 0. 1.]
NCT02195232,59:74:treatment,central line associated events whereby patients completed anticoagulation,"['central' 'line' 'associated' 'events' 'whereby' 'patients' 'completed'
 'anticoagulation']",[0. 0. 0. 0. 0. 0. 0. 1.]
NCT02074436,19:34:treatment,Patient receiving anticoagulation,['Patient' 'receiving' 'anticoagulation'],[0. 0. 1.]
NCT01999179,55:70:treatment,Participation in another clinical trial that requires anticoagulation,"['Participation' 'in' 'another' 'clinical' 'trial' 'that' 'requires'
 'anticoagulation']",[0. 0. 0. 0. 0. 0. 0. 1.]
NCT01890590,",35:50:treatment",Decreased platelet count and / or anticoagulation parameters that would preclude transcutaneous placement of fiducials,"['Decreased' 'platelet' 'count' 'and' '/' 'or' 'anticoagulation'
 'parameters' 'that' 'would' 'preclude' 'transcutaneous' 'placement' 'of'
 'fiducials']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01781611,25:40:treatment,Current requirement for anticoagulation,['Current' 'requirement' 'for' 'anticoagulation'],[0. 0. 0. 1.]
NCT03181516,"8:16:chronic_disease,",Active diarrhea (diarrhea is defined in this study as three or more loose stools per day for two consecutive days),"['Active' 'diarrhea' '(' 'diarrhea' 'is' 'defined' 'in' 'this' 'study'
 'as' 'three' 'or' 'more' 'loose' 'stools' 'per' 'day' 'for' 'two'
 'consecutive' 'days' ')']",[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03114319,8:16:chronic_disease,Active diarrhea,['Active' 'diarrhea'],[0. 2.]
NCT02236000,",45:53:chronic_disease",Persistent greater than or equal to grade 2 diarrhea regardless of etiology,"['Persistent' 'greater' 'than' 'or' 'equal' 'to' 'grade' '2' 'diarrhea'
 'regardless' 'of' 'etiology']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0.]
NCT02134392,26:34:chronic_disease,Documentation of ongoing diarrhea at time of recruitment,['Documentation' 'of' 'ongoing' 'diarrhea' 'at' 'time' 'of' 'recruitment'],[0. 0. 0. 2. 0. 0. 0. 0.]
NCT01670877,",33:41:chronic_disease",Experiencing grade 2 or greater diarrhea,['Experiencing' 'grade' '2' 'or' 'greater' 'diarrhea'],[0. 0. 0. 0. 0. 2.]
NCT01494662,",76:84:chronic_disease",Any predisposing chronic condition resulting in baseline grade 2 or higher diarrhea,"['Any' 'predisposing' 'chronic' 'condition' 'resulting' 'in' 'baseline'
 'grade' '2' 'or' 'higher' 'diarrhea']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT01072370,1:9:chronic_disease,diarrhea,['diarrhea'],[2.]
NCT03170375,1:16:chronic_disease,hepatic disease,['hepatic' 'disease'],[2. 2.]
NCT02844907,13:28:chronic_disease,Significant hepatic disease,['Significant' 'hepatic' 'disease'],[0. 2. 2.]
NCT02836574,"24:39:chronic_disease,,,",clinically significant hepatic disease (ALT or AST greater than 3-times the upper limit of normal) as assessed at the Screening Visit,"['clinically' 'significant' 'hepatic' 'disease' '(' 'ALT' 'or' 'AST'
 'greater' 'than' '3-times' 'the' 'upper' 'limit' 'of' 'normal' ')' 'as'
 'assessed' 'at' 'the' 'Screening' 'Visit']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02834403,1:16:chronic_disease,hepatic disease,['hepatic' 'disease'],[2. 2.]
NCT02833207,26:41:chronic_disease,Self-reported history of hepatic disease,['Self-reported' 'history' 'of' 'hepatic' 'disease'],[0. 0. 0. 2. 2.]
NCT02408120,21:36:chronic_disease,Clinically relevant hepatic disease,['Clinically' 'relevant' 'hepatic' 'disease'],[0. 0. 2. 2.]
NCT00368355,"22:37:chronic_disease,,,,",Patients with severe hepatic disease (direct bilirubin greater than 3 ug/dl or SGPT (serum glutamic-pyruvic transaminase) greater than 500 ug/dl),"['Patients' 'with' 'severe' 'hepatic' 'disease' '(' 'direct' 'bilirubin'
 'greater' 'than' '3' 'ug/dl' 'or' 'SGPT' '(' 'serum' 'glutamic-pyruvic'
 'transaminase' ')' 'greater' 'than' '500' 'ug/dl' ')']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03153410,"69:92:treatment,",Currently is participating or has participated in a study using any investigational therapy within the past 28 days or is currently using an investigational device,"['Currently' 'is' 'participating' 'or' 'has' 'participated' 'in' 'a'
 'study' 'using' 'any' 'investigational' 'therapy' 'within' 'the' 'past'
 '28' 'days' 'or' 'is' 'currently' 'using' 'an' 'investigational' 'device']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT03125902,"16:39:treatment,",Treatment with investigational therapy within 30 days prior to initiation of study treatment,"['Treatment' 'with' 'investigational' 'therapy' 'within' '30' 'days'
 'prior' 'to' 'initiation' 'of' 'study' 'treatment']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02680535,"10:33:treatment,",received investigational therapy within a period of 5 half-lives of the investigational therapy in question prior to the day of dosing with the PEGylated AuroShell particles,"['received' 'investigational' 'therapy' 'within' 'a' 'period' 'of' '5'
 'half-lives' 'of' 'the' 'investigational' 'therapy' 'in' 'question'
 'prior' 'to' 'the' 'day' 'of' 'dosing' 'with' 'the' 'PEGylated'
 'AuroShell' 'particles']","[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02496585,"7:30:treatment,",Other investigational therapy received within 8 weeks prior to screening visit,"['Other' 'investigational' 'therapy' 'received' 'within' '8' 'weeks'
 'prior' 'to' 'screening' 'visit']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02291848,"37:60:treatment,",Patients should have been off other investigational therapy for one month prior to entry in this study,"['Patients' 'should' 'have' 'been' 'off' 'other' 'investigational'
 'therapy' 'for' 'one' 'month' 'prior' 'to' 'entry' 'in' 'this' 'study']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02004275,"4:27:treatment,",No investigational therapy within 14 days prior to registration,"['No' 'investigational' 'therapy' 'within' '14' 'days' 'prior' 'to'
 'registration']",[0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT01333046,"37:60:treatment,",Patients should have been off other investigational therapy for one month prior to entry in this study,"['Patients' 'should' 'have' 'been' 'off' 'other' 'investigational'
 'therapy' 'for' 'one' 'month' 'prior' 'to' 'entry' 'in' 'this' 'study']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03138733,33:42:chronic_disease,Community- or hospital-acquired pneumonia,['Community-' 'or' 'hospital-acquired' 'pneumonia'],[0. 0. 0. 2.]
NCT03121352,50:59:chronic_disease,"Patients with evidence of active, non-infectious pneumonia","['Patients' 'with' 'evidence' 'of' 'active' ',' 'non-infectious'
 'pneumonia']",[0. 0. 0. 0. 0. 0. 0. 2.]
NCT03060473,1:10:chronic_disease,pneumonia,['pneumonia'],[2.]
NCT03007745,1:10:chronic_disease,pneumonia,['pneumonia'],[2.]
NCT02696902,101:110:chronic_disease,"expected to require prolonged intubation and mechanical ventilation, without any evidence of active pneumonia","['expected' 'to' 'require' 'prolonged' 'intubation' 'and' 'mechanical'
 'ventilation' ',' 'without' 'any' 'evidence' 'of' 'active' 'pneumonia']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02329652,1:10:chronic_disease,pneumonia,['pneumonia'],[2.]
NCT01568177,1:10:chronic_disease,pneumonia,['pneumonia'],[2.]
NCT03101566,30:53:chronic_disease,"Must have no ongoing active, uncontrolled infections","['Must' 'have' 'no' 'ongoing' 'active' ',' 'uncontrolled' 'infections']",[0. 0. 0. 0. 0. 0. 2. 2.]
NCT02479698,21:44:chronic_disease,Patients with other uncontrolled infections,['Patients' 'with' 'other' 'uncontrolled' 'infections'],[0. 0. 0. 2. 2.]
NCT02203903,15:38:chronic_disease,Patients with uncontrolled infections,['Patients' 'with' 'uncontrolled' 'infections'],[0. 0. 2. 2.]
NCT02135874,23:46:chronic_disease,"Patients with active, uncontrolled infections","['Patients' 'with' 'active' ',' 'uncontrolled' 'infections']",[0. 0. 0. 0. 2. 2.]
NCT01945814,21:44:chronic_disease,Patients with other uncontrolled infections (see 2.3.2 for definitions),"['Patients' 'with' 'other' 'uncontrolled' 'infections' '(' 'see' '2.3.2'
 'for' 'definitions' ')']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT01620216,4:27:chronic_disease,No uncontrolled infections as determined by the investigator,"['No' 'uncontrolled' 'infections' 'as' 'determined' 'by' 'the'
 'investigator']",[0. 2. 2. 0. 0. 0. 0. 0.]
NCT00432094,23:46:chronic_disease,Patients with serious uncontrolled infections,['Patients' 'with' 'serious' 'uncontrolled' 'infections'],[0. 0. 0. 2. 2.]
NCT03092635,"1:19:treatment,","Prior chemotherapy is allowed, but last dose must have been at least 2 months prior to enrollment","['Prior' 'chemotherapy' 'is' 'allowed' ',' 'but' 'last' 'dose' 'must'
 'have' 'been' 'at' 'least' '2' 'months' 'prior' 'to' 'enrollment']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02555189,1:19:treatment,Prior chemotherapy,['Prior' 'chemotherapy'],[1. 1.]
NCT02207439,"1:19:treatment,",Prior chemotherapy within the past 5 years,['Prior' 'chemotherapy' 'within' 'the' 'past' '5' 'years'],[1. 1. 0. 0. 0. 0. 0.]
NCT02143726,"1:19:treatment,",Prior chemotherapy is allowed if ≥ 28 days prior to registration on this protocol,"['Prior' 'chemotherapy' 'is' 'allowed' 'if' '≥' '28' 'days' 'prior' 'to'
 'registration' 'on' 'this' 'protocol']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01570998,1:19:treatment,Prior chemotherapy,['Prior' 'chemotherapy'],[1. 1.]
NCT01312857,"1:19:treatment,",Prior chemotherapy is acceptable if last dose given ≥ 3 weeks prior to registration to this study,"['Prior' 'chemotherapy' 'is' 'acceptable' 'if' 'last' 'dose' 'given' '≥'
 '3' 'weeks' 'prior' 'to' 'registration' 'to' 'this' 'study']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00412594,"1:19:treatment,",Prior chemotherapy (last 4 weeks),['Prior' 'chemotherapy' '(' 'last' '4' 'weeks' ')'],[1. 1. 0. 0. 0. 0. 0.]
NCT03079297,21:40:chronic_disease,lifetime history of psychotic disorders,['lifetime' 'history' 'of' 'psychotic' 'disorders'],[0. 0. 0. 2. 2.]
NCT02669030,24:43:chronic_disease,history or presence of psychotic disorders,['history' 'or' 'presence' 'of' 'psychotic' 'disorders'],[0. 0. 0. 0. 2. 2.]
NCT02607514,1:20:chronic_disease,psychotic disorders,['psychotic' 'disorders'],[2. 2.]
NCT02562430,1:20:chronic_disease,psychotic disorders,['psychotic' 'disorders'],[2. 2.]
NCT02481245,1:20:chronic_disease,psychotic disorders not elsewhere classified,['psychotic' 'disorders' 'not' 'elsewhere' 'classified'],[2. 2. 0. 0. 0.]
NCT02133898,7:26:chronic_disease,other psychotic disorders,['other' 'psychotic' 'disorders'],[0. 2. 2.]
NCT01782599,1:20:chronic_disease,psychotic disorders not elsewhere classified (measured via the SCID 5),"['psychotic' 'disorders' 'not' 'elsewhere' 'classified' '(' 'measured'
 'via' 'the' 'SCID' '5' ')']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03058029,5:13:chronic_disease,Non-diabetic subjects,['Non-diabetic' 'subjects'],[2. 0.]
NCT03043963,"1:9:chronic_disease,,",diabetic patients who are insulin dependent (or have HbA1c>9.0%),"['diabetic' 'patients' 'who' 'are' 'insulin' 'dependent' '(' 'or' 'have'
 'HbA1c' '>' '9.0' '%' ')']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02572856,"1:9:chronic_disease,,,,",diabetic (both Type 1 & 2) patients who are self-monitoring glucose levels (via finger stick measurements) two to three times daily,"['diabetic' '(' 'both' 'Type' '1' '&' '2' ')' 'patients' 'who' 'are'
 'self-monitoring' 'glucose' 'levels' '(' 'via' 'finger' 'stick'
 'measurements' ')' 'two' 'to' 'three' 'times' 'daily']","[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02488057,1:9:chronic_disease,diabetic,['diabetic'],[2.]
NCT02488057,5:13:chronic_disease,pre-diabetic,['pre-diabetic'],[2.]
NCT02213068,",,,40:48:chronic_disease",Proteinuria >1 g/day or > 0.5 g/day if diabetic,['Proteinuria' '>' '1' 'g/day' 'or' '>' '0.5' 'g/day' 'if' 'diabetic'],[0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT00678145,5:13:chronic_disease,Non-diabetic individuals,['Non-diabetic' 'individuals'],[2. 0.]
NCT03023449,16:36:chronic_disease,History of any neurological disease,['History' 'of' 'any' 'neurological' 'disease'],[0. 0. 0. 2. 2.]
NCT02982226,25:45:chronic_disease,Evidence of significant neurological disease of either foot,"['Evidence' 'of' 'significant' 'neurological' 'disease' 'of' 'either'
 'foot']",[0. 0. 0. 2. 2. 0. 0. 0.]
NCT02875301,19:39:chronic_disease,No diagnosis of a neurological disease,['No' 'diagnosis' 'of' 'a' 'neurological' 'disease'],[0. 0. 0. 0. 2. 2.]
NCT02565199,4:24:chronic_disease,No neurological disease,['No' 'neurological' 'disease'],[0. 2. 2.]
NCT02155946,12:32:chronic_disease,History of neurological disease or injury,['History' 'of' 'neurological' 'disease' 'or' 'injury'],[0. 0. 2. 2. 0. 0.]
NCT02139436,7:27:chronic_disease,other neurological disease,['other' 'neurological' 'disease'],[0. 2. 2.]
NCT01715571,",10:30:chronic_disease",Men with neurological disease,['Men' 'with' 'neurological' 'disease'],[0. 0. 2. 2.]
NCT03014687,54:77:chronic_disease,"Concurrent antibiotics for another indication (i.e., urinary tract infection)","['Concurrent' 'antibiotics' 'for' 'another' 'indication' '(' 'i.e.' ','
 'urinary' 'tract' 'infection' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0.]
NCT02836574,15:38:chronic_disease,evidence of a urinary tract infection,['evidence' 'of' 'a' 'urinary' 'tract' 'infection'],[0. 0. 0. 2. 2. 2.]
NCT02680535,7:30:chronic_disease,Acute urinary tract infection,['Acute' 'urinary' 'tract' 'infection'],[0. 2. 2. 2.]
NCT02339233,1:24:chronic_disease,urinary tract infection that might interfere with stand or step training,"['urinary' 'tract' 'infection' 'that' 'might' 'interfere' 'with' 'stand'
 'or' 'step' 'training']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02329652,1:24:chronic_disease,urinary tract infection,['urinary' 'tract' 'infection'],[2. 2. 2.]
NCT01754779,",,36:59:chronic_disease",high pH as >6.40 in the absence of urinary tract infection,"['high' 'pH' 'as' '>' '6.40' 'in' 'the' 'absence' 'of' 'urinary' 'tract'
 'infection']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT01608438,30:53:chronic_disease,Concurrent pressure sores or urinary tract infection,['Concurrent' 'pressure' 'sores' 'or' 'urinary' 'tract' 'infection'],[0. 0. 0. 0. 2. 2. 2.]
NCT02932956,1:23:chronic_disease,Uncontrolled infection,['Uncontrolled' 'infection'],[2. 2.]
NCT02776059,1:23:chronic_disease,Uncontrolled infection,['Uncontrolled' 'infection'],[2. 2.]
NCT02574728,1:23:chronic_disease,Uncontrolled infection,['Uncontrolled' 'infection'],[2. 2.]
NCT02400255,1:23:chronic_disease,Uncontrolled infection,['Uncontrolled' 'infection'],[2. 2.]
NCT02162420,1:23:chronic_disease,Uncontrolled infection,['Uncontrolled' 'infection'],[2. 2.]
NCT02109627,1:23:chronic_disease,Uncontrolled infection,['Uncontrolled' 'infection'],[2. 2.]
NCT00711373,1:23:chronic_disease,Uncontrolled infection,['Uncontrolled' 'infection'],[2. 2.]
NCT02796209,1:24:chronic_disease,Impaired renal function,['Impaired' 'renal' 'function'],[2. 2. 2.]
NCT02784535,"1:24:chronic_disease,,",Impaired renal function (serum creatinine equal or more than 1.6 mg/dl),"['Impaired' 'renal' 'function' '(' 'serum' 'creatinine' 'equal' 'or'
 'more' 'than' '1.6' 'mg/dl' ')']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02540330,1:24:chronic_disease,Impaired renal function,['Impaired' 'renal' 'function'],[2. 2. 2.]
NCT02514083,1:24:chronic_disease,Impaired renal function,['Impaired' 'renal' 'function'],[2. 2. 2.]
NCT02169739,"1:24:chronic_disease,,",Impaired renal function: estimated GFR <40,['Impaired' 'renal' 'function' ':' 'estimated' 'GFR' '<' '40'],[2. 2. 2. 0. 0. 0. 0. 0.]
NCT02130687,"1:24:chronic_disease,,",Impaired renal function (eGFR< 50mL/min/1.73m2 as determined by the MDRD equation),"['Impaired' 'renal' 'function' '(' 'eGFR' '<' '50mL/min/1.73m2' 'as'
 'determined' 'by' 'the' 'MDRD' 'equation' ')']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02053363,"1:24:chronic_disease,,",Impaired renal function or creatinine clearance <60 ml/min,"['Impaired' 'renal' 'function' 'or' 'creatinine' 'clearance' '<' '60'
 'ml/min']",[2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02684201,20:30:treatment,have an upper-limb amputation,['have' 'an' 'upper-limb' 'amputation'],[0. 0. 0. 1.]
NCT02383979,36:46:treatment,"Cooperative, patient scheduled for amputation, with time and availability to do fMRI prior to their operative date","['Cooperative' ',' 'patient' 'scheduled' 'for' 'amputation' ',' 'with'
 'time' 'and' 'availability' 'to' 'do' 'fMRI' 'prior' 'to' 'their'
 'operative' 'date']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01714596,32:42:treatment,Patients who have high risk of amputation of the study limb (based on opinion of the initial managing physician),"['Patients' 'who' 'have' 'high' 'risk' 'of' 'amputation' 'of' 'the'
 'study' 'limb' '(' 'based' 'on' 'opinion' 'of' 'the' 'initial' 'managing'
 'physician' ')']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01293214,10:20:treatment,"Level of amputation anywhere from the wrist (or ankle) joint to just below the shoulder (or hip) joint, which should be functional","['Level' 'of' 'amputation' 'anywhere' 'from' 'the' 'wrist' '(' 'or'
 'ankle' ')' 'joint' 'to' 'just' 'below' 'the' 'shoulder' '(' 'or' 'hip'
 ')' 'joint' ',' 'which' 'should' 'be' 'functional']","[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT01293214,"20:30:treatment,,",Time elapsed since amputation more than 6 months but less than 15 years,"['Time' 'elapsed' 'since' 'amputation' 'more' 'than' '6' 'months' 'but'
 'less' 'than' '15' 'years']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00711373,29:39:treatment,Excessive proximal level of amputation: some presence of proximal muscles is required to motor a functioning hand,"['Excessive' 'proximal' 'level' 'of' 'amputation' ':' 'some' 'presence'
 'of' 'proximal' 'muscles' 'is' 'required' 'to' 'motor' 'a' 'functioning'
 'hand']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00711373,"12:22:chronic_disease,",History of amputation of less than six months,['History' 'of' 'amputation' 'of' 'less' 'than' 'six' 'months'],[0. 0. 2. 0. 0. 0. 0. 0.]
NCT02635893,"1:4:chronic_disease,",SCI ( ≥1 month of injury),['SCI' '(' '≥1' 'month' 'of' 'injury' ')'],[2. 0. 0. 0. 0. 0. 0.]
NCT02524379,"17:20:chronic_disease,,,",Non-penetrating SCI at neurologic level from C2 to C8,['Non-penetrating' 'SCI' 'at' 'neurologic' 'level' 'from' 'C2' 'to' 'C8'],[0. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02495545,18:21:chronic_disease,Prior history of SCI,['Prior' 'history' 'of' 'SCI'],[0. 0. 0. 2.]
NCT02451683,39:42:chronic_disease,Any debilitating disease prior to the SCI that caused exercise intolerance,"['Any' 'debilitating' 'disease' 'prior' 'to' 'the' 'SCI' 'that' 'caused'
 'exercise' 'intolerance']",[0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0.]
NCT02446210,41:44:chronic_disease,Exclusion criteria for individuals with SCI and Healthy Controls,"['Exclusion' 'criteria' 'for' 'individuals' 'with' 'SCI' 'and' 'Healthy'
 'Controls']",[0. 0. 0. 0. 0. 2. 0. 0. 0.]
NCT02446210,41:44:chronic_disease,Inclusion criteria for individuals with SCI,['Inclusion' 'criteria' 'for' 'individuals' 'with' 'SCI'],[0. 0. 0. 0. 0. 2.]
NCT01983475,52:55:chronic_disease,Extensive life-threatening injuries in addition to SCI,['Extensive' 'life-threatening' 'injuries' 'in' 'addition' 'to' 'SCI'],[0. 0. 0. 0. 0. 0. 2.]
NCT02542657,"27:34:cancer,",Baseline marrow burden or myeloma of at least 30%,['Baseline' 'marrow' 'burden' 'or' 'myeloma' 'of' 'at' 'least' '30' '%'],[0. 0. 0. 0. 3. 0. 0. 0. 0. 0.]
NCT02542657,",121:128:cancer,",For patients without a measurable serum or urine M-component or serum free light chain level: % marrow involvement with myeloma (absolute increase must be >= 10%),"['For' 'patients' 'without' 'a' 'measurable' 'serum' 'or' 'urine'
 'M-component' 'or' 'serum' 'free' 'light' 'chain' 'level' ':' '%'
 'marrow' 'involvement' 'with' 'myeloma' '(' 'absolute' 'increase' 'must'
 'be' '>' '=' '10' '%' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02516696,",,,85:92:cancer",Subject has a Karnofsky performance status ≥60% (>50% if due to bony involvement of myeloma (see Appendix IV),"['Subject' 'has' 'a' 'Karnofsky' 'performance' 'status' '≥60' '%' '(' '>'
 '50' '%' 'if' 'due' 'to' 'bony' 'involvement' 'of' 'myeloma' '(' 'see'
 'Appendix' 'IV' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0.]
NCT02101944,98:105:cancer,Evidence of any end organ damage criteria listed below (at any time) attributed to the patient's myeloma,"['Evidence' 'of' 'any' 'end' 'organ' 'damage' 'criteria' 'listed' 'below'
 '(' 'at' 'any' 'time' ')' 'attributed' 'to' 'the' 'patient' ""'s""
 'myeloma']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT02004275,"27:34:cancer,",Baseline marrow burden of myeloma of at least 30%,['Baseline' 'marrow' 'burden' 'of' 'myeloma' 'of' 'at' 'least' '30' '%'],[0. 0. 0. 0. 3. 0. 0. 0. 0. 0.]
NCT02004275,"18:25:cancer,",Marrow burden of myeloma of at least 30%,['Marrow' 'burden' 'of' 'myeloma' 'of' 'at' 'least' '30' '%'],[0. 0. 0. 3. 0. 0. 0. 0. 0.]
NCT00734877,",,37:44:cancer","Platelet count < 30 x 109/L, unless myeloma-related","['Platelet' 'count' '<' '30' 'x' '109/L' ',' 'unless' 'myeloma-related']",[0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT03166371,1:17:chronic_disease,eating disorders,['eating' 'disorders'],[2. 2.]
NCT03097536,10:26:chronic_disease,comorbid eating disorders,['comorbid' 'eating' 'disorders'],[0. 2. 2.]
NCT03058029,"12:28:chronic_disease,,,,",History of eating disorders including binge eating (except for mild binge eating)or emesis ≥2/week from any cause Weight change >3% within three(3) months prior to and during the Screening period,"['History' 'of' 'eating' 'disorders' 'including' 'binge' 'eating' '('
 'except' 'for' 'mild' 'binge' 'eating' ')' 'or' 'emesis' '≥2/week' 'from'
 'any' 'cause' 'Weight' 'change' '>' '3' '%' 'within' 'three' '(' '3' ')'
 'months' 'prior' 'to' 'and' 'during' 'the' 'Screening' 'period']","[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02962128,39:55:chronic_disease,Having a current or recent history of eating disorders,['Having' 'a' 'current' 'or' 'recent' 'history' 'of' 'eating' 'disorders'],[0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02607514,1:17:chronic_disease,eating disorders,['eating' 'disorders'],[2. 2.]
NCT02487251,21:37:chronic_disease,Significant feeding/eating disorders that would preclude participation in the interventions,"['Significant' 'feeding/eating' 'disorders' 'that' 'would' 'preclude'
 'participation' 'in' 'the' 'interventions']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT03153410,45:75:cancer,Have histologically or cytologically proven adenocarcinoma of the pancreas,"['Have' 'histologically' 'or' 'cytologically' 'proven' 'adenocarcinoma'
 'of' 'the' 'pancreas']",[0. 0. 0. 0. 0. 3. 3. 3. 3.]
NCT02873598,48:78:cancer,Histologically or cytopathologically confirmed adenocarcinoma of the pancreas,"['Histologically' 'or' 'cytopathologically' 'confirmed' 'adenocarcinoma'
 'of' 'the' 'pancreas']",[0. 0. 0. 0. 3. 3. 3. 3.]
NCT02442323,31:61:cancer,Have histologically confirmed adenocarcinoma of the pancreas,"['Have' 'histologically' 'confirmed' 'adenocarcinoma' 'of' 'the'
 'pancreas']",[0. 0. 0. 3. 3. 3. 3.]
NCT02427841,62:92:cancer,Subjects must have histologically or cytologically confirmed adenocarcinoma of the pancreas,"['Subjects' 'must' 'have' 'histologically' 'or' 'cytologically'
 'confirmed' 'adenocarcinoma' 'of' 'the' 'pancreas']",[0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3.]
NCT02394535,34:64:cancer,Cytologic or histologic proof of adenocarcinoma of the pancreas,"['Cytologic' 'or' 'histologic' 'proof' 'of' 'adenocarcinoma' 'of' 'the'
 'pancreas']",[0. 0. 0. 0. 0. 3. 3. 3. 3.]
NCT02207465,26:56:cancer,Pathologically confirmed adenocarcinoma of the pancreas,['Pathologically' 'confirmed' 'adenocarcinoma' 'of' 'the' 'pancreas'],[0. 0. 3. 3. 3. 3.]
NCT03143985,22:34:treatment,Prior treatment with pomalidomide,['Prior' 'treatment' 'with' 'pomalidomide'],[0. 0. 0. 1.]
NCT02343042,52:64:treatment,"In the expansion arm at RP2D, patients must not be pomalidomide refractory","['In' 'the' 'expansion' 'arm' 'at' 'RP2D' ',' 'patients' 'must' 'not' 'be'
 'pomalidomide' 'refractory']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02287558,",,,,,,205:217:treatment,,,","Females of childbearing potential (FCBP)† must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 - 14 days prior to and again within 24 hours of prescribing pomalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking pomalidomide","['Females' 'of' 'childbearing' 'potential' '(' 'FCBP' ')' '†' 'must'
 'have' 'a' 'negative' 'serum' 'or' 'urine' 'pregnancy' 'test' 'with' 'a'
 'sensitivity' 'of' 'at' 'least' '25' 'mIU/mL' 'within' '10' '-' '14'
 'days' 'prior' 'to' 'and' 'again' 'within' '24' 'hours' 'of'
 'prescribing' 'pomalidomide' 'and' 'must' 'either' 'commit' 'to'
 'continued' 'abstinence' 'from' 'heterosexual' 'intercourse' 'or' 'begin'
 'TWO' 'acceptable' 'methods' 'of' 'birth' 'control' ',' 'one' 'highly'
 'effective' 'method' 'and' 'one' 'additional' 'effective' 'method' 'AT'
 'THE' 'SAME' 'TIME' ',' 'at' 'least' '28' 'days' 'before' 'she' 'starts'
 'taking' 'pomalidomide']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02004275,",,228:240:treatment","Must either commit to complete abstinence from heterosexual contact or begin TWO acceptable methods of birth control, one highly effective method and one additional effective (barrier) method, AT THE SAME TIME, before starting pomalidomide","['Must' 'either' 'commit' 'to' 'complete' 'abstinence' 'from'
 'heterosexual' 'contact' 'or' 'begin' 'TWO' 'acceptable' 'methods' 'of'
 'birth' 'control' ',' 'one' 'highly' 'effective' 'method' 'and' 'one'
 'additional' 'effective' '(' 'barrier' ')' 'method' ',' 'AT' 'THE' 'SAME'
 'TIME' ',' 'before' 'starting' 'pomalidomide']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02004275,",,,,199:211:treatment",Must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mlU/ml no more than 14 days prior to registration and must agree to repeat this test within 24 hours of starting pomalidomide,"['Must' 'have' 'a' 'negative' 'serum' 'or' 'urine' 'pregnancy' 'test'
 'with' 'a' 'sensitivity' 'of' 'at' 'least' '25' 'mlU/ml' 'no' 'more'
 'than' '14' 'days' 'prior' 'to' 'registration' 'and' 'must' 'agree' 'to'
 'repeat' 'this' 'test' 'within' '24' 'hours' 'of' 'starting'
 'pomalidomide']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT01464034,",52:64:treatment,",Male pts cannot donate semen or sperm while taking pomalidomide and for 28 days after completing the study,"['Male' 'pts' 'can' 'not' 'donate' 'semen' 'or' 'sperm' 'while' 'taking'
 'pomalidomide' 'and' 'for' '28' 'days' 'after' 'completing' 'the' 'study']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03135522,14:25:cancer,negative for lung cancer,['negative' 'for' 'lung' 'cancer'],[0. 0. 3. 3.]
NCT02989974,30:41:cancer,Caregiver of a participating lung cancer survivor,['Caregiver' 'of' 'a' 'participating' 'lung' 'cancer' 'survivor'],[0. 0. 0. 0. 3. 3. 0.]
NCT02989974,42:53:cancer,Individuals who have been diagnosed with lung cancer (survivor),"['Individuals' 'who' 'have' 'been' 'diagnosed' 'with' 'lung' 'cancer' '('
 'survivor' ')']",[0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0.]
NCT02950337,36:47:cancer,Patients with any prior history of lung cancer,['Patients' 'with' 'any' 'prior' 'history' 'of' 'lung' 'cancer'],[0. 0. 0. 0. 0. 0. 3. 3.]
NCT02950337,18:29:cancer,Prior history of lung cancer,['Prior' 'history' 'of' 'lung' 'cancer'],[0. 0. 0. 3. 3.]
NCT02905591,22:33:cancer,At least part of the lung cancer must be viewable and measurable by CT or MRI,"['At' 'least' 'part' 'of' 'the' 'lung' 'cancer' 'must' 'be' 'viewable'
 'and' 'measurable' 'by' 'CT' 'or' 'MRI']",[0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03104699,41:54:cancer,Histologic confirmation of the original primary tumor is required via pathology report,"['Histologic' 'confirmation' 'of' 'the' 'original' 'primary' 'tumor' 'is'
 'required' 'via' 'pathology' 'report']",[0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0.]
NCT02542202,"27:40:cancer,,",this will be defined as a primary tumor < 10 cm in size or a primary lesion which can be treated to a dose of >= 8 Gy x 5 without excessive perceived risk of toxicity,"['this' 'will' 'be' 'defined' 'as' 'a' 'primary' 'tumor' '<' '10' 'cm'
 'in' 'size' 'or' 'a' 'primary' 'lesion' 'which' 'can' 'be' 'treated' 'to'
 'a' 'dose' 'of' '>' '=' '8' 'Gy' 'x' '5' 'without' 'excessive'
 'perceived' 'risk' 'of' 'toxicity']","[0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02488967,27:40:cancer,"By pathologic evaluation, primary tumor must be pT1-3","['By' 'pathologic' 'evaluation' ',' 'primary' 'tumor' 'must' 'be' 'pT1-3']",[0. 0. 0. 0. 3. 3. 0. 0. 0.]
NCT02176967,",,,51:64:cancer,",> 6 months and < 12 months of age with an adrenal primary tumor < 5 cm in greatest diameter,"['>' '6' 'months' 'and' '<' '12' 'months' 'of' 'age' 'with' 'an' 'adrenal'
 'primary' 'tumor' '<' '5' 'cm' 'in' 'greatest' 'diameter']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0.]
NCT02095184,"40:53:cancer,,","Evidence of hormone sensitive, ER rich primary tumor defined by an Allred score of ≥6","['Evidence' 'of' 'hormone' 'sensitive' ',' 'ER' 'rich' 'primary' 'tumor'
 'defined' 'by' 'an' 'Allred' 'score' 'of' '≥6']",[0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT00579514,68:81:cancer,All patients who have two or more histologic diagnoses of the same primary tumor type involving the above sites,"['All' 'patients' 'who' 'have' 'two' 'or' 'more' 'histologic' 'diagnoses'
 'of' 'the' 'same' 'primary' 'tumor' 'type' 'involving' 'the' 'above'
 'sites']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0.]
NCT03078907,8:30:chronic_disease,Severe coronary heart disease,['Severe' 'coronary' 'heart' 'disease'],[0. 2. 2. 2.]
NCT03072238,11:33:chronic_disease,untreated coronary heart disease (symptomatic or with ischemia demonstrated by diagnostic testing),"['untreated' 'coronary' 'heart' 'disease' '(' 'symptomatic' 'or' 'with'
 'ischemia' 'demonstrated' 'by' 'diagnostic' 'testing' ')']",[0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02471430,13:35:chronic_disease,Evidence of coronary heart disease,['Evidence' 'of' 'coronary' 'heart' 'disease'],[0. 0. 2. 2. 2.]
NCT02471430,25:47:chronic_disease,No evidence of clinical coronary heart disease,['No' 'evidence' 'of' 'clinical' 'coronary' 'heart' 'disease'],[0. 0. 0. 0. 2. 2. 2.]
NCT02471430,16:38:chronic_disease,No evidence of coronary heart disease,['No' 'evidence' 'of' 'coronary' 'heart' 'disease'],[0. 0. 0. 2. 2. 2.]
NCT01553214,12:34:chronic_disease,History of coronary heart disease,['History' 'of' 'coronary' 'heart' 'disease'],[0. 0. 2. 2. 2.]
NCT03069469,1:23:chronic_disease,Malabsorption syndrome or other illness that could affect oral absorption,"['Malabsorption' 'syndrome' 'or' 'other' 'illness' 'that' 'could' 'affect'
 'oral' 'absorption']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02496208,1:23:chronic_disease,Malabsorption syndrome,['Malabsorption' 'syndrome'],[2. 2.]
NCT02236000,1:23:chronic_disease,Malabsorption syndrome,['Malabsorption' 'syndrome'],[2. 2.]
NCT02132598,1:23:chronic_disease,Malabsorption syndrome,['Malabsorption' 'syndrome'],[2. 2.]
NCT01568255,1:23:chronic_disease,Malabsorption syndrome,['Malabsorption' 'syndrome'],[2. 2.]
NCT01532687,1:23:chronic_disease,Malabsorption syndrome,['Malabsorption' 'syndrome'],[2. 2.]
NCT03016130,30:34:treatment,Underlying diagnosis for non-HSCT patients,['Underlying' 'diagnosis' 'for' 'non-HSCT' 'patients'],[0. 0. 0. 1. 0.]
NCT02675959,41:45:treatment,Patients who have previously received a HSCT will not be eligible,"['Patients' 'who' 'have' 'previously' 'received' 'a' 'HSCT' 'will' 'not'
 'be' 'eligible']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02234934,27:31:treatment,Ineligible for autologous HSCT by the criteria at the clinical site,"['Ineligible' 'for' 'autologous' 'HSCT' 'by' 'the' 'criteria' 'at' 'the'
 'clinical' 'site']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02105766,14:18:treatment,Eligible for HSCT,['Eligible' 'for' 'HSCT'],[0. 0. 1.]
NCT01461837,23:27:treatment,Previously received a HSCT,['Previously' 'received' 'a' 'HSCT'],[0. 0. 0. 1.]
NCT01174108,",,110:114:treatment",ECOG performance status of 3 or more (See Bone & Marrow Transplant Consortium Supportive Care Guidelines for HSCT Recipients),"['ECOG' 'performance' 'status' 'of' '3' 'or' 'more' '(' 'See' 'Bone' '&'
 'Marrow' 'Transplant' 'Consortium' 'Supportive' 'Care' 'Guidelines' 'for'
 'HSCT' 'Recipients' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.]
NCT03001830,"1:18:chronic_disease,,",liver dysfunction (persistently elevated ALT >1.5X upper limit of normal),"['liver' 'dysfunction' '(' 'persistently' 'elevated' 'ALT' '>' '1.5X'
 'upper' 'limit' 'of' 'normal' ')']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02816736,"8:25:chronic_disease,",Severe liver dysfunction (Childs-Pugh Class C),['Severe' 'liver' 'dysfunction' '(' 'Childs-Pugh' 'Class' 'C' ')'],[0. 2. 2. 0. 0. 0. 0. 0.]
NCT02266745,8:25:chronic_disease,Severe liver dysfunction (Child-Pugh Class B or C),['Severe' 'liver' 'dysfunction' '(' 'Child-Pugh' 'Class' 'B' 'or' 'C' ')'],[0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02111824,"15:32:chronic_disease,,,,,","Patients with liver dysfunction: total bilirubin > 2.5 mg/dl; albumin < 2.5 mg/dl; alanine aminotransferase (ALT), aspartate aminotransferase (AST) > 5 times upper limits of normal","['Patients' 'with' 'liver' 'dysfunction' ':' 'total' 'bilirubin' '>' '2.5'
 'mg/dl' ';' 'albumin' '<' '2.5' 'mg/dl' ';' 'alanine' 'aminotransferase'
 '(' 'ALT' ')' ',' 'aspartate' 'aminotransferase' '(' 'AST' ')' '>' '5'
 'times' 'upper' 'limits' 'of' 'normal']","[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02092324,",,,,234:251:chronic_disease",Subjects with inadequate liver (alanine aminotransferase [ALT]/serum glutamate pyruvate transaminase [SGPT] above 4 X upper limit of normal [ULN] or direct bilirubin 4 X ULN AND the lab abnormalities are felt to be due to underlying liver dysfunction),"['Subjects' 'with' 'inadequate' 'liver' '(' 'alanine' 'aminotransferase'
 '[' 'ALT' ']' '/serum' 'glutamate' 'pyruvate' 'transaminase' '[' 'SGPT'
 ']' 'above' '4' 'X' 'upper' 'limit' 'of' 'normal' '[' 'ULN' ']' 'or'
 'direct' 'bilirubin' '4' 'X' 'ULN' 'AND' 'the' 'lab' 'abnormalities'
 'are' 'felt' 'to' 'be' 'due' 'to' 'underlying' 'liver' 'dysfunction' ')']","[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01648751,7:24:chronic_disease,Known liver dysfunction,['Known' 'liver' 'dysfunction'],[0. 2. 2.]
NCT02946892,"1:18:chronic_disease,,",Renal dysfunction defined as serum creatinine >2.0mg/dL,['Renal' 'dysfunction' 'defined' 'as' 'serum' 'creatinine' '>' '2.0mg/dL'],[2. 2. 0. 0. 0. 0. 0. 0.]
NCT02739035,1:18:chronic_disease,Renal dysfunction,['Renal' 'dysfunction'],[2. 2.]
NCT02700451,1:18:chronic_disease,Renal dysfunction,['Renal' 'dysfunction'],[2. 2.]
NCT02536170,"1:18:chronic_disease,,",Renal dysfunction of creatinine greater than 1.0,['Renal' 'dysfunction' 'of' 'creatinine' 'greater' 'than' '1.0'],[2. 2. 0. 0. 0. 0. 0.]
NCT01895777,1:18:chronic_disease,Renal dysfunction,['Renal' 'dysfunction'],[2. 2.]
NCT01842399,"1:18:chronic_disease,,",Renal dysfunction (GFR less than 60 mL/min),['Renal' 'dysfunction' '(' 'GFR' 'less' 'than' '60' 'mL/min' ')'],[2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02914483,1:19:chronic_disease,pulmonary embolism,['pulmonary' 'embolism'],[2. 2.]
NCT02664909,12:30:chronic_disease,history of pulmonary embolism,['history' 'of' 'pulmonary' 'embolism'],[0. 0. 2. 2.]
NCT02473536,28:46:chronic_disease,Subjects with a history of pulmonary embolism is excluded,"['Subjects' 'with' 'a' 'history' 'of' 'pulmonary' 'embolism' 'is'
 'excluded']",[0. 0. 0. 0. 0. 2. 2. 0. 0.]
NCT02370095,13:31:chronic_disease,Presence of pulmonary embolism,['Presence' 'of' 'pulmonary' 'embolism'],[0. 0. 2. 2.]
NCT02188745,1:19:chronic_disease,pulmonary embolism,['pulmonary' 'embolism'],[2. 2.]
NCT00969332,1:19:chronic_disease,pulmonary embolism,['pulmonary' 'embolism'],[2. 2.]
NCT02842658,9:32:chronic_disease,Complex ventricular arrhythmias,['Complex' 'ventricular' 'arrhythmias'],[0. 2. 2.]
NCT02585973,21:44:chronic_disease,severe uncontrolled ventricular arrhythmias,['severe' 'uncontrolled' 'ventricular' 'arrhythmias'],[0. 0. 2. 2.]
NCT02203695,35:58:chronic_disease,History of clinically significant ventricular arrhythmias,['History' 'of' 'clinically' 'significant' 'ventricular' 'arrhythmias'],[0. 0. 0. 0. 2. 2.]
NCT01925573,45:68:chronic_disease,History or presence of serious uncontrolled ventricular arrhythmias,"['History' 'or' 'presence' 'of' 'serious' 'uncontrolled' 'ventricular'
 'arrhythmias']",[0. 0. 0. 0. 0. 0. 2. 2.]
NCT01894061,45:68:chronic_disease,History or presence of serious uncontrolled ventricular arrhythmias,"['History' 'or' 'presence' 'of' 'serious' 'uncontrolled' 'ventricular'
 'arrhythmias']",[0. 0. 0. 0. 0. 0. 2. 2.]
NCT01366612,21:44:chronic_disease,severe uncontrolled ventricular arrhythmias,['severe' 'uncontrolled' 'ventricular' 'arrhythmias'],[0. 0. 2. 2.]
NCT02776891,1:6:cancer,DLBCL without myc translocation or overexpression by the above methods,"['DLBCL' 'without' 'myc' 'translocation' 'or' 'overexpression' 'by' 'the'
 'above' 'methods']",[3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02564744,127:132:cancer,"For Part 2 and Part 3 of the study, participants must have histopathologically and clinically confirmed diagnosis of relapsed DLBCL","['For' 'Part' '2' 'and' 'Part' '3' 'of' 'the' 'study' ',' 'participants'
 'must' 'have' 'histopathologically' 'and' 'clinically' 'confirmed'
 'diagnosis' 'of' 'relapsed' 'DLBCL']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT02564744,42:47:cancer,The following participants with relapsed DLBCL will be enrolled,"['The' 'following' 'participants' 'with' 'relapsed' 'DLBCL' 'will' 'be'
 'enrolled']",[0. 0. 0. 0. 0. 3. 0. 0. 0.]
NCT02061761,79:84:cancer,For dose escalation and dose expansion in combination with BMS-936558: HL and DLBCL,"['For' 'dose' 'escalation' 'and' 'dose' 'expansion' 'in' 'combination'
 'with' 'BMS-936558' ':' 'HL' 'and' 'DLBCL']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT01959698,",,,31:36:cancer",Ann Arbor stage I to stage IV DLBCL at the time of relapsed/refractory disease to be eligible,"['Ann' 'Arbor' 'stage' 'I' 'to' 'stage' 'IV' 'DLBCL' 'at' 'the' 'time'
 'of' 'relapsed/refractory' 'disease' 'to' 'be' 'eligible']",[0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01829958,26:31:cancer,Previously untreated for DLBCL,['Previously' 'untreated' 'for' 'DLBCL'],[0. 0. 0. 3.]
NCT02669966,34:37:chronic_disease,"The donor candidate must be anti-HCV positive by ELISA and HCV RNA negative by PCR, with both tests repeated for confirmation, as per standard protocol","['The' 'donor' 'candidate' 'must' 'be' 'anti-HCV' 'positive' 'by' 'ELISA'
 'and' 'HCV' 'RNA' 'negative' 'by' 'PCR' ',' 'with' 'both' 'tests'
 'repeated' 'for' 'confirmation' ',' 'as' 'per' 'standard' 'protocol']","[0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02573376,"35:38:chronic_disease,",Considered an active drug user by HCV provider and self-reported drug use within the past month,"['Considered' 'an' 'active' 'drug' 'user' 'by' 'HCV' 'provider' 'and'
 'self-reported' 'drug' 'use' 'within' 'the' 'past' 'month']",[0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02573376,"1:4:chronic_disease,,,","HCV genotype 1, 4, 5, 6","['HCV' 'genotype' '1' ',' '4' ',' '5' ',' '6']",[2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02474199,1:4:chronic_disease,HCV RNA negative at time of study enrollment,['HCV' 'RNA' 'negative' 'at' 'time' 'of' 'study' 'enrollment'],[2. 0. 0. 0. 0. 0. 0. 0.]
NCT02471430,10:13:chronic_disease,negative HCV PCR if anti-HCV antibodies are positive,['negative' 'HCV' 'PCR' 'if' 'anti-HCV' 'antibodies' 'are' 'positive'],[0. 2. 0. 0. 0. 0. 0. 0.]
NCT02016924,27:30:chronic_disease,individuals with positive HCV antibody and without detectable HCV RNA are permitted to enroll,"['individuals' 'with' 'positive' 'HCV' 'antibody' 'and' 'without'
 'detectable' 'HCV' 'RNA' 'are' 'permitted' 'to' 'enroll']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02543983,130:138:allergy_name,A medical finding or condition that in the clinical judgement of the investigator increases the risk of adverse effects from the ketamine administration (for example: findings suggesting difficulties with kidney or cardiac function that may be contradictions for an experimental intervention),"['A' 'medical' 'finding' 'or' 'condition' 'that' 'in' 'the' 'clinical'
 'judgement' 'of' 'the' 'investigator' 'increases' 'the' 'risk' 'of'
 'adverse' 'effects' 'from' 'the' 'ketamine' 'administration' '(' 'for'
 'example' ':' 'findings' 'suggesting' 'difficulties' 'with' 'kidney' 'or'
 'cardiac' 'function' 'that' 'may' 'be' 'contradictions' 'for' 'an'
 'experimental' 'intervention' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02543983,44:52:treatment,Intolerable or serious adverse reaction to ketamine during Phase II,"['Intolerable' 'or' 'serious' 'adverse' 'reaction' 'to' 'ketamine'
 'during' 'Phase' 'II']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02341963,12:20:allergy_name,Allergy to ketamine,['Allergy' 'to' 'ketamine'],[0. 0. 4.]
NCT02341963,46:54:treatment,the inability to avoid these products during ketamine administration,"['the' 'inability' 'to' 'avoid' 'these' 'products' 'during' 'ketamine'
 'administration']",[0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02165449,21:29:allergy_name,Contraindication to ketamine,['Contraindication' 'to' 'ketamine'],[0. 0. 4.]
NCT02165449,29:37:treatment,Voluntary patient receiving ketamine,['Voluntary' 'patient' 'receiving' 'ketamine'],[0. 0. 0. 1.]
NCT02513797,8:20:chronic_disease,Active endocarditis,['Active' 'endocarditis'],[0. 2.]
NCT02494869,8:20:chronic_disease,Active endocarditis,['Active' 'endocarditis'],[0. 2.]
NCT02453373,21:33:chronic_disease,Suspected/confirmed endocarditis,['Suspected/confirmed' 'endocarditis'],[0. 2.]
NCT02216227,46:58:chronic_disease,Have an ICD-9 diagnosis code consistent with endocarditis,['Have' 'an' 'ICD-9' 'diagnosis' 'code' 'consistent' 'with' 'endocarditis'],[0. 0. 0. 0. 0. 0. 0. 2.]
NCT01568177,1:13:chronic_disease,endocarditis,['endocarditis'],[2.]
NCT00291525,22:34:chronic_disease,Patients with active endocarditis at the time of implant,"['Patients' 'with' 'active' 'endocarditis' 'at' 'the' 'time' 'of'
 'implant']",[0. 0. 0. 2. 0. 0. 0. 0. 0.]
NCT02339922,"1:22:treatment,",platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollment,"['platelet' 'transfusions' 'to' 'help' 'patients' 'meet' 'eligibility'
 'criteria' 'are' 'not' 'allowed' 'within' '3' 'days' 'before' 'study'
 'enrollment']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02304458,",,82:103:treatment,","Platelet count >= 75,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)","['Platelet' 'count' '>' '=' '75,000/mm^3' '(' 'transfusion' 'independent'
 ',' 'defined' 'as' 'not' 'receiving' 'platelet' 'transfusions' 'for' 'at'
 'least' '7' 'days' 'prior' 'to' 'enrollment' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02124772,",,83:104:treatment,","platelets >=75,000/ microliter (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment)","['platelets' '>' '=75,000/' 'microliter' '(' 'transfusion' 'independent'
 ',' 'defined' 'as' 'not' 'receiving' 'platelet' 'transfusions' 'within'
 'a' '7' 'day' 'period' 'prior' 'to' 'enrollment' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02004275,"4:25:treatment,",No platelet transfusions within 7 days of registration to meet eligibility criteria,"['No' 'platelet' 'transfusions' 'within' '7' 'days' 'of' 'registration'
 'to' 'meet' 'eligibility' 'criteria']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01880567,1:22:treatment,platelet transfusions,['platelet' 'transfusions'],[1. 1.]
NCT01464034,",51:72:treatment,",Screening platelet count should be independent of platelet transfusions for at least 2 weeks,"['Screening' 'platelet' 'count' 'should' 'be' 'independent' 'of'
 'platelet' 'transfusions' 'for' 'at' 'least' '2' 'weeks']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03179605,"15:24:chronic_disease,,","Subjects with psoriasis involving ≥10% Body Surface Area (BSA), not including the face, scalp, groin, axillae and other intertriginous areas at the Baseline Visit","['Subjects' 'with' 'psoriasis' 'involving' '≥10' '%' 'Body' 'Surface'
 'Area' '(' 'BSA' ')' ',' 'not' 'including' 'the' 'face' ',' 'scalp' ','
 'groin' ',' 'axillae' 'and' 'other' 'intertriginous' 'areas' 'at' 'the'
 'Baseline' 'Visit']","[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT03168347,16:25:chronic_disease,Diagnosed with psoriasis (ICD-9: 696.1),['Diagnosed' 'with' 'psoriasis' '(' 'ICD-9' ':' '696.1' ')'],[0. 0. 2. 0. 0. 0. 0. 0.]
NCT02595866,77:86:chronic_disease,"Mild autoimmunity not impacting the function of major organs (e.g., limited psoriasis)","['Mild' 'autoimmunity' 'not' 'impacting' 'the' 'function' 'of' 'major'
 'organs' '(' 'e.g.' ',' 'limited' 'psoriasis' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0.]
NCT02527421,"15:24:chronic_disease,,",Subjects with psoriasis involving ≥ 10% BSA,['Subjects' 'with' 'psoriasis' 'involving' '≥' '10' '%' 'BSA'],[0. 0. 2. 0. 0. 0. 0. 0.]
NCT01631617,1:10:chronic_disease,psoriasis,['psoriasis'],[2.]
NCT03166930,1:23:chronic_disease,neurological condition other than MS that is known to cause spasticity,"['neurological' 'condition' 'other' 'than' 'MS' 'that' 'is' 'known' 'to'
 'cause' 'spasticity']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02890485,15:37:chronic_disease,Presence of a neurological condition that would affect movement,"['Presence' 'of' 'a' 'neurological' 'condition' 'that' 'would' 'affect'
 'movement']",[0. 0. 0. 2. 2. 0. 0. 0. 0.]
NCT02410954,13:35:chronic_disease,Any current neurological condition,['Any' 'current' 'neurological' 'condition'],[0. 0. 2. 2.]
NCT02361554,15:37:chronic_disease,Subject has a neurological condition,['Subject' 'has' 'a' 'neurological' 'condition'],[0. 0. 0. 2. 2.]
NCT02314221,7:29:chronic_disease,Other neurological condition that the study physician considers in his/her clinical judgment to be exclusionary,"['Other' 'neurological' 'condition' 'that' 'the' 'study' 'physician'
 'considers' 'in' 'his/her' 'clinical' 'judgment' 'to' 'be' 'exclusionary']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03159702,30:54:cancer,Patients with a diagnosis of hematological malignancy undergoing a related donor haploidentical HCT,"['Patients' 'with' 'a' 'diagnosis' 'of' 'hematological' 'malignancy'
 'undergoing' 'a' 'related' 'donor' 'haploidentical' 'HCT']",[0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0.]
NCT02931110,65:89:cancer,"Rapidly progressive, clinically unstable central nervous system hematological malignancy","['Rapidly' 'progressive' ',' 'clinically' 'unstable' 'central' 'nervous'
 'system' 'hematological' 'malignancy']",[0. 0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT02611063,23:47:cancer,Complete remission of hematological malignancy prior to transplantation,"['Complete' 'remission' 'of' 'hematological' 'malignancy' 'prior' 'to'
 'transplantation']",[0. 0. 0. 3. 3. 0. 0. 0.]
NCT02323191,"31:55:cancer,",Participants has a history of hematological malignancy within the last 5 years prior to study entry,"['Participants' 'has' 'a' 'history' 'of' 'hematological' 'malignancy'
 'within' 'the' 'last' '5' 'years' 'prior' 'to' 'study' 'entry']",[0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02074436,",,17:41:cancer",Age > 18 with a hematological malignancy,['Age' '>' '18' 'with' 'a' 'hematological' 'malignancy'],[0. 0. 0. 0. 0. 3. 3.]
NCT03135522,"26:70:chronic_disease,,,,,",Diagnosis or evidence of chronic obstructive pulmonary disease (COPD) as defined by forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) < 0.70 and FEV1% predicted < 80%,"['Diagnosis' 'or' 'evidence' 'of' 'chronic' 'obstructive' 'pulmonary'
 'disease' '(' 'COPD' ')' 'as' 'defined' 'by' 'forced' 'expiratory'
 'volume' 'in' '1' 'second' '(' 'FEV1' ')' '/forced' 'vital' 'capacity'
 '(' 'FVC' ')' '<' '0.70' 'and' 'FEV1' '%' 'predicted' '<' '80' '%']","[0. 0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03067571,"11:55:chronic_disease,,",has known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) < 50% of predicted normal,"['has' 'known' 'chronic' 'obstructive' 'pulmonary' 'disease' '(' 'COPD'
 ')' 'with' 'a' 'forced' 'expiratory' 'volume' 'in' '1' 'second' '('
 'FEV1' ')' '<' '50' '%' 'of' 'predicted' 'normal']","[0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02578641,1:45:chronic_disease,chronic obstructive pulmonary disease (COPD),['chronic' 'obstructive' 'pulmonary' 'disease' '(' 'COPD' ')'],[2. 2. 2. 2. 2. 0. 0.]
NCT02523443,"22:66:chronic_disease,,",Patients with severe chronic obstructive pulmonary disease (COPD) defined as an FEV1 <50%,"['Patients' 'with' 'severe' 'chronic' 'obstructive' 'pulmonary' 'disease'
 '(' 'COPD' ')' 'defined' 'as' 'an' 'FEV1' '<' '50' '%']",[0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01983462,12:56:chronic_disease,History of chronic obstructive pulmonary disease (COPD),"['History' 'of' 'chronic' 'obstructive' 'pulmonary' 'disease' '(' 'COPD'
 ')']",[0. 0. 2. 2. 2. 2. 2. 0. 0.]
NCT03125902,38:51:chronic_disease,clinically significant (symptomatic) hypercalcemia,['clinically' 'significant' '(' 'symptomatic' ')' 'hypercalcemia'],[0. 0. 0. 0. 0. 2.]
NCT02332928,"1:14:chronic_disease,,",hypercalcemia (calcium >11 mg/dL) Ca = SerumCa + 0.8 * (NormalAlbumin - PatientAlbumin),"['hypercalcemia' '(' 'calcium' '>' '11' 'mg/dL' ')' 'Ca' '=' 'SerumCa' '+'
 '0.8' '*' '(' 'NormalAlbumin' '-' 'PatientAlbumin' ')']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02172651,"14:27:chronic_disease,,,","Pre-existing hypercalcemia (defined as baseline serum calcium above the institutional ULN, corrected for albumin level if albumin is not within institutional limits of normal)","['Pre-existing' 'hypercalcemia' '(' 'defined' 'as' 'baseline' 'serum'
 'calcium' 'above' 'the' 'institutional' 'ULN' ',' 'corrected' 'for'
 'albumin' 'level' 'if' 'albumin' 'is' 'not' 'within' 'institutional'
 'limits' 'of' 'normal' ')']","[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02091141,29:42:chronic_disease,Uncontrolled or symptomatic hypercalcemia,['Uncontrolled' 'or' 'symptomatic' 'hypercalcemia'],[0. 0. 0. 2.]
NCT01572480,12:25:chronic_disease,Absence of hypercalcemia,['Absence' 'of' 'hypercalcemia'],[0. 0. 2.]
NCT03105700,1:9:treatment,caffeine,['caffeine'],[1.]
NCT02665338,1:9:treatment,caffeine,['caffeine'],[1.]
NCT02067975,"31:39:treatment,","Excessive self-reported daily caffeine intake, defined as intake exceeding 1000 mg or the equivalent of 8 cups of coffee","['Excessive' 'self-reported' 'daily' 'caffeine' 'intake' ',' 'defined'
 'as' 'intake' 'exceeding' '1000' 'mg' 'or' 'the' 'equivalent' 'of' '8'
 'cups' 'of' 'coffee']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01940822,21:29:allergy_name,No prior history of caffeine sensitivity or allergy,['No' 'prior' 'history' 'of' 'caffeine' 'sensitivity' 'or' 'allergy'],[0. 0. 0. 0. 4. 0. 0. 0.]
NCT01940822,18:26:allergy_name,Prior history of caffeine sensitivity or allergy,['Prior' 'history' 'of' 'caffeine' 'sensitivity' 'or' 'allergy'],[0. 0. 0. 4. 0. 0. 0.]
NCT03096886,21:45:treatment,Willing to not take psychotropic medications for the duration of the study,"['Willing' 'to' 'not' 'take' 'psychotropic' 'medications' 'for' 'the'
 'duration' 'of' 'the' 'study']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02874898,"18:42:treatment,",Unstable dose of psychotropic medications in the prior 3 months,"['Unstable' 'dose' 'of' 'psychotropic' 'medications' 'in' 'the' 'prior'
 '3' 'months']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02768727,27:51:treatment,History or current use of psychotropic medications,['History' 'or' 'current' 'use' 'of' 'psychotropic' 'medications'],[0. 0. 0. 0. 0. 1. 1.]
NCT02647723,8:32:treatment,Use of psychotropic medications,['Use' 'of' 'psychotropic' 'medications'],[0. 0. 1. 1.]
NCT02316574,22:46:treatment,Currently taking any psychotropic medications,['Currently' 'taking' 'any' 'psychotropic' 'medications'],[0. 0. 0. 1. 1.]
NCT03072381,68:74:treatment,"self-reported failure of at least 2 of the most common treatments (NSAIDs, relative rest, ice, bracing) for CLE","['self-reported' 'failure' 'of' 'at' 'least' '2' 'of' 'the' 'most'
 'common' 'treatments' '(' 'NSAIDs' ',' 'relative' 'rest' ',' 'ice' ','
 'bracing' ')' 'for' 'CLE']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02844751,"19:25:treatment,",Consistent use of NSAIDs within 48 hours of procedure,['Consistent' 'use' 'of' 'NSAIDs' 'within' '48' 'hours' 'of' 'procedure'],[0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02739035,16:22:allergy_name,Intolerance to NSAIDs,['Intolerance' 'to' 'NSAIDs'],[0. 0. 4.]
NCT02700451,23:29:allergy_name,Documented allergy to NSAIDs,['Documented' 'allergy' 'to' 'NSAIDs'],[0. 0. 0. 4.]
NCT02650206,"1:7:treatment,",NSAIDs (must cease use 4 weeks prior to study enrollment),"['NSAIDs' '(' 'must' 'cease' 'use' '4' 'weeks' 'prior' 'to' 'study'
 'enrollment' ')']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03060096,"16:25:chronic_disease,",Self -reported psychotic symptoms in the last 30 days,['Self' '-reported' 'psychotic' 'symptoms' 'in' 'the' 'last' '30' 'days'],[0. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT02397889,29:38:chronic_disease,Past or current presence of psychotic symptoms,['Past' 'or' 'current' 'presence' 'of' 'psychotic' 'symptoms'],[0. 0. 0. 0. 0. 2. 0.]
NCT02305537,24:33:chronic_disease,those who are actively psychotic,['those' 'who' 'are' 'actively' 'psychotic'],[0. 0. 0. 0. 2.]
NCT02149823,23:32:chronic_disease,Currently meets for a psychotic episode,['Currently' 'meets' 'for' 'a' 'psychotic' 'episode'],[0. 0. 0. 0. 2. 0.]
NCT02056873,13:22:chronic_disease,Presence of psychotic features,['Presence' 'of' 'psychotic' 'features'],[0. 0. 2. 0.]
NCT03055767,14:31:chronic_disease,Diagnosis of Myasthenia gravis,['Diagnosis' 'of' 'Myasthenia' 'gravis'],[0. 0. 2. 2.]
NCT02849639,1:18:chronic_disease,Myasthenia gravis,['Myasthenia' 'gravis'],[2. 2.]
NCT02823665,1:18:chronic_disease,Myasthenia gravis,['Myasthenia' 'gravis'],[2. 2.]
NCT02418195,1:18:chronic_disease,Myasthenia gravis,['Myasthenia' 'gravis'],[2. 2.]
NCT02097121,1:18:chronic_disease,Myasthenia gravis,['Myasthenia' 'gravis'],[2. 2.]
NCT03018704,"1:15:treatment,",tubal ligation or are less than two years postmenopausal,"['tubal' 'ligation' 'or' 'are' 'less' 'than' 'two' 'years'
 'postmenopausal']",[1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02950337,",,104:118:treatment","A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice)","['A' 'female' 'of' 'child-bearing' 'potential' 'is' 'any' 'woman' '('
 'regardless' 'of' 'sexual' 'orientation' ',' 'having' 'undergone' 'a'
 'tubal' 'ligation' ',' 'or' 'remaining' 'celibate' 'by' 'choice' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02536794,",76:90:treatment","A FOCBP is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice)","['A' 'FOCBP' 'is' 'any' 'woman' '(' 'regardless' 'of' 'sexual'
 'orientation' ',' 'having' 'undergone' 'a' 'tubal' 'ligation' ',' 'or'
 'remaining' 'celibate' 'by' 'choice' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02452697,3:17:treatment,A tubal ligation is adequate documentation that a patient is not of child bearing potential,"['A' 'tubal' 'ligation' 'is' 'adequate' 'documentation' 'that' 'a'
 'patient' 'is' 'not' 'of' 'child' 'bearing' 'potential']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01896999,",,114:128:treatment","a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation","['a' 'female' 'of' 'childbearing' 'potential' 'is' 'any' 'woman' ','
 'regardless' 'of' 'sexual' 'orientation' 'or' 'whether' 'they' 'have'
 'undergone' 'tubal' 'ligation']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT03005782,"21:54:cancer,",Untreated or active central nervous system metastases - Ongoing or recent (within 5 years) evidence of significant autoimmune disease,"['Untreated' 'or' 'active' 'central' 'nervous' 'system' 'metastases' '-'
 'Ongoing' 'or' 'recent' '(' 'within' '5' 'years' ')' 'evidence' 'of'
 'significant' 'autoimmune' 'disease']",[0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03001882,25:58:cancer,Patients with untreated central nervous system metastases,['Patients' 'with' 'untreated' 'central' 'nervous' 'system' 'metastases'],[0. 0. 0. 3. 3. 3. 3.]
NCT02303977,11:44:cancer,Untreated central nervous system metastases,['Untreated' 'central' 'nervous' 'system' 'metastases'],[0. 3. 3. 3. 3.]
NCT02091999,14:47:cancer,Uncontrolled central nervous system metastases,['Uncontrolled' 'central' 'nervous' 'system' 'metastases'],[0. 3. 3. 3. 3.]
NCT01522768,15:48:cancer,"Asymptomatic, central nervous system metastases","['Asymptomatic' ',' 'central' 'nervous' 'system' 'metastases']",[0. 0. 3. 3. 3. 3.]
NCT02981082,1:23:chronic_disease,Pulmonary hypertension,['Pulmonary' 'hypertension'],[2. 2.]
NCT02950337,1:23:chronic_disease,Pulmonary hypertension,['Pulmonary' 'hypertension'],[2. 2.]
NCT02562235,1:23:chronic_disease,Pulmonary hypertension related to conditions other than specified in the inclusion criteria,"['Pulmonary' 'hypertension' 'related' 'to' 'conditions' 'other' 'than'
 'specified' 'in' 'the' 'inclusion' 'criteria']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02503722,1:23:chronic_disease,Pulmonary hypertension,['Pulmonary' 'hypertension'],[2. 2.]
NCT02436070,1:23:chronic_disease,Pulmonary hypertension,['Pulmonary' 'hypertension'],[2. 2.]
NCT02914171,12:22:chronic_disease,history of thrombosis,['history' 'of' 'thrombosis'],[0. 0. 2.]
NCT02496585,"41:51:chronic_disease,,,,,","Inherited predisposition to bleeding or thrombosis, INR >2, PT and PTT >1.5x ULN","['Inherited' 'predisposition' 'to' 'bleeding' 'or' 'thrombosis' ',' 'INR'
 '>' '2' ',' 'PT' 'and' 'PTT' '>' '1.5x' 'ULN']",[0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02496585,35:45:chronic_disease,Known inherited predisposition to thrombosis,['Known' 'inherited' 'predisposition' 'to' 'thrombosis'],[0. 0. 0. 0. 2.]
NCT02489045,15:25:chronic_disease,"Patients with thrombosis within the hepatic, portal, or mesenteric veins","['Patients' 'with' 'thrombosis' 'within' 'the' 'hepatic' ',' 'portal' ','
 'or' 'mesenteric' 'veins']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00540761,82:92:treatment,"high-risk and complex lesions, including tortuous blood vessels and lesions with thrombosis","['high-risk' 'and' 'complex' 'lesions' ',' 'including' 'tortuous' 'blood'
 'vessels' 'and' 'lesions' 'with' 'thrombosis']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02861417,1:24:chronic_disease,Uncontrolled infections,['Uncontrolled' 'infections'],[2. 2.]
NCT02663622,1:24:chronic_disease,Uncontrolled infections,['Uncontrolled' 'infections'],[2. 2.]
NCT02203903,1:24:chronic_disease,Uncontrolled infections,['Uncontrolled' 'infections'],[2. 2.]
NCT01904136,1:24:chronic_disease,Uncontrolled infections; principal investigator (PI) is the final arbiter of this criterion,"['Uncontrolled' 'infections' ';' 'principal' 'investigator' '(' 'PI' ')'
 'is' 'the' 'final' 'arbiter' 'of' 'this' 'criterion']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00959140,1:24:chronic_disease,"Uncontrolled infections, defined as positive blood cultures","['Uncontrolled' 'infections' ',' 'defined' 'as' 'positive' 'blood'
 'cultures']",[2. 2. 0. 0. 0. 0. 0. 0.]
NCT02820350,1:5:chronic_disease,AIDS,['AIDS'],[2.]
NCT02392286,1:5:chronic_disease,AIDS or AIDS-defining illness,['AIDS' 'or' 'AIDS-defining' 'illness'],[2. 0. 0. 0.]
NCT02130388,"1:5:chronic_disease,,",AIDS defining illness or Cluster of Differentiation 4 < 200,"['AIDS' 'defining' 'illness' 'or' 'Cluster' 'of' 'Differentiation' '4' '<'
 '200']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02016924,"4:8:chronic_disease,",An AIDS defining condition with onset within 30 days prior to screening,"['An' 'AIDS' 'defining' 'condition' 'with' 'onset' 'within' '30' 'days'
 'prior' 'to' 'screening']",[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01415752,15:19:chronic_disease,No history of AIDS-defining conditions,['No' 'history' 'of' 'AIDS-defining' 'conditions'],[0. 0. 0. 2. 0.]
NCT02762006,12:41:chronic_disease,History of leptomeningeal carcinomatosis,['History' 'of' 'leptomeningeal' 'carcinomatosis'],[0. 0. 2. 2.]
NCT02592551,12:41:cancer,History of leptomeningeal carcinomatosis,['History' 'of' 'leptomeningeal' 'carcinomatosis'],[0. 0. 3. 3.]
NCT02568267,42:71:cancer,"Patients with CNS involvement, including leptomeningeal carcinomatosis, which is either asymptomatic or previously-treated and controlled","['Patients' 'with' 'CNS' 'involvement' ',' 'including' 'leptomeningeal'
 'carcinomatosis' ',' 'which' 'is' 'either' 'asymptomatic' 'or'
 'previously-treated' 'and' 'controlled']",[0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02401347,15:44:cancer,Subjects with leptomeningeal carcinomatosis,['Subjects' 'with' 'leptomeningeal' 'carcinomatosis'],[0. 0. 3. 3.]
NCT02336451,33:62:cancer,Patients must be diagnosed with leptomeningeal carcinomatosis,"['Patients' 'must' 'be' 'diagnosed' 'with' 'leptomeningeal'
 'carcinomatosis']",[0. 0. 0. 0. 0. 3. 3.]
NCT02710396,24:58:chronic_disease,Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies),"['Has' 'a' 'known' 'history' 'of' 'Human' 'Immunodeficiency' 'Virus' '('
 'HIV' ')' '(' 'HIV' '1/2' 'antibodies' ')']",[0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02578641,1:35:chronic_disease,Human Immunodeficiency Virus (HIV) negative,['Human' 'Immunodeficiency' 'Virus' '(' 'HIV' ')' 'negative'],[2. 2. 2. 2. 0. 0. 0.]
NCT02324582,"12:46:chronic_disease,",history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies),"['history' 'of' 'Human' 'Immunodeficiency' 'Virus' '(' 'HIV' ')' '(' 'HIV'
 '1/2' 'antibodies' ')']",[0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT01947140,21:55:chronic_disease,Patient known to be Human Immunodeficiency Virus (HIV)-positive,"['Patient' 'known' 'to' 'be' 'Human' 'Immunodeficiency' 'Virus' '(' 'HIV'
 ')' '-positive']",[0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0.]
NCT01676753,24:58:chronic_disease,Patient is known to be Human Immunodeficiency Virus (HIV)-positive,"['Patient' 'is' 'known' 'to' 'be' 'Human' 'Immunodeficiency' 'Virus' '('
 'HIV' ')' '-positive']",[0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0.]
NCT02667418,1:12:chronic_disease,hypotension,['hypotension'],[2.]
NCT02620579,"1:12:chronic_disease,,",hypotension (resting systolic blood pressure below 90 mm Hg),"['hypotension' '(' 'resting' 'systolic' 'blood' 'pressure' 'below' '90'
 'mm' 'Hg' ')']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02263729,"6:17:chronic_disease,,,,,",Have hypotension (blood pressure less than or equal to 90 mmHg systolic pressure or less than or equal to 60 mmHg diastolic pressure),"['Have' 'hypotension' '(' 'blood' 'pressure' 'less' 'than' 'or' 'equal'
 'to' '90' 'mmHg' 'systolic' 'pressure' 'or' 'less' 'than' 'or' 'equal'
 'to' '60' 'mmHg' 'diastolic' 'pressure' ')']","[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02178566,"10:21:chronic_disease,,",Systemic hypotension with systolic blood pressure < 85 mmHg,"['Systemic' 'hypotension' 'with' 'systolic' 'blood' 'pressure' '<' '85'
 'mmHg']",[0. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02098876,",,,,,50:61:chronic_disease,",Systolic BP >160mmHg or diastolic BP>100 mmHg or hypotension (BP <90/60 mmHg),"['Systolic' 'BP' '>' '160mmHg' 'or' 'diastolic' 'BP' '>' '100' 'mmHg' 'or'
 'hypotension' '(' 'BP' '<' '90/60' 'mmHg' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT02636530,8:23:treatment,use of glucocorticoids,['use' 'of' 'glucocorticoids'],[0. 0. 1.]
NCT02401035,24:39:treatment,Chronic (daily) use of glucocorticoids,['Chronic' '(' 'daily' ')' 'use' 'of' 'glucocorticoids'],[0. 0. 0. 0. 0. 0. 1.]
NCT02343042,23:38:treatment,Patients on long-term glucocorticoids during Screening do not require a washout period,"['Patients' 'on' 'long-term' 'glucocorticoids' 'during' 'Screening' 'do'
 'not' 'require' 'a' 'washout' 'period']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02302235,26:41:treatment,Planned continued use of glucocorticoids,['Planned' 'continued' 'use' 'of' 'glucocorticoids'],[0. 0. 0. 0. 1.]
NCT01865162,26:41:treatment,Planned continued use of glucocorticoids,['Planned' 'continued' 'use' 'of' 'glucocorticoids'],[0. 0. 0. 0. 1.]
NCT02576431,23:33:cancer,Subjects with primary CNS tumors are eligible,['Subjects' 'with' 'primary' 'CNS' 'tumors' 'are' 'eligible'],[0. 0. 0. 3. 3. 0. 0.]
NCT02564198,43:53:cancer,participants with recurrent or refractory CNS tumors,['participants' 'with' 'recurrent' 'or' 'refractory' 'CNS' 'tumors'],[0. 0. 0. 0. 0. 3. 3.]
NCT02451215,18:28:cancer,Other high grade CNS tumors,['Other' 'high' 'grade' 'CNS' 'tumors'],[0. 0. 0. 3. 3.]
NCT02451215,17:27:cancer,Other low-grade CNS tumors,['Other' 'low-grade' 'CNS' 'tumors'],[0. 0. 3. 3.]
NCT01505569,16:26:cancer,Arm B: Certain CNS tumors,['Arm' 'B' ':' 'Certain' 'CNS' 'tumors'],[0. 0. 0. 0. 3. 3.]
NCT02561988,"1:11:chronic_disease,,",Cytopenias: ANC < 1.0 × 10⁹/L,['Cytopenias' ':' 'ANC' '<' '1.0' '×' '10⁹/L'],[2. 0. 0. 0. 0. 0. 0.]
NCT02315612,1:11:chronic_disease,Cytopenias deemed to be disease-related and not therapy-related,"['Cytopenias' 'deemed' 'to' 'be' 'disease-related' 'and' 'not'
 'therapy-related']",[2. 0. 0. 0. 0. 0. 0. 0.]
NCT01829958,"1:11:chronic_disease,,,,","Cytopenias (leukocytes <1 × 109/L and/or platelets ,100 × 109/L)","['Cytopenias' '(' 'leukocytes' '<' '1' '×' '109/L' 'and/or' 'platelets'
 ',100' '×' '109/L' ')']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01430390,1:11:chronic_disease,Cytopenias deemed to be disease-related and not therapy-related,"['Cytopenias' 'deemed' 'to' 'be' 'disease-related' 'and' 'not'
 'therapy-related']",[2. 0. 0. 0. 0. 0. 0. 0.]
NCT01389024,1:11:chronic_disease,Cytopenias,['Cytopenias'],[2.]
NCT02542202,32:55:treatment,Patients may not have received prior radiation therapy to a site of recurrence which would require overlap of appreciable radiation dose,"['Patients' 'may' 'not' 'have' 'received' 'prior' 'radiation' 'therapy'
 'to' 'a' 'site' 'of' 'recurrence' 'which' 'would' 'require' 'overlap'
 'of' 'appreciable' 'radiation' 'dose']",[0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02192359,41:64:treatment,there is no time period requirement for prior radiation therapy,"['there' 'is' 'no' 'time' 'period' 'requirement' 'for' 'prior' 'radiation'
 'therapy']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02143726,"15:38:treatment,,",have received prior radiation therapy to index lesions ≥ 28 days prior to registration on this protocol if there has been documented progression by RECIST criteria,"['have' 'received' 'prior' 'radiation' 'therapy' 'to' 'index' 'lesions'
 '≥' '28' 'days' 'prior' 'to' 'registration' 'on' 'this' 'protocol' 'if'
 'there' 'has' 'been' 'documented' 'progression' 'by' 'RECIST' 'criteria']","[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT01822522,"1:24:treatment,","prior radiation therapy to the thoracic cavity, abdomen, or pelvis must be completed at least 3 months prior to registration","['prior' 'radiation' 'therapy' 'to' 'the' 'thoracic' 'cavity' ','
 'abdomen' ',' 'or' 'pelvis' 'must' 'be' 'completed' 'at' 'least' '3'
 'months' 'prior' 'to' 'registration']",[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01618357,19:42:treatment,not have received prior radiation therapy to the involved breast at any time for any reason,"['not' 'have' 'received' 'prior' 'radiation' 'therapy' 'to' 'the'
 'involved' 'breast' 'at' 'any' 'time' 'for' 'any' 'reason']",[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02503358,"96:99:cancer,",Measurable disease as defined by RECIST v1.1 criteria. Baseline measurements and evaluation of ALL sites of disease must be obtained within 4 weeks prior to Enrollment,"['Measurable' 'disease' 'as' 'defined' 'by' 'RECIST' 'v1.1' 'criteria' '.'
 'Baseline' 'measurements' 'and' 'evaluation' 'of' 'ALL' 'sites' 'of'
 'disease' 'must' 'be' 'obtained' 'within' '4' 'weeks' 'prior' 'to'
 'Enrollment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT01760655,1:4:cancer,ALL with any morphological evidence of disease will not be eligible,"['ALL' 'with' 'any' 'morphological' 'evidence' 'of' 'disease' 'will' 'not'
 'be' 'eligible']",[3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01614197,"36:39:cancer,",Bone marrow involvement defined as ALL ≥ 25% blasts (M2 or M3) with or without extramedullary involvement,"['Bone' 'marrow' 'involvement' 'defined' 'as' 'ALL' '≥' '25' '%' 'blasts'
 '(' 'M2' 'or' 'M3' ')' 'with' 'or' 'without' 'extramedullary'
 'involvement']",[0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01430390,76:79:cancer,Patients will be excluded if they have isolated extra-medullary relapse of ALL,"['Patients' 'will' 'be' 'excluded' 'if' 'they' 'have' 'isolated'
 'extra-medullary' 'relapse' 'of' 'ALL']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT01371630,36:39:cancer,"Patients with previously untreated ALL of pre-B, Philadelphia chromosome (Ph-) negative ALL","['Patients' 'with' 'previously' 'untreated' 'ALL' 'of' 'pre-B' ','
 'Philadelphia' 'chromosome' '(' 'Ph-' ')' 'negative' 'ALL']",[0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02474927,1:12:chronic_disease,Neutropenia,['Neutropenia'],[2.]
NCT02343549,"1:12:chronic_disease,,",Neutropenia (absolute neutrophil count < 1.5 x 103 ),['Neutropenia' '(' 'absolute' 'neutrophil' 'count' '<' '1.5' 'x' '103' ')'],[2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02234934,"1:12:chronic_disease,,","Neutropenia (absolute granulocyte count <1,000/mm3)","['Neutropenia' '(' 'absolute' 'granulocyte' 'count' '<' '1,000/mm3' ')']",[2. 0. 0. 0. 0. 0. 0. 0.]
NCT01597518,"1:12:chronic_disease,,",Neutropenia measured as absolute neutrophil count (ANC) measured in cells per microliter of blood of < 1500 at screening visit,"['Neutropenia' 'measured' 'as' 'absolute' 'neutrophil' 'count' '(' 'ANC'
 ')' 'measured' 'in' 'cells' 'per' 'microliter' 'of' 'blood' 'of' '<'
 '1500' 'at' 'screening' 'visit']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01059786,"1:12:chronic_disease,,",Neutropenia (ANC less than 1000 cells/microl),['Neutropenia' '(' 'ANC' 'less' 'than' '1000' 'cells/microl' ')'],[2. 0. 0. 0. 0. 0. 0. 0.]
NCT02452697,68:89:treatment,Patients likely to have a significantly better durable response to allogeneic transplant alone (better than 60% progression free longer than 2 years),"['Patients' 'likely' 'to' 'have' 'a' 'significantly' 'better' 'durable'
 'response' 'to' 'allogeneic' 'transplant' 'alone' '(' 'better' 'than'
 '60' '%' 'progression' 'free' 'longer' 'than' '2' 'years' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02165007,7:28:treatment,First allogeneic transplant,['First' 'allogeneic' 'transplant'],[0. 1. 1.]
NCT02162511,37:58:treatment,"Participant does not qualify for an allogeneic transplant due to medical screening, underlying disease, or lack of alternative donors","['Participant' 'does' 'not' 'qualify' 'for' 'an' 'allogeneic' 'transplant'
 'due' 'to' 'medical' 'screening' ',' 'underlying' 'disease' ',' 'or'
 'lack' 'of' 'alternative' 'donors']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02140554,21:42:treatment,Prior receipt of an allogeneic transplant,['Prior' 'receipt' 'of' 'an' 'allogeneic' 'transplant'],[0. 0. 0. 0. 1. 1.]
NCT00630565,17:38:treatment,patient refuses allogeneic transplant,['patient' 'refuses' 'allogeneic' 'transplant'],[0. 0. 1. 1.]
NCT02390752,46:55:chronic_disease,Subjects who are wheelchair bound because of paralysis will be considered ambulatory when they are up in their wheelchair,"['Subjects' 'who' 'are' 'wheelchair' 'bound' 'because' 'of' 'paralysis'
 'will' 'be' 'considered' 'ambulatory' 'when' 'they' 'are' 'up' 'in'
 'their' 'wheelchair']",[0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02114229,44:53:chronic_disease,"Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered to be ambulatory for the purpose of assessing the performance score","['Patients' 'who' 'are' 'unable' 'to' 'walk' 'because' 'of' 'paralysis'
 ',' 'but' 'who' 'are' 'up' 'in' 'a' 'wheelchair' ',' 'will' 'be'
 'considered' 'to' 'be' 'ambulatory' 'for' 'the' 'purpose' 'of'
 'assessing' 'the' 'performance' 'score']","[0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02076906,44:53:chronic_disease,"Patients who are unable to walk because of paralysis or motor weakness, but who are up in a wheelchair will be considered ambulatory for the purpose of calculating the performance score","['Patients' 'who' 'are' 'unable' 'to' 'walk' 'because' 'of' 'paralysis'
 'or' 'motor' 'weakness' ',' 'but' 'who' 'are' 'up' 'in' 'a' 'wheelchair'
 'will' 'be' 'considered' 'ambulatory' 'for' 'the' 'purpose' 'of'
 'calculating' 'the' 'performance' 'score']","[0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01570816,"29:38:chronic_disease,",problems walking because of paralysis for more than 6 months,"['problems' 'walking' 'because' 'of' 'paralysis' 'for' 'more' 'than' '6'
 'months']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 0.]
NCT01504373,37:46:chronic_disease,Patients who are receiving chemical paralysis,['Patients' 'who' 'are' 'receiving' 'chemical' 'paralysis'],[0. 0. 0. 0. 0. 2.]
NCT02346253,32:45:treatment,Prior allergic reaction to the study drug(s) involved in this protocol,"['Prior' 'allergic' 'reaction' 'to' 'the' 'study' 'drug' '(' 's' ')'
 'involved' 'in' 'this' 'protocol']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02203513,",,196:209:treatment",All subjects of reproductive potential must also agree to use both a barrier method and a second method of birth control during the course of the study and for four months after the last dose of study drug(s),"['All' 'subjects' 'of' 'reproductive' 'potential' 'must' 'also' 'agree'
 'to' 'use' 'both' 'a' 'barrier' 'method' 'and' 'a' 'second' 'method' 'of'
 'birth' 'control' 'during' 'the' 'course' 'of' 'the' 'study' 'and' 'for'
 'four' 'months' 'after' 'the' 'last' 'dose' 'of' 'study' 'drug' '(' 's'
 ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02131597,",,,,,157:170:treatment",Women who are able to become pregnant and men who can father a child must use birth control while on study and for at least 8 weeks after your last dose of study drug(s),"['Women' 'who' 'are' 'able' 'to' 'become' 'pregnant' 'and' 'men' 'who'
 'can' 'father' 'a' 'child' 'must' 'use' 'birth' 'control' 'while' 'on'
 'study' 'and' 'for' 'at' 'least' '8' 'weeks' 'after' 'your' 'last' 'dose'
 'of' 'study' 'drug' '(' 's' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01822522,",,,,,217:230:treatment,","sexually active participants (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for 6 months after the last dose of study drug(s), even if oral contraceptives are also used","['sexually' 'active' 'participants' '(' 'men' 'and' 'women' ')' 'must'
 'agree' 'to' 'use' 'medically' 'accepted' 'barrier' 'methods' 'of'
 'contraception' '(' 'e.g.' ',' 'male' 'or' 'female' 'condom' ')' 'during'
 'the' 'course' 'of' 'the' 'study' 'and' 'for' '6' 'months' 'after' 'the'
 'last' 'dose' 'of' 'study' 'drug' '(' 's' ')' ',' 'even' 'if' 'oral'
 'contraceptives' 'are' 'also' 'used']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT01639508,",,,,,342:355:treatment,,,,","The subject is capable of understanding and complying with the protocol requirements and has signed the informed consent document. Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (eg, male or female condom) during the course of the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used. All subjects of reproductive potential must agree to use both a barrier method and a second method of birth control. Women of childbearing potential must have a negative pregnancy test at screening","['The' 'subject' 'is' 'capable' 'of' 'understanding' 'and' 'complying'
 'with' 'the' 'protocol' 'requirements' 'and' 'has' 'signed' 'the'
 'informed' 'consent' 'document' '.' 'Sexually' 'active' 'subjects' '('
 'men' 'and' 'women' ')' 'must' 'agree' 'to' 'use' 'medically' 'accepted'
 'barrier' 'methods' 'of' 'contraception' '(' 'eg' ',' 'male' 'or'
 'female' 'condom' ')' 'during' 'the' 'course' 'of' 'the' 'study' 'and'
 'for' '4' 'months' 'after' 'the' 'last' 'dose' 'of' 'study' 'drug' '('
 's' ')' ',' 'even' 'if' 'oral' 'contraceptives' 'are' 'also' 'used' '.'
 'All' 'subjects' 'of' 'reproductive' 'potential' 'must' 'agree' 'to'
 'use' 'both' 'a' 'barrier' 'method' 'and' 'a' 'second' 'method' 'of'
 'birth' 'control' '.' 'Women' 'of' 'childbearing' 'potential' 'must'
 'have' 'a' 'negative' 'pregnancy' 'test' 'at' 'screening']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03185208,1:26:chronic_disease,Major psychiatric illness,['Major' 'psychiatric' 'illness'],[2. 2. 2.]
NCT02706288,1:26:chronic_disease,Major psychiatric illness,['Major' 'psychiatric' 'illness'],[2. 2. 2.]
NCT02563574,1:26:chronic_disease,Major psychiatric illness,['Major' 'psychiatric' 'illness'],[2. 2. 2.]
NCT02137122,1:26:chronic_disease,Major psychiatric illness,['Major' 'psychiatric' 'illness'],[2. 2. 2.]
NCT03179449,27:38:allergy_name,Known hypersensitivity to ferumoxytol or any of its components,"['Known' 'hypersensitivity' 'to' 'ferumoxytol' 'or' 'any' 'of' 'its'
 'components']",[0. 0. 0. 4. 0. 0. 0. 0. 0.]
NCT02857218,40:51:allergy_name,a known history of hypersensitivity to ferumoxytol,['a' 'known' 'history' 'of' 'hypersensitivity' 'to' 'ferumoxytol'],[0. 0. 0. 0. 0. 0. 4.]
NCT02857218,110:121:treatment,because there is an unknown but potential risk for adverse events in nursing infants secondary to the use of ferumoxytol as a contrast agent in the mother,"['because' 'there' 'is' 'an' 'unknown' 'but' 'potential' 'risk' 'for'
 'adverse' 'events' 'in' 'nursing' 'infants' 'secondary' 'to' 'the' 'use'
 'of' 'ferumoxytol' 'as' 'a' 'contrast' 'agent' 'in' 'the' 'mother']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02359097,"27:38:treatment,",Subject who have received ferumoxytol within 3 weeks of study entry,"['Subject' 'who' 'have' 'received' 'ferumoxytol' 'within' '3' 'weeks' 'of'
 'study' 'entry']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT03154476,61:93:treatment,All adult Fontan patients who have no contraindications for magnetic resonance imaging (MRI) will be eligible for the study,"['All' 'adult' 'Fontan' 'patients' 'who' 'have' 'no' 'contraindications'
 'for' 'magnetic' 'resonance' 'imaging' '(' 'MRI' ')' 'will' 'be'
 'eligible' 'for' 'the' 'study']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02217345,22:54:treatment,Contraindications to magnetic resonance imaging (MRI),['Contraindications' 'to' 'magnetic' 'resonance' 'imaging' '(' 'MRI' ')'],[0. 0. 1. 1. 1. 1. 0. 0.]
NCT02133573,31:63:treatment,Maternal contraindication for magnetic resonance imaging (MRI),"['Maternal' 'contraindication' 'for' 'magnetic' 'resonance' 'imaging' '('
 'MRI' ')']",[0. 0. 0. 1. 1. 1. 1. 0. 0.]
NCT02046330,56:88:treatment,Any clinically significant abnormality on preoperative magnetic resonance imaging (MRI),"['Any' 'clinically' 'significant' 'abnormality' 'on' 'preoperative'
 'magnetic' 'resonance' 'imaging' '(' 'MRI' ')']",[0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0.]
NCT03148379,1:23:chronic_disease,inflammatory arthritis,['inflammatory' 'arthritis'],[2. 2.]
NCT02501733,15:37:chronic_disease,Patients with inflammatory arthritis,['Patients' 'with' 'inflammatory' 'arthritis'],[0. 0. 2. 2.]
NCT02219581,15:37:chronic_disease,Patients with inflammatory arthritis,['Patients' 'with' 'inflammatory' 'arthritis'],[0. 0. 2. 2.]
NCT01754298,1:23:chronic_disease,inflammatory arthritis,['inflammatory' 'arthritis'],[2. 2.]
NCT03144206,1:8:cancer,Sarcoma location other than lower extremity,['Sarcoma' 'location' 'other' 'than' 'lower' 'extremity'],[3. 0. 0. 0. 0. 0.]
NCT03144206,1:8:cancer,Sarcoma of lower extremity location,['Sarcoma' 'of' 'lower' 'extremity' 'location'],[3. 0. 0. 0. 0.]
NCT02423863,1:8:cancer,Sarcoma,['Sarcoma'],[3.]
NCT02423863,"1:8:cancer,,",Sarcoma Patients must be 14 years of age or older,['Sarcoma' 'Patients' 'must' 'be' '14' 'years' 'of' 'age' 'or' 'older'],[3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03132636,19:46:treatment,Having received a solid organ transplantation,['Having' 'received' 'a' 'solid' 'organ' 'transplantation'],[0. 0. 0. 1. 1. 1.]
NCT02774421,30:57:treatment,who have previously received solid organ transplantation,['who' 'have' 'previously' 'received' 'solid' 'organ' 'transplantation'],[0. 0. 0. 0. 1. 1. 1.]
NCT02509507,12:39:treatment,history of solid organ transplantation,['history' 'of' 'solid' 'organ' 'transplantation'],[0. 0. 1. 1. 1.]
NCT02354547,30:57:treatment,Patients who have received a solid organ transplantation,['Patients' 'who' 'have' 'received' 'a' 'solid' 'organ' 'transplantation'],[0. 0. 0. 0. 0. 1. 1. 1.]
NCT03127722,15:37:cancer,Subjects with gynecologic malignancy,['Subjects' 'with' 'gynecologic' 'malignancy'],[0. 0. 3. 3.]
NCT03037346,"23:45:cancer,,",Diagnosis of invasive gynecologic malignancy stages 1-4,['Diagnosis' 'of' 'invasive' 'gynecologic' 'malignancy' 'stages' '1-4'],[0. 0. 0. 3. 3. 0. 0.]
NCT02573883,35:57:cancer,Current or prior diagnosis of any gynecologic malignancy,['Current' 'or' 'prior' 'diagnosis' 'of' 'any' 'gynecologic' 'malignancy'],[0. 0. 0. 0. 0. 0. 3. 3.]
NCT02209545,12:34:cancer,history of gynecologic malignancy,['history' 'of' 'gynecologic' 'malignancy'],[0. 0. 3. 3.]
NCT03121352,15:39:cancer,Patients with carcinomatous meningitis,['Patients' 'with' 'carcinomatous' 'meningitis'],[0. 0. 3. 3.]
NCT02576444,12:36:cancer,History of carcinomatous meningitis,['History' 'of' 'carcinomatous' 'meningitis'],[0. 0. 3. 3.]
NCT02091141,12:36:cancer,History of carcinomatous meningitis,['History' 'of' 'carcinomatous' 'meningitis'],[0. 0. 3. 3.]
NCT01928576,28:52:cancer,Patients with a history of carcinomatous meningitis are not eligible,"['Patients' 'with' 'a' 'history' 'of' 'carcinomatous' 'meningitis' 'are'
 'not' 'eligible']",[0. 0. 0. 0. 0. 3. 3. 0. 0. 0.]
NCT03112759,16:36:chronic_disease,Diagnosed with chronic pancreatitis,['Diagnosed' 'with' 'chronic' 'pancreatitis'],[0. 0. 2. 2.]
NCT03112759,62:82:chronic_disease,Participating in another clinical trial for the treatment of chronic pancreatitis at the time of screening,"['Participating' 'in' 'another' 'clinical' 'trial' 'for' 'the' 'treatment'
 'of' 'chronic' 'pancreatitis' 'at' 'the' 'time' 'of' 'screening']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02992483,12:32:chronic_disease,History of chronic pancreatitis,['History' 'of' 'chronic' 'pancreatitis'],[0. 0. 2. 2.]
NCT02979366,11:31:chronic_disease,active or chronic pancreatitis,['active' 'or' 'chronic' 'pancreatitis'],[0. 0. 2. 2.]
NCT03074474,"29:51:treatment,",Subject has participated in another clinical trial within the past 30 days or is currently involved in another clinical trial,"['Subject' 'has' 'participated' 'in' 'another' 'clinical' 'trial' 'within'
 'the' 'past' '30' 'days' 'or' 'is' 'currently' 'involved' 'in' 'another'
 'clinical' 'trial']",[0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02776761,26:48:treatment,Ongoing participation in another clinical trial (subjects continuing through Day 365 will not join other new studies until their final visit),"['Ongoing' 'participation' 'in' 'another' 'clinical' 'trial' '('
 'subjects' 'continuing' 'through' 'Day' '365' 'will' 'not' 'join' 'other'
 'new' 'studies' 'until' 'their' 'final' 'visit' ')']",[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02495545,"18:40:treatment,",Participation in another clinical trial within the past 30 days,"['Participation' 'in' 'another' 'clinical' 'trial' 'within' 'the' 'past'
 '30' 'days']",[0. 0. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02169037,115:137:treatment,"willingness, ability and commitment to participate in baseline and follow-up evaluations without participation in another clinical trial (unless documented approval received from both sponsors)","['willingness' ',' 'ability' 'and' 'commitment' 'to' 'participate' 'in'
 'baseline' 'and' 'follow-up' 'evaluations' 'without' 'participation' 'in'
 'another' 'clinical' 'trial' '(' 'unless' 'documented' 'approval'
 'received' 'from' 'both' 'sponsors' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT03070184,"1:14:chronic_disease,,",Renal disease (eGFR < 60ml/min/1.73m2),['Renal' 'disease' '(' 'eGFR' '<' '60ml/min/1.73m2' ')'],[2. 2. 0. 0. 0. 0. 0.]
NCT02872857,"1:14:chronic_disease,,",Renal disease as defined by creatinine clearance less than 9 milliliters/min,"['Renal' 'disease' 'as' 'defined' 'by' 'creatinine' 'clearance' 'less'
 'than' '9' 'milliliters/min']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00739362,"1:14:chronic_disease,,",Renal disease (serum creatinine concentrations greater than or equal to 1.5 mg/dl and/or overt proteinuria),"['Renal' 'disease' '(' 'serum' 'creatinine' 'concentrations' 'greater'
 'than' 'or' 'equal' 'to' '1.5' 'mg/dl' 'and/or' 'overt' 'proteinuria' ')']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00716066,"1:14:chronic_disease,,,,",Renal disease with estimated glomerular filtration rate (GFR) by creatinine clearance or iothalamate clearance < 50 ml/min/1.73 m^2 body surface area,"['Renal' 'disease' 'with' 'estimated' 'glomerular' 'filtration' 'rate' '('
 'GFR' ')' 'by' 'creatinine' 'clearance' 'or' 'iothalamate' 'clearance'
 '<' '50' 'ml/min/1.73' 'm^2' 'body' 'surface' 'area']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03058679,1:15:chronic_disease,Celiac disease,['Celiac' 'disease'],[2. 2.]
NCT03035799,7:21:chronic_disease,Known Celiac disease,['Known' 'Celiac' 'disease'],[0. 2. 2.]
NCT02778867,1:15:chronic_disease,Celiac disease,['Celiac' 'disease'],[2. 2.]
NCT02202681,",50:64:chronic_disease",Subjects must be over 16 years for patients with Celiac disease,"['Subjects' 'must' 'be' 'over' '16' 'years' 'for' 'patients' 'with'
 'Celiac' 'disease']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT03041441,1:9:treatment,sedation,['sedation'],[1.]
NCT02410707,",,,106:114:treatment","American Society of Anesthesiologists (ASA) Physical Status Classification 1 or 2, who will be receiving sedation for an Emergency Department procedure","['American' 'Society' 'of' 'Anesthesiologists' '(' 'ASA' ')' 'Physical'
 'Status' 'Classification' '1' 'or' '2' ',' 'who' 'will' 'be' 'receiving'
 'sedation' 'for' 'an' 'Emergency' 'Department' 'procedure']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT01389024,",,34:42:treatment",Temperature >38˚ C on the day of sedation,['Temperature' '>' '38˚' 'C' 'on' 'the' 'day' 'of' 'sedation'],[0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01389024,51:59:treatment,The parents or guardians must provide consent for sedation,"['The' 'parents' 'or' 'guardians' 'must' 'provide' 'consent' 'for'
 'sedation']",[0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT03036280,"48:73:chronic_disease,","Participants who have a history of moderate to severe hepatic impairment (eg, Child-Pugh Class B or C)","['Participants' 'who' 'have' 'a' 'history' 'of' 'moderate' 'to' 'severe'
 'hepatic' 'impairment' '(' 'eg' ',' 'Child-Pugh' 'Class' 'B' 'or' 'C' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02496585,15:40:chronic_disease,Patients with severe hepatic impairment,['Patients' 'with' 'severe' 'hepatic' 'impairment'],[0. 0. 2. 2. 2.]
NCT02340156,13:38:chronic_disease,Moderate to severe hepatic impairment,['Moderate' 'to' 'severe' 'hepatic' 'impairment'],[0. 0. 2. 2. 2.]
NCT02048722,"15:40:chronic_disease,",Patients with severe hepatic impairment (Child-Pugh class C),"['Patients' 'with' 'severe' 'hepatic' 'impairment' '(' 'Child-Pugh'
 'class' 'C' ')']",[0. 0. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT03016351,"1:12:chronic_disease,",Head injury within last 6 months,['Head' 'injury' 'within' 'last' '6' 'months'],[2. 2. 0. 0. 0. 0.]
NCT03004807,"1:12:chronic_disease,,",Head injury with loss of consciousness of > 5 minutes in the last 5 years,"['Head' 'injury' 'with' 'loss' 'of' 'consciousness' 'of' '>' '5' 'minutes'
 'in' 'the' 'last' '5' 'years']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02418195,"1:12:chronic_disease,",Head injury of loss of consciousness in the past 6 months,"['Head' 'injury' 'of' 'loss' 'of' 'consciousness' 'in' 'the' 'past' '6'
 'months']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01869322,1:12:chronic_disease,Head injury,['Head' 'injury'],[2. 2.]
NCT03000998,63:74:treatment,the participant has already received any or all doses for the HPV vaccine,"['the' 'participant' 'has' 'already' 'received' 'any' 'or' 'all' 'doses'
 'for' 'the' 'HPV' 'vaccine']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02994290,42:53:treatment,Have not already received 3 doses of the HPV vaccine at time of delivery,"['Have' 'not' 'already' 'received' '3' 'doses' 'of' 'the' 'HPV' 'vaccine'
 'at' 'time' 'of' 'delivery']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0.]
NCT02864147,"48:59:treatment,,",Patients who have received their first dose of HPV vaccine < 4 weeks ago or their second dose < 12 weeks ago,"['Patients' 'who' 'have' 'received' 'their' 'first' 'dose' 'of' 'HPV'
 'vaccine' '<' '4' 'weeks' 'ago' 'or' 'their' 'second' 'dose' '<' '12'
 'weeks' 'ago']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02382419,17:28:treatment,Prior use of an HPV vaccine,['Prior' 'use' 'of' 'an' 'HPV' 'vaccine'],[0. 0. 0. 0. 1. 1.]
NCT02985554,15:31:chronic_disease,patients with Gilbert Syndrome,['patients' 'with' 'Gilbert' 'Syndrome'],[0. 0. 2. 2.]
NCT02259621,",,51:67:chronic_disease,,","Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)","['Total' 'Bilirubin' '≤' '1.5' 'x' 'ULN' '(' 'except' 'subjects' 'with'
 'Gilbert' 'Syndrome' ',' 'who' 'can' 'have' 'total' 'bilirubin' '<' '3.0'
 'mg/dL' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02124902,",,,,158:174:chronic_disease",Serum bilirubin within (or under ) normal limits (OR total bilirubin ≤ 3.0 x IULN with direct bilirubin within normal range in patients with well documented Gilbert Syndrome),"['Serum' 'bilirubin' 'within' '(' 'or' 'under' ')' 'normal' 'limits' '('
 'OR' 'total' 'bilirubin' '≤' '3.0' 'x' 'IULN' 'with' 'direct' 'bilirubin'
 'within' 'normal' 'range' 'in' 'patients' 'with' 'well' 'documented'
 'Gilbert' 'Syndrome' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 2. 2. 0.]"
NCT01990209,"24:40:chronic_disease,,,,","in patients with known Gilbert Syndrome, a total bilirubin ≤3.0 x ULN, with direct bilirubin ≤1.5 x ULN","['in' 'patients' 'with' 'known' 'Gilbert' 'Syndrome' ',' 'a' 'total'
 'bilirubin' '≤3.0' 'x' 'ULN' ',' 'with' 'direct' 'bilirubin' '≤1.5' 'x'
 'ULN']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02957149,32:56:cancer,Metastatic or locally advanced prostatic adenocarcinoma on preoperative evaluation,"['Metastatic' 'or' 'locally' 'advanced' 'prostatic' 'adenocarcinoma' 'on'
 'preoperative' 'evaluation']",[0. 0. 0. 0. 3. 3. 0. 0. 0.]
NCT02957149,39:63:cancer,"Newly diagnosed, clinically localized prostatic adenocarcinoma","['Newly' 'diagnosed' ',' 'clinically' 'localized' 'prostatic'
 'adenocarcinoma']",[0. 0. 0. 0. 0. 3. 3.]
NCT02064036,"70:94:cancer,",Pathologically (histologically or cytologically) proven diagnosis of prostatic adenocarcinoma within 180 days of registration at moderate to high risk for recurrence,"['Pathologically' '(' 'histologically' 'or' 'cytologically' ')' 'proven'
 'diagnosis' 'of' 'prostatic' 'adenocarcinoma' 'within' '180' 'days' 'of'
 'registration' 'at' 'moderate' 'to' 'high' 'risk' 'for' 'recurrence']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02040610,"51:75:cancer,",Pathological (histologically) proven diagnosis of prostatic adenocarcinoma within 365 days (1 year),"['Pathological' '(' 'histologically' ')' 'proven' 'diagnosis' 'of'
 'prostatic' 'adenocarcinoma' 'within' '365' 'days' '(' '1' 'year' ')']",[0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT02932280,"1:9:cancer,",Leukemia patients must have >10% blasts (or blast equivalent) in the bone marrow,"['Leukemia' 'patients' 'must' 'have' '>' '10' '%' 'blasts' '(' 'or'
 'blast' 'equivalent' ')' 'in' 'the' 'bone' 'marrow']",[3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01920737,1:9:cancer,"Leukemia cell samples will be obtained from all patients enrolled before starting protocol treatment and submitted for Philadelphia chromosome testing by either karyotyping, or for bcr/abl1 translocation by FISH or by PCR for bcr/abl1","['Leukemia' 'cell' 'samples' 'will' 'be' 'obtained' 'from' 'all'
 'patients' 'enrolled' 'before' 'starting' 'protocol' 'treatment' 'and'
 'submitted' 'for' 'Philadelphia' 'chromosome' 'testing' 'by' 'either'
 'karyotyping' ',' 'or' 'for' 'bcr/abl1' 'translocation' 'by' 'FISH' 'or'
 'by' 'PCR' 'for' 'bcr/abl1']","[3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01773395,1:9:cancer,Leukemia with active CNS involvement,['Leukemia' 'with' 'active' 'CNS' 'involvement'],[3. 0. 0. 0. 0.]
NCT01614197,1:9:cancer,Leukemia,['Leukemia'],[3.]
NCT02923921,27:55:chronic_disease,History of positivity for human immunodeficiency virus,['History' 'of' 'positivity' 'for' 'human' 'immunodeficiency' 'virus'],[0. 0. 0. 0. 2. 2. 2.]
NCT02474667,21:49:chronic_disease,History of positive human immunodeficiency virus test,['History' 'of' 'positive' 'human' 'immunodeficiency' 'virus' 'test'],[0. 0. 0. 2. 2. 2. 0.]
NCT01865162,12:40:chronic_disease,History of human immunodeficiency virus,['History' 'of' 'human' 'immunodeficiency' 'virus'],[0. 0. 2. 2. 2.]
NCT00293475,24:52:chronic_disease,Seropositivity for the human immunodeficiency virus,['Seropositivity' 'for' 'the' 'human' 'immunodeficiency' 'virus'],[0. 0. 0. 2. 2. 2.]
NCT02918981,1:19:chronic_disease,Autoimmune disease,['Autoimmune' 'disease'],[2. 2.]
NCT02061761,1:19:chronic_disease,Autoimmune disease,['Autoimmune' 'disease'],[2. 2.]
NCT01968109,1:19:chronic_disease,Autoimmune disease,['Autoimmune' 'disease'],[2. 2.]
NCT00788164,1:19:chronic_disease,Autoimmune disease,['Autoimmune' 'disease'],[2. 2.]
NCT02908906,9:29:treatment,limited palliative radiation,['limited' 'palliative' 'radiation'],[0. 1. 1.]
NCT02553642,33:53:treatment,The lesion being considered for palliative radiation is not a target lesion,"['The' 'lesion' 'being' 'considered' 'for' 'palliative' 'radiation' 'is'
 'not' 'a' 'target' 'lesion']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02535533,21:41:treatment,3 days wash out for palliative radiation,['3' 'days' 'wash' 'out' 'for' 'palliative' 'radiation'],[0. 0. 0. 0. 0. 1. 1.]
NCT02408861,33:53:treatment,The lesion being considered for palliative radiation is not a target lesion,"['The' 'lesion' 'being' 'considered' 'for' 'palliative' 'radiation' 'is'
 'not' 'a' 'target' 'lesion']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02895945,29:51:treatment,scheduled to participate in another clinical study involving an investigational product (IP) or investigational device during the course of this study,"['scheduled' 'to' 'participate' 'in' 'another' 'clinical' 'study'
 'involving' 'an' 'investigational' 'product' '(' 'IP' ')' 'or'
 'investigational' 'device' 'during' 'the' 'course' 'of' 'this' 'study']",[0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02479906,"39:61:treatment,",Subject is currently participating in another clinical study or enrolled in another clinical study within 30 days prior to this study,"['Subject' 'is' 'currently' 'participating' 'in' 'another' 'clinical'
 'study' 'or' 'enrolled' 'in' 'another' 'clinical' 'study' 'within' '30'
 'days' 'prior' 'to' 'this' 'study']",[0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02335242,18:40:treatment,Participating in another clinical study which may interfere,"['Participating' 'in' 'another' 'clinical' 'study' 'which' 'may'
 'interfere']",[0. 0. 1. 1. 1. 0. 0. 0.]
NCT01726257,32:54:treatment,Participating in enrollment of another clinical study,['Participating' 'in' 'enrollment' 'of' 'another' 'clinical' 'study'],[0. 0. 0. 0. 1. 1. 1.]
NCT02875301,1:32:treatment,coronary artery bypass grafting,['coronary' 'artery' 'bypass' 'grafting'],[1. 1. 1. 1.]
NCT02816736,1:32:treatment,coronary artery bypass grafting,['coronary' 'artery' 'bypass' 'grafting'],[1. 1. 1. 1.]
NCT02664909,11:42:treatment,undergone coronary artery bypass grafting,['undergone' 'coronary' 'artery' 'bypass' 'grafting'],[0. 1. 1. 1. 1.]
NCT02276456,23:54:treatment,Patients treated with coronary artery bypass grafting will be excluded for the purposes of this trial to avoid conflicts with usual post-operative management,"['Patients' 'treated' 'with' 'coronary' 'artery' 'bypass' 'grafting'
 'will' 'be' 'excluded' 'for' 'the' 'purposes' 'of' 'this' 'trial' 'to'
 'avoid' 'conflicts' 'with' 'usual' 'post-operative' 'management']",[0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02864160,21:41:chronic_disease,Clinic diagnosis of diabetic retinopathy,['Clinic' 'diagnosis' 'of' 'diabetic' 'retinopathy'],[0. 0. 0. 2. 2.]
NCT02841540,1:21:chronic_disease,diabetic retinopathy,['diabetic' 'retinopathy'],[2. 2.]
NCT02402660,1:21:chronic_disease,diabetic retinopathy,['diabetic' 'retinopathy'],[2. 2.]
NCT01474889,25:45:chronic_disease,Untreated proliferative diabetic retinopathy,['Untreated' 'proliferative' 'diabetic' 'retinopathy'],[0. 0. 2. 2.]
NCT02856594,24:42:treatment,Scheduled for a second surgical procedure during hospital stay,"['Scheduled' 'for' 'a' 'second' 'surgical' 'procedure' 'during' 'hospital'
 'stay']",[0. 0. 0. 0. 1. 1. 0. 0. 0.]
NCT02555280,",15:33:treatment",More than one surgical procedure at any combination of lumbar levels,"['More' 'than' 'one' 'surgical' 'procedure' 'at' 'any' 'combination' 'of'
 'lumbar' 'levels']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02252081,"27:45:treatment,",Recent hospitalization or surgical procedure within 1 month prior to the study for any cause,"['Recent' 'hospitalization' 'or' 'surgical' 'procedure' 'within' '1'
 'month' 'prior' 'to' 'the' 'study' 'for' 'any' 'cause']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01959204,"21:39:treatment,",an outpatient for a surgical procedure and is expected to remain hospitalized for at least 24 hours after dosing with study drug,"['an' 'outpatient' 'for' 'a' 'surgical' 'procedure' 'and' 'is' 'expected'
 'to' 'remain' 'hospitalized' 'for' 'at' 'least' '24' 'hours' 'after'
 'dosing' 'with' 'study' 'drug']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02822378,"1:16:treatment,,,","bisphosphonates, parathyroid hormone or strontium within the past 12 months","['bisphosphonates' ',' 'parathyroid' 'hormone' 'or' 'strontium' 'within'
 'the' 'past' '12' 'months']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02128230,1:16:treatment,bisphosphonates,['bisphosphonates'],[1.]
NCT02107703,16:31:treatment,Have initiated bisphosphonates,['Have' 'initiated' 'bisphosphonates'],[0. 0. 1.]
NCT01554371,20:35:treatment,Concomitant use of bisphosphonates,['Concomitant' 'use' 'of' 'bisphosphonates'],[0. 0. 0. 1.]
NCT02793921,1:18:chronic_disease,pulmonary disease,['pulmonary' 'disease'],[2. 2.]
NCT02663934,1:18:chronic_disease,pulmonary disease that precludes ability to safely exercise,"['pulmonary' 'disease' 'that' 'precludes' 'ability' 'to' 'safely'
 'exercise']",[2. 2. 0. 0. 0. 0. 0. 0.]
NCT02154568,21:38:chronic_disease,Negative history of pulmonary disease,['Negative' 'history' 'of' 'pulmonary' 'disease'],[0. 0. 0. 2. 2.]
NCT00065676,1:18:chronic_disease,pulmonary disease,['pulmonary' 'disease'],[2. 2.]
NCT02744430,",,,59:66:treatment",Single unilateral ureteral calculus 4 to 10 mm visible on CT scan within the ureter,"['Single' 'unilateral' 'ureteral' 'calculus' '4' 'to' '10' 'mm' 'visible'
 'on' 'CT' 'scan' 'within' 'the' 'ureter']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.]
NCT02584309,",147:154:treatment,","measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 10 mm with CT scan, as ≥ 20 mm by chest x-ray, or ≥ 10 mm with calipers by clinical exam","['measurable' 'disease' 'defined' 'as' 'lesions' 'that' 'can' 'be'
 'accurately' 'measured' 'in' 'at' 'least' 'one' 'dimension' '(' 'longest'
 'diameter' 'to' 'be' 'recorded' ')' 'as' '≥' '10' 'mm' 'with' 'CT' 'scan'
 ',' 'as' '≥' '20' 'mm' 'by' 'chest' 'x-ray' ',' 'or' '≥' '10' 'mm' 'with'
 'calipers' 'by' 'clinical' 'exam']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02290951,",,,82:89:treatment",Must have at least one bi-dimensionally measurable lesion ≥1.5 cm) documented by CT scan,"['Must' 'have' 'at' 'least' 'one' 'bi-dimensionally' 'measurable' 'lesion'
 '≥1.5' 'cm' ')' 'documented' 'by' 'CT' 'scan']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02210650,"9:16:treatment,",Current CT scan within the 90-day pre-operative period,['Current' 'CT' 'scan' 'within' 'the' '90-day' 'pre-operative' 'period'],[0. 1. 1. 0. 0. 0. 0. 0.]
NCT02675114,"16:43:chronic_disease,",Evidence of an acute myocardial infarction ≤ 1 month (30 days) before randomization,"['Evidence' 'of' 'an' 'acute' 'myocardial' 'infarction' '≤' '1' 'month'
 '(' '30' 'days' ')' 'before' 'randomization']",[0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02637947,"20:47:chronic_disease,",subject has had an acute myocardial infarction within 30 days prior to enrollment,"['subject' 'has' 'had' 'an' 'acute' 'myocardial' 'infarction' 'within'
 '30' 'days' 'prior' 'to' 'enrollment']",[0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02277613,39:66:chronic_disease,Mechanical complications of the index acute myocardial infarction,"['Mechanical' 'complications' 'of' 'the' 'index' 'acute' 'myocardial'
 'infarction']",[0. 0. 0. 0. 0. 2. 2. 2.]
NCT02188745,1:28:chronic_disease,acute myocardial infarction,['acute' 'myocardial' 'infarction'],[2. 2. 2.]
NCT02650206,1:23:chronic_disease,Cardiovascular disease,['Cardiovascular' 'disease'],[2. 2.]
NCT02533882,"1:23:chronic_disease,",Cardiovascular disease event within the past six months,['Cardiovascular' 'disease' 'event' 'within' 'the' 'past' 'six' 'months'],[2. 2. 0. 0. 0. 0. 0. 0.]
NCT02519322,1:23:chronic_disease,Cardiovascular disease-related requirement for daily supplemental oxygen,"['Cardiovascular' 'disease-related' 'requirement' 'for' 'daily'
 'supplemental' 'oxygen']",[2. 2. 0. 0. 0. 0. 0.]
NCT02143726,1:23:chronic_disease,Cardiovascular disease,['Cardiovascular' 'disease'],[2. 2.]
NCT02589977,21:37:chronic_disease,moderate or greater valvular disease,['moderate' 'or' 'greater' 'valvular' 'disease'],[0. 0. 0. 2. 2.]
NCT02503722,13:29:chronic_disease,Significant valvular disease,['Significant' 'valvular' 'disease'],[0. 2. 2.]
NCT02053246,9:25:chronic_disease,Primary valvular disease,['Primary' 'valvular' 'disease'],[0. 2. 2.]
NCT02006069,9:25:chronic_disease,Primary valvular disease,['Primary' 'valvular' 'disease'],[0. 2. 2.]
NCT02577406,39:76:cancer,Subject has or is suspected of having central nervous system (CNS) leukemia,"['Subject' 'has' 'or' 'is' 'suspected' 'of' 'having' 'central' 'nervous'
 'system' '(' 'CNS' ')' 'leukemia']",[0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 0. 0.]
NCT02520011,13:50:cancer,Have active central nervous system (CNS) leukemia,['Have' 'active' 'central' 'nervous' 'system' '(' 'CNS' ')' 'leukemia'],[0. 0. 3. 3. 3. 3. 3. 0. 0.]
NCT02400255,25:62:cancer,Active and/or untreated central nervous system (CNS) leukemia,"['Active' 'and/or' 'untreated' 'central' 'nervous' 'system' '(' 'CNS' ')'
 'leukemia']",[0. 0. 0. 3. 3. 3. 3. 3. 0. 0.]
NCT02152956,7:44:cancer,Known central nervous system (CNS) leukemia,['Known' 'central' 'nervous' 'system' '(' 'CNS' ')' 'leukemia'],[0. 3. 3. 3. 3. 3. 0. 0.]
NCT02564744,122:130:cancer,Participants must have evaluable or measurable disease in accordance with the International Working Group Guidelines for Lymphoma,"['Participants' 'must' 'have' 'evaluable' 'or' 'measurable' 'disease' 'in'
 'accordance' 'with' 'the' 'International' 'Working' 'Group' 'Guidelines'
 'for' 'Lymphoma']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT02512926,1:9:cancer,Lymphoma patients are permitted,['Lymphoma' 'patients' 'are' 'permitted'],[3. 0. 0. 0.]
NCT02167958,1:9:cancer,Lymphoma,['Lymphoma'],[3.]
NCT01614197,1:9:cancer,Lymphoma,['Lymphoma'],[3.]
NCT02553161,"13:31:chronic_disease,,","evidence of mental retardation (IQ < 70) as determined by the Weschler Abbreviated Scale of Intelligence (WASI; Psychological Corporation, 1999)","['evidence' 'of' 'mental' 'retardation' '(' 'IQ' '<' '70' ')' 'as'
 'determined' 'by' 'the' 'Weschler' 'Abbreviated' 'Scale' 'of'
 'Intelligence' '(' 'WASI' ';' 'Psychological' 'Corporation' ',' '1999'
 ')']","[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02361554,28:46:chronic_disease,Subject has a diagnosis of mental retardation,['Subject' 'has' 'a' 'diagnosis' 'of' 'mental' 'retardation'],[0. 0. 0. 0. 0. 2. 2.]
NCT02346929,1:19:chronic_disease,mental retardation,['mental' 'retardation'],[2. 2.]
NCT02155699,1:19:chronic_disease,mental retardation,['mental' 'retardation'],[2. 2.]
NCT02522429,13:15:treatment,an abnormal CT,['an' 'abnormal' 'CT'],[0. 0. 1.]
NCT02469129,",,36:38:treatment",Non-measurable disease (< 1 cm) by CT (Kinetic Studies Arm only; disease-free participants can be enrolled in the Dosimetry Studies Arm),"['Non-measurable' 'disease' '(' '<' '1' 'cm' ')' 'by' 'CT' '(' 'Kinetic'
 'Studies' 'Arm' 'only' ';' 'disease-free' 'participants' 'can' 'be'
 'enrolled' 'in' 'the' 'Dosimetry' 'Studies' 'Arm' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02232516,",,69:71:treatment",Patients must have bi-dimensionally measurable disease (>= 1 cm) by CT imaging,"['Patients' 'must' 'have' 'bi-dimensionally' 'measurable' 'disease' '('
 '>' '=' '1' 'cm' ')' 'by' 'CT' 'imaging']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT00492778,"3:5:treatment,",a CT of the pelvis and abdomen with IV and oral (PO) contrast performed using multi-detector CT and equal or less than 5 mm slice thickness,"['a' 'CT' 'of' 'the' 'pelvis' 'and' 'abdomen' 'with' 'IV' 'and' 'oral' '('
 'PO' ')' 'contrast' 'performed' 'using' 'multi-detector' 'CT' 'and'
 'equal' 'or' 'less' 'than' '5' 'mm' 'slice' 'thickness']","[0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02512926,",,53:72:treatment",Pulse Oximetry measurement ≥ 95% saturation without supplemental oxygen,"['Pulse' 'Oximetry' 'measurement' '≥' '95' '%' 'saturation' 'without'
 'supplemental' 'oxygen']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02508038,4:23:treatment,No supplemental oxygen requirement,['No' 'supplemental' 'oxygen' 'requirement'],[0. 1. 1. 0.]
NCT02208362,"31:50:treatment,,,",Research participant requires supplemental oxygen to keep saturation greater than 95% and the situation is not expected to resolve within 2 weeks,"['Research' 'participant' 'requires' 'supplemental' 'oxygen' 'to' 'keep'
 'saturation' 'greater' 'than' '95' '%' 'and' 'the' 'situation' 'is' 'not'
 'expected' 'to' 'resolve' 'within' '2' 'weeks']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02129803,18:37:treatment,Subject requires supplemental oxygen,['Subject' 'requires' 'supplemental' 'oxygen'],[0. 0. 1. 1.]
NCT02496208,1:28:chronic_disease,Active peptic ulcer disease,['Active' 'peptic' 'ulcer' 'disease'],[2. 2. 2. 2.]
NCT02072148,1:28:chronic_disease,Active peptic ulcer disease defined as unhealed or clinically active,"['Active' 'peptic' 'ulcer' 'disease' 'defined' 'as' 'unhealed' 'or'
 'clinically' 'active']",[2. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT01822522,1:28:chronic_disease,Active peptic ulcer disease,['Active' 'peptic' 'ulcer' 'disease'],[2. 2. 2. 2.]
NCT01532687,1:28:chronic_disease,Active peptic ulcer disease,['Active' 'peptic' 'ulcer' 'disease'],[2. 2. 2. 2.]
NCT02479620,1:14:chronic_disease,osteomyelitis of the metatarsal or more proximal region,['osteomyelitis' 'of' 'the' 'metatarsal' 'or' 'more' 'proximal' 'region'],[2. 0. 0. 0. 0. 0. 0. 0.]
NCT02335905,108:121:chronic_disease,Requirement for other reasons for another antibiotic potentially active against organisms commonly causing osteomyelitis in children,"['Requirement' 'for' 'other' 'reasons' 'for' 'another' 'antibiotic'
 'potentially' 'active' 'against' 'organisms' 'commonly' 'causing'
 'osteomyelitis' 'in' 'children']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0.]
NCT02099240,32:45:chronic_disease,Pathology report indicative of osteomyelitis,['Pathology' 'report' 'indicative' 'of' 'osteomyelitis'],[0. 0. 0. 0. 2.]
NCT02015390,14:27:chronic_disease,Disseminated osteomyelitis throughout the bone,['Disseminated' 'osteomyelitis' 'throughout' 'the' 'bone'],[0. 2. 0. 0. 0.]
NCT02465060,20:44:chronic_disease,"a patient with any gastrointestinal disease that would impair ability to swallow, retain, or absorb drug is not eligible","['a' 'patient' 'with' 'any' 'gastrointestinal' 'disease' 'that' 'would'
 'impair' 'ability' 'to' 'swallow' ',' 'retain' ',' 'or' 'absorb' 'drug'
 'is' 'not' 'eligible']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02352025,70:94:chronic_disease,Patients may not have any impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of the study drug,"['Patients' 'may' 'not' 'have' 'any' 'impairment' 'of' 'gastrointestinal'
 'function' 'or' 'gastrointestinal' 'disease' 'that' 'may' 'significantly'
 'alter' 'the' 'absorption' 'of' 'the' 'study' 'drug']",[0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01989546,5:29:chronic_disease,"Any gastrointestinal disease which would impair ability to swallow, retain, or absorb drug is not allowed","['Any' 'gastrointestinal' 'disease' 'which' 'would' 'impair' 'ability'
 'to' 'swallow' ',' 'retain' ',' 'or' 'absorb' 'drug' 'is' 'not' 'allowed']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01943851,13:37:chronic_disease,Presence of gastrointestinal disease that would significantly affect compound absorption,"['Presence' 'of' 'gastrointestinal' 'disease' 'that' 'would'
 'significantly' 'affect' 'compound' 'absorption']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02385110,85:88:chronic_disease,It must be noted that no diagnostic criteria have been established for diagnosis of HLH in adult patients as this was a hitherto poorly identified and considered to be a very rare disease in adults,"['It' 'must' 'be' 'noted' 'that' 'no' 'diagnostic' 'criteria' 'have'
 'been' 'established' 'for' 'diagnosis' 'of' 'HLH' 'in' 'adult' 'patients'
 'as' 'this' 'was' 'a' 'hitherto' 'poorly' 'identified' 'and' 'considered'
 'to' 'be' 'a' 'very' 'rare' 'disease' 'in' 'adults']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02385110,73:76:chronic_disease,The diagnostic criteria that have been traditionally used for children (HLH 1991 and HLH 2004) may not adequately diagnose HLH in adults,"['The' 'diagnostic' 'criteria' 'that' 'have' 'been' 'traditionally' 'used'
 'for' 'children' '(' 'HLH' '1991' 'and' 'HLH' '2004' ')' 'may' 'not'
 'adequately' 'diagnose' 'HLH' 'in' 'adults']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02385110,"47:50:chronic_disease,",We have seen an increasing number of cases of HLH at our institution over the last 2 years partly due to referrals and partly due to better understanding of the disease through discussions with our collaborators Dr Kenneth McClain and Dr Carl Allen at TCH (experts in pediatric HLH),"['We' 'have' 'seen' 'an' 'increasing' 'number' 'of' 'cases' 'of' 'HLH'
 'at' 'our' 'institution' 'over' 'the' 'last' '2' 'years' 'partly' 'due'
 'to' 'referrals' 'and' 'partly' 'due' 'to' 'better' 'understanding' 'of'
 'the' 'disease' 'through' 'discussions' 'with' 'our' 'collaborators' 'Dr'
 'Kenneth' 'McClain' 'and' 'Dr' 'Carl' 'Allen' 'at' 'TCH' '(' 'experts'
 'in' 'pediatric' 'HLH' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02007239,",46:49:chronic_disease","Fulfill the clinical diagnostic criteria for HLH, as defined by the Histiocyte Society (see Table 1). Only patients with de novo HLH are eligible","['Fulfill' 'the' 'clinical' 'diagnostic' 'criteria' 'for' 'HLH' ',' 'as'
 'defined' 'by' 'the' 'Histiocyte' 'Society' '(' 'see' 'Table' '1' ')' '.'
 'Only' 'patients' 'with' 'de' 'novo' 'HLH' 'are' 'eligible']","[0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02358187,"1:15:treatment,",corticosteroid for at least one week prior to study registration,"['corticosteroid' 'for' 'at' 'least' 'one' 'week' 'prior' 'to' 'study'
 'registration']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02271711,9:23:treatment,Chronic corticosteroid dependence,['Chronic' 'corticosteroid' 'dependence'],[0. 1. 0.]
NCT01754298,22:36:treatment,History of prolonged corticosteroid,['History' 'of' 'prolonged' 'corticosteroid'],[0. 0. 0. 1.]
NCT01524536,23:37:treatment,subjects on a current corticosteroid taper,['subjects' 'on' 'a' 'current' 'corticosteroid' 'taper'],[0. 0. 0. 0. 1. 0.]
NCT02343549,1:22:cancer,Infra-tentorial tumor,['Infra-tentorial' 'tumor'],[3. 3.]
NCT01954576,1:22:cancer,Infra-tentorial tumor,['Infra-tentorial' 'tumor'],[3. 3.]
NCT01925573,1:22:cancer,Infra-tentorial tumor,['Infra-tentorial' 'tumor'],[3. 3.]
NCT01894061,1:22:cancer,Infra-tentorial tumor,['Infra-tentorial' 'tumor'],[3. 3.]
NCT02266719,1:27:chronic_disease,Uncorrectable coagulopathy,['Uncorrectable' 'coagulopathy'],[2. 2.]
NCT02089607,1:27:chronic_disease,Uncorrectable coagulopathy,['Uncorrectable' 'coagulopathy'],[2. 2.]
NCT02050113,1:27:chronic_disease,Uncorrectable coagulopathy,['Uncorrectable' 'coagulopathy'],[2. 2.]
NCT00488696,1:27:chronic_disease,Uncorrectable coagulopathy,['Uncorrectable' 'coagulopathy'],[2. 2.]
NCT02223520,39:56:treatment,Allergies to any agent used in either treatment regimen,['Allergies' 'to' 'any' 'agent' 'used' 'in' 'either' 'treatment' 'regimen'],[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01968109,",58:75:treatment","Progressed, or been intolerant to, at least one standard treatment regimen, except for subjects in 1st line cohorts","['Progressed' ',' 'or' 'been' 'intolerant' 'to' ',' 'at' 'least' 'one'
 'standard' 'treatment' 'regimen' ',' 'except' 'for' 'subjects' 'in' '1st'
 'line' 'cohorts']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01618357,",87:104:treatment",Patients must not be pregnant due to the potential for fetal harm as a result of this treatment regimen,"['Patients' 'must' 'not' 'be' 'pregnant' 'due' 'to' 'the' 'potential'
 'for' 'fetal' 'harm' 'as' 'a' 'result' 'of' 'this' 'treatment' 'regimen']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01614197,",,122:139:treatment",Refractory bone marrow involvement defined as MRD ≥ 0.1% blasts done at a COG-approved MRD testing lab after most recent treatment regimen. in the bone marrow (M23) and any CNS status,"['Refractory' 'bone' 'marrow' 'involvement' 'defined' 'as' 'MRD' '≥' '0.1'
 '%' 'blasts' 'done' 'at' 'a' 'COG-approved' 'MRD' 'testing' 'lab' 'after'
 'most' 'recent' 'treatment' 'regimen' '.' 'in' 'the' 'bone' 'marrow' '('
 'M23' ')' 'and' 'any' 'CNS' 'status']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02132598,32:43:chronic_disease,Any history of congenital long QT syndrome,['Any' 'history' 'of' 'congenital' 'long' 'QT' 'syndrome'],[0. 0. 0. 0. 0. 2. 2.]
NCT01639508,32:43:chronic_disease,Any congenital history of long QT syndrome,['Any' 'congenital' 'history' 'of' 'long' 'QT' 'syndrome'],[0. 0. 0. 0. 0. 2. 2.]
NCT01554371,",,68:79:chronic_disease",QTc prolongation >480 msec (Bazett's Formula) or congenitally long QT syndrome,"['QTc' 'prolongation' '>' '480' 'msec' '(' 'Bazett' ""'s"" 'Formula' ')'
 'or' 'congenitally' 'long' 'QT' 'syndrome']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT00872950,14:25:chronic_disease,No prolonged QT syndrome as indicated by baseline EKG,['No' 'prolonged' 'QT' 'syndrome' 'as' 'indicated' 'by' 'baseline' 'EKG'],[0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT01954173,1:18:chronic_disease,immunocompromised patients,['immunocompromised' 'patients'],[2. 0.]
NCT01873131,9:26:chronic_disease,who are immunocompromised,['who' 'are' 'immunocompromised'],[0. 0. 2.]
NCT01220583,49:66:chronic_disease,Protocol-specific requirements may also exclude immunocompromised patients,"['Protocol-specific' 'requirements' 'may' 'also' 'exclude'
 'immunocompromised' 'patients']",[0. 0. 0. 0. 0. 2. 0.]
NCT00670358,5:22:chronic_disease,Not immunocompromised,['Not' 'immunocompromised'],[0. 2.]
NCT03185130,12:37:chronic_disease,History of intracranial hypertension,['History' 'of' 'intracranial' 'hypertension'],[0. 0. 2. 2.]
NCT03179605,38:63:chronic_disease,Subject has a history or presence of intracranial hypertension,"['Subject' 'has' 'a' 'history' 'or' 'presence' 'of' 'intracranial'
 'hypertension']",[0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT01525901,1:26:chronic_disease,intracranial hypertension,['intracranial' 'hypertension'],[2. 2.]
NCT03181516,1:21:chronic_disease,Congenital anomalies,['Congenital' 'anomalies'],[2. 2.]
NCT03019367,1:21:chronic_disease,Congenital anomalies,['Congenital' 'anomalies'],[2. 2.]
NCT02847689,1:21:chronic_disease,Congenital anomalies,['Congenital' 'anomalies'],[2. 2.]
NCT03179397,1:10:chronic_disease,Amblyopia,['Amblyopia'],[2.]
NCT02365090,"1:10:chronic_disease,,,,,,","Amblyopia with amblyopic eye visual acuity 20/40-20/125, fellow eye visual acuity 20/16-20/25,","['Amblyopia' 'with' 'amblyopic' 'eye' 'visual' 'acuity' '20/40-20/125' ','
 'fellow' 'eye' 'visual' 'acuity' '20/16-20/25' ',']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02332369,1:10:chronic_disease,Amblyopia,['Amblyopia'],[2.]
NCT03171480,46:58:chronic_disease,Induction of labor for clinical diagnosis of preeclampsia,['Induction' 'of' 'labor' 'for' 'clinical' 'diagnosis' 'of' 'preeclampsia'],[0. 0. 0. 0. 0. 0. 0. 2.]
NCT02221830,"14:26:chronic_disease,,,,,,,,,,,,","diagnosis of preeclampsia (PE defined using standard definitions based on the ACOG bulletin and the NIH Working Group on High Blood Pressure in Pregnancy (i.e., a systolic blood pressure greater than 140 mm Hg or a diastolic blood pressure greater than 90 mm Hg on at least 2 occasions at least 6 hours apart after 20 weeks gestation and proteinuria of > 300mg per 24 hour period or > 1+ on dipstick)","['diagnosis' 'of' 'preeclampsia' '(' 'PE' 'defined' 'using' 'standard'
 'definitions' 'based' 'on' 'the' 'ACOG' 'bulletin' 'and' 'the' 'NIH'
 'Working' 'Group' 'on' 'High' 'Blood' 'Pressure' 'in' 'Pregnancy' '('
 'i.e.' ',' 'a' 'systolic' 'blood' 'pressure' 'greater' 'than' '140' 'mm'
 'Hg' 'or' 'a' 'diastolic' 'blood' 'pressure' 'greater' 'than' '90' 'mm'
 'Hg' 'on' 'at' 'least' '2' 'occasions' 'at' 'least' '6' 'hours' 'apart'
 'after' '20' 'weeks' 'gestation' 'and' 'proteinuria' 'of' '>' '300mg'
 'per' '24' 'hour' 'period' 'or' '>' '1+' 'on' 'dipstick' ')']","[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT00881660,16:28:chronic_disease,"Preterm labor, preeclampsia","['Preterm' 'labor' ',' 'preeclampsia']",[0. 0. 0. 2.]
NCT03166371,19:37:chronic_disease,other significant movement disorders precluding protocol functional strength testing,"['other' 'significant' 'movement' 'disorders' 'precluding' 'protocol'
 'functional' 'strength' 'testing']",[0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT03053908,7:25:chronic_disease,other movement disorders,['other' 'movement' 'disorders'],[0. 2. 2.]
NCT02261519,"5:23:chronic_disease,,,,","Any movement disorders with a total score higher than 6 on SAS scale, or more than 2 on any items of the AIMS scale","['Any' 'movement' 'disorders' 'with' 'a' 'total' 'score' 'higher' 'than'
 '6' 'on' 'SAS' 'scale' ',' 'or' 'more' 'than' '2' 'on' 'any' 'items' 'of'
 'the' 'AIMS' 'scale']","[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT03153982,1:16:chronic_disease,Acute hepatitis,['Acute' 'hepatitis'],[2. 2.]
NCT02409810,1:16:chronic_disease,Acute hepatitis,['Acute' 'hepatitis'],[2. 2.]
NCT02162420,1:16:chronic_disease,Acute hepatitis,['Acute' 'hepatitis'],[2. 2.]
NCT03149549,12:35:treatment,history of corneal transplantation,['history' 'of' 'corneal' 'transplantation'],[0. 0. 1. 1.]
NCT02138669,10:33:treatment,Who have corneal transplantation as the only remaining option to improve their functional vision,"['Who' 'have' 'corneal' 'transplantation' 'as' 'the' 'only' 'remaining'
 'option' 'to' 'improve' 'their' 'functional' 'vision']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02091999,12:35:treatment,History of corneal transplantation,['History' 'of' 'corneal' 'transplantation'],[0. 0. 1. 1.]
NCT03138733,"1:12:chronic_disease,,",tachycardia (heart rate > 90 bpm),['tachycardia' '(' 'heart' 'rate' '>' '90' 'bpm' ')'],[2. 0. 0. 0. 0. 0. 0. 0.]
NCT02624765,11:22:chronic_disease,Untreated tachycardia at time of enrollment,['Untreated' 'tachycardia' 'at' 'time' 'of' 'enrollment'],[0. 2. 0. 0. 0. 0.]
NCT02624765,1:12:chronic_disease,tachycardia,['tachycardia'],[2.]
NCT03131960,55:64:treatment,"Current requirement, or likely future requirement, of diathermy during the study duration","['Current' 'requirement' ',' 'or' 'likely' 'future' 'requirement' ',' 'of'
 'diathermy' 'during' 'the' 'study' 'duration']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02357784,5:14:treatment,has diathermy,['has' 'diathermy'],[0. 1.]
NCT02046330,35:44:treatment,Presence of a condition requiring diathermy,['Presence' 'of' 'a' 'condition' 'requiring' 'diathermy'],[0. 0. 0. 0. 0. 1.]
NCT03118973,39:43:treatment,Patient has a clinical indication for ERCP,['Patient' 'has' 'a' 'clinical' 'indication' 'for' 'ERCP'],[0. 0. 0. 0. 0. 0. 1.]
NCT03098082,"8:12:treatment,",Recent ERCP (i.e. within 1 month),['Recent' 'ERCP' '(' 'i.e' '.' 'within' '1' 'month' ')'],[0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT03098082,23:27:treatment,Undergoing Outpatient ERCP,['Undergoing' 'Outpatient' 'ERCP'],[0. 0. 1.]
NCT03112590,"26:53:cancer,,,",histologically confirmed HER2 positive breast cancer (by ImmunoHistoChemistry (IHC) 3+ or fluorescence in situ hybridization (FISH) ratio ≥ 2.0),"['histologically' 'confirmed' 'HER2' 'positive' 'breast' 'cancer' '(' 'by'
 'ImmunoHistoChemistry' '(' 'IHC' ')' '3+' 'or' 'fluorescence' 'in' 'situ'
 'hybridization' '(' 'FISH' ')' 'ratio' '≥' '2.0' ')']","[0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02401347,1:28:cancer,HER2 positive breast cancer (Cohort B only),['HER2' 'positive' 'breast' 'cancer' '(' 'Cohort' 'B' 'only' ')'],[3. 3. 3. 3. 0. 0. 0. 0. 0.]
NCT02401347,34:61:cancer,Hormone receptor positive and/or HER2 positive breast cancer (Cohort A only),"['Hormone' 'receptor' 'positive' 'and/or' 'HER2' 'positive' 'breast'
 'cancer' '(' 'Cohort' 'A' 'only' ')']",[0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0.]
NCT03104699,"44:65:allergy_name,,",Known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE grade ≥3),"['Known' 'severe' 'hypersensitivity' 'reactions' 'to' 'monoclonal'
 'antibodies' '(' 'NCI' 'CTCAE' 'grade' '≥3' ')']",[0. 0. 0. 0. 0. 4. 4. 0. 0. 0. 0. 0. 0.]
NCT01676259,1:22:treatment,monoclonal antibodies,['monoclonal' 'antibodies'],[1. 1.]
NCT01473628,37:58:allergy_name,No prior known allergic reaction to monoclonal antibodies,['No' 'prior' 'known' 'allergic' 'reaction' 'to' 'monoclonal' 'antibodies'],[0. 0. 0. 0. 0. 0. 4. 4.]
NCT03096366,12:38:chronic_disease,History of deep vein thrombosis (DVT),['History' 'of' 'deep' 'vein' 'thrombosis' '(' 'DVT' ')'],[0. 0. 2. 2. 2. 2. 0. 0.]
NCT02053363,12:38:chronic_disease,History of deep vein thrombosis (DVT),['History' 'of' 'deep' 'vein' 'thrombosis' '(' 'DVT' ')'],[0. 0. 2. 2. 2. 2. 0. 0.]
NCT01684397,12:38:chronic_disease,History of deep vein thrombosis (DVT),['History' 'of' 'deep' 'vein' 'thrombosis' '(' 'DVT' ')'],[0. 0. 2. 2. 2. 2. 0. 0.]
NCT03088709,1:33:cancer,Acute myelogenous leukemia (AML),['Acute' 'myelogenous' 'leukemia' '(' 'AML' ')'],[3. 3. 3. 3. 0. 0.]
NCT02593123,1:33:cancer,Acute myelogenous leukemia (AML),['Acute' 'myelogenous' 'leukemia' '(' 'AML' ')'],[3. 3. 3. 3. 0. 0.]
NCT02181478,1:33:cancer,Acute myelogenous leukemia (AML),['Acute' 'myelogenous' 'leukemia' '(' 'AML' ')'],[3. 3. 3. 3. 0. 0.]
NCT03078530,24:39:chronic_disease,Clinically significant chronic disease,['Clinically' 'significant' 'chronic' 'disease'],[0. 0. 2. 2.]
NCT02425566,19:34:chronic_disease,Subjects with any chronic disease,['Subjects' 'with' 'any' 'chronic' 'disease'],[0. 0. 0. 2. 2.]
NCT01269034,5:20:chronic_disease,Any chronic disease,['Any' 'chronic' 'disease'],[0. 2. 2.]
NCT03065465,32:44:chronic_disease,Presence of a benign appearing peptic ulcer,['Presence' 'of' 'a' 'benign' 'appearing' 'peptic' 'ulcer'],[0. 0. 0. 0. 0. 2. 2.]
NCT02332850,8:20:chronic_disease,active peptic ulcer,['active' 'peptic' 'ulcer'],[0. 2. 2.]
NCT01900093,35:47:chronic_disease,"History of, or the presence of, a peptic ulcer","['History' 'of' ',' 'or' 'the' 'presence' 'of' ',' 'a' 'peptic' 'ulcer']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT03058783,19:36:chronic_disease,Current or recent serious infection,['Current' 'or' 'recent' 'serious' 'infection'],[0. 0. 0. 2. 2.]
NCT02920710,21:38:chronic_disease,"Evidence of current serious infection, or a history of chronic or recurring infections","['Evidence' 'of' 'current' 'serious' 'infection' ',' 'or' 'a' 'history'
 'of' 'chronic' 'or' 'recurring' 'infections']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02774421,26:43:chronic_disease,who have an uncontrolled serious infection,['who' 'have' 'an' 'uncontrolled' 'serious' 'infection'],[0. 0. 0. 0. 2. 2.]
NCT03053908,1:14:chronic_disease,hydrocephalus,['hydrocephalus'],[2.]
NCT02359864,12:25:chronic_disease,History of hydrocephalus,['History' 'of' 'hydrocephalus'],[0. 0. 2.]
NCT02122328,1:14:chronic_disease,hydrocephalus,['hydrocephalus'],[2.]
NCT03038620,1:26:treatment,minor surgical procedures,['minor' 'surgical' 'procedures'],[1. 1. 1.]
NCT01993719,"29:54:treatment,,","Patients may have undergone minor surgical procedures within the past 3 weeks, as long as all toxicities have recovered to grade 1 or less","['Patients' 'may' 'have' 'undergone' 'minor' 'surgical' 'procedures'
 'within' 'the' 'past' '3' 'weeks' ',' 'as' 'long' 'as' 'all' 'toxicities'
 'have' 'recovered' 'to' 'grade' '1' 'or' 'less']","[0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT01967823,"29:54:treatment,,","Patients may have undergone minor surgical procedures within the past three weeks, as long as all toxicities have recovered to grade 1 or less","['Patients' 'may' 'have' 'undergone' 'minor' 'surgical' 'procedures'
 'within' 'the' 'past' 'three' 'weeks' ',' 'as' 'long' 'as' 'all'
 'toxicities' 'have' 'recovered' 'to' 'grade' '1' 'or' 'less']","[0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT03033212,1:10:chronic_disease,scoliosis,['scoliosis'],[2.]
NCT02513797,18:27:chronic_disease,Untreated severe scoliosis (documented and clinically defined by treating physician),"['Untreated' 'severe' 'scoliosis' '(' 'documented' 'and' 'clinically'
 'defined' 'by' 'treating' 'physician' ')']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02271100,13:22:chronic_disease,Significant scoliosis,['Significant' 'scoliosis'],[0. 2.]
NCT03019133,8:20:treatment,Use of vasopressors,['Use' 'of' 'vasopressors'],[0. 0. 1.]
NCT02579265,28:40:treatment,History of shock requiring vasopressors,['History' 'of' 'shock' 'requiring' 'vasopressors'],[0. 0. 0. 0. 1.]
NCT01459107,48:60:treatment,"Stable donor (i.e., does not require excessive vasopressors to maintain blood pressure)","['Stable' 'donor' '(' 'i.e.' ',' 'does' 'not' 'require' 'excessive'
 'vasopressors' 'to' 'maintain' 'blood' 'pressure' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT03016351,",15:43:treatment",more than one anti-hypertensive medication,['more' 'than' 'one' 'anti-hypertensive' 'medication'],[0. 0. 0. 1. 1.]
NCT02444689,18:46:treatment,New / changes in anti-hypertensive medication,['New' '/' 'changes' 'in' 'anti-hypertensive' 'medication'],[0. 0. 0. 0. 1. 1.]
NCT01684397,",,120:148:treatment",the 3 values have to be below 150/90 mm Hg for eligibility and can only be obtained after 2 days of the last change in anti-hypertensive medication,"['the' '3' 'values' 'have' 'to' 'be' 'below' '150/90' 'mm' 'Hg' 'for'
 'eligibility' 'and' 'can' 'only' 'be' 'obtained' 'after' '2' 'days' 'of'
 'the' 'last' 'change' 'in' 'anti-hypertensive' 'medication']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 1.]"
NCT03005782,"1:23:treatment,,",Corticosteroid therapy (>10 mg prednisone/day or equivalent) within 1 week prior to the first dose of study drug,"['Corticosteroid' 'therapy' '(' '>' '10' 'mg' 'prednisone/day' 'or'
 'equivalent' ')' 'within' '1' 'week' 'prior' 'to' 'the' 'first' 'dose'
 'of' 'study' 'drug']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02408120,1:23:treatment,Corticosteroid therapy,['Corticosteroid' 'therapy'],[1. 1.]
NCT02320292,1:23:treatment,Corticosteroid therapy at the time the patient enters the protocol,"['Corticosteroid' 'therapy' 'at' 'the' 'time' 'the' 'patient' 'enters'
 'the' 'protocol']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02988960,55:74:treatment,"In addition, participants must have received only one prior immunotherapy","['In' 'addition' ',' 'participants' 'must' 'have' 'received' 'only' 'one'
 'prior' 'immunotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02358187,28:47:treatment,Patients who have received prior immunotherapy,['Patients' 'who' 'have' 'received' 'prior' 'immunotherapy'],[0. 0. 0. 0. 1. 1.]
NCT01795313,28:47:treatment,Patients who have received prior immunotherapy,['Patients' 'who' 'have' 'received' 'prior' 'immunotherapy'],[0. 0. 0. 0. 1. 1.]
NCT02959762,28:31:allergy_name,Subjects with a history of soy allergy,['Subjects' 'with' 'a' 'history' 'of' 'soy' 'allergy'],[0. 0. 0. 0. 0. 4. 0.]
NCT02366481,28:31:allergy_name,Subjects with a history of soy allergy,['Subjects' 'with' 'a' 'history' 'of' 'soy' 'allergy'],[0. 0. 0. 0. 0. 4. 0.]
NCT01972113,28:31:allergy_name,Subjects with a history of soy allergy,['Subjects' 'with' 'a' 'history' 'of' 'soy' 'allergy'],[0. 0. 0. 0. 0. 4. 0.]
NCT02946658,23:32:chronic_disease,Patients positive for Hepatitis,['Patients' 'positive' 'for' 'Hepatitis'],[0. 0. 0. 2.]
NCT02347891,1:10:chronic_disease,Hepatitis status will be obtained from patients' medical records,"['Hepatitis' 'status' 'will' 'be' 'obtained' 'from' 'patients' ""'""
 'medical' 'records']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00678145,1:10:chronic_disease,Hepatitis,['Hepatitis'],[2.]
NCT02931110,34:61:chronic_disease,Ongoing risk for bleeding due to active peptic ulcer disease,"['Ongoing' 'risk' 'for' 'bleeding' 'due' 'to' 'active' 'peptic' 'ulcer'
 'disease']",[0. 0. 0. 0. 0. 0. 2. 2. 2. 2.]
NCT02101736,1:28:chronic_disease,active peptic ulcer disease,['active' 'peptic' 'ulcer' 'disease'],[2. 2. 2. 2.]
NCT01835626,1:28:chronic_disease,active peptic ulcer disease,['active' 'peptic' 'ulcer' 'disease'],[2. 2. 2. 2.]
NCT02926248,35:45:allergy_name,Patients with reported allergy to colchicine,['Patients' 'with' 'reported' 'allergy' 'to' 'colchicine'],[0. 0. 0. 0. 0. 4.]
NCT02594111,12:22:treatment,History of colchicine intolerance,['History' 'of' 'colchicine' 'intolerance'],[0. 0. 1. 0.]
NCT02576301,16:26:treatment,Treatment with colchicine,['Treatment' 'with' 'colchicine'],[0. 0. 1.]
NCT02920086,",,,,,80:93:chronic_disease","Chronic obstructive lung disease - 2 of the 4 of: baseline PaCO2 of > 45 torr, cor pulmonale","['Chronic' 'obstructive' 'lung' 'disease' '-' '2' 'of' 'the' '4' 'of' ':'
 'baseline' 'PaCO2' 'of' '>' '45' 'torr' ',' 'cor' 'pulmonale']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02525861,"68:81:chronic_disease,,",The participant is experiencing or has a history of chronic severe cor pulmonale (resting mean pulmonary artery pressure ≥40 millimeter(s) of mercury (mm Hg)),"['The' 'participant' 'is' 'experiencing' 'or' 'has' 'a' 'history' 'of'
 'chronic' 'severe' 'cor' 'pulmonale' '(' 'resting' 'mean' 'pulmonary'
 'artery' 'pressure' '≥40' 'millimeter' '(' 's' ')' 'of' 'mercury' '('
 'mm' 'Hg' ')' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02416102,22:35:chronic_disease,clinical evidence of cor pulmonale,['clinical' 'evidence' 'of' 'cor' 'pulmonale'],[0. 0. 0. 2. 2.]
NCT02913430,77:96:treatment,Patients may be pre- or post-menopausal; pre-menopausal patients must be on ovarian suppression and must be adequately suppressed on LHRH agonists with estradiol levels in the post-menopausal range,"['Patients' 'may' 'be' 'pre-' 'or' 'post-menopausal' ';' 'pre-menopausal'
 'patients' 'must' 'be' 'on' 'ovarian' 'suppression' 'and' 'must' 'be'
 'adequately' 'suppressed' 'on' 'LHRH' 'agonists' 'with' 'estradiol'
 'levels' 'in' 'the' 'post-menopausal' 'range']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02913430,",,99:118:treatment",Premenopausal patients cannot be pregnant and must agree to adequate birth control in addition to ovarian suppression,"['Premenopausal' 'patients' 'can' 'not' 'be' 'pregnant' 'and' 'must'
 'agree' 'to' 'adequate' 'birth' 'control' 'in' 'addition' 'to' 'ovarian'
 'suppression']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01990209,51:70:treatment,This group of patients may be pre-menopausal with ovarian suppression or post-menopausal,"['This' 'group' 'of' 'patients' 'may' 'be' 'pre-menopausal' 'with'
 'ovarian' 'suppression' 'or' 'post-menopausal']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.]
NCT02907983,1:28:treatment,anticoagulation medications will be discontinued with the permission of the participant's prescribing physician,"['anticoagulation' 'medications' 'will' 'be' 'discontinued' 'with' 'the'
 'permission' 'of' 'the' 'participant' ""'s"" 'prescribing' 'physician']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02520778,10:37:treatment,low-dose anticoagulation medications that are used to maintain the patency of a central intravenous catheter,"['low-dose' 'anticoagulation' 'medications' 'that' 'are' 'used' 'to'
 'maintain' 'the' 'patency' 'of' 'a' 'central' 'intravenous' 'catheter']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02250157,28:55:treatment,Require therapeutic use of anticoagulation medications,['Require' 'therapeutic' 'use' 'of' 'anticoagulation' 'medications'],[0. 0. 0. 0. 1. 1.]
NCT02901067,9:19:chronic_disease,Ongoing hemorrhage requiring blood product transfusion,['Ongoing' 'hemorrhage' 'requiring' 'blood' 'product' 'transfusion'],[0. 2. 0. 0. 0. 0.]
NCT02706249,"28:38:chronic_disease,",Any history of significant hemorrhage (requiring hospitalization or transfusion) within the last 6 months (excluding hemorrhage during operative procedure),"['Any' 'history' 'of' 'significant' 'hemorrhage' '(' 'requiring'
 'hospitalization' 'or' 'transfusion' ')' 'within' 'the' 'last' '6'
 'months' '(' 'excluding' 'hemorrhage' 'during' 'operative' 'procedure'
 ')']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02048371,"5:15:chronic_disease,,,",Any hemorrhage or bleeding event ≥ NCI CTCAE Grade 3 within 4 weeks prior to study registration,"['Any' 'hemorrhage' 'or' 'bleeding' 'event' '≥' 'NCI' 'CTCAE' 'Grade' '3'
 'within' '4' 'weeks' 'prior' 'to' 'study' 'registration']",[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02875301,1:13:chronic_disease,brain injury,['brain' 'injury'],[2. 2.]
NCT02563678,18:30:chronic_disease,Co-enrollment in brain injury study,['Co-enrollment' 'in' 'brain' 'injury' 'study'],[0. 0. 2. 2. 0.]
NCT02445768,9:21:chronic_disease,another brain injury or illness related to the brain that has lasting effects or effects experienced at the moment of recruitment,"['another' 'brain' 'injury' 'or' 'illness' 'related' 'to' 'the' 'brain'
 'that' 'has' 'lasting' 'effects' 'or' 'effects' 'experienced' 'at' 'the'
 'moment' 'of' 'recruitment']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02865135,1:10:chronic_disease,dysphagia,['dysphagia'],[2.]
NCT02429830,"13:22:chronic_disease,,",Symptoms of dysphagia more than once per week within the last 3 months,"['Symptoms' 'of' 'dysphagia' 'more' 'than' 'once' 'per' 'week' 'within'
 'the' 'last' '3' 'months']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01341080,23:32:chronic_disease,Significant degree of dysphagia,['Significant' 'degree' 'of' 'dysphagia'],[0. 0. 0. 2.]
NCT02852057,1:12:chronic_disease,Bradycardia,['Bradycardia'],[2.]
NCT02453373,"1:12:chronic_disease,,",Bradycardia (heart rate ≤ 50),['Bradycardia' '(' 'heart' 'rate' '≤' '50' ')'],[2. 0. 0. 0. 0. 0. 0.]
NCT02192398,"1:12:chronic_disease,,",Bradycardia (resting heart rate < 60 bpm) will be reviewed by a study physician,"['Bradycardia' '(' 'resting' 'heart' 'rate' '<' '60' 'bpm' ')' 'will' 'be'
 'reviewed' 'by' 'a' 'study' 'physician']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02844465,"38:42:treatment,","Willing and able to remain on stable AEDs (and stable VNS setting, if applicable) for 12 months following the Visualase procedure","['Willing' 'and' 'able' 'to' 'remain' 'on' 'stable' 'AEDs' '(' 'and'
 'stable' 'VNS' 'setting' ',' 'if' 'applicable' ')' 'for' '12' 'months'
 'following' 'the' 'Visualase' 'procedure']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02477839,",,80:84:treatment",Subject is on a stable (concurrently or sequentially) dosage regimen of 1 to 3 AEDs,"['Subject' 'is' 'on' 'a' 'stable' '(' 'concurrently' 'or' 'sequentially'
 ')' 'dosage' 'regimen' 'of' '1' 'to' '3' 'AEDs']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02011971,",20:24:treatment",Taking more than 3 AEDs,['Taking' 'more' 'than' '3' 'AEDs'],[0. 0. 0. 0. 1.]
NCT02826382,12:31:chronic_disease,history of hyperparathyroidism,['history' 'of' 'hyperparathyroidism'],[0. 0. 2.]
NCT02088554,13:32:chronic_disease,Patient has hyperparathyroidism,['Patient' 'has' 'hyperparathyroidism'],[0. 0. 2.]
NCT01568255,"36:55:chronic_disease,",A co-existent diagnosis of primary hyperparathyroidism within the previous 6 months,"['A' 'co-existent' 'diagnosis' 'of' 'primary' 'hyperparathyroidism'
 'within' 'the' 'previous' '6' 'months']",[0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0.]
NCT02819635,1:19:treatment,immunosuppressants,['immunosuppressants'],[1.]
NCT02776761,",58:76:treatment",Administration of chronic (defined as more than 14 days) immunosuppressants,"['Administration' 'of' 'chronic' '(' 'defined' 'as' 'more' 'than' '14'
 'days' ')' 'immunosuppressants']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01293214,17:35:treatment,Willing to take immunosuppressants - drugs that help prevent rejection of the transplant - for life,"['Willing' 'to' 'take' 'immunosuppressants' '-' 'drugs' 'that' 'help'
 'prevent' 'rejection' 'of' 'the' 'transplant' '-' 'for' 'life']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02809677,13:30:chronic_disease,symptoms of persistent asthma in children not on a daily controller medication,"['symptoms' 'of' 'persistent' 'asthma' 'in' 'children' 'not' 'on' 'a'
 'daily' 'controller' 'medication']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02809677,25:42:chronic_disease,who have a diagnosis of persistent asthma,['who' 'have' 'a' 'diagnosis' 'of' 'persistent' 'asthma'],[0. 0. 0. 0. 0. 2. 2.]
NCT02588326,16:33:chronic_disease,ntermittent or persistent asthma,['ntermittent' 'or' 'persistent' 'asthma'],[0. 0. 2. 2.]
NCT02796209,1:11:treatment,fluoxetine,['fluoxetine'],[1.]
NCT02737930,72:82:treatment,Current use of a medication likely to have an adverse interaction with fluoxetine,"['Current' 'use' 'of' 'a' 'medication' 'likely' 'to' 'have' 'an' 'adverse'
 'interaction' 'with' 'fluoxetine']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02556606,23:33:treatment,Patients currently on fluoxetine,['Patients' 'currently' 'on' 'fluoxetine'],[0. 0. 0. 1.]
NCT02776059,27:52:chronic_disease,uncontrolled recent upper gastrointestinal bleeding,['uncontrolled' 'recent' 'upper' 'gastrointestinal' 'bleeding'],[0. 0. 0. 2. 2.]
NCT02197351,38:63:chronic_disease,Patients who have evidence of active gastrointestinal bleeding will be excluded,"['Patients' 'who' 'have' 'evidence' 'of' 'active' 'gastrointestinal'
 'bleeding' 'will' 'be' 'excluded']",[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0.]
NCT01943851,"18:43:chronic_disease,",History of major gastrointestinal bleeding within the last 3 months or any evidence of active gastrointestinal bleeding excludes the subject,"['History' 'of' 'major' 'gastrointestinal' 'bleeding' 'within' 'the'
 'last' '3' 'months' 'or' 'any' 'evidence' 'of' 'active'
 'gastrointestinal' 'bleeding' 'excludes' 'the' 'subject']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02753283,",12:21:treatment,","Those with vitamin D levels < 25ng/mL will be treated with vitamin D 50,000 IU/wk for 8 weeks","['Those' 'with' 'vitamin' 'D' 'levels' '<' '25ng/mL' 'will' 'be' 'treated'
 'with' 'vitamin' 'D' '50,000' 'IU/wk' 'for' '8' 'weeks']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02172651,102:111:allergy_name,History of allergic reactions attributed to compounds of similar chemical or biologic composition to vitamin D,"['History' 'of' 'allergic' 'reactions' 'attributed' 'to' 'compounds' 'of'
 'similar' 'chemical' 'or' 'biologic' 'composition' 'to' 'vitamin' 'D']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 4.]
NCT02172651,"29:38:treatment,,","Regular use of supplemental vitamin D totaling ≥ 2,000 IU/day in the past year","['Regular' 'use' 'of' 'supplemental' 'vitamin' 'D' 'totaling' '≥' '2,000'
 'IU/day' 'in' 'the' 'past' 'year']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02740361,6:23:chronic_disease,very severe depression that would interfere with the ability to participate in the study (based on clinical judgment by the physician at the recruitment site),"['very' 'severe' 'depression' 'that' 'would' 'interfere' 'with' 'the'
 'ability' 'to' 'participate' 'in' 'the' 'study' '(' 'based' 'on'
 'clinical' 'judgment' 'by' 'the' 'physician' 'at' 'the' 'recruitment'
 'site' ')']","[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02544503,13:30:chronic_disease,Moderate or severe depression,['Moderate' 'or' 'severe' 'depression'],[0. 0. 2. 2.]
NCT01128816,186:203:chronic_disease,"Any other medical, social, or geographical factor, which would make it unlikely that the patient will comply with the study procedures (e.g. alcohol abuse, lack of permanent residence, severe depression, disorientation, distant location, or history of non-compliance)","['Any' 'other' 'medical' ',' 'social' ',' 'or' 'geographical' 'factor' ','
 'which' 'would' 'make' 'it' 'unlikely' 'that' 'the' 'patient' 'will'
 'comply' 'with' 'the' 'study' 'procedures' '(' 'e.g' '.' 'alcohol'
 'abuse' ',' 'lack' 'of' 'permanent' 'residence' ',' 'severe' 'depression'
 ',' 'disorientation' ',' 'distant' 'location' ',' 'or' 'history' 'of'
 'non-compliance' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02721303,1:18:treatment,Bariatric surgery,['Bariatric' 'surgery'],[1. 1.]
NCT02650206,7:24:treatment,Prior Bariatric surgery,['Prior' 'Bariatric' 'surgery'],[0. 1. 1.]
NCT02448498,1:18:treatment,Bariatric surgery,['Bariatric' 'surgery'],[1. 1.]
NCT02686528,31:53:treatment,Patients undergoing a primary total hip arthroplasty via the posterior approach by participating attending surgeons at this institution,"['Patients' 'undergoing' 'a' 'primary' 'total' 'hip' 'arthroplasty' 'via'
 'the' 'posterior' 'approach' 'by' 'participating' 'attending' 'surgeons'
 'at' 'this' 'institution']",[0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02507505,1:23:treatment,total hip arthroplasty,['total' 'hip' 'arthroplasty'],[1. 1. 1.]
NCT01917929,36:58:treatment,Patient is a candidate for primary total hip arthroplasty,"['Patient' 'is' 'a' 'candidate' 'for' 'primary' 'total' 'hip'
 'arthroplasty']",[0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02674529,55:67:treatment,Have a history of inadequate response/tolerability to escitalopram,"['Have' 'a' 'history' 'of' 'inadequate' 'response/tolerability' 'to'
 'escitalopram']",[0. 0. 0. 0. 0. 0. 0. 1.]
NCT01931202,44:56:allergy_name,history of allergic or adverse reaction to escitalopram,['history' 'of' 'allergic' 'or' 'adverse' 'reaction' 'to' 'escitalopram'],[0. 0. 0. 0. 0. 0. 0. 4.]
NCT01931202,"35:47:treatment,",non-response to adequate trial of escitalopram (at least 4 weeks at dose of 20mg) during the current episode,"['non-response' 'to' 'adequate' 'trial' 'of' 'escitalopram' '(' 'at'
 'least' '4' 'weeks' 'at' 'dose' 'of' '20mg' ')' 'during' 'the' 'current'
 'episode']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02642939,13:29:chronic_disease,Significant cardiac diseases includes second/third degree heart block,"['Significant' 'cardiac' 'diseases' 'includes' 'second/third' 'degree'
 'heart' 'block']",[0. 2. 2. 0. 0. 0. 0. 0.]
NCT02158858,53:69:chronic_disease,Impaired cardiac function or clinically significant cardiac diseases,"['Impaired' 'cardiac' 'function' 'or' 'clinically' 'significant' 'cardiac'
 'diseases']",[0. 2. 2. 0. 0. 0. 0. 0.]
NCT01894061,67:83:chronic_disease,Patients with impaired cardiac function or clinically significant cardiac diseases,"['Patients' 'with' 'impaired' 'cardiac' 'function' 'or' 'clinically'
 'significant' 'cardiac' 'diseases']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02608125,15:38:cancer,Patients with glioblastoma multiforme,['Patients' 'with' 'glioblastoma' 'multiforme'],[0. 0. 3. 3.]
NCT02344355,",102:125:cancer","Patients must have newly diagnosed (i.e., within 5 weeks), histologically or cytologically confirmed glioblastoma multiforme","['Patients' 'must' 'have' 'newly' 'diagnosed' '(' 'i.e.' ',' 'within' '5'
 'weeks' ')' ',' 'histologically' 'or' 'cytologically' 'confirmed'
 'glioblastoma' 'multiforme']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT01811498,50:73:chronic_disease,Patients with documented histologic diagnosis of glioblastoma multiforme (newly diagnosed),"['Patients' 'with' 'documented' 'histologic' 'diagnosis' 'of'
 'glioblastoma' 'multiforme' '(' 'newly' 'diagnosed' ')']",[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0.]
NCT02593123,1:35:cancer,Chronic myelogenous leukemia (CML),['Chronic' 'myelogenous' 'leukemia' '(' 'CML' ')'],[3. 3. 3. 3. 0. 0.]
NCT02424968,1:35:chronic_disease,Chronic myelogenous leukemia (CML),['Chronic' 'myelogenous' 'leukemia' '(' 'CML' ')'],[2. 2. 2. 2. 0. 0.]
NCT02181478,1:35:cancer,Chronic myelogenous leukemia (CML) in second chronic phase after accelerated or blast crisis; blast crisis defined as,"['Chronic' 'myelogenous' 'leukemia' '(' 'CML' ')' 'in' 'second' 'chronic'
 'phase' 'after' 'accelerated' 'or' 'blast' 'crisis' ';' 'blast' 'crisis'
 'defined' 'as']",[3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02573883,8:11:chronic_disease,Active UTI,['Active' 'UTI'],[0. 2.]
NCT01994538,"15:18:chronic_disease,",Treatment for UTI in past 14 days,['Treatment' 'for' 'UTI' 'in' 'past' '14' 'days'],[0. 0. 2. 0. 0. 0. 0.]
NCT01595529,"27:30:chronic_disease,",A child with a history of UTI within the past 30 days,"['A' 'child' 'with' 'a' 'history' 'of' 'UTI' 'within' 'the' 'past' '30'
 'days']",[0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0.]
NCT02554786,8:18:treatment,Repeat spirometry may be allowed once in an ad-hoc visit if the spirometry did not qualify due to ATS/ERS criteria,"['Repeat' 'spirometry' 'may' 'be' 'allowed' 'once' 'in' 'an' 'ad-hoc'
 'visit' 'if' 'the' 'spirometry' 'did' 'not' 'qualify' 'due' 'to'
 'ATS/ERS' 'criteria']",[0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02554786,33:43:treatment,have not achieved an acceptable spirometry results at Visit 101 in accordance with American Thoracic Society/European Respiratory Society (ATS/ERS) criteria for acceptability and repeatability (rescreening allowed only once),"['have' 'not' 'achieved' 'an' 'acceptable' 'spirometry' 'results' 'at'
 'Visit' '101' 'in' 'accordance' 'with' 'American' 'Thoracic'
 'Society/European' 'Respiratory' 'Society' '(' 'ATS/ERS' ')' 'criteria'
 'for' 'acceptability' 'and' 'repeatability' '(' 'rescreening' 'allowed'
 'only' 'once' ')']","[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02240069,125:135:treatment,"Capable and willing to record symptom data and wood stove usage data, as well as complete pulmonary function testing (i.e., spirometry)","['Capable' 'and' 'willing' 'to' 'record' 'symptom' 'data' 'and' 'wood'
 'stove' 'usage' 'data' ',' 'as' 'well' 'as' 'complete' 'pulmonary'
 'function' 'testing' '(' 'i.e.' ',' 'spirometry' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 0.]"
NCT02544880,29:34:cancer,Recurrent or second primary HNSCC arises within the previously irradiated field,"['Recurrent' 'or' 'second' 'primary' 'HNSCC' 'arises' 'within' 'the'
 'previously' 'irradiated' 'field']",[0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0.]
NCT02544880,52:57:cancer,"Surgically resectable, recurrent or second primary HNSCC","['Surgically' 'resectable' ',' 'recurrent' 'or' 'second' 'primary' 'HNSCC']",[0. 0. 0. 0. 0. 0. 0. 3.]
NCT02433626,9:14:cancer,"Part 2: HNSCC, with confirmed p53 mutations","['Part' '2' ':' 'HNSCC' ',' 'with' 'confirmed' 'p53' 'mutations']",[0. 0. 0. 3. 0. 0. 0. 0. 0.]
NCT02541903,1:17:chronic_disease,chronic diarrhea,['chronic' 'diarrhea'],[2. 2.]
NCT02047474,15:31:chronic_disease,No history of chronic diarrhea,['No' 'history' 'of' 'chronic' 'diarrhea'],[0. 0. 0. 2. 2.]
NCT00065676,1:17:chronic_disease,chronic diarrhea,['chronic' 'diarrhea'],[2. 2.]
NCT02530463,",73:84:treatment",No response will be lack of clinical benefit after at least 6 cycles of HMA therapy,"['No' 'response' 'will' 'be' 'lack' 'of' 'clinical' 'benefit' 'after' 'at'
 'least' '6' 'cycles' 'of' 'HMA' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02530463,76:87:treatment,Patients need to have relapsed or progressed after any number of cycles of HMA therapy,"['Patients' 'need' 'to' 'have' 'relapsed' 'or' 'progressed' 'after' 'any'
 'number' 'of' 'cycles' 'of' 'HMA' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02530463,33:44:treatment,Patients that do not respond to HMA therapy will also be allowed in the study,"['Patients' 'that' 'do' 'not' 'respond' 'to' 'HMA' 'therapy' 'will' 'also'
 'be' 'allowed' 'in' 'the' 'study']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02525692,102:108:treatment,History of allergic reactions attributed to compounds of similar chemical or biologic composition to ONC201 or its excipients,"['History' 'of' 'allergic' 'reactions' 'attributed' 'to' 'compounds' 'of'
 'similar' 'chemical' 'or' 'biologic' 'composition' 'to' 'ONC201' 'or'
 'its' 'excipients']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02525692,"16:22:treatment,,,,,,,,","The effects of ONC201 on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately","['The' 'effects' 'of' 'ONC201' 'on' 'the' 'developing' 'human' 'fetus'
 'are' 'unknown' '.' 'For' 'this' 'reason' ',' 'women' 'of' 'childbearing'
 'potential' 'and' 'men' 'must' 'agree' 'to' 'use' 'adequate'
 'contraception' '(' 'hormonal' 'or' 'barrier' 'method' 'of' 'birth'
 'control' ';' 'abstinence' ')' 'prior' 'to' 'study' 'entry' 'and' 'for'
 'the' 'duration' 'of' 'study' 'participation' '.' 'Should' 'a' 'woman'
 'become' 'pregnant' 'or' 'suspect' 'she' 'is' 'pregnant' 'while' 'she'
 'or' 'her' 'partner' 'is' 'participating' 'in' 'this' 'study' ',' 'she'
 'should' 'inform' 'her' 'treating' 'physician' 'immediately']","[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02392572,",67:73:treatment",Pregnant and nursing patients are excluded because the effects of ONC201on a fetus or nursing child are unknown,"['Pregnant' 'and' 'nursing' 'patients' 'are' 'excluded' 'because' 'the'
 'effects' 'of' 'ONC201on' 'a' 'fetus' 'or' 'nursing' 'child' 'are'
 'unknown']",[1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.]
NCT02515708,12:45:treatment,History of prior solid organ transplantation,['History' 'of' 'prior' 'solid' 'organ' 'transplantation'],[0. 0. 1. 1. 1. 1.]
NCT02323880,30:63:treatment,Patients who have received a prior solid organ transplantation,"['Patients' 'who' 'have' 'received' 'a' 'prior' 'solid' 'organ'
 'transplantation']",[0. 0. 0. 0. 0. 1. 1. 1. 1.]
NCT02304458,28:61:treatment,Patients who have received prior solid organ transplantation,"['Patients' 'who' 'have' 'received' 'prior' 'solid' 'organ'
 'transplantation']",[0. 0. 0. 0. 1. 1. 1. 1.]
NCT02513797,1:16:treatment,medical illness or comorbidity which would make the subject unsuitable to participate in this study as determined by the clinical site Primary Investigator,"['medical' 'illness' 'or' 'comorbidity' 'which' 'would' 'make' 'the'
 'subject' 'unsuitable' 'to' 'participate' 'in' 'this' 'study' 'as'
 'determined' 'by' 'the' 'clinical' 'site' 'Primary' 'Investigator']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02069925,10:25:chronic_disease,Unstable medical illness,['Unstable' 'medical' 'illness'],[0. 2. 2.]
NCT00715611,32:47:chronic_disease,Patients with serious unstable medical illness,['Patients' 'with' 'serious' 'unstable' 'medical' 'illness'],[0. 0. 0. 0. 2. 2.]
NCT02496208,1:29:chronic_disease,Gastrointestinal perforation,['Gastrointestinal' 'perforation'],[2. 2.]
NCT02132598,1:29:chronic_disease,Gastrointestinal perforation,['Gastrointestinal' 'perforation'],[2. 2.]
NCT01822522,1:29:chronic_disease,Gastrointestinal perforation,['Gastrointestinal' 'perforation'],[2. 2.]
NCT02478684,11:31:chronic_disease,Any major congenital anomalies,['Any' 'major' 'congenital' 'anomalies'],[0. 0. 2. 2.]
NCT02148796,7:27:chronic_disease,major congenital anomalies,['major' 'congenital' 'anomalies'],[0. 2. 2.]
NCT01595529,24:44:chronic_disease,A child diagnosed with congenital anomalies of the genitourinary tract,"['A' 'child' 'diagnosed' 'with' 'congenital' 'anomalies' 'of' 'the'
 'genitourinary' 'tract']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 0.]
NCT02474199,9:27:cancer,without cholangiocarcinoma morphology,['without' 'cholangiocarcinoma' 'morphology'],[0. 3. 0.]
NCT02150967,48:66:cancer,with histologically or cytologically confirmed cholangiocarcinoma at the time of diagnosis,"['with' 'histologically' 'or' 'cytologically' 'confirmed'
 'cholangiocarcinoma' 'at' 'the' 'time' 'of' 'diagnosis']",[0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0.]
NCT00737399,14:32:cancer,Diagnosis of cholangiocarcinoma,['Diagnosis' 'of' 'cholangiocarcinoma'],[0. 0. 3.]
NCT02464696,29:34:treatment,Inability to cooperate with NIPPV,['Inability' 'to' 'cooperate' 'with' 'NIPPV'],[0. 0. 0. 0. 1.]
NCT02464696,20:25:treatment,Patient already on NIPPV at the time of screening,['Patient' 'already' 'on' 'NIPPV' 'at' 'the' 'time' 'of' 'screening'],[0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02464696,20:25:treatment,Refusal to receive NIPPV,['Refusal' 'to' 'receive' 'NIPPV'],[0. 0. 0. 1.]
NCT02451982,45:59:treatment,Surgically resectable disease (R0 or R1) by spiral CT scan,"['Surgically' 'resectable' 'disease' '(' 'R0' 'or' 'R1' ')' 'by' 'spiral'
 'CT' 'scan']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02427841,",,,,,,295:309:treatment","Subjects must have measurable disease (by RECIST 1.1), defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm with conventional techniques or as >= 10 mm with spiral CT scan","['Subjects' 'must' 'have' 'measurable' 'disease' '(' 'by' 'RECIST' '1.1'
 ')' ',' 'defined' 'as' 'at' 'least' 'one' 'lesion' 'that' 'can' 'be'
 'accurately' 'measured' 'in' 'at' 'least' 'one' 'dimension' '(' 'longest'
 'diameter' 'to' 'be' 'recorded' 'for' 'non-nodal' 'lesions' 'and' 'short'
 'axis' 'for' 'nodal' 'lesions' ')' 'as' '>' '=' '20' 'mm' 'with'
 'conventional' 'techniques' 'or' 'as' '>' '=' '10' 'mm' 'with' 'spiral'
 'CT' 'scan']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]"
NCT01827384,",,,224:238:treatment","Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 20 mm with conventional techniques or as >= 10 mm with spiral CT scan","['Patients' 'must' 'have' 'measurable' 'disease' ',' 'defined' 'as' 'at'
 'least' 'one' 'lesion' 'that' 'can' 'be' 'accurately' 'measured' 'in'
 'at' 'least' 'one' 'dimension' '(' 'longest' 'diameter' 'to' 'be'
 'recorded' ')' 'as' '>' '=' '20' 'mm' 'with' 'conventional' 'techniques'
 'or' 'as' '>' '=' '10' 'mm' 'with' 'spiral' 'CT' 'scan']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]"
NCT02442102,",49:59:treatment",Patient is not expected to require ≥48 hours of intubation,"['Patient' 'is' 'not' 'expected' 'to' 'require' '≥48' 'hours' 'of'
 'intubation']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02109081,31:41:treatment,anticipation of postoperative intubation,['anticipation' 'of' 'postoperative' 'intubation'],[0. 0. 0. 1.]
NCT01742338,23:33:treatment,Patients who requires intubation at time of recruitment,['Patients' 'who' 'requires' 'intubation' 'at' 'time' 'of' 'recruitment'],[0. 0. 0. 1. 0. 0. 0. 0.]
NCT02413970,56:68:treatment,Documentation the subject not effectively treated with CPAP therapy,"['Documentation' 'the' 'subject' 'not' 'effectively' 'treated' 'with'
 'CPAP' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02261857,19:31:treatment,On-going need for CPAP therapy based on polysomnography,['On-going' 'need' 'for' 'CPAP' 'therapy' 'based' 'on' 'polysomnography'],[0. 0. 0. 1. 1. 0. 0. 0.]
NCT02261857,28:40:treatment,Subjects no longer needing CPAP therapy,['Subjects' 'no' 'longer' 'needing' 'CPAP' 'therapy'],[0. 0. 0. 0. 1. 1.]
NCT02407028,8:15:chronic_disease,Severe hypoxia,['Severe' 'hypoxia'],[0. 2.]
NCT02374333,",,50:57:chronic_disease",Adequate pulmonary function defined as < Grade 3 hypoxia,"['Adequate' 'pulmonary' 'function' 'defined' 'as' '<' 'Grade' '3'
 'hypoxia']",[0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02159495,"41:48:chronic_disease,,,,",ONLY research participants experiencing hypoxia with oxygen saturation less than 92% are required to have diffusion capacity of carbon monoxide (DLCO) or forced expiratory volume in one second (FEV1) > 45% predicted,"['ONLY' 'research' 'participants' 'experiencing' 'hypoxia' 'with' 'oxygen'
 'saturation' 'less' 'than' '92' '%' 'are' 'required' 'to' 'have'
 'diffusion' 'capacity' 'of' 'carbon' 'monoxide' '(' 'DLCO' ')' 'or'
 'forced' 'expiratory' 'volume' 'in' 'one' 'second' '(' 'FEV1' ')' '>'
 '45' '%' 'predicted']","[0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02395614,52:62:allergy_name,patients allergic to one or more components of the antibiotic solution,"['patients' 'allergic' 'to' 'one' 'or' 'more' 'components' 'of' 'the'
 'antibiotic' 'solution']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 0.]
NCT02134392,"4:14:treatment,",No antibiotic use within the last 90 days,['No' 'antibiotic' 'use' 'within' 'the' 'last' '90' 'days'],[0. 1. 0. 0. 0. 0. 0. 0.]
NCT01595529,95:105:treatment,A child whose urine culture reveals an organism that is resistant to the initially prescribed antibiotic,"['A' 'child' 'whose' 'urine' 'culture' 'reveals' 'an' 'organism' 'that'
 'is' 'resistant' 'to' 'the' 'initially' 'prescribed' 'antibiotic']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02383979,50:54:treatment,"Cooperative, with time and availability to do an fMRI","['Cooperative' ',' 'with' 'time' 'and' 'availability' 'to' 'do' 'an'
 'fMRI']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02383979,22:26:treatment,Subjects who opt for fMRI portion of the study are willing and/or able to tolerate fMRI,"['Subjects' 'who' 'opt' 'for' 'fMRI' 'portion' 'of' 'the' 'study' 'are'
 'willing' 'and/or' 'able' 'to' 'tolerate' 'fMRI']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02383979,30:34:treatment,Willing and able to tolerate fMRI,['Willing' 'and' 'able' 'to' 'tolerate' 'fMRI'],[0. 0. 0. 0. 0. 1.]
NCT02369900,12:31:chronic_disease,Pronounced cardiac dysfunction,['Pronounced' 'cardiac' 'dysfunction'],[0. 2. 2.]
NCT02092324,1:20:chronic_disease,cardiac dysfunction,['cardiac' 'dysfunction'],[2. 2.]
NCT01937884,16:35:chronic_disease,No evidence of cardiac dysfunction,['No' 'evidence' 'of' 'cardiac' 'dysfunction'],[0. 0. 0. 2. 2.]
NCT02347891,",,,,,,78:86:chronic_disease,,,,,,,,,,","Presence of positive autoantibody (ANA >1:80 or RNP or SSA/SSB or any of the myositis specific autoantibody: antisynthetase autoantibodies (anti-Jo-1, PL-7, PL-12, EJ, OJ, KS), anti-SRP, anti-Mi-2, anti-p140)","['Presence' 'of' 'positive' 'autoantibody' '(' 'ANA' '>' '1:80' 'or' 'RNP'
 'or' 'SSA/SSB' 'or' 'any' 'of' 'the' 'myositis' 'specific' 'autoantibody'
 ':' 'antisynthetase' 'autoantibodies' '(' 'anti-Jo-1' ',' 'PL-7' ','
 'PL-12' ',' 'EJ' ',' 'OJ' ',' 'KS' ')' ',' 'anti-SRP' ',' 'anti-Mi-2' ','
 'anti-p140' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02245841,78:86:chronic_disease,"Although not mandatory, patients with evidence of current or previous active myositis","['Although' 'not' 'mandatory' ',' 'patients' 'with' 'evidence' 'of'
 'current' 'or' 'previous' 'active' 'myositis']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02245841,44:52:chronic_disease,Patients with clear features of an overlap myositis,['Patients' 'with' 'clear' 'features' 'of' 'an' 'overlap' 'myositis'],[0. 0. 0. 0. 0. 0. 0. 2.]
NCT02329327,"1:15:chronic_disease,,,",Acute bleeding associated with a hemoglobin level of ≤8 g/dL if no baseline hemoglobin is available,"['Acute' 'bleeding' 'associated' 'with' 'a' 'hemoglobin' 'level' 'of' '≤8'
 'g/dL' 'if' 'no' 'baseline' 'hemoglobin' 'is' 'available']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02329327,1:15:chronic_disease,"Acute bleeding in a critical area or organ such as intraspinal, pericardial, or intracranial","['Acute' 'bleeding' 'in' 'a' 'critical' 'area' 'or' 'organ' 'such' 'as'
 'intraspinal' ',' 'pericardial' ',' 'or' 'intracranial']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02329327,1:15:chronic_disease,Acute bleeding that is potentially life-threatening,['Acute' 'bleeding' 'that' 'is' 'potentially' 'life-threatening'],[2. 2. 0. 0. 0. 0.]
NCT02315612,1:12:chronic_disease,Hematologic function,['Hematologic' 'function'],[2. 0.]
NCT01505569,"1:12:chronic_disease,,,,","Hematologic: ANC ≥ 750/mm3, platelets ≥ 75,000/mm3","['Hematologic' ':' 'ANC' '≥' '750/mm3' ',' 'platelets' '≥' '75,000/mm3']",[2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01505569,"1:12:chronic_disease,,,,","Hematologic: hemoglobin of >9 gm/dl and platelet count > 20,000/μl","['Hematologic' ':' 'hemoglobin' 'of' '>' '9' 'gm/dl' 'and' 'platelet'
 'count' '>' '20,000/μl']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02304458,47:63:cancer,Part B3: patients with relapsed or refractory rhabdomyosarcoma,"['Part' 'B3' ':' 'patients' 'with' 'relapsed' 'or' 'refractory'
 'rhabdomyosarcoma']",[0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT02304458,47:63:cancer,Part D3: Patients with relapsed or refractory rhabdomyosarcoma,"['Part' 'D3' ':' 'Patients' 'with' 'relapsed' 'or' 'refractory'
 'rhabdomyosarcoma']",[0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT02304458,47:63:cancer,Part E3: Patients with relapsed or refractory rhabdomyosarcoma,"['Part' 'E3' ':' 'Patients' 'with' 'relapsed' 'or' 'refractory'
 'rhabdomyosarcoma']",[0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT02285114,"4:27:chronic_disease,",No opportunistic infection within 30 days of study entry (at baseline/Day 1),"['No' 'opportunistic' 'infection' 'within' '30' 'days' 'of' 'study'
 'entry' '(' 'at' 'baseline/Day' '1' ')']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02016924,"4:27:chronic_disease,",No opportunistic infection within 30 days of study entry (at Day -10),"['No' 'opportunistic' 'infection' 'within' '30' 'days' 'of' 'study'
 'entry' '(' 'at' 'Day' '-10' ')']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01861106,32:55:chronic_disease,No history of life-threatening opportunistic infection,['No' 'history' 'of' 'life-threatening' 'opportunistic' 'infection'],[0. 0. 0. 0. 2. 2.]
NCT02270619,7:23:chronic_disease,other chronic diseases,['other' 'chronic' 'diseases'],[0. 2. 2.]
NCT01438073,4:20:chronic_disease,no chronic diseases,['no' 'chronic' 'diseases'],[0. 2. 2.]
NCT00914823,4:20:chronic_disease,no chronic diseases,['no' 'chronic' 'diseases'],[0. 2. 2.]
NCT02237183,131:139:allergy_name,Participants must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition of iloprost,"['Participants' 'must' 'not' 'have' 'a' 'history' 'of' 'allergic'
 'reactions' 'attributed' 'to' 'compounds' 'of' 'similar' 'chemical' 'or'
 'biologic' 'composition' 'of' 'iloprost']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4.]
NCT02237183,46:54:treatment,Participants must not have been treated with iloprost at any time,"['Participants' 'must' 'not' 'have' 'been' 'treated' 'with' 'iloprost'
 'at' 'any' 'time']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02237183,45:53:treatment,participants on the placebo arm of previous iloprost trials,"['participants' 'on' 'the' 'placebo' 'arm' 'of' 'previous' 'iloprost'
 'trials']",[0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02215096,"13:25:treatment,",Most recent enzalutamide dose received is 160 mg once daily with no change in dose for at least 2 weeks prior to Screening,"['Most' 'recent' 'enzalutamide' 'dose' 'received' 'is' '160' 'mg' 'once'
 'daily' 'with' 'no' 'change' 'in' 'dose' 'for' 'at' 'least' '2' 'weeks'
 'prior' 'to' 'Screening']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02012296,",,38:50:treatment",PSA =<1.25 times the PSA at start of enzalutamide,['PSA' '=' '<' '1.25' 'times' 'the' 'PSA' 'at' 'start' 'of' 'enzalutamide'],[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02012296,"21:33:treatment,",Record of subject's enzalutamide start date and baseline PSA (within 28 days of starting) before starting enzalutamide available,"['Record' 'of' 'subject' ""'s"" 'enzalutamide' 'start' 'date' 'and'
 'baseline' 'PSA' '(' 'within' '28' 'days' 'of' 'starting' ')' 'before'
 'starting' 'enzalutamide' 'available']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02163317,",60:71:treatment",PSA should not be obtained prior to 90 days after stopping dutasteride,"['PSA' 'should' 'not' 'be' 'obtained' 'prior' 'to' '90' 'days' 'after'
 'stopping' 'dutasteride']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02163317,"8:19:treatment,",Use of dutasteride within 90 days prior to registration,['Use' 'of' 'dutasteride' 'within' '90' 'days' 'prior' 'to' 'registration'],[0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT02064036,",41:52:treatment",within 90 days after discontinuation of dutasteride,['within' '90' 'days' 'after' 'discontinuation' 'of' 'dutasteride'],[0. 0. 0. 0. 0. 0. 1.]
NCT02140255,14:18:treatment,"Able to take ARVs by mouth, nasogastric tube, or gastrostomy tube","['Able' 'to' 'take' 'ARVs' 'by' 'mouth' ',' 'nasogastric' 'tube' ',' 'or'
 'gastrostomy' 'tube']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02140255,"24:28:treatment,",Mother did not receive ARVs during the current pregnancy per criteria above,"['Mother' 'did' 'not' 'receive' 'ARVs' 'during' 'the' 'current'
 'pregnancy' 'per' 'criteria' 'above']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02140255,"15:19:treatment,",No receipt of ARVs during the current pregnancy,['No' 'receipt' 'of' 'ARVs' 'during' 'the' 'current' 'pregnancy'],[0. 0. 0. 1. 0. 0. 0. 0.]
NCT02097121,27:35:treatment,Current use of indwelling catheter or clean intermittent catheterization to empty the bladder,"['Current' 'use' 'of' 'indwelling' 'catheter' 'or' 'clean' 'intermittent'
 'catheterization' 'to' 'empty' 'the' 'bladder']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01959204,26:34:treatment,Has an indwelling access catheter for blood sampling,['Has' 'an' 'indwelling' 'access' 'catheter' 'for' 'blood' 'sampling'],[0. 0. 0. 0. 1. 0. 0. 0.]
NCT01595529,16:24:treatment,A child with a catheter-associated UTI,['A' 'child' 'with' 'a' 'catheter-associated' 'UTI'],[0. 0. 0. 0. 1. 0.]
NCT02033941,16:37:chronic_disease,No evidence of hepatic insufficiency,['No' 'evidence' 'of' 'hepatic' 'insufficiency'],[0. 0. 0. 2. 2.]
NCT01950351,1:22:chronic_disease,hepatic insufficiency resulting in clinical jaundice,['hepatic' 'insufficiency' 'resulting' 'in' 'clinical' 'jaundice'],[2. 2. 0. 0. 0. 0.]
NCT01525901,1:22:chronic_disease,hepatic insufficiency,['hepatic' 'insufficiency'],[2. 2.]
NCT01880567,1:24:cancer,Relapsed/refractory MCL: Any serious medical condition that places the patient at unacceptable risk and/or would prevent the subject from signing the informed consent form,"['Relapsed/refractory' 'MCL' ':' 'Any' 'serious' 'medical' 'condition'
 'that' 'places' 'the' 'patient' 'at' 'unacceptable' 'risk' 'and/or'
 'would' 'prevent' 'the' 'subject' 'from' 'signing' 'the' 'informed'
 'consent' 'form']","[3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT01880567,"1:24:cancer,,",Relapsed/refractory MCL: Creatinine (Cr) clearance >= 30 mL/min,"['Relapsed/refractory' 'MCL' ':' 'Creatinine' '(' 'Cr' ')' 'clearance' '>'
 '=' '30' 'mL/min']",[3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01880567,"1:24:cancer,,",Relapsed/refractory MCL: Serum bilirubin < 1.5 mg/dl,['Relapsed/refractory' 'MCL' ':' 'Serum' 'bilirubin' '<' '1.5' 'mg/dl'],[3. 3. 0. 0. 0. 0. 0. 0.]
NCT01823198,1:23:cancer,Acute myeloid leukemia in first remission with any of the following high risk features defined,"['Acute' 'myeloid' 'leukemia' 'in' 'first' 'remission' 'with' 'any' 'of'
 'the' 'following' 'high' 'risk' 'features' 'defined']",[3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01760655,1:23:cancer,Acute myeloid leukemia with high risk features,['Acute' 'myeloid' 'leukemia' 'with' 'high' 'risk' 'features'],[3. 3. 3. 0. 0. 0. 0.]
NCT00357565,1:23:cancer,Acute myeloid leukemia,['Acute' 'myeloid' 'leukemia'],[3. 3. 3.]
NCT01572480,5:8:cancer,IgA SMM,['IgA' 'SMM'],[0. 3.]
NCT01572480,",59:62:cancer,,,",Progressive increase in M protein level (evolving type of SMM; increase in serum M protein by greater than or equal to 25% on 2 successive evaluations within a 6-month period),"['Progressive' 'increase' 'in' 'M' 'protein' 'level' '(' 'evolving' 'type'
 'of' 'SMM' ';' 'increase' 'in' 'serum' 'M' 'protein' 'by' 'greater'
 'than' 'or' 'equal' 'to' '25' '%' 'on' '2' 'successive' 'evaluations'
 'within' 'a' '6-month' 'period' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01572480,47:50:cancer,patients must also be classified as high-risk SMM per Mayo Clinic or Spanish PETHEMA criteria,"['patients' 'must' 'also' 'be' 'classified' 'as' 'high-risk' 'SMM' 'per'
 'Mayo' 'Clinic' 'or' 'Spanish' 'PETHEMA' 'criteria']",[0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT00930228,",81:97:chronic_disease",Controls will be healthy women with regular menstrual cycles and no evidence of hyperandrogenism,"['Controls' 'will' 'be' 'healthy' 'women' 'with' 'regular' 'menstrual'
 'cycles' 'and' 'no' 'evidence' 'of' 'hyperandrogenism']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT00929006,",19:35:chronic_disease",For girls without hyperandrogenism: serum (calculated) free testosterone concentration within the Tanner stage-specific reference range and the absence of hirsutism,"['For' 'girls' 'without' 'hyperandrogenism' ':' 'serum' '(' 'calculated'
 ')' 'free' 'testosterone' 'concentration' 'within' 'the' 'Tanner'
 'stage-specific' 'reference' 'range' 'and' 'the' 'absence' 'of'
 'hirsutism']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00594217,",56:72:chronic_disease",women with regular menstrual cycles and no evidence of hyperandrogenism,"['women' 'with' 'regular' 'menstrual' 'cycles' 'and' 'no' 'evidence' 'of'
 'hyperandrogenism']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT03186937,58:87:chronic_disease,Participants must have histologically confirmed operable triple negative breast cancer,"['Participants' 'must' 'have' 'histologically' 'confirmed' 'operable'
 'triple' 'negative' 'breast' 'cancer']",[0. 0. 0. 0. 0. 0. 2. 2. 2. 2.]
NCT02531932,"26:55:cancer,,,,,,,","Histologically confirmed triple negative breast cancer (ER< 10%, PR < 10%, Her2neu IHC 0 or 1 or FISH/ISH negative)","['Histologically' 'confirmed' 'triple' 'negative' 'breast' 'cancer' '('
 'ER' '<' '10' '%' ',' 'PR' '<' '10' '%' ',' 'Her2neu' 'IHC' '0' 'or' '1'
 'or' 'FISH/ISH' 'negative' ')']","[0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT03182907,66:86:treatment,is currently participating in or scheduled to participate in any other clinical study with an investigational agent during the 12-week study period,"['is' 'currently' 'participating' 'in' 'or' 'scheduled' 'to' 'participate'
 'in' 'any' 'other' 'clinical' 'study' 'with' 'an' 'investigational'
 'agent' 'during' 'the' '12-week' 'study' 'period']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02508038,19:39:treatment,Enrollment in any other clinical study from screening up to Day 100,"['Enrollment' 'in' 'any' 'other' 'clinical' 'study' 'from' 'screening'
 'up' 'to' 'Day' '100']",[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT03181516,1:13:treatment,Tetracycline,['Tetracycline'],[1.]
NCT02203552,1:13:allergy_name,Tetracycline allergy,['Tetracycline' 'allergy'],[4. 0.]
NCT03179163,1:16:chronic_disease,kidney problems,['kidney' 'problems'],[2. 2.]
NCT00737893,1:16:chronic_disease,kidney problems,['kidney' 'problems'],[2. 2.]
NCT03171480,1:10:chronic_disease,Eclampsia,['Eclampsia'],[2.]
NCT03011567,1:10:chronic_disease,Eclampsia,['Eclampsia'],[2.]
NCT03170401,1:24:chronic_disease,enterocutaneous fistula,['enterocutaneous' 'fistula'],[2. 2.]
NCT03034213,23:46:chronic_disease,Suspected presence of enterocutaneous fistula,['Suspected' 'presence' 'of' 'enterocutaneous' 'fistula'],[0. 0. 0. 2. 2.]
NCT03170375,6:9:chronic_disease,with HTN,['with' 'HTN'],[0. 2.]
NCT01836354,33:36:chronic_disease,Vascular risk factors including HTN history or elevated blood pressure,"['Vascular' 'risk' 'factors' 'including' 'HTN' 'history' 'or' 'elevated'
 'blood' 'pressure']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 0.]
NCT03158974,"1:24:treatment,",Topical corticosteroids if greater than 2 gm/day,['Topical' 'corticosteroids' 'if' 'greater' 'than' '2' 'gm/day'],[1. 1. 0. 0. 0. 0. 0.]
NCT01795313,1:24:treatment,Topical corticosteroids,['Topical' 'corticosteroids'],[1. 1.]
NCT03153410,32:43:treatment,Patient's acceptance to have a core biopsy,"['Patient' ""'s"" 'acceptance' 'to' 'have' 'a' 'core' 'biopsy']",[0. 0. 0. 0. 0. 0. 1. 1.]
NCT02259621,12:23:treatment,Diagnostic core biopsy specimens must be reviewed by a faculty pathologist at SKCCC or MSKCC,"['Diagnostic' 'core' 'biopsy' 'specimens' 'must' 'be' 'reviewed' 'by' 'a'
 'faculty' 'pathologist' 'at' 'SKCCC' 'or' 'MSKCC']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03151330,",50:68:chronic_disease",The subject has known elevated bilirubin levels (hyperbilirubinemia),"['The' 'subject' 'has' 'known' 'elevated' 'bilirubin' 'levels' '('
 'hyperbilirubinemia' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 0.]
NCT03143985,",,,85:103:treatment",Serum total bilirubin ≤ 2.0 mg/dL or >3.0 x ULN for subjects with hereditary benign hyperbilirubinemia,"['Serum' 'total' 'bilirubin' '≤' '2.0' 'mg/dL' 'or' '>' '3.0' 'x' 'ULN'
 'for' 'subjects' 'with' 'hereditary' 'benign' 'hyperbilirubinemia']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT03145298,1:15:chronic_disease,LV dysfunction,['LV' 'dysfunction'],[2. 2.]
NCT00573027,1:15:chronic_disease,LV dysfunction,['LV' 'dysfunction'],[2. 2.]
NCT03143985,41:72:treatment,Patients who are primarily eligible for autologous stem cell transplant,"['Patients' 'who' 'are' 'primarily' 'eligible' 'for' 'autologous' 'stem'
 'cell' 'transplant']",[0. 0. 0. 0. 0. 0. 1. 1. 1. 1.]
NCT02309580,"29:60:treatment,",Patients who have undergone autologous stem cell transplant > 6 months prior,"['Patients' 'who' 'have' 'undergone' 'autologous' 'stem' 'cell'
 'transplant' '>' '6' 'months' 'prior']",[0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0.]
NCT03137082,26:54:chronic_disease,Having any other current Axis I psychiatric disorders or medical conditions requiring treatment or medication,"['Having' 'any' 'other' 'current' 'Axis' 'I' 'psychiatric' 'disorders'
 'or' 'medical' 'conditions' 'requiring' 'treatment' 'or' 'medication']",[0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02332291,36:64:chronic_disease,Current or past diagnoses of other Axis I psychiatric disorders,"['Current' 'or' 'past' 'diagnoses' 'of' 'other' 'Axis' 'I' 'psychiatric'
 'disorders']",[0. 0. 0. 0. 0. 0. 2. 2. 2. 2.]
NCT03135522,1:12:cancer,Lung cancer,['Lung' 'cancer'],[3. 3.]
NCT00924027,1:12:cancer,Lung cancer,['Lung' 'cancer'],[3. 3.]
NCT03133793,1:17:treatment,Heart transplant,['Heart' 'transplant'],[1. 1.]
NCT02519946,"1:17:treatment,",Heart transplant >11 months before baseline visit,['Heart' 'transplant' '>' '11' 'months' 'before' 'baseline' 'visit'],[1. 1. 0. 0. 0. 0. 0. 0.]
NCT03131037,44:56:allergy_name,Known sensitivity or allergic reactions to valacyclovir,['Known' 'sensitivity' 'or' 'allergic' 'reactions' 'to' 'valacyclovir'],[0. 0. 0. 0. 0. 0. 4.]
NCT02446093,1:13:treatment,valacyclovir,['valacyclovir'],[1.]
NCT03127358,14:27:treatment,Eligible for HCV treatment per 2016 AASLD/IDSA guidelines,['Eligible' 'for' 'HCV' 'treatment' 'per' '2016' 'AASLD/IDSA' 'guidelines'],[0. 0. 1. 1. 0. 0. 0. 0.]
NCT03127358,20:33:treatment,Willing to receive HCV treatment on-site at DoSA clinics,"['Willing' 'to' 'receive' 'HCV' 'treatment' 'on-site' 'at' 'DoSA'
 'clinics']",[0. 0. 0. 1. 1. 0. 0. 0. 0.]
NCT03119363,"8:32:chronic_disease,","Severe psychological impairment (e.g., hospitalization for depressive episode in the past 12 months)","['Severe' 'psychological' 'impairment' '(' 'e.g.' ',' 'hospitalization'
 'for' 'depressive' 'episode' 'in' 'the' 'past' '12' 'months' ')']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03090672,13:37:chronic_disease,Systemic or psychological impairment which would preclude patient tolerance and understanding of procedures and follow up,"['Systemic' 'or' 'psychological' 'impairment' 'which' 'would' 'preclude'
 'patient' 'tolerance' 'and' 'understanding' 'of' 'procedures' 'and'
 'follow' 'up']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03116464,11:38:chronic_disease,Caregiver severe cognitive impairment,['Caregiver' 'severe' 'cognitive' 'impairment'],[0. 2. 2. 2.]
NCT02707471,45:72:chronic_disease,"unable to provide meaningful consent (e.g., severe cognitive impairment)","['unable' 'to' 'provide' 'meaningful' 'consent' '(' 'e.g.' ',' 'severe'
 'cognitive' 'impairment' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0.]
NCT03112902,1:23:chronic_disease,restless legs syndrome,['restless' 'legs' 'syndrome'],[2. 2. 2.]
NCT03109210,"1:23:chronic_disease,,",restless legs syndrome (score of >11 in the IRLS),"['restless' 'legs' 'syndrome' '(' 'score' 'of' '>' '11' 'in' 'the' 'IRLS'
 ')']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03112603,16:62:treatment,"Have undergone allogeneic stem cell transplantation (alloSCT) from any donor source (matched unrelated donor, sibling, haplo-identical) using bone marrow, peripheral blood stem cells, or cord blood","['Have' 'undergone' 'allogeneic' 'stem' 'cell' 'transplantation' '('
 'alloSCT' ')' 'from' 'any' 'donor' 'source' '(' 'matched' 'unrelated'
 'donor' ',' 'sibling' ',' 'haplo-identical' ')' 'using' 'bone' 'marrow'
 ',' 'peripheral' 'blood' 'stem' 'cells' ',' 'or' 'cord' 'blood']","[0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02159495,139:185:treatment,In the case of a related donor: The identified donor must be the original donor whose stem cells were used for the research participant's allogeneic stem cell transplantation (alloSCT),"['In' 'the' 'case' 'of' 'a' 'related' 'donor' ':' 'The' 'identified'
 'donor' 'must' 'be' 'the' 'original' 'donor' 'whose' 'stem' 'cells'
 'were' 'used' 'for' 'the' 'research' 'participant' ""'s"" 'allogeneic'
 'stem' 'cell' 'transplantation' '(' 'alloSCT' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 1. 1. 1. 1. 0. 0.]"
NCT03106220,1:28:chronic_disease,"portopulmonary hypertension, inability to perform exercise","['portopulmonary' 'hypertension' ',' 'inability' 'to' 'perform' 'exercise']",[2. 2. 0. 0. 0. 0. 0.]
NCT01481974,41:68:chronic_disease,Those currently receiving treatment for portopulmonary hypertension,"['Those' 'currently' 'receiving' 'treatment' 'for' 'portopulmonary'
 'hypertension']",[0. 0. 0. 0. 0. 2. 2.]
NCT03102580,1:23:chronic_disease,Inflammatory arthritis,['Inflammatory' 'arthritis'],[2. 2.]
NCT03059004,1:23:chronic_disease,Inflammatory arthritis,['Inflammatory' 'arthritis'],[2. 2.]
NCT03097588,48:71:treatment,Subjects who have concurrent illness requiring systemic corticosteroid use,"['Subjects' 'who' 'have' 'concurrent' 'illness' 'requiring' 'systemic'
 'corticosteroid' 'use']",[0. 0. 0. 0. 0. 0. 1. 1. 0.]
NCT02995733,",,,147:170:treatment","Participant must also have an ACT score of 19 or less, or a history of one or more exacerbations in the past year that required patient report of systemic corticosteroid use","['Participant' 'must' 'also' 'have' 'an' 'ACT' 'score' 'of' '19' 'or'
 'less' ',' 'or' 'a' 'history' 'of' 'one' 'or' 'more' 'exacerbations' 'in'
 'the' 'past' 'year' 'that' 'required' 'patient' 'report' 'of' 'systemic'
 'corticosteroid' 'use']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 1. 0.]"
NCT03091790,28:49:treatment,Patient scheduled for open ventral hernia repair at LBJ General Hospital,"['Patient' 'scheduled' 'for' 'open' 'ventral' 'hernia' 'repair' 'at' 'LBJ'
 'General' 'Hospital']",[0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0.]
NCT02969187,1:22:treatment,ventral hernia repair with mesh,['ventral' 'hernia' 'repair' 'with' 'mesh'],[1. 1. 1. 0. 0.]
NCT03088709,23:53:chronic_disease,Transfusion dependent myelodysplastic syndrome (MDS),['Transfusion' 'dependent' 'myelodysplastic' 'syndrome' '(' 'MDS' ')'],[0. 0. 2. 2. 2. 0. 0.]
NCT00357565,11:41:chronic_disease,Preceding myelodysplastic syndrome (MDS),['Preceding' 'myelodysplastic' 'syndrome' '(' 'MDS' ')'],[0. 2. 2. 2. 0. 0.]
NCT03088033,25:38:chronic_disease,Presence of significant valve disease defined by the site cardiologist,"['Presence' 'of' 'significant' 'valve' 'disease' 'defined' 'by' 'the'
 'site' 'cardiologist']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02145351,35:48:chronic_disease,"Significant left sided structural valve disease (>mild stenosis, >moderate regurgitation)","['Significant' 'left' 'sided' 'structural' 'valve' 'disease' '(' '>'
 'mild' 'stenosis' ',' '>' 'moderate' 'regurgitation' ')']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03085485,20:35:chronic_disease,Known Diagnosis of Cystic Fibrosis,['Known' 'Diagnosis' 'of' 'Cystic' 'Fibrosis'],[0. 0. 0. 2. 2.]
NCT02498535,24:39:chronic_disease,Confirmed diagnosis of Cystic Fibrosis,['Confirmed' 'diagnosis' 'of' 'Cystic' 'Fibrosis'],[0. 0. 0. 2. 2.]
NCT03085043,"28:38:cancer,,",Patient is at low risk for metastasis with Gleason score at diagnosis < 8,"['Patient' 'is' 'at' 'low' 'risk' 'for' 'metastasis' 'with' 'Gleason'
 'score' 'at' 'diagnosis' '<' '8']",[0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT01815359,46:56:cancer,Presence of clinically apparent or suspected metastasis to sites other than lymph nodes or peritoneal surfaces,"['Presence' 'of' 'clinically' 'apparent' 'or' 'suspected' 'metastasis'
 'to' 'sites' 'other' 'than' 'lymph' 'nodes' 'or' 'peritoneal' 'surfaces']",[0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03078504,1:5:treatment,CRRT duration of 48 hours or less using NxStage System One dialysis system,"['CRRT' 'duration' 'of' '48' 'hours' 'or' 'less' 'using' 'NxStage'
 'System' 'One' 'dialysis' 'system']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03078504,"24:28:treatment,",successfully tolerated CRRT for at least 4 hours without clotting or hemodynamic instability,"['successfully' 'tolerated' 'CRRT' 'for' 'at' 'least' '4' 'hours'
 'without' 'clotting' 'or' 'hemodynamic' 'instability']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03076333,1:22:chronic_disease,intracranial aneurysm clip,['intracranial' 'aneurysm' 'clip'],[2. 2. 0.]
NCT01801072,13:34:chronic_disease,Presence of intracranial aneurysm (with or without rupture),"['Presence' 'of' 'intracranial' 'aneurysm' '(' 'with' 'or' 'without'
 'rupture' ')']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT03072238,20:58:cancer,adequately treated non-melanomatous carcinoma of the skin,['adequately' 'treated' 'non-melanomatous' 'carcinoma' 'of' 'the' 'skin'],[0. 0. 3. 3. 3. 3. 3.]
NCT02177838,1:39:cancer,non-melanomatous carcinoma of the skin,['non-melanomatous' 'carcinoma' 'of' 'the' 'skin'],[3. 3. 3. 3. 3.]
NCT03069911,62:93:chronic_disease,meet Diagnostic and Statistical Manual (DSM)-IV criteria for major depressive disorder (MDD) as diagnosed by the M.I.N.I. at screening,"['meet' 'Diagnostic' 'and' 'Statistical' 'Manual' '(' 'DSM' ')' '-IV'
 'criteria' 'for' 'major' 'depressive' 'disorder' '(' 'MDD' ')' 'as'
 'diagnosed' 'by' 'the' 'M.I.N.I' '.' 'at' 'screening']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02938559,14:45:chronic_disease,"Diagnosis of major depressive disorder (MDD), first episode, recurrent or chronic, according to DSM-5","['Diagnosis' 'of' 'major' 'depressive' 'disorder' '(' 'MDD' ')' ','
 'first' 'episode' ',' 'recurrent' 'or' 'chronic' ',' 'according' 'to'
 'DSM-5']",[0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03061201,"12:33:chronic_disease,,",History of chronic renal disease or creatinine ≥ 1.5 mg/dL,"['History' 'of' 'chronic' 'renal' 'disease' 'or' 'creatinine' '≥' '1.5'
 'mg/dL']",[0. 0. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT02857283,1:22:chronic_disease,chronic renal disease,['chronic' 'renal' 'disease'],[2. 2. 2.]
NCT03059888,23:40:chronic_disease,Diagnosis of DEFINITE Myasthenia Gravis,['Diagnosis' 'of' 'DEFINITE' 'Myasthenia' 'Gravis'],[0. 0. 0. 2. 2.]
NCT00716066,1:18:chronic_disease,Myasthenia Gravis,['Myasthenia' 'Gravis'],[2. 2.]
NCT03059030,50:80:cancer,worsens postoperative survival in the setting of hepatocellular carcinoma (HCC),"['worsens' 'postoperative' 'survival' 'in' 'the' 'setting' 'of'
 'hepatocellular' 'carcinoma' '(' 'HCC' ')']",[0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 0.]
NCT02762266,11:41:cancer,Confirmed hepatocellular carcinoma (HCC),['Confirmed' 'hepatocellular' 'carcinoma' '(' 'HCC' ')'],[0. 3. 3. 3. 0. 0.]
NCT03058029,"1:25:treatment,",Systemic corticosteroids within one (1) month prior to Screening Visit,"['Systemic' 'corticosteroids' 'within' 'one' '(' '1' ')' 'month' 'prior'
 'to' 'Screening' 'Visit']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02309580,1:25:treatment,Systemic corticosteroids are permissible in the following circumstances,"['Systemic' 'corticosteroids' 'are' 'permissible' 'in' 'the' 'following'
 'circumstances']",[1. 1. 0. 0. 0. 0. 0. 0.]
NCT03054519,1:23:chronic_disease,Critical limb ischemia,['Critical' 'limb' 'ischemia'],[2. 2. 2.]
NCT02388685,1:23:chronic_disease,Critical limb ischemia,['Critical' 'limb' 'ischemia'],[2. 2. 2.]
NCT03052270,7:22:chronic_disease,Major fetal anomalies,['Major' 'fetal' 'anomalies'],[0. 2. 2.]
NCT02469519,13:28:chronic_disease,Known major fetal anomalies,['Known' 'major' 'fetal' 'anomalies'],[0. 0. 2. 2.]
NCT03043794,1:26:cancer,Invasive ductal carcinoma,['Invasive' 'ductal' 'carcinoma'],[3. 3. 3.]
NCT00909909,1:26:cancer,Invasive ductal carcinoma,['Invasive' 'ductal' 'carcinoma'],[3. 3. 3.]
NCT03042767,"1:14:chronic_disease,,,",Acute illness within past 2 weeks prior to enrollment (defined as fever > 100.4ºF),"['Acute' 'illness' 'within' 'past' '2' 'weeks' 'prior' 'to' 'enrollment'
 '(' 'defined' 'as' 'fever' '>' '100.4ºF' ')']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02519946,1:14:chronic_disease,Acute illness,['Acute' 'illness'],[2. 2.]
NCT03040778,17:37:chronic_disease,Patients with a vitamin K deficiency due to any cause,['Patients' 'with' 'a' 'vitamin' 'K' 'deficiency' 'due' 'to' 'any' 'cause'],[0. 0. 0. 2. 2. 2. 0. 0. 0. 0.]
NCT02053792,1:21:chronic_disease,vitamin K deficiency of the newborn,['vitamin' 'K' 'deficiency' 'of' 'the' 'newborn'],[2. 2. 2. 0. 0. 0.]
NCT03036280,"19:55:treatment,",Have received any live vaccine/live attenuated vaccine in the 3 months before randomization,"['Have' 'received' 'any' 'live' 'vaccine/live' 'attenuated' 'vaccine' 'in'
 'the' '3' 'months' 'before' 'randomization']",[0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02956486,"19:55:treatment,",Have received any live vaccine/live attenuated vaccine in the 3 months before randomization,"['Have' 'received' 'any' 'live' 'vaccine/live' 'attenuated' 'vaccine' 'in'
 'the' '3' 'months' 'before' 'randomization']",[0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT03034811,39:59:chronic_disease,Uncooperative patient or patient with neurologic disorders who is incapable of following directions,"['Uncooperative' 'patient' 'or' 'patient' 'with' 'neurologic' 'disorders'
 'who' 'is' 'incapable' 'of' 'following' 'directions']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02607514,1:21:chronic_disease,neurologic disorders,['neurologic' 'disorders'],[2. 2.]
NCT03030118,"78:124:treatment,","Starting, stopping, or changing the dose of over the counter or prescription non-steroidal anti-inflammatory drugs (NSAIDs) in the three months prior to Visit 1","['Starting' ',' 'stopping' ',' 'or' 'changing' 'the' 'dose' 'of' 'over'
 'the' 'counter' 'or' 'prescription' 'non-steroidal' 'anti-inflammatory'
 'drugs' '(' 'NSAIDs' ')' 'in' 'the' 'three' 'months' 'prior' 'to' 'Visit'
 '1']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02833207,1:47:treatment,non-steroidal anti-inflammatory drugs (NSAIDs),['non-steroidal' 'anti-inflammatory' 'drugs' '(' 'NSAIDs' ')'],[1. 1. 1. 1. 0. 0.]
NCT03028012,1:13:chronic_disease,Fibromyalgia,['Fibromyalgia'],[2.]
NCT02657993,1:13:chronic_disease,Fibromyalgia,['Fibromyalgia'],[2.]
NCT03021486,1:9:chronic_disease,"Delirium as per DSM-V criteria (The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5))","['Delirium' 'as' 'per' 'DSM-V' 'criteria' '(' 'The' 'Diagnostic' 'and'
 'Statistical' 'Manual' 'of' 'Mental' 'Disorders' ',' 'Fifth' 'Edition'
 '(' 'DSM-5' ')' ')']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02159560,1:9:chronic_disease,Delirium,['Delirium'],[2.]
NCT03014687,1:17:chronic_disease,Immunodeficiency,['Immunodeficiency'],[2.]
NCT02554383,1:17:chronic_disease,Immunodeficiency,['Immunodeficiency'],[2.]
NCT03009981,"8:35:treatment,",Use of 5-alpha reductase inhibitor within 42 days prior to cycle 1 day 1,"['Use' 'of' '5-alpha' 'reductase' 'inhibitor' 'within' '42' 'days' 'prior'
 'to' 'cycle' '1' 'day' '1']",[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02167009,"95:122:treatment,",Patient has experienced an irregular voiding pattern despite medical management with a stable 5-alpha reductase inhibitor dosage for 3 months or longer,"['Patient' 'has' 'experienced' 'an' 'irregular' 'voiding' 'pattern'
 'despite' 'medical' 'management' 'with' 'a' 'stable' '5-alpha'
 'reductase' 'inhibitor' 'dosage' 'for' '3' 'months' 'or' 'longer']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT03007745,1:30:chronic_disease,obstructive sleep apnea (OSA),['obstructive' 'sleep' 'apnea' '(' 'OSA' ')'],[2. 2. 2. 2. 0. 0.]
NCT02962557,34:63:chronic_disease,Patients with known or suspected obstructive sleep apnea (OSA),"['Patients' 'with' 'known' 'or' 'suspected' 'obstructive' 'sleep' 'apnea'
 '(' 'OSA' ')']",[0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT03006562,22:25:treatment,Active treatment for VTE,['Active' 'treatment' 'for' 'VTE'],[0. 0. 0. 1.]
NCT02464969,22:25:chronic_disease,Presence of an index VTE which is confirmed by imaging,"['Presence' 'of' 'an' 'index' 'VTE' 'which' 'is' 'confirmed' 'by'
 'imaging']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 0.]
NCT02996227,"26:44:treatment,",Expected requirement for parenteral opioids for at least 72 hours for postoperative pain,"['Expected' 'requirement' 'for' 'parenteral' 'opioids' 'for' 'at' 'least'
 '72' 'hours' 'for' 'postoperative' 'pain']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02536170,213:231:treatment,"Pain requiring medical care in an acute care setting (such as the emergency department or ED, hospital ward, day hospital, clinic) not attributable to non-sickle cell causes, that is moderate-to-severe requiring parenteral opioids","['Pain' 'requiring' 'medical' 'care' 'in' 'an' 'acute' 'care' 'setting'
 '(' 'such' 'as' 'the' 'emergency' 'department' 'or' 'ED' ',' 'hospital'
 'ward' ',' 'day' 'hospital' ',' 'clinic' ')' 'not' 'attributable' 'to'
 'non-sickle' 'cell' 'causes' ',' 'that' 'is' 'moderate-to-severe'
 'requiring' 'parenteral' 'opioids']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]"
NCT02993406,",33:40:treatment","inability to tolerate 2 or more statins, one at a low dose","['inability' 'to' 'tolerate' '2' 'or' 'more' 'statins' ',' 'one' 'at' 'a'
 'low' 'dose']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT02433977,"9:16:treatment,","Current statins use (statins lower ADMA levels), patients may stop and re-enroll after 2 weeks of stopping statins","['Current' 'statins' 'use' '(' 'statins' 'lower' 'ADMA' 'levels' ')' ','
 'patients' 'may' 'stop' 'and' 're-enroll' 'after' '2' 'weeks' 'of'
 'stopping' 'statins']",[0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02991248,"1:16:treatment,",Botox injection within 6 months of starting the study,['Botox' 'injection' 'within' '6' 'months' 'of' 'starting' 'the' 'study'],[1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02359253,"1:16:treatment,",Botox injection in upper extremity within 4 months,['Botox' 'injection' 'in' 'upper' 'extremity' 'within' '4' 'months'],[1. 1. 0. 0. 0. 0. 0. 0.]
NCT02986087,1:16:chronic_disease,placenta previa,['placenta' 'previa'],[2. 2.]
NCT02478684,15:30:chronic_disease,Bleeding from placenta previa,['Bleeding' 'from' 'placenta' 'previa'],[0. 0. 2. 2.]
NCT02981069,"30:64:chronic_disease,,,,,,,","Individuals with evidence of proliferative diabetic retinopathy, plasma creatinine >1.4 females or >1.5 males, or 24-hour urine albumin excretion > 300 mg will be excluded","['Individuals' 'with' 'evidence' 'of' 'proliferative' 'diabetic'
 'retinopathy' ',' 'plasma' 'creatinine' '>' '1.4' 'females' 'or' '>'
 '1.5' 'males' ',' 'or' '24-hour' 'urine' 'albumin' 'excretion' '>' '300'
 'mg' 'will' 'be' 'excluded']","[0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02464878,23:57:chronic_disease,Untreated or unstable proliferative diabetic retinopathy,['Untreated' 'or' 'unstable' 'proliferative' 'diabetic' 'retinopathy'],[0. 0. 0. 2. 2. 2.]
NCT02977299,",46:70:treatment","not responded to more than five FDA-approved antidepressant treatment trials of adequate dose and duration during the current episode, or who did not respond to ECT in previous episodes","['not' 'responded' 'to' 'more' 'than' 'five' 'FDA-approved'
 'antidepressant' 'treatment' 'trials' 'of' 'adequate' 'dose' 'and'
 'duration' 'during' 'the' 'current' 'episode' ',' 'or' 'who' 'did' 'not'
 'respond' 'to' 'ECT' 'in' 'previous' 'episodes']","[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02562430,"30:54:treatment,",Patients must have either no antidepressant treatment or stable (for at least 4 weeks prior to screening),"['Patients' 'must' 'have' 'either' 'no' 'antidepressant' 'treatment' 'or'
 'stable' '(' 'for' 'at' 'least' '4' 'weeks' 'prior' 'to' 'screening' ')']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02960555,1:21:cancer,Plasma cell leukemia,['Plasma' 'cell' 'leukemia'],[3. 3. 3.]
NCT02538198,1:21:cancer,Plasma cell leukemia,['Plasma' 'cell' 'leukemia'],[3. 3. 3.]
NCT02946268,1:15:chronic_disease,skin infection involving the neck,['skin' 'infection' 'involving' 'the' 'neck'],[2. 2. 0. 0. 0.]
NCT01698658,11:25:chronic_disease,No active skin infection,['No' 'active' 'skin' 'infection'],[0. 0. 2. 2.]
NCT02942095,49:57:treatment,"Patients that have previously been treated with ixazomib, or participated in a study with ixazomib whether treated with ixazomib or not","['Patients' 'that' 'have' 'previously' 'been' 'treated' 'with' 'ixazomib'
 ',' 'or' 'participated' 'in' 'a' 'study' 'with' 'ixazomib' 'whether'
 'treated' 'with' 'ixazomib' 'or' 'not']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02339922,18:26:allergy_name,"Known allergy to ixazomib, its analogues, or excipients in the various formulations of ixazomib","['Known' 'allergy' 'to' 'ixazomib' ',' 'its' 'analogues' ',' 'or'
 'excipients' 'in' 'the' 'various' 'formulations' 'of' 'ixazomib']",[0. 0. 0. 4. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02932410,6:38:chronic_disease,with pulmonary veno-occlusive disease,['with' 'pulmonary' 'veno-occlusive' 'disease'],[0. 2. 2. 2.]
NCT02554903,12:44:chronic_disease,Documented pulmonary veno-occlusive disease,['Documented' 'pulmonary' 'veno-occlusive' 'disease'],[0. 2. 2. 2.]
NCT02931110,1:21:treatment,dabigatran etexilate,['dabigatran' 'etexilate'],[1. 1.]
NCT02815670,17:37:treatment,Patients taking dabigatran etexilate in the paediatric trials 1160.106 or 1160.108,"['Patients' 'taking' 'dabigatran' 'etexilate' 'in' 'the' 'paediatric'
 'trials' '1160.106' 'or' '1160.108']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02926378,1:18:chronic_disease,"Cerebral aneurysm clips - if magnetic, can move","['Cerebral' 'aneurysm' 'clips' '-' 'if' 'magnetic' ',' 'can' 'move']",[2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02479906,1:18:chronic_disease,Cerebral aneurysm,['Cerebral' 'aneurysm'],[2. 2.]
NCT02924441,20:29:treatment,May not have taken ibuprofen or other pain medication within the Space last 12 hours (ASA 81 mg dose is allowed),"['May' 'not' 'have' 'taken' 'ibuprofen' 'or' 'other' 'pain' 'medication'
 'within' 'the' 'Space' 'last' '12' 'hours' '(' 'ASA' '81' 'mg' 'dose'
 'is' 'allowed' ')']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01238120,20:29:allergy_name,Have an allergy to ibuprofen,['Have' 'an' 'allergy' 'to' 'ibuprofen'],[0. 0. 0. 0. 4.]
NCT02923544,43:55:treatment,Participant must be scheduled for a total laparoscopic,['Participant' 'must' 'be' 'scheduled' 'for' 'a' 'total' 'laparoscopic'],[0. 0. 0. 0. 0. 0. 0. 1.]
NCT02908841,",40:52:treatment",Women scheduled for standard multiport laparoscopic,['Women' 'scheduled' 'for' 'standard' 'multiport' 'laparoscopic'],[0. 0. 0. 0. 0. 1.]
NCT02915744,19:44:chronic_disease,Significant known cardiovascular impairment,['Significant' 'known' 'cardiovascular' 'impairment'],[0. 0. 2. 2.]
NCT01554371,13:38:chronic_disease,Significant cardiovascular impairment,['Significant' 'cardiovascular' 'impairment'],[0. 2. 2.]
NCT02912572,1:19:cancer,Endometrial cancer is very rare in the pediatric population,"['Endometrial' 'cancer' 'is' 'very' 'rare' 'in' 'the' 'pediatric'
 'population']",[3. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT00924027,1:19:cancer,Endometrial cancer,['Endometrial' 'cancer'],[3. 3.]
NCT02911116,1:15:chronic_disease,Active disease is defined,['Active' 'disease' 'is' 'defined'],[2. 2. 0. 0.]
NCT02514083,"1:15:chronic_disease,",Active disease as defined by at least one of the following (IWCLL consensus criteria),"['Active' 'disease' 'as' 'defined' 'by' 'at' 'least' 'one' 'of' 'the'
 'following' '(' 'IWCLL' 'consensus' 'criteria' ')']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02907918,91:103:cancer,Patients with histologically confirmed palpable lymph nodes may be enrolled regardless of breast tumor size,"['Patients' 'with' 'histologically' 'confirmed' 'palpable' 'lymph' 'nodes'
 'may' 'be' 'enrolled' 'regardless' 'of' 'breast' 'tumor' 'size']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0.]
NCT02515110,138:150:cancer,"Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) testing performed on the primary breast tumor","['Estrogen' 'receptor' '(' 'ER' ')' ',' 'progesterone' 'receptor' '(' 'PR'
 ')' ',' 'and' 'human' 'epidermal' 'growth' 'factor' 'receptor' '2' '('
 'HER2' ')' 'testing' 'performed' 'on' 'the' 'primary' 'breast' 'tumor']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 3. 3.]"
NCT02905370,1:17:chronic_disease,Terminal illness,['Terminal' 'illness'],[2. 2.]
NCT02762604,"1:17:chronic_disease,,",Terminal illness with life expectancy <12 months,['Terminal' 'illness' 'with' 'life' 'expectancy' '<' '12' 'months'],[2. 2. 0. 0. 0. 0. 0. 0.]
NCT02901067,14:38:treatment,Inclusion in any other clinical trial,['Inclusion' 'in' 'any' 'other' 'clinical' 'trial'],[0. 0. 1. 1. 1. 1.]
NCT01853163,"21:45:treatment,",has participated in any other clinical trial within 30 days prior to enrolling in this study,"['has' 'participated' 'in' 'any' 'other' 'clinical' 'trial' 'within' '30'
 'days' 'prior' 'to' 'enrolling' 'in' 'this' 'study']",[0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02890979,1:34:chronic_disease,Uncontrolled intercurrent illness,['Uncontrolled' 'intercurrent' 'illness'],[2. 2. 2.]
NCT01659203,1:34:chronic_disease,Uncontrolled intercurrent illness,['Uncontrolled' 'intercurrent' 'illness'],[2. 2. 2.]
NCT02877394,16:33:treatment,Current use of opioid analgesics,['Current' 'use' 'of' 'opioid' 'analgesics'],[0. 0. 0. 1. 1.]
NCT02270619,1:18:treatment,opioid analgesics,['opioid' 'analgesics'],[1. 1.]
NCT02875405,18:30:chronic_disease,preoperative non-sinus rhythm,['preoperative' 'non-sinus' 'rhythm'],[0. 2. 2.]
NCT02750319,13:25:chronic_disease,Patients in sinus rhythm,['Patients' 'in' 'sinus' 'rhythm'],[0. 0. 2. 2.]
NCT02865135,1:18:cancer,carcinoma in situ of the cervix or bladder,['carcinoma' 'in' 'situ' 'of' 'the' 'cervix' 'or' 'bladder'],[3. 3. 3. 0. 0. 0. 0. 0.]
NCT01597518,"15:32:cancer,",Patients with carcinoma in situ of the uterine cervix treated definitely more than 1 year prior to enrollment may enter the study,"['Patients' 'with' 'carcinoma' 'in' 'situ' 'of' 'the' 'uterine' 'cervix'
 'treated' 'definitely' 'more' 'than' '1' 'year' 'prior' 'to' 'enrollment'
 'may' 'enter' 'the' 'study']",[0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02862938,34:43:treatment,Participant has a requirement of acyclovir and/or related products during study duration,"['Participant' 'has' 'a' 'requirement' 'of' 'acyclovir' 'and/or' 'related'
 'products' 'during' 'study' 'duration']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT02446093,23:32:allergy_name,allergic reactions to acyclovir,['allergic' 'reactions' 'to' 'acyclovir'],[0. 0. 0. 4.]
NCT02857218,20:39:chronic_disease,Patients must have regional adenopathy,['Patients' 'must' 'have' 'regional' 'adenopathy'],[0. 0. 0. 2. 2.]
NCT01684904,19:38:chronic_disease,"Patients may have regional adenopathy including para-esophageal, gastric, gastroheptaic and celiac nodes","['Patients' 'may' 'have' 'regional' 'adenopathy' 'including'
 'para-esophageal' ',' 'gastric' ',' 'gastroheptaic' 'and' 'celiac'
 'nodes']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02851407,",,,,206:217:treatment,",Female patients (and female partners of male patients) of childbearing potential who are sexually active must agree to use a highly effective method of contraception with their partners during exposure to defibrotide and for 1 week after the last dose of defibrotide,"['Female' 'patients' '(' 'and' 'female' 'partners' 'of' 'male' 'patients'
 ')' 'of' 'childbearing' 'potential' 'who' 'are' 'sexually' 'active'
 'must' 'agree' 'to' 'use' 'a' 'highly' 'effective' 'method' 'of'
 'contraception' 'with' 'their' 'partners' 'during' 'exposure' 'to'
 'defibrotide' 'and' 'for' '1' 'week' 'after' 'the' 'last' 'dose' 'of'
 'defibrotide']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02675959,47:58:allergy_name,Patients with contraindications to the use of defibrotide,['Patients' 'with' 'contraindications' 'to' 'the' 'use' 'of' 'defibrotide'],[0. 0. 0. 0. 0. 0. 0. 4.]
NCT02844751,"1:25:treatment,",Corticosteroid injection at treatment site within 1 month,['Corticosteroid' 'injection' 'at' 'treatment' 'site' 'within' '1' 'month'],[1. 1. 0. 0. 0. 0. 0. 0.]
NCT02844738,"1:25:treatment,",Corticosteroid injection at treatment site within 1 month,['Corticosteroid' 'injection' 'at' 'treatment' 'site' 'within' '1' 'month'],[1. 1. 0. 0. 0. 0. 0. 0.]
NCT02835729,10:19:treatment,Previous allo-HSCT of any kind,['Previous' 'allo-HSCT' 'of' 'any' 'kind'],[0. 1. 0. 0. 0.]
NCT02203903,37:46:treatment,Patients (Arm A) who have undergone allo-HSCT with high risk for relapse or residual/recurrent disease,"['Patients' '(' 'Arm' 'A' ')' 'who' 'have' 'undergone' 'allo-HSCT' 'with'
 'high' 'risk' 'for' 'relapse' 'or' 'residual/recurrent' 'disease']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02826681,"1:23:chronic_disease,,,,,,,","Iron-deficiency anemia defined as an Hgb <12 g/dl with a ferritin <20 ng/mL, or ferritin <100 when TSAT is <18%","['Iron-deficiency' 'anemia' 'defined' 'as' 'an' 'Hgb' '<' '12' 'g/dl'
 'with' 'a' 'ferritin' '<' '20' 'ng/mL' ',' 'or' 'ferritin' '<' '100'
 'when' 'TSAT' 'is' '<' '18' '%']","[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02531880,1:23:chronic_disease,Iron-deficiency anemia,['Iron-deficiency' 'anemia'],[2. 2.]
NCT02822599,53:71:treatment,Neonatal and infant cardiac patients presenting for open-heart surgery at Nicklaus Children's Hospital,"['Neonatal' 'and' 'infant' 'cardiac' 'patients' 'presenting' 'for'
 'open-heart' 'surgery' 'at' 'Nicklaus' 'Children' ""'s"" 'Hospital']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02718001,15:33:treatment,High risk for open-heart surgery,['High' 'risk' 'for' 'open-heart' 'surgery'],[0. 0. 0. 1. 1.]
NCT02816736,1:26:chronic_disease,constrictive pericarditis,['constrictive' 'pericarditis'],[2. 2.]
NCT01445821,20:45:chronic_disease,Occult or clinical constrictive pericarditis,['Occult' 'or' 'clinical' 'constrictive' 'pericarditis'],[0. 0. 0. 2. 2.]
NCT02811510,8:28:treatment,Taking estrogen supplements,['Taking' 'estrogen' 'supplements'],[0. 1. 1.]
NCT02781519,"8:28:treatment,,",taking estrogen supplements or oral contraceptive pills (for women),"['taking' 'estrogen' 'supplements' 'or' 'oral' 'contraceptive' 'pills' '('
 'for' 'women' ')']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02796209,21:32:allergy_name,"Hypersensitivity to atomoxetine (severe allergic reaction, rash, urticaria, anaphylaxis)","['Hypersensitivity' 'to' 'atomoxetine' '(' 'severe' 'allergic' 'reaction'
 ',' 'rash' ',' 'urticaria' ',' 'anaphylaxis' ')']",[0. 0. 4. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02784535,21:32:allergy_name,Hypersensitivity to atomoxetine,['Hypersensitivity' 'to' 'atomoxetine'],[0. 0. 4.]
NCT02793375,25:36:allergy_name,those with allergies to Montelukast and those currently using Montelukast,"['those' 'with' 'allergies' 'to' 'Montelukast' 'and' 'those' 'currently'
 'using' 'Montelukast']",[0. 0. 0. 0. 4. 0. 0. 0. 0. 0.]
NCT01597518,1:12:treatment,Montelukast,['Montelukast'],[1.]
NCT02781103,26:61:chronic_disease,"Any condition, including neurological or psychiatric illness, which per investigators' judgement may increase subject risk","['Any' 'condition' ',' 'including' 'neurological' 'or' 'psychiatric'
 'illness' ',' 'which' 'per' 'investigators' ""'"" 'judgement' 'may'
 'increase' 'subject' 'risk']",[0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02452203,29:64:chronic_disease,"free of any current or past neurological or psychiatric illness, and capable of performing all tasks during each session of the experiment","['free' 'of' 'any' 'current' 'or' 'past' 'neurological' 'or' 'psychiatric'
 'illness' ',' 'and' 'capable' 'of' 'performing' 'all' 'tasks' 'during'
 'each' 'session' 'of' 'the' 'experiment']",[0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02770547,"1:22:chronic_disease,,,",Uncontrolled Diabetes (HbA1C > 8.5 measured within 3 months prior to date of consent),"['Uncontrolled' 'Diabetes' '(' 'HbA1C' '>' '8.5' 'measured' 'within' '3'
 'months' 'prior' 'to' 'date' 'of' 'consent' ')']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02225548,"1:22:chronic_disease,,",Uncontrolled Diabetes (Hemoglobin A1C > 7.5),['Uncontrolled' 'Diabetes' '(' 'Hemoglobin' 'A1C' '>' '7.5' ')'],[2. 2. 0. 0. 0. 0. 0. 0.]
NCT02762266,107:111:treatment,"Radiographic evidence of persistent, progressive, or recurrent disease in an area previously treated with TACE","['Radiographic' 'evidence' 'of' 'persistent' ',' 'progressive' ',' 'or'
 'recurrent' 'disease' 'in' 'an' 'area' 'previously' 'treated' 'with'
 'TACE']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02762266,",40:44:treatment",determined from 3 months after initial TACE,['determined' 'from' '3' 'months' 'after' 'initial' 'TACE'],[0. 0. 0. 0. 0. 0. 1.]
NCT02759120,"10:31:treatment,",Received antimicrobial therapy in the past 30 days,['Received' 'antimicrobial' 'therapy' 'in' 'the' 'past' '30' 'days'],[0. 1. 1. 0. 0. 0. 0. 0.]
NCT01500551,"53:74:treatment,","Any infection requiring hospitalization, parenteral antimicrobial therapy or judged to be opportunistic by the investigator within the 6 months prior to the first dose of study drug","['Any' 'infection' 'requiring' 'hospitalization' ',' 'parenteral'
 'antimicrobial' 'therapy' 'or' 'judged' 'to' 'be' 'opportunistic' 'by'
 'the' 'investigator' 'within' 'the' '6' 'months' 'prior' 'to' 'the'
 'first' 'dose' 'of' 'study' 'drug']","[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02746458,",173:192:treatment","Additional fracture, dislocations or soft tissue injuries to the study limb that would compromise the ability to weight bear as tolerated and initiate PT within 28 days of definitive fixation","['Additional' 'fracture' ',' 'dislocations' 'or' 'soft' 'tissue'
 'injuries' 'to' 'the' 'study' 'limb' 'that' 'would' 'compromise' 'the'
 'ability' 'to' 'weight' 'bear' 'as' 'tolerated' 'and' 'initiate' 'PT'
 'within' '28' 'days' 'of' 'definitive' 'fixation']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 1.]"
NCT02746458,",156:175:treatment",Injuries to other body systems (or other medical conditions) that would preclude the ability to weight bear as tolerated and initiate PT within 28 days of definitive fixation,"['Injuries' 'to' 'other' 'body' 'systems' '(' 'or' 'other' 'medical'
 'conditions' ')' 'that' 'would' 'preclude' 'the' 'ability' 'to' 'weight'
 'bear' 'as' 'tolerated' 'and' 'initiate' 'PT' 'within' '28' 'days' 'of'
 'definitive' 'fixation']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 1.]"
NCT02743494,16:45:cancer,Diagnosed with cervical esophageal carcinoma,['Diagnosed' 'with' 'cervical' 'esophageal' 'carcinoma'],[0. 0. 3. 3. 3.]
NCT01684904,15:44:cancer,Patients with cervical esophageal carcinoma,['Patients' 'with' 'cervical' 'esophageal' 'carcinoma'],[0. 0. 3. 3. 3.]
NCT02740543,"1:11:treatment,,,,,",Spirometry in the past 6 months or on day of evaluation with a bronchodilator* response of ≥ 12% and 200 ml improvement in FEV,"['Spirometry' 'in' 'the' 'past' '6' 'months' 'or' 'on' 'day' 'of'
 'evaluation' 'with' 'a' 'bronchodilator' '*' 'response' 'of' '≥' '12' '%'
 'and' '200' 'ml' 'improvement' 'in' 'FEV']","[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02181257,42:52:treatment,For patients who are monitored with home Spirometry (subject to Institutional Review Board (IRB) approval),"['For' 'patients' 'who' 'are' 'monitored' 'with' 'home' 'Spirometry' '('
 'subject' 'to' 'Institutional' 'Review' 'Board' '(' 'IRB' ')' 'approval'
 ')']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02734602,12:27:treatment,History of prior radiation exposure for research purposes within the past year such that participation in this study would place them over FDA limits for annual radiation exposure,"['History' 'of' 'prior' 'radiation' 'exposure' 'for' 'research' 'purposes'
 'within' 'the' 'past' 'year' 'such' 'that' 'participation' 'in' 'this'
 'study' 'would' 'place' 'them' 'over' 'FDA' 'limits' 'for' 'annual'
 'radiation' 'exposure']","[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02122081,"18:33:treatment,",Patients who had prior radiation to more than 20% bone marrow containing areas or to any areas exceeding 2000 cGy,"['Patients' 'who' 'had' 'prior' 'radiation' 'to' 'more' 'than' '20' '%'
 'bone' 'marrow' 'containing' 'areas' 'or' 'to' 'any' 'areas' 'exceeding'
 '2000' 'cGy']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02724540,1:23:chronic_disease,hepatic encephalopathy,['hepatic' 'encephalopathy'],[2. 2.]
NCT02562755,1:23:chronic_disease,hepatic encephalopathy,['hepatic' 'encephalopathy'],[2. 2.]
NCT02721303,10:23:chronic_disease,Advanced organ failure,['Advanced' 'organ' 'failure'],[0. 2. 2.]
NCT01816152,7:20:chronic_disease,major organ failure,['major' 'organ' 'failure'],[0. 2. 2.]
NCT02710396,1:36:cancer,squamous cell carcinoma of the skin,['squamous' 'cell' 'carcinoma' 'of' 'the' 'skin'],[3. 3. 3. 3. 3. 3.]
NCT02343549,1:36:cancer,squamous cell carcinoma of the skin,['squamous' 'cell' 'carcinoma' 'of' 'the' 'skin'],[3. 3. 3. 3. 3. 3.]
NCT02706249,21:42:chronic_disease,History of previous venous thromboembolic event (excluding superficial vein thrombosis),"['History' 'of' 'previous' 'venous' 'thromboembolic' 'event' '('
 'excluding' 'superficial' 'vein' 'thrombosis' ')']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02195232,"29:50:chronic_disease,",Prior history of documented venous thromboembolic event within the last 2 years,"['Prior' 'history' 'of' 'documented' 'venous' 'thromboembolic' 'event'
 'within' 'the' 'last' '2' 'years']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02703220,",12:24:chronic_disease",Males with hypogonadism,['Males' 'with' 'hypogonadism'],[0. 0. 2.]
NCT01983475,",16:28:chronic_disease",Men with known hypogonadism prior to SCI,['Men' 'with' 'known' 'hypogonadism' 'prior' 'to' 'SCI'],[0. 0. 0. 2. 0. 0. 0.]
NCT02688647,",48:51:chronic_disease,",Chronic use of N-acetylcysteine prescribed for IPF (> 600 mg/day),"['Chronic' 'use' 'of' 'N-acetylcysteine' 'prescribed' 'for' 'IPF' '(' '>'
 '600' 'mg/day' ')']",[0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0.]
NCT02478268,23:26:chronic_disease,Clinical diagnosis of IPF by established means,['Clinical' 'diagnosis' 'of' 'IPF' 'by' 'established' 'means'],[0. 0. 0. 2. 0. 0. 0.]
NCT02682316,",27:33:allergy_name",Women with sensitivity to silver,['Women' 'with' 'sensitivity' 'to' 'silver'],[0. 0. 0. 0. 4.]
NCT02389023,27:33:allergy_name,Sensitivity or allergy to silver,['Sensitivity' 'or' 'allergy' 'to' 'silver'],[0. 0. 0. 0. 4.]
NCT02679560,"29:45:treatment,",Administration of any other local anesthetic in the 2 hours prior to the study enrollment,"['Administration' 'of' 'any' 'other' 'local' 'anesthetic' 'in' 'the' '2'
 'hours' 'prior' 'to' 'the' 'study' 'enrollment']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02148003,53:69:allergy_name,Subjects who have a history of adverse reactions to local anesthetic,"['Subjects' 'who' 'have' 'a' 'history' 'of' 'adverse' 'reactions' 'to'
 'local' 'anesthetic']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 4.]
NCT02667418,",,,,74:92:treatment",Negative pregnancy test required for females <61 years of age or without prior hysterectomy,"['Negative' 'pregnancy' 'test' 'required' 'for' 'females' '<' '61' 'years'
 'of' 'age' 'or' 'without' 'prior' 'hysterectomy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01037790,",,80:98:treatment,",Females of childbearing potential are defined as sexually mature women without prior hysterectomy or who have had any evidence of menses in the past 12 months,"['Females' 'of' 'childbearing' 'potential' 'are' 'defined' 'as' 'sexually'
 'mature' 'women' 'without' 'prior' 'hysterectomy' 'or' 'who' 'have' 'had'
 'any' 'evidence' 'of' 'menses' 'in' 'the' 'past' '12' 'months']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02665338,1:14:treatment,brain surgery,['brain' 'surgery'],[1. 1.]
NCT01686373,12:25:treatment,History of brain surgery,['History' 'of' 'brain' 'surgery'],[0. 0. 1. 1.]
NCT02660528,1:6:chronic_disease,mania,['mania'],[2.]
NCT02519543,1:6:chronic_disease,mania,['mania'],[2.]
NCT02643381,",52:75:treatment",Adult patient (male or female) requiring emergency endotracheal intubation,"['Adult' 'patient' '(' 'male' 'or' 'female' ')' 'requiring' 'emergency'
 'endotracheal' 'intubation']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02643381,13:36:treatment,who require endotracheal intubation without sedative medication,"['who' 'require' 'endotracheal' 'intubation' 'without' 'sedative'
 'medication']",[0. 0. 1. 1. 0. 0. 0.]
NCT02639546,1:37:chronic_disease,Impaired gastrointestinal absorption,['Impaired' 'gastrointestinal' 'absorption'],[2. 2. 2.]
NCT01433965,1:37:chronic_disease,Impaired gastrointestinal absorption,['Impaired' 'gastrointestinal' 'absorption'],[2. 2. 2.]
NCT02632721,33:69:treatment,Patients who are candidates for allogeneic stem cell transplantation,"['Patients' 'who' 'are' 'candidates' 'for' 'allogeneic' 'stem' 'cell'
 'transplantation']",[0. 0. 0. 0. 0. 1. 1. 1. 1.]
NCT02520791,29:65:treatment,Patients who have undergone allogeneic stem cell transplantation,"['Patients' 'who' 'have' 'undergone' 'allogeneic' 'stem' 'cell'
 'transplantation']",[0. 0. 0. 0. 1. 1. 1. 1.]
NCT02627495,12:24:treatment,"History of neurosurgery, as self-reported","['History' 'of' 'neurosurgery' ',' 'as' 'self-reported']",[0. 0. 1. 0. 0. 0.]
NCT02192359,67:79:treatment,Neurosurgeon finds the prospective participant is able to undergo neurosurgery,"['Neurosurgeon' 'finds' 'the' 'prospective' 'participant' 'is' 'able' 'to'
 'undergo' 'neurosurgery']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02621944,45:55:chronic_disease,clinical signs and symptoms consistent with meningitis detected upon sepsis evaluation,"['clinical' 'signs' 'and' 'symptoms' 'consistent' 'with' 'meningitis'
 'detected' 'upon' 'sepsis' 'evaluation']",[0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0.]
NCT02061761,1:11:chronic_disease,meningitis,['meningitis'],[2.]
NCT02609685,64:91:cancer,Pathologically confirmed Bethesda V or VI thyroid nodules with papillary thyroid carcinoma,"['Pathologically' 'confirmed' 'Bethesda' 'V' 'or' 'VI' 'thyroid' 'nodules'
 'with' 'papillary' 'thyroid' 'carcinoma']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3.]
NCT02138214,"9:36:cancer,",Largest papillary thyroid carcinoma < 1 cm in size on ultrasound,"['Largest' 'papillary' 'thyroid' 'carcinoma' '<' '1' 'cm' 'in' 'size' 'on'
 'ultrasound']",[0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT02595372,"17:53:cancer,,,","Newly diagnosed triple negative breast cancer (TNBC) clinical stage Ic, II, or III","['Newly' 'diagnosed' 'triple' 'negative' 'breast' 'cancer' '(' 'TNBC' ')'
 'clinical' 'stage' 'Ic' ',' 'II' ',' 'or' 'III']",[0. 0. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02264678,22:58:cancer,Second or third line triple negative breast cancer (TNBC),"['Second' 'or' 'third' 'line' 'triple' 'negative' 'breast' 'cancer' '('
 'TNBC' ')']",[0. 0. 0. 0. 3. 3. 3. 3. 3. 0. 0.]
NCT02593123,1:20:chronic_disease,bacterial infection,['bacterial' 'infection'],[2. 2.]
NCT01364467,10:29:chronic_disease,signs of bacterial infection,['signs' 'of' 'bacterial' 'infection'],[0. 0. 2. 2.]
NCT02591147,18:24:chronic_disease,is adjacent to a lesion that is either filled or will receive a filling at the time of enrollment,"['is' 'adjacent' 'to' 'a' 'lesion' 'that' 'is' 'either' 'filled' 'or'
 'will' 'receive' 'a' 'filling' 'at' 'the' 'time' 'of' 'enrollment']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02272998,25:31:chronic_disease,defined as at least one lesion that can be accurately measured in at least one dimension,"['defined' 'as' 'at' 'least' 'one' 'lesion' 'that' 'can' 'be' 'accurately'
 'measured' 'in' 'at' 'least' 'one' 'dimension']",[0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02588326,1:10:chronic_disease,sinusitis,['sinusitis'],[2.]
NCT02554383,61:70:chronic_disease,Meets criteria for persistent or worsening presentations of sinusitis,"['Meets' 'criteria' 'for' 'persistent' 'or' 'worsening' 'presentations'
 'of' 'sinusitis']",[0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02584933,55:64:treatment,Patient currently has unresolved toxicities for which ceritinib dosing has been interrupted in the parent study,"['Patient' 'currently' 'has' 'unresolved' 'toxicities' 'for' 'which'
 'ceritinib' 'dosing' 'has' 'been' 'interrupted' 'in' 'the' 'parent'
 'study']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02584933,64:73:treatment,Patient has been permanently and prematurely discontinued from ceritinib study treatment in the parent study due to any reason,"['Patient' 'has' 'been' 'permanently' 'and' 'prematurely' 'discontinued'
 'from' 'ceritinib' 'study' 'treatment' 'in' 'the' 'parent' 'study' 'due'
 'to' 'any' 'reason']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02582827,19:30:cancer,"Centrally-located lung tumors originating in the lungs and situated in the carinal bifurcation, the lung hila, or the main bronchi","['Centrally-located' 'lung' 'tumors' 'originating' 'in' 'the' 'lungs'
 'and' 'situated' 'in' 'the' 'carinal' 'bifurcation' ',' 'the' 'lung'
 'hila' ',' 'or' 'the' 'main' 'bronchi']",[0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02434809,16:27:cancer,Patients whose lung tumors are being monitored by MR imaging as part of standard clinical care,"['Patients' 'whose' 'lung' 'tumors' 'are' 'being' 'monitored' 'by' 'MR'
 'imaging' 'as' 'part' 'of' 'standard' 'clinical' 'care']",[0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02579044,28:36:chronic_disease,Drugs to treat symptoms of progeria are permitted,['Drugs' 'to' 'treat' 'symptoms' 'of' 'progeria' 'are' 'permitted'],[0. 0. 0. 0. 0. 2. 0. 0.]
NCT02579044,23:31:chronic_disease,Genetically-confirmed progeria,['Genetically-confirmed' 'progeria'],[0. 2.]
NCT02576444,43:51:allergy_name,Patients with a known hypersensitivity to olaparib or any of the excipients of the product,"['Patients' 'with' 'a' 'known' 'hypersensitivity' 'to' 'olaparib' 'or'
 'any' 'of' 'the' 'excipients' 'of' 'the' 'product']",[0. 0. 0. 0. 0. 0. 4. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01858168,27:35:allergy_name,Known hypersensitivity to olaparib or any of the excipients of the product,"['Known' 'hypersensitivity' 'to' 'olaparib' 'or' 'any' 'of' 'the'
 'excipients' 'of' 'the' 'product']",[0. 0. 0. 4. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02574728,"25:37:treatment,",Patients must be off of cannabis oil for 3 days prior to enrollment,"['Patients' 'must' 'be' 'off' 'of' 'cannabis' 'oil' 'for' '3' 'days'
 'prior' 'to' 'enrollment']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02574728,12:24:treatment,The use of cannabis oil is prohibited during the first 2 cycles of this protocol,"['The' 'use' 'of' 'cannabis' 'oil' 'is' 'prohibited' 'during' 'the'
 'first' '2' 'cycles' 'of' 'this' 'protocol']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02573883,12:27:allergy_name,Allergy to topical steroid,['Allergy' 'to' 'topical' 'steroid'],[0. 0. 4. 4.]
NCT02310464,21:36:treatment,Uses of inhaled and topical steroids are allowed,['Uses' 'of' 'inhaled' 'and' 'topical' 'steroids' 'are' 'allowed'],[0. 0. 0. 0. 1. 1. 0. 0.]
NCT02573246,1:24:chronic_disease,Intellectual disability,['Intellectual' 'disability'],[2. 2.]
NCT02242110,1:24:chronic_disease,Intellectual disability,['Intellectual' 'disability'],[2. 2.]
NCT02570984,1:17:treatment,thoracic surgery,['thoracic' 'surgery'],[1. 1.]
NCT02416102,12:28:treatment,History of thoracic surgery,['History' 'of' 'thoracic' 'surgery'],[0. 0. 1. 1.]
NCT02566395,1:29:cancer,Acute lymphoblastic leukemia,['Acute' 'lymphoblastic' 'leukemia'],[3. 3. 3.]
NCT01951885,1:29:cancer,Acute lymphoblastic leukemia,['Acute' 'lymphoblastic' 'leukemia'],[3. 3. 3.]
NCT02565446,1:14:treatment,aneurysm clip,['aneurysm' 'clip'],[1. 1.]
NCT01508390,4:17:treatment,No aneurysm clip in the brain,['No' 'aneurysm' 'clip' 'in' 'the' 'brain'],[0. 1. 1. 0. 0. 0.]
NCT02563678,"19:37:treatment,",Prior work in the hyperbaric chamber in the last 72 hours,"['Prior' 'work' 'in' 'the' 'hyperbaric' 'chamber' 'in' 'the' 'last' '72'
 'hours']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02563678,30:48:treatment,"medically cleared to work as hyperbaric chamber inside attendants, reporting for a regular duty day","['medically' 'cleared' 'to' 'work' 'as' 'hyperbaric' 'chamber' 'inside'
 'attendants' ',' 'reporting' 'for' 'a' 'regular' 'duty' 'day']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02562755,1:28:chronic_disease,bleeding esophageal varices,['bleeding' 'esophageal' 'varices'],[2. 2. 2.]
NCT01811368,14:41:chronic_disease,A history of bleeding esophageal varices,['A' 'history' 'of' 'bleeding' 'esophageal' 'varices'],[0. 0. 0. 2. 2. 2.]
NCT02562040,"19:43:chronic_disease,,",History of severe developmental disability or Adaptive Behavior Assessment System (ABAS-3) score ≤60,"['History' 'of' 'severe' 'developmental' 'disability' 'or' 'Adaptive'
 'Behavior' 'Assessment' 'System' '(' 'ABAS-3' ')' 'score' '≤60']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02481713,13:37:chronic_disease,evidence of developmental disability,['evidence' 'of' 'developmental' 'disability'],[0. 0. 2. 2.]
NCT02556606,42:62:chronic_disease,"Patients with any clinically significant personality disorder that would, in the investigator's judgment, preclude safe study participation","['Patients' 'with' 'any' 'clinically' 'significant' 'personality'
 'disorder' 'that' 'would' ',' 'in' 'the' 'investigator' ""'s"" 'judgment'
 ',' 'preclude' 'safe' 'study' 'participation']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02418195,11:31:chronic_disease,Cluster A personality disorder,['Cluster' 'A' 'personality' 'disorder'],[0. 0. 2. 2.]
NCT02553460,13:37:treatment,one dose of intrathecal chemotherapy,['one' 'dose' 'of' 'intrathecal' 'chemotherapy'],[0. 0. 0. 1. 1.]
NCT02512926,35:59:treatment,"This restriction does not include intrathecal chemotherapy, which is permitted","['This' 'restriction' 'does' 'not' 'include' 'intrathecal' 'chemotherapy'
 ',' 'which' 'is' 'permitted']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0.]
NCT02548546,"50:53:chronic_disease,,",Patients with either symptomatic or asymptomatic AAA as defined by aortic diameter ≥ 1.5x normal diameter,"['Patients' 'with' 'either' 'symptomatic' 'or' 'asymptomatic' 'AAA' 'as'
 'defined' 'by' 'aortic' 'diameter' '≥' '1.5x' 'normal' 'diameter']",[0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01726257,"6:9:chronic_disease,,",Have AAA with sac diameter ≥5.0cm,['Have' 'AAA' 'with' 'sac' 'diameter' '≥5.0cm'],[0. 2. 0. 0. 0. 0.]
NCT02544503,8:24:treatment,Normal MRI of the brain,['Normal' 'MRI' 'of' 'the' 'brain'],[0. 1. 1. 1. 1.]
NCT01389024,175:191:treatment,"Presence or planned permanent (or semi-permanent) metallic structures attached to their body. (e.g., braces on teeth), which their physicians believe will interfere with the MRI of the brain","['Presence' 'or' 'planned' 'permanent' '(' 'or' 'semi-permanent' ')'
 'metallic' 'structures' 'attached' 'to' 'their' 'body' '.' '(' 'e.g.' ','
 'braces' 'on' 'teeth' ')' ',' 'which' 'their' 'physicians' 'believe'
 'will' 'interfere' 'with' 'the' 'MRI' 'of' 'the' 'brain']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1.]"
NCT02543983,"1:33:treatment,",Treatment with a reversible MAOI within 2 weeks prior to study Phase II,"['Treatment' 'with' 'a' 'reversible' 'MAOI' 'within' '2' 'weeks' 'prior'
 'to' 'study' 'Phase' 'II']",[1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02543983,"1:33:treatment,",Treatment with a reversible MAOI within 2 weeks prior to study Phase III,"['Treatment' 'with' 'a' 'reversible' 'MAOI' 'within' '2' 'weeks' 'prior'
 'to' 'study' 'Phase' 'III']",[1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02541903,8:29:chronic_disease,active hepatitis C infection (defined as presence of Hep C RNA),"['active' 'hepatitis' 'C' 'infection' '(' 'defined' 'as' 'presence' 'of'
 'Hep' 'C' 'RNA' ')']",[0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02273375,14:35:chronic_disease,known active hepatitis C infection,['known' 'active' 'hepatitis' 'C' 'infection'],[0. 0. 2. 2. 2.]
NCT02538198,32:66:treatment,"Patients requiring continuous, systemic immunosuppressive therapy","['Patients' 'requiring' 'continuous' ',' 'systemic' 'immunosuppressive'
 'therapy']",[0. 0. 0. 0. 1. 1. 1.]
NCT02439450,36:70:treatment,Any condition requiring concurrent systemic immunosuppressive therapy,"['Any' 'condition' 'requiring' 'concurrent' 'systemic' 'immunosuppressive'
 'therapy']",[0. 0. 0. 0. 1. 1. 1.]
NCT02535312,92:98:treatment,No studies have been performed to assess potential metabolic and transport interactions of TRC102,"['No' 'studies' 'have' 'been' 'performed' 'to' 'assess' 'potential'
 'metabolic' 'and' 'transport' 'interactions' 'of' 'TRC102']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02535312,",,53:59:treatment",Pregnant women are excluded from this study because TRC102 is agent with the potential for teratogenic or abortifacient effects,"['Pregnant' 'women' 'are' 'excluded' 'from' 'this' 'study' 'because'
 'TRC102' 'is' 'agent' 'with' 'the' 'potential' 'for' 'teratogenic' 'or'
 'abortifacient' 'effects']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02531932,43:54:allergy_name,Patients with a known hypersensitivity to carboplatin,['Patients' 'with' 'a' 'known' 'hypersensitivity' 'to' 'carboplatin'],[0. 0. 0. 0. 0. 0. 4.]
NCT02264678,37:48:allergy_name,Contra-indicated for treatment with carboplatin,['Contra-indicated' 'for' 'treatment' 'with' 'carboplatin'],[0. 0. 0. 0. 4.]
NCT02527200,1:32:chronic_disease,Type 2 diabetes mellitus (T2DM),['Type' '2' 'diabetes' 'mellitus' '(' 'T2DM' ')'],[2. 2. 2. 2. 2. 0. 0.]
NCT02412540,"19:50:chronic_disease,,",Poorly controlled Type 2 diabetes mellitus (T2DM) defined as hemoglobin A1C (HgbA1c) > 10%,"['Poorly' 'controlled' 'Type' '2' 'diabetes' 'mellitus' '(' 'T2DM' ')'
 'defined' 'as' 'hemoglobin' 'A1C' '(' 'HgbA1c' ')' '>' '10' '%']",[0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02525029,",42:50:chronic_disease,","Active or recent (within prior 3 months) thrombus, irrespective of anticoagulation status","['Active' 'or' 'recent' '(' 'within' 'prior' '3' 'months' ')' 'thrombus'
 ',' 'irrespective' 'of' 'anticoagulation' 'status']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0.]
NCT02479620,7:15:chronic_disease,Acute thrombus in the target limb,['Acute' 'thrombus' 'in' 'the' 'target' 'limb'],[0. 2. 0. 0. 0. 0.]
NCT02519322,",,87:111:cancer",Patients must have histologically or cytologically confirmed stage IIIB/C or stage IV oligometastatic melanoma,"['Patients' 'must' 'have' 'histologically' 'or' 'cytologically'
 'confirmed' 'stage' 'IIIB/C' 'or' 'stage' 'IV' 'oligometastatic'
 'melanoma']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT02519322,"1:25:cancer,",oligometastatic melanoma is defined as three or fewer areas of resectable disease excluding central nervous system and bone involvement,"['oligometastatic' 'melanoma' 'is' 'defined' 'as' 'three' 'or' 'fewer'
 'areas' 'of' 'resectable' 'disease' 'excluding' 'central' 'nervous'
 'system' 'and' 'bone' 'involvement']",[3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02516670,34:52:cancer,Have a pathological diagnosis of prostate carcinoma,['Have' 'a' 'pathological' 'diagnosis' 'of' 'prostate' 'carcinoma'],[0. 0. 0. 0. 0. 3. 3.]
NCT00467987,5:23:cancer,h/o prostate carcinoma,['h/o' 'prostate' 'carcinoma'],[0. 3. 3.]
NCT02513485,61:69:treatment,"Substance dependence [or abuse within the past year (except nicotine)], unless otherwise approved by the PI or PI's designee","['Substance' 'dependence' '[' 'or' 'abuse' 'within' 'the' 'past' 'year'
 '(' 'except' 'nicotine' ')' ']' ',' 'unless' 'otherwise' 'approved' 'by'
 'the' 'PI' 'or' 'PI' ""'s"" 'designee']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02268448,"8:16:treatment,",Use of nicotine-containing products for the past 6 months prior to study start,"['Use' 'of' 'nicotine-containing' 'products' 'for' 'the' 'past' '6'
 'months' 'prior' 'to' 'study' 'start']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02508311,21:30:allergy_name,Hypersensitivity to albuterol or any of its' constituents,"['Hypersensitivity' 'to' 'albuterol' 'or' 'any' 'of' 'its' ""'""
 'constituents']",[0. 0. 4. 0. 0. 0. 0. 0. 0.]
NCT02401074,"5:14:treatment,,",Pre-albuterol forced expiratory volume in the first second (FEV1) of >70% of the predicted value,"['Pre-albuterol' 'forced' 'expiratory' 'volume' 'in' 'the' 'first'
 'second' '(' 'FEV1' ')' 'of' '>' '70' '%' 'of' 'the' 'predicted' 'value']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02507011,",,24:32:chronic_disease",Second or third degree AV block without a permanent pacemaker,"['Second' 'or' 'third' 'degree' 'AV' 'block' 'without' 'a' 'permanent'
 'pacemaker']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 0.]
NCT02453373,13:21:chronic_disease,High degree AV block,['High' 'degree' 'AV' 'block'],[0. 0. 2. 2.]
NCT02503722,1:31:chronic_disease,Uncontrolled diabetes mellitus,['Uncontrolled' 'diabetes' 'mellitus'],[2. 2. 2.]
NCT02405078,1:31:chronic_disease,Uncontrolled diabetes mellitus,['Uncontrolled' 'diabetes' 'mellitus'],[2. 2. 2.]
NCT02501954,34:55:cancer,Patients with a history of other invasive malignancies,['Patients' 'with' 'a' 'history' 'of' 'other' 'invasive' 'malignancies'],[0. 0. 0. 0. 0. 0. 3. 3.]
NCT00492778,34:55:cancer,Patients with a history of other invasive malignancies,['Patients' 'with' 'a' 'history' 'of' 'other' 'invasive' 'malignancies'],[0. 0. 0. 0. 0. 0. 3. 3.]
NCT02501473,80:94:cancer,"During Patient Expansion, enrollment will be limited to relapsed or refractory follicular NHL","['During' 'Patient' 'Expansion' ',' 'enrollment' 'will' 'be' 'limited'
 'to' 'relapsed' 'or' 'refractory' 'follicular' 'NHL']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT02501473,60:74:cancer,"In Part 4, enrollment is limited to relapsed or refractory follicular NHL patients","['In' 'Part' '4' ',' 'enrollment' 'is' 'limited' 'to' 'relapsed' 'or'
 'refractory' 'follicular' 'NHL' 'patients']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0.]
NCT02498951,",53:65:treatment",Effective contraception is required while receiving obinutuzumab,"['Effective' 'contraception' 'is' 'required' 'while' 'receiving'
 'obinutuzumab']",[0. 0. 0. 0. 0. 0. 1.]
NCT02498951,",,,100:112:treatment","for women, effective contraception is required to continue for >= 12 months after the last dose of obinutuzumab","['for' 'women' ',' 'effective' 'contraception' 'is' 'required' 'to'
 'continue' 'for' '>' '=' '12' 'months' 'after' 'the' 'last' 'dose' 'of'
 'obinutuzumab']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02496611,1:22:chronic_disease,Neurological disorder,['Neurological' 'disorder'],[2. 2.]
NCT02386605,1:22:chronic_disease,Neurological disorder,['Neurological' 'disorder'],[2. 2.]
NCT02495415,"28:53:treatment,",Participation in any other investigational treatment within the 6 weeks prior to enrollment or concurrent with this study,"['Participation' 'in' 'any' 'other' 'investigational' 'treatment' 'within'
 'the' '6' 'weeks' 'prior' 'to' 'enrollment' 'or' 'concurrent' 'with'
 'this' 'study']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02495168,"18:43:treatment,",plans to receive investigational treatment within 30 days after the study is completed,"['plans' 'to' 'receive' 'investigational' 'treatment' 'within' '30' 'days'
 'after' 'the' 'study' 'is' 'completed']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02494869,1:20:chronic_disease,Respiratory failure,['Respiratory' 'failure'],[2. 2.]
NCT02332187,1:20:chronic_disease,Respiratory failure present,['Respiratory' 'failure' 'present'],[2. 2. 0.]
NCT02493257,73:90:chronic_disease,Confirmed negative skin prick test to common allergens (which rules out allergic rhinitis),"['Confirmed' 'negative' 'skin' 'prick' 'test' 'to' 'common' 'allergens'
 '(' 'which' 'rules' 'out' 'allergic' 'rhinitis' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0.]
NCT01976429,1:18:allergy_name,allergic rhinitis symptoms or cold on day of testing,['allergic' 'rhinitis' 'symptoms' 'or' 'cold' 'on' 'day' 'of' 'testing'],[4. 4. 0. 0. 0. 0. 0. 0. 0.]
NCT02489045,15:39:chronic_disease,Patients with congenital heart defects,['Patients' 'with' 'congenital' 'heart' 'defects'],[0. 0. 2. 2. 2.]
NCT02460653,19:43:chronic_disease,Patients who have congenital heart defects,['Patients' 'who' 'have' 'congenital' 'heart' 'defects'],[0. 0. 0. 2. 2. 2.]
NCT02487797,1:33:chronic_disease,spontaneous rupture of membranes,['spontaneous' 'rupture' 'of' 'membranes'],[2. 2. 2. 2.]
NCT02121184,1:33:chronic_disease,spontaneous rupture of membranes,['spontaneous' 'rupture' 'of' 'membranes'],[2. 2. 2. 2.]
NCT02485418,"16:31:treatment,",No long acting triptan therapy within 24 hours,['No' 'long' 'acting' 'triptan' 'therapy' 'within' '24' 'hours'],[0. 0. 0. 1. 1. 0. 0. 0.]
NCT02485418,"19:34:treatment,",No shorter acting triptan therapy within 6 hours,['No' 'shorter' 'acting' 'triptan' 'therapy' 'within' '6' 'hours'],[0. 0. 0. 1. 1. 0. 0. 0.]
NCT02481245,1:20:chronic_disease,delusional disorder,['delusional' 'disorder'],[2. 2.]
NCT02214667,1:20:chronic_disease,delusional disorder,['delusional' 'disorder'],[2. 2.]
NCT02476409,1:19:chronic_disease,Active myocarditis,['Active' 'myocarditis'],[2. 2.]
NCT01128816,1:19:chronic_disease,Active myocarditis,['Active' 'myocarditis'],[2. 2.]
NCT02474199,81:98:treatment,"Any other condition, in the investigator's judgment, that increases the risk of darTregs infusion or prevents safe trial participation","['Any' 'other' 'condition' ',' 'in' 'the' 'investigator' ""'s"" 'judgment'
 ',' 'that' 'increases' 'the' 'risk' 'of' 'darTregs' 'infusion' 'or'
 'prevents' 'safe' 'trial' 'participation']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02474199,",51:68:treatment",IS withdrawal resumes no later than 14 days after darTregs infusion,"['IS' 'withdrawal' 'resumes' 'no' 'later' 'than' '14' 'days' 'after'
 'darTregs' 'infusion']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02471430,30:44:chronic_disease,History or other evidence of severe illness or other conditions,"['History' 'or' 'other' 'evidence' 'of' 'severe' 'illness' 'or' 'other'
 'conditions']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0.]
NCT02075671,28:42:chronic_disease,"Any history or evidence of severe illness or any other condition that would make the patient, in the opinion of the investigator, unsuitable for the study","['Any' 'history' 'or' 'evidence' 'of' 'severe' 'illness' 'or' 'any'
 'other' 'condition' 'that' 'would' 'make' 'the' 'patient' ',' 'in' 'the'
 'opinion' 'of' 'the' 'investigator' ',' 'unsuitable' 'for' 'the' 'study']","[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02468661,21:37:cancer,Locally advanced or metastatic NSCLC,['Locally' 'advanced' 'or' 'metastatic' 'NSCLC'],[0. 0. 0. 3. 3.]
NCT02323126,62:78:cancer,"histologically documented locally advanced, recurrent and/or metastatic NSCLC","['histologically' 'documented' 'locally' 'advanced' ',' 'recurrent'
 'and/or' 'metastatic' 'NSCLC']",[0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT02465060,24:43:chronic_disease,subjects with moderate valvular thickening should not be entered on study,"['subjects' 'with' 'moderate' 'valvular' 'thickening' 'should' 'not' 'be'
 'entered' 'on' 'study']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02257424,24:43:chronic_disease,Subjects with moderate valvular thickening,['Subjects' 'with' 'moderate' 'valvular' 'thickening'],[0. 0. 0. 2. 2.]
NCT02463305,25:46:chronic_disease,"Positive stool test for Clostridium difficile, ova and parasites, or routine stool culture","['Positive' 'stool' 'test' 'for' 'Clostridium' 'difficile' ',' 'ova' 'and'
 'parasites' ',' 'or' 'routine' 'stool' 'culture']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02200445,25:46:chronic_disease,Positive stool test for Clostridium difficile,['Positive' 'stool' 'test' 'for' 'Clostridium' 'difficile'],[0. 0. 0. 0. 2. 2.]
NCT02457845,"1:22:treatment,",Monoclonal antibodies: At least 3 half-lives must have elapsed prior to study entry,"['Monoclonal' 'antibodies' ':' 'At' 'least' '3' 'half-lives' 'must' 'have'
 'elapsed' 'prior' 'to' 'study' 'entry']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01925131,"1:22:treatment,",Monoclonal antibodies must not have been received for 1 week prior to registration,"['Monoclonal' 'antibodies' 'must' 'not' 'have' 'been' 'received' 'for' '1'
 'week' 'prior' 'to' 'registration']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02451553,"1:15:treatment,","Platelet count >= 100,000/uL","['Platelet' 'count' '>' '=' '100,000/uL']",[1. 1. 0. 0. 0.]
NCT01494324,"1:15:treatment,","Platelet count of <50,000 that cannot be corrected with transfusion","['Platelet' 'count' 'of' '<' '50,000' 'that' 'can' 'not' 'be' 'corrected'
 'with' 'transfusion']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02442635,19:38:treatment,Requiring chronic home oxygen therapy,['Requiring' 'chronic' 'home' 'oxygen' 'therapy'],[0. 0. 1. 1. 1.]
NCT02094118,8:27:treatment,Use of home oxygen therapy,['Use' 'of' 'home' 'oxygen' 'therapy'],[0. 0. 1. 1. 1.]
NCT02442297,",124:139:treatment",Sexually active subjects must be willing to utilize one of the more effective birth control methods for 6 months after the T cell infusion,"['Sexually' 'active' 'subjects' 'must' 'be' 'willing' 'to' 'utilize' 'one'
 'of' 'the' 'more' 'effective' 'birth' 'control' 'methods' 'for' '6'
 'months' 'after' 'the' 'T' 'cell' 'infusion']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02146924,70:85:treatment,Research participant has a released cryopreserved T cell product for T cell infusion on approximately day 0,"['Research' 'participant' 'has' 'a' 'released' 'cryopreserved' 'T' 'cell'
 'product' 'for' 'T' 'cell' 'infusion' 'on' 'approximately' 'day' '0']",[0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02437110,29:40:treatment,History of having undergone gastrostomy at the time of screening,"['History' 'of' 'having' 'undergone' 'gastrostomy' 'at' 'the' 'time' 'of'
 'screening']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02127398,1:12:treatment,gastrostomy,['gastrostomy'],[1.]
NCT02433626,1:16:chronic_disease,Angina pectoris,['Angina' 'pectoris'],[2. 2.]
NCT01737502,1:16:chronic_disease,Angina pectoris,['Angina' 'pectoris'],[2. 2.]
NCT02427841,32:60:treatment,Subjects who are receiving any other investigational agents,"['Subjects' 'who' 'are' 'receiving' 'any' 'other' 'investigational'
 'agents']",[0. 0. 0. 0. 0. 1. 1. 1.]
NCT02013492,35:63:treatment,Patients may not be receiving any other investigational agents,"['Patients' 'may' 'not' 'be' 'receiving' 'any' 'other' 'investigational'
 'agents']",[0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02423863,69:84:chronic_disease,"While animal reproductive studies have been negative, the simulated viral infection and anti-proliferative activity of this experimental drug may theoretically affect the developing fetus or nursing infant","['While' 'animal' 'reproductive' 'studies' 'have' 'been' 'negative' ','
 'the' 'simulated' 'viral' 'infection' 'and' 'anti-proliferative'
 'activity' 'of' 'this' 'experimental' 'drug' 'may' 'theoretically'
 'affect' 'the' 'developing' 'fetus' 'or' 'nursing' 'infant']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02404155,1:16:chronic_disease,viral infection,['viral' 'infection'],[2. 2.]
NCT02419495,26:45:treatment,must be recovered from a prior major surgery,['must' 'be' 'recovered' 'from' 'a' 'prior' 'major' 'surgery'],[0. 0. 0. 0. 0. 1. 1. 1.]
NCT02135588,",22:41:treatment",At least 7 days from prior major surgery,['At' 'least' '7' 'days' 'from' 'prior' 'major' 'surgery'],[0. 0. 0. 0. 0. 1. 1. 1.]
NCT02416674,12:34:chronic_disease,Documented psychological disorder(s) or incomplete psychological clearance,"['Documented' 'psychological' 'disorder' '(' 's' ')' 'or' 'incomplete'
 'psychological' 'clearance']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02131389,44:66:chronic_disease,Is a known drug or alcohol abuser or has a psychological disorder that could affect the ability to complete patient reported questionnaires,"['Is' 'a' 'known' 'drug' 'or' 'alcohol' 'abuser' 'or' 'has' 'a'
 'psychological' 'disorder' 'that' 'could' 'affect' 'the' 'ability' 'to'
 'complete' 'patient' 'reported' 'questionnaires']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02414139,29:32:cancer,Patients with characterized ALK-positive rearrangement,['Patients' 'with' 'characterized' 'ALK-positive' 'rearrangement'],[0. 0. 0. 3. 0.]
NCT02201992,31:34:treatment,Patient registered to and the ALK fusion status performed centrally on the ALCHEMIST-SCREEN (ALLIANCE A151216),"['Patient' 'registered' 'to' 'and' 'the' 'ALK' 'fusion' 'status'
 'performed' 'centrally' 'on' 'the' 'ALCHEMIST-SCREEN' '(' 'ALLIANCE'
 'A151216' ')']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02408861,1:18:treatment,anabolic steroids,['anabolic' 'steroids'],[1. 1.]
NCT02408861,8:25:treatment,use of anabolic steroids,['use' 'of' 'anabolic' 'steroids'],[0. 0. 1. 1.]
NCT02401347,14:31:chronic_disease,Known active hepatitis B virus,['Known' 'active' 'hepatitis' 'B' 'virus'],[0. 0. 2. 2. 2.]
NCT01676259,1:18:chronic_disease,hepatitis B virus,['hepatitis' 'B' 'virus'],[2. 2. 2.]
NCT02401074,1:27:chronic_disease,type I or type II diabetes,['type' 'I' 'or' 'type' 'II' 'diabetes'],[2. 2. 2. 2. 2. 2.]
NCT02322203,"28:54:chronic_disease,,",Patients with a history of type I or type II diabetes or HbA1c greater than 6.5%,"['Patients' 'with' 'a' 'history' 'of' 'type' 'I' 'or' 'type' 'II'
 'diabetes' 'or' 'HbA1c' 'greater' 'than' '6.5' '%']",[0. 0. 0. 0. 0. 2. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02393885,"36:50:treatment,",Currently or has participated in a clinical study in the last 3 months prior to signing informed consent,"['Currently' 'or' 'has' 'participated' 'in' 'a' 'clinical' 'study' 'in'
 'the' 'last' '3' 'months' 'prior' 'to' 'signing' 'informed' 'consent']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02366481,"37:51:treatment,",Subjects who have participated in a clinical study more recently than one month before the current study,"['Subjects' 'who' 'have' 'participated' 'in' 'a' 'clinical' 'study' 'more'
 'recently' 'than' 'one' 'month' 'before' 'the' 'current' 'study']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02389517,23:31:allergy_name,History of allergy to mannitol,['History' 'of' 'allergy' 'to' 'mannitol'],[0. 0. 0. 0. 4.]
NCT01754857,63:71:allergy_name,Subjects must not have a known history of hypersensitivity to mannitol,"['Subjects' 'must' 'not' 'have' 'a' 'known' 'history' 'of'
 'hypersensitivity' 'to' 'mannitol']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4.]
NCT02387905,21:43:treatment,Patients undergoing bisphosphonate therapy,['Patients' 'undergoing' 'bisphosphonate' 'therapy'],[0. 0. 1. 1.]
NCT01968590,"1:23:treatment,",bisphosphonate therapy for more than 3 months,['bisphosphonate' 'therapy' 'for' 'more' 'than' '3' 'months'],[1. 1. 0. 0. 0. 0. 0.]
NCT02370056,12:23:treatment,completion proctectomy,['completion' 'proctectomy'],[0. 1.]
NCT02160288,7:18:treatment,Prior proctectomy,['Prior' 'proctectomy'],[0. 1.]
NCT02366819,14:42:treatment,Eligible for surgery with curative intent,['Eligible' 'for' 'surgery' 'with' 'curative' 'intent'],[0. 0. 1. 1. 1. 1.]
NCT01730118,",46:74:treatment",Greater than or equal to 6 weeks s/p primary surgery with curative intent,"['Greater' 'than' 'or' 'equal' 'to' '6' 'weeks' 's/p' 'primary' 'surgery'
 'with' 'curative' 'intent']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1.]
NCT02362308,24:51:chronic_disease,Clinically significant gastrointestinal impairment that could interfere with drug absorption,"['Clinically' 'significant' 'gastrointestinal' 'impairment' 'that' 'could'
 'interfere' 'with' 'drug' 'absorption']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02130687,24:51:chronic_disease,Clinically significant gastrointestinal impairment that could interfere with drug absorption,"['Clinically' 'significant' 'gastrointestinal' 'impairment' 'that' 'could'
 'interfere' 'with' 'drug' 'absorption']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02355002,1:22:treatment,deep brain stimulator,['deep' 'brain' 'stimulator'],[1. 1. 1.]
NCT02343549,1:22:treatment,deep brain stimulator,['deep' 'brain' 'stimulator'],[1. 1. 1.]
NCT02354547,72:102:treatment,Patients must have fully recovered from the acute toxic effects of all prior anti-cancer chemotherapy,"['Patients' 'must' 'have' 'fully' 'recovered' 'from' 'the' 'acute' 'toxic'
 'effects' 'of' 'all' 'prior' 'anti-cancer' 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT01614197,72:102:treatment,Patients must have fully recovered from the acute toxic effects of all prior anti-cancer chemotherapy,"['Patients' 'must' 'have' 'fully' 'recovered' 'from' 'the' 'acute' 'toxic'
 'effects' 'of' 'all' 'prior' 'anti-cancer' 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02352480,"22:30:treatment,",Subject has received UCC care for ≥ 2 weeks at treating wound clinic,"['Subject' 'has' 'received' 'UCC' 'care' 'for' '≥' '2' 'weeks' 'at'
 'treating' 'wound' 'clinic']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02352454,"22:30:treatment,",Subject has received UCC care for ≥ 2 weeks at treating wound clinic,"['Subject' 'has' 'received' 'UCC' 'care' 'for' '≥' '2' 'weeks' 'at'
 'treating' 'wound' 'clinic']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02347891,"13:46:treatment,,",Patients on intravenous gamma globulin (IVIG) have to be on a stable dose and frequency regimen for ≥ 3 months,"['Patients' 'on' 'intravenous' 'gamma' 'globulin' '(' 'IVIG' ')' 'have'
 'to' 'be' 'on' 'a' 'stable' 'dose' 'and' 'frequency' 'regimen' 'for' '≥'
 '3' 'months']",[0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01306019,"30:63:treatment,,,",demonstrated requirement for intravenous gamma globulin (IVIG) (significant drop over 3 to 6 weeks between peak and trough IgG levels),"['demonstrated' 'requirement' 'for' 'intravenous' 'gamma' 'globulin' '('
 'IVIG' ')' '(' 'significant' 'drop' 'over' '3' 'to' '6' 'weeks' 'between'
 'peak' 'and' 'trough' 'IgG' 'levels' ')']",[0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02343042,14:33:chronic_disease,"Known active hepatitis A, B or C","['Known' 'active' 'hepatitis' 'A' ',' 'B' 'or' 'C']",[0. 0. 2. 2. 2. 2. 2. 0.]
NCT01895777,24:43:chronic_disease,"including known active hepatitis A, B or C","['including' 'known' 'active' 'hepatitis' 'A' ',' 'B' 'or' 'C']",[0. 0. 0. 2. 2. 2. 2. 2. 0.]
NCT02341209,",,,152:163:treatment",Women of childbearing potential (WOCBP) must have a negative pregnancy test within 7 days of receiving study medication and monthly while on receiving doxycycline,"['Women' 'of' 'childbearing' 'potential' '(' 'WOCBP' ')' 'must' 'have' 'a'
 'negative' 'pregnancy' 'test' 'within' '7' 'days' 'of' 'receiving'
 'study' 'medication' 'and' 'monthly' 'while' 'on' 'receiving'
 'doxycycline']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1.]"
NCT01917721,45:56:treatment,Patients whose parents refuse to administer doxycycline,['Patients' 'whose' 'parents' 'refuse' 'to' 'administer' 'doxycycline'],[0. 0. 0. 0. 0. 0. 1.]
NCT02339233,34:57:chronic_disease,stable medical condition without cardiopulmonary disease,['stable' 'medical' 'condition' 'without' 'cardiopulmonary' 'disease'],[0. 0. 0. 0. 2. 2.]
NCT02329652,8:31:chronic_disease,severe cardiopulmonary disease,['severe' 'cardiopulmonary' 'disease'],[0. 2. 2.]
NCT02332369,14:30:chronic_disease,Preoperative ocular infection,['Preoperative' 'ocular' 'infection'],[0. 2. 2.]
NCT02148263,8:24:chronic_disease,Active ocular infection,['Active' 'ocular' 'infection'],[0. 2. 2.]
NCT02327403,12:26:treatment,patient on mTOR inhibitor,['patient' 'on' 'mTOR' 'inhibitor'],[0. 0. 1. 1.]
NCT01734512,51:65:treatment,Patients who have been previously treated with an mTOR inhibitor,"['Patients' 'who' 'have' 'been' 'previously' 'treated' 'with' 'an' 'mTOR'
 'inhibitor']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02323191,1:23:cancer,Leptomeningeal disease,['Leptomeningeal' 'disease'],[3. 3.]
NCT01622868,1:23:cancer,Leptomeningeal disease,['Leptomeningeal' 'disease'],[3. 3.]
NCT02317991,10:21:chronic_disease,Adequate hematologic,['Adequate' 'hematologic'],[0. 2.]
NCT01999179,9:20:chronic_disease,Current hematologic,['Current' 'hematologic'],[0. 2.]
NCT02315612,43:73:treatment,There is no time restriction in regard to prior intrathecal chemotherapy provided there is complete recovery from any acute toxic effects,"['There' 'is' 'no' 'time' 'restriction' 'in' 'regard' 'to' 'prior'
 'intrathecal' 'chemotherapy' 'provided' 'there' 'is' 'complete'
 'recovery' 'from' 'any' 'acute' 'toxic' 'effects']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01430390,43:73:treatment,There is no time restriction in regard to prior intrathecal chemotherapy provided tere is complete recovery from any acute toxic effects of such,"['There' 'is' 'no' 'time' 'restriction' 'in' 'regard' 'to' 'prior'
 'intrathecal' 'chemotherapy' 'provided' 'tere' 'is' 'complete' 'recovery'
 'from' 'any' 'acute' 'toxic' 'effects' 'of' 'such']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02309580,56:75:cancer,Patients who have a standard curative option for their lymphoid malignancy at current state of disease,"['Patients' 'who' 'have' 'a' 'standard' 'curative' 'option' 'for' 'their'
 'lymphoid' 'malignancy' 'at' 'current' 'state' 'of' 'disease']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0.]
NCT01994382,21:40:cancer,Prior treatment for lymphoid malignancy for progressive /refractory disease,"['Prior' 'treatment' 'for' 'lymphoid' 'malignancy' 'for' 'progressive'
 '/refractory' 'disease']",[0. 0. 0. 3. 3. 0. 0. 0. 0.]
NCT02304458,47:63:treatment,"Parts C, D, and E: patients who have received prior ipilimumab","['Parts' 'C' ',' 'D' ',' 'and' 'E' ':' 'patients' 'who' 'have' 'received'
 'prior' 'ipilimumab']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01896999,32:48:treatment,patients may not have received prior ipilimumab,['patients' 'may' 'not' 'have' 'received' 'prior' 'ipilimumab'],[0. 0. 0. 0. 0. 1. 1.]
NCT02290951,52:64:allergy_name,History of hypersensitivity to any compound in the tetracycline antibiotics group,"['History' 'of' 'hypersensitivity' 'to' 'any' 'compound' 'in' 'the'
 'tetracycline' 'antibiotics' 'group']",[0. 0. 0. 0. 0. 0. 0. 0. 4. 0. 0.]
NCT02133885,7:19:treatment,other tetracycline,['other' 'tetracycline'],[0. 1.]
NCT02272998,1:30:treatment,anti-hypertensive medications are permitted,['anti-hypertensive' 'medications' 'are' 'permitted'],[1. 1. 0. 0.]
NCT02133885,6:35:treatment,more anti-hypertensive medications of different classes,['more' 'anti-hypertensive' 'medications' 'of' 'different' 'classes'],[0. 1. 1. 0. 0. 0.]
NCT02266784,38:53:chronic_disease,Has a primary diagnosis of any other Axis I Disorder (determined by the Structured Diagnostic Interview for DSM; SCID) that is significantly impairing and would contraindicate participation in the present study,"['Has' 'a' 'primary' 'diagnosis' 'of' 'any' 'other' 'Axis' 'I' 'Disorder'
 '(' 'determined' 'by' 'the' 'Structured' 'Diagnostic' 'Interview' 'for'
 'DSM' ';' 'SCID' ')' 'that' 'is' 'significantly' 'impairing' 'and'
 'would' 'contraindicate' 'participation' 'in' 'the' 'present' 'study']","[0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02067975,20:35:chronic_disease,No DSM-IV-TR/DSM-5 Axis I Disorder (documented by SCID),"['No' 'DSM-IV-TR/DSM-5' 'Axis' 'I' 'Disorder' '(' 'documented' 'by' 'SCID'
 ')']",[0. 0. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT02255383,1:20:chronic_disease,Skeletal immaturity,['Skeletal' 'immaturity'],[2. 2.]
NCT02015390,"1:20:chronic_disease,,",Skeletal immaturity (open growth plate and/or age <18 years),"['Skeletal' 'immaturity' '(' 'open' 'growth' 'plate' 'and/or' 'age' '<'
 '18' 'years' ')']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02250664,43:66:chronic_disease,Be without current (within the past year) serious mental disorder that would interfere with study results or completion as determined by the licensed medical professional or PI,"['Be' 'without' 'current' '(' 'within' 'the' 'past' 'year' ')' 'serious'
 'mental' 'disorder' 'that' 'would' 'interfere' 'with' 'study' 'results'
 'or' 'completion' 'as' 'determined' 'by' 'the' 'licensed' 'medical'
 'professional' 'or' 'PI']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02250534,40:63:chronic_disease,without current (within the past year) serious mental disorder,"['without' 'current' '(' 'within' 'the' 'past' 'year' ')' 'serious'
 'mental' 'disorder']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT02243813,"33:51:treatment,","Agree to refrain from using any psychoactive drugs, including alcoholic beverages and nicotine, 24 hours before and after each drug administration","['Agree' 'to' 'refrain' 'from' 'using' 'any' 'psychoactive' 'drugs' ','
 'including' 'alcoholic' 'beverages' 'and' 'nicotine' ',' '24' 'hours'
 'before' 'and' 'after' 'each' 'drug' 'administration']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02233868,20:38:treatment,Urine positive for psychoactive drugs (clinical laboratory results) on study days involving imaging (PET and MRI) and neuropsychological testing,"['Urine' 'positive' 'for' 'psychoactive' 'drugs' '(' 'clinical'
 'laboratory' 'results' ')' 'on' 'study' 'days' 'involving' 'imaging' '('
 'PET' 'and' 'MRI' ')' 'and' 'neuropsychological' 'testing']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02233868,12:32:chronic_disease,"History of coagulation disorder (clinical laboratory results, medical history)","['History' 'of' 'coagulation' 'disorder' '(' 'clinical' 'laboratory'
 'results' ',' 'medical' 'history' ')']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01912612,24:44:chronic_disease,Clinically significant coagulation disorder,['Clinically' 'significant' 'coagulation' 'disorder'],[0. 0. 2. 2.]
NCT02232516,1:35:cancer,Angioimmunoblastic T-cell lymphoma,['Angioimmunoblastic' 'T-cell' 'lymphoma'],[3. 3. 3.]
NCT01787409,1:35:cancer,Angioimmunoblastic T-cell lymphoma,['Angioimmunoblastic' 'T-cell' 'lymphoma'],[3. 3. 3.]
NCT02221830,21:29:allergy_name,contraindication to oxytocin,['contraindication' 'to' 'oxytocin'],[0. 0. 4.]
NCT02121184,9:17:treatment,Receive oxytocin,['Receive' 'oxytocin'],[0. 1.]
NCT02208362,44:57:treatment,Research participant must have appropriate venous access,['Research' 'participant' 'must' 'have' 'appropriate' 'venous' 'access'],[0. 0. 0. 0. 0. 1. 1.]
NCT02146924,30:43:treatment,he/she must have appropriate venous access,['he/she' 'must' 'have' 'appropriate' 'venous' 'access'],[0. 0. 0. 0. 1. 1.]
NCT02197351,16:31:treatment,presenting for upper endoscopy for gastric indications,['presenting' 'for' 'upper' 'endoscopy' 'for' 'gastric' 'indications'],[0. 0. 1. 1. 0. 0. 0.]
NCT01953575,33:48:treatment,undergoing clinically indicated upper endoscopy,['undergoing' 'clinically' 'indicated' 'upper' 'endoscopy'],[0. 0. 0. 1. 1.]
NCT02192398,"7:17:treatment,",Takes vitamin B2 > 1.6mg/day during the study,['Takes' 'vitamin' 'B2' '>' '1.6mg/day' 'during' 'the' 'study'],[0. 1. 1. 0. 0. 0. 0. 0.]
NCT01681264,"7:17:treatment,",Takes vitamin B2 > 1.6mg/day during the study,['Takes' 'vitamin' 'B2' '>' '1.6mg/day' 'during' 'the' 'study'],[0. 1. 1. 0. 0. 0. 0. 0.]
NCT02181478,95:110:chronic_disease,subjects must be in CNS remission at the time of protocol enrollment if there is a history of CNS involvement,"['subjects' 'must' 'be' 'in' 'CNS' 'remission' 'at' 'the' 'time' 'of'
 'protocol' 'enrollment' 'if' 'there' 'is' 'a' 'history' 'of' 'CNS'
 'involvement']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01896999,50:65:chronic_disease,Patient must have no current or prior history of CNS involvement,"['Patient' 'must' 'have' 'no' 'current' 'or' 'prior' 'history' 'of' 'CNS'
 'involvement']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02177292,12:42:treatment,History of prior pelvic radiation therapy,['History' 'of' 'prior' 'pelvic' 'radiation' 'therapy'],[0. 0. 1. 1. 1. 1.]
NCT02008656,4:34:treatment,No prior pelvic radiation therapy,['No' 'prior' 'pelvic' 'radiation' 'therapy'],[0. 1. 1. 1. 1.]
NCT02159495,37:52:cancer,Research participants has undergone lymphodepletion,['Research' 'participants' 'has' 'undergone' 'lymphodepletion'],[0. 0. 0. 0. 3.]
NCT02146924,36:51:treatment,Research participant has undergone lymphodepletion,['Research' 'participant' 'has' 'undergone' 'lymphodepletion'],[0. 0. 0. 0. 1.]
NCT02152995,58:68:treatment,Animal reproductive studies have not been conducted with trametinib,"['Animal' 'reproductive' 'studies' 'have' 'not' 'been' 'conducted' 'with'
 'trametinib']",[0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02152995,",,,182:192:treatment","men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of trametinib administration","['men' 'treated' 'or' 'enrolled' 'on' 'this' 'protocol' 'must' 'also'
 'agree' 'to' 'use' 'adequate' 'contraception' 'prior' 'to' 'the' 'study'
 ',' 'for' 'the' 'duration' 'of' 'study' 'participation' ',' 'and' '4'
 'months' 'after' 'completion' 'of' 'trametinib' 'administration']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]"
NCT02152956,20:37:chronic_disease,resolved childhood atopic dermatitis,['resolved' 'childhood' 'atopic' 'dermatitis'],[0. 0. 2. 2.]
NCT02148796,21:38:chronic_disease,Physician-diagnosed atopic dermatitis in the participant,['Physician-diagnosed' 'atopic' 'dermatitis' 'in' 'the' 'participant'],[0. 2. 2. 0. 0. 0.]
NCT02145351,13:44:chronic_disease,Non-group 2 pulmonary arterial hypertension,['Non-group' '2' 'pulmonary' 'arterial' 'hypertension'],[0. 0. 2. 2. 2.]
NCT01620216,7:38:chronic_disease,Known pulmonary arterial hypertension,['Known' 'pulmonary' 'arterial' 'hypertension'],[0. 2. 2. 2.]
NCT02140255,1:12:treatment,ART regimen (described in criteria above) was taken daily from date of initiation until study entry,"['ART' 'regimen' '(' 'described' 'in' 'criteria' 'above' ')' 'was' 'taken'
 'daily' 'from' 'date' 'of' 'initiation' 'until' 'study' 'entry']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01896921,",,,57:68:treatment",HIV RNA ≤ 50 copies/ml for ≥ 12 months while taking any ART regimen,"['HIV' 'RNA' '≤' '50' 'copies/ml' 'for' '≥' '12' 'months' 'while' 'taking'
 'any' 'ART' 'regimen']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02131467,1:13:treatment,pioglitazone,['pioglitazone'],[1.]
NCT00904046,21:33:treatment,Contraindication to pioglitazone use,['Contraindication' 'to' 'pioglitazone' 'use'],[0. 0. 1. 0.]
NCT02128906,",54:71:cancer",must be disease-free for at least 2 years except for carcinoma-in-situ of cervix,"['must' 'be' 'disease-free' 'for' 'at' 'least' '2' 'years' 'except' 'for'
 'carcinoma-in-situ' 'of' 'cervix']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0.]
NCT01737502,1:18:cancer,carcinoma-in-situ of the cervix,['carcinoma-in-situ' 'of' 'the' 'cervix'],[3. 0. 0. 0.]
NCT02124772,",,,,149:176:treatment","Adequate bone marrow function defined as absolute neutrophil count (ANC) >=1000/microliter, hemoglobin >=8.0 gram per deciliter (g/dL) (may receive red blood cell transfusions)","['Adequate' 'bone' 'marrow' 'function' 'defined' 'as' 'absolute'
 'neutrophil' 'count' '(' 'ANC' ')' '>' '=1000/microliter' ','
 'hemoglobin' '>' '=8.0' 'gram' 'per' 'deciliter' '(' 'g/dL' ')' '(' 'may'
 'receive' 'red' 'blood' 'cell' 'transfusions' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 1. 1. 1. 0.]"
NCT02004275,1:28:treatment,red blood cell transfusions are allowed at any time,['red' 'blood' 'cell' 'transfusions' 'are' 'allowed' 'at' 'any' 'time'],[1. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02111850,1:36:treatment,Concurrent systemic steroid therapy,['Concurrent' 'systemic' 'steroid' 'therapy'],[1. 1. 1. 1.]
NCT01174121,1:36:treatment,Concurrent systemic steroid therapy,['Concurrent' 'systemic' 'steroid' 'therapy'],[1. 1. 1. 1.]
NCT02107261,16:24:chronic_disease,Patients whose dystonia is not severe enough to interfere with musical performance in the opinion of a skilled examiner,"['Patients' 'whose' 'dystonia' 'is' 'not' 'severe' 'enough' 'to'
 'interfere' 'with' 'musical' 'performance' 'in' 'the' 'opinion' 'of' 'a'
 'skilled' 'examiner']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02107261,35:43:chronic_disease,Patients with focal task-specific dystonia of one or both hands,"['Patients' 'with' 'focal' 'task-specific' 'dystonia' 'of' 'one' 'or'
 'both' 'hands']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 0.]
NCT02089607,40:54:treatment,"A sealing zone in the target aorta (or surgical graft) that is proximal to the primary dissection, such that a stent-graft would be anticipated to seal off the dissection lumen","['A' 'sealing' 'zone' 'in' 'the' 'target' 'aorta' '(' 'or' 'surgical'
 'graft' ')' 'that' 'is' 'proximal' 'to' 'the' 'primary' 'dissection' ','
 'such' 'that' 'a' 'stent-graft' 'would' 'be' 'anticipated' 'to' 'seal'
 'off' 'the' 'dissection' 'lumen']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02089607,17:31:treatment,Native aorta or surgical graft,['Native' 'aorta' 'or' 'surgical' 'graft'],[0. 0. 0. 1. 1.]
NCT02085941,32:44:treatment,may not be receiving any other study agents,['may' 'not' 'be' 'receiving' 'any' 'other' 'study' 'agents'],[0. 0. 0. 0. 0. 0. 1. 1.]
NCT01898793,46:58:allergy_name,Known hypersensitivity to one or more of the study agents,"['Known' 'hypersensitivity' 'to' 'one' 'or' 'more' 'of' 'the' 'study'
 'agents']",[0. 0. 0. 0. 0. 0. 0. 0. 4. 4.]
NCT02074631,31:42:allergy_name,Known or suspected allergy to pamidronate or related products,"['Known' 'or' 'suspected' 'allergy' 'to' 'pamidronate' 'or' 'related'
 'products']",[0. 0. 0. 0. 0. 4. 0. 0. 0.]
NCT02074631,",,,,189:200:treatment",Pregnancy or breastfeeding - menstruating females must have a negative pregnancy test prior to study enrollment and agree to repeat pregnancy testing and contraception use per protocol as pamidronate is Pregnancy Category D - positive evidence of human fetal risk based on adverse reaction data,"['Pregnancy' 'or' 'breastfeeding' '-' 'menstruating' 'females' 'must'
 'have' 'a' 'negative' 'pregnancy' 'test' 'prior' 'to' 'study'
 'enrollment' 'and' 'agree' 'to' 'repeat' 'pregnancy' 'testing' 'and'
 'contraception' 'use' 'per' 'protocol' 'as' 'pamidronate' 'is'
 'Pregnancy' 'Category' 'D' '-' 'positive' 'evidence' 'of' 'human' 'fetal'
 'risk' 'based' 'on' 'adverse' 'reaction' 'data']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02040610,",,59:68:treatment",Patients with 2 or 3 risk factors will require a negative bone scan for eligibility,"['Patients' 'with' '2' 'or' '3' 'risk' 'factors' 'will' 'require' 'a'
 'negative' 'bone' 'scan' 'for' 'eligibility']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.]
NCT02012296,",26:35:treatment",2 or more new lesions on bone scan,['2' 'or' 'more' 'new' 'lesions' 'on' 'bone' 'scan'],[0. 0. 0. 0. 0. 0. 1. 1.]
NCT02030028,1:24:chronic_disease,Abnormal renal function,['Abnormal' 'renal' 'function'],[2. 2. 2.]
NCT01851694,1:24:chronic_disease,Abnormal renal function,['Abnormal' 'renal' 'function'],[2. 2. 2.]
NCT02015390,49:72:treatment,Defect and/or soft tissue status ineligible for surgical reconstruction,"['Defect' 'and/or' 'soft' 'tissue' 'status' 'ineligible' 'for' 'surgical'
 'reconstruction']",[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02015390,",101:124:treatment","Presence of an extremity long bone (femur, tibia, humerus, ulna, radius) segmental defect requiring surgical reconstruction with at least one of the following etiologies","['Presence' 'of' 'an' 'extremity' 'long' 'bone' '(' 'femur' ',' 'tibia'
 ',' 'humerus' ',' 'ulna' ',' 'radius' ')' 'segmental' 'defect'
 'requiring' 'surgical' 'reconstruction' 'with' 'at' 'least' 'one' 'of'
 'the' 'following' 'etiologies']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02003222,68:80:treatment,Patients should meet the eligibility criteria for RANDOMIZATION TO BLINATUMOMAB OR NO BLINATUMOMAB-STEP 3,"['Patients' 'should' 'meet' 'the' 'eligibility' 'criteria' 'for'
 'RANDOMIZATION' 'TO' 'BLINATUMOMAB' 'OR' 'NO' 'BLINATUMOMAB-STEP' '3']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02003222,18:30:treatment,RANDOMIZATION TO BLINATUMOMAB OR NO BLINATUMOMAB-STEP 3,['RANDOMIZATION' 'TO' 'BLINATUMOMAB' 'OR' 'NO' 'BLINATUMOMAB-STEP' '3'],[0. 0. 1. 0. 0. 0. 0.]
NCT01976429,43:55:chronic_disease,no recent history of non-activity related otitis media,['no' 'recent' 'history' 'of' 'non-activity' 'related' 'otitis' 'media'],[0. 0. 0. 0. 0. 0. 2. 2.]
NCT01976429,26:38:chronic_disease,syndrome predisposing to otitis media,['syndrome' 'predisposing' 'to' 'otitis' 'media'],[0. 0. 0. 2. 2.]
NCT01970345,21:30:chronic_disease,Active or suspected neoplasia,['Active' 'or' 'suspected' 'neoplasia'],[0. 0. 0. 2.]
NCT01525901,21:30:cancer,active or suspected neoplasia,['active' 'or' 'suspected' 'neoplasia'],[0. 0. 0. 3.]
NCT01966367,10:17:chronic_disease,Adequate cardiac function per protocol,['Adequate' 'cardiac' 'function' 'per' 'protocol'],[0. 2. 0. 0. 0.]
NCT01653093,19:26:chronic_disease,Patients who have cardiac,['Patients' 'who' 'have' 'cardiac'],[0. 0. 0. 2.]
NCT01954966,1:17:chronic_disease,thrombophlebitis,['thrombophlebitis'],[2.]
NCT01239160,"20:36:chronic_disease,",Diagnosis of acute thrombophlebitis (in last 2 months),"['Diagnosis' 'of' 'acute' 'thrombophlebitis' '(' 'in' 'last' '2' 'months'
 ')']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT01943851,"1:22:treatment,",Chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity within the last 2 weeks,"['Chemotherapy' 'regimens' 'given' 'continuously' 'or' 'on' 'a' 'weekly'
 'basis' 'with' 'limited' 'potential' 'for' 'delayed' 'toxicity' 'within'
 'the' 'last' '2' 'weeks']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01943851,"1:22:treatment,",Chemotherapy regimens with delayed toxicity within the last 4 weeks,"['Chemotherapy' 'regimens' 'with' 'delayed' 'toxicity' 'within' 'the'
 'last' '4' 'weeks']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01898793,16:42:treatment,Relapsed after allogeneic transplantation,['Relapsed' 'after' 'allogeneic' 'transplantation'],[0. 0. 1. 1.]
NCT01512888,43:69:treatment,Availability of a HLA matched sibling for allogeneic transplantation,"['Availability' 'of' 'a' 'HLA' 'matched' 'sibling' 'for' 'allogeneic'
 'transplantation']",[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01884740,1:18:cancer,oligodendroglioma,['oligodendroglioma'],[3.]
NCT01130077,19:36:cancer,Patients with any oligodendroglioma component,['Patients' 'with' 'any' 'oligodendroglioma' 'component'],[0. 0. 0. 3. 0.]
NCT01865162,16:40:treatment,6 weeks from a nitrosourea chemotherapy,['6' 'weeks' 'from' 'a' 'nitrosourea' 'chemotherapy'],[0. 0. 0. 0. 1. 1.]
NCT01849146,",16:40:treatment",6 weeks from a nitrosourea chemotherapy,['6' 'weeks' 'from' 'a' 'nitrosourea' 'chemotherapy'],[0. 0. 0. 0. 1. 1.]
NCT01824836,102:113:treatment,"Patients must have adequate hepatic, hematologic and renal functioning to be able to be administered anastrozole at the discretion of the treating physician","['Patients' 'must' 'have' 'adequate' 'hepatic' ',' 'hematologic' 'and'
 'renal' 'functioning' 'to' 'be' 'able' 'to' 'be' 'administered'
 'anastrozole' 'at' 'the' 'discretion' 'of' 'the' 'treating' 'physician']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT01824836,"20:31:treatment,",Plan to treat with anastrozole for at least 12 months,['Plan' 'to' 'treat' 'with' 'anastrozole' 'for' 'at' 'least' '12' 'months'],[0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT01810588,1:16:chronic_disease,Aplastic anemia,['Aplastic' 'anemia'],[2. 2.]
NCT00258427,"1:16:chronic_disease,,,,,,,","Aplastic anemia is defined as having at least one of the following (with or without cytogenetic abnormalities): platelet count <20 * 10^9, - absolute neutrophil count (ANC) <5 * 10^8/L, - Hgb <8 g/dL /","['Aplastic' 'anemia' 'is' 'defined' 'as' 'having' 'at' 'least' 'one' 'of'
 'the' 'following' '(' 'with' 'or' 'without' 'cytogenetic' 'abnormalities'
 ')' ':' 'platelet' 'count' '<' '20' '*' '10^9' ',' '-' 'absolute'
 'neutrophil' 'count' '(' 'ANC' ')' '<' '5' '*' '10^8/L' ',' '-' 'Hgb' '<'
 '8' 'g/dL' '/']","[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01801072,1:12:cancer,Brain tumor,['Brain' 'tumor'],[3. 3.]
NCT01539109,1:12:cancer,Brain tumor,['Brain' 'tumor'],[3. 3.]
NCT01774487,21:43:treatment,Infants receiving a Kasai portoenterostomy at another institution,"['Infants' 'receiving' 'a' 'Kasai' 'portoenterostomy' 'at' 'another'
 'institution']",[0. 0. 0. 1. 1. 0. 0. 0.]
NCT01774487,13:35:treatment,No previous Kasai portoenterostomy performed at another institution,"['No' 'previous' 'Kasai' 'portoenterostomy' 'performed' 'at' 'another'
 'institution']",[0. 0. 1. 1. 0. 0. 0. 0.]
NCT01703117,"31:62:allergy_name,","previously unable to tolerate acetylcholinesterase inhibitors and as a result, are no longer on the medication for at least 2 months","['previously' 'unable' 'to' 'tolerate' 'acetylcholinesterase' 'inhibitors'
 'and' 'as' 'a' 'result' ',' 'are' 'no' 'longer' 'on' 'the' 'medication'
 'for' 'at' 'least' '2' 'months']",[0. 0. 0. 0. 4. 4. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01584076,52:83:allergy_name,Known allergies or contraindications to the use of acetylcholinesterase inhibitors,"['Known' 'allergies' 'or' 'contraindications' 'to' 'the' 'use' 'of'
 'acetylcholinesterase' 'inhibitors']",[0. 0. 0. 0. 0. 0. 0. 0. 4. 4.]
NCT01666665,14:38:chronic_disease,Pre-existing type 1 diabetes mellitus,['Pre-existing' 'type' '1' 'diabetes' 'mellitus'],[0. 2. 2. 2. 2.]
NCT00678145,15:39:chronic_disease,Patients with type 1 diabetes mellitus,['Patients' 'with' 'type' '1' 'diabetes' 'mellitus'],[0. 0. 2. 2. 2. 2.]
NCT01631617,28:55:allergy_name,Known allergic reaction to sodium hypochlorite (NaOCl),"['Known' 'allergic' 'reaction' 'to' 'sodium' 'hypochlorite' '(' 'NaOCl'
 ')']",[0. 0. 0. 0. 4. 4. 4. 0. 0.]
NCT01631617,33:60:allergy_name,Known allergy or sensitivity to sodium hypochlorite (NaOCl),"['Known' 'allergy' 'or' 'sensitivity' 'to' 'sodium' 'hypochlorite' '('
 'NaOCl' ')']",[0. 0. 0. 0. 0. 4. 4. 4. 0. 0.]
NCT01585402,33:37:chronic_disease,Subjects must be diagnosed with ACDC based on genetic tests confirming mutation(s) in NT5E and evidence of lower extremity arterial calcifications,"['Subjects' 'must' 'be' 'diagnosed' 'with' 'ACDC' 'based' 'on' 'genetic'
 'tests' 'confirming' 'mutation' '(' 's' ')' 'in' 'NT5E' 'and' 'evidence'
 'of' 'lower' 'extremity' 'arterial' 'calcifications']",[0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01585402,29:33:chronic_disease,Subjects not diagnosed with ACDC,['Subjects' 'not' 'diagnosed' 'with' 'ACDC'],[0. 0. 0. 0. 2.]
NCT01532687,",94:103:treatment",within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of pazopanib,"['within' '14' 'days' 'or' 'five' 'half-lives' 'of' 'a' 'drug' '('
 'whichever' 'is' 'longer' ')' 'prior' 'to' 'the' 'first' 'dose' 'of'
 'pazopanib']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01532687,",43:52:treatment",within 14 days prior to the first dose of pazopanib,['within' '14' 'days' 'prior' 'to' 'the' 'first' 'dose' 'of' 'pazopanib'],[0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01494662,42:65:treatment,Cohort 3a will have participants with no prior lapatinib therapy,"['Cohort' '3a' 'will' 'have' 'participants' 'with' 'no' 'prior'
 'lapatinib' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT01494662,25:48:treatment,Cohort 3b will have had prior lapatinib therapy,['Cohort' '3b' 'will' 'have' 'had' 'prior' 'lapatinib' 'therapy'],[0. 0. 0. 0. 0. 1. 1. 1.]
NCT01436968,1:26:cancer,Localized prostate cancer meeting the NCCN criteria of Intermediate Risk or patients having only one NCCN high-risk feature,"['Localized' 'prostate' 'cancer' 'meeting' 'the' 'NCCN' 'criteria' 'of'
 'Intermediate' 'Risk' 'or' 'patients' 'having' 'only' 'one' 'NCCN'
 'high-risk' 'feature']",[3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00737893,1:26:cancer,Localized prostate cancer,['Localized' 'prostate' 'cancer'],[3. 3. 3.]
NCT01419561,"33:37:chronic_disease,,","Immunohistochemical evidence of KSHV in tissues (for example by staining for LANA or vIL-6). Confirmed in the Laboratory of Pathology, CCR, NCI","['Immunohistochemical' 'evidence' 'of' 'KSHV' 'in' 'tissues' '(' 'for'
 'example' 'by' 'staining' 'for' 'LANA' 'or' 'vIL-6' ')' '.' 'Confirmed'
 'in' 'the' 'Laboratory' 'of' 'Pathology' ',' 'CCR' ',' 'NCI']","[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT01419561,23:27:chronic_disease,"Molecular evidence of KSHV in whole blood, confirmed by testing at Focus Laboratories, CA (HHV-8 Quantitative PCR, Focus Unit Code 45700)","['Molecular' 'evidence' 'of' 'KSHV' 'in' 'whole' 'blood' ',' 'confirmed'
 'by' 'testing' 'at' 'Focus' 'Laboratories' ',' 'CA' '(' 'HHV-8'
 'Quantitative' 'PCR' ',' 'Focus' 'Unit' 'Code' '45700' ')']","[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT01059786,"13:16:treatment,,,,","Evidence of HCL by flow cytometry of blood or a solid (lymph node) mass, confirmed by the Laboratory of Pathology, NCI, including positivity for CD19, CD22, CD20, and CD11c","['Evidence' 'of' 'HCL' 'by' 'flow' 'cytometry' 'of' 'blood' 'or' 'a'
 'solid' '(' 'lymph' 'node' ')' 'mass' ',' 'confirmed' 'by' 'the'
 'Laboratory' 'of' 'Pathology' ',' 'NCI' ',' 'including' 'positivity'
 'for' 'CD19' ',' 'CD22' ',' 'CD20' ',' 'and' 'CD11c']","[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT00412594,14:17:cancer,Diagnosis of HCL established by bone marrow examination,['Diagnosis' 'of' 'HCL' 'established' 'by' 'bone' 'marrow' 'examination'],[0. 0. 3. 0. 0. 0. 0. 0.]
NCT00719888,11:22:treatment,High-dose TBI regimen,['High-dose' 'TBI' 'regimen'],[0. 1. 1.]
NCT00719888,18:29:treatment,Middle-intensity TBI regimen,['Middle-intensity' 'TBI' 'regimen'],[0. 1. 1.]
NCT00230607,38:47:treatment,be born to a mother who is receiving Fabrazyme during lactation,"['be' 'born' 'to' 'a' 'mother' 'who' 'is' 'receiving' 'Fabrazyme' 'during'
 'lactation']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.]
NCT00230607,49:58:treatment,be enrolled in the Fabry Registry and receiving Fabrazyme while lactating,"['be' 'enrolled' 'in' 'the' 'Fabry' 'Registry' 'and' 'receiving'
 'Fabrazyme' 'while' 'lactating']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.]
NCT03188042,21:38:allergy_name,Photosensitivity to flickering lights,['Photosensitivity' 'to' 'flickering' 'lights'],[0. 0. 4. 4.]
NCT03187951,1:22:cancer,Neuroendocrine cancer,['Neuroendocrine' 'cancer'],[3. 3.]
NCT03187379,21:45:treatment,previous history of roux-en-y gastric bypass,['previous' 'history' 'of' 'roux-en-y' 'gastric' 'bypass'],[0. 0. 0. 1. 1. 1.]
NCT03187028,1:26:chronic_disease,severe emotional distress,['severe' 'emotional' 'distress'],[2. 2. 2.]
NCT03185130,"1:16:treatment,",Lumbar puncture within the previous two weeks,['Lumbar' 'puncture' 'within' 'the' 'previous' 'two' 'weeks'],[1. 1. 0. 0. 0. 0. 0.]
NCT03183102,"1:30:chronic_disease,,,,,","Chronic hepatobiliary disease, conservatively defined as liver function tests (AST, ALT, alkaline phosphatase, Total Bilirubin) >1.5 times the upper limit of normal","['Chronic' 'hepatobiliary' 'disease' ',' 'conservatively' 'defined' 'as'
 'liver' 'function' 'tests' '(' 'AST' ',' 'ALT' ',' 'alkaline'
 'phosphatase' ',' 'Total' 'Bilirubin' ')' '>' '1.5' 'times' 'the' 'upper'
 'limit' 'of' 'normal']","[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT03182907,21:46:chronic_disease,Has an uncontrolled chronic diarrheal illness,['Has' 'an' 'uncontrolled' 'chronic' 'diarrheal' 'illness'],[0. 0. 0. 2. 2. 2.]
NCT03182751,46:67:treatment,Surgically treated with sliding hip screw or cephalomedullary nail (short or long),"['Surgically' 'treated' 'with' 'sliding' 'hip' 'screw' 'or'
 'cephalomedullary' 'nail' '(' 'short' 'or' 'long' ')']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT03181516,12:22:allergy_name,Allergy to strawberry,['Allergy' 'to' 'strawberry'],[0. 0. 4.]
NCT03181516,1:11:treatment,Cefadroxil,['Cefadroxil'],[1.]
NCT03181516,1:11:treatment,Cephradine,['Cephradine'],[1.]
NCT03181516,1:20:treatment,Mefoxin (Cefoxitin),['Mefoxin' '(' 'Cefoxitin' ')'],[1. 1. 0. 0.]
NCT03181516,1:13:treatment,Trimethoprim,['Trimethoprim'],[1.]
NCT03181126,17:27:treatment,Participants on venetoclax at screening may enroll and remain on venetoclax,"['Participants' 'on' 'venetoclax' 'at' 'screening' 'may' 'enroll' 'and'
 'remain' 'on' 'venetoclax']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03180086,",36:45:treatment",women who have taken or are taking tamoxifen,['women' 'who' 'have' 'taken' 'or' 'are' 'taking' 'tamoxifen'],[0. 0. 0. 0. 0. 0. 0. 1.]
NCT03179397,1:21:chronic_disease,Diabetic retinopathy,['Diabetic' 'retinopathy'],[2. 2.]
NCT03179397,10:25:treatment,Previous corneal surgery,['Previous' 'corneal' 'surgery'],[0. 1. 1.]
NCT03179163,12:27:allergy_name,allergy to test substances,['allergy' 'to' 'test' 'substances'],[0. 0. 4. 4.]
NCT03178552,69:79:cancer,Histologically or cytologically confirmed diagnosis of unresectable Stage IIIb,"['Histologically' 'or' 'cytologically' 'confirmed' 'diagnosis' 'of'
 'unresectable' 'Stage' 'IIIb']",[0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT03176784,56:75:treatment,desire to quit smoking but not be engaged currently in cessation treatment,"['desire' 'to' 'quit' 'smoking' 'but' 'not' 'be' 'engaged' 'currently'
 'in' 'cessation' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT03175978,15:44:chronic_disease,Patients with active extramedullary disease,['Patients' 'with' 'active' 'extramedullary' 'disease'],[0. 0. 2. 2. 2.]
NCT03171493,14:54:cancer,"Diagnosis of Urothelial carcinoma (UC) of the bladder, with histologic confirmation of primary UC pathology","['Diagnosis' 'of' 'Urothelial' 'carcinoma' '(' 'UC' ')' 'of' 'the'
 'bladder' ',' 'with' 'histologic' 'confirmation' 'of' 'primary' 'UC'
 'pathology']",[0. 0. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03171168,10:38:chronic_disease,No major cardiovascular comorbidities (able to enroll in an active exercise program),"['No' 'major' 'cardiovascular' 'comorbidities' '(' 'able' 'to' 'enroll'
 'in' 'an' 'active' 'exercise' 'program' ')']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03170856,12:32:treatment,History of neurological surgery,['History' 'of' 'neurological' 'surgery'],[0. 0. 1. 1.]
NCT03170453,1:23:chronic_disease,Organic brain syndrome,['Organic' 'brain' 'syndrome'],[2. 2. 2.]
NCT03170375,1:42:chronic_disease,moderate or severe valvular heart disease,['moderate' 'or' 'severe' 'valvular' 'heart' 'disease'],[2. 2. 2. 2. 2. 2.]
NCT03170349,19:22:treatment,Patient in whom a TEE is contraindicated or screening TEE is unsuccessful,"['Patient' 'in' 'whom' 'a' 'TEE' 'is' 'contraindicated' 'or' 'screening'
 'TEE' 'is' 'unsuccessful']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT03169543,1:32:chronic_disease,debilitating medical conditions,['debilitating' 'medical' 'conditions'],[2. 2. 2.]
NCT03168776,29:69:treatment,an acceptable candidate for percutaneous coronary intervention (PCI) with drug-eluting stents,"['an' 'acceptable' 'candidate' 'for' 'percutaneous' 'coronary'
 'intervention' '(' 'PCI' ')' 'with' 'drug-eluting' 'stents']",[0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT03168659,",25:45:treatment",failure of at least one anti-arrhythmic drug,['failure' 'of' 'at' 'least' 'one' 'anti-arrhythmic' 'drug'],[0. 0. 0. 0. 0. 1. 1.]
NCT03167216,16:57:chronic_disease,Diagnosed with Category III Chronic Pelvic Pain Syndrome,['Diagnosed' 'with' 'Category' 'III' 'Chronic' 'Pelvic' 'Pain' 'Syndrome'],[0. 0. 2. 2. 2. 2. 2. 2.]
NCT03165227,11:24:treatment,bilateral salpingectomy,['bilateral' 'salpingectomy'],[0. 1.]
NCT03161028,53:66:treatment,Scheduled (every 3 months or more frequently) IV or oral steroids in the year prior to enrolment,"['Scheduled' '(' 'every' '3' 'months' 'or' 'more' 'frequently' ')' 'IV'
 'or' 'oral' 'steroids' 'in' 'the' 'year' 'prior' 'to' 'enrolment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT03159936,"1:17:treatment,",Systemic therapy is allowed if on a stable dose and using for at least 3 months -background therapies outlined in Protocol,"['Systemic' 'therapy' 'is' 'allowed' 'if' 'on' 'a' 'stable' 'dose' 'and'
 'using' 'for' 'at' 'least' '3' 'months' '-background' 'therapies'
 'outlined' 'in' 'Protocol']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03159754,1:18:chronic_disease,Immunocompromized state,['Immunocompromized' 'state'],[2. 0.]
NCT03158974,17:50:chronic_disease,"Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events","['Are' 'free' 'of' 'any' 'systemic' 'or' 'dermatologic' 'disorder' ','
 'which' ',' 'in' 'the' 'opinion' 'of' 'the' 'investigator' ',' 'will'
 'interfere' 'with' 'the' 'study' 'results' 'or' 'increase' 'the' 'risk'
 'of' 'adverse' 'events']","[0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT03158974,",33:51:cancer","If female, have any evidence of cervical dysplasia","['If' 'female' ',' 'have' 'any' 'evidence' 'of' 'cervical' 'dysplasia']",[0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT03157713,1:34:chronic_disease,Chronic Kidney Disease stage IV/V,['Chronic' 'Kidney' 'Disease' 'stage' 'IV/V'],[2. 2. 2. 2. 2.]
NCT03156543,29:50:treatment,Limited to total or reverse shoulder arthroplasty,['Limited' 'to' 'total' 'or' 'reverse' 'shoulder' 'arthroplasty'],[0. 0. 0. 0. 0. 1. 1.]
NCT03154567,1:19:chronic_disease,Pulmonary diseases,['Pulmonary' 'diseases'],[2. 2.]
NCT03153982,1:15:cancer,"Primary tumors of any head and neck (oral cavity, oropharynx, hypopharynx, or larynx) site will be included","['Primary' 'tumors' 'of' 'any' 'head' 'and' 'neck' '(' 'oral' 'cavity' ','
 'oropharynx' ',' 'hypopharynx' ',' 'or' 'larynx' ')' 'site' 'will' 'be'
 'included']",[3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03153969,38:56:treatment,Teeth that are non-vital or have had root canal therapy,"['Teeth' 'that' 'are' 'non-vital' 'or' 'have' 'had' 'root' 'canal'
 'therapy']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT03153319,14:25:chronic_disease,Diagnosis of MPS I or II,['Diagnosis' 'of' 'MPS' 'I' 'or' 'II'],[0. 0. 2. 2. 2. 2.]
NCT03153319,"4:22:treatment,",no treatment with ERT for ≥1 year,['no' 'treatment' 'with' 'ERT' 'for' '≥1' 'year'],[0. 1. 1. 1. 0. 0. 0.]
NCT03152058,58:70:allergy_name,Known contraindications or relative contraindications to certolizumab,"['Known' 'contraindications' 'or' 'relative' 'contraindications' 'to'
 'certolizumab']",[0. 0. 0. 0. 0. 0. 4.]
NCT03151330,7:30:chronic_disease,Known fetal genetic anomalies that are incompatible with life,"['Known' 'fetal' 'genetic' 'anomalies' 'that' 'are' 'incompatible' 'with'
 'life']",[0. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT03150004,1:29:cancer,Acute Promyelocytic Leukemia,['Acute' 'Promyelocytic' 'Leukemia'],[3. 3. 3.]
NCT03149783,39:50:allergy_name,Patients with a documented allergy to ropivacaine,['Patients' 'with' 'a' 'documented' 'allergy' 'to' 'ropivacaine'],[0. 0. 0. 0. 0. 0. 4.]
NCT03149549,11:35:chronic_disease,Active or chronic corneal disorder,['Active' 'or' 'chronic' 'corneal' 'disorder'],[0. 0. 2. 2. 2.]
NCT03149549,1:24:chronic_disease,alcoholic liver disease,['alcoholic' 'liver' 'disease'],[2. 2. 2.]
NCT03148379,1:24:chronic_disease,knee avascular necrosis,['knee' 'avascular' 'necrosis'],[2. 2. 2.]
NCT03146663,",27:50:treatment",Received at least 3 prior chemotherapy-containing regimens,['Received' 'at' 'least' '3' 'prior' 'chemotherapy-containing' 'regimens'],[0. 0. 0. 0. 0. 1. 0.]
NCT03145298,"1:31:chronic_disease,,",Non-pulmonary vascular disease with life expectancy of < 3 years,"['Non-pulmonary' 'vascular' 'disease' 'with' 'life' 'expectancy' 'of' '<'
 '3' 'years']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT03145181,"1:29:treatment,",Proteasome inhibitor therapy within 14 days,['Proteasome' 'inhibitor' 'therapy' 'within' '14' 'days'],[1. 1. 1. 0. 0. 0.]
NCT03144206,1:28:chronic_disease,Active deep vein thrombosis in the treatment extremity,['Active' 'deep' 'vein' 'thrombosis' 'in' 'the' 'treatment' 'extremity'],[2. 2. 2. 2. 0. 0. 0. 0.]
NCT03143985,13:22:chronic_disease,Presence of aneurisms of the ascending aorta or aortic stress,"['Presence' 'of' 'aneurisms' 'of' 'the' 'ascending' 'aorta' 'or' 'aortic'
 'stress']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT03141164,1:19:chronic_disease,visual impairments due to partial vision loss,['visual' 'impairments' 'due' 'to' 'partial' 'vision' 'loss'],[2. 2. 0. 0. 0. 0. 0.]
NCT03140488,12:38:treatment,History of previous cesarean delivery,['History' 'of' 'previous' 'cesarean' 'delivery'],[0. 0. 1. 1. 1.]
NCT03138733,28:53:treatment,Requirement for continuous renal-replacement therapy,['Requirement' 'for' 'continuous' 'renal-replacement' 'therapy'],[0. 0. 0. 1. 1.]
NCT03137771,53:81:cancer,Clinical or radiologic evidence of untreated and/or progressive brain metastases,"['Clinical' 'or' 'radiologic' 'evidence' 'of' 'untreated' 'and/or'
 'progressive' 'brain' 'metastases']",[0. 0. 0. 0. 0. 0. 0. 3. 3. 3.]
NCT03137758,18:48:treatment,standard of care androgen deprivation treatment,['standard' 'of' 'care' 'androgen' 'deprivation' 'treatment'],[0. 0. 0. 1. 1. 1.]
NCT03137173,1:48:chronic_disease,Uncomplicated skin and skin structure infection,['Uncomplicated' 'skin' 'and' 'skin' 'structure' 'infection'],[2. 2. 2. 2. 2. 2.]
NCT03136029,1:21:cancer,End-stage Malignancy,['End-stage' 'Malignancy'],[3. 3.]
NCT03136029,1:33:chronic_disease,Sleep-related Breathing Disorder,['Sleep-related' 'Breathing' 'Disorder'],[2. 2. 2.]
NCT03135171,1:38:chronic_disease,Primary or secondary immunodeficiency (history of or currently active) unless related to primary disease under investigation,"['Primary' 'or' 'secondary' 'immunodeficiency' '(' 'history' 'of' 'or'
 'currently' 'active' ')' 'unless' 'related' 'to' 'primary' 'disease'
 'under' 'investigation']",[2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03133793,1:24:chronic_disease,Severe cardiac fibrosis,['Severe' 'cardiac' 'fibrosis'],[2. 2. 2.]
NCT03132636,24:36:cancer,Confirmed diagnosis of invasive BCC,['Confirmed' 'diagnosis' 'of' 'invasive' 'BCC'],[0. 0. 0. 3. 3.]
NCT03131960,"1:27:chronic_disease,,",Severe or worse depression (Beck Depression Scale > 29),"['Severe' 'or' 'worse' 'depression' '(' 'Beck' 'Depression' 'Scale' '>'
 '29' ')']",[2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT03131037,1:33:chronic_disease,end-stage liver or renal disease,['end-stage' 'liver' 'or' 'renal' 'disease'],[2. 2. 2. 2. 2.]
NCT03129880,18:32:chronic_disease,Diagnosed with a Voice disorder,['Diagnosed' 'with' 'a' 'Voice' 'disorder'],[0. 0. 0. 2. 2.]
NCT03129542,1:24:treatment,Fludrocortisone acetate is a current home medication,['Fludrocortisone' 'acetate' 'is' 'a' 'current' 'home' 'medication'],[1. 1. 0. 0. 0. 0. 0.]
NCT03128268,1:5:treatment,ICDs implanted,['ICDs' 'implanted'],[1. 0.]
NCT03128008,14:45:cancer,"Unresectable stage II, IIIA, or IIIB disease","['Unresectable' 'stage' 'II' ',' 'IIIA' ',' 'or' 'IIIB' 'disease']",[0. 3. 3. 3. 3. 3. 3. 0. 0.]
NCT03125902,1:15:cancer,Leptomeningeal disease,['Leptomeningeal' 'disease'],[3. 0.]
NCT03125226,4:20:treatment,No prior cystectomy,['No' 'prior' 'cystectomy'],[0. 1. 1.]
NCT03123068,12:42:allergy_name,"Allergy to active ingredient of CocoaVia®, the study intervention","['Allergy' 'to' 'active' 'ingredient' 'of' 'CocoaVia®' ',' 'the' 'study'
 'intervention']",[0. 0. 4. 4. 4. 4. 0. 0. 0. 0.]
NCT03123055,",50:67:chronic_disease,",History of clinically significant coagulation or platelet disorder in the past 12 months,"['History' 'of' 'clinically' 'significant' 'coagulation' 'or' 'platelet'
 'disorder' 'in' 'the' 'past' '12' 'months']",[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT03122535,49:64:treatment,Subjects who are deemed suitable candidates for bilateral LASIK will be considered eligible for participation in this study,"['Subjects' 'who' 'are' 'deemed' 'suitable' 'candidates' 'for' 'bilateral'
 'LASIK' 'will' 'be' 'considered' 'eligible' 'for' 'participation' 'in'
 'this' 'study']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03121586,1:12:treatment,Cariprazine,['Cariprazine'],[1.]
NCT03121352,10:31:treatment,A second post-treatment biopsy will be offered but will not be mandated,"['A' 'second' 'post-treatment' 'biopsy' 'will' 'be' 'offered' 'but' 'will'
 'not' 'be' 'mandated']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03121352,"23:38:treatment,",must not have been on steroid therapy for at least 4 weeks,"['must' 'not' 'have' 'been' 'on' 'steroid' 'therapy' 'for' 'at' 'least'
 '4' 'weeks']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT03120728,1:23:cancer,hepatocellular adenoma,['hepatocellular' 'adenoma'],[3. 3.]
NCT03120728,1:29:chronic_disease,systemic lupus erythematosus with positive antiphospholipid antibodies,"['systemic' 'lupus' 'erythematosus' 'with' 'positive' 'antiphospholipid'
 'antibodies']",[2. 2. 2. 0. 0. 0. 0.]
NCT03119363,1:74:treatment,Previous use of light therapy to alleviate fatigue or depressive symptoms,"['Previous' 'use' 'of' 'light' 'therapy' 'to' 'alleviate' 'fatigue' 'or'
 'depressive' 'symptoms']",[1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.]
NCT03118050,1:13:chronic_disease,Pre-diabetes per American Diabetes Association criteria,['Pre-diabetes' 'per' 'American' 'Diabetes' 'Association' 'criteria'],[2. 0. 0. 0. 0. 0.]
NCT03116997,"27:63:chronic_disease,,",History of severe chronic obstructive pulmonary disease (COPD) defined as an FEV1 < 50% of predicted,"['History' 'of' 'severe' 'chronic' 'obstructive' 'pulmonary' 'disease' '('
 'COPD' ')' 'defined' 'as' 'an' 'FEV1' '<' '50' '%' 'of' 'predicted']",[0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03116685,"20:30:treatment,",Patients receiving vitamin B6 must be receiving a stable dose for at least 3 months prior to screening and must not change the dose during the study,"['Patients' 'receiving' 'vitamin' 'B6' 'must' 'be' 'receiving' 'a'
 'stable' 'dose' 'for' 'at' 'least' '3' 'months' 'prior' 'to' 'screening'
 'and' 'must' 'not' 'change' 'the' 'dose' 'during' 'the' 'study']","[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT03115424,"14:41:treatment,",Prior use of glucose lowering medication in the 3 months prior to screening,"['Prior' 'use' 'of' 'glucose' 'lowering' 'medication' 'in' 'the' '3'
 'months' 'prior' 'to' 'screening']",[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT03114891,19:37:chronic_disease,meet criteria for trauma-induced MDD,['meet' 'criteria' 'for' 'trauma-induced' 'MDD'],[0. 0. 0. 2. 2.]
NCT03114020,18:33:chronic_disease,Individuals with PiMZ deficiency are not allowed in the study,"['Individuals' 'with' 'PiMZ' 'deficiency' 'are' 'not' 'allowed' 'in' 'the'
 'study']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT03113825,1:40:treatment,Radiation therapy to ipsilateral breast [Period 1],['Radiation' 'therapy' 'to' 'ipsilateral' 'breast' '[' 'Period' '1' ']'],[1. 1. 1. 1. 1. 0. 0. 0. 0.]
NCT03113760,25:76:chronic_disease,Patients suffering from familial hemophagocytic lymphohistiocytosis (f HLH),"['Patients' 'suffering' 'from' 'familial' 'hemophagocytic'
 'lymphohistiocytosis' '(' 'f' 'HLH' ')']",[0. 0. 0. 2. 2. 2. 2. 2. 0. 0.]
NCT03113760,1:48:treatment,disease modifying anti rheumatic drugs (DMARDs),['disease' 'modifying' 'anti' 'rheumatic' 'drugs' '(' 'DMARDs' ')'],[1. 1. 1. 1. 1. 1. 0. 0.]
NCT03113695,1:21:cancer,clonal large B-cells in peripheral blood or bone marrow,['clonal' 'large' 'B-cells' 'in' 'peripheral' 'blood' 'or' 'bone' 'marrow'],[3. 3. 3. 0. 0. 0. 0. 0. 0.]
NCT03112902,1:7:chronic_disease,eczema or sensitive skin,['eczema' 'or' 'sensitive' 'skin'],[2. 0. 0. 0.]
NCT03112824,1:21:chronic_disease,Oral Corticosteroids,['Oral' 'Corticosteroids'],[2. 2.]
NCT03112824,1:25:treatment,anti-insomnia medication on a regular basis,['anti-insomnia' 'medication' 'on' 'a' 'regular' 'basis'],[1. 1. 0. 0. 0. 0.]
NCT03112603,52:64:chronic_disease,Participants with clinically diagnosed moderate to severe cGvHD according to NIH Consensus Criteria prior to randomization,"['Participants' 'with' 'clinically' 'diagnosed' 'moderate' 'to' 'severe'
 'cGvHD' 'according' 'to' 'NIH' 'Consensus' 'Criteria' 'prior' 'to'
 'randomization']",[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03112590,14:58:cancer,unresectable locally advanced or metastatic breast cancer,['unresectable' 'locally' 'advanced' 'or' 'metastatic' 'breast' 'cancer'],[0. 3. 3. 3. 3. 3. 3.]
NCT03110354,",,,141:177:treatment","Has prolonged corrected QT interval by Fridericia's method (QTcF) at rest, where the mean QTcF interval is > 450 milliseconds (ms) based on triplicate electrocardiograms (ECGs)","['Has' 'prolonged' 'corrected' 'QT' 'interval' 'by' 'Fridericia' ""'s""
 'method' '(' 'QTcF' ')' 'at' 'rest' ',' 'where' 'the' 'mean' 'QTcF'
 'interval' 'is' '>' '450' 'milliseconds' '(' 'ms' ')' 'based' 'on'
 'triplicate' 'electrocardiograms' '(' 'ECGs' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 1. 1. 0. 0.]"
NCT03108820,1:18:chronic_disease,Parkinson disease,['Parkinson' 'disease'],[2. 2.]
NCT03107897,25:77:chronic_disease,Subject has significant severe un-revascularized epicardial coronary disease,"['Subject' 'has' 'significant' 'severe' 'un-revascularized' 'epicardial'
 'coronary' 'disease']",[0. 0. 0. 2. 2. 2. 2. 2.]
NCT03107520,7:35:chronic_disease,Known heart or pulmonary condition,['Known' 'heart' 'or' 'pulmonary' 'condition'],[0. 2. 2. 2. 2.]
NCT03105362,40:57:chronic_disease,Patients with a primary diagnosis of a motility disorder,"['Patients' 'with' 'a' 'primary' 'diagnosis' 'of' 'a' 'motility'
 'disorder']",[0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT03105362,1:25:chronic_disease,epithelial cell disorder,['epithelial' 'cell' 'disorder'],[2. 2. 2.]
NCT03104725,10:43:treatment,Taking a monoamine oxidase (MAO) inhibitor,['Taking' 'a' 'monoamine' 'oxidase' '(' 'MAO' ')' 'inhibitor'],[0. 0. 1. 1. 1. 1. 0. 0.]
NCT03104699,1:45:cancer,basal or squamous cell carcinoma of the skin,['basal' 'or' 'squamous' 'cell' 'carcinoma' 'of' 'the' 'skin'],[3. 3. 3. 3. 3. 3. 3. 3.]
NCT03104699,1:19:chronic_disease,immunodeficiencies,['immunodeficiencies'],[2.]
NCT03104517,",,,74:77:chronic_disease,","50 to 75 years of age who has primary and moderate-to-severe symptoms of SUI for at least 6 months, as confirmed by patient medical history and clinical symptoms, including a focused incontinence evaluation","['50' 'to' '75' 'years' 'of' 'age' 'who' 'has' 'primary' 'and'
 'moderate-to-severe' 'symptoms' 'of' 'SUI' 'for' 'at' 'least' '6'
 'months' ',' 'as' 'confirmed' 'by' 'patient' 'medical' 'history' 'and'
 'clinical' 'symptoms' ',' 'including' 'a' 'focused' 'incontinence'
 'evaluation']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03102320,1:34:chronic_disease,Active hepatitis B or C infection,['Active' 'hepatitis' 'B' 'or' 'C' 'infection'],[2. 2. 2. 2. 2. 2.]
NCT03101956,1:35:chronic_disease,Nervous system disease or disorder,['Nervous' 'system' 'disease' 'or' 'disorder'],[2. 2. 2. 2. 2.]
NCT03101085,17:70:treatment,Use any type of systemic estrogen or testosterone replacement therapy,"['Use' 'any' 'type' 'of' 'systemic' 'estrogen' 'or' 'testosterone'
 'replacement' 'therapy']",[0. 0. 0. 0. 1. 1. 1. 1. 1. 1.]
NCT03100461,1:22:chronic_disease,Acute medical illness,['Acute' 'medical' 'illness'],[2. 2. 2.]
NCT03100370,4:34:chronic_disease,No neuropsychiatric comorbidities,['No' 'neuropsychiatric' 'comorbidities'],[0. 2. 2.]
NCT03098394,35:65:chronic_disease,Signs or symptoms consistent with sexually transmitted infection,"['Signs' 'or' 'symptoms' 'consistent' 'with' 'sexually' 'transmitted'
 'infection']",[0. 0. 0. 0. 0. 2. 2. 2.]
NCT03097536,1:17:chronic_disease,Chronic migraine,['Chronic' 'migraine'],[2. 2.]
NCT03096418,33:68:treatment,Patients must be candidates for neoadjuvant paclitaxel chemotherapy by their treating oncologist,"['Patients' 'must' 'be' 'candidates' 'for' 'neoadjuvant' 'paclitaxel'
 'chemotherapy' 'by' 'their' 'treating' 'oncologist']",[0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0.]
NCT03096288,51:61:allergy_name,History of a serious hypersensitivity reaction to evolocumab,"['History' 'of' 'a' 'serious' 'hypersensitivity' 'reaction' 'to'
 'evolocumab']",[0. 0. 0. 0. 0. 0. 0. 4.]
NCT03096288,1:12:treatment,rivaroxaban,['rivaroxaban'],[1.]
NCT03093909,23:26:treatment,Subjects who received GCB systemically previously are eligible for participation,"['Subjects' 'who' 'received' 'GCB' 'systemically' 'previously' 'are'
 'eligible' 'for' 'participation']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT03092609,6:13:chronic_disease,High Anxiety,['High' 'Anxiety'],[0. 2.]
NCT03091803,24:45:cancer,Patient with suspected intracranial neoplasm scheduled for routine MRI with GBCA (gadolinium naive patients),"['Patient' 'with' 'suspected' 'intracranial' 'neoplasm' 'scheduled' 'for'
 'routine' 'MRI' 'with' 'GBCA' '(' 'gadolinium' 'naive' 'patients' ')']",[0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03090607,",,41:52:treatment",GERD-HRQL score ≥15 after discontinuing PPI therapy,['GERD-HRQL' 'score' '≥15' 'after' 'discontinuing' 'PPI' 'therapy'],[0. 0. 0. 0. 0. 1. 1.]
NCT03090607,7:30:treatment,Prior gastric or GERD surgery,['Prior' 'gastric' 'or' 'GERD' 'surgery'],[0. 1. 1. 1. 1.]
NCT03089853,10:44:treatment,Those on invasive or mechanical ventilation will not be enrolled,"['Those' 'on' 'invasive' 'or' 'mechanical' 'ventilation' 'will' 'not' 'be'
 'enrolled']",[0. 0. 1. 1. 1. 1. 0. 0. 0. 0.]
NCT03089515,",,60:71:treatment,",Using ICS/LABA (Advair HFA equivalent > 115/21 mcg bid) or Fluticasone (110 mcg bid or equivalent) for at least 1 month before Study Visit 1,"['Using' 'ICS/LABA' '(' 'Advair' 'HFA' 'equivalent' '>' '115/21' 'mcg'
 'bid' ')' 'or' 'Fluticasone' '(' '110' 'mcg' 'bid' 'or' 'equivalent' ')'
 'for' 'at' 'least' '1' 'month' 'before' 'Study' 'Visit' '1']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT03089125,1:36:chronic_disease,Cognitive or psychiatric conditions prohibiting study consent or participation,"['Cognitive' 'or' 'psychiatric' 'conditions' 'prohibiting' 'study'
 'consent' 'or' 'participation']",[2. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT03088072,1:37:treatment,LAA closure with the WATCHMAN device is planned,['LAA' 'closure' 'with' 'the' 'WATCHMAN' 'device' 'is' 'planned'],[1. 1. 1. 1. 1. 1. 0. 0.]
NCT03088033,",,53:55:chronic_disease",Tricuspid valve regurgitation defined as grade > 2+ TR,['Tricuspid' 'valve' 'regurgitation' 'defined' 'as' 'grade' '>' '2+' 'TR'],[0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT03086369,12:59:cancer,Have known central nervous system malignancy or metastasis,"['Have' 'known' 'central' 'nervous' 'system' 'malignancy' 'or'
 'metastasis']",[0. 0. 3. 3. 3. 3. 3. 3.]
NCT03085485,1:7:chronic_disease,Angina symptoms,['Angina' 'symptoms'],[2. 0.]
NCT03085485,1:31:chronic_disease,stable coronary artery disease,['stable' 'coronary' 'artery' 'disease'],[2. 2. 2. 2.]
NCT03085095,12:31:treatment,History of surgical castration,['History' 'of' 'surgical' 'castration'],[0. 0. 1. 1.]
NCT03085004,52:56:chronic_disease,solid mass component within or associated with the cyst,['solid' 'mass' 'component' 'within' 'or' 'associated' 'with' 'the' 'cyst'],[0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT03084640,40:72:treatment,currently receiving treatment with the anti-PD-1 antibody pembrolizumab either alone or in combination,"['currently' 'receiving' 'treatment' 'with' 'the' 'anti-PD-1' 'antibody'
 'pembrolizumab' 'either' 'alone' 'or' 'in' 'combination']",[0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT03081390,40:63:allergy_name,Allergies or sensitivity to any of the ingredients of the meal,"['Allergies' 'or' 'sensitivity' 'to' 'any' 'of' 'the' 'ingredients' 'of'
 'the' 'meal']",[0. 0. 0. 0. 0. 0. 0. 4. 4. 4. 4.]
NCT03080844,5:39:chronic_disease,Any neurologic or psychiatric disorder,['Any' 'neurologic' 'or' 'psychiatric' 'disorder'],[0. 2. 2. 2. 2.]
NCT03079401,15:39:chronic_disease,Patients with aortic or mitral atresia,['Patients' 'with' 'aortic' 'or' 'mitral' 'atresia'],[0. 0. 2. 2. 2. 2.]
NCT03079297,1:25:chronic_disease,Psychiatric co-morbidity posing safety risk,['Psychiatric' 'co-morbidity' 'posing' 'safety' 'risk'],[2. 2. 0. 0. 0.]
NCT03078530,",44:58:chronic_disease",Negative Tissue transglutaminase (TTG) for celiac disease,"['Negative' 'Tissue' 'transglutaminase' '(' 'TTG' ')' 'for' 'celiac'
 'disease']",[0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT03078491,"1:30:chronic_disease,,",End stage renal insufficiency (eGFR<30),['End' 'stage' 'renal' 'insufficiency' '(' 'eGFR' '<' '30' ')'],[2. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT03077243,1:20:chronic_disease,Psoriatic arthritis,['Psoriatic' 'arthritis'],[2. 2.]
NCT03076658,1:22:chronic_disease,Severe osteoarthritis of the hips/knees/ankles,['Severe' 'osteoarthritis' 'of' 'the' 'hips/knees/ankles'],[2. 2. 0. 0. 0.]
NCT03075761,21:40:allergy_name,Contraindication to increasing activity,['Contraindication' 'to' 'increasing' 'activity'],[0. 0. 4. 4.]
NCT03074240,16:33:treatment,Chronic use of opioid medication,['Chronic' 'use' 'of' 'opioid' 'medication'],[0. 0. 0. 1. 1.]
NCT03073785,"48:54:treatment,",Patients may not be receiving or have received Zometa during/or within 3 weeks prior to treatment with Zometa,"['Patients' 'may' 'not' 'be' 'receiving' 'or' 'have' 'received' 'Zometa'
 'during/or' 'within' '3' 'weeks' 'prior' 'to' 'treatment' 'with' 'Zometa']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03073629,",87:101:chronic_disease",comprehensive echocardiogram within 3 months of index hospital visit showing isolated RV dysfunction,"['comprehensive' 'echocardiogram' 'within' '3' 'months' 'of' 'index'
 'hospital' 'visit' 'showing' 'isolated' 'RV' 'dysfunction']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT03073070,"16:34:treatment,",consumption of biotin supplements or raw eggs within 30 days,"['consumption' 'of' 'biotin' 'supplements' 'or' 'raw' 'eggs' 'within' '30'
 'days']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT03072238,"22:55:treatment,","Administration of an investigational therapeutic agent within 28 days of Cycle 1, Day 1","['Administration' 'of' 'an' 'investigational' 'therapeutic' 'agent'
 'within' '28' 'days' 'of' 'Cycle' '1' ',' 'Day' '1']",[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03072238,1:21:treatment,Radiopharmaceuticals for the purpose of imaging are permitted,"['Radiopharmaceuticals' 'for' 'the' 'purpose' 'of' 'imaging' 'are'
 'permitted']",[1. 0. 0. 0. 0. 0. 0. 0.]
NCT03071393,",23:46:chronic_disease",Greater than 6 months post-spinal cord injury,['Greater' 'than' '6' 'months' 'post-spinal' 'cord' 'injury'],[0. 0. 0. 0. 2. 2. 2.]
NCT03070899,12:26:treatment,History of uterus surgery that would interfere with the study,"['History' 'of' 'uterus' 'surgery' 'that' 'would' 'interfere' 'with' 'the'
 'study']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT03070535,1:26:chronic_disease,cholesterol abnormalities as defined by the Adult Treatment Panel III classification,"['cholesterol' 'abnormalities' 'as' 'defined' 'by' 'the' 'Adult'
 'Treatment' 'Panel' 'III' 'classification']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03069716,"1:39:treatment,",Stable PAH-specific medication regimen for three months prior to enrollment,"['Stable' 'PAH-specific' 'medication' 'regimen' 'for' 'three' 'months'
 'prior' 'to' 'enrollment']",[1. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT03068780,1:20:chronic_disease,dystrophic EB (DEB),['dystrophic' 'EB' '(' 'DEB' ')'],[2. 2. 2. 0. 0.]
NCT03068442,6:18:allergy_name,"[18F]Flutemetamol contraindications per manufacturer guidelines, including patients with prior reactions","['[' '18F' ']' 'Flutemetamol' 'contraindications' 'per' 'manufacturer'
 'guidelines' ',' 'including' 'patients' 'with' 'prior' 'reactions']",[0. 0. 0. 4. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03067051,7:32:chronic_disease,other severe concurrent disease,['other' 'severe' 'concurrent' 'disease'],[0. 2. 2. 2.]
NCT03065907,"22:66:chronic_disease,",Primary diagnosis of neovascular age-related macular degeneration in the index eye or in both eyes if habitual visual acuity (HVA) is equivalent in both eyes,"['Primary' 'diagnosis' 'of' 'neovascular' 'age-related' 'macular'
 'degeneration' 'in' 'the' 'index' 'eye' 'or' 'in' 'both' 'eyes' 'if'
 'habitual' 'visual' 'acuity' '(' 'HVA' ')' 'is' 'equivalent' 'in' 'both'
 'eyes']","[0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT03065465,",,54:84:chronic_disease",Life expectancy of at least 30 days based on lack of severe or terminal comorbidity as judged by the generalist or subspecialist caring for the patient,"['Life' 'expectancy' 'of' 'at' 'least' '30' 'days' 'based' 'on' 'lack'
 'of' 'severe' 'or' 'terminal' 'comorbidity' 'as' 'judged' 'by' 'the'
 'generalist' 'or' 'subspecialist' 'caring' 'for' 'the' 'patient']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT03063892,1:23:treatment,Active hormone therapy,['Active' 'hormone' 'therapy'],[1. 1. 1.]
NCT03062462,1:43:chronic_disease,severe congestive heart failure NYHA II-IV,['severe' 'congestive' 'heart' 'failure' 'NYHA' 'II-IV'],[2. 2. 2. 2. 2. 2.]
NCT03061903,21:57:treatment,Patients undergoing primary total hip arthroplasty (THA) through a direct anterior approach by one of the investigating surgeons,"['Patients' 'undergoing' 'primary' 'total' 'hip' 'arthroplasty' '(' 'THA'
 ')' 'through' 'a' 'direct' 'anterior' 'approach' 'by' 'one' 'of' 'the'
 'investigating' 'surgeons']",[0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03060772,14:36:treatment,Currently on pioglitazone treatment for another reason,['Currently' 'on' 'pioglitazone' 'treatment' 'for' 'another' 'reason'],[0. 0. 1. 1. 0. 0. 0.]
NCT03060473,",,37:58:treatment",Cervical dilation visually ≤ 5cm on sterile speculum exam,"['Cervical' 'dilation' 'visually' '≤' '5cm' 'on' 'sterile' 'speculum'
 'exam']",[0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT03060096,16:33:cancer,Diagnosis of a second malignancy,['Diagnosis' 'of' 'a' 'second' 'malignancy'],[0. 0. 0. 3. 3.]
NCT03059407,18:22:allergy_name,known allergy to dogs,['known' 'allergy' 'to' 'dogs'],[0. 0. 0. 4.]
NCT03059355,1:23:chronic_disease,Elevated triglycerides,['Elevated' 'triglycerides'],[2. 2.]
NCT03059030,1:23:chronic_disease,Von Willebrand disease,['Von' 'Willebrand' 'disease'],[2. 2. 2.]
NCT03058952,14:45:chronic_disease,Diagnosis of borderline personality disorder,['Diagnosis' 'of' 'borderline' 'personality' 'disorder'],[0. 0. 2. 2. 2.]
NCT03058796,1:30:chronic_disease,uncontrolled seizure disorder,['uncontrolled' 'seizure' 'disorder'],[2. 2. 2.]
NCT03058679,"32:37:treatment,",Start or change in dose of any 5-ASA medications within 2 weeks of screening,"['Start' 'or' 'change' 'in' 'dose' 'of' 'any' '5-ASA' 'medications'
 'within' '2' 'weeks' 'of' 'screening']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT03057730,46:69:treatment,Areas that have previously been treated with root coverage surgeries,"['Areas' 'that' 'have' 'previously' 'been' 'treated' 'with' 'root'
 'coverage' 'surgeries']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT03056339,13:44:chronic_disease,Presence of active neurological disorder(s),['Presence' 'of' 'active' 'neurological' 'disorder' '(' 's' ')'],[0. 0. 2. 2. 2. 0. 0. 0.]
NCT03055767,1:23:chronic_disease,Eaton Lambert Syndrome,['Eaton' 'Lambert' 'Syndrome'],[2. 2. 2.]
NCT03054519,",,,59:77:treatment",have an ABI > 0.90 with a 20% or higher drop in ABI after heel-rise exercise will be eligible,"['have' 'an' 'ABI' '>' '0.90' 'with' 'a' '20' '%' 'or' 'higher' 'drop'
 'in' 'ABI' 'after' 'heel-rise' 'exercise' 'will' 'be' 'eligible']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.]
NCT03053908,48:85:chronic_disease,Presence of any known or suspected obstructive disease of the gastrointestinal tract,"['Presence' 'of' 'any' 'known' 'or' 'suspected' 'obstructive' 'disease'
 'of' 'the' 'gastrointestinal' 'tract']",[0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 2.]
NCT03053908,1:10:chronic_disease,pulmonary,['pulmonary'],[2.]
NCT03053453,70:87:chronic_disease,Patients will be screened for eligibility based on whether they have chronic knee pain as a result of an arthritis-related condition,"['Patients' 'will' 'be' 'screened' 'for' 'eligibility' 'based' 'on'
 'whether' 'they' 'have' 'chronic' 'knee' 'pain' 'as' 'a' 'result' 'of'
 'an' 'arthritis-related' 'condition']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT03053271,1:26:chronic_disease,cyclic Cushing's syndrome,"['cyclic' 'Cushing' ""'s"" 'syndrome']",[2. 2. 2. 0.]
NCT03051516,"40:44:chronic_disease,","patients whose screening visit reveals HSIL on biopsy, may be re-screened >= 2 months after therapy","['patients' 'whose' 'screening' 'visit' 'reveals' 'HSIL' 'on' 'biopsy' ','
 'may' 'be' 're-screened' '>' '=' '2' 'months' 'after' 'therapy']",[0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03051282,28:37:allergy_name,Subjects hypersensitive to enalapril,['Subjects' 'hypersensitive' 'to' 'enalapril'],[0. 0. 0. 4.]
NCT03049189,16:39:treatment,Indication for surgical lesion removal with curative potential,"['Indication' 'for' 'surgical' 'lesion' 'removal' 'with' 'curative'
 'potential']",[0. 0. 1. 1. 1. 0. 0. 0.]
NCT03049189,1:30:chronic_disease,Serious non-malignant disease,['Serious' 'non-malignant' 'disease'],[2. 2. 2.]
NCT03049033,45:65:treatment,Participants whose insurance does not cover Occupational Therapy costs or who have no insurance,"['Participants' 'whose' 'insurance' 'does' 'not' 'cover' 'Occupational'
 'Therapy' 'costs' 'or' 'who' 'have' 'no' 'insurance']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT03046030,28:79:chronic_disease,"Current or past history of major medical, neurological, or psychiatric illness","['Current' 'or' 'past' 'history' 'of' 'major' 'medical' ',' 'neurological'
 ',' 'or' 'psychiatric' 'illness']",[0. 0. 0. 0. 0. 2. 2. 2. 2. 2. 2. 0. 0.]
NCT03043794,1:15:treatment,Breast implant in the involved breast,['Breast' 'implant' 'in' 'the' 'involved' 'breast'],[1. 1. 0. 0. 0. 0.]
NCT03043742,"10:23:treatment,",Previous heart surgery within the last 6 months,['Previous' 'heart' 'surgery' 'within' 'the' 'last' '6' 'months'],[0. 1. 1. 0. 0. 0. 0. 0.]
NCT03042689,14:55:cancer,Diagnosis of relapsed/refractory advanced malignancies,['Diagnosis' 'of' 'relapsed/refractory' 'advanced' 'malignancies'],[0. 0. 3. 3. 3.]
NCT03042689,1:36:chronic_disease,noninvasive aerodigestive neoplasms,['noninvasive' 'aerodigestive' 'neoplasms'],[2. 2. 2.]
NCT03040804,"14:38:chronic_disease,,,","Diagnosis of Hidradenitis Suppurativa made at the Montefiore Hidradenitis Suppurativa Treatment Center, with Hurley Stage 2-3 (defined as recurrent abscesses or boils with diffuse or broad involvement, multiple interconnected sinus tracts in the whole area)","['Diagnosis' 'of' 'Hidradenitis' 'Suppurativa' 'made' 'at' 'the'
 'Montefiore' 'Hidradenitis' 'Suppurativa' 'Treatment' 'Center' ',' 'with'
 'Hurley' 'Stage' '2-3' '(' 'defined' 'as' 'recurrent' 'abscesses' 'or'
 'boils' 'with' 'diffuse' 'or' 'broad' 'involvement' ',' 'multiple'
 'interconnected' 'sinus' 'tracts' 'in' 'the' 'whole' 'area' ')']","[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03040778,15:38:chronic_disease,Patients with ischemic heart diseases,['Patients' 'with' 'ischemic' 'heart' 'diseases'],[0. 0. 2. 2. 2.]
NCT03040778,1:14:treatment,ciprofloxacin,['ciprofloxacin'],[1.]
NCT03038867,1:27:chronic_disease,current sexual dysfunction (classified as moderate or worse on IIEF),"['current' 'sexual' 'dysfunction' '(' 'classified' 'as' 'moderate' 'or'
 'worse' 'on' 'IIEF' ')']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03038620,"39:63:treatment,",Current participation in an organized weight reduction program or within the last 1 month prior to screening for this trial,"['Current' 'participation' 'in' 'an' 'organized' 'weight' 'reduction'
 'program' 'or' 'within' 'the' 'last' '1' 'month' 'prior' 'to' 'screening'
 'for' 'this' 'trial']",[0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03038308,1:25:chronic_disease,Untreated hypothyroidism,['Untreated' 'hypothyroidism'],[2. 2.]
NCT03038269,1:22:treatment,Dorsal root rhizotomy,['Dorsal' 'root' 'rhizotomy'],[1. 1. 1.]
NCT03038269,8:31:treatment,use of anti-seizure medication,['use' 'of' 'anti-seizure' 'medication'],[0. 0. 1. 1.]
NCT03037879,1:27:chronic_disease,Acute illness or infection,['Acute' 'illness' 'or' 'infection'],[2. 2. 2. 2.]
NCT03037385,75:88:treatment,Patients in Groups 1-5 and 7 (Part 2) previously treated with a selective RET inhibitor,"['Patients' 'in' 'Groups' '1-5' 'and' '7' '(' 'Part' '2' ')' 'previously'
 'treated' 'with' 'a' 'selective' 'RET' 'inhibitor']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT03036280,24:47:chronic_disease,Positive biomarker for brain amyloid pathology as indicated by either amyloid PET or CSF AD assessment or both,"['Positive' 'biomarker' 'for' 'brain' 'amyloid' 'pathology' 'as'
 'indicated' 'by' 'either' 'amyloid' 'PET' 'or' 'CSF' 'AD' 'assessment'
 'or' 'both']",[0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03036098,1:43:cancer,Metastatic or inoperable urothelial cancer,['Metastatic' 'or' 'inoperable' 'urothelial' 'cancer'],[3. 3. 3. 3. 3.]
NCT03035890,1:34:chronic_disease,primary immunodeficiency syndrome,['primary' 'immunodeficiency' 'syndrome'],[2. 2. 2.]
NCT03035474,22:30:chronic_disease,Hospitalizations for acute HF will be determined by local clinician-investigators,"['Hospitalizations' 'for' 'acute' 'HF' 'will' 'be' 'determined' 'by'
 'local' 'clinician-investigators']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT03034564,4:15:chronic_disease,No orthostatic symptoms,['No' 'orthostatic' 'symptoms'],[0. 2. 0.]
NCT03034564,1:15:treatment,gastric bypass,['gastric' 'bypass'],[1. 1.]
NCT03033498,105:113:treatment,Consideration by the investigator for any reason that the subject is an unsuitable candidate to receive ABBV-951,"['Consideration' 'by' 'the' 'investigator' 'for' 'any' 'reason' 'that'
 'the' 'subject' 'is' 'an' 'unsuitable' 'candidate' 'to' 'receive'
 'ABBV-951']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT03033212,12:28:chronic_disease,History of spinal infection,['History' 'of' 'spinal' 'infection'],[0. 0. 2. 2.]
NCT03033212,1:20:chronic_disease,facet joint disease,['facet' 'joint' 'disease'],[2. 2. 2.]
NCT03032705,"5:26:treatment,",Any restorative treatment of the teeth involved in the study in the last 12 months,"['Any' 'restorative' 'treatment' 'of' 'the' 'teeth' 'involved' 'in' 'the'
 'study' 'in' 'the' 'last' '12' 'months']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03030859,1:27:treatment,Post HNC primary treatment,['Post' 'HNC' 'primary' 'treatment'],[1. 1. 1. 1.]
NCT03030118,1:60:chronic_disease,"Active bacterial, viral, fungal, or opportunistic infection","['Active' 'bacterial' ',' 'viral' ',' 'fungal' ',' 'or' 'opportunistic'
 'infection']",[2. 2. 2. 2. 2. 2. 2. 0. 0. 0.]
NCT03029884,1:28:chronic_disease,Stroke of ischemic etiology only,['Stroke' 'of' 'ischemic' 'etiology' 'only'],[2. 2. 2. 2. 0.]
NCT03028831,21:31:chronic_disease,any form of chronic GI disease resulting in disturbed gut function,"['any' 'form' 'of' 'chronic' 'GI' 'disease' 'resulting' 'in' 'disturbed'
 'gut' 'function']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT03028298,"1:29:treatment,",Pre-ictal sildenafil therapy (last dose within 1 week of presentation),"['Pre-ictal' 'sildenafil' 'therapy' '(' 'last' 'dose' 'within' '1' 'week'
 'of' 'presentation' ')']",[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03027388,",,67:82:treatment",Pregnant women are excluded from this study because the safety of PP2A inhibition on a developing fetus has not been established,"['Pregnant' 'women' 'are' 'excluded' 'from' 'this' 'study' 'because' 'the'
 'safety' 'of' 'PP2A' 'inhibition' 'on' 'a' 'developing' 'fetus' 'has'
 'not' 'been' 'established']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03026816,9:34:chronic_disease,"Stable, motor-complete paraplegia","['Stable' ',' 'motor-complete' 'paraplegia']",[0. 0. 2. 2.]
NCT03023449,1:22:chronic_disease,"Acute ischemic stroke in the territory of the anterior, middle, or posterior cerebral artery, on either side of the brain","['Acute' 'ischemic' 'stroke' 'in' 'the' 'territory' 'of' 'the' 'anterior'
 ',' 'middle' ',' 'or' 'posterior' 'cerebral' 'artery' ',' 'on' 'either'
 'side' 'of' 'the' 'brain']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03022292,1:44:treatment,Prior or current systemic anti-VEGF therapy,['Prior' 'or' 'current' 'systemic' 'anti-VEGF' 'therapy'],[1. 1. 1. 1. 1. 1.]
NCT03021902,1:54:chronic_disease,Pre-existing cognitive impairment or language barrier that prohibits outcomes assessment,"['Pre-existing' 'cognitive' 'impairment' 'or' 'language' 'barrier' 'that'
 'prohibits' 'outcomes' 'assessment']",[2. 2. 2. 2. 2. 2. 0. 0. 0. 0.]
NCT03019510,",,,,,,154:178:chronic_disease,,,,,,",body mass index (BMI): 30-45 kg/m2 for the obese subjects <24.5 kg/m2 for the non-obese subjects weight stable during prior 6 months non-smokers OB with impaired fasting glucose: elevated elevated morning fasting glucose levels >110 mg/dL for 5 of 7 days non-obese and OB subjects: fasting glucose levels < 100 mg/dL - 2hr OGTT glucose value <140 mg/dL,"['body' 'mass' 'index' '(' 'BMI' ')' ':' '30-45' 'kg/m2' 'for' 'the'
 'obese' 'subjects' '<' '24.5' 'kg/m2' 'for' 'the' 'non-obese' 'subjects'
 'weight' 'stable' 'during' 'prior' '6' 'months' 'non-smokers' 'OB' 'with'
 'impaired' 'fasting' 'glucose' ':' 'elevated' 'elevated' 'morning'
 'fasting' 'glucose' 'levels' '>' '110' 'mg/dL' 'for' '5' 'of' '7' 'days'
 'non-obese' 'and' 'OB' 'subjects' ':' 'fasting' 'glucose' 'levels' '<'
 '100' 'mg/dL' '-' '2hr' 'OGTT' 'glucose' 'value' '<' '140' 'mg/dL']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03019133,1:44:treatment,Ventilator support via an endotracheal tube,['Ventilator' 'support' 'via' 'an' 'endotracheal' 'tube'],[1. 1. 1. 1. 1. 1.]
NCT03018704,9:27:treatment,current treatment with TOP or a medication approved for AUD,"['current' 'treatment' 'with' 'TOP' 'or' 'a' 'medication' 'approved' 'for'
 'AUD']",[0. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT03017937,"18:29:chronic_disease,,",Able to tolerate hypercapnia for 1-2 minutes,['Able' 'to' 'tolerate' 'hypercapnia' 'for' '1-2' 'minutes'],[0. 0. 0. 2. 0. 0. 0.]
NCT03017118,1:30:chronic_disease,Post-traumatic osteoarthritis,['Post-traumatic' 'osteoarthritis'],[2. 2.]
NCT03016351,12:59:chronic_disease,History of cardiovascular disease or cardiovascular events,['History' 'of' 'cardiovascular' 'disease' 'or' 'cardiovascular' 'events'],[0. 0. 2. 2. 2. 2. 2.]
NCT03016130,"21:51:treatment,,","patients undergoing reduced intensity conditioning, only those regimens in which the expected neutropenia is ≥ 7 days are permitted and the patient must reside in the hospital","['patients' 'undergoing' 'reduced' 'intensity' 'conditioning' ',' 'only'
 'those' 'regimens' 'in' 'which' 'the' 'expected' 'neutropenia' 'is' '≥'
 '7' 'days' 'are' 'permitted' 'and' 'the' 'patient' 'must' 'reside' 'in'
 'the' 'hospital']","[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT03015272,",93:107:treatment",demonstrate minimal progress in speech acquisition despite having had at least 18 months of speech therapy,"['demonstrate' 'minimal' 'progress' 'in' 'speech' 'acquisition' 'despite'
 'having' 'had' 'at' 'least' '18' 'months' 'of' 'speech' 'therapy']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03014687,10:23:treatment,Previous sinus surgery,['Previous' 'sinus' 'surgery'],[0. 1. 1.]
NCT03013543,1:28:chronic_disease,Heterozygous POMC mutations,['Heterozygous' 'POMC' 'mutations'],[2. 2. 2.]
NCT03013543,6:21:chronic_disease,Rare genetic disease patients genetically confirmed diagnoses (may be confirmed by test at Screening),"['Rare' 'genetic' 'disease' 'patients' 'genetically' 'confirmed'
 'diagnoses' '(' 'may' 'be' 'confirmed' 'by' 'test' 'at' 'Screening' ')']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03011801,19:37:chronic_disease,An HPA axis or an endocrine disorder,['An' 'HPA' 'axis' 'or' 'an' 'endocrine' 'disorder'],[0. 0. 0. 0. 0. 2. 2.]
NCT03011567,1:25:chronic_disease,Gestational hypertension,['Gestational' 'hypertension'],[2. 2.]
NCT03011567,"1:30:chronic_disease,,,",Significant liver dysfunction (AST or ALT >500),['Significant' 'liver' 'dysfunction' '(' 'AST' 'or' 'ALT' '>' '500' ')'],[2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT03009110,1:16:chronic_disease,Irradiated skin,['Irradiated' 'skin'],[2. 2.]
NCT03008616,",34:53:chronic_disease",Meets modified ACOG criteria for severe preeclampsia,['Meets' 'modified' 'ACOG' 'criteria' 'for' 'severe' 'preeclampsia'],[0. 0. 0. 0. 0. 2. 2.]
NCT03008070,1:22:chronic_disease,Diabetic ketoacidosis,['Diabetic' 'ketoacidosis'],[2. 2.]
NCT03008070,1:33:cancer,cutaneous basocellular carcinoma,['cutaneous' 'basocellular' 'carcinoma'],[3. 3. 3.]
NCT03007030,27:57:allergy_name,Known hypersensitivity to brentuximab vedotin components,['Known' 'hypersensitivity' 'to' 'brentuximab' 'vedotin' 'components'],[0. 0. 0. 4. 4. 4.]
NCT03006770,"1:27:chronic_disease,",CLI with major tissue loss (Rutherford Category 6) in either leg,"['CLI' 'with' 'major' 'tissue' 'loss' '(' 'Rutherford' 'Category' '6' ')'
 'in' 'either' 'leg']",[2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03006770,1:53:chronic_disease,acquired immunodeficiency syndrome (AIDS) infections,['acquired' 'immunodeficiency' 'syndrome' '(' 'AIDS' ')' 'infections'],[2. 2. 2. 2. 2. 0. 0.]
NCT03006562,1:19:treatment,Epidural analgesia,['Epidural' 'analgesia'],[1. 1.]
NCT03005951,1:20:chronic_disease,Developmental delay,['Developmental' 'delay'],[2. 2.]
NCT03004807,1:10:chronic_disease,Dysphagia or difficulty swallowing,['Dysphagia' 'or' 'difficulty' 'swallowing'],[2. 0. 0. 0.]
NCT03003780,1:24:chronic_disease,COPD or HF exacerbation in the previous month,['COPD' 'or' 'HF' 'exacerbation' 'in' 'the' 'previous' 'month'],[2. 2. 2. 2. 0. 0. 0. 0.]
NCT03003689,"7:26:treatment,",taken systemic antibiotic medications within the previous 6 months,"['taken' 'systemic' 'antibiotic' 'medications' 'within' 'the' 'previous'
 '6' 'months']",[0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT03002389,12:43:chronic_disease,History of alpha 1 anti-trypsin deficiency,['History' 'of' 'alpha' '1' 'anti-trypsin' 'deficiency'],[0. 0. 2. 2. 2. 2.]
NCT03001830,"31:44:chronic_disease,,","confirmed diagnosis of severe Haemophilia A defined as baseline plasma FVIII levels of <1% of normal as assessed by a validated one-stage clotting assay or a chromogenic assay, resulting from intron 22 inversions, intron 1 inversions, splice-site mutations, small deletions/insertions and missense mutations","['confirmed' 'diagnosis' 'of' 'severe' 'Haemophilia' 'A' 'defined' 'as'
 'baseline' 'plasma' 'FVIII' 'levels' 'of' '<' '1' '%' 'of' 'normal' 'as'
 'assessed' 'by' 'a' 'validated' 'one-stage' 'clotting' 'assay' 'or' 'a'
 'chromogenic' 'assay' ',' 'resulting' 'from' 'intron' '22' 'inversions'
 ',' 'intron' '1' 'inversions' ',' 'splice-site' 'mutations' ',' 'small'
 'deletions/insertions' 'and' 'missense' 'mutations']","[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT03000439,10:40:treatment,Previous JIA treatment with tofacitinib,['Previous' 'JIA' 'treatment' 'with' 'tofacitinib'],[0. 1. 1. 1. 1.]
NCT03000257,19:56:chronic_disease,"participants with chronic or active hepatitis A, B or C","['participants' 'with' 'chronic' 'or' 'active' 'hepatitis' 'A' ',' 'B'
 'or' 'C']",[0. 0. 2. 2. 2. 2. 2. 2. 2. 2. 0.]
NCT02996227,1:31:treatment,laparoscopic abdominal surgery,['laparoscopic' 'abdominal' 'surgery'],[1. 1. 1.]
NCT02993900,1:36:cancer,"Carcinoma of the uterus: Stage IIIB (vaginal involvement), inoperable, or vaginal recurrence","['Carcinoma' 'of' 'the' 'uterus' ':' 'Stage' 'IIIB' '(' 'vaginal'
 'involvement' ')' ',' 'inoperable' ',' 'or' 'vaginal' 'recurrence']",[3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02992275,1:21:chronic_disease,Cardiovascular Risks,['Cardiovascular' 'Risks'],[2. 2.]
NCT02991677,",15:35:treatment",History of >1 chemotherapy regimen,['History' 'of' '>' '1' 'chemotherapy' 'regimen'],[0. 0. 0. 0. 1. 1.]
NCT02991651,25:55:treatment,Prior treatment with an EGFR tyrosine kinase inhibitor,['Prior' 'treatment' 'with' 'an' 'EGFR' 'tyrosine' 'kinase' 'inhibitor'],[0. 0. 0. 0. 1. 1. 1. 1.]
NCT02991144,"19:44:treatment,",On stable dose of ammonia scavenger therapy for ≥4 weeks,"['On' 'stable' 'dose' 'of' 'ammonia' 'scavenger' 'therapy' 'for' '≥4'
 'weeks']",[0. 0. 0. 0. 1. 1. 1. 0. 0. 0.]
NCT02990481,60:90:cancer,Patients with histologically confirmed locally advanced or metastatic cholangiocarcinomas in Arm 3,"['Patients' 'with' 'histologically' 'confirmed' 'locally' 'advanced' 'or'
 'metastatic' 'cholangiocarcinomas' 'in' 'Arm' '3']",[0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0.]
NCT02990377,",26:47:treatment",Past 3-month non-medical opioid analgesic (OA) use,['Past' '3-month' 'non-medical' 'opioid' 'analgesic' '(' 'OA' ')' 'use'],[0. 0. 0. 1. 1. 1. 0. 0. 0.]
NCT02989597,1:24:chronic_disease,Obstructive sleep apnea,['Obstructive' 'sleep' 'apnea'],[2. 2. 2.]
NCT02988960,48:88:cancer,Participant must not have a known uncontrolled malignancy of the central nervous system,"['Participant' 'must' 'not' 'have' 'a' 'known' 'uncontrolled' 'malignancy'
 'of' 'the' 'central' 'nervous' 'system']",[0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 3.]
NCT02988895,197:213:chronic_disease,other co-morbidities that in the investigator's opinion could require medical or surgical intervention to prevent or treat visual loss or media opacity that might result from that condition (i.e. severe cataracts),"['other' 'co-morbidities' 'that' 'in' 'the' 'investigator' ""'s"" 'opinion'
 'could' 'require' 'medical' 'or' 'surgical' 'intervention' 'to' 'prevent'
 'or' 'treat' 'visual' 'loss' 'or' 'media' 'opacity' 'that' 'might'
 'result' 'from' 'that' 'condition' '(' 'i.e' '.' 'severe' 'cataracts' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0.]"
NCT02986087,1:25:chronic_disease,Maternal uterine anomaly,['Maternal' 'uterine' 'anomaly'],[2. 2. 2.]
NCT02983903,1:18:chronic_disease,Bullous emphysema in region of nodule,['Bullous' 'emphysema' 'in' 'region' 'of' 'nodule'],[2. 2. 0. 0. 0. 0.]
NCT02983240,"1:32:chronic_disease,,",Severe fetal growth restriction (EFW < 5%),['Severe' 'fetal' 'growth' 'restriction' '(' 'EFW' '<' '5' '%' ')'],[2. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02982772,1:32:treatment,Treatment for vascular problems,['Treatment' 'for' 'vascular' 'problems'],[1. 1. 1. 1.]
NCT02982226,37:59:treatment,Express an unwillingness to receive human allograft tissue,"['Express' 'an' 'unwillingness' 'to' 'receive' 'human' 'allograft'
 'tissue']",[0. 0. 0. 0. 0. 1. 1. 1.]
NCT02981173,10:26:chronic_disease,Episodic cluster headache with periods that are predictable,"['Episodic' 'cluster' 'headache' 'with' 'periods' 'that' 'are'
 'predictable']",[0. 2. 2. 0. 0. 0. 0. 0.]
NCT02981082,1:45:chronic_disease,Moderate to severe interstitial lung disease,['Moderate' 'to' 'severe' 'interstitial' 'lung' 'disease'],[2. 2. 2. 2. 2. 2.]
NCT02979366,1:40:chronic_disease,Uncontrolled hepatitis B or C infection,['Uncontrolled' 'hepatitis' 'B' 'or' 'C' 'infection'],[2. 2. 2. 2. 2. 2.]
NCT02978885,7:32:treatment,other major abdominal surgeries,['other' 'major' 'abdominal' 'surgeries'],[0. 1. 1. 1.]
NCT02975986,"76:89:chronic_disease,,","In the Control group (N=10), we will include volunteers with no history of stone disease matched for age (within 5 years)","['In' 'the' 'Control' 'group' '(' 'N=10' ')' ',' 'we' 'will' 'include'
 'volunteers' 'with' 'no' 'history' 'of' 'stone' 'disease' 'matched' 'for'
 'age' '(' 'within' '5' 'years' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02974686,",92:113:treatment",Experiencing GI toxicity from MPA as determined by the treating physician within 12 months post-renal transplant,"['Experiencing' 'GI' 'toxicity' 'from' 'MPA' 'as' 'determined' 'by' 'the'
 'treating' 'physician' 'within' '12' 'months' 'post-renal' 'transplant']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02974257,",20:34:chronic_disease",Within 12 hours of cardiac arrest event,['Within' '12' 'hours' 'of' 'cardiac' 'arrest' 'event'],[0. 0. 0. 0. 2. 2. 0.]
NCT02971202,1:23:chronic_disease,diabetes comorbidities,['diabetes' 'comorbidities'],[2. 2.]
NCT02969187,22:67:treatment,Planned operation of laparoscopic Roux-en Y gastric bypass (LRYGB),"['Planned' 'operation' 'of' 'laparoscopic' 'Roux-en' 'Y' 'gastric'
 'bypass' '(' 'LRYGB' ')']",[0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0.]
NCT02969187,1:19:treatment,laparoscopic bowel,['laparoscopic' 'bowel'],[1. 1.]
NCT02968602,9:50:treatment,Current treatment with tetracycline or derivative,['Current' 'treatment' 'with' 'tetracycline' 'or' 'derivative'],[0. 1. 1. 1. 1. 1.]
NCT02967315,15:85:chronic_disease,patients with anomalous coronary crossing the right ventricular outflow tract (RVOT),"['patients' 'with' 'anomalous' 'coronary' 'crossing' 'the' 'right'
 'ventricular' 'outflow' 'tract' '(' 'RVOT' ')']",[0. 0. 2. 2. 2. 2. 2. 2. 2. 2. 2. 0. 0.]
NCT02966223,51:63:treatment,Subjects who have contraindications for receiving Y-90 therapy and any routine procedures and imaging associated with Y-90 therapy,"['Subjects' 'who' 'have' 'contraindications' 'for' 'receiving' 'Y-90'
 'therapy' 'and' 'any' 'routine' 'procedures' 'and' 'imaging' 'associated'
 'with' 'Y-90' 'therapy']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02964741,"15:35:treatment,,","No overuse of analgesic medication, defined as regular intake on ≥15 days per month for more than 3 months","['No' 'overuse' 'of' 'analgesic' 'medication' ',' 'defined' 'as' 'regular'
 'intake' 'on' '≥15' 'days' 'per' 'month' 'for' 'more' 'than' '3' 'months']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02964182,1:10:treatment,Bupropion,['Bupropion'],[1.]
NCT02963831,1:15:cancer,"Archival tumor samples are requested, but are not required for eligibility","['Archival' 'tumor' 'samples' 'are' 'requested' ',' 'but' 'are' 'not'
 'required' 'for' 'eligibility']",[3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02961114,1:16:chronic_disease,Severe nocturia,['Severe' 'nocturia'],[2. 2.]
NCT02960113,1:15:chronic_disease,Coagulopathies,['Coagulopathies'],[2.]
NCT02959671,24:39:allergy_name,Known allergies to any study materials,['Known' 'allergies' 'to' 'any' 'study' 'materials'],[0. 0. 0. 0. 4. 4.]
NCT02958462,1:53:chronic_disease,Idiopathic cytopenias of unclear significance (ICUS),['Idiopathic' 'cytopenias' 'of' 'unclear' 'significance' '(' 'ICUS' ')'],[2. 2. 2. 2. 2. 2. 0. 0.]
NCT02955537,1:13:chronic_disease,Hypertensive,['Hypertensive'],[2.]
NCT02954185,1:20:treatment,Cortisone injection,['Cortisone' 'injection'],[1. 1.]
NCT02953509,1:26:treatment,Prior treatment with CD47,['Prior' 'treatment' 'with' 'CD47'],[1. 1. 1. 1.]
NCT02953392,4:19:chronic_disease,No apical disorder/inflammation at the area of the implant site,"['No' 'apical' 'disorder/inflammation' 'at' 'the' 'area' 'of' 'the'
 'implant' 'site']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02952534,29:64:chronic_disease,molecular evidence of other homologous recombination deficiency,"['molecular' 'evidence' 'of' 'other' 'homologous' 'recombination'
 'deficiency']",[0. 0. 0. 0. 2. 2. 2.]
NCT02950649,7:39:chronic_disease,known severe peripheral artery disease,['known' 'severe' 'peripheral' 'artery' 'disease'],[0. 2. 2. 2. 2.]
NCT02950337,"1:30:treatment,",post-operative predicted FEV1<30% predicted,['post-operative' 'predicted' 'FEV1' '<' '30' '%' 'predicted'],[1. 1. 1. 0. 0. 0. 0.]
NCT02947945,1:19:chronic_disease,"Glomerulonephritis (haematuria, red cell casts, proteinuria)","['Glomerulonephritis' '(' 'haematuria' ',' 'red' 'cell' 'casts' ','
 'proteinuria' ')']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02946892,41:95:chronic_disease,History or current clinical evidence of moderate-to-severe fixed obstructive pulmonary disease,"['History' 'or' 'current' 'clinical' 'evidence' 'of' 'moderate-to-severe'
 'fixed' 'obstructive' 'pulmonary' 'disease']",[0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 2.]
NCT02946892,1:26:chronic_disease,nondilated cardiomyopathy,['nondilated' 'cardiomyopathy'],[2. 2.]
NCT02946658,1:12:chronic_disease,Hepatitis A history,['Hepatitis' 'A' 'history'],[2. 2. 0.]
NCT02945969,1:24:treatment,Prior kidney transplant based on self-report,['Prior' 'kidney' 'transplant' 'based' 'on' 'self-report'],[1. 1. 1. 0. 0. 0.]
NCT02945293,1:27:chronic_disease,cerebral vascular accident,['cerebral' 'vascular' 'accident'],[2. 2. 2.]
NCT02944825,1:28:treatment,shockwave lithotripsy [SWL],['shockwave' 'lithotripsy' '[' 'SWL' ']'],[1. 1. 1. 0. 0.]
NCT02943915,1:33:chronic_disease,Severe muscular or skeletal pain,['Severe' 'muscular' 'or' 'skeletal' 'pain'],[2. 2. 2. 2. 2.]
NCT02943746,1:12:chronic_disease,Stage 2 NEC prior to tolerating fortified feeds,['Stage' '2' 'NEC' 'prior' 'to' 'tolerating' 'fortified' 'feeds'],[2. 2. 2. 0. 0. 0. 0. 0.]
NCT02943408,1:41:chronic_disease,"major depression with psychotic features (296.24, 296.34)","['major' 'depression' 'with' 'psychotic' 'features' '(' '296.24' ','
 '296.34' ')']",[2. 2. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT02942095,1:27:cancer,Non-small cell lung cancer,['Non-small' 'cell' 'lung' 'cancer'],[3. 3. 3. 3.]
NCT02940288,19:30:treatment,Patients naïve to acupuncture,['Patients' 'naïve' 'to' 'acupuncture'],[0. 0. 0. 1.]
NCT02939183,"1:32:treatment,",Autologous stem cell transplant < 90 days prior to study day 1,"['Autologous' 'stem' 'cell' 'transplant' '<' '90' 'days' 'prior' 'to'
 'study' 'day' '1']",[1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02937402,53:87:treatment,Enrollment into this study may occur in tandem with other clinical therapeutics trials occurring at Vanderbilt University Medical Center (VUMC) as long as this trial does not violate protocol or inclusion criteria of that study,"['Enrollment' 'into' 'this' 'study' 'may' 'occur' 'in' 'tandem' 'with'
 'other' 'clinical' 'therapeutics' 'trials' 'occurring' 'at' 'Vanderbilt'
 'University' 'Medical' 'Center' '(' 'VUMC' ')' 'as' 'long' 'as' 'this'
 'trial' 'does' 'not' 'violate' 'protocol' 'or' 'inclusion' 'criteria'
 'of' 'that' 'study']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02933034,6:33:chronic_disease,have NYHA Grade IV heart failure,['have' 'NYHA' 'Grade' 'IV' 'heart' 'failure'],[0. 2. 2. 2. 2. 2.]
NCT02932410,",41:64:treatment",Subjects receiving a combination of > 2 PAH-specific treatments at randomization,"['Subjects' 'receiving' 'a' 'combination' 'of' '>' '2' 'PAH-specific'
 'treatments' 'at' 'randomization']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.]
NCT02932410,1:36:chronic_disease,pulmonary capillary hemangiomatosis,['pulmonary' 'capillary' 'hemangiomatosis'],[2. 2. 2.]
NCT02932280,",,,134:151:treatment",Negative β-human chorionic gonadotropin (hCG) pregnancy test for female patients of child-bearing potential ≤ 7 days before starting neratinib therapy,"['Negative' 'β-human' 'chorionic' 'gonadotropin' '(' 'hCG' ')' 'pregnancy'
 'test' 'for' 'female' 'patients' 'of' 'child-bearing' 'potential' '≤' '7'
 'days' 'before' 'starting' 'neratinib' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02931110,1:11:treatment,enoxaparin,['enoxaparin'],[1.]
NCT02931110,1:29:treatment,low-molecular-weight heparin,['low-molecular-weight' 'heparin'],[1. 1.]
NCT02930018,"1:17:chronic_disease,,",Disabling stroke defined as a baseline National Institutes of Health Stroke Score (NIHSS) > 5 at the time of randomization,"['Disabling' 'stroke' 'defined' 'as' 'a' 'baseline' 'National'
 'Institutes' 'of' 'Health' 'Stroke' 'Score' '(' 'NIHSS' ')' '>' '5' 'at'
 'the' 'time' 'of' 'randomization']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02930018,15:47:chronic_disease,Patient has a severe or fatal comorbid illness that will prevent improvement or follow-up,"['Patient' 'has' 'a' 'severe' 'or' 'fatal' 'comorbid' 'illness' 'that'
 'will' 'prevent' 'improvement' 'or' 'follow-up']",[0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02928991,1:29:chronic_disease,Congenital Dyserythropoietic,['Congenital' 'Dyserythropoietic'],[2. 2.]
NCT02928991,"62:76:chronic_disease,,","Patients with clinically diagnosed and/or genetically proven iBMF syndromes, resulting in chronic red blood cell or platelet-transfusion dependence and/or an absolute neutrophil count <500/µL","['Patients' 'with' 'clinically' 'diagnosed' 'and/or' 'genetically'
 'proven' 'iBMF' 'syndromes' ',' 'resulting' 'in' 'chronic' 'red' 'blood'
 'cell' 'or' 'platelet-transfusion' 'dependence' 'and/or' 'an' 'absolute'
 'neutrophil' 'count' '<' '500/µL']","[0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02928991,11:49:chronic_disease,diagnosed inherited bone marrow failure syndrome,['diagnosed' 'inherited' 'bone' 'marrow' 'failure' 'syndrome'],[0. 2. 2. 2. 2. 2.]
NCT02927392,",26:44:treatment",Women who have undergone surgical menopause,['Women' 'who' 'have' 'undergone' 'surgical' 'menopause'],[0. 0. 0. 0. 1. 1.]
NCT02926924,10:25:chronic_disease,Previous spine infection,['Previous' 'spine' 'infection'],[0. 2. 2.]
NCT02926378,1:25:treatment,IV anticoagulant therapy,['IV' 'anticoagulant' 'therapy'],[1. 1. 1.]
NCT02926248,20:33:treatment,Patients requiring bilateral MUA,['Patients' 'requiring' 'bilateral' 'MUA'],[0. 0. 1. 1.]
NCT02925923,1:15:treatment,Clarithromycin,['Clarithromycin'],[1.]
NCT02925923,1:10:treatment,Lopinavir,['Lopinavir'],[1.]
NCT02925923,1:12:treatment,Rivaroxaban,['Rivaroxaban'],[1.]
NCT02925923,1:23:treatment,anti-retroviral agents,['anti-retroviral' 'agents'],[1. 1.]
NCT02924363,1:18:treatment,Cochlear implants,['Cochlear' 'implants'],[1. 1.]
NCT02924194,8:32:treatment,Use of cholinesterase inhibitor,['Use' 'of' 'cholinesterase' 'inhibitor'],[0. 0. 1. 1.]
NCT02923167,"15:51:treatment,",Recent use of upper-limb robotic-assisted training within the last 3 months,"['Recent' 'use' 'of' 'upper-limb' 'robotic-assisted' 'training' 'within'
 'the' 'last' '3' 'months']",[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02923011,10:20:cancer,"Targeted bone/tumor interface is accessible to the ExAblate device and located in a rib, extremity (excluding intra-articular location), pelvis, shoulders (including clavicles), or the sternum","['Targeted' 'bone/tumor' 'interface' 'is' 'accessible' 'to' 'the'
 'ExAblate' 'device' 'and' 'located' 'in' 'a' 'rib' ',' 'extremity' '('
 'excluding' 'intra-articular' 'location' ')' ',' 'pelvis' ',' 'shoulders'
 '(' 'including' 'clavicles' ')' ',' 'or' 'the' 'sternum']","[0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02921022,31:53:chronic_disease,"Known, clinically significant carotid artery disease","['Known' ',' 'clinically' 'significant' 'carotid' 'artery' 'disease']",[0. 0. 0. 0. 2. 2. 2.]
NCT02920710,14:34:allergy_name,Allergies to pig-derived proteins,['Allergies' 'to' 'pig-derived' 'proteins'],[0. 0. 4. 4.]
NCT02920086,1:13:treatment,Vasopressors,['Vasopressors'],[1.]
NCT02918981,1:22:chronic_disease,Phenylketonuria (PKU),['Phenylketonuria' '(' 'PKU' ')'],[2. 2. 0. 0.]
NCT02916524,",41:63:chronic_disease","At least 6 months post-onset of single, left-hemisphere stroke","['At' 'least' '6' 'months' 'post-onset' 'of' 'single' ','
 'left-hemisphere' 'stroke']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02914834,1:23:chronic_disease,autoimmune dysfunction,['autoimmune' 'dysfunction'],[2. 2.]
NCT02914483,1:36:chronic_disease,acute exacerbation of heart failure,['acute' 'exacerbation' 'of' 'heart' 'failure'],[2. 2. 2. 2. 2.]
NCT02914171,156:179:treatment,Individuals who have other clinical concerns as documented by a site investigator that could reasonably increase the risk of complications during or after surgical Ebstein repair,"['Individuals' 'who' 'have' 'other' 'clinical' 'concerns' 'as'
 'documented' 'by' 'a' 'site' 'investigator' 'that' 'could' 'reasonably'
 'increase' 'the' 'risk' 'of' 'complications' 'during' 'or' 'after'
 'surgical' 'Ebstein' 'repair']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 1. 1.]"
NCT02914171,",67:89:treatment",Individuals with the following conditions within 60 days prior to Ebstein repair surgery,"['Individuals' 'with' 'the' 'following' 'conditions' 'within' '60' 'days'
 'prior' 'to' 'Ebstein' 'repair' 'surgery']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02913495,1:8:chronic_disease,accreta,['accreta'],[2.]
NCT02913430,"25:27:treatment,",The minimum duration of AI in the adjuvant setting is 2 years,"['The' 'minimum' 'duration' 'of' 'AI' 'in' 'the' 'adjuvant' 'setting' 'is'
 '2' 'years']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02913430,1:29:cancer,skin squamous cell carcinoma,['skin' 'squamous' 'cell' 'carcinoma'],[3. 3. 3. 3.]
NCT02912572,1:20:cancer,"Endometrial cancers that are MSS as determined by normal immunohistochemical nuclear expression of all the mismatch repair genes MSH2, MSH6, MLH1 and PMS2","['Endometrial' 'cancers' 'that' 'are' 'MSS' 'as' 'determined' 'by'
 'normal' 'immunohistochemical' 'nuclear' 'expression' 'of' 'all' 'the'
 'mismatch' 'repair' 'genes' 'MSH2' ',' 'MSH6' ',' 'MLH1' 'and' 'PMS2']","[3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02911831,34:69:cancer,Patients with known or suspected endometrial/ovarian/cervical cancer,"['Patients' 'with' 'known' 'or' 'suspected' 'endometrial/ovarian/cervical'
 'cancer']",[0. 0. 0. 0. 0. 3. 3.]
NCT02911792,1:27:chronic_disease,major organ system disease,['major' 'organ' 'system' 'disease'],[2. 2. 2. 2.]
NCT02911467,",30:70:chronic_disease","Patients who because of age, general medical or psychiatric condition, or physiologic status cannot give valid informed consent","['Patients' 'who' 'because' 'of' 'age' ',' 'general' 'medical' 'or'
 'psychiatric' 'condition' ',' 'or' 'physiologic' 'status' 'can' 'not'
 'give' 'valid' 'informed' 'consent']",[0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02911467,",,29:38:chronic_disease,",bilirubin <1.5x ULN (unless Gilbert's is suspected in which case total bilirubin < 3 x ULN),"['bilirubin' '<' '1.5x' 'ULN' '(' 'unless' 'Gilbert' ""'s"" 'is' 'suspected'
 'in' 'which' 'case' 'total' 'bilirubin' '<' '3' 'x' 'ULN' ')']",[2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2.]
NCT02911116,1:40:treatment,surgical sterilization (tubal ligation),['surgical' 'sterilization' '(' 'tubal' 'ligation' ')'],[1. 1. 1. 1. 0. 0.]
NCT02910700,21:49:cancer,they have untreated leptomeningeal disease (LMD) as long as they fulfill all other eligibility requirements,"['they' 'have' 'untreated' 'leptomeningeal' 'disease' '(' 'LMD' ')' 'as'
 'long' 'as' 'they' 'fulfill' 'all' 'other' 'eligibility' 'requirements']",[0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02908906,45:57:cancer,Participants enrolled into Part 2 must have tumor tissue available for correlative studies,"['Participants' 'enrolled' 'into' 'Part' '2' 'must' 'have' 'tumor'
 'tissue' 'available' 'for' 'correlative' 'studies']",[0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0.]
NCT02908906,1:37:chronic_disease,psychiatric illness/social situation that would limited compliance with study requirements,"['psychiatric' 'illness/social' 'situation' 'that' 'would' 'limited'
 'compliance' 'with' 'study' 'requirements']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02908841,6:28:treatment,open abdominal hysterectomy,['open' 'abdominal' 'hysterectomy'],[0. 1. 1.]
NCT02907983,",26:37:treatment",for women who refuse any oral therap,['for' 'women' 'who' 'refuse' 'any' 'oral' 'therap'],[0. 0. 0. 0. 0. 1. 1.]
NCT02907983,1:52:treatment,serotonin norepinephrine reuptake inhibitors (SNRI),['serotonin' 'norepinephrine' 'reuptake' 'inhibitors' '(' 'SNRI' ')'],[1. 1. 1. 1. 1. 0. 0.]
NCT02905929,1:14:cancer,Active cancer,['Active' 'cancer'],[3. 3.]
NCT02905591,1:27:cancer,Exudative pleural effusion,['Exudative' 'pleural' 'effusion'],[3. 3. 3.]
NCT02905578,97:131:treatment,"If all of the above are met, the potential participant will receive a 15 gram challenge dose of ascorbate via intravenous infusion. This is the final screening procedure","['If' 'all' 'of' 'the' 'above' 'are' 'met' ',' 'the' 'potential'
 'participant' 'will' 'receive' 'a' '15' 'gram' 'challenge' 'dose' 'of'
 'ascorbate' 'via' 'intravenous' 'infusion' '.' 'This' 'is' 'the' 'final'
 'screening' 'procedure']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02905370,1:25:chronic_disease,Congestive Heart Failure,['Congestive' 'Heart' 'Failure'],[2. 2. 2.]
NCT02905370,1:23:chronic_disease,Gastrointestinal Bleed,['Gastrointestinal' 'Bleed'],[2. 2.]
NCT02905370,1:28:chronic_disease,Peripheral Arterial Disease,['Peripheral' 'Arterial' 'Disease'],[2. 2. 2.]
NCT02905188,11:47:treatment,Available autologous transduced T cell product,['Available' 'autologous' 'transduced' 'T' 'cell' 'product'],[0. 1. 1. 1. 1. 1.]
NCT02903446,12:42:chronic_disease,History of osteonecrosis of the jaw (ONJ),['History' 'of' 'osteonecrosis' 'of' 'the' 'jaw' '(' 'ONJ' ')'],[0. 0. 2. 2. 2. 2. 2. 0. 0.]
NCT02903446,"1:21:chronic_disease,,,",Vitamin D deficiency [25(OH) vitamin D level < 20 ng/mL (<49.9 nmol/L)]†,"['Vitamin' 'D' 'deficiency' '[' '25' '(' 'OH' ')' 'vitamin' 'D' 'level'
 '<' '20' 'ng/mL' '(' '<' '49.9' 'nmol/L' ')' ']' '†']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02901314,23:61:treatment,Currently enrolled in another experimental HF research study,"['Currently' 'enrolled' 'in' 'another' 'experimental' 'HF' 'research'
 'study']",[0. 0. 0. 1. 1. 1. 1. 1.]
NCT02901067,27:56:allergy_name,Known contraindication to pharmacologic anticoagulation,['Known' 'contraindication' 'to' 'pharmacologic' 'anticoagulation'],[0. 0. 0. 4. 4.]
NCT02901041,18:30:allergy_name,Known allergy to sulfonamides,['Known' 'allergy' 'to' 'sulfonamides'],[0. 0. 0. 4.]
NCT02900794,1:20:treatment,Prior sinus surgery,['Prior' 'sinus' 'surgery'],[1. 1. 1.]
NCT02898701,1:23:chronic_disease,acute medical problems,['acute' 'medical' 'problems'],[2. 2. 2.]
NCT02895945,",69:92:chronic_disease",Participant has an ongoing or recent (within 3 months of screening) thrombo-embolic disease,"['Participant' 'has' 'an' 'ongoing' 'or' 'recent' '(' 'within' '3'
 'months' 'of' 'screening' ')' 'thrombo-embolic' 'disease']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02895945,"8:44:chronic_disease,,","Severe chronic liver dysfunction or disease (e.g., ≥ 5 × upper limit of normal [ULN] alanine aminotransferase [ALT], as confirmed by central laboratory at screening","['Severe' 'chronic' 'liver' 'dysfunction' 'or' 'disease' '(' 'e.g.' ','
 '≥' '5' '×' 'upper' 'limit' 'of' 'normal' '[' 'ULN' ']' 'alanine'
 'aminotransferase' '[' 'ALT' ']' ',' 'as' 'confirmed' 'by' 'central'
 'laboratory' 'at' 'screening']","[0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02891850,"26:43:chronic_disease,,",Patients with underlying medical disorders with an anticipated life expectancy below 2 years,"['Patients' 'with' 'underlying' 'medical' 'disorders' 'with' 'an'
 'anticipated' 'life' 'expectancy' 'below' '2' 'years']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02891447,1:29:cancer,Positive peritoneal cytology,['Positive' 'peritoneal' 'cytology'],[3. 3. 3.]
NCT02890485,19:42:treatment,Received previous dry needling treatments,['Received' 'previous' 'dry' 'needling' 'treatments'],[0. 0. 1. 1. 1.]
NCT02885649,1:15:cancer,Metastatic RCC,['Metastatic' 'RCC'],[3. 3.]
NCT02881320,52:74:treatment,Individuals undergoing dose modifications to their antiretroviral regimen for growth or who are switching medication formulation(s) are considered to be on a stable antiretroviral regimen,"['Individuals' 'undergoing' 'dose' 'modifications' 'to' 'their'
 'antiretroviral' 'regimen' 'for' 'growth' 'or' 'who' 'are' 'switching'
 'medication' 'formulation' '(' 's' ')' 'are' 'considered' 'to' 'be' 'on'
 'a' 'stable' 'antiretroviral' 'regimen']","[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02880215,8:47:treatment,stable psychiatric and neurological medication usage,['stable' 'psychiatric' 'and' 'neurological' 'medication' 'usage'],[0. 1. 1. 1. 1. 0.]
NCT02877381,73:76:allergy_name,"Patients scheduled for a head and liner/poly exchange, known allergy to TXA, acquired disturbances of color vision, refusal of blood products","['Patients' 'scheduled' 'for' 'a' 'head' 'and' 'liner/poly' 'exchange' ','
 'known' 'allergy' 'to' 'TXA' ',' 'acquired' 'disturbances' 'of' 'color'
 'vision' ',' 'refusal' 'of' 'blood' 'products']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02876510,106:113:treatment,Patient is a candidate for a maximum of one further line of established therapy (prior to treatment with ACTolog),"['Patient' 'is' 'a' 'candidate' 'for' 'a' 'maximum' 'of' 'one' 'further'
 'line' 'of' 'established' 'therapy' '(' 'prior' 'to' 'treatment' 'with'
 'ACTolog' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02875405,1:16:chronic_disease,chest deformity,['chest' 'deformity'],[2. 2.]
NCT02875301,1:12:chronic_disease,Parkinson's,"['Parkinson' ""'s""]",[2. 2.]
NCT02875301,15:39:chronic_disease,not including general anxiety disorder,['not' 'including' 'general' 'anxiety' 'disorder'],[0. 0. 2. 2. 2.]
NCT02873598,21:32:allergy_name,Contraindication to IV contrast,['Contraindication' 'to' 'IV' 'contrast'],[0. 0. 4. 4.]
NCT02871726,1:22:treatment,Prior prostate biopsy,['Prior' 'prostate' 'biopsy'],[1. 1. 1.]
NCT02869789,26:73:cancer,Histologically confirmed Stage 4 or recurrent non-small cell lung cancer,"['Histologically' 'confirmed' 'Stage' '4' 'or' 'recurrent' 'non-small'
 'cell' 'lung' 'cancer']",[0. 0. 3. 3. 3. 3. 3. 3. 3. 3.]
NCT02866279,1:28:chronic_disease,Polycystic Ovarian Syndrome,['Polycystic' 'Ovarian' 'Syndrome'],[2. 2. 2.]
NCT02864147,"50:76:cancer,","All Patients must have a histologic diagnosis of CIN 2,3 cervical lesion(s) confirmed by a study pathologist within past 10 weeks","['All' 'Patients' 'must' 'have' 'a' 'histologic' 'diagnosis' 'of' 'CIN'
 '2,3' 'cervical' 'lesion' '(' 's' ')' 'confirmed' 'by' 'a' 'study'
 'pathologist' 'within' 'past' '10' 'weeks']",[0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02864147,1:15:chronic_disease,cardiac issues as above,['cardiac' 'issues' 'as' 'above'],[2. 2. 0. 0.]
NCT02863809,1:20:chronic_disease,Autoimmune diseases,['Autoimmune' 'diseases'],[2. 2.]
NCT02863809,41:58:chronic_disease,Inability to wear a contact lens due to lid abnormalities or shortened fornix,"['Inability' 'to' 'wear' 'a' 'contact' 'lens' 'due' 'to' 'lid'
 'abnormalities' 'or' 'shortened' 'fornix']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0.]
NCT02863809,1:29:chronic_disease,systemic lupus erythematosis,['systemic' 'lupus' 'erythematosis'],[2. 2. 2.]
NCT02862938,17:36:chronic_disease,Participant has optic nerve atrophy beyond modest pallor,['Participant' 'has' 'optic' 'nerve' 'atrophy' 'beyond' 'modest' 'pallor'],[0. 0. 2. 2. 2. 0. 0. 0.]
NCT02862210,8:33:treatment,Use of antipsychotic medications,['Use' 'of' 'antipsychotic' 'medications'],[0. 0. 1. 1.]
NCT02860702,1:12:chronic_disease,Heterotaxia,['Heterotaxia'],[2.]
NCT02859142,33:50:allergy_name,History of adverse reactions to varenicline (VAR),['History' 'of' 'adverse' 'reactions' 'to' 'varenicline' '(' 'VAR' ')'],[0. 0. 0. 0. 0. 4. 4. 0. 0.]
NCT02857270,6:51:cancer,Have symptomatic central nervous system malignancy or metastasis,"['Have' 'symptomatic' 'central' 'nervous' 'system' 'malignancy' 'or'
 'metastasis']",[0. 3. 3. 3. 3. 3. 0. 0.]
NCT02857218,20:53:allergy_name,have an allergy to gadolinium (Gd) contrast material,"['have' 'an' 'allergy' 'to' 'gadolinium' '(' 'Gd' ')' 'contrast'
 'material']",[0. 0. 0. 0. 4. 4. 4. 4. 0. 0.]
NCT02856412,1:20:chronic_disease,neurologic disorder,['neurologic' 'disorder'],[2. 2.]
NCT02852538,1:37:chronic_disease,Severe comorbid psychiatric disorder,['Severe' 'comorbid' 'psychiatric' 'disorder'],[2. 2. 2. 2.]
NCT02851914,1:29:chronic_disease,premorbid bipolar depression,['premorbid' 'bipolar' 'depression'],[2. 2. 2.]
NCT02851407,"13:27:chronic_disease,",Patient has acute bleeding that is clinically significant within 24 hours before the start of study treatment,"['Patient' 'has' 'acute' 'bleeding' 'that' 'is' 'clinically' 'significant'
 'within' '24' 'hours' 'before' 'the' 'start' 'of' 'study' 'treatment']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02849639,1:20:chronic_disease,Acid reflux disease,['Acid' 'reflux' 'disease'],[2. 2. 2.]
NCT02848417,1:10:chronic_disease,Dementias of any type,['Dementias' 'of' 'any' 'type'],[2. 0. 0. 0.]
NCT02848417,1:24:chronic_disease,Primary sleep disorders,['Primary' 'sleep' 'disorders'],[2. 2. 2.]
NCT02847689,1:25:chronic_disease,Active seizure disorders,['Active' 'seizure' 'disorders'],[2. 2. 2.]
NCT02847689,1:42:chronic_disease,Intraventricular Hemorrhage Grades III-IV,['Intraventricular' 'Hemorrhage' 'Grades' 'III-IV'],[2. 2. 2. 2.]
NCT02846532,44:70:chronic_disease,History of or signs/symptoms suggestive of protein-losing enteropathy,"['History' 'of' 'or' 'signs/symptoms' 'suggestive' 'of' 'protein-losing'
 'enteropathy']",[0. 0. 0. 0. 0. 0. 2. 2.]
NCT02845596,24:38:chronic_disease,Confirmed diagnosis of idiopathic SAA,['Confirmed' 'diagnosis' 'of' 'idiopathic' 'SAA'],[0. 0. 0. 2. 2.]
NCT02845336,20:48:chronic_disease,Vision loss due to compressive optic neuropathy,['Vision' 'loss' 'due' 'to' 'compressive' 'optic' 'neuropathy'],[0. 0. 0. 0. 2. 2. 2.]
NCT02844465,",34:64:chronic_disease",MRI has evidence consistent with mesial temporal lobe sclerosis,"['MRI' 'has' 'evidence' 'consistent' 'with' 'mesial' 'temporal' 'lobe'
 'sclerosis']",[0. 0. 0. 0. 0. 2. 2. 2. 2.]
NCT02843568,51:67:chronic_disease,One biopsy site is adequate for multiple sites of thoracic disease,"['One' 'biopsy' 'site' 'is' 'adequate' 'for' 'multiple' 'sites' 'of'
 'thoracic' 'disease']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02842658,1:35:chronic_disease,Symptomatic severe aortic stenosis,['Symptomatic' 'severe' 'aortic' 'stenosis'],[2. 2. 2. 2.]
NCT02841540,24:54:chronic_disease,Known prior or current retinal or optic nerve disease,['Known' 'prior' 'or' 'current' 'retinal' 'or' 'optic' 'nerve' 'disease'],[0. 0. 0. 0. 2. 2. 2. 2. 2.]
NCT02840643,14:24:chronic_disease,Diagnosis of hemiplegia,['Diagnosis' 'of' 'hemiplegia'],[0. 0. 2.]
NCT02838797,"1:19:chronic_disease,,,,",active suicidality as measured by a most severe suicide ideation score of 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS),"['active' 'suicidality' 'as' 'measured' 'by' 'a' 'most' 'severe' 'suicide'
 'ideation' 'score' 'of' '4' 'or' '5' 'on' 'the' 'Columbia-Suicide'
 'Severity' 'Rating' 'Scale' '(' 'C-SSRS' ')']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02837510,1:20:treatment,Anti-anxiety agents,['Anti-anxiety' 'agents'],[1. 1.]
NCT02837510,5:20:chronic_disease,any Axis 1 disorder,['any' 'Axis' '1' 'disorder'],[0. 2. 2. 2.]
NCT02836899,"1:35:treatment,,",Elective cardiac or aortic surgery with CPB>90 minutes,"['Elective' 'cardiac' 'or' 'aortic' 'surgery' 'with' 'CPB' '>' '90'
 'minutes']",[1. 1. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02836574,54:67:treatment,anatomic abnormalities that would interfere with the NKA injection procedure,"['anatomic' 'abnormalities' 'that' 'would' 'interfere' 'with' 'the' 'NKA'
 'injection' 'procedure']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0.]
NCT02836574,44:70:treatment,"subject is not a good candidate to undergo percutaneous NKA injection, in the judgment of the surgeon or physician who will perform the procedure","['subject' 'is' 'not' 'a' 'good' 'candidate' 'to' 'undergo' 'percutaneous'
 'NKA' 'injection' ',' 'in' 'the' 'judgment' 'of' 'the' 'surgeon' 'or'
 'physician' 'who' 'will' 'perform' 'the' 'procedure']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02834403,"23:32:treatment,",Patients who received docetaxel at any line of treatment within the past 12 months,"['Patients' 'who' 'received' 'docetaxel' 'at' 'any' 'line' 'of'
 'treatment' 'within' 'the' 'past' '12' 'months']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02833792,12:29:cancer,History of cerebral neoplasm,['History' 'of' 'cerebral' 'neoplasm'],[0. 0. 3. 3.]
NCT02832167,16:49:cancer,Diagnosed with advanced or metastatic malignancy,['Diagnosed' 'with' 'advanced' 'or' 'metastatic' 'malignancy'],[0. 0. 3. 3. 3. 3.]
NCT02832115,8:23:chronic_disease,Severe Aortic Stenosis,['Severe' 'Aortic' 'Stenosis'],[0. 2. 2.]
NCT02830074,",,102:110:chronic_disease",the investigators will offer to re-contact patients 90 days after a health event or after 90 days of sobriety,"['the' 'investigators' 'will' 'offer' 'to' 're-contact' 'patients' '90'
 'days' 'after' 'a' 'health' 'event' 'or' 'after' '90' 'days' 'of'
 'sobriety']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02829268,25:41:chronic_disease,definitive diagnosis of Wolfram syndrome,['definitive' 'diagnosis' 'of' 'Wolfram' 'syndrome'],[0. 0. 0. 2. 2.]
NCT02828618,"17:51:cancer,,",newly diagnosed invasive epithelial ovarian cancer FIGO stage IIIB-IV,"['newly' 'diagnosed' 'invasive' 'epithelial' 'ovarian' 'cancer' 'FIGO'
 'stage' 'IIIB-IV']",[0. 0. 3. 3. 3. 3. 0. 0. 0.]
NCT02826681,8:41:chronic_disease,Active acute or known chronic infections,['Active' 'acute' 'or' 'known' 'chronic' 'infections'],[0. 2. 2. 2. 2. 2.]
NCT02826577,30:33:treatment,Have a counter indication to EEG,['Have' 'a' 'counter' 'indication' 'to' 'EEG'],[0. 0. 0. 0. 0. 1.]
NCT02824276,"1:5:chronic_disease,",CLBP lasting for more than 6 months as the primary complaint,"['CLBP' 'lasting' 'for' 'more' 'than' '6' 'months' 'as' 'the' 'primary'
 'complaint']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02823665,"1:18:chronic_disease,,",Hypoglycemic RYGB patients with documented blood glucose level <50 mg/dl,"['Hypoglycemic' 'RYGB' 'patients' 'with' 'documented' 'blood' 'glucose'
 'level' '<' '50' 'mg/dl']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02822378,"18:38:treatment,",systemic oral or transdermal estrogen within the past 3 months,"['systemic' 'oral' 'or' 'transdermal' 'estrogen' 'within' 'the' 'past' '3'
 'months']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02819843,",,76:102:treatment",History of high grade (CTCAE ≥ Grade 3) immune mediated adverse event from prior cancer immunotherapy,"['History' 'of' 'high' 'grade' '(' 'CTCAE' '≥' 'Grade' '3' ')' 'immune'
 'mediated' 'adverse' 'event' 'from' 'prior' 'cancer' 'immunotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02819635,"10:37:treatment,",Received intravenous corticosteroids within 14 days prior to Screening or during the Screening Period,"['Received' 'intravenous' 'corticosteroids' 'within' '14' 'days' 'prior'
 'to' 'Screening' 'or' 'during' 'the' 'Screening' 'Period']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02819440,16:32:treatment,Current use of organic nitrates,['Current' 'use' 'of' 'organic' 'nitrates'],[0. 0. 0. 1. 1.]
NCT02816736,1:24:chronic_disease,Symptomatic hypotension at randomization,['Symptomatic' 'hypotension' 'at' 'randomization'],[2. 2. 0. 0.]
NCT02815917,20:63:treatment,Currently requires treatment with any psychoactive medications,"['Currently' 'requires' 'treatment' 'with' 'any' 'psychoactive'
 'medications']",[0. 0. 1. 1. 1. 1. 1.]
NCT02811263,1:21:chronic_disease,Perinatal depression based on at least one of the following,"['Perinatal' 'depression' 'based' 'on' 'at' 'least' 'one' 'of' 'the'
 'following']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02808442,1:45:cancer,Active Central Nervous System (CNS) leukemia,['Active' 'Central' 'Nervous' 'System' '(' 'CNS' ')' 'leukemia'],[3. 3. 3. 3. 3. 3. 0. 0.]
NCT02807883,17:33:chronic_disease,Medications for GVHD prophylaxis,['Medications' 'for' 'GVHD' 'prophylaxis'],[0. 0. 2. 2.]
NCT02807272,19:76:treatment,Concurrent use of granulocyte macrophage colony-stimulating factor (GM-CSF),"['Concurrent' 'use' 'of' 'granulocyte' 'macrophage' 'colony-stimulating'
 'factor' '(' 'GM-CSF' ')']",[0. 0. 0. 1. 1. 1. 1. 1. 0. 0.]
NCT02805504,12:23:allergy_name,Allergy to bupivacaine,['Allergy' 'to' 'bupivacaine'],[0. 0. 4.]
NCT02804230,1:39:chronic_disease,Lesions in the brainstem or cerebellum,['Lesions' 'in' 'the' 'brainstem' 'or' 'cerebellum'],[2. 2. 2. 2. 2. 2.]
NCT02803359,12:25:allergy_name,Allergy to Oxymetazoline,['Allergy' 'to' 'Oxymetazoline'],[0. 0. 4.]
NCT02803359,12:30:chronic_disease,History of Neurologic Disease,['History' 'of' 'Neurologic' 'Disease'],[0. 0. 2. 2.]
NCT02803164,8:31:chronic_disease,Patent bronchopleural fistulas,['Patent' 'bronchopleural' 'fistulas'],[0. 2. 2.]
NCT02802176,1:68:chronic_disease,"Vaginal inflammation or genital (vaginal, uterine, tubal) infection","['Vaginal' 'inflammation' 'or' 'genital' '(' 'vaginal' ',' 'uterine' ','
 'tubal' ')' 'infection']",[2. 2. 2. 2. 2. 2. 2. 2. 0. 0. 0. 0.]
NCT02801136,84:88:chronic_disease,Family member (parent if a minor) willing to participate and that the subject with PNES chooses,"['Family' 'member' '(' 'parent' 'if' 'a' 'minor' ')' 'willing' 'to'
 'participate' 'and' 'that' 'the' 'subject' 'with' 'PNES' 'chooses']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0.]
NCT02799095,59:68:allergy_name,Subjects with known hypersensitivity to any components of ALKS 4230,"['Subjects' 'with' 'known' 'hypersensitivity' 'to' 'any' 'components' 'of'
 'ALKS' '4230']",[0. 0. 0. 0. 0. 0. 0. 0. 4. 4.]
NCT02798458,1:29:treatment,Endoscopic mucosal resection,['Endoscopic' 'mucosal' 'resection'],[1. 1. 1.]
NCT02796391,1:21:treatment,Clopidogrel (Plavix),['Clopidogrel' '(' 'Plavix' ')'],[1. 1. 0. 0.]
NCT02796391,1:20:chronic_disease,Fluvoxamine (Luvox),['Fluvoxamine' '(' 'Luvox' ')'],[2. 2. 0. 0.]
NCT02796391,1:4:treatment,THC will be tested but will not be an exclusionary criterion,"['THC' 'will' 'be' 'tested' 'but' 'will' 'not' 'be' 'an' 'exclusionary'
 'criterion']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02796209,1:22:treatment,Effexor (venlafaxine),['Effexor' '(' 'venlafaxine' ')'],[1. 1. 0. 0.]
NCT02796209,1:23:treatment,Wellbutrin (Bupropion),['Wellbutrin' '(' 'Bupropion' ')'],[1. 1. 0. 0.]
NCT02793921,5:26:treatment,Any breast cancer surgery complications,['Any' 'breast' 'cancer' 'surgery' 'complications'],[0. 1. 1. 1. 0.]
NCT02793921,52:78:chronic_disease,other symptoms that indicate increased risk for an acute cardiovascular event,"['other' 'symptoms' 'that' 'indicate' 'increased' 'risk' 'for' 'an'
 'acute' 'cardiovascular' 'event']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT02792257,16:23:treatment,Current use of lithium,['Current' 'use' 'of' 'lithium'],[0. 0. 0. 1.]
NCT02789228,15:25:chronic_disease,Patients with active HIV,['Patients' 'with' 'active' 'HIV'],[0. 0. 2. 2.]
NCT02784535,1:10:chronic_disease,urticaria,['urticaria'],[2.]
NCT02780401,1:39:chronic_disease,Symptomatic restrictive cardiomyopathy,['Symptomatic' 'restrictive' 'cardiomyopathy'],[2. 2. 2.]
NCT02779244,1:11:chronic_disease,Polytrauma patients,['Polytrauma' 'patients'],[2. 0.]
NCT02778867,6:31:chronic_disease,Have pathological eosinophilia in segments of the GI tract other than the esophagus determined by local review,"['Have' 'pathological' 'eosinophilia' 'in' 'segments' 'of' 'the' 'GI'
 'tract' 'other' 'than' 'the' 'esophagus' 'determined' 'by' 'local'
 'review']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02778529,1:15:chronic_disease,Cerebral palsy participants,['Cerebral' 'palsy' 'participants'],[2. 2. 0.]
NCT02778282,21:44:treatment,Seeking to initiate buprenorphine treatment or currently receiving buprenorphine treatment but had recent positive illicit opioid urine toxicology or missed scheduled urine toxicology,"['Seeking' 'to' 'initiate' 'buprenorphine' 'treatment' 'or' 'currently'
 'receiving' 'buprenorphine' 'treatment' 'but' 'had' 'recent' 'positive'
 'illicit' 'opioid' 'urine' 'toxicology' 'or' 'missed' 'scheduled' 'urine'
 'toxicology']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02776761,12:37:chronic_disease,history of severe allergic reactions,['history' 'of' 'severe' 'allergic' 'reactions'],[0. 0. 2. 2. 2.]
NCT02775162,5:34:chronic_disease,has acute/fulminant liver failure,['has' 'acute/fulminant' 'liver' 'failure'],[0. 2. 2. 2.]
NCT02774421,1:13:cancer,mixed glioma,['mixed' 'glioma'],[3. 3.]
NCT02772562,1:42:treatment,Prior solid organ or stem cell transplant,['Prior' 'solid' 'organ' 'or' 'stem' 'cell' 'transplant'],[1. 1. 1. 1. 1. 1. 1.]
NCT02772302,1:16:chronic_disease,Locked-in state,['Locked-in' 'state'],[2. 2.]
NCT02771626,1:58:chronic_disease,Active known or suspected exclusionary autoimmune disease,['Active' 'known' 'or' 'suspected' 'exclusionary' 'autoimmune' 'disease'],[2. 2. 2. 2. 2. 2. 2.]
NCT02770547,1:38:chronic_disease,Chronic Obstructive Pulmonary Disease,['Chronic' 'Obstructive' 'Pulmonary' 'Disease'],[2. 2. 2. 2.]
NCT02770547,1:12:chronic_disease,paresthesia in the legs,['paresthesia' 'in' 'the' 'legs'],[2. 0. 0. 0.]
NCT02770326,9:38:chronic_disease,Serious cardiopulmonary comorbidities,['Serious' 'cardiopulmonary' 'comorbidities'],[0. 2. 2.]
NCT02769611,15:49:chronic_disease,Patients with uncontrolled arterial hypertension,['Patients' 'with' 'uncontrolled' 'arterial' 'hypertension'],[0. 0. 2. 2. 2.]
NCT02768727,23:46:chronic_disease,Current or history of chronic sleep disorders,['Current' 'or' 'history' 'of' 'chronic' 'sleep' 'disorders'],[0. 0. 0. 0. 2. 2. 2.]
NCT02767518,24:38:treatment,Medical clearance from cardiothoracic surgeon,['Medical' 'clearance' 'from' 'cardiothoracic' 'surgeon'],[0. 0. 0. 1. 0.]
NCT02765633,"38:62:chronic_disease,,,,,,,,",Participants with evidence of severe hepatic or renal failure [aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than three times normal for age or total bilirubin greater than 20 milligrams (mg)/deciliter (dL); creatinine greater than 2 times the normal upper limit],"['Participants' 'with' 'evidence' 'of' 'severe' 'hepatic' 'or' 'renal'
 'failure' '[' 'aspartate' 'aminotransferase' '(' 'AST' ')' 'or' 'alanine'
 'aminotransferase' '(' 'ALT' ')' 'greater' 'than' 'three' 'times'
 'normal' 'for' 'age' 'or' 'total' 'bilirubin' 'greater' 'than' '20'
 'milligrams' '(' 'mg' ')' '/deciliter' '(' 'dL' ')' ';' 'creatinine'
 'greater' 'than' '2' 'times' 'the' 'normal' 'upper' 'limit' ']']","[0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02765425,24:63:chronic_disease,Significant history of cardiac or peripheral vascular problems that would preclude seated ankle exercises,"['Significant' 'history' 'of' 'cardiac' 'or' 'peripheral' 'vascular'
 'problems' 'that' 'would' 'preclude' 'seated' 'ankle' 'exercises']",[0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02764801,1:36:chronic_disease,unstable cardiopulmonary conditions,['unstable' 'cardiopulmonary' 'conditions'],[2. 2. 2.]
NCT02763917,1:18:chronic_disease,Persistent asthma (NAEPP criteria),['Persistent' 'asthma' '(' 'NAEPP' 'criteria' ')'],[2. 2. 0. 0. 0. 0.]
NCT02763033,52:109:treatment,Subjects undergoing matched related full intensity allogeneic HSCT (hematopoietic stem cell transplantation),"['Subjects' 'undergoing' 'matched' 'related' 'full' 'intensity'
 'allogeneic' 'HSCT' '(' 'hematopoietic' 'stem' 'cell' 'transplantation'
 ')']",[0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0.]
NCT02762773,40:61:treatment,Patients who are expected to receive a Pfannenstiel incision,"['Patients' 'who' 'are' 'expected' 'to' 'receive' 'a' 'Pfannenstiel'
 'incision']",[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02762266,"1:30:chronic_disease,",Active gastrointestinal bleed within 2 weeks of study enrollment,"['Active' 'gastrointestinal' 'bleed' 'within' '2' 'weeks' 'of' 'study'
 'enrollment']",[2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02762266,1:36:treatment,Prior radiofrequency ablation (RFA) to index lesion,['Prior' 'radiofrequency' 'ablation' '(' 'RFA' ')' 'to' 'index' 'lesion'],[1. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02762032,1:19:treatment,Hydochlorothiazide,['Hydochlorothiazide'],[1.]
NCT02762006,1:31:chronic_disease,controlled atrial fibrillation,['controlled' 'atrial' 'fibrillation'],[2. 2. 2.]
NCT02759575,18:42:chronic_disease,Known history of active tuberculosis (TB),['Known' 'history' 'of' 'active' 'tuberculosis' '(' 'TB' ')'],[0. 0. 0. 2. 2. 2. 0. 0.]
NCT02759146,14:34:chronic_disease,Diagnosis of major mental illness on the medical record (verified by the recruiter),"['Diagnosis' 'of' 'major' 'mental' 'illness' 'on' 'the' 'medical' 'record'
 '(' 'verified' 'by' 'the' 'recruiter' ')']",[0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02755896,",35:60:treatment",Post-menopausal women with status post segmental mastectomy,['Post-menopausal' 'women' 'with' 'status' 'post' 'segmental' 'mastectomy'],[0. 0. 0. 0. 1. 1. 1.]
NCT02755116,1:22:chronic_disease,Narrow angle glaucoma,['Narrow' 'angle' 'glaucoma'],[2. 2. 2.]
NCT02752191,38:56:treatment,other causes (for subjects receiving Feraheme injection only),"['other' 'causes' '(' 'for' 'subjects' 'receiving' 'Feraheme' 'injection'
 'only' ')']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 0.]
NCT02750319,",38:63:treatment",Patients ≥18 years old scheduled for elective thoracic surgery,"['Patients' '≥18' 'years' 'old' 'scheduled' 'for' 'elective' 'thoracic'
 'surgery']",[0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02749786,"8:66:treatment,",Use of topical prescription medications or procedures to the face within one month of enrollment,"['Use' 'of' 'topical' 'prescription' 'medications' 'or' 'procedures' 'to'
 'the' 'face' 'within' 'one' 'month' 'of' 'enrollment']",[0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02748070,1:44:chronic_disease,chronic rhinosinusitis with polyps (CRSwNP),['chronic' 'rhinosinusitis' 'with' 'polyps' '(' 'CRSwNP' ')'],[2. 2. 2. 2. 2. 0. 0.]
NCT02747238,7:25:chronic_disease,Known spinal deformities,['Known' 'spinal' 'deformities'],[0. 2. 2.]
NCT02746458,12:82:chronic_disease,History of Peripheral Artery Disease and/or Peripheral Vascular Disease (PAD/PVD),"['History' 'of' 'Peripheral' 'Artery' 'Disease' 'and/or' 'Peripheral'
 'Vascular' 'Disease' '(' 'PAD/PVD' ')']",[0. 0. 2. 2. 2. 2. 2. 2. 2. 2. 0. 0.]
NCT02746458,1:12:treatment,Skin grafts in which all bleeding points must be readily distinguished,"['Skin' 'grafts' 'in' 'which' 'all' 'bleeding' 'points' 'must' 'be'
 'readily' 'distinguished']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02744911,1:23:treatment,Bilateral hearing aids (since one free ear is required for use of the SpeechVive device),"['Bilateral' 'hearing' 'aids' '(' 'since' 'one' 'free' 'ear' 'is'
 'required' 'for' 'use' 'of' 'the' 'SpeechVive' 'device' ')']",[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02744430,4:29:treatment,On immunosuppressant therapy,['On' 'immunosuppressant' 'therapy'],[0. 1. 1.]
NCT02744391,",45:133:treatment","Current or recent (within the past 4 weeks) treatment with antidepressants, antipsychotics, dopaminergic agents, or mood stabilizers","['Current' 'or' 'recent' '(' 'within' 'the' 'past' '4' 'weeks' ')'
 'treatment' 'with' 'antidepressants' ',' 'antipsychotics' ','
 'dopaminergic' 'agents' ',' 'or' 'mood' 'stabilizers']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0.]
NCT02743728,1:50:chronic_disease,Disorders of Cellular Migration and Proliferation,['Disorders' 'of' 'Cellular' 'Migration' 'and' 'Proliferation'],[2. 2. 2. 2. 2. 2.]
NCT02743637,30:54:treatment,Patients that have undergone organ transplant surgery,['Patients' 'that' 'have' 'undergone' 'organ' 'transplant' 'surgery'],[0. 0. 0. 0. 1. 1. 1.]
NCT02741791,51:76:treatment,History of inadequate response to 1 or 2 adequate antidepressant treatments,"['History' 'of' 'inadequate' 'response' 'to' '1' 'or' '2' 'adequate'
 'antidepressant' 'treatments']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02740543,",,28:46:treatment",FEV1 <60% predicted normal pre-bronchodilator,['FEV1' '<' '60' '%' 'predicted' 'normal' 'pre-bronchodilator'],[0. 0. 0. 0. 0. 0. 1.]
NCT02740361,"9:24:treatment,",started pharmacotherapy for depression within the last 2 months,"['started' 'pharmacotherapy' 'for' 'depression' 'within' 'the' 'last' '2'
 'months']",[0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02738749,9:46:chronic_disease,have an acute or chronic inflammatory illness that might alter white cell mRNA expression,"['have' 'an' 'acute' 'or' 'chronic' 'inflammatory' 'illness' 'that'
 'might' 'alter' 'white' 'cell' 'mRNA' 'expression']",[0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02737202,10:30:treatment,Previous lung transplantation,['Previous' 'lung' 'transplantation'],[0. 1. 1.]
NCT02734134,1:18:chronic_disease,Fungal infections,['Fungal' 'infections'],[2. 2.]
NCT02730481,",56:77:treatment",Have not recovered to ≤ Grade 1 toxicity from previous anticancer treatments or previous investigational products (IPs),"['Have' 'not' 'recovered' 'to' '≤' 'Grade' '1' 'toxicity' 'from'
 'previous' 'anticancer' 'treatments' 'or' 'previous' 'investigational'
 'products' '(' 'IPs' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02728050,11:38:cancer,high-risk myeloproliferative neoplasm,['high-risk' 'myeloproliferative' 'neoplasm'],[0. 3. 3.]
NCT02726347,",,,122:146:chronic_disease",individuals between the age of 19 and 80 who have a history of frequent bacterial infections and are being evaluated for humoral immunodeficiency,"['individuals' 'between' 'the' 'age' 'of' '19' 'and' '80' 'who' 'have' 'a'
 'history' 'of' 'frequent' 'bacterial' 'infections' 'and' 'are' 'being'
 'evaluated' 'for' 'humoral' 'immunodeficiency']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02725567,"57:81:treatment,",Use of any moderate or strong inducers or inhibitors of cytochrome P450 (CYP) 3A within 2 weeks before Day 1,"['Use' 'of' 'any' 'moderate' 'or' 'strong' 'inducers' 'or' 'inhibitors'
 'of' 'cytochrome' 'P450' '(' 'CYP' ')' '3A' 'within' '2' 'weeks' 'before'
 'Day' '1']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02724540,22:49:treatment,Contraindications to hepatic artery embolization,['Contraindications' 'to' 'hepatic' 'artery' 'embolization'],[0. 0. 1. 1. 1.]
NCT02724540,1:34:cancer,morphologically progressive tumor by RECIST,['morphologically' 'progressive' 'tumor' 'by' 'RECIST'],[3. 3. 3. 0. 0.]
NCT02723994,1:14:cancer,CNS3 leukemia,['CNS3' 'leukemia'],[3. 3.]
NCT02723994,1:30:treatment,Systemic steroid pretreatment without presteroid WBC documentation,"['Systemic' 'steroid' 'pretreatment' 'without' 'presteroid' 'WBC'
 'documentation']",[1. 1. 1. 0. 0. 0. 0.]
NCT02721303,63:79:treatment,Use of any medication known to significantly affect appetite (anti-depressants are allowable),"['Use' 'of' 'any' 'medication' 'known' 'to' 'significantly' 'affect'
 'appetite' '(' 'anti-depressants' 'are' 'allowable' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02719327,39:54:treatment,Use of medications that interact with icosapent ethyl,['Use' 'of' 'medications' 'that' 'interact' 'with' 'icosapent' 'ethyl'],[0. 0. 0. 0. 0. 0. 1. 1.]
NCT02715583,"1:30:treatment,",Systemic radioisotope therapy within 24 weeks prior to study enrollment,"['Systemic' 'radioisotope' 'therapy' 'within' '24' 'weeks' 'prior' 'to'
 'study' 'enrollment']",[1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02710968,"1:20:chronic_disease,,",Maternal depression as assessed by a Beck Depression Inventory score equal to or greater than 17,"['Maternal' 'depression' 'as' 'assessed' 'by' 'a' 'Beck' 'Depression'
 'Inventory' 'score' 'equal' 'to' 'or' 'greater' 'than' '17']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02709980,1:31:chronic_disease,psychiatric comorbid condition,['psychiatric' 'comorbid' 'condition'],[2. 2. 2.]
NCT02707692,12:34:chronic_disease,History of Gullian Barre syndrome,['History' 'of' 'Gullian' 'Barre' 'syndrome'],[0. 0. 2. 2. 2.]
NCT02706288,1:26:chronic_disease,Polycystic ovary syndrome,['Polycystic' 'ovary' 'syndrome'],[2. 2. 2.]
NCT02703220,"15:33:chronic_disease,,",Patients with severe sleep apnea (AHI>20/hr),['Patients' 'with' 'severe' 'sleep' 'apnea' '(' 'AHI' '>' '20/hr' ')'],[0. 0. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT02700451,1:21:chronic_disease,Peptic Ulcer Disease,['Peptic' 'Ulcer' 'Disease'],[2. 2. 2.]
NCT02700178,20:30:chronic_disease,disease leading to paraplegia,['disease' 'leading' 'to' 'paraplegia'],[0. 0. 0. 2.]
NCT02695043,25:42:chronic_disease,Significant symptoms of receptive aphasia,['Significant' 'symptoms' 'of' 'receptive' 'aphasia'],[0. 0. 0. 2. 2.]
NCT02693990,30:59:chronic_disease,Patients may or may not have neurofibromatosis type 1 or 2,"['Patients' 'may' 'or' 'may' 'not' 'have' 'neurofibromatosis' 'type' '1'
 'or' '2']",[0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 2.]
NCT02690116,"14:21:chronic_disease,,",Experiencing fatigue (scoring < 75 on Vitality scale of Short Form (SF)-36),"['Experiencing' 'fatigue' '(' 'scoring' '<' '75' 'on' 'Vitality' 'scale'
 'of' 'Short' 'Form' '(' 'SF' ')' '-36' ')']",[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02688647,"1:25:chronic_disease,,",Obstructive lung disease: FEV1/ FVC ratio < 0.70,['Obstructive' 'lung' 'disease' ':' 'FEV1/' 'FVC' 'ratio' '<' '0.70'],[2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02688569,22:66:treatment,"participation in any nonpharmacological treatment (including CBT) for pain, sleep, fatigue, or mood outside the current study","['participation' 'in' 'any' 'nonpharmacological' 'treatment' '('
 'including' 'CBT' ')' 'for' 'pain' ',' 'sleep' ',' 'fatigue' ',' 'or'
 'mood' 'outside' 'the' 'current' 'study']",[0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02687906,43:65:allergy_name,Known significant hypersensitivity to any beta-lactam antibiotic,"['Known' 'significant' 'hypersensitivity' 'to' 'any' 'beta-lactam'
 'antibiotic']",[0. 0. 0. 0. 0. 4. 4.]
NCT02687464,39:47:cancer,presentation with an appendix mass or phlegmon (on physical examination and/or imaging),"['presentation' 'with' 'an' 'appendix' 'mass' 'or' 'phlegmon' '(' 'on'
 'physical' 'examination' 'and/or' 'imaging' ')']",[0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT02685605,10:35:treatment,Previous cranial radiation therapy,['Previous' 'cranial' 'radiation' 'therapy'],[0. 1. 1. 1.]
NCT02682407,"33:57:chronic_disease,",Have systemic manifestations of Henoch-Schonlein purpura within 2 years prior to Screening,"['Have' 'systemic' 'manifestations' 'of' 'Henoch-Schonlein' 'purpura'
 'within' '2' 'years' 'prior' 'to' 'Screening']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02680574,1:21:chronic_disease,Severe heart failure at Screening (New York Heart Association Class IV),"['Severe' 'heart' 'failure' 'at' 'Screening' '(' 'New' 'York' 'Heart'
 'Association' 'Class' 'IV' ')']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02680535,",50:58:treatment",Prior MRI results dated within 120 days prior to ablation,"['Prior' 'MRI' 'results' 'dated' 'within' '120' 'days' 'prior' 'to'
 'ablation']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02680535,1:25:cancer,seminal vesicle invasion,['seminal' 'vesicle' 'invasion'],[3. 3. 3.]
NCT02678910,21:54:cancer,Participants with a large cancerous mass in the ovary that is being removed; cryopreservation will not be performed on portions of the ovary,"['Participants' 'with' 'a' 'large' 'cancerous' 'mass' 'in' 'the' 'ovary'
 'that' 'is' 'being' 'removed' ';' 'cryopreservation' 'will' 'not' 'be'
 'performed' 'on' 'portions' 'of' 'the' 'ovary']",[0. 0. 0. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02674984,"8:18:treatment,",Use of probiotics in the last 90 days,['Use' 'of' 'probiotics' 'in' 'the' 'last' '90' 'days'],[0. 0. 1. 0. 0. 0. 0. 0.]
NCT02674529,1:14:chronic_disease,schizophrenic,['schizophrenic'],[2.]
NCT02671435,25:53:treatment,Subjects must be at the recurrent/metastatic setting,['Subjects' 'must' 'be' 'at' 'the' 'recurrent/metastatic' 'setting'],[0. 0. 0. 0. 0. 1. 1.]
NCT02670837,5:31:treatment,Off immune suppressive therapy,['Off' 'immune' 'suppressive' 'therapy'],[0. 1. 1. 1.]
NCT02669173,1:55:chronic_disease,Active infection with hepatitis B or hepatitis C virus,['Active' 'infection' 'with' 'hepatitis' 'B' 'or' 'hepatitis' 'C' 'virus'],[2. 2. 2. 2. 2. 2. 2. 2. 2.]
NCT02667418,"36:65:treatment,",Anticipation of need for long term systemic antibiotic treatment (beyond 7 days),"['Anticipation' 'of' 'need' 'for' 'long' 'term' 'systemic' 'antibiotic'
 'treatment' '(' 'beyond' '7' 'days' ')']",[0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02667418,8:13:chronic_disease,severe ileus,['severe' 'ileus'],[0. 2.]
NCT02666378,31:47:treatment,Scheduled to receive standard clinical therapy designed by their treating oncologist,"['Scheduled' 'to' 'receive' 'standard' 'clinical' 'therapy' 'designed'
 'by' 'their' 'treating' 'oncologist']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02665338,28:44:chronic_disease,Life time history of major Axis I disorders,['Life' 'time' 'history' 'of' 'major' 'Axis' 'I' 'disorders'],[0. 0. 0. 0. 0. 2. 2. 2.]
NCT02664909,12:22:chronic_disease,History of hemophilia,['History' 'of' 'hemophilia'],[0. 0. 2.]
NCT02664909,6:23:chronic_disease,with coronary ischemia,['with' 'coronary' 'ischemia'],[0. 2. 2.]
NCT02663934,1:21:chronic_disease,behavioral disorders that would prevent ability to follow the protocol,"['behavioral' 'disorders' 'that' 'would' 'prevent' 'ability' 'to' 'follow'
 'the' 'protocol']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02663596,1:43:treatment,CVVH-continuous veno-venous hemofiltration,['CVVH-continuous' 'veno-venous' 'hemofiltration'],[1. 1. 1.]
NCT02660528,"1:37:chronic_disease,,,",Abnormal thyroid-stimulating hormone (TSH <0.4 or >5.0mlU/L),"['Abnormal' 'thyroid-stimulating' 'hormone' '(' 'TSH' '<' '0.4' 'or' '>'
 '5.0mlU/L' ')']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02660528,21:59:treatment,having received the Bacillus Calmette-Guérin (BCG) vaccine,"['having' 'received' 'the' 'Bacillus' 'Calmette-Guérin' '(' 'BCG' ')'
 'vaccine']",[0. 0. 0. 1. 1. 1. 1. 0. 0.]
NCT02658565,37:58:chronic_disease,"Preoperative evaluation to rule-out extra-uterine disease may include CT scan, MRI, or ultrasound","['Preoperative' 'evaluation' 'to' 'rule-out' 'extra-uterine' 'disease'
 'may' 'include' 'CT' 'scan' ',' 'MRI' ',' 'or' 'ultrasound']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02657993,"1:30:treatment,",Non-steroidal joint injection within the last 3 months,['Non-steroidal' 'joint' 'injection' 'within' 'the' 'last' '3' 'months'],[1. 1. 1. 0. 0. 0. 0. 0.]
NCT02655692,12:30:chronic_disease,history of severe head injury,['history' 'of' 'severe' 'head' 'injury'],[0. 0. 2. 2. 2.]
NCT02652247,",,,,,,160:188:chronic_disease,,,,","Conditions limiting the subject's ability to tolerate collection of lavage specimens, including: FIO2 > 80%; PEEP > 16 cmH2O; Intracranial pressure >20 cmH2O; Tracheal or mucosal bleeding; Platelet count < 20,000 cells/uL; INR > 2.0","['Conditions' 'limiting' 'the' 'subject' ""'s"" 'ability' 'to' 'tolerate'
 'collection' 'of' 'lavage' 'specimens' ',' 'including' ':' 'FIO2' '>'
 '80' '%' ';' 'PEEP' '>' '16' 'cmH2O' ';' 'Intracranial' 'pressure' '>'
 '20' 'cmH2O' ';' 'Tracheal' 'or' 'mucosal' 'bleeding' ';' 'Platelet'
 'count' '<' '20,000' 'cells/uL' ';' 'INR' '>' '2.0']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02650206,1:32:chronic_disease,Pancreatitis (acute or chronic),['Pancreatitis' '(' 'acute' 'or' 'chronic' ')'],[2. 2. 2. 2. 0. 0.]
NCT02648347,"5:37:treatment,",Any erythropoietic stimulating agent within 8 weeks prior to randomization,"['Any' 'erythropoietic' 'stimulating' 'agent' 'within' '8' 'weeks' 'prior'
 'to' 'randomization']",[0. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02646930,10:37:treatment,previous uterine artery embolization,['previous' 'uterine' 'artery' 'embolization'],[0. 1. 1. 1.]
NCT02645539,",25:34:treatment",Receiving more than two inotropes,['Receiving' 'more' 'than' 'two' 'inotropes'],[0. 0. 0. 0. 1.]
NCT02642640,12:26:chronic_disease,History of sleep disorder or regular use of sleep-promoting medication,"['History' 'of' 'sleep' 'disorder' 'or' 'regular' 'use' 'of'
 'sleep-promoting' 'medication']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02640950,"29:47:chronic_disease,,",The duration of the current depressive episode must be at least 4 weeks and no longer than 3 years in length,"['The' 'duration' 'of' 'the' 'current' 'depressive' 'episode' 'must' 'be'
 'at' 'least' '4' 'weeks' 'and' 'no' 'longer' 'than' '3' 'years' 'in'
 'length']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02640638,"1:15:chronic_disease,,",Morbid Obesity with BMI >49.99,['Morbid' 'Obesity' 'with' 'BMI' '>' '49.99'],[2. 2. 0. 0. 0. 0.]
NCT02639390,"1:31:chronic_disease,",Ischemic or hemorrhagic stroke (with confirmatory neuroimaging) that occurred more than 6 months before entering the study,"['Ischemic' 'or' 'hemorrhagic' 'stroke' '(' 'with' 'confirmatory'
 'neuroimaging' ')' 'that' 'occurred' 'more' 'than' '6' 'months' 'before'
 'entering' 'the' 'study']",[2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02639065,32:42:allergy_name,History of hypersensitivity to durvalumab or any excipient,"['History' 'of' 'hypersensitivity' 'to' 'durvalumab' 'or' 'any'
 'excipient']",[0. 0. 0. 0. 4. 0. 0. 0.]
NCT02638935,",12:27:treatment",Women with breast implants on the same side as the lesion,"['Women' 'with' 'breast' 'implants' 'on' 'the' 'same' 'side' 'as' 'the'
 'lesion']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02638454,1:30:treatment,Angiotensin receptor blockers,['Angiotensin' 'receptor' 'blockers'],[1. 1. 1.]
NCT02637349,1:15:chronic_disease,"Severe illness that would preclude conversation or interface with a computer (e.g.,persistent nausea/vomiting, severe pain)","['Severe' 'illness' 'that' 'would' 'preclude' 'conversation' 'or'
 'interface' 'with' 'a' 'computer' '(' 'e.g.' ',' 'persistent'
 'nausea/vomiting' ',' 'severe' 'pain' ')']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02636283,26:51:chronic_disease,"Subject with symptoms of intermittent claudication, such as exercise-induced pain, cramps, fatigue, or other equivalent discomfort, involving large muscle groups of the leg(s) (calf, thigh, buttocks), relieved by rest","['Subject' 'with' 'symptoms' 'of' 'intermittent' 'claudication' ',' 'such'
 'as' 'exercise-induced' 'pain' ',' 'cramps' ',' 'fatigue' ',' 'or'
 'other' 'equivalent' 'discomfort' ',' 'involving' 'large' 'muscle'
 'groups' 'of' 'the' 'leg' '(' 's' ')' '(' 'calf' ',' 'thigh' ','
 'buttocks' ')' ',' 'relieved' 'by' 'rest']","[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02634957,1:10:cancer,Dysplasia,['Dysplasia'],[3.]
NCT02634957,1:30:cancer,SCC (squamous cell carcinoma),['SCC' '(' 'squamous' 'cell' 'carcinoma' ')'],[3. 3. 3. 3. 0. 0.]
NCT02633111,32:59:cancer,Histology-confirmed aggressive B-cell Non-Hodgkin lymphoma,['Histology-confirmed' 'aggressive' 'B-cell' 'Non-Hodgkin' 'lymphoma'],[0. 0. 3. 3. 3.]
NCT02632422,29:42:chronic_disease,non-progressive etiology of spinal injury,['non-progressive' 'etiology' 'of' 'spinal' 'injury'],[0. 0. 0. 2. 2.]
NCT02631850,"11:24:treatment,",Receiving Botox therapy currently or in the past 3 months,"['Receiving' 'Botox' 'therapy' 'currently' 'or' 'in' 'the' 'past' '3'
 'months']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02628535,"1:15:chronic_disease,",GI perforation within 1 year,['GI' 'perforation' 'within' '1' 'year'],[2. 2. 0. 0. 0.]
NCT02624765,1:21:treatment,Antiarrhythmic drugs,['Antiarrhythmic' 'drugs'],[1. 1.]
NCT02624765,31:57:chronic_disease,Relevant preexisting maternal obstructive airway disease,['Relevant' 'preexisting' 'maternal' 'obstructive' 'airway' 'disease'],[0. 0. 0. 2. 2. 2.]
NCT02624765,"1:38:chronic_disease,,",severe congenital fetal abnormalities (T 13 or 18; surgery or death expected < 1 month),"['severe' 'congenital' 'fetal' 'abnormalities' '(' 'T' '13' 'or' '18' ';'
 'surgery' 'or' 'death' 'expected' '<' '1' 'month' ')']",[2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02624518,1:32:treatment,Post radical prostatectomy (RP),['Post' 'radical' 'prostatectomy' '(' 'RP' ')'],[1. 1. 1. 1. 0. 0.]
NCT02624258,"1:38:treatment,","Anti-CD20 monoclonal antibody therapy within the last 3 months, or absence of circulating B cells","['Anti-CD20' 'monoclonal' 'antibody' 'therapy' 'within' 'the' 'last' '3'
 'months' ',' 'or' 'absence' 'of' 'circulating' 'B' 'cells']",[1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02624258,23:38:allergy_name,History of allergy to murine proteins,['History' 'of' 'allergy' 'to' 'murine' 'proteins'],[0. 0. 0. 0. 4. 4.]
NCT02622984,14:31:treatment,Currently in alcohol treatment,['Currently' 'in' 'alcohol' 'treatment'],[0. 0. 1. 1.]
NCT02622295,1:21:chronic_disease,Deep vein thrombosis,['Deep' 'vein' 'thrombosis'],[2. 2. 2.]
NCT02620761,14:25:treatment,Infants with antenatally,['Infants' 'with' 'antenatally'],[0. 0. 1.]
NCT02620579,1:25:chronic_disease,nonallergic bronchospasm,['nonallergic' 'bronchospasm'],[2. 2.]
NCT02617589,11:37:cancer,Any known tumor outside of the brain,['Any' 'known' 'tumor' 'outside' 'of' 'the' 'brain'],[0. 0. 3. 3. 3. 3. 3.]
NCT02615249,"1:73:treatment,",Topical treatment with corticosteroids or other immunosuppressive agents on or near the test area during the 14 days prior to inclusion in this study,"['Topical' 'treatment' 'with' 'corticosteroids' 'or' 'other'
 'immunosuppressive' 'agents' 'on' 'or' 'near' 'the' 'test' 'area'
 'during' 'the' '14' 'days' 'prior' 'to' 'inclusion' 'in' 'this' 'study']",[1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02613936,5:17:chronic_disease,any skull defect,['any' 'skull' 'defect'],[0. 2. 2.]
NCT02611427,47:62:chronic_disease,Patients will be excluded if they had any new cardiopulmonary symptoms since surgery,"['Patients' 'will' 'be' 'excluded' 'if' 'they' 'had' 'any' 'new'
 'cardiopulmonary' 'symptoms' 'since' 'surgery']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0.]
NCT02610374,"8:49:treatment,",Use of systemic (oral or parenteral) antibiotics within two months prior to study entry,"['Use' 'of' 'systemic' '(' 'oral' 'or' 'parenteral' ')' 'antibiotics'
 'within' 'two' 'months' 'prior' 'to' 'study' 'entry']",[0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02607748,1:54:chronic_disease,Multiple premature ventricular or atrial contractions,['Multiple' 'premature' 'ventricular' 'or' 'atrial' 'contractions'],[2. 2. 2. 2. 2. 2.]
NCT02606396,20:40:chronic_disease,Prior diagnosis of esophageal achalasia,['Prior' 'diagnosis' 'of' 'esophageal' 'achalasia'],[0. 0. 0. 2. 2.]
NCT02606045,1:40:chronic_disease,Mild or moderate von Willebrand disease,['Mild' 'or' 'moderate' 'von' 'Willebrand' 'disease'],[2. 2. 2. 2. 2. 2.]
NCT02604277,12:38:chronic_disease,History of mood incongruent psychotic symptoms,['History' 'of' 'mood' 'incongruent' 'psychotic' 'symptoms'],[0. 0. 2. 2. 2. 0.]
NCT02600897,",41:56:cancer",Histologically documented CD20-positive B-cell lymphoma as determined by the local laboratory,"['Histologically' 'documented' 'CD20-positive' 'B-cell' 'lymphoma' 'as'
 'determined' 'by' 'the' 'local' 'laboratory']",[0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0.]
NCT02600026,1:20:chronic_disease,language impairment that would interfere with the ability to participate in the educational intervention,"['language' 'impairment' 'that' 'would' 'interfere' 'with' 'the' 'ability'
 'to' 'participate' 'in' 'the' 'educational' 'intervention']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02598713,1:18:chronic_disease,Status asthmatics,['Status' 'asthmatics'],[2. 2.]
NCT02595996,1:21:chronic_disease,Secondary lymphedema,['Secondary' 'lymphedema'],[2. 2.]
NCT02595372,1:27:treatment,Dexlansoprazole (Dexilant),['Dexlansoprazole' '(' 'Dexilant' ')'],[1. 1. 0. 0.]
NCT02595372,1:19:treatment,Prior hysterectomy,['Prior' 'hysterectomy'],[1. 1.]
NCT02594384,1:38:cancer,diffuse large B-cell lymphoma (DLBCL),['diffuse' 'large' 'B-cell' 'lymphoma' '(' 'DLBCL' ')'],[3. 3. 3. 3. 3. 0. 0.]
NCT02594111,"1:11:treatment,",Colchicine use within 1 month,['Colchicine' 'use' 'within' '1' 'month'],[1. 0. 0. 0. 0.]
NCT02594111,1:13:treatment,ketoconazole,['ketoconazole'],[1.]
NCT02593526,",,52:68:treatment",Life expectancy <6 months or intention to withdraw dialysis therapy within 6 months,"['Life' 'expectancy' '<' '6' 'months' 'or' 'intention' 'to' 'withdraw'
 'dialysis' 'therapy' 'within' '6' 'months']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.]
NCT02593123,1:22:cancer,Hodgkin lymphoma (HL),['Hodgkin' 'lymphoma' '(' 'HL' ')'],[3. 3. 3. 0. 0.]
NCT02593123,1:44:treatment,Previous therapeutic radiation therapy (RT) that exceeds critical structure tolerance doses as determined by a radiation oncologist,"['Previous' 'therapeutic' 'radiation' 'therapy' '(' 'RT' ')' 'that'
 'exceeds' 'critical' 'structure' 'tolerance' 'doses' 'as' 'determined'
 'by' 'a' 'radiation' 'oncologist']",[1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02593123,"1:35:treatment,",previous treatment with equine ATG is allowed if more than 3 months ago,"['previous' 'treatment' 'with' 'equine' 'ATG' 'is' 'allowed' 'if' 'more'
 'than' '3' 'months' 'ago']",[1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02593110,12:16:allergy_name,Allergy to ARBs,['Allergy' 'to' 'ARBs'],[0. 0. 4.]
NCT02593110,1:23:chronic_disease,critical limb ischemia,['critical' 'limb' 'ischemia'],[2. 2. 2.]
NCT02592707,14:24:chronic_disease,Diagnosis of thymic NET,['Diagnosis' 'of' 'thymic' 'NET'],[0. 0. 2. 2.]
NCT02592551,32:40:allergy_name,History of hypersensitivity to MEDI4736 or any excipient,['History' 'of' 'hypersensitivity' 'to' 'MEDI4736' 'or' 'any' 'excipient'],[0. 0. 0. 0. 4. 0. 0. 0.]
NCT02592551,"12:21:treatment,",Receipt of sunitinib within 3 months of receiving tremelimumab,"['Receipt' 'of' 'sunitinib' 'within' '3' 'months' 'of' 'receiving'
 'tremelimumab']",[0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT02592291,1:42:chronic_disease,severe and persistent psychiatric illness,['severe' 'and' 'persistent' 'psychiatric' 'illness'],[2. 2. 2. 2. 2.]
NCT02589977,1:31:chronic_disease,primary pulmonary hypertension,['primary' 'pulmonary' 'hypertension'],[2. 2. 2.]
NCT02589938,36:57:treatment,Over the counter products used for salivary substitution,['Over' 'the' 'counter' 'products' 'used' 'for' 'salivary' 'substitution'],[0. 0. 0. 0. 0. 0. 1. 1.]
NCT02589522,102:108:allergy_name,History of allergic reactions attributed to compounds of similar chemical or biologic composition to VX-970,"['History' 'of' 'allergic' 'reactions' 'attributed' 'to' 'compounds' 'of'
 'similar' 'chemical' 'or' 'biologic' 'composition' 'to' 'VX-970']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4.]
NCT02589340,6:29:chronic_disease,Have proprioceptive deficits,['Have' 'proprioceptive' 'deficits'],[0. 2. 2.]
NCT02588664,1:47:chronic_disease,subdural or aneurysmal subarachnoid hemorrhage,['subdural' 'or' 'aneurysmal' 'subarachnoid' 'hemorrhage'],[2. 2. 2. 2. 2.]
NCT02588391,1:30:chronic_disease,"Major neurosensory impairment (i.e., blind, deaf) or technology dependence (i.e., ventilator dependent) that interferes with testing","['Major' 'neurosensory' 'impairment' '(' 'i.e.' ',' 'blind' ',' 'deaf' ')'
 'or' 'technology' 'dependence' '(' 'i.e.' ',' 'ventilator' 'dependent'
 ')' 'that' 'interferes' 'with' 'testing']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02588326,1:12:chronic_disease,common cold,['common' 'cold'],[2. 2.]
NCT02588027,28:53:treatment,Patients with a history of prior rotator cuff repair,['Patients' 'with' 'a' 'history' 'of' 'prior' 'rotator' 'cuff' 'repair'],[0. 0. 0. 0. 0. 1. 1. 1. 1.]
NCT02587598,20:33:treatment,Prior receipt of a PIM inhibitor,['Prior' 'receipt' 'of' 'a' 'PIM' 'inhibitor'],[0. 0. 0. 0. 1. 1.]
NCT02585973,1:16:chronic_disease,HPV (-) disease,['HPV' '(' '-' ')' 'disease'],[2. 2. 2. 0. 0.]
NCT02585973,1:28:cancer,non-invasive bladder cancer,['non-invasive' 'bladder' 'cancer'],[3. 3. 3.]
NCT02585232,34:42:chronic_disease,Dyads experiencing low levels of distress,['Dyads' 'experiencing' 'low' 'levels' 'of' 'distress'],[0. 0. 0. 0. 0. 2.]
NCT02584647,33:82:cancer,"Phase 2: Advanced, unresectable malignant peripheral nerve sheath tumors (MPNSTs)","['Phase' '2' ':' 'Advanced' ',' 'unresectable' 'malignant' 'peripheral'
 'nerve' 'sheath' 'tumors' '(' 'MPNSTs' ')']",[0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 3. 0. 0.]
NCT02584309,1:20:cancer,Epithelioid sarcoma,['Epithelioid' 'sarcoma'],[3. 3.]
NCT02584309,1:31:cancer,Malignant fibrous histiocytoma,['Malignant' 'fibrous' 'histiocytoma'],[3. 3. 3.]
NCT02584309,1:17:cancer,Synovial sarcoma,['Synovial' 'sarcoma'],[3. 3.]
NCT02584270,28:65:treatment,Patients with a history of prior head and neck radiation therapy,"['Patients' 'with' 'a' 'history' 'of' 'prior' 'head' 'and' 'neck'
 'radiation' 'therapy']",[0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1.]
NCT02584244,",,,,,192:222:treatment","Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) starting the day entering the study, and for 60 days after injection of the imaging agent","['Women' 'of' 'child-bearing' 'potential' 'must' 'agree' 'to' 'use'
 'adequate' 'contraception' '(' 'hormonal' 'or' 'barrier' 'method' 'of'
 'birth' 'control' ',' 'abstinence' ')' 'starting' 'the' 'day' 'entering'
 'the' 'study' ',' 'and' 'for' '60' 'days' 'after' 'injection' 'of' 'the'
 'imaging' 'agent']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1.]"
NCT02583893,15:47:chronic_disease,Subjects with uncontrolled high blood pressure,['Subjects' 'with' 'uncontrolled' 'high' 'blood' 'pressure'],[0. 0. 2. 2. 2. 2.]
NCT02582957,32:62:treatment,Lack of availability of Dräger Evita Infinity V500 ventilator as this is the only ventilator capable of delivering sigh breaths as described in the protocol,"['Lack' 'of' 'availability' 'of' 'Dräger' 'Evita' 'Infinity' 'V500'
 'ventilator' 'as' 'this' 'is' 'the' 'only' 'ventilator' 'capable' 'of'
 'delivering' 'sigh' 'breaths' 'as' 'described' 'in' 'the' 'protocol']","[0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02582827,74:93:allergy_name,History of allergy or hypersensitivity to any of the constituents of the ABI-011 formulation,"['History' 'of' 'allergy' 'or' 'hypersensitivity' 'to' 'any' 'of' 'the'
 'constituents' 'of' 'the' 'ABI-011' 'formulation']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 4.]
NCT02582827,",,,,,241:267:treatment,",QTc prolongation defined as a QTc interval according to Bazett's formula of ≥ 450 msec for male patients or ≥470 msec for female patients at Baseline. Interval determination will be based on a mean value obtained from 3 sequential baseline electrocardiographs (ECGs) obtained at least 5 minutes apart,"['QTc' 'prolongation' 'defined' 'as' 'a' 'QTc' 'interval' 'according' 'to'
 'Bazett' ""'s"" 'formula' 'of' '≥' '450' 'msec' 'for' 'male' 'patients'
 'or' '≥470' 'msec' 'for' 'female' 'patients' 'at' 'Baseline' '.'
 'Interval' 'determination' 'will' 'be' 'based' 'on' 'a' 'mean' 'value'
 'obtained' 'from' '3' 'sequential' 'baseline' 'electrocardiographs' '('
 'ECGs' ')' 'obtained' 'at' 'least' '5' 'minutes' 'apart']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02581982,18:27:chronic_disease,Known history of active TB,['Known' 'history' 'of' 'active' 'TB'],[0. 0. 0. 2. 2.]
NCT02581787,12:29:cancer,history of basal cell cancer is allowed,['history' 'of' 'basal' 'cell' 'cancer' 'is' 'allowed'],[0. 0. 3. 3. 3. 0. 0.]
NCT02581384,1:33:treatment,focal radiotherapy to the thorax,['focal' 'radiotherapy' 'to' 'the' 'thorax'],[1. 1. 1. 1. 1.]
NCT02580604,20:45:treatment,Currently taking a bisphosphonate medication,['Currently' 'taking' 'a' 'bisphosphonate' 'medication'],[0. 0. 0. 1. 1.]
NCT02580162,1:31:chronic_disease,Physical disability or illness in either the participating parent or the child that precludes moderate intensity physical activity,"['Physical' 'disability' 'or' 'illness' 'in' 'either' 'the'
 'participating' 'parent' 'or' 'the' 'child' 'that' 'precludes' 'moderate'
 'intensity' 'physical' 'activity']",[2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02579265,7:34:chronic_disease,Known inborn errors of metabolism,['Known' 'inborn' 'errors' 'of' 'metabolism'],[0. 2. 2. 2. 2.]
NCT02579265,1:26:chronic_disease,necrotizing enterocolitis,['necrotizing' 'enterocolitis'],[2. 2.]
NCT02579174,60:71:treatment,Ligamentous instability that may necessitate a constrained TKR implant,"['Ligamentous' 'instability' 'that' 'may' 'necessitate' 'a' 'constrained'
 'TKR' 'implant']",[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02579096,34:77:treatment,Patients with a history of prior solid organ / hematopoietic transplantation,"['Patients' 'with' 'a' 'history' 'of' 'prior' 'solid' 'organ' '/'
 'hematopoietic' 'transplantation']",[0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1.]
NCT02579044,",,109:134:treatment",It is permissible for female subjects to take oral contraceptives or other hormonal methods while receiving treatment with everolimus,"['It' 'is' 'permissible' 'for' 'female' 'subjects' 'to' 'take' 'oral'
 'contraceptives' 'or' 'other' 'hormonal' 'methods' 'while' 'receiving'
 'treatment' 'with' 'everolimus']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02578901,10:33:chronic_disease,Acquired storage pool deficiency,['Acquired' 'storage' 'pool' 'deficiency'],[0. 2. 2. 2.]
NCT02578641,1:22:treatment,Adjuvant chemotherapy,['Adjuvant' 'chemotherapy'],[1. 1.]
NCT02578641,1:40:treatment,Prior radiotherapy with curative intent,['Prior' 'radiotherapy' 'with' 'curative' 'intent'],[1. 1. 1. 1. 1.]
NCT02578641,1:29:chronic_disease,ischemic heart disease (IHD),['ischemic' 'heart' 'disease' '(' 'IHD' ')'],[2. 2. 2. 2. 0. 0.]
NCT02577731,15:38:chronic_disease,Patients with End Stage Renal Disease,['Patients' 'with' 'End' 'Stage' 'Renal' 'Disease'],[0. 0. 2. 2. 2. 2.]
NCT02577549,33:52:chronic_disease,Knee Pain plus ACR Criteria for Knee Osteoarthritis,['Knee' 'Pain' 'plus' 'ACR' 'Criteria' 'for' 'Knee' 'Osteoarthritis'],[2. 2. 0. 0. 0. 0. 0. 0.]
NCT02577406,1:32:cancer,Carcinoma in situ of the cervix,['Carcinoma' 'in' 'situ' 'of' 'the' 'cervix'],[3. 3. 3. 3. 3. 3.]
NCT02577406,65:78:treatment,"Subject is eligible for and willing to receive the pre-selected CCR treatment option, according to the investigator's assessment","['Subject' 'is' 'eligible' 'for' 'and' 'willing' 'to' 'receive' 'the'
 'pre-selected' 'CCR' 'treatment' 'option' ',' 'according' 'to' 'the'
 'investigator' ""'s"" 'assessment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02576444,41:59:treatment,"Patients with concomitant use of drugs, herbal supplements and/or ingestion of foods known to strongly modulate CYP3A4 enzyme activity as specified in the drug specific appendix","['Patients' 'with' 'concomitant' 'use' 'of' 'drugs' ',' 'herbal'
 'supplements' 'and/or' 'ingestion' 'of' 'foods' 'known' 'to' 'strongly'
 'modulate' 'CYP3A4' 'enzyme' 'activity' 'as' 'specified' 'in' 'the'
 'drug' 'specific' 'appendix']","[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02576444,"1:24:treatment,",Whole blood transfusion in the last 120 days prior to entry to the study,"['Whole' 'blood' 'transfusion' 'in' 'the' 'last' '120' 'days' 'prior' 'to'
 'entry' 'to' 'the' 'study']",[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02575404,41:60:treatment,Patients who have previously received a galectin antagonist,"['Patients' 'who' 'have' 'previously' 'received' 'a' 'galectin'
 'antagonist']",[0. 0. 0. 0. 0. 0. 1. 1.]
NCT02574728,1:22:cancer,optic pathway gliomas,['optic' 'pathway' 'gliomas'],[3. 3. 3.]
NCT02574650,1:13:chronic_disease,NYHA II - IV,['NYHA' 'II' '-' 'IV'],[2. 2. 2. 2.]
NCT02574455,21:111:treatment,Prior exposure to a taxane (paclitaxel or docetaxel)-based regimen in localized or advanced/metastatic setting,"['Prior' 'exposure' 'to' 'a' 'taxane' '(' 'paclitaxel' 'or' 'docetaxel'
 ')' '-based' 'regimen' 'in' 'localized' 'or' 'advanced/metastatic'
 'setting']",[0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0.]
NCT02573883,1:34:treatment,Previous pelvic radiation therapy,['Previous' 'pelvic' 'radiation' 'therapy'],[1. 1. 1. 1.]
NCT02573597,1:11:chronic_disease,ASA I & II,['ASA' 'I' '&' 'II'],[2. 2. 2. 2.]
NCT02573493,15:24:cancer,Patients with T1 tumors,['Patients' 'with' 'T1' 'tumors'],[0. 0. 3. 3.]
NCT02572856,19:43:treatment,Scheduled to have elective general surgery at UW Medical Center,"['Scheduled' 'to' 'have' 'elective' 'general' 'surgery' 'at' 'UW'
 'Medical' 'Center']",[0. 0. 0. 1. 1. 1. 0. 0. 0. 0.]
NCT02570984,"13:42:treatment,",Enrolled in any clinical medication trial within the past 30 days,"['Enrolled' 'in' 'any' 'clinical' 'medication' 'trial' 'within' 'the'
 'past' '30' 'days']",[0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02570984,1:27:chronic_disease,chronic pulmonary diseases,['chronic' 'pulmonary' 'diseases'],[2. 2. 2.]
NCT02570854,23:29:treatment,Patients who received CSJ137 dose in the pas,['Patients' 'who' 'received' 'CSJ137' 'dose' 'in' 'the' 'pas'],[0. 0. 0. 1. 0. 0. 0. 0.]
NCT02570321,1:14:chronic_disease,Corneal ulcer that is smear positive for either bacteria or filamentous fungus,"['Corneal' 'ulcer' 'that' 'is' 'smear' 'positive' 'for' 'either'
 'bacteria' 'or' 'filamentous' 'fungus']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02570256,1:7:chronic_disease,STROKE SURVIVORS,['STROKE' 'SURVIVORS'],[2. 0.]
NCT02568267,20:31:treatment,Ability to swallow entrectinib intact,['Ability' 'to' 'swallow' 'entrectinib' 'intact'],[0. 0. 0. 1. 0.]
NCT02568267,25:62:cancer,Patients diagnosed with anaplastic large cell lymphoma (ALCL) harboring a gene rearrangement of interest may be eligible,"['Patients' 'diagnosed' 'with' 'anaplastic' 'large' 'cell' 'lymphoma' '('
 'ALCL' ')' 'harboring' 'a' 'gene' 'rearrangement' 'of' 'interest' 'may'
 'be' 'eligible']",[0. 0. 0. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02567448,"1:27:treatment,",chest or abdominal surgery in the past three months,['chest' 'or' 'abdominal' 'surgery' 'in' 'the' 'past' 'three' 'months'],[1. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02567422,1:10:cancer,Carcinoma of the neck of unknown primary site origin (regardless of HPV/p16 status),"['Carcinoma' 'of' 'the' 'neck' 'of' 'unknown' 'primary' 'site' 'origin'
 '(' 'regardless' 'of' 'HPV/p16' 'status' ')']",[3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02567422,1:26:cancer,nasopharyngeal carcinomas,['nasopharyngeal' 'carcinomas'],[3. 3.]
NCT02566928,39:43:chronic_disease,presents with signs and symptoms of a SSTI,['presents' 'with' 'signs' 'and' 'symptoms' 'of' 'a' 'SSTI'],[0. 0. 0. 0. 0. 0. 0. 2.]
NCT02565901,"22:49:treatment,","Administration of an investigational therapeutic within 30 days of cycle 1, day -2","['Administration' 'of' 'an' 'investigational' 'therapeutic' 'within' '30'
 'days' 'of' 'cycle' '1' ',' 'day' '-2']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02565901,4:18:cancer,In situ carcinoma of any site,['In' 'situ' 'carcinoma' 'of' 'any' 'site'],[0. 3. 3. 0. 0. 0.]
NCT02565901,1:31:cancer,neuroendocrine differentiation,['neuroendocrine' 'differentiation'],[3. 3.]
NCT02565498,24:66:treatment,Deemed appropriate for preoperative or postoperative radiotherapy,"['Deemed' 'appropriate' 'for' 'preoperative' 'or' 'postoperative'
 'radiotherapy']",[0. 0. 0. 1. 1. 1. 1.]
NCT02565446,1:32:treatment,ventriculoperitoneal (VP) shunt,['ventriculoperitoneal' '(' 'VP' ')' 'shunt'],[1. 1. 1. 0. 0.]
NCT02564978,",,,,,,377:405:treatment","Any female participant of childbearing potential (see Appendix 1 for definition) and any male participant able to father children must have (or have a partner who has) had a hysterectomy or vasectomy, be completely abstinent* from intercourse or must agree to practice two acceptable methods of contraception throughout the course of the study and for at least one week after investigational product (IP) discontinuation","['Any' 'female' 'participant' 'of' 'childbearing' 'potential' '(' 'see'
 'Appendix' '1' 'for' 'definition' ')' 'and' 'any' 'male' 'participant'
 'able' 'to' 'father' 'children' 'must' 'have' '(' 'or' 'have' 'a'
 'partner' 'who' 'has' ')' 'had' 'a' 'hysterectomy' 'or' 'vasectomy' ','
 'be' 'completely' 'abstinent' '*' 'from' 'intercourse' 'or' 'must'
 'agree' 'to' 'practice' 'two' 'acceptable' 'methods' 'of' 'contraception'
 'throughout' 'the' 'course' 'of' 'the' 'study' 'and' 'for' 'at' 'least'
 'one' 'week' 'after' 'investigational' 'product' '(' 'IP' ')'
 'discontinuation']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0.]"
NCT02564978,57:60:chronic_disease,Participant must have evidence of early or intermediate AMD as defined by characteristic presence of drusen and/or pigmentary changes,"['Participant' 'must' 'have' 'evidence' 'of' 'early' 'or' 'intermediate'
 'AMD' 'as' 'defined' 'by' 'characteristic' 'presence' 'of' 'drusen'
 'and/or' 'pigmentary' 'changes']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02564978,",98:105:chronic_disease",The study eye must have at least (Omega) disc area (approximately 1 mm(2)) of GA compatible with dry AMD,"['The' 'study' 'eye' 'must' 'have' 'at' 'least' '(' 'Omega' ')' 'disc'
 'area' '(' 'approximately' '1' 'mm' '(' '2' ')' ')' 'of' 'GA'
 'compatible' 'with' 'dry' 'AMD']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 2. 2.]"
NCT02564796,26:40:chronic_disease,Infants with significant co-morbidities,['Infants' 'with' 'significant' 'co-morbidities'],[0. 0. 0. 2.]
NCT02564744,79:97:treatment,"For Part 2 and Part 3 of the study, participants that are eligible to undergo first time HD-ASCT","['For' 'Part' '2' 'and' 'Part' '3' 'of' 'the' 'study' ',' 'participants'
 'that' 'are' 'eligible' 'to' 'undergo' 'first' 'time' 'HD-ASCT']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02564744,25:40:treatment,"Prior treatment with an anti-CD20 agent, either alone or in combination, is allowed","['Prior' 'treatment' 'with' 'an' 'anti-CD20' 'agent' ',' 'either' 'alone'
 'or' 'in' 'combination' ',' 'is' 'allowed']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02563678,"1:18:treatment,",Hyperbaric oxygen exposure within the last 30 days,['Hyperbaric' 'oxygen' 'exposure' 'within' 'the' 'last' '30' 'days'],[1. 1. 0. 0. 0. 0. 0. 0.]
NCT02563678,"63:94:treatment,",Time interval between removal from carbon monoxide source and first hyperbaric oxygen session >12 hours,"['Time' 'interval' 'between' 'removal' 'from' 'carbon' 'monoxide' 'source'
 'and' 'first' 'hyperbaric' 'oxygen' 'session' '>' '12' 'hours']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0.]
NCT02562755,1:14:cancer,Bulky disease patients,['Bulky' 'disease' 'patients'],[3. 3. 0.]
NCT02562716,"20:36:treatment,",Patients must have surgical consult to verify patient is a surgical candidate within 21 days prior to registration,"['Patients' 'must' 'have' 'surgical' 'consult' 'to' 'verify' 'patient'
 'is' 'a' 'surgical' 'candidate' 'within' '21' 'days' 'prior' 'to'
 'registration']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02562430,53:61:allergy_name,History of inadequate response/poor tolerability to bupropio,"['History' 'of' 'inadequate' 'response/poor' 'tolerability' 'to'
 'bupropio']",[0. 0. 0. 0. 0. 0. 4.]
NCT02562235,1:26:chronic_disease,Connective tissue disease,['Connective' 'tissue' 'disease'],[2. 2. 2.]
NCT02562235,"1:13:treatment,,",Pretreatment with NO donors (e.g. nitrates) within the last 2-weeks before visit 1,"['Pretreatment' 'with' 'NO' 'donors' '(' 'e.g' '.' 'nitrates' ')' 'within'
 'the' 'last' '2-weeks' 'before' 'visit' '1']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02562040,24:26:chronic_disease,"Primary indication for AT is nocturnal obstructive symptoms (i.e., not recurrent infections or other indications)","['Primary' 'indication' 'for' 'AT' 'is' 'nocturnal' 'obstructive'
 'symptoms' '(' 'i.e.' ',' 'not' 'recurrent' 'infections' 'or' 'other'
 'indications' ')']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02561988,1:17:cancer,Brain malignancy,['Brain' 'malignancy'],[3. 3.]
NCT02561988,1:7:cancer,SM-AHN,['SM-AHN'],[3.]
NCT02561104,40:54:chronic_disease,"Active, significant external ocular or eyelid disease","['Active' ',' 'significant' 'external' 'ocular' 'or' 'eyelid' 'disease']",[0. 0. 0. 0. 0. 0. 2. 2.]
NCT02561104,13:27:treatment,presence of cornea implant,['presence' 'of' 'cornea' 'implant'],[0. 0. 1. 1.]
NCT02559817,28:37:treatment,willing to discontinue any laxatives used before the Pretreatment Visit in favor of the protocol-permitted rescue medicine,"['willing' 'to' 'discontinue' 'any' 'laxatives' 'used' 'before' 'the'
 'Pretreatment' 'Visit' 'in' 'favor' 'of' 'the' 'protocol-permitted'
 'rescue' 'medicine']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02558010,1:21:chronic_disease,Idiopathic scoliosis,['Idiopathic' 'scoliosis'],[2. 2.]
NCT02557321,1:71:cancer,"Stage IV or Stage III (unresectable, in-transit or satellite) melanoma","['Stage' 'IV' 'or' 'Stage' 'III' '(' 'unresectable' ',' 'in-transit' 'or'
 'satellite' ')' 'melanoma']",[3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 0. 0. 0.]
NCT02556606,85:104:treatment,"Past intolerance or hypersensitivity to ketamine, or history of recreational use of phencyclidine (PCP) or ketamine","['Past' 'intolerance' 'or' 'hypersensitivity' 'to' 'ketamine' ',' 'or'
 'history' 'of' 'recreational' 'use' 'of' 'phencyclidine' '(' 'PCP' ')'
 'or' 'ketamine']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0.]
NCT02555280,"1:22:chronic_disease,,",Mild lumbar scoliosis (Cobb angle up to 25º),['Mild' 'lumbar' 'scoliosis' '(' 'Cobb' 'angle' 'up' 'to' '25º' ')'],[2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02555280,17:35:cancer,Patients with a primary bony tumor,['Patients' 'with' 'a' 'primary' 'bony' 'tumor'],[0. 0. 0. 3. 3. 3.]
NCT02555280,8:25:chronic_disease,Severe facet hypertrophy that requires extensive bone removal which would cause instability,"['Severe' 'facet' 'hypertrophy' 'that' 'requires' 'extensive' 'bone'
 'removal' 'which' 'would' 'cause' 'instability']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02555280,1:11:chronic_disease,osteopenia,['osteopenia'],[2.]
NCT02555189,"1:64:treatment,","Prior isotope therapy with strontium-89, samarium or radium-223 within 12 weeks of enrollment","['Prior' 'isotope' 'therapy' 'with' 'strontium-89' ',' 'samarium' 'or'
 'radium-223' 'within' '12' 'weeks' 'of' 'enrollment']",[1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02554903,",80:93:treatment",negative serum pregnancy test result during the Screening period (Visit 1) and Randomization (Visit 2),"['negative' 'serum' 'pregnancy' 'test' 'result' 'during' 'the' 'Screening'
 'period' '(' 'Visit' '1' ')' 'and' 'Randomization' '(' 'Visit' '2' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02554383,12:35:allergy_name,Allergy to amoxicillin-clavulanate,['Allergy' 'to' 'amoxicillin-clavulanate'],[0. 0. 4.]
NCT02554253,1:26:chronic_disease,immunodeficiency syndrome,['immunodeficiency' 'syndrome'],[2. 2.]
NCT02553941,1:64:treatment,Prior treatment with a Bruton's tyrosine kinase (BTK) inhibitor,"['Prior' 'treatment' 'with' 'a' 'Bruton' ""'s"" 'tyrosine' 'kinase' '('
 'BTK' ')' 'inhibitor']",[1. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0.]
NCT02553642,1:23:treatment,Prior therapy with BCG,['Prior' 'therapy' 'with' 'BCG'],[1. 1. 1. 1.]
NCT02553265,24:26:chronic_disease,Confirmed diagnosis of FD (genetic testing),['Confirmed' 'diagnosis' 'of' 'FD' '(' 'genetic' 'testing' ')'],[0. 0. 0. 2. 0. 0. 0. 0.]
NCT02553265,43:69:allergy_name,Patients with a known hypersensitivity to any component of this drug,"['Patients' 'with' 'a' 'known' 'hypersensitivity' 'to' 'any' 'component'
 'of' 'this' 'drug']",[0. 0. 0. 0. 0. 0. 4. 4. 4. 4. 4.]
NCT02551679,9:33:treatment,Chronic cytotoxic drug treatment,['Chronic' 'cytotoxic' 'drug' 'treatment'],[0. 1. 1. 1.]
NCT02551679,39:72:chronic_disease,Severe concurrent disease (other than Peripheral Vascular Disease (PAD),"['Severe' 'concurrent' 'disease' '(' 'other' 'than' 'Peripheral'
 'Vascular' 'Disease' '(' 'PAD' ')']",[0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT02551679,13:42:chronic_disease,Uncorrected aorto-iliac occlusive disease,['Uncorrected' 'aorto-iliac' 'occlusive' 'disease'],[0. 2. 2. 2.]
NCT02549833,34:51:chronic_disease,History or clinical suspicion of neurofibromatosis,['History' 'or' 'clinical' 'suspicion' 'of' 'neurofibromatosis'],[0. 0. 0. 0. 0. 2.]
NCT02548351,"24:28:chronic_disease,",Histologic evidence of NASH upon central read of a liver biopsy obtained no more than 6 months before Day 1 defined by presence of all 3 key histological features of NASH according to NASH CRN criteria,"['Histologic' 'evidence' 'of' 'NASH' 'upon' 'central' 'read' 'of' 'a'
 'liver' 'biopsy' 'obtained' 'no' 'more' 'than' '6' 'months' 'before'
 'Day' '1' 'defined' 'by' 'presence' 'of' 'all' '3' 'key' 'histological'
 'features' 'of' 'NASH' 'according' 'to' 'NASH' 'CRN' 'criteria']","[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02548104,1:19:chronic_disease,Systemic infection,['Systemic' 'infection'],[2. 2.]
NCT02547818,"1:23:treatment,",Investigational agents are prohibited one month prior to entry and for the duration of the trial,"['Investigational' 'agents' 'are' 'prohibited' 'one' 'month' 'prior' 'to'
 'entry' 'and' 'for' 'the' 'duration' 'of' 'the' 'trial']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02547818,8:32:treatment,Taking inhaled protein products on a chronic basis,['Taking' 'inhaled' 'protein' 'products' 'on' 'a' 'chronic' 'basis'],[0. 1. 1. 1. 0. 0. 0. 0.]
NCT02547662,",,146:160:treatment","Diarrhea > grade 1, based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grading, in the absence of antidiarrheals","['Diarrhea' '>' 'grade' '1' ',' 'based' 'on' 'the' 'National' 'Cancer'
 'Institute' 'Common' 'Terminology' 'Criteria' 'for' 'Adverse' 'Events'
 '(' 'NCI' 'CTCAE' ')' 'grading' ',' 'in' 'the' 'absence' 'of'
 'antidiarrheals']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1.]"
NCT02546583,",,46:56:treatment",Study Visit 1 loop diuretic dose ≤ 160 mg of furosemide equivalents,"['Study' 'Visit' '1' 'loop' 'diuretic' 'dose' '≤' '160' 'mg' 'of'
 'furosemide' 'equivalents']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02544503,8:24:treatment,Use of CNS active drugs,['Use' 'of' 'CNS' 'active' 'drugs'],[0. 0. 1. 1. 1.]
NCT02544373,27:38:treatment,Unwillingness to initiate PAP therapy if clinically indicated,"['Unwillingness' 'to' 'initiate' 'PAP' 'therapy' 'if' 'clinically'
 'indicated']",[0. 0. 0. 1. 1. 0. 0. 0.]
NCT02543944,1:23:chronic_disease,3rd degree heart block,['3rd' 'degree' 'heart' 'block'],[2. 2. 2. 2.]
NCT02543944,21:74:chronic_disease,pre-existing severe gastrointestinal narrowing (pathologic or iatrogenic),"['pre-existing' 'severe' 'gastrointestinal' 'narrowing' '(' 'pathologic'
 'or' 'iatrogenic' ')']",[0. 0. 2. 2. 2. 2. 2. 0. 0.]
NCT02543866,32:56:chronic_disease,Lack of intestinal carriage of ESC-R Enterobacteriaceae (negative selective stool culture for ESC-R Enterobacteriaceae),"['Lack' 'of' 'intestinal' 'carriage' 'of' 'ESC-R' 'Enterobacteriaceae' '('
 'negative' 'selective' 'stool' 'culture' 'for' 'ESC-R'
 'Enterobacteriaceae' ')']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02542657,45:73:cancer,Definite development of new bone lesions or extramedullary plasmacytomas or definite increase in the size of existing bone lesions or extramedullary plasmacytomas,"['Definite' 'development' 'of' 'new' 'bone' 'lesions' 'or'
 'extramedullary' 'plasmacytomas' 'or' 'definite' 'increase' 'in' 'the'
 'size' 'of' 'existing' 'bone' 'lesions' 'or' 'extramedullary'
 'plasmacytomas']",[0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02541955,20:67:treatment,Stable concomitant Disease Modifying Anti-Rheumatic Drugs (DMARDs),"['Stable' 'concomitant' 'Disease' 'Modifying' 'Anti-Rheumatic' 'Drugs' '('
 'DMARDs' ')']",[0. 0. 1. 1. 1. 1. 1. 0. 0.]
NCT02541903,15:63:cancer,Patients with metastatic or locally advanced unresectable PSCC,"['Patients' 'with' 'metastatic' 'or' 'locally' 'advanced' 'unresectable'
 'PSCC']",[0. 0. 3. 3. 3. 3. 3. 3.]
NCT02541565,1:35:treatment,positron emission tomography (PET),['positron' 'emission' 'tomography' '(' 'PET' ')'],[1. 1. 1. 1. 0. 0.]
NCT02540330,14:26:allergy_name,Allergies to imaging dyes,['Allergies' 'to' 'imaging' 'dyes'],[0. 0. 4. 4.]
NCT02540330,1:11:cancer,Non-Ductal Pathology: Lobular or Colloid type presence,['Non-Ductal' 'Pathology' ':' 'Lobular' 'or' 'Colloid' 'type' 'presence'],[3. 0. 0. 0. 0. 0. 0. 0.]
NCT02539160,8:29:chronic_disease,Active pathological bleeding,['Active' 'pathological' 'bleeding'],[0. 2. 2.]
NCT02538198,15:60:cancer,"Patients with progressive or refractory plasma cell myeloma, as defined by International Myeloma Workshop Consensus Panel criteria","['Patients' 'with' 'progressive' 'or' 'refractory' 'plasma' 'cell'
 'myeloma' ',' 'as' 'defined' 'by' 'International' 'Myeloma' 'Workshop'
 'Consensus' 'Panel' 'criteria']",[0. 0. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02536794,12:44:chronic_disease,History of primary immunodeficiency disease,['History' 'of' 'primary' 'immunodeficiency' 'disease'],[0. 0. 2. 2. 2.]
NCT02536794,",27:59:treatment",within 12 months of their last adjuvant systemic treatment,"['within' '12' 'months' 'of' 'their' 'last' 'adjuvant' 'systemic'
 'treatment']",[0. 0. 0. 0. 0. 1. 1. 1. 1.]
NCT02535832,1:13:chronic_disease,Severe edema,['Severe' 'edema'],[2. 2.]
NCT02535325,16:37:treatment,The effects of methoxyamine (TRC102) on the developing human fetus are unknown,"['The' 'effects' 'of' 'methoxyamine' '(' 'TRC102' ')' 'on' 'the'
 'developing' 'human' 'fetus' 'are' 'unknown']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02535312,1:25:treatment,anti-seizure medications are eligible to participate,['anti-seizure' 'medications' 'are' 'eligible' 'to' 'participate'],[1. 1. 0. 0. 0. 0.]
NCT02533674,1:32:chronic_disease,Concomitant diseases/conditions,['Concomitant' 'diseases/conditions'],[2. 2.]
NCT02533674,1:35:cancer,Non-small cell lung cancer (NSCLC),['Non-small' 'cell' 'lung' 'cancer' '(' 'NSCLC' ')'],[3. 3. 3. 3. 3. 0. 0.]
NCT02533674,1:18:cancer,Urothelial cancer,['Urothelial' 'cancer'],[3. 3.]
NCT02532621,53:88:chronic_disease,Subject has a documented and unsuccessfully treated ipsilateral central venous stenosis as determined by imaging,"['Subject' 'has' 'a' 'documented' 'and' 'unsuccessfully' 'treated'
 'ipsilateral' 'central' 'venous' 'stenosis' 'as' 'determined' 'by'
 'imaging']",[0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0.]
NCT02532543,",,185:209:chronic_disease","Teeth adjacent (mesial and distal) to study site must consist of two stable natural teeth with minimal restorations, without signs of periodontal bone loss (> 3 mm) and/or significant soft tissue deficiencies","['Teeth' 'adjacent' '(' 'mesial' 'and' 'distal' ')' 'to' 'study' 'site'
 'must' 'consist' 'of' 'two' 'stable' 'natural' 'teeth' 'with' 'minimal'
 'restorations' ',' 'without' 'signs' 'of' 'periodontal' 'bone' 'loss' '('
 '>' '3' 'mm' ')' 'and/or' 'significant' 'soft' 'tissue' 'deficiencies']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2.]"
NCT02531932,71:95:treatment,Patient should also avoid close contact with others who have received live attenuated vaccines,"['Patient' 'should' 'also' 'avoid' 'close' 'contact' 'with' 'others' 'who'
 'have' 'received' 'live' 'attenuated' 'vaccines']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02531711,1:22:chronic_disease,Cognitive dysfunction preventing informed consent,['Cognitive' 'dysfunction' 'preventing' 'informed' 'consent'],[2. 2. 0. 0. 0.]
NCT02530463,",,,155:188:treatment",Males who have partners of childbearing potential must agree to use an effective contraceptive method during the study and a period of 31 weeks after the last dose of investigational drug,"['Males' 'who' 'have' 'partners' 'of' 'childbearing' 'potential' 'must'
 'agree' 'to' 'use' 'an' 'effective' 'contraceptive' 'method' 'during'
 'the' 'study' 'and' 'a' 'period' 'of' '31' 'weeks' 'after' 'the' 'last'
 'dose' 'of' 'investigational' 'drug']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 1. 1. 1. 1.]"
NCT02530073,8:17:treatment,Normal Karyotype,['Normal' 'Karyotype'],[0. 1.]
NCT02530034,1:49:cancer,chronic myeloid leukemia in blast phase (CML-BP),['chronic' 'myeloid' 'leukemia' 'in' 'blast' 'phase' '(' 'CML-BP' ')'],[3. 3. 3. 3. 3. 3. 3. 0. 0.]
NCT02527421,1:13:treatment,PUVA therapy,['PUVA' 'therapy'],[1. 1.]
NCT02527265,"23:53:treatment,",Currently receiving a regimen of basal/bolus insulin administered by MDI for at least 6 weeks prior to enrollment,"['Currently' 'receiving' 'a' 'regimen' 'of' 'basal/bolus' 'insulin'
 'administered' 'by' 'MDI' 'for' 'at' 'least' '6' 'weeks' 'prior' 'to'
 'enrollment']",[0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02526511,38:45:allergy_name,Subjects with established allergy to IV GBCA,['Subjects' 'with' 'established' 'allergy' 'to' 'IV' 'GBCA'],[0. 0. 0. 0. 0. 4. 4.]
NCT02525029,16:45:cancer,Diagnosis of a hormone responsive malignancy,['Diagnosis' 'of' 'a' 'hormone' 'responsive' 'malignancy'],[0. 0. 0. 3. 3. 3.]
NCT02524379,"22:30:treatment,",Known treatment with Bosentan within past 7 days,['Known' 'treatment' 'with' 'Bosentan' 'within' 'past' '7' 'days'],[0. 0. 0. 1. 0. 0. 0. 0.]
NCT02522871,1:44:treatment,Prior solid organ or bone marrow transplant,['Prior' 'solid' 'organ' 'or' 'bone' 'marrow' 'transplant'],[1. 1. 1. 1. 1. 1. 1.]
NCT02522715,1:10:treatment,Flutamide; approximate half-life: 6 hours; washout period required: 36 hours,"['Flutamide' ';' 'approximate' 'half-life' ':' '6' 'hours' ';' 'washout'
 'period' 'required' ':' '36' 'hours']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02522715,23:34:treatment,may not have received cabazitaxel in the past,['may' 'not' 'have' 'received' 'cabazitaxel' 'in' 'the' 'past'],[0. 0. 0. 0. 1. 0. 0. 0.]
NCT02522429,1:14:treatment,deep sedation,['deep' 'sedation'],[1. 1.]
NCT02521103,22:49:treatment,Patient has a failed unicondylar knee prosthesis,['Patient' 'has' 'a' 'failed' 'unicondylar' 'knee' 'prosthesis'],[0. 0. 0. 0. 1. 1. 1.]
NCT02520791,"25:43:treatment,",Receipt of live or live attenuated vaccine within 12 weeks prior to enrollment,"['Receipt' 'of' 'live' 'or' 'live' 'attenuated' 'vaccine' 'within' '12'
 'weeks' 'prior' 'to' 'enrollment']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02520791,1:9:chronic_disease,Vitiligo,['Vitiligo'],[2.]
NCT02520778,23:46:treatment,be treatment naive to T790M-directed EGFR TKI,['be' 'treatment' 'naive' 'to' 'T790M-directed' 'EGFR' 'TKI'],[0. 0. 0. 0. 1. 1. 1.]
NCT02520713,25:41:cancer,Histologic diagnosis of solid malignancy,['Histologic' 'diagnosis' 'of' 'solid' 'malignancy'],[0. 0. 0. 3. 3.]
NCT02520713,25:44:treatment,Patient has already had molecular profiling,['Patient' 'has' 'already' 'had' 'molecular' 'profiling'],[0. 0. 0. 0. 1. 1.]
NCT02520427,28:51:treatment,"Unresolved toxicities from prior antitumor therapy, defined as not having resolved to CTCAE, version 4.0 grade 1","['Unresolved' 'toxicities' 'from' 'prior' 'antitumor' 'therapy' ','
 'defined' 'as' 'not' 'having' 'resolved' 'to' 'CTCAE' ',' 'version' '4.0'
 'grade' '1']",[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02520011,",36:48:treatment",Received >360 mg/m2 equivalents of daunorubicin,['Received' '>' '360' 'mg/m2' 'equivalents' 'of' 'daunorubicin'],[0. 0. 0. 0. 0. 0. 1.]
NCT02519543,13:26:chronic_disease,presence of rapid cycling (by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5 criteria),"['presence' 'of' 'rapid' 'cycling' '(' 'by' 'the' 'Diagnostic' 'and'
 'Statistical' 'Manual' 'of' 'Mental' 'Disorders' '(' 'DSM-5' 'criteria'
 ')']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02519452,",70:90:treatment",Prior treatment with less than or equal to (>=) 2 treatment lines of anti-myeloma therapy,"['Prior' 'treatment' 'with' 'less' 'than' 'or' 'equal' 'to' '(' '>' '='
 ')' '2' 'treatment' 'lines' 'of' 'anti-myeloma' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02519452,"26:69:treatment,",participant has received autologous stem cell transplantation (ASCT) within 12 weeks before Cycle 1 Day 1,"['participant' 'has' 'received' 'autologous' 'stem' 'cell'
 'transplantation' '(' 'ASCT' ')' 'within' '12' 'weeks' 'before' 'Cycle'
 '1' 'Day' '1']",[0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02519322,5:33:treatment,the 28-8 clone for PD-L1 testing is required for assessment of PD-L1 status,"['the' '28-8' 'clone' 'for' 'PD-L1' 'testing' 'is' 'required' 'for'
 'assessment' 'of' 'PD-L1' 'status']",[0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02518594,"20:44:treatment,,",Cervical length on transvaginal examination of less than 30 mm within 10 days prior to randomization by a study certified sonographer,"['Cervical' 'length' 'on' 'transvaginal' 'examination' 'of' 'less' 'than'
 '30' 'mm' 'within' '10' 'days' 'prior' 'to' 'randomization' 'by' 'a'
 'study' 'certified' 'sonographer']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02518594,"18:46:treatment,",Participation in another interventional study that influences gestational age at delivery or neonatal morbidity or mortality,"['Participation' 'in' 'another' 'interventional' 'study' 'that'
 'influences' 'gestational' 'age' 'at' 'delivery' 'or' 'neonatal'
 'morbidity' 'or' 'mortality']",[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02516813,66:80:treatment,Measurable or evaluable disease by RECIST v1.1 (not required for ancillary cPoP part of the study),"['Measurable' 'or' 'evaluable' 'disease' 'by' 'RECIST' 'v1.1' '(' 'not'
 'required' 'for' 'ancillary' 'cPoP' 'part' 'of' 'the' 'study' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02516462,",,,98:129:treatment",Infertile women of advanced maternal age (>35 years) who desire to conceive and come to CCRM for infertility treatment using IVF,"['Infertile' 'women' 'of' 'advanced' 'maternal' 'age' '(' '>' '35' 'years'
 ')' 'who' 'desire' 'to' 'conceive' 'and' 'come' 'to' 'CCRM' 'for'
 'infertility' 'treatment' 'using' 'IVF']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1.]
NCT02515708,92:128:treatment,Liver in which the investigator is unwilling or unable (for logistical reasons) to perform normothermic machine perfusion (NMP) preservation,"['Liver' 'in' 'which' 'the' 'investigator' 'is' 'unwilling' 'or' 'unable'
 '(' 'for' 'logistical' 'reasons' ')' 'to' 'perform' 'normothermic'
 'machine' 'perfusion' '(' 'NMP' ')' 'preservation']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0.]
NCT02515110,1:23:treatment,Bilateral oophorectomy,['Bilateral' 'oophorectomy'],[1. 1.]
NCT02514915,23:50:cancer,Patients must have an extra-cranial primary tumor diagnosis,"['Patients' 'must' 'have' 'an' 'extra-cranial' 'primary' 'tumor'
 'diagnosis']",[0. 0. 0. 0. 3. 3. 3. 0.]
NCT02514083,10:26:chronic_disease,Impaired hepatic function,['Impaired' 'hepatic' 'function'],[0. 2. 2.]
NCT02513797,"20:51:treatment,",Based on screening computed tomography angiography performed within 90 days prior to study intervention as confirmed by the core lab,"['Based' 'on' 'screening' 'computed' 'tomography' 'angiography'
 'performed' 'within' '90' 'days' 'prior' 'to' 'study' 'intervention' 'as'
 'confirmed' 'by' 'the' 'core' 'lab']",[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02513797,",,35:58:treatment",LA diameter > 6 cm as measured by computerized tomography and confirmed by the imaging core laboratory,"['LA' 'diameter' '>' '6' 'cm' 'as' 'measured' 'by' 'computerized'
 'tomography' 'and' 'confirmed' 'by' 'the' 'imaging' 'core' 'laboratory']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02512926,",,,64:83:treatment",ANC ≥ 750 - cannot be transfused (must be ≥ 72 hours from last neutrophil infusion),"['ANC' '≥' '750' '-' 'can' 'not' 'be' 'transfused' '(' 'must' 'be' '≥'
 '72' 'hours' 'from' 'last' 'neutrophil' 'infusion' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.]
NCT02512926,1:25:treatment,Myelosuppressive therapy,['Myelosuppressive' 'therapy'],[1. 1.]
NCT02512718,12:59:treatment,History of parenteral nutrition use with SOLE prior to HCT,"['History' 'of' 'parenteral' 'nutrition' 'use' 'with' 'SOLE' 'prior' 'to'
 'HCT']",[0. 0. 1. 1. 1. 1. 1. 1. 1. 1.]
NCT02512497,"50:66:chronic_disease,,,,","An EKG recorded at screening showing evidence of cardiac ischemia (ST depression depression of >/= 2 mm, measured from isoelectric line to the ST segment)","['An' 'EKG' 'recorded' 'at' 'screening' 'showing' 'evidence' 'of'
 'cardiac' 'ischemia' '(' 'ST' 'depression' 'depression' 'of' '>' '/=' '2'
 'mm' ',' 'measured' 'from' 'isoelectric' 'line' 'to' 'the' 'ST' 'segment'
 ')']","[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02512497,17:30:treatment,stable doses of beta-blockers,['stable' 'doses' 'of' 'beta-blockers'],[0. 0. 0. 1.]
NCT02510456,26:46:treatment,No contraindications for primary chemotherapy,['No' 'contraindications' 'for' 'primary' 'chemotherapy'],[0. 0. 0. 1. 1.]
NCT02509507,1:13:cancer,Liver tumors must not be estimated to invade approximately more than one-third of the liver,"['Liver' 'tumors' 'must' 'not' 'be' 'estimated' 'to' 'invade'
 'approximately' 'more' 'than' 'one-third' 'of' 'the' 'liver']",[3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02509507,"15:37:treatment,",have received live-virus vaccination within 30 days of planned treatment start,"['have' 'received' 'live-virus' 'vaccination' 'within' '30' 'days' 'of'
 'planned' 'treatment' 'start']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02509260,1:21:treatment,intestinal resection,['intestinal' 'resection'],[1. 1.]
NCT02508467,65:68:treatment,"For Part 3, the patient has not received prior treatment with a TKI","['For' 'Part' '3' ',' 'the' 'patient' 'has' 'not' 'received' 'prior'
 'treatment' 'with' 'a' 'TKI']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02508311,",,,45:56:chronic_disease",Neurological level of injury between C3-C8 (Tetraplegia),"['Neurological' 'level' 'of' 'injury' 'between' 'C3-C8' '(' 'Tetraplegia'
 ')']",[0. 0. 0. 0. 0. 0. 0. 2. 0.]
NCT02508038,57:76:treatment,Is free from communicable disease risks associated with xenotransplantation,"['Is' 'free' 'from' 'communicable' 'disease' 'risks' 'associated' 'with'
 'xenotransplantation']",[0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02508038,6:14:chronic_disease,RPR (Syphilis TP),['RPR' '(' 'Syphilis' 'TP' ')'],[0. 0. 2. 0. 0.]
NCT02508038,8:46:chronic_disease,active Central Nervous System (CNS) infection,['active' 'Central' 'Nervous' 'System' '(' 'CNS' ')' 'infection'],[0. 2. 2. 2. 2. 2. 0. 0.]
NCT02507505,31:48:allergy_name,Absolute contraindications to spinal anesthesia,['Absolute' 'contraindications' 'to' 'spinal' 'anesthesia'],[0. 0. 0. 4. 4.]
NCT02507011,46:66:treatment,Patient can be on either mono or combination PAH-specific therapy,"['Patient' 'can' 'be' 'on' 'either' 'mono' 'or' 'combination'
 'PAH-specific' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02507011,5:47:chronic_disease,WHO category 1 pulmonary arterial hypertension (Nice 2013),"['WHO' 'category' '1' 'pulmonary' 'arterial' 'hypertension' '(' 'Nice'
 '2013' ')']",[0. 2. 2. 2. 2. 2. 0. 0. 0. 0.]
NCT02506192,25:30:chronic_disease,Has been diagnosed with Lupus,['Has' 'been' 'diagnosed' 'with' 'Lupus'],[0. 0. 0. 0. 2.]
NCT02506192,1:11:chronic_disease,Vasculitis,['Vasculitis'],[2.]
NCT02505035,"1:45:chronic_disease,",Chronic obstructive pulmonary disease (COPD) with home oxygen dependence or 2 or more hospitalizations in the past 12 months,"['Chronic' 'obstructive' 'pulmonary' 'disease' '(' 'COPD' ')' 'with'
 'home' 'oxygen' 'dependence' 'or' '2' 'or' 'more' 'hospitalizations' 'in'
 'the' 'past' '12' 'months']",[2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02503722,23:51:treatment,No concomitant use of proton pump inhibitors (PPI),['No' 'concomitant' 'use' 'of' 'proton' 'pump' 'inhibitors' '(' 'PPI' ')'],[0. 0. 0. 0. 1. 1. 1. 1. 0. 0.]
NCT02503722,",,,99:118:treatment",Women under 50 years must be postmenopausal for at least 12 months following the end of exogenous hormonal treatments and with LH and FSH levels in the post-menopausal range for the institution,"['Women' 'under' '50' 'years' 'must' 'be' 'postmenopausal' 'for' 'at'
 'least' '12' 'months' 'following' 'the' 'end' 'of' 'exogenous' 'hormonal'
 'treatments' 'and' 'with' 'LH' 'and' 'FSH' 'levels' 'in' 'the'
 'post-menopausal' 'range' 'for' 'the' 'institution']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02503358,1:28:chronic_disease,Ophthalmological conditions,['Ophthalmological' 'conditions'],[2. 2.]
NCT02501954,23:60:treatment,Patients who have had pelvic or abdominal radiation therapy,"['Patients' 'who' 'have' 'had' 'pelvic' 'or' 'abdominal' 'radiation'
 'therapy']",[0. 0. 0. 0. 1. 1. 1. 1. 1.]
NCT02501954,15:43:cancer,Patients with recurrent endometrial cancer,['Patients' 'with' 'recurrent' 'endometrial' 'cancer'],[0. 0. 3. 3. 3.]
NCT02501733,22:52:treatment,Patients requiring a primary total knee replacement,['Patients' 'requiring' 'a' 'primary' 'total' 'knee' 'replacement'],[0. 0. 0. 1. 1. 1. 1.]
NCT02501473,1:62:treatment,Prior administration of other intratumoral immunotherapeutics,['Prior' 'administration' 'of' 'other' 'intratumoral' 'immunotherapeutics'],[1. 1. 1. 1. 1. 1.]
NCT02500602,45:72:chronic_disease,"Subjects meeting DSM-5 criteria for current bipolar affective disorders, as the study protocol may be therapeutically insufficient","['Subjects' 'meeting' 'DSM-5' 'criteria' 'for' 'current' 'bipolar'
 'affective' 'disorders' ',' 'as' 'the' 'study' 'protocol' 'may' 'be'
 'therapeutically' 'insufficient']",[0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02498951,"1:39:treatment,",Brain magnetic resonance imaging (MRI) documenting CR must be obtained within 30 days of study enrollment,"['Brain' 'magnetic' 'resonance' 'imaging' '(' 'MRI' ')' 'documenting' 'CR'
 'must' 'be' 'obtained' 'within' '30' 'days' 'of' 'study' 'enrollment']",[1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02498613,"4:19:treatment,,",An ultrasound (US) within the last 6 months prior to registration will be required to document that it is =< 5 cm,"['An' 'ultrasound' '(' 'US' ')' 'within' 'the' 'last' '6' 'months' 'prior'
 'to' 'registration' 'will' 'be' 'required' 'to' 'document' 'that' 'it'
 'is' '=' '<' '5' 'cm']","[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02498535,"1:12:treatment,",Chest x-ray within the last six (6) months,['Chest' 'x-ray' 'within' 'the' 'last' 'six' '(' '6' ')' 'months'],[1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02498301,15:34:chronic_disease,"Subject has a concomitant disease or condition that could interfere with, or for which treatment could interfere with, the conduct of the study, or could in the opinion of the investigator increase the risk of AEs during the subject's participation in the study","['Subject' 'has' 'a' 'concomitant' 'disease' 'or' 'condition' 'that'
 'could' 'interfere' 'with' ',' 'or' 'for' 'which' 'treatment' 'could'
 'interfere' 'with' ',' 'the' 'conduct' 'of' 'the' 'study' ',' 'or'
 'could' 'in' 'the' 'opinion' 'of' 'the' 'investigator' 'increase' 'the'
 'risk' 'of' 'AEs' 'during' 'the' 'subject' ""'s"" 'participation' 'in'
 'the' 'study']","[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02498301,1:20:treatment,warfarin (Coumadin),['warfarin' '(' 'Coumadin' ')'],[1. 1. 0. 0.]
NCT02497300,1:30:chronic_disease,Diabetes mellitus (DM) type 1,['Diabetes' 'mellitus' '(' 'DM' ')' 'type' '1'],[2. 2. 2. 2. 2. 0. 0.]
NCT02496611,1:16:chronic_disease,Bulimia nervosa,['Bulimia' 'nervosa'],[2. 2.]
NCT02496611,36:63:cancer,Personal- and/or family history of medullary thyroid carcinoma,"['Personal-' 'and/or' 'family' 'history' 'of' 'medullary' 'thyroid'
 'carcinoma']",[0. 0. 0. 0. 0. 3. 3. 3.]
NCT02496585,16:46:chronic_disease,Active chronic Hepatitis C and/or B infection,['Active' 'chronic' 'Hepatitis' 'C' 'and/or' 'B' 'infection'],[0. 0. 2. 2. 2. 2. 2.]
NCT02496208,16:52:cancer,Non-resectable squamous cell carcinoma of the penis,['Non-resectable' 'squamous' 'cell' 'carcinoma' 'of' 'the' 'penis'],[0. 3. 3. 3. 3. 3. 3.]
NCT02495753,",19:49:chronic_disease",women with active herpes simplex virus infection,['women' 'with' 'active' 'herpes' 'simplex' 'virus' 'infection'],[0. 0. 0. 2. 2. 2. 2.]
NCT02495415,",48:76:treatment",Diseases refractory/relapsed after one or more systemic cytotoxic therapies,"['Diseases' 'refractory/relapsed' 'after' 'one' 'or' 'more' 'systemic'
 'cytotoxic' 'therapies']",[0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02495415,26:46:chronic_disease,Patients with any active hepatitis infections,['Patients' 'with' 'any' 'active' 'hepatitis' 'infections'],[0. 0. 0. 0. 2. 2.]
NCT02495415,48:81:cancer,with histologically or cytologically confirmed Peripheral T-cell lymphoma (PTCL),"['with' 'histologically' 'or' 'cytologically' 'confirmed' 'Peripheral'
 'T-cell' 'lymphoma' '(' 'PTCL' ')']",[0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0.]
NCT02495168,1:25:treatment,Oral (not inhaled) SABAs for 24 hours,['Oral' '(' 'not' 'inhaled' ')' 'SABAs' 'for' '24' 'hours'],[1. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02495168,",42:70:treatment",at least 24 hours after the last dose of long-acting β agonist (LABA) at the screening visit (Visit 1),"['at' 'least' '24' 'hours' 'after' 'the' 'last' 'dose' 'of' 'long-acting'
 'β' 'agonist' '(' 'LABA' ')' 'at' 'the' 'screening' 'visit' '(' 'Visit'
 '1' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02494869,124:148:treatment,Any other condition or intercurrent illness that in the opinion of the investigator makes the subject a poor candidate for core biopsy or the trial,"['Any' 'other' 'condition' 'or' 'intercurrent' 'illness' 'that' 'in' 'the'
 'opinion' 'of' 'the' 'investigator' 'makes' 'the' 'subject' 'a' 'poor'
 'candidate' 'for' 'core' 'biopsy' 'or' 'the' 'trial']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1.
 1.]"
NCT02494869,1:22:cancer,Metastatic malignancy of any kind,['Metastatic' 'malignancy' 'of' 'any' 'kind'],[3. 3. 0. 0. 0.]
NCT02494869,1:11:chronic_disease,Thrombosis of lower extremities,['Thrombosis' 'of' 'lower' 'extremities'],[2. 0. 0. 0.]
NCT02494141,1:6:chronic_disease,ADPKD diagnosis,['ADPKD' 'diagnosis'],[2. 0.]
NCT02493530,",60:85:treatment",Recovery to ≤ Grade 1 or baseline of any toxicities due to prior systemic treatments,"['Recovery' 'to' '≤' 'Grade' '1' 'or' 'baseline' 'of' 'any' 'toxicities'
 'due' 'to' 'prior' 'systemic' 'treatments']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02493426,25:44:treatment,Individuals that are on antipsychotic drugs will be excluded from participation. All subjects must lack a significant medical history,"['Individuals' 'that' 'are' 'on' 'antipsychotic' 'drugs' 'will' 'be'
 'excluded' 'from' 'participation' '.' 'All' 'subjects' 'must' 'lack' 'a'
 'significant' 'medical' 'history']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02493257,"1:19:treatment,",Intranasal steroid use >4 wks,['Intranasal' 'steroid' 'use' '>' '4' 'wks'],[1. 1. 0. 0. 0. 0.]
NCT02492867,29:70:cancer,Patients with evidence of a malignant pleural or pericardial effusion,"['Patients' 'with' 'evidence' 'of' 'a' 'malignant' 'pleural' 'or'
 'pericardial' 'effusion']",[0. 0. 0. 0. 0. 3. 3. 3. 3. 3.]
NCT02490631,12:28:chronic_disease,history of spine infections,['history' 'of' 'spine' 'infections'],[0. 0. 2. 2.]
NCT02489591,1:20:chronic_disease,Periodontal disease and/or insufficient number of teeth,['Periodontal' 'disease' 'and/or' 'insufficient' 'number' 'of' 'teeth'],[2. 2. 0. 0. 0. 0. 0.]
NCT02489045,68:82:chronic_disease,"Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable","['Patients' 'who' 'are' 'medically' 'unstable' ',' 'patients' 'who' 'are'
 'seriously' 'or' 'terminally' 'ill' ',' 'and' 'patients' 'whose'
 'clinical' 'course' 'is' 'unpredictable']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02488967,23:53:chronic_disease,History of documented congestive heart failure (CHF),['History' 'of' 'documented' 'congestive' 'heart' 'failure' '(' 'CHF' ')'],[0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT02487797,",35:55:chronic_disease,",Diagnosed with at least 6 regular uterine contractions in an observation period of no more than 60 minutes,"['Diagnosed' 'with' 'at' 'least' '6' 'regular' 'uterine' 'contractions'
 'in' 'an' 'observation' 'period' 'of' 'no' 'more' 'than' '60' 'minutes']",[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02487095,43:70:chronic_disease,Subjects with both platinum-sensitive and platinum-refractory disease,"['Subjects' 'with' 'both' 'platinum-sensitive' 'and' 'platinum-refractory'
 'disease']",[0. 0. 0. 0. 0. 2. 2.]
NCT02485639,91:115:allergy_name,a history of severe reactions following previous immunization with licensed or unlicensed influenza virus vaccines,"['a' 'history' 'of' 'severe' 'reactions' 'following' 'previous'
 'immunization' 'with' 'licensed' 'or' 'unlicensed' 'influenza' 'virus'
 'vaccines']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 4. 4.]
NCT02484950,1:17:treatment,Revision surgery,['Revision' 'surgery'],[1. 1.]
NCT02484404,29:81:treatment,Patients must have received prior treatment with enzalutamide and/or abiraterone,"['Patients' 'must' 'have' 'received' 'prior' 'treatment' 'with'
 'enzalutamide' 'and/or' 'abiraterone']",[0. 0. 0. 0. 1. 1. 1. 1. 1. 1.]
NCT02484404,28:53:treatment,Patients who have received anti-angiogenesis therapy are eligible,"['Patients' 'who' 'have' 'received' 'anti-angiogenesis' 'therapy' 'are'
 'eligible']",[0. 0. 0. 0. 1. 1. 0. 0.]
NCT02484404,",29:62:treatment",within 6 weeks prior to the first dose of the study treatment are not eligible,"['within' '6' 'weeks' 'prior' 'to' 'the' 'first' 'dose' 'of' 'the' 'study'
 'treatment' 'are' 'not' 'eligible']",[0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0.]
NCT02484248,1:34:treatment,previous treatment with ketotifen,['previous' 'treatment' 'with' 'ketotifen'],[1. 1. 1. 1.]
NCT02483468,41:59:treatment,Unable or unwilling discontinue current behavioral therapy,['Unable' 'or' 'unwilling' 'discontinue' 'current' 'behavioral' 'therapy'],[0. 0. 0. 0. 0. 1. 1.]
NCT02481765,1:11:treatment,Normal EEG,['Normal' 'EEG'],[1. 1.]
NCT02481310,6:28:cancer,MYC+ plasmablastic lymphoma by histology,['MYC+' 'plasmablastic' 'lymphoma' 'by' 'histology'],[0. 3. 3. 0. 0.]
NCT02481245,1:12:chronic_disease,Cyclothymia,['Cyclothymia'],[2.]
NCT02481245,",46:61:treatment",Subjects having failed two or more trials of somatic therapy,"['Subjects' 'having' 'failed' 'two' 'or' 'more' 'trials' 'of' 'somatic'
 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02480036,52:105:treatment,Patients with clinical or radiographic evidence of spinal cord or cauda equine compression or effacement,"['Patients' 'with' 'clinical' 'or' 'radiographic' 'evidence' 'of' 'spinal'
 'cord' 'or' 'cauda' 'equine' 'compression' 'or' 'effacement']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 1.]
NCT02479906,"1:26:chronic_disease,",Transient ischemic attack within two years,['Transient' 'ischemic' 'attack' 'within' 'two' 'years'],[2. 2. 2. 0. 0. 0.]
NCT02479620,32:60:chronic_disease,"Patient has documented chronic Critical Limb Ischemia (CLI) in the target limb from the popliteal artery to the ankle joint prior to the study procedure with Rutherford Category 4, 5 or 6","['Patient' 'has' 'documented' 'chronic' 'Critical' 'Limb' 'Ischemia' '('
 'CLI' ')' 'in' 'the' 'target' 'limb' 'from' 'the' 'popliteal' 'artery'
 'to' 'the' 'ankle' 'joint' 'prior' 'to' 'the' 'study' 'procedure' 'with'
 'Rutherford' 'Category' '4' ',' '5' 'or' '6']","[0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02479230,"1:18:treatment,",Prior GEM therapy is acceptable as long as the last dose was ≥ 3 months from registration on this study,"['Prior' 'GEM' 'therapy' 'is' 'acceptable' 'as' 'long' 'as' 'the' 'last'
 'dose' 'was' '≥' '3' 'months' 'from' 'registration' 'on' 'this' 'study']",[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02478684,1:21:chronic_disease,Terminal bradycardia,['Terminal' 'bradycardia'],[2. 2.]
NCT02477839,16:42:chronic_disease,Subject has an arrhythmic heart condition requiring medical therapy,"['Subject' 'has' 'an' 'arrhythmic' 'heart' 'condition' 'requiring'
 'medical' 'therapy']",[0. 0. 0. 2. 2. 2. 0. 0. 0.]
NCT02476786,21:53:treatment,Currently receiving any other investigational agents,['Currently' 'receiving' 'any' 'other' 'investigational' 'agents'],[0. 0. 1. 1. 1. 1.]
NCT02476409,20:33:treatment,Daily oral dose of loop diuretic,['Daily' 'oral' 'dose' 'of' 'loop' 'diuretic'],[0. 0. 0. 0. 1. 1.]
NCT02476409,15:39:chronic_disease,Patients with symptomatic hyponatremia will be excluded from the study,"['Patients' 'with' 'symptomatic' 'hyponatremia' 'will' 'be' 'excluded'
 'from' 'the' 'study']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02475707,44:102:treatment,Only patients who receive infusions in the integrated Cell and Gene Therapy (CAGT) Transplant program at Texas Children's Hospital (TCH) or Houston Methodist Hospital (HMH),"['Only' 'patients' 'who' 'receive' 'infusions' 'in' 'the' 'integrated'
 'Cell' 'and' 'Gene' 'Therapy' '(' 'CAGT' ')' 'Transplant' 'program' 'at'
 'Texas' 'Children' ""'s"" 'Hospital' '(' 'TCH' ')' 'or' 'Houston'
 'Methodist' 'Hospital' '(' 'HMH' ')']","[0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02474667,",43:67:treatment",Must have a negative serum pregnancy test prior to transplantation,"['Must' 'have' 'a' 'negative' 'serum' 'pregnancy' 'test' 'prior' 'to'
 'transplantation']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02474667,23:39:chronic_disease,Signs and symptoms of volume depletion,['Signs' 'and' 'symptoms' 'of' 'volume' 'depletion'],[0. 0. 0. 0. 2. 2.]
NCT02474368,1:13:treatment,Cyclosporine,['Cyclosporine'],[1.]
NCT02474199,",,54:80:treatment",Clinical evidence of viral syndrome less than 7 days prior to darTregs infusion,"['Clinical' 'evidence' 'of' 'viral' 'syndrome' 'less' 'than' '7' 'days'
 'prior' 'to' 'darTregs' 'infusion']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1.]
NCT02474199,1:26:chronic_disease,primary biliary cirrhosis,['primary' 'biliary' 'cirrhosis'],[2. 2. 2.]
NCT02473536,22:44:treatment,Patient eligible for IVC tumor thrombectomy as decided by the treating urologist,"['Patient' 'eligible' 'for' 'IVC' 'tumor' 'thrombectomy' 'as' 'decided'
 'by' 'the' 'treating' 'urologist']",[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02473354,30:42:chronic_disease,has a clinically significant abnormal EKG [assessment by PI or delegate],"['has' 'a' 'clinically' 'significant' 'abnormal' 'EKG' '[' 'assessment'
 'by' 'PI' 'or' 'delegate' ']']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02473250,24:51:chronic_disease,Diagnosis of any other major psychiatric disorders,['Diagnosis' 'of' 'any' 'other' 'major' 'psychiatric' 'disorders'],[0. 0. 0. 0. 2. 2. 2.]
NCT02473250,1:23:chronic_disease,autonomic neuropathies,['autonomic' 'neuropathies'],[2. 2.]
NCT02473250,1:17:chronic_disease,endocrinopathies,['endocrinopathies'],[2.]
NCT02472834,27:37:allergy_name,History of allergy to any amino acid compound,['History' 'of' 'allergy' 'to' 'any' 'amino' 'acid' 'compound'],[0. 0. 0. 0. 0. 4. 4. 0.]
NCT02472223,"1:12:treatment,",Eye surgery in the last 3 months,['Eye' 'surgery' 'in' 'the' 'last' '3' 'months'],[1. 1. 0. 0. 0. 0. 0.]
NCT02471911,",52:118:treatment",Patients must have received at least two cycles of anthracycline based chemotherapy administered with curative intent,"['Patients' 'must' 'have' 'received' 'at' 'least' 'two' 'cycles' 'of'
 'anthracycline' 'based' 'chemotherapy' 'administered' 'with' 'curative'
 'intent']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1.]
NCT02471430,12:73:treatment,History of solid organ transplantation with an existing functional graft,"['History' 'of' 'solid' 'organ' 'transplantation' 'with' 'an' 'existing'
 'functional' 'graft']",[0. 0. 1. 1. 1. 1. 1. 1. 1. 1.]
NCT02471430,29:61:chronic_disease,past or current evidence of immunologically mediated disease,"['past' 'or' 'current' 'evidence' 'of' 'immunologically' 'mediated'
 'disease']",[0. 0. 0. 0. 0. 2. 2. 2.]
NCT02469857,"1:32:chronic_disease,,",Chronic neurological impairment that leads to a neuro mSOFA component ≥2,"['Chronic' 'neurological' 'impairment' 'that' 'leads' 'to' 'a' 'neuro'
 'mSOFA' 'component' '≥2']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02469662,97:111:chronic_disease,Instability or loss of motion when the degree of joint or soft tissue damage precludes reliable osteosynthesis,"['Instability' 'or' 'loss' 'of' 'motion' 'when' 'the' 'degree' 'of'
 'joint' 'or' 'soft' 'tissue' 'damage' 'precludes' 'reliable'
 'osteosynthesis']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02469662,12:32:chronic_disease,Patient is mentally incompetent or unable to understand what participation in the study entails,"['Patient' 'is' 'mentally' 'incompetent' 'or' 'unable' 'to' 'understand'
 'what' 'participation' 'in' 'the' 'study' 'entails']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02469129,"22:36:treatment,","Unable to lie in the PET/CT scanner for the time required for scanning, up to 1 hour and 15 min at a time and possibly with arms raised above the head for lung imaging","['Unable' 'to' 'lie' 'in' 'the' 'PET/CT' 'scanner' 'for' 'the' 'time'
 'required' 'for' 'scanning' ',' 'up' 'to' '1' 'hour' 'and' '15' 'min'
 'at' 'a' 'time' 'and' 'possibly' 'with' 'arms' 'raised' 'above' 'the'
 'head' 'for' 'lung' 'imaging']","[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02468778,18:77:treatment,Participation in another clinical study of an investigational drug or device that has not met its primary endpoint,"['Participation' 'in' 'another' 'clinical' 'study' 'of' 'an'
 'investigational' 'drug' 'or' 'device' 'that' 'has' 'not' 'met' 'its'
 'primary' 'endpoint']",[0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02468024,10:42:treatment,No prior intra-thoracic radiation therapy,['No' 'prior' 'intra-thoracic' 'radiation' 'therapy'],[0. 0. 1. 1. 1.]
NCT02467478,"1:29:chronic_disease,,",Chronic Kidney disease (CKD) Stages 1-3,['Chronic' 'Kidney' 'disease' '(' 'CKD' ')' 'Stages' '1-3'],[2. 2. 2. 2. 0. 0. 0. 0.]
NCT02466971,29:80:chronic_disease,Patient does not have known glucose‐6‐phosphate dehydrogenase (G6PD) deficiency (G6PD testing optional),"['Patient' 'does' 'not' 'have' 'known' 'glucose‐6‐phosphate'
 'dehydrogenase' '(' 'G6PD' ')' 'deficiency' '(' 'G6PD' 'testing'
 'optional' ')']",[0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02466750,41:62:treatment,Have any unresolved AE resulting from a previous immunization,"['Have' 'any' 'unresolved' 'AE' 'resulting' 'from' 'a' 'previous'
 'immunization']",[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02466685,18:36:chronic_disease,Individuals with tardive dyskinesia,['Individuals' 'with' 'tardive' 'dyskinesia'],[0. 0. 2. 2.]
NCT02466009,27:40:chronic_disease,"Substance abuse, medical, psychological, or social conditions that may interfere with the subject's participation in the study","['Substance' 'abuse' ',' 'medical' ',' 'psychological' ',' 'or' 'social'
 'conditions' 'that' 'may' 'interfere' 'with' 'the' 'subject' ""'s""
 'participation' 'in' 'the' 'study']",[0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02465268,1:42:cancer,Recurrent or multifocal malignant gliomas,['Recurrent' 'or' 'multifocal' 'malignant' 'gliomas'],[3. 3. 3. 3. 3.]
NCT02465060,50:84:treatment,Registration to Step 0 must occur after stopping prior systemic anti-cancer therapy,"['Registration' 'to' 'Step' '0' 'must' 'occur' 'after' 'stopping' 'prior'
 'systemic' 'anti-cancer' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1.]
NCT02465060,1:29:treatment,low molecular weight heparin is permitted for prophylactic or therapeutic use,"['low' 'molecular' 'weight' 'heparin' 'is' 'permitted' 'for'
 'prophylactic' 'or' 'therapeutic' 'use']",[1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02464969,"1:24:treatment,",Anticoagulant treatment for the index VTE for greater than 7 days prior to randomization,"['Anticoagulant' 'treatment' 'for' 'the' 'index' 'VTE' 'for' 'greater'
 'than' '7' 'days' 'prior' 'to' 'randomization']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02464878,"19:45:treatment,",Administration of live attenuated vaccine(s) within 2 months of enrollment,"['Administration' 'of' 'live' 'attenuated' 'vaccine' '(' 's' ')' 'within'
 '2' 'months' 'of' 'enrollment']",[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02464878,"1:35:chronic_disease,,,",Selective or severe IgA deficiency (levels < 5-7 mg/dL),"['Selective' 'or' 'severe' 'IgA' 'deficiency' '(' 'levels' '<' '5-7'
 'mg/dL' ')']",[2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02464696,22:35:treatment,Contraindications to NIPPV therapy,['Contraindications' 'to' 'NIPPV' 'therapy'],[0. 0. 1. 1.]
NCT02464696,1:6:chronic_disease,Shock,['Shock'],[2.]
NCT02464436,28:30:chronic_disease,Have clinical diagnosis of RP,['Have' 'clinical' 'diagnosis' 'of' 'RP'],[0. 0. 0. 0. 2.]
NCT02463305,14:23:chronic_disease,Diagnosis of severe UC,['Diagnosis' 'of' 'severe' 'UC'],[0. 0. 2. 2.]
NCT02462590,1:46:treatment,percutaneous gastric or jejunal feeding tubes already in situ as per Health Canada guidance,"['percutaneous' 'gastric' 'or' 'jejunal' 'feeding' 'tubes' 'already' 'in'
 'situ' 'as' 'per' 'Health' 'Canada' 'guidance']",[1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02461927,1:28:chronic_disease,Acute narrow-angle glaucoma,['Acute' 'narrow-angle' 'glaucoma'],[2. 2. 2.]
NCT02460835,20:57:allergy_name,known allergies to intravenous iodinated contrast agents,['known' 'allergies' 'to' 'intravenous' 'iodinated' 'contrast' 'agents'],[0. 0. 0. 4. 4. 4. 4.]
NCT02460783,",,56:67:treatment",weight less than or equal to 350 lbs (weight limit for MRI scanner),"['weight' 'less' 'than' 'or' 'equal' 'to' '350' 'lbs' '(' 'weight' 'limit'
 'for' 'MRI' 'scanner' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.]
NCT02458482,38:64:treatment,Patients who have received nebulized bronchodilator medications at either a referring facility or at home will be included,"['Patients' 'who' 'have' 'received' 'nebulized' 'bronchodilator'
 'medications' 'at' 'either' 'a' 'referring' 'facility' 'or' 'at' 'home'
 'will' 'be' 'included']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02458014,"1:30:treatment,",Monoclonal antibodies therapy within 2 weeks before study entry,"['Monoclonal' 'antibodies' 'therapy' 'within' '2' 'weeks' 'before' 'study'
 'entry']",[1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02457832,1:31:treatment,Deep brain stimulator implants,['Deep' 'brain' 'stimulator' 'implants'],[1. 1. 1. 1.]
NCT02457702,1:31:chronic_disease,Portal systemic encephalopathy,['Portal' 'systemic' 'encephalopathy'],[2. 2. 2.]
NCT02456298,1:47:chronic_disease,Unstable or degenerative neurological disorder,['Unstable' 'or' 'degenerative' 'neurological' 'disorder'],[2. 2. 2. 2. 2.]
NCT02453373,8:25:chronic_disease,Active internal bleeding,['Active' 'internal' 'bleeding'],[0. 2. 2.]
NCT02453373,1:25:chronic_disease,Ventricular fibrillation,['Ventricular' 'fibrillation'],[2. 2.]
NCT02452697,34:54:chronic_disease,This may include patients with a mixed chimeric state or disease persistence or at high risk of relapse,"['This' 'may' 'include' 'patients' 'with' 'a' 'mixed' 'chimeric' 'state'
 'or' 'disease' 'persistence' 'or' 'at' 'high' 'risk' 'of' 'relapse']",[0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02452268,"34:72:treatment,",autoimmune event associated with prior ipilimumab (anti-CTLA-4) therapy that has been completely resolved for more than 4 weeks prior to C1D1,"['autoimmune' 'event' 'associated' 'with' 'prior' 'ipilimumab' '('
 'anti-CTLA-4' ')' 'therapy' 'that' 'has' 'been' 'completely' 'resolved'
 'for' 'more' 'than' '4' 'weeks' 'prior' 'to' 'C1D1']",[0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02451982,1:22:chronic_disease,Stage I or II disease,['Stage' 'I' 'or' 'II' 'disease'],[2. 2. 2. 2. 2.]
NCT02451553,",15:92:treatment",#ERROR!,['#' 'ERROR' '!'],[0. 1. 0.]
NCT02451488,15:41:treatment,Scheduled for sentinel lymph node biopsy as part of their standard surgical management,"['Scheduled' 'for' 'sentinel' 'lymph' 'node' 'biopsy' 'as' 'part' 'of'
 'their' 'standard' 'surgical' 'management']",[0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02451436,1:16:chronic_disease,Sleep disorders,['Sleep' 'disorders'],[2. 2.]
NCT02451423,39:63:treatment,Patients may be transfused or receive erythropoietic treatment to meet this criterion,"['Patients' 'may' 'be' 'transfused' 'or' 'receive' 'erythropoietic'
 'treatment' 'to' 'meet' 'this' 'criterion']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0.]
NCT02451423,16:25:treatment,The effects of MPDL3280A on the developing human fetus are unknown,"['The' 'effects' 'of' 'MPDL3280A' 'on' 'the' 'developing' 'human' 'fetus'
 'are' 'unknown']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02451215,1:40:cancer,Atypical teratoid rhabdoid tumor (ATRT),['Atypical' 'teratoid' 'rhabdoid' 'tumor' '(' 'ATRT' ')'],[3. 3. 3. 3. 3. 0. 0.]
NCT02451215,1:11:cancer,Ependymoma,['Ependymoma'],[3.]
NCT02451215,",,17:23:cancer",Grade III or IV glioma,['Grade' 'III' 'or' 'IV' 'glioma'],[0. 0. 0. 0. 3.]
NCT02449980,",,,70:82:chronic_disease",Children ages 5 to 18 with clinical diagnosis of primary spontaneous pneumothorax (symptoms of chest pain and/or shortness of breath and pneumothorax demonstrated on chest radiograph) and no prior history of pneumothorax,"['Children' 'ages' '5' 'to' '18' 'with' 'clinical' 'diagnosis' 'of'
 'primary' 'spontaneous' 'pneumothorax' '(' 'symptoms' 'of' 'chest' 'pain'
 'and/or' 'shortness' 'of' 'breath' 'and' 'pneumothorax' 'demonstrated'
 'on' 'chest' 'radiograph' ')' 'and' 'no' 'prior' 'history' 'of'
 'pneumothorax']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02446886,39:43:allergy_name,Patients with known or new allergy to ACTH,['Patients' 'with' 'known' 'or' 'new' 'allergy' 'to' 'ACTH'],[0. 0. 0. 0. 0. 0. 0. 4.]
NCT02446236,39:95:treatment,Patients who have previously received high-dose chemotherapy with peripheral stem cell support,"['Patients' 'who' 'have' 'previously' 'received' 'high-dose'
 'chemotherapy' 'with' 'peripheral' 'stem' 'cell' 'support']",[0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1.]
NCT02446093,7:39:treatment,other systemic immunosuppressive drugs,['other' 'systemic' 'immunosuppressive' 'drugs'],[0. 1. 1. 1.]
NCT02442622,12:38:treatment,History of cortical steroid injection to affected wrist and/or thumb,"['History' 'of' 'cortical' 'steroid' 'injection' 'to' 'affected' 'wrist'
 'and/or' 'thumb']",[0. 0. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02442323,1:19:cancer,mucinous carcinoma,['mucinous' 'carcinoma'],[3. 3.]
NCT02442297,14:18:cancer,Diagnosis of DIPG,['Diagnosis' 'of' 'DIPG'],[0. 0. 3.]
NCT02442102,10:37:treatment,Expected tracheostomy tube placement while in hospital,['Expected' 'tracheostomy' 'tube' 'placement' 'while' 'in' 'hospital'],[0. 1. 1. 1. 0. 0. 0.]
NCT02441140,27:43:chronic_disease,Known or suspected active pelvic infection,['Known' 'or' 'suspected' 'active' 'pelvic' 'infection'],[0. 0. 0. 0. 2. 2.]
NCT02440815,8:39:treatment,Use of cognitive enhancing medications,['Use' 'of' 'cognitive' 'enhancing' 'medications'],[0. 0. 1. 1. 1.]
NCT02440581,"24:36:treatment,",Planned or anticipated oral surgery within the next 12 months,"['Planned' 'or' 'anticipated' 'oral' 'surgery' 'within' 'the' 'next' '12'
 'months']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02439450,1:35:chronic_disease,Significant cardiovascular disease,['Significant' 'cardiovascular' 'disease'],[2. 2. 2.]
NCT02438995,",25:48:treatment",Less than 6 months from prior Radiation Therapy (Arm 1),"['Less' 'than' '6' 'months' 'from' 'prior' 'Radiation' 'Therapy' '(' 'Arm'
 '1' ')']",[0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0.]
NCT02438371,"1:26:treatment,",prior tocolytic treatment during their pregnancy,['prior' 'tocolytic' 'treatment' 'during' 'their' 'pregnancy'],[1. 1. 1. 0. 0. 0.]
NCT02437773,"16:48:chronic_disease,",No evidence of suicidal intentions or behaviors in the past 6 months,"['No' 'evidence' 'of' 'suicidal' 'intentions' 'or' 'behaviors' 'in' 'the'
 'past' '6' 'months']",[0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT02437110,7:18:allergy_name,Known sulfonamide allergy,['Known' 'sulfonamide' 'allergy'],[0. 4. 0.]
NCT02436070,7:27:chronic_disease,Other chronic lung disease,['Other' 'chronic' 'lung' 'disease'],[0. 2. 2. 2.]
NCT02435667,78:101:chronic_disease,individuals who are able to exercise (i.e. without orthopedic limitations or neuromuscular disorders),"['individuals' 'who' 'are' 'able' 'to' 'exercise' '(' 'i.e' '.' 'without'
 'orthopedic' 'limitations' 'or' 'neuromuscular' 'disorders' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0.]
NCT02434809,45:66:treatment,Deemed unable to safely undergo or tolerate flexible bronchoscopy as per institutional guidelines,"['Deemed' 'unable' 'to' 'safely' 'undergo' 'or' 'tolerate' 'flexible'
 'bronchoscopy' 'as' 'per' 'institutional' 'guidelines']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0.]
NCT02433977,31:49:allergy_name,Intolerance or allergy to the intervention drugs,['Intolerance' 'or' 'allergy' 'to' 'the' 'intervention' 'drugs'],[0. 0. 0. 0. 0. 4. 4.]
NCT02433210,8:34:chronic_disease,Stable arteriovenous (AV) fistula vascular access,['Stable' 'arteriovenous' '(' 'AV' ')' 'fistula' 'vascular' 'access'],[0. 2. 2. 2. 0. 0. 0. 0.]
NCT02431897,12:31:treatment,History of vaginal irradiation,['History' 'of' 'vaginal' 'irradiation'],[0. 0. 1. 1.]
NCT02430077,1:24:chronic_disease,Acute medical illnesses precluding participation in the studies,"['Acute' 'medical' 'illnesses' 'precluding' 'participation' 'in' 'the'
 'studies']",[2. 2. 2. 0. 0. 0. 0. 0.]
NCT02430077,"45:62:treatment,",Use of drugs which can potentially decrease hepatic steatosis during previous 3 months,"['Use' 'of' 'drugs' 'which' 'can' 'potentially' 'decrease' 'hepatic'
 'steatosis' 'during' 'previous' '3' 'months']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0.]
NCT02429830,"32:36:chronic_disease,",Documented typical symptoms of GERD for longer than 6 months,"['Documented' 'typical' 'symptoms' 'of' 'GERD' 'for' 'longer' 'than' '6'
 'months']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 0.]
NCT02429830,1:16:chronic_disease,gastric varices,['gastric' 'varices'],[2. 2.]
NCT02427841,102:110:chronic_disease,History of allergic reactions attributed to compounds of similar chemical or biologic composition to ABRAXANE or other agents used in the study,"['History' 'of' 'allergic' 'reactions' 'attributed' 'to' 'compounds' 'of'
 'similar' 'chemical' 'or' 'biologic' 'composition' 'to' 'ABRAXANE' 'or'
 'other' 'agents' 'used' 'in' 'the' 'study']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02427581,1:44:cancer,Invasive cancer in the contralateral breast,['Invasive' 'cancer' 'in' 'the' 'contralateral' 'breast'],[3. 3. 3. 3. 3. 3.]
NCT02426047,1:15:chronic_disease,Kidney disease,['Kidney' 'disease'],[2. 2.]
NCT02424968,",171:210:treatment","Must be in a state of general good health and have completed a donor evaluation with history, medical examination and standard blood tests within 35 days of starting the hematopoietic cell collection procedure","['Must' 'be' 'in' 'a' 'state' 'of' 'general' 'good' 'health' 'and' 'have'
 'completed' 'a' 'donor' 'evaluation' 'with' 'history' ',' 'medical'
 'examination' 'and' 'standard' 'blood' 'tests' 'within' '35' 'days' 'of'
 'starting' 'the' 'hematopoietic' 'cell' 'collection' 'procedure']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 1. 1. 1.]"
NCT02423876,31:49:treatment,Patients must be eligible for epidural placement,['Patients' 'must' 'be' 'eligible' 'for' 'epidural' 'placement'],[0. 0. 0. 0. 0. 1. 1.]
NCT02423863,26:40:treatment,Persistent toxicity from recent therapy that has not sufficiently resolved in the judgment of the study physician,"['Persistent' 'toxicity' 'from' 'recent' 'therapy' 'that' 'has' 'not'
 'sufficiently' 'resolved' 'in' 'the' 'judgment' 'of' 'the' 'study'
 'physician']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02423525,177:186:treatment,Any history of or concomitant condition that would compromise the patient's ability to comply with the study or interfere with the evaluation of the efficacy and safety of the test drug,"['Any' 'history' 'of' 'or' 'concomitant' 'condition' 'that' 'would'
 'compromise' 'the' 'patient' ""'s"" 'ability' 'to' 'comply' 'with' 'the'
 'study' 'or' 'interfere' 'with' 'the' 'evaluation' 'of' 'the' 'efficacy'
 'and' 'safety' 'of' 'the' 'test' 'drug']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 1.]"
NCT02422641,"1:27:treatment,,,","Partial brain radiotherapy (i.e., less than or equal to 40% of total brain volume) within the last two weeks","['Partial' 'brain' 'radiotherapy' '(' 'i.e.' ',' 'less' 'than' 'or'
 'equal' 'to' '40' '%' 'of' 'total' 'brain' 'volume' ')' 'within' 'the'
 'last' 'two' 'weeks']",[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02421380,10:34:chronic_disease,unstable cardiovascular condition,['unstable' 'cardiovascular' 'condition'],[0. 2. 2.]
NCT02421315,18:39:chronic_disease,Major medical or neurological problems,['Major' 'medical' 'or' 'neurological' 'problems'],[0. 0. 0. 2. 2.]
NCT02421276,11:21:chronic_disease,Confirmed trisomy 21,['Confirmed' 'trisomy' '21'],[0. 2. 2.]
NCT02419560,22:46:treatment,Must be referred for treatment with ibrutinib,['Must' 'be' 'referred' 'for' 'treatment' 'with' 'ibrutinib'],[0. 0. 0. 0. 1. 1. 1.]
NCT02419495,18:54:treatment,must have failed prior standard curative chemotherapy for their disease,"['must' 'have' 'failed' 'prior' 'standard' 'curative' 'chemotherapy' 'for'
 'their' 'disease']",[0. 0. 0. 1. 1. 1. 1. 0. 0. 0.]
NCT02418195,12:24:chronic_disease,Autoimmune polymyositis,['Autoimmune' 'polymyositis'],[0. 2.]
NCT02418195,14:17:chronic_disease,Diagnosis of MDE as determined by the MINI (MDD participants),"['Diagnosis' 'of' 'MDE' 'as' 'determined' 'by' 'the' 'MINI' '(' 'MDD'
 'participants' ')']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02418195,1:21:chronic_disease,Polyarteritis nodosa,['Polyarteritis' 'nodosa'],[2. 2.]
NCT02418195,1:20:chronic_disease,Transverse myelitis,['Transverse' 'myelitis'],[2. 2.]
NCT02417701,45:119:allergy_name,History of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228),"['History' 'of' 'allergic' 'reactions' 'attributed' 'to' 'compounds' 'of'
 'similar' 'chemical' 'or' 'biologic' 'composition' 'to' 'MLN0128' '('
 'TAK-228' ')']",[0. 0. 0. 0. 0. 0. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 0. 0.]
NCT02416206,"66:70:treatment,",Availability of Cryopreserved peripheral blood stem cells with a CD34 dose of at least 2x106/kg,"['Availability' 'of' 'Cryopreserved' 'peripheral' 'blood' 'stem' 'cells'
 'with' 'a' 'CD34' 'dose' 'of' 'at' 'least' '2x106/kg']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02415556,1:25:chronic_disease,Serious systemic disease that would interfere with conduction of clinical trial,"['Serious' 'systemic' 'disease' 'that' 'would' 'interfere' 'with'
 'conduction' 'of' 'clinical' 'trial']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02414607,33:52:allergy_name,Known history of sensitivity to elderberry products,['Known' 'history' 'of' 'sensitivity' 'to' 'elderberry' 'products'],[0. 0. 0. 0. 0. 4. 4.]
NCT02414139,20:69:treatment,Patients receiving treatment with any enzyme-inducing anticonvulsant,"['Patients' 'receiving' 'treatment' 'with' 'any' 'enzyme-inducing'
 'anticonvulsant']",[0. 0. 1. 1. 1. 1. 1.]
NCT02412540,"16:25:treatment,",Stable dose of vitamin E that was started 12 months or more prior to biopsy is allowed,"['Stable' 'dose' 'of' 'vitamin' 'E' 'that' 'was' 'started' '12' 'months'
 'or' 'more' 'prior' 'to' 'biopsy' 'is' 'allowed']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02411773,1:20:chronic_disease,Diabetic Neuropathy,['Diabetic' 'Neuropathy'],[2. 2.]
NCT02411656,45:78:treatment,Is currently participating in a study of an investigational anti-cancer agent,"['Is' 'currently' 'participating' 'in' 'a' 'study' 'of' 'an'
 'investigational' 'anti-cancer' 'agent']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02409888,47:80:treatment,individuals reporting current enrollment in a substance abuse treatment program,"['individuals' 'reporting' 'current' 'enrollment' 'in' 'a' 'substance'
 'abuse' 'treatment' 'program']",[0. 0. 0. 0. 0. 0. 1. 1. 1. 1.]
NCT02408861,"1:12:cancer,,,",Solid Tumor Expansion Cohort: CD4+ cell count greater than 200 cells/mm^3 obtained within 2 weeks prior to enrollment at any U.S. laboratory that has a clinical laboratory improvement amendments (CLIA) certification or its equivalent,"['Solid' 'Tumor' 'Expansion' 'Cohort' ':' 'CD4+' 'cell' 'count' 'greater'
 'than' '200' 'cells/mm^3' 'obtained' 'within' '2' 'weeks' 'prior' 'to'
 'enrollment' 'at' 'any' 'U.S.' 'laboratory' 'that' 'has' 'a' 'clinical'
 'laboratory' 'improvement' 'amendments' '(' 'CLIA' ')' 'certification'
 'or' 'its' 'equivalent']","[3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02408120,"18:42:chronic_disease,",Known history of Type 2 diabetes mellitus for >3 months,"['Known' 'history' 'of' 'Type' '2' 'diabetes' 'mellitus' 'for' '>' '3'
 'months']",[0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0.]
NCT02408120,1:16:treatment,insulin therapy,['insulin' 'therapy'],[1. 1.]
NCT02407028,39:46:chronic_disease,Coma suspected to de due to primarily non-TBI causes,['Coma' 'suspected' 'to' 'de' 'due' 'to' 'primarily' 'non-TBI' 'causes'],[0. 0. 0. 0. 0. 0. 0. 2. 0.]
NCT02406885,13:27:treatment,Inducers of p-glycoprotein,['Inducers' 'of' 'p-glycoprotein'],[0. 0. 1.]
NCT02406599,1:30:treatment,Neo-adjuvant systemic therapy,['Neo-adjuvant' 'systemic' 'therapy'],[1. 1. 1.]
NCT02405078,"16:65:treatment,",Negative serum beta-human chorionic gonadotropin (beta-hCG) test (women of childbearing potential only),"['Negative' 'serum' 'beta-human' 'chorionic' 'gonadotropin' '(' 'beta-hCG'
 ')' 'test' '(' 'women' 'of' 'childbearing' 'potential' 'only' ')']",[0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02404155,9:36:cancer,Current treated or untreated cancer,['Current' 'treated' 'or' 'untreated' 'cancer'],[0. 3. 3. 3. 3.]
NCT02404155,12:27:chronic_disease,History of paralytic ileus,['History' 'of' 'paralytic' 'ileus'],[0. 0. 2. 2.]
NCT02404012,"17:32:treatment,",Subject has had parenteral iron less than one month before screening visit,"['Subject' 'has' 'had' 'parenteral' 'iron' 'less' 'than' 'one' 'month'
 'before' 'screening' 'visit']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02403193,30:46:cancer,Symptomatic and/or untreated Brain Metastases,['Symptomatic' 'and/or' 'untreated' 'Brain' 'Metastases'],[0. 0. 0. 3. 3.]
NCT02402907,24:40:treatment,unplanned or emergency cesarean section,['unplanned' 'or' 'emergency' 'cesarean' 'section'],[0. 0. 0. 1. 1.]
NCT02401347,1:49:cancer,Brain or central nervous system (CNS) metastases,['Brain' 'or' 'central' 'nervous' 'system' '(' 'CNS' ')' 'metastases'],[3. 3. 3. 3. 3. 3. 3. 0. 0.]
NCT02401074,"1:16:chronic_disease,",Unstable asthma as indicated by self report of increased symptoms or increased beta-agonist use over the 2 weeks preceding the screening visit,"['Unstable' 'asthma' 'as' 'indicated' 'by' 'self' 'report' 'of'
 'increased' 'symptoms' 'or' 'increased' 'beta-agonist' 'use' 'over' 'the'
 '2' 'weeks' 'preceding' 'the' 'screening' 'visit']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02400554,",19:38:chronic_disease",Women who exhibit serious psychiatric symptoms determined by CNO trained staff,"['Women' 'who' 'exhibit' 'serious' 'psychiatric' 'symptoms' 'determined'
 'by' 'CNO' 'trained' 'staff']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02400463,25:41:cancer,tissue demonstration of hemophagocytosis,['tissue' 'demonstration' 'of' 'hemophagocytosis'],[0. 0. 0. 3.]
NCT02398773,44:70:treatment,"Patient is not now, and never has received adjuvant endocrine therapy OR patient is currently receiving or has received adjuvant endocrine therapy in the past","['Patient' 'is' 'not' 'now' ',' 'and' 'never' 'has' 'received' 'adjuvant'
 'endocrine' 'therapy' 'OR' 'patient' 'is' 'currently' 'receiving' 'or'
 'has' 'received' 'adjuvant' 'endocrine' 'therapy' 'in' 'the' 'past']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02398240,",,36:39:treatment",Females who are pregnant (positive HCG),['Females' 'who' 'are' 'pregnant' '(' 'positive' 'HCG' ')'],[0. 0. 0. 0. 0. 0. 1. 0.]
NCT02397889,",,100:120:treatment",Women of childbearing potential must have a negative pregnancy test at screening and prior to each intravenous infusion,"['Women' 'of' 'childbearing' 'potential' 'must' 'have' 'a' 'negative'
 'pregnancy' 'test' 'at' 'screening' 'and' 'prior' 'to' 'each'
 'intravenous' 'infusion']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02397083,9:22:chronic_disease,Genital actinomycosis,['Genital' 'actinomycosis'],[0. 2.]
NCT02395614,11:25:treatment,bilateral reconstruction using other techniques,['bilateral' 'reconstruction' 'using' 'other' 'techniques'],[0. 1. 0. 0. 0.]
NCT02395393,35:58:treatment,to be unable to safely tolerate a bronchoscopic procedure,"['to' 'be' 'unable' 'to' 'safely' 'tolerate' 'a' 'bronchoscopic'
 'procedure']",[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02394704,1:20:chronic_disease,Psychotic disorders,['Psychotic' 'disorders'],[2. 2.]
NCT02394535,17:25:treatment,low dose (1 mg) Coumadin is allowed,['low' 'dose' '(' '1' 'mg' ')' 'Coumadin' 'is' 'allowed'],[0. 0. 0. 0. 0. 0. 1. 0. 0.]
NCT02394028,"1:17:treatment,",anti-TNF therapy within 5 years from screening,['anti-TNF' 'therapy' 'within' '5' 'years' 'from' 'screening'],[1. 1. 0. 0. 0. 0. 0.]
NCT02393885,1:24:chronic_disease,Refractory hypertension,['Refractory' 'hypertension'],[2. 2.]
NCT02393794,"1:25:chronic_disease,,","ncontrolled hypertension, i.e., blood pressure (BP) of ≥ 160/95","['ncontrolled' 'hypertension' ',' 'i.e.' ',' 'blood' 'pressure' '(' 'BP'
 ')' 'of' '≥' '160/95']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02393690,35:53:chronic_disease,"For patients with non-measurable, structural disease","['For' 'patients' 'with' 'non-measurable' ',' 'structural' 'disease']",[0. 0. 0. 0. 0. 2. 2.]
NCT02393157,1:17:cancer,Burkitt Lymphoma,['Burkitt' 'Lymphoma'],[3. 3.]
NCT02393157,56:94:cancer,Patients in first relapse or primary induction failure CD20 positive B-cell leukemia/lymphoma,"['Patients' 'in' 'first' 'relapse' 'or' 'primary' 'induction' 'failure'
 'CD20' 'positive' 'B-cell' 'leukemia/lymphoma']",[0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3.]
NCT02393157,1:34:treatment,Prior solid organ transplantation,['Prior' 'solid' 'organ' 'transplantation'],[1. 1. 1. 1.]
NCT02392286,6:27:chronic_disease,NYHA Class 4 heart failure,['NYHA' 'Class' '4' 'heart' 'failure'],[0. 2. 2. 2. 2.]
NCT02390752,30:33:chronic_disease,A first-degree relative with NF1,['A' 'first-degree' 'relative' 'with' 'NF1'],[0. 0. 0. 0. 2.]
NCT02390752,28:36:cancer,"Histologic confirmation of PN tumor is not necessary in the presence of consistent clinical and radiographic findings, but should be considered if malignant degeneration of a PN is clinically suspected","['Histologic' 'confirmation' 'of' 'PN' 'tumor' 'is' 'not' 'necessary' 'in'
 'the' 'presence' 'of' 'consistent' 'clinical' 'and' 'radiographic'
 'findings' ',' 'but' 'should' 'be' 'considered' 'if' 'malignant'
 'degeneration' 'of' 'a' 'PN' 'is' 'clinically' 'suspected']","[0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02390752,1:21:cancer,Optic pathway glioma are located in the optic pathway and are typically hypo- or iso-intense on T1 and hyperintense on T2-weighted images,"['Optic' 'pathway' 'glioma' 'are' 'located' 'in' 'the' 'optic' 'pathway'
 'and' 'are' 'typically' 'hypo-' 'or' 'iso-intense' 'on' 'T1' 'and'
 'hyperintense' 'on' 'T2-weighted' 'images']",[3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02390752,"25:42:chronic_disease,,","patients with confirmed Gilberts syndrome, the TBil should be less than or equal to 1.5 (SqrRoot) ULN","['patients' 'with' 'confirmed' 'Gilberts' 'syndrome' ',' 'the' 'TBil'
 'should' 'be' 'less' 'than' 'or' 'equal' 'to' '1.5' '(' 'SqrRoot' ')'
 'ULN']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02389517,",,38:53:treatment",Diarrhea > grade 1 in the absence of anti-diarrheals,['Diarrhea' '>' 'grade' '1' 'in' 'the' 'absence' 'of' 'anti-diarrheals'],[0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02389023,1:21:treatment,Infrainguinal bypass without a groin incision including popliteal-tibial or pedal bypass,"['Infrainguinal' 'bypass' 'without' 'a' 'groin' 'incision' 'including'
 'popliteal-tibial' 'or' 'pedal' 'bypass']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02387905,14:30:chronic_disease,Patents with cord compression,['Patents' 'with' 'cord' 'compression'],[0. 0. 2. 2.]
NCT02387216,",13:52:treatment",Received >2 prior systemic anti-cancer drug regimen for locally advanced disease,"['Received' '>' '2' 'prior' 'systemic' 'anti-cancer' 'drug' 'regimen'
 'for' 'locally' 'advanced' 'disease']",[0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0.]
NCT02383979,15:34:treatment,scheduled for elective amputation,['scheduled' 'for' 'elective' 'amputation'],[0. 0. 1. 1.]
NCT02382549,1:14:treatment,MEK inhibitor,['MEK' 'inhibitor'],[1. 1.]
NCT02382549,29:48:chronic_disease,Participants with an active autoimmune disorder requiring these therapies are also excluded,"['Participants' 'with' 'an' 'active' 'autoimmune' 'disorder' 'requiring'
 'these' 'therapies' 'are' 'also' 'excluded']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02382419,8:22:chronic_disease,Active genital ulcers,['Active' 'genital' 'ulcers'],[0. 2. 2.]
NCT02379156,20:43:allergy_name,Known allergies to midodrine hydrochloride,['Known' 'allergies' 'to' 'midodrine' 'hydrochloride'],[0. 0. 0. 4. 4.]
NCT02378714,27:56:chronic_disease,medications indicated for bipolar or psychotic disorder if prescribed for bipolar or psychotic disorder,"['medications' 'indicated' 'for' 'bipolar' 'or' 'psychotic' 'disorder'
 'if' 'prescribed' 'for' 'bipolar' 'or' 'psychotic' 'disorder']",[0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02378428,18:38:treatment,Have undergone a prior allogeneic BMT,['Have' 'undergone' 'a' 'prior' 'allogeneic' 'BMT'],[0. 0. 0. 1. 1. 1.]
NCT02376205,",19:33:treatment",More than 2-level ACDF surgeries,['More' 'than' '2-level' 'ACDF' 'surgeries'],[0. 0. 0. 1. 1.]
NCT02376153,1:39:treatment,vascular prosthetic graft implantation,['vascular' 'prosthetic' 'graft' 'implantation'],[1. 1. 1. 1.]
NCT02374333,114:128:treatment,beyond 1st CR with relapsed or persistent disease and not eligible or appropriate for conventional allogeneic or autologous SCT,"['beyond' '1st' 'CR' 'with' 'relapsed' 'or' 'persistent' 'disease' 'and'
 'not' 'eligible' 'or' 'appropriate' 'for' 'conventional' 'allogeneic'
 'or' 'autologous' 'SCT']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02374021,"1:16:treatment,,,",MTX monotherapy for ≥ 8 weeks at ≥ 15mg weekly or ≥ 7.5 mg weekly with a documented intolerance to higher doses,"['MTX' 'monotherapy' 'for' '≥' '8' 'weeks' 'at' '≥' '15mg' 'weekly' 'or'
 '≥' '7.5' 'mg' 'weekly' 'with' 'a' 'documented' 'intolerance' 'to'
 'higher' 'doses']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02374021,1:22:chronic_disease,demyelinating disease,['demyelinating' 'disease'],[2. 2.]
NCT02373644,1:17:treatment,ASIS compression,['ASIS' 'compression'],[1. 1.]
NCT02373644,21:43:chronic_disease,Patient must report sacroiliac dysfunction,['Patient' 'must' 'report' 'sacroiliac' 'dysfunction'],[0. 0. 0. 2. 2.]
NCT02370732,19:51:treatment,In evaluation for Roux-en-Y gastric bypass surgery,['In' 'evaluation' 'for' 'Roux-en-Y' 'gastric' 'bypass' 'surgery'],[0. 0. 0. 1. 1. 1. 1.]
NCT02370095,15:26:treatment,Patient has a tracheotomy,['Patient' 'has' 'a' 'tracheotomy'],[0. 0. 0. 1.]
NCT02370056,1:27:treatment,Segmental colon resections,['Segmental' 'colon' 'resections'],[1. 1. 1.]
NCT02369770,1:15:chronic_disease,Pressure ulcer,['Pressure' 'ulcer'],[2. 2.]
NCT02369406,1:16:treatment,Hospitalization for severe medical illness,['Hospitalization' 'for' 'severe' 'medical' 'illness'],[1. 0. 0. 0. 0.]
NCT02367040,38:94:treatment,Documented evidence of resistance to prior treatment with idelalisib or other PI3K inhibitors,"['Documented' 'evidence' 'of' 'resistance' 'to' 'prior' 'treatment' 'with'
 'idelalisib' 'or' 'other' 'PI3K' 'inhibitors']",[0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 1.]
NCT02367040,"1:32:cancer,,",Small lymphocytic lymphoma(SLL) with absolute lymphocyte count <5x10*9/L at study entry,"['Small' 'lymphocytic' 'lymphoma' '(' 'SLL' ')' 'with' 'absolute'
 'lymphocyte' 'count' '<' '5x10' '*' '9/L' 'at' 'study' 'entry']",[3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02366871,1:28:chronic_disease,antithrombin III deficiency,['antithrombin' 'III' 'deficiency'],[2. 2. 2.]
NCT02366871,11:27:chronic_disease,potential bleeding lesions,['potential' 'bleeding' 'lesions'],[0. 2. 2.]
NCT02366819,"1:9:chronic_disease,","Diarrhea, grade 1 or greater by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, version [v] 4.0)","['Diarrhea' ',' 'grade' '1' 'or' 'greater' 'by' 'the' 'National' 'Cancer'
 'Institute' 'Common' 'Terminology' 'Criteria' 'for' 'Adverse' 'Events'
 '(' 'NCI-CTCAE' ',' 'version' '[' 'v' ']' '4.0' ')']","[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02365766,1:26:cancer,Clinical stage cT2-4aN0M0,['Clinical' 'stage' 'cT2-4aN0M0'],[3. 3. 3.]
NCT02365467,51:68:allergy_name,Subject has a known allergy or intolerance to the device components,"['Subject' 'has' 'a' 'known' 'allergy' 'or' 'intolerance' 'to' 'the'
 'device' 'components']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 4.]
NCT02365467,",,215:244:treatment",Subject has circumferential calcification in the external iliac artery or in the common iliac artery with an intraluminal diameter (ID) less than 10mm at any point proximal to or at the access vessel site unless a surgical adjunctive procedure is planned,"['Subject' 'has' 'circumferential' 'calcification' 'in' 'the' 'external'
 'iliac' 'artery' 'or' 'in' 'the' 'common' 'iliac' 'artery' 'with' 'an'
 'intraluminal' 'diameter' '(' 'ID' ')' 'less' 'than' '10mm' 'at' 'any'
 'point' 'proximal' 'to' 'or' 'at' 'the' 'access' 'vessel' 'site' 'unless'
 'a' 'surgical' 'adjunctive' 'procedure' 'is' 'planned']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0.]"
NCT02365467,44:72:treatment,Subject must be considered a candidate for revascularization of the LSA,"['Subject' 'must' 'be' 'considered' 'a' 'candidate' 'for'
 'revascularization' 'of' 'the' 'LSA']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1.]
NCT02362308,13:31:chronic_disease,Biochemical hyperaldosteronism,['Biochemical' 'hyperaldosteronism'],[0. 2.]
NCT02362308,"1:55:treatment,,",Treatment with chronic systemic glucocorticoid therapy (more than 7 consecutive days in 1 month),"['Treatment' 'with' 'chronic' 'systemic' 'glucocorticoid' 'therapy' '('
 'more' 'than' '7' 'consecutive' 'days' 'in' '1' 'month' ')']",[1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02361554,"29:84:treatment,",Subject has participated in another investigational drug trial or therapeutic trial within 30 days of Baseline Visit,"['Subject' 'has' 'participated' 'in' 'another' 'investigational' 'drug'
 'trial' 'or' 'therapeutic' 'trial' 'within' '30' 'days' 'of' 'Baseline'
 'Visit']",[0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02360579,1:44:treatment,Intrauterine hormone-releasing system (IUS),['Intrauterine' 'hormone-releasing' 'system' '(' 'IUS' ')'],[1. 1. 1. 1. 0. 0.]
NCT02359864,36:58:treatment,Patient currently participating in another Clinical Trial,['Patient' 'currently' 'participating' 'in' 'another' 'Clinical' 'Trial'],[0. 0. 0. 0. 1. 1. 1.]
NCT02359825,",47:61:treatment",repair within 48 hours of injury that require nerve grafting,"['repair' 'within' '48' 'hours' 'of' 'injury' 'that' 'require' 'nerve'
 'grafting']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02359097,66:84:cancer,Subjects must have a known or presumed radiological diagnosis of glioblastoma (GBM),"['Subjects' 'must' 'have' 'a' 'known' 'or' 'presumed' 'radiological'
 'diagnosis' 'of' 'glioblastoma' '(' 'GBM' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0.]
NCT02358681,31:40:treatment,Contraindication to receiving ketorolac,['Contraindication' 'to' 'receiving' 'ketorolac'],[0. 0. 0. 1.]
NCT02357784,16:44:chronic_disease,diagnosed with idiopathic dual incontinence,['diagnosed' 'with' 'idiopathic' 'dual' 'incontinence'],[0. 0. 2. 2. 2.]
NCT02357784,36:58:treatment,planning to undergo placement of a sacral nerve modulator,"['planning' 'to' 'undergo' 'placement' 'of' 'a' 'sacral' 'nerve'
 'modulator']",[0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02356848,1:22:treatment,Prior foot amputation,['Prior' 'foot' 'amputation'],[1. 1. 1.]
NCT02356653,9:18:cancer,Chronic leukemias,['Chronic' 'leukemias'],[0. 3.]
NCT02355912,1:20:treatment,Lower Limb Amputees,['Lower' 'Limb' 'Amputees'],[1. 1. 1.]
NCT02355535,1:8:cancer,Gliomas,['Gliomas'],[3.]
NCT02355002,"46:51:treatment,","Use of other psychotropic medications (e.g., SSRIs) will be allowed provided the dose has been stable for > 12 weeks","['Use' 'of' 'other' 'psychotropic' 'medications' '(' 'e.g.' ',' 'SSRIs'
 ')' 'will' 'be' 'allowed' 'provided' 'the' 'dose' 'has' 'been' 'stable'
 'for' '>' '12' 'weeks']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02354703,",,,,,201:228:chronic_disease","Evidence of hepatic failure and/or ascites, prolonged prothrombin time (International Normalized Ratio [INR] > or = 1.7), bilirubin >10% above the upper limit of the central lab's normal range and/or esophageal variceal disease","['Evidence' 'of' 'hepatic' 'failure' 'and/or' 'ascites' ',' 'prolonged'
 'prothrombin' 'time' '(' 'International' 'Normalized' 'Ratio' '[' 'INR'
 ']' '>' 'or' '=' '1.7' ')' ',' 'bilirubin' '>' '10' '%' 'above' 'the'
 'upper' 'limit' 'of' 'the' 'central' 'lab' ""'s"" 'normal' 'range' 'and/or'
 'esophageal' 'variceal' 'disease']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2.]"
NCT02354547,",43:68:treatment",At least 14 days after the last dose of a long-acting growth factor,"['At' 'least' '14' 'days' 'after' 'the' 'last' 'dose' 'of' 'a'
 'long-acting' 'growth' 'factor']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02354547,15:50:cancer,Patients with relapsed or refractory solid tumors,['Patients' 'with' 'relapsed' 'or' 'refractory' 'solid' 'tumors'],[0. 0. 3. 3. 3. 3. 3.]
NCT02353728,"32:44:chronic_disease,",Clinically significant resting brachycardia (<50 beats per minute),"['Clinically' 'significant' 'resting' 'brachycardia' '(' '<' '50' 'beats'
 'per' 'minute' ')']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02353728,"1:44:treatment,",Treatment with other investigational agents within 30 days of Day 1,"['Treatment' 'with' 'other' 'investigational' 'agents' 'within' '30'
 'days' 'of' 'Day' '1']",[1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02352025,53:83:treatment,Patient may not be concurrently enrolled in another investigational drug treatment study,"['Patient' 'may' 'not' 'be' 'concurrently' 'enrolled' 'in' 'another'
 'investigational' 'drug' 'treatment' 'study']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0.]
NCT02351544,15:33:chronic_disease,Patients with episodic migraines,['Patients' 'with' 'episodic' 'migraines'],[0. 0. 2. 2.]
NCT02350764,57:85:treatment,There is no restriction on the number of prior lines of systemic anti-cancer therapy,"['There' 'is' 'no' 'restriction' 'on' 'the' 'number' 'of' 'prior' 'lines'
 'of' 'systemic' 'anti-cancer' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02349867,1:15:treatment,Anticoagulants at therapeutic doses,['Anticoagulants' 'at' 'therapeutic' 'doses'],[1. 0. 0. 0.]
NCT02349035,3:24:treatment,A upper limb amputation at the transradial level,['A' 'upper' 'limb' 'amputation' 'at' 'the' 'transradial' 'level'],[0. 1. 1. 1. 0. 0. 0. 0.]
NCT02347891,",,,,,,124:148:treatment","Clinically significant elevation of GGT (>1.5xULN), bilirubin (>1.25xULN, direct 35%), or INR (>1.2, excluding patients on anti-coagulant therapies) or other clinically significant abnormal laboratory value in the opinion of the investigator","['Clinically' 'significant' 'elevation' 'of' 'GGT' '(' '>' '1.5xULN' ')'
 ',' 'bilirubin' '(' '>' '1.25xULN' ',' 'direct' '35' '%' ')' ',' 'or'
 'INR' '(' '>' '1.2' ',' 'excluding' 'patients' 'on' 'anti-coagulant'
 'therapies' ')' 'or' 'other' 'clinically' 'significant' 'abnormal'
 'laboratory' 'value' 'in' 'the' 'opinion' 'of' 'the' 'investigator']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02347891,"17:51:treatment,,",Have received a non-biologic investigational agent within 30 days or 5 half-lives of the agent (whichever is longer) prior to Screening,"['Have' 'received' 'a' 'non-biologic' 'investigational' 'agent' 'within'
 '30' 'days' 'or' '5' 'half-lives' 'of' 'the' 'agent' '(' 'whichever' 'is'
 'longer' ')' 'prior' 'to' 'Screening']",[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02347202,76:79:treatment,for counselors to be research participants in both the pilot study and the RCT,"['for' 'counselors' 'to' 'be' 'research' 'participants' 'in' 'both' 'the'
 'pilot' 'study' 'and' 'the' 'RCT']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02347111,23:42:chronic_disease,History of typical or lone symptomatic AF,['History' 'of' 'typical' 'or' 'lone' 'symptomatic' 'AF'],[0. 0. 0. 0. 2. 2. 2.]
NCT02346929,1:21:chronic_disease,High acuity/distress per the Attending ED physician,['High' 'acuity/distress' 'per' 'the' 'Attending' 'ED' 'physician'],[2. 2. 0. 0. 0. 0. 0.]
NCT02346526,"10:31:treatment,",Received previous radiotherapy to approximately >25% of bone marrow,"['Received' 'previous' 'radiotherapy' 'to' 'approximately' '>' '25' '%'
 'of' 'bone' 'marrow']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02346201,"24:30:chronic_disease,",Clinically significant apathy for at least four weeks for which either,"['Clinically' 'significant' 'apathy' 'for' 'at' 'least' 'four' 'weeks'
 'for' 'which' 'either']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02344355,",33:42:treatment",Tolerate one test dose (15g) of ascorbate,['Tolerate' 'one' 'test' 'dose' '(' '15g' ')' 'of' 'ascorbate'],[0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02343549,"19:38:treatment,",Inability to wear NovoTTF-100A System for an average of 18 hours per 24 hours,"['Inability' 'to' 'wear' 'NovoTTF-100A' 'System' 'for' 'an' 'average' 'of'
 '18' 'hours' 'per' '24' 'hours']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02343549,11:21:cancer,localized basal cell,['localized' 'basal' 'cell'],[0. 3. 3.]
NCT02343042,1:14:cancer,Smoldering MM,['Smoldering' 'MM'],[3. 3.]
NCT02342808,"1:11:chronic_disease,,",Severe CKD (eGFR <40 ml/min/1.73m2),['Severe' 'CKD' '(' 'eGFR' '<' '40' 'ml/min/1.73m2' ')'],[2. 2. 0. 0. 0. 0. 0. 0.]
NCT02342782,",,,174:179:cancer",Serum glutamic oxaloacetic transaminase (SGOT) AND serum glutamate pyruvate transaminase (SGPT) < 2 x normal except in cases where abnormal LFTS are due to involvement with T-NHL,"['Serum' 'glutamic' 'oxaloacetic' 'transaminase' '(' 'SGOT' ')' 'AND'
 'serum' 'glutamate' 'pyruvate' 'transaminase' '(' 'SGPT' ')' '<' '2' 'x'
 'normal' 'except' 'in' 'cases' 'where' 'abnormal' 'LFTS' 'are' 'due' 'to'
 'involvement' 'with' 'T-NHL']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 3.]"
NCT02341235,13:31:chronic_disease,Evidence of disease recurrence,['Evidence' 'of' 'disease' 'recurrence'],[0. 0. 2. 2.]
NCT02340156,39:57:allergy_name,Have a history of hypersensitivity to dacarbazine (DTIC),"['Have' 'a' 'history' 'of' 'hypersensitivity' 'to' 'dacarbazine' '('
 'DTIC' ')']",[0. 0. 0. 0. 0. 0. 4. 4. 0. 0.]
NCT02340156,11:25:treatment,Requiring renal dialysis,['Requiring' 'renal' 'dialysis'],[0. 1. 1.]
NCT02339948,",32:36:treatment,",Prostate volume as assessed by TRUS > 60 cc,['Prostate' 'volume' 'as' 'assessed' 'by' 'TRUS' '>' '60' 'cc'],[0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02339922,",,71:91:treatment","Patient has >= grade 2 peripheral neuropathy, or grade 1 with pain on clinical examination during the screening period","['Patient' 'has' '>' '=' 'grade' '2' 'peripheral' 'neuropathy' ',' 'or'
 'grade' '1' 'with' 'pain' 'on' 'clinical' 'examination' 'during' 'the'
 'screening' 'period']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0.]
NCT02339233,1:13:chronic_disease,dysautonomia that would contraindicate standing,['dysautonomia' 'that' 'would' 'contraindicate' 'standing'],[2. 0. 0. 0. 0.]
NCT02339233,1:14:chronic_disease,pressure sore that might interfere with training,['pressure' 'sore' 'that' 'might' 'interfere' 'with' 'training'],[2. 2. 0. 0. 0. 0. 0.]
NCT02338947,"24:52:treatment,","with the indication of myocardial revascularization with ≥2 criteria of frailty by Fried Frailty Criteria, and suitable to undergo either Off-pump or On-pump CABG","['with' 'the' 'indication' 'of' 'myocardial' 'revascularization' 'with'
 '≥2' 'criteria' 'of' 'frailty' 'by' 'Fried' 'Frailty' 'Criteria' ','
 'and' 'suitable' 'to' 'undergo' 'either' 'Off-pump' 'or' 'On-pump' 'CABG']","[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02338232,1:10:treatment,Melphalan 140 mg/m2,['Melphalan' '140' 'mg/m2'],[1. 0. 0.]
NCT02336451,104:128:treatment,Patients must wait for the central laboratory result of the ALK rearrangement status before initiating treatment with ceritinib,"['Patients' 'must' 'wait' 'for' 'the' 'central' 'laboratory' 'result' 'of'
 'the' 'ALK' 'rearrangement' 'status' 'before' 'initiating' 'treatment'
 'with' 'ceritinib']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02335905,1:22:chronic_disease,isseminated infection or is admitted to the pediatric intensive care unit,"['isseminated' 'infection' 'or' 'is' 'admitted' 'to' 'the' 'pediatric'
 'intensive' 'care' 'unit']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02335242,1:11:treatment,Amlodipine,['Amlodipine'],[1.]
NCT02335242,37:40:chronic_disease,Has ulcerated or currently infected LMs,['Has' 'ulcerated' 'or' 'currently' 'infected' 'LMs'],[0. 0. 0. 0. 0. 2.]
NCT02334579,18:48:treatment,High risk group: three hormone therapy regimens,['High' 'risk' 'group' ':' 'three' 'hormone' 'therapy' 'regimens'],[0. 0. 0. 0. 1. 1. 1. 1.]
NCT02333162,40:48:treatment,Since these patients already had first allo-SCT,['Since' 'these' 'patients' 'already' 'had' 'first' 'allo-SCT'],[0. 0. 0. 0. 0. 0. 1.]
NCT02332863,1:4:treatment,EUS evidence of vessel interfering with path of fiducial marker,"['EUS' 'evidence' 'of' 'vessel' 'interfering' 'with' 'path' 'of'
 'fiducial' 'marker']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02332850,39:57:treatment,must be > than four half-lives of the experimental agent,"['must' 'be' '>' 'than' 'four' 'half-lives' 'of' 'the' 'experimental'
 'agent']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02332668,1:9:cancer,Tumor(s) involving the brain stem,['Tumor' '(' 's' ')' 'involving' 'the' 'brain' 'stem'],[3. 3. 3. 3. 3. 3. 3. 3.]
NCT02332369,116:139:treatment,Capsular bag tearing beyond the point where the surgeon thinks it is in the best interest of the patient to have a capsular ring implanted,"['Capsular' 'bag' 'tearing' 'beyond' 'the' 'point' 'where' 'the' 'surgeon'
 'thinks' 'it' 'is' 'in' 'the' 'best' 'interest' 'of' 'the' 'patient' 'to'
 'have' 'a' 'capsular' 'ring' 'implanted']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.
 1.]"
NCT02332369,1:13:chronic_disease,Iris atrophy,['Iris' 'atrophy'],[2. 2.]
NCT02332369,1:21:chronic_disease,Retinal degeneration,['Retinal' 'degeneration'],[2. 2.]
NCT02332291,5:40:chronic_disease,Any physical or intellectual disability adversely affecting ability to complete assessments,"['Any' 'physical' 'or' 'intellectual' 'disability' 'adversely' 'affecting'
 'ability' 'to' 'complete' 'assessments']",[0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02332291,1:35:chronic_disease,generalized anxiety disorder (GAD) symptoms occurring during a depressive episode,"['generalized' 'anxiety' 'disorder' '(' 'GAD' ')' 'symptoms' 'occurring'
 'during' 'a' 'depressive' 'episode']",[2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02329652,36:50:treatment,Disorder or condition that require MRI monitoring,['Disorder' 'or' 'condition' 'that' 'require' 'MRI' 'monitoring'],[0. 0. 0. 0. 0. 1. 1.]
NCT02329327,11:38:treatment,minimally invasive surgery/procedures,['minimally' 'invasive' 'surgery/procedures'],[0. 1. 1.]
NCT02327403,14:41:chronic_disease,active acute antibody-mediated rejection,['active' 'acute' 'antibody-mediated' 'rejection'],[0. 0. 2. 2.]
NCT02327312,1:20:chronic_disease,Open angle Glaucoma,['Open' 'angle' 'Glaucoma'],[2. 2. 2.]
NCT02324582,"1:26:treatment,",Prior monoclonal antibody within 4 weeks prior to study,['Prior' 'monoclonal' 'antibody' 'within' '4' 'weeks' 'prior' 'to' 'study'],[1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02324582,1:26:chronic_disease,substance abuse disorders,['substance' 'abuse' 'disorders'],[2. 2. 2.]
NCT02324439,26:46:chronic_disease,Patients with concurrent uncontrolled illness,['Patients' 'with' 'concurrent' 'uncontrolled' 'illness'],[0. 0. 0. 2. 2.]
NCT02324387,1:18:chronic_disease,nodal involvement (N0 - N3),['nodal' 'involvement' '(' 'N0' '-' 'N3' ')'],[2. 2. 0. 0. 0. 0. 0.]
NCT02323880,",,49:82:treatment",Hemoglobin >= 8.0 g/dL at baseline (may receive red blood cell [RBC] transfusions),"['Hemoglobin' '>' '=' '8.0' 'g/dL' 'at' 'baseline' '(' 'may' 'receive'
 'red' 'blood' 'cell' '[' 'RBC' ']' 'transfusions' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0.]
NCT02323698,12:39:treatment,Undergoing concurrent physical therapy,['Undergoing' 'concurrent' 'physical' 'therapy'],[0. 1. 1. 1.]
NCT02323126,43:63:allergy_name,History of allergy or hypersensitivity to nivolumab components,"['History' 'of' 'allergy' 'or' 'hypersensitivity' 'to' 'nivolumab'
 'components']",[0. 0. 0. 0. 0. 0. 4. 4.]
NCT02323100,"1:14:treatment,",Sinus surgery within 6 weeks of Screening Visit,['Sinus' 'surgery' 'within' '6' 'weeks' 'of' 'Screening' 'Visit'],[1. 1. 0. 0. 0. 0. 0. 0.]
NCT02321501,1:49:treatment,Strong inhibitors or strong inducers of CYP3A4/5,['Strong' 'inhibitors' 'or' 'strong' 'inducers' 'of' 'CYP3A4/5'],[1. 1. 1. 1. 1. 1. 1.]
NCT02320292,28:31:treatment,Meet standard criteria for RIT,['Meet' 'standard' 'criteria' 'for' 'RIT'],[0. 0. 0. 0. 1.]
NCT02319369,",,,,,,180:205:treatment","Has prolongation of corrected QT interval using Fridericia's method (QTcF) at rest, where the mean QTcF interval is > 450 ms for males or > 470 ms for females based on triplicate electrocardiograms (ECGs)","['Has' 'prolongation' 'of' 'corrected' 'QT' 'interval' 'using'
 'Fridericia' ""'s"" 'method' '(' 'QTcF' ')' 'at' 'rest' ',' 'where' 'the'
 'mean' 'QTcF' 'interval' 'is' '>' '450' 'ms' 'for' 'males' 'or' '>' '470'
 'ms' 'for' 'females' 'based' 'on' 'triplicate' 'electrocardiograms' '('
 'ECGs' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.]"
NCT02319369,1:39:treatment,Prior treatment with an MDM2 inhibitor,['Prior' 'treatment' 'with' 'an' 'MDM2' 'inhibitor'],[1. 1. 1. 1. 1. 1.]
NCT02317991,1:25:treatment,Major surgical procedure,['Major' 'surgical' 'procedure'],[1. 1. 1.]
NCT02317523,"1:15:treatment,",Glucocorticoid use in the 2 weeks prior to enrollment,['Glucocorticoid' 'use' 'in' 'the' '2' 'weeks' 'prior' 'to' 'enrollment'],[1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02316886,1:13:treatment,Bypass graft lesion,['Bypass' 'graft' 'lesion'],[1. 1. 0.]
NCT02316574,34:54:chronic_disease,Meets DSM-V criteria for current Alcohol Use Disorder,['Meets' 'DSM-V' 'criteria' 'for' 'current' 'Alcohol' 'Use' 'Disorder'],[0. 0. 0. 0. 0. 2. 2. 2.]
NCT02315612,1:18:cancer,Hyperleukocytosis,['Hyperleukocytosis'],[3.]
NCT02314377,"24:42:chronic_disease,",Clinically significant thrombotic episode within the last 24 weeks,"['Clinically' 'significant' 'thrombotic' 'episode' 'within' 'the' 'last'
 '24' 'weeks']",[0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02314221,14:33:chronic_disease,Diagnosis of neurological injury other than SCI,['Diagnosis' 'of' 'neurological' 'injury' 'other' 'than' 'SCI'],[0. 0. 2. 2. 0. 0. 0.]
NCT02313753,9:27:chronic_disease,Current psychotic symptoms severe enough to impair study participation,"['Current' 'psychotic' 'symptoms' 'severe' 'enough' 'to' 'impair' 'study'
 'participation']",[0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02313428,1:29:treatment,Debridement of infected bone if necessary,['Debridement' 'of' 'infected' 'bone' 'if' 'necessary'],[1. 1. 1. 1. 0. 0.]
NCT02312596,13:21:chronic_disease,Presence of Gangrene,['Presence' 'of' 'Gangrene'],[0. 0. 2.]
NCT02312245,83:110:treatment,Uncontrolled intercurrent illness judged by the treating investigator to preclude treatment with chemotherapy,"['Uncontrolled' 'intercurrent' 'illness' 'judged' 'by' 'the' 'treating'
 'investigator' 'to' 'preclude' 'treatment' 'with' 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02311621,19:41:cancer,Patients may have CNS intracranial tumor,['Patients' 'may' 'have' 'CNS' 'intracranial' 'tumor'],[0. 0. 0. 3. 3. 3.]
NCT02311621,1:20:cancer,Skull based disease with soft tissue extension,['Skull' 'based' 'disease' 'with' 'soft' 'tissue' 'extension'],[3. 3. 3. 0. 0. 0. 0.]
NCT02311361,32:40:cancer,Each case will be discussed at GI tumor board with multidisciplinary team,"['Each' 'case' 'will' 'be' 'discussed' 'at' 'GI' 'tumor' 'board' 'with'
 'multidisciplinary' 'team']",[0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0.]
NCT02310867,79:107:chronic_disease,Inability or unwillingness to comply with protocol monitoring and therapy and immunodeficiency syndrome(s),"['Inability' 'or' 'unwillingness' 'to' 'comply' 'with' 'protocol'
 'monitoring' 'and' 'therapy' 'and' 'immunodeficiency' 'syndrome' '(' 's'
 ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0.]
NCT02310399,"90:111:treatment,",Clear surgical reason for poor CI performance that can be remediated with revision CI or contralateral surgery rather than ABI,"['Clear' 'surgical' 'reason' 'for' 'poor' 'CI' 'performance' 'that' 'can'
 'be' 'remediated' 'with' 'revision' 'CI' 'or' 'contralateral' 'surgery'
 'rather' 'than' 'ABI']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.]
NCT02310399,18:40:treatment,Involvement in a rehabilitation program that emphasizes development of auditory skills with or without the use of supplementary visual communication,"['Involvement' 'in' 'a' 'rehabilitation' 'program' 'that' 'emphasizes'
 'development' 'of' 'auditory' 'skills' 'with' 'or' 'without' 'the' 'use'
 'of' 'supplementary' 'visual' 'communication']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02310399,6:29:chronic_disease,Post-meningitis ossification,['Post-meningitis' 'ossification'],[2. 2.]
NCT02310399,39:42:chronic_disease,normal cochlea and cochlear nerves or NF2,['normal' 'cochlea' 'and' 'cochlear' 'nerves' 'or' 'NF2'],[0. 0. 0. 0. 0. 0. 2.]
NCT02309580,16:41:chronic_disease,without active graft-versus-host-disease,['without' 'active' 'graft-versus-host-disease'],[0. 0. 2.]
NCT02307058,20:59:treatment,Distinct lesion on dynamic contrast-enhanced MRI (DCE-MRI) with early enhancement and later washout,"['Distinct' 'lesion' 'on' 'dynamic' 'contrast-enhanced' 'MRI' '('
 'DCE-MRI' ')' 'with' 'early' 'enhancement' 'and' 'later' 'washout']",[0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02306954,15:67:chronic_disease,"Patients with active systemic, pulmonary, or pericardial infection","['Patients' 'with' 'active' 'systemic' ',' 'pulmonary' ',' 'or'
 'pericardial' 'infection']",[0. 0. 2. 2. 2. 2. 2. 2. 0. 0.]
NCT02305537,26:64:chronic_disease,those who exhibit severe behavioral disinhibition or aggression,"['those' 'who' 'exhibit' 'severe' 'behavioral' 'disinhibition' 'or'
 'aggression']",[0. 0. 0. 0. 2. 2. 2. 2.]
NCT02304458,28:59:treatment,Patients who have received prior anti-PD1 directed therapy (monoclonal antibody [mAb] or small molecule),"['Patients' 'who' 'have' 'received' 'prior' 'anti-PD1' 'directed'
 'therapy' '(' 'monoclonal' 'antibody' '[' 'mAb' ']' 'or' 'small'
 'molecule' ')']",[0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02304458,42:62:chronic_disease,these patients will not be evaluable for hematologic toxicity,"['these' 'patients' 'will' 'not' 'be' 'evaluable' 'for' 'hematologic'
 'toxicity']",[0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02301663,1:18:treatment,metallic implants,['metallic' 'implants'],[1. 1.]
NCT02299414,1:36:chronic_disease,Class C or higher diabetes mellitus,['Class' 'C' 'or' 'higher' 'diabetes' 'mellitus'],[2. 2. 2. 2. 2. 2.]
NCT02298790,1:19:chronic_disease,Hearing impairment,['Hearing' 'impairment'],[2. 2.]
NCT02298504,1:14:chronic_disease,pulp necrosis,['pulp' 'necrosis'],[2. 2.]
NCT02293096,1:31:chronic_disease,active reactive airway disease,['active' 'reactive' 'airway' 'disease'],[2. 2. 2. 2.]
NCT02291978,15:39:chronic_disease,Patients with gross spinal instability on imaging,['Patients' 'with' 'gross' 'spinal' 'instability' 'on' 'imaging'],[0. 0. 2. 2. 2. 0. 0.]
NCT02291523,"15:37:treatment,",Have received probiotic preparations ≤ 4 weeks prior to randomization,"['Have' 'received' 'probiotic' 'preparations' '≤' '4' 'weeks' 'prior' 'to'
 'randomization']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02290028,78:94:chronic_disease,"Presence of another life-threatening, underlying illness separate from their cardiac disorder","['Presence' 'of' 'another' 'life-threatening' ',' 'underlying' 'illness'
 'separate' 'from' 'their' 'cardiac' 'disorder']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02287558,",39:83:treatment",Recurrent bleeding after at least one previous interventional endoscopic procedure,"['Recurrent' 'bleeding' 'after' 'at' 'least' 'one' 'previous'
 'interventional' 'endoscopic' 'procedure']",[0. 0. 0. 0. 0. 0. 1. 1. 1. 1.]
NCT02285101,1:46:treatment,Prior treatment with arginine depleting agent,['Prior' 'treatment' 'with' 'arginine' 'depleting' 'agent'],[1. 1. 1. 1. 1. 1.]
NCT02281409,17:38:treatment,Subjects on any immunomodulatory drug,['Subjects' 'on' 'any' 'immunomodulatory' 'drug'],[0. 0. 0. 1. 1.]
NCT02278367,47:72:chronic_disease,Have a history of additional risk factors for Torsades de Pointes (TdP),"['Have' 'a' 'history' 'of' 'additional' 'risk' 'factors' 'for' 'Torsades'
 'de' 'Pointes' '(' 'TdP' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT02278315,",38:56:treatment","Grade 2 or greater toxicities due to previous therapies, subject to laboratory abnormalities listed below","['Grade' '2' 'or' 'greater' 'toxicities' 'due' 'to' 'previous' 'therapies'
 ',' 'subject' 'to' 'laboratory' 'abnormalities' 'listed' 'below']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02278315,1:35:treatment,Serum free light chain (FLC) assay,['Serum' 'free' 'light' 'chain' '(' 'FLC' ')' 'assay'],[1. 1. 1. 1. 1. 1. 0. 0.]
NCT02277782,1:31:chronic_disease,prolonged rupture of membranes,['prolonged' 'rupture' 'of' 'membranes'],[2. 2. 2. 2.]
NCT02276716,14:35:chronic_disease,Diagnosis of familial dysautonomia (with mutation testing),"['Diagnosis' 'of' 'familial' 'dysautonomia' '(' 'with' 'mutation'
 'testing' ')']",[0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02274116,1:30:chronic_disease,cardiopulmonary complications,['cardiopulmonary' 'complications'],[2. 2.]
NCT02273375,15:51:cancer,Patients with large-cell neuroendocrine carcinomas are not eligible,"['Patients' 'with' 'large-cell' 'neuroendocrine' 'carcinomas' 'are' 'not'
 'eligible']",[0. 0. 3. 3. 3. 0. 0. 0.]
NCT02273362,"3:24:treatment,",A clinical liver biopsy (with research tissue specimens available for analysis) =< 3 months prior to pre-registration,"['A' 'clinical' 'liver' 'biopsy' '(' 'with' 'research' 'tissue'
 'specimens' 'available' 'for' 'analysis' ')' '=' '<' '3' 'months' 'prior'
 'to' 'pre-registration']",[0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02272998,28:55:treatment,Patients who have received prior FGFR targeted therapy,['Patients' 'who' 'have' 'received' 'prior' 'FGFR' 'targeted' 'therapy'],[0. 0. 0. 0. 1. 1. 1. 1.]
NCT02272634,13:36:chronic_disease,Evidence of pulmonary heart disease,['Evidence' 'of' 'pulmonary' 'heart' 'disease'],[0. 0. 2. 2. 2.]
NCT02272556,1:32:chronic_disease,Untreated Psychiatric Disorders,['Untreated' 'Psychiatric' 'Disorders'],[2. 2. 2.]
NCT02272218,27:34:chronic_disease,clinically diagnosed with knee OA using American College of Rheumatology (ACR) criteria,"['clinically' 'diagnosed' 'with' 'knee' 'OA' 'using' 'American' 'College'
 'of' 'Rheumatology' '(' 'ACR' ')' 'criteria']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02271711,135:151:treatment,"Extensive disease, disease location, and/or co-morbid condition that the PI or designee considers unsafe for surgical intervention of NK cell infusion","['Extensive' 'disease' ',' 'disease' 'location' ',' 'and/or' 'co-morbid'
 'condition' 'that' 'the' 'PI' 'or' 'designee' 'considers' 'unsafe' 'for'
 'surgical' 'intervention' 'of' 'NK' 'cell' 'infusion']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02271100,1:24:treatment,Previous spinal surgery in the lumbar or sacral area (L1 through Sacrum),"['Previous' 'spinal' 'surgery' 'in' 'the' 'lumbar' 'or' 'sacral' 'area'
 '(' 'L1' 'through' 'Sacrum' ')']",[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02270970,"1:17:treatment,",oral antibiotics within two weeks of first dose,['oral' 'antibiotics' 'within' 'two' 'weeks' 'of' 'first' 'dose'],[1. 1. 0. 0. 0. 0. 0. 0.]
NCT02269293,22:55:treatment,Patient who have had previous treatment with selinexor,['Patient' 'who' 'have' 'had' 'previous' 'treatment' 'with' 'selinexor'],[0. 0. 0. 0. 1. 1. 1. 1.]
NCT02269124,32:55:chronic_disease,with mild to moderately severe unilateral hearing loss,['with' 'mild' 'to' 'moderately' 'severe' 'unilateral' 'hearing' 'loss'],[0. 0. 0. 0. 0. 2. 2. 2.]
NCT02268448,"8:44:treatment,",Use of topical or oral anti-pruritic agents for 2 weeks prior to the study start,"['Use' 'of' 'topical' 'or' 'oral' 'anti-pruritic' 'agents' 'for' '2'
 'weeks' 'prior' 'to' 'the' 'study' 'start']",[0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02267863,24:49:chronic_disease,Clinically significant intravascular coagulation,['Clinically' 'significant' 'intravascular' 'coagulation'],[0. 0. 2. 2.]
NCT02266719,15:39:chronic_disease,Patients with ruptured aortic aneurysm requiring urgent or emergent repair,"['Patients' 'with' 'ruptured' 'aortic' 'aneurysm' 'requiring' 'urgent'
 'or' 'emergent' 'repair']",[0. 0. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT02266329,",398:413:treatment",Participation in a headache support group or other activity such as meditation or yoga intended to mitigate headache or other chronic pain must be stable for at least 4 weeks prior to beginning the preliminary screening period and should be intended to be continued for the duration of the trial. Participants will be encouraged to defer enrolling in such activities until they have completed the treatment trial,"['Participation' 'in' 'a' 'headache' 'support' 'group' 'or' 'other'
 'activity' 'such' 'as' 'meditation' 'or' 'yoga' 'intended' 'to'
 'mitigate' 'headache' 'or' 'other' 'chronic' 'pain' 'must' 'be' 'stable'
 'for' 'at' 'least' '4' 'weeks' 'prior' 'to' 'beginning' 'the'
 'preliminary' 'screening' 'period' 'and' 'should' 'be' 'intended' 'to'
 'be' 'continued' 'for' 'the' 'duration' 'of' 'the' 'trial' '.'
 'Participants' 'will' 'be' 'encouraged' 'to' 'defer' 'enrolling' 'in'
 'such' 'activities' 'until' 'they' 'have' 'completed' 'the' 'treatment'
 'trial']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]"
NCT02265315,18:54:chronic_disease,Individuals with Idiopathic Parkinson's disease (IPD),"['Individuals' 'with' 'Idiopathic' 'Parkinson' ""'s"" 'disease' '(' 'IPD'
 ')']",[0. 0. 2. 2. 2. 2. 0. 0. 0.]
NCT02264678,17:24:allergy_name,Bad reaction to AZD6738,['Bad' 'reaction' 'to' 'AZD6738'],[0. 0. 0. 4.]
NCT02264678,19:41:cancer,The presence of a solid malignant tumour that is not considered appropriate for further standard treatment,"['The' 'presence' 'of' 'a' 'solid' 'malignant' 'tumour' 'that' 'is' 'not'
 'considered' 'appropriate' 'for' 'further' 'standard' 'treatment']",[0. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02263274,7:23:allergy_name,Known adhesive allergy,['Known' 'adhesive' 'allergy'],[0. 4. 4.]
NCT02262806,1:22:chronic_disease,Partial lipodystrophy (either genetic or acquired),['Partial' 'lipodystrophy' '(' 'either' 'genetic' 'or' 'acquired' ')'],[2. 2. 0. 0. 0. 0. 0. 0.]
NCT02261519,37:42:treatment,The subject has previously received NaBen,['The' 'subject' 'has' 'previously' 'received' 'NaBen'],[0. 0. 0. 0. 0. 1.]
NCT02261519,1:28:treatment,systemic hormonal treatment,['systemic' 'hormonal' 'treatment'],[1. 1. 1.]
NCT02259621,23:44:allergy_name,History of allergy to study drug components,['History' 'of' 'allergy' 'to' 'study' 'drug' 'components'],[0. 0. 0. 0. 4. 4. 4.]
NCT02258438,1:21:chronic_disease,type 1 or 2 diabetes,['type' '1' 'or' '2' 'diabetes'],[2. 2. 2. 2. 2.]
NCT02256631,28:47:treatment,Prior participation in any HIV-1 vaccine trial,['Prior' 'participation' 'in' 'any' 'HIV-1' 'vaccine' 'trial'],[0. 0. 0. 0. 1. 1. 1.]
NCT02255383,18:29:treatment,"Stable, painless arthrodesis in a satisfactory functional position","['Stable' ',' 'painless' 'arthrodesis' 'in' 'a' 'satisfactory'
 'functional' 'position']",[0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02254863,24:61:treatment,Prior participation in any gene or regenerative cell therapy study,"['Prior' 'participation' 'in' 'any' 'gene' 'or' 'regenerative' 'cell'
 'therapy' 'study']",[0. 0. 0. 1. 1. 1. 1. 1. 1. 0.]
NCT02253316,22:39:chronic_disease,clinically important autonomic disease,['clinically' 'important' 'autonomic' 'disease'],[0. 0. 2. 2.]
NCT02252432,10:21:treatment,Emergent laminectomy,['Emergent' 'laminectomy'],[0. 1.]
NCT02252081,29:49:chronic_disease,"Severe, unstable, or active inflammatory disease","['Severe' ',' 'unstable' ',' 'or' 'active' 'inflammatory' 'disease']",[0. 0. 0. 0. 0. 0. 2. 2.]
NCT02251431,1:24:treatment,Prior bariatric surgery,['Prior' 'bariatric' 'surgery'],[1. 1. 1.]
NCT02250157,",,,,187:189:treatment",Sexually active male subjects must use a barrier method of contraception during the study and agree to continue the use of male contraception for at least 30 days after the last dose of IP,"['Sexually' 'active' 'male' 'subjects' 'must' 'use' 'a' 'barrier' 'method'
 'of' 'contraception' 'during' 'the' 'study' 'and' 'agree' 'to' 'continue'
 'the' 'use' 'of' 'male' 'contraception' 'for' 'at' 'least' '30' 'days'
 'after' 'the' 'last' 'dose' 'of' 'IP']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02249039,38:50:treatment,Any infant or child who is receiving ECMO therapy,['Any' 'infant' 'or' 'child' 'who' 'is' 'receiving' 'ECMO' 'therapy'],[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02245997,"15:19:cancer,,",Patients with INSS stage 2a or 2b,['Patients' 'with' 'INSS' 'stage' '2a' 'or' '2b'],[0. 0. 3. 0. 0. 0. 0.]
NCT02245841,15:52:cancer,Patients with malignancy-associated dermatomyositis,['Patients' 'with' 'malignancy-associated' 'dermatomyositis'],[0. 0. 3. 3.]
NCT02245841,1:30:chronic_disease,juvenile dermatomyositis (JD),['juvenile' 'dermatomyositis' '(' 'JD' ')'],[2. 2. 2. 0. 0.]
NCT02244814,18:41:chronic_disease,Risk factors for placental insufficiency,['Risk' 'factors' 'for' 'placental' 'insufficiency'],[0. 0. 0. 2. 2.]
NCT02244814,1:15:chronic_disease,overt diabetes,['overt' 'diabetes'],[2. 2.]
NCT02243631,1:17:chronic_disease,Blood dyscrasias,['Blood' 'dyscrasias'],[2. 2.]
NCT02242526,1:22:chronic_disease,"Paraesophageal hernia with clinically relevant symptoms such as heartburn, chest pain, regurgitation, dysphagia, postprandial abdominal pain, shortness of breath, or early satiety","['Paraesophageal' 'hernia' 'with' 'clinically' 'relevant' 'symptoms'
 'such' 'as' 'heartburn' ',' 'chest' 'pain' ',' 'regurgitation' ','
 'dysphagia' ',' 'postprandial' 'abdominal' 'pain' ',' 'shortness' 'of'
 'breath' ',' 'or' 'early' 'satiety']","[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02242110,"11:29:treatment,",Stable on bipolar medication for at least 2 months,['Stable' 'on' 'bipolar' 'medication' 'for' 'at' 'least' '2' 'months'],[0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02240498,10:46:chronic_disease,Severely compromised cardiopulmonary function,['Severely' 'compromised' 'cardiopulmonary' 'function'],[0. 2. 2. 2.]
NCT02236377,1:28:chronic_disease,acute or apparent psychosis,['acute' 'or' 'apparent' 'psychosis'],[2. 2. 2. 2.]
NCT02236013,"49:85:cancer,",Subject has a diagnosis of previously-untreated de novo acute myeloid leukemia (AML) according to WHO classification (2008) documented within 28 days prior to enrollment,"['Subject' 'has' 'a' 'diagnosis' 'of' 'previously-untreated' 'de' 'novo'
 'acute' 'myeloid' 'leukemia' '(' 'AML' ')' 'according' 'to' 'WHO'
 'classification' '(' '2008' ')' 'documented' 'within' '28' 'days' 'prior'
 'to' 'enrollment']","[0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02236013,18:50:treatment,Subject requires treatment with concomitant drugs that target serotonin 5HT1R or 5HT2BR receptors or sigma nonspecific receptor with the exception of drugs that are considered absolutely essential for the care of the subject,"['Subject' 'requires' 'treatment' 'with' 'concomitant' 'drugs' 'that'
 'target' 'serotonin' '5HT1R' 'or' '5HT2BR' 'receptors' 'or' 'sigma'
 'nonspecific' 'receptor' 'with' 'the' 'exception' 'of' 'drugs' 'that'
 'are' 'considered' 'absolutely' 'essential' 'for' 'the' 'care' 'of' 'the'
 'subject']","[0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02235623,1:25:chronic_disease,Bilateral cryptorchidism,['Bilateral' 'cryptorchidism'],[2. 2.]
NCT02234934,"18:59:treatment,",Participation in another experimental therapeutic protocol within 6 months prior to baseline and during the study period,"['Participation' 'in' 'another' 'experimental' 'therapeutic' 'protocol'
 'within' '6' 'months' 'prior' 'to' 'baseline' 'and' 'during' 'the'
 'study' 'period']",[0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02234934,63:83:treatment,there is deemed to be an unacceptable risk associated with an allogeneic procedure,"['there' 'is' 'deemed' 'to' 'be' 'an' 'unacceptable' 'risk' 'associated'
 'with' 'an' 'allogeneic' 'procedure']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02234193,15:28:allergy_name,Subjects with tape adhesive allergies,['Subjects' 'with' 'tape' 'adhesive' 'allergies'],[0. 0. 4. 4. 0.]
NCT02233868,1:25:treatment,anorexics (sibuteramine),['anorexics' '(' 'sibuteramine' ')'],[1. 1. 0. 0.]
NCT02233868,1:29:treatment,antifungal agents (systemic),['antifungal' 'agents' '(' 'systemic' ')'],[1. 1. 1. 0. 0.]
NCT02233868,1:12:treatment,antiobesity,['antiobesity'],[1.]
NCT02232516,1:42:cancer,Hepatosplenic gamma-delta T-cell lymphoma,['Hepatosplenic' 'gamma-delta' 'T-cell' 'lymphoma'],[3. 3. 3. 3.]
NCT02232516,1:27:cancer,"Peripheral T-cell lymphoma, unspecified (not otherwise specified [NOS])","['Peripheral' 'T-cell' 'lymphoma' ',' 'unspecified' '(' 'not' 'otherwise'
 'specified' '[' 'NOS' ']' ')']",[3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02232516,"36:55:treatment,,",all patients must agree to undergo counseling sessions every 28 days about pregnancy precautions and risks of fetal exposure,"['all' 'patients' 'must' 'agree' 'to' 'undergo' 'counseling' 'sessions'
 'every' '28' 'days' 'about' 'pregnancy' 'precautions' 'and' 'risks' 'of'
 'fetal' 'exposure']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02232165,38:52:allergy_name,Allergy or other contraindication to norepinephrine,['Allergy' 'or' 'other' 'contraindication' 'to' 'norepinephrine'],[0. 0. 0. 0. 0. 4.]
NCT02231073,78:90:chronic_disease,"Capable of following directions. iPD subjects: UK Brain Bank criteria, i.e., bradykinesia","['Capable' 'of' 'following' 'directions' '.' 'iPD' 'subjects' ':' 'UK'
 'Brain' 'Bank' 'criteria' ',' 'i.e.' ',' 'bradykinesia']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02230189,"8:27:treatment,",Use of Xolair (omalizumab) within the last 6 months,"['Use' 'of' 'Xolair' '(' 'omalizumab' ')' 'within' 'the' 'last' '6'
 'months']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02227199,",35:79:treatment",Prior failed (< 5 x 10^6 CD34/kg) peripheral blood stem cell (PBSC) collection,"['Prior' 'failed' '(' '<' '5' 'x' '10^6' 'CD34/kg' ')' 'peripheral'
 'blood' 'stem' 'cell' '(' 'PBSC' ')' 'collection']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0.]
NCT02226341,"8:39:treatment,",Use of experimental therapeutic agents within the past 60 days,"['Use' 'of' 'experimental' 'therapeutic' 'agents' 'within' 'the' 'past'
 '60' 'days']",[0. 0. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02225548,27:53:chronic_disease,Subject with a history of congenital QT prolongation,['Subject' 'with' 'a' 'history' 'of' 'congenital' 'QT' 'prolongation'],[0. 0. 0. 0. 0. 2. 2. 2.]
NCT02225548,",11:20:treatment,",an IIEF-5 tadalafil-alone baseline score that is ≤ 18,['an' 'IIEF-5' 'tadalafil-alone' 'baseline' 'score' 'that' 'is' '≤' '18'],[0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT02222545,6:14:chronic_disease,Have STEC-HUS,['Have' 'STEC-HUS'],[0. 2.]
NCT02219711,26:48:chronic_disease,History of a significant cardiovascular illness,['History' 'of' 'a' 'significant' 'cardiovascular' 'illness'],[0. 0. 0. 0. 2. 2.]
NCT02219581,38:45:treatment,Patients that have an intolerance to Toradol,['Patients' 'that' 'have' 'an' 'intolerance' 'to' 'Toradol'],[0. 0. 0. 0. 0. 0. 1.]
NCT02219555,1:12:chronic_disease,amyloidosis,['amyloidosis'],[2.]
NCT02219555,1:25:chronic_disease,peripheral nerve disease,['peripheral' 'nerve' 'disease'],[2. 2. 2.]
NCT02217345,44:57:chronic_disease,use of any medications prescribed to treat hyperglycemia,['use' 'of' 'any' 'medications' 'prescribed' 'to' 'treat' 'hyperglycemia'],[0. 0. 0. 0. 0. 0. 0. 2.]
NCT02215096,",32:74:treatment",Completed at least 12 weeks of prior continuous therapy with enzalutamide,"['Completed' 'at' 'least' '12' 'weeks' 'of' 'prior' 'continuous' 'therapy'
 'with' 'enzalutamide']",[0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1.]
NCT02214667,1:23:chronic_disease,"bipolar disorder I, II, or NOS","['bipolar' 'disorder' 'I' ',' 'II' ',' 'or' 'NOS']",[2. 2. 2. 2. 0. 0. 0. 0.]
NCT02214550,"8:31:chronic_disease,",active genitourinary infection in the last four weeks,['active' 'genitourinary' 'infection' 'in' 'the' 'last' 'four' 'weeks'],[0. 2. 2. 0. 0. 0. 0. 0.]
NCT02213289,4:43:treatment,No prior treatment with any targeted agent,['No' 'prior' 'treatment' 'with' 'any' 'targeted' 'agent'],[0. 1. 1. 1. 1. 1. 1.]
NCT02213068,12:31:treatment,History of previous transplant,['History' 'of' 'previous' 'transplant'],[0. 0. 1. 1.]
NCT02210650,1:24:chronic_disease,medullary sponge kidney,['medullary' 'sponge' 'kidney'],[2. 2. 2.]
NCT02210078,15:26:chronic_disease,Patients with CMV disease,['Patients' 'with' 'CMV' 'disease'],[0. 0. 2. 2.]
NCT02209636,1:15:chronic_disease,CKD stage IIIb,['CKD' 'stage' 'IIIb'],[2. 2. 2.]
NCT02208362,",76:101:treatment",An interval of at least 12 weeks must have elapsed since the completion of initial radiation therapy,"['An' 'interval' 'of' 'at' 'least' '12' 'weeks' 'must' 'have' 'elapsed'
 'since' 'the' 'completion' 'of' 'initial' 'radiation' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02207465,1:18:cancer,In-situ carcinoma is allowed,['In-situ' 'carcinoma' 'is' 'allowed'],[3. 3. 0. 0.]
NCT02207465,"1:52:treatment,",Treatment with an investigational anti-cancer agent within 4 weeks prior to enrollment into the study,"['Treatment' 'with' 'an' 'investigational' 'anti-cancer' 'agent' 'within'
 '4' 'weeks' 'prior' 'to' 'enrollment' 'into' 'the' 'study']",[1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02207439,",,,61:83:chronic_disease",Weight loss of > 10% over the past 6 months which is due to tumor wasting syndrome,"['Weight' 'loss' 'of' '>' '10' '%' 'over' 'the' 'past' '6' 'months'
 'which' 'is' 'due' 'to' 'tumor' 'wasting' 'syndrome']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT02206945,1:10:treatment,anafranil,['anafranil'],[1.]
NCT02204098,1:17:treatment,Hormonal therapy,['Hormonal' 'therapy'],[1. 1.]
NCT02203903,8:41:chronic_disease,Active Bronchiolitis obliterans syndrome,['Active' 'Bronchiolitis' 'obliterans' 'syndrome'],[0. 2. 2. 2.]
NCT02203695,1:41:treatment,Primary treatment with radiation therapy,['Primary' 'treatment' 'with' 'radiation' 'therapy'],[1. 1. 1. 1. 1.]
NCT02203513,",51:77:cancer",Patients with gBRCA1/2m with history of or active breast and ovarian cancers are considered for Cohort 1,"['Patients' 'with' 'gBRCA1/2m' 'with' 'history' 'of' 'or' 'active'
 'breast' 'and' 'ovarian' 'cancers' 'are' 'considered' 'for' 'Cohort' '1']",[0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0.]
NCT02202681,28:54:chronic_disease,Subjects with a history of intestinal Crohn's disease,"['Subjects' 'with' 'a' 'history' 'of' 'intestinal' 'Crohn' ""'s"" 'disease']",[0. 0. 0. 0. 0. 2. 2. 2. 0.]
NCT02200445,10:17:chronic_disease,Abnormal thyroid function tests,['Abnormal' 'thyroid' 'function' 'tests'],[0. 2. 0. 0.]
NCT02200445,"18:48:treatment,",Received another investigational new drug (IND) within 5 half-lives of that agent before the planned commencement of SC IL-2,"['Received' 'another' 'investigational' 'new' 'drug' '(' 'IND' ')'
 'within' '5' 'half-lives' 'of' 'that' 'agent' 'before' 'the' 'planned'
 'commencement' 'of' 'SC' 'IL-2']",[0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02199236,1:18:treatment,Prior pelvic EBRT,['Prior' 'pelvic' 'EBRT'],[1. 1. 1.]
NCT02195232,1:28:chronic_disease,Familial bleeding diathesis,['Familial' 'bleeding' 'diathesis'],[2. 2. 2.]
NCT02193932,54:86:treatment,Patients who meet the regular exclusion criteria for Magnetic Resonance Imaging (MRI) studies per the prescreening form reviewed with all patients prior to exams,"['Patients' 'who' 'meet' 'the' 'regular' 'exclusion' 'criteria' 'for'
 'Magnetic' 'Resonance' 'Imaging' '(' 'MRI' ')' 'studies' 'per' 'the'
 'prescreening' 'form' 'reviewed' 'with' 'all' 'patients' 'prior' 'to'
 'exams']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02193841,15:20:chronic_disease,Patients with cysts crossing the growth plate (area where bone grows),"['Patients' 'with' 'cysts' 'crossing' 'the' 'growth' 'plate' '(' 'area'
 'where' 'bone' 'grows' ')']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02193373,19:26:chronic_disease,Current or recent illness,['Current' 'or' 'recent' 'illness'],[0. 0. 0. 2.]
NCT02192359,44:52:cancer,Imaging studies show evidence of recurrent tumor(s),"['Imaging' 'studies' 'show' 'evidence' 'of' 'recurrent' 'tumor' '(' 's'
 ')']",[3. 3. 3. 3. 3. 3. 3. 3. 3. 3.]
NCT02189889,1:24:chronic_disease,coagulation abnormality,['coagulation' 'abnormality'],[2. 2.]
NCT02189798,4:54:treatment,No previous cochlear implant experience in either ear,['No' 'previous' 'cochlear' 'implant' 'experience' 'in' 'either' 'ear'],[0. 1. 1. 1. 1. 1. 1. 1.]
NCT02188745,40:53:treatment,Patient must have been treated with an anti-estrogen at any time in their disease history,"['Patient' 'must' 'have' 'been' 'treated' 'with' 'an' 'anti-estrogen' 'at'
 'any' 'time' 'in' 'their' 'disease' 'history']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02187848,1:27:chronic_disease,Cardiac conduction defects,['Cardiac' 'conduction' 'defects'],[2. 2. 2.]
NCT02187848,1:32:treatment,Prior therapy targeting CEACAM5,['Prior' 'therapy' 'targeting' 'CEACAM5'],[1. 1. 1. 1.]
NCT02186418,10:38:treatment,Abnormal pulmonary function tests PFT,['Abnormal' 'pulmonary' 'function' 'tests' 'PFT'],[0. 1. 1. 1. 1.]
NCT02185417,"15:34:treatment,,",Are receiving hydrochlorothiazide from the VA pharmacy at a daily dose of 25 or 50 mg,"['Are' 'receiving' 'hydrochlorothiazide' 'from' 'the' 'VA' 'pharmacy' 'at'
 'a' 'daily' 'dose' 'of' '25' 'or' '50' 'mg']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02184520,1:16:chronic_disease,pseudoarthrosis (failed previous fusion),['pseudoarthrosis' '(' 'failed' 'previous' 'fusion' ')'],[2. 0. 0. 0. 0. 0.]
NCT02181478,1:19:cancer,Myelofibrosis (MF),['Myelofibrosis' '(' 'MF' ')'],[3. 3. 0. 0.]
NCT02180412,",149:158:chronic_disease","Acute symptoms (7 days duration or less to time of enrollment) such as abdominal, back and/or limb pain, diagnosed by the investigator as caused by porphyria after initial evaluation has excluded other causes","['Acute' 'symptoms' '(' '7' 'days' 'duration' 'or' 'less' 'to' 'time' 'of'
 'enrollment' ')' 'such' 'as' 'abdominal' ',' 'back' 'and/or' 'limb'
 'pain' ',' 'diagnosed' 'by' 'the' 'investigator' 'as' 'caused' 'by'
 'porphyria' 'after' 'initial' 'evaluation' 'has' 'excluded' 'other'
 'causes']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT02180412,"52:96:treatment,","Most (~90 percent) will have deficient activity of erythrocyte porphobilinogen deaminase (PBGD), and almost all (>95 percent) will have a demonstrable disease-causing PBGD mutation","['Most' '(' '~90' 'percent' ')' 'will' 'have' 'deficient' 'activity' 'of'
 'erythrocyte' 'porphobilinogen' 'deaminase' '(' 'PBGD' ')' ',' 'and'
 'almost' 'all' '(' '>' '95' 'percent' ')' 'will' 'have' 'a'
 'demonstrable' 'disease-causing' 'PBGD' 'mutation']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02179853,12:44:chronic_disease,History of tuberculosis (TB) or TB exposure,['History' 'of' 'tuberculosis' '(' 'TB' ')' 'or' 'TB' 'exposure'],[0. 0. 2. 2. 2. 2. 2. 0. 0.]
NCT02178566,"17:49:treatment,",Initiation of a pulmonary rehabilitation program within 3 months prior to screening or initiation or changes during the study,"['Initiation' 'of' 'a' 'pulmonary' 'rehabilitation' 'program' 'within' '3'
 'months' 'prior' 'to' 'screening' 'or' 'initiation' 'or' 'changes'
 'during' 'the' 'study']",[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02177838,",,17:46:cancer","Stage III/IVa/b squamous cell carcinoma (SCC) by American Joint Committee on Cancer (AJCC) 7 criteria (advanced, but not metastatic)","['Stage' 'III/IVa/b' 'squamous' 'cell' 'carcinoma' '(' 'SCC' ')' 'by'
 'American' 'Joint' 'Committee' 'on' 'Cancer' '(' 'AJCC' ')' '7'
 'criteria' '(' 'advanced' ',' 'but' 'not' 'metastatic' ')']","[0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02177695,",37:60:treatment",disease measuring at least 10 mm on cross-sectional imaging,"['disease' 'measuring' 'at' 'least' '10' 'mm' 'on' 'cross-sectional'
 'imaging']",[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02176967,",,,51:64:cancer",< 12 months (< 365 days) of age at diagnosis with INRG stage L1,"['<' '12' 'months' '(' '<' '365' 'days' ')' 'of' 'age' 'at' 'diagnosis'
 'with' 'INRG' 'stage' 'L1']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3.]
NCT02176902,1:19:cancer,Clinical stage T2c or less,['Clinical' 'stage' 'T2c' 'or' 'less'],[3. 3. 3. 0. 0.]
NCT02176161,1:35:cancer,non-muscle invasive bladder cancer,['non-muscle' 'invasive' 'bladder' 'cancer'],[3. 3. 3. 3.]
NCT02174549,1:41:cancer,Liver metastatic gastrointestinal cancer,['Liver' 'metastatic' 'gastrointestinal' 'cancer'],[3. 3. 3. 3.]
NCT02172950,",,47:77:chronic_disease,,",Males of any age who have been diagnosed with severe congenital hemophilia A (FVIII activity levels < 1%),"['Males' 'of' 'any' 'age' 'who' 'have' 'been' 'diagnosed' 'with' 'severe'
 'congenital' 'hemophilia' 'A' '(' 'FVIII' 'activity' 'levels' '<' '1' '%'
 ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02171429,25:46:treatment,Naive to treatment with TNF inhibitor therapy,['Naive' 'to' 'treatment' 'with' 'TNF' 'inhibitor' 'therapy'],[0. 0. 0. 0. 1. 1. 1.]
NCT02171104,1:23:chronic_disease,Aspartylglucosaminuria,['Aspartylglucosaminuria'],[2.]
NCT02171104,1:28:chronic_disease,Globoid cell leukodystrophy,['Globoid' 'cell' 'leukodystrophy'],[2. 2. 2.]
NCT02171104,1:25:chronic_disease,MPS IH (Hurler syndrome),['MPS' 'IH' '(' 'Hurler' 'syndrome' ')'],[2. 2. 2. 2. 0. 0.]
NCT02171104,1:60:chronic_disease,Mitochondrial Neurogastrointestingal Encephalopathy (MNGIE),['Mitochondrial' 'Neurogastrointestingal' 'Encephalopathy' '(' 'MNGIE' ')'],[2. 2. 2. 2. 0. 0.]
NCT02171104,1:25:chronic_disease,Niemann-Pick C subtype 2,['Niemann-Pick' 'C' 'subtype' '2'],[2. 2. 2. 2.]
NCT02171104,1:19:chronic_disease,Zellweger syndrome,['Zellweger' 'syndrome'],[2. 2.]
NCT02169739,33:53:chronic_disease,Absence of signs or symptoms of cortical dysfunction,['Absence' 'of' 'signs' 'or' 'symptoms' 'of' 'cortical' 'dysfunction'],[0. 0. 0. 0. 0. 0. 2. 2.]
NCT02169739,",,112:123:treatment",Well delinated hypointense lesion <1.5 cm in size at the largest dimension (including rostro-caudal extent) on FLAIR or T1 corresponding to the clinical syndrome,"['Well' 'delinated' 'hypointense' 'lesion' '<' '1.5' 'cm' 'in' 'size' 'at'
 'the' 'largest' 'dimension' '(' 'including' 'rostro-caudal' 'extent' ')'
 'on' 'FLAIR' 'or' 'T1' 'corresponding' 'to' 'the' 'clinical' 'syndrome']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0.
 0. 0. 0.]"
NCT02169089,1:20:treatment,Oral contraceptives are disallowed,['Oral' 'contraceptives' 'are' 'disallowed'],[1. 1. 0. 0.]
NCT02169089,7:27:cancer,cured squamous cell cancer,['cured' 'squamous' 'cell' 'cancer'],[0. 3. 3. 3.]
NCT02169037,9:12:treatment,in whom PVI has low success and 55 mm baskets are too small for the atria,"['in' 'whom' 'PVI' 'has' 'low' 'success' 'and' '55' 'mm' 'baskets' 'are'
 'too' 'small' 'for' 'the' 'atria']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02169037,1:17:chronic_disease,vascular disease (1 point),['vascular' 'disease' '(' '1' 'point' ')'],[2. 2. 0. 0. 0. 0.]
NCT02167022,1:41:treatment,Anticipated pharmacological intervention or procedure or participation in other studies that may interfere with this study,"['Anticipated' 'pharmacological' 'intervention' 'or' 'procedure' 'or'
 'participation' 'in' 'other' 'studies' 'that' 'may' 'interfere' 'with'
 'this' 'study']",[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02167009,12:19:allergy_name,History of gelatin allergy,['History' 'of' 'gelatin' 'allergy'],[0. 0. 4. 0.]
NCT02167009,"1:5:treatment,",TURP within the last two years,['TURP' 'within' 'the' 'last' 'two' 'years'],[1. 0. 0. 0. 0. 0.]
NCT02165449,35:65:chronic_disease,Diagnosis: DSM-IV TR criteria for non-psychotic major depression,"['Diagnosis' ':' 'DSM-IV' 'TR' 'criteria' 'for' 'non-psychotic' 'major'
 'depression']",[0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT02165007,14:37:chronic_disease,Patient with active Hepatitis B or C determined by serology and/or NAAT,"['Patient' 'with' 'active' 'Hepatitis' 'B' 'or' 'C' 'determined' 'by'
 'serology' 'and/or' 'NAAT']",[0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT02164422,",59:96:chronic_disease",Meet DSM-IV criteria for current (past-6 month) attention deficit hyperactivity disorder (ADHD),"['Meet' 'DSM-IV' 'criteria' 'for' 'current' '(' 'past-6' 'month' ')'
 'attention' 'deficit' 'hyperactivity' 'disorder' '(' 'ADHD' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT02162420,14:55:chronic_disease,Diagnosis of DC with a triad of mucocutaneous features,['Diagnosis' 'of' 'DC' 'with' 'a' 'triad' 'of' 'mucocutaneous' 'features'],[0. 0. 2. 2. 2. 2. 2. 2. 2.]
NCT02162420,"1:21:cancer,,,,",Refractory cytopenia defined by bone marrow cellularity <50% (with < 30% residual hematopoietic cells),"['Refractory' 'cytopenia' 'defined' 'by' 'bone' 'marrow' 'cellularity' '<'
 '50' '%' '(' 'with' '<' '30' '%' 'residual' 'hematopoietic' 'cells' ')']",[3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02162420,1:15:chronic_disease,nail dystrophy,['nail' 'dystrophy'],[2. 2.]
NCT02162420,1:23:chronic_disease,severe portal fibrosis,['severe' 'portal' 'fibrosis'],[2. 2. 2.]
NCT02161380,1:21:treatment,Previous eye surgery in the eye selected for injection,['Previous' 'eye' 'surgery' 'in' 'the' 'eye' 'selected' 'for' 'injection'],[1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02160288,13:31:chronic_disease,Presence of fecal incontinence,['Presence' 'of' 'fecal' 'incontinence'],[0. 0. 2. 2.]
NCT02160288,25:30:treatment,Previous treatment with Botox (possible antibodies),['Previous' 'treatment' 'with' 'Botox' '(' 'possible' 'antibodies' ')'],[0. 0. 0. 1. 0. 0. 0. 0.]
NCT02159560,1:13:chronic_disease,Chronic pain,['Chronic' 'pain'],[2. 2.]
NCT02159495,1:13:cancer,Relapsed AML is defined as patients that had a first complete remission (CR) before developing recurrent disease (increased bone marrow blasts),"['Relapsed' 'AML' 'is' 'defined' 'as' 'patients' 'that' 'had' 'a' 'first'
 'complete' 'remission' '(' 'CR' ')' 'before' 'developing' 'recurrent'
 'disease' '(' 'increased' 'bone' 'marrow' 'blasts' ')']","[3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02159027,12:17:chronic_disease,History of HIV-2,['History' 'of' 'HIV-2'],[0. 0. 2.]
NCT02159027,15:32:chronic_disease,other serious medical illnesses (in the opinion of the site investigator),"['other' 'serious' 'medical' 'illnesses' '(' 'in' 'the' 'opinion' 'of'
 'the' 'site' 'investigator' ')']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02158858,4:29:treatment,No prior treatment with JAKi allowed,['No' 'prior' 'treatment' 'with' 'JAKi' 'allowed'],[0. 1. 1. 1. 1. 0.]
NCT02158793,1:23:chronic_disease,Serious co-morbidities,['Serious' 'co-morbidities'],[2. 2.]
NCT02155946,14:26:chronic_disease,"Diagnosis of amnestic MCI based on criteria set forth by Petersen (2004). Additionally, other potential causes of cognitive deficit ruled out by the referring physician","['Diagnosis' 'of' 'amnestic' 'MCI' 'based' 'on' 'criteria' 'set' 'forth'
 'by' 'Petersen' '(' '2004' ')' '.' 'Additionally' ',' 'other' 'potential'
 'causes' 'of' 'cognitive' 'deficit' 'ruled' 'out' 'by' 'the' 'referring'
 'physician']","[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02154568,1:18:chronic_disease,Pulmonary Disease Subjects,['Pulmonary' 'Disease' 'Subjects'],[2. 2. 0.]
NCT02152995,1:4:treatment,RAI-refractory disease on structural imaging,['RAI-refractory' 'disease' 'on' 'structural' 'imaging'],[1. 0. 0. 0. 0.]
NCT02152995,24:46:cancer,patients with indolent secondary malignancies,['patients' 'with' 'indolent' 'secondary' 'malignancies'],[0. 0. 0. 3. 3.]
NCT02152956,1:20:treatment,ophthalmic solution,['ophthalmic' 'solution'],[1. 1.]
NCT02151175,17:50:chronic_disease,Subjects with a cognitive or psychiatric disorder that limits the ability to give informed consent or are unable to cooperate with the testing,"['Subjects' 'with' 'a' 'cognitive' 'or' 'psychiatric' 'disorder' 'that'
 'limits' 'the' 'ability' 'to' 'give' 'informed' 'consent' 'or' 'are'
 'unable' 'to' 'cooperate' 'with' 'the' 'testing']",[0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02150967,11:25:treatment,selective FGFR inhibitor (Cohorts 1 and 2 only),['selective' 'FGFR' 'inhibitor' '(' 'Cohorts' '1' 'and' '2' 'only' ')'],[0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02148796,1:14:treatment,chest surgery,['chest' 'surgery'],[1. 1.]
NCT02148796,1:38:chronic_disease,primary or secondary immunodeficiency,['primary' 'or' 'secondary' 'immunodeficiency'],[2. 2. 2. 2.]
NCT02148263,"1:18:treatment,",Topical eye drops within the last two hours of the study visit,"['Topical' 'eye' 'drops' 'within' 'the' 'last' 'two' 'hours' 'of' 'the'
 'study' 'visit']",[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02145351,27:43:allergy_name,Any contraindication to a pacemaker system,['Any' 'contraindication' 'to' 'a' 'pacemaker' 'system'],[0. 0. 0. 0. 4. 4.]
NCT02145351,"8:31:treatment,",Stable cardiac medical therapy for ≥30 days,['Stable' 'cardiac' 'medical' 'therapy' 'for' '≥30' 'days'],[0. 1. 1. 1. 0. 0. 0.]
NCT02143830,1:27:cancer,"Acute Myelogenous Leukemia (untreated, in remission or with refractory or relapsed disease)","['Acute' 'Myelogenous' 'Leukemia' '(' 'untreated' ',' 'in' 'remission'
 'or' 'with' 'refractory' 'or' 'relapsed' 'disease' ')']",[3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02143726,1:58:treatment,Chronic concomitant treatment with strong CYP3A4 inducers,['Chronic' 'concomitant' 'treatment' 'with' 'strong' 'CYP3A4' 'inducers'],[1. 1. 1. 1. 1. 1. 1.]
NCT02143726,21:42:chronic_disease,No known history of prolonged QT syndrome,['No' 'known' 'history' 'of' 'prolonged' 'QT' 'syndrome'],[0. 0. 0. 0. 2. 2. 2.]
NCT02143726,41:68:cancer,must have histopathologically confirmed Hürthle cell thyroid cancer by central review,"['must' 'have' 'histopathologically' 'confirmed' 'Hürthle' 'cell'
 'thyroid' 'cancer' 'by' 'central' 'review']",[0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0.]
NCT02141919,15:29:cancer,Biopsy proven Renal neoplasm,['Biopsy' 'proven' 'Renal' 'neoplasm'],[0. 0. 3. 3.]
NCT02141074,"32:45:chronic_disease,,",Patients with the diagnosis of haemophilia B (FIX (coagulation factor IX) activity level below or equal to 2%) based on medical records or central laboratory results,"['Patients' 'with' 'the' 'diagnosis' 'of' 'haemophilia' 'B' '(' 'FIX' '('
 'coagulation' 'factor' 'IX' ')' 'activity' 'level' 'below' 'or' 'equal'
 'to' '2' '%' ')' 'based' 'on' 'medical' 'records' 'or' 'central'
 'laboratory' 'results']","[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02140554,51:75:chronic_disease,Immediate family member with a known or suspected Familial Cancer Syndrome,"['Immediate' 'family' 'member' 'with' 'a' 'known' 'or' 'suspected'
 'Familial' 'Cancer' 'Syndrome']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT02140255,",,180:200:treatment,","Greater than or equal to 36 weeks gestational age at birth (assessment of gestational age will be based on the best clinical estimate determined by date of last menstrual period, antenatal ultrasound, fundal height, or Ballard Score)","['Greater' 'than' 'or' 'equal' 'to' '36' 'weeks' 'gestational' 'age' 'at'
 'birth' '(' 'assessment' 'of' 'gestational' 'age' 'will' 'be' 'based'
 'on' 'the' 'best' 'clinical' 'estimate' 'determined' 'by' 'date' 'of'
 'last' 'menstrual' 'period' ',' 'antenatal' 'ultrasound' ',' 'fundal'
 'height' ',' 'or' 'Ballard' 'Score' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02139436,27:30:treatment,leg muscles responsive to FES,['leg' 'muscles' 'responsive' 'to' 'FES'],[0. 0. 0. 0. 1.]
NCT02138669,1:18:chronic_disease,corneal dystrophy,['corneal' 'dystrophy'],[2. 2.]
NCT02138617,18:45:chronic_disease,Prior history of hypertensive encephalopathy,['Prior' 'history' 'of' 'hypertensive' 'encephalopathy'],[0. 0. 0. 2. 2.]
NCT02138214,10:25:treatment,Previous thyroid surgery,['Previous' 'thyroid' 'surgery'],[0. 1. 1.]
NCT02135874,29:66:cancer,Newly diagnosed or relapsed mixed phenotype acute leukemia (MPAL),"['Newly' 'diagnosed' 'or' 'relapsed' 'mixed' 'phenotype' 'acute'
 'leukemia' '(' 'MPAL' ')']",[0. 0. 0. 0. 3. 3. 3. 3. 3. 0. 0.]
NCT02135588,17:34:cancer,Presence of any intracranial mass,['Presence' 'of' 'any' 'intracranial' 'mass'],[0. 0. 0. 3. 3.]
NCT02134392,19:37:allergy_name,History of severe anaphylactic shock,['History' 'of' 'severe' 'anaphylactic' 'shock'],[0. 0. 0. 4. 4.]
NCT02134392,24:48:chronic_disease,Symptoms indicative of irritable bowel syndrome,['Symptoms' 'indicative' 'of' 'irritable' 'bowel' 'syndrome'],[0. 0. 0. 2. 2. 2.]
NCT02133898,1:15:treatment,Concurrent ECT,['Concurrent' 'ECT'],[1. 1.]
NCT02133898,1:52:treatment,repetitive transcranial magnetic stimulation (rTMS),['repetitive' 'transcranial' 'magnetic' 'stimulation' '(' 'rTMS' ')'],[1. 1. 1. 1. 1. 0. 0.]
NCT02133872,",49:65:treatment",More than one in-patient hospitalization for an antihypertensive crisis within the year,"['More' 'than' 'one' 'in-patient' 'hospitalization' 'for' 'an'
 'antihypertensive' 'crisis' 'within' 'the' 'year']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02133196,24:61:chronic_disease,Clinically significant atrial and/or ventricular arrhythmias,['Clinically' 'significant' 'atrial' 'and/or' 'ventricular' 'arrhythmias'],[0. 0. 2. 2. 2. 2.]
NCT02132598,72:117:allergy_name,The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation,"['The' 'subject' 'has' 'a' 'previously' 'identified' 'allergy' 'or'
 'hypersensitivity' 'to' 'components' 'of' 'the' 'study' 'treatment'
 'formulation']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 4. 4. 4. 4. 4.]
NCT02132130,104:107:treatment,"Immunocompromised patients, as judged by the investigators based on patient history, physical exam and CBC","['Immunocompromised' 'patients' ',' 'as' 'judged' 'by' 'the'
 'investigators' 'based' 'on' 'patient' 'history' ',' 'physical' 'exam'
 'and' 'CBC']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02132130,",93:136:treatment",Patients with intact vestibular function in at least one ear (non-study ear) as measured by vestibular evoked myogenic potential (VEMP),"['Patients' 'with' 'intact' 'vestibular' 'function' 'in' 'at' 'least'
 'one' 'ear' '(' 'non-study' 'ear' ')' 'as' 'measured' 'by' 'vestibular'
 'evoked' 'myogenic' 'potential' '(' 'VEMP' ')']",[0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02131467,",,,46:71:chronic_disease",18-65 year old male and female patients with primary cervical dystonia,"['18-65' 'year' 'old' 'male' 'and' 'female' 'patients' 'with' 'primary'
 'cervical' 'dystonia']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT02131467,1:10:treatment,efavirenz,['efavirenz'],[1.]
NCT02131389,7:31:treatment,Has a contralateral amputation,['Has' 'a' 'contralateral' 'amputation'],[0. 0. 1. 1.]
NCT02130687,"1:44:treatment,",Treatment with antihypertensive medications for a minimum of 6 months,"['Treatment' 'with' 'antihypertensive' 'medications' 'for' 'a' 'minimum'
 'of' '6' 'months']",[1. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02129348,"1:27:chronic_disease,",glomerular filtration rate less than 44ml/min/ 1.73m2,['glomerular' 'filtration' 'rate' 'less' 'than' '44ml/min/' '1.73m2'],[2. 2. 2. 0. 0. 0. 0.]
NCT02128906,37:61:cancer,with the exception of patients with bilateral tonsil cancers,"['with' 'the' 'exception' 'of' 'patients' 'with' 'bilateral' 'tonsil'
 'cancers']",[0. 0. 0. 0. 0. 0. 3. 3. 3.]
NCT02128802,7:26:treatment,Prior weight loss surgery,['Prior' 'weight' 'loss' 'surgery'],[0. 1. 1. 1.]
NCT02127658,"12:20:treatment,",who had an incision and drainage of a culture-confirmed MRSA abscess in the Riley Emergency Department or Riley Operating Room within the two weeks prior to enrollment,"['who' 'had' 'an' 'incision' 'and' 'drainage' 'of' 'a' 'culture-confirmed'
 'MRSA' 'abscess' 'in' 'the' 'Riley' 'Emergency' 'Department' 'or' 'Riley'
 'Operating' 'Room' 'within' 'the' 'two' 'weeks' 'prior' 'to' 'enrollment']","[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02125786,"23:44:cancer,,",Any patient with both metastatic ependymoma and age < 3 years at the time of enrollment,"['Any' 'patient' 'with' 'both' 'metastatic' 'ependymoma' 'and' 'age' '<'
 '3' 'years' 'at' 'the' 'time' 'of' 'enrollment']",[0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02124902,1:27:treatment,Sentinel lymph node biopsy,['Sentinel' 'lymph' 'node' 'biopsy'],[1. 1. 1. 1.]
NCT02124772,12:44:chronic_disease,History of heparin-induced thrombocytopenia,['History' 'of' 'heparin-induced' 'thrombocytopenia'],[0. 0. 2. 2.]
NCT02124772,1:31:treatment,prior treatment with sorafenib,['prior' 'treatment' 'with' 'sorafenib'],[1. 1. 1. 1.]
NCT02122328,11:15:chronic_disease,Confirmed TTTS patients,['Confirmed' 'TTTS' 'patients'],[0. 2. 0.]
NCT02122328,1:29:treatment,Prior intentional septostomy (purposely making a hole in the dividing membrane),"['Prior' 'intentional' 'septostomy' '(' 'purposely' 'making' 'a' 'hole'
 'in' 'the' 'dividing' 'membrane' ')']",[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02122185,",,,,49:58:cancer",CEA ratio > 25 OR CA =< 250 with no evidence of GI cancer,"['CEA' 'ratio' '>' '25' 'OR' 'CA' '=' '<' '250' 'with' 'no' 'evidence'
 'of' 'GI' 'cancer']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT02122081,1:17:chronic_disease,HIV seropositive,['HIV' 'seropositive'],[2. 2.]
NCT02121184,16:37:treatment,Use of chronic analgesic medications,['Use' 'of' 'chronic' 'analgesic' 'medications'],[0. 0. 0. 1. 1.]
NCT02121158,21:44:treatment,Stable condition on Optimal Medical Therapy,['Stable' 'condition' 'on' 'Optimal' 'Medical' 'Therapy'],[0. 0. 0. 1. 1. 1.]
NCT02120222,22:61:cancer,Patients with active central nervous system (CNS) malignancy,"['Patients' 'with' 'active' 'central' 'nervous' 'system' '(' 'CNS' ')'
 'malignancy']",[0. 0. 0. 3. 3. 3. 3. 3. 0. 0.]
NCT02118610,8:41:treatment,Taking herbal or homeopathic medications where the metabolism of the drug is not known,"['Taking' 'herbal' 'or' 'homeopathic' 'medications' 'where' 'the'
 'metabolism' 'of' 'the' 'drug' 'is' 'not' 'known']",[0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02115685,1:18:chronic_disease,unhealed decubiti,['unhealed' 'decubiti'],[2. 2.]
NCT02111850,58:94:allergy_name,History of severe immediate hypersensitivity reaction to any of the agents used in this study,"['History' 'of' 'severe' 'immediate' 'hypersensitivity' 'reaction' 'to'
 'any' 'of' 'the' 'agents' 'used' 'in' 'this' 'study']",[0. 0. 0. 0. 0. 0. 0. 4. 4. 4. 4. 4. 4. 4. 4.]
NCT02111824,",,92:129:treatment",subjects with peripheral lung lesions that are <1.5 cm in size who are planning to undergo percutaneous image guided lung biopsy as part of their routine medical care,"['subjects' 'with' 'peripheral' 'lung' 'lesions' 'that' 'are' '<' '1.5'
 'cm' 'in' 'size' 'who' 'are' 'planning' 'to' 'undergo' 'percutaneous'
 'image' 'guided' 'lung' 'biopsy' 'as' 'part' 'of' 'their' 'routine'
 'medical' 'care']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02110069,1:33:cancer,Kaposiform Hemangioendotheliomas,['Kaposiform' 'Hemangioendotheliomas'],[3. 3.]
NCT02110069,1:15:cancer,Tufted angioma,['Tufted' 'angioma'],[3. 3.]
NCT02109627,16:28:treatment,The effects of ficlatuzumab on the developing human fetus are unknown,"['The' 'effects' 'of' 'ficlatuzumab' 'on' 'the' 'developing' 'human'
 'fetus' 'are' 'unknown']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02108860,"16:19:treatment,",Treatment with CYC within 3 months prior to screening,['Treatment' 'with' 'CYC' 'within' '3' 'months' 'prior' 'to' 'screening'],[0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT02107703,",62:86:treatment",Have received recent (within 28 days prior to randomization) yellow fever vaccination,"['Have' 'received' 'recent' '(' 'within' '28' 'days' 'prior' 'to'
 'randomization' ')' 'yellow' 'fever' 'vaccination']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02106988,31:68:cancer,Patients with newly diagnosed stage I and II nasal NK cell lymphoma,"['Patients' 'with' 'newly' 'diagnosed' 'stage' 'I' 'and' 'II' 'nasal' 'NK'
 'cell' 'lymphoma']",[0. 0. 0. 0. 3. 3. 3. 3. 3. 3. 3. 3.]
NCT02106598,40:57:treatment,Newly diagnosed patients with previous excisional biopsy,['Newly' 'diagnosed' 'patients' 'with' 'previous' 'excisional' 'biopsy'],[0. 0. 0. 0. 0. 1. 1.]
NCT02106052,5:16:chronic_disease,All MS subtypes,['All' 'MS' 'subtypes'],[0. 2. 2.]
NCT02105766,76:91:treatment,Major anticipated illness or organ failure incompatible with survival from PBSC transplant,"['Major' 'anticipated' 'illness' 'or' 'organ' 'failure' 'incompatible'
 'with' 'survival' 'from' 'PBSC' 'transplant']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02105545,29:62:chronic_disease,"Patients may have existing, non-oncological genetic disorders","['Patients' 'may' 'have' 'existing' ',' 'non-oncological' 'genetic'
 'disorders']",[0. 0. 0. 0. 0. 2. 2. 2.]
NCT02102113,27:49:chronic_disease,Current or lifetime major DSM-IV Axis I disorder,['Current' 'or' 'lifetime' 'major' 'DSM-IV' 'Axis' 'I' 'disorder'],[0. 0. 0. 0. 2. 2. 2. 2.]
NCT02101944,32:72:treatment,Patients who are receiving any other therapeutic investigational agents,"['Patients' 'who' 'are' 'receiving' 'any' 'other' 'therapeutic'
 'investigational' 'agents']",[0. 0. 0. 0. 0. 1. 1. 1. 1.]
NCT02101853,18:23:cancer,"First relapse of B-ALL, allowable sites of disease include isolated bone marrow, combined bone marrow and CNS and/or testicular, and isolated CNS and/or testicular; extramedullary sites are limited to the CNS and testicles","['First' 'relapse' 'of' 'B-ALL' ',' 'allowable' 'sites' 'of' 'disease'
 'include' 'isolated' 'bone' 'marrow' ',' 'combined' 'bone' 'marrow' 'and'
 'CNS' 'and/or' 'testicular' ',' 'and' 'isolated' 'CNS' 'and/or'
 'testicular' ';' 'extramedullary' 'sites' 'are' 'limited' 'to' 'the'
 'CNS' 'and' 'testicles']","[0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02101853,21:32:chronic_disease,Patients with known optic nerve and/or retinal involvement,"['Patients' 'with' 'known' 'optic' 'nerve' 'and/or' 'retinal'
 'involvement']",[0. 0. 0. 2. 2. 0. 0. 0.]
NCT02101736,77:92:chronic_disease,Dental braces or prosthesis that interferes with volumetric analysis of the neurofibroma(s),"['Dental' 'braces' 'or' 'prosthesis' 'that' 'interferes' 'with'
 'volumetric' 'analysis' 'of' 'the' 'neurofibroma' '(' 's' ')']",[2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2.]
NCT02101034,1:31:treatment,Prior treatment with cetuximab for incurable disease is not permitted,"['Prior' 'treatment' 'with' 'cetuximab' 'for' 'incurable' 'disease' 'is'
 'not' 'permitted']",[1. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02100891,1:41:cancer,Diffuse intrinsic pontine gliomas (DIPG) are excluded,['Diffuse' 'intrinsic' 'pontine' 'gliomas' '(' 'DIPG' ')' 'are' 'excluded'],[3. 3. 3. 3. 3. 0. 0. 0. 0.]
NCT02099591,17:31:chronic_disease,newly diagnosed constatipation,['newly' 'diagnosed' 'constatipation'],[0. 0. 2.]
NCT02099058,26:45:treatment,Subjects enrolled on the combination therapy phase must satisfy the above exclusion criteria,"['Subjects' 'enrolled' 'on' 'the' 'combination' 'therapy' 'phase' 'must'
 'satisfy' 'the' 'above' 'exclusion' 'criteria']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02098252,53:72:treatment,Hemorrhagic presentation with mass effect requiring surgical management,"['Hemorrhagic' 'presentation' 'with' 'mass' 'effect' 'requiring'
 'surgical' 'management']",[0. 0. 0. 0. 0. 0. 1. 1.]
NCT02097121,1:4:chronic_disease,OAB symptoms not adequately managed by 1 or more anticholinergic agents,"['OAB' 'symptoms' 'not' 'adequately' 'managed' 'by' '1' 'or' 'more'
 'anticholinergic' 'agents']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02095678,39:75:allergy_name,Known history of allergic reaction to Magnetic Resonance contrast material,"['Known' 'history' 'of' 'allergic' 'reaction' 'to' 'Magnetic' 'Resonance'
 'contrast' 'material']",[0. 0. 0. 0. 0. 0. 4. 4. 4. 4.]
NCT02094794,",58:84:chronic_disease,,,,,,","Agreement of men AND women-of-child-bearing-potential to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately","['Agreement' 'of' 'men' 'AND' 'women-of-child-bearing-potential' 'to'
 'use' 'adequate' 'contraception' '(' 'hormonal' 'or' 'barrier' 'method'
 'of' 'birth' 'control' 'or' 'abstinence' ')' 'prior' 'to' 'study' 'entry'
 'and' 'for' 'six' 'months' 'following' 'duration' 'of' 'study'
 'participation' ';' 'should' 'a' 'woman' 'become' 'pregnant' 'or'
 'suspect' 'that' 'she' 'is' 'pregnant' 'while' 'participating' 'on' 'the'
 'trial' ',' 'she' 'should' 'inform' 'her' 'treating' 'physician'
 'immediately']","[0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02094118,1:34:chronic_disease,Immunoglobulin A (IgA) deficiency,['Immunoglobulin' 'A' '(' 'IgA' ')' 'deficiency'],[2. 2. 2. 2. 0. 0.]
NCT02092324,32:61:allergy_name,Previous allergic reactions to janus kinase (JAK) inhibitors or excipients,"['Previous' 'allergic' 'reactions' 'to' 'janus' 'kinase' '(' 'JAK' ')'
 'inhibitors' 'or' 'excipients']",[0. 0. 0. 0. 4. 4. 4. 4. 0. 0. 0. 0.]
NCT02092324,28:48:chronic_disease,subjects with a history of Hepatitis B and/or C are allowed on trial if the virus is undetected at the time of enrollment,"['subjects' 'with' 'a' 'history' 'of' 'Hepatitis' 'B' 'and/or' 'C' 'are'
 'allowed' 'on' 'trial' 'if' 'the' 'virus' 'is' 'undetected' 'at' 'the'
 'time' 'of' 'enrollment']",[0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02091999,9:34:treatment,Routine antimicrobial prophylaxis is permitted,['Routine' 'antimicrobial' 'prophylaxis' 'is' 'permitted'],[0. 1. 1. 0. 0.]
NCT02091141,",,82:89:chronic_disease",History or presence of clinically significant ventricular or atrial dysrhythmia >Grade 2 per NCI CTCAE v4.0,"['History' 'or' 'presence' 'of' 'clinically' 'significant' 'ventricular'
 'or' 'atrial' 'dysrhythmia' '>' 'Grade' '2' 'per' 'NCI' 'CTCAE' 'v4.0']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0.]
NCT02091141,19:42:chronic_disease,Participants with symptomatic bradycardia,['Participants' 'with' 'symptomatic' 'bradycardia'],[0. 0. 2. 2.]
NCT02089607,51:72:chronic_disease,Absence of a non-aneurysmal aortic segment in the distal thoracic aorta above the diaphragmatic hiatus,"['Absence' 'of' 'a' 'non-aneurysmal' 'aortic' 'segment' 'in' 'the'
 'distal' 'thoracic' 'aorta' 'above' 'the' 'diaphragmatic' 'hiatus']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0.]
NCT02089607,1:18:chronic_disease,Innominate artery,['Innominate' 'artery'],[2. 2.]
NCT02089607,24:40:chronic_disease,"Patients with ruptured aortic aneurysms requiring urgent or emergent repair, with the exception of patients with contained, stable ruptures with anatomy suitable for an off-the-shelf design","['Patients' 'with' 'ruptured' 'aortic' 'aneurysms' 'requiring' 'urgent'
 'or' 'emergent' 'repair' ',' 'with' 'the' 'exception' 'of' 'patients'
 'with' 'contained' ',' 'stable' 'ruptures' 'with' 'anatomy' 'suitable'
 'for' 'an' 'off-the-shelf' 'design']","[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02089607,39:55:treatment,The two vessels incorporated into the endograft repair would most commonly be the innominate artery and left common carotid artery,"['The' 'two' 'vessels' 'incorporated' 'into' 'the' 'endograft' 'repair'
 'would' 'most' 'commonly' 'be' 'the' 'innominate' 'artery' 'and' 'left'
 'common' 'carotid' 'artery']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02088554,1:20:treatment,Hostile mediastinum,['Hostile' 'mediastinum'],[1. 1.]
NCT02088554,22:43:chronic_disease,Patient has Grade IV Diastolic Dysfunction,['Patient' 'has' 'Grade' 'IV' 'Diastolic' 'Dysfunction'],[0. 0. 0. 0. 2. 2.]
NCT02088554,1:16:chronic_disease,Porcelain aorta,['Porcelain' 'aorta'],[2. 2.]
NCT02086500,"1:12:chronic_disease,,",Tachycardia (heart rate >110 beats per minute),['Tachycardia' '(' 'heart' 'rate' '>' '110' 'beats' 'per' 'minute' ')'],[2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02081404,12:25:treatment,A negative esophageal pH result and absence of erosions will be inclusion criteria for these patients,"['A' 'negative' 'esophageal' 'pH' 'result' 'and' 'absence' 'of' 'erosions'
 'will' 'be' 'inclusion' 'criteria' 'for' 'these' 'patients']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02081404,13:44:chronic_disease,Presence of macroscopic erosive esophagitis,['Presence' 'of' 'macroscopic' 'erosive' 'esophagitis'],[0. 0. 2. 2. 2.]
NCT02079857,1:15:chronic_disease,Alarm symptoms according to ROME III,['Alarm' 'symptoms' 'according' 'to' 'ROME' 'III'],[2. 2. 0. 0. 0. 0.]
NCT02078102,"33:55:treatment,",Patients must not have received myeloid growth factors within 2 weeks before mobilization attempt on this study,"['Patients' 'must' 'not' 'have' 'received' 'myeloid' 'growth' 'factors'
 'within' '2' 'weeks' 'before' 'mobilization' 'attempt' 'on' 'this'
 'study']",[0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02076906,50:54:treatment,Inability to tolerate stationary position during HIFU,['Inability' 'to' 'tolerate' 'stationary' 'position' 'during' 'HIFU'],[0. 0. 0. 0. 0. 0. 1.]
NCT02076906,1:26:treatment,Stem Cell Transplantation,['Stem' 'Cell' 'Transplantation'],[1. 1. 1.]
NCT02075710,1:30:chronic_disease,type 1 or 2 diabetes mellitus,['type' '1' 'or' '2' 'diabetes' 'mellitus'],[2. 2. 2. 2. 2. 2.]
NCT02075671,"8:47:treatment,",Use of laser or light based rosacea treatments (on the face) within 1 month prior to Visit 1,"['Use' 'of' 'laser' 'or' 'light' 'based' 'rosacea' 'treatments' '(' 'on'
 'the' 'face' ')' 'within' '1' 'month' 'prior' 'to' 'Visit' '1']",[0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02074631,"233:238:treatment,","Clinically significant fractures as defined by ISCD (a long bone fracture of the lower extremities, vertebral compression fracture, or two or more long bone fractures of the upper extremities) (88,89) indicated by a cast or a spine x-ray within the last 2 weeks","['Clinically' 'significant' 'fractures' 'as' 'defined' 'by' 'ISCD' '(' 'a'
 'long' 'bone' 'fracture' 'of' 'the' 'lower' 'extremities' ',' 'vertebral'
 'compression' 'fracture' ',' 'or' 'two' 'or' 'more' 'long' 'bone'
 'fractures' 'of' 'the' 'upper' 'extremities' ')' '(' '88,89' ')'
 'indicated' 'by' 'a' 'cast' 'or' 'a' 'spine' 'x-ray' 'within' 'the'
 'last' '2' 'weeks']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.
 0.]"
NCT02074436,1:26:chronic_disease,Grade 2 renal dysfunction,['Grade' '2' 'renal' 'dysfunction'],[2. 2. 2. 2.]
NCT02074436,19:38:treatment,Patient receiving antiplatelet agents,['Patient' 'receiving' 'antiplatelet' 'agents'],[0. 0. 1. 1.]
NCT02072148,"21:59:treatment,",Participation in an investigational therapeutic drug trial within 30 days of study entry,"['Participation' 'in' 'an' 'investigational' 'therapeutic' 'drug' 'trial'
 'within' '30' 'days' 'of' 'study' 'entry']",[0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02069925,",25:40:chronic_disease",Within first 3 years of psychosis onset (per pre-defined SOS threshold criteria),"['Within' 'first' '3' 'years' 'of' 'psychosis' 'onset' '(' 'per'
 'pre-defined' 'SOS' 'threshold' 'criteria' ')']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02068092,1:31:treatment,Prior breast reduction surgery,['Prior' 'breast' 'reduction' 'surgery'],[1. 1. 1. 1.]
NCT02064296,45:67:treatment,Able to travel to the study site to receive acupuncture treatments up to two times weekly,"['Able' 'to' 'travel' 'to' 'the' 'study' 'site' 'to' 'receive'
 'acupuncture' 'treatments' 'up' 'to' 'two' 'times' 'weekly']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02064036,1:26:treatment,Previous hormonal therapy,['Previous' 'hormonal' 'therapy'],[1. 1. 1.]
NCT02063438,21:36:chronic_disease,Previous history of thoracic trauma on the operative side,"['Previous' 'history' 'of' 'thoracic' 'trauma' 'on' 'the' 'operative'
 'side']",[0. 0. 0. 2. 2. 0. 0. 0. 0.]
NCT02061293,"12:24:treatment,,","History of hallucinogen use disorder, or any use in the past 1 year, or >25 lifetime uses","['History' 'of' 'hallucinogen' 'use' 'disorder' ',' 'or' 'any' 'use' 'in'
 'the' 'past' '1' 'year' ',' 'or' '>' '25' 'lifetime' 'uses']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02059239,",,,,95:98:treatment",Partial response of >50% reduction in bidirectional area of masses and SUV reduction to <8 in PET avid areas Subjects must have evaluable disease,"['Partial' 'response' 'of' '>' '50' '%' 'reduction' 'in' 'bidirectional'
 'area' 'of' 'masses' 'and' 'SUV' 'reduction' 'to' '<' '8' 'in' 'PET'
 'avid' 'areas' 'Subjects' 'must' 'have' 'evaluable' 'disease']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02058095,1:10:treatment,Doxazosin,['Doxazosin'],[1.]
NCT02058095,1:11:treatment,Tamsulosin,['Tamsulosin'],[1.]
NCT02057133,46:83:treatment,"For Parts A, B, C, D, E, F, H: Have received prior therapy with a CDK4/6 inhibitor","['For' 'Parts' 'A' ',' 'B' ',' 'C' ',' 'D' ',' 'E' ',' 'F' ',' 'H' ':'
 'Have' 'received' 'prior' 'therapy' 'with' 'a' 'CDK4/6' 'inhibitor']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1.]
NCT02056873,31:74:treatment,History of noncompliance with previous medical and psychosocial treatment efforts,"['History' 'of' 'noncompliance' 'with' 'previous' 'medical' 'and'
 'psychosocial' 'treatment' 'efforts']",[0. 0. 0. 0. 1. 1. 1. 1. 1. 0.]
NCT02056470,20:35:treatment,Patients requiring knee prosthesis,['Patients' 'requiring' 'knee' 'prosthesis'],[0. 0. 1. 1.]
NCT02056470,1:28:chronic_disease,systemic lupus erythmatosus,['systemic' 'lupus' 'erythmatosus'],[2. 2. 2.]
NCT02053909,",,53:74:treatment",Serum creatinine >1.8 mg/dL (need for contrast with CT coronary angiogram),"['Serum' 'creatinine' '>' '1.8' 'mg/dL' '(' 'need' 'for' 'contrast' 'with'
 'CT' 'coronary' 'angiogram' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0.]
NCT02053792,"20:26:treatment,",Intravenous use of rIX-FP within 14 days of subcutaneous administration of rIX-FP,"['Intravenous' 'use' 'of' 'rIX-FP' 'within' '14' 'days' 'of'
 'subcutaneous' 'administration' 'of' 'rIX-FP']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02053792,12:26:chronic_disease,congenital FIX deficiency,['congenital' 'FIX' 'deficiency'],[0. 2. 2.]
NCT02053766,33:58:chronic_disease,Subject has been diagnosed with mitochondrial dysfunction based on modified Walker criteria,"['Subject' 'has' 'been' 'diagnosed' 'with' 'mitochondrial' 'dysfunction'
 'based' 'on' 'modified' 'Walker' 'criteria']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02053246,"32:62:chronic_disease,,,,",with World Health Organization Group 2 Pulmonary Hypertension (Mean pulmonary artery pressure ≥ 25 mmHg and pulmonary capillary wedge pressure ≥ 15 mmHg),"['with' 'World' 'Health' 'Organization' 'Group' '2' 'Pulmonary'
 'Hypertension' '(' 'Mean' 'pulmonary' 'artery' 'pressure' '≥' '25' 'mmHg'
 'and' 'pulmonary' 'capillary' 'wedge' 'pressure' '≥' '15' 'mmHg' ')']","[0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02050347,",,141:153:treatment",Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after ATL infusion,"['Sexually' 'active' 'patients' 'must' 'be' 'willing' 'to' 'utilize' 'one'
 'of' 'the' 'more' 'effective' 'birth' 'control' 'methods' 'during' 'the'
 'study' 'and' 'for' '6' 'months' 'after' 'ATL' 'infusion']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 1.]"
NCT02050113,"12:23:treatment,,,",For use of Zenith Flex: diameter >32 mm or <18 mm,"['For' 'use' 'of' 'Zenith' 'Flex' ':' 'diameter' '>' '32' 'mm' 'or' '<'
 '18' 'mm']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02050113,71:75:treatment,"Proximal neck, measured outer wall to outer wall on a sectional image (CT)","['Proximal' 'neck' ',' 'measured' 'outer' 'wall' 'to' 'outer' 'wall' 'on'
 'a' 'sectional' 'image' '(' 'CT' ')']",[1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.]
NCT02048371,52:63:cancer,"Patients with documentation of well differentiated liposarcoma only (of the well differentiated/dedifferentiated liposarcoma family) are specifically excluded, owing to its characteristically slow growth","['Patients' 'with' 'documentation' 'of' 'well' 'differentiated'
 'liposarcoma' 'only' '(' 'of' 'the' 'well'
 'differentiated/dedifferentiated' 'liposarcoma' 'family' ')' 'are'
 'specifically' 'excluded' ',' 'owing' 'to' 'its' 'characteristically'
 'slow' 'growth']","[0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02046395,1:16:chronic_disease,Type 2 Diabetes,['Type' '2' 'Diabetes'],[2. 2. 2.]
NCT02046330,43:47:treatment,Presence of a condition requiring routine MRIs,['Presence' 'of' 'a' 'condition' 'requiring' 'routine' 'MRIs'],[0. 0. 0. 0. 0. 0. 1.]
NCT02043392,46:68:treatment,Requires non-emergent operation to create an intestinal anastomosis for maintenance of intestinal continuity in which the Magnamosis device can be used instead of sutures or staples,"['Requires' 'non-emergent' 'operation' 'to' 'create' 'an' 'intestinal'
 'anastomosis' 'for' 'maintenance' 'of' 'intestinal' 'continuity' 'in'
 'which' 'the' 'Magnamosis' 'device' 'can' 'be' 'used' 'instead' 'of'
 'sutures' 'or' 'staples']","[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02041936,"59:81:treatment,","Receive non-conventional fractionation schedules, such as stereotactic radiation (5 fractions or less)","['Receive' 'non-conventional' 'fractionation' 'schedules' ',' 'such' 'as'
 'stereotactic' 'radiation' '(' '5' 'fractions' 'or' 'less' ')']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02041936,1:20:treatment,pancuronium bromide,['pancuronium' 'bromide'],[1. 1.]
NCT02038257,12:26:chronic_disease,History of Acral Vitiligo,['History' 'of' 'Acral' 'Vitiligo'],[0. 0. 2. 2.]
NCT02037048,28:61:treatment,Patients who have received pelvic external beam radiotherapy are not eligible,"['Patients' 'who' 'have' 'received' 'pelvic' 'external' 'beam'
 'radiotherapy' 'are' 'not' 'eligible']",[0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0.]
NCT02036853,23:63:chronic_disease,"History of or current suicidal ideation, behavior and attempts","['History' 'of' 'or' 'current' 'suicidal' 'ideation' ',' 'behavior' 'and'
 'attempts']",[0. 0. 0. 0. 2. 2. 2. 2. 2. 0.]
NCT02035137,11:26:chronic_disease,They have active diarhhea,['They' 'have' 'active' 'diarhhea'],[0. 0. 2. 2.]
NCT02033616,1:41:cancer,Active central nervous system metastases at the time of treatment,"['Active' 'central' 'nervous' 'system' 'metastases' 'at' 'the' 'time' 'of'
 'treatment']",[3. 3. 3. 3. 3. 0. 0. 0. 0. 0.]
NCT02031250,1:30:treatment,Prior head and neck radiation,['Prior' 'head' 'and' 'neck' 'radiation'],[1. 1. 1. 1. 1.]
NCT02030015,33:77:chronic_disease,Subjects must have a documented infantile or juvenile gangliosidosis disease,"['Subjects' 'must' 'have' 'a' 'documented' 'infantile' 'or' 'juvenile'
 'gangliosidosis' 'disease']",[0. 0. 0. 0. 0. 2. 2. 2. 2. 2.]
NCT02025543,21:47:treatment,contraindication to magnetic resonance imaging,['contraindication' 'to' 'magnetic' 'resonance' 'imaging'],[0. 0. 1. 1. 1.]
NCT02025023,20:28:chronic_disease,Single or multiple chalazia in a single eyelid,['Single' 'or' 'multiple' 'chalazia' 'in' 'a' 'single' 'eyelid'],[0. 0. 0. 2. 0. 0. 0. 0.]
NCT02021578,1:10:chronic_disease,Bipolar I (parent or child),['Bipolar' 'I' '(' 'parent' 'or' 'child' ')'],[2. 2. 0. 0. 0. 0. 0.]
NCT02020707,"1:28:treatment,,",Therapeutic anticoagulation requiring international normalized ratio (INR) > 2.0,"['Therapeutic' 'anticoagulation' 'requiring' 'international' 'normalized'
 'ratio' '(' 'INR' ')' '>' '2.0']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02020018,1:8:treatment,Steroid-dependent patients,['Steroid-dependent' 'patients'],[1. 0.]
NCT02019940,"1:23:chronic_disease,",Substance use disorder during the 3 months prior to screening; except for Cannabis and Alcohol use Disorders,"['Substance' 'use' 'disorder' 'during' 'the' '3' 'months' 'prior' 'to'
 'screening' ';' 'except' 'for' 'Cannabis' 'and' 'Alcohol' 'use'
 'Disorders']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02019641,1:27:chronic_disease,Severe psychiatric disease,['Severe' 'psychiatric' 'disease'],[2. 2. 2.]
NCT02016781,1:45:chronic_disease,Human Immunodeficiency Virus (HIV) infection,['Human' 'Immunodeficiency' 'Virus' '(' 'HIV' ')' 'infection'],[2. 2. 2. 2. 2. 0. 0.]
NCT02016781,"15:26:chronic_disease,","Patients with de novo MDS who have, or have previously had, Intermediate-2 or High risk disease as determined by the International Prognostic Scoring System (IPSS)","['Patients' 'with' 'de' 'novo' 'MDS' 'who' 'have' ',' 'or' 'have'
 'previously' 'had' ',' 'Intermediate-2' 'or' 'High' 'risk' 'disease' 'as'
 'determined' 'by' 'the' 'International' 'Prognostic' 'Scoring' 'System'
 '(' 'IPSS' ')']","[0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02016781,"1:18:chronic_disease,",Refractory anemia with ringed sideroblasts (RARS),['Refractory' 'anemia' 'with' 'ringed' 'sideroblasts' '(' 'RARS' ')'],[2. 2. 0. 0. 0. 0. 0. 0.]
NCT02015390,1:71:chronic_disease,"Ipsilateral extremity defect (eg, tibia and femur ipsilateral defects)","['Ipsilateral' 'extremity' 'defect' '(' 'eg' ',' 'tibia' 'and' 'femur'
 'ipsilateral' 'defects' ')']",[2. 2. 2. 2. 2. 2. 2. 2. 2. 0. 0. 0.]
NCT02013778,1:11:treatment,Prior TACE,['Prior' 'TACE'],[1. 1.]
NCT02013154,7:35:cancer,Known osteoblastic bony metastasis,['Known' 'osteoblastic' 'bony' 'metastasis'],[0. 3. 3. 3.]
NCT02013154,"1:33:treatment,",Treatment with radiation therapy within 14 days prior to study entry,"['Treatment' 'with' 'radiation' 'therapy' 'within' '14' 'days' 'prior'
 'to' 'study' 'entry']",[1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02011971,"8:40:treatment,,",Stable antiepileptic drug (AED) therapy for last 2 months or more and willing not to change for 2 months,"['Stable' 'antiepileptic' 'drug' '(' 'AED' ')' 'therapy' 'for' 'last' '2'
 'months' 'or' 'more' 'and' 'willing' 'not' 'to' 'change' 'for' '2'
 'months']",[0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02008656,1:13:cancer,Rectal tumor at baseline which would be considered to require complete TME,"['Rectal' 'tumor' 'at' 'baseline' 'which' 'would' 'be' 'considered' 'to'
 'require' 'complete' 'TME']",[3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02008136,1:19:chronic_disease,myotonic dystrophy,['myotonic' 'dystrophy'],[2. 2.]
NCT02007239,38:93:treatment,On-going or planned participation in another clinical trial involving HLH-directed treatment,"['On-going' 'or' 'planned' 'participation' 'in' 'another' 'clinical'
 'trial' 'involving' 'HLH-directed' 'treatment']",[0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1.]
NCT02006069,1:14:chronic_disease,Persistent AF at the time of enrollment,['Persistent' 'AF' 'at' 'the' 'time' 'of' 'enrollment'],[2. 2. 0. 0. 0. 0. 0.]
NCT02004275,55:69:treatment,Patients randomized to Arm 1 may opt to switch to the 3-drug regimen following disease progression; these patients must be re-registered to the study and meet the eligibility criteria,"['Patients' 'randomized' 'to' 'Arm' '1' 'may' 'opt' 'to' 'switch' 'to'
 'the' '3-drug' 'regimen' 'following' 'disease' 'progression' ';' 'these'
 'patients' 'must' 'be' 're-registered' 'to' 'the' 'study' 'and' 'meet'
 'the' 'eligibility' 'criteria']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02004275,16:48:treatment,progression on lenalidomide maintenance therapy after initial induction +/- consolidation,"['progression' 'on' 'lenalidomide' 'maintenance' 'therapy' 'after'
 'initial' 'induction' '+/-' 'consolidation']",[0. 0. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02003690,22:47:treatment,willing to engage in pharmacotherapy treatment at the CABS specialty clinic,"['willing' 'to' 'engage' 'in' 'pharmacotherapy' 'treatment' 'at' 'the'
 'CABS' 'specialty' 'clinic']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02003222,1:20:treatment,MAINTENANCE THERAPY,['MAINTENANCE' 'THERAPY'],[1. 1.]
NCT02003222,26:57:chronic_disease,Patient must not have an antecedent hematologic disorder,['Patient' 'must' 'not' 'have' 'an' 'antecedent' 'hematologic' 'disorder'],[0. 0. 0. 0. 0. 2. 2. 2.]
NCT02000115,37:69:treatment,Subjects with pre-existing surgical bioprosthetic aortic heart valve should be considered for the Valve-in-Valve registry,"['Subjects' 'with' 'pre-existing' 'surgical' 'bioprosthetic' 'aortic'
 'heart' 'valve' 'should' 'be' 'considered' 'for' 'the' 'Valve-in-Valve'
 'registry']",[0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT01996449,21:34:allergy_name,Hypersensitivity to nitroprusside,['Hypersensitivity' 'to' 'nitroprusside'],[0. 0. 4.]
NCT01994538,29:50:treatment,Treatment initiated with an empiric antimicrobial to which the organism isolated in the urine culture is non-susceptible based on standard laboratory criteria,"['Treatment' 'initiated' 'with' 'an' 'empiric' 'antimicrobial' 'to'
 'which' 'the' 'organism' 'isolated' 'in' 'the' 'urine' 'culture' 'is'
 'non-susceptible' 'based' 'on' 'standard' 'laboratory' 'criteria']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01994382,10:36:treatment,Received BCR and/or BCL2 inhibitors were intolerant or had relapsed/refractory disease afterwards,"['Received' 'BCR' 'and/or' 'BCL2' 'inhibitors' 'were' 'intolerant' 'or'
 'had' 'relapsed/refractory' 'disease' 'afterwards']",[0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT01993810,15:45:chronic_disease,Patients with non-malignant pleural effusion,['Patients' 'with' 'non-malignant' 'pleural' 'effusion'],[0. 0. 2. 2. 2.]
NCT01992861,15:59:cancer,Patients with small cell/neuroendocrine cervical carcinoma,['Patients' 'with' 'small' 'cell/neuroendocrine' 'cervical' 'carcinoma'],[0. 0. 3. 3. 3. 3.]
NCT01990209,",,97:121:treatment",Patient has recovered (to Grade ≤1) from all clinically significant toxicities related to prior antineoplastic therapies,"['Patient' 'has' 'recovered' '(' 'to' 'Grade' '≤1' ')' 'from' 'all'
 'clinically' 'significant' 'toxicities' 'related' 'to' 'prior'
 'antineoplastic' 'therapies']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01990209,"1:16:cancer,,,",Triple negative (ER-/PR-/HER2-),['Triple' 'negative' '(' 'ER-/PR-/HER2-' ')'],[3. 3. 0. 0. 0.]
NCT01989546,23:63:treatment,Patients who have had prior treatment with any PARP inhibitors are ineligible,"['Patients' 'who' 'have' 'had' 'prior' 'treatment' 'with' 'any' 'PARP'
 'inhibitors' 'are' 'ineligible']",[0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0.]
NCT01988246,"1:70:treatment,",Intravitreal anti-VEGF (vascular endothelial growth factor) treatment in the study eye within 6 months of the pre-operative baseline visit,"['Intravitreal' 'anti-VEGF' '(' 'vascular' 'endothelial' 'growth' 'factor'
 ')' 'treatment' 'in' 'the' 'study' 'eye' 'within' '6' 'months' 'of' 'the'
 'pre-operative' 'baseline' 'visit']",[1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01986075,1:26:chronic_disease,Coronary vascular disease,['Coronary' 'vascular' 'disease'],[2. 2. 2.]
NCT01983462,"1:29:treatment,,,,,,,,","Blood chemistries indicative of normal renal (creatinine <2.0 mg/dl), liver (<3 times upper limit for ALT, AST), and thyroid function (TSH between 0.4 - 5.0 mU/L)","['Blood' 'chemistries' 'indicative' 'of' 'normal' 'renal' '(' 'creatinine'
 '<' '2.0' 'mg/dl' ')' ',' 'liver' '(' '<' '3' 'times' 'upper' 'limit'
 'for' 'ALT' ',' 'AST' ')' ',' 'and' 'thyroid' 'function' '(' 'TSH'
 'between' '0.4' '-' '5.0' 'mU/L' ')']","[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01978509,1:14:chronic_disease,Toxic colitis,['Toxic' 'colitis'],[2. 2.]
NCT01976429,10:28:chronic_disease,existing middle-ear disease,['existing' 'middle-ear' 'disease'],[0. 2. 2.]
NCT01974609,36:65:treatment,All patients undergoing elective a primary carpal tunnel release,"['All' 'patients' 'undergoing' 'elective' 'a' 'primary' 'carpal' 'tunnel'
 'release']",[0. 0. 0. 0. 0. 1. 1. 1. 1.]
NCT01973283,"25:28:treatment,",Currently followed by a PCP (had an eval in last 6-months),"['Currently' 'followed' 'by' 'a' 'PCP' '(' 'had' 'an' 'eval' 'in' 'last'
 '6-months' ')']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01972919,36:46:chronic_disease,Patients with and without regional adenopathy are eligible,"['Patients' 'with' 'and' 'without' 'regional' 'adenopathy' 'are'
 'eligible']",[0. 0. 0. 0. 0. 2. 0. 0.]
NCT01970345,105:125:treatment,Patients with comorbid conditions deemed too medically compromised to tolerate the risk of experimental treatment with IGF-1,"['Patients' 'with' 'comorbid' 'conditions' 'deemed' 'too' 'medically'
 'compromised' 'to' 'tolerate' 'the' 'risk' 'of' 'experimental'
 'treatment' 'with' 'IGF-1']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT01970306,47:64:allergy_name,Patients with known sensitivity or allergy to porcine materials,"['Patients' 'with' 'known' 'sensitivity' 'or' 'allergy' 'to' 'porcine'
 'materials']",[0. 0. 0. 0. 0. 0. 0. 4. 4.]
NCT01969643,25:48:treatment,prior treatment with an MMAE-containing therapy,['prior' 'treatment' 'with' 'an' 'MMAE-containing' 'therapy'],[0. 0. 0. 0. 1. 1.]
NCT01968590,1:48:cancer,malignant peripheral nerve sheath tumor (MPNST),['malignant' 'peripheral' 'nerve' 'sheath' 'tumor' '(' 'MPNST' ')'],[3. 3. 3. 3. 3. 3. 0. 0.]
NCT01967823,25:35:cancer,PATIENTS WITH MALIGNANT MENINGIOMA,['PATIENTS' 'WITH' 'MALIGNANT' 'MENINGIOMA'],[0. 0. 0. 3.]
NCT01967238,40:60:treatment,Willing to receive a single dose of an FDA-approved vaccine,"['Willing' 'to' 'receive' 'a' 'single' 'dose' 'of' 'an' 'FDA-approved'
 'vaccine']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01966367,1:23:chronic_disease,Seropositivity for HIV,['Seropositivity' 'for' 'HIV'],[2. 2. 2.]
NCT01964261,1:22:chronic_disease,Autonomic dysreflexia,['Autonomic' 'dysreflexia'],[2. 2.]
NCT01964261,1:19:treatment,Prior cranioplasty,['Prior' 'cranioplasty'],[1. 1.]
NCT01962415,1:31:chronic_disease,Bare Lymphocyte Syndrome (BLS),['Bare' 'Lymphocyte' 'Syndrome' '(' 'BLS' ')'],[2. 2. 2. 2. 0. 0.]
NCT01962415,1:52:chronic_disease,Combined Variable Immune Deficiency (CVID) syndrome,['Combined' 'Variable' 'Immune' 'Deficiency' '(' 'CVID' ')' 'syndrome'],[2. 2. 2. 2. 2. 2. 0. 0.]
NCT01962415,1:28:chronic_disease,Dyskeratosis Congenita (DC),['Dyskeratosis' 'Congenita' '(' 'DC' ')'],[2. 2. 2. 0. 0.]
NCT01962415,1:25:chronic_disease,Hunter syndrome (MPS II),['Hunter' 'syndrome' '(' 'MPS' 'II' ')'],[2. 2. 2. 2. 0. 0.]
NCT01962415,1:30:chronic_disease,Leukocyte adhesion deficiency,['Leukocyte' 'adhesion' 'deficiency'],[2. 2. 2.]
NCT01962415,1:22:chronic_disease,Mucopolysaccharidoses,['Mucopolysaccharidoses'],[2.]
NCT01962415,1:25:chronic_disease,Primary Immunodeficiency syndromes,['Primary' 'Immunodeficiency' 'syndromes'],[2. 2. 0.]
NCT01962415,8:32:chronic_disease,Severe acquired aplastic anemia,['Severe' 'acquired' 'aplastic' 'anemia'],[0. 2. 2. 2.]
NCT01962415,1:36:chronic_disease,X-linked adrenoleukodystrophy (ALD),['X-linked' 'adrenoleukodystrophy' '(' 'ALD' ')'],[2. 2. 2. 0. 0.]
NCT01961778,22:42:allergy_name,contraindications to endoscopic treatment,['contraindications' 'to' 'endoscopic' 'treatment'],[0. 0. 4. 4.]
NCT01959698,"1:19:chronic_disease,",Myocardial infarct within 6 months before enrollment,['Myocardial' 'infarct' 'within' '6' 'months' 'before' 'enrollment'],[2. 2. 0. 0. 0. 0. 0.]
NCT01956084,"31:60:treatment,",Patients should have been off other investigational therapy for one month prior to entry in this study,"['Patients' 'should' 'have' 'been' 'off' 'other' 'investigational'
 'therapy' 'for' 'one' 'month' 'prior' 'to' 'entry' 'in' 'this' 'study']",[0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01954173,1:43:chronic_disease,Acquired immune deficiency syndrome (AIDS),['Acquired' 'immune' 'deficiency' 'syndrome' '(' 'AIDS' ')'],[2. 2. 2. 2. 2. 0. 0.]
NCT01953900,7:32:chronic_disease,Known primary immune deficiency,['Known' 'primary' 'immune' 'deficiency'],[0. 2. 2. 2.]
NCT01953588,1:18:treatment,Surgical axillary staging procedure prior to study entry,['Surgical' 'axillary' 'staging' 'procedure' 'prior' 'to' 'study' 'entry'],[1. 1. 0. 0. 0. 0. 0. 0.]
NCT01953263,15:35:chronic_disease,Patients with urinary incontinence other than the categories being investigated,"['Patients' 'with' 'urinary' 'incontinence' 'other' 'than' 'the'
 'categories' 'being' 'investigated']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT01952730,1:19:cancer,Hepatic metastases involving both branches of the portal vein or all three hepatic veins,"['Hepatic' 'metastases' 'involving' 'both' 'branches' 'of' 'the' 'portal'
 'vein' 'or' 'all' 'three' 'hepatic' 'veins']",[3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01951885,",,47:56:treatment",Total body irradiation (TBI) (≥ 1200 cGy) and etoposide (60 mg/kg),"['Total' 'body' 'irradiation' '(' 'TBI' ')' '(' '≥' '1200' 'cGy' ')' 'and'
 'etoposide' '(' '60' 'mg/kg' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT01947140,57:90:chronic_disease,Patients must have histologically confirmed relapsed or refractory Non-Hodgkin's lymphoma,"['Patients' 'must' 'have' 'histologically' 'confirmed' 'relapsed' 'or'
 'refractory' 'Non-Hodgkin' ""'s"" 'lymphoma']",[0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0.]
NCT01945814,11:54:treatment,Available multivirus-specific cytotoxic T lymphocytes,['Available' 'multivirus-specific' 'cytotoxic' 'T' 'lymphocytes'],[0. 1. 1. 1. 1.]
NCT01943851,1:22:chronic_disease,Cardiac abnormalities as evidenced by,['Cardiac' 'abnormalities' 'as' 'evidenced' 'by'],[2. 2. 0. 0. 0.]
NCT01942018,1:32:chronic_disease,Acute gastrointestinal bleeding,['Acute' 'gastrointestinal' 'bleeding'],[2. 2. 2.]
NCT01942018,7:30:chronic_disease,Large esophageal diverticulum,['Large' 'esophageal' 'diverticulum'],[0. 2. 2.]
NCT01942018,"6:27:chronic_disease,,,",with symptomatic dysphagia (dysphagia score ≥2) EGOO that is diagnosed by high resolution manometry,"['with' 'symptomatic' 'dysphagia' '(' 'dysphagia' 'score' '≥2' ')' 'EGOO'
 'that' 'is' 'diagnosed' 'by' 'high' 'resolution' 'manometry']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01941316,43:70:treatment,Patients must have disease outside of the previous surgical resection area or a new lesion must be present,"['Patients' 'must' 'have' 'disease' 'outside' 'of' 'the' 'previous'
 'surgical' 'resection' 'area' 'or' 'a' 'new' 'lesion' 'must' 'be'
 'present']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01940757,12:34:chronic_disease,History of iron deficiency anemia,['History' 'of' 'iron' 'deficiency' 'anemia'],[0. 0. 2. 2. 2.]
NCT01937884,16:38:chronic_disease,A pre-existing bronchopleural fistula,['A' 'pre-existing' 'bronchopleural' 'fistula'],[0. 0. 2. 2.]
NCT01937884,4:46:treatment,On extracorporeal membrane oxygenation (ECMO),['On' 'extracorporeal' 'membrane' 'oxygenation' '(' 'ECMO' ')'],[0. 1. 1. 1. 1. 0. 0.]
NCT01931202,1:20:chronic_disease,Adjustment Disorder,['Adjustment' 'Disorder'],[2. 2.]
NCT01925573,5:35:treatment,Any prior therapy with bevacizumab,['Any' 'prior' 'therapy' 'with' 'bevacizumab'],[0. 1. 1. 1. 1.]
NCT01925131,"1:40:treatment,",Chimeric antigen receptor (CAR) T-cells must not have been received for 28 days prior to registration,"['Chimeric' 'antigen' 'receptor' '(' 'CAR' ')' 'T-cells' 'must' 'not'
 'have' 'been' 'received' 'for' '28' 'days' 'prior' 'to' 'registration']",[1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01925131,75:106:allergy_name,Patients with a history of a serious allergic or anaphylactic reaction to humanized monoclonal antibodies are not eligible,"['Patients' 'with' 'a' 'history' 'of' 'a' 'serious' 'allergic' 'or'
 'anaphylactic' 'reaction' 'to' 'humanized' 'monoclonal' 'antibodies'
 'are' 'not' 'eligible']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 4. 4. 0. 0. 0.]
NCT01925131,"29:46:chronic_disease,",patients must have negative hepatitis B and C serologies performed within 28 days prior to registration,"['patients' 'must' 'have' 'negative' 'hepatitis' 'B' 'and' 'C'
 'serologies' 'performed' 'within' '28' 'days' 'prior' 'to' 'registration']",[0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01923662,12:34:chronic_disease,"History of vestibular dysfunction, balance problems or spontaneous falls","['History' 'of' 'vestibular' 'dysfunction' ',' 'balance' 'problems' 'or'
 'spontaneous' 'falls']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT01919619,7:26:chronic_disease,Prior auto-immune disease,['Prior' 'auto-immune' 'disease'],[0. 2. 2.]
NCT01918683,"1:24:chronic_disease,",Active GI ulcer disease within 4 weeks of study enrollment,"['Active' 'GI' 'ulcer' 'disease' 'within' '4' 'weeks' 'of' 'study'
 'enrollment']",[2. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT01918644,30:68:cancer,Patients with no evidence of regional or distant metastatic disease based on CT scan of the chest/ abdomen/pelvis,"['Patients' 'with' 'no' 'evidence' 'of' 'regional' 'or' 'distant'
 'metastatic' 'disease' 'based' 'on' 'CT' 'scan' 'of' 'the' 'chest/'
 'abdomen/pelvis']",[0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01917929,15:55:chronic_disease,"Patient has a neuromuscular or neurosensory deficiency that would create an unacceptable risk of instability, prosthesis fixation failure or complications in postoperative care, or which limits the ability to evaluate the safety and efficacy of the device","['Patient' 'has' 'a' 'neuromuscular' 'or' 'neurosensory' 'deficiency'
 'that' 'would' 'create' 'an' 'unacceptable' 'risk' 'of' 'instability' ','
 'prosthesis' 'fixation' 'failure' 'or' 'complications' 'in'
 'postoperative' 'care' ',' 'or' 'which' 'limits' 'the' 'ability' 'to'
 'evaluate' 'the' 'safety' 'and' 'efficacy' 'of' 'the' 'device']","[0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01915095,71:81:treatment,Able to perform some small wrist flexion and extension (measured by a goniometer),"['Able' 'to' 'perform' 'some' 'small' 'wrist' 'flexion' 'and' 'extension'
 '(' 'measured' 'by' 'a' 'goniometer' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT01913106,1:21:cancer,Second active cancer,['Second' 'active' 'cancer'],[3. 3. 3.]
NCT01912612,14:35:chronic_disease,Uncontrolled narrow-angle glaucoma,['Uncontrolled' 'narrow-angle' 'glaucoma'],[0. 2. 2.]
NCT01908777,11:32:chronic_disease,Any known cardiac abnormalities,['Any' 'known' 'cardiac' 'abnormalities'],[0. 0. 2. 2.]
NCT01908777,1:42:cancer,Hepatosplenic Gamma Delta T cell lymphoma,['Hepatosplenic' 'Gamma' 'Delta' 'T' 'cell' 'lymphoma'],[3. 3. 3. 3. 3. 3.]
NCT01908777,1:42:treatment,prior autologous or allogeneic transplant,['prior' 'autologous' 'or' 'allogeneic' 'transplant'],[1. 1. 1. 1. 1.]
NCT01905046,20:25:treatment,Willing to provide RPFNA and blood samples for correlative research purposes,"['Willing' 'to' 'provide' 'RPFNA' 'and' 'blood' 'samples' 'for'
 'correlative' 'research' 'purposes']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT01903330,13:45:cancer,presence of punctate hemorrhage in the tumor,['presence' 'of' 'punctate' 'hemorrhage' 'in' 'the' 'tumor'],[0. 0. 3. 3. 3. 3. 3.]
NCT01901562,6:26:cancer,Have BRCA 1 or 2 mutation,['Have' 'BRCA' '1' 'or' '2' 'mutation'],[0. 3. 3. 3. 3. 3.]
NCT01900093,"12:43:treatment,",Received a live or live attenuated vaccine in the last 30 days before baseline,"['Received' 'a' 'live' 'or' 'live' 'attenuated' 'vaccine' 'in' 'the'
 'last' '30' 'days' 'before' 'baseline']",[0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT01896999,68:100:cancer,Patients must have pathologically confirmed relapsed or refractory classical Hodgkin lymphoma (cHL),"['Patients' 'must' 'have' 'pathologically' 'confirmed' 'relapsed' 'or'
 'refractory' 'classical' 'Hodgkin' 'lymphoma' '(' 'cHL' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0.]
NCT01896921,"1:37:chronic_disease,",Chronic active hepatitis B infection as defined by presence of HBsAg,"['Chronic' 'active' 'hepatitis' 'B' 'infection' 'as' 'defined' 'by'
 'presence' 'of' 'HBsAg']",[2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT01895777,88:95:allergy_name,Patients who are allergic/sensitive to any component of the study medication including solvent,"['Patients' 'who' 'are' 'allergic/sensitive' 'to' 'any' 'component' 'of'
 'the' 'study' 'medication' 'including' 'solvent']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4.]
NCT01895777,1:29:treatment,unfractionated heparin (UFH),['unfractionated' 'heparin' '(' 'UFH' ')'],[1. 1. 1. 0. 0.]
NCT01894061,24:41:treatment,Minimum interval since last drug therapy,['Minimum' 'interval' 'since' 'last' 'drug' 'therapy'],[0. 0. 0. 1. 1. 1.]
NCT01893307,11:25:treatment,Bilateral Neck Radiation,['Bilateral' 'Neck' 'Radiation'],[0. 1. 1.]
NCT01891812,36:39:treatment,any contraindications to receiving N2O,['any' 'contraindications' 'to' 'receiving' 'N2O'],[0. 0. 0. 0. 1.]
NCT01890590,39:49:treatment,Inability to deliver target dose with CyberKnife due to normal tissue dose constraints,"['Inability' 'to' 'deliver' 'target' 'dose' 'with' 'CyberKnife' 'due' 'to'
 'normal' 'tissue' 'dose' 'constraints']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT01884740,32:39:treatment,Because of known concerns with Avastin and wound healing,"['Because' 'of' 'known' 'concerns' 'with' 'Avastin' 'and' 'wound'
 'healing']",[0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT01884740,1:28:cancer,anaplastic astrocytoma (AA),['anaplastic' 'astrocytoma' '(' 'AA' ')'],[3. 3. 3. 0. 0.]
NCT01884740,26:42:cancer,radiologically diagnosed brainstem glioma,['radiologically' 'diagnosed' 'brainstem' 'glioma'],[0. 0. 3. 3.]
NCT01883076,20:53:treatment,undergoing planned Stage II palliative Glenn surgery,['undergoing' 'planned' 'Stage' 'II' 'palliative' 'Glenn' 'surgery'],[0. 0. 1. 1. 1. 1. 1.]
NCT01877382,80:88:treatment,"Confirmation of TP53 nonmutant status is encouraged, but not required prior to DS-3032b dosing","['Confirmation' 'of' 'TP53' 'nonmutant' 'status' 'is' 'encouraged' ','
 'but' 'not' 'required' 'prior' 'to' 'DS-3032b' 'dosing']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT01877382,32:59:treatment,current participation in other therapeutic investigational procedures,"['current' 'participation' 'in' 'other' 'therapeutic' 'investigational'
 'procedures']",[0. 0. 0. 0. 1. 1. 0.]
NCT01876511,28:72:treatment,Requires any other form of systemic or localized antineoplastic therapy while on study,"['Requires' 'any' 'other' 'form' 'of' 'systemic' 'or' 'localized'
 'antineoplastic' 'therapy' 'while' 'on' 'study']",[0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0.]
NCT01872975,"15:33:treatment,,",Patients with pathologic staging of ypN0(i+) or ypN0(mol+),"['Patients' 'with' 'pathologic' 'staging' 'of' 'ypN0' '(' 'i+' ')' 'or'
 'ypN0' '(' 'mol+' ')']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01871766,"1:17:chronic_disease,",Serum creatinine based on age and gender,['Serum' 'creatinine' 'based' 'on' 'age' 'and' 'gender'],[2. 2. 0. 0. 0. 0. 0.]
NCT01871727,1:34:treatment,Prior denileukin diftitox therapy,['Prior' 'denileukin' 'diftitox' 'therapy'],[1. 1. 1. 1.]
NCT01871454,70:85:cancer,Pathologic or clinical diagnosis of a new or loco-regional recurrent lung malignancy,"['Pathologic' 'or' 'clinical' 'diagnosis' 'of' 'a' 'new' 'or'
 'loco-regional' 'recurrent' 'lung' 'malignancy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT01865162,12:39:chronic_disease,History of uncontrolled hyperlipidemia,['History' 'of' 'uncontrolled' 'hyperlipidemia'],[0. 0. 2. 2.]
NCT01864265,12:43:chronic_disease,History of severe congestive heart failure,['History' 'of' 'severe' 'congestive' 'heart' 'failure'],[0. 0. 2. 2. 2. 2.]
NCT01864265,41:85:cancer,with the exception of treated and cured squamous or basal cell carcinoma of the skin,"['with' 'the' 'exception' 'of' 'treated' 'and' 'cured' 'squamous' 'or'
 'basal' 'cell' 'carcinoma' 'of' 'the' 'skin']",[0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 3. 3. 3.]
NCT01859819,1:53:cancer,B-Cell Anaplastic Large cell Ki 1 positive lymphomas,['B-Cell' 'Anaplastic' 'Large' 'cell' 'Ki' '1' 'positive' 'lymphomas'],[3. 3. 3. 3. 3. 3. 3. 3.]
NCT01859819,1:43:cancer,Primary Mediastinal B-Cell Lymphoma (PMBL),['Primary' 'Mediastinal' 'B-Cell' 'Lymphoma' '(' 'PMBL' ')'],[3. 3. 3. 3. 3. 0. 0.]
NCT01853163,35:49:treatment,0.025 mmol per kg body weight for Gadoxetic acid and 0.1 mmol per kg body weight for all other agents,"['0.025' 'mmol' 'per' 'kg' 'body' 'weight' 'for' 'Gadoxetic' 'acid' 'and'
 '0.1' 'mmol' 'per' 'kg' 'body' 'weight' 'for' 'all' 'other' 'agents']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01851694,1:25:chronic_disease,Pancreatic insufficiency,['Pancreatic' 'insufficiency'],[2. 2.]
NCT01851369,61:72:treatment,Patients must be able to swallow whole tablets or capsules; nasogastric or G-tube administration is not allowed,"['Patients' 'must' 'be' 'able' 'to' 'swallow' 'whole' 'tablets' 'or'
 'capsules' ';' 'nasogastric' 'or' 'G-tube' 'administration' 'is' 'not'
 'allowed']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT01850758,1:35:chronic_disease,Symptomatic lumbar spine pathology (e.g. radicular pain),"['Symptomatic' 'lumbar' 'spine' 'pathology' '(' 'e.g' '.' 'radicular'
 'pain' ')']",[2. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT01849146,",18:90:treatment",4 weeks from any investigational (not Food and Drug Administration [FDA]-approved) agents,"['4' 'weeks' 'from' 'any' 'investigational' '(' 'not' 'Food' 'and' 'Drug'
 'Administration' '[' 'FDA' ']' '-approved' ')' 'agents']",[0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT01849146,21:43:treatment,unlimited number of prior therapy regimens,['unlimited' 'number' 'of' 'prior' 'therapy' 'regimens'],[0. 0. 0. 1. 1. 1.]
NCT01842399,64:91:treatment,Unable to perform knee strength testing due to reasons such as bilateral knee replacements,"['Unable' 'to' 'perform' 'knee' 'strength' 'testing' 'due' 'to' 'reasons'
 'such' 'as' 'bilateral' 'knee' 'replacements']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT01841333,",,24:44:treatment",Between days 28 and 50 post transplantation at the time of initiation of the study drug,"['Between' 'days' '28' 'and' '50' 'post' 'transplantation' 'at' 'the'
 'time' 'of' 'initiation' 'of' 'the' 'study' 'drug']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01841333,1:18:treatment,azole antifungals,['azole' 'antifungals'],[1. 1.]
NCT01835626,1:17:treatment,Prior vismodegib or other antagonists of the Hh pathway,['Prior' 'vismodegib' 'or' 'other' 'antagonists' 'of' 'the' 'Hh' 'pathway'],[1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT01829958,1:26:chronic_disease,Systemic fungal infection,['Systemic' 'fungal' 'infection'],[2. 2. 2.]
NCT01824836,7:16:treatment,daily analgesic medication for active,['daily' 'analgesic' 'medication' 'for' 'active'],[0. 1. 0. 0. 0.]
NCT01822522,1:42:treatment,Prior treatment with cabozantinib (XL184),['Prior' 'treatment' 'with' 'cabozantinib' '(' 'XL184' ')'],[1. 1. 1. 1. 1. 0. 0.]
NCT01822522,",,,182:194:treatment","men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of cabozantinib administration","['men' 'treated' 'or' 'enrolled' 'on' 'this' 'protocol' 'must' 'also'
 'agree' 'to' 'use' 'adequate' 'contraception' 'prior' 'to' 'the' 'study'
 ',' 'for' 'the' 'duration' 'of' 'study' 'participation' ',' 'and' '6'
 'months' 'after' 'completion' 'of' 'cabozantinib' 'administration']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]"
NCT01821690,"4:13:treatment,",No surgeries planned during the 91-day participation,['No' 'surgeries' 'planned' 'during' 'the' '91-day' 'participation'],[0. 1. 0. 0. 0. 0. 0.]
NCT01817751,12:41:treatment,Current or prior valproic acid treatment is allowed,['Current' 'or' 'prior' 'valproic' 'acid' 'treatment' 'is' 'allowed'],[0. 0. 1. 1. 1. 1. 0. 0.]
NCT01815359,70:80:treatment,Any condition that would preclude the ability to deliver appropriate IP therapy,"['Any' 'condition' 'that' 'would' 'preclude' 'the' 'ability' 'to'
 'deliver' 'appropriate' 'IP' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01812174,123:156:treatment,"Patients who are sufficiently ill to warrant replacement of their diseased natural or prosthetic valve, based on standard cardiovascular diagnostic workups","['Patients' 'who' 'are' 'sufficiently' 'ill' 'to' 'warrant' 'replacement'
 'of' 'their' 'diseased' 'natural' 'or' 'prosthetic' 'valve' ',' 'based'
 'on' 'standard' 'cardiovascular' 'diagnostic' 'workups']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT01811368,1:20:chronic_disease,Alcoholic hepatitis,['Alcoholic' 'hepatitis'],[2. 2.]
NCT01811368,18:51:treatment,Patients fit for non-myeloablative transplantation or best treatment that have an available matched (9/10 or better) related or unrelated donor,"['Patients' 'fit' 'for' 'non-myeloablative' 'transplantation' 'or' 'best'
 'treatment' 'that' 'have' 'an' 'available' 'matched' '(' '9/10' 'or'
 'better' ')' 'related' 'or' 'unrelated' 'donor']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01810588,1:35:chronic_disease,Chronic myeloproliferative disease,['Chronic' 'myeloproliferative' 'disease'],[2. 2. 2.]
NCT01809002,1:24:chronic_disease,Peripheral Nerve Injury,['Peripheral' 'Nerve' 'Injury'],[2. 2. 2.]
NCT01807897,"21:40:treatment,",No change in active cardiac medications for 4 weeks prior to randomization,"['No' 'change' 'in' 'active' 'cardiac' 'medications' 'for' '4' 'weeks'
 'prior' 'to' 'randomization']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT01807611,10:22:cancer,"If prior CNS leukemia, it must be treated and in CNS CR","['If' 'prior' 'CNS' 'leukemia' ',' 'it' 'must' 'be' 'treated' 'and' 'in'
 'CNS' 'CR']",[0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01804634,1:25:cancer,Metastatic Ewing Sarcoma,['Metastatic' 'Ewing' 'Sarcoma'],[3. 3. 3.]
NCT01804634,1:21:cancer,ganglioneuroblastoma,['ganglioneuroblastoma'],[3.]
NCT01804465,"1:27:treatment,,,","Prior radiopharmaceuticals (strontium, samarium) must be completed ≥ 8 weeks prior to enrollment","['Prior' 'radiopharmaceuticals' '(' 'strontium' ',' 'samarium' ')' 'must'
 'be' 'completed' '≥' '8' 'weeks' 'prior' 'to' 'enrollment']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01799538,1:21:chronic_disease,Cognitive Impairment,['Cognitive' 'Impairment'],[2. 2.]
NCT01799538,22:67:treatment,high serum levels of vascular endothelial growth factor D (VGEF-D)(1),"['high' 'serum' 'levels' 'of' 'vascular' 'endothelial' 'growth' 'factor'
 'D' '(' 'VGEF-D' ')' '(' '1' ')']",[0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT01795313,"28:42:treatment,",Patients may have received re-irradiation but not to the index lesion within 4 weeks,"['Patients' 'may' 'have' 'received' 're-irradiation' 'but' 'not' 'to'
 'the' 'index' 'lesion' 'within' '4' 'weeks']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01794793,"1:19:treatment,,,",Male sterilization (at least 6 months prior to enrolling). For female patients on the study the vasectomized male partner should be the sole partner for that patient,"['Male' 'sterilization' '(' 'at' 'least' '6' 'months' 'prior' 'to'
 'enrolling' ')' '.' 'For' 'female' 'patients' 'on' 'the' 'study' 'the'
 'vasectomized' 'male' 'partner' 'should' 'be' 'the' 'sole' 'partner'
 'for' 'that' 'patient']","[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT01794559,25:41:chronic_disease,"History of, or current, open head trauma","['History' 'of' ',' 'or' 'current' ',' 'open' 'head' 'trauma']",[0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT01793519,26:40:treatment,Unwilling to discontinue anti-TNF agent,['Unwilling' 'to' 'discontinue' 'anti-TNF' 'agent'],[0. 0. 0. 1. 1.]
NCT01791543,"1:33:chronic_disease,",Thrombotic myocardial infarction within the preceding two (2) months,"['Thrombotic' 'myocardial' 'infarction' 'within' 'the' 'preceding' 'two'
 '(' '2' ')' 'months']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01789333,1:19:chronic_disease,Thinning of cornea,['Thinning' 'of' 'cornea'],[2. 2. 2.]
NCT01787682,"13:18:chronic_disease,",Presence of fever within the last 3 days,['Presence' 'of' 'fever' 'within' 'the' 'last' '3' 'days'],[0. 0. 2. 0. 0. 0. 0. 0.]
NCT01787409,30:55:treatment,Capable of swallowing intact study medication capsules,['Capable' 'of' 'swallowing' 'intact' 'study' 'medication' 'capsules'],[0. 0. 0. 0. 1. 1. 1.]
NCT01787409,50:69:treatment,patient is permitted to participate in any other therapeutic therapy for their disease as long as it does not concern vitamin D,"['patient' 'is' 'permitted' 'to' 'participate' 'in' 'any' 'other'
 'therapeutic' 'therapy' 'for' 'their' 'disease' 'as' 'long' 'as' 'it'
 'does' 'not' 'concern' 'vitamin' 'D']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01782599,",27:37:treatment",Be pregnant (measured via urinalysis),['Be' 'pregnant' '(' 'measured' 'via' 'urinalysis' ')'],[0. 0. 0. 0. 0. 1. 0.]
NCT01777035,1:19:chronic_disease,Terminal condition,['Terminal' 'condition'],[2. 2.]
NCT01774019,1:38:treatment,Previous biliary drainage by ERCP/PTC,['Previous' 'biliary' 'drainage' 'by' 'ERCP/PTC'],[1. 1. 1. 1. 1.]
NCT01773707,18:38:chronic_disease,Have evidence of active EBV infection,['Have' 'evidence' 'of' 'active' 'EBV' 'infection'],[0. 0. 0. 2. 2. 2.]
NCT01773694,",,66:80:treatment",will not be returning to the dermatology clinic in 7-14 days for suture removal,"['will' 'not' 'be' 'returning' 'to' 'the' 'dermatology' 'clinic' 'in'
 '7-14' 'days' 'for' 'suture' 'removal']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01766297,32:48:cancer,Histologic examination showing invasive lobular histology,['Histologic' 'examination' 'showing' 'invasive' 'lobular' 'histology'],[0. 0. 0. 3. 3. 0.]
NCT01766297,28:53:cancer,Must have pathology proven invasive ductal carcinoma,['Must' 'have' 'pathology' 'proven' 'invasive' 'ductal' 'carcinoma'],[0. 0. 0. 0. 3. 3. 3.]
NCT01763970,1:19:cancer,tumor malignancies must meet certain criteria to be eligible,"['tumor' 'malignancies' 'must' 'meet' 'certain' 'criteria' 'to' 'be'
 'eligible']",[3. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT01760655,",,85:115:chronic_disease",Patients with life expectancy of < 6 months for reasons other than their underlying hematologic/oncologic disorder,"['Patients' 'with' 'life' 'expectancy' 'of' '<' '6' 'months' 'for'
 'reasons' 'other' 'than' 'their' 'underlying' 'hematologic/oncologic'
 'disorder']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT01757418,"1:41:treatment,",Vaccination with a live attenuated virus in the preceding 6 weeks,"['Vaccination' 'with' 'a' 'live' 'attenuated' 'virus' 'in' 'the'
 'preceding' '6' 'weeks']",[1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT01756040,1:32:chronic_disease,Lethal chromosome abnormalities,['Lethal' 'chromosome' 'abnormalities'],[2. 2. 2.]
NCT01754779,",,26:36:treatment",>300mg/d in men prior to indapamide use,['>' '300mg/d' 'in' 'men' 'prior' 'to' 'indapamide' 'use'],[0. 0. 0. 0. 0. 0. 1. 0.]
NCT01754298,23:43:treatment,Completed a course of conservative therapy,['Completed' 'a' 'course' 'of' 'conservative' 'therapy'],[0. 0. 0. 0. 1. 1.]
NCT01754298,1:24:chronic_disease,osteogenesis imperfecta,['osteogenesis' 'imperfecta'],[2. 2.]
NCT01750567,7:29:chronic_disease,Known diabetes (type 1 or 2),['Known' 'diabetes' '(' 'type' '1' 'or' '2' ')'],[0. 2. 2. 2. 2. 2. 0. 0.]
NCT01743950,1:18:cancer,"Recurrent disease based on combination of clinical, imaging or histologic confirmation","['Recurrent' 'disease' 'based' 'on' 'combination' 'of' 'clinical' ','
 'imaging' 'or' 'histologic' 'confirmation']",[3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01742182,8:28:treatment,Use of hypno-sedative drugs for sleep or stimulants,['Use' 'of' 'hypno-sedative' 'drugs' 'for' 'sleep' 'or' 'stimulants'],[0. 0. 1. 1. 0. 0. 0. 0.]
NCT01737502,1:20:chronic_disease,labile hypertension,['labile' 'hypertension'],[2. 2.]
NCT01734512,"29:71:treatment,",Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period,"['Patients' 'should' 'not' 'receive' 'immunization' 'with' 'attenuated'
 'live' 'vaccines' 'within' 'one' 'week' 'of' 'study' 'entry' 'or'
 'during' 'study' 'period']",[0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01730794,",34:48:chronic_disease",Equal to or greater than 3 total organ failures,['Equal' 'to' 'or' 'greater' 'than' '3' 'total' 'organ' 'failures'],[0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT01730118,",,,,,,,212:225:treatment","Willingness of female and male subjects to use effective contraception e.g. oral contraceptives, barrier device, intrauterine device, or condoms, during the study and for three months following the last dose of study vaccine","['Willingness' 'of' 'female' 'and' 'male' 'subjects' 'to' 'use'
 'effective' 'contraception' 'e.g' '.' 'oral' 'contraceptives' ','
 'barrier' 'device' ',' 'intrauterine' 'device' ',' 'or' 'condoms' ','
 'during' 'the' 'study' 'and' 'for' 'three' 'months' 'following' 'the'
 'last' 'dose' 'of' 'study' 'vaccine']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01726257,1:36:chronic_disease,Proximal non-aneurysmal aortic neck,['Proximal' 'non-aneurysmal' 'aortic' 'neck'],[2. 2. 2. 2.]
NCT01720836,4:25:treatment,No prior vaccine therapy,['No' 'prior' 'vaccine' 'therapy'],[0. 1. 1. 1.]
NCT01716806,44:70:cancer,"Histopathologically-confirmed diagnosis of classical Hodgkin lymphoma (Parts A, B, C, D, and E)","['Histopathologically-confirmed' 'diagnosis' 'of' 'classical' 'Hodgkin'
 'lymphoma' '(' 'Parts' 'A' ',' 'B' ',' 'C' ',' 'D' ',' 'and' 'E' ')']",[0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01715571,"15:35:chronic_disease,,,",mild-moderate erectile dysfunction based on International Index of Erectile Function (IIEF) erectile function score 13-25,"['mild-moderate' 'erectile' 'dysfunction' 'based' 'on' 'International'
 'Index' 'of' 'Erectile' 'Function' '(' 'IIEF' ')' 'erectile' 'function'
 'score' '13-25']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01714596,100:129:chronic_disease,"Patients likely to have severe problems maintaining follow-up, including patients diagnosed with a severe psychiatric conditions, patients who live too far outside the hospital's catchment area","['Patients' 'likely' 'to' 'have' 'severe' 'problems' 'maintaining'
 'follow-up' ',' 'including' 'patients' 'diagnosed' 'with' 'a' 'severe'
 'psychiatric' 'conditions' ',' 'patients' 'who' 'live' 'too' 'far'
 'outside' 'the' 'hospital' ""'s"" 'catchment' 'area']","[0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT01712308,1:18:treatment,Prior sotatercept,['Prior' 'sotatercept'],[1. 1.]
NCT01705119,8:30:chronic_disease,Active gastrointestinal blood loss,['Active' 'gastrointestinal' 'blood' 'loss'],[0. 2. 2. 0.]
NCT01703949,"1:19:treatment,",Radioimmunotherapy within 12 weeks,['Radioimmunotherapy' 'within' '12' 'weeks'],[1. 0. 0. 0.]
NCT01703117,"27:36:treatment,",Subjects who have been on donepezil for longer than 5 years,"['Subjects' 'who' 'have' 'been' 'on' 'donepezil' 'for' 'longer' 'than' '5'
 'years']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT01697865,1:24:chronic_disease,Teres minor dysfunction,['Teres' 'minor' 'dysfunction'],[2. 2. 2.]
NCT01697371,34:46:treatment,Tense ascites requiring frequent paracentesis,['Tense' 'ascites' 'requiring' 'frequent' 'paracentesis'],[0. 0. 0. 0. 1.]
NCT01697293,"1:18:treatment,",tamoxifen therapy or other hormonal agents should be discontinued at least 1 week before the patient is enrolled on this study,"['tamoxifen' 'therapy' 'or' 'other' 'hormonal' 'agents' 'should' 'be'
 'discontinued' 'at' 'least' '1' 'week' 'before' 'the' 'patient' 'is'
 'enrolled' 'on' 'this' 'study']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01696734,1:20:chronic_disease,Torsades de pointes,['Torsades' 'de' 'pointes'],[2. 2. 2.]
NCT01695967,1:39:chronic_disease,congenital head and neck malformations,['congenital' 'head' 'and' 'neck' 'malformations'],[2. 2. 2. 2. 2.]
NCT01690468,102:108:allergy_name,History of allergic reactions attributed to compounds of similar chemical or biologic composition to TCN-PM,"['History' 'of' 'allergic' 'reactions' 'attributed' 'to' 'compounds' 'of'
 'similar' 'chemical' 'or' 'biologic' 'composition' 'to' 'TCN-PM']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4.]
NCT01690468,20:38:cancer,platinum-resistant epithelial ovarian,['platinum-resistant' 'epithelial' 'ovarian'],[0. 3. 3.]
NCT01685411,14:48:treatment,eligible for TBI containing preparative regimen,['eligible' 'for' 'TBI' 'containing' 'preparative' 'regimen'],[0. 0. 1. 1. 1. 1.]
NCT01684397,24:62:chronic_disease,History of symptomatic chronic congestive heart failure (CHF),"['History' 'of' 'symptomatic' 'chronic' 'congestive' 'heart' 'failure' '('
 'CHF' ')']",[0. 0. 0. 2. 2. 2. 2. 2. 0. 0.]
NCT01681589,"1:13:chronic_disease,",Brain Injury at least 6 months prior,['Brain' 'Injury' 'at' 'least' '6' 'months' 'prior'],[2. 2. 0. 0. 0. 0. 0.]
NCT01676753,37:57:chronic_disease,"Patient has known history of active Hepatitis A, B, or C","['Patient' 'has' 'known' 'history' 'of' 'active' 'Hepatitis' 'A' ',' 'B'
 ',' 'or' 'C']",[0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 2. 0. 0.]
NCT01676259,"5:20:treatment,",All radiology scans must be performed within 28 days prior to registration,"['All' 'radiology' 'scans' 'must' 'be' 'performed' 'within' '28' 'days'
 'prior' 'to' 'registration']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01676259,1:15:cancer,in situ cancer,['in' 'situ' 'cancer'],[3. 3. 3.]
NCT01675154,1:28:chronic_disease,Type I hyperlipoproteinemia,['Type' 'I' 'hyperlipoproteinemia'],[2. 2. 2.]
NCT01668602,"9:19:chronic_disease,","Neglect/hemianopia, or unexplained dizziness in last 6 months","['Neglect/hemianopia' ',' 'or' 'unexplained' 'dizziness' 'in' 'last' '6'
 'months']",[2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01666769,23:64:treatment,Supported with either venoarterial (VA) or venovenous (VV) ECMO,"['Supported' 'with' 'either' 'venoarterial' '(' 'VA' ')' 'or' 'venovenous'
 '(' 'VV' ')' 'ECMO']",[0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0.]
NCT01660607,",,22:54:chronic_disease",Complex karyotype(≥3 clonal chromosomal abnormalities),['Complex' 'karyotype' '(' '≥3' 'clonal' 'chromosomal' 'abnormalities' ')'],[0. 0. 0. 0. 2. 2. 2. 0.]
NCT01660607,1:30:treatment,hematopoietic cell transplant,['hematopoietic' 'cell' 'transplant'],[1. 1. 1.]
NCT01659541,1:38:chronic_disease,Spinal cord injury C8 level or higher,['Spinal' 'cord' 'injury' 'C8' 'level' 'or' 'higher'],[2. 2. 2. 2. 2. 2. 2.]
NCT01653093,34:50:cancer,Patients with known or suspected prostate disease based on clinical data,"['Patients' 'with' 'known' 'or' 'suspected' 'prostate' 'disease' 'based'
 'on' 'clinical' 'data']",[0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0.]
NCT01652092,1:36:chronic_disease,Chronic Granulomatous Disease (CGD),['Chronic' 'Granulomatous' 'Disease' '(' 'CGD' ')'],[2. 2. 2. 2. 0. 0.]
NCT01652092,14:48:chronic_disease,Other severe Combined Immune Deficiencies (CID),['Other' 'severe' 'Combined' 'Immune' 'Deficiencies' '(' 'CID' ')'],[0. 0. 2. 2. 2. 2. 0. 0.]
NCT01648751,"10:41:treatment,",Previous bilateral salpingo-oophorectomy (women with 1 ovary will be eligible),"['Previous' 'bilateral' 'salpingo-oophorectomy' '(' 'women' 'with' '1'
 'ovary' 'will' 'be' 'eligible' ')']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01648023,"15:37:chronic_disease,,",Patients with liver-dominant disease defined as ≥80% tumor burden confined to the liver,"['Patients' 'with' 'liver-dominant' 'disease' 'defined' 'as' '≥80' '%'
 'tumor' 'burden' 'confined' 'to' 'the' 'liver']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01647321,19:60:chronic_disease,Subjects having a Stage 2 or greater sacral decubitus ulcer,"['Subjects' 'having' 'a' 'Stage' '2' 'or' 'greater' 'sacral' 'decubitus'
 'ulcer']",[0. 0. 0. 2. 2. 2. 2. 2. 2. 2.]
NCT01643473,18:41:chronic_disease,Have significant psychiatric comorbidity,['Have' 'significant' 'psychiatric' 'comorbidity'],[0. 0. 2. 2.]
NCT01639508,1:34:treatment,Prior treatment with cabozantinib,['Prior' 'treatment' 'with' 'cabozantinib'],[1. 1. 1. 1.]
NCT01639508,1:24:chronic_disease,intra-abdominal abscess,['intra-abdominal' 'abscess'],[2. 2.]
NCT01631617,33:56:treatment,Subjects must be co-enrolled in NIH protocol 08-HG-0059,['Subjects' 'must' 'be' 'co-enrolled' 'in' 'NIH' 'protocol' '08-HG-0059'],[0. 0. 0. 0. 0. 1. 1. 1.]
NCT01626079,70:91:chronic_disease,American College of Cardiology /American Heart Association (ACC/AHA) Stage D heart failure,"['American' 'College' 'of' 'Cardiology' '/American' 'Heart' 'Association'
 '(' 'ACC/AHA' ')' 'Stage' 'D' 'heart' 'failure']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2.]
NCT01626079,",,65:99:treatment,",Mitral valve orifice area < 4.0 cm2 assessed by site based on a transthoracic echocardiogram (TTE) within 90 days prior to subject registration,"['Mitral' 'valve' 'orifice' 'area' '<' '4.0' 'cm2' 'assessed' 'by' 'site'
 'based' 'on' 'a' 'transthoracic' 'echocardiogram' '(' 'TTE' ')' 'within'
 '90' 'days' 'prior' 'to' 'subject' 'registration']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT01626079,18:56:treatment,Subjects in whom transesophageal echocardiography (TEE) is contraindicated or high risk,"['Subjects' 'in' 'whom' 'transesophageal' 'echocardiography' '(' 'TEE' ')'
 'is' 'contraindicated' 'or' 'high' 'risk']",[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT01626079,"1:46:treatment,",Transcatheter aortic valve replacement (TAVR) within 30 days prior to subject registration,"['Transcatheter' 'aortic' 'valve' 'replacement' '(' 'TAVR' ')' 'within'
 '30' 'days' 'prior' 'to' 'subject' 'registration']",[1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01625923,24:35:chronic_disease,Subject has pronounced dehydration,['Subject' 'has' 'pronounced' 'dehydration'],[0. 0. 0. 2.]
NCT01625234,23:40:chronic_disease,patients with a known ALK 1198 mutation,['patients' 'with' 'a' 'known' 'ALK' '1198' 'mutation'],[0. 0. 0. 0. 2. 2. 2.]
NCT01624090,1:8:treatment,Dextran,['Dextran'],[1.]
NCT01624090,61:81:treatment,"Normal ionized calcium, magnesium and phosphorus (can be on oral supplementation)","['Normal' 'ionized' 'calcium' ',' 'magnesium' 'and' 'phosphorus' '(' 'can'
 'be' 'on' 'oral' 'supplementation' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.]
NCT01624090,1:20:treatment,Thrombolytic agents,['Thrombolytic' 'agents'],[1. 1.]
NCT01623167,"1:23:chronic_disease,,",Severe aplastic anemia characterized by Bone marrow cellularity less than 30 percent,"['Severe' 'aplastic' 'anemia' 'characterized' 'by' 'Bone' 'marrow'
 'cellularity' 'less' 'than' '30' 'percent']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01620216,11:43:treatment,No active graft versus host disease (GVHD),['No' 'active' 'graft' 'versus' 'host' 'disease' '(' 'GVHD' ')'],[0. 0. 1. 1. 1. 1. 1. 0. 0.]
NCT01617161,1:38:chronic_disease,Chronic obstructive pulmonary disease exacerbation,['Chronic' 'obstructive' 'pulmonary' 'disease' 'exacerbation'],[2. 2. 2. 2. 0.]
NCT01616108,1:21:chronic_disease,Paralytic strabismus,['Paralytic' 'strabismus'],[2. 2.]
NCT01614197,"12:26:treatment,",A positive fungal culture within 30 days,['A' 'positive' 'fungal' 'culture' 'within' '30' 'days'],[0. 0. 1. 1. 0. 0. 0.]
NCT01614197,"29:50:treatment,,",Patients must have been off blinatumomab infusion for at least 4 days and all drug-related toxicity must have resolved to grade 2 or lower as outlined in the inclusion and exclusion criteria,"['Patients' 'must' 'have' 'been' 'off' 'blinatumomab' 'infusion' 'for'
 'at' 'least' '4' 'days' 'and' 'all' 'drug-related' 'toxicity' 'must'
 'have' 'resolved' 'to' 'grade' '2' 'or' 'lower' 'as' 'outlined' 'in'
 'the' 'inclusion' 'and' 'exclusion' 'criteria']","[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01608438,110:130:treatment,"Administration of drugs that potentially lower seizure threshold [62], without concomitant administration of anticonvulsant drugs which potentially protect against seizures occurrence","['Administration' 'of' 'drugs' 'that' 'potentially' 'lower' 'seizure'
 'threshold' '[' '62' ']' ',' 'without' 'concomitant' 'administration'
 'of' 'anticonvulsant' 'drugs' 'which' 'potentially' 'protect' 'against'
 'seizures' 'occurrence']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT01600040,1:28:cancer,endometrial stromal sarcoma,['endometrial' 'stromal' 'sarcoma'],[3. 3. 3.]
NCT01599559,200:245:cancer,"Patients must have histological confirmation of the diagnosis (it is recommended that the immunohistochemical panel includes: CD45, CD20, CD30, CD15, CD10, BCL6, BCL2, MUM-1), and in addition have a dominant mass within the anterior mediastinum","['Patients' 'must' 'have' 'histological' 'confirmation' 'of' 'the'
 'diagnosis' '(' 'it' 'is' 'recommended' 'that' 'the'
 'immunohistochemical' 'panel' 'includes' ':' 'CD45' ',' 'CD20' ',' 'CD30'
 ',' 'CD15' ',' 'CD10' ',' 'BCL6' ',' 'BCL2' ',' 'MUM-1' ')' ',' 'and'
 'in' 'addition' 'have' 'a' 'dominant' 'mass' 'within' 'the' 'anterior'
 'mediastinum']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 3.]"
NCT01597518,21:29:allergy_name,Hypersensitivity to riluzole or any of its components,['Hypersensitivity' 'to' 'riluzole' 'or' 'any' 'of' 'its' 'components'],[0. 0. 4. 0. 0. 0. 0. 0.]
NCT01597518,1:11:treatment,Mexiletine,['Mexiletine'],[1.]
NCT01597518,1:14:treatment,Thiabendazole,['Thiabendazole'],[1.]
NCT01595529,56:64:allergy_name,A child with known anaphylactic allergies to the study products,"['A' 'child' 'with' 'known' 'anaphylactic' 'allergies' 'to' 'the' 'study'
 'products']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 4.]
NCT01595529,11:40:chronic_disease,Confirmed UTI (Urinary Tract Infection) diagnosis,['Confirmed' 'UTI' '(' 'Urinary' 'Tract' 'Infection' ')' 'diagnosis'],[0. 2. 2. 2. 2. 0. 0. 0.]
NCT01595529,1:11:chronic_disease,flank pain,['flank' 'pain'],[2. 2.]
NCT01595061,54:90:cancer,"Patients with locally advanced, previously untreated squamous cell carcinoma of the vulva","['Patients' 'with' 'locally' 'advanced' ',' 'previously' 'untreated'
 'squamous' 'cell' 'carcinoma' 'of' 'the' 'vulva']",[0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 3.]
NCT01589263,"13:36:treatment,",Enrolled in another treatment trial for any disease within the past 30 days,"['Enrolled' 'in' 'another' 'treatment' 'trial' 'for' 'any' 'disease'
 'within' 'the' 'past' '30' 'days']",[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01589263,",,67:76:treatment",Serum prostate specific antigen (PSA) level greater than 8 ng/ml (Hybritech),"['Serum' 'prostate' 'specific' 'antigen' '(' 'PSA' ')' 'level' 'greater'
 'than' '8' 'ng/ml' '(' 'Hybritech' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT01584076,59:75:treatment,Inability to swallow pills equivalent in size to the 5 mg donepezil tablet,"['Inability' 'to' 'swallow' 'pills' 'equivalent' 'in' 'size' 'to' 'the'
 '5' 'mg' 'donepezil' 'tablet']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01584076,"1:19:treatment,",Strabismus surgery planned within 22 weeks,['Strabismus' 'surgery' 'planned' 'within' '22' 'weeks'],[1. 1. 0. 0. 0. 0.]
NCT01581580,18:20:chronic_disease,The diagnosis of ET will be confirmed on clinical examination in the NIH Movement Disorders Clinic (the diagnosis of ET will be based on bilateral,"['The' 'diagnosis' 'of' 'ET' 'will' 'be' 'confirmed' 'on' 'clinical'
 'examination' 'in' 'the' 'NIH' 'Movement' 'Disorders' 'Clinic' '(' 'the'
 'diagnosis' 'of' 'ET' 'will' 'be' 'based' 'on' 'bilateral']","[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT01573754,1:24:chronic_disease,Blistering skin lesions due to another condition,['Blistering' 'skin' 'lesions' 'due' 'to' 'another' 'condition'],[2. 2. 2. 0. 0. 0. 0.]
NCT01572480,",84:94:treatment","Absence of lytic bone lesion on X-ray, CT, or PET/CT and not more than 1 lesion on spinal MRI","['Absence' 'of' 'lytic' 'bone' 'lesion' 'on' 'X-ray' ',' 'CT' ',' 'or'
 'PET/CT' 'and' 'not' 'more' 'than' '1' 'lesion' 'on' 'spinal' 'MRI']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01572480,1:31:treatment,Treatment with corticosteroids for other indications is permitted,"['Treatment' 'with' 'corticosteroids' 'for' 'other' 'indications' 'is'
 'permitted']",[1. 1. 1. 0. 0. 0. 0. 0.]
NCT01570998,1:20:cancer,Multicentric cancer in the same breast as diagnosed by clinical examination,"['Multicentric' 'cancer' 'in' 'the' 'same' 'breast' 'as' 'diagnosed' 'by'
 'clinical' 'examination']",[3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01570998,1:25:treatment,prior in-field radiation,['prior' 'in-field' 'radiation'],[1. 1. 1.]
NCT01570816,1:20:chronic_disease,severe osteoporosis,['severe' 'osteoporosis'],[2. 2.]
NCT01568918,1:22:treatment,Cervical Foraminotomy,['Cervical' 'Foraminotomy'],[1. 1.]
NCT01568918,1:23:chronic_disease,Lumbar Anterior Fusion,['Lumbar' 'Anterior' 'Fusion'],[2. 2. 2.]
NCT01568918,1:19:treatment,Lumbar Laminectomy,['Lumbar' 'Laminectomy'],[1. 1.]
NCT01568255,24:38:treatment,An indication to be on statin therapy,['An' 'indication' 'to' 'be' 'on' 'statin' 'therapy'],[0. 0. 0. 0. 0. 1. 1.]
NCT01568177,21:31:treatment,Contraindication to Dobutamine,['Contraindication' 'to' 'Dobutamine'],[0. 0. 1.]
NCT01568177,13:34:chronic_disease,significant aortic valve stenosis,['significant' 'aortic' 'valve' 'stenosis'],[0. 2. 2. 2.]
NCT01562626,13:24:chronic_disease,Presence of GI bleeding,['Presence' 'of' 'GI' 'bleeding'],[0. 0. 2. 2.]
NCT01555905,16:41:chronic_disease,Diagnosis of a primary pulmonary disease,['Diagnosis' 'of' 'a' 'primary' 'pulmonary' 'disease'],[0. 0. 0. 2. 2. 2.]
NCT01555554,1:20:treatment,Sub-arachnoid block (spinal),['Sub-arachnoid' 'block' '(' 'spinal' ')'],[1. 1. 0. 0. 0.]
NCT01554410,41:64:cancer,"Histologically-proven, invasive primary carcinoma of the cervix","['Histologically-proven' ',' 'invasive' 'primary' 'carcinoma' 'of' 'the'
 'cervix']",[0. 0. 0. 0. 3. 3. 3. 3.]
NCT01554371,21:40:chronic_disease,"Patients with other significant disease or disorders that, in the Investigator's opinion","['Patients' 'with' 'other' 'significant' 'disease' 'or' 'disorders' 'that'
 ',' 'in' 'the' 'Investigator' ""'s"" 'opinion']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01553942,7:23:treatment,Prior EGFR TKI therapy,['Prior' 'EGFR' 'TKI' 'therapy'],[0. 1. 1. 1.]
NCT01547429,1:29:chronic_disease,Chronic or recurrent uveitis or history of the same,['Chronic' 'or' 'recurrent' 'uveitis' 'or' 'history' 'of' 'the' 'same'],[2. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT01543490,"10:24:treatment,",Have had eyelid surgery in the study eye within twelve (12) months prior to Visit 1 or plan to have eyelid surgery during the study,"['Have' 'had' 'eyelid' 'surgery' 'in' 'the' 'study' 'eye' 'within'
 'twelve' '(' '12' ')' 'months' 'prior' 'to' 'Visit' '1' 'or' 'plan' 'to'
 'have' 'eyelid' 'surgery' 'during' 'the' 'study']","[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT01542879,58:72:allergy_name,patients with a positive history of allergic reaction to iron compounds or other severe allergic reactions,"['patients' 'with' 'a' 'positive' 'history' 'of' 'allergic' 'reaction'
 'to' 'iron' 'compounds' 'or' 'other' 'severe' 'allergic' 'reactions']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 4. 0. 0. 0. 0. 0.]
NCT01538966,23:35:cancer,The patient harbors a macroadenoma with visual field defects due to chiasmatic compression,"['The' 'patient' 'harbors' 'a' 'macroadenoma' 'with' 'visual' 'field'
 'defects' 'due' 'to' 'chiasmatic' 'compression']",[0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01534104,"1:33:cancer,","Primary or secondary brain tumor (enhancing mass lesion ± nonenhancing abnormality), known or suspected, located near (< 2 cm) any portion of the motor cortex","['Primary' 'or' 'secondary' 'brain' 'tumor' '(' 'enhancing' 'mass'
 'lesion' '±' 'nonenhancing' 'abnormality' ')' ',' 'known' 'or'
 'suspected' ',' 'located' 'near' '(' '<' '2' 'cm' ')' 'any' 'portion'
 'of' 'the' 'motor' 'cortex']","[3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT01532687,13:27:treatment,Implants of levonorgestrel,['Implants' 'of' 'levonorgestrel'],[0. 0. 1.]
NCT01532687,24:81:treatment,Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1,"['Measurable' 'disease' 'per' 'Response' 'Evaluation' 'Criteria' 'in'
 'Solid' 'Tumors' '(' 'RECIST' ')' '1.1']",[0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0.]
NCT01530958,1:18:treatment,Kidney transplant recipients,['Kidney' 'transplant' 'recipients'],[1. 1. 0.]
NCT01525901,8:17:chronic_disease,closed epiphyses,['closed' 'epiphyses'],[0. 2.]
NCT01522768,"59:79:treatment,,",HER2 overexpression and/or amplification as determined by immunohistochemistry (3+) or FISH (≥2.0),"['HER2' 'overexpression' 'and/or' 'amplification' 'as' 'determined' 'by'
 'immunohistochemistry' '(' '3+' ')' 'or' 'FISH' '(' '≥2.0' ')']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01522768,",,107:115:treatment","Patients aged 18 years or older, as no dosing or adverse event data are currently available on the use of afatinib in patients <18 years of age","['Patients' 'aged' '18' 'years' 'or' 'older' ',' 'as' 'no' 'dosing' 'or'
 'adverse' 'event' 'data' 'are' 'currently' 'available' 'on' 'the' 'use'
 'of' 'afatinib' 'in' 'patients' '<' '18' 'years' 'of' 'age']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.
 0. 0. 0. 0. 0.]"
NCT01508390,"21:30:cancer,,",Moderate high risk: Stage cT3 and Gleason 7 and any prostate-specific antigen,"['Moderate' 'high' 'risk' ':' 'Stage' 'cT3' 'and' 'Gleason' '7' 'and'
 'any' 'prostate-specific' 'antigen']",[0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT01505569,",67:88:treatment,,",Camera method is NOT allowed as measure of GFR prior to or during Consolidation therapy for patients with GFR or creatinine clearance of < 100 ml/min/1.73m2.),"['Camera' 'method' 'is' 'NOT' 'allowed' 'as' 'measure' 'of' 'GFR' 'prior'
 'to' 'or' 'during' 'Consolidation' 'therapy' 'for' 'patients' 'with'
 'GFR' 'or' 'creatinine' 'clearance' 'of' '<' '100' 'ml/min/1.73m2' '.'
 ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT01505569,33:48:treatment,"Organ Function, Arm C (to begin TI chemotherapy)","['Organ' 'Function' ',' 'Arm' 'C' '(' 'to' 'begin' 'TI' 'chemotherapy' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.]
NCT01505569,1:56:cancer,Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET),['Supra-tentorial' 'Primative' 'Neuro-Ectodermal' 'Tumor' '(' 'PNET' ')'],[3. 3. 3. 3. 3. 0. 0.]
NCT01505062,20:47:treatment,Participation in a prior gene transfer therapy study,['Participation' 'in' 'a' 'prior' 'gene' 'transfer' 'therapy' 'study'],[0. 0. 0. 1. 1. 1. 1. 0.]
NCT01504373,1:34:chronic_disease,Congenital cyanotic heart defects,['Congenital' 'cyanotic' 'heart' 'defects'],[2. 2. 2. 2.]
NCT01500551,1:19:chronic_disease,Chronic infections,['Chronic' 'infections'],[2. 2.]
NCT01495637,16:33:treatment,Presence of an endotracheal tube at the time of enrollment,"['Presence' 'of' 'an' 'endotracheal' 'tube' 'at' 'the' 'time' 'of'
 'enrollment']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT01494662,4:32:treatment,No prior therapy with neratinib,['No' 'prior' 'therapy' 'with' 'neratinib'],[0. 1. 1. 1. 1.]
NCT01494324,30:58:cancer,Patients with diagnosed with secondary hepatic malignancy,['Patients' 'with' 'diagnosed' 'with' 'secondary' 'hepatic' 'malignancy'],[0. 0. 0. 0. 3. 3. 3.]
NCT01474889,"1:63:treatment,",Treatment with any anti-diabetic medication other than insulin within 4 weeks of enrollment,"['Treatment' 'with' 'any' 'anti-diabetic' 'medication' 'other' 'than'
 'insulin' 'within' '4' 'weeks' 'of' 'enrollment']",[1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT01473628,32:70:treatment,Patient with concurrent use of complementary or alternative medicines,"['Patient' 'with' 'concurrent' 'use' 'of' 'complementary' 'or'
 'alternative' 'medicines']",[0. 0. 0. 0. 0. 1. 1. 1. 1.]
NCT01465100,22:36:chronic_disease,Subject has positive HIV serostatus,['Subject' 'has' 'positive' 'HIV' 'serostatus'],[0. 0. 0. 2. 2.]
NCT01464034,1:15:chronic_disease,POEMS syndrome,['POEMS' 'syndrome'],[2. 2.]
NCT01459107,1:26:treatment,Below-shoulder amputation,['Below-shoulder' 'amputation'],[1. 1.]
NCT01459107,1:22:chronic_disease,Paralysis of ischemic or traumatic origin,['Paralysis' 'of' 'ischemic' 'or' 'traumatic' 'origin'],[2. 2. 2. 0. 0. 0.]
NCT01459107,1:14:chronic_disease,Toxoplasmosis,['Toxoplasmosis'],[2.]
NCT01453088,"1:38:chronic_disease,",Sensory peripheral neuropathy grade 4 within 14 days of enrollment,"['Sensory' 'peripheral' 'neuropathy' 'grade' '4' 'within' '14' 'days' 'of'
 'enrollment']",[2. 2. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT01446094,24:44:treatment,Scheduled for invasive coronary angiography,['Scheduled' 'for' 'invasive' 'coronary' 'angiography'],[0. 0. 0. 1. 1.]
NCT01444209,45:80:cancer,Pathological or radiographic diagnosis of a pan-invasive pituitary macroadenoma,"['Pathological' 'or' 'radiographic' 'diagnosis' 'of' 'a' 'pan-invasive'
 'pituitary' 'macroadenoma']",[0. 0. 0. 0. 0. 0. 3. 3. 3.]
NCT01436968,30:54:treatment,Patients planning to receive whole pelvic irradiation,['Patients' 'planning' 'to' 'receive' 'whole' 'pelvic' 'irradiation'],[0. 0. 0. 0. 1. 1. 1.]
NCT01433315,54:86:chronic_disease,The investigators will exclude subjects who have any medical or psychiatric disorders,"['The' 'investigators' 'will' 'exclude' 'subjects' 'who' 'have' 'any'
 'medical' 'or' 'psychiatric' 'disorders']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2.]
NCT01430390,1:38:treatment,Previous infusion of CD19 CAR T cells at another institution,"['Previous' 'infusion' 'of' 'CD19' 'CAR' 'T' 'cells' 'at' 'another'
 'institution']",[1. 1. 1. 1. 1. 1. 1. 0. 0. 0.]
NCT01422746,1:18:chronic_disease,Hyperandrogenemic,['Hyperandrogenemic'],[2.]
NCT01422005,26:43:chronic_disease,Subjects must have had a unilateral stroke,['Subjects' 'must' 'have' 'had' 'a' 'unilateral' 'stroke'],[0. 0. 0. 0. 0. 2. 2.]
NCT01421797,"9:17:treatment,",Morning Cortisol <5 g/dL,['Morning' 'Cortisol' '<' '5' 'g/dL'],[0. 1. 0. 0. 0.]
NCT01421095,1:33:treatment,pelvic or total body irradiation,['pelvic' 'or' 'total' 'body' 'irradiation'],[1. 1. 1. 1. 1.]
NCT01419561,1:21:chronic_disease,Altered mental state,['Altered' 'mental' 'state'],[2. 2. 2.]
NCT01415882,"1:15:treatment,",Anthracyclines =< 14 days prior to registration,['Anthracyclines' '=' '<' '14' 'days' 'prior' 'to' 'registration'],[1. 0. 0. 0. 0. 0. 0. 0.]
NCT01407809,"8:28:chronic_disease,","Severe visual function loss, defined as grades 4 and 5 on the Humphrey Visual Field Analyzer SITA Standard 24-2 Test grading scale (Table 4) at initial presentation","['Severe' 'visual' 'function' 'loss' ',' 'defined' 'as' 'grades' '4' 'and'
 '5' 'on' 'the' 'Humphrey' 'Visual' 'Field' 'Analyzer' 'SITA' 'Standard'
 '24-2' 'Test' 'grading' 'scale' '(' 'Table' '4' ')' 'at' 'initial'
 'presentation']","[0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT01399476,1:43:treatment,Previous mediastinal or esophageal surgery,['Previous' 'mediastinal' 'or' 'esophageal' 'surgery'],[1. 1. 1. 1. 1.]
NCT01389024,19:43:chronic_disease,Other significant organ system dysfunction,['Other' 'significant' 'organ' 'system' 'dysfunction'],[0. 0. 2. 2. 2.]
NCT01384513,"1:29:treatment,,,,,",ematopoietic Cell Transplant-Comorbidity Index (HCT-CI) Score > 4 points for patients ≥ 60 years old or > 5 points for patients < 60,"['ematopoietic' 'Cell' 'Transplant-Comorbidity' 'Index' '(' 'HCT-CI' ')'
 'Score' '>' '4' 'points' 'for' 'patients' '≥' '60' 'years' 'old' 'or' '>'
 '5' 'points' 'for' 'patients' '<' '60']","[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT01379573,15:38:chronic_disease,developmental tricuspid valve disease,['developmental' 'tricuspid' 'valve' 'disease'],[0. 2. 2. 2.]
NCT01373112,21:43:treatment,Medically unfit for operative intervention,['Medically' 'unfit' 'for' 'operative' 'intervention'],[0. 0. 0. 1. 1.]
NCT01371630,"15:38:cancer,",Patients with refractory-relapsed ALL of any age are eligible,"['Patients' 'with' 'refractory-relapsed' 'ALL' 'of' 'any' 'age' 'are'
 'eligible']",[0. 0. 3. 3. 0. 0. 0. 0. 0.]
NCT01367444,"83:110:treatment,,",Enlargement in the area of central macular retinal thinning/photoreceptor loss by ocular coherence tomography at a rate of ≥0.5 mm^2,"['Enlargement' 'in' 'the' 'area' 'of' 'central' 'macular' 'retinal'
 'thinning/photoreceptor' 'loss' 'by' 'ocular' 'coherence' 'tomography'
 'at' 'a' 'rate' 'of' '≥0.5' 'mm^2']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT01367444,",,65:79:treatment",Reduction in macular mean sensitivity of ≥1.2 dB as assessed by microperimetry,"['Reduction' 'in' 'macular' 'mean' 'sensitivity' 'of' '≥1.2' 'dB' 'as'
 'assessed' 'by' 'microperimetry']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01366612,7:25:chronic_disease,Known amyloid deposition in heart,['Known' 'amyloid' 'deposition' 'in' 'heart'],[0. 2. 2. 0. 0.]
NCT01364363,",,19:45:treatment",Weight < 70kg for cord blood transplantation,['Weight' '<' '70kg' 'for' 'cord' 'blood' 'transplantation'],[0. 0. 0. 0. 1. 1. 1.]
NCT01356290,1:20:chronic_disease,Active peptic ulcer,['Active' 'peptic' 'ulcer'],[2. 2. 2.]
NCT01351103,1:25:chronic_disease,Pathologic bone fracture,['Pathologic' 'bone' 'fracture'],[2. 2. 2.]
NCT01341080,33:55:chronic_disease,Subjects will be diagnosed with Parkinson Disease (PD) by the UK Brain Bank criteria,"['Subjects' 'will' 'be' 'diagnosed' 'with' 'Parkinson' 'Disease' '(' 'PD'
 ')' 'by' 'the' 'UK' 'Brain' 'Bank' 'criteria']",[0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01333046,31:40:treatment,multiply relapsed patients in remission who are at a high risk of relapse,"['multiply' 'relapsed' 'patients' 'in' 'remission' 'who' 'are' 'at' 'a'
 'high' 'risk' 'of' 'relapse']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01313533,",44:79:treatment",Any patient was has undergone more than 20 computerized tomography (CAT) scans,"['Any' 'patient' 'was' 'has' 'undergone' 'more' 'than' '20' 'computerized'
 'tomography' '(' 'CAT' ')' 'scans']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0.]
NCT01312857,41:64:treatment,"However, patients who have responded to prior anti-EGFR therapy are eligible","['However' ',' 'patients' 'who' 'have' 'responded' 'to' 'prior'
 'anti-EGFR' 'therapy' 'are' 'eligible']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0.]
NCT01293214,25:49:treatment,Single dominant hand or multiple limb amputation,['Single' 'dominant' 'hand' 'or' 'multiple' 'limb' 'amputation'],[0. 0. 0. 0. 1. 1. 1.]
NCT01280669,12:30:chronic_disease,History of herpetic infection in the study eye or adnexa,"['History' 'of' 'herpetic' 'infection' 'in' 'the' 'study' 'eye' 'or'
 'adnexa']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT01280669,1:19:chronic_disease,Pupillary dilation inadequate for quality fundus photography in the study eye,"['Pupillary' 'dilation' 'inadequate' 'for' 'quality' 'fundus'
 'photography' 'in' 'the' 'study' 'eye']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01269034,1:30:chronic_disease,juvenile rheumatoid arthritis,['juvenile' 'rheumatoid' 'arthritis'],[2. 2. 2.]
NCT01261728,1:39:treatment,Prior radiation therapy to the bladder,['Prior' 'radiation' 'therapy' 'to' 'the' 'bladder'],[1. 1. 1. 1. 1. 1.]
NCT01245712,1:36:treatment,Prior radiation to the index breast,['Prior' 'radiation' 'to' 'the' 'index' 'breast'],[1. 1. 1. 1. 1. 1.]
NCT01243931,6:23:chronic_disease,Deep corneal opacities and irregularities,['Deep' 'corneal' 'opacities' 'and' 'irregularities'],[0. 2. 2. 0. 0.]
NCT01239160,21:111:cancer,have a diagnosis of primary or secondary late Stage 2 or 3 unilateral or bilateral lower extremity lymphoedema,"['have' 'a' 'diagnosis' 'of' 'primary' 'or' 'secondary' 'late' 'Stage' '2'
 'or' '3' 'unilateral' 'or' 'bilateral' 'lower' 'extremity' 'lymphoedema']",[0. 0. 0. 0. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3.]
NCT01220583,",,71:95:cancer",High-grade acinic cell carcinoma or high-grade (>30% solid component) adenoid cystic carcinoma,"['High-grade' 'acinic' 'cell' 'carcinoma' 'or' 'high-grade' '(' '>' '30'
 '%' 'solid' 'component' ')' 'adenoid' 'cystic' 'carcinoma']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3.]
NCT01200940,1:34:chronic_disease,"Psychiatric or cognitive disorder that will, in the opinion of the investigators, limit the subject's ability to provide informed consent, or to comply with study procedures","['Psychiatric' 'or' 'cognitive' 'disorder' 'that' 'will' ',' 'in' 'the'
 'opinion' 'of' 'the' 'investigators' ',' 'limit' 'the' 'subject' ""'s""
 'ability' 'to' 'provide' 'informed' 'consent' ',' 'or' 'to' 'comply'
 'with' 'study' 'procedures']","[2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT01189786,1:24:chronic_disease,Psychiatric disturbance,['Psychiatric' 'disturbance'],[2. 2.]
NCT01187368,51:68:treatment,Patients with an unacceptable risk for successful LVAD implantation and maintenance,"['Patients' 'with' 'an' 'unacceptable' 'risk' 'for' 'successful' 'LVAD'
 'implantation' 'and' 'maintenance']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.]
NCT01185210,14:36:chronic_disease,Diagnosis of fructose malabsorption,['Diagnosis' 'of' 'fructose' 'malabsorption'],[0. 0. 2. 2.]
NCT01185132,"1:31:cancer,",Microscopic multifocal disease is only allowed when the entire span of identified disease measures 3.0 cm or less,"['Microscopic' 'multifocal' 'disease' 'is' 'only' 'allowed' 'when' 'the'
 'entire' 'span' 'of' 'identified' 'disease' 'measures' '3.0' 'cm' 'or'
 'less']",[3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01185132,"1:20:chronic_disease,",microscopic disease greater than 3.0 cm,['microscopic' 'disease' 'greater' 'than' '3.0' 'cm'],[2. 2. 0. 0. 0. 0.]
NCT01184547,1:22:chronic_disease,Malignant neuroleptic hyperthermia,['Malignant' 'neuroleptic' 'hyperthermia'],[2. 2. 0.]
NCT01174121,42:72:treatment,Grade 3 or 4 major organ irAEs following treatment with anti-PD-1/PD-L1,"['Grade' '3' 'or' '4' 'major' 'organ' 'irAEs' 'following' 'treatment'
 'with' 'anti-PD-1/PD-L1']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT01174108,1:24:treatment,Telomere Length Testing,['Telomere' 'Length' 'Testing'],[1. 1. 1.]
NCT01128816,30:54:chronic_disease,Exercise capacity limited by class IV angina pectoris,['Exercise' 'capacity' 'limited' 'by' 'class' 'IV' 'angina' 'pectoris'],[0. 0. 0. 0. 2. 2. 2. 2.]
NCT01099644,",,83:106:treatment,,",Pregnancy testing will be carried out within two weeks prior to administration of radioiodinated Burtomab in females of childbearing age,"['Pregnancy' 'testing' 'will' 'be' 'carried' 'out' 'within' 'two' 'weeks'
 'prior' 'to' 'administration' 'of' 'radioiodinated' 'Burtomab' 'in'
 'females' 'of' 'childbearing' 'age']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT01072370,64:81:chronic_disease,Clinical evidence of a non-progressive motor disability due to brain dysfunction,"['Clinical' 'evidence' 'of' 'a' 'non-progressive' 'motor' 'disability'
 'due' 'to' 'brain' 'dysfunction']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT01072370,1:39:chronic_disease,Severe intrauterine growth restriction,['Severe' 'intrauterine' 'growth' 'restriction'],[2. 2. 2. 2.]
NCT01059786,58:74:treatment,Efficacy and/or safety of immunization during periods of B-cell depletion have not been adequately studied,"['Efficacy' 'and/or' 'safety' 'of' 'immunization' 'during' 'periods' 'of'
 'B-cell' 'depletion' 'have' 'not' 'been' 'adequately' 'studied']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT01050855,1:76:chronic_disease,Immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome,"['Immunodysregulation' 'polyendocrinopathy' 'enteropathy' 'X-linked' '('
 'IPEX' ')' 'syndrome']",[2. 2. 2. 2. 2. 2. 0. 0.]
NCT01050855,8:32:cancer,severe Langerhans histiocytosis,['severe' 'Langerhans' 'histiocytosis'],[0. 3. 3.]
NCT01037790,1:37:cancer,ER positive metastatic breast tumors (data now shows all to be Rb positive.),"['ER' 'positive' 'metastatic' 'breast' 'tumors' '(' 'data' 'now' 'shows'
 'all' 'to' 'be' 'Rb' 'positive' '.' ')']",[3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01028846,12:15:chronic_disease,History of CAD,['History' 'of' 'CAD'],[0. 0. 2.]
NCT01011777,1:24:chronic_disease,Grade IV hydronephrosis (Grade III dilation plus parenchymal thinning),"['Grade' 'IV' 'hydronephrosis' '(' 'Grade' 'III' 'dilation' 'plus'
 'parenchymal' 'thinning' ')']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01011777,57:81:chronic_disease,"Renal ultrasound demonstrating Society of Fetal Urology Grade III hydronephrosis (widely split renal pelvis, renal calices uniformly dilated, no parenchymal thinning)","['Renal' 'ultrasound' 'demonstrating' 'Society' 'of' 'Fetal' 'Urology'
 'Grade' 'III' 'hydronephrosis' '(' 'widely' 'split' 'renal' 'pelvis' ','
 'renal' 'calices' 'uniformly' 'dilated' ',' 'no' 'parenchymal' 'thinning'
 ')']","[0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT00985205,"10:30:treatment,",Received glutamine supplement for > 24 hrs prior to randomization,"['Received' 'glutamine' 'supplement' 'for' '>' '24' 'hrs' 'prior' 'to'
 'randomization']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT00975520,10:31:treatment,Complete macroscopic resection of all known disease,['Complete' 'macroscopic' 'resection' 'of' 'all' 'known' 'disease'],[0. 1. 1. 0. 0. 0. 0.]
NCT00969332,1:22:treatment,Anticoagulant therapy,['Anticoagulant' 'therapy'],[1. 1.]
NCT00967785,27:32:chronic_disease,Absence of a diagnosis of WHIMS,['Absence' 'of' 'a' 'diagnosis' 'of' 'WHIMS'],[0. 0. 0. 0. 0. 2.]
NCT00967577,",,43:84:chronic_disease","Platelet count <150,000/mm3 or history of platelet count abnormality or dysfunction","['Platelet' 'count' '<' '150,000/mm3' 'or' 'history' 'of' 'platelet'
 'count' 'abnormality' 'or' 'dysfunction']",[0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 2.]
NCT00959140,"1:5:treatment,,",DLCO (alveolar diffusion capacity for carbon monoxide) (corrected for hemoglobin) ≥ 50% of predicted,"['DLCO' '(' 'alveolar' 'diffusion' 'capacity' 'for' 'carbon' 'monoxide'
 ')' '(' 'corrected' 'for' 'hemoglobin' ')' '≥' '50' '%' 'of' 'predicted']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00946192,",62:76:chronic_disease,,,,","absence of menses for > three months (74) within a period of oligomenorrhea (cycle length > six weeks) for >six months, or absence of menarche at >16 years","['absence' 'of' 'menses' 'for' '>' 'three' 'months' '(' '74' ')' 'within'
 'a' 'period' 'of' 'oligomenorrhea' '(' 'cycle' 'length' '>' 'six' 'weeks'
 ')' 'for' '>' 'six' 'months' ',' 'or' 'absence' 'of' 'menarche' 'at' '>'
 '16' 'years']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT00929006,23:46:allergy_name,History of allergy to micronized progesterone,['History' 'of' 'allergy' 'to' 'micronized' 'progesterone'],[0. 0. 0. 0. 4. 4.]
NCT00926237,39:54:chronic_disease,Subjects must not have any history of Bipolar Disease,['Subjects' 'must' 'not' 'have' 'any' 'history' 'of' 'Bipolar' 'Disease'],[0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT00924027,41:80:treatment,Patients currently receiving concurrent investigational chemotherapeutic agents,"['Patients' 'currently' 'receiving' 'concurrent' 'investigational'
 'chemotherapeutic' 'agents']",[0. 0. 0. 0. 1. 1. 1.]
NCT00920972,1:19:chronic_disease,Invasive infection,['Invasive' 'infection'],[2. 2.]
NCT00919503,"19:36:treatment,",Receiving another experimental drug within 4 weeks of initiation of conditioning (day -6) unless approved by the PI,"['Receiving' 'another' 'experimental' 'drug' 'within' '4' 'weeks' 'of'
 'initiation' 'of' 'conditioning' '(' 'day' '-6' ')' 'unless' 'approved'
 'by' 'the' 'PI']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00914823,23:47:treatment,willing to complete a dopamine agonist washout,['willing' 'to' 'complete' 'a' 'dopamine' 'agonist' 'washout'],[0. 0. 0. 0. 1. 1. 1.]
NCT00911560,"1:23:chronic_disease,",bone marrow metastases plus high urine catecholamine levels,"['bone' 'marrow' 'metastases' 'plus' 'high' 'urine' 'catecholamine'
 'levels']",[2. 2. 2. 0. 0. 0. 0. 0.]
NCT00909909,1:20:cancer,Medullary carcinoma,['Medullary' 'carcinoma'],[3. 3.]
NCT00909909,1:20:cancer,Papillary carcinoma,['Papillary' 'carcinoma'],[3. 3.]
NCT00904046,15:45:chronic_disease,Subjects with uric acid kidney stone disease,['Subjects' 'with' 'uric' 'acid' 'kidney' 'stone' 'disease'],[0. 0. 2. 2. 2. 2. 2.]
NCT00902720,21:49:treatment,patients undergoing elective removal of an ovary for fertility preservation only,"['patients' 'undergoing' 'elective' 'removal' 'of' 'an' 'ovary' 'for'
 'fertility' 'preservation' 'only']",[0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0.]
NCT00887146,35:42:cancer,Patients with codeleted low grade gliomas must also be considered high risk by exhibiting one or more of the following characteristics,"['Patients' 'with' 'codeleted' 'low' 'grade' 'gliomas' 'must' 'also' 'be'
 'considered' 'high' 'risk' 'by' 'exhibiting' 'one' 'or' 'more' 'of' 'the'
 'following' 'characteristics']",[0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00881660,24:79:chronic_disease,"Confirmed diagnosis of severe or extremely severe left, right or bilateral CDH of the fetus","['Confirmed' 'diagnosis' 'of' 'severe' 'or' 'extremely' 'severe' 'left'
 ',' 'right' 'or' 'bilateral' 'CDH' 'of' 'the' 'fetus']",[0. 0. 0. 2. 2. 2. 2. 2. 2. 2. 2. 2. 0. 0. 0. 0.]
NCT00881660,1:11:chronic_disease,Severe CDH: -Fetal liver herniated into the hemithorax,['Severe' 'CDH' ':' '-Fetal' 'liver' 'herniated' 'into' 'the' 'hemithorax'],[2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT00872950,22:41:allergy_name,"Known sensitivity to 3,4-DIAMINOPYRIDINE","['Known' 'sensitivity' 'to' '3,4-DIAMINOPYRIDINE']",[0. 0. 0. 4.]
NCT00862446,"13:26:treatment,",Anticipated TPN treatment for at least one month,['Anticipated' 'TPN' 'treatment' 'for' 'at' 'least' 'one' 'month'],[0. 1. 1. 0. 0. 0. 0. 0.]
NCT00857207,"1:24:chronic_disease,",Frontal Lobe impairment will be determined by 1.5 standard deviations below the mean on either the D-KEFS Color Word Interference Testorthe EXAMINER composite score,"['Frontal' 'Lobe' 'impairment' 'will' 'be' 'determined' 'by' '1.5'
 'standard' 'deviations' 'below' 'the' 'mean' 'on' 'either' 'the' 'D-KEFS'
 'Color' 'Word' 'Interference' 'Testorthe' 'EXAMINER' 'composite' 'score']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00846742,12:20:cancer,defined as Stage IB,['defined' 'as' 'Stage' 'IB'],[0. 0. 3. 3.]
NCT00819208,21:33:cancer,Synchronous primary colon cancer,['Synchronous' 'primary' 'colon' 'cancer'],[0. 0. 3. 3.]
NCT00799864,31:78:chronic_disease,Has diagnosed with documented human immuno deficiency virus (HIV-1) infection,"['Has' 'diagnosed' 'with' 'documented' 'human' 'immuno' 'deficiency'
 'virus' '(' 'HIV-1' ')' 'infection']",[0. 0. 0. 0. 2. 2. 2. 2. 2. 2. 0. 0.]
NCT00788164,1:27:chronic_disease,Human papillomavirus (HPV) 16-positive disease by PCR,['Human' 'papillomavirus' '(' 'HPV' ')' '16-positive' 'disease' 'by' 'PCR'],[2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT00788164,15:19:allergy_name,No allergy to eggs,['No' 'allergy' 'to' 'eggs'],[0. 0. 0. 4.]
NCT00788164,"4:28:treatment,",No investigational agent(s) within the past 6 months,"['No' 'investigational' 'agent' '(' 's' ')' 'within' 'the' 'past' '6'
 'months']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00788164,1:38:chronic_disease,Traumatic or pruritic skin conditions,['Traumatic' 'or' 'pruritic' 'skin' 'conditions'],[2. 2. 2. 2. 2.]
NCT00738101,"24:45:treatment,",Be expected to require intravenous nutrition for at least an additional 28 days,"['Be' 'expected' 'to' 'require' 'intravenous' 'nutrition' 'for' 'at'
 'least' 'an' 'additional' '28' 'days']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT00737893,30:56:chronic_disease,The patient has a history of high or low blood pressure that is not controlled,"['The' 'patient' 'has' 'a' 'history' 'of' 'high' 'or' 'low' 'blood'
 'pressure' 'that' 'is' 'not' 'controlled']",[0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0.]
NCT00737893,42:50:treatment,The patient is taking medications called nitrates,['The' 'patient' 'is' 'taking' 'medications' 'called' 'nitrates'],[0. 0. 0. 0. 0. 0. 1.]
NCT00734877,",,46:69:cancer","Zubrod ≤ 2, unless solely due to symptoms of MM-related bone disease","['Zubrod' '≤' '2' ',' 'unless' 'solely' 'due' 'to' 'symptoms' 'of'
 'MM-related' 'bone' 'disease']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3.]
NCT00720785,",30:53:treatment",At least 2 weeks since prior palliative radiotherapy,['At' 'least' '2' 'weeks' 'since' 'prior' 'palliative' 'radiotherapy'],[0. 0. 0. 0. 0. 0. 1. 1.]
NCT00720785,1:27:cancer,metastatic Ewing's sarcoma,"['metastatic' 'Ewing' ""'s"" 'sarcoma']",[3. 3. 3. 0.]
NCT00719888,"11:35:treatment,",Any prior myeloablative transplant within the last 6 months,"['Any' 'prior' 'myeloablative' 'transplant' 'within' 'the' 'last' '6'
 'months']",[0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT00719888,49:75:treatment,UCB units will be selected according to current umbilical cord blood graft selection algorithm,"['UCB' 'units' 'will' 'be' 'selected' 'according' 'to' 'current'
 'umbilical' 'cord' 'blood' 'graft' 'selection' 'algorithm']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0.]
NCT00719888,",142:159:treatment",these patients must be discussed with the PI prior to enrollment; patients persistently aplastic for greater than one month since completing last chemotherapy are also eligible with PI approval,"['these' 'patients' 'must' 'be' 'discussed' 'with' 'the' 'PI' 'prior' 'to'
 'enrollment' ';' 'patients' 'persistently' 'aplastic' 'for' 'greater'
 'than' 'one' 'month' 'since' 'completing' 'last' 'chemotherapy' 'are'
 'also' 'eligible' 'with' 'PI' 'approval']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.
 0. 0. 0. 0. 0. 0.]"
NCT00716066,16:50:chronic_disease,Concordant for autoimmune neurological disease(s) as determined by neurological evaluation,"['Concordant' 'for' 'autoimmune' 'neurological' 'disease' '(' 's' ')' 'as'
 'determined' 'by' 'neurological' 'evaluation']",[0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00716066,",47:60:treatment",Patients must have failed at least 2 lines of stand therapy as outlined for the specific diseases,"['Patients' 'must' 'have' 'failed' 'at' 'least' '2' 'lines' 'of' 'stand'
 'therapy' 'as' 'outlined' 'for' 'the' 'specific' 'diseases']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT00715611,1:18:treatment,Prior nephrectomy on the contralateral side of MPM,['Prior' 'nephrectomy' 'on' 'the' 'contralateral' 'side' 'of' 'MPM'],[1. 1. 0. 0. 0. 0. 0. 0.]
NCT00713492,29:52:chronic_disease,Current or prior history of serious medical illness,['Current' 'or' 'prior' 'history' 'of' 'serious' 'medical' 'illness'],[0. 0. 0. 0. 0. 2. 2. 2.]
NCT00711373,1:10:chronic_disease,Blindness: blind amputees may be poor candidates because sensory return in the hand may not provide sufficient protective sensation,"['Blindness' ':' 'blind' 'amputees' 'may' 'be' 'poor' 'candidates'
 'because' 'sensory' 'return' 'in' 'the' 'hand' 'may' 'not' 'provide'
 'sufficient' 'protective' 'sensation']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00703105,59:84:cancer,Patients must have a histologic or cytologic diagnosis of epithelial ovarian cancer,"['Patients' 'must' 'have' 'a' 'histologic' 'or' 'cytologic' 'diagnosis'
 'of' 'epithelial' 'ovarian' 'cancer']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3.]
NCT00703105,133:151:treatment,"there is an unknown but potential risk for adverse events in nursing infants, breastfeeding should be discontinued if the mother is treated with Ontak","['there' 'is' 'an' 'unknown' 'but' 'potential' 'risk' 'for' 'adverse'
 'events' 'in' 'nursing' 'infants' ',' 'breastfeeding' 'should' 'be'
 'discontinued' 'if' 'the' 'mother' 'is' 'treated' 'with' 'Ontak']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.
 1.]"
NCT00673842,",22:42:treatment",> / = 3 months after coronary angioplasty,['>' '/' '=' '3' 'months' 'after' 'coronary' 'angioplasty'],[0. 0. 0. 0. 0. 0. 1. 1.]
NCT00673842,3:28:treatment,a cardiac resynchronization device,['a' 'cardiac' 'resynchronization' 'device'],[0. 1. 1. 0.]
NCT00670358,4:55:chronic_disease,No post-transplant lymphoproliferative disorder (PTLD),['No' 'post-transplant' 'lymphoproliferative' 'disorder' '(' 'PTLD' ')'],[0. 2. 2. 2. 2. 0. 0.]
NCT00632853,44:73:cancer,Histologically or cytologically documented small cell lung cancer (SCLC),"['Histologically' 'or' 'cytologically' 'documented' 'small' 'cell' 'lung'
 'cancer' '(' 'SCLC' ')']",[0. 0. 0. 0. 3. 3. 3. 3. 3. 0. 0.]
NCT00630253,"7:60:cancer,,","Early myelodysplastic syndrome, with multilineage dysplasia with < 5% blasts, with or without chromosomal anomalies","['Early' 'myelodysplastic' 'syndrome' ',' 'with' 'multilineage'
 'dysplasia' 'with' '<' '5' '%' 'blasts' ',' 'with' 'or' 'without'
 'chromosomal' 'anomalies']",[0. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00625417,1:28:treatment,excisional biopsy procedure,['excisional' 'biopsy' 'procedure'],[1. 1. 1.]
NCT00606411,21:42:treatment,Previous history of Topiramate or Topamax use for any condition,"['Previous' 'history' 'of' 'Topiramate' 'or' 'Topamax' 'use' 'for' 'any'
 'condition']",[0. 0. 0. 1. 1. 1. 0. 0. 0. 0.]
NCT00542373,52:63:cancer,Patients with either pre-malignant or a history of oral cancer based on patient history and clinical presentations,"['Patients' 'with' 'either' 'pre-malignant' 'or' 'a' 'history' 'of' 'oral'
 'cancer' 'based' 'on' 'patient' 'history' 'and' 'clinical'
 'presentations']",[0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT00540761,13:46:chronic_disease,unprotected left main coronary artery disease,['unprotected' 'left' 'main' 'coronary' 'artery' 'disease'],[0. 2. 2. 2. 2. 2.]
NCT00488696,26:43:allergy_name,Anaphylactic reaction to contrast material,['Anaphylactic' 'reaction' 'to' 'contrast' 'material'],[0. 0. 0. 4. 4.]
NCT00483249,58:89:treatment,Anticipated mortality comparable to published rates with conventional surgical treatment,"['Anticipated' 'mortality' 'comparable' 'to' 'published' 'rates' 'with'
 'conventional' 'surgical' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT00483249,"8:23:chronic_disease,",and/or iliac aneurysms larger than 4 cm in diameter,['and/or' 'iliac' 'aneurysms' 'larger' 'than' '4' 'cm' 'in' 'diameter'],[0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT00467987,8:67:treatment,Use of over the counter health supplements which contain androgens,"['Use' 'of' 'over' 'the' 'counter' 'health' 'supplements' 'which'
 'contain' 'androgens']",[0. 0. 1. 1. 1. 1. 1. 1. 1. 1.]
NCT00409435,14:43:chronic_disease,Diagnosis of postural tachycardia syndrome,['Diagnosis' 'of' 'postural' 'tachycardia' 'syndrome'],[0. 0. 2. 2. 2.]
NCT00392756,117:129:treatment,with a single serum sample demonstrating low estradiol (estrogen) in association with low or inappropriately normal gonadotropin levels,"['with' 'a' 'single' 'serum' 'sample' 'demonstrating' 'low' 'estradiol'
 '(' 'estrogen' ')' 'in' 'association' 'with' 'low' 'or' 'inappropriately'
 'normal' 'gonadotropin' 'levels']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT00383656,11:49:treatment,receiving physiologic glucocorticoid replacement if needed,['receiving' 'physiologic' 'glucocorticoid' 'replacement' 'if' 'needed'],[0. 1. 1. 1. 0. 0.]
NCT00358657,"1:26:chronic_disease,",Cardiac ejection fraction < 30%,['Cardiac' 'ejection' 'fraction' '<' '30' '%'],[2. 2. 2. 0. 0. 0.]
NCT00357565,",84:100:treatment,,","All patients must be in CR as defined by hematological recovery, AND <5% blasts by light microscopy within the bone marrow with a cellularity of ≥15%","['All' 'patients' 'must' 'be' 'in' 'CR' 'as' 'defined' 'by'
 'hematological' 'recovery' ',' 'AND' '<' '5' '%' 'blasts' 'by' 'light'
 'microscopy' 'within' 'the' 'bone' 'marrow' 'with' 'a' 'cellularity' 'of'
 '≥15' '%']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT00351611,",,25:44:treatment",Currently taking 1 to 3 antiepileptic drugs,['Currently' 'taking' '1' 'to' '3' 'antiepileptic' 'drugs'],[0. 0. 0. 0. 0. 1. 1.]
NCT00338377,",,,140:161:treatment",Patients must have a documented negative pregnancy test (urine or serum) for women who have menstruation in the past 12 months and without sterilization surgery,"['Patients' 'must' 'have' 'a' 'documented' 'negative' 'pregnancy' 'test'
 '(' 'urine' 'or' 'serum' ')' 'for' 'women' 'who' 'have' 'menstruation'
 'in' 'the' 'past' '12' 'months' 'and' 'without' 'sterilization' 'surgery']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 1.]"
NCT00293475,1:18:cancer,Systemic lymphoma,['Systemic' 'lymphoma'],[3. 3.]
NCT00293475,1:20:treatment,spinal radiotherapy,['spinal' 'radiotherapy'],[1. 1.]
NCT00291525,1:35:chronic_disease,Left or right ventricular aneurysm,['Left' 'or' 'right' 'ventricular' 'aneurysm'],[2. 2. 2. 2. 2.]
NCT00291525,1:19:chronic_disease,Vascular pathology,['Vascular' 'pathology'],[2. 2.]
NCT00258427,1:26:cancer,Biallelic BRCA2 mutations,['Biallelic' 'BRCA2' 'mutations'],[3. 3. 3.]
NCT00209235,91:115:chronic_disease,"For the portion of the study in which growth hormone is used for participants who are not growth hormone deficient (ie., growth hormone sufficient)","['For' 'the' 'portion' 'of' 'the' 'study' 'in' 'which' 'growth' 'hormone'
 'is' 'used' 'for' 'participants' 'who' 'are' 'not' 'growth' 'hormone'
 'deficient' '(' 'ie.' ',' 'growth' 'hormone' 'sufficient' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT00186927,1:16:cancer,Immunodeficient household members,['Immunodeficient' 'household' 'members'],[3. 0. 0.]
NCT00167219,35:39:cancer,Patients must have a diagnosis of JMML and fulfill these minimal criteria (International diagnostic criteria for JMML),"['Patients' 'must' 'have' 'a' 'diagnosis' 'of' 'JMML' 'and' 'fulfill'
 'these' 'minimal' 'criteria' '(' 'International' 'diagnostic' 'criteria'
 'for' 'JMML' ')']",[0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00147056,22:37:allergy_name,Known sensitivity to gadolinium-DTPA,['Known' 'sensitivity' 'to' 'gadolinium-DTPA'],[0. 0. 0. 4.]
NCT00107289,1:24:chronic_disease,grade 3 hearing deficit is acceptable,['grade' '3' 'hearing' 'deficit' 'is' 'acceptable'],[2. 2. 2. 2. 0. 0.]
NCT00085982,14:27:chronic_disease,"Syndromes of lipodystrophy are similar, but we already have approval to treat this group of patients","['Syndromes' 'of' 'lipodystrophy' 'are' 'similar' ',' 'but' 'we' 'already'
 'have' 'approval' 'to' 'treat' 'this' 'group' 'of' 'patients']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00065676,1:39:chronic_disease,eye damage (proliferative retinopathy),['eye' 'damage' '(' 'proliferative' 'retinopathy' ')'],[2. 2. 2. 2. 0. 0.]
NCT00004317,",,33:53:chronic_disease",Pregnant women with evidence of toxoplasma infection by clinical observation and amniotic fluid sampling,"['Pregnant' 'women' 'with' 'evidence' 'of' 'toxoplasma' 'infection' 'by'
 'clinical' 'observation' 'and' 'amniotic' 'fluid' 'sampling']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02535312,"77:93:chronic_disease,107:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease,182:219:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' ',' 'ongoing' 'or' 'active' 'infection' ',' 'symptomatic'
 'congestive' 'heart' 'failure' ',' 'unstable' 'angina' 'pectoris' ','
 'cardiac' 'arrhythmia' ',' 'or' 'psychiatric' 'illness/social'
 'situations' 'that' 'would' 'limit' 'compliance' 'with' 'study'
 'requirements']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 2. 0.
 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT02516670,"81:97:chronic_disease,111:135:chronic_disease,137:161:chronic_disease,163:181:chronic_disease,186:223:chronic_disease","Have uncontrolled intercurrent illness, including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Have' 'uncontrolled' 'intercurrent' 'illness' ',' 'including' 'but'
 'not' 'limited' 'to' 'ongoing' 'or' 'active' 'infection' ','
 'symptomatic' 'congestive' 'heart' 'failure' ',' 'unstable' 'angina'
 'pectoris' ',' 'cardiac' 'arrhythmia' ',' 'or' 'psychiatric'
 'illness/social' 'situations' 'that' 'would' 'limit' 'compliance' 'with'
 'study' 'requirements']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 2. 0.
 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT02510456,"77:93:chronic_disease,107:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease,182:219:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' ',' 'ongoing' 'or' 'active' 'infection' ',' 'symptomatic'
 'congestive' 'heart' 'failure' ',' 'unstable' 'angina' 'pectoris' ','
 'cardiac' 'arrhythmia' ',' 'or' 'psychiatric' 'illness/social'
 'situations' 'that' 'would' 'limit' 'compliance' 'with' 'study'
 'requirements']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 2. 0.
 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT02498613,"77:93:chronic_disease,107:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease,182:219:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' ',' 'ongoing' 'or' 'active' 'infection' ',' 'symptomatic'
 'congestive' 'heart' 'failure' ',' 'unstable' 'angina' 'pectoris' ','
 'cardiac' 'arrhythmia' ',' 'or' 'psychiatric' 'illness/social'
 'situations' 'that' 'would' 'limit' 'compliance' 'with' 'study'
 'requirements']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 2. 0.
 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT02474368,"75:91:chronic_disease,105:129:chronic_disease,131:155:chronic_disease,157:175:chronic_disease,180:217:chronic_disease","Uncontrolled intercurrent illness including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'intercurrent' 'illness' 'including' 'but' 'not' 'limited'
 'to' 'ongoing' 'or' 'active' 'infection' ',' 'symptomatic' 'congestive'
 'heart' 'failure' ',' 'unstable' 'angina' 'pectoris' ',' 'cardiac'
 'arrhythmia' ',' 'or' 'psychiatric' 'illness/social' 'situations' 'that'
 'would' 'limit' 'compliance' 'with' 'study' 'requirements']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 2. 0. 2. 2.
 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT02390752,"77:93:chronic_disease,107:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease,182:219:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' ',' 'ongoing' 'or' 'active' 'infection' ',' 'symptomatic'
 'congestive' 'heart' 'failure' ',' 'unstable' 'angina' 'pectoris' ','
 'cardiac' 'arrhythmia' ',' 'or' 'psychiatric' 'illness/social'
 'situations' 'that' 'would' 'limit' 'compliance' 'with' 'study'
 'requirements']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 2. 0.
 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT02237183,"12:28:chronic_disease,42:66:chronic_disease,68:92:chronic_disease,94:112:chronic_disease,117:154:chronic_disease","ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that in the opinion of investigators would jeopardize patient safety of data integrity","['ongoing' 'or' 'active' 'infection' ',' 'symptomatic' 'congestive'
 'heart' 'failure' ',' 'unstable' 'angina' 'pectoris' ',' 'cardiac'
 'arrhythmia' ',' 'or' 'psychiatric' 'illness/social' 'situations' 'that'
 'in' 'the' 'opinion' 'of' 'investigators' 'would' 'jeopardize' 'patient'
 'safety' 'of' 'data' 'integrity']","[0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 2. 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02201992,"108:124:chronic_disease,138:162:chronic_disease,164:188:chronic_disease,203:221:chronic_disease,226:263:chronic_disease","Patients must NOT have uncontrolled intercurrent illness including, but not limited to, serious ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Patients' 'must' 'NOT' 'have' 'uncontrolled' 'intercurrent' 'illness'
 'including' ',' 'but' 'not' 'limited' 'to' ',' 'serious' 'ongoing' 'or'
 'active' 'infection' ',' 'symptomatic' 'congestive' 'heart' 'failure' ','
 'unstable' 'angina' 'pectoris' ',' 'uncontrolled' 'cardiac' 'arrhythmia'
 ',' 'or' 'psychiatric' 'illness/social' 'situations' 'that' 'would'
 'limit' 'compliance' 'with' 'study' 'requirements']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2.
 0. 2. 2. 2. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT02101034,"77:93:chronic_disease,106:130:chronic_disease,132:156:chronic_disease,158:176:chronic_disease,181:218:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' ',' 'ongoing' 'or' 'active' 'infection' 'symptomatic'
 'congestive' 'heart' 'failure' ',' 'unstable' 'angina' 'pectoris' ','
 'cardiac' 'arrhythmia' ',' 'or' 'psychiatric' 'illness/social'
 'situations' 'that' 'would' 'limit' 'compliance' 'with' 'study'
 'requirements']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 2. 0. 2. 2. 2. 0. 2.
 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT02059239,"57:73:chronic_disease,87:111:chronic_disease,113:137:chronic_disease,139:157:chronic_disease,162:199:chronic_disease","olled illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['olled' 'illness' 'including' ',' 'but' 'not' 'limited' 'to' ','
 'ongoing' 'or' 'active' 'infection' ',' 'symptomatic' 'congestive'
 'heart' 'failure' ',' 'unstable' 'angina' 'pectoris' ',' 'cardiac'
 'arrhythmia' ',' 'or' 'psychiatric' 'illness/social' 'situations' 'that'
 'would' 'limit' 'compliance' 'with' 'study' 'requirements']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 2. 0. 2.
 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT02020707,"77:93:chronic_disease,107:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease,182:219:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' ',' 'ongoing' 'or' 'active' 'infection' ',' 'symptomatic'
 'congestive' 'heart' 'failure' ',' 'unstable' 'angina' 'pectoris' ','
 'cardiac' 'arrhythmia' ',' 'or' 'psychiatric' 'illness/social'
 'situations' 'that' 'would' 'limit' 'compliance' 'with' 'study'
 'requirements']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 2. 0.
 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT02013492,"77:93:chronic_disease,107:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease,182:219:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' ',' 'ongoing' 'or' 'active' 'infection' ',' 'symptomatic'
 'congestive' 'heart' 'failure' ',' 'unstable' 'angina' 'pectoris' ','
 'cardiac' 'arrhythmia' ',' 'or' 'psychiatric' 'illness/social'
 'situations' 'that' 'would' 'limit' 'compliance' 'with' 'study'
 'requirements']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 2. 0.
 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT01905046,"77:93:chronic_disease,107:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease,182:219:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' ',' 'ongoing' 'or' 'active' 'infection' ',' 'symptomatic'
 'congestive' 'heart' 'failure' ',' 'unstable' 'angina' 'pectoris' ','
 'cardiac' 'arrhythmia' ',' 'or' 'psychiatric' 'illness/social'
 'situations' 'that' 'would' 'limit' 'compliance' 'with' 'study'
 'requirements']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 2. 0.
 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT01670877,"77:93:chronic_disease,106:130:chronic_disease,132:156:chronic_disease,158:176:chronic_disease,181:218:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' ',' 'ongoing' 'or' 'active' 'infection' 'symptomatic'
 'congestive' 'heart' 'failure' ',' 'unstable' 'angina' 'pectoris' ','
 'cardiac' 'arrhythmia' ',' 'or' 'psychiatric' 'illness/social'
 'situations' 'that' 'would' 'limit' 'compliance' 'with' 'study'
 'requirements']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 2. 0. 2. 2. 2. 0. 2.
 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT00887146,"77:93:chronic_disease,107:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease,182:219:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' ',' 'ongoing' 'or' 'active' 'infection' ',' 'symptomatic'
 'congestive' 'heart' 'failure' ',' 'unstable' 'angina' 'pectoris' ','
 'cardiac' 'arrhythmia' ',' 'or' 'psychiatric' 'illness/social'
 'situations' 'that' 'would' 'limit' 'compliance' 'with' 'study'
 'requirements']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 2. 0.
 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT02547662,"13:20:chronic_disease,24:43:chronic_disease,132:141:treatment","Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol","['Any' 'serious' 'medical' 'or' 'psychiatric' 'illness' 'that' 'could' ','
 'in' 'the' 'investigator' ""'s"" 'opinion' ',' 'potentially' 'interfere'
 'with' 'the' 'completion' 'of' 'treatment' 'according' 'to' 'this'
 'protocol']","[0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.
 0. 0.]"
NCT02542657,"13:20:chronic_disease,24:43:chronic_disease,132:141:treatment","Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol","['Any' 'serious' 'medical' 'or' 'psychiatric' 'illness' 'that' 'could' ','
 'in' 'the' 'investigator' ""'s"" 'opinion' ',' 'potentially' 'interfere'
 'with' 'the' 'completion' 'of' 'treatment' 'according' 'to' 'this'
 'protocol']","[0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.
 0. 0.]"
NCT02481310,"27:34:chronic_disease,38:57:chronic_disease,146:155:treatment","Patients with any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol","['Patients' 'with' 'any' 'serious' 'medical' 'or' 'psychiatric' 'illness'
 'that' 'could' ',' 'in' 'the' 'investigator' ""'s"" 'opinion' ','
 'potentially' 'interfere' 'with' 'the' 'completion' 'of' 'treatment'
 'according' 'to' 'this' 'protocol']","[0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 0. 0. 0. 0.]"
NCT02339948,"9:16:chronic_disease,20:39:chronic_disease,64:73:treatment",Current medical or psychiatric illness that may interfere with treatment completion and followup,"['Current' 'medical' 'or' 'psychiatric' 'illness' 'that' 'may' 'interfere'
 'with' 'treatment' 'completion' 'and' 'followup']",[0. 2. 0. 2. 2. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02253316,"13:20:chronic_disease,24:43:chronic_disease,132:141:treatment","Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol","['Any' 'serious' 'medical' 'or' 'psychiatric' 'illness' 'that' 'could' ','
 'in' 'the' 'investigator' ""'s"" 'opinion' ',' 'potentially' 'interfere'
 'with' 'the' 'completion' 'of' 'treatment' 'according' 'to' 'this'
 'protocol']","[0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.
 0. 0.]"
NCT01618357,"34:41:chronic_disease,45:64:chronic_disease,116:125:treatment",Patients must not have a serious medical or psychiatric illness which prevents informed consent or compliance with treatment,"['Patients' 'must' 'not' 'have' 'a' 'serious' 'medical' 'or' 'psychiatric'
 'illness' 'which' 'prevents' 'informed' 'consent' 'or' 'compliance'
 'with' 'treatment']",[0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01045148,"7:14:chronic_disease,18:37:chronic_disease,104:113:treatment","Major medical or psychiatric illness, which in the investigator's opinion, would prevent completion of treatment and would interfere with follow-up","['Major' 'medical' 'or' 'psychiatric' 'illness' ',' 'which' 'in' 'the'
 'investigator' ""'s"" 'opinion' ',' 'would' 'prevent' 'completion' 'of'
 'treatment' 'and' 'would' 'interfere' 'with' 'follow-up']",[0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02562716,"90:106:chronic_disease,120:144:chronic_disease,146:161:chronic_disease,172:190:chronic_disease,195:214:chronic_disease","Patients with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Patients' 'with' 'uncontrolled' 'intercurrent' 'illness' 'including' ','
 'but' 'not' 'limited' 'to' 'ongoing' 'or' 'active' 'infection' ','
 'symptomatic' 'congestive' 'heart' 'failure' ',' 'unstable' 'angina'
 'pectoris' ',' 'cardiac' 'arrhythmia' ',' 'or' 'psychiatric'
 'illness/social' 'situations' 'that' 'would' 'limit' 'compliance' 'with'
 'study' 'requirements']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 0.
 0. 2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02427841,"77:93:chronic_disease,107:131:chronic_disease,133:148:chronic_disease,159:177:chronic_disease,182:201:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' ',' 'ongoing' 'or' 'active' 'infection' ',' 'symptomatic'
 'congestive' 'heart' 'failure' ',' 'unstable' 'angina' 'pectoris' ','
 'cardiac' 'arrhythmia' ',' 'or' 'psychiatric' 'illness/social'
 'situations' 'that' 'would' 'limit' 'compliance' 'with' 'study'
 'requirements']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 0. 0.
 2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02425904,"76:92:chronic_disease,106:130:chronic_disease,132:147:chronic_disease,158:176:chronic_disease,181:200:chronic_disease","Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' 'ongoing' 'or' 'active' 'infection' ',' 'symptomatic'
 'congestive' 'heart' 'failure' ',' 'unstable' 'angina' 'pectoris' ','
 'cardiac' 'arrhythmia' ',' 'or' 'psychiatric' 'illness/social'
 'situations' 'that' 'would' 'limit' 'compliance' 'with' 'study'
 'requirements']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 0. 0. 2.
 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02362997,"64:80:chronic_disease,94:118:chronic_disease,120:135:chronic_disease,146:164:chronic_disease,169:188:chronic_disease","Uncontrolled illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements or pose excess risk to the participant in the opinion of the treating clinician","['Uncontrolled' 'illness' 'including' ',' 'but' 'not' 'limited' 'to' ','
 'ongoing' 'or' 'active' 'infection' ',' 'symptomatic' 'congestive'
 'heart' 'failure' ',' 'unstable' 'angina' 'pectoris' ',' 'cardiac'
 'arrhythmia' ',' 'or' 'psychiatric' 'illness/social' 'situations' 'that'
 'would' 'limit' 'compliance' 'with' 'study' 'requirements' 'or' 'pose'
 'excess' 'risk' 'to' 'the' 'participant' 'in' 'the' 'opinion' 'of' 'the'
 'treating' 'clinician']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 0. 0. 2.
 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT01720836,"77:93:chronic_disease,107:131:chronic_disease,133:148:chronic_disease,159:177:chronic_disease,182:201:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' ',' 'ongoing' 'or' 'active' 'infection' ',' 'symptomatic'
 'congestive' 'heart' 'failure' ',' 'unstable' 'angina' 'pectoris' ','
 'cardiac' 'arrhythmia' ',' 'or' 'psychiatric' 'illness/social'
 'situations' 'that' 'would' 'limit' 'compliance' 'with' 'study'
 'requirements']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 0. 0.
 2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02567422,",,,,,299:335:treatment,337:369:treatment,374:382:treatment","Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm (>= 2 cm) with conventional techniques or as >= 10 mm (>= 1 cm) with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam","['Patients' 'must' 'have' 'measurable' 'disease' ',' 'defined' 'as' 'at'
 'least' 'one' 'lesion' 'that' 'can' 'be' 'accurately' 'measured' 'in'
 'at' 'least' 'one' 'dimension' '(' 'longest' 'diameter' 'to' 'be'
 'recorded' 'for' 'non-nodal' 'lesions' 'and' 'short' 'axis' 'for' 'nodal'
 'lesions' ')' 'as' '>' '=' '20' 'mm' '(' '>' '=' '2' 'cm' ')' 'with'
 'conventional' 'techniques' 'or' 'as' '>' '=' '10' 'mm' '(' '>' '=' '1'
 'cm' ')' 'with' 'spiral' 'computed' 'tomography' '(' 'CT' ')' 'scan' ','
 'magnetic' 'resonance' 'imaging' '(' 'MRI' ')' ',' 'or' 'calipers' 'by'
 'clinical' 'exam']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0.
 0. 1. 1. 1. 1. 0. 0. 0. 0. 1. 0. 0. 0.]"
NCT02474173,",,,,,,,282:318:treatment,320:352:treatment,357:365:treatment","Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm (>= 2 cm) with conventional techniques or as >= 10 mm (>= 1 cm) with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam","['Measurable' 'disease' 'is' 'defined' 'as' 'at' 'least' 'one' 'lesion'
 'that' 'can' 'be' 'accurately' 'measured' 'in' 'at' 'least' 'one'
 'dimension' '(' 'longest' 'diameter' 'to' 'be' 'recorded' 'for'
 'non-nodal' 'lesions' 'and' 'short' 'axis' 'for' 'nodal' 'lesions' ')'
 'as' '>' '=' '20' 'mm' '(' '>' '=' '2' 'cm' ')' 'with' 'conventional'
 'techniques' 'or' 'as' '>' '=' '10' 'mm' '(' '>' '=' '1' 'cm' ')' 'with'
 'spiral' 'computed' 'tomography' '(' 'CT' ')' 'scan' ',' 'magnetic'
 'resonance' 'imaging' '(' 'MRI' ')' ',' 'or' 'calipers' 'by' 'clinical'
 'exam']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 1. 1.
 1. 1. 0. 0. 0. 0. 1. 0. 0. 0.]"
NCT02408861,",,,,,,283:319:treatment,321:353:treatment,358:366:treatment","Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm with conventional techniques or as >= 10 mm with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam","['Participants' 'must' 'have' 'measurable' 'disease' ',' 'defined' 'as'
 'at' 'least' 'one' 'lesion' 'that' 'can' 'be' 'accurately' 'measured'
 'in' 'at' 'least' 'one' 'dimension' '(' 'longest' 'diameter' 'to' 'be'
 'recorded' 'for' 'non-nodal' 'lesions' 'and' 'short' 'axis' 'for' 'nodal'
 'lesions' ')' 'as' '>' '=' '20' 'mm' 'with' 'conventional' 'techniques'
 'or' 'as' '>' '=' '10' 'mm' 'with' 'spiral' 'computed' 'tomography' '('
 'CT' ')' 'scan' ',' 'magnetic' 'resonance' 'imaging' '(' 'MRI' ')' ','
 'or' 'calipers' 'by' 'clinical' 'exam']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 1. 0. 0.
 0.]"
NCT02272998,",,,,150:186:treatment,188:220:treatment,225:233:treatment","longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm with conventional techniques or as >= 10 mm with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam","['longest' 'diameter' 'to' 'be' 'recorded' 'for' 'non-nodal' 'lesions'
 'and' 'short' 'axis' 'for' 'nodal' 'lesions' ')' 'as' '>' '=' '20' 'mm'
 'with' 'conventional' 'techniques' 'or' 'as' '>' '=' '10' 'mm' 'with'
 'spiral' 'computed' 'tomography' '(' 'CT' ')' 'scan' ',' 'magnetic'
 'resonance' 'imaging' '(' 'MRI' ')' ',' 'or' 'calipers' 'by' 'clinical'
 'exam']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 1. 0.
 0. 0.]"
NCT02370693,"33:43:allergy_name,45:50:allergy_name,54:62:allergy_name","Patient has hypersensitivity to bortezomib, boron or mannitol","['Patient' 'has' 'hypersensitivity' 'to' 'bortezomib' ',' 'boron' 'or'
 'mannitol']",[0. 0. 0. 0. 4. 0. 4. 0. 4.]
NCT01415752,"44:54:treatment,56:61:treatment,66:74:treatment","Patients must not have hypersensitivity to bortezomib, boron, or mannitol","['Patients' 'must' 'not' 'have' 'hypersensitivity' 'to' 'bortezomib' ','
 'boron' ',' 'or' 'mannitol']",[0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 1.]
NCT00734877,"21:31:allergy_name,33:38:allergy_name,43:51:allergy_name","Hypersensitivity to bortezomib, boron, or mannitol","['Hypersensitivity' 'to' 'bortezomib' ',' 'boron' ',' 'or' 'mannitol']",[0. 0. 4. 0. 4. 0. 0. 4.]
NCT00720785,"32:42:allergy_name,44:49:allergy_name,53:61:allergy_name","Allergy or hypersensitivity to bortezomib, boron or mannitol by history","['Allergy' 'or' 'hypersensitivity' 'to' 'bortezomib' ',' 'boron' 'or'
 'mannitol' 'by' 'history']",[0. 0. 0. 0. 4. 0. 4. 0. 4. 0. 0.]
NCT03153410,"33:44:chronic_disease,59:67:treatment,92:117:chronic_disease","Has history of (non-infectious) pneumonitis that required steroids, history or evidence of interstitial lung disease or active, non-infectious pneumonitis","['Has' 'history' 'of' '(' 'non-infectious' ')' 'pneumonitis' 'that'
 'required' 'steroids' ',' 'history' 'or' 'evidence' 'of' 'interstitial'
 'lung' 'disease' 'or' 'active' ',' 'non-infectious' 'pneumonitis']",[0. 0. 0. 0. 0. 0. 2. 0. 0. 1. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT02501473,"29:40:chronic_disease,55:63:treatment,94:119:chronic_disease",History of (non-infectious) pneumonitis that required steroids or has current pneumonitis or interstitial lung disease,"['History' 'of' '(' 'non-infectious' ')' 'pneumonitis' 'that' 'required'
 'steroids' 'or' 'has' 'current' 'pneumonitis' 'or' 'interstitial' 'lung'
 'disease']",[0. 0. 0. 0. 0. 2. 0. 0. 1. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT02407171,"29:40:chronic_disease,55:63:treatment,100:125:chronic_disease","history of (non-infectious) pneumonitis that required steroids, current pneumonitis or evidence of interstitial lung disease","['history' 'of' '(' 'non-infectious' ')' 'pneumonitis' 'that' 'required'
 'steroids' ',' 'current' 'pneumonitis' 'or' 'evidence' 'of'
 'interstitial' 'lung' 'disease']",[0. 0. 0. 0. 0. 2. 0. 0. 1. 0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT02959762,"20:38:treatment,42:59:treatment,121:132:treatment,134:145:treatment","Subjects receiving systemic treatment or topical treatment likely to interfere with evaluation of the study parameters (salicylates, antibiotics)","['Subjects' 'receiving' 'systemic' 'treatment' 'or' 'topical' 'treatment'
 'likely' 'to' 'interfere' 'with' 'evaluation' 'of' 'the' 'study'
 'parameters' '(' 'salicylates' ',' 'antibiotics' ')']",[0. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0.]
NCT02366481,"20:38:treatment,42:59:treatment,121:132:treatment,134:145:treatment","Subjects receiving systemic treatment or topical treatment likely to interfere with evaluation of the study parameters (salicylates, antibiotics)","['Subjects' 'receiving' 'systemic' 'treatment' 'or' 'topical' 'treatment'
 'likely' 'to' 'interfere' 'with' 'evaluation' 'of' 'the' 'study'
 'parameters' '(' 'salicylates' ',' 'antibiotics' ')']",[0. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0.]
NCT01972113,"20:38:treatment,42:59:treatment,121:132:treatment,134:145:treatment","Subjects receiving systemic treatment or topical treatment likely to interfere with evaluation of the study parameters (salicylates, antibiotics)","['Subjects' 'receiving' 'systemic' 'treatment' 'or' 'topical' 'treatment'
 'likely' 'to' 'interfere' 'with' 'evaluation' 'of' 'the' 'study'
 'parameters' '(' 'salicylates' ',' 'antibiotics' ')']",[0. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0.]
NCT02639065,"20:38:chronic_disease,49:67:treatment,,187:204:treatment,208:232:treatment","Evidence of active autoimmune disease requiring systemic treatment within preceding 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents","['Evidence' 'of' 'active' 'autoimmune' 'disease' 'requiring' 'systemic'
 'treatment' 'within' 'preceding' '3' 'months' 'or' 'a' 'documented'
 'history' 'of' 'clinically' 'severe' 'autoimmune' 'disease' ',' 'or' 'a'
 'syndrome' 'that' 'requires' 'systemic' 'steroids' 'or'
 'immunosuppressive' 'agents']","[0. 0. 0. 2. 2. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 1.]"
NCT02407171,"8:26:chronic_disease,37:55:treatment,,174:191:treatment,195:219:treatment","active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents","['active' 'autoimmune' 'disease' 'requiring' 'systemic' 'treatment'
 'within' 'the' 'past' '3' 'months' 'or' 'a' 'documented' 'history' 'of'
 'clinically' 'severe' 'autoimmune' 'disease' ',' 'or' 'a' 'syndrome'
 'that' 'requires' 'systemic' 'steroids' 'or' 'immunosuppressive' 'agents']","[0. 2. 2. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 1.]"
NCT02365766,"15:33:chronic_disease,44:62:treatment,,181:198:treatment,202:226:treatment","Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents","['Has' 'an' 'active' 'autoimmune' 'disease' 'requiring' 'systemic'
 'treatment' 'within' 'the' 'past' '3' 'months' 'or' 'a' 'documented'
 'history' 'of' 'clinically' 'severe' 'autoimmune' 'disease' ',' 'or' 'a'
 'syndrome' 'that' 'requires' 'systemic' 'steroids' 'or'
 'immunosuppressive' 'agents']","[0. 0. 0. 2. 2. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 1. 1.]"
NCT02515110,"8:33:chronic_disease,48:63:chronic_disease,,137:146:chronic_disease,148:176:chronic_disease,181:192:chronic_disease","Active collagen vascular disease, specifically dermatomyositis with a creatine phosphokinase (CPK) level above normal or with an active skin rash, systemic lupus erythematosus, or scleroderma","['Active' 'collagen' 'vascular' 'disease' ',' 'specifically'
 'dermatomyositis' 'with' 'a' 'creatine' 'phosphokinase' '(' 'CPK' ')'
 'level' 'above' 'normal' 'or' 'with' 'an' 'active' 'skin' 'rash' ','
 'systemic' 'lupus' 'erythematosus' ',' 'or' 'scleroderma']","[0. 2. 2. 2. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0.
 2. 2. 2. 0. 0. 2.]"
NCT01872975,"8:33:chronic_disease,48:63:chronic_disease,,139:148:chronic_disease,150:178:chronic_disease,183:194:chronic_disease","Active collagen vascular disease, specifically dermatomyositis with a creatinine phosphokinase (CPK) level above normal or with an active skin rash, systemic lupus erythematosus, or scleroderma","['Active' 'collagen' 'vascular' 'disease' ',' 'specifically'
 'dermatomyositis' 'with' 'a' 'creatinine' 'phosphokinase' '(' 'CPK' ')'
 'level' 'above' 'normal' 'or' 'with' 'an' 'active' 'skin' 'rash' ','
 'systemic' 'lupus' 'erythematosus' ',' 'or' 'scleroderma']","[0. 2. 2. 2. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0.
 2. 2. 2. 0. 0. 2.]"
NCT01245712,"25:50:chronic_disease,65:80:chronic_disease,,156:165:chronic_disease,167:195:chronic_disease,200:211:chronic_disease","Documented diagnosis of collagen vascular disease, specifically dermatomyositis with a creatinine phosphokinase (CPK) level above normal or with an active skin rash, systemic lupus erythematosus, or scleroderma","['Documented' 'diagnosis' 'of' 'collagen' 'vascular' 'disease' ','
 'specifically' 'dermatomyositis' 'with' 'a' 'creatinine' 'phosphokinase'
 '(' 'CPK' ')' 'level' 'above' 'normal' 'or' 'with' 'an' 'active' 'skin'
 'rash' ',' 'systemic' 'lupus' 'erythematosus' ',' 'or' 'scleroderma']","[0. 0. 0. 2. 2. 2. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.
 2. 0. 2. 2. 2. 0. 0. 2.]"
NCT02487095,"33:45:treatment,60:73:treatment,,93:105:treatment,","Subjects must not have received chemotherapy, or undergone major surgery within 4 weeks and radiotherapy within 24 hours prior to enrollment","['Subjects' 'must' 'not' 'have' 'received' 'chemotherapy' ',' 'or'
 'undergone' 'major' 'surgery' 'within' '4' 'weeks' 'and' 'radiotherapy'
 'within' '24' 'hours' 'prior' 'to' 'enrollment']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT02311361,"45:57:treatment,59:71:treatment,76:89:treatment,","Patients must not have had standard of care chemotherapy, radiotherapy, or major surgery within the last 2 weeks prior to entering the study","['Patients' 'must' 'not' 'have' 'had' 'standard' 'of' 'care'
 'chemotherapy' ',' 'radiotherapy' ',' 'or' 'major' 'surgery' 'within'
 'the' 'last' '2' 'weeks' 'prior' 'to' 'entering' 'the' 'study']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT01306045,"23:36:treatment,38:50:treatment,54:66:treatment,,","Patients who have had major surgery, chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier","['Patients' 'who' 'have' 'had' 'major' 'surgery' ',' 'chemotherapy' 'or'
 'radiotherapy' 'within' '2' 'weeks' 'prior' 'to' 'entering' 'the' 'study'
 'or' 'those' 'who' 'have' 'not' 'recovered' 'from' 'adverse' 'events'
 'due' 'to' 'agents' 'administered' 'more' 'than' '2' 'weeks' 'earlier']","[0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02314377,"37:54:chronic_disease,56:84:chronic_disease,89:112:chronic_disease,","Patients must not have a history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment","['Patients' 'must' 'not' 'have' 'a' 'history' 'of' 'abdominal' 'fistula'
 ',' 'gastrointestinal' 'perforation' ',' 'or' 'intra-abdominal' 'abscess'
 'within' '6' 'months' 'prior' 'to' 'study' 'enrollment']",[0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT01903330,"12:29:chronic_disease,31:59:chronic_disease,64:87:chronic_disease,","History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 1","['History' 'of' 'abdominal' 'fistula' ',' 'gastrointestinal' 'perforation'
 ',' 'or' 'intra-abdominal' 'abscess' 'within' '6' 'months' 'prior' 'to'
 'Day' '1']",[0. 0. 2. 2. 0. 2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT01532687,"12:29:chronic_disease,31:59:chronic_disease,64:87:chronic_disease","History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess","['History' 'of' 'abdominal' 'fistula' ',' 'gastrointestinal' 'perforation'
 ',' 'or' 'intra-abdominal' 'abscess']",[0. 0. 2. 2. 0. 2. 2. 0. 0. 2. 2.]
NCT02132598,"26:40:chronic_disease,44:63:chronic_disease,,109:118:treatment",Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment,"['Concurrent' 'uncompensated' 'hypothyroidism' 'or' 'thyroid'
 'dysfunction' 'within' '7' 'days' 'before' 'the' 'first' 'dose' 'of'
 'study' 'treatment']",[0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01822522,"26:40:chronic_disease,44:63:chronic_disease,,109:118:treatment",Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment,"['Concurrent' 'uncompensated' 'hypothyroidism' 'or' 'thyroid'
 'dysfunction' 'within' '7' 'days' 'before' 'the' 'first' 'dose' 'of'
 'study' 'treatment']",[0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01639508,"26:40:chronic_disease,44:63:chronic_disease,,109:118:treatment",concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment,"['concurrent' 'uncompensated' 'hypothyroidism' 'or' 'thyroid'
 'dysfunction' 'within' '7' 'days' 'before' 'the' 'first' 'dose' 'of'
 'study' 'treatment']",[0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT03150004,"15:18:cancer,34:37:cancer,85:98:treatment",Patients with MDS transformed to AML will be eligible even if they had not received prior therapy for AML,"['Patients' 'with' 'MDS' 'transformed' 'to' 'AML' 'will' 'be' 'eligible'
 'even' 'if' 'they' 'had' 'not' 'received' 'prior' 'therapy' 'for' 'AML']",[0. 0. 3. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.]
NCT01515527,"26:29:cancer,45:48:cancer,82:95:treatment",Patients with history of MDS transformed to AML are eligible regardless of their prior therapy for MDS provided,"['Patients' 'with' 'history' 'of' 'MDS' 'transformed' 'to' 'AML' 'are'
 'eligible' 'regardless' 'of' 'their' 'prior' 'therapy' 'for' 'MDS'
 'provided']",[0. 0. 0. 0. 3. 0. 0. 3. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.]
NCT02955394,"1:38:treatment,40:51:treatment,53:60:treatment,62:74:treatment,76:88:treatment,90:97:treatment,99:106:treatment,108:115:treatment,117:124:treatment,126:132:treatment","Prior treatment with an anti-androgen (abiraterone, ARN-509, bicalutamide, enzalutamide, ODM-201, TAK-448, TAK-683, TAK-700, VT-464)","['Prior' 'treatment' 'with' 'an' 'anti-androgen' '(' 'abiraterone' ','
 'ARN-509' ',' 'bicalutamide' ',' 'enzalutamide' ',' 'ODM-201' ','
 'TAK-448' ',' 'TAK-683' ',' 'TAK-700' ',' 'VT-464' ')']",[1. 1. 1. 1. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0.]
NCT02953860,"1:38:treatment,40:51:treatment,53:60:treatment,62:74:treatment,76:88:treatment,90:97:treatment,99:106:treatment,108:115:treatment,117:124:treatment,126:132:treatment","Prior treatment with an anti-androgen (abiraterone, ARN-509, bicalutamide, enzalutamide, ODM-201, TAK-448, TAK-683, TAK-700, VT-464)","['Prior' 'treatment' 'with' 'an' 'anti-androgen' '(' 'abiraterone' ','
 'ARN-509' ',' 'bicalutamide' ',' 'enzalutamide' ',' 'ODM-201' ','
 'TAK-448' ',' 'TAK-683' ',' 'TAK-700' ',' 'VT-464' ')']",[1. 1. 1. 1. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0.]
NCT02862210,"18:34:chronic_disease,38:51:chronic_disease,55:79:chronic_disease",The diagnosis of bipolar disorder or schizophrenia or schizoaffective disorder,"['The' 'diagnosis' 'of' 'bipolar' 'disorder' 'or' 'schizophrenia' 'or'
 'schizoaffective' 'disorder']",[0. 0. 0. 2. 2. 0. 2. 0. 2. 2.]
NCT02809677,"23:39:chronic_disease,43:56:chronic_disease,60:84:chronic_disease",depression as part of bipolar disorder or schizophrenia or schizoaffective disorder,"['depression' 'as' 'part' 'of' 'bipolar' 'disorder' 'or' 'schizophrenia'
 'or' 'schizoaffective' 'disorder']",[0. 0. 0. 0. 2. 2. 0. 2. 0. 2. 2.]
NCT02707471,"28:37:treatment,45:52:treatment,54:66:treatment,68:77:treatment","completed local definitive treatment (i.e., surgery, chemotherapy, radiation)","['completed' 'local' 'definitive' 'treatment' '(' 'i.e.' ',' 'surgery' ','
 'chemotherapy' ',' 'radiation' ')']",[0. 0. 0. 1. 0. 0. 0. 1. 0. 1. 0. 1. 0.]
NCT02085941,"35:44:treatment,54:63:treatment,65:77:treatment,79:86:treatment","must have sustained all available treatment options (radiation, chemotherapy, surgery) as verified by the Dana Farber Cancer Institute's Head and Neck Tumor Board","['must' 'have' 'sustained' 'all' 'available' 'treatment' 'options' '('
 'radiation' ',' 'chemotherapy' ',' 'surgery' ')' 'as' 'verified' 'by'
 'the' 'Dana' 'Farber' 'Cancer' 'Institute' ""'s"" 'Head' 'and' 'Neck'
 'Tumor' 'Board']","[0. 0. 0. 0. 0. 1. 0. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02656706,"1:17:cancer,58:80:cancer,90:105:cancer","Brain metastases, whether resected or not, and any known leptomeningeal disease or known bone metastases","['Brain' 'metastases' ',' 'whether' 'resected' 'or' 'not' ',' 'and' 'any'
 'known' 'leptomeningeal' 'disease' 'or' 'known' 'bone' 'metastases']",[3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 3. 3.]
NCT02519322,"1:17:cancer,19:41:cancer,45:60:cancer","Brain metastases, leptomeningeal disease or bone metastases","['Brain' 'metastases' ',' 'leptomeningeal' 'disease' 'or' 'bone'
 'metastases']",[3. 3. 0. 3. 3. 0. 3. 3.]
NCT02583893,"1:10:treatment,18:26:treatment,28:35:treatment,37:44:treatment","Verapamil (e.g., Calan SR, Isoptin, Verelan)","['Verapamil' '(' 'e.g.' ',' 'Calan' 'SR' ',' 'Isoptin' ',' 'Verelan' ')']",[1. 0. 0. 0. 1. 1. 0. 1. 0. 1. 0.]
NCT01869114,"1:10:treatment,17:25:treatment,27:34:treatment,36:43:treatment","Verapamil (e.g. Calan SR, Isoptin, Verelan)","['Verapamil' '(' 'e.g' '.' 'Calan' 'SR' ',' 'Isoptin' ',' 'Verelan' ')']",[1. 0. 0. 0. 1. 1. 0. 1. 0. 1. 0.]
NCT02576444,"27:44:cancer,46:58:cancer,74:98:cancer","Histologically documented metastatic cancer (solid tumors, not including hematologic malignancies)","['Histologically' 'documented' 'metastatic' 'cancer' '(' 'solid' 'tumors'
 ',' 'not' 'including' 'hematologic' 'malignancies' ')']",[0. 0. 3. 3. 0. 3. 3. 0. 0. 0. 3. 3. 0.]
NCT02091141,"27:44:cancer,46:58:cancer,74:98:cancer","Histologically documented metastatic cancer (solid tumors, not including hematologic malignancies)","['Histologically' 'documented' 'metastatic' 'cancer' '(' 'solid' 'tumors'
 ',' 'not' 'including' 'hematologic' 'malignancies' ')']",[0. 0. 3. 3. 0. 3. 3. 0. 0. 0. 3. 3. 0.]
NCT02555189,",23:36:treatment,59:68:treatment,76:83:treatment",At least 4 weeks from prior therapy completion (including radiation and/or surgery) to enrollment,"['At' 'least' '4' 'weeks' 'from' 'prior' 'therapy' 'completion' '('
 'including' 'radiation' 'and/or' 'surgery' ')' 'to' 'enrollment']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 0. 1. 0. 0. 0.]
NCT02419495,",16:29:treatment,52:61:treatment,69:76:treatment",> 4 weeks from prior therapy completion (including radiation and/or surgery),"['>' '4' 'weeks' 'from' 'prior' 'therapy' 'completion' '(' 'including'
 'radiation' 'and/or' 'surgery' ')']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 0. 1. 0.]
NCT02547818,"46:57:treatment,,114:145:treatment,153:162:treatment,","subjects must be on a stable dose of current medications for 4 weeks prior to study entry, with the exception of acetylcholinesterase inhibitors and/or memantine, which must be on a stable dose for at least 12 weeks prior to study entry","['subjects' 'must' 'be' 'on' 'a' 'stable' 'dose' 'of' 'current'
 'medications' 'for' '4' 'weeks' 'prior' 'to' 'study' 'entry' ',' 'with'
 'the' 'exception' 'of' 'acetylcholinesterase' 'inhibitors' 'and/or'
 'memantine' ',' 'which' 'must' 'be' 'on' 'a' 'stable' 'dose' 'for' 'at'
 'least' '12' 'weeks' 'prior' 'to' 'study' 'entry']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.
 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02547818,"20:51:treatment,59:68:treatment,103:114:treatment,",subjects receiving acetylcholinesterase inhibitors and/or memantine should be on stable dose of those medications for at least 12 weeks prior to study start with every effort to maintain stable dose for the duration of the study,"['subjects' 'receiving' 'acetylcholinesterase' 'inhibitors' 'and/or'
 'memantine' 'should' 'be' 'on' 'stable' 'dose' 'of' 'those' 'medications'
 'for' 'at' 'least' '12' 'weeks' 'prior' 'to' 'study' 'start' 'with'
 'every' 'effort' 'to' 'maintain' 'stable' 'dose' 'for' 'the' 'duration'
 'of' 'the' 'study']","[0. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02542657,"1:10:treatment,21:24:chronic_disease,36:52:treatment,","Treatment sensitive HIV and, if on anti-HIV therapy, HIV viral load < 50 copies/mm^3","['Treatment' 'sensitive' 'HIV' 'and' ',' 'if' 'on' 'anti-HIV' 'therapy'
 ',' 'HIV' 'viral' 'load' '<' '50' 'copies/mm^3']",[1. 0. 2. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02004275,"1:10:treatment,21:24:chronic_disease,36:52:treatment,,,","Treatment sensitive HIV and, if on anti-HIV therapy, HIV viral load < 50 copies/mm^3 within 28 days prior to registration","['Treatment' 'sensitive' 'HIV' 'and' ',' 'if' 'on' 'anti-HIV' 'therapy'
 ',' 'HIV' 'viral' 'load' '<' '50' 'copies/mm^3' 'within' '28' 'days'
 'prior' 'to' 'registration']",[1. 0. 2. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02534922,"5:21:treatment,38:53:cancer,,132:159:treatment",Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration. Continuation of hormone replacement therapy is permitted,"['Any' 'hormonal' 'therapy' 'directed' 'at' 'the' 'malignant' 'tumor'
 'must' 'be' 'discontinued' 'at' 'least' 'one' 'week' 'prior' 'to'
 'registration' '.' 'Continuation' 'of' 'hormone' 'replacement' 'therapy'
 'is' 'permitted']","[0. 1. 1. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.
 0. 0.]"
NCT01042522,"5:21:treatment,38:53:cancer,,132:159:treatment",Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration; continuation of hormone replacement therapy is permitted,"['Any' 'hormonal' 'therapy' 'directed' 'at' 'the' 'malignant' 'tumor'
 'must' 'be' 'discontinued' 'at' 'least' 'one' 'week' 'prior' 'to'
 'registration' ';' 'continuation' 'of' 'hormone' 'replacement' 'therapy'
 'is' 'permitted']","[0. 1. 1. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.
 0. 0.]"
NCT02516670,"1:12:treatment,14:28:treatment,30:42:treatment,44:57:treatment,59:73:treatment","Antibiotics: clarithromycin, erythromycin, telithromycin, troleandomycin","['Antibiotics' ':' 'clarithromycin' ',' 'erythromycin' ',' 'telithromycin'
 ',' 'troleandomycin']",[1. 0. 1. 0. 1. 0. 1. 0. 1.]
NCT01822522,"1:12:treatment,14:28:treatment,30:42:treatment,44:57:treatment,59:73:treatment","Antibiotics: clarithromycin, erythromycin, telithromycin, troleandomycin","['Antibiotics' ':' 'clarithromycin' ',' 'erythromycin' ',' 'telithromycin'
 ',' 'troleandomycin']",[1. 0. 1. 0. 1. 0. 1. 0. 1.]
NCT02512718,"12:15:allergy_name,17:21:allergy_name,26:29:allergy_name,30:45:allergy_name","Allergy to egg, fish, or soy/legume products","['Allergy' 'to' 'egg' ',' 'fish' ',' 'or' 'soy/legume' 'products']",[0. 0. 4. 0. 4. 0. 0. 4. 4.]
NCT02512718,"12:15:allergy_name,17:21:allergy_name,26:29:allergy_name,30:45:allergy_name","allergy to egg, fish, or soy/legume products","['allergy' 'to' 'egg' ',' 'fish' ',' 'or' 'soy/legume' 'products']",[0. 0. 4. 0. 4. 0. 0. 4. 4.]
NCT02496663,"55:66:treatment,68:86:treatment,143:149:treatment","all patients must try to avoid concomitant use of any medications, herbal supplements and/or ingestion of foods with known inducer effects of CYP3A4","['all' 'patients' 'must' 'try' 'to' 'avoid' 'concomitant' 'use' 'of' 'any'
 'medications' ',' 'herbal' 'supplements' 'and/or' 'ingestion' 'of'
 'foods' 'with' 'known' 'inducer' 'effects' 'of' 'CYP3A4']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01620216,"12:23:treatment,27:45:treatment,88:94:treatment",Taking any medications or herbal supplements that are known to be strong inhibitors of CYP3A4,"['Taking' 'any' 'medications' 'or' 'herbal' 'supplements' 'that' 'are'
 'known' 'to' 'be' 'strong' 'inhibitors' 'of' 'CYP3A4']",[0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02488967,"12:35:cancer,48:63:cancer,80:94:treatment,99:109:cancer,114:150:cancer,",History of non-breast malignancies (except for in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin) within 5 years prior to randomization,"['History' 'of' 'non-breast' 'malignancies' '(' 'except' 'for' 'in' 'situ'
 'cancers' 'treated' 'only' 'by' 'local' 'excision' 'and' 'basal' 'cell'
 'and' 'squamous' 'cell' 'carcinomas' 'of' 'the' 'skin' ')' 'within' '5'
 'years' 'prior' 'to' 'randomization']","[0. 0. 3. 3. 0. 0. 0. 3. 3. 3. 0. 0. 0. 1. 1. 0. 3. 3. 0. 3. 3. 3. 3. 3.
 3. 0. 0. 0. 0. 0. 0. 0.]"
NCT01872975,"12:35:cancer,48:63:cancer,80:94:treatment,99:109:cancer,114:150:cancer,",History of non-breast malignancies (except for in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin) within 5 years prior to randomization,"['History' 'of' 'non-breast' 'malignancies' '(' 'except' 'for' 'in' 'situ'
 'cancers' 'treated' 'only' 'by' 'local' 'excision' 'and' 'basal' 'cell'
 'and' 'squamous' 'cell' 'carcinomas' 'of' 'the' 'skin' ')' 'within' '5'
 'years' 'prior' 'to' 'randomization']","[0. 0. 3. 3. 0. 0. 0. 3. 3. 3. 0. 0. 0. 1. 1. 0. 3. 3. 0. 3. 3. 3. 3. 3.
 3. 0. 0. 0. 0. 0. 0. 0.]"
NCT02468024,"10:29:cancer,,100:124:cancer,126:141:cancer","No prior invasive malignancy, unless disease-free for ≥ 3 years prior to registration (exceptions: non-melanoma skin cancer, in-situ cancers)","['No' 'prior' 'invasive' 'malignancy' ',' 'unless' 'disease-free' 'for'
 '≥' '3' 'years' 'prior' 'to' 'registration' '(' 'exceptions' ':'
 'non-melanoma' 'skin' 'cancer' ',' 'in-situ' 'cancers' ')']",[0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 3. 3. 0.]
NCT02468024,"7:26:cancer,,97:121:cancer,123:138:cancer","prior invasive malignancy, unless disease-free for ≥ 3 years prior to registration (exceptions: non-melanoma skin cancer, in-situ cancers)","['prior' 'invasive' 'malignancy' ',' 'unless' 'disease-free' 'for' '≥' '3'
 'years' 'prior' 'to' 'registration' '(' 'exceptions' ':' 'non-melanoma'
 'skin' 'cancer' ',' 'in-situ' 'cancers' ')']",[0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 3. 3. 0.]
NCT02451423,"82:90:allergy_name,94:114:allergy_name,118:133:allergy_name","History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins","['History' 'of' 'severe' 'allergic' ',' 'anaphylactic' ',' 'or' 'other'
 'hypersensitivity' 'reactions' 'to' 'chimeric' 'or' 'humanized'
 'antibodies' 'or' 'fusion' 'proteins']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 0. 4. 4. 0. 4. 4.]
NCT02091141,"82:90:allergy_name,94:114:allergy_name,118:133:allergy_name","History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins","['History' 'of' 'severe' 'allergic' ',' 'anaphylactic' ',' 'or' 'other'
 'hypersensitivity' 'reactions' 'to' 'chimeric' 'or' 'humanized'
 'antibodies' 'or' 'fusion' 'proteins']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 0. 4. 4. 0. 4. 4.]
NCT02414269,"1:45:treatment,52:65:treatment,67:81:treatment,85:100:treatment,,175:190:treatment","Prior immunotherapy with checkpoint blockade (i.e. PD1 inhibitor, PDL1 inhibitor or CTL4-antagonist or similar agent) must have been completed more than 1 month prior to the T cell infusion","['Prior' 'immunotherapy' 'with' 'checkpoint' 'blockade' '(' 'i.e' '.'
 'PD1' 'inhibitor' ',' 'PDL1' 'inhibitor' 'or' 'CTL4-antagonist' 'or'
 'similar' 'agent' ')' 'must' 'have' 'been' 'completed' 'more' 'than' '1'
 'month' 'prior' 'to' 'the' 'T' 'cell' 'infusion']","[1. 1. 1. 1. 1. 0. 0. 0. 1. 1. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 1. 1.]"
NCT02414269,"1:45:treatment,52:65:treatment,67:81:treatment,85:100:treatment,,175:190:treatment","Prior immunotherapy with checkpoint blockade (i.e. PD1 inhibitor, PDL1 inhibitor or CTL4-antagonist or similar agent) must have been completed more than 1 month1prior to the T cell infusion","['Prior' 'immunotherapy' 'with' 'checkpoint' 'blockade' '(' 'i.e' '.'
 'PD1' 'inhibitor' ',' 'PDL1' 'inhibitor' 'or' 'CTL4-antagonist' 'or'
 'similar' 'agent' ')' 'must' 'have' 'been' 'completed' 'more' 'than' '1'
 'month1prior' 'to' 'the' 'T' 'cell' 'infusion']","[1. 1. 1. 1. 1. 0. 0. 0. 1. 1. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 1. 1.]"
NCT02394535,"31:38:chronic_disease,56:61:chronic_disease,63:74:chronic_disease,76:85:chronic_disease,87:116:chronic_disease,130:158:chronic_disease","history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis or pulmonary hypersensitivity pneumonitis","['history' 'of' 'slowly' 'progressive' 'dyspnea' 'and' 'unproductive'
 'cough' ',' 'sarcoidosis' ',' 'silicosis' ',' 'idiopathic' 'pulmonary'
 'fibrosis' 'or' 'pulmonary' 'hypersensitivity' 'pneumonitis']",[0. 0. 0. 0. 2. 0. 0. 2. 0. 2. 0. 2. 0. 2. 2. 2. 0. 0. 2. 2.]
NCT02080221,"31:38:chronic_disease,56:61:chronic_disease,63:74:chronic_disease,76:85:chronic_disease,87:116:chronic_disease,128:156:chronic_disease","history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis","['history' 'of' 'slowly' 'progressive' 'dyspnea' 'and' 'unproductive'
 'cough' ',' 'sarcoidosis' ',' 'silicosis' ',' 'idiopathic' 'pulmonary'
 'fibrosis' ',' 'pulmonary' 'hypersensitivity' 'pneumonitis']",[0. 0. 0. 0. 2. 0. 0. 2. 0. 2. 0. 2. 0. 2. 2. 2. 0. 0. 2. 2.]
NCT02390752,"1:30:treatment,,72:101:treatment,120:131:treatment",Myelosuppressive chemotherapy: At least 21 days after the last dose of myelosuppressive chemotherapy (42 days if prior nitrosourea),"['Myelosuppressive' 'chemotherapy' ':' 'At' 'least' '21' 'days' 'after'
 'the' 'last' 'dose' 'of' 'myelosuppressive' 'chemotherapy' '(' '42'
 'days' 'if' 'prior' 'nitrosourea' ')']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 0.]
NCT02323880,"1:30:treatment,,72:101:treatment,,120:131:treatment",Myelosuppressive chemotherapy: At least 21 days after the last dose of myelosuppressive chemotherapy (42 days if prior nitrosourea),"['Myelosuppressive' 'chemotherapy' ':' 'At' 'least' '21' 'days' 'after'
 'the' 'last' 'dose' 'of' 'myelosuppressive' 'chemotherapy' '(' '42'
 'days' 'if' 'prior' 'nitrosourea' ')']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 0.]
NCT02358187,"58:78:chronic_disease,89:98:treatment,102:127:treatment","Patients must not have a history of, or currently active autoimmune disorders requiring cytotoxic or immunosuppressive therapy, or autoimmune disorders with visceral involvement","['Patients' 'must' 'not' 'have' 'a' 'history' 'of' ',' 'or' 'currently'
 'active' 'autoimmune' 'disorders' 'requiring' 'cytotoxic' 'or'
 'immunosuppressive' 'therapy' ',' 'or' 'autoimmune' 'disorders' 'with'
 'visceral' 'involvement']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02334865,"11:31:chronic_disease,42:51:treatment,55:80:treatment",Any prior autoimmune disorders requiring cytotoxic or immunosuppressive therapy or autoimmune disorders with visceral involvement,"['Any' 'prior' 'autoimmune' 'disorders' 'requiring' 'cytotoxic' 'or'
 'immunosuppressive' 'therapy' 'or' 'autoimmune' 'disorders' 'with'
 'visceral' 'involvement']",[0. 0. 2. 2. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02334865,"34:49:chronic_disease,55:89:chronic_disease,91:114:chronic_disease,118:141:chronic_disease","Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV)","['Known' 'seropositive' 'for' 'or' 'active' 'viral' 'infection' 'with'
 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')' ',' 'hepatitis' 'B'
 'virus' '(' 'HBV' ')' 'or' 'hepatitis' 'C' 'virus' '(' 'HCV' ')']","[0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 2. 2. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02293109,"32:47:chronic_disease,53:87:chronic_disease,89:112:chronic_disease,116:139:chronic_disease","Known sero-positive for active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV)","['Known' 'sero-positive' 'for' 'active' 'viral' 'infection' 'with' 'human'
 'immunodeficiency' 'virus' '(' 'HIV' ')' ',' 'hepatitis' 'B' 'virus' '('
 'HBV' ')' 'or' 'hepatitis' 'C' 'virus' '(' 'HCV' ')']","[0. 0. 0. 0. 2. 2. 0. 2. 2. 2. 2. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02319369,"130:145:treatment,169:185:chronic_disease,227:234:treatment","Is able to provide written informed consent (or authorized representative), comply with protocol visits and procedures, and take oral medication, and does not have any active infection or comorbidity that would interfere with therapy","['Is' 'able' 'to' 'provide' 'written' 'informed' 'consent' '(' 'or'
 'authorized' 'representative' ')' ',' 'comply' 'with' 'protocol' 'visits'
 'and' 'procedures' ',' 'and' 'take' 'oral' 'medication' ',' 'and' 'does'
 'not' 'have' 'any' 'active' 'infection' 'or' 'comorbidity' 'that' 'would'
 'interfere' 'with' 'therapy']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.
 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 1.]"
NCT01877382,"121:136:treatment,155:171:chronic_disease,213:220:treatment","Subject should be able to provide written informed consent, comply with protocol visits and procedures, be able to take oral medication, and not have any active infection or comorbidity that would interfere with therapy","['Subject' 'should' 'be' 'able' 'to' 'provide' 'written' 'informed'
 'consent' ',' 'comply' 'with' 'protocol' 'visits' 'and' 'procedures' ','
 'be' 'able' 'to' 'take' 'oral' 'medication' ',' 'and' 'not' 'have' 'any'
 'active' 'infection' 'or' 'comorbidity' 'that' 'would' 'interfere' 'with'
 'therapy']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.
 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 1.]"
NCT02304458,"21:55:chronic_disease,59:70:chronic_disease,74:75:chronic_disease",Patients with known human immunodeficiency virus (HIV) or hepatitis B or C,"['Patients' 'with' 'known' 'human' 'immunodeficiency' 'virus' '(' 'HIV'
 ')' 'or' 'hepatitis' 'B' 'or' 'C']",[0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 2. 2. 0. 2.]
NCT02101944,"30:64:chronic_disease,85:96:chronic_disease,100:101:chronic_disease",Patients must not have known human immunodeficiency virus (HIV) infection or active hepatitis B or C infections,"['Patients' 'must' 'not' 'have' 'known' 'human' 'immunodeficiency' 'virus'
 '(' 'HIV' ')' 'infection' 'or' 'active' 'hepatitis' 'B' 'or' 'C'
 'infections']",[0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 2. 2. 0. 2. 0.]
NCT02217709,"77:93:chronic_disease,95:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease,182:201:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' ',' 'ongoing' 'or' 'active' 'infection' ',' 'symptomatic'
 'congestive' 'heart' 'failure' ',' 'unstable' 'angina' 'pectoris' ','
 'cardiac' 'arrhythmia' ',' 'or' 'psychiatric' 'illness/social'
 'situations' 'that' 'would' 'limit' 'compliance' 'with' 'study'
 'requirements']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 2. 2. 0. 2. 2. 2. 0.
 2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01989546,"77:93:chronic_disease,95:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease,182:201:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' ',' 'ongoing' 'or' 'active' 'infection' ',' 'symptomatic'
 'congestive' 'heart' 'failure' ',' 'unstable' 'angina' 'pectoris' ','
 'cardiac' 'arrhythmia' ',' 'or' 'psychiatric' 'illness/social'
 'situations' 'that' 'would' 'limit' 'compliance' 'with' 'study'
 'requirements']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 2. 2. 0. 2. 2. 2. 0.
 2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02165007,"28:37:chronic_disease,39:44:chronic_disease,48:65:chronic_disease,90:99:treatment,","Patients with uncontrolled bacterial, viral or fungal infections (undergoing appropriate treatment and with progression of clinical symptoms) within 1 month prior to conditioning","['Patients' 'with' 'uncontrolled' 'bacterial' ',' 'viral' 'or' 'fungal'
 'infections' '(' 'undergoing' 'appropriate' 'treatment' 'and' 'with'
 'progression' 'of' 'clinical' 'symptoms' ')' 'within' '1' 'month' 'prior'
 'to' 'conditioning']","[0. 0. 0. 2. 0. 2. 0. 2. 2. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02122081,"35:44:chronic_disease,46:51:chronic_disease,55:72:chronic_disease,97:106:treatment","Patients with active uncontrolled bacterial, viral or fungal infections (undergoing appropriate treatment and with progression of clinical symptoms)","['Patients' 'with' 'active' 'uncontrolled' 'bacterial' ',' 'viral' 'or'
 'fungal' 'infections' '(' 'undergoing' 'appropriate' 'treatment' 'and'
 'with' 'progression' 'of' 'clinical' 'symptoms' ')']",[0. 0. 0. 0. 2. 0. 2. 0. 2. 2. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02133196,"1:27:chronic_disease,45:69:treatment,72:93:chronic_disease,137:154:chronic_disease","Active systemic infections (e.g.: requiring anti-infective treatment), coagulation disorders or any other active or uncompensated major medical illnesses","['Active' 'systemic' 'infections' '(' 'e.g' '.' ':' 'requiring'
 'anti-infective' 'treatment' ')' ',' 'coagulation' 'disorders' 'or' 'any'
 'other' 'active' 'or' 'uncompensated' 'major' 'medical' 'illnesses']",[2. 2. 2. 0. 0. 0. 0. 0. 1. 1. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT01967823,"1:27:chronic_disease,38:62:treatment,64:85:chronic_disease,130:147:chronic_disease","Active systemic infections requiring anti-infective treatment, coagulation disorders, or any other active or uncompensated major medical illnesses","['Active' 'systemic' 'infections' 'requiring' 'anti-infective' 'treatment'
 ',' 'coagulation' 'disorders' ',' 'or' 'any' 'other' 'active' 'or'
 'uncompensated' 'major' 'medical' 'illnesses']",[2. 2. 2. 0. 1. 1. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02101736,"25:37:chronic_disease,,,,,,116:150:treatment,141:150:treatment,","Concurrent uncontrolled hypertension defined as sustained BP > 140 mm Hg systolic, or > 90 mm Hg diastolic despite optimal antihypertensive treatment within 7 days before the first dose of study treatment","['Concurrent' 'uncontrolled' 'hypertension' 'defined' 'as' 'sustained'
 'BP' '>' '140' 'mm' 'Hg' 'systolic' ',' 'or' '>' '90' 'mm' 'Hg'
 'diastolic' 'despite' 'optimal' 'antihypertensive' 'treatment' 'within'
 '7' 'days' 'before' 'the' 'first' 'dose' 'of' 'study' 'treatment']","[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01822522,"25:37:chronic_disease,,,,,131:165:treatment,156:165:treatment,","Concurrent uncontrolled hypertension defined as sustained blood pressure (BP) > 140 mmHg systolic, or > 90 mmHg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment","['Concurrent' 'uncontrolled' 'hypertension' 'defined' 'as' 'sustained'
 'blood' 'pressure' '(' 'BP' ')' '>' '140' 'mmHg' 'systolic' ',' 'or' '>'
 '90' 'mmHg' 'diastolic' 'despite' 'optimal' 'antihypertensive'
 'treatment' 'within' '7' 'days' 'of' 'the' 'first' 'dose' 'of' 'study'
 'treatment']","[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02058095,"17:34:treatment,38:68:treatment,70:82:treatment,84:96:treatment,98:110:treatment,112:122:treatment,124:134:treatment,138:164:treatment,169:172:chronic_disease,204:215:treatment","Patients taking alpha antagonists or cytochrome P450 3A4 inhibitors (ketoconazole, itraconazole, erythromycin, saquinavir, cimetidine or serum proteases inhibitors for HIV) who cannot be taken off these medications for the duration of the study","['Patients' 'taking' 'alpha' 'antagonists' 'or' 'cytochrome' 'P450' '3A4'
 'inhibitors' '(' 'ketoconazole' ',' 'itraconazole' ',' 'erythromycin' ','
 'saquinavir' ',' 'cimetidine' 'or' 'serum' 'proteases' 'inhibitors' 'for'
 'HIV' ')' 'who' 'can' 'not' 'be' 'taken' 'off' 'these' 'medications'
 'for' 'the' 'duration' 'of' 'the' 'study']","[0. 0. 1. 1. 0. 1. 1. 1. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 1. 1. 0.
 2. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]"
NCT01970176,"17:34:treatment,38:68:treatment,70:82:treatment,84:96:treatment,98:110:treatment,112:122:treatment,124:134:treatment,138:164:treatment,169:172:chronic_disease,204:215:treatment","Patients taking alpha antagonists or cytochrome P450 3A4 inhibitors (ketoconazole, itraconazole, erythromycin, saquinavir, cimetidine or serum proteases inhibitors for HIV) who cannot be taken off these medications for the duration of the study","['Patients' 'taking' 'alpha' 'antagonists' 'or' 'cytochrome' 'P450' '3A4'
 'inhibitors' '(' 'ketoconazole' ',' 'itraconazole' ',' 'erythromycin' ','
 'saquinavir' ',' 'cimetidine' 'or' 'serum' 'proteases' 'inhibitors' 'for'
 'HIV' ')' 'who' 'can' 'not' 'be' 'taken' 'off' 'these' 'medications'
 'for' 'the' 'duration' 'of' 'the' 'study']","[0. 0. 1. 1. 0. 1. 1. 1. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 1. 1. 0.
 2. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]"
NCT01925573,",56:66:treatment,68:94:chronic_disease,103:118:chronic_disease,120:155:treatment,157:187:chronic_disease,189:219:chronic_disease,221:252:chronic_disease,254:277:chronic_disease","Any of the following within 6 months prior to starting study drug: myocardial infarction (MI), severe/unstable angina, Coronary Artery Bypass Graft (CABG), Congestive Heart Failure (CHF), Cerebrovascular Accident (CVA), Transient Ischemic Attack (TIA), Pulmonary Embolism (PE)","['Any' 'of' 'the' 'following' 'within' '6' 'months' 'prior' 'to'
 'starting' 'study' 'drug' ':' 'myocardial' 'infarction' '(' 'MI' ')' ','
 'severe/unstable' 'angina' ',' 'Coronary' 'Artery' 'Bypass' 'Graft' '('
 'CABG' ')' ',' 'Congestive' 'Heart' 'Failure' '(' 'CHF' ')' ','
 'Cerebrovascular' 'Accident' '(' 'CVA' ')' ',' 'Transient' 'Ischemic'
 'Attack' '(' 'TIA' ')' ',' 'Pulmonary' 'Embolism' '(' 'PE' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 2. 2. 2. 0. 0. 0. 2. 2. 0. 1. 1.
 1. 1. 1. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 2. 2. 2. 0. 0. 0. 2. 2. 2. 2. 0.
 0. 0. 2. 2. 2. 0. 0.]"
NCT01894061,",56:66:treatment,68:94:chronic_disease,103:118:chronic_disease,120:155:treatment,157:187:chronic_disease,189:219:chronic_disease,221:252:chronic_disease,254:277:chronic_disease","Any of the following within 6 months prior to starting study drug: myocardial infarction (MI), severe/unstable angina, Coronary Artery Bypass Graft (CABG), Congestive Heart Failure (CHF), Cerebrovascular Accident (CVA), Transient Ischemic Attack (TIA), Pulmonary Embolism (PE)","['Any' 'of' 'the' 'following' 'within' '6' 'months' 'prior' 'to'
 'starting' 'study' 'drug' ':' 'myocardial' 'infarction' '(' 'MI' ')' ','
 'severe/unstable' 'angina' ',' 'Coronary' 'Artery' 'Bypass' 'Graft' '('
 'CABG' ')' ',' 'Congestive' 'Heart' 'Failure' '(' 'CHF' ')' ','
 'Cerebrovascular' 'Accident' '(' 'CVA' ')' ',' 'Transient' 'Ischemic'
 'Attack' '(' 'TIA' ')' ',' 'Pulmonary' 'Embolism' '(' 'PE' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 2. 2. 2. 0. 0. 0. 2. 2. 0. 1. 1.
 1. 1. 1. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 2. 2. 2. 0. 0. 0. 2. 2. 2. 2. 0.
 0. 0. 2. 2. 2. 0. 0.]"
NCT01804634,"14:19:chronic_disease,21:30:chronic_disease,35:52:chronic_disease","Uncontrolled viral, bacterial, or fungal infections","['Uncontrolled' 'viral' ',' 'bacterial' ',' 'or' 'fungal' 'infections']",[0. 2. 0. 2. 0. 0. 2. 2.]
NCT01701986,"21:30:chronic_disease,32:37:chronic_disease,41:58:chronic_disease","Active uncontrolled bacterial, viral or fungal infections","['Active' 'uncontrolled' 'bacterial' ',' 'viral' 'or' 'fungal'
 'infections']",[0. 0. 2. 0. 2. 0. 2. 2.]
NCT01438073,"52:63:treatment,80:97:treatment,99:108:treatment,116:147:treatment,152:174:treatment","all medical conditions stable and well controlled, medications allowed include asthma medication (albuterol only), hypercholesterolemia medication and psychiatric medication","['all' 'medical' 'conditions' 'stable' 'and' 'well' 'controlled' ','
 'medications' 'allowed' 'include' 'asthma' 'medication' '(' 'albuterol'
 'only' ')' ',' 'hypercholesterolemia' 'medication' 'and' 'psychiatric'
 'medication']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 1. 0. 1. 0. 0. 0. 1. 1. 0. 1. 1.]
NCT01438073,"17:28:treatment,,73:90:treatment,92:101:treatment,109:140:treatment,145:167:treatment","no prescription medications for at least 2 months with the exception of asthma medication (albuterol only), hypercholesterolemia medication and psychiatric medication","['no' 'prescription' 'medications' 'for' 'at' 'least' '2' 'months' 'with'
 'the' 'exception' 'of' 'asthma' 'medication' '(' 'albuterol' 'only' ')'
 ',' 'hypercholesterolemia' 'medication' 'and' 'psychiatric' 'medication']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 0. 0. 1. 1. 0. 1. 1.]
NCT03188185,"50:62:chronic_disease,64:75:chronic_disease,80:89:chronic_disease","Has any other significant medical condition (eg, neurological, psychiatric, or metabolic) or clinical symptom that could unduly risk the subject or affect the interpretation of study data","['Has' 'any' 'other' 'significant' 'medical' 'condition' '(' 'eg' ','
 'neurological' ',' 'psychiatric' ',' 'or' 'metabolic' ')' 'or' 'clinical'
 'symptom' 'that' 'could' 'unduly' 'risk' 'the' 'subject' 'or' 'affect'
 'the' 'interpretation' 'of' 'study' 'data']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03188042,"1:24:chronic_disease,81:89:chronic_disease,91:97:chronic_disease","End-stage organ disease or medical condition with subsequent vision loss (e.g., diabetes, stroke)","['End-stage' 'organ' 'disease' 'or' 'medical' 'condition' 'with'
 'subsequent' 'vision' 'loss' '(' 'e.g.' ',' 'diabetes' ',' 'stroke' ')']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0.]
NCT03183388,"12:34:chronic_disease,58:69:chronic_disease,,129:145:chronic_disease,147:162:chronic_disease,166:183:cancer,188:214:chronic_disease","history of neurologic abnormality, including significant head trauma (defined by loss of consciousness of ≥5-minutes duration), seizure disorder, cerebrovascular or neoplastic lesion, or neurodegenerative disorder","['history' 'of' 'neurologic' 'abnormality' ',' 'including' 'significant'
 'head' 'trauma' '(' 'defined' 'by' 'loss' 'of' 'consciousness' 'of'
 '≥5-minutes' 'duration' ')' ',' 'seizure' 'disorder' ','
 'cerebrovascular' 'or' 'neoplastic' 'lesion' ',' 'or' 'neurodegenerative'
 'disorder']","[0. 0. 2. 2. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2.
 0. 3. 3. 0. 0. 2. 2.]"
NCT03182751,"12:15:chronic_disease,17:19:chronic_disease,24:27:chronic_disease,","History of CVA, MI, or VTE within the previous 30 days","['History' 'of' 'CVA' ',' 'MI' ',' 'or' 'VTE' 'within' 'the' 'previous'
 '30' 'days']",[0. 0. 2. 0. 2. 0. 0. 2. 0. 0. 0. 0. 0.]
NCT03181893,"19:41:chronic_disease,50:68:chronic_disease,86:107:chronic_disease","Have pre existing demyelinating disorder such as multiple sclerosis, or other severe neurological deficits","['Have' 'pre' 'existing' 'demyelinating' 'disorder' 'such' 'as' 'multiple'
 'sclerosis' ',' 'or' 'other' 'severe' 'neurological' 'deficits']",[0. 0. 0. 2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 2. 2.]
NCT03180905,"10:18:chronic_disease,20:32:chronic_disease,34:44:chronic_disease,48:72:chronic_disease","No known physical, neurological, behavioral or psychological impairment that would affect their ability to perform the test","['No' 'known' 'physical' ',' 'neurological' ',' 'behavioral' 'or'
 'psychological' 'impairment' 'that' 'would' 'affect' 'their' 'ability'
 'to' 'perform' 'the' 'test']",[0. 0. 2. 0. 2. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03179397,"17:34:chronic_disease,42:52:chronic_disease,66:87:chronic_disease","Clinical severe corneal dystrophy (e.g., epithelial, stromal, or endothelial dystrophy)","['Clinical' 'severe' 'corneal' 'dystrophy' '(' 'e.g.' ',' 'epithelial' ','
 'stromal' ',' 'or' 'endothelial' 'dystrophy' ')']",[0. 0. 2. 2. 0. 0. 0. 2. 0. 0. 0. 0. 2. 2. 0.]
NCT03179163,"28:41:treatment,76:85:treatment,87:97:treatment","history of having taken an ACE inhibitor with antioxidant properties (e.g. Captopril, Zofenopril)","['history' 'of' 'having' 'taken' 'an' 'ACE' 'inhibitor' 'with'
 'antioxidant' 'properties' '(' 'e.g' '.' 'Captopril' ',' 'Zofenopril' ')']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0.]
NCT03176979,",23:31:treatment,33:40:treatment,45:62:treatment,67:80:cancer","Women with history of surgical, medical, or radiation therapy for breast cancer","['Women' 'with' 'history' 'of' 'surgical' ',' 'medical' ',' 'or'
 'radiation' 'therapy' 'for' 'breast' 'cancer']",[0. 0. 0. 0. 1. 0. 1. 0. 0. 1. 1. 0. 3. 3.]
NCT03175978,"16:24:chronic_disease,30:46:chronic_disease,66:74:chronic_disease",Any history of epilepsy or a seizure disorder or any known prior seizures,"['Any' 'history' 'of' 'epilepsy' 'or' 'a' 'seizure' 'disorder' 'or' 'any'
 'known' 'prior' 'seizures']",[0. 0. 0. 2. 0. 0. 2. 2. 0. 0. 0. 0. 2.]
NCT03171493,"20:30:cancer,34:59:cancer,53:59:cancer,61:84:cancer,105:125:cancer",Adequately treated basal cell or squamous cell skin cancer; In situ cervical cancer; Adequately treated Stage I or II cancer from which the patient is currently incomplete remission or other cancer from which the patient has been disease-free for 2 years,"['Adequately' 'treated' 'basal' 'cell' 'or' 'squamous' 'cell' 'skin'
 'cancer' ';' 'In' 'situ' 'cervical' 'cancer' ';' 'Adequately' 'treated'
 'Stage' 'I' 'or' 'II' 'cancer' 'from' 'which' 'the' 'patient' 'is'
 'currently' 'incomplete' 'remission' 'or' 'other' 'cancer' 'from' 'which'
 'the' 'patient' 'has' 'been' 'disease-free' 'for' '2' 'years']","[0. 0. 3. 3. 0. 3. 3. 3. 3. 0. 3. 3. 3. 3. 0. 0. 0. 3. 3. 3. 3. 3. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03171480,"1:4:chronic_disease,8:25:chronic_disease,33:46:treatment",DIC or active hemorrhage before randomization,['DIC' 'or' 'active' 'hemorrhage' 'before' 'randomization'],[2. 0. 2. 2. 0. 1.]
NCT03169543,"12:28:chronic_disease,30:38:chronic_disease,40:48:chronic_disease,50:67:chronic_disease,69:82:chronic_disease,93:112:chronic_disease","History of bipolar disorder, delirium, dementia, amnestic disorder, schizophrenia and other psychotic disorders","['History' 'of' 'bipolar' 'disorder' ',' 'delirium' ',' 'dementia' ','
 'amnestic' 'disorder' ',' 'schizophrenia' 'and' 'other' 'psychotic'
 'disorders']",[0. 0. 2. 2. 0. 2. 0. 2. 0. 2. 2. 0. 2. 0. 0. 2. 2.]
NCT03167125,"16:34:chronic_disease,42:60:chronic_disease,64:73:treatment","Persons having colorectal disease (e.g., ulcerative colitis or colectomy)","['Persons' 'having' 'colorectal' 'disease' '(' 'e.g.' ',' 'ulcerative'
 'colitis' 'or' 'colectomy' ')']",[0. 0. 2. 2. 0. 0. 0. 2. 2. 0. 1. 0.]
NCT03165227,",,,102:109:treatment,111:149:treatment,157:185:treatment","Patients with type 1 or type 2 diabetes mellitus, diagnosed before informed consent and treated with insulin, glucagon-like peptide (GLP) 1 agonists and/or oral antidiabetic medication","['Patients' 'with' 'type' '1' 'or' 'type' '2' 'diabetes' 'mellitus' ','
 'diagnosed' 'before' 'informed' 'consent' 'and' 'treated' 'with'
 'insulin' ',' 'glucagon-like' 'peptide' '(' 'GLP' ')' '1' 'agonists'
 'and/or' 'oral' 'antidiabetic' 'medication']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 1. 1. 1.
 0. 0. 0. 1. 1. 1.]"
NCT03162731,"18:34:chronic_disease,38:71:treatment,,95:105:treatment,",Any diagnosis of immunodeficiency or current immunosuppressive therapy including >10mg/day of prednisone within 14 days of enrollment is not permitted,"['Any' 'diagnosis' 'of' 'immunodeficiency' 'or' 'current'
 'immunosuppressive' 'therapy' 'including' '>' '10mg/day' 'of'
 'prednisone' 'within' '14' 'days' 'of' 'enrollment' 'is' 'not'
 'permitted']",[0. 0. 0. 2. 0. 1. 1. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03162731,"15:23:chronic_disease,25:49:chronic_disease,73:79:chronic_disease,80:85:chronic_disease","subjects with vitiligo, type I diabetes mellitus, or resolved childhood asthma/atopy would be an exception to this rule","['subjects' 'with' 'vitiligo' ',' 'type' 'I' 'diabetes' 'mellitus' ','
 'or' 'resolved' 'childhood' 'asthma/atopy' 'would' 'be' 'an' 'exception'
 'to' 'this' 'rule']",[0. 0. 2. 0. 2. 2. 2. 2. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT03161028,"9:34:chronic_disease,46:48:chronic_disease,56:62:cancer,64:77:chronic_disease,89:112:chronic_disease,114:144:chronic_disease","Current major disease or disorder other than MS (e.g., cancer, renal disease, end-stage cardiopulmonary disease, post-traumatic stress disorder, etc.) that may interfere with study procedures","['Current' 'major' 'disease' 'or' 'disorder' 'other' 'than' 'MS' '('
 'e.g.' ',' 'cancer' ',' 'renal' 'disease' ',' 'end-stage'
 'cardiopulmonary' 'disease' ',' 'post-traumatic' 'stress' 'disorder' ','
 'etc' '.' ')' 'that' 'may' 'interfere' 'with' 'study' 'procedures']","[0. 2. 2. 2. 2. 0. 0. 2. 0. 0. 0. 3. 0. 2. 2. 0. 0. 2. 2. 0. 2. 2. 2. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03158519,"19:34:treatment,66:75:treatment,79:98:treatment,111:118:treatment,120:129:treatment,138:150:treatment,","Completion of all primary therapy (with the exception of ongoing endocrine or trastuzumab therapy), including surgery, radiation, and/or chemotherapy greater than 4 weeks prior to study enrollment","['Completion' 'of' 'all' 'primary' 'therapy' '(' 'with' 'the' 'exception'
 'of' 'ongoing' 'endocrine' 'or' 'trastuzumab' 'therapy' ')' ','
 'including' 'surgery' ',' 'radiation' ',' 'and/or' 'chemotherapy'
 'greater' 'than' '4' 'weeks' 'prior' 'to' 'study' 'enrollment']","[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 1. 0. 1. 0. 0. 1.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03154580,"1:22:chronic_disease,29:35:chronic_disease,37:45:chronic_disease","Neurological diseases (e.g. stroke, seizures)","['Neurological' 'diseases' '(' 'e.g' '.' 'stroke' ',' 'seizures' ')']",[2. 2. 0. 0. 0. 2. 0. 2. 0.]
NCT03154151,"29:44:chronic_disease,46:67:chronic_disease,120:131:chronic_disease","have a current uncontrolled medical illness, neurological disorder affecting the central nervous system, or history of head injury","['have' 'a' 'current' 'uncontrolled' 'medical' 'illness' ','
 'neurological' 'disorder' 'affecting' 'the' 'central' 'nervous' 'system'
 ',' 'or' 'history' 'of' 'head' 'injury']",[0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT03153982,"1:14:treatment,19:39:cancer,110:126:treatment,,202:211:treatment,304:324:treatment","Prior therapy for head and neck cancer is allowed, and the number of treatments is not limited. However, any systemic therapy should have been completed at least 30 days prior to study enrollment. Any radiation to the head and neck should have been completed at least 30 days prior to study enrollment. Palliative radiation outside of the head and neck does not require a washout","['Prior' 'therapy' 'for' 'head' 'and' 'neck' 'cancer' 'is' 'allowed' ','
 'and' 'the' 'number' 'of' 'treatments' 'is' 'not' 'limited' '.' 'However'
 ',' 'any' 'systemic' 'therapy' 'should' 'have' 'been' 'completed' 'at'
 'least' '30' 'days' 'prior' 'to' 'study' 'enrollment' '.' 'Any'
 'radiation' 'to' 'the' 'head' 'and' 'neck' 'should' 'have' 'been'
 'completed' 'at' 'least' '30' 'days' 'prior' 'to' 'study' 'enrollment'
 '.' 'Palliative' 'radiation' 'outside' 'of' 'the' 'head' 'and' 'neck'
 'does' 'not' 'require' 'a' 'washout']","[1. 1. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03153319,"1:24:chronic_disease,32:70:chronic_disease,81:99:chronic_disease,104:118:chronic_disease,123:158:chronic_disease,169:192:chronic_disease","Demyelinating disorders (e.g., central nervous system [CNS] disorders including multiple sclerosis and optic neuritis and peripheral nervous system disorders including Guillain-Barre syndrome)","['Demyelinating' 'disorders' '(' 'e.g.' ',' 'central' 'nervous' 'system'
 '[' 'CNS' ']' 'disorders' 'including' 'multiple' 'sclerosis' 'and'
 'optic' 'neuritis' 'and' 'peripheral' 'nervous' 'system' 'disorders'
 'including' 'Guillain-Barre' 'syndrome' ')']","[2. 2. 0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 2. 2. 0. 2. 2. 0. 2. 2. 2. 2. 0.
 2. 2. 0.]"
NCT03152058,"12:31:chronic_disease,39:59:chronic_disease,64:87:chronic_disease","History of recurrent infection, e.g., recurrent cellulitis, or opportunistic infection","['History' 'of' 'recurrent' 'infection' ',' 'e.g.' ',' 'recurrent'
 'cellulitis' ',' 'or' 'opportunistic' 'infection']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT03150004,",,,,,165:168:cancer,172:188:chronic_disease,192:201:chronic_disease","Direct bilirubin ≤ 1.5 X the upper limit of the normal range (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 X ULN unless related to AML or Gilbert syndrome or hemolysis","['Direct' 'bilirubin' '≤' '1.5' 'X' 'the' 'upper' 'limit' 'of' 'the'
 'normal' 'range' '(' 'ULN' ')' ',' 'alanine' 'aminotransferase' '(' 'ALT'
 ')' 'and' 'aspartate' 'aminotransferase' '(' 'AST' ')' '≤' '3' 'X' 'ULN'
 'unless' 'related' 'to' 'AML' 'or' 'Gilbert' 'syndrome' 'or' 'hemolysis']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 2. 2. 0. 2.]"
NCT03148795,",146:156:treatment,158:168:treatment,170:184:treatment,186:196:treatment,198:207:treatment,209:220:treatment,222:234:treatment,236:245:treatment,247:259:treatment,261:273:treatment,275:284:treatment,286:295:treatment,297:308:treatment,310:319:treatment,321:331:treatment,333:342:treatment,344:354:treatment,356:366:treatment,368:378:treatment,380:389:treatment,395:404:treatment","Current or anticipated use within 7 days prior to first dose of study drug or anticipated use during the study of the following P gp inhibitors (amiodarone, carvedilol, clarithromycin, cobicistat, darunavir, dronedarone, erythromycin, indinavir, itraconazole, ketoconazole, lapatinib, lopinavir, propafenone, quinidine, ranolazine, ritonavir, saquinavir, telaprevir, tipranavir, verapamil, and valspodar)","['Current' 'or' 'anticipated' 'use' 'within' '7' 'days' 'prior' 'to'
 'first' 'dose' 'of' 'study' 'drug' 'or' 'anticipated' 'use' 'during'
 'the' 'study' 'of' 'the' 'following' 'P' 'gp' 'inhibitors' '('
 'amiodarone' ',' 'carvedilol' ',' 'clarithromycin' ',' 'cobicistat' ','
 'darunavir' ',' 'dronedarone' ',' 'erythromycin' ',' 'indinavir' ','
 'itraconazole' ',' 'ketoconazole' ',' 'lapatinib' ',' 'lopinavir' ','
 'propafenone' ',' 'quinidine' ',' 'ranolazine' ',' 'ritonavir' ','
 'saquinavir' ',' 'telaprevir' ',' 'tipranavir' ',' 'verapamil' ',' 'and'
 'valspodar' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1.
 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 1. 0.]"
NCT03146663,"16:31:chronic_disease,58:74:chronic_disease,85:99:treatment","Presence of an serious illness, uncontrolled illness, or active infection requiring IV antibiotics","['Presence' 'of' 'an' 'serious' 'illness' ',' 'uncontrolled' 'illness' ','
 'or' 'active' 'infection' 'requiring' 'IV' 'antibiotics']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 2. 2. 0. 1. 1.]
NCT03145298,"33:37:chronic_disease,39:43:chronic_disease,45:52:chronic_disease,54:61:chronic_disease","Confirmed clinical diagnosis of IPAH, HPAH, PAH-CTD, PAH-HIV","['Confirmed' 'clinical' 'diagnosis' 'of' 'IPAH' ',' 'HPAH' ',' 'PAH-CTD'
 ',' 'PAH-HIV']",[0. 0. 0. 0. 2. 0. 2. 0. 2. 0. 2.]
NCT03145298,"15:25:cancer,29:52:cancer,62:80:chronic_disease,100:123:cancer","resected skin basal cell or squamous cell carcinoma, treated cervical dysplasia or treated in-situ cervical cancer grade 1","['resected' 'skin' 'basal' 'cell' 'or' 'squamous' 'cell' 'carcinoma' ','
 'treated' 'cervical' 'dysplasia' 'or' 'treated' 'in-situ' 'cervical'
 'cancer' 'grade' '1']",[0. 0. 3. 3. 0. 3. 3. 3. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0.]
NCT03144245,",22:31:treatment,32:48:treatment,58:72:chronic_disease,,99:119:treatment","No more than 3 prior induction/salvage regimens to treat active disease, and no more than 1 prior stem cell transplant","['No' 'more' 'than' '3' 'prior' 'induction/salvage' 'regimens' 'to'
 'treat' 'active' 'disease' ',' 'and' 'no' 'more' 'than' '1' 'prior'
 'stem' 'cell' 'transplant']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT03144206,"1:17:chronic_disease,83:92:treatment,109:136:chronic_disease,161:181:chronic_disease","Vascular disease resulting in clinically apparent compromise in blood flow to the treatment extremity (i.e. peripheral vascular disease with diminished pulses, venous insufficiency with clinical evidence of vascular congestion)","['Vascular' 'disease' 'resulting' 'in' 'clinically' 'apparent'
 'compromise' 'in' 'blood' 'flow' 'to' 'the' 'treatment' 'extremity' '('
 'i.e' '.' 'peripheral' 'vascular' 'disease' 'with' 'diminished' 'pulses'
 ',' 'venous' 'insufficiency' 'with' 'clinical' 'evidence' 'of' 'vascular'
 'congestion' ')']","[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0.
 2. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT03143985,"42:59:treatment,66:79:treatment,84:95:treatment,",Patients should have discontinued strong CYP1A2 inhibitors (e.g. ciprofloxacin and fluvoxamine) at least five half-lives before beginning study treatment,"['Patients' 'should' 'have' 'discontinued' 'strong' 'CYP1A2' 'inhibitors'
 '(' 'e.g' '.' 'ciprofloxacin' 'and' 'fluvoxamine' ')' 'at' 'least' 'five'
 'half-lives' 'before' 'beginning' 'study' 'treatment']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03143894,"1:11:chronic_disease,15:22:chronic_disease,52:77:treatment,82:92:chronic_disease,",Depression or anxiety as defined either by ongoing pharmacological treatment for depression or anxiety or a HADS score on initial screening,"['Depression' 'or' 'anxiety' 'as' 'defined' 'either' 'by' 'ongoing'
 'pharmacological' 'treatment' 'for' 'depression' 'or' 'anxiety' 'or' 'a'
 'HADS' 'score' 'on' 'initial' 'screening']",[2. 0. 2. 0. 0. 0. 0. 0. 1. 1. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03141359,"10:34:cancer,45:60:cancer,82:97:cancer,99:131:cancer,176:182:cancer,","However, non-melanoma skin cancer, low risk prostate cancer, well differentiated thyroid cancers, in situ carcinomas of the breast, oral cavity, cervix, and other organs, and tumors that are not thought to impact the life expectancy of the subject according to the treating investigator is permissible","['However' ',' 'non-melanoma' 'skin' 'cancer' ',' 'low' 'risk' 'prostate'
 'cancer' ',' 'well' 'differentiated' 'thyroid' 'cancers' ',' 'in' 'situ'
 'carcinomas' 'of' 'the' 'breast' ',' 'oral' 'cavity' ',' 'cervix' ','
 'and' 'other' 'organs' ',' 'and' 'tumors' 'that' 'are' 'not' 'thought'
 'to' 'impact' 'the' 'life' 'expectancy' 'of' 'the' 'subject' 'according'
 'to' 'the' 'treating' 'investigator' 'is' 'permissible']","[0. 0. 3. 3. 3. 0. 0. 0. 3. 3. 0. 0. 0. 3. 3. 0. 3. 3. 3. 3. 3. 3. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT03140527,"27:61:chronic_disease,63:98:chronic_disease,103:137:chronic_disease","Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus antibody (HCVAb)","['Positive' 'blood' 'screen' 'for' 'human' 'immunodeficiency' 'virus' '('
 'HIV' ')' ',' 'hepatitis' 'B' 'surface' 'antigen' '(' 'HBsAg' ')' ','
 'or' 'hepatitis' 'C' 'virus' 'antibody' '(' 'HCVAb' ')']","[0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT03139318,"25:45:treatment,50:65:treatment,74:83:treatment,87:124:cancer",Subject is eligible for routine chemotherapy and routine surgery for the treatment of non-metastatic extremity osteosarcoma,"['Subject' 'is' 'eligible' 'for' 'routine' 'chemotherapy' 'and' 'routine'
 'surgery' 'for' 'the' 'treatment' 'of' 'non-metastatic' 'extremity'
 'osteosarcoma']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 0. 3. 3. 3.]
NCT03138733,"1:54:chronic_disease,130:142:treatment,146:155:treatment",Bloodstream or non-bloodstream concomitant infections with Gram-negative bacteria that are known to be non-susceptible to either ceftobiprole or aztreonam,"['Bloodstream' 'or' 'non-bloodstream' 'concomitant' 'infections' 'with'
 'Gram-negative' 'bacteria' 'that' 'are' 'known' 'to' 'be'
 'non-susceptible' 'to' 'either' 'ceftobiprole' 'or' 'aztreonam']",[2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1.]
NCT03137771,"20:36:treatment,38:68:treatment,74:79:cancer",Patients receiving targeted therapy (non-cytotoxic systemic therapy) for NSCLC in the first-line setting,"['Patients' 'receiving' 'targeted' 'therapy' '(' 'non-cytotoxic'
 'systemic' 'therapy' ')' 'for' 'NSCLC' 'in' 'the' 'first-line' 'setting']",[0. 0. 1. 1. 0. 1. 1. 1. 0. 0. 3. 0. 0. 0. 0.]
NCT03137771,"31:49:cancer,,,107:112:cancer,136:146:cancer",patients newly diagnosed with metastatic disease or those initially diagnosed and treated for stage I-III NSCLC who ultimately develop metastases,"['patients' 'newly' 'diagnosed' 'with' 'metastatic' 'disease' 'or' 'those'
 'initially' 'diagnosed' 'and' 'treated' 'for' 'stage' 'I-III' 'NSCLC'
 'who' 'ultimately' 'develop' 'metastases']",[0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 3.]
NCT03137498,"26:43:chronic_disease,49:58:chronic_disease,84:106:chronic_disease,,162:190:chronic_disease,192:200:chronic_disease,234:243:treatment,259:285:chronic_disease,362:371:chronic_disease","Past medical history of: liver dysfunction (ie: cirrhosis), chronic alcohol abuse, gastrointestinal bleed or recent gastrointestinal bleed (within past 5 days), renal dysfunction or disease, seizures (or currently actively receiving treatment for seizures), inflammatory bowel disease (or currently actively receiving treatment for inflammatory bowel disease), hepatitis (or currently actively receiving treatment for hepatitis)","['Past' 'medical' 'history' 'of' ':' 'liver' 'dysfunction' '(' 'ie' ':'
 'cirrhosis' ')' ',' 'chronic' 'alcohol' 'abuse' ',' 'gastrointestinal'
 'bleed' 'or' 'recent' 'gastrointestinal' 'bleed' '(' 'within' 'past' '5'
 'days' ')' ',' 'renal' 'dysfunction' 'or' 'disease' ',' 'seizures' '('
 'or' 'currently' 'actively' 'receiving' 'treatment' 'for' 'seizures' ')'
 ',' 'inflammatory' 'bowel' 'disease' '(' 'or' 'currently' 'actively'
 'receiving' 'treatment' 'for' 'inflammatory' 'bowel' 'disease' ')' ','
 'hepatitis' '(' 'or' 'currently' 'actively' 'receiving' 'treatment' 'for'
 'hepatitis' ')']","[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 2. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 2. 2.
 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03137121,"19:31:treatment,35:44:treatment,,94:110:treatment,114:130:treatment,176:208:treatment",Have not received chemotherapy or radiation for >14 days (advanced cancer patients receiving hormonal therapy or targeted therapy that does not come with a recommendation for prophylactic anti-emetic therapy are eligible),"['Have' 'not' 'received' 'chemotherapy' 'or' 'radiation' 'for' '>' '14'
 'days' '(' 'advanced' 'cancer' 'patients' 'receiving' 'hormonal'
 'therapy' 'or' 'targeted' 'therapy' 'that' 'does' 'not' 'come' 'with' 'a'
 'recommendation' 'for' 'prophylactic' 'anti-emetic' 'therapy' 'are'
 'eligible' ')']","[0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 1. 1. 0. 0. 0.]"
NCT03136029,"35:49:chronic_disease,51:59:chronic_disease,64:76:chronic_disease,,,,,,146:163:treatment","subjects with a history of stable cardiomyopathy (ischemic and non-ischemic, >3 months duration, ages 45-75 yrs) despite a minimum of 6 weeks of optimal treatment","['subjects' 'with' 'a' 'history' 'of' 'stable' 'cardiomyopathy' '('
 'ischemic' 'and' 'non-ischemic' ',' '>' '3' 'months' 'duration' ','
 'ages' '45-75' 'yrs' ')' 'despite' 'a' 'minimum' 'of' '6' 'weeks' 'of'
 'optimal' 'treatment']","[0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 1.]"
NCT03135522,"14:39:chronic_disease,49:74:chronic_disease,76:105:chronic_disease,107:116:chronic_disease,121:123:chronic_disease","negative for parenchymal lung diseases (such as interstitial lung disease, idiopathic pulmonary fibrosis, pneumonia, or TB)","['negative' 'for' 'parenchymal' 'lung' 'diseases' '(' 'such' 'as'
 'interstitial' 'lung' 'disease' ',' 'idiopathic' 'pulmonary' 'fibrosis'
 ',' 'pneumonia' ',' 'or' 'TB' ')']",[0. 0. 2. 2. 2. 0. 0. 0. 2. 2. 2. 0. 2. 2. 2. 0. 2. 0. 0. 2. 0.]
NCT03135171,",,127:138:treatment,140:151:treatment,156:166:treatment","must use two forms of effective contraception during the duration of the trial and for minimum of 7 months after last dose of tocilizumab, trastuzumab, or pertuzumab","['must' 'use' 'two' 'forms' 'of' 'effective' 'contraception' 'during'
 'the' 'duration' 'of' 'the' 'trial' 'and' 'for' 'minimum' 'of' '7'
 'months' 'after' 'last' 'dose' 'of' 'tocilizumab' ',' 'trastuzumab' ','
 'or' 'pertuzumab']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 0. 1. 0. 0. 1.]"
NCT03131960,"1:17:treatment,25:62:treatment,,110:117:treatment",Botox injections or any other non-study active rehabilitation of the upper extremity within 4 weeks prior to therapy through the post-30 day visit (Visit 6),"['Botox' 'injections' 'or' 'any' 'other' 'non-study' 'active'
 'rehabilitation' 'of' 'the' 'upper' 'extremity' 'within' '4' 'weeks'
 'prior' 'to' 'therapy' 'through' 'the' 'post-30' 'day' 'visit' '('
 'Visit' '6' ')']","[1. 1. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT03131037,"23:47:chronic_disease,57:72:chronic_disease,74:98:chronic_disease,112:156:chronic_disease","Presence of any other life-threatening illness, such as unstable angina, severe oxygen dependence, significant chronic obstructive pulmonary disease (COPD)","['Presence' 'of' 'any' 'other' 'life-threatening' 'illness' ',' 'such'
 'as' 'unstable' 'angina' ',' 'severe' 'oxygen' 'dependence' ','
 'significant' 'chronic' 'obstructive' 'pulmonary' 'disease' '(' 'COPD'
 ')']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 2. 0. 2. 2. 2. 0. 0. 2. 2. 2. 2. 2. 0. 0.]
NCT03130543,"63:87:chronic_disease,95:116:chronic_disease,133:149:chronic_disease,157:177:chronic_disease","Patients with any pre-existing significant medical diagnosis (congenital heart disease, known neurologic impairment with or without seizure disorder, other congenital anomalies)","['Patients' 'with' 'any' 'pre-existing' 'significant' 'medical'
 'diagnosis' '(' 'congenital' 'heart' 'disease' ',' 'known' 'neurologic'
 'impairment' 'with' 'or' 'without' 'seizure' 'disorder' ',' 'other'
 'congenital' 'anomalies' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 2. 2. 0. 0. 0. 2. 2. 0. 0. 0. 0.
 0.]"
NCT03127358,"37:45:allergy_name,47:58:allergy_name,63:72:allergy_name","Known hypersensitivity (allergy) to elbasvir, grazoprevir, or ribavirin","['Known' 'hypersensitivity' '(' 'allergy' ')' 'to' 'elbasvir' ','
 'grazoprevir' ',' 'or' 'ribavirin']",[0. 0. 0. 0. 0. 0. 4. 0. 4. 0. 0. 4.]
NCT03125902,",,,135:144:treatment,,201:213:treatment,214:221:treatment,,271:281:treatment","For men and women of child bearing potential: agreement to remain abstinent or use protocol defined contraceptive measures during the treatment period and for at least 5 months after the last dose of atezolizumab/placebo, or for at least 6 months after the last dose of paclitaxel","['For' 'men' 'and' 'women' 'of' 'child' 'bearing' 'potential' ':'
 'agreement' 'to' 'remain' 'abstinent' 'or' 'use' 'protocol' 'defined'
 'contraceptive' 'measures' 'during' 'the' 'treatment' 'period' 'and'
 'for' 'at' 'least' '5' 'months' 'after' 'the' 'last' 'dose' 'of'
 'atezolizumab/placebo' ',' 'or' 'for' 'at' 'least' '6' 'months' 'after'
 'the' 'last' 'dose' 'of' 'paclitaxel']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT03125226,"1:10:treatment,,67:86:treatment,67:76:treatment,115:127:treatment","Treatment plan for bladder must include at least 4 weeks of daily radiation treatment (most patients will receive chemotherapy concurrent with radiation, but this is not required for trial enrollment)","['Treatment' 'plan' 'for' 'bladder' 'must' 'include' 'at' 'least' '4'
 'weeks' 'of' 'daily' 'radiation' 'treatment' '(' 'most' 'patients' 'will'
 'receive' 'chemotherapy' 'concurrent' 'with' 'radiation' ',' 'but' 'this'
 'is' 'not' 'required' 'for' 'trial' 'enrollment' ')']","[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03123783,"44:63:treatment,67:77:treatment,91:101:cancer,122:148:cancer,174:183:treatment","Histologically or cytologically confirmed, immunotherapy naïve or PD-1/PD-L1 pre-treated, metastatic or locally advanced non-small cell lung cancer not amenable to curative treatment","['Histologically' 'or' 'cytologically' 'confirmed' ',' 'immunotherapy'
 'naïve' 'or' 'PD-1/PD-L1' 'pre-treated' ',' 'metastatic' 'or' 'locally'
 'advanced' 'non-small' 'cell' 'lung' 'cancer' 'not' 'amenable' 'to'
 'curative' 'treatment']",[0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 0. 3. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 1.]
NCT03123783,"15:39:cancer,67:81:treatment,89:110:treatment,120:143:treatment",Subjects with BRAF activating mutation could have also received a BRAF inhibitor and/or MEK inhibitor regimen prior to anti-PD-1/PD-L1 therapy,"['Subjects' 'with' 'BRAF' 'activating' 'mutation' 'could' 'have' 'also'
 'received' 'a' 'BRAF' 'inhibitor' 'and/or' 'MEK' 'inhibitor' 'regimen'
 'prior' 'to' 'anti-PD-1/PD-L1' 'therapy']",[0. 0. 1. 1. 3. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 1. 1.]
NCT03123055,"38:70:treatment,,94:105:treatment,109:127:treatment",Have progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy,"['Have' 'progression' 'during' 'or' 'following' 'platinum-containing'
 'chemotherapy' 'or' 'within' '12' 'months' 'of' 'neoadjuvant' 'or'
 'adjuvant' 'treatment' 'with' 'platinum-containing' 'chemotherapy']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0.]
NCT03122912,"13:20:allergy_name,22:33:allergy_name,35:42:allergy_name,46:53:allergy_name","Allergic to soybean, soybean oil, peanuts or seafood","['Allergic' 'to' 'soybean' ',' 'soybean' 'oil' ',' 'peanuts' 'or'
 'seafood']",[0. 0. 4. 4. 0. 0. 0. 4. 0. 4.]
NCT03121586,"59:70:chronic_disease,72:82:chronic_disease,84:98:chronic_disease,100:111:chronic_disease,113:129:chronic_disease,131:136:chronic_disease,138:145:chronic_disease,147:158:chronic_disease,169:185:chronic_disease,197:203:cancer,207:219:cancer","Patient has current evidence of a serious and/or unstable psychiatric, neurologic, cardiovascular, respiratory, gastrointestinal, renal, hepatic, hematologic, or other medical disorder, including cancer or malignancies, which would affect the patient's ability to participate in the program","['Patient' 'has' 'current' 'evidence' 'of' 'a' 'serious' 'and/or'
 'unstable' 'psychiatric' ',' 'neurologic' ',' 'cardiovascular' ','
 'respiratory' ',' 'gastrointestinal' ',' 'renal' ',' 'hepatic' ','
 'hematologic' ',' 'or' 'other' 'medical' 'disorder' ',' 'including'
 'cancer' 'or' 'malignancies' ',' 'which' 'would' 'affect' 'the' 'patient'
 ""'s"" 'ability' 'to' 'participate' 'in' 'the' 'program']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 2. 0. 2. 0. 2. 0. 2. 0. 2. 0. 2.
 0. 0. 0. 2. 2. 0. 0. 3. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03121352,"15:28:treatment,34:74:treatment,82:91:treatment,93:103:treatment","Patients with prior therapy with antibodies that modulate T-cell function (e.g., anti-PD-1, anti-PD-L1)","['Patients' 'with' 'prior' 'therapy' 'with' 'antibodies' 'that' 'modulate'
 'T-cell' 'function' '(' 'e.g.' ',' 'anti-PD-1' ',' 'anti-PD-L1' ')']",[0. 0. 1. 1. 0. 1. 1. 1. 1. 1. 0. 0. 0. 1. 0. 1. 0.]
NCT03120585,"1:27:chronic_disease,31:63:chronic_disease,67:83:chronic_disease",Neonates with hypoglycemia or clinical evidence of dehydration or volume depletion requiring fluid bolus,"['Neonates' 'with' 'hypoglycemia' 'or' 'clinical' 'evidence' 'of'
 'dehydration' 'or' 'volume' 'depletion' 'requiring' 'fluid' 'bolus']",[2. 2. 2. 0. 2. 2. 2. 2. 0. 2. 2. 0. 0. 0.]
NCT03118973,"1:30:treatment,36:60:treatment,62:89:treatment","Complex post-surgical anatomy e.g. Billroth type II anatomy, Roux-en-Y-gastrojejunostomy","['Complex' 'post-surgical' 'anatomy' 'e.g' '.' 'Billroth' 'type' 'II'
 'anatomy' ',' 'Roux-en-Y-gastrojejunostomy']",[1. 1. 1. 0. 0. 1. 1. 1. 1. 0. 1.]
NCT03116685,"54:77:treatment,79:87:treatment,,154:157:treatment,198:223:treatment","Participation in any interventional study of another investigational product, biologic, device, or other agent within 60 days prior to the first dose of OC5 or not willing to forego other forms of investigational treatment during this study","['Participation' 'in' 'any' 'interventional' 'study' 'of' 'another'
 'investigational' 'product' ',' 'biologic' ',' 'device' ',' 'or' 'other'
 'agent' 'within' '60' 'days' 'prior' 'to' 'the' 'first' 'dose' 'of' 'OC5'
 'or' 'not' 'willing' 'to' 'forego' 'other' 'forms' 'of' 'investigational'
 'treatment' 'during' 'this' 'study']","[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03115424,"18:30:chronic_disease,32:46:chronic_disease,50:63:chronic_disease","Prior history of pancreatitis, cholelithiasis or cholecystitis","['Prior' 'history' 'of' 'pancreatitis' ',' 'cholelithiasis' 'or'
 'cholecystitis']",[0. 0. 0. 2. 0. 2. 0. 2.]
NCT03114891,"64:67:treatment,69:79:treatment,81:95:treatment,97:104:treatment","Medication use that substantially reduces seizure threshold to TMS (olanzapine, chlorpromazine, lithium)","['Medication' 'use' 'that' 'substantially' 'reduces' 'seizure' 'threshold'
 'to' 'TMS' '(' 'olanzapine' ',' 'chlorpromazine' ',' 'lithium' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0.]
NCT03113825,"1:27:treatment,31:41:treatment,44:48:treatment,52:56:treatment,64:74:treatment",Primary surgical treatment is lumpectomy + SLNB or ALND --or-- mastectomy + ALND,"['Primary' 'surgical' 'treatment' 'is' 'lumpectomy' '+' 'SLNB' 'or' 'ALND'
 '--' 'or' '--' 'mastectomy' '+' 'ALND']",[1. 1. 1. 0. 1. 0. 1. 0. 1. 0. 0. 0. 1. 0. 0.]
NCT03113136,"51:62:chronic_disease,64:70:chronic_disease,75:88:chronic_disease","unstable or significant medical condition such as respiratory, kidney, or liver disease that could potentially affect biomarker data","['unstable' 'or' 'significant' 'medical' 'condition' 'such' 'as'
 'respiratory' ',' 'kidney' ',' 'or' 'liver' 'disease' 'that' 'could'
 'potentially' 'affect' 'biomarker' 'data']",[0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT03112603,"1:8:treatment,20:25:chronic_disease,58:89:treatment,107:127:treatment,131:141:cancer",Steroid refractory cGvHD occurring after a non-scheduled donor lymphocyte infusion (DLI) administered for preemptive treatment of malignancy recurrence,"['Steroid' 'refractory' 'cGvHD' 'occurring' 'after' 'a' 'non-scheduled'
 'donor' 'lymphocyte' 'infusion' '(' 'DLI' ')' 'administered' 'for'
 'preemptive' 'treatment' 'of' 'malignancy' 'recurrence']",[1. 0. 2. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 1. 1. 0. 3. 0.]
NCT03112174,"71:84:treatment,90:99:treatment,109:123:treatment",Concurrent enrollment in another therapeutic investigational study or prior therapy with ibrutinib or other BTK inhibitors,"['Concurrent' 'enrollment' 'in' 'another' 'therapeutic' 'investigational'
 'study' 'or' 'prior' 'therapy' 'with' 'ibrutinib' 'or' 'other' 'BTK'
 'inhibitors']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 0. 1. 1.]
NCT03110354,"5:8:cancer,12:15:cancer,31:54:treatment,86:99:treatment",Has AML or ALL and failed any prior induction therapy regimen or have relapsed after prior therapy,"['Has' 'AML' 'or' 'ALL' 'and' 'failed' 'any' 'prior' 'induction' 'therapy'
 'regimen' 'or' 'have' 'relapsed' 'after' 'prior' 'therapy']",[0. 3. 0. 3. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT03110107,"1:17:treatment,,74:99:treatment,118:131:treatment","Cytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior anti-cancer therapy and initiation of study therapy","['Cytotoxic' 'agents' ',' 'unless' 'at' 'least' '4' 'weeks' 'have'
 'elapsed' 'from' 'last' 'dose' 'of' 'prior' 'anti-cancer' 'therapy' 'and'
 'initiation' 'of' 'study' 'therapy']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 1. 1.]
NCT03109210,"1:17:chronic_disease,25:31:cancer,37:70:chronic_disease,78:86:chronic_disease","terminal illness (e.g., cancer), or neurological degenerative disease (e.g., dementia)","['terminal' 'illness' '(' 'e.g.' ',' 'cancer' ')' ',' 'or' 'neurological'
 'degenerative' 'disease' '(' 'e.g.' ',' 'dementia' ')']",[2. 2. 0. 0. 0. 3. 0. 0. 0. 2. 2. 2. 0. 0. 0. 2. 0.]
NCT03104725,"19:50:treatment,58:76:treatment,78:83:treatment","Already taking an anti-oxidant dietary supplement (e.g., Olive Leaf Extract, MitoQ)","['Already' 'taking' 'an' 'anti-oxidant' 'dietary' 'supplement' '(' 'e.g.'
 ',' 'Olive' 'Leaf' 'Extract' ',' 'MitoQ' ')']",[0. 0. 0. 1. 1. 1. 0. 0. 0. 1. 1. 1. 0. 1. 0.]
NCT03104699,"40:50:cancer,71:83:cancer,97:113:treatment",Histologically or cytologically proven metastatic or locally advanced solid tumors for which no standard therapy exists or standard therapy has failed,"['Histologically' 'or' 'cytologically' 'proven' 'metastatic' 'or'
 'locally' 'advanced' 'solid' 'tumors' 'for' 'which' 'no' 'standard'
 'therapy' 'exists' 'or' 'standard' 'therapy' 'has' 'failed']",[0. 0. 0. 0. 3. 0. 0. 0. 3. 3. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT03104699,"20:34:treatment,38:47:treatment,75:84:treatment,,129:137:treatment",Subjects receiving bisphosphonate or denosumab are eligible provided that treatment was initiated ≥14 days before first dose of AGEN2034,"['Subjects' 'receiving' 'bisphosphonate' 'or' 'denosumab' 'are' 'eligible'
 'provided' 'that' 'treatment' 'was' 'initiated' '≥14' 'days' 'before'
 'first' 'dose' 'of' 'AGEN2034']",[0. 0. 1. 0. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT03101566,"19:43:chronic_disease,45:59:chronic_disease,75:94:treatment,96:110:chronic_disease,120:128:chronic_disease,130:139:chronic_disease,144:152:chronic_disease,168:186:treatment","Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll","['Participants' 'with' 'type' 'I' 'diabetes' 'mellitus' ','
 'hypothyroidism' 'only' 'requiring' 'hormone' 'replacement' ',' 'skin'
 'disorders' '(' 'such' 'as' 'vitiligo' ',' 'psoriasis' ',' 'or'
 'alopecia' ')' 'not' 'requiring' 'systemic' 'treatment' ',' 'or'
 'conditions' 'not' 'expected' 'to' 'recur' 'in' 'the' 'absence' 'of' 'an'
 'external' 'trigger' 'are' 'permitted' 'to' 'enroll']","[0. 0. 2. 2. 2. 2. 0. 2. 0. 0. 1. 1. 0. 2. 2. 0. 0. 0. 2. 0. 2. 0. 0. 2.
 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03101085,"16:22:cancer,39:51:treatment,55:72:treatment,",any history of cancer that required a chemotherapy or radiation therapy intervention within the past 5 years,"['any' 'history' 'of' 'cancer' 'that' 'required' 'a' 'chemotherapy' 'or'
 'radiation' 'therapy' 'intervention' 'within' 'the' 'past' '5' 'years']",[0. 0. 0. 3. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT03099590,"13:25:chronic_disease,27:37:chronic_disease,42:60:chronic_disease","Presence of neurological, infectious, or neoplastic disease","['Presence' 'of' 'neurological' ',' 'infectious' ',' 'or' 'neoplastic'
 'disease']",[0. 0. 2. 0. 2. 0. 0. 2. 2.]
NCT03096288,"4:13:treatment,23:41:treatment,53:60:treatment,65:76:treatment,",On treatment with any antiplatelet agent other than aspirin and clopidogrel in the past 14 days,"['On' 'treatment' 'with' 'any' 'antiplatelet' 'agent' 'other' 'than'
 'aspirin' 'and' 'clopidogrel' 'in' 'the' 'past' '14' 'days']",[0. 1. 0. 0. 1. 1. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0.]
NCT03093909,"37:51:treatment,62:74:treatment,76:89:treatment,94:110:treatment","Patients receiving other concurrent cancer therapy including chemotherapy, immunotherapy, or biologic therapy","['Patients' 'receiving' 'other' 'concurrent' 'cancer' 'therapy'
 'including' 'chemotherapy' ',' 'immunotherapy' ',' 'or' 'biologic'
 'therapy']",[0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 0. 0. 1. 1.]
NCT03093272,"1:8:chronic_disease,52:59:chronic_disease,96:102:chronic_disease,104:129:chronic_disease,,168:200:chronic_disease,205:224:cancer,233:244:cancer,249:260:cancer,278:283:chronic_disease","Seizure or known condition that may pre-dispose to seizure (including but not limited to prior stroke, transient ischemic attack within 1 year prior to randomization, brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect)","['Seizure' 'or' 'known' 'condition' 'that' 'may' 'pre-dispose' 'to'
 'seizure' '(' 'including' 'but' 'not' 'limited' 'to' 'prior' 'stroke' ','
 'transient' 'ischemic' 'attack' 'within' '1' 'year' 'prior' 'to'
 'randomization' ',' 'brain' 'arteriovenous' 'malformation' ';' 'or'
 'intracranial' 'masses' 'such' 'as' 'schwannomas' 'and' 'meningiomas'
 'that' 'are' 'causing' 'edema' 'or' 'mass' 'effect' ')']","[2. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 2. 0. 0. 0.
 0. 0. 0. 0. 2. 2. 2. 0. 0. 3. 3. 0. 0. 3. 0. 3. 0. 0. 0. 2. 0. 0. 0. 0.]"
NCT03092635,",21:38:treatment,69:82:cancer,84:97:cancer",More than two prior endocrine therapy regimens for the treatment of metastatic ER+ breast cancer,"['More' 'than' 'two' 'prior' 'endocrine' 'therapy' 'regimens' 'for' 'the'
 'treatment' 'of' 'metastatic' 'ER+' 'breast' 'cancer']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 3. 3. 3. 3.]
NCT03090607,"48:75:chronic_disease,87:104:chronic_disease,106:119:treatment,138:146:chronic_disease,150:169:chronic_disease","Has a condition that could lead to significant postoperative complications, including current infection, anticoagulant use, uncontrolled diabetes or autoimmune disorder","['Has' 'a' 'condition' 'that' 'could' 'lead' 'to' 'significant'
 'postoperative' 'complications' ',' 'including' 'current' 'infection' ','
 'anticoagulant' 'use' ',' 'uncontrolled' 'diabetes' 'or' 'autoimmune'
 'disorder']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 0. 1. 0. 0. 0. 2. 0. 2. 2.]
NCT03089853,"24:48:chronic_disease,59:81:chronic_disease,124:133:chronic_disease,135:149:chronic_disease,154:165:cancer","Secondary diagnosis of congestive heart failure and other respiratory conditions that could confound the diagnosis such as pneumonia, bronchiectasis and lung cancer will be excluded","['Secondary' 'diagnosis' 'of' 'congestive' 'heart' 'failure' 'and' 'other'
 'respiratory' 'conditions' 'that' 'could' 'confound' 'the' 'diagnosis'
 'such' 'as' 'pneumonia' ',' 'bronchiectasis' 'and' 'lung' 'cancer' 'will'
 'be' 'excluded']","[0. 0. 0. 2. 2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 3. 3. 0.
 0. 0.]"
NCT03088072,"36:61:treatment,67:74:treatment,79:90:treatment",A need for on-going treatment with dual antiplatelet therapy with aspirin and clopidogrel,"['A' 'need' 'for' 'on-going' 'treatment' 'with' 'dual' 'antiplatelet'
 'therapy' 'with' 'aspirin' 'and' 'clopidogrel']",[0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 1. 0. 1.]
NCT03088033,",,,107:135:chronic_disease,128:135:chronic_disease,137:146:chronic_disease,","NYHA class II with a history of > NYHA class II; OR NYHA class III, or ambulatory NYHA class IV symptoms (paroxysmal nocturnal dyspnea, orthopnea, dyspnea on mild or moderate exertion) at screening; or signs (any rales post cough, chest x-ray demonstrating pulmonary congestion,) within past 12 months","['NYHA' 'class' 'II' 'with' 'a' 'history' 'of' '>' 'NYHA' 'class' 'II' ';'
 'OR' 'NYHA' 'class' 'III' ',' 'or' 'ambulatory' 'NYHA' 'class' 'IV'
 'symptoms' '(' 'paroxysmal' 'nocturnal' 'dyspnea' ',' 'orthopnea' ','
 'dyspnea' 'on' 'mild' 'or' 'moderate' 'exertion' ')' 'at' 'screening' ';'
 'or' 'signs' '(' 'any' 'rales' 'post' 'cough' ',' 'chest' 'x-ray'
 'demonstrating' 'pulmonary' 'congestion' ',' ')' 'within' 'past' '12'
 'months']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 2. 2. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03087903,"1:14:treatment,16:25:treatment,30:75:treatment,,94:109:treatment","Major surgery, radiation, or treatment with any other investigational drug within 2 weeks of study treatment","['Major' 'surgery' ',' 'radiation' ',' 'or' 'treatment' 'with' 'any'
 'other' 'investigational' 'drug' 'within' '2' 'weeks' 'of' 'study'
 'treatment']",[1. 1. 0. 1. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 1. 1.]
NCT03085784,"18:45:treatment,62:86:cancer,122:143:chronic_disease",Undergone either ocular or orbital radiation for any primary ocular or orbital cancer within clinical evidence of having radiation retinopathy,"['Undergone' 'either' 'ocular' 'or' 'orbital' 'radiation' 'for' 'any'
 'primary' 'ocular' 'or' 'orbital' 'cancer' 'within' 'clinical' 'evidence'
 'of' 'having' 'radiation' 'retinopathy']",[0. 0. 3. 3. 3. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03085485,"28:50:treatment,65:72:treatment,77:94:chronic_disease,",Subjects should not have a pulmonary exacerbation or changes in therapy for pulmonary disease within 28 days before receiving the first dose of study drug,"['Subjects' 'should' 'not' 'have' 'a' 'pulmonary' 'exacerbation' 'or'
 'changes' 'in' 'therapy' 'for' 'pulmonary' 'disease' 'within' '28' 'days'
 'before' 'receiving' 'the' 'first' 'dose' 'of' 'study' 'drug']","[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT03084640,"75:90:treatment,92:99:treatment,103:128:treatment,146:161:cancer","Requires prohibited treatment that is, non-protocol specified anticancer. pharmacotherapy, surgery or conventional radiotherapy for treatment of malignant tumor)","['Requires' 'prohibited' 'treatment' 'that' 'is' ',' 'non-protocol'
 'specified' 'anticancer' '.' 'pharmacotherapy' ',' 'surgery' 'or'
 'conventional' 'radiotherapy' 'for' 'treatment' 'of' 'malignant' 'tumor'
 ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 1. 0. 0. 0. 3. 3. 0.]
NCT03084146,"8:44:treatment,49:58:chronic_disease,,97:114:treatment,","use of systemic immunosuppressive treatment for psoriasis within 4 weeks of baseline, or use of topical treatment for psoriasis within 2 weeks","['use' 'of' 'systemic' 'immunosuppressive' 'treatment' 'for' 'psoriasis'
 'within' '4' 'weeks' 'of' 'baseline' ',' 'or' 'use' 'of' 'topical'
 'treatment' 'for' 'psoriasis' 'within' '2' 'weeks']",[0. 0. 1. 1. 1. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT03078530,"1:4:chronic_disease,6:13:chronic_disease,15:24:chronic_disease,26:33:chronic_disease,37:54:chronic_disease","HIV, cardiac, pulmonary, hepatic or renal dysfunction","['HIV' ',' 'cardiac' ',' 'pulmonary' ',' 'hepatic' 'or' 'renal'
 'dysfunction']",[2. 0. 2. 0. 2. 0. 2. 0. 2. 2.]
NCT03078491,"8:21:chronic_disease,80:88:chronic_disease,97:114:chronic_disease,123:146:chronic_disease","Severe comorbidities that prevent completing outcome measurements (e.g. severe dementia, severe vision impairment, severe functional disabilities, inability to perform basic activities of daily living)","['Severe' 'comorbidities' 'that' 'prevent' 'completing' 'outcome'
 'measurements' '(' 'e.g' '.' 'severe' 'dementia' ',' 'severe' 'vision'
 'impairment' ',' 'severe' 'functional' 'disabilities' ',' 'inability'
 'to' 'perform' 'basic' 'activities' 'of' 'daily' 'living' ')']","[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 2. 2. 0. 0. 2. 2. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT03078023,"16:25:chronic_disease,40:49:treatment,56:74:chronic_disease,76:85:chronic_disease,87:90:chronic_disease,92:96:chronic_disease,98:107:chronic_disease,109:128:cancer","Other cause of dysphagia identified at endoscopy (e.g. reflux esophagitis, stricture, web, ring, achalasia, esophageal neoplasm)","['Other' 'cause' 'of' 'dysphagia' 'identified' 'at' 'endoscopy' '(' 'e.g'
 '.' 'reflux' 'esophagitis' ',' 'stricture' ',' 'web' ',' 'ring' ','
 'achalasia' ',' 'esophageal' 'neoplasm' ')']",[0. 0. 0. 2. 0. 0. 1. 0. 0. 0. 2. 2. 0. 2. 0. 2. 0. 2. 0. 2. 0. 3. 3. 0.]
NCT03077243,"1:7:treatment,15:38:cancer,47:50:chronic_disease",Biopsy proven squamous cell carcinoma that is HPV and/or p16 positive,"['Biopsy' 'proven' 'squamous' 'cell' 'carcinoma' 'that' 'is' 'HPV'
 'and/or' 'p16' 'positive']",[1. 0. 3. 3. 3. 0. 0. 2. 0. 0. 0.]
NCT03076658,"10:16:chronic_disease,20:29:chronic_disease,65:72:treatment",Previous trauma or fractures of the lower extremities requiring surgery,"['Previous' 'trauma' 'or' 'fractures' 'of' 'the' 'lower' 'extremities'
 'requiring' 'surgery']",[0. 2. 0. 2. 0. 0. 0. 0. 0. 1.]
NCT03075826,"1:34:chronic_disease,66:75:chronic_disease,77:113:chronic_disease,115:139:chronic_disease,141:159:chronic_disease,164:201:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' ',' 'infection' ',' 'symptomatic' 'congestive' 'heart'
 'failure' ',' 'unstable' 'angina' 'pectoris' ',' 'cardiac' 'arrhythmia'
 ',' 'or' 'psychiatric' 'illness/social' 'situations' 'that' 'would'
 'limit' 'compliance' 'with' 'study' 'requirements']","[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 2. 2. 0. 2. 2. 2. 0. 2. 2. 0.
 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT03073785,"21:31:cancer,79:118:cancer,139:161:cancer,172:179:cancer,","Patients with prior malignancy will be excluded except for adequately treated basal cell or squamous cell skin cancer, adequately treated noninvasive carcinomas, or other cancers from which the patient has been disease-free for at least 5 years","['Patients' 'with' 'prior' 'malignancy' 'will' 'be' 'excluded' 'except'
 'for' 'adequately' 'treated' 'basal' 'cell' 'or' 'squamous' 'cell' 'skin'
 'cancer' ',' 'adequately' 'treated' 'noninvasive' 'carcinomas' ',' 'or'
 'other' 'cancers' 'from' 'which' 'the' 'patient' 'has' 'been'
 'disease-free' 'for' 'at' 'least' '5' 'years']","[0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 3. 3. 0. 0. 0. 3. 3. 0.
 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03073629,"12:37:chronic_disease,41:55:chronic_disease,73:89:treatment",those with indeterminate RV function OR LV dysfunction on comprehensive echocardiography,"['those' 'with' 'indeterminate' 'RV' 'function' 'OR' 'LV' 'dysfunction'
 'on' 'comprehensive' 'echocardiography']",[0. 0. 2. 2. 2. 0. 2. 2. 0. 0. 1.]
NCT03072238,"13:32:chronic_disease,44:63:chronic_disease,78:93:treatment",Any ongoing cardiac arrhythmias (including atrial fibrillation) that require medical therapy,"['Any' 'ongoing' 'cardiac' 'arrhythmias' '(' 'including' 'atrial'
 'fibrillation' ')' 'that' 'require' 'medical' 'therapy']",[0. 0. 2. 2. 0. 0. 2. 2. 0. 0. 0. 1. 1.]
NCT03072238,"51:67:chronic_disease,73:76:chronic_disease,102:129:treatment",Immunocompromised status because of current known active infection with HIV or because of the use of immunosuppressive therapies for other conditions,"['Immunocompromised' 'status' 'because' 'of' 'current' 'known' 'active'
 'infection' 'with' 'HIV' 'or' 'because' 'of' 'the' 'use' 'of'
 'immunosuppressive' 'therapies' 'for' 'other' 'conditions']",[0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.]
NCT03072238,"10:19:treatment,25:34:treatment,36:60:treatment,51:60:treatment,73:82:treatment,84:96:treatment,98:108:treatment,113:136:treatment","Previous treatment with flutamide, steroidal anti-androgens, androgens, estrogens, bicalutamide, nilutamide, or 5-α reductase inhibitor is permitted","['Previous' 'treatment' 'with' 'flutamide' ',' 'steroidal'
 'anti-androgens' ',' 'androgens' ',' 'estrogens' ',' 'bicalutamide' ','
 'nilutamide' ',' 'or' '5-α' 'reductase' 'inhibitor' 'is' 'permitted']",[0. 1. 0. 1. 0. 1. 1. 0. 0. 0. 1. 0. 1. 0. 1. 0. 0. 1. 1. 1. 0. 0.]
NCT03072238,"57:68:chronic_disease,70:84:chronic_disease,86:98:chronic_disease","clinically significant electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia, hypocalcemia)","['clinically' 'significant' 'electrolyte' 'abnormalities' '(' 'e.g.' ','
 'hypokalemia' ',' 'hypomagnesemia' ',' 'hypocalcemia' ')']",[0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 2. 0.]
NCT03071692,"13:32:chronic_disease,38:63:chronic_disease,65:74:chronic_disease,76:111:chronic_disease,116:132:treatment,,","Symptomatic lower extremity PAD (ie, intermittent claudication, rest pain, lower extremity ischemic ulceration, or major amputation with either ankle-brachial index ≤ 0.9 or other diagnostic testing [eg, toe-brachial index, angiogram, or other imaging study])","['Symptomatic' 'lower' 'extremity' 'PAD' '(' 'ie' ',' 'intermittent'
 'claudication' ',' 'rest' 'pain' ',' 'lower' 'extremity' 'ischemic'
 'ulceration' ',' 'or' 'major' 'amputation' 'with' 'either'
 'ankle-brachial' 'index' '≤' '0.9' 'or' 'other' 'diagnostic' 'testing'
 '[' 'eg' ',' 'toe-brachial' 'index' ',' 'angiogram' ',' 'or' 'other'
 'imaging' 'study' ']' ')']","[0. 2. 2. 2. 2. 0. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03071328,",39:43:cancer,45:55:cancer,60:76:cancer","Radiographic evidence of at least one bone, lymph node, or liver metastasis, that is amenable to iodinated contrast injection, as judged by the study radiologist","['Radiographic' 'evidence' 'of' 'at' 'least' 'one' 'bone' ',' 'lymph'
 'node' ',' 'or' 'liver' 'metastasis' ',' 'that' 'is' 'amenable' 'to'
 'iodinated' 'contrast' 'injection' ',' 'as' 'judged' 'by' 'the' 'study'
 'radiologist']","[0. 0. 0. 0. 0. 0. 3. 0. 3. 3. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT03070535,"1:6:chronic_disease,11:25:chronic_disease,27:47:chronic_disease",Liver and kidney disease: Active liver disease will be excluded,"['Liver' 'and' 'kidney' 'disease' ':' 'Active' 'liver' 'disease' 'will'
 'be' 'excluded']",[2. 0. 2. 2. 0. 2. 2. 2. 0. 0. 0.]
NCT03070535,"47:62:treatment,74:92:cancer,127:142:treatment","Those with medical conditions that preclude a lumbar puncture such as an intracranial tumor, lower spinal hardware, or use of anticoagulation","['Those' 'with' 'medical' 'conditions' 'that' 'preclude' 'a' 'lumbar'
 'puncture' 'such' 'as' 'an' 'intracranial' 'tumor' ',' 'lower' 'spinal'
 'hardware' ',' 'or' 'use' 'of' 'anticoagulation']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT03070340,",57:76:treatment,81:94:cancer,118:137:treatment,142:151:treatment",Any woman who has completed or is nearing completion of neoadjuvant therapy for breast cancer and is scheduled for a post-NAT breast MRI and mammogram,"['Any' 'woman' 'who' 'has' 'completed' 'or' 'is' 'nearing' 'completion'
 'of' 'neoadjuvant' 'therapy' 'for' 'breast' 'cancer' 'and' 'is'
 'scheduled' 'for' 'a' 'post-NAT' 'breast' 'MRI' 'and' 'mammogram']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 3. 3. 0. 0. 0. 0. 0. 1. 1. 1. 0.
 1.]"
NCT03070145,"1:15:chronic_disease,17:28:chronic_disease,32:55:chronic_disease,59:64:chronic_disease","Cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity","['Cardiovascular' ',' 'respiratory' 'or' 'musculoskeletal' 'disease' 'or'
 'joint' 'problems' 'that' 'preclude' 'moderate' 'physical' 'activity']",[2. 0. 2. 0. 2. 2. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT03069716,"16:26:chronic_disease,28:37:chronic_disease,54:79:chronic_disease,99:136:chronic_disease","Diagnosed with idiopathic, heritable, or associated (connective tissue disease, drugs, or toxins) pulmonary arterial hypertension (PAH) according to World Health Organization consensus recommendations","['Diagnosed' 'with' 'idiopathic' ',' 'heritable' ',' 'or' 'associated' '('
 'connective' 'tissue' 'disease' ',' 'drugs' ',' 'or' 'toxins' ')'
 'pulmonary' 'arterial' 'hypertension' '(' 'PAH' ')' 'according' 'to'
 'World' 'Health' 'Organization' 'consensus' 'recommendations']","[0. 0. 2. 0. 2. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT03068442,"7:20:cancer,31:49:chronic_disease,53:64:cancer",Known stroke mimics including multiple sclerosis or brain tumor,"['Known' 'stroke' 'mimics' 'including' 'multiple' 'sclerosis' 'or' 'brain'
 'tumor']",[0. 3. 3. 0. 2. 2. 0. 3. 3.]
NCT03065465,"1:21:treatment,30:35:chronic_disease,53:62:treatment",UGI post-polypectomy induced ulcer with some SRH on endoscopy,"['UGI' 'post-polypectomy' 'induced' 'ulcer' 'with' 'some' 'SRH' 'on'
 'endoscopy']",[1. 1. 0. 2. 0. 0. 0. 0. 1.]
NCT03059030,"100:116:chronic_disease,118:137:chronic_disease,156:180:chronic_disease,184:203:chronic_disease","Any serious medical condition likely to impede successful completion of the study, such as certain mental disorders, cardiac arrhythmias, and uncontrolled congestive heart failure or respiratory disease","['Any' 'serious' 'medical' 'condition' 'likely' 'to' 'impede' 'successful'
 'completion' 'of' 'the' 'study' ',' 'such' 'as' 'certain' 'mental'
 'disorders' ',' 'cardiac' 'arrhythmias' ',' 'and' 'uncontrolled'
 'congestive' 'heart' 'failure' 'or' 'respiratory' 'disease']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 0.
 2. 2. 2. 0. 2. 2.]"
NCT03058679,"28:50:treatment,70:73:chronic_disease,79:94:treatment",Currently participating in another clinical trial of a drug to treat IBD or a dietary therapy for any indication,"['Currently' 'participating' 'in' 'another' 'clinical' 'trial' 'of' 'a'
 'drug' 'to' 'treat' 'IBD' 'or' 'a' 'dietary' 'therapy' 'for' 'any'
 'indication']",[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 2. 0. 0. 1. 1. 0. 0. 0.]
NCT03058146,"15:36:chronic_disease,38:51:chronic_disease,69:87:chronic_disease","Chronic major psychiatric disorders (schizophrenia, major recurrent affective disorder)","['Chronic' 'major' 'psychiatric' 'disorders' '(' 'schizophrenia' ','
 'major' 'recurrent' 'affective' 'disorder' ')']",[0. 0. 2. 2. 0. 2. 0. 0. 0. 2. 2. 0.]
NCT03058029,"19:37:treatment,39:57:treatment,59:69:treatment,73:83:treatment","Administration of Prototype 2 (GSP2), Prototype 3 (GSP3), Gelesis100,or Gelesis200 in a previous study","['Administration' 'of' 'Prototype' '2' '(' 'GSP2' ')' ',' 'Prototype' '3'
 '(' 'GSP3' ')' ',' 'Gelesis100' ',' 'or' 'Gelesis200' 'in' 'a' 'previous'
 'study']",[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 0. 0. 0. 0.]
NCT03056339,",,60:80:chronic_disease,101:105:treatment,109:113:treatment","Cardiac: Cardiac ejection fraction >/= 50%, no evidence of pericardial effusion as determined by an ECHO or MUGA, and no clinically significant ECG findings","['Cardiac' ':' 'Cardiac' 'ejection' 'fraction' '>' '/=' '50' '%' ',' 'no'
 'evidence' 'of' 'pericardial' 'effusion' 'as' 'determined' 'by' 'an'
 'ECHO' 'or' 'MUGA' ',' 'and' 'no' 'clinically' 'significant' 'ECG'
 'findings']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 1. 0. 1. 0. 0.
 0. 0. 0. 0. 0.]"
NCT03056339,"13:19:chronic_disease,21:30:chronic_disease,32:37:chronic_disease,48:57:chronic_disease,68:85:treatment","Presence of fungal, bacterial, viral, or other infection requiring IV antimicrobials for management","['Presence' 'of' 'fungal' ',' 'bacterial' ',' 'viral' ',' 'or' 'other'
 'infection' 'requiring' 'IV' 'antimicrobials' 'for' 'management']",[0. 0. 2. 0. 2. 0. 2. 0. 0. 0. 2. 0. 1. 1. 0. 0.]
NCT03053518,"19:32:chronic_disease,34:48:chronic_disease,53:64:chronic_disease","have a history of heart disease, kidney disease, or retinopathy (to rule-out those with long-standing, undiagnosed T2D)","['have' 'a' 'history' 'of' 'heart' 'disease' ',' 'kidney' 'disease' ','
 'or' 'retinopathy' '(' 'to' 'rule-out' 'those' 'with' 'long-standing' ','
 'undiagnosed' 'T2D' ')']",[0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03050801,"13:55:chronic_disease,85:91:chronic_disease,93:110:chronic_disease,112:129:chronic_disease,131:144:chronic_disease,148:164:chronic_disease","Any current major neurological or psychiatric disorder such as (but not limited to) stroke, Parkinson disease, Alzheimer disease, schizophrenia or major depression","['Any' 'current' 'major' 'neurological' 'or' 'psychiatric' 'disorder'
 'such' 'as' '(' 'but' 'not' 'limited' 'to' ')' 'stroke' ',' 'Parkinson'
 'disease' ',' 'Alzheimer' 'disease' ',' 'schizophrenia' 'or' 'major'
 'depression']","[0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 2. 2. 0. 2.
 0. 0. 0.]"
NCT03049189,"27:31:allergy_name,33:45:allergy_name,54:78:allergy_name,82:92:allergy_name,96:126:allergy_name","Known hypersensitivity to DOTA, lutetium-177, or any excipient of edotreotide or everolimus or any other Rapamycin derivative","['Known' 'hypersensitivity' 'to' 'DOTA' ',' 'lutetium-177' ',' 'or' 'any'
 'excipient' 'of' 'edotreotide' 'or' 'everolimus' 'or' 'any' 'other'
 'Rapamycin' 'derivative']",[0. 0. 0. 4. 0. 4. 0. 0. 4. 4. 4. 4. 0. 4. 0. 0. 0. 0. 0.]
NCT03048448,"8:22:treatment,63:89:treatment,114:118:treatment,120:127:treatment,133:137:treatment,168:178:treatment,180:189:treatment,191:204:treatment,210:218:treatment","Use of co-medications that may impact QAW039 exposure such as broad range UGT inhibitors or strong inhibitors of OAT3, OATP1B3, and P-gp, including but not limited to probenecid, ritonavir, valproic acid, and rifampin","['Use' 'of' 'co-medications' 'that' 'may' 'impact' 'QAW039' 'exposure'
 'such' 'as' 'broad' 'range' 'UGT' 'inhibitors' 'or' 'strong' 'inhibitors'
 'of' 'OAT3' ',' 'OATP1B3' ',' 'and' 'P-gp' ',' 'including' 'but' 'not'
 'limited' 'to' 'probenecid' ',' 'ritonavir' ',' 'valproic' 'acid' ','
 'and' 'rifampin']","[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 1. 0. 1. 0. 0. 1.
 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 1. 0. 0. 1.]"
NCT03043807,"1:23:chronic_disease,35:48:chronic_disease,50:86:chronic_disease,91:112:chronic_disease,","Active cardiac disease defined as active angina, symptomatic congestive heart failure, or myocardial infarction within previous six months","['Active' 'cardiac' 'disease' 'defined' 'as' 'active' 'angina' ','
 'symptomatic' 'congestive' 'heart' 'failure' ',' 'or' 'myocardial'
 'infarction' 'within' 'previous' 'six' 'months']",[2. 2. 2. 0. 0. 2. 2. 0. 2. 2. 2. 2. 0. 0. 2. 2. 0. 0. 0. 0.]
NCT03043807,"1:33:treatment,43:58:cancer,65:82:treatment,84:97:treatment","Prior local non-surgical therapy to treat prostate cancer (e.g. radiation therapy, brachytherapy)","['Prior' 'local' 'non-surgical' 'therapy' 'to' 'treat' 'prostate' 'cancer'
 '(' 'e.g' '.' 'radiation' 'therapy' ',' 'brachytherapy' ')']",[1. 1. 1. 1. 0. 0. 3. 3. 0. 0. 0. 1. 1. 0. 1. 0.]
NCT03042689,"14:35:chronic_disease,78:94:chronic_disease,108:132:chronic_disease,134:159:chronic_disease,161:185:chronic_disease,200:218:chronic_disease,223:260:chronic_disease","Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'inter-current' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' ',' 'ongoing' 'or' 'active' 'infection' ',' 'symptomatic'
 'congestive' 'heart' 'failure' ',' 'uncontrolled' 'hypertension' ','
 'unstable' 'angina' 'pectoris' ',' 'uncontrolled' 'cardiac' 'arrhythmia'
 ',' 'or' 'psychiatric' 'illness/social' 'situations' 'that' 'would'
 'limit' 'compliance' 'with' 'study' 'requirements']","[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 0. 2.
 2. 2. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT03040778,"46:60:allergy_name,62:71:allergy_name,76:86:allergy_name","Patients with allergy or hypersensitivity to pentoxifylline, xanthines, or tocopherol","['Patients' 'with' 'allergy' 'or' 'hypersensitivity' 'to' 'pentoxifylline'
 ',' 'xanthines' ',' 'or' 'tocopherol']",[0. 0. 0. 0. 0. 0. 4. 0. 4. 0. 0. 4.]
NCT03040726,"14:50:treatment,52:62:treatment,64:78:treatment,80:90:treatment,92:101:treatment,103:115:treatment,117:129:treatment,131:140:treatment,141:150:treatment,152:162:treatment,164:174:treatment,176:186:treatment,188:200:treatment,213:223:treatment,225:235:treatment,237:250:treatment,252:264:treatment,266:276:treatment,278:288:treatment,290:300:treatment,302:315:treatment,317:326:treatment,338:347:treatment,349:361:treatment,363:374:treatment,376:389:treatment,391:407:treatment,409:417:treatment,419:428:treatment,","On scheduled strong or moderate CYP3A4 inhibitors (boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole; amprenavir, aprepitant, atazanavir, ciprofloxacin, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, imatinib, verapamil) within one week of study enrollment","['On' 'scheduled' 'strong' 'or' 'moderate' 'CYP3A4' 'inhibitors' '('
 'boceprevir' ',' 'clarithromycin' ',' 'conivaptan' ',' 'indinavir' ','
 'itraconazole' ',' 'ketoconazole' ',' 'lopinavir/ritonavir' ','
 'mibefradil' ',' 'nefazodone' ',' 'nelfinavir' ',' 'posaconazole' ','
 'ritonavir' ',' 'saquinavir' ',' 'telaprevir' ',' 'telithromycin' ','
 'voriconazole' ';' 'amprenavir' ',' 'aprepitant' ',' 'atazanavir' ','
 'ciprofloxacin' ',' 'darunavir/ritonavir' ',' 'diltiazem' ','
 'erythromycin' ',' 'fluconazole' ',' 'fosamprenavir' ',' 'grapefruit'
 'juice' ',' 'imatinib' ',' 'verapamil' ')' 'within' 'one' 'week' 'of'
 'study' 'enrollment']","[0. 0. 1. 1. 1. 1. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0.
 1. 0. 1. 0. 1. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0.
 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0.]"
NCT03038620,"12:31:chronic_disease,33:47:chronic_disease,51:64:chronic_disease",History of gallbladder disease (cholelithiasis or cholecystitis),"['History' 'of' 'gallbladder' 'disease' '(' 'cholelithiasis' 'or'
 'cholecystitis' ')']",[0. 0. 2. 2. 0. 2. 0. 2. 0.]
NCT03037983,"8:19:chronic_disease,21:37:chronic_disease,47:84:chronic_disease,100:122:chronic_disease","Have a mass lesion, cerebral infarct or other active central nervous system disease, or history of traumatic brain injury","['Have' 'a' 'mass' 'lesion' ',' 'cerebral' 'infarct' 'or' 'other' 'active'
 'central' 'nervous' 'system' 'disease' ',' 'or' 'history' 'of'
 'traumatic' 'brain' 'injury']",[0. 0. 2. 2. 0. 2. 2. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 2. 2. 2.]
NCT03037931,"8:21:chronic_disease,,,,38:76:treatment,,158:171:treatment",Stable heart failure (NYHA II-IV) on maximally-tolerated background therapy (as determined by the site Principle Investigator) for at least 2 weeks prior to randomization,"['Stable' 'heart' 'failure' '(' 'NYHA' 'II-IV' ')' 'on'
 'maximally-tolerated' 'background' 'therapy' '(' 'as' 'determined' 'by'
 'the' 'site' 'Principle' 'Investigator' ')' 'for' 'at' 'least' '2'
 'weeks' 'prior' 'to' 'randomization']","[0. 2. 2. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1.]"
NCT03037554,"95:122:treatment,124:133:treatment,135:145:treatment,150:161:treatment,206:215:chronic_disease","Unable to taper off, with health care provider's agreement, hypnotic or sedative medications, hormone replacement therapy, clonidine, gabapentin, or isoflavones and other botanical compounds used to treat vasomotor symptoms of menopause","['Unable' 'to' 'taper' 'off' ',' 'with' 'health' 'care' 'provider' ""'s""
 'agreement' ',' 'hypnotic' 'or' 'sedative' 'medications' ',' 'hormone'
 'replacement' 'therapy' ',' 'clonidine' ',' 'gabapentin' ',' 'or'
 'isoflavones' 'and' 'other' 'botanical' 'compounds' 'used' 'to' 'treat'
 'vasomotor' 'symptoms' 'of' 'menopause']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 1. 0. 1.
 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0.]"
NCT03036280,"1:22:chronic_disease,42:56:chronic_disease,58:74:chronic_disease,76:85:chronic_disease","Psychiatric diagnosis or symptoms (e.g., hallucinations, major depression, delusions, etc.)","['Psychiatric' 'diagnosis' 'or' 'symptoms' '(' 'e.g.' ',' 'hallucinations'
 ',' 'major' 'depression' ',' 'delusions' ',' 'etc' '.' ')']",[2. 2. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 2. 0. 0. 0. 0.]
NCT03035773,"1:9:cancer,13:30:cancer,37:50:cancer",prostate or colorectal cancer (i.e. Stage 0 or IV),"['prostate' 'or' 'colorectal' 'cancer' '(' 'i.e' '.' 'Stage' '0' 'or' 'IV'
 ')']",[3. 0. 3. 3. 0. 0. 0. 3. 3. 3. 3. 0.]
NCT03034811,"1:10:chronic_disease,12:18:chronic_disease,24:37:chronic_disease","Infection, sepsis, and osteomyelitis","['Infection' ',' 'sepsis' ',' 'and' 'osteomyelitis']",[2. 0. 2. 0. 0. 2.]
NCT03034213,"19:33:chronic_disease,43:52:chronic_disease,54:64:chronic_disease,68:84:chronic_disease","Any other type of ventral hernia, such as umbilical, epigastric or Spigelian hernia","['Any' 'other' 'type' 'of' 'ventral' 'hernia' ',' 'such' 'as' 'umbilical'
 ',' 'epigastric' 'or' 'Spigelian' 'hernia']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 0. 2. 0. 2. 2.]
NCT03033498,"24:52:chronic_disease,60:69:chronic_disease,71:88:chronic_disease","History of significant skin conditions or disorders (e.g., psoriasis, atopic dermatitis, etc.)","['History' 'of' 'significant' 'skin' 'conditions' 'or' 'disorders' '('
 'e.g.' ',' 'psoriasis' ',' 'atopic' 'dermatitis' ',' 'etc' '.' ')']",[0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0.]
NCT03030118,"26:57:treatment,35:49:treatment,,80:90:treatment,","Co-morbidities requiring systemic corticosteroid therapy greater than 10 mg of prednisone per day, or equivalent, or a change in corticosteroid dose within the 3 months prior to Visit 1","['Co-morbidities' 'requiring' 'systemic' 'corticosteroid' 'therapy'
 'greater' 'than' '10' 'mg' 'of' 'prednisone' 'per' 'day' ',' 'or'
 'equivalent' ',' 'or' 'a' 'change' 'in' 'corticosteroid' 'dose' 'within'
 'the' '3' 'months' 'prior' 'to' 'Visit' '1']","[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT03030118,"51:68:treatment,70:86:treatment,91:112:treatment","The subject is currently or has been treated with immunosuppressive, immune modifying, or cytotoxic medications as listed in Section 7.2","['The' 'subject' 'is' 'currently' 'or' 'has' 'been' 'treated' 'with'
 'immunosuppressive' ',' 'immune' 'modifying' ',' 'or' 'cytotoxic'
 'medications' 'as' 'listed' 'in' 'Section' '7.2']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT03029884,"19:27:treatment,31:64:treatment,69:76:treatment",Inability to stop Coumadin or platelet anti-aggregation therapy for surgery and after surgery,"['Inability' 'to' 'stop' 'Coumadin' 'or' 'platelet' 'anti-aggregation'
 'therapy' 'for' 'surgery' 'and' 'after' 'surgery']",[0. 0. 0. 1. 0. 1. 1. 1. 0. 1. 0. 0. 0.]
NCT03029884,"1:22:chronic_disease,29:58:chronic_disease,60:91:chronic_disease,108:135:chronic_disease","personality disorders (e.g. multiple personality disorder, borderline personality disorder, etc.) or other neuropsychiatric conditions that evaluating psychiatrist would recommend exclusion of patient after neuropsychiatric evaluation","['personality' 'disorders' '(' 'e.g' '.' 'multiple' 'personality'
 'disorder' ',' 'borderline' 'personality' 'disorder' ',' 'etc' '.' ')'
 'or' 'other' 'neuropsychiatric' 'conditions' 'that' 'evaluating'
 'psychiatrist' 'would' 'recommend' 'exclusion' 'of' 'patient' 'after'
 'neuropsychiatric' 'evaluation']","[2. 2. 0. 0. 0. 2. 2. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT03028350,"5:32:treatment,62:74:treatment,76:88:treatment,90:103:treatment,105:115:treatment,117:121:treatment,123:136:treatment,138:151:treatment,153:171:treatment,173:185:treatment,191:207:treatment,","Any immunosuppressive treatment including but not limited to methotrexate, cyclosporine, mycophenolate, tacrolimus, gold, penicillamine, sulfasalazine, hydroxychloroquine, azathioprine, and cyclophosphamide in the last two weeks before starting treatment","['Any' 'immunosuppressive' 'treatment' 'including' 'but' 'not' 'limited'
 'to' 'methotrexate' ',' 'cyclosporine' ',' 'mycophenolate' ','
 'tacrolimus' ',' 'gold' ',' 'penicillamine' ',' 'sulfasalazine' ','
 'hydroxychloroquine' ',' 'azathioprine' ',' 'and' 'cyclophosphamide' 'in'
 'the' 'last' 'two' 'weeks' 'before' 'starting' 'treatment']","[0. 1. 1. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0.
 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03028012,"36:41:allergy_name,43:45:allergy_name,50:66:allergy_name","Allergy or contraindication to any NSAID, CS, or local anesthetic","['Allergy' 'or' 'contraindication' 'to' 'any' 'NSAID' ',' 'CS' ',' 'or'
 'local' 'anesthetic']",[0. 0. 0. 0. 0. 4. 0. 4. 0. 0. 4. 4.]
NCT03025828,"12:18:cancer,27:44:cancer,49:62:cancer,67:91:cancer","History of cancer, except carcinoma in situ and treated basal and squamous cell carcinomas","['History' 'of' 'cancer' ',' 'except' 'carcinoma' 'in' 'situ' 'and'
 'treated' 'basal' 'and' 'squamous' 'cell' 'carcinomas']",[0. 0. 3. 0. 0. 3. 3. 3. 0. 3. 3. 0. 3. 3. 3.]
NCT03023631,",54:76:cancer,,,104:145:treatment,169:207:treatment",All English-speaking adult MD Anderson patients with hematologic malignancy at 6-12 months +/- 8 weeks post allogeneic stem cell transplantation who will receive usual post-stem cell transplant vaccinations,"['All' 'English-speaking' 'adult' 'MD' 'Anderson' 'patients' 'with'
 'hematologic' 'malignancy' 'at' '6-12' 'months' '+/-' '8' 'weeks' 'post'
 'allogeneic' 'stem' 'cell' 'transplantation' 'who' 'will' 'receive'
 'usual' 'post-stem' 'cell' 'transplant' 'vaccinations']","[0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0.
 1. 1. 1. 1.]"
NCT03023059,"5:18:chronic_disease,43:63:chronic_disease,109:125:treatment","Any eye condition, disease, or history of trauma in either eye, which can impair vision, except cataract or cataract surgery","['Any' 'eye' 'condition' ',' 'disease' ',' 'or' 'history' 'of' 'trauma'
 'in' 'either' 'eye' ',' 'which' 'can' 'impair' 'vision' ',' 'except'
 'cataract' 'or' 'cataract' 'surgery']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.]
NCT03022292,"1:37:treatment,,143:174:treatment,176:220:treatment","Prior focal corticosteroid treatment is allowed, as long as the study eye is not involved. However prior (within 90 days of Day 0) or current systemic corticosteroid therapy (oral or intravenous corticosteroid treatment) is not permitted","['Prior' 'focal' 'corticosteroid' 'treatment' 'is' 'allowed' ',' 'as'
 'long' 'as' 'the' 'study' 'eye' 'is' 'not' 'involved' '.' 'However'
 'prior' '(' 'within' '90' 'days' 'of' 'Day' '0' ')' 'or' 'current'
 'systemic' 'corticosteroid' 'therapy' '(' 'oral' 'or' 'intravenous'
 'corticosteroid' 'treatment' ')' 'is' 'not' 'permitted']","[1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 1. 1. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0.]"
NCT03017118,"13:21:treatment,22:30:treatment,31:37:treatment,38:45:treatment",Patients on Coumadin/Steroids/NSAIDs/Tylenol,['Patients' 'on' 'Coumadin/Steroids/NSAIDs/Tylenol'],[0. 0. 1.]
NCT03016871,"29:31:treatment,38:55:treatment,71:89:chronic_disease",patients who do not achieve CR after induction therapy are considered primary refractory and are allowed to enter study,"['patients' 'who' 'do' 'not' 'achieve' 'CR' 'after' 'induction' 'therapy'
 'are' 'considered' 'primary' 'refractory' 'and' 'are' 'allowed' 'to'
 'enter' 'study']",[0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT03013543,"33:42:chronic_disease,44:51:chronic_disease,56:73:chronic_disease","Current, clinically significant pulmonary, cardiac, or oncologic disease, if these were severe enough to interfere with the study and/or would confound the results","['Current' ',' 'clinically' 'significant' 'pulmonary' ',' 'cardiac' ','
 'or' 'oncologic' 'disease' ',' 'if' 'these' 'were' 'severe' 'enough' 'to'
 'interfere' 'with' 'the' 'study' 'and/or' 'would' 'confound' 'the'
 'results']","[0. 0. 0. 0. 2. 0. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT03011684,"20:39:treatment,44:60:treatment,70:86:treatment",Desires to undergo ovarian stimulation and oocyte retrieval prior to cancer treatment,"['Desires' 'to' 'undergo' 'ovarian' 'stimulation' 'and' 'oocyte'
 'retrieval' 'prior' 'to' 'cancer' 'treatment']",[0. 0. 0. 1. 1. 0. 1. 1. 0. 0. 1. 1.]
NCT03010137,"73:82:allergy_name,99:113:treatment,133:154:treatment","All patients who previously demonstrated a hypersensitivity reaction to adhesives and qualify for panniculectomy in preparation for renal transplantation, or all patients who are undergoing panniculectomy for reasons other than in preparation for renal transplantation (i.e. after massive weight loss or for cosmetic reasons)","['All' 'patients' 'who' 'previously' 'demonstrated' 'a' 'hypersensitivity'
 'reaction' 'to' 'adhesives' 'and' 'qualify' 'for' 'panniculectomy' 'in'
 'preparation' 'for' 'renal' 'transplantation' ',' 'or' 'all' 'patients'
 'who' 'are' 'undergoing' 'panniculectomy' 'for' 'reasons' 'other' 'than'
 'in' 'preparation' 'for' 'renal' 'transplantation' '(' 'i.e' '.' 'after'
 'massive' 'weight' 'loss' 'or' 'for' 'cosmetic' 'reasons' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 0. 0. 0. 1. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03009981,"1:10:treatment,7:10:treatment,18:92:treatment,126:135:treatment,139:146:treatment,201:231:treatment,,,","Prior ADT and/or first generation anti-androgen in the (neo)adjuvant and/or salvage setting before, during, and/or following radiation or surgery is allowed provided last effective dose of ADT and/or first-generation anti-androgen is > 9 months prior to date of randomization and total duration of prior therapy is ≤ 36 months","['Prior' 'ADT' 'and/or' 'first' 'generation' 'anti-androgen' 'in' 'the'
 '(' 'neo' ')' 'adjuvant' 'and/or' 'salvage' 'setting' 'before' ','
 'during' ',' 'and/or' 'following' 'radiation' 'or' 'surgery' 'is'
 'allowed' 'provided' 'last' 'effective' 'dose' 'of' 'ADT' 'and/or'
 'first-generation' 'anti-androgen' 'is' '>' '9' 'months' 'prior' 'to'
 'date' 'of' 'randomization' 'and' 'total' 'duration' 'of' 'prior'
 'therapy' 'is' '≤' '36' 'months']","[1. 1. 0. 1. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT03008408,"19:28:cancer,104:118:treatment,135:151:cancer",Clinically stable CNS tumor at the time of screening and not receiving steroids and/or enzyme-inducing anti-epileptic medications for brain metastases,"['Clinically' 'stable' 'CNS' 'tumor' 'at' 'the' 'time' 'of' 'screening'
 'and' 'not' 'receiving' 'steroids' 'and/or' 'enzyme-inducing'
 'anti-epileptic' 'medications' 'for' 'brain' 'metastases']",[0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 3. 3.]
NCT03008408,"29:47:treatment,53:68:treatment,80:103:treatment","Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent","['Patients' 'receiving' 'chronic' ',' 'systemic' 'treatment' 'with'
 'corticosteroids' 'or' 'another' 'immunosuppressive' 'agent']",[0. 0. 0. 0. 1. 1. 0. 1. 0. 0. 1. 1.]
NCT03008070,"12:60:treatment,,153:168:treatment,170:189:treatment,191:203:treatment,205:217:treatment,221:231:treatment,","History of gastrointestinal malabsorptive bariatric surgery within less than 5 years or ingestion of drugs known to produce hepatic steatosis including corticosteroids, high-dose estrogens, methotrexate, tetracycline or amiodarone in the previous 6 months","['History' 'of' 'gastrointestinal' 'malabsorptive' 'bariatric' 'surgery'
 'within' 'less' 'than' '5' 'years' 'or' 'ingestion' 'of' 'drugs' 'known'
 'to' 'produce' 'hepatic' 'steatosis' 'including' 'corticosteroids' ','
 'high-dose' 'estrogens' ',' 'methotrexate' ',' 'tetracycline' 'or'
 'amiodarone' 'in' 'the' 'previous' '6' 'months']","[0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1.
 1. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0.]"
NCT03008070,",,47:55:chronic_disease,,,118:130:chronic_disease,140:157:treatment,158:171:chronic_disease,175:196:treatment,211:218:treatment,","Weight change > 5kg in the last three months, diabetes with poor glycemic control (HbA1c > 8.5%), introduction of an antidiabetic or of an anti-obesity drug/malabsorptive or restrictive bariatric (weight loss) surgery in the past 6 months prior to screening","['Weight' 'change' '>' '5kg' 'in' 'the' 'last' 'three' 'months' ','
 'diabetes' 'with' 'poor' 'glycemic' 'control' '(' 'HbA1c' '>' '8.5' '%'
 ')' ',' 'introduction' 'of' 'an' 'antidiabetic' 'or' 'of' 'an'
 'anti-obesity' 'drug/malabsorptive' 'or' 'restrictive' 'bariatric' '('
 'weight' 'loss' ')' 'surgery' 'in' 'the' 'past' '6' 'months' 'prior' 'to'
 'screening']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 2. 0. 0. 0. 1. 2. 0. 1. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03006770,"8:33:treatment,35:46:treatment,48:71:treatment,73:93:treatment,95:109:treatment,149:187:treatment","Use of hyperbaric oxygen therapy, prostanoids, spinal cord stimulation, lumbar sympathectomy, wound dressing containing cells or growth factors, or topical platelet derived growth factor","['Use' 'of' 'hyperbaric' 'oxygen' 'therapy' ',' 'prostanoids' ',' 'spinal'
 'cord' 'stimulation' ',' 'lumbar' 'sympathectomy' ',' 'wound' 'dressing'
 'containing' 'cells' 'or' 'growth' 'factors' ',' 'or' 'topical'
 'platelet' 'derived' 'growth' 'factor']","[0. 0. 1. 1. 1. 0. 1. 0. 1. 1. 1. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 1. 1. 1. 1. 1.]"
NCT03006302,"5:23:chronic_disease,35:62:chronic_disease,67:89:chronic_disease,","New pulmonary embolism, extremity deep venous thromboembolism, or portal vein thrombosis within 2 months of study enrollment","['New' 'pulmonary' 'embolism' ',' 'extremity' 'deep' 'venous'
 'thromboembolism' ',' 'or' 'portal' 'vein' 'thrombosis' 'within' '2'
 'months' 'of' 'study' 'enrollment']",[0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT03005418,"1:22:treatment,157:184:chronic_disease,232:249:treatment","Autologous vein graft is either not feasible in the judgment of the treating surgeon (e.g. because of lack of availability of suitable conduit, presence of severe venous insufficiency) or is not desirable because of the urgency of revascularization","['Autologous' 'vein' 'graft' 'is' 'either' 'not' 'feasible' 'in' 'the'
 'judgment' 'of' 'the' 'treating' 'surgeon' '(' 'e.g' '.' 'because' 'of'
 'lack' 'of' 'availability' 'of' 'suitable' 'conduit' ',' 'presence' 'of'
 'severe' 'venous' 'insufficiency' ')' 'or' 'is' 'not' 'desirable'
 'because' 'of' 'the' 'urgency' 'of' 'revascularization']","[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT03004807,"14:20:cancer,26:38:treatment,42:61:treatment,",diagnosis of cancer with chemotherapy or radiation treatment during the previous 5 years,"['diagnosis' 'of' 'cancer' 'with' 'chemotherapy' 'or' 'radiation'
 'treatment' 'during' 'the' 'previous' '5' 'years']",[0. 0. 3. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT03004287,"19:31:chronic_disease,33:50:chronic_disease,75:84:chronic_disease","Poorly controlled hypertension, diabetes mellitus, active or uncontrolled hepatitis","['Poorly' 'controlled' 'hypertension' ',' 'diabetes' 'mellitus' ','
 'active' 'or' 'uncontrolled' 'hepatitis']",[0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 2.]
NCT03002519,"1:7:chronic_disease,17:27:chronic_disease,29:44:chronic_disease","anemia (such as blood loss, iron deficiency, etc.)","['anemia' '(' 'such' 'as' 'blood' 'loss' ',' 'iron' 'deficiency' ',' 'etc'
 '.' ')']",[2. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0.]
NCT03001830,"1:24:chronic_disease,8:24:chronic_disease,30:35:chronic_disease,39:42:chronic_disease,99:116:treatment","active hepatitis B or C, and HBsAg or HCV RNA viral load positivity, respectively or currently on antiviral therapy for hepatitis B or C","['active' 'hepatitis' 'B' 'or' 'C' ',' 'and' 'HBsAg' 'or' 'HCV' 'RNA'
 'viral' 'load' 'positivity' ',' 'respectively' 'or' 'currently' 'on'
 'antiviral' 'therapy' 'for' 'hepatitis' 'B' 'or' 'C']","[2. 2. 2. 2. 2. 0. 0. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.
 0. 0.]"
NCT03000257,"20:36:chronic_disease,38:65:treatment,67:95:cancer,97:124:treatment,160:172:chronic_disease","History of primary immunodeficiency, bone marrow transplantation, chronic lymphocytic leukemia, solid organ transplantation, or previous clinical diagnosis of tuberculosis","['History' 'of' 'primary' 'immunodeficiency' ',' 'bone' 'marrow'
 'transplantation' ',' 'chronic' 'lymphocytic' 'leukemia' ',' 'solid'
 'organ' 'transplantation' ',' 'or' 'previous' 'clinical' 'diagnosis' 'of'
 'tuberculosis']",[0. 0. 0. 2. 0. 1. 1. 1. 0. 3. 3. 3. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 2.]
NCT02998918,"21:44:treatment,48:65:treatment,82:94:chronic_disease",Taking prescription anti-inflammatory drugs or supplements/drugs that may affect inflammation,"['Taking' 'prescription' 'anti-inflammatory' 'drugs' 'or'
 'supplements/drugs' 'that' 'may' 'affect' 'inflammation']",[0. 0. 1. 1. 0. 1. 0. 0. 0. 2.]
NCT02995590,"1:15:chronic_disease,17:35:treatment,37:45:chronic_disease,100:109:treatment,139:150:treatment","Claustrophobia, inner ear implants, aneurysm or other surgical clips, metal foreign bodies in eye, pacemaker or other contraindication to MR scanning","['Claustrophobia' ',' 'inner' 'ear' 'implants' ',' 'aneurysm' 'or' 'other'
 'surgical' 'clips' ',' 'metal' 'foreign' 'bodies' 'in' 'eye' ','
 'pacemaker' 'or' 'other' 'contraindication' 'to' 'MR' 'scanning']","[2. 0. 1. 1. 1. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 1.
 1.]"
NCT02995330,"1:19:treatment,21:30:treatment,32:43:treatment,49:83:cancer","Prior chemotherapy (docetaxel, cabazitaxel) for castrate resistant prostate cancer","['Prior' 'chemotherapy' '(' 'docetaxel' ',' 'cabazitaxel' ')' 'for'
 'castrate' 'resistant' 'prostate' 'cancer']",[1. 1. 0. 1. 0. 1. 0. 0. 3. 3. 3. 3.]
NCT02994940,"15:28:treatment,33:46:treatment,51:74:chronic_disease,127:142:treatment,144:179:treatment,181:212:treatment,220:228:treatment","scheduled for tonsillectomy and adenoidectomy for obstructive sleep apnea with or without additional minor procedures such as sleep endoscopy, unilateral or bilateral myringotomy, insertion of tympanostomy tubes and/or ear exam. ( Minor additional procedures that are frequently combined with tonsillectomy and adenoidectomy but are not commonly considered to have pain that is significantly greater than the tonsillectomy and adenoidectomy)","['scheduled' 'for' 'tonsillectomy' 'and' 'adenoidectomy' 'for'
 'obstructive' 'sleep' 'apnea' 'with' 'or' 'without' 'additional' 'minor'
 'procedures' 'such' 'as' 'sleep' 'endoscopy' ',' 'unilateral' 'or'
 'bilateral' 'myringotomy' ',' 'insertion' 'of' 'tympanostomy' 'tubes'
 'and/or' 'ear' 'exam' '.' '(' 'Minor' 'additional' 'procedures' 'that'
 'are' 'frequently' 'combined' 'with' 'tonsillectomy' 'and'
 'adenoidectomy' 'but' 'are' 'not' 'commonly' 'considered' 'to' 'have'
 'pain' 'that' 'is' 'significantly' 'greater' 'than' 'the' 'tonsillectomy'
 'and' 'adenoidectomy' ')']","[0. 0. 1. 0. 1. 0. 2. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1.
 0. 1. 1. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02992899,"32:45:chronic_disease,47:71:chronic_disease,76:84:chronic_disease,98:102:chronic_disease","Current or lifetime history of schizophrenia, schizoaffective disorder, or bulimia, based on the SCID","['Current' 'or' 'lifetime' 'history' 'of' 'schizophrenia' ','
 'schizoaffective' 'disorder' ',' 'or' 'bulimia' ',' 'based' 'on' 'the'
 'SCID']",[2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2.]
NCT02991651,"45:52:allergy_name,56:65:allergy_name,93:101:allergy_name,105:125:allergy_name",History of allergic reactions attributed to IRX4204 or erlotinib or to compounds of similar chemical or biologic composition,"['History' 'of' 'allergic' 'reactions' 'attributed' 'to' 'IRX4204' 'or'
 'erlotinib' 'or' 'to' 'compounds' 'of' 'similar' 'chemical' 'or'
 'biologic' 'composition']",[0. 0. 0. 0. 0. 0. 4. 0. 4. 0. 0. 0. 0. 0. 4. 0. 4. 4.]
NCT02990481,"16:33:treatment,35:42:treatment,44:56:treatment,61:84:treatment,","Treatment with radiation therapy, surgery, chemotherapy, or investigational therapy within four weeks prior to study entry","['Treatment' 'with' 'radiation' 'therapy' ',' 'surgery' ',' 'chemotherapy'
 ',' 'or' 'investigational' 'therapy' 'within' 'four' 'weeks' 'prior' 'to'
 'study' 'entry']",[0. 0. 1. 1. 0. 1. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02988960,"40:64:chronic_disease,66:93:treatment,95:123:cancer,125:152:treatment,185:197:chronic_disease,199:225:chronic_disease,227:252:chronic_disease,273:284:chronic_disease","Participant must not have a history of primary immunodeficiency, bone marrow transplantation, chronic lymphocytic leukemia, solid organ transplantation, previous clinical diagnosis of tuberculosis, inflammatory bowel disease, interstitial lung disease, or immune-mediated pneumonitis","['Participant' 'must' 'not' 'have' 'a' 'history' 'of' 'primary'
 'immunodeficiency' ',' 'bone' 'marrow' 'transplantation' ',' 'chronic'
 'lymphocytic' 'leukemia' ',' 'solid' 'organ' 'transplantation' ','
 'previous' 'clinical' 'diagnosis' 'of' 'tuberculosis' ',' 'inflammatory'
 'bowel' 'disease' ',' 'interstitial' 'lung' 'disease' ',' 'or'
 'immune-mediated' 'pneumonitis']","[0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 1. 1. 1. 0. 3. 3. 3. 0. 1. 1. 1. 0. 0. 0.
 0. 0. 2. 0. 2. 2. 2. 0. 2. 2. 2. 0. 0. 0. 2.]"
NCT02988895,",,76:79:chronic_disease,81:113:chronic_disease,126:144:chronic_disease","Fellow eye with a BCVA of 20/63 Snellen Equivalent or worse, with advanced AMD (neovascular or non-exudative AMD with foveal geographic atrophy)","['Fellow' 'eye' 'with' 'a' 'BCVA' 'of' '20/63' 'Snellen' 'Equivalent' 'or'
 'worse' ',' 'with' 'advanced' 'AMD' '(' 'neovascular' 'or'
 'non-exudative' 'AMD' 'with' 'foveal' 'geographic' 'atrophy' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 2. 2. 0. 0. 2. 2.
 0.]"
NCT02986087,"1:13:chronic_disease,15:25:chronic_disease,27:38:chronic_disease","Maternal HIV, Hepatits B, Hepatitis C","['Maternal' 'HIV' ',' 'Hepatits' 'B' ',' 'Hepatitis' 'C']",[2. 2. 0. 2. 2. 0. 2. 2.]
NCT02985554,"15:40:chronic_disease,22:40:chronic_disease,141:169:treatment,180:204:treatment","Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids","['Patients' 'with' 'active' 'autoimmune' 'disease' 'or' 'history' 'of'
 'autoimmune' 'disease' 'that' 'might' 'recur' ',' 'which' 'may' 'affect'
 'vital' 'organ' 'function' 'or' 'require' 'immune' 'suppressive'
 'treatment' 'including' 'systemic' 'corticosteroids']","[0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.
 1. 0. 1. 1.]"
NCT02985554,"15:23:chronic_disease,25:47:chronic_disease,58:69:chronic_disease,126:141:treatment","Patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids","['Patients' 'with' 'vitiligo' ',' 'endocrine' 'deficiencies' 'including'
 'thyroiditis' 'managed' 'with' 'replacement' 'hormones' 'including'
 'physiologic' 'corticosteroids']",[0. 0. 2. 0. 2. 2. 0. 2. 0. 0. 0. 0. 0. 0. 1.]
NCT02985411,"7:24:chronic_disease,80:101:chronic_disease,103:131:treatment,,,148:157:chronic_disease,159:167:chronic_disease,169:178:chronic_disease,190:210:chronic_disease,215:236:chronic_disease,238:262:chronic_disease,292:298:treatment,302:317:treatment","Has a medical condition that precludes safe pursuit of gardening, i.e., severe orthopedic conditions, pending hip/knee replacement (within 6 mo.), paralysis, dementia, blindness, untreated stage 3 hypertension, or myocardial infarction, congestive heart failure, or conditions that required oxygen or hospitalization within 6 mo","['Has' 'a' 'medical' 'condition' 'that' 'precludes' 'safe' 'pursuit' 'of'
 'gardening' ',' 'i.e.' ',' 'severe' 'orthopedic' 'conditions' ','
 'pending' 'hip/knee' 'replacement' '(' 'within' '6' 'mo' '.' ')' ','
 'paralysis' ',' 'dementia' ',' 'blindness' ',' 'untreated' 'stage' '3'
 'hypertension' ',' 'or' 'myocardial' 'infarction' ',' 'congestive'
 'heart' 'failure' ',' 'or' 'conditions' 'that' 'required' 'oxygen' 'or'
 'hospitalization' 'within' '6' 'mo']","[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 1. 1. 1. 0. 0. 0. 0.
 0. 0. 0. 2. 0. 2. 0. 2. 0. 0. 2. 2. 2. 0. 0. 2. 2. 0. 2. 2. 2. 0. 0. 0.
 0. 0. 1. 0. 1. 0. 0. 0.]"
NCT02979574,"10:26:treatment,28:35:treatment,37:49:treatment,58:70:treatment,,140:157:treatment","Complete active treatment (surgery, chemotherapy, and/or radiotherapy) at least one month prior to study initiation (patients on continued hormone treatment will not be excluded)","['Complete' 'active' 'treatment' '(' 'surgery' ',' 'chemotherapy' ','
 'and/or' 'radiotherapy' ')' 'at' 'least' 'one' 'month' 'prior' 'to'
 'study' 'initiation' '(' 'patients' 'on' 'continued' 'hormone'
 'treatment' 'will' 'not' 'be' 'excluded' ')']","[0. 1. 1. 0. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 1. 0. 0. 0. 0. 0.]"
NCT02978443,"84:89:cancer,101:131:treatment,136:158:treatment",Patients must have a tissue block (or 20 unstained slides) available with adequate tumor to perform multiplex immunohistochemistry and nucleic acids analyses ( i.e. whole exome sequencing),"['Patients' 'must' 'have' 'a' 'tissue' 'block' '(' 'or' '20' 'unstained'
 'slides' ')' 'available' 'with' 'adequate' 'tumor' 'to' 'perform'
 'multiplex' 'immunohistochemistry' 'and' 'nucleic' 'acids' 'analyses' '('
 'i.e' '.' 'whole' 'exome' 'sequencing' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 1. 1. 0. 1. 1. 1.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02977468,"23:48:cancer,87:104:treatment,106:127:treatment,132:145:treatment,149:152:treatment,157:161:treatment","Histologically proven invasive breast carcinoma with triple negative receptor status (Estrogen receptor, Progesterone receptor and HER2 negative by IHC and FISH)","['Histologically' 'proven' 'invasive' 'breast' 'carcinoma' 'with' 'triple'
 'negative' 'receptor' 'status' '(' 'Estrogen' 'receptor' ','
 'Progesterone' 'receptor' 'and' 'HER2' 'negative' 'by' 'IHC' 'and' 'FISH'
 ')']",[0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 1. 1. 0. 1. 0. 1. 0.]
NCT02975986,"22:27:treatment,25:27:treatment,,58:79:chronic_disease,,,107:118:treatment,120:150:treatment,170:186:chronic_disease,203:216:chronic_disease,,,,,368:374:chronic_disease,380:447:treatment,456:480:treatment","Contraindications to SPECT/CT, pregnancy, breastfeeding, chronic renal disease (eGFR < 60 ml/min/1.73m2), proteinuria, genetic diseases of the kidney, inborn defects of lipid metabolism, alcohol abuse, liver disease (patients with highly elevated total bilirubin, elevated liver enzymes AST, ALT and alkaline phosphatase and those with an established liver disease), anemia, and pharmacological treatment with insulin or insulin-sensitizing drugs such as thiazolidinediones (TZD)","['Contraindications' 'to' 'SPECT/CT' ',' 'pregnancy' ',' 'breastfeeding'
 ',' 'chronic' 'renal' 'disease' '(' 'eGFR' '<' '60' 'ml/min/1.73m2' ')'
 ',' 'proteinuria' ',' 'genetic' 'diseases' 'of' 'the' 'kidney' ','
 'inborn' 'defects' 'of' 'lipid' 'metabolism' ',' 'alcohol' 'abuse' ','
 'liver' 'disease' '(' 'patients' 'with' 'highly' 'elevated' 'total'
 'bilirubin' ',' 'elevated' 'liver' 'enzymes' 'AST' ',' 'ALT' 'and'
 'alkaline' 'phosphatase' 'and' 'those' 'with' 'an' 'established' 'liver'
 'disease' ')' ',' 'anemia' ',' 'and' 'pharmacological' 'treatment' 'with'
 'insulin' 'or' 'insulin-sensitizing' 'drugs' 'such' 'as'
 'thiazolidinediones' '(' 'TZD' ')']","[0. 0. 1. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 1. 1.
 1. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 1. 1. 1. 1. 1. 1.
 1. 0. 0. 1. 1. 0. 0.]"
NCT02973139,"10:26:treatment,30:50:treatment,63:72:chronic_disease",Previous thoracic surgery or thrombolytic therapy for pleural infection,"['Previous' 'thoracic' 'surgery' 'or' 'thrombolytic' 'therapy' 'for'
 'pleural' 'infection']",[0. 1. 1. 0. 1. 1. 0. 0. 2.]
NCT02968446,"18:30:treatment,32:42:treatment,44:58:treatment,60:73:treatment,75:84:treatment,89:100:treatment","Currently taking ketoconazole, colestipol, cholestyramine, phenobarbitol, phenytoin, or mineral oil","['Currently' 'taking' 'ketoconazole' ',' 'colestipol' ',' 'cholestyramine'
 ',' 'phenobarbitol' ',' 'phenytoin' ',' 'or' 'mineral' 'oil']",[0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 1. 1.]
NCT02966665,"43:47:chronic_disease,49:52:chronic_disease,54:56:chronic_disease,61:73:chronic_disease","Subject has physical ailments (other than COPD, PAH, HF, or hypertension) that would prevent them from study participation in the judgment of the investigator","['Subject' 'has' 'physical' 'ailments' '(' 'other' 'than' 'COPD' ',' 'PAH'
 ',' 'HF' ',' 'or' 'hypertension' ')' 'that' 'would' 'prevent' 'them'
 'from' 'study' 'participation' 'in' 'the' 'judgment' 'of' 'the'
 'investigator']","[0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 2. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02964741,"34:52:chronic_disease,59:72:chronic_disease,94:101:chronic_disease,105:128:chronic_disease,,","History or current evidence of a psychotic disorder (e.g. schizophrenia) or substance abuse; bipolar or severe major depression, as evidenced by Beck Depression score of ≥ 30","['History' 'or' 'current' 'evidence' 'of' 'a' 'psychotic' 'disorder' '('
 'e.g' '.' 'schizophrenia' ')' 'or' 'substance' 'abuse' ';' 'bipolar' 'or'
 'severe' 'major' 'depression' ',' 'as' 'evidenced' 'by' 'Beck'
 'Depression' 'score' 'of' '≥' '30']","[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 0. 0. 0. 0. 0. 2. 0. 2. 2. 2. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02963831,"15:33:cancer,50:77:treatment,114:139:cancer,143:177:cancer",Subjects with peritoneal disease who have failed prior standard chemotherapy and have histologic confirmation of epithelial ovarian cancer or metastatic colorectal cancer (CRC) including cancer originating from the appendix,"['Subjects' 'with' 'peritoneal' 'disease' 'who' 'have' 'failed' 'prior'
 'standard' 'chemotherapy' 'and' 'have' 'histologic' 'confirmation' 'of'
 'epithelial' 'ovarian' 'cancer' 'or' 'metastatic' 'colorectal' 'cancer'
 '(' 'CRC' ')' 'including' 'cancer' 'originating' 'from' 'the' 'appendix']","[0. 0. 3. 3. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 3. 3. 3. 0. 3. 3. 3. 3. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02962557,"27:50:treatment,52:65:treatment,67:84:treatment,90:103:treatment","Sample procedures include major extremity surgery, spine surgery, abdominal surgery, and chest surgery that require a post operative in patient hospital stay","['Sample' 'procedures' 'include' 'major' 'extremity' 'surgery' ',' 'spine'
 'surgery' ',' 'abdominal' 'surgery' ',' 'and' 'chest' 'surgery' 'that'
 'require' 'a' 'post' 'operative' 'in' 'patient' 'hospital' 'stay']","[0. 0. 0. 1. 1. 1. 0. 1. 1. 0. 1. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02960763,"23:47:chronic_disease,49:62:chronic_disease,64:88:chronic_disease,90:115:chronic_disease,117:136:chronic_disease","Lifetime diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms","['Lifetime' 'diagnosis' 'of' 'bipolar' 'I' 'or' 'II' 'disorder' ','
 'schizophrenia' ',' 'schizoaffective' 'disorder' ',' 'schizophreniform'
 'disorder' ',' 'delusional' 'disorder' ',' 'or' 'current' 'psychotic'
 'symptoms']",[0. 0. 0. 2. 2. 2. 2. 2. 0. 2. 0. 2. 2. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02960555,"41:58:chronic_disease,,188:194:chronic_disease,196:233:chronic_disease,,323:334:chronic_disease","Patients with pre-existing uncontrolled pulmonary disease will be excluded; uncontrolled refers to patients having had at least one hospitalization due to pulmonary disease (for example, asthma, chronic obstructive pulmonary disease) within the 6 months prior to enrollment in the study; patients with previous history of pneumonitis will be excluded","['Patients' 'with' 'pre-existing' 'uncontrolled' 'pulmonary' 'disease'
 'will' 'be' 'excluded' ';' 'uncontrolled' 'refers' 'to' 'patients'
 'having' 'had' 'at' 'least' 'one' 'hospitalization' 'due' 'to'
 'pulmonary' 'disease' '(' 'for' 'example' ',' 'asthma' ',' 'chronic'
 'obstructive' 'pulmonary' 'disease' ')' 'within' 'the' '6' 'months'
 'prior' 'to' 'enrollment' 'in' 'the' 'study' ';' 'patients' 'with'
 'previous' 'history' 'of' 'pneumonitis' 'will' 'be' 'excluded']","[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 2. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 2. 0. 0. 0.]"
NCT02960113,"12:31:chronic_disease,33:41:chronic_disease,45:54:chronic_disease","History of open angle glaucoma, seizures or psychosis","['History' 'of' 'open' 'angle' 'glaucoma' ',' 'seizures' 'or' 'psychosis']",[0. 0. 2. 2. 2. 0. 2. 0. 2.]
NCT02957149,"8:15:treatment,19:26:treatment,42:63:treatment",Use of aspirin or heparin 2 weeks before radical prostatectomy,"['Use' 'of' 'aspirin' 'or' 'heparin' '2' 'weeks' 'before' 'radical'
 'prostatectomy']",[0. 0. 1. 0. 1. 0. 0. 0. 1. 1.]
NCT02955537,"23:50:chronic_disease,52:79:chronic_disease,90:113:chronic_disease","Previous diagnosis of acute myocardial infarction, angina (stable or unstable), or known coronary artery disease","['Previous' 'diagnosis' 'of' 'acute' 'myocardial' 'infarction' ','
 'angina' '(' 'stable' 'or' 'unstable' ')' ',' 'or' 'known' 'coronary'
 'artery' 'disease']",[0. 0. 0. 2. 2. 2. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT02955251,"51:62:cancer,80:89:treatment,93:109:treatment",combination therapy cohorts must have an advanced solid tumor where the use of nivolumab is standard therapy,"['combination' 'therapy' 'cohorts' 'must' 'have' 'an' 'advanced' 'solid'
 'tumor' 'where' 'the' 'use' 'of' 'nivolumab' 'is' 'standard' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 1. 0. 1. 1.]
NCT02952534,"1:16:treatment,26:40:treatment,42:54:treatment,56:72:treatment,80:107:treatment","Prior treatment with any PARP inhibitor, mitoxantrone, cyclophosphamide or any platinum-based chemotherapy","['Prior' 'treatment' 'with' 'any' 'PARP' 'inhibitor' ',' 'mitoxantrone'
 ',' 'cyclophosphamide' 'or' 'any' 'platinum-based' 'chemotherapy']",[1. 1. 0. 0. 1. 1. 0. 1. 0. 1. 0. 0. 1. 1.]
NCT02950337,"1:20:treatment,22:29:treatment,33:45:treatment,85:90:cancer","Prior local therapy (surgery or radiotherapy) for the current, clinically-diagnosed NSCLC","['Prior' 'local' 'therapy' '(' 'surgery' 'or' 'radiotherapy' ')' 'for'
 'the' 'current' ',' 'clinically-diagnosed' 'NSCLC']",[1. 1. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 3.]
NCT02947945,"30:70:treatment,48:51:treatment,,188:194:treatment,,","Subjects who have received a cyclophosphamide (CYC) induction regimen may be included a minimum of 2 weeks after the last dose of daily oral CYC, or 3 weeks after the last dose of pulsed IV CYC prior to visit 1, if their total WBC is ≥4x109/L prior to visit 1","['Subjects' 'who' 'have' 'received' 'a' 'cyclophosphamide' '(' 'CYC' ')'
 'induction' 'regimen' 'may' 'be' 'included' 'a' 'minimum' 'of' '2'
 'weeks' 'after' 'the' 'last' 'dose' 'of' 'daily' 'oral' 'CYC' ',' 'or'
 '3' 'weeks' 'after' 'the' 'last' 'dose' 'of' 'pulsed' 'IV' 'CYC' 'prior'
 'to' 'visit' '1' ',' 'if' 'their' 'total' 'WBC' 'is' '≥4x109/L' 'prior'
 'to' 'visit' '1']","[0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02947165,"15:23:chronic_disease,25:49:chronic_disease,51:74:chronic_disease,90:109:treatment,111:120:chronic_disease,135:153:treatment","Patients with vitiligo, type I diabetes mellitus, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger","['Patients' 'with' 'vitiligo' ',' 'type' 'I' 'diabetes' 'mellitus' ','
 'residual' 'hypothyroidism' 'only' 'requiring' 'hormone' 'replacement'
 ',' 'psoriasis' 'not' 'requiring' 'systemic' 'treatment' ',' 'or'
 'conditions' 'not' 'expected' 'to' 'recur' 'in' 'the' 'absence' 'of' 'an'
 'external' 'trigger']","[0. 0. 2. 0. 2. 2. 2. 2. 0. 2. 2. 0. 0. 1. 1. 0. 2. 0. 0. 1. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02946892,"1:50:chronic_disease,67:79:treatment,97:122:treatment",Sustained or symptomatic ventricular dysrhythmias uncontrolled by drug therapy or the use of an implantable defibrillator,"['Sustained' 'or' 'symptomatic' 'ventricular' 'dysrhythmias'
 'uncontrolled' 'by' 'drug' 'therapy' 'or' 'the' 'use' 'of' 'an'
 'implantable' 'defibrillator']",[2. 2. 2. 2. 2. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 1.]
NCT02946697,"18:35:treatment,37:44:treatment,46:58:treatment,63:75:treatment,","having completed primary treatment (surgery, chemotherapy, or radiotherapy) within the last 36 months","['having' 'completed' 'primary' 'treatment' '(' 'surgery' ','
 'chemotherapy' ',' 'or' 'radiotherapy' ')' 'within' 'the' 'last' '36'
 'months']",[0. 0. 1. 1. 0. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT02945800,"24:37:treatment,50:61:treatment,65:79:treatment",Must not have received prior therapy with either gemcitabine or nab-paclitaxel,"['Must' 'not' 'have' 'received' 'prior' 'therapy' 'with' 'either'
 'gemcitabine' 'or' 'nab-paclitaxel']",[0. 0. 0. 0. 1. 1. 0. 0. 1. 0. 1.]
NCT02945800,"36:48:cancer,50:63:cancer,68:84:cancer,92:128:cancer","have had a histologic diagnosis of osteosarcoma, Ewing sarcoma, or rhabdomyosarcoma or non-rhabdomyosarcoma soft tissue sarcoma either at diagnosis or relapse","['have' 'had' 'a' 'histologic' 'diagnosis' 'of' 'osteosarcoma' ',' 'Ewing'
 'sarcoma' ',' 'or' 'rhabdomyosarcoma' 'or' 'non-rhabdomyosarcoma' 'soft'
 'tissue' 'sarcoma' 'either' 'at' 'diagnosis' 'or' 'relapse']",[0. 0. 0. 0. 0. 0. 3. 0. 3. 3. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT02942095,"34:59:chronic_disease,71:96:chronic_disease,111:130:chronic_disease,144:168:chronic_disease,170:185:chronic_disease,190:211:chronic_disease,","Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months","['Evidence' 'of' 'current' 'uncontrolled' 'cardiovascular' 'conditions'
 ',' 'including' 'uncontrolled' 'hypertension' ',' 'uncontrolled'
 'cardiac' 'arrhythmias' ',' 'symptomatic' 'congestive' 'heart' 'failure'
 ',' 'unstable' 'angina' ',' 'or' 'myocardial' 'infarction' 'within' 'the'
 'past' '6' 'months']","[0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 0. 0.
 2. 2. 0. 0. 0. 0. 0.]"
NCT02942095,"28:54:cancer,59:91:cancer,123:171:treatment",first 5 patients from both non-small cell lung cancer and pancreatic ductal adenocarcinoma patients will need to agree to mandatory pre- and post-treatment tumor biopsies,"['first' '5' 'patients' 'from' 'both' 'non-small' 'cell' 'lung' 'cancer'
 'and' 'pancreatic' 'ductal' 'adenocarcinoma' 'patients' 'will' 'need'
 'to' 'agree' 'to' 'mandatory' 'pre-' 'and' 'post-treatment' 'tumor'
 'biopsies']","[0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1.
 1.]"
NCT02939183,"72:97:cancer,72:88:cancer,102:132:chronic_disease,,159:166:treatment","Subject must have a pathologically documented, definitively diagnosed, multiple myeloma relapsed, or refractory progressive disease after at least 2 lines of therapy for multiple myeloma","['Subject' 'must' 'have' 'a' 'pathologically' 'documented' ','
 'definitively' 'diagnosed' ',' 'multiple' 'myeloma' 'relapsed' ',' 'or'
 'refractory' 'progressive' 'disease' 'after' 'at' 'least' '2' 'lines'
 'of' 'therapy' 'for' 'multiple' 'myeloma']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0.
 1. 0. 0. 0.]"
NCT02937402,"1:29:treatment,31:41:treatment,43:53:treatment,55:65:treatment,70:90:treatment,102:112:treatment,166:172:cancer","Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)","['Prior' 'therapy' 'with' 'anti-PD-1' ',' 'anti-PD-L1' ',' 'anti-PD-L2'
 ',' 'anti-CD137' ',' 'or' 'anti-CTLA-4' 'antibody' '(' 'including'
 'ipilimumab' 'or' 'any' 'other' 'antibody' 'or' 'drug' 'specifically'
 'targeting' 'T-cell' 'co-stimulation' 'or' 'checkpoint' 'pathways' ')']","[1. 1. 1. 1. 0. 1. 0. 1. 0. 1. 0. 0. 1. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 3. 0. 0. 0. 0. 0.]"
NCT02932280,"25:57:chronic_disease,52:56:chronic_disease,71:96:treatment",Active acute or chronic graft-versus-host-disease (GvHD) or receiving immunosuppressive therapy as treatment for GvHD,"['Active' 'acute' 'or' 'chronic' 'graft-versus-host-disease' '(' 'GvHD'
 ')' 'or' 'receiving' 'immunosuppressive' 'therapy' 'as' 'treatment' 'for'
 'GvHD']",[0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 1. 1. 0. 0. 0. 0.]
NCT02931110,"19:22:cancer,26:29:cancer,,85:112:treatment,,","For subjects with ALL or AML, presence of >5% blasts in the bone marrow (based on a bone marrow aspirate/biopsy sample with ≥200 nucleated cells and the presence of bone marrow spicules)","['For' 'subjects' 'with' 'ALL' 'or' 'AML' ',' 'presence' 'of' '>' '5' '%'
 'blasts' 'in' 'the' 'bone' 'marrow' '(' 'based' 'on' 'a' 'bone' 'marrow'
 'aspirate/biopsy' 'sample' 'with' '≥200' 'nucleated' 'cells' 'and' 'the'
 'presence' 'of' 'bone' 'marrow' 'spicules' ')']","[0. 0. 0. 3. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02931110,"41:46:cancer,48:50:cancer,52:55:cancer,57:59:cancer,61:64:cancer,65:68:cancer,70:73:cancer,75:77:cancer,82:85:cancer","Part 2 (Cohort Expansion): Diagnosis of DLBCL, FL, MCL, HL, CLL/SLL, ALL, MM, or AML as documented in medical records","['Part' '2' '(' 'Cohort' 'Expansion' ')' ':' 'Diagnosis' 'of' 'DLBCL' ','
 'FL' ',' 'MCL' ',' 'HL' ',' 'CLL/SLL' ',' 'ALL' ',' 'MM' ',' 'or' 'AML'
 'as' 'documented' 'in' 'medical' 'records']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 3. 0. 3. 0. 3. 0. 3. 0. 3. 0. 3. 0. 0.
 3. 0. 0. 0. 0. 0.]"
NCT02929589,"36:49:treatment,56:107:treatment,179:188:treatment,189:202:treatment,219:228:treatment,333:339:treatment,341:348:treatment,350:361:treatment,363:376:treatment,378:386:treatment,388:397:treatment,399:410:treatment,412:432:treatment","Elective, open unilateral inguinal herniorrhaphy using Lichtenstein (tension free with mesh) hernia repair technique Agree to take only the prescribed oral analgesic medication (oxycodone/acetaminophen), plus or minus ibuprofen, for the initial fourteen-day post-operative period, with allowed exception of any currently prescribed opioid (codeine, hydrocodone, hydromorphone, morphine, methadone, oxymorphone, transdermal fentanyl), which can be continued.Agree to honestly complete a depression screening questionnaire, illicit drug use personal history and questionnaire, and physical activity assessment questionnaire, with the knowledge that if the patient is an active duty member, this information could result in a referral to medical or command authorities for potential Uniform Code of Military Justice (UCMJ) violations or concerns for subject health and fitness for duty","['Elective' ',' 'open' 'unilateral' 'inguinal' 'herniorrhaphy' 'using'
 'Lichtenstein' '(' 'tension' 'free' 'with' 'mesh' ')' 'hernia' 'repair'
 'technique' 'Agree' 'to' 'take' 'only' 'the' 'prescribed' 'oral'
 'analgesic' 'medication' '(' 'oxycodone/acetaminophen' ')' ',' 'plus'
 'or' 'minus' 'ibuprofen' ',' 'for' 'the' 'initial' 'fourteen-day'
 'post-operative' 'period' ',' 'with' 'allowed' 'exception' 'of' 'any'
 'currently' 'prescribed' 'opioid' '(' 'codeine' ',' 'hydrocodone' ','
 'hydromorphone' ',' 'morphine' ',' 'methadone' ',' 'oxymorphone' ','
 'transdermal' 'fentanyl' ')' ',' 'which' 'can' 'be' 'continued.Agree'
 'to' 'honestly' 'complete' 'a' 'depression' 'screening' 'questionnaire'
 ',' 'illicit' 'drug' 'use' 'personal' 'history' 'and' 'questionnaire' ','
 'and' 'physical' 'activity' 'assessment' 'questionnaire' ',' 'with' 'the'
 'knowledge' 'that' 'if' 'the' 'patient' 'is' 'an' 'active' 'duty'
 'member' ',' 'this' 'information' 'could' 'result' 'in' 'a' 'referral'
 'to' 'medical' 'or' 'command' 'authorities' 'for' 'potential' 'Uniform'
 'Code' 'of' 'Military' 'Justice' '(' 'UCMJ' ')' 'violations' 'or'
 'concerns' 'for' 'subject' 'health' 'and' 'fitness' 'for' 'duty']","[0. 0. 0. 0. 0. 1. 0. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02926729,"14:39:treatment,41:51:treatment,56:65:treatment","Eligible for breast conserving surgery, lumpectomy and radiation","['Eligible' 'for' 'breast' 'conserving' 'surgery' ',' 'lumpectomy' 'and'
 'radiation']",[0. 0. 1. 1. 1. 0. 1. 0. 1.]
NCT02926248,"15:30:chronic_disease,38:51:chronic_disease,53:62:chronic_disease,,","Patients with hepatic disease (known liver disease, cirrhosis, and/or AST/ALT>60)","['Patients' 'with' 'hepatic' 'disease' '(' 'known' 'liver' 'disease' ','
 'cirrhosis' ',' 'and/or' 'AST/ALT' '>' '60' ')']",[0. 0. 2. 2. 0. 0. 2. 2. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT02924402,"21:46:cancer,25:28:cancer,54:57:cancer",Diagnosis of either Non-CLL B cell malignancy or CLL/SLL,"['Diagnosis' 'of' 'either' 'Non-CLL' 'B' 'cell' 'malignancy' 'or'
 'CLL/SLL']",[0. 0. 0. 3. 3. 3. 3. 0. 3.]
NCT02924194,"49:66:treatment,68:81:treatment,83:98:treatment,103:119:treatment","Subjects with an implanted stimulator such as a cardiac pacemaker, defibrillator, neurostimulator and cochlear implant","['Subjects' 'with' 'an' 'implanted' 'stimulator' 'such' 'as' 'a' 'cardiac'
 'pacemaker' ',' 'defibrillator' ',' 'neurostimulator' 'and' 'cochlear'
 'implant']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 0. 1. 1.]
NCT02923921,"32:70:chronic_disease,79:97:chronic_disease,99:113:chronic_disease,117:147:chronic_disease","Participants with a history of immune-mediated neurological disorders such as multiple sclerosis, Guillain-Barré or inflammatory CNS/PNS disorders","['Participants' 'with' 'a' 'history' 'of' 'immune-mediated' 'neurological'
 'disorders' 'such' 'as' 'multiple' 'sclerosis' ',' 'Guillain-Barré' 'or'
 'inflammatory' 'CNS/PNS' 'disorders']",[0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 2. 2. 0. 2. 0. 2. 2. 2.]
NCT02923011,"18:34:chronic_disease,45:58:chronic_disease,60:72:chronic_disease,83:103:chronic_disease","Patients with an active infection or severe hematological, neurological, or other uncontrolled disease","['Patients' 'with' 'an' 'active' 'infection' 'or' 'severe' 'hematological'
 ',' 'neurological' ',' 'or' 'other' 'uncontrolled' 'disease']",[0. 0. 0. 2. 2. 0. 0. 2. 0. 2. 0. 0. 0. 2. 2.]
NCT02921022,"13:25:treatment,27:34:treatment,36:48:treatment,53:76:treatment","no previous radiotherapy, surgery, chemotherapy, or investigational therapy for the treatment of PDAC","['no' 'previous' 'radiotherapy' ',' 'surgery' ',' 'chemotherapy' ',' 'or'
 'investigational' 'therapy' 'for' 'the' 'treatment' 'of' 'PDAC']",[0. 0. 1. 0. 1. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02920086,"1:19:chronic_disease,11:19:chronic_disease,132:145:chronic_disease","End-stage dementia (inability to perform all ADLs, mutism or minimal verbal output secondary to dementia, bed-bound state prior to acute illness)","['End-stage' 'dementia' '(' 'inability' 'to' 'perform' 'all' 'ADLs' ','
 'mutism' 'or' 'minimal' 'verbal' 'output' 'secondary' 'to' 'dementia' ','
 'bed-bound' 'state' 'prior' 'to' 'acute' 'illness' ')']","[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.
 0.]"
NCT02918175,"1:22:chronic_disease,9:22:chronic_disease,,,,84:93:treatment,99:110:treatment,","Chronic heart failure, New York Heart Association (NYHA) class II-IV, with ongoing treatment with medications for heart failure for at least 1 month prior to enrollment","['Chronic' 'heart' 'failure' ',' 'New' 'York' 'Heart' 'Association' '('
 'NYHA' ')' 'class' 'II-IV' ',' 'with' 'ongoing' 'treatment' 'with'
 'medications' 'for' 'heart' 'failure' 'for' 'at' 'least' '1' 'month'
 'prior' 'to' 'enrollment']","[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02915744,"7:17:cancer,30:43:cancer,,114:127:treatment",Prior malignancy (other than breast cancer) unless diagnosed and definitively treated more than 5 years prior to randomization,"['Prior' 'malignancy' '(' 'other' 'than' 'breast' 'cancer' ')' 'unless'
 'diagnosed' 'and' 'definitively' 'treated' 'more' 'than' '5' 'years'
 'prior' 'to' 'randomization']",[0. 3. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02914561,",162:171:treatment,201:216:treatment,218:234:treatment,236:282:treatment,287:298:treatment","Previously demonstrated an inadequate clinical response, loss of response to, or intolerance to at least 1 of the following agents (depending on current country treatment recommendations/guidelines): corticosteroids, immunomodulators, tumor necrosis factor alpha (TNFa) antagonists, or vedolizumab","['Previously' 'demonstrated' 'an' 'inadequate' 'clinical' 'response' ','
 'loss' 'of' 'response' 'to' ',' 'or' 'intolerance' 'to' 'at' 'least' '1'
 'of' 'the' 'following' 'agents' '(' 'depending' 'on' 'current' 'country'
 'treatment' 'recommendations/guidelines' ')' ':' 'corticosteroids' ','
 'immunomodulators' ',' 'tumor' 'necrosis' 'factor' 'alpha' '(' 'TNFa' ')'
 'antagonists' ',' 'or' 'vedolizumab']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 0. 0. 0. 1. 0. 1. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 1.]"
NCT02913495,"7:20:chronic_disease,34:44:treatment,54:74:chronic_disease",Major fetal anomaly diagnosed on ultrasound or known chromosomal disorder,"['Major' 'fetal' 'anomaly' 'diagnosed' 'on' 'ultrasound' 'or' 'known'
 'chromosomal' 'disorder']",[0. 2. 2. 0. 0. 1. 0. 0. 2. 2.]
NCT02912572,",94:118:treatment,120:142:treatment,147:168:treatment,","Females of childbearing potential are defined as those who are not surgically sterile (i.e., bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or post-menopausal (defined as ≥ 12 months with no menses without an alternative medical cause)","['Females' 'of' 'childbearing' 'potential' 'are' 'defined' 'as' 'those'
 'who' 'are' 'not' 'surgically' 'sterile' '(' 'i.e.' ',' 'bilateral'
 'tubal' 'ligation' ',' 'bilateral' 'oophorectomy' ',' 'or' 'complete'
 'hysterectomy' ')' 'or' 'post-menopausal' '(' 'defined' 'as' '≥' '12'
 'months' 'with' 'no' 'menses' 'without' 'an' 'alternative' 'medical'
 'cause' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0.
 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02912572,"14:34:chronic_disease,77:101:chronic_disease,103:127:chronic_disease,129:147:chronic_disease,152:171:chronic_disease,172:189:chronic_disease","Uncontrolled intercurrent illness including, but not limited to symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' 'symptomatic' 'congestive' 'heart' 'failure' ','
 'unstable' 'angina' 'pectoris' ',' 'cardiac' 'arrhythmia' ',' 'or'
 'psychiatric' 'illness/social' 'situations' 'that' 'would' 'limit'
 'compliance' 'with' 'study' 'requirements']","[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 2. 2. 2. 0. 2. 2. 0. 0. 2. 2.
 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT02911831,"21:48:chronic_disease,65:80:chronic_disease,92:114:chronic_disease,118:136:chronic_disease",Patients with known bleeding/clotting disorders or a history of thromboembolism (including deep venous thrombosis or pulmonary embolism),"['Patients' 'with' 'known' 'bleeding/clotting' 'disorders' 'or' 'a'
 'history' 'of' 'thromboembolism' '(' 'including' 'deep' 'venous'
 'thrombosis' 'or' 'pulmonary' 'embolism' ')']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 2. 0. 0. 2. 2. 2. 0. 2. 2. 0.]
NCT02911467,"26:51:allergy_name,75:121:treatment,125:130:allergy_name","No contra-indications to endorectal coil insertion (e.g., patients with a prior abdominoperineal resection of the rectum or latex allergy)","['No' 'contra-indications' 'to' 'endorectal' 'coil' 'insertion' '(' 'e.g.'
 ',' 'patients' 'with' 'a' 'prior' 'abdominoperineal' 'resection' 'of'
 'the' 'rectum' 'or' 'latex' 'allergy' ')']",[0. 0. 0. 4. 4. 4. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 4. 0. 0.]
NCT02910700,"26:56:cancer,60:82:cancer,107:134:treatment",Histologically confirmed metastatic melanoma (stage IV) or unresectable stage III that have progressed on prior PD-1 directed therapy,"['Histologically' 'confirmed' 'metastatic' 'melanoma' '(' 'stage' 'IV' ')'
 'or' 'unresectable' 'stage' 'III' 'that' 'have' 'progressed' 'on' 'prior'
 'PD-1' 'directed' 'therapy']",[0. 0. 3. 3. 3. 3. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 1. 1. 1. 1.]
NCT02910700,"1:11:cancer,,121:130:treatment,,183:192:treatment",metastases have been treated and there is no magnetic resonance imaging (MRI) evidence of progression for 2 weeks after treatment is complete and within 14 days of the first dose of nivolumab administration,"['metastases' 'have' 'been' 'treated' 'and' 'there' 'is' 'no' 'magnetic'
 'resonance' 'imaging' '(' 'MRI' ')' 'evidence' 'of' 'progression' 'for'
 '2' 'weeks' 'after' 'treatment' 'is' 'complete' 'and' 'within' '14'
 'days' 'of' 'the' 'first' 'dose' 'of' 'nivolumab' 'administration']","[3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]"
NCT02907983,",75:90:treatment,98:113:treatment,117:127:treatment","post-menopausal women whose vasomotor symptoms are refractory to approved oral treatments (i.e., hormone therapy or paroxetine)","['post-menopausal' 'women' 'whose' 'vasomotor' 'symptoms' 'are'
 'refractory' 'to' 'approved' 'oral' 'treatments' '(' 'i.e.' ',' 'hormone'
 'therapy' 'or' 'paroxetine' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 1. 0. 1. 0.]
NCT02905591,"42:48:treatment,50:61:treatment,63:75:treatment,82:108:cancer","Pathologic diagnosis (i.e., cell sample, biopsy, tissue swap, bronchoscopy) with non-small cell lung cancer","['Pathologic' 'diagnosis' '(' 'i.e.' ',' 'cell' 'sample' ',' 'biopsy' ','
 'tissue' 'swap' ',' 'bronchoscopy' ')' 'with' 'non-small' 'cell' 'lung'
 'cancer']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 1. 0. 0. 3. 3. 3. 3.]
NCT02901314,"27:29:chronic_disease,31:43:chronic_disease,47:82:chronic_disease,84:108:chronic_disease,112:136:chronic_disease","A non-traditional form of HF (hypertrophic or restrictive forms of cardiomyopathy, congenital heart disease or Takotsubo cardiomyopathy)","['A' 'non-traditional' 'form' 'of' 'HF' '(' 'hypertrophic' 'or'
 'restrictive' 'forms' 'of' 'cardiomyopathy' ',' 'congenital' 'heart'
 'disease' 'or' 'Takotsubo' 'cardiomyopathy' ')']",[0. 0. 0. 0. 2. 0. 2. 0. 2. 2. 2. 2. 0. 2. 2. 2. 0. 2. 2. 0.]
NCT02901041,"31:43:treatment,45:58:treatment,60:89:treatment,91:100:treatment,106:120:treatment","drugs with sulfa moiety (e.g. sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics)","['drugs' 'with' 'sulfa' 'moiety' '(' 'e.g' '.' 'sulfonamides' ','
 'sulfonylureas' ',' 'carbonic' 'anhydrase' 'inhibitors' ',' 'thiazides'
 ',' 'and' 'loop' 'diuretics' ')']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 1. 1. 0. 1. 0. 0. 1. 1. 0.]
NCT02898597,"12:36:chronic_disease,44:57:chronic_disease,62:78:chronic_disease","History of serious mental illnesses (e.g., schizophrenia and bipolar disorder)","['History' 'of' 'serious' 'mental' 'illnesses' '(' 'e.g.' ','
 'schizophrenia' 'and' 'bipolar' 'disorder' ')']",[0. 0. 2. 2. 2. 0. 0. 0. 2. 0. 2. 2. 0.]
NCT02891681,"22:46:treatment,93:115:cancer,140:169:treatment,152:169:treatment,196:203:treatment,232:268:cancer","Scheduled to receive neoadjuvant chemotherapy for the treatment of newly diagnosed, locally advanced breast cancer or scheduled to receive neoadjuvant endocrine therapy with the eventual goal of surgery of newly diagnosed clinical stage II-III ER+ HER2- breast cancer (for the endocrine therapy cohort)","['Scheduled' 'to' 'receive' 'neoadjuvant' 'chemotherapy' 'for' 'the'
 'treatment' 'of' 'newly' 'diagnosed' ',' 'locally' 'advanced' 'breast'
 'cancer' 'or' 'scheduled' 'to' 'receive' 'neoadjuvant' 'endocrine'
 'therapy' 'with' 'the' 'eventual' 'goal' 'of' 'surgery' 'of' 'newly'
 'diagnosed' 'clinical' 'stage' 'II-III' 'ER+' 'HER2-' 'breast' 'cancer'
 '(' 'for' 'the' 'endocrine' 'therapy' 'cohort' ')']","[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 1. 1. 0.
 0. 0. 0. 0. 1. 0. 0. 0. 0. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0.]"
NCT02890979,"21:38:cancer,40:54:cancer,58:81:cancer",Subjects with known esophageal cancer (adenocarcinoma or squamous cell carcinoma),"['Subjects' 'with' 'known' 'esophageal' 'cancer' '(' 'adenocarcinoma' 'or'
 'squamous' 'cell' 'carcinoma' ')']",[0. 0. 0. 3. 3. 0. 3. 0. 3. 3. 3. 0.]
NCT02886572,"53:73:cancer,75:91:cancer,93:101:cancer,103:111:cancer,117:133:cancer","Primary lesion with radiosensitive histology (i.e., small cell carcinoma, germ-cell tumors, lymphoma, leukemia, and multiple myeloma)","['Primary' 'lesion' 'with' 'radiosensitive' 'histology' '(' 'i.e.' ','
 'small' 'cell' 'carcinoma' ',' 'germ-cell' 'tumors' ',' 'lymphoma' ','
 'leukemia' ',' 'and' 'multiple' 'myeloma' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 3. 3. 0. 3. 0. 3. 0. 0. 3. 3. 0.]
NCT02881320,"42:61:treatment,63:78:treatment,83:128:treatment","No documented or suspected resistance to emtricitabine (FTC), tenofovir (TFV), or integrase strand transfer inhibitors (INSTIs) including, but not limited to, the reverse transcriptase resistance mutations K65R and M184V/I","['No' 'documented' 'or' 'suspected' 'resistance' 'to' 'emtricitabine' '('
 'FTC' ')' ',' 'tenofovir' '(' 'TFV' ')' ',' 'or' 'integrase' 'strand'
 'transfer' 'inhibitors' '(' 'INSTIs' ')' 'including' ',' 'but' 'not'
 'limited' 'to' ',' 'the' 'reverse' 'transcriptase' 'resistance'
 'mutations' 'K65R' 'and' 'M184V/I']","[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02879136,"118:132:chronic_disease,134:144:chronic_disease,148:157:chronic_disease,159:167:chronic_disease,169:184:chronic_disease,186:194:chronic_disease,196:214:chronic_disease,227:244:chronic_disease,246:261:chronic_disease","Comorbidities that contraindicate the use of the methylphenidate or atomoxetine: history of substance abuse, current severe anxiety, depression or psychosis, epilepsy, hyperthyroidism, glaucoma, cardiac arrhythmia, history of Tourette syndrome, hepatic disease, allergy to methylphenidate or atomoxetine","['Comorbidities' 'that' 'contraindicate' 'the' 'use' 'of' 'the'
 'methylphenidate' 'or' 'atomoxetine' ':' 'history' 'of' 'substance'
 'abuse' ',' 'current' 'severe' 'anxiety' ',' 'depression' 'or'
 'psychosis' ',' 'epilepsy' ',' 'hyperthyroidism' ',' 'glaucoma' ','
 'cardiac' 'arrhythmia' ',' 'history' 'of' 'Tourette' 'syndrome' ','
 'hepatic' 'disease' ',' 'allergy' 'to' 'methylphenidate' 'or'
 'atomoxetine']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 0. 2. 0.
 2. 0. 2. 0. 2. 0. 2. 2. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0.]"
NCT02877394,"16:32:treatment,39:52:treatment,54:67:treatment,69:80:treatment","Current use of anticholinergics (e.g. nortriptyline, amitriptyline, hyoscyamine)","['Current' 'use' 'of' 'anticholinergics' '(' 'e.g' '.' 'nortriptyline' ','
 'amitriptyline' ',' 'hyoscyamine' ')']",[0. 0. 0. 1. 0. 0. 0. 1. 0. 1. 0. 1. 0.]
NCT02877134,",,,,177:188:treatment,219:228:chronic_disease,,337:347:cancer","A participant who has had extensive colitis for greater than or equal to (>=) 8 years, or disease limited to the left side of the colon for >= 12 years, must either have had a colonoscopy to assess for the presence of dysplasia within 1 year before the first administration of study agent or a colonoscopy to assess for the presence of malignancy at the screening visit, with no evidence of malignancy","['A' 'participant' 'who' 'has' 'had' 'extensive' 'colitis' 'for' 'greater'
 'than' 'or' 'equal' 'to' '(' '>' '=' ')' '8' 'years' ',' 'or' 'disease'
 'limited' 'to' 'the' 'left' 'side' 'of' 'the' 'colon' 'for' '>' '=' '12'
 'years' ',' 'must' 'either' 'have' 'had' 'a' 'colonoscopy' 'to' 'assess'
 'for' 'the' 'presence' 'of' 'dysplasia' 'within' '1' 'year' 'before'
 'the' 'first' 'administration' 'of' 'study' 'agent' 'or' 'a'
 'colonoscopy' 'to' 'assess' 'for' 'the' 'presence' 'of' 'malignancy' 'at'
 'the' 'screening' 'visit' ',' 'with' 'no' 'evidence' 'of' 'malignancy']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.
 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02876302,"26:28:cancer,30:32:cancer,38:42:cancer,61:97:cancer","Patients must have known ER, PR, and HER2 status defined as triple-negative breast cancer (TNBC)","['Patients' 'must' 'have' 'known' 'ER' ',' 'PR' ',' 'and' 'HER2' 'status'
 'defined' 'as' 'triple-negative' 'breast' 'cancer' '(' 'TNBC' ')']",[0. 0. 0. 0. 3. 0. 3. 0. 0. 3. 0. 0. 0. 3. 3. 3. 3. 0. 0.]
NCT02873715,",146:171:chronic_disease,211:225:chronic_disease,490:508:treatment,,546:563:chronic_disease,662:681:treatment,729:751:treatment,842:863:treatment,874:902:treatment,924:935:chronic_disease","The participating parent or child will not have had a concussion in the past three months; will not have any significant developmental delays or intellectual disabilities; will not be receiving treatment for a DSM-5 disorder that interferes with treatment delivered as part of the intervention; will not have a physical disability or diagnosis that prevents performance of physical activity at a level equivalent to a brisk walk or that places severe restriction on diet; will not be on a medication regimen that affects weight; will not have a medical condition that alters nutritional status, intestinal absorption, or affects weight; will not have undergone weight loss surgery; and will not be participating in an alternate weight control program. Families in which either the participating child or parent is actively involved in other weight-loss treatment, is using weight-affecting medications, or has an impairing psychiatric or medical condition that would hinder participation in the study will be excluded as identified by the screening assessments","['The' 'participating' 'parent' 'or' 'child' 'will' 'not' 'have' 'had' 'a'
 'concussion' 'in' 'the' 'past' 'three' 'months' ';' 'will' 'not' 'have'
 'any' 'significant' 'developmental' 'delays' 'or' 'intellectual'
 'disabilities' ';' 'will' 'not' 'be' 'receiving' 'treatment' 'for' 'a'
 'DSM-5' 'disorder' 'that' 'interferes' 'with' 'treatment' 'delivered'
 'as' 'part' 'of' 'the' 'intervention' ';' 'will' 'not' 'have' 'a'
 'physical' 'disability' 'or' 'diagnosis' 'that' 'prevents' 'performance'
 'of' 'physical' 'activity' 'at' 'a' 'level' 'equivalent' 'to' 'a' 'brisk'
 'walk' 'or' 'that' 'places' 'severe' 'restriction' 'on' 'diet' ';' 'will'
 'not' 'be' 'on' 'a' 'medication' 'regimen' 'that' 'affects' 'weight' ';'
 'will' 'not' 'have' 'a' 'medical' 'condition' 'that' 'alters'
 'nutritional' 'status' ',' 'intestinal' 'absorption' ',' 'or' 'affects'
 'weight' ';' 'will' 'not' 'have' 'undergone' 'weight' 'loss' 'surgery'
 ';' 'and' 'will' 'not' 'be' 'participating' 'in' 'an' 'alternate'
 'weight' 'control' 'program' '.' 'Families' 'in' 'which' 'either' 'the'
 'participating' 'child' 'or' 'parent' 'is' 'actively' 'involved' 'in'
 'other' 'weight-loss' 'treatment' ',' 'is' 'using' 'weight-affecting'
 'medications' ',' 'or' 'has' 'an' 'impairing' 'psychiatric' 'or'
 'medical' 'condition' 'that' 'would' 'hinder' 'participation' 'in' 'the'
 'study' 'will' 'be' 'excluded' 'as' 'identified' 'by' 'the' 'screening'
 'assessments']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 1. 1. 1. 0. 0. 0. 2. 2. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.
 0. 0. 1. 1. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02867696,"85:102:chronic_disease,104:110:cancer,112:139:chronic_disease,141:156:chronic_disease,158:172:chronic_disease,174:195:chronic_disease","Reports being treated for a current medical condition that could affect body weigh (diabetes mellitus, cancer, chronic renal insufficiency, hyperthyroidism, hypothyroidism, chronic liver disease)","['Reports' 'being' 'treated' 'for' 'a' 'current' 'medical' 'condition'
 'that' 'could' 'affect' 'body' 'weigh' '(' 'diabetes' 'mellitus' ','
 'cancer' ',' 'chronic' 'renal' 'insufficiency' ',' 'hyperthyroidism' ','
 'hypothyroidism' ',' 'chronic' 'liver' 'disease' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 3. 0. 2. 2. 2. 0. 2.
 0. 2. 0. 0. 0. 0. 0.]"
NCT02867124,"26:42:treatment,102:111:treatment,113:126:treatment","Willingness to enroll in XR-NTX treatment in prison [not currently in or planning to pursue agonist (methadone, buprenorphine) treatment at release]","['Willingness' 'to' 'enroll' 'in' 'XR-NTX' 'treatment' 'in' 'prison' '['
 'not' 'currently' 'in' 'or' 'planning' 'to' 'pursue' 'agonist' '('
 'methadone' ',' 'buprenorphine' ')' 'treatment' 'at' 'release' ']']","[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0.
 0. 0.]"
NCT02865135,"111:132:treatment,176:183:treatment,187:204:treatment",Relapsed or progressive disease at the primary site and/or regional lymph nodes after initial treatment (e.g. systemic chemotherapy) with no potentially curative option (i.e. surgery or chemoradiotherapy),"['Relapsed' 'or' 'progressive' 'disease' 'at' 'the' 'primary' 'site'
 'and/or' 'regional' 'lymph' 'nodes' 'after' 'initial' 'treatment' '('
 'e.g' '.' 'systemic' 'chemotherapy' ')' 'with' 'no' 'potentially'
 'curative' 'option' '(' 'i.e' '.' 'surgery' 'or' 'chemoradiotherapy' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 0. 1. 0.]"
NCT02864862,"41:44:allergy_name,46:56:allergy_name,58:67:allergy_name,69:78:allergy_name,80:91:allergy_name,96:106:allergy_name","allergy to antibiotics contained in the ADM (Gentimicin, Cefoxitin, Lincomcin, polymixin B and Vancomycin) will not be included in the immediate implant combined with ADM group","['allergy' 'to' 'antibiotics' 'contained' 'in' 'the' 'ADM' '('
 'Gentimicin' ',' 'Cefoxitin' ',' 'Lincomcin' ',' 'polymixin' 'B' 'and'
 'Vancomycin' ')' 'will' 'not' 'be' 'included' 'in' 'the' 'immediate'
 'implant' 'combined' 'with' 'ADM' 'group']","[0. 0. 0. 0. 0. 0. 4. 0. 4. 0. 4. 0. 4. 0. 4. 4. 0. 4. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02864147,"1:17:chronic_disease,18:24:chronic_disease,35:49:treatment",active infection/sepsis requiring IV antibiotics,['active' 'infection/sepsis' 'requiring' 'IV' 'antibiotics'],[2. 2. 0. 1. 1.]
NCT02863991,",48:69:chronic_disease,78:93:chronic_disease,95:134:treatment,148:172:chronic_disease,174:198:chronic_disease,200:225:chronic_disease,241:259:chronic_disease","Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack or symptomatic pulmonary embolism","['Any' 'of' 'the' 'following' 'in' 'the' 'previous' '6' 'months' ':'
 'myocardial' 'infarction' ',' 'severe/unstable' 'angina' ','
 'coronary/peripheral' 'artery' 'bypass' 'graft' ',' 'symptomatic'
 'congestive' 'heart' 'failure' ',' 'cerebrovascular' 'accident' ','
 'transient' 'ischemic' 'attack' 'or' 'symptomatic' 'pulmonary' 'embolism']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 1. 1. 1. 1. 0. 0. 2. 2.
 2. 0. 2. 2. 0. 2. 2. 2. 0. 0. 2. 2.]"
NCT02860702,"1:20:chronic_disease,39:53:chronic_disease,55:78:chronic_disease,80:99:chronic_disease","Metabolic disorders affecting growth: homocystinuria, methylmalonic acidemias, propionic acidemias, urea cycle defects","['Metabolic' 'disorders' 'affecting' 'growth' ':' 'homocystinuria' ','
 'methylmalonic' 'acidemias' ',' 'propionic' 'acidemias' ',' 'urea'
 'cycle' 'defects']",[2. 2. 0. 0. 0. 2. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0.]
NCT02860000,"22:47:treatment,51:72:treatment,77:93:cancer,153:156:treatment,","Patients who receive stereotactic radiosurgery or whole brain radiation for brain metastases are eligible only if they are asymptomatic and have stable MRI scans for 3 consecutive months, including < 28 days prior to pre-registration","['Patients' 'who' 'receive' 'stereotactic' 'radiosurgery' 'or' 'whole'
 'brain' 'radiation' 'for' 'brain' 'metastases' 'are' 'eligible' 'only'
 'if' 'they' 'are' 'asymptomatic' 'and' 'have' 'stable' 'MRI' 'scans'
 'for' '3' 'consecutive' 'months' ',' 'including' '<' '28' 'days' 'prior'
 'to' 'pre-registration']","[0. 0. 0. 1. 1. 0. 1. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02857218,"1:35:chronic_disease,57:91:treatment,136:164:treatment,170:181:treatment",Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with ferumoxytol,"['Human' 'immunodeficiency' 'virus' '(' 'HIV' ')' '-positive' 'patients'
 'on' 'combination' 'antiretroviral' 'therapy' 'are' 'ineligible'
 'because' 'of' 'the' 'potential' 'for' 'pharmacokinetic' 'interactions'
 'with' 'ferumoxytol']",[2. 2. 2. 2. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1.]
NCT02851914,"20:35:treatment,44:80:treatment,82:135:treatment","Currently on other antidepressants such as monoamine oxidase inhibitors (MAOIs), selective norepinephrine re-uptake inhibitors (SNRIs) etc","['Currently' 'on' 'other' 'antidepressants' 'such' 'as' 'monoamine'
 'oxidase' 'inhibitors' '(' 'MAOIs' ')' ',' 'selective' 'norepinephrine'
 're-uptake' 'inhibitors' '(' 'SNRIs' ')' 'etc']",[0. 0. 0. 1. 0. 0. 1. 1. 1. 1. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0.]
NCT02849457,"17:36:treatment,45:55:treatment,59:68:treatment",Has received an oral mTOR inhibitor such as everolimus or sirolimus,"['Has' 'received' 'an' 'oral' 'mTOR' 'inhibitor' 'such' 'as' 'everolimus'
 'or' 'sirolimus']",[0. 0. 0. 1. 1. 1. 0. 0. 1. 0. 1.]
NCT02848417,"1:17:chronic_disease,23:32:chronic_disease,36:47:chronic_disease",Major depression with psychotic or melancholic features,['Major' 'depression' 'with' 'psychotic' 'or' 'melancholic' 'features'],[2. 2. 0. 2. 0. 2. 0.]
NCT02844738,"1:11:treatment,17:36:treatment,,88:111:chronic_disease",Treatments with strong opioid drugs in the previous 4 weeks for other pain rather than shoulder osteoarthritis,"['Treatments' 'with' 'strong' 'opioid' 'drugs' 'in' 'the' 'previous' '4'
 'weeks' 'for' 'other' 'pain' 'rather' 'than' 'shoulder' 'osteoarthritis']",[1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02843945,"17:28:treatment,30:42:treatment,47:72:treatment","with concurrent gemcitabine, capecitabine, or infusional 5-fluorouracil","['with' 'concurrent' 'gemcitabine' ',' 'capecitabine' ',' 'or'
 'infusional' '5-fluorouracil']",[0. 0. 1. 0. 1. 0. 0. 1. 1.]
NCT02841540,"19:52:chronic_disease,54:86:chronic_disease,88:119:chronic_disease,121:142:chronic_disease,163:184:chronic_disease","Family history of Leber Hereditary Optic Neuropathy, Autosomal Dominant Optic Atrophy, Late-Onset Retinal Degeneration, Familial Dysautonomia or other hereditary mitochondrial disease, unless the causative mutation(s) in the family have been determined and the participant has tested negative for the mutation(s)","['Family' 'history' 'of' 'Leber' 'Hereditary' 'Optic' 'Neuropathy' ','
 'Autosomal' 'Dominant' 'Optic' 'Atrophy' ',' 'Late-Onset' 'Retinal'
 'Degeneration' ',' 'Familial' 'Dysautonomia' 'or' 'other' 'hereditary'
 'mitochondrial' 'disease' ',' 'unless' 'the' 'causative' 'mutation' '('
 's' ')' 'in' 'the' 'family' 'have' 'been' 'determined' 'and' 'the'
 'participant' 'has' 'tested' 'negative' 'for' 'the' 'mutation' '(' 's'
 ')']","[0. 0. 0. 2. 2. 2. 2. 0. 2. 2. 2. 2. 0. 2. 2. 2. 0. 2. 2. 0. 0. 0. 2. 2.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02837510,"1:17:treatment,19:29:treatment,31:37:treatment,66:71:treatment,73:83:treatment,84:89:treatment","Anti-depressants (tricyclics, SSRI's, selective and nonselective MAOIs, Wellbutrin/Zyban)","['Anti-depressants' '(' 'tricyclics' ',' 'SSRI' ""'s"" ',' 'selective' 'and'
 'nonselective' 'MAOIs' ',' 'Wellbutrin/Zyban' ')']",[1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.]
NCT02836574,"35:59:treatment,95:121:chronic_disease,,141:154:treatment","immunocompromised or is receiving immunosuppressive agents, including individuals treated for chronic glomerulonephritis within 3 months of NKA injection","['immunocompromised' 'or' 'is' 'receiving' 'immunosuppressive' 'agents'
 ',' 'including' 'individuals' 'treated' 'for' 'chronic'
 'glomerulonephritis' 'within' '3' 'months' 'of' 'NKA' 'injection']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 1. 1.]
NCT02835729,"59:62:cancer,107:129:cancer,141:171:chronic_disease",A histologically or pathologically confirmed diagnosis of AML based on WHO classification with or without extramedullary disease except for central nervous system disease,"['A' 'histologically' 'or' 'pathologically' 'confirmed' 'diagnosis' 'of'
 'AML' 'based' 'on' 'WHO' 'classification' 'with' 'or' 'without'
 'extramedullary' 'disease' 'except' 'for' 'central' 'nervous' 'system'
 'disease']",[0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 2. 2. 2. 2.]
NCT02834780,"26:43:chronic_disease,52:69:chronic_disease,73:90:chronic_disease","Uncontrolled significant active infections, except Hepatitis B (HBV) or Hepatitis C (HCV)","['Uncontrolled' 'significant' 'active' 'infections' ',' 'except'
 'Hepatitis' 'B' '(' 'HBV' ')' 'or' 'Hepatitis' 'C' '(' 'HCV' ')']",[0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02833805,"7:19:cancer,37:52:cancer,64:90:cancer,92:98:cancer,,162:169:cancer",Prior malignancies except: resected basal carcinoma or treated cervical carcinoma in situ; cancer treated with curative intent > 5 years previously. Other prior cancers will not be allowed unless approved by the PI,"['Prior' 'malignancies' 'except' ':' 'resected' 'basal' 'carcinoma' 'or'
 'treated' 'cervical' 'carcinoma' 'in' 'situ' ';' 'cancer' 'treated'
 'with' 'curative' 'intent' '>' '5' 'years' 'previously' '.' 'Other'
 'prior' 'cancers' 'will' 'not' 'be' 'allowed' 'unless' 'approved' 'by'
 'the' 'PI']","[0. 3. 0. 0. 0. 3. 3. 0. 0. 3. 3. 3. 3. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02832687,"1:16:treatment,20:26:treatment,53:77:chronic_disease",Chronic steroid or opioid user (as prescribed for a chronic systemic illness),"['Chronic' 'steroid' 'or' 'opioid' 'user' '(' 'as' 'prescribed' 'for' 'a'
 'chronic' 'systemic' 'illness' ')']",[1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0.]
NCT02832115,"8:18:treatment,20:31:treatment,36:62:treatment,","Use of sublingual, transdermal, or intravenous nitroglycerine within 6 hours prior to IP administration","['Use' 'of' 'sublingual' ',' 'transdermal' ',' 'or' 'intravenous'
 'nitroglycerine' 'within' '6' 'hours' 'prior' 'to' 'IP' 'administration']",[0. 0. 1. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02826681,"240:250:cancer,252:277:chronic_disease,279:310:chronic_disease,315:345:chronic_disease","Any other pre-existing laboratory abnormality, medical condition, or disease that, in the opinion of Investigator, may cause the subject to be unsuitable for the study or place the subject at potential risk from being in the study, e.g. a malignancy, uncontrolled hypertension, unstable ischemic heart disease, or uncontrolled diabetes mellitus","['Any' 'other' 'pre-existing' 'laboratory' 'abnormality' ',' 'medical'
 'condition' ',' 'or' 'disease' 'that' ',' 'in' 'the' 'opinion' 'of'
 'Investigator' ',' 'may' 'cause' 'the' 'subject' 'to' 'be' 'unsuitable'
 'for' 'the' 'study' 'or' 'place' 'the' 'subject' 'at' 'potential' 'risk'
 'from' 'being' 'in' 'the' 'study' ',' 'e.g' '.' 'a' 'malignancy' ','
 'uncontrolled' 'hypertension' ',' 'unstable' 'ischemic' 'heart' 'disease'
 ',' 'or' 'uncontrolled' 'diabetes' 'mellitus']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 2.
 2. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0.]"
NCT02826681,"1:16:treatment,18:50:treatment,58:75:treatment,","Parenteral iron, erythropoiesis stimulating agent use or blood transfusion within six weeks prior to the screening visit","['Parenteral' 'iron' ',' 'erythropoiesis' 'stimulating' 'agent' 'use' 'or'
 'blood' 'transfusion' 'within' 'six' 'weeks' 'prior' 'to' 'the'
 'screening' 'visit']",[1. 1. 0. 1. 1. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02826343,"12:38:chronic_disease,41:47:chronic_disease,73:85:chronic_disease","History of myocardial infarction (MI) , stroke and/or poorly controlled hypertension","['History' 'of' 'myocardial' 'infarction' '(' 'MI' ')' ',' 'stroke'
 'and/or' 'poorly' 'controlled' 'hypertension']",[0. 0. 2. 2. 2. 0. 0. 0. 2. 0. 0. 0. 2.]
NCT02822378,"14:17:chronic_disease,19:24:chronic_disease,28:49:chronic_disease,54:64:cancer","positive for HIV, Hep-C or Hep-B surface antigen and malignancy","['positive' 'for' 'HIV' ',' 'Hep-C' 'or' 'Hep-B' 'surface' 'antigen' 'and'
 'malignancy']",[0. 0. 2. 0. 2. 0. 2. 2. 2. 0. 3.]
NCT02820350,"17:39:treatment,56:67:treatment,71:91:treatment,",Patients with a solid organ transplant or those with a bone marrow or stem cell transplant in the previous 100 days or who have not engrafted,"['Patients' 'with' 'a' 'solid' 'organ' 'transplant' 'or' 'those' 'with'
 'a' 'bone' 'marrow' 'or' 'stem' 'cell' 'transplant' 'in' 'the' 'previous'
 '100' 'days' 'or' 'who' 'have' 'not' 'engrafted']","[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 1. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02819635,"10:22:treatment,24:34:treatment,36:57:treatment,62:73:treatment,","Received cyclosporine, tacrolimus, mycophenolate mofetil, or thalidomide within 30 days prior to Baseline","['Received' 'cyclosporine' ',' 'tacrolimus' ',' 'mycophenolate' 'mofetil'
 ',' 'or' 'thalidomide' 'within' '30' 'days' 'prior' 'to' 'Baseline']",[0. 1. 0. 1. 0. 1. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT02819141,"8:43:chronic_disease,53:57:chronic_disease,59:67:chronic_disease","Severe cognition or communication problems (such as coma, deafness without signing literacy, physician-documented dementia)","['Severe' 'cognition' 'or' 'communication' 'problems' '(' 'such' 'as'
 'coma' ',' 'deafness' 'without' 'signing' 'literacy' ','
 'physician-documented' 'dementia' ')']",[0. 2. 2. 2. 2. 0. 0. 0. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02816736,"62:70:allergy_name,76:80:allergy_name,84:87:allergy_name,147:168:chronic_disease","History of hypersensitivity or intolerance (unmodifiable) to Entresto™, an ACEI or ARB as well as known or suspected contraindications (including hereditary angioedema) to the study drugs","['History' 'of' 'hypersensitivity' 'or' 'intolerance' '(' 'unmodifiable'
 ')' 'to' 'Entresto™' ',' 'an' 'ACEI' 'or' 'ARB' 'as' 'well' 'as' 'known'
 'or' 'suspected' 'contraindications' '(' 'including' 'hereditary'
 'angioedema' ')' 'to' 'the' 'study' 'drugs']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 0. 0. 4. 0. 4. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 2. 2. 0. 0. 0. 0. 0.]"
NCT02815670,"36:43:treatment,47:65:treatment,81:92:treatment",A condition requiring an emergency surgery or invasive procedure where adequate haemostasis,"['A' 'condition' 'requiring' 'an' 'emergency' 'surgery' 'or' 'invasive'
 'procedure' 'where' 'adequate' 'haemostasis']",[0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 1.]
NCT02811679,"26:36:cancer,49:73:cancer,75:108:cancer,123:138:cancer,","Prior history of another malignancy (except for non-melanoma skin cancer, in situ cervical or breast cancer, or localized prostate cancer) unless disease free for at least one year and felt at low risk of relapse by treating physician","['Prior' 'history' 'of' 'another' 'malignancy' '(' 'except' 'for'
 'non-melanoma' 'skin' 'cancer' ',' 'in' 'situ' 'cervical' 'or' 'breast'
 'cancer' ',' 'or' 'localized' 'prostate' 'cancer' ')' 'unless' 'disease'
 'free' 'for' 'at' 'least' 'one' 'year' 'and' 'felt' 'at' 'low' 'risk'
 'of' 'relapse' 'by' 'treating' 'physician']","[0. 0. 0. 0. 3. 0. 0. 0. 3. 3. 3. 0. 3. 3. 3. 3. 3. 3. 0. 0. 0. 3. 3. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02811263,"45:63:treatment,77:105:treatment,116:128:treatment,130:146:treatment,151:155:treatment","Need for resuscitation at 10 minutes (i.e., chest compressions, or positive pressure respiratory support including endotracheal, mask ventilation, or CPAP)","['Need' 'for' 'resuscitation' 'at' '10' 'minutes' '(' 'i.e.' ',' 'chest'
 'compressions' ',' 'or' 'positive' 'pressure' 'respiratory' 'support'
 'including' 'endotracheal' ',' 'mask' 'ventilation' ',' 'or' 'CPAP' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 1. 1. 0. 1. 0. 1. 1. 0. 0.
 1. 0.]"
NCT02809677,"11:43:chronic_disease,67:93:chronic_disease,100:124:chronic_disease,126:141:chronic_disease,143:170:chronic_disease,175:181:cancer,222:228:chronic_disease,230:237:chronic_disease,239:249:chronic_disease","severe or life-threatening medical illness, such as other serious cardiopulmonary conditions (e.g. congenital heart disease, cystic fibrosis, alpha-1-antitrypsin disease) or cancer, which would confound the assessment of asthma, anxiety, depression or quality of life","['severe' 'or' 'life-threatening' 'medical' 'illness' ',' 'such' 'as'
 'other' 'serious' 'cardiopulmonary' 'conditions' '(' 'e.g' '.'
 'congenital' 'heart' 'disease' ',' 'cystic' 'fibrosis' ','
 'alpha-1-antitrypsin' 'disease' ')' 'or' 'cancer' ',' 'which' 'would'
 'confound' 'the' 'assessment' 'of' 'asthma' ',' 'anxiety' ','
 'depression' 'or' 'quality' 'of' 'life']","[0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 2. 2. 0. 2. 2. 0. 2. 2.
 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 2. 0. 0. 0. 0.]"
NCT02807272,"1:19:chronic_disease,20:44:chronic_disease,56:60:cancer",Myeloproliferative/myelodysplastic syndrome other than CMML,['Myeloproliferative/myelodysplastic' 'syndrome' 'other' 'than' 'CMML'],[2. 2. 0. 0. 3.]
NCT02806570,"54:93:treatment,97:145:treatment,150:188:treatment",Implant or revision of any rhythm management device (cardiac resynchronization therapy (CRT) or cardiac resynchronization therapy device (CRT-D)) or implantable cardioverter defibrillator within the prior month,"['Implant' 'or' 'revision' 'of' 'any' 'rhythm' 'management' 'device' '('
 'cardiac' 'resynchronization' 'therapy' '(' 'CRT' ')' 'or' 'cardiac'
 'resynchronization' 'therapy' 'device' '(' 'CRT-D' ')' ')' 'or'
 'implantable' 'cardioverter' 'defibrillator' 'within' 'the' 'prior'
 'month']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 1. 1. 0. 0. 0. 0.]"
NCT02805504,"8:22:chronic_disease,24:31:chronic_disease,33:46:chronic_disease,50:73:chronic_disease","Severe cardiovascular, hepatic, renal disease or neurological impairment","['Severe' 'cardiovascular' ',' 'hepatic' ',' 'renal' 'disease' 'or'
 'neurological' 'impairment']",[0. 2. 0. 2. 0. 2. 2. 0. 2. 2.]
NCT02800629,"98:107:chronic_disease,,,,,,,209:232:chronic_disease,,,278:300:chronic_disease","While this supplement is considered very safe and low risk, patients with underlying significant cytopenia (white blood cell count less than 4.0, hemoglobin less than 10, or platelets less than 100), or with impaired renal function (glomerular filtration rate less than 60) or elevated liver enzymes will be excluded as well","['While' 'this' 'supplement' 'is' 'considered' 'very' 'safe' 'and' 'low'
 'risk' ',' 'patients' 'with' 'underlying' 'significant' 'cytopenia' '('
 'white' 'blood' 'cell' 'count' 'less' 'than' '4.0' ',' 'hemoglobin'
 'less' 'than' '10' ',' 'or' 'platelets' 'less' 'than' '100' ')' ',' 'or'
 'with' 'impaired' 'renal' 'function' '(' 'glomerular' 'filtration' 'rate'
 'less' 'than' '60' ')' 'or' 'elevated' 'liver' 'enzymes' 'will' 'be'
 'excluded' 'as' 'well']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0.]"
NCT02798458,"38:51:treatment,60:92:treatment,,124:133:treatment",Symptomatic subjects necessitating a sigmoidoscopy who are enzyme replacement therapy (ERT) naive OR less than 6 months of treatment,"['Symptomatic' 'subjects' 'necessitating' 'a' 'sigmoidoscopy' 'who' 'are'
 'enzyme' 'replacement' 'therapy' '(' 'ERT' ')' 'naive' 'OR' 'less' 'than'
 '6' 'months' 'of' 'treatment']",[0. 0. 0. 0. 1. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02789228,"1:19:chronic_disease,21:48:chronic_disease,59:79:treatment,83:99:chronic_disease","Refractory disease, residual detectable disease following conventional therapy or relapsed disease","['Refractory' 'disease' ',' 'residual' 'detectable' 'disease' 'following'
 'conventional' 'therapy' 'or' 'relapsed' 'disease']",[2. 2. 0. 2. 2. 2. 0. 1. 1. 0. 2. 2.]
NCT02784535,"60:82:treatment,84:105:treatment,107:128:treatment,130:154:treatment,156:177:treatment","Use of other norepinephrine transporter inhibitors such as Wellbutrin (Bupropion), Cymbalta (Duloxetine), Effexor (venlafaxine), Pristiq (desvenlafaxine), Savella (milnacipran)","['Use' 'of' 'other' 'norepinephrine' 'transporter' 'inhibitors' 'such'
 'as' 'Wellbutrin' '(' 'Bupropion' ')' ',' 'Cymbalta' '(' 'Duloxetine' ')'
 ',' 'Effexor' '(' 'venlafaxine' ')' ',' 'Pristiq' '(' 'desvenlafaxine'
 ')' ',' 'Savella' '(' 'milnacipran' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 1. 0. 0. 0. 1. 1. 0. 0. 0. 1.
 1. 0. 0. 0. 1. 1. 0. 0.]"
NCT02780401,",35:62:treatment,64:76:treatment,78:97:treatment,111:127:treatment","Patients must be at least 28 days post cytotoxic chemotherapy, radiotherapy, monoclonal antibody and/or other biologic therapy, prior to enrollment","['Patients' 'must' 'be' 'at' 'least' '28' 'days' 'post' 'cytotoxic'
 'chemotherapy' ',' 'radiotherapy' ',' 'monoclonal' 'antibody' 'and/or'
 'other' 'biologic' 'therapy' ',' 'prior' 'to' 'enrollment']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 1. 0. 1. 1. 0. 0. 1. 1. 0. 0. 0. 0.]
NCT02780271,",18:35:treatment,37:53:treatment,58:75:treatment,76:85:treatment,93:107:treatment,124:140:treatment,161:170:treatment,175:195:treatment","At least 90 days post chemotherapy, biologic therapy, or radiation therapy treatment and/or breast surgery. Current use of hormonal therapy is permitted (e.g., tamoxifen and aromatase inhibitors)","['At' 'least' '90' 'days' 'post' 'chemotherapy' ',' 'biologic' 'therapy'
 ',' 'or' 'radiation' 'therapy' 'treatment' 'and/or' 'breast' 'surgery'
 '.' 'Current' 'use' 'of' 'hormonal' 'therapy' 'is' 'permitted' '(' 'e.g.'
 ',' 'tamoxifen' 'and' 'aromatase' 'inhibitors' ')']","[0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 0. 1. 1. 1. 0. 1. 1. 0. 0. 0. 0. 1. 1. 0.
 0. 0. 0. 0. 1. 0. 1. 1. 0.]"
NCT02776761,"5:42:chronic_disease,54:62:chronic_disease,67:75:chronic_disease","Any chronic or active neurologic disorder, including seizures and epilepsy","['Any' 'chronic' 'or' 'active' 'neurologic' 'disorder' ',' 'including'
 'seizures' 'and' 'epilepsy']",[0. 2. 2. 2. 2. 2. 0. 0. 2. 0. 2.]
NCT02776761,"15:23:treatment,28:37:treatment,41:47:chronic_disease",daily inhaled steroids for treatment of asthma,['daily' 'inhaled' 'steroids' 'for' 'treatment' 'of' 'asthma'],[0. 0. 1. 0. 1. 0. 2.]
NCT02772562,"1:13:chronic_disease,17:42:chronic_disease,51:57:chronic_disease,59:68:chronic_disease","Inflammatory or exfoliative skin diseases such as eczema, psoriasis that disrupt epidermis","['Inflammatory' 'or' 'exfoliative' 'skin' 'diseases' 'such' 'as' 'eczema'
 ',' 'psoriasis' 'that' 'disrupt' 'epidermis']",[2. 0. 2. 2. 2. 0. 0. 2. 0. 2. 0. 0. 0.]
NCT02771626,"1:17:chronic_disease,39:50:treatment,52:62:treatment,67:78:treatment,,117:127:treatment","Active infection requiring parenteral antibiotics, antivirals, or antifungals within 2 weeks prior to first dose of study drug","['Active' 'infection' 'requiring' 'parenteral' 'antibiotics' ','
 'antivirals' ',' 'or' 'antifungals' 'within' '2' 'weeks' 'prior' 'to'
 'first' 'dose' 'of' 'study' 'drug']",[2. 2. 0. 0. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02771626,"1:14:treatment,18:36:treatment,41:62:treatment,","Immunotherapy or biological therapy, or investigational agent within 3 weeks","['Immunotherapy' 'or' 'biological' 'therapy' ',' 'or' 'investigational'
 'agent' 'within' '3' 'weeks']",[1. 0. 1. 1. 0. 0. 1. 1. 0. 0. 0.]
NCT02770326,"63:71:chronic_disease,,110:128:treatment,132:142:cancer",Clinical and microbiologic relapse of C. difficile associated diarrhea after at least one course of adequate antibiotic therapy or refractory disease that does not respond to treatment,"['Clinical' 'and' 'microbiologic' 'relapse' 'of' 'C.' 'difficile'
 'associated' 'diarrhea' 'after' 'at' 'least' 'one' 'course' 'of'
 'adequate' 'antibiotic' 'therapy' 'or' 'refractory' 'disease' 'that'
 'does' 'not' 'respond' 'to' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 3. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02763228,",90:105:treatment,107:119:treatment,123:140:treatment,172:188:treatment,193:209:treatment","Patients who have completed treatment but are within five years of treatment completion (primary surgery, chemotherapy or radiation therapy), whichever was received last. Hormonal therapy and targeted therapy are allowed","['Patients' 'who' 'have' 'completed' 'treatment' 'but' 'are' 'within'
 'five' 'years' 'of' 'treatment' 'completion' '(' 'primary' 'surgery' ','
 'chemotherapy' 'or' 'radiation' 'therapy' ')' ',' 'whichever' 'was'
 'received' 'last' '.' 'Hormonal' 'therapy' 'and' 'targeted' 'therapy'
 'are' 'allowed']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 1. 0. 0. 0.
 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 0.]"
NCT02762006,"25:53:treatment,,94:104:treatment,144:167:treatment,152:166:treatment,171:195:treatment,,257:267:treatment","Current or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid","['Current' 'or' 'prior' 'use' 'of' 'immunosuppressive' 'medication'
 'within' '28' 'days' 'before' 'the' 'first' 'dose' 'of' 'durvalumab' ','
 'with' 'the' 'exceptions' 'of' 'intranasal' 'and' 'inhaled'
 'corticosteroids' 'or' 'systemic' 'corticosteroids' 'at' 'physiological'
 'doses' ',' 'which' 'are' 'not' 'to' 'exceed' '10' 'mg/day' 'of'
 'prednisone' ',' 'or' 'an' 'equivalent' 'corticosteroid']","[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 1.
 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 1.]"
NCT02762006,"8:26:chronic_disease,84:103:chronic_disease,105:116:chronic_disease,137:171:chronic_disease","active bleeding diathesis including any subject known to have evidence of acute or chronic hepatitis B, hepatitis C (detectable RNA) or human immunodeficiency virus (HIV)","['active' 'bleeding' 'diathesis' 'including' 'any' 'subject' 'known' 'to'
 'have' 'evidence' 'of' 'acute' 'or' 'chronic' 'hepatitis' 'B' ','
 'hepatitis' 'C' '(' 'detectable' 'RNA' ')' 'or' 'human'
 'immunodeficiency' 'virus' '(' 'HIV' ')']","[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 2. 2. 2. 2. 0. 0.]"
NCT02759211,"42:57:chronic_disease,59:92:chronic_disease,111:145:chronic_disease,147:185:chronic_disease,187:210:chronic_disease,214:234:chronic_disease,247:250:chronic_disease,252:269:chronic_disease,273:285:chronic_disease,287:311:chronic_disease,313:338:chronic_disease,344:365:chronic_disease","Current self-reported medical history of unstable angina, uncontrolled cardiac dysrhythmias causing symptoms, symptomatic severe aortic stenosis, uncontrolled symptomatic heart failure, acute pulmonary embolus or pulmonary infarction, history of DVT, acute myocarditis or pericarditis, acute systemic infection, uncontrolled hypertension, and uncontrolled diabetes [11]","['Current' 'self-reported' 'medical' 'history' 'of' 'unstable' 'angina'
 ',' 'uncontrolled' 'cardiac' 'dysrhythmias' 'causing' 'symptoms' ','
 'symptomatic' 'severe' 'aortic' 'stenosis' ',' 'uncontrolled'
 'symptomatic' 'heart' 'failure' ',' 'acute' 'pulmonary' 'embolus' 'or'
 'pulmonary' 'infarction' ',' 'history' 'of' 'DVT' ',' 'acute'
 'myocarditis' 'or' 'pericarditis' ',' 'acute' 'systemic' 'infection' ','
 'uncontrolled' 'hypertension' ',' 'and' 'uncontrolled' 'diabetes' '['
 '11' ']']","[0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 2. 2. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0.
 2. 2. 2. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02758847,"39:67:chronic_disease,98:123:treatment,128:155:treatment,159:177:chronic_disease",Patient population: all patients with CLI (critical limb ischemia) and tissue loss scheduled for endovascular intervention for femoral popliteal occlusive or multilevel disease,"['Patient' 'population' ':' 'all' 'patients' 'with' 'CLI' '(' 'critical'
 'limb' 'ischemia' ')' 'and' 'tissue' 'loss' 'scheduled' 'for'
 'endovascular' 'intervention' 'for' 'femoral' 'popliteal' 'occlusive'
 'or' 'multilevel' 'disease']","[0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 1. 0.
 2. 2.]"
NCT02753283,"20:27:treatment,39:53:treatment,55:64:treatment,69:81:treatment,,,173:188:treatment","Those currently on therapy (including bisphosphonate, denosumab, or teriparatide) or who have been on a bisphosphonate for > 1year during the previous 2 years because some bisphosphonates are long acting","['Those' 'currently' 'on' 'therapy' '(' 'including' 'bisphosphonate' ','
 'denosumab' ',' 'or' 'teriparatide' ')' 'or' 'who' 'have' 'been' 'on' 'a'
 'bisphosphonate' 'for' '>' '1year' 'during' 'the' 'previous' '2' 'years'
 'because' 'some' 'bisphosphonates' 'are' 'long' 'acting']","[0. 0. 0. 1. 0. 0. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]"
NCT02748109,"1:21:chronic_disease,77:107:chronic_disease,109:115:chronic_disease,117:129:chronic_disease,131:157:treatment","neurological illness that could potentially explain balance deficits (e.g., Central Nervous System disease, stroke, moderate TBI, lower extremity amputation)","['neurological' 'illness' 'that' 'could' 'potentially' 'explain' 'balance'
 'deficits' '(' 'e.g.' ',' 'Central' 'Nervous' 'System' 'disease' ','
 'stroke' ',' 'moderate' 'TBI' ',' 'lower' 'extremity' 'amputation' ')']","[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 2. 0. 2. 2. 0. 1. 1. 1.
 0.]"
NCT02744391,"21:46:chronic_disease,48:57:chronic_disease,62:72:chronic_disease","DSM 5 non-psychotic Major Depressive Disorder, Dysthymia, or Depression Not Otherwise Specified","['DSM' '5' 'non-psychotic' 'Major' 'Depressive' 'Disorder' ',' 'Dysthymia'
 ',' 'or' 'Depression' 'Not' 'Otherwise' 'Specified']",[0. 0. 0. 2. 2. 2. 0. 2. 0. 0. 2. 0. 0. 0.]
NCT02744391,"56:59:chronic_disease,61:70:chronic_disease,75:89:chronic_disease,97:122:treatment,126:139:treatment","Prefer not to be treated with a standard treatment for MDD, Dysthymia, or Depression NOS (e.g., antidepressant medication or psychotherapy)","['Prefer' 'not' 'to' 'be' 'treated' 'with' 'a' 'standard' 'treatment'
 'for' 'MDD' ',' 'Dysthymia' ',' 'or' 'Depression' 'NOS' '(' 'e.g.' ','
 'antidepressant' 'medication' 'or' 'psychotherapy' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 0. 2. 2. 0. 0. 0. 1. 1. 0. 1.
 0.]"
NCT02743637,"1:40:chronic_disease,,,,,78:89:chronic_disease,,,129:146:treatment","Uncontrolled or refractory hypertension: systolic >180 or diastolic >110, or hypotension: systolic <90 or diastolic <50 despite medical treatment","['Uncontrolled' 'or' 'refractory' 'hypertension' ':' 'systolic' '>' '180'
 'or' 'diastolic' '>' '110' ',' 'or' 'hypotension' ':' 'systolic' '<' '90'
 'or' 'diastolic' '<' '50' 'despite' 'medical' 'treatment']","[2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 1.]"
NCT02740543,"1:19:chronic_disease,28:60:chronic_disease,64:89:chronic_disease",Pulmonary diseases such as Chronic Pulmonary Disease (COPD) or Interstitial Lung Disease,"['Pulmonary' 'diseases' 'such' 'as' 'Chronic' 'Pulmonary' 'Disease' '('
 'COPD' ')' 'or' 'Interstitial' 'Lung' 'Disease']",[2. 2. 0. 0. 2. 2. 2. 2. 0. 0. 0. 2. 2. 2.]
NCT02739620,"1:19:cancer,40:46:cancer,58:82:cancer,104:116:treatment","metastatic disease, a prior history of cancer, excluding non-melanoma skin cancer, or prior receipt of chemotherapy","['metastatic' 'disease' ',' 'a' 'prior' 'history' 'of' 'cancer' ','
 'excluding' 'non-melanoma' 'skin' 'cancer' ',' 'or' 'prior' 'receipt'
 'of' 'chemotherapy']",[3. 3. 0. 0. 0. 0. 0. 3. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 1.]
NCT02737475,"34:46:allergy_name,48:56:allergy_name,61:75:allergy_name","Patients with known allergies to egg products, neomycin, or tetanus toxoid","['Patients' 'with' 'known' 'allergies' 'to' 'egg' 'products' ','
 'neomycin' ',' 'or' 'tetanus' 'toxoid']",[0. 0. 0. 0. 0. 4. 4. 0. 4. 0. 0. 4. 4.]
NCT02734771,"17:30:treatment,35:40:cancer,44:46:chronic_disease,81:91:treatment,,134:142:cancer,179:198:cancer,219:257:treatment","Has received no prior therapy for DLBCL or HT with the exception of a course of prednisone of less than or equal to 7 days given for lymphoma related symptoms; prior therapy for follicular lymphoma is accepted, but no prior anthracycline-containing therapy","['Has' 'received' 'no' 'prior' 'therapy' 'for' 'DLBCL' 'or' 'HT' 'with'
 'the' 'exception' 'of' 'a' 'course' 'of' 'prednisone' 'of' 'less' 'than'
 'or' 'equal' 'to' '7' 'days' 'given' 'for' 'lymphoma' 'related'
 'symptoms' ';' 'prior' 'therapy' 'for' 'follicular' 'lymphoma' 'is'
 'accepted' ',' 'but' 'no' 'prior' 'anthracycline-containing' 'therapy']","[0. 0. 0. 1. 1. 1. 3. 0. 2. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02734602,"42:51:chronic_disease,53:57:chronic_disease,62:78:chronic_disease","No first-degree relative with history of psychotic, mood, or anxiety disorder","['No' 'first-degree' 'relative' 'with' 'history' 'of' 'psychotic' ','
 'mood' ',' 'or' 'anxiety' 'disorder']",[0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 0. 2. 2.]
NCT02728284,"70:78:chronic_disease,82:106:chronic_disease,150:164:chronic_disease","pre-existing medical conditions including a likelihood of developing seizures or claustrophobic reactions, and any greater than normal potential for cardiac arrest","['pre-existing' 'medical' 'conditions' 'including' 'a' 'likelihood' 'of'
 'developing' 'seizures' 'or' 'claustrophobic' 'reactions' ',' 'and' 'any'
 'greater' 'than' 'normal' 'potential' 'for' 'cardiac' 'arrest']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02728050,"16:19:chronic_disease,23:26:chronic_disease,63:66:cancer,129:145:treatment",such high-risk MDS or MPN have natural history much closer to AML than to lower risk MDS or MPN and have responded similarly to AML-type therapy,"['such' 'high-risk' 'MDS' 'or' 'MPN' 'have' 'natural' 'history' 'much'
 'closer' 'to' 'AML' 'than' 'to' 'lower' 'risk' 'MDS' 'or' 'MPN' 'and'
 'have' 'responded' 'similarly' 'to' 'AML-type' 'therapy']","[0. 0. 2. 0. 2. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 1.]"
NCT02725177,"1:17:chronic_disease,,60:83:treatment,142:157:treatment","Anterior uveitis requiring 4 or more daily applications of topical corticosteroids to maintain control of inflammation, or uncontrolled with topical therapy","['Anterior' 'uveitis' 'requiring' '4' 'or' 'more' 'daily' 'applications'
 'of' 'topical' 'corticosteroids' 'to' 'maintain' 'control' 'of'
 'inflammation' ',' 'or' 'uncontrolled' 'with' 'topical' 'therapy']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02724540,"1:17:chronic_disease,31:40:chronic_disease,45:61:chronic_disease",Active infection (Symptomatic bacterial and fungal infection - newly diagnosed and/or requiring treatment),"['Active' 'infection' '(' 'Symptomatic' 'bacterial' 'and' 'fungal'
 'infection' '-' 'newly' 'diagnosed' 'and/or' 'requiring' 'treatment' ')']",[2. 2. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02723266,"13:16:chronic_disease,33:51:chronic_disease,53:65:chronic_disease,,,,","at risk for GDM (such as having metabolic syndrome, pre-diabetes, or BMI > 85%; and an A1C < 6.5%)","['at' 'risk' 'for' 'GDM' '(' 'such' 'as' 'having' 'metabolic' 'syndrome'
 ',' 'pre-diabetes' ',' 'or' 'BMI' '>' '85' '%' ';' 'and' 'an' 'A1C' '<'
 '6.5' '%' ')']","[0. 0. 0. 2. 0. 0. 0. 0. 2. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02715583,"12:18:treatment,51:85:cancer,95:113:cancer",History of biopsy proven or clinically documented castrate resistant prostate cancer which is metastatic to bone as assessed by medical record review,"['History' 'of' 'biopsy' 'proven' 'or' 'clinically' 'documented'
 'castrate' 'resistant' 'prostate' 'cancer' 'which' 'is' 'metastatic' 'to'
 'bone' 'as' 'assessed' 'by' 'medical' 'record' 'review']",[0. 0. 1. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0.]
NCT02706353,",106:121:treatment,123:125:treatment,129:132:treatment,160:169:chronic_disease,171:183:treatment,185:190:chronic_disease,,","At least two injectable lesions (amenable for direct injection or through the use of image guidance such ultrasound [US], CT or MRI) defined as any injectable cutaneous, subcutaneous, nodal, or visceral melanoma lesion >/= 10 mm in longest diameter","['At' 'least' 'two' 'injectable' 'lesions' '(' 'amenable' 'for' 'direct'
 'injection' 'or' 'through' 'the' 'use' 'of' 'image' 'guidance' 'such'
 'ultrasound' '[' 'US' ']' ',' 'CT' 'or' 'MRI' ')' 'defined' 'as' 'any'
 'injectable' 'cutaneous' ',' 'subcutaneous' ',' 'nodal' ',' 'or'
 'visceral' 'melanoma' 'lesion' '>' '/=' '10' 'mm' 'in' 'longest'
 'diameter']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1.
 0. 1. 0. 0. 0. 0. 0. 2. 0. 1. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02706249,"13:37:chronic_disease,44:59:chronic_disease,61:88:chronic_disease,90:115:chronic_disease,117:140:chronic_disease","Established hereditary thrombophilia (e.g. Factor V Leiden, G20210 prothrombin mutation, protein C or S deficiency, antithrombin deficiency)","['Established' 'hereditary' 'thrombophilia' '(' 'e.g' '.' 'Factor' 'V'
 'Leiden' ',' 'G20210' 'prothrombin' 'mutation' ',' 'protein' 'C' 'or' 'S'
 'deficiency' ',' 'antithrombin' 'deficiency' ')']",[0. 2. 2. 0. 0. 0. 2. 2. 2. 0. 2. 2. 2. 0. 2. 2. 2. 2. 2. 0. 2. 2. 0.]
NCT02703272,"25:34:allergy_name,36:52:allergy_name,72:81:allergy_name","Participants with known allergies, hypersensitivity, or intolerance to ibrutinib or its excipients (refer to Investigator's Brochure)","['Participants' 'with' 'known' 'allergies' ',' 'hypersensitivity' ',' 'or'
 'intolerance' 'to' 'ibrutinib' 'or' 'its' 'excipients' '(' 'refer' 'to'
 'Investigator' ""'s"" 'Brochure' ')']",[0. 0. 0. 4. 0. 4. 0. 0. 0. 0. 4. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02702492,"21:34:treatment,39:48:treatment,61:79:cancer,83:86:cancer",Time since the last prior therapy for treatment of advanced solid malignancies or NHL,"['Time' 'since' 'the' 'last' 'prior' 'therapy' 'for' 'treatment' 'of'
 'advanced' 'solid' 'malignancies' 'or' 'NHL']",[0. 0. 0. 0. 1. 1. 0. 1. 0. 0. 3. 3. 0. 3.]
NCT02699697,"12:33:treatment,35:51:treatment,66:81:treatment,127:139:treatment","Changes in systemic chemotherapy, hormonal therapy or the use of bisphosphonates for 4 weeks before and after the delivery of radiotherapy are allowed, but recording and accounting for this in the statistical analysis is required","['Changes' 'in' 'systemic' 'chemotherapy' ',' 'hormonal' 'therapy' 'or'
 'the' 'use' 'of' 'bisphosphonates' 'for' '4' 'weeks' 'before' 'and'
 'after' 'the' 'delivery' 'of' 'radiotherapy' 'are' 'allowed' ',' 'but'
 'recording' 'and' 'accounting' 'for' 'this' 'in' 'the' 'statistical'
 'analysis' 'is' 'required']","[0. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02695043,",,60:70:treatment,72:80:treatment,84:96:treatment","GCS in emergency department of less than 13 (unless due to intubation, sedation or intoxication)","['GCS' 'in' 'emergency' 'department' 'of' 'less' 'than' '13' '(' 'unless'
 'due' 'to' 'intubation' ',' 'sedation' 'or' 'intoxication' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0.]
NCT02692651,"64:76:treatment,78:90:chronic_disease,101:127:chronic_disease,129:138:chronic_disease","Patients with severe-complicated disease that would compromise oral therapy (hypotenstion or shock, ileus or bowel obstruction, megacolon)","['Patients' 'with' 'severe-complicated' 'disease' 'that' 'would'
 'compromise' 'oral' 'therapy' '(' 'hypotenstion' 'or' 'shock' ',' 'ileus'
 'or' 'bowel' 'obstruction' ',' 'megacolon' ')']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 2. 0. 0. 0. 2. 2. 2. 2. 0. 2. 0.]
NCT02688647,"1:18:treatment,22:37:treatment,48:64:treatment,69:81:treatment",Immunosuppressive or cytotoxic drugs including cyclophosphamide and azathioprine,"['Immunosuppressive' 'or' 'cytotoxic' 'drugs' 'including'
 'cyclophosphamide' 'and' 'azathioprine']",[1. 0. 1. 1. 0. 1. 0. 1.]
NCT02688309,"35:65:chronic_disease,145:180:chronic_disease,182:201:chronic_disease,204:212:chronic_disease,214:223:chronic_disease,225:249:chronic_disease,255:270:chronic_disease","Patients with active or suspected ocular or periocular infection, including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases","['Patients' 'with' 'active' 'or' 'suspected' 'ocular' 'or' 'periocular'
 'infection' ',' 'including' 'most' 'viral' 'diseases' 'of' 'the' 'cornea'
 'and' 'conjunctiva' ',' 'including' 'active' 'epithelial' 'herpes'
 'simplex' 'keratitis' '(' 'dendritic' 'keratitis' ')' ',' 'vaccinia' ','
 'varicella' ',' 'mycobacterial' 'infections' ',' 'and' 'fungal'
 'diseases']","[0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.
 2. 2. 0. 2. 2. 0. 0. 2. 0. 2. 0. 2. 2. 0. 0. 2. 2.]"
NCT02682836,"33:36:chronic_disease,,66:78:treatment,82:99:treatment","Receiving treatment regimen for MBC, but no more than 3 previous chemotherapy or biologic regimens","['Receiving' 'treatment' 'regimen' 'for' 'MBC' ',' 'but' 'no' 'more'
 'than' '3' 'previous' 'chemotherapy' 'or' 'biologic' 'regimens']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1.]
NCT02682147,"1:18:treatment,24:35:treatment,40:52:chronic_disease,57:82:chronic_disease","antihypertensives, and medications for osteoporosis and gastrointestinal diseases","['antihypertensives' ',' 'and' 'medications' 'for' 'osteoporosis' 'and'
 'gastrointestinal' 'diseases']",[1. 0. 0. 1. 0. 2. 0. 2. 2.]
NCT02679560,"12:19:chronic_disease,12:28:chronic_disease,59:83:chronic_disease","History of seizure disorder, recent seizure or a document intra-cranial hemorrhage","['History' 'of' 'seizure' 'disorder' ',' 'recent' 'seizure' 'or' 'a'
 'document' 'intra-cranial' 'hemorrhage']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02674984,"1:26:chronic_disease,35:49:chronic_disease,51:77:chronic_disease","Gastrointestinal diseases such as celiac disease, inflammatory bowel disease","['Gastrointestinal' 'diseases' 'such' 'as' 'celiac' 'disease' ','
 'inflammatory' 'bowel' 'disease']",[2. 2. 0. 0. 2. 2. 0. 2. 2. 2.]
NCT02670044,"109:140:chronic_disease,141:180:chronic_disease,182:210:chronic_disease,215:247:chronic_disease","History or evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for neurosensory retinal detachment/central serous chorioretinopathy (CSCR), retinal vein occlusion (RVO), or neovascular macular degeneration","['History' 'or' 'evidence' 'of' 'retinal' 'pathology' 'on'
 'ophthalmologic' 'examination' 'that' 'is' 'considered' 'a' 'risk'
 'factor' 'for' 'neurosensory' 'retinal' 'detachment/central' 'serous'
 'chorioretinopathy' '(' 'CSCR' ')' ',' 'retinal' 'vein' 'occlusion' '('
 'RVO' ')' ',' 'or' 'neovascular' 'macular' 'degeneration']","[0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 2. 2. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2.]"
NCT02669966,"22:34:chronic_disease,22:25:chronic_disease,82:94:chronic_disease,98:101:treatment",The recipient may be HCV antibody negative or anti-HCV antibody positive but HCV RNA negative by PCR,"['The' 'recipient' 'may' 'be' 'HCV' 'antibody' 'negative' 'or' 'anti-HCV'
 'antibody' 'positive' 'but' 'HCV' 'RNA' 'negative' 'by' 'PCR']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 1.]
NCT02666638,"15:30:chronic_disease,32:42:chronic_disease,44:56:cancer","no history of chronic illness, concussion, malignancies, etc","['no' 'history' 'of' 'chronic' 'illness' ',' 'concussion' ','
 'malignancies' ',' 'etc']",[0. 0. 0. 2. 2. 0. 2. 0. 3. 0. 0.]
NCT02665338,"28:49:chronic_disease,86:99:chronic_disease,115:134:chronic_disease",History or MRI evidence of neurological disorder that would lead to local or diffuse brain lesions or significant physical impairment,"['History' 'or' 'MRI' 'evidence' 'of' 'neurological' 'disorder' 'that'
 'would' 'lead' 'to' 'local' 'or' 'diffuse' 'brain' 'lesions' 'or'
 'significant' 'physical' 'impairment']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2.]
NCT02663622,"8:24:treatment,57:60:treatment,62:73:treatment","Use of T cell depletion either ex vivo or in vivo (i.e. ATG, alemtuzumab) is prohibited","['Use' 'of' 'T' 'cell' 'depletion' 'either' 'ex' 'vivo' 'or' 'in' 'vivo'
 '(' 'i.e' '.' 'ATG' ',' 'alemtuzumab' ')' 'is' 'prohibited']",[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0.]
NCT02660528,"23:41:chronic_disease,53:71:chronic_disease,76:102:chronic_disease","History of or current autoimmune disease, including multiple sclerosis and inflammatory bowel disease","['History' 'of' 'or' 'current' 'autoimmune' 'disease' ',' 'including'
 'multiple' 'sclerosis' 'and' 'inflammatory' 'bowel' 'disease']",[0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 0. 2. 2. 2.]
NCT02658565,"42:54:treatment,59:90:treatment,95:128:treatment",must be surgical candidates for complete hysterectomy and bilateral salpingo-oophorectomy and pelvic and aortic lymphadenectomy,"['must' 'be' 'surgical' 'candidates' 'for' 'complete' 'hysterectomy' 'and'
 'bilateral' 'salpingo-oophorectomy' 'and' 'pelvic' 'and' 'aortic'
 'lymphadenectomy']",[0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 1. 1. 1. 1.]
NCT02656706,"15:30:chronic_disease,61:77:chronic_disease,,114:135:chronic_disease,",Patients with unstable angina (anginal symptoms at rest) or new-onset angina (began within the last 3 months) or myocardial infarction within the past 6 months,"['Patients' 'with' 'unstable' 'angina' '(' 'anginal' 'symptoms' 'at'
 'rest' ')' 'or' 'new-onset' 'angina' '(' 'began' 'within' 'the' 'last'
 '3' 'months' ')' 'or' 'myocardial' 'infarction' 'within' 'the' 'past' '6'
 'months']","[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.
 0. 0. 0. 0. 0.]"
NCT02654236,"42:56:chronic_disease,65:81:chronic_disease,83:90:chronic_disease,106:124:chronic_disease,128:150:chronic_disease","Previous history of jaundice or signs of liver diseases such as spider angiomata, ascites, or history of esophageal varices or hepatic encephalopathy","['Previous' 'history' 'of' 'jaundice' 'or' 'signs' 'of' 'liver' 'diseases'
 'such' 'as' 'spider' 'angiomata' ',' 'ascites' ',' 'or' 'history' 'of'
 'esophageal' 'varices' 'or' 'hepatic' 'encephalopathy']",[0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 0. 2. 0. 0. 0. 0. 2. 2. 0. 2. 2.]
NCT02648282,"28:48:chronic_disease,90:106:chronic_disease,119:143:chronic_disease,145:169:chronic_disease,171:189:chronic_disease,193:214:chronic_disease","Patients with uncontrolled intercurrent illness, including but not limited to ongoing or active infection, systematic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric condition that would limit compliance with study requirements","['Patients' 'with' 'uncontrolled' 'intercurrent' 'illness' ',' 'including'
 'but' 'not' 'limited' 'to' 'ongoing' 'or' 'active' 'infection' ','
 'systematic' 'congestive' 'heart' 'failure' ',' 'unstable' 'angina'
 'pectoris' ',' 'cardiac' 'arrhythmia' 'or' 'psychiatric' 'condition'
 'that' 'would' 'limit' 'compliance' 'with' 'study' 'requirements']","[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 2.
 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT02646930,"63:74:treatment,83:94:treatment,99:135:treatment,139:154:treatment,200:218:treatment,","Post-enrollment exclusion will include patients receiving any antibiotics, except prophylaxis for transvaginal oocyte retrieval (TVOR) or glucocorticoids, except nasal preparations, from the time of endometrial biopsy until initial transvaginal ultrasound (TVUS) for pregnancy","['Post-enrollment' 'exclusion' 'will' 'include' 'patients' 'receiving'
 'any' 'antibiotics' ',' 'except' 'prophylaxis' 'for' 'transvaginal'
 'oocyte' 'retrieval' '(' 'TVOR' ')' 'or' 'glucocorticoids' ',' 'except'
 'nasal' 'preparations' ',' 'from' 'the' 'time' 'of' 'endometrial'
 'biopsy' 'until' 'initial' 'transvaginal' 'ultrasound' '(' 'TVUS' ')'
 'for' 'pregnancy']","[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 0. 1. 1. 1. 1. 0. 0. 0. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02642939,"19:31:chronic_disease,33:57:chronic_disease,242:249:chronic_disease","poorly controlled hypertension; congestive heart failure of New York Heart Association (NYHA) Class II or worse (slight limitation of physical activity; comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea)","['poorly' 'controlled' 'hypertension' ';' 'congestive' 'heart' 'failure'
 'of' 'New' 'York' 'Heart' 'Association' '(' 'NYHA' ')' 'Class' 'II' 'or'
 'worse' '(' 'slight' 'limitation' 'of' 'physical' 'activity' ';'
 'comfortable' 'at' 'rest' ',' 'but' 'ordinary' 'physical' 'activity'
 'results' 'in' 'fatigue' ',' 'palpitation' ',' 'or' 'dyspnea' ')']","[0. 0. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0.]"
NCT02639546,"116:143:treatment,145:164:treatment,166:179:treatment","Measurable disease as defined by mINRC, RANO criteria for HGG, RANO criteria for LGG, RECIST v1.1, or evaluable by nuclear medicine techniques, immunocytochemistry, tumor markers, or other reliable measures","['Measurable' 'disease' 'as' 'defined' 'by' 'mINRC' ',' 'RANO' 'criteria'
 'for' 'HGG' ',' 'RANO' 'criteria' 'for' 'LGG' ',' 'RECIST' 'v1.1' ','
 'or' 'evaluable' 'by' 'nuclear' 'medicine' 'techniques' ','
 'immunocytochemistry' ',' 'tumor' 'markers' ',' 'or' 'other' 'reliable'
 'measures']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 1. 1. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0.]"
NCT02639208,"42:54:treatment,91:118:treatment,122:131:treatment,",Patients who did not enroll during their chemotherapy are still eligible to enroll during subsequent hormonal therapy or radiation as long as it is within 6 months of diagnosis,"['Patients' 'who' 'did' 'not' 'enroll' 'during' 'their' 'chemotherapy'
 'are' 'still' 'eligible' 'to' 'enroll' 'during' 'subsequent' 'hormonal'
 'therapy' 'or' 'radiation' 'as' 'long' 'as' 'it' 'is' 'within' '6'
 'months' 'of' 'diagnosis']","[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02639065,"1:39:treatment,24:38:treatment,43:67:treatment,,129:139:treatment","intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid","['intranasal' 'and' 'inhaled' 'corticosteroids' 'or' 'systemic'
 'corticosteroids' 'at' 'physiological' 'doses' ',' 'which' 'are' 'not'
 'to' 'exceed' '10' 'mg/day' 'of' 'prednisone' ',' 'or' 'an' 'equivalent'
 'corticosteroid']","[1. 1. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.
 1.]"
NCT02637349,"30:39:chronic_disease,41:49:chronic_disease,51:65:chronic_disease","Altered mental status (e.g., psychosis, delirium, disorientation)","['Altered' 'mental' 'status' '(' 'e.g.' ',' 'psychosis' ',' 'delirium' ','
 'disorientation' ')']",[0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 2. 0.]
NCT02633163,"17:26:treatment,,75:84:treatment,94:127:treatment,","Having received belimumab within 2 months of Baseline, or having received rituximab or other B cell depleting biologic therapy within 6 months of Baseline","['Having' 'received' 'belimumab' 'within' '2' 'months' 'of' 'Baseline' ','
 'or' 'having' 'received' 'rituximab' 'or' 'other' 'B' 'cell' 'depleting'
 'biologic' 'therapy' 'within' '6' 'months' 'of' 'Baseline']","[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0.
 0.]"
NCT02633163,",43:56:treatment,,81:97:treatment,127:139:treatment",Therapy must include at least 6 months of mycophenolate or at least 3 months of cyclophosphamide followed by mycophenolate or azathioprine,"['Therapy' 'must' 'include' 'at' 'least' '6' 'months' 'of' 'mycophenolate'
 'or' 'at' 'least' '3' 'months' 'of' 'cyclophosphamide' 'followed' 'by'
 'mycophenolate' 'or' 'azathioprine']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 1.]
NCT02632422,"1:10:chronic_disease,17:24:chronic_disease,27:39:chronic_disease,41:63:chronic_disease,65:82:chronic_disease,84:103:chronic_disease,135:159:chronic_disease,200:216:chronic_disease","infection (e.g. bladder), hypertension, cardiovascular disease, pulmonary disease, severe osteoporosis (history of fractures), active heterotopic ossification in the lower extremities, or history of peripheral nerve injury in the legs","['infection' '(' 'e.g' '.' 'bladder' ')' ',' 'hypertension' ','
 'cardiovascular' 'disease' ',' 'pulmonary' 'disease' ',' 'severe'
 'osteoporosis' '(' 'history' 'of' 'fractures' ')' ',' 'active'
 'heterotopic' 'ossification' 'in' 'the' 'lower' 'extremities' ',' 'or'
 'history' 'of' 'peripheral' 'nerve' 'injury' 'in' 'the' 'legs']","[2. 0. 0. 0. 2. 0. 0. 2. 0. 2. 2. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.
 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0.]"
NCT02628535,"8:13:chronic_disease,15:24:chronic_disease,29:54:chronic_disease,65:85:treatment,","Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days of first study drug administration","['Active' 'viral' ',' 'bacterial' ',' 'or' 'systemic' 'fungal' 'infection'
 'requiring' 'parenteral' 'treatment' 'within' '7' 'days' 'of' 'first'
 'study' 'drug' 'administration']",[0. 2. 0. 2. 0. 0. 2. 2. 2. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02628535,"1:21:cancer,23:40:cancer,,,46:62:treatment","pleural mesothelioma, pancreatic cancer: 1-3 prior treatments","['pleural' 'mesothelioma' ',' 'pancreatic' 'cancer' ':' '1-3' 'prior'
 'treatments']",[3. 3. 0. 3. 3. 0. 0. 1. 1.]
NCT02624258,"69:88:allergy_name,90:94:allergy_name,100:110:allergy_name","History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40)","['History' 'of' 'allergy' 'or' 'hypersensitivity' 'to' 'study' 'product'
 'excipients' '(' 'human' 'serum' 'albumin' ',' 'DMSO' ',' 'and' 'Dextran'
 '40' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 4. 4. 0. 4. 0. 0. 4. 4. 0.]
NCT02617589,"17:29:cancer,33:38:cancer,46:58:cancer,62:65:cancer",Newly-diagnosed brain cancer or tumor called glioblastoma or GBM,"['Newly-diagnosed' 'brain' 'cancer' 'or' 'tumor' 'called' 'glioblastoma'
 'or' 'GBM']",[0. 3. 3. 0. 3. 0. 3. 0. 3.]
NCT02616185,"22:42:chronic_disease,74:91:chronic_disease,93:104:chronic_disease,106:117:chronic_disease,119:139:chronic_disease,141:159:chronic_disease,161:189:chronic_disease,191:202:chronic_disease","History of or active autoimmune disorders (including but not limited to: myasthenia gravis, thyroiditis, pneumonitis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, scleroderma) and other conditions that disorganize or alter the immune system","['History' 'of' 'or' 'active' 'autoimmune' 'disorders' '(' 'including'
 'but' 'not' 'limited' 'to' ':' 'myasthenia' 'gravis' ',' 'thyroiditis'
 ',' 'pneumonitis' ',' 'rheumatoid' 'arthritis' ',' 'multiple' 'sclerosis'
 ',' 'systemic' 'lupus' 'erythematosus' ',' 'scleroderma' ')' 'and'
 'other' 'conditions' 'that' 'disorganize' 'or' 'alter' 'the' 'immune'
 'system']","[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 0. 2. 0. 2. 2. 0. 2.
 2. 0. 2. 2. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02615249,",,,155:167:treatment,169:190:treatment,192:208:treatment,212:236:treatment","Inability to become pregnant includes all male subjects and female subjects who are postmenopausal for at least 1 year, or surgically sterile- have had a hysterectomy, bilateral ovariectomy, uterine ablation or bilateral tubal ligation","['Inability' 'to' 'become' 'pregnant' 'includes' 'all' 'male' 'subjects'
 'and' 'female' 'subjects' 'who' 'are' 'postmenopausal' 'for' 'at' 'least'
 '1' 'year' ',' 'or' 'surgically' 'sterile-' 'have' 'had' 'a'
 'hysterectomy' ',' 'bilateral' 'ovariectomy' ',' 'uterine' 'ablation'
 'or' 'bilateral' 'tubal' 'ligation']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0.]"
NCT02614365,"14:26:chronic_disease,28:38:chronic_disease,84:92:chronic_disease","persons with neurological, psychiatry or other clinical conditions likely to cause dementia","['persons' 'with' 'neurological' ',' 'psychiatry' 'or' 'other' 'clinical'
 'conditions' 'likely' 'to' 'cause' 'dementia']",[0. 0. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02611063,"20:34:treatment,80:92:chronic_disease,142:149:treatment,153:163:chronic_disease",Participation in a clinical trial evaluating another preventative strategy for chronic GVHD or ongoing participation in a clinical trial for therapy of acute GVHD,"['Participation' 'in' 'a' 'clinical' 'trial' 'evaluating' 'another'
 'preventative' 'strategy' 'for' 'chronic' 'GVHD' 'or' 'ongoing'
 'participation' 'in' 'a' 'clinical' 'trial' 'for' 'therapy' 'of' 'acute'
 'GVHD']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 2. 2.]
NCT02608125,"28:61:treatment,,106:117:treatment,119:129:treatment,134:145:treatment","Patients who have received prior systemic anticancer therapy ≤ 3 weeks prior to study start (6 weeks for nitrosourea, antibodies, or mitomycin-C)","['Patients' 'who' 'have' 'received' 'prior' 'systemic' 'anticancer'
 'therapy' '≤' '3' 'weeks' 'prior' 'to' 'study' 'start' '(' '6' 'weeks'
 'for' 'nitrosourea' ',' 'antibodies' ',' 'or' 'mitomycin-C' ')']","[0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0.
 1. 0.]"
NCT02607748,"1:24:chronic_disease,49:77:chronic_disease,,124:153:treatment,",Acute Coronary Syndrome group: 40 patients with type 1 myocardial infarction within 21 days prior to the imaging visit and invasive coronary angiography with angiographic evidence of at least a 50% stenosis in one or more coronary arteries,"['Acute' 'Coronary' 'Syndrome' 'group' ':' '40' 'patients' 'with' 'type'
 '1' 'myocardial' 'infarction' 'within' '21' 'days' 'prior' 'to' 'the'
 'imaging' 'visit' 'and' 'invasive' 'coronary' 'angiography' 'with'
 'angiographic' 'evidence' 'of' 'at' 'least' 'a' '50' '%' 'stenosis' 'in'
 'one' 'or' 'more' 'coronary' 'arteries']","[2. 2. 2. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02607514,"1:19:chronic_disease,62:79:chronic_disease,81:103:chronic_disease,105:117:chronic_disease,,,,156:167:chronic_disease,,223:246:chronic_disease,328:348:chronic_disease,350:360:cancer,365:386:chronic_disease","Medical conditions that may make participation unsafe (e.g., diabetes [I & II], cardiovascular disease, hypertension [>140 systolic and/or >90 diastolic], hypotension [<90 systolic and/or <60 diastolic, during screening], orthostatic hypotension [systolic drop of 20 points or 10 point diastolic or heart rate increase by 10], autoimmune disorders, malignancy, or autonomic dysfunction)","['Medical' 'conditions' 'that' 'may' 'make' 'participation' 'unsafe' '('
 'e.g.' ',' 'diabetes' '[' 'I' '&' 'II' ']' ',' 'cardiovascular' 'disease'
 ',' 'hypertension' '[' '>' '140' 'systolic' 'and/or' '>' '90' 'diastolic'
 ']' ',' 'hypotension' '[' '<' '90' 'systolic' 'and/or' '<' '60'
 'diastolic' ',' 'during' 'screening' ']' ',' 'orthostatic' 'hypotension'
 '[' 'systolic' 'drop' 'of' '20' 'points' 'or' '10' 'point' 'diastolic'
 'or' 'heart' 'rate' 'increase' 'by' '10' ']' ',' 'autoimmune' 'disorders'
 ',' 'malignancy' ',' 'or' 'autonomic' 'dysfunction' ')']","[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 2. 2. 0. 2. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 3. 0. 0. 2.
 2. 0.]"
NCT02606045,"20:38:treatment,40:54:treatment,56:63:treatment,65:72:treatment,76:82:treatment","Concomitant use of antiplatelet drugs, anticoagulants, dextran, aspirin or NSAIDs","['Concomitant' 'use' 'of' 'antiplatelet' 'drugs' ',' 'anticoagulants' ','
 'dextran' ',' 'aspirin' 'or' 'NSAIDs']",[0. 0. 0. 1. 1. 0. 1. 0. 1. 0. 1. 0. 1.]
NCT02601027,"10:30:chronic_disease,39:52:chronic_disease,56:72:chronic_disease",Specific mental health issues such as schizophrenia or bipolar disorder,"['Specific' 'mental' 'health' 'issues' 'such' 'as' 'schizophrenia' 'or'
 'bipolar' 'disorder']",[0. 2. 2. 2. 0. 0. 2. 0. 2. 2.]
NCT02600897,"1:25:treatment,31:39:cancer,47:81:treatment","fluorodeoxyglucose (FDG)-avid lymphoma (i.e., positron emission tomography (PET)-positive lymphoma)","['fluorodeoxyglucose' '(' 'FDG' ')' '-avid' 'lymphoma' '(' 'i.e.' ','
 'positron' 'emission' 'tomography' '(' 'PET' ')' '-positive' 'lymphoma'
 ')']",[1. 1. 0. 0. 0. 3. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02595866,"28:35:treatment,,56:71:treatment,92:99:chronic_disease,110:132:treatment,153:162:treatment,167:186:chronic_disease","patients who are receiving therapy beyond month one of initial therapy with no evidence of TB IRIS requiring corticosteroid therapy, or those receiving treatment for latent tuberculosis (INH or alternative) may be eligible after discussion with the protocol P.I","['patients' 'who' 'are' 'receiving' 'therapy' 'beyond' 'month' 'one' 'of'
 'initial' 'therapy' 'with' 'no' 'evidence' 'of' 'TB' 'IRIS' 'requiring'
 'corticosteroid' 'therapy' ',' 'or' 'those' 'receiving' 'treatment' 'for'
 'latent' 'tuberculosis' '(' 'INH' 'or' 'alternative' ')' 'may' 'be'
 'eligible' 'after' 'discussion' 'with' 'the' 'protocol' 'P.I']","[0. 0. 0. 0. 1. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 2. 2. 0. 1. 1. 0. 0. 0. 0.
 1. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02594501,"56:59:allergy_name,61:72:allergy_name,74:82:allergy_name","Known allergy or intolerance to the study medications: ASA, clopidogrel, coumadin and its derivatives","['Known' 'allergy' 'or' 'intolerance' 'to' 'the' 'study' 'medications' ':'
 'ASA' ',' 'clopidogrel' ',' 'coumadin' 'and' 'its' 'derivatives']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 0. 4. 0. 4. 0. 0. 0.]
NCT02594384,"17:34:chronic_disease,38:62:chronic_disease,64:98:chronic_disease,100:111:chronic_disease,115:126:chronic_disease","Past history of tuberculosis (TB) or active infection with TB, human immunodeficiency virus (HIV), hepatitis B or hepatitis C","['Past' 'history' 'of' 'tuberculosis' '(' 'TB' ')' 'or' 'active'
 'infection' 'with' 'TB' ',' 'human' 'immunodeficiency' 'virus' '(' 'HIV'
 ')' ',' 'hepatitis' 'B' 'or' 'hepatitis' 'C']","[0. 0. 0. 2. 2. 0. 0. 0. 2. 2. 2. 2. 0. 2. 2. 2. 2. 0. 0. 0. 2. 2. 0. 0.
 0.]"
NCT02593123,"1:8:chronic_disease,10:23:chronic_disease,28:44:chronic_disease","Medical, psychological, or social condition that, in the opinion of the investigator, may increase the patient's risk or limit the patient's adherence with study requirements","['Medical' ',' 'psychological' ',' 'or' 'social' 'condition' 'that' ','
 'in' 'the' 'opinion' 'of' 'the' 'investigator' ',' 'may' 'increase' 'the'
 'patient' ""'s"" 'risk' 'or' 'limit' 'the' 'patient' ""'s"" 'adherence'
 'with' 'study' 'requirements']","[2. 0. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02592707,"20:29:treatment,33:43:treatment,72:79:cancer,84:92:cancer,124:150:treatment","In countries where sunitinib or everolimus are marketed, patients with GEP NET and lung NET will be progressive under this prior anti-tumor treatment for the respective indication","['In' 'countries' 'where' 'sunitinib' 'or' 'everolimus' 'are' 'marketed'
 ',' 'patients' 'with' 'GEP' 'NET' 'and' 'lung' 'NET' 'will' 'be'
 'progressive' 'under' 'this' 'prior' 'anti-tumor' 'treatment' 'for' 'the'
 'respective' 'indication']","[0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 3. 3. 0. 3. 3. 0. 0. 0. 0. 0. 1. 1. 1.
 0. 0. 0. 0.]"
NCT02592707,"22:36:cancer,102:147:cancer,152:175:cancer",unresectable typical lung carcinoid or atypical lung carcinoid are acceptable (with the exception of Large Cell Bronchial Neuroendocrine Neoplasms and Small Cell Lung Cancers) (Caplin 2015),"['unresectable' 'typical' 'lung' 'carcinoid' 'or' 'atypical' 'lung'
 'carcinoid' 'are' 'acceptable' '(' 'with' 'the' 'exception' 'of' 'Large'
 'Cell' 'Bronchial' 'Neuroendocrine' 'Neoplasms' 'and' 'Small' 'Cell'
 'Lung' 'Cancers' ')' '(' 'Caplin' '2015' ')']","[0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 0. 3. 3. 3.
 3. 0. 0. 0. 0. 0.]"
NCT02592551,"9:28:treatment,33:36:cancer,38:70:treatment,74:109:treatment",Planned resectional surgery for MPM [extrapleural pneumonectomy (EPP) or pleurectomy and decortication (P/D)],"['Planned' 'resectional' 'surgery' 'for' 'MPM' '[' 'extrapleural'
 'pneumonectomy' '(' 'EPP' ')' 'or' 'pleurectomy' 'and' 'decortication'
 '(' 'P/D' ')' ']']",[0. 1. 1. 0. 3. 0. 1. 1. 1. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0.]
NCT02592551,"29:45:cancer,56:76:treatment,110:117:treatment,119:128:treatment,137:152:treatment","Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation, and/or corticosteroids","['Symptomatic' 'or' 'uncontrolled' 'brain' 'metastases' 'requiring'
 'concurrent' 'treatment' ',' 'inclusive' 'of' 'but' 'not' 'limited' 'to'
 'surgery' ',' 'radiation' ',' 'and/or' 'corticosteroids']",[0. 0. 0. 3. 3. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 1.]
NCT02592473,"23:41:treatment,43:59:treatment,64:118:treatment,","Patients on long-term narcotic analgesia, androgen therapy, or GNRH (gonadotropin-releasing hormone) analogue therapy within 2 months of study","['Patients' 'on' 'long-term' 'narcotic' 'analgesia' ',' 'androgen'
 'therapy' ',' 'or' 'GNRH' '(' 'gonadotropin-releasing' 'hormone' ')'
 'analogue' 'therapy' 'within' '2' 'months' 'of' 'study']",[0. 0. 0. 1. 1. 0. 1. 1. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02589977,"7:29:chronic_disease,31:51:chronic_disease,62:81:treatment","known cardiovascular disease, cardiac risk factors or use of cardiac medications","['known' 'cardiovascular' 'disease' ',' 'cardiac' 'risk' 'factors' 'or'
 'use' 'of' 'cardiac' 'medications']",[0. 2. 2. 0. 1. 1. 2. 0. 0. 0. 0. 0.]
NCT02589522,"28:59:treatment,61:74:treatment,,116:120:treatment,,,298:318:treatment,332:354:treatment,,,404:416:treatment,420:431:treatment,477:486:treatment","Patients who have received systemic cytotoxic chemotherapy, immunotherapy for 3 weeks before initiation of planned WBRT or patients who have not recovered from serious (Common Terminology Criteria for Adverse Events [CTCAE] grade 3 or more) adverse events from the previously received agents; for oral targeted agents or any other investigational agents, at least 4 half-lives of the agent (6 weeks for nitrosoureas or mitomycin C) should have elapsed prior to starting study treatment","['Patients' 'who' 'have' 'received' 'systemic' 'cytotoxic' 'chemotherapy'
 ',' 'immunotherapy' 'for' '3' 'weeks' 'before' 'initiation' 'of'
 'planned' 'WBRT' 'or' 'patients' 'who' 'have' 'not' 'recovered' 'from'
 'serious' '(' 'Common' 'Terminology' 'Criteria' 'for' 'Adverse' 'Events'
 '[' 'CTCAE' ']' 'grade' '3' 'or' 'more' ')' 'adverse' 'events' 'from'
 'the' 'previously' 'received' 'agents' ';' 'for' 'oral' 'targeted'
 'agents' 'or' 'any' 'other' 'investigational' 'agents' ',' 'at' 'least'
 '4' 'half-lives' 'of' 'the' 'agent' '(' '6' 'weeks' 'for' 'nitrosoureas'
 'or' 'mitomycin' 'C' ')' 'should' 'have' 'elapsed' 'prior' 'to'
 'starting' 'study' 'treatment']","[0. 0. 0. 0. 1. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 1. 1. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02588612,"1:17:chronic_disease,23:57:chronic_disease,53:56:chronic_disease,59:82:chronic_disease,84:107:chronic_disease,111:149:chronic_disease,211:239:chronic_disease,289:317:chronic_disease,369:381:treatment,646:657:chronic_disease","Active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) or human T-cell lymphotropic virus (HTLV) as minimally defined below: a) Positive serology for HIV. b) Active hepatitis B infection as determined by hepatitis B surface antigen. c) Active hepatitis C infection as determined by hepatitis C RNA; A subject who is HCV antibody positive will be screened for HCV ribonucleic acid (RNA) by any reverse transcriptase (RT) polymerase chain reaction (PCR) or bDNA assay. If HCV antibody is positive, eligibility will be determined based on a negative screening RNA value. d) Positive serology for HTLV 1 or 2","['Active' 'infection' 'with' 'human' 'immunodeficiency' 'virus' '(' 'HIV'
 ')' ',' 'hepatitis' 'B' 'virus' '(' 'HBV' ')' ',' 'hepatitis' 'C' 'virus'
 '(' 'HCV' ')' 'or' 'human' 'T-cell' 'lymphotropic' 'virus' '(' 'HTLV' ')'
 'as' 'minimally' 'defined' 'below' ':' 'a' ')' 'Positive' 'serology'
 'for' 'HIV' '.' 'b' ')' 'Active' 'hepatitis' 'B' 'infection' 'as'
 'determined' 'by' 'hepatitis' 'B' 'surface' 'antigen' '.' 'c' ')'
 'Active' 'hepatitis' 'C' 'infection' 'as' 'determined' 'by' 'hepatitis'
 'C' 'RNA' ';' 'A' 'subject' 'who' 'is' 'HCV' 'antibody' 'positive' 'will'
 'be' 'screened' 'for' 'HCV' 'ribonucleic' 'acid' '(' 'RNA' ')' 'by' 'any'
 'reverse' 'transcriptase' '(' 'RT' ')' 'polymerase' 'chain' 'reaction'
 '(' 'PCR' ')' 'or' 'bDNA' 'assay' '.' 'If' 'HCV' 'antibody' 'is'
 'positive' ',' 'eligibility' 'will' 'be' 'determined' 'based' 'on' 'a'
 'negative' 'screening' 'RNA' 'value' '.' 'd' ')' 'Positive' 'serology'
 'for' 'HTLV' '1' 'or' '2']","[2. 2. 2. 2. 2. 2. 2. 2. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.
 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02588612,"1:15:treatment,27:54:treatment,82:100:treatment","Immune therapy (including monoclonal antibody therapy, checkpoint inhibitors) or biological therapy with no wash-out times required","['Immune' 'therapy' '(' 'including' 'monoclonal' 'antibody' 'therapy' ','
 'checkpoint' 'inhibitors' ')' 'or' 'biological' 'therapy' 'with' 'no'
 'wash-out' 'times' 'required']",[1. 1. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02588612,"1:16:treatment,30:55:treatment,,80:93:treatment",corticosteroids or any other immunosuppressive therapy within 2 weeks prior to leukapheresis,"['corticosteroids' 'or' 'any' 'other' 'immunosuppressive' 'therapy'
 'within' '2' 'weeks' 'prior' 'to' 'leukapheresis']",[1. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1.]
NCT02588326,"21:40:chronic_disease,50:65:chronic_disease,69:73:chronic_disease",No history of major respiratory disease (such as cystic fibrosis or COPD),"['No' 'history' 'of' 'major' 'respiratory' 'disease' '(' 'such' 'as'
 'cystic' 'fibrosis' 'or' 'COPD' ')']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 2. 0. 2. 0.]
NCT02588326,"12:20:treatment,22:29:treatment,31:38:treatment,43:63:treatment,","Use of any systemic, topical, inhaled, or nasal corticosteroid within 30 days prior to enrollment","['Use' 'of' 'any' 'systemic' ',' 'topical' ',' 'inhaled' ',' 'or' 'nasal'
 'corticosteroid' 'within' '30' 'days' 'prior' 'to' 'enrollment']",[0. 0. 0. 1. 0. 1. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02587962,"47:72:cancer,58:72:cancer,74:99:cancer,103:136:cancer,194:201:treatment","Patients must have a histologically confirmed epithelial ovarian cancer, primary peritoneal cancer or fallopian tube solid tumor cancer that is locally advanced or metastatic with no available therapy options that are known to provide clinical benefit per institutional standard of care. (ovarian cancer cohort only)","['Patients' 'must' 'have' 'a' 'histologically' 'confirmed' 'epithelial'
 'ovarian' 'cancer' ',' 'primary' 'peritoneal' 'cancer' 'or' 'fallopian'
 'tube' 'solid' 'tumor' 'cancer' 'that' 'is' 'locally' 'advanced' 'or'
 'metastatic' 'with' 'no' 'available' 'therapy' 'options' 'that' 'are'
 'known' 'to' 'provide' 'clinical' 'benefit' 'per' 'institutional'
 'standard' 'of' 'care' '.' '(' 'ovarian' 'cancer' 'cohort' 'only' ')']","[0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 3. 3. 3. 0. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02587962,"62:99:cancer,157:164:treatment,261:273:cancer",Patients must have histologically or cytologically confirmed head and neck squamous cell carcinoma that is locally advanced or metastatic with no available therapy options that are known to provide clinical benefit per institutional standard of care. (various solid tumors cohort: head and neck squamous cell carcinoma groups only),"['Patients' 'must' 'have' 'histologically' 'or' 'cytologically'
 'confirmed' 'head' 'and' 'neck' 'squamous' 'cell' 'carcinoma' 'that' 'is'
 'locally' 'advanced' 'or' 'metastatic' 'with' 'no' 'available' 'therapy'
 'options' 'that' 'are' 'known' 'to' 'provide' 'clinical' 'benefit' 'per'
 'institutional' 'standard' 'of' 'care' '.' '(' 'various' 'solid' 'tumors'
 'cohort' ':' 'head' 'and' 'neck' 'squamous' 'cell' 'carcinoma' 'groups'
 'only' ')']","[0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02587962,"1:19:treatment,21:52:treatment,56:68:treatment,,107:117:treatment","Prior chemotherapy, targeted small molecule therapy or radiotherapy within 2 weeks prior to first dose of study drug","['Prior' 'chemotherapy' ',' 'targeted' 'small' 'molecule' 'therapy' 'or'
 'radiotherapy' 'within' '2' 'weeks' 'prior' 'to' 'first' 'dose' 'of'
 'study' 'drug']",[1. 1. 0. 1. 1. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02587598,",52:55:cancer,64:73:treatment,94:116:treatment",Elderly subjects (≥ 65 years) with newly diagnosed AML must be treatment naive and unfit for intensive chemotherapy,"['Elderly' 'subjects' '(' '≥' '65' 'years' ')' 'with' 'newly' 'diagnosed'
 'AML' 'must' 'be' 'treatment' 'naive' 'and' 'unfit' 'for' 'intensive'
 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 1. 0. 0. 0. 0. 1. 1.]
NCT02587403,"21:31:cancer,51:63:treatment,,,164:167:cancer,171:174:cancer",Have a known active malignancy present and/or had chemotherapy 12 weeks prior to screening or planned chemotherapy within 12 weeks of enrollment with exception of BCC or SCC,"['Have' 'a' 'known' 'active' 'malignancy' 'present' 'and/or' 'had'
 'chemotherapy' '12' 'weeks' 'prior' 'to' 'screening' 'or' 'planned'
 'chemotherapy' 'within' '12' 'weeks' 'of' 'enrollment' 'with' 'exception'
 'of' 'BCC' 'or' 'SCC']","[0. 0. 0. 0. 3. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 3. 0. 3.]"
NCT02585973,"39:42:treatment,72:94:chronic_disease,106:109:chronic_disease,128:145:chronic_disease","Not deemed a candidate for concurrent CRT for medical reasons, such as uncontrolled infection (including HIV), or uncontrolled diabetes mellitus which in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient","['Not' 'deemed' 'a' 'candidate' 'for' 'concurrent' 'CRT' 'for' 'medical'
 'reasons' ',' 'such' 'as' 'uncontrolled' 'infection' '(' 'including'
 'HIV' ')' ',' 'or' 'uncontrolled' 'diabetes' 'mellitus' 'which' 'in'
 'the' 'opinion' 'of' 'the' 'treating' 'physician' ',' 'would' 'make'
 'this' 'protocol' 'unreasonably' 'hazardous' 'for' 'the' 'patient']","[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 0. 0. 0. 0. 2. 2.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02585791,"34:38:chronic_disease,40:46:chronic_disease,48:62:chronic_disease","Presence of airflow obstruction (COPD, asthma, bronchiectasis)","['Presence' 'of' 'airflow' 'obstruction' '(' 'COPD' ',' 'asthma' ','
 'bronchiectasis' ')']",[0. 0. 0. 0. 0. 2. 0. 2. 0. 2. 0.]
NCT02584647,"32:37:cancer,41:76:cancer,78:109:cancer,","Examples of the latter include basal or squamous cell carcinoma of the skin, in-situ carcinoma of the cervix, and isolated elevation of prostate-specific antigen","['Examples' 'of' 'the' 'latter' 'include' 'basal' 'or' 'squamous' 'cell'
 'carcinoma' 'of' 'the' 'skin' ',' 'in-situ' 'carcinoma' 'of' 'the'
 'cervix' ',' 'and' 'isolated' 'elevation' 'of' 'prostate-specific'
 'antigen']","[0. 0. 0. 0. 0. 3. 0. 3. 3. 3. 3. 3. 3. 0. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02584647,"10:15:cancer,,,25:50:treatment,55:73:treatment",Phase 2: MPNST with 0-3 prior systemic treatments (no prior radiotherapy is necessary),"['Phase' '2' ':' 'MPNST' 'with' '0-3' 'prior' 'systemic' 'treatments' '('
 'no' 'prior' 'radiotherapy' 'is' 'necessary' ')']",[0. 0. 0. 3. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02584647,"8:24:treatment,33:45:treatment,49:65:treatment",Strong CYP3A inhibitors such as ketoconazole or grapefruit juice are not permitted,"['Strong' 'CYP3A' 'inhibitors' 'such' 'as' 'ketoconazole' 'or'
 'grapefruit' 'juice' 'are' 'not' 'permitted']",[0. 1. 1. 0. 0. 1. 0. 1. 1. 0. 0. 0.]
NCT02584647,"10:33:chronic_disease,35:61:chronic_disease,,128:146:chronic_disease",unstable coronary artery disease (myocardial infarction (MI) more than 6 months prior to study entry is permitted); or serious cardiac arrhythmia,"['unstable' 'coronary' 'artery' 'disease' '(' 'myocardial' 'infarction'
 '(' 'MI' ')' 'more' 'than' '6' 'months' 'prior' 'to' 'study' 'entry' 'is'
 'permitted' ')' ';' 'or' 'serious' 'cardiac' 'arrhythmia']","[0. 2. 2. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 2. 2.]"
NCT02584309,"10:37:cancer,,72:103:cancer,120:135:cancer,140:150:cancer,154:189:cancer,214:229:treatment","Prior or second primary malignancies within the last two years (except carcinoma in situ of the cervix, non-metastatic prostate cancer, or basal cell or squamous cell carcinoma of the skin which were treated with local resection only","['Prior' 'or' 'second' 'primary' 'malignancies' 'within' 'the' 'last'
 'two' 'years' '(' 'except' 'carcinoma' 'in' 'situ' 'of' 'the' 'cervix'
 ',' 'non-metastatic' 'prostate' 'cancer' ',' 'or' 'basal' 'cell' 'or'
 'squamous' 'cell' 'carcinoma' 'of' 'the' 'skin' 'which' 'were' 'treated'
 'with' 'local' 'resection' 'only']","[0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 3. 0. 0. 3. 3. 0. 0.
 3. 3. 0. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 1. 1. 0.]"
NCT02584244,"62:72:cancer,74:84:cancer,88:113:cancer,155:161:treatment,171:178:treatment,205:223:treatment","Subjects must have histologically or cytologically confirmed esophageal, colorectal or pancreatic adenocarcinoma (inclusive of high grade dysplasia) on a biopsy prior to surgery and must be scheduled for surgical resection","['Subjects' 'must' 'have' 'histologically' 'or' 'cytologically'
 'confirmed' 'esophageal' ',' 'colorectal' 'or' 'pancreatic'
 'adenocarcinoma' '(' 'inclusive' 'of' 'high' 'grade' 'dysplasia' ')' 'on'
 'a' 'biopsy' 'prior' 'to' 'surgery' 'and' 'must' 'be' 'scheduled' 'for'
 'surgical' 'resection']","[0. 0. 0. 0. 0. 0. 0. 3. 0. 3. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.
 0. 1. 0. 0. 0. 0. 0. 1. 1.]"
NCT02583893,"13:21:cancer,41:65:treatment,94:111:cancer",Evidence of leukemia recurrence after a nadir bone marrow biopsy demonstrates no evidence of residual leukemia,"['Evidence' 'of' 'leukemia' 'recurrence' 'after' 'a' 'nadir' 'bone'
 'marrow' 'biopsy' 'demonstrates' 'no' 'evidence' 'of' 'residual'
 'leukemia']",[0. 0. 3. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 3. 3.]
NCT02583893,"1:11:treatment,18:25:treatment,43:54:treatment,56:68:treatment,70:82:treatment,84:96:treatment,102:114:treatment,","Tacrolimus (e.g. Prograf) Subjects taking fluconozole, voriconizole, itraconazole, posaconazole, and ketokonazole within 72 hours of study drug starting","['Tacrolimus' '(' 'e.g' '.' 'Prograf' ')' 'Subjects' 'taking'
 'fluconozole' ',' 'voriconizole' ',' 'itraconazole' ',' 'posaconazole'
 ',' 'and' 'ketokonazole' 'within' '72' 'hours' 'of' 'study' 'drug'
 'starting']","[1. 0. 0. 0. 1. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02583789,"1:26:chronic_disease,28:45:chronic_disease,58:81:chronic_disease,83:97:chronic_disease,101:122:chronic_disease,,152:162:cancer,175:188:treatment","Uncontrolled hypertension, diabetes mellitus, history of orthostatic hypotension, acute coronary or cerebrovascular event within 3 months, evidence of malignancy, history of sympathectomy","['Uncontrolled' 'hypertension' ',' 'diabetes' 'mellitus' ',' 'history'
 'of' 'orthostatic' 'hypotension' ',' 'acute' 'coronary' 'or'
 'cerebrovascular' 'event' 'within' '3' 'months' ',' 'evidence' 'of'
 'malignancy' ',' 'history' 'of' 'sympathectomy']","[2. 2. 0. 2. 2. 0. 0. 0. 2. 2. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 3. 0.
 0. 0. 1.]"
NCT02583360,"1:22:chronic_disease,,,44:77:chronic_disease,81:110:chronic_disease,112:130:chronic_disease,134:140:chronic_disease","Neurological diseases such as Grade 3 or 4 intraventricular hemorrhage (IVH) or intracranial hemorrhage (ICH), perinatal asphyxia or stroke","['Neurological' 'diseases' 'such' 'as' 'Grade' '3' 'or' '4'
 'intraventricular' 'hemorrhage' '(' 'IVH' ')' 'or' 'intracranial'
 'hemorrhage' '(' 'ICH' ')' ',' 'perinatal' 'asphyxia' 'or' 'stroke']",[2. 2. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 2. 2. 2. 0. 0. 0. 2. 2. 0. 2.]
NCT02582905,"1:15:chronic_disease,27:34:chronic_disease,,,56:80:chronic_disease,100:111:chronic_disease,113:134:chronic_disease,136:149:chronic_disease,196:215:chronic_disease,258:265:chronic_disease","Mood disorders other than bipolar I or II disorders or schizoaffective disorder bipolar type (e.g. bipolar NOS, cyclothymic disorders, schizophrenia, schizoaffective disorder depressive type, or unipolar depression based on the SCID); other disorders (e.g. anxiety, will be allowed)","['Mood' 'disorders' 'other' 'than' 'bipolar' 'I' 'or' 'II' 'disorders'
 'or' 'schizoaffective' 'disorder' 'bipolar' 'type' '(' 'e.g' '.'
 'bipolar' 'NOS' ',' 'cyclothymic' 'disorders' ',' 'schizophrenia' ','
 'schizoaffective' 'disorder' 'depressive' 'type' ',' 'or' 'unipolar'
 'depression' 'based' 'on' 'the' 'SCID' ')' ';' 'other' 'disorders' '('
 'e.g' '.' 'anxiety' ',' 'will' 'be' 'allowed' ')']","[2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2.
 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0.
 0. 0.]"
NCT02582827,"34:42:chronic_disease,51:69:treatment,71:78:treatment,83:95:treatment,","All adverse events (AEs) (except alopecia) of any prior chemotherapy, surgery, or radiotherapy must have resolved to Grade ≤ 1","['All' 'adverse' 'events' '(' 'AEs' ')' '(' 'except' 'alopecia' ')' 'of'
 'any' 'prior' 'chemotherapy' ',' 'surgery' ',' 'or' 'radiotherapy' 'must'
 'have' 'resolved' 'to' 'Grade' '≤' '1']","[0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 1. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02582827,"1:18:treatment,74:96:chronic_disease,101:125:chronic_disease","Electrocardiogram findings suggestive of significant current or previous ischemic heart disease, or left bundle branch block","['Electrocardiogram' 'findings' 'suggestive' 'of' 'significant' 'current'
 'or' 'previous' 'ischemic' 'heart' 'disease' ',' 'or' 'left' 'bundle'
 'branch' 'block']",[1. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 2. 2. 2. 2.]
NCT02582827,"12:23:chronic_disease,35:55:chronic_disease,125:134:treatment","History of retinopathy, including diabetic retinopathy. All patients must be evaluated by an ophthalmologist prior to study treatment","['History' 'of' 'retinopathy' ',' 'including' 'diabetic' 'retinopathy' '.'
 'All' 'patients' 'must' 'be' 'evaluated' 'by' 'an' 'ophthalmologist'
 'prior' 'to' 'study' 'treatment']",[0. 0. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02582827,"1:14:treatment,,65:75:treatment,97:115:treatment,160:173:treatment","Major surgery within 6 weeks before the first administration of study drug; needle aspirations, bone marrow biopsy and other similar procedures are allowable; minor surgery may be allowable following discussion and approval by Medical Monitor","['Major' 'surgery' 'within' '6' 'weeks' 'before' 'the' 'first'
 'administration' 'of' 'study' 'drug' ';' 'needle' 'aspirations' ','
 'bone' 'marrow' 'biopsy' 'and' 'other' 'similar' 'procedures' 'are'
 'allowable' ';' 'minor' 'surgery' 'may' 'be' 'allowable' 'following'
 'discussion' 'and' 'approval' 'by' 'Medical' 'Monitor']","[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0.
 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02582775,"27:36:chronic_disease,48:63:treatment,75:91:chronic_disease,",Active untreated systemic infection at time of transplantation (including active infection with Aspergillus or other mold within 30 days),"['Active' 'untreated' 'systemic' 'infection' 'at' 'time' 'of'
 'transplantation' '(' 'including' 'active' 'infection' 'with'
 'Aspergillus' 'or' 'other' 'mold' 'within' '30' 'days' ')']",[0. 0. 0. 2. 0. 0. 0. 1. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02581982,"14:30:chronic_disease,47:71:treatment,93:118:treatment,,160:175:treatment",Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment,"['Diagnosis' 'of' 'immunodeficiency' 'or' 'is' 'receiving' 'systemic'
 'steroid' 'therapy' 'or' 'any' 'other' 'form' 'of' 'immunosuppressive'
 'therapy' 'within' '7' 'days' 'prior' 'to' 'the' 'first' 'dose' 'of'
 'trial' 'treatment']","[0. 0. 2. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 1.]"
NCT02581982,"1:58:treatment,60:103:treatment,108:157:treatment","Prior therapy with an anti-programmed cell death 1 (PD-1), anti-programmed cell death-ligand 1 (PD-L1), or anti-programmed cell death-ligand 2 (PD-L2) agent","['Prior' 'therapy' 'with' 'an' 'anti-programmed' 'cell' 'death' '1' '('
 'PD-1' ')' ',' 'anti-programmed' 'cell' 'death-ligand' '1' '(' 'PD-L1'
 ')' ',' 'or' 'anti-programmed' 'cell' 'death-ligand' '2' '(' 'PD-L2' ')'
 'agent']","[1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02581215,"10:15:cancer,53:99:treatment,103:135:treatment",Baseline tumor assessment should be performed using high resolution computed tomography (CT) scans or magnetic resonance imaging (MRI),"['Baseline' 'tumor' 'assessment' 'should' 'be' 'performed' 'using' 'high'
 'resolution' 'computed' 'tomography' '(' 'CT' ')' 'scans' 'or' 'magnetic'
 'resonance' 'imaging' '(' 'MRI' ')']",[0. 3. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0. 1. 1. 1. 1. 0. 0.]
NCT02581215,"1:14:treatment,,43:73:treatment,78:91:treatment,92:135:treatment,","Major surgery within 28 days prior to the first dose of protocol therapy, or minor surgery/subcutaneous venous access device placement within 2 days prior to first dose of protocol therapy","['Major' 'surgery' 'within' '28' 'days' 'prior' 'to' 'the' 'first' 'dose'
 'of' 'protocol' 'therapy' ',' 'or' 'minor' 'surgery/subcutaneous'
 'venous' 'access' 'device' 'placement' 'within' '2' 'days' 'prior' 'to'
 'first' 'dose' 'of' 'protocol' 'therapy']","[1. 1. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02581215,"57:83:treatment,87:102:treatment,110:118:treatment,122:133:treatment",Subjects whose disease has progressed after 6 months of last systemic chemotherapy or chemo-radiation in the adjuvant or neoadjuvant setting,"['Subjects' 'whose' 'disease' 'has' 'progressed' 'after' '6' 'months' 'of'
 'last' 'systemic' 'chemotherapy' 'or' 'chemo-radiation' 'in' 'the'
 'adjuvant' 'or' 'neoadjuvant' 'setting']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 1. 0. 0. 1. 0. 1. 0.]
NCT02580604,"32:47:treatment,,109:127:treatment,129:149:treatment","Use of medications (other than bisphosphonates) in the past 6 months known to affect bone metabolism (e.g., thiazide diuretics, oral glucocorticoids)","['Use' 'of' 'medications' '(' 'other' 'than' 'bisphosphonates' ')' 'in'
 'the' 'past' '6' 'months' 'known' 'to' 'affect' 'bone' 'metabolism' '('
 'e.g.' ',' 'thiazide' 'diuretics' ',' 'oral' 'glucocorticoids' ')']","[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.
 1. 1. 0.]"
NCT02579967,",124:136:chronic_disease,138:141:chronic_disease,143:146:chronic_disease,148:152:chronic_disease,154:158:chronic_disease","Chronic elevation in the blood (greater than or equal to 2 documented elevations over a period of 6 months or longer) of a latent virus (EBV, CMV, HHV6, HHV8, etc.)","['Chronic' 'elevation' 'in' 'the' 'blood' '(' 'greater' 'than' 'or'
 'equal' 'to' '2' 'documented' 'elevations' 'over' 'a' 'period' 'of' '6'
 'months' 'or' 'longer' ')' 'of' 'a' 'latent' 'virus' '(' 'EBV' ',' 'CMV'
 ',' 'HHV6' ',' 'HHV8' ',' 'etc' '.' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 2. 2. 0. 2. 0. 2. 0. 2. 0. 2. 0. 0. 0. 0.]"
NCT02579967,",,,75:99:treatment,94:98:treatment,103:107:treatment,,,209:212:treatment,214:217:treatment,222:229:treatment,,413:416:treatment","Left ventricular ejection fraction (LVEF) greater than or equal to 40% by 2D echocardiogram (ECHO) or MUGA, or left ventricular shortening fraction greater than or equal to 20% by ECHO for patients receiving MAC, RIC, or RIC-MMF, or LVEF greater than or equal to 30% if the patient has radiologic evidence of aortic, renal, or coronary artery vasculitis. LVEF greater than or equal to 30% for patients receiving IOC","['Left' 'ventricular' 'ejection' 'fraction' '(' 'LVEF' ')' 'greater'
 'than' 'or' 'equal' 'to' '40' '%' 'by' '2D' 'echocardiogram' '(' 'ECHO'
 ')' 'or' 'MUGA' ',' 'or' 'left' 'ventricular' 'shortening' 'fraction'
 'greater' 'than' 'or' 'equal' 'to' '20' '%' 'by' 'ECHO' 'for' 'patients'
 'receiving' 'MAC' ',' 'RIC' ',' 'or' 'RIC-MMF' ',' 'or' 'LVEF' 'greater'
 'than' 'or' 'equal' 'to' '30' '%' 'if' 'the' 'patient' 'has' 'radiologic'
 'evidence' 'of' 'aortic' ',' 'renal' ',' 'or' 'coronary' 'artery'
 'vasculitis' '.' 'LVEF' 'greater' 'than' 'or' 'equal' 'to' '30' '%' 'for'
 'patients' 'receiving' 'IOC']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 1. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 1. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02579967,"15:49:chronic_disease,53:83:chronic_disease,109:117:cancer,165:189:chronic_disease",Patients with hemophagocytic lymphohistiocytosis or macrophage activation syndrome related to an underlying lymphoma with no other clinical history suggestive of a primary immunodeficiency,"['Patients' 'with' 'hemophagocytic' 'lymphohistiocytosis' 'or'
 'macrophage' 'activation' 'syndrome' 'related' 'to' 'an' 'underlying'
 'lymphoma' 'with' 'no' 'other' 'clinical' 'history' 'suggestive' 'of' 'a'
 'primary' 'immunodeficiency']",[0. 0. 2. 2. 0. 2. 2. 2. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02579096,"16:28:treatment,30:44:treatment,46:56:treatment,58:74:treatment,79:89:treatment","Current use of azathioprine, mercaptopurine, didanosine, cyclophosphamide, or probenecid","['Current' 'use' 'of' 'azathioprine' ',' 'mercaptopurine' ',' 'didanosine'
 ',' 'cyclophosphamide' ',' 'or' 'probenecid']",[0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 1.]
NCT02579044,"130:138:chronic_disease,153:165:chronic_disease,167:183:chronic_disease,185:204:chronic_disease,206:219:chronic_disease,223:236:chronic_disease,245:270:chronic_disease","Other concurrent severe and/or uncontrolled medical disease that could compromise participation in the study (i.e., uncontrolled diabetes, uncontrolled hypertension, severe infection, severe malnutrition, chronic liver or renal disease, active upper GI tract ulceration)","['Other' 'concurrent' 'severe' 'and/or' 'uncontrolled' 'medical' 'disease'
 'that' 'could' 'compromise' 'participation' 'in' 'the' 'study' '(' 'i.e.'
 ',' 'uncontrolled' 'diabetes' ',' 'uncontrolled' 'hypertension' ','
 'severe' 'infection' ',' 'severe' 'malnutrition' ',' 'chronic' 'liver'
 'or' 'renal' 'disease' ',' 'active' 'upper' 'GI' 'tract' 'ulceration' ')']","[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 2. 0. 0.
 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 2. 2. 2. 2. 0.]"
NCT02578901,"12:15:chronic_disease,17:20:chronic_disease,24:27:chronic_disease","History of ITP, TTP or HUS","['History' 'of' 'ITP' ',' 'TTP' 'or' 'HUS']",[0. 0. 2. 0. 2. 0. 2.]
NCT02578901,"54:62:chronic_disease,66:87:chronic_disease,106:129:chronic_disease,131:158:chronic_disease,163:179:chronic_disease,183:200:chronic_disease","Subjects with a past history or current diagnosis of arterial or venous thromboembolic disease including acute coronary syndrome, peripheral vascular disease and retinal arterial or venous thrombosis","['Subjects' 'with' 'a' 'past' 'history' 'or' 'current' 'diagnosis' 'of'
 'arterial' 'or' 'venous' 'thromboembolic' 'disease' 'including' 'acute'
 'coronary' 'syndrome' ',' 'peripheral' 'vascular' 'disease' 'and'
 'retinal' 'arterial' 'or' 'venous' 'thrombosis']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 2. 0. 2.
 2. 0. 0. 0.]"
NCT02578732,"28:53:chronic_disease,85:92:chronic_disease,117:128:chronic_disease,130:139:chronic_disease,141:170:chronic_disease,172:210:chronic_disease","Patients with a history of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies that in the investigator's opinion would put the patient at an increased risk","['Patients' 'with' 'a' 'history' 'of' 'interstitial' 'lung' 'disease' ','
 'history' 'of' 'slowly' 'progressive' 'dyspnea' 'and' 'unproductive'
 'cough' ',' 'sarcoidosis' ',' 'silicosis' ',' 'idiopathic' 'pulmonary'
 'fibrosis' ',' 'pulmonary' 'hypersensitivity' 'pneumonitis' 'or'
 'multiple' 'allergies' 'that' 'in' 'the' 'investigator' ""'s"" 'opinion'
 'would' 'put' 'the' 'patient' 'at' 'an' 'increased' 'risk']","[0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 2. 0. 2. 0. 2. 2.
 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02578641,"18:21:cancer,64:79:treatment,83:90:treatment",undifferentiated NPC* who do not have curative options such as chemo-radiation or surgery,"['undifferentiated' 'NPC' '*' 'who' 'do' 'not' 'have' 'curative' 'options'
 'such' 'as' 'chemo-radiation' 'or' 'surgery']",[0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1.]
NCT02577406,",,,,,389:398:treatment,436:446:treatment,484:495:treatment","Male subjects must agree to practice true abstinence from sexual intercourse or to the use of highly effective contraceptive methods (as described above) with non-pregnant female partners of childbearing potential at screening and throughout the course of the study, and should avoid conception with their partners during the course of the study and for 4 months following the last study treatment (6 months following the last dose of cytarabine; 6 months following the last dose of azacitidine in Canada)","['Male' 'subjects' 'must' 'agree' 'to' 'practice' 'true' 'abstinence'
 'from' 'sexual' 'intercourse' 'or' 'to' 'the' 'use' 'of' 'highly'
 'effective' 'contraceptive' 'methods' '(' 'as' 'described' 'above' ')'
 'with' 'non-pregnant' 'female' 'partners' 'of' 'childbearing' 'potential'
 'at' 'screening' 'and' 'throughout' 'the' 'course' 'of' 'the' 'study' ','
 'and' 'should' 'avoid' 'conception' 'with' 'their' 'partners' 'during'
 'the' 'course' 'of' 'the' 'study' 'and' 'for' '4' 'months' 'following'
 'the' 'last' 'study' 'treatment' '(' '6' 'months' 'following' 'the'
 'last' 'dose' 'of' 'cytarabine' ';' '6' 'months' 'following' 'the' 'last'
 'dose' 'of' 'azacitidine' 'in' 'Canada' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]"
NCT02577406,"42:48:chronic_disease,50:59:chronic_disease,64:79:chronic_disease,70:79:chronic_disease,180:191:treatment,193:210:treatment,225:234:treatment","Subject has active uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment)","['Subject' 'has' 'active' 'uncontrolled' 'systemic' 'fungal' ','
 'bacterial' ',' 'or' 'viral' 'infection' '(' 'defined' 'as' 'ongoing'
 'signs/symptoms' 'related' 'to' 'the' 'infection' 'without' 'improvement'
 'despite' 'appropriate' 'antibiotics' ',' 'antiviral' 'therapy' ','
 'and/or' 'other' 'treatment' ')']","[0. 0. 0. 0. 0. 2. 0. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 0. 1. 1. 0. 0. 0. 1. 0.]"
NCT02577406,"22:49:treatment,53:65:treatment,,104:113:treatment",Subject has received systemic anticancer therapy or radiotherapy < 14 days prior to the start of study treatment,"['Subject' 'has' 'received' 'systemic' 'anticancer' 'therapy' 'or'
 'radiotherapy' '<' '14' 'days' 'prior' 'to' 'the' 'start' 'of' 'study'
 'treatment']",[0. 0. 0. 1. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02577406,"40:68:cancer,78:88:treatment,90:105:treatment,107:122:treatment,127:136:treatment","Subject is suspected or proven to have acute promyelocytic leukemia based on morphology, immunophenotype, molecular assay, or karyotype","['Subject' 'is' 'suspected' 'or' 'proven' 'to' 'have' 'acute'
 'promyelocytic' 'leukemia' 'based' 'on' 'morphology' ','
 'immunophenotype' ',' 'molecular' 'assay' ',' 'or' 'karyotype']",[0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 0. 1. 0. 1. 0. 1. 1. 0. 0. 1.]
NCT02577406,",,52:73:treatment,77:112:treatment,,165:174:treatment",left ventricular ejection fraction (LVEF) < 40% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan obtained within 28 days prior to the start of study treatment,"['left' 'ventricular' 'ejection' 'fraction' '(' 'LVEF' ')' '<' '40' '%'
 'by' 'echocardiogram' '(' 'ECHO' ')' 'or' 'multi-gated' 'acquisition' '('
 'MUGA' ')' 'scan' 'obtained' 'within' '28' 'days' 'prior' 'to' 'the'
 'start' 'of' 'study' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02576444,",,,,,189:213:treatment,210:212:treatment,217:249:treatment,245:248:treatment,266:274:treatment,278:291:treatment,392:403:treatment","At least one lesion, not previously irradiated, that can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes which must have short axis ≥ 15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI) or ≥ 10 mm with calipers by clinical exam OR At least one lesion (measurable and/or non-measurable) that can be accurately assessed by CT/MRI/plain x-ray/clinical exam at baseline and follow up visits","['At' 'least' 'one' 'lesion' ',' 'not' 'previously' 'irradiated' ','
 'that' 'can' 'be' 'accurately' 'measured' 'at' 'baseline' 'as' '≥' '10'
 'mm' 'in' 'the' 'longest' 'diameter' '(' 'except' 'lymph' 'nodes' 'which'
 'must' 'have' 'short' 'axis' '≥' '15' 'mm' ')' 'with' 'computed'
 'tomography' '(' 'CT' ')' 'or' 'magnetic' 'resonance' 'imaging' '(' 'MRI'
 ')' 'or' '≥' '10' 'mm' 'with' 'calipers' 'by' 'clinical' 'exam' 'OR' 'At'
 'least' 'one' 'lesion' '(' 'measurable' 'and/or' 'non-measurable' ')'
 'that' 'can' 'be' 'accurately' 'assessed' 'by' 'CT/MRI/plain'
 'x-ray/clinical' 'exam' 'at' 'baseline' 'and' 'follow' 'up' 'visits']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 1. 1. 1. 1.
 1. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]"
NCT02576444,"72:88:chronic_disease,90:120:chronic_disease,124:130:chronic_disease,132:154:chronic_disease,211:233:chronic_disease,235:262:chronic_disease,274:296:chronic_disease,300:309:treatment,317:337:chronic_disease","Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, superior vena cava syndrome, extensive bilateral lung disease on HRCT scan or any psychiatric disorder that prohibits obtaining informed consent","['Patients' 'considered' 'a' 'poor' 'medical' 'risk' 'due' 'to' 'a'
 'serious' ',' 'uncontrolled' 'medical' 'disorder' ',' 'non-malignant'
 'systemic' 'disease' 'or' 'active' ',' 'uncontrolled' 'infection' '.'
 'Examples' 'include' ',' 'but' 'are' 'not' 'limited' 'to' ','
 'uncontrolled' 'ventricular' 'arrhythmia' ',' 'superior' 'vena' 'cava'
 'syndrome' ',' 'extensive' 'bilateral' 'lung' 'disease' 'on' 'HRCT'
 'scan' 'or' 'any' 'psychiatric' 'disorder' 'that' 'prohibits' 'obtaining'
 'informed' 'consent']","[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 2. 2. 0. 0. 2. 2. 2. 0. 1.
 1. 0. 0. 2. 2. 0. 0. 0. 0. 0.]"
NCT02576444,"66:81:chronic_disease,89:105:chronic_disease,145:163:treatment","Patients with known (testing is not part of the protocol) active hepatic disease (i.e., Hepatitis B or C) due to risk of drug interactions with anti-viral therapy","['Patients' 'with' 'known' '(' 'testing' 'is' 'not' 'part' 'of' 'the'
 'protocol' ')' 'active' 'hepatic' 'disease' '(' 'i.e.' ',' 'Hepatitis'
 'B' 'or' 'C' ')' 'due' 'to' 'risk' 'of' 'drug' 'interactions' 'with'
 'anti-viral' 'therapy']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 2. 2. 2. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 1.]"
NCT02576444,"41:66:chronic_disease,73:99:chronic_disease,116:131:treatment","Refractory nausea and vomiting, chronic gastrointestinal diseases (e.g. inflammatory bowel disease) or significant bowel resection that would preclude adequate absorption","['Refractory' 'nausea' 'and' 'vomiting' ',' 'chronic' 'gastrointestinal'
 'diseases' '(' 'e.g' '.' 'inflammatory' 'bowel' 'disease' ')' 'or'
 'significant' 'bowel' 'resection' 'that' 'would' 'preclude' 'adequate'
 'absorption']",[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02575404,"22:40:chronic_disease,52:74:chronic_disease,78:86:chronic_disease",Patients with active autoimmune disease except for autoimmune thyroiditis or vitiligo,"['Patients' 'with' 'active' 'autoimmune' 'disease' 'except' 'for'
 'autoimmune' 'thyroiditis' 'or' 'vitiligo']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 2.]
NCT02574910,"1:40:chronic_disease,52:77:chronic_disease,133:152:treatment",Concurrent medical condition or disease other than 21-hydroxylase deficiency that may interfere with linear growth or that requires concomitant therapy that is likely to interfere with study procedures or results,"['Concurrent' 'medical' 'condition' 'or' 'disease' 'other' 'than'
 '21-hydroxylase' 'deficiency' 'that' 'may' 'interfere' 'with' 'linear'
 'growth' 'or' 'that' 'requires' 'concomitant' 'therapy' 'that' 'is'
 'likely' 'to' 'interfere' 'with' 'study' 'procedures' 'or' 'results']","[2. 2. 2. 2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02574910,"1:61:treatment,63:90:treatment,92:104:treatment,106:118:treatment,120:134:treatment,136:146:treatment,148:158:treatment,160:170:treatment,172:185:treatment,187:196:treatment,198:207:treatment,209:219:treatment,221:233:treatment,239:254:treatment,262:271:treatment,273:286:treatment,288:296:treatment,298:307:treatment,309:320:treatment,322:335:treatment","Treatment with potentially hepatotoxic medications (statins); strong inhibitors of CYP3A4 (ketoconazole, itraconazole, clarithromycin, atazanavir, nefazodone, saquinavir, telithromycin, ritonavir, indinavir, nelfinavir, voriconazole), or CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital)","['Treatment' 'with' 'potentially' 'hepatotoxic' 'medications' '('
 'statins' ')' ';' 'strong' 'inhibitors' 'of' 'CYP3A4' '(' 'ketoconazole'
 ',' 'itraconazole' ',' 'clarithromycin' ',' 'atazanavir' ',' 'nefazodone'
 ',' 'saquinavir' ',' 'telithromycin' ',' 'ritonavir' ',' 'indinavir' ','
 'nelfinavir' ',' 'voriconazole' ')' ',' 'or' 'CYP3A4' 'inducers' '('
 'e.g.' ',' 'phenytoin' ',' 'carbamazepine' ',' 'rifampin' ',' 'rifabutin'
 ',' 'rifapentine' ',' 'phenobarbital' ')']","[1. 1. 1. 1. 1. 1. 0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0.
 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1.
 0. 1. 0. 1. 0. 1. 0.]"
NCT02573883,"1:31:treatment,33:43:treatment,45:57:treatment","topical calcineurin inhibitors (tacrolimus, pimecrolimus)","['topical' 'calcineurin' 'inhibitors' '(' 'tacrolimus' ',' 'pimecrolimus'
 ')']",[1. 1. 1. 0. 1. 0. 1. 0.]
NCT02573493,"1:19:treatment,21:48:treatment,53:76:treatment,81:86:cancer","Prior chemotherapy, prior EGFR targeted therapy, or prior radiation therapy for HNSCC","['Prior' 'chemotherapy' ',' 'prior' 'EGFR' 'targeted' 'therapy' ',' 'or'
 'prior' 'radiation' 'therapy' 'for' 'HNSCC']",[1. 1. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 3.]
NCT02573376,"76:86:treatment,97:110:treatment,112:157:treatment,159:171:treatment,173:183:treatment","Medications not recommended per the SOF/LDV prescribing information (e.g., tipranavir and other P-gp inducers, tenofovir disoproxil fumarate plus cobicistat, rosuvastatin, amiodarone)","['Medications' 'not' 'recommended' 'per' 'the' 'SOF/LDV' 'prescribing'
 'information' '(' 'e.g.' ',' 'tipranavir' 'and' 'other' 'P-gp' 'inducers'
 ',' 'tenofovir' 'disoproxil' 'fumarate' 'plus' 'cobicistat' ','
 'rosuvastatin' ',' 'amiodarone' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 1. 0. 1. 1. 1. 1. 1. 0. 1.
 0. 1. 0.]"
NCT02573246,"26:35:treatment,47:60:treatment,104:124:treatment,",Has any of the following treatment histories: TMS treatment at any point in their lifetime; use of any investigational drug or device within 4 weeks of the screening,"['Has' 'any' 'of' 'the' 'following' 'treatment' 'histories' ':' 'TMS'
 'treatment' 'at' 'any' 'point' 'in' 'their' 'lifetime' ';' 'use' 'of'
 'any' 'investigational' 'drug' 'or' 'device' 'within' '4' 'weeks' 'of'
 'the' 'screening']","[0. 0. 0. 0. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02573246,"47:57:chronic_disease,59:66:chronic_disease,68:88:chronic_disease,90:97:chronic_disease,99:110:chronic_disease,112:118:chronic_disease,123:129:chronic_disease,134:158:chronic_disease","Meets diagnostic criteria for a current DSM-5 depressive, anxiety, obsessive-compulsive, somatic, personality, eating, or trauma and stress-related disorders (including in partial remission)","['Meets' 'diagnostic' 'criteria' 'for' 'a' 'current' 'DSM-5' 'depressive'
 ',' 'anxiety' ',' 'obsessive-compulsive' ',' 'somatic' ',' 'personality'
 ',' 'eating' ',' 'or' 'trauma' 'and' 'stress-related' 'disorders' '('
 'including' 'in' 'partial' 'remission' ')']","[0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 2. 0. 2. 0. 2. 0. 2. 0. 0. 2. 0. 2. 2.
 0. 0. 0. 0. 0. 0.]"
NCT02572791,",59:75:chronic_disease,100:127:treatment,140:148:treatment,168:191:treatment","Patients with traditional risk factors for HA-MRSA (e.g., immunodeficiency, indwelling catheter or percutaneous medical device, undergoing dialysis, presenting with a surgical site infection, or residing in a long-term care facility within the past year)","['Patients' 'with' 'traditional' 'risk' 'factors' 'for' 'HA-MRSA' '('
 'e.g.' ',' 'immunodeficiency' ',' 'indwelling' 'catheter' 'or'
 'percutaneous' 'medical' 'device' ',' 'undergoing' 'dialysis' ','
 'presenting' 'with' 'a' 'surgical' 'site' 'infection' ',' 'or' 'residing'
 'in' 'a' 'long-term' 'care' 'facility' 'within' 'the' 'past' 'year' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 1. 1. 1. 0. 0. 1. 0. 0. 0.
 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02572323,"37:62:treatment,71:77:treatment,124:148:treatment,153:167:treatment,237:246:treatment","Anticipated need to start new daily anti-inflammatory therapy such as NSAIDs (excluding aspirin for vascular prophylaxis), systemic corticosteroids, or anti-malarials, or plan to discontinue regular dosing with these drugs during study treatment","['Anticipated' 'need' 'to' 'start' 'new' 'daily' 'anti-inflammatory'
 'therapy' 'such' 'as' 'NSAIDs' '(' 'excluding' 'aspirin' 'for' 'vascular'
 'prophylaxis' ')' ',' 'systemic' 'corticosteroids' ',' 'or'
 'anti-malarials' ',' 'or' 'plan' 'to' 'discontinue' 'regular' 'dosing'
 'with' 'these' 'drugs' 'during' 'study' 'treatment']","[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02572323,"12:49:chronic_disease,111:117:chronic_disease,132:150:chronic_disease,152:181:chronic_disease,193:220:chronic_disease","History of neurocognitive confounding conditions that explain current impairment including but not limited to stroke, head injury, psychotic disorder, active substance use disorder by DSM, or opportunistic CNS infection","['History' 'of' 'neurocognitive' 'confounding' 'conditions' 'that'
 'explain' 'current' 'impairment' 'including' 'but' 'not' 'limited' 'to'
 'stroke' ',' 'head' 'injury' ',' 'psychotic' 'disorder' ',' 'active'
 'substance' 'use' 'disorder' 'by' 'DSM' ',' 'or' 'opportunistic' 'CNS'
 'infection']","[0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 2. 2. 0. 2. 2.
 2. 2. 0. 0. 0. 0. 2. 2. 2.]"
NCT02570984,",36:44:chronic_disease,49:71:chronic_disease,75:80:chronic_disease,","More than four days of symptoms of wheezing, or tightness in the chest or cough in the past two weeks causing at least minimal limitation of activity","['More' 'than' 'four' 'days' 'of' 'symptoms' 'of' 'wheezing' ',' 'or'
 'tightness' 'in' 'the' 'chest' 'or' 'cough' 'in' 'the' 'past' 'two'
 'weeks' 'causing' 'at' 'least' 'minimal' 'limitation' 'of' 'activity']","[0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 2. 2. 2. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02570854,"20:35:chronic_disease,37:59:cancer,61:81:cancer,85:109:cancer","Known diagnosis of hemochromatosis, bone marrow malignancy, lymphatic malignancy or myelodysplastic syndrome","['Known' 'diagnosis' 'of' 'hemochromatosis' ',' 'bone' 'marrow'
 'malignancy' ',' 'lymphatic' 'malignancy' 'or' 'myelodysplastic'
 'syndrome']",[0. 0. 0. 2. 0. 3. 3. 3. 0. 3. 3. 0. 3. 3.]
NCT02570672,"28:41:chronic_disease,,,99:116:chronic_disease,118:125:chronic_disease,208:220:treatment",History of moderate-severe heart disease (New York Heart Classification greater than grade II) or pulmonary disease (dyspnea on exertion upon climbing one flight of stairs or less; abnormal breath sounds on auscultation),"['History' 'of' 'moderate-severe' 'heart' 'disease' '(' 'New' 'York'
 'Heart' 'Classification' 'greater' 'than' 'grade' 'II' ')' 'or'
 'pulmonary' 'disease' '(' 'dyspnea' 'on' 'exertion' 'upon' 'climbing'
 'one' 'flight' 'of' 'stairs' 'or' 'less' ';' 'abnormal' 'breath' 'sounds'
 'on' 'auscultation' ')']","[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]"
NCT02568267,"7:32:chronic_disease,47:55:chronic_disease,105:116:chronic_disease","Known interstitial lung disease, interstitial fibrosis, or history of tyrosine kinase inhibitor-induced pneumonitis","['Known' 'interstitial' 'lung' 'disease' ',' 'interstitial' 'fibrosis' ','
 'or' 'history' 'of' 'tyrosine' 'kinase' 'inhibitor-induced' 'pneumonitis']",[0. 2. 2. 2. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02567448,"21:26:allergy_name,28:37:allergy_name,41:50:allergy_name","hypersensitivity to Afrin, Lidocaine or albuterol","['hypersensitivity' 'to' 'Afrin' ',' 'Lidocaine' 'or' 'albuterol']",[0. 0. 4. 0. 4. 0. 4.]
NCT02567422,"12:28:chronic_disease,39:62:treatment,78:87:treatment",Ongoing or active infection requiring intravenous antibiotics at the time of treatment initiation,"['Ongoing' 'or' 'active' 'infection' 'requiring' 'intravenous'
 'antibiotics' 'at' 'the' 'time' 'of' 'treatment' 'initiation']",[0. 0. 2. 2. 0. 1. 1. 0. 0. 0. 0. 1. 0.]
NCT02567266,"40:63:chronic_disease,113:140:chronic_disease,276:283:treatment","Adolescents with a reported history of intellectual disability or for whom there is substantial evidence (e.g., multiple learning disorders, extensive school-based accommodations for learning) that the cognitive level of the UP-A would make it inappropriate as an individual therapy modality, as determined via Family Background Questionnaire and/or based on PI judgement","['Adolescents' 'with' 'a' 'reported' 'history' 'of' 'intellectual'
 'disability' 'or' 'for' 'whom' 'there' 'is' 'substantial' 'evidence' '('
 'e.g.' ',' 'multiple' 'learning' 'disorders' ',' 'extensive'
 'school-based' 'accommodations' 'for' 'learning' ')' 'that' 'the'
 'cognitive' 'level' 'of' 'the' 'UP-A' 'would' 'make' 'it' 'inappropriate'
 'as' 'an' 'individual' 'therapy' 'modality' ',' 'as' 'determined' 'via'
 'Family' 'Background' 'Questionnaire' 'and/or' 'based' 'on' 'PI'
 'judgement']","[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02567227,"5:22:chronic_disease,26:44:treatment,56:68:treatment,133:149:chronic_disease,,","Any medical condition or chronic medication use (e.g., neuroleptics) that will compromise safety or affect cognitive functioning or terminal illness with life expectancy less than 12 months","['Any' 'medical' 'condition' 'or' 'chronic' 'medication' 'use' '(' 'e.g.'
 ',' 'neuroleptics' ')' 'that' 'will' 'compromise' 'safety' 'or' 'affect'
 'cognitive' 'functioning' 'or' 'terminal' 'illness' 'with' 'life'
 'expectancy' 'less' 'than' '12' 'months']","[0. 2. 2. 0. 1. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02566304,"28:39:treatment,43:65:treatment,,88:98:treatment,131:140:treatment",Patients who have received alemtuzumab or antithymocyte globulin within 8 weeks of the transplant admission. The absence of these therapies in the medical record will serve as documentation that they were not given,"['Patients' 'who' 'have' 'received' 'alemtuzumab' 'or' 'antithymocyte'
 'globulin' 'within' '8' 'weeks' 'of' 'the' 'transplant' 'admission' '.'
 'The' 'absence' 'of' 'these' 'therapies' 'in' 'the' 'medical' 'record'
 'will' 'serve' 'as' 'documentation' 'that' 'they' 'were' 'not' 'given']","[0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02565901,"1:20:chronic_disease,31:49:chronic_disease,68:75:treatment","Atrial fibrillation, or other cardiac arrhythmia requiring medical therapy","['Atrial' 'fibrillation' ',' 'or' 'other' 'cardiac' 'arrhythmia'
 'requiring' 'medical' 'therapy']",[2. 2. 0. 0. 0. 2. 2. 0. 0. 1.]
NCT02565901,"17:35:cancer,48:72:treatment,76:100:treatment,94:100:treatment,119:149:cancer,151:157:cancer,159:164:cancer,168:175:cancer,179:190:cancer,194:210:cancer","The presence of metastatic disease amenable to computed tomography (CT) or ultrasound guided biopsy; this may include thoracolumbar vertebral bodies, pelvis, femur or humerus or soft tissue or nodal metastasis amenable to biopsy","['The' 'presence' 'of' 'metastatic' 'disease' 'amenable' 'to' 'computed'
 'tomography' '(' 'CT' ')' 'or' 'ultrasound' 'guided' 'biopsy' ';' 'this'
 'may' 'include' 'thoracolumbar' 'vertebral' 'bodies' ',' 'pelvis' ','
 'femur' 'or' 'humerus' 'or' 'soft' 'tissue' 'or' 'nodal' 'metastasis'
 'amenable' 'to' 'biopsy']","[0. 0. 0. 3. 3. 0. 0. 1. 1. 1. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 3. 3. 3. 0.
 3. 0. 3. 0. 3. 0. 3. 3. 0. 3. 3. 0. 0. 0.]"
NCT02565498,"12:22:cancer,64:84:cancer,100:117:cancer",concurrent malignancy with the exception of adequately treated basal cell carcinoma of the skin or carcinoma in-situ of the cervix,"['concurrent' 'malignancy' 'with' 'the' 'exception' 'of' 'adequately'
 'treated' 'basal' 'cell' 'carcinoma' 'of' 'the' 'skin' 'or' 'carcinoma'
 'in-situ' 'of' 'the' 'cervix']",[0. 3. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02565407,"25:49:treatment,56:75:treatment,84:109:treatment",Is currently taking any pro-epileptic medication (e.g. epileptogenic drugs such as tricyclic antidepressants),"['Is' 'currently' 'taking' 'any' 'pro-epileptic' 'medication' '(' 'e.g'
 '.' 'epileptogenic' 'drugs' 'such' 'as' 'tricyclic' 'antidepressants' ')']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 1. 0. 0. 1. 1. 0.]
NCT02564978,"27:37:treatment,73:84:treatment,93:107:treatment",Participant is taking any medication that could adversely interact with minocycline such as methoxyflurane,"['Participant' 'is' 'taking' 'any' 'medication' 'that' 'could' 'adversely'
 'interact' 'with' 'minocycline' 'such' 'as' 'methoxyflurane']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 1. 0. 0. 1.]
NCT02564744,"29:51:cancer,53:62:cancer,67:83:cancer,94:110:cancer","Participants who have known central nervous system, meningeal, or epidural disease including brain metastases","['Participants' 'who' 'have' 'known' 'central' 'nervous' 'system' ','
 'meningeal' ',' 'or' 'epidural' 'disease' 'including' 'brain'
 'metastases']",[0. 0. 0. 0. 3. 3. 3. 0. 3. 0. 0. 3. 3. 0. 3. 3.]
NCT02563678,"51:73:chronic_disease,75:102:chronic_disease,104:111:chronic_disease,115:161:chronic_disease,163:181:chronic_disease,183:206:chronic_disease,208:235:chronic_disease,237:243:chronic_disease,245:251:chronic_disease,253:269:chronic_disease,273:286:chronic_disease,288:307:chronic_disease,309:326:chronic_disease,331:345:chronic_disease,346:361:chronic_disease","History of significant health problems, including metabolic bone disease, skeletal muscle pathologies, cardiac or peripheral cardiovascular system abnormalities, clotting disorders, coronary artery disease, peripheral vascular disease, stroke, cancer, high cholesterol or triglycerides, high blood pressure, diabetes mellitus, or impaired liver/kidney function","['History' 'of' 'significant' 'health' 'problems' ',' 'including'
 'metabolic' 'bone' 'disease' ',' 'skeletal' 'muscle' 'pathologies' ','
 'cardiac' 'or' 'peripheral' 'cardiovascular' 'system' 'abnormalities' ','
 'clotting' 'disorders' ',' 'coronary' 'artery' 'disease' ',' 'peripheral'
 'vascular' 'disease' ',' 'stroke' ',' 'cancer' ',' 'high' 'cholesterol'
 'or' 'triglycerides' ',' 'high' 'blood' 'pressure' ',' 'diabetes'
 'mellitus' ',' 'or' 'impaired' 'liver/kidney' 'function']","[0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 2. 2. 2. 0. 2. 0. 2. 2. 2. 2. 0. 2. 2.
 0. 2. 2. 2. 0. 0. 0. 0. 0. 2. 0. 2. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 2. 2.
 0. 0. 2. 2. 2.]"
NCT02563678,",12:29:treatment,102:133:chronic_disease,137:161:chronic_disease",at least 4 hyperbaric oxygen sessions for chronic clinical indications (possible indications include diabetic lower extremity wounds or refractory osteomyelitis),"['at' 'least' '4' 'hyperbaric' 'oxygen' 'sessions' 'for' 'chronic'
 'clinical' 'indications' '(' 'possible' 'indications' 'include'
 'diabetic' 'lower' 'extremity' 'wounds' 'or' 'refractory' 'osteomyelitis'
 ')']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 2. 2. 0.]
NCT02562755,"19:35:chronic_disease,69:72:chronic_disease,73:77:chronic_disease","Known significant immunodeficiency due to underlying illness (e.g., HIV/AIDS)","['Known' 'significant' 'immunodeficiency' 'due' 'to' 'underlying'
 'illness' '(' 'e.g.' ',' 'HIV/AIDS' ')']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 2. 0.]
NCT02562430,"53:56:treatment,58:61:treatment,65:69:treatment","Receiving or have received during the index episode VNS, ECT or rTMS","['Receiving' 'or' 'have' 'received' 'during' 'the' 'index' 'episode' 'VNS'
 ',' 'ECT' 'or' 'rTMS']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1.]
NCT02562430,"30:44:chronic_disease,46:59:chronic_disease,61:65:chronic_disease,67:70:chronic_disease,75:78:chronic_disease","current primary diagnoses of panic disorder, social phobia, PTSD, GAD, or OCD","['current' 'primary' 'diagnoses' 'of' 'panic' 'disorder' ',' 'social'
 'phobia' ',' 'PTSD' ',' 'GAD' ',' 'or' 'OCD']",[0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 2. 0. 2. 0. 0. 2.]
NCT02562235,"34:45:treatment,47:83:treatment,93:103:treatment,105:114:treatment,116:126:treatment,145:179:treatment,181:193:treatment,195:207:treatment,210:218:treatment,241:253:treatment","Concomitant use of the following medications: phosphodiesterase (PDE) 5 inhibitors (such as sildenafil, tadalafil, vardenafil) and non-specific phosphodiesterase (PDE) inhibitors (theophylline, dipyridamole), nitrates or NO donors (such as amyl nitrite) in any form","['Concomitant' 'use' 'of' 'the' 'following' 'medications' ':'
 'phosphodiesterase' '(' 'PDE' ')' '5' 'inhibitors' '(' 'such' 'as'
 'sildenafil' ',' 'tadalafil' ',' 'vardenafil' ')' 'and' 'non-specific'
 'phosphodiesterase' '(' 'PDE' ')' 'inhibitors' '(' 'theophylline' ','
 'dipyridamole' ')' ',' 'nitrates' 'or' 'NO' 'donors' '(' 'such' 'as'
 'amyl' 'nitrite' ')' 'in' 'any' 'form']","[0. 0. 0. 0. 0. 1. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0.]"
NCT02562235,"38:53:treatment,64:101:treatment,109:137:treatment,","Patients must be on standard of care PAH medications, allowing Endothelin Receptor Antagonists (ERA) and/or Prostacyclin Analogues (PCA), for at least 12 weeks prior to baseline visit","['Patients' 'must' 'be' 'on' 'standard' 'of' 'care' 'PAH' 'medications'
 ',' 'allowing' 'Endothelin' 'Receptor' 'Antagonists' '(' 'ERA' ')'
 'and/or' 'Prostacyclin' 'Analogues' '(' 'PCA' ')' ',' 'for' 'at' 'least'
 '12' 'weeks' 'prior' 'to' 'baseline' 'visit']","[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 1. 1. 1. 1. 0. 0. 0. 1. 1. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02562066,"23:26:chronic_disease,37:66:chronic_disease,68:85:chronic_disease,87:102:chronic_disease,104:120:chronic_disease,122:137:chronic_disease,138:156:chronic_disease,162:183:chronic_disease","Genetically-confirmed CMS involving acetylcholine receptor defect, Rapsyn deficiency, MuSK deficiency, Dok-7 deficiency, SYT2 deficiency,SNAP25B deficiency, and fast channel syndrome","['Genetically-confirmed' 'CMS' 'involving' 'acetylcholine' 'receptor'
 'defect' ',' 'Rapsyn' 'deficiency' ',' 'MuSK' 'deficiency' ',' 'Dok-7'
 'deficiency' ',' 'SYT2' 'deficiency' ',' 'SNAP25B' 'deficiency' ',' 'and'
 'fast' 'channel' 'syndrome']","[0. 2. 0. 2. 2. 2. 0. 2. 2. 0. 2. 2. 0. 2. 2. 0. 2. 2. 0. 2. 2. 0. 0. 2.
 2. 2.]"
NCT02562040,"46:54:chronic_disease,56:66:chronic_disease,72:96:chronic_disease","Other severe chronic health problems such as diabetes, narcolepsy, and poorly controlled asthma","['Other' 'severe' 'chronic' 'health' 'problems' 'such' 'as' 'diabetes' ','
 'narcolepsy' ',' 'and' 'poorly' 'controlled' 'asthma']",[0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 0. 2. 2. 2.]
NCT02561988,"1:22:treatment,23:39:chronic_disease,,,,,,,186:202:treatment","Transfusion-dependent thrombocytopenia, defined as: transfusion of ≥ 6 units of apheresed platelets (or ≥ 6 pools of random donor or buffy coat platelets) during the 12 weeks preceding treatment (C1D1)","['Transfusion-dependent' 'thrombocytopenia' ',' 'defined' 'as' ':'
 'transfusion' 'of' '≥' '6' 'units' 'of' 'apheresed' 'platelets' '(' 'or'
 '≥' '6' 'pools' 'of' 'random' 'donor' 'or' 'buffy' 'coat' 'platelets' ')'
 'during' 'the' '12' 'weeks' 'preceding' 'treatment' '(' 'C1D1' ')']","[1. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.]"
NCT02561104,"41:65:chronic_disease,70:86:chronic_disease,98:135:treatment",History of lens abnormalities including posterior polar cataract and zonular weakness precluding standard non‐complex cataract surgery,"['History' 'of' 'lens' 'abnormalities' 'including' 'posterior' 'polar'
 'cataract' 'and' 'zonular' 'weakness' 'precluding' 'standard'
 'non‐complex' 'cataract' 'surgery']",[0. 0. 0. 0. 0. 2. 2. 2. 0. 2. 2. 0. 1. 1. 1. 1.]
NCT02560766,"28:36:chronic_disease,57:78:treatment,123:130:chronic_disease,","Patients with a history of epilepsy, subjects currently prescribed treatments for epilepsy, or subjects with a history of seizure in the last 5 years","['Patients' 'with' 'a' 'history' 'of' 'epilepsy' ',' 'subjects'
 'currently' 'prescribed' 'treatments' 'for' 'epilepsy' ',' 'or'
 'subjects' 'with' 'a' 'history' 'of' 'seizure' 'in' 'the' 'last' '5'
 'years']","[0. 0. 0. 0. 0. 2. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0.
 0. 0.]"
NCT02560623,"34:58:chronic_disease,60:69:chronic_disease,73:97:chronic_disease","Patients with current history of eosinophilic esophagitis, achalasia or uninvestigated dysphagia","['Patients' 'with' 'current' 'history' 'of' 'eosinophilic' 'esophagitis'
 ',' 'achalasia' 'or' 'uninvestigated' 'dysphagia']",[0. 0. 0. 0. 0. 2. 2. 0. 2. 0. 2. 2.]
NCT02558010,"1:9:allergy_name,11:24:allergy_name,28:37:allergy_name","Morphine, hydromorphone or methadone allergies","['Morphine' ',' 'hydromorphone' 'or' 'methadone' 'allergies']",[4. 0. 4. 0. 4. 0.]
NCT02557321,"32:47:treatment,49:54:cancer,58:81:cancer,83:114:cancer,116:159:cancer,161:184:cancer,203:217:cancer","adequately treated (i.e., with curative intent) basal or squamous cell carcinoma, in situ carcinoma of the cervix, in situ ductal adenocarcinoma of the breast, in situ prostate cancer, or limited stage bladder cancer","['adequately' 'treated' '(' 'i.e.' ',' 'with' 'curative' 'intent' ')'
 'basal' 'or' 'squamous' 'cell' 'carcinoma' ',' 'in' 'situ' 'carcinoma'
 'of' 'the' 'cervix' ',' 'in' 'situ' 'ductal' 'adenocarcinoma' 'of' 'the'
 'breast' ',' 'in' 'situ' 'prostate' 'cancer' ',' 'or' 'limited' 'stage'
 'bladder' 'cancer']","[0. 0. 0. 0. 0. 0. 1. 1. 0. 3. 0. 3. 3. 3. 0. 3. 3. 3. 3. 3. 3. 3. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3.]"
NCT02556619,",,37:55:treatment,57:65:treatment,69:89:treatment","Child-Pugh A, not eligible for TXP, surgical resection, ablation or locoregional therapy","['Child-Pugh' 'A' ',' 'not' 'eligible' 'for' 'TXP' ',' 'surgical'
 'resection' ',' 'ablation' 'or' 'locoregional' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 1.]
NCT02556606,"22:57:chronic_disease,61:76:chronic_disease,78:93:chronic_disease,97:113:chronic_disease",Current diagnosis of obsessive-compulsive disorder (OCD) or eating disorder [bulimia nervosa or anorexia nervosa],"['Current' 'diagnosis' 'of' 'obsessive-compulsive' 'disorder' '(' 'OCD'
 ')' 'or' 'eating' 'disorder' '[' 'bulimia' 'nervosa' 'or' 'anorexia'
 'nervosa' ']']",[0. 0. 0. 2. 2. 2. 0. 0. 0. 2. 2. 0. 2. 2. 0. 2. 2. 0.]
NCT02556606,"56:92:treatment,96:119:treatment,127:135:treatment,137:147:treatment,149:160:treatment,162:171:treatment,173:183:treatment,185:201:treatment,203:216:treatment,226:243:treatment","Patients taking medications with known activity at the N-methyl-D-aspartate receptor (NMDA) or AMPA glutamate receptor [e.g., riluzole, amantadine, lamotrigine, memantine, topiramate, dextromethorphan, D-cycloserine], or the muopioid receptor","['Patients' 'taking' 'medications' 'with' 'known' 'activity' 'at' 'the'
 'N-methyl-D-aspartate' 'receptor' '(' 'NMDA' ')' 'or' 'AMPA' 'glutamate'
 'receptor' '[' 'e.g.' ',' 'riluzole' ',' 'amantadine' ',' 'lamotrigine'
 ',' 'memantine' ',' 'topiramate' ',' 'dextromethorphan' ','
 'D-cycloserine' ']' ',' 'or' 'the' 'muopioid' 'receptor']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 1. 1. 1. 0. 0. 0. 1. 0. 1. 0.
 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0. 1. 1.]"
NCT02555280,"1:22:chronic_disease,35:53:chronic_disease,62:78:chronic_disease,104:159:chronic_disease","Cauda equina syndrome, defined as neural compression causing neurogenic bowel (rectal incontinence) or bladder (bladder retention or incontinence) dysfunction","['Cauda' 'equina' 'syndrome' ',' 'defined' 'as' 'neural' 'compression'
 'causing' 'neurogenic' 'bowel' '(' 'rectal' 'incontinence' ')' 'or'
 'bladder' '(' 'bladder' 'retention' 'or' 'incontinence' ')' 'dysfunction']",[2. 2. 2. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 2. 2. 2. 2. 2. 2. 0. 0.]
NCT02555280,"64:68:chronic_disease,70:73:chronic_disease,82:91:chronic_disease","Known or documented history of communicable disease, including AIDS, HIV, active Hepatitis","['Known' 'or' 'documented' 'history' 'of' 'communicable' 'disease' ','
 'including' 'AIDS' ',' 'HIV' ',' 'active' 'Hepatitis']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 0. 2.]
NCT02555189,"19:36:treatment,38:50:treatment,52:63:treatment","Administration of antifungal agents (itraconazole, fluconazole, etc) within 4 weeks of enrollment or unrecovered AEs due to agents administered more than 4 weeks of enrollment","['Administration' 'of' 'antifungal' 'agents' '(' 'itraconazole' ','
 'fluconazole' ',' 'etc' ')' 'within' '4' 'weeks' 'of' 'enrollment' 'or'
 'unrecovered' 'AEs' 'due' 'to' 'agents' 'administered' 'more' 'than' '4'
 'weeks' 'of' 'enrollment']","[0. 0. 1. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02555189,"12:21:chronic_disease,25:44:chronic_disease,74:83:chronic_disease,87:108:chronic_disease","History of pituitary or adrenal dysfunction, active or symptomatic viral hepatitis or chronic liver disease","['History' 'of' 'pituitary' 'or' 'adrenal' 'dysfunction' ',' 'active' 'or'
 'symptomatic' 'viral' 'hepatitis' 'or' 'chronic' 'liver' 'disease']",[0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 2. 0. 2. 2. 2.]
NCT02555189,"13:57:chronic_disease,61:71:chronic_disease,123:134:treatment,142:161:chronic_disease,194:202:chronic_disease,204:226:chronic_disease,231:252:chronic_disease","Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)","['Patient' 'has' 'impairment' 'of' 'gastrointestinal' '(' 'GI' ')'
 'function' 'or' 'GI' 'disease' 'that' 'may' 'significantly' 'alter' 'the'
 'absorption' 'of' 'the' 'study' 'drugs' '(' 'e.g.' ',' 'ulcerative'
 'diseases' ',' 'uncontrolled' 'nausea' ',' 'vomiting' ',' 'diarrhea' ','
 'malabsorption' 'syndrome' ',' 'or' 'small' 'bowel' 'resection' ')']","[0. 0. 2. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.
 0. 2. 2. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 2. 2. 2. 0.]"
NCT02555189,"35:56:treatment,35:48:treatment,64:73:treatment,75:87:treatment,89:99:treatment,","Patients on long term (>6 months) anti-androgen therapy (e.g., flutamide, bicalutamide, nilutamide) will need to be off anti-androgen for 4 weeks (wash out period) and show evidence of disease progression off the anti-androgen. Patients that have been on an anti-androgen 6 months or less will need to discontinue anti-androgen therapy prior to enrollment (no wash out period required)","['Patients' 'on' 'long' 'term' '(' '>' '6' 'months' ')' 'anti-androgen'
 'therapy' '(' 'e.g.' ',' 'flutamide' ',' 'bicalutamide' ',' 'nilutamide'
 ')' 'will' 'need' 'to' 'be' 'off' 'anti-androgen' 'for' '4' 'weeks' '('
 'wash' 'out' 'period' ')' 'and' 'show' 'evidence' 'of' 'disease'
 'progression' 'off' 'the' 'anti-androgen' '.' 'Patients' 'that' 'have'
 'been' 'on' 'an' 'anti-androgen' '6' 'months' 'or' 'less' 'will' 'need'
 'to' 'discontinue' 'anti-androgen' 'therapy' 'prior' 'to' 'enrollment'
 '(' 'no' 'wash' 'out' 'period' 'required' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02555189,"1:8:treatment,14:21:treatment,23:58:treatment,62:74:treatment","Therapy with heparin, low molecular weight heparin (LMWH) or fondaparinux","['Therapy' 'with' 'heparin' ',' 'low' 'molecular' 'weight' 'heparin' '('
 'LMWH' ')' 'or' 'fondaparinux']",[1. 0. 1. 0. 1. 1. 1. 1. 1. 0. 0. 0. 1.]
NCT02554903,"1:54:treatment,56:93:treatment,101:113:treatment,125:141:treatment,146:175:treatment,183:195:treatment,221:230:treatment","Treatment with endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE5) inhibitors, i.v., subcutaneous (s.c.), or oral prostanoids, or guanylate cyclase stimulators within 7 days prior to Baseline RHC or study treatment initiation","['Treatment' 'with' 'endothelin' 'receptor' 'antagonists' '(' 'ERAs' ')'
 ',' 'phosphodiesterase-5' '(' 'PDE5' ')' 'inhibitors' ',' 'i.v.' ','
 'subcutaneous' '(' 's.c.' ')' ',' 'or' 'oral' 'prostanoids' ',' 'or'
 'guanylate' 'cyclase' 'stimulators' 'within' '7' 'days' 'prior' 'to'
 'Baseline' 'RHC' 'or' 'study' 'treatment' 'initiation']","[1. 1. 1. 1. 1. 1. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 1.
 1. 0. 0. 1. 1. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 1. 0.]"
NCT02554812,"40:45:cancer,41:45:cancer,70:86:treatment,79:86:treatment,168:176:cancer,178:183:cancer,185:189:cancer","Combination A: Phase 1b, patients with NSCLC that have progressed on standard therapy or for which no standard therapy is available, and Phase 2, patients with NSCLC, melanoma, SCCHN, TNBC in any line of therapy, SCLC, 1st line NSCLC","['Combination' 'A' ':' 'Phase' '1b' ',' 'patients' 'with' 'NSCLC' 'that'
 'have' 'progressed' 'on' 'standard' 'therapy' 'or' 'for' 'which' 'no'
 'standard' 'therapy' 'is' 'available' ',' 'and' 'Phase' '2' ','
 'patients' 'with' 'NSCLC' ',' 'melanoma' ',' 'SCCHN' ',' 'TNBC' 'in'
 'any' 'line' 'of' 'therapy' ',' 'SCLC' ',' '1st' 'line' 'NSCLC']","[0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 3. 0. 3. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0.]"
NCT02554786,"13:19:chronic_disease,50:67:treatment,71:86:treatment,",have had an asthma attack/exacerbation requiring systemic steroids or hospitalization or emergency room visit within 6 weeks of Visit 1 (Screening),"['have' 'had' 'an' 'asthma' 'attack/exacerbation' 'requiring' 'systemic'
 'steroids' 'or' 'hospitalization' 'or' 'emergency' 'room' 'visit'
 'within' '6' 'weeks' 'of' 'Visit' '1' '(' 'Screening' ')']",[0. 0. 0. 2. 0. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02554383,"7:27:chronic_disease,35:44:chronic_disease,46:64:chronic_disease,66:91:chronic_disease","Other concurrent infection (e.g., pneumonia, acute otitis media, streptococcal pharyngitis)","['Other' 'concurrent' 'infection' '(' 'e.g.' ',' 'pneumonia' ',' 'acute'
 'otitis' 'media' ',' 'streptococcal' 'pharyngitis' ')']",[0. 2. 2. 0. 0. 0. 2. 0. 2. 2. 2. 0. 2. 2. 0.]
NCT02553941,"1:11:cancer,25:40:treatment,,122:132:treatment",Malignancy treated with curative intent and with no known active disease present for >= 1 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician,"['Malignancy' 'treated' 'with' 'curative' 'intent' 'and' 'with' 'no'
 'known' 'active' 'disease' 'present' 'for' '>' '=' '1' 'years' 'before'
 'the' 'first' 'dose' 'of' 'study' 'drug' 'and' 'felt' 'to' 'be' 'at'
 'low' 'risk' 'for' 'recurrence' 'by' 'treating' 'physician']","[3. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02553642,"29:45:chronic_disease,149:159:treatment,230:237:treatment","Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy or interfere with the interpretation of study results","['Any' 'serious' 'or' 'uncontrolled' 'medical' 'disorder' 'that' ',' 'in'
 'the' 'opinion' 'of' 'the' 'investigator' ',' 'may' 'increase' 'the'
 'risk' 'associated' 'with' 'study' 'participation' 'or' 'study' 'drug'
 'administration' ',' 'impair' 'the' 'ability' 'of' 'the' 'subject' 'to'
 'receive' 'protocol' 'therapy' 'or' 'interfere' 'with' 'the'
 'interpretation' 'of' 'study' 'results']","[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02553642,",32:42:treatment,47:56:treatment,58:83:treatment,88:112:treatment","Must be at least 28 days since craniotomy and resection, stereotactic radiosurgery, or whole brain radiotherapy","['Must' 'be' 'at' 'least' '28' 'days' 'since' 'craniotomy' 'and'
 'resection' ',' 'stereotactic' 'radiosurgery' ',' 'or' 'whole' 'brain'
 'radiotherapy']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 1. 0. 0. 1. 1. 1.]
NCT02553642,"19:42:chronic_disease,38:41:chronic_disease,105:128:chronic_disease,124:127:chronic_disease,194:220:chronic_disease",Positive test for hepatitis B virus (HBV) using HBV surface antigen (HBV sAg) test or positive test for hepatitis C virus (HCV) using HCV ribonucleic acid (RNA) or HCV antibody test indicating acute or chronic infection,"['Positive' 'test' 'for' 'hepatitis' 'B' 'virus' '(' 'HBV' ')' 'using'
 'HBV' 'surface' 'antigen' '(' 'HBV' 'sAg' ')' 'test' 'or' 'positive'
 'test' 'for' 'hepatitis' 'C' 'virus' '(' 'HCV' ')' 'using' 'HCV'
 'ribonucleic' 'acid' '(' 'RNA' ')' 'or' 'HCV' 'antibody' 'test'
 'indicating' 'acute' 'or' 'chronic' 'infection']","[0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2.]"
NCT02553642,",68:79:treatment,83:99:treatment,104:118:cancer",Subjects with disease recurrence within 1 year of a platinum based neoadjuvant or adjuvant therapy for bladder cancer,"['Subjects' 'with' 'disease' 'recurrence' 'within' '1' 'year' 'of' 'a'
 'platinum' 'based' 'neoadjuvant' 'or' 'adjuvant' 'therapy' 'for'
 'bladder' 'cancer']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 3. 3.]
NCT02553642,"5:11:treatment,89:94:cancer,106:119:treatment","The biopsy site must, in the opinion of the investigator, be likely to yield acceptable tumor sample for core biopsies as described in Appendix 4","['The' 'biopsy' 'site' 'must' ',' 'in' 'the' 'opinion' 'of' 'the'
 'investigator' ',' 'be' 'likely' 'to' 'yield' 'acceptable' 'tumor'
 'sample' 'for' 'core' 'biopsies' 'as' 'described' 'in' 'Appendix' '4']","[0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 1. 1. 0. 0.
 0. 0. 0.]"
NCT02553265,"17:34:treatment,36:47:treatment,52:66:treatment",Patients taking neuroleptic drugs (haloperidol and chlorpromazine),"['Patients' 'taking' 'neuroleptic' 'drugs' '(' 'haloperidol' 'and'
 'chlorpromazine' ')']",[0. 0. 1. 1. 0. 1. 0. 1. 0.]
NCT02553161,"26:50:chronic_disease,69:74:chronic_disease,76:89:chronic_disease,94:110:chronic_disease,116:125:chronic_disease","any history of syndromal bipolar I or II disorder (i.e., history of mania, mixed episode, or major depression with hypomania)","['any' 'history' 'of' 'syndromal' 'bipolar' 'I' 'or' 'II' 'disorder' '('
 'i.e.' ',' 'history' 'of' 'mania' ',' 'mixed' 'episode' ',' 'or' 'major'
 'depression' 'with' 'hypomania' ')']","[0. 0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 2. 2. 0. 2.
 0.]"
NCT02551679,"1:22:chronic_disease,26:58:chronic_disease,80:93:chronic_disease",Myocardial infarction or uncontrolled myocardial ischemia or persistent severe heart failure,"['Myocardial' 'infarction' 'or' 'uncontrolled' 'myocardial' 'ischemia'
 'or' 'persistent' 'severe' 'heart' 'failure']",[2. 2. 0. 2. 2. 2. 0. 0. 0. 2. 2.]
NCT02549937,"24:48:chronic_disease,67:74:chronic_disease,75:89:chronic_disease,93:111:chronic_disease,116:133:chronic_disease,151:173:cancer,269:302:chronic_disease,306:317:chronic_disease","History or presence of digestive tract diseases, including active gastric/duodenal ulcer or ulcerative colitis, or active hemorrhage of an unresected gastrointestinal tumor, or an evaluation by investigators of having any other condition that could possibly result in gastrointestinal tract hemorrhage or perforation","['History' 'or' 'presence' 'of' 'digestive' 'tract' 'diseases' ','
 'including' 'active' 'gastric/duodenal' 'ulcer' 'or' 'ulcerative'
 'colitis' ',' 'or' 'active' 'hemorrhage' 'of' 'an' 'unresected'
 'gastrointestinal' 'tumor' ',' 'or' 'an' 'evaluation' 'by'
 'investigators' 'of' 'having' 'any' 'other' 'condition' 'that' 'could'
 'possibly' 'result' 'in' 'gastrointestinal' 'tract' 'hemorrhage' 'or'
 'perforation']","[0. 0. 0. 0. 2. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 2.
 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]"
NCT02549937,"10:35:treatment,39:61:treatment,,90:128:treatment",Received investigational treatment in another clinical study within 4 weeks prior to the initiation of investigational treatmen,"['Received' 'investigational' 'treatment' 'in' 'another' 'clinical'
 'study' 'within' '4' 'weeks' 'prior' 'to' 'the' 'initiation' 'of'
 'investigational' 'treatmen']",[0. 1. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1.]
NCT02549937,"21:36:cancer,60:70:treatment,72:81:treatment","locally advanced or metastatic pNET that has progressed on everolimus, sunitinib or both, during the expansion phase","['locally' 'advanced' 'or' 'metastatic' 'pNET' 'that' 'has' 'progressed'
 'on' 'everolimus' ',' 'sunitinib' 'or' 'both' ',' 'during' 'the'
 'expansion' 'phase']",[0. 0. 0. 3. 3. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02549833,"13:27:treatment,,70:89:treatment,73:89:treatment,",must be off corticosteroid for at least for 2 weeks before the first neoadjuvant vaccine and for at least 2 weeks prior to the first adjuvant vaccine,"['must' 'be' 'off' 'corticosteroid' 'for' 'at' 'least' 'for' '2' 'weeks'
 'before' 'the' 'first' 'neoadjuvant' 'vaccine' 'and' 'for' 'at' 'least'
 '2' 'weeks' 'prior' 'to' 'the' 'first' 'adjuvant' 'vaccine']","[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 1.]"
NCT02548351,"40:61:chronic_disease,70:93:chronic_disease,95:106:chronic_disease,108:119:chronic_disease,121:124:chronic_disease,126:129:chronic_disease,131:151:chronic_disease,153:167:chronic_disease,169:182:chronic_disease,184:214:chronic_disease,216:241:chronic_disease,262:292:cancer","Evidence of other known forms of known chronic liver disease such as alcoholic liver disease, hepatitis B, hepatitis C, PBC, PSC, autoimmune hepatitis, Wilson disease, iron overload, alpha-1-antitrypsin deficiency, drug-induced liver injury, known or suspected hepatocellular carcinoma (HCC)","['Evidence' 'of' 'other' 'known' 'forms' 'of' 'known' 'chronic' 'liver'
 'disease' 'such' 'as' 'alcoholic' 'liver' 'disease' ',' 'hepatitis' 'B'
 ',' 'hepatitis' 'C' ',' 'PBC' ',' 'PSC' ',' 'autoimmune' 'hepatitis' ','
 'Wilson' 'disease' ',' 'iron' 'overload' ',' 'alpha-1-antitrypsin'
 'deficiency' ',' 'drug-induced' 'liver' 'injury' ',' 'known' 'or'
 'suspected' 'hepatocellular' 'carcinoma' '(' 'HCC' ')']","[0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 0. 0. 0. 0. 2. 0.
 2. 0. 2. 2. 0. 2. 2. 0. 2. 2. 0. 2. 2. 0. 2. 2. 2. 0. 0. 0. 0. 3. 3. 3.
 0. 0.]"
NCT02547662,"13:37:cancer,39:77:cancer,53:62:cancer","EXCEPTIONS: Non-melanoma skin cancer, ductal breast carcinoma in situ (DCIS) or carcinoma-in-situ of the cervix","['EXCEPTIONS' ':' 'Non-melanoma' 'skin' 'cancer' ',' 'ductal' 'breast'
 'carcinoma' 'in' 'situ' '(' 'DCIS' ')' 'or' 'carcinoma-in-situ' 'of'
 'the' 'cervix']",[0. 0. 3. 3. 3. 0. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT02546583,"18:63:treatment,,74:88:treatment,,102:112:treatment,117:126:treatment",Use of high dose mineralocorticoid receptor antagonist therapy (>50mg of spironolactone or >100mg of eplerenone) or amiloride,"['Use' 'of' 'high' 'dose' 'mineralocorticoid' 'receptor' 'antagonist'
 'therapy' '(' '>' '50mg' 'of' 'spironolactone' 'or' '>' '100mg' 'of'
 'eplerenone' ')' 'or' 'amiloride']",[0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0. 1. 0. 0. 1.]
NCT02544880,"7:16:treatment,39:46:treatment,54:66:treatment,117:122:cancer","Prior radiation with or without prior surgery and/or chemotherapy, to the head and neck for definitive treatment of HNSCC of the oral cavity, oropharynx, hypopharynx or larynx with previously documented complete clinical or radiographic response to initial treatment","['Prior' 'radiation' 'with' 'or' 'without' 'prior' 'surgery' 'and/or'
 'chemotherapy' ',' 'to' 'the' 'head' 'and' 'neck' 'for' 'definitive'
 'treatment' 'of' 'HNSCC' 'of' 'the' 'oral' 'cavity' ',' 'oropharynx' ','
 'hypopharynx' 'or' 'larynx' 'with' 'previously' 'documented' 'complete'
 'clinical' 'or' 'radiographic' 'response' 'to' 'initial' 'treatment']","[0. 1. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02544880,"1:20:chronic_disease,25:44:chronic_disease,60:74:treatment","Unilateral deafness, or severe hearing loss dependent upon hearing aid(s) for serviceable communication","['Unilateral' 'deafness' ',' 'or' 'severe' 'hearing' 'loss' 'dependent'
 'upon' 'hearing' 'aid' '(' 's' ')' 'for' 'serviceable' 'communication']",[2. 2. 0. 0. 2. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02544373,"13:40:chronic_disease,102:111:chronic_disease,115:131:chronic_disease",Concomitant systemic autoimmune disease with secondary central nervous system involvement (including CNS lupus or neurosarcoidosis),"['Concomitant' 'systemic' 'autoimmune' 'disease' 'with' 'secondary'
 'central' 'nervous' 'system' 'involvement' '(' 'including' 'CNS' 'lupus'
 'or' 'neurosarcoidosis' ')']",[0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 0.]
NCT02543983,"21:30:chronic_disease,58:71:chronic_disease,85:103:chronic_disease",Presence of current psychotic features or a diagnosis of Schizophrenia or any other psychotic disorder as defined in the DSM-IV,"['Presence' 'of' 'current' 'psychotic' 'features' 'or' 'a' 'diagnosis'
 'of' 'Schizophrenia' 'or' 'any' 'other' 'psychotic' 'disorder' 'as'
 'defined' 'in' 'the' 'DSM-IV']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02543944,"14:34:chronic_disease,36:45:chronic_disease,47:60:chronic_disease,62:69:chronic_disease","have a major psychiatric disorder (psychosis, schizophrenia, bipolar)","['have' 'a' 'major' 'psychiatric' 'disorder' '(' 'psychosis' ','
 'schizophrenia' ',' 'bipolar' ')']",[0. 0. 0. 2. 2. 0. 2. 0. 2. 0. 2. 0.]
NCT02543866,"30:64:chronic_disease,92:112:treatment,103:112:treatment",Patients with current active ESC-R Enterobacteriaceae infection who have not yet completed antibiotic treatment will be excluded until their treatment is completed,"['Patients' 'with' 'current' 'active' 'ESC-R' 'Enterobacteriaceae'
 'infection' 'who' 'have' 'not' 'yet' 'completed' 'antibiotic' 'treatment'
 'will' 'be' 'excluded' 'until' 'their' 'treatment' 'is' 'completed']",[0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02542657,"34:59:chronic_disease,71:96:chronic_disease,119:130:chronic_disease,155:168:chronic_disease,170:185:chronic_disease,190:211:chronic_disease,","Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months","['Evidence' 'of' 'current' 'uncontrolled' 'cardiovascular' 'conditions'
 ',' 'including' 'uncontrolled' 'hypertension' ',' 'uncontrolled'
 'cardiac' 'arrhythmias' ',' 'symptomatic' 'congestive' 'heart' 'failure'
 ',' 'unstable' 'angina' ',' 'or' 'myocardial' 'infarction' 'within' 'the'
 'past' '6' 'months']","[0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0.
 2. 2. 0. 0. 0. 0. 0.]"
NCT02542202,"1:3:treatment,7:39:treatment,89:107:chronic_disease",CT or magnetic resonance imaging (MRI) of the brain is only required in the presence of neurologic symptoms,"['CT' 'or' 'magnetic' 'resonance' 'imaging' '(' 'MRI' ')' 'of' 'the'
 'brain' 'is' 'only' 'required' 'in' 'the' 'presence' 'of' 'neurologic'
 'symptoms']",[1. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02542202,"27:39:treatment,32:39:treatment,41:54:treatment,56:68:treatment,","Patients must have had no radiotherapy, immunotherapy, chemotherapy or therapy with targeted agents within the last 1 month","['Patients' 'must' 'have' 'had' 'no' 'radiotherapy' ',' 'immunotherapy'
 ',' 'chemotherapy' 'or' 'therapy' 'with' 'targeted' 'agents' 'within'
 'the' 'last' '1' 'month']",[0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02541955,"36:60:treatment,,103:113:treatment,122:136:treatment",Subjects who have received live or live attenuated vaccines within 6 weeks prior to the first dose of study drug (or the zoster vaccine),"['Subjects' 'who' 'have' 'received' 'live' 'or' 'live' 'attenuated'
 'vaccines' 'within' '6' 'weeks' 'prior' 'to' 'the' 'first' 'dose' 'of'
 'study' 'drug' '(' 'or' 'the' 'zoster' 'vaccine' ')']","[0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1.
 1. 0.]"
NCT02541565,"35:40:cancer,71:79:cancer,88:107:cancer","Discordant presentations, such as DLBCL in a lymph node and low-grade lymphoma such as follicular lymphoma in the bone marrow","['Discordant' 'presentations' ',' 'such' 'as' 'DLBCL' 'in' 'a' 'lymph'
 'node' 'and' 'low-grade' 'lymphoma' 'such' 'as' 'follicular' 'lymphoma'
 'in' 'the' 'bone' 'marrow']",[0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 3. 0. 0. 3. 3. 0. 0. 0. 0.]
NCT02541565,"13:21:cancer,27:32:cancer,84:97:treatment","Transformed lymphoma with DLBCL histology, as long as the patient has not received prior therapy for lymphoma","['Transformed' 'lymphoma' 'with' 'DLBCL' 'histology' ',' 'as' 'long' 'as'
 'the' 'patient' 'has' 'not' 'received' 'prior' 'therapy' 'for' 'lymphoma']",[0. 3. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.]
NCT02540616,"57:79:treatment,81:95:treatment,97:117:treatment,119:136:treatment","Implanted metal in the head or neck (metal or shrapnel, deep brain stimulators, aneurysm clips, cochlear stimulators, retinal implants, etc)","['Implanted' 'metal' 'in' 'the' 'head' 'or' 'neck' '(' 'metal' 'or'
 'shrapnel' ',' 'deep' 'brain' 'stimulators' ',' 'aneurysm' 'clips' ','
 'cochlear' 'stimulators' ',' 'retinal' 'implants' ',' 'etc' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 1. 1. 0. 1. 1. 0. 1. 1.
 0. 0. 0.]"
NCT02540330,"1:19:chronic_disease,21:37:chronic_disease,49:62:treatment","bleeding diatheses, thrombocytopenia or current anticoagulant use","['bleeding' 'diatheses' ',' 'thrombocytopenia' 'or' 'current'
 'anticoagulant' 'use']",[2. 2. 0. 2. 0. 0. 1. 0.]
NCT02539160,"12:32:treatment,41:48:treatment,53:64:treatment",Use of any antiplatelet therapy (except aspirin and clopidogrel),"['Use' 'of' 'any' 'antiplatelet' 'therapy' '(' 'except' 'aspirin' 'and'
 'clopidogrel' ')']",[0. 0. 0. 1. 1. 0. 0. 1. 0. 1. 0.]
NCT02538198,"15:27:treatment,55:62:treatment,,255:275:treatment","Refractory to lenalidomide in the most recent line of therapy, as defined by the International Myeloma Consensus Panel criteria [47]- as failure to achieve minimal response or development of progressive disease while on lenalidomide or within 30 days of lenalidomide therapy","['Refractory' 'to' 'lenalidomide' 'in' 'the' 'most' 'recent' 'line' 'of'
 'therapy' ',' 'as' 'defined' 'by' 'the' 'International' 'Myeloma'
 'Consensus' 'Panel' 'criteria' '[' '47' ']' '-' 'as' 'failure' 'to'
 'achieve' 'minimal' 'response' 'or' 'development' 'of' 'progressive'
 'disease' 'while' 'on' 'lenalidomide' 'or' 'within' '30' 'days' 'of'
 'lenalidomide' 'therapy']","[0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02536846,"30:44:chronic_disease,46:64:chronic_disease,82:88:treatment,107:130:treatment,132:160:treatment,168:192:treatment,194:214:treatment,216:228:treatment,230:242:treatment,252:275:treatment,400:427:treatment,429:450:treatment","Contraindication to MR scan (claustrophobia, cardiac pacemakers, metal clips and stents on blood vessels, artificial heart valves, artificial arms, hands, legs, etc., brain stimulator devices, implanted drug pumps, ear implants, eye implants or known metal fragments in eyes, exposure to shrapnel or metal filings, other metallic surgical hardware in vital areas, certain tattoos with metallic ink, certain transdermal patches, metal-containing IUDs)","['Contraindication' 'to' 'MR' 'scan' '(' 'claustrophobia' ',' 'cardiac'
 'pacemakers' ',' 'metal' 'clips' 'and' 'stents' 'on' 'blood' 'vessels'
 ',' 'artificial' 'heart' 'valves' ',' 'artificial' 'arms' ',' 'hands' ','
 'legs' ',' 'etc.' ',' 'brain' 'stimulator' 'devices' ',' 'implanted'
 'drug' 'pumps' ',' 'ear' 'implants' ',' 'eye' 'implants' 'or' 'known'
 'metal' 'fragments' 'in' 'eyes' ',' 'exposure' 'to' 'shrapnel' 'or'
 'metal' 'filings' ',' 'other' 'metallic' 'surgical' 'hardware' 'in'
 'vital' 'areas' ',' 'certain' 'tattoos' 'with' 'metallic' 'ink' ','
 'certain' 'transdermal' 'patches' ',' 'metal-containing' 'IUDs' ')']","[0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 1. 1. 1. 1. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 1. 1. 1. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0.
 0. 0. 0. 0. 1. 1. 0.]"
NCT02536794,"57:64:treatment,66:70:treatment,72:95:treatment,97:102:treatment,106:157:treatment","including but not limited to cluster of differentiation [CD]137, OX40, programmed death [PD]-1, PD-L1 or cytotoxic T-lymphocyte antigen 4 [CTLA4] inhibitors","['including' 'but' 'not' 'limited' 'to' 'cluster' 'of' 'differentiation'
 '[' 'CD' ']' '137' ',' 'OX40' ',' 'programmed' 'death' '[' 'PD' ']' '-1'
 ',' 'PD-L1' 'or' 'cytotoxic' 'T-lymphocyte' 'antigen' '4' '[' 'CTLA4' ']'
 'inhibitors']","[1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.
 1. 1. 1. 1. 1. 1. 1. 1.]"
NCT02535923,"82:105:chronic_disease,,,121:140:chronic_disease,,,,,172:188:chronic_disease","Diagnostic and Statistical Manual of Disorders, 5th edition (DSM 5) diagnosis of schizophrenic disorders (295.0-295.9), affective psychoses (296.0-296.1, 296.4-296.8), or major depression with psychotic features (296.24, 296.34)","['Diagnostic' 'and' 'Statistical' 'Manual' 'of' 'Disorders' ',' '5th'
 'edition' '(' 'DSM' '5' ')' 'diagnosis' 'of' 'schizophrenic' 'disorders'
 '(' '295.0-295.9' ')' ',' 'affective' 'psychoses' '(' '296.0-296.1' ','
 '296.4-296.8' ')' ',' 'or' 'major' 'depression' 'with' 'psychotic'
 'features' '(' '296.24' ',' '296.34' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 2. 2. 0.
 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02535312,"16:22:treatment,118:136:treatment,,,,,,,425:436:treatment","The effects of TRC102 on the developing human fetus are unknown; for this reason and because TRC102 as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and 4 months after completion of the study drugs","['The' 'effects' 'of' 'TRC102' 'on' 'the' 'developing' 'human' 'fetus'
 'are' 'unknown' ';' 'for' 'this' 'reason' 'and' 'because' 'TRC102' 'as'
 'well' 'as' 'other' 'therapeutic' 'agents' 'used' 'in' 'this' 'trial'
 'are' 'known' 'to' 'be' 'teratogenic' ',' 'women' 'of' 'child-bearing'
 'potential' 'and' 'men' 'must' 'agree' 'to' 'use' 'adequate'
 'contraception' '(' 'hormonal' 'or' 'barrier' 'method' 'of' 'birth'
 'control' ';' 'abstinence' ')' 'prior' 'to' 'study' 'entry' ',' 'for'
 'the' 'duration' 'of' 'study' 'participation' ',' 'and' '4' 'months'
 'after' 'completion' 'of' 'the' 'study' 'drugs']","[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02535286,"1:27:chronic_disease,51:78:chronic_disease,82:85:chronic_disease",Active autoimmune disorder (with the exception of autoimmune hemolytic anemia or ITP),"['Active' 'autoimmune' 'disorder' '(' 'with' 'the' 'exception' 'of'
 'autoimmune' 'hemolytic' 'anemia' 'or' 'ITP' ')']",[2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0.]
NCT02534922,"5:18:treatment,35:50:cancer,62:80:treatment,85:97:treatment,,,175:187:treatment,191:202:treatment","Any prior therapy directed at the malignant tumor, including immunologic agents and chemotherapy, must be discontinued at least four weeks prior to registration (6 weeks for nitrosoureas or mitomycin C)","['Any' 'prior' 'therapy' 'directed' 'at' 'the' 'malignant' 'tumor' ','
 'including' 'immunologic' 'agents' 'and' 'chemotherapy' ',' 'must' 'be'
 'discontinued' 'at' 'least' 'four' 'weeks' 'prior' 'to' 'registration'
 '(' '6' 'weeks' 'for' 'nitrosoureas' 'or' 'mitomycin' 'C' ')']","[0. 1. 1. 0. 0. 0. 3. 3. 0. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 0. 1. 1. 0.]"
NCT02533674,"24:39:chronic_disease,41:62:chronic_disease,64:88:chronic_disease,93:138:chronic_disease,","History or presence of unstable angina, myocardial infarction, congestive heart failure, or clinically significant valvular heart disease within last year","['History' 'or' 'presence' 'of' 'unstable' 'angina' ',' 'myocardial'
 'infarction' ',' 'congestive' 'heart' 'failure' ',' 'or' 'clinically'
 'significant' 'valvular' 'heart' 'disease' 'within' 'last' 'year']",[0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 2. 2. 2. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0.]
NCT02531932,"24:51:treatment,59:71:treatment,73:85:treatment,87:96:treatment,101:121:treatment","Co-administration with strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, ritonavir) or P-glycoprotein (PgP)","['Co-administration' 'with' 'strong' 'inhibitors' 'of' 'CYP3A4' '(' 'e.g.'
 ',' 'ketoconazole' ',' 'itraconazole' ',' 'ritonavir' ')' 'or'
 'P-glycoprotein' '(' 'PgP' ')']",[0. 0. 1. 1. 1. 1. 0. 0. 0. 1. 0. 1. 0. 1. 0. 0. 1. 1. 0. 0.]
NCT02531932,"28:66:treatment,68:77:treatment,79:91:treatment,93:103:treatment","Patients who have received prior treatment with an mTOR inhibitor (sirolimus, temsirolimus, everolimus)","['Patients' 'who' 'have' 'received' 'prior' 'treatment' 'with' 'an' 'mTOR'
 'inhibitor' '(' 'sirolimus' ',' 'temsirolimus' ',' 'everolimus' ')']",[0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 1. 0. 1. 0. 1. 0.]
NCT02531932,"1:7:chronic_disease,9:14:chronic_disease,18:25:chronic_disease,30:60:chronic_disease",active (acute or chronic) or uncontrolled severe infections,"['active' '(' 'acute' 'or' 'chronic' ')' 'or' 'uncontrolled' 'severe'
 'infections']",[2. 0. 2. 0. 2. 0. 0. 2. 2. 2.]
NCT02531880,"58:75:treatment,79:92:treatment,102:119:treatment","(e.g., any non-organic implant or other device such as a cardiac pacemaker or infusion pump or other metallic implants, objects or body piercings that cannot be removed, or history of being a welder or metal worker due to small metal fragments in the eye)","['(' 'e.g.' ',' 'any' 'non-organic' 'implant' 'or' 'other' 'device' 'such'
 'as' 'a' 'cardiac' 'pacemaker' 'or' 'infusion' 'pump' 'or' 'other'
 'metallic' 'implants' ',' 'objects' 'or' 'body' 'piercings' 'that' 'can'
 'not' 'be' 'removed' ',' 'or' 'history' 'of' 'being' 'a' 'welder' 'or'
 'metal' 'worker' 'due' 'to' 'small' 'metal' 'fragments' 'in' 'the' 'eye'
 ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 0. 1. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02531711,"8:17:treatment,55:65:cancer,67:77:chronic_disease,79:105:chronic_disease","Active treatment for a major medical illness, such as malignancy, autoimmune, immune deficiency disorder","['Active' 'treatment' 'for' 'a' 'major' 'medical' 'illness' ',' 'such'
 'as' 'malignancy' ',' 'autoimmune' ',' 'immune' 'deficiency' 'disorder']",[0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 2. 0. 2. 2. 2.]
NCT02530463,"5:18:treatment,20:32:treatment,34:46:treatment,48:64:treatment,66:79:treatment,81:101:treatment,,130:159:treatment","Any major surgery, radiotherapy, chemotherapy, biologic therapy, immunotherapy, experimental therapy within 2 weeks prior to the first dose of the study drugs","['Any' 'major' 'surgery' ',' 'radiotherapy' ',' 'chemotherapy' ','
 'biologic' 'therapy' ',' 'immunotherapy' ',' 'experimental' 'therapy'
 'within' '2' 'weeks' 'prior' 'to' 'the' 'first' 'dose' 'of' 'the' 'study'
 'drugs']","[0. 1. 1. 0. 1. 0. 1. 0. 1. 1. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1. 1. 1.
 1. 1. 1.]"
NCT02530463,"35:46:chronic_disease,89:110:chronic_disease,89:100:chronic_disease,156:173:treatment,",Patients known to be positive for hepatitis B surface antigen expression or with active hepatitis C infection (positive by polymerase chain reaction or on antiviral therapy for hepatitis C within the last 6 months),"['Patients' 'known' 'to' 'be' 'positive' 'for' 'hepatitis' 'B' 'surface'
 'antigen' 'expression' 'or' 'with' 'active' 'hepatitis' 'C' 'infection'
 '(' 'positive' 'by' 'polymerase' 'chain' 'reaction' 'or' 'on' 'antiviral'
 'therapy' 'for' 'hepatitis' 'C' 'within' 'the' 'last' '6' 'months' ')']","[0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02530034,"66:81:treatment,93:103:treatment,,150:166:treatment,,197:216:treatment","In the absence of rapidly progressing disease, the interval from prior treatment to time of study drug administration should be at least 2 weeks for cytotoxic agents, or at least 5 half-lives for noncytotoxic agents","['In' 'the' 'absence' 'of' 'rapidly' 'progressing' 'disease' ',' 'the'
 'interval' 'from' 'prior' 'treatment' 'to' 'time' 'of' 'study' 'drug'
 'administration' 'should' 'be' 'at' 'least' '2' 'weeks' 'for' 'cytotoxic'
 'agents' ',' 'or' 'at' 'least' '5' 'half-lives' 'for' 'noncytotoxic'
 'agents']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1.]"
NCT02530034,"65:87:chronic_disease,78:87:chronic_disease,,,,225:244:chronic_disease,308:321:chronic_disease,342:363:chronic_disease,,402:425:chronic_disease,450:461:chronic_disease,480:490:treatment,508:532:chronic_disease,,,","Uncontrolled intercurrent illness including, but not limited to uncontrolled infection (patients must have no temperature >= 38.3 degree Celsius [C] due to infection for at least 48 hrs to consider an infection controlled), psychiatric illness that would limit compliance with study requirements, or active heart disease including confirmed myocardial infarction within previous 3 months, symptomatic coronary artery disease, clinically significant arrhythmias not controlled by medication, or uncontrolled congestive heart failure New York (NY) Heart Association class III or IV","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' 'uncontrolled' 'infection' '(' 'patients' 'must' 'have'
 'no' 'temperature' '>' '=' '38.3' 'degree' 'Celsius' '[' 'C' ']' 'due'
 'to' 'infection' 'for' 'at' 'least' '48' 'hrs' 'to' 'consider' 'an'
 'infection' 'controlled' ')' ',' 'psychiatric' 'illness' 'that' 'would'
 'limit' 'compliance' 'with' 'study' 'requirements' ',' 'or' 'active'
 'heart' 'disease' 'including' 'confirmed' 'myocardial' 'infarction'
 'within' 'previous' '3' 'months' ',' 'symptomatic' 'coronary' 'artery'
 'disease' ',' 'clinically' 'significant' 'arrhythmias' 'not' 'controlled'
 'by' 'medication' ',' 'or' 'uncontrolled' 'congestive' 'heart' 'failure'
 'New' 'York' '(' 'NY' ')' 'Heart' 'Association' 'class' 'III' 'or' 'IV']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 2. 0.
 0. 0. 1. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02527564,"137:164:chronic_disease,166:194:chronic_disease,199:215:chronic_disease,266:274:chronic_disease,286:311:chronic_disease","Adult outpatients meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for bipolar I disorder (296.70), bipolar II disorder (296.89), or bipolar disorder not otherwise specified (296.80), with concurrent insomnia related to bipolar disorder (307.42)","['Adult' 'outpatients' 'meeting' 'Diagnostic' 'and' 'Statistical' 'Manual'
 'of' 'Mental' 'Disorders' ',' 'Fourth' 'Edition' ',' 'Text' 'Revision'
 '(' 'DSM-IV-TR' ')' 'criteria' 'for' 'bipolar' 'I' 'disorder' '('
 '296.70' ')' ',' 'bipolar' 'II' 'disorder' '(' '296.89' ')' ',' 'or'
 'bipolar' 'disorder' 'not' 'otherwise' 'specified' '(' '296.80' ')' ','
 'with' 'concurrent' 'insomnia' 'related' 'to' 'bipolar' 'disorder' '('
 '307.42' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2.
 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02527421,"12:28:treatment,39:56:treatment,58:61:chronic_disease","History of organ transplant requiring immunosuppression, HIV, or other immunocompromised state","['History' 'of' 'organ' 'transplant' 'requiring' 'immunosuppression' ','
 'HIV' ',' 'or' 'other' 'immunocompromised' 'state']",[0. 0. 1. 1. 0. 1. 0. 2. 0. 0. 0. 0. 0.]
NCT02527421,"1:34:treatment,42:63:treatment,65:78:treatment,80:93:treatment","systemic anti-inflammatory agents (e.g., mycophenolate mofetil, sulfasalazine, 6-thioguanine)","['systemic' 'anti-inflammatory' 'agents' '(' 'e.g.' ',' 'mycophenolate'
 'mofetil' ',' 'sulfasalazine' ',' '6-thioguanine' ')']",[1. 1. 1. 0. 0. 0. 1. 1. 0. 1. 0. 1. 0.]
NCT02527265,"35:41:chronic_disease,76:93:chronic_disease,109:120:treatment","History of physician diagnosis of asthma or any other clinically important pulmonary disease, or use of any medications to treat such conditions within the last year","['History' 'of' 'physician' 'diagnosis' 'of' 'asthma' 'or' 'any' 'other'
 'clinically' 'important' 'pulmonary' 'disease' ',' 'or' 'use' 'of' 'any'
 'medications' 'to' 'treat' 'such' 'conditions' 'within' 'the' 'last'
 'year']","[0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02526511,"19:42:cancer,19:29:cancer,85:105:cancer,,154:156:treatment,160:163:treatment","For patients with metastatic renal tumors to be enrolled, a histologic diagnosis of renal cell carcinoma must exist and any burden of disease >= 1 cm by CT or MRI is acceptable; the metastatic sites may be kidney, intra-abdominal (such as liver), brain, bone, or lymph nodes; lung lesions are NOT eligible because of the motion artifact caused by respiration","['For' 'patients' 'with' 'metastatic' 'renal' 'tumors' 'to' 'be'
 'enrolled' ',' 'a' 'histologic' 'diagnosis' 'of' 'renal' 'cell'
 'carcinoma' 'must' 'exist' 'and' 'any' 'burden' 'of' 'disease' '>' '='
 '1' 'cm' 'by' 'CT' 'or' 'MRI' 'is' 'acceptable' ';' 'the' 'metastatic'
 'sites' 'may' 'be' 'kidney' ',' 'intra-abdominal' '(' 'such' 'as' 'liver'
 ')' ',' 'brain' ',' 'bone' ',' 'or' 'lymph' 'nodes' ';' 'lung' 'lesions'
 'are' 'NOT' 'eligible' 'because' 'of' 'the' 'motion' 'artifact' 'caused'
 'by' 'respiration']","[0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02525861,"31:44:treatment,48:69:treatment,79:87:treatment,92:103:treatment,,,266:280:treatment,298:314:treatment","If a participant is receiving anticoagulant or anti-platelet therapy (such as warfarin and clopidogrel), the participant is unwilling to or unable to safely discontinue anticoagulant or anti-platelet therapy within 7 days prior to until at least 24 hours after the BAL procedures. An exception is low-dose aspirin alone which is allowed","['If' 'a' 'participant' 'is' 'receiving' 'anticoagulant' 'or'
 'anti-platelet' 'therapy' '(' 'such' 'as' 'warfarin' 'and' 'clopidogrel'
 ')' ',' 'the' 'participant' 'is' 'unwilling' 'to' 'or' 'unable' 'to'
 'safely' 'discontinue' 'anticoagulant' 'or' 'anti-platelet' 'therapy'
 'within' '7' 'days' 'prior' 'to' 'until' 'at' 'least' '24' 'hours'
 'after' 'the' 'BAL' 'procedures' '.' 'An' 'exception' 'is' 'low-dose'
 'aspirin' 'alone' 'which' 'is' 'allowed']","[0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.
 0. 1. 1. 0. 0. 0. 0.]"
NCT02525861,"34:38:treatment,48:64:treatment,54:64:treatment,118:136:treatment","The participant has a history of lung or other organ transplant, is currently on a transplant list, or has undergone major lung surgery","['The' 'participant' 'has' 'a' 'history' 'of' 'lung' 'or' 'other' 'organ'
 'transplant' ',' 'is' 'currently' 'on' 'a' 'transplant' 'list' ',' 'or'
 'has' 'undergone' 'major' 'lung' 'surgery']","[0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.
 1.]"
NCT02525861,"37:59:treatment,73:96:treatment,100:122:treatment,116:122:treatment,",The participant has participated in another clinical study involving an investigational product or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an investigational product or device during the course of this study,"['The' 'participant' 'has' 'participated' 'in' 'another' 'clinical'
 'study' 'involving' 'an' 'investigational' 'product' 'or'
 'investigational' 'device' 'within' '30' 'days' 'prior' 'to' 'enrollment'
 'or' 'is' 'scheduled' 'to' 'participate' 'in' 'another' 'clinical'
 'study' 'involving' 'an' 'investigational' 'product' 'or' 'device'
 'during' 'the' 'course' 'of' 'this' 'study']","[0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 1. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02525861,",63:88:treatment,98:122:treatment,,158:168:treatment,190:211:treatment,213:225:treatment,227:243:treatment,249:258:treatment","The participant is receiving or requires long-term (>4 weeks) immunosuppressive therapy, such as systemic corticosteroids at doses greater than 10 mg/day of prednisone (or its equivalent), mycophenolate mofetil, azathioprine, cyclophosphamide, and rituximab","['The' 'participant' 'is' 'receiving' 'or' 'requires' 'long-term' '(' '>'
 '4' 'weeks' ')' 'immunosuppressive' 'therapy' ',' 'such' 'as' 'systemic'
 'corticosteroids' 'at' 'doses' 'greater' 'than' '10' 'mg/day' 'of'
 'prednisone' '(' 'or' 'its' 'equivalent' ')' ',' 'mycophenolate'
 'mofetil' ',' 'azathioprine' ',' 'cyclophosphamide' ',' 'and' 'rituximab']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.
 0. 0. 1. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 0. 0. 1.]"
NCT02525692,"20:39:treatment,51:60:treatment,,118:128:treatment",Concomitant use of CYP3A4/5 inhibitors during the treatment phase of the study and within 72 hours prior to starting study drug administration,"['Concomitant' 'use' 'of' 'CYP3A4/5' 'inhibitors' 'during' 'the'
 'treatment' 'phase' 'of' 'the' 'study' 'and' 'within' '72' 'hours'
 'prior' 'to' 'starting' 'study' 'drug' 'administration']",[0. 0. 0. 1. 1. 0. 0. 1. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02525692,"18:28:cancer,68:77:treatment,,105:115:treatment,136:168:cancer,170:205:cancer,210:233:cancer,265:281:treatment","Known additional malignancy that is progressing or requires active treatment within 3 years of start of study drug. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy","['Known' 'additional' 'malignancy' 'that' 'is' 'progressing' 'or'
 'requires' 'active' 'treatment' 'within' '3' 'years' 'of' 'start' 'of'
 'study' 'drug' '.' 'Exceptions' 'include' 'basal' 'cell' 'carcinoma' 'of'
 'the' 'skin' ',' 'squamous' 'cell' 'carcinoma' 'of' 'the' 'skin' ',' 'or'
 'in' 'situ' 'cervical' 'cancer' 'that' 'has' 'undergone' 'potentially'
 'curative' 'therapy']","[0. 0. 3. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 3. 3. 3.
 3. 3. 3. 0. 3. 3. 3. 3. 3. 3. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 1. 1.]"
NCT02525692,"1:32:treatment,34:68:treatment,72:85:treatment,102:108:treatment,176:181:cancer,260:299:treatment,320:329:treatment","Prior stereotactic radiotherapy, convection enhanced delivery (CED) or brachytherapy must have had a biopsy to confirm radiographic progression is consistent with progressive tumor and not treatment-related necrosis. If the recurrent lesion is outside of any prior high-dose radiation target volume or distant from the prior CED or brachytherapy site, subjects will be considered eligible","['Prior' 'stereotactic' 'radiotherapy' ',' 'convection' 'enhanced'
 'delivery' '(' 'CED' ')' 'or' 'brachytherapy' 'must' 'have' 'had' 'a'
 'biopsy' 'to' 'confirm' 'radiographic' 'progression' 'is' 'consistent'
 'with' 'progressive' 'tumor' 'and' 'not' 'treatment-related' 'necrosis'
 '.' 'If' 'the' 'recurrent' 'lesion' 'is' 'outside' 'of' 'any' 'prior'
 'high-dose' 'radiation' 'target' 'volume' 'or' 'distant' 'from' 'the'
 'prior' 'CED' 'or' 'brachytherapy' 'site' ',' 'subjects' 'will' 'be'
 'considered' 'eligible']","[1. 1. 1. 0. 1. 1. 1. 1. 0. 0. 0. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02525510,"1:13:chronic_disease,15:38:chronic_disease,40:64:chronic_disease,79:93:chronic_disease","Coagulopathy, Hemodynamic instability, Electrolyte deficiencies, Pre-existing kidney disease (per study protocol)","['Coagulopathy' ',' 'Hemodynamic' 'instability' ',' 'Electrolyte'
 'deficiencies' ',' 'Pre-existing' 'kidney' 'disease' '(' 'per' 'study'
 'protocol' ')']",[2. 0. 2. 2. 0. 2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02525029,",,,39:42:treatment,,,70:88:chronic_disease,92:120:chronic_disease","Pediatric or adult (ages 12-76 years) HCT recipient with grade II-IV steroid refractory or steroid-dependent acute GVHD, defined as any one of the following","['Pediatric' 'or' 'adult' '(' 'ages' '12-76' 'years' ')' 'HCT' 'recipient'
 'with' 'grade' 'II-IV' 'steroid' 'refractory' 'or' 'steroid-dependent'
 'acute' 'GVHD' ',' 'defined' 'as' 'any' 'one' 'of' 'the' 'following']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 2. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02524275,"23:67:cancer,143:150:treatment,158:175:treatment,208:226:cancer",Histologically proven squamous cell carcinoma of the head and neck with measurable disease that is either recurrent after attempted cure with surgery and/or radiation therapy or newly diagnosed disease with distant metastases or incurable at diagnosis,"['Histologically' 'proven' 'squamous' 'cell' 'carcinoma' 'of' 'the' 'head'
 'and' 'neck' 'with' 'measurable' 'disease' 'that' 'is' 'either'
 'recurrent' 'after' 'attempted' 'cure' 'with' 'surgery' 'and/or'
 'radiation' 'therapy' 'or' 'newly' 'diagnosed' 'disease' 'with' 'distant'
 'metastases' 'or' 'incurable' 'at' 'diagnosis']","[0. 0. 3. 3. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1.
 1. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0.]"
NCT02523443,"21:38:allergy_name,59:77:chronic_disease,79:104:chronic_disease,106:141:chronic_disease,143:165:chronic_disease,171:188:chronic_disease,191:215:chronic_disease,217:235:chronic_disease,237:268:chronic_disease,272:315:chronic_disease,318:348:treatment,352:374:chronic_disease,397:411:treatment,499:525:chronic_disease,,,,,,,","Contraindication to epidural catheter placement including bleeding diathesis (essential thrombocythemia, idiopathic thrombocytopenic purpura, von Willebrand disease, and hemophilia A or B), neurological dysfunction (multiple sclerosis, subacute myelo-opticoneuropathy or preexisting lower limb neurological deficit), prior extensive spinal surgery or major spinal deformity, pre-operative use of anti-coagulant with planned use of therapeutic dose of anti-coagulant in post-operatively, documented pre-operative coagulopathy (INR greater than 1.3 not on Coumadin or PTT greater than 42), platelets less than 100,000/μL, or evidence of infection at potential epidural site","['Contraindication' 'to' 'epidural' 'catheter' 'placement' 'including'
 'bleeding' 'diathesis' '(' 'essential' 'thrombocythemia' ',' 'idiopathic'
 'thrombocytopenic' 'purpura' ',' 'von' 'Willebrand' 'disease' ',' 'and'
 'hemophilia' 'A' 'or' 'B' ')' ',' 'neurological' 'dysfunction' '('
 'multiple' 'sclerosis' ',' 'subacute' 'myelo-opticoneuropathy' 'or'
 'preexisting' 'lower' 'limb' 'neurological' 'deficit' ')' ',' 'prior'
 'extensive' 'spinal' 'surgery' 'or' 'major' 'spinal' 'deformity' ','
 'pre-operative' 'use' 'of' 'anti-coagulant' 'with' 'planned' 'use' 'of'
 'therapeutic' 'dose' 'of' 'anti-coagulant' 'in' 'post-operatively' ','
 'documented' 'pre-operative' 'coagulopathy' '(' 'INR' 'greater' 'than'
 '1.3' 'not' 'on' 'Coumadin' 'or' 'PTT' 'greater' 'than' '42' ')' ','
 'platelets' 'less' 'than' '100,000/μL' ',' 'or' 'evidence' 'of'
 'infection' 'at' 'potential' 'epidural' 'site']","[0. 0. 4. 4. 0. 0. 2. 2. 0. 2. 2. 0. 2. 2. 2. 0. 2. 2. 2. 0. 0. 2. 2. 2.
 2. 0. 0. 2. 2. 0. 2. 2. 0. 2. 2. 0. 2. 2. 2. 2. 2. 0. 0. 1. 1. 1. 1. 0.
 2. 2. 2. 0. 2. 2. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02522715,",,61:70:allergy_name,72:86:allergy_name,141:153:allergy_name,165:173:allergy_name,175:199:allergy_name,205:229:allergy_name","History of severe hypersensitivity reaction (>= grade 3) to docetaxel, polysorbate 80 containing drugs, or any of the capsule components of enzalutamide, including Labrasol, butylated hydroxyanisole, and butylated hydroxytoluene","['History' 'of' 'severe' 'hypersensitivity' 'reaction' '(' '>' '=' 'grade'
 '3' ')' 'to' 'docetaxel' ',' 'polysorbate' '80' 'containing' 'drugs' ','
 'or' 'any' 'of' 'the' 'capsule' 'components' 'of' 'enzalutamide' ','
 'including' 'Labrasol' ',' 'butylated' 'hydroxyanisole' ',' 'and'
 'butylated' 'hydroxytoluene']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 0. 4. 4. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 4. 0. 0. 4. 0. 4. 4. 0. 0. 0. 0.]"
NCT02522715,"1:13:treatment,20:33:treatment,23:33:treatment,54:82:cancer,119:125:cancer,","chemotherapy given neoadjuvantly, adjuvantly, or for hormone sensitive metastatic disease is permitted as long as the cancer did not progress on chemotherapy AND > 6 months have elapsed","['chemotherapy' 'given' 'neoadjuvantly' ',' 'adjuvantly' ',' 'or' 'for'
 'hormone' 'sensitive' 'metastatic' 'disease' 'is' 'permitted' 'as' 'long'
 'as' 'the' 'cancer' 'did' 'not' 'progress' 'on' 'chemotherapy' 'AND' '>'
 '6' 'months' 'have' 'elapsed']","[1. 0. 1. 0. 1. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02522715,"21:30:treatment,67:76:treatment,78:91:treatment,93:105:treatment,134:143:treatment","may not be on other therapies that affect hormone levels, such as estrogens, testosterones, ketoconazole during this study; however, megestrol for hot flashes is permitted","['may' 'not' 'be' 'on' 'other' 'therapies' 'that' 'affect' 'hormone'
 'levels' ',' 'such' 'as' 'estrogens' ',' 'testosterones' ','
 'ketoconazole' 'during' 'this' 'study' ';' 'however' ',' 'megestrol'
 'for' 'hot' 'flashes' 'is' 'permitted']","[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0.
 1. 0. 0. 0. 0. 0.]"
NCT02521493,",43:53:treatment,63:72:treatment,76:79:chronic_disease",Patients =< 30 days from the last dose of cytarabine used for treatment of TMD,"['Patients' '=' '<' '30' 'days' 'from' 'the' 'last' 'dose' 'of'
 'cytarabine' 'used' 'for' 'treatment' 'of' 'TMD']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 0. 2.]
NCT02520791,"16:48:cancer,43:47:cancer,73:109:cancer,114:136:chronic_disease,,215:228:treatment,235:245:treatment,247:260:treatment,262:280:treatment,282:292:treatment,300:348:cancer,353:376:chronic_disease","Advanced stage cutaneous T-cell lymphoma (CTCL), specifically CTCL NOS, small/medium T-cell lymphoma (SMTCL) and mycosis fungoides (MF) stage IB, IIA, IIB, III and IV that have relapsed after at least one specific prior therapy (e.g. interferon, photopheresis, denileukin difitox, bexarotene, etc); anaplastic cutaneous large cell lymphoma (ACLCL) and lymphomatoid papulopsis","['Advanced' 'stage' 'cutaneous' 'T-cell' 'lymphoma' '(' 'CTCL' ')' ','
 'specifically' 'CTCL' 'NOS' ',' 'small/medium' 'T-cell' 'lymphoma' '('
 'SMTCL' ')' 'and' 'mycosis' 'fungoides' '(' 'MF' ')' 'stage' 'IB' ','
 'IIA' ',' 'IIB' ',' 'III' 'and' 'IV' 'that' 'have' 'relapsed' 'after'
 'at' 'least' 'one' 'specific' 'prior' 'therapy' '(' 'e.g' '.'
 'interferon' ',' 'photopheresis' ',' 'denileukin' 'difitox' ','
 'bexarotene' ',' 'etc' ')' ';' 'anaplastic' 'cutaneous' 'large' 'cell'
 'lymphoma' '(' 'ACLCL' ')' 'and' 'lymphomatoid' 'papulopsis']","[0. 0. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 2. 2. 2. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.
 1. 0. 1. 0. 1. 1. 0. 1. 0. 0. 0. 0. 3. 3. 3. 3. 3. 3. 0. 0. 0. 2. 2.]"
NCT02520791,"24:57:cancer,61:102:cancer,,138:153:treatment",Confirmed diagnosis of peripheral T-cell lymphoma (PTCL) or angioimmunoblastic T-cell lymphoma (AITL) that is refractory to at least one line of therapy,"['Confirmed' 'diagnosis' 'of' 'peripheral' 'T-cell' 'lymphoma' '(' 'PTCL'
 ')' 'or' 'angioimmunoblastic' 'T-cell' 'lymphoma' '(' 'AITL' ')' 'that'
 'is' 'refractory' 'to' 'at' 'least' 'one' 'line' 'of' 'therapy']","[0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 1. 1.]"
NCT02520791,",88:124:treatment,126:163:treatment,203:207:cancer,209:213:cancer,218:237:cancer,326:335:cancer,337:341:cancer,346:348:cancer","Patients must have at least one measurable lesion that can be accurately measured with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI) scan, or physical exam (by calipers only); (PTCL, AITL and follicular lymphoma patients will be assessed on this study using the Lugano criteria for the evaluation of lymphomas; CTCL and MF patients will be assessed using International Society for Cutaneous Lymphomas [ISCL] and European Organization for Research and Treatment of Cancer [EORTC criteria])","['Patients' 'must' 'have' 'at' 'least' 'one' 'measurable' 'lesion' 'that'
 'can' 'be' 'accurately' 'measured' 'with' 'spiral' 'computed'
 'tomography' '(' 'CT' ')' 'scan' ',' 'magnetic' 'resonance' 'imaging' '('
 'MRI' ')' 'scan' ',' 'or' 'physical' 'exam' '(' 'by' 'calipers' 'only'
 ')' ';' '(' 'PTCL' ',' 'AITL' 'and' 'follicular' 'lymphoma' 'patients'
 'will' 'be' 'assessed' 'on' 'this' 'study' 'using' 'the' 'Lugano'
 'criteria' 'for' 'the' 'evaluation' 'of' 'lymphomas' ';' 'CTCL' 'and'
 'MF' 'patients' 'will' 'be' 'assessed' 'using' 'International' 'Society'
 'for' 'Cutaneous' 'Lymphomas' '[' 'ISCL' ']' 'and' 'European'
 'Organization' 'for' 'Research' 'and' 'Treatment' 'of' 'Cancer' '['
 'EORTC' 'criteria' ']' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 1. 1.
 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 3. 0. 3. 3. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 3. 0. 3. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02520791,"77:93:chronic_disease,107:131:chronic_disease,142:157:chronic_disease,159:177:chronic_disease,182:219:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' ',' 'ongoing' 'or' 'active' 'infection' ',' 'symptomatic'
 'congestive' 'heart' 'failure' ',' 'unstable' 'angina' 'pectoris' ','
 'cardiac' 'arrhythmia' ',' 'or' 'psychiatric' 'illness/social'
 'situations' 'that' 'would' 'limit' 'compliance' 'with' 'study'
 'requirements']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 2. 2. 0.
 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT02520778,"15:34:cancer,46:51:cancer,69:104:treatment,185:193:cancer,197:220:cancer",Patients with active malignancies other than NSCLC or patients with prior curatively treated malignancy at high risk of relapse during the study period with the exception of localized squamous or basal cell skin cancers,"['Patients' 'with' 'active' 'malignancies' 'other' 'than' 'NSCLC' 'or'
 'patients' 'with' 'prior' 'curatively' 'treated' 'malignancy' 'at' 'high'
 'risk' 'of' 'relapse' 'during' 'the' 'study' 'period' 'with' 'the'
 'exception' 'of' 'localized' 'squamous' 'or' 'basal' 'cell' 'skin'
 'cancers']","[0. 0. 3. 3. 0. 0. 3. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 3. 0. 3. 3. 3. 3.]"
NCT02520778,",95:102:treatment,104:115:treatment,119:137:treatment,171:186:treatment,188:196:treatment,198:209:treatment,211:233:treatment,288:296:treatment,298:309:treatment,311:333:treatment","currently receiving (or unable to stop use at least 1 week prior to receiving the 1st dose of AZD9291) medications or herbal supplements known to be potent inhibitors of cytochrome P450, family 2, subfamily C, polypeptide 8 (CYP2C8) and potent inhibitors or inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4)","['currently' 'receiving' '(' 'or' 'unable' 'to' 'stop' 'use' 'at' 'least'
 '1' 'week' 'prior' 'to' 'receiving' 'the' '1st' 'dose' 'of' 'AZD9291' ')'
 'medications' 'or' 'herbal' 'supplements' 'known' 'to' 'be' 'potent'
 'inhibitors' 'of' 'cytochrome' 'P450' ',' 'family' '2' ',' 'subfamily'
 'C' ',' 'polypeptide' '8' '(' 'CYP2C8' ')' 'and' 'potent' 'inhibitors'
 'or' 'inducers' 'of' 'cytochrome' 'P450' ',' 'family' '3' ',' 'subfamily'
 'A' ',' 'polypeptide' '4' '(' 'CYP3A4' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1.
 1. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 1. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02520011,",42:44:treatment,61:78:treatment,90:93:treatment,100:135:treatment,141:154:treatment,155:165:treatment,168:177:treatment","Be in first relapse (within 24 months of CR) or have failed induction therapy* (no CR or CRi after treatment with an intensive regimen (eg, anthracycline/cytarabine ± etoposide, gemtuzumab ozogamicin, or cladribine)","['Be' 'in' 'first' 'relapse' '(' 'within' '24' 'months' 'of' 'CR' ')' 'or'
 'have' 'failed' 'induction' 'therapy' '*' '(' 'no' 'CR' 'or' 'CRi'
 'after' 'treatment' 'with' 'an' 'intensive' 'regimen' '(' 'eg' ','
 'anthracycline/cytarabine' '±' 'etoposide' ',' 'gemtuzumab' 'ozogamicin'
 ',' 'or' 'cladribine' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 0. 1.
 1. 1. 1. 1. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0.]"
NCT02520011,"10:30:treatment,23:30:treatment,,78:89:treatment",Received antileukemic therapy within the last 3 weeks (with the exception of hydroxyurea or if the patient has definite refractory disease). Refractory patients who received therapy within the last 3 weeks may be eligible with prior approval of the Medical Monitor,"['Received' 'antileukemic' 'therapy' 'within' 'the' 'last' '3' 'weeks' '('
 'with' 'the' 'exception' 'of' 'hydroxyurea' 'or' 'if' 'the' 'patient'
 'has' 'definite' 'refractory' 'disease' ')' '.' 'Refractory' 'patients'
 'who' 'received' 'therapy' 'within' 'the' 'last' '3' 'weeks' 'may' 'be'
 'eligible' 'with' 'prior' 'approval' 'of' 'the' 'Medical' 'Monitor']","[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02519452,"17:25:cancer,30:63:cancer,68:99:cancer,104:114:cancer","(exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence)","['(' 'exceptions' 'are' 'squamous' 'and' 'basal' 'cell' 'carcinomas' 'of'
 'the' 'skin' 'and' 'carcinoma' 'in' 'situ' 'of' 'the' 'cervix' ',' 'or'
 'malignancy' 'that' 'in' 'the' 'opinion' 'of' 'the' 'investigator' ','
 'with' 'concurrence' 'with' 'the' 'sponsor' ""'s"" 'medical' 'monitor' ','
 'is' 'considered' 'cured' 'with' 'minimal' 'risk' 'of' 'recurrence' ')']","[0. 0. 0. 3. 0. 3. 3. 3. 3. 3. 3. 0. 3. 3. 3. 3. 3. 3. 0. 0. 3. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02519452,"4:32:treatment,43:54:treatment,56:68:treatment,70:82:treatment,118:127:treatment","an immunomodulatory drug (IMiD) (example, thalidomide, lenalidomide, pomalidomide) in any order during the course of treatment","['an' 'immunomodulatory' 'drug' '(' 'IMiD' ')' '(' 'example' ','
 'thalidomide' ',' 'lenalidomide' ',' 'pomalidomide' ')' 'in' 'any'
 'order' 'during' 'the' 'course' 'of' 'treatment']",[0. 1. 1. 1. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02519348,"58:67:treatment,73:82:treatment,103:106:treatment","Have either progressed on, are intolerant to, or refused treatment with sorafenib or another approved TKI","['Have' 'either' 'progressed' 'on' ',' 'are' 'intolerant' 'to' ',' 'or'
 'refused' 'treatment' 'with' 'sorafenib' 'or' 'another' 'approved' 'TKI']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 1.]
NCT02519322,"30:41:chronic_disease,45:46:chronic_disease,64:69:chronic_disease,73:90:chronic_disease",Any positive test result for hepatitis B or C virus indicating acute or chronic infection,"['Any' 'positive' 'test' 'result' 'for' 'hepatitis' 'B' 'or' 'C' 'virus'
 'indicating' 'acute' 'or' 'chronic' 'infection']",[0. 0. 0. 0. 0. 2. 2. 0. 2. 0. 0. 2. 0. 2. 2.]
NCT02519322,",33:41:cancer,74:80:treatment,,117:128:treatment",Patients will have at least one melanoma deposit that can undergo serial biopsy (at least 2 time points) during the neoadjuvant phase of the protocol,"['Patients' 'will' 'have' 'at' 'least' 'one' 'melanoma' 'deposit' 'that'
 'can' 'undergo' 'serial' 'biopsy' '(' 'at' 'least' '2' 'time' 'points'
 ')' 'during' 'the' 'neoadjuvant' 'phase' 'of' 'the' 'protocol']","[0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.
 0. 0. 0.]"
NCT02519322,"63:237:treatment,318:337:treatment,344:358:chronic_disease","Subjects with history of life-threatening toxicity related to prior immune therapy (e.g., anti-CTLA-4 or anti-PD-1/PD-L1 treatment or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways) except those that are unlikely to re-occur with standard countermeasures (e.g., hormone replacement after endocrinopathy)","['Subjects' 'with' 'history' 'of' 'life-threatening' 'toxicity' 'related'
 'to' 'prior' 'immune' 'therapy' '(' 'e.g.' ',' 'anti-CTLA-4' 'or'
 'anti-PD-1/PD-L1' 'treatment' 'or' 'any' 'other' 'antibody' 'or' 'drug'
 'specifically' 'targeting' 'T-cell' 'co-stimulation' 'or' 'immune'
 'checkpoint' 'pathways' ')' 'except' 'those' 'that' 'are' 'unlikely' 'to'
 're-occur' 'with' 'standard' 'countermeasures' '(' 'e.g.' ',' 'hormone'
 'replacement' 'after' 'endocrinopathy' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.
 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.
 0. 2. 0.]"
NCT02519322,"1:8:treatment,12:28:treatment,34:61:treatment,,85:95:treatment,147:165:chronic_disease","inhaled or topical steroids, and adrenal replacement steroid doses of > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease","['inhaled' 'or' 'topical' 'steroids' ',' 'and' 'adrenal' 'replacement'
 'steroid' 'doses' 'of' '>' '10' 'mg' 'daily' 'prednisone' 'equivalent'
 ',' 'are' 'permitted' 'in' 'the' 'absence' 'of' 'active' 'autoimmune'
 'disease']","[1. 0. 1. 1. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 2. 2.]"
NCT02518594,"18:49:chronic_disease,51:57:chronic_disease,62:68:chronic_disease","Active, unhealed herpetic lesion on labia minora, vagina, or cervix due to the potential for significant patient discomfort or increasing genital tract viral spread. Once lesion(s) heal and the patient is asymptomatic, she may be randomized","['Active' ',' 'unhealed' 'herpetic' 'lesion' 'on' 'labia' 'minora' ','
 'vagina' ',' 'or' 'cervix' 'due' 'to' 'the' 'potential' 'for'
 'significant' 'patient' 'discomfort' 'or' 'increasing' 'genital' 'tract'
 'viral' 'spread' '.' 'Once' 'lesion' '(' 's' ')' 'heal' 'and' 'the'
 'patient' 'is' 'asymptomatic' ',' 'she' 'may' 'be' 'randomized']","[0. 0. 0. 2. 2. 2. 2. 2. 0. 2. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02518594,"1:14:chronic_disease,70:86:chronic_disease,175:188:chronic_disease,190:202:chronic_disease,212:236:chronic_disease,,","Fetal anomaly in either twin or imminent fetal demise. This includes lethal anomalies, or anomalies that may lead to early delivery or increased risk of neonatal death e.g., gastroschisis, spina bifida, serious karyotypic abnormalities). An ultrasound examination from 14 weeks 0 days to 23 weeks 6 days by project EDC (estimated date of conception) must be performed prior to randomization to evaluate the fetuses for anomalies","['Fetal' 'anomaly' 'in' 'either' 'twin' 'or' 'imminent' 'fetal' 'demise'
 '.' 'This' 'includes' 'lethal' 'anomalies' ',' 'or' 'anomalies' 'that'
 'may' 'lead' 'to' 'early' 'delivery' 'or' 'increased' 'risk' 'of'
 'neonatal' 'death' 'e.g.' ',' 'gastroschisis' ',' 'spina' 'bifida' ','
 'serious' 'karyotypic' 'abnormalities' ')' '.' 'An' 'ultrasound'
 'examination' 'from' '14' 'weeks' '0' 'days' 'to' '23' 'weeks' '6' 'days'
 'by' 'project' 'EDC' '(' 'estimated' 'date' 'of' 'conception' ')' 'must'
 'be' 'performed' 'prior' 'to' 'randomization' 'to' 'evaluate' 'the'
 'fetuses' 'for' 'anomalies']","[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02518594,"29:46:chronic_disease,48:51:chronic_disease,178:197:treatment,198:202:treatment,203:207:treatment","Specifically, patients with seizure disorders, HIV, and other medical conditions not specifically associated with an increased risk of indicated preterm birth are not excluded. Prior cervical cone/LOOP/LEEP","['Specifically' ',' 'patients' 'with' 'seizure' 'disorders' ',' 'HIV' ','
 'and' 'other' 'medical' 'conditions' 'not' 'specifically' 'associated'
 'with' 'an' 'increased' 'risk' 'of' 'indicated' 'preterm' 'birth' 'are'
 'not' 'excluded' '.' 'Prior' 'cervical' 'cone/LOOP/LEEP']","[0. 0. 0. 0. 2. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 1. 1.]"
NCT02516969,"1:37:treatment,30:37:treatment,95:101:treatment,105:115:treatment",Macroscopic complete salvage surgery with curative intent (surgery was not performed only for biopsy or palliation),"['Macroscopic' 'complete' 'salvage' 'surgery' 'with' 'curative' 'intent'
 '(' 'surgery' 'was' 'not' 'performed' 'only' 'for' 'biopsy' 'or'
 'palliation' ')']",[1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0.]
NCT02516813,"11:19:treatment,,,84:101:treatment,102:127:treatment,",Extensive prior RT on ≥30% of bone marrow reserve as judged by the investigator or prior bone marrow/stem cell transplantation within 5 years before trial start,"['Extensive' 'prior' 'RT' 'on' '≥30' '%' 'of' 'bone' 'marrow' 'reserve'
 'as' 'judged' 'by' 'the' 'investigator' 'or' 'prior' 'bone' 'marrow/stem'
 'cell' 'transplantation' 'within' '5' 'years' 'before' 'trial' 'start']","[0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0.
 0. 0. 0.]"
NCT02516813,"16:25:treatment,46:51:cancer,69:87:treatment,102:116:treatment,161:166:cancer,232:241:treatment",Phase Ib part: treatment-naïve Stage III A/B NSCLC not eligible for surgical resection or concurrent chemoradiation (Arm A expansion cohort) or treatment-naïve SCCHN eligible for fractionated curatively intended RT with concurrent cisplatin (Arm B expansion cohort),"['Phase' 'Ib' 'part' ':' 'treatment-naïve' 'Stage' 'III' 'A/B' 'NSCLC'
 'not' 'eligible' 'for' 'surgical' 'resection' 'or' 'concurrent'
 'chemoradiation' '(' 'Arm' 'A' 'expansion' 'cohort' ')' 'or'
 'treatment-naïve' 'SCCHN' 'eligible' 'for' 'fractionated' 'curatively'
 'intended' 'RT' 'with' 'concurrent' 'cisplatin' '(' 'Arm' 'B' 'expansion'
 'cohort' ')']","[0. 0. 0. 0. 1. 0. 0. 0. 3. 0. 0. 0. 1. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]"
NCT02516813,"104:115:treatment,119:137:treatment,171:186:treatment,187:194:treatment,198:205:treatment,,260:265:treatment,,344:381:treatment,","Subjects currently receiving (or unable to stop using prior to receiving the first dose of trial drug) medications or herbal supplements known to be potent inhibitors of cytochrome P450 (CYP)3A or CYP2C19 (must stop at least 1 week prior), potent inducers of CYP3A or CYP2C19 (must stop at least 3 weeks prior), or drugs mainly metabolized by CYP3A with a narrow therapeutic index (must stop at least one day prior)","['Subjects' 'currently' 'receiving' '(' 'or' 'unable' 'to' 'stop' 'using'
 'prior' 'to' 'receiving' 'the' 'first' 'dose' 'of' 'trial' 'drug' ')'
 'medications' 'or' 'herbal' 'supplements' 'known' 'to' 'be' 'potent'
 'inhibitors' 'of' 'cytochrome' 'P450' '(' 'CYP' ')' '3A' 'or' 'CYP2C19'
 '(' 'must' 'stop' 'at' 'least' '1' 'week' 'prior' ')' ',' 'potent'
 'inducers' 'of' 'CYP3A' 'or' 'CYP2C19' '(' 'must' 'stop' 'at' 'least' '3'
 'weeks' 'prior' ')' ',' 'or' 'drugs' 'mainly' 'metabolized' 'by' 'CYP3A'
 'with' 'a' 'narrow' 'therapeutic' 'index' '(' 'must' 'stop' 'at' 'least'
 'one' 'day' 'prior' ')']","[1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.
 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.
 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.
 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.]"
NCT02516696,"13:25:chronic_disease,29:49:chronic_disease,136:145:treatment",Subject has active viral or bacterial infections or any coexisting medical problem that would significantly increase the risks of this treatment program,"['Subject' 'has' 'active' 'viral' 'or' 'bacterial' 'infections' 'or' 'any'
 'coexisting' 'medical' 'problem' 'that' 'would' 'significantly'
 'increase' 'the' 'risks' 'of' 'this' 'treatment' 'program']",[0. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02516696,",,,,,,271:286:cancer,,347:358:treatment,362:365:treatment","Subject has measurable disease as defined by > 0.5 g/dL serum monoclonal protein, >10 mg/dL involved serum free light chain (either kappa or lambda) provided that the serum free light chain ratio is abnormal, >0.2 g/24 hrs urinary M-protein excretion, and/or measurable plasmacytoma(s) of at least 1cm in greatest dimension as measured by either CT scanning or MRI","['Subject' 'has' 'measurable' 'disease' 'as' 'defined' 'by' '>' '0.5'
 'g/dL' 'serum' 'monoclonal' 'protein' ',' '>' '10' 'mg/dL' 'involved'
 'serum' 'free' 'light' 'chain' '(' 'either' 'kappa' 'or' 'lambda' ')'
 'provided' 'that' 'the' 'serum' 'free' 'light' 'chain' 'ratio' 'is'
 'abnormal' ',' '>' '0.2' 'g/24' 'hrs' 'urinary' 'M-protein' 'excretion'
 ',' 'and/or' 'measurable' 'plasmacytoma' '(' 's' ')' 'of' 'at' 'least'
 '1cm' 'in' 'greatest' 'dimension' 'as' 'measured' 'by' 'either' 'CT'
 'scanning' 'or' 'MRI']","[3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3.
 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3.
 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 1. 1. 3. 1.]"
NCT02516670,"24:47:treatment,49:56:treatment,61:106:treatment",Are being treated with anticoagulation therapy (aspirin and nonsteroidal anti-inflammatory drugs [NSAIDS] are allowed),"['Are' 'being' 'treated' 'with' 'anticoagulation' 'therapy' '(' 'aspirin'
 'and' 'nonsteroidal' 'anti-inflammatory' 'drugs' '[' 'NSAIDS' ']' 'are'
 'allowed' ')']",[0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02516670,"10:30:treatment,34:59:treatment,,102:112:treatment",Have had palliative radiation or biological cancer therapy within 2 weeks prior to the first dose of study drug,"['Have' 'had' 'palliative' 'radiation' 'or' 'biological' 'cancer'
 'therapy' 'within' '2' 'weeks' 'prior' 'to' 'the' 'first' 'dose' 'of'
 'study' 'drug']",[0. 0. 1. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02516332,"4:6:treatment,10:46:treatment,54:58:treatment,62:96:treatment,","An MI or coronary revascularization procedure (i.e., CABG or percutaneous coronary intervention) within the last 3 months","['An' 'MI' 'or' 'coronary' 'revascularization' 'procedure' '(' 'i.e.' ','
 'CABG' 'or' 'percutaneous' 'coronary' 'intervention' ')' 'within' 'the'
 'last' '3' 'months']",[0. 1. 0. 1. 1. 1. 0. 0. 0. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02516241,"1:17:chronic_disease,28:40:chronic_disease,42:53:chronic_disease,55:66:chronic_disease,71:105:chronic_disease","Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)","['Active' 'infection' 'including' 'tuberculosis' ',' 'hepatitis' 'B' ','
 'hepatitis' 'C' ',' 'or' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')']",[2. 2. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT02516241,"25:53:treatment,,94:122:treatment,174:184:treatment,186:193:treatment,195:211:treatment,216:240:treatment,246:271:treatment,275:299:treatment,303:320:treatment,,348:358:treatment,379:387:treatment,441:462:treatment","Current or prior use of immunosuppressive medication within 14 days before the first dose of investigational product (IP). The following are exceptions to this criterion: • Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra articular injection) • Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent • Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication)","['Current' 'or' 'prior' 'use' 'of' 'immunosuppressive' 'medication'
 'within' '14' 'days' 'before' 'the' 'first' 'dose' 'of' 'investigational'
 'product' '(' 'IP' ')' '.' 'The' 'following' 'are' 'exceptions' 'to'
 'this' 'criterion' ':' '•' 'Intranasal' ',' 'inhaled' ',' 'topical'
 'steroids' ',' 'or' 'local' 'steroid' 'injections' '(' 'eg' ',' 'intra'
 'articular' 'injection' ')' '•' 'Systemic' 'corticosteroids' 'at'
 'physiologic' 'doses' 'not' 'to' 'exceed' '10' 'mg/day' 'of' 'prednisone'
 'or' 'its' 'equivalent' '•' 'Steroids' 'as' 'premedication' 'for'
 'hypersensitivity' 'reactions' '(' 'eg' ',' 'CT' 'scan' 'premedication'
 ')']","[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 1. 0. 0. 1. 1. 1. 0. 0. 0. 1. 1. 1. 0.
 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 1. 1. 0.]"
NCT02515773,"1:8:chronic_disease,1:10:chronic_disease,12:22:chronic_disease,56:65:chronic_disease,67:112:chronic_disease,114:134:chronic_disease,194:207:chronic_disease","bipolar I, bipolar II, unspecified bipolar and related disorders, Disruptive Mood Dysregulation Disorder (DMDD), cyclothymic disorder, other specified bipolar and related disorders, as well as mood disorder not otherwise specified (if diagnosed in the past as per DSM-IV)","['bipolar' 'I' ',' 'bipolar' 'II' ',' 'unspecified' 'bipolar' 'and'
 'related' 'disorders' ',' 'Disruptive' 'Mood' 'Dysregulation' 'Disorder'
 '(' 'DMDD' ')' ',' 'cyclothymic' 'disorder' ',' 'other' 'specified'
 'bipolar' 'and' 'related' 'disorders' ',' 'as' 'well' 'as' 'mood'
 'disorder' 'not' 'otherwise' 'specified' '(' 'if' 'diagnosed' 'in' 'the'
 'past' 'as' 'per' 'DSM-IV' ')']","[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 2. 2. 2. 0. 0. 0. 2. 2. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02515110,"1:13:treatment,,55:67:treatment,72:85:cancer,106:127:treatment",Radiotherapy must begin within 10 weeks following the last surgery for breast cancer or the last dose of adjuvant chemotherapy,"['Radiotherapy' 'must' 'begin' 'within' '10' 'weeks' 'following' 'the'
 'last' 'surgery' 'for' 'breast' 'cancer' 'or' 'the' 'last' 'dose' 'of'
 'adjuvant' 'chemotherapy']",[1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 3. 3. 0. 0. 0. 0. 0. 1. 1.]
NCT02514083,"1:37:treatment,39:51:treatment,53:65:treatment,69:89:treatment","Concomitant immunomodulatory therapy, chemotherapy, radiotherapy or experimental therapy","['Concomitant' 'immunomodulatory' 'therapy' ',' 'chemotherapy' ','
 'radiotherapy' 'or' 'experimental' 'therapy']",[1. 1. 1. 0. 1. 0. 1. 0. 1. 1.]
NCT02514083,"1:17:treatment,29:49:treatment,99:102:cancer",Immunophenotypic profile or immunohistochemistry read by an expert pathologist as consistent with CLL,"['Immunophenotypic' 'profile' 'or' 'immunohistochemistry' 'read' 'by' 'an'
 'expert' 'pathologist' 'as' 'consistent' 'with' 'CLL']",[1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT02514083,"1:4:cancer,6:21:chronic_disease,52:55:cancer,","SLL: lymphadenopathy with the tissue morphology of CLL but that are not leukemic, < 5,000 cells/microL","['SLL' ':' 'lymphadenopathy' 'with' 'the' 'tissue' 'morphology' 'of' 'CLL'
 'but' 'that' 'are' 'not' 'leukemic' ',' '<' '5,000' 'cells/microL']",[3. 0. 2. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02514083,"1:10:treatment,17:20:cancer,34:56:treatment,58:74:treatment,84:98:treatment,100:121:treatment,127:199:treatment","Treatment-naive CLL indicates no prior anti-CLL therapy. Anti-CLL therapy includes chemotherapies, monoclonal antibodies, and targeted agents with known or reasonably expected anti-leukemic activity","['Treatment-naive' 'CLL' 'indicates' 'no' 'prior' 'anti-CLL' 'therapy' '.'
 'Anti-CLL' 'therapy' 'includes' 'chemotherapies' ',' 'monoclonal'
 'antibodies' ',' 'and' 'targeted' 'agents' 'with' 'known' 'or'
 'reasonably' 'expected' 'anti-leukemic' 'activity']","[1. 3. 0. 0. 1. 1. 1. 0. 1. 1. 0. 1. 0. 1. 1. 0. 0. 1. 1. 1. 1. 1. 1. 1.
 1. 1.]"
NCT02514070,"23:30:treatment,40:53:treatment,57:79:treatment,81:87:treatment",Subjects taking daily aspirin or other anti-platelet or anti-coagulants agents (Plavix),"['Subjects' 'taking' 'daily' 'aspirin' 'or' 'other' 'anti-platelet' 'or'
 'anti-coagulants' 'agents' '(' 'Plavix' ')']",[0. 0. 0. 1. 0. 0. 1. 0. 1. 1. 0. 1. 0.]
NCT02514070,"36:51:chronic_disease,82:101:chronic_disease,103:112:chronic_disease,117:126:chronic_disease","Subjects with clinically diagnosed hepatic disease (including but not limited to auto immune disease, hepatitis and cirrhosis)","['Subjects' 'with' 'clinically' 'diagnosed' 'hepatic' 'disease' '('
 'including' 'but' 'not' 'limited' 'to' 'auto' 'immune' 'disease' ','
 'hepatitis' 'and' 'cirrhosis' ')']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 2. 0. 2. 0.]
NCT02513797,"12:26:chronic_disease,28:53:chronic_disease,57:77:chronic_disease,","Documented embolic stroke, transient ischemic attach or suspected neurologic event within 3 months prior to the planned intervention","['Documented' 'embolic' 'stroke' ',' 'transient' 'ischemic' 'attach' 'or'
 'suspected' 'neurologic' 'event' 'within' '3' 'months' 'prior' 'to' 'the'
 'planned' 'intervention']",[0. 2. 2. 0. 2. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02513797,"95:123:treatment,125:146:treatment,148:161:treatment","Prior procedure involving opening of the pericardium or entering the pericardial space (e.g., coronary artery bypass graft, heart transplantation, valve surgery) where adhesions are suspected","['Prior' 'procedure' 'involving' 'opening' 'of' 'the' 'pericardium' 'or'
 'entering' 'the' 'pericardial' 'space' '(' 'e.g.' ',' 'coronary' 'artery'
 'bypass' 'graft' ',' 'heart' 'transplantation' ',' 'valve' 'surgery' ')'
 'where' 'adhesions' 'are' 'suspected']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 1. 1. 0. 1.
 1. 0. 0. 0. 0. 0.]"
NCT02513485,"23:32:chronic_disease,34:42:chronic_disease,44:52:cancer,57:74:chronic_disease","Current or history of migraines, glaucoma, melanoma, or bleeding disorder of any kind","['Current' 'or' 'history' 'of' 'migraines' ',' 'glaucoma' ',' 'melanoma'
 ',' 'or' 'bleeding' 'disorder' 'of' 'any' 'kind']",[0. 0. 0. 0. 2. 0. 2. 0. 3. 0. 0. 2. 2. 0. 0. 0.]
NCT02513485,"27:40:chronic_disease,42:66:chronic_disease,79:92:chronic_disease,94:103:chronic_disease,105:115:chronic_disease,150:168:chronic_disease,170:178:chronic_disease","History of the following: schizophrenia, schizoaffective disorder, other (non mood disorder) psychosis, depression secondary to a medical condition, mental retardation, dementia, or delirium","['History' 'of' 'the' 'following' ':' 'schizophrenia' ','
 'schizoaffective' 'disorder' ',' 'other' '(' 'non' 'mood' 'disorder' ')'
 'psychosis' ',' 'depression' 'secondary' 'to' 'a' 'medical' 'condition'
 ',' 'mental' 'retardation' ',' 'dementia' ',' 'or' 'delirium']","[0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 2. 2. 0. 2. 0. 2. 0. 0. 0. 0. 0.
 0. 2. 2. 0. 2. 0. 0. 0.]"
NCT02512926,"32:37:cancer,41:54:cancer,64:69:cancer,85:96:cancer","Patients may have asymptomatic CNS 1 or CNS 2 disease, but not CNS 3 or symptomatic CNS disease","['Patients' 'may' 'have' 'asymptomatic' 'CNS' '1' 'or' 'CNS' '2' 'disease'
 ',' 'but' 'not' 'CNS' '3' 'or' 'symptomatic' 'CNS' 'disease']",[0. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02512718,"132:156:treatment,170:173:chronic_disease,,,213:221:treatment,243:266:treatment","Planned myeloablative allogeneic bone marrow, cord, or peripheral blood stem cell (from any donor, including haploidentical donor) HCT conditioning regimen using either TBI (planned cumulative dose >1100 cGy) or busulfan in addition to other chemotherapeutic agents","['Planned' 'myeloablative' 'allogeneic' 'bone' 'marrow' ',' 'cord' ','
 'or' 'peripheral' 'blood' 'stem' 'cell' '(' 'from' 'any' 'donor' ','
 'including' 'haploidentical' 'donor' ')' 'HCT' 'conditioning' 'regimen'
 'using' 'either' 'TBI' '(' 'planned' 'cumulative' 'dose' '>' '1100' 'cGy'
 ')' 'or' 'busulfan' 'in' 'addition' 'to' 'other' 'chemotherapeutic'
 'agents']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.
 1. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 1. 1.]"
NCT02512497,"1:31:chronic_disease,,,,,158:172:treatment,180:183:treatment",Congestive heart failure (CHF) that meets New York Heart Association (NYHA) Class II to IV definitions and/or ejection fraction <40% by MUGA scan or <50% by echocardiogram and/or MRI,"['Congestive' 'heart' 'failure' '(' 'CHF' ')' 'that' 'meets' 'New' 'York'
 'Heart' 'Association' '(' 'NYHA' ')' 'Class' 'II' 'to' 'IV' 'definitions'
 'and/or' 'ejection' 'fraction' '<' '40' '%' 'by' 'MUGA' 'scan' 'or' '<'
 '50' '%' 'by' 'echocardiogram' 'and/or' 'MRI']","[2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1.]"
NCT02512497,"1:26:chronic_disease,14:26:chronic_disease,,,127:137:treatment","Uncontrolled hypertension, i.e., blood pressure (BP) of >/= 160/95; patients who have a history of hypertension controlled by medication must be on a stable dose and meet all other inclusion criteria","['Uncontrolled' 'hypertension' ',' 'i.e.' ',' 'blood' 'pressure' '(' 'BP'
 ')' 'of' '>' '/=' '160/95' ';' 'patients' 'who' 'have' 'a' 'history' 'of'
 'hypertension' 'controlled' 'by' 'medication' 'must' 'be' 'on' 'a'
 'stable' 'dose' 'and' 'meet' 'all' 'other' 'inclusion' 'criteria']","[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02510456,"20:34:treatment,36:46:treatment,50:60:treatment,61:80:treatment,106:125:treatment",Planned definitive breast surgery (mastectomy or lumpectomy/breast conservation) following completion of neoadjuvant therapy,"['Planned' 'definitive' 'breast' 'surgery' '(' 'mastectomy' 'or'
 'lumpectomy/breast' 'conservation' ')' 'following' 'completion' 'of'
 'neoadjuvant' 'therapy']",[0. 0. 1. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 1. 1.]
NCT02509546,"60:94:treatment,99:116:treatment,134:143:treatment","Current or planned use of other investigational agents, or concurrent biological chemotherapy, or radiation therapy during the study treatment period","['Current' 'or' 'planned' 'use' 'of' 'other' 'investigational' 'agents'
 ',' 'or' 'concurrent' 'biological' 'chemotherapy' ',' 'or' 'radiation'
 'therapy' 'during' 'the' 'study' 'treatment' 'period']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 1. 1. 0. 0. 0. 1. 0.]
NCT02509507,"5:8:cancer,20:50:chronic_disease,52:55:chronic_disease,63:66:chronic_disease,91:123:treatment,173:189:treatment,,234:255:treatment","For HCC with prior hepatitis B and/or C infection, HBV and/or HCV viral load by real time polymerase chain reaction (qPCR) must be undetectable, and they must not have had recent treatment within 12 weeks for HBV or HCV with certain antiviral medications","['For' 'HCC' 'with' 'prior' 'hepatitis' 'B' 'and/or' 'C' 'infection' ','
 'HBV' 'and/or' 'HCV' 'viral' 'load' 'by' 'real' 'time' 'polymerase'
 'chain' 'reaction' '(' 'qPCR' ')' 'must' 'be' 'undetectable' ',' 'and'
 'they' 'must' 'not' 'have' 'had' 'recent' 'treatment' 'within' '12'
 'weeks' 'for' 'HBV' 'or' 'HCV' 'with' 'certain' 'antiviral' 'medications']","[0. 3. 0. 0. 2. 2. 2. 2. 2. 0. 2. 0. 2. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]"
NCT02509507,"1:8:cancer,,48:99:treatment,118:126:cancer,130:148:cancer",Non-HCC subjects must have received at least 1 prior standard of care systemic anti-cancer therapy for their locally advanced or metastatic disease,"['Non-HCC' 'subjects' 'must' 'have' 'received' 'at' 'least' '1' 'prior'
 'standard' 'of' 'care' 'systemic' 'anti-cancer' 'therapy' 'for' 'their'
 'locally' 'advanced' 'or' 'metastatic' 'disease']",[3. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 3. 0. 3. 3.]
NCT02509507,"58:60:cancer,62:65:cancer,67:70:cancer,72:80:cancer,82:87:cancer,92:95:cancer,101:117:cancer,121:124:cancer","They must have histologically or cytologically confirmed BC, CRC, GEC, melanoma, NSCLC, or RCC with liver metastases or HCC","['They' 'must' 'have' 'histologically' 'or' 'cytologically' 'confirmed'
 'BC' ',' 'CRC' ',' 'GEC' ',' 'melanoma' ',' 'NSCLC' ',' 'or' 'RCC' 'with'
 'liver' 'metastases' 'or' 'HCC']",[0. 0. 0. 0. 0. 0. 0. 3. 0. 3. 0. 3. 0. 3. 0. 3. 0. 0. 3. 0. 3. 3. 0. 3.]
NCT02508038,"10:14:chronic_disease,26:30:chronic_disease,42:45:chronic_disease","MPX for: HepB (HBV-PCR), HepC (HCV-PCR), HIV (HIV-PCR)","['MPX' 'for' ':' 'HepB' '(' 'HBV-PCR' ')' ',' 'HepC' '(' 'HCV-PCR' ')' ','
 'HIV' '(' 'HIV-PCR' ')']",[0. 0. 0. 2. 0. 0. 0. 0. 2. 0. 0. 0. 0. 2. 0. 0. 0.]
NCT02508038,"15:24:cancer,28:43:cancer,74:81:treatment,89:101:treatment",Relapsed with pulmonary or bone metastases and did not achieve a CR with surgery and/or chemotherapy,"['Relapsed' 'with' 'pulmonary' 'or' 'bone' 'metastases' 'and' 'did' 'not'
 'achieve' 'a' 'CR' 'with' 'surgery' 'and/or' 'chemotherapy']",[0. 0. 3. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1.]
NCT02507687,"1:12:treatment,24:40:treatment,49:66:treatment,",Eye surgery (including cataract surgery) and or eye laser surgery within the past 6 months,"['Eye' 'surgery' '(' 'including' 'cataract' 'surgery' ')' 'and' 'or' 'eye'
 'laser' 'surgery' 'within' 'the' 'past' '6' 'months']",[1. 1. 0. 0. 1. 1. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02507232,"1:22:cancer,24:37:cancer,39:67:cancer,72:111:cancer","Pilocytic astrocytoma, ganglioglioma, pleomorphic xanthastrocytoma, or dysembryoplastic neuroepithelial tumors","['Pilocytic' 'astrocytoma' ',' 'ganglioglioma' ',' 'pleomorphic'
 'xanthastrocytoma' ',' 'or' 'dysembryoplastic' 'neuroepithelial' 'tumors']",[3. 3. 0. 3. 0. 3. 3. 0. 0. 3. 3. 3.]
NCT02506192,"1:7:cancer,20:42:cancer,55:64:treatment,,,","Cancer (other than basal cell skin cancer), requiring treatment within the past 12 months, or life expectancy of less than 1 year","['Cancer' '(' 'other' 'than' 'basal' 'cell' 'skin' 'cancer' ')' ','
 'requiring' 'treatment' 'within' 'the' 'past' '12' 'months' ',' 'or'
 'life' 'expectancy' 'of' 'less' 'than' '1' 'year']","[3. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02506192,"1:14:chronic_disease,27:39:chronic_disease,42:55:chronic_disease,59:81:chronic_disease,","Heart Disease (other than Hypertension), Heart Failure or Coronary Heart Disease requiring hospitalization within the past 12 months","['Heart' 'Disease' '(' 'other' 'than' 'Hypertension' ')' ',' 'Heart'
 'Failure' 'or' 'Coronary' 'Heart' 'Disease' 'requiring' 'hospitalization'
 'within' 'the' 'past' '12' 'months']",[2. 2. 0. 0. 0. 2. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02505165,"35:43:cancer,47:55:cancer,57:78:cancer,83:104:cancer","The child has been diagnosed with leukemia or lymphoma, malignant solid tumor, or malignant brain tumor","['The' 'child' 'has' 'been' 'diagnosed' 'with' 'leukemia' 'or' 'lymphoma'
 ',' 'malignant' 'solid' 'tumor' ',' 'or' 'malignant' 'brain' 'tumor']",[0. 0. 0. 0. 0. 0. 3. 0. 3. 0. 3. 3. 3. 0. 0. 0. 0. 0.]
NCT02504489,"1:9:treatment,13:37:treatment,45:60:treatment,101:123:treatment",Adjuvant or neoadjuvant chemotherapy and/or chemo-radiation for early stage disease do not count as prior systemic therapy,"['Adjuvant' 'or' 'neoadjuvant' 'chemotherapy' 'and/or' 'chemo-radiation'
 'for' 'early' 'stage' 'disease' 'do' 'not' 'count' 'as' 'prior'
 'systemic' 'therapy']",[1. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02503722,"31:53:treatment,57:69:treatment,71:93:treatment,129:143:treatment","Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation","['Documentation' 'of' 'irreversible' 'surgical' 'sterilization' 'by'
 'hysterectomy' ',' 'bilateral' 'oophorectomy' 'or' 'bilateral'
 'salpingectomy' 'but' 'not' 'tubal' 'ligation']",[0. 0. 0. 1. 1. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 1. 1.]
NCT02503722,"1:20:chronic_disease,38:44:chronic_disease,55:62:treatment,67:91:treatment","Ischemic myocardial event, including angina requiring therapy and artery revascularization procedures","['Ischemic' 'myocardial' 'event' ',' 'including' 'angina' 'requiring'
 'therapy' 'and' 'artery' 'revascularization' 'procedures']",[2. 2. 0. 0. 0. 2. 0. 1. 0. 1. 1. 0.]
NCT02503722,"1:21:treatment,,87:107:treatment,,,177:185:chronic_disease",Prior EGFR inhibitor: A minimum of 7 days must have elapsed from the last dose of the prior EGFR inhibitor and resolution of any drug-related toxicity to =< grade 1 except for alopecia,"['Prior' 'EGFR' 'inhibitor' ':' 'A' 'minimum' 'of' '7' 'days' 'must'
 'have' 'elapsed' 'from' 'the' 'last' 'dose' 'of' 'the' 'prior' 'EGFR'
 'inhibitor' 'and' 'resolution' 'of' 'any' 'drug-related' 'toxicity' 'to'
 '=' '<' 'grade' '1' 'except' 'for' 'alopecia']","[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]"
NCT02503722,"4:13:treatment,39:47:treatment,49:56:treatment,61:82:treatment,88:103:treatment",be treatment naive for 3rd generation EGFR-TKI (CO-1686 and osimertinib [AZD9291]) and mTOR inhibitors,"['be' 'treatment' 'naive' 'for' '3rd' 'generation' 'EGFR-TKI' '('
 'CO-1686' 'and' 'osimertinib' '[' 'AZD9291' ']' ')' 'and' 'mTOR'
 'inhibitors']",[0. 1. 0. 0. 0. 0. 1. 0. 1. 0. 1. 1. 0. 0. 0. 0. 1. 1.]
NCT02503722,"15:24:treatment,28:34:treatment,64:89:treatment,",substrates of CYP 3A4/5 or CYP1A2 that are sensitive or have a narrow therapeutic window at least three weeks prior to study registration,"['substrates' 'of' 'CYP' '3A4/5' 'or' 'CYP1A2' 'that' 'are' 'sensitive'
 'or' 'have' 'a' 'narrow' 'therapeutic' 'window' 'at' 'least' 'three'
 'weeks' 'prior' 'to' 'study' 'registration']",[0. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02503709,"21:37:cancer,41:65:cancer,141:157:cancer,191:225:treatment,,244:253:treatment,263:271:treatment,275:301:treatment","Patients with known brain metastases or carcinomatous meningitis are excluded from this clinical trial, with the exception of patients with brain metastatic disease that has previously been treated and remained stable on MRI >= 2 months after treatment, without steroids or anti-epileptic medications; these patients may be enrolled at the discretion of the principal investigator","['Patients' 'with' 'known' 'brain' 'metastases' 'or' 'carcinomatous'
 'meningitis' 'are' 'excluded' 'from' 'this' 'clinical' 'trial' ',' 'with'
 'the' 'exception' 'of' 'patients' 'with' 'brain' 'metastatic' 'disease'
 'that' 'has' 'previously' 'been' 'treated' 'and' 'remained' 'stable' 'on'
 'MRI' '>' '=' '2' 'months' 'after' 'treatment' ',' 'without' 'steroids'
 'or' 'anti-epileptic' 'medications' ';' 'these' 'patients' 'may' 'be'
 'enrolled' 'at' 'the' 'discretion' 'of' 'the' 'principal' 'investigator']","[0. 0. 0. 3. 3. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 1. 0. 0. 1. 0. 1. 1. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02503358,"34:45:treatment,77:85:treatment,89:93:treatment","A history of hypersensitivity to selumetinib, or any excipient agents (e.g. Captisol or TPGS- a water soluble form of Vitamin E)","['A' 'history' 'of' 'hypersensitivity' 'to' 'selumetinib' ',' 'or' 'any'
 'excipient' 'agents' '(' 'e.g' '.' 'Captisol' 'or' 'TPGS-' 'a' 'water'
 'soluble' 'form' 'of' 'Vitamin' 'E' ')']","[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02503358,"48:66:treatment,86:95:treatment,119:131:treatment,142:163:treatment,165:177:treatment,179:189:treatment,191:202:treatment,204:214:treatment,216:225:treatment,227:237:treatment,239:248:treatment,253:263:treatment,281:291:treatment,293:306:treatment,308:317:treatment,319:328:treatment,333:343:treatment,421:432:treatment","Caution should be exercised when administering paclitaxel (Taxol) concomitantly with medicines known to inhibit (e.g. ketoconazole and other imidazole antifungals, erythromycin, fluoxetine, gemfibrozil, cimetidine, ritonavir, saquinavir, indinavir and nelfinavir) OR induce (e.g. rifampicin, carbamazepine, phenytoin, efavirenz and nevirapine) either CYP2C8 or CYP3A4. Based on the in vitro data and SimCYP simulations, selumetinib is considered unlikely to perpetrate clinically significant drug-drug interaction via inhibition or induction of CYP enzymes","['Caution' 'should' 'be' 'exercised' 'when' 'administering' 'paclitaxel'
 '(' 'Taxol' ')' 'concomitantly' 'with' 'medicines' 'known' 'to' 'inhibit'
 '(' 'e.g' '.' 'ketoconazole' 'and' 'other' 'imidazole' 'antifungals' ','
 'erythromycin' ',' 'fluoxetine' ',' 'gemfibrozil' ',' 'cimetidine' ','
 'ritonavir' ',' 'saquinavir' ',' 'indinavir' 'and' 'nelfinavir' ')' 'OR'
 'induce' '(' 'e.g' '.' 'rifampicin' ',' 'carbamazepine' ',' 'phenytoin'
 ',' 'efavirenz' 'and' 'nevirapine' ')' 'either' 'CYP2C8' 'or' 'CYP3A4'
 '.' 'Based' 'on' 'the' 'in' 'vitro' 'data' 'and' 'SimCYP' 'simulations'
 ',' 'selumetinib' 'is' 'considered' 'unlikely' 'to' 'perpetrate'
 'clinically' 'significant' 'drug-drug' 'interaction' 'via' 'inhibition'
 'or' 'induction' 'of' 'CYP' 'enzymes']","[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 1.
 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 1. 0.
 1. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02502708,"34:46:treatment,48:64:treatment,73:82:treatment","Patients previously treated with temozolomide, cyclophosphamide, and/or etoposide are eligible for enrollment","['Patients' 'previously' 'treated' 'with' 'temozolomide' ','
 'cyclophosphamide' ',' 'and/or' 'etoposide' 'are' 'eligible' 'for'
 'enrollment']",[0. 0. 0. 0. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0.]
NCT02502006,"6:35:treatment,17:35:treatment,47:58:treatment,60:69:treatment,71:79:treatment,","Used dietary or herbal supplements containing salicylates, Vitamin E, fish oil, or any other herbal supplements, within 14 days of study drug administration","['Used' 'dietary' 'or' 'herbal' 'supplements' 'containing' 'salicylates'
 ',' 'Vitamin' 'E' ',' 'fish' 'oil' ',' 'or' 'any' 'other' 'herbal'
 'supplements' ',' 'within' '14' 'days' 'of' 'study' 'drug'
 'administration']","[0. 1. 1. 1. 1. 0. 1. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02501954,"28:49:chronic_disease,51:66:chronic_disease,71:94:chronic_disease,","Patients with a history of myocardial infarction, unstable angina, or uncontrolled arrhythmia within 3 months from enrollment","['Patients' 'with' 'a' 'history' 'of' 'myocardial' 'infarction' ','
 'unstable' 'angina' ',' 'or' 'uncontrolled' 'arrhythmia' 'within' '3'
 'months' 'from' 'enrollment']",[0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02501473,"41:49:cancer,61:72:cancer,77:99:cancer","Central nervous system involvement with lymphoma, including parenchymal and leptomeningeal disease","['Central' 'nervous' 'system' 'involvement' 'with' 'lymphoma' ','
 'including' 'parenchymal' 'and' 'leptomeningeal' 'disease']",[0. 0. 0. 0. 0. 3. 0. 0. 3. 0. 3. 3.]
NCT02501473,"18:24:cancer,,48:83:cancer,88:114:cancer",History of other cancer within 2 years (except non-melanoma cutaneous malignancies and cervical carcinoma in situ),"['History' 'of' 'other' 'cancer' 'within' '2' 'years' '(' 'except'
 'non-melanoma' 'cutaneous' 'malignancies' 'and' 'cervical' 'carcinoma'
 'in' 'situ' ')']",[0. 0. 0. 3. 0. 0. 0. 0. 0. 3. 3. 3. 0. 3. 3. 3. 3. 0.]
NCT02501473,",46:55:chronic_disease,57:76:chronic_disease,99:110:chronic_disease,112:123:chronic_disease,127:140:chronic_disease","Recent (< 1 week ago) clinically significant infection, active tuberculosis or evidence of active hepatitis B, hepatitis C or HIV infection","['Recent' '(' '<' '1' 'week' 'ago' ')' 'clinically' 'significant'
 'infection' ',' 'active' 'tuberculosis' 'or' 'evidence' 'of' 'active'
 'hepatitis' 'B' ',' 'hepatitis' 'C' 'or' 'HIV' 'infection']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 2.
 2.]"
NCT02501096,"9:43:chronic_disease,48:56:cancer,112:146:treatment,148:158:treatment,163:178:treatment","For the non-small cell lung cancer (NSCLC) and melanoma cohorts, participants must have progressed on or after prior treatment with one anti-PD-1, anti-PD-L1, or anti-PDL2 agent","['For' 'the' 'non-small' 'cell' 'lung' 'cancer' '(' 'NSCLC' ')' 'and'
 'melanoma' 'cohorts' ',' 'participants' 'must' 'have' 'progressed' 'on'
 'or' 'after' 'prior' 'treatment' 'with' 'one' 'anti-PD-1' ','
 'anti-PD-L1' ',' 'or' 'anti-PDL2' 'agent']","[0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1.
 1. 0. 1. 0. 0. 1. 1.]"
NCT02501096,"16:38:treatment,,57:74:treatment,91:103:treatment",Has received a live-virus vaccination within 30 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted,"['Has' 'received' 'a' 'live-virus' 'vaccination' 'within' '30' 'days' 'of'
 'planned' 'treatment' 'start' '.' 'Seasonal' 'flu' 'vaccines' 'that' 'do'
 'not' 'contain' 'live' 'virus' 'are' 'permitted']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02501096,",28:52:chronic_disease,,75:90:chronic_disease,92:113:chronic_disease,","New York Heart Association congestive heart failure of grade II or above, unstable angina, myocardial infarction within the past 6 months","['New' 'York' 'Heart' 'Association' 'congestive' 'heart' 'failure' 'of'
 'grade' 'II' 'or' 'above' ',' 'unstable' 'angina' ',' 'myocardial'
 'infarction' 'within' 'the' 'past' '6' 'months']",[0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02501096,"24:40:cancer,85:106:treatment,116:140:treatment,142:167:treatment,180:198:treatment,269:277:treatment,,315:330:treatment","articipants with known brain metastases will be eligible if they have completed the primary brain therapy (such as whole brain radiotherapy, stereotactic radiosurgery or complete surgical resection) and if they have remained clinically stable, asymptomatic and off of steroids for at least 28 days before starting study treatment","['articipants' 'with' 'known' 'brain' 'metastases' 'will' 'be' 'eligible'
 'if' 'they' 'have' 'completed' 'the' 'primary' 'brain' 'therapy' '('
 'such' 'as' 'whole' 'brain' 'radiotherapy' ',' 'stereotactic'
 'radiosurgery' 'or' 'complete' 'surgical' 'resection' ')' 'and' 'if'
 'they' 'have' 'remained' 'clinically' 'stable' ',' 'asymptomatic' 'and'
 'off' 'of' 'steroids' 'for' 'at' 'least' '28' 'days' 'before' 'starting'
 'study' 'treatment']","[0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 1. 1. 1. 0. 1.
 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.
 0. 0. 1. 1.]"
NCT02500602,"17:31:chronic_disease,107:110:treatment,150:167:treatment,169:184:treatment,218:226:treatment,228:251:treatment,253:264:treatment,266:281:treatment,341:357:treatment,359:378:treatment,380:385:treatment,390:402:treatment,404:422:treatment,431:441:treatment,448:453:treatment,458:473:treatment,475:493:treatment,495:520:treatment,522:537:treatment,542:554:treatment,556:569:treatment,571:595:treatment,597:608:treatment,609:612:treatment,613:619:treatment,620:625:treatment,640:654:treatment","MRI exclusions: Claustrophobia; tattoos above the shoulders after evaluation by MRI technician; permanent eyeliner or permanent artificial eyebrows; cardiac pacemaker; metal fragments in eye, skin, or body, including shrapnel; heart valve replacement; brain clips; venous umbrella; being a sheet-metal worker or welder; lifetime history of aneurysm surgery; intracranial bypass, renal, or aortic clips; prosthetic devices such as middle ear, eye, joint, or penile implants; joint replacements; non-removable hearing aid, neurostimulator, or insulin pump; shunts/stents; metal mesh/coil implants; metal plate/pin/screws/wires; or any other metal implants","['MRI' 'exclusions' ':' 'Claustrophobia' ';' 'tattoos' 'above' 'the'
 'shoulders' 'after' 'evaluation' 'by' 'MRI' 'technician' ';' 'permanent'
 'eyeliner' 'or' 'permanent' 'artificial' 'eyebrows' ';' 'cardiac'
 'pacemaker' ';' 'metal' 'fragments' 'in' 'eye' ',' 'skin' ',' 'or' 'body'
 ',' 'including' 'shrapnel' ';' 'heart' 'valve' 'replacement' ';' 'brain'
 'clips' ';' 'venous' 'umbrella' ';' 'being' 'a' 'sheet-metal' 'worker'
 'or' 'welder' ';' 'lifetime' 'history' 'of' 'aneurysm' 'surgery' ';'
 'intracranial' 'bypass' ',' 'renal' ',' 'or' 'aortic' 'clips' ';'
 'prosthetic' 'devices' 'such' 'as' 'middle' 'ear' ',' 'eye' ',' 'joint'
 ',' 'or' 'penile' 'implants' ';' 'joint' 'replacements' ';'
 'non-removable' 'hearing' 'aid' ',' 'neurostimulator' ',' 'or' 'insulin'
 'pump' ';' 'shunts/stents' ';' 'metal' 'mesh/coil' 'implants' ';' 'metal'
 'plate/pin/screws/wires' ';' 'or' 'any' 'other' 'metal' 'implants']","[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.
 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 1. 0. 1. 1. 0. 1. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 1. 0. 0. 1. 1. 0. 1. 1.
 0. 0. 1. 1. 0. 0. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 1. 1. 1. 0. 1. 0. 0. 1.
 1. 0. 1. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]"
NCT02500407,"1:19:chronic_disease,61:75:chronic_disease,93:124:chronic_disease,129:145:chronic_disease","Autoimmune disease with the exception of controlled/treated hypothyroidism, disease-related immune thrombocytopenic purpura, or hemolytic anemia","['Autoimmune' 'disease' 'with' 'the' 'exception' 'of' 'controlled/treated'
 'hypothyroidism' ',' 'disease-related' 'immune' 'thrombocytopenic'
 'purpura' ',' 'or' 'hemolytic' 'anemia']",[2. 2. 0. 0. 0. 0. 0. 2. 0. 0. 2. 2. 2. 0. 0. 2. 2.]
NCT02500407,"1:28:treatment,,63:72:treatment,74:87:treatment",Treatment with radiotherapy within 2 weeks prior to the first BTCT4465A (Mosunetuzumab) administration,"['Treatment' 'with' 'radiotherapy' 'within' '2' 'weeks' 'prior' 'to' 'the'
 'first' 'BTCT4465A' '(' 'Mosunetuzumab' ')' 'administration']",[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0.]
NCT02500147,"1:8:allergy_name,63:78:treatment,82:101:treatment","Insulin secretion and sensitivity, or the GH-IGF-I axis (e.g. steroid hormone or thyroid replacement)","['Insulin' 'secretion' 'and' 'sensitivity' ',' 'or' 'the' 'GH-IGF-I'
 'axis' '(' 'e.g' '.' 'steroid' 'hormone' 'or' 'thyroid' 'replacement' ')']",[4. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0.]
NCT02498951,"47:52:cancer,56:91:cancer,95:126:cancer",Patients with a history of curatively treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix,"['Patients' 'with' 'a' 'history' 'of' 'curatively' 'treated' 'basal' 'or'
 'squamous' 'cell' 'carcinoma' 'of' 'the' 'skin' 'or' 'in' 'situ'
 'carcinoma' 'of' 'the' 'cervix']",[0. 0. 0. 0. 0. 0. 0. 3. 0. 3. 3. 3. 3. 3. 3. 0. 3. 3. 3. 3. 3. 3.]
NCT02498613,",41:68:treatment,81:89:cancer,93:111:cancer,138:143:cancer,154:159:cancer,155:159:cancer,174:194:treatment,199:231:treatment,239:269:treatment,276:289:treatment,323:327:cancer,369:389:treatment,391:402:treatment,408:438:treatment,462:479:treatment","Must have received at least one line of standard systemic treatment for locally advanced or metastatic disease setting of the respective tumor type; for NSCLC, it is either PD-1/PD-L1 inhibitor, or platinum-containing chemotherapy, or an EGFR tyrosine kinase inhibitor or an ALK inhibitor if sensitizing mutation present; TNBC: platinum-containing chemotherapy; PDAC: fluorouracil (5-FU-), gemcitabine-, or taxane-containing chemotherapy either with or without radiation therapy; SCLC: platinum-containing chemotherapy for limited or extensive stage disease","['Must' 'have' 'received' 'at' 'least' 'one' 'line' 'of' 'standard'
 'systemic' 'treatment' 'for' 'locally' 'advanced' 'or' 'metastatic'
 'disease' 'setting' 'of' 'the' 'respective' 'tumor' 'type' ';' 'for'
 'NSCLC' ',' 'it' 'is' 'either' 'PD-1/PD-L1' 'inhibitor' ',' 'or'
 'platinum-containing' 'chemotherapy' ',' 'or' 'an' 'EGFR' 'tyrosine'
 'kinase' 'inhibitor' 'or' 'an' 'ALK' 'inhibitor' 'if' 'sensitizing'
 'mutation' 'present' ';' 'TNBC' ':' 'platinum-containing' 'chemotherapy'
 ';' 'PDAC' ':' 'fluorouracil' '(' '5-FU-' ')' ',' 'gemcitabine-' ',' 'or'
 'taxane-containing' 'chemotherapy' 'either' 'with' 'or' 'without'
 'radiation' 'therapy' ';' 'SCLC' ':' 'platinum-containing' 'chemotherapy'
 'for' 'limited' 'or' 'extensive' 'stage' 'disease']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 3. 0. 3. 3. 0. 0. 0. 0. 3. 0. 0.
 0. 3. 0. 0. 0. 0. 1. 1. 0. 0. 1. 1. 0. 0. 0. 1. 1. 1. 1. 0. 0. 1. 1. 0.
 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 0. 0. 1. 1. 0. 0. 0.
 0. 1. 1. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02498613,"73:83:cancer,112:146:cancer,152:187:cancer,,,,284:310:treatment,350:391:treatment,417:449:cancer,458:487:cancer","Patients must have histologically confirmed, metastatic or unresectable malignancy of the following types: (a) non-small cell lung cancer (NSCLC), (b) triple-negative breast cancer (TNBC; defined by estrogen receptor [ER] < 1%, progesterone receptor [PR] < 1% and HER2 1+ or less by immunohistochemistry [IHC]; if HER-2 expression is 2+, a negative fluorescence in situ hybridization [FISH] testing is required) (c) pancreatic adenocarcinoma (PDAC), or (d) small cell lung cancer (SCLC)","['Patients' 'must' 'have' 'histologically' 'confirmed' ',' 'metastatic'
 'or' 'unresectable' 'malignancy' 'of' 'the' 'following' 'types' ':' '('
 'a' ')' 'non-small' 'cell' 'lung' 'cancer' '(' 'NSCLC' ')' ',' '(' 'b'
 ')' 'triple-negative' 'breast' 'cancer' '(' 'TNBC' ';' 'defined' 'by'
 'estrogen' 'receptor' '[' 'ER' ']' '<' '1' '%' ',' 'progesterone'
 'receptor' '[' 'PR' ']' '<' '1' '%' 'and' 'HER2' '1+' 'or' 'less' 'by'
 'immunohistochemistry' '[' 'IHC' ']' ';' 'if' 'HER-2' 'expression' 'is'
 '2+' ',' 'a' 'negative' 'fluorescence' 'in' 'situ' 'hybridization' '['
 'FISH' ']' 'testing' 'is' 'required' ')' '(' 'c' ')' 'pancreatic'
 'adenocarcinoma' '(' 'PDAC' ')' ',' 'or' '(' 'd' ')' 'small' 'cell'
 'lung' 'cancer' '(' 'SCLC' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 0.
 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02498613,",,53:61:treatment,66:75:treatment,248:257:treatment","Pregnant women are excluded from this study because olaparib and cediranib have the potential for teratogenic or abortifacient effects; due to the fact that there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with olaparib and cediranib, breastfeeding should be discontinued if the mother is treated with cediranib and olaparib","['Pregnant' 'women' 'are' 'excluded' 'from' 'this' 'study' 'because'
 'olaparib' 'and' 'cediranib' 'have' 'the' 'potential' 'for' 'teratogenic'
 'or' 'abortifacient' 'effects' ';' 'due' 'to' 'the' 'fact' 'that' 'there'
 'is' 'an' 'unknown' 'but' 'potential' 'risk' 'for' 'adverse' 'events'
 'in' 'nursing' 'infants' 'secondary' 'to' 'treatment' 'of' 'the' 'mother'
 'with' 'olaparib' 'and' 'cediranib' ',' 'breastfeeding' 'should' 'be'
 'discontinued' 'if' 'the' 'mother' 'is' 'treated' 'with' 'cediranib'
 'and' 'olaparib']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02498613,"58:81:treatment,72:81:treatment,90:104:chronic_disease","patients with long-standing stable grade 2 neuropathy or prior grade 2 treatment-related hypothyroidism requiring treatment, provided free T4 within normal range, may be considered eligible after discussion with the study principal investigator (PI)","['patients' 'with' 'long-standing' 'stable' 'grade' '2' 'neuropathy' 'or'
 'prior' 'grade' '2' 'treatment-related' 'hypothyroidism' 'requiring'
 'treatment' ',' 'provided' 'free' 'T4' 'within' 'normal' 'range' ','
 'may' 'be' 'considered' 'eligible' 'after' 'discussion' 'with' 'the'
 'study' 'principal' 'investigator' '(' 'PI' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02498535,"19:38:treatment,46:55:treatment,57:66:treatment,69:86:treatment,88:100:treatment,102:106:treatment,109:116:treatment,","Initiation of any new chronic therapy (e.g., ibuprofen, Pulmozyme®, hypertonic saline, azithromycin, TOBI®, Cayston®) within 4 weeks prior to screening","['Initiation' 'of' 'any' 'new' 'chronic' 'therapy' '(' 'e.g.' ','
 'ibuprofen' ',' 'Pulmozyme®' ',' 'hypertonic' 'saline' ',' 'azithromycin'
 ',' 'TOBI®' ',' 'Cayston®' ')' 'within' '4' 'weeks' 'prior' 'to'
 'screening']","[0. 0. 0. 1. 1. 1. 0. 0. 0. 1. 0. 1. 0. 1. 1. 0. 1. 0. 1. 0. 1. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02496663,"33:39:treatment,82:99:treatment,128:146:treatment",Adequate archival tissue from a biopsy performed after progression of disease on previous EGFR-TKI or willing to consent for a fresh tumor biopsy,"['Adequate' 'archival' 'tissue' 'from' 'a' 'biopsy' 'performed' 'after'
 'progression' 'of' 'disease' 'on' 'previous' 'EGFR-TKI' 'or' 'willing'
 'to' 'consent' 'for' 'a' 'fresh' 'tumor' 'biopsy']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02496663,"96:105:treatment,107:118:treatment,122:140:treatment,172:178:treatment,",Patients currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be potent inducers of CYP3A4 (at least 3 weeks prior),"['Patients' 'currently' 'receiving' '(' 'or' 'unable' 'to' 'stop' 'use'
 'prior' 'to' 'receiving' 'the' 'first' 'dose' 'of' 'study' 'treatment'
 ')' 'medications' 'or' 'herbal' 'supplements' 'known' 'to' 'be' 'potent'
 'inducers' 'of' 'CYP3A4' '(' 'at' 'least' '3' 'weeks' 'prior' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 1. 0.
 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]"
NCT02496663,"38:46:treatment,48:59:treatment,61:93:treatment,111:137:treatment","be treatment naive to 3rd generation EGFR-TKI (rociletinib, EGFR inhibitor HM61713 [HM61713] and AZD9291) and EGFR monoclonal antibodies","['be' 'treatment' 'naive' 'to' '3rd' 'generation' 'EGFR-TKI' '('
 'rociletinib' ',' 'EGFR' 'inhibitor' 'HM61713' '[' 'HM61713' ']' 'and'
 'AZD9291' ')' 'and' 'EGFR' 'monoclonal' 'antibodies']",[0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02496663,"6:12:treatment,16:21:cancer,49:58:treatment,60:69:treatment,73:81:treatment,,154:163:treatment,","have biopsy of tumor taken after progression on erlotinib, gefitinib or afatinib which must be EGFR-T790M negative confirmed by central testing prior to treatment (if EGFR-T790M status is unknown, patients may consent for trial and for biopsy and testing for EGFR T790M will be performed as part of initial biopsy for trial)","['have' 'biopsy' 'of' 'tumor' 'taken' 'after' 'progression' 'on'
 'erlotinib' ',' 'gefitinib' 'or' 'afatinib' 'which' 'must' 'be'
 'EGFR-T790M' 'negative' 'confirmed' 'by' 'central' 'testing' 'prior' 'to'
 'treatment' '(' 'if' 'EGFR-T790M' 'status' 'is' 'unknown' ',' 'patients'
 'may' 'consent' 'for' 'trial' 'and' 'for' 'biopsy' 'and' 'testing' 'for'
 'EGFR' 'T790M' 'will' 'be' 'performed' 'as' 'part' 'of' 'initial'
 'biopsy' 'for' 'trial' ')']","[0. 1. 0. 3. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02496611,"23:38:chronic_disease,40:53:chronic_disease,55:71:chronic_disease","Clinical diagnosis of bipolar illness, schizophrenia, conduct disorder, and/or substance use/abuse","['Clinical' 'diagnosis' 'of' 'bipolar' 'illness' ',' 'schizophrenia' ','
 'conduct' 'disorder' ',' 'and/or' 'substance' 'use/abuse']",[0. 0. 0. 2. 2. 0. 2. 0. 2. 2. 0. 0. 0. 0.]
NCT02496585,"9:18:treatment,24:36:treatment,48:57:treatment,61:81:treatment,91:101:cancer","Ongoing treatment with radiotherapy to thorax, cytotoxic or biological therapies for this malignancy","['Ongoing' 'treatment' 'with' 'radiotherapy' 'to' 'thorax' ',' 'cytotoxic'
 'or' 'biological' 'therapies' 'for' 'this' 'malignancy']",[0. 1. 0. 1. 0. 0. 0. 1. 0. 1. 1. 0. 0. 3.]
NCT02496208,",91:106:treatment,118:128:cancer,144:162:treatment",For disease specific studies: the subject has had evidence within 2 years of the start of study treatment of another malignancy which required systemic treatment,"['For' 'disease' 'specific' 'studies' ':' 'the' 'subject' 'has' 'had'
 'evidence' 'within' '2' 'years' 'of' 'the' 'start' 'of' 'study'
 'treatment' 'of' 'another' 'malignancy' 'which' 'required' 'systemic'
 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 3. 0. 0.
 1. 1.]"
NCT02496208,"1:16:treatment,22:33:treatment,26:33:treatment,176:196:cancer",Prior treatment with any therapy on the programmed cell death 1 (PD-1)/PD-L1 axis or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors unless enrolling the urothelial carcinoma with previous checkpoint inhibition therapy expansion cohort,"['Prior' 'treatment' 'with' 'any' 'therapy' 'on' 'the' 'programmed' 'cell'
 'death' '1' '(' 'PD-1' ')' '/PD-L1' 'axis' 'or' 'anti-cytotoxic'
 'T-lymphocyte-associated' 'protein' '4' '(' 'CTLA-4' ')' 'inhibitors'
 'unless' 'enrolling' 'the' 'urothelial' 'carcinoma' 'with' 'previous'
 'checkpoint' 'inhibition' 'therapy' 'expansion' 'cohort']","[1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0.]"
NCT02496208,"97:109:treatment,,322:355:treatment,373:391:treatment,427:438:treatment,,,,,,,,946:963:treatment,","The effects of the drugs used in this trial on the developing human fetus are unknown; however, cabozantinib was embryolethal in rats at exposures below the 140mg dose in the label, with increased incidences of skeletal variations in rats and visceral variations and malformations in rabbits; for this reason and because tyrosine kinase inhibitors agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception, as defined below, prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 7 months after completion of all study medications; women treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and for 5 months after completion of all study medications","['The' 'effects' 'of' 'the' 'drugs' 'used' 'in' 'this' 'trial' 'on' 'the'
 'developing' 'human' 'fetus' 'are' 'unknown' ';' 'however' ','
 'cabozantinib' 'was' 'embryolethal' 'in' 'rats' 'at' 'exposures' 'below'
 'the' '140mg' 'dose' 'in' 'the' 'label' ',' 'with' 'increased'
 'incidences' 'of' 'skeletal' 'variations' 'in' 'rats' 'and' 'visceral'
 'variations' 'and' 'malformations' 'in' 'rabbits' ';' 'for' 'this'
 'reason' 'and' 'because' 'tyrosine' 'kinase' 'inhibitors' 'agents' 'as'
 'well' 'as' 'other' 'therapeutic' 'agents' 'used' 'in' 'this' 'trial'
 'are' 'known' 'to' 'be' 'teratogenic' ',' 'women' 'of' 'child-bearing'
 'potential' 'and' 'men' 'must' 'agree' 'to' 'use' 'adequate'
 'contraception' ',' 'as' 'defined' 'below' ',' 'prior' 'to' 'study'
 'entry' 'and' 'for' 'the' 'duration' 'of' 'study' 'participation' ';'
 'should' 'a' 'woman' 'become' 'pregnant' 'or' 'suspect' 'she' 'is'
 'pregnant' 'while' 'she' 'is' 'participating' 'in' 'this' 'study' ','
 'she' 'should' 'inform' 'her' 'treating' 'physician' 'immediately' ';'
 'men' 'treated' 'or' 'enrolled' 'on' 'this' 'protocol' 'must' 'also'
 'agree' 'to' 'use' 'adequate' 'contraception' 'prior' 'to' 'the' 'study'
 ',' 'for' 'the' 'duration' 'of' 'study' 'participation' ',' 'and' '7'
 'months' 'after' 'completion' 'of' 'all' 'study' 'medications' ';'
 'women' 'treated' 'or' 'enrolled' 'on' 'this' 'protocol' 'must' 'also'
 'agree' 'to' 'use' 'adequate' 'contraception' 'prior' 'to' 'the' 'study'
 ',' 'for' 'the' 'duration' 'of' 'study' 'participation' ',' 'and' 'for'
 '5' 'months' 'after' 'completion' 'of' 'all' 'study' 'medications']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02496208,"26:63:treatment,32:41:treatment,,,219:281:treatment","The subject has received prior treatment with hormonal therapy within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment; subjects receiving gonadotropin-releasing hormone (GnRH) agonists and antagonists are allowed to participate","['The' 'subject' 'has' 'received' 'prior' 'treatment' 'with' 'hormonal'
 'therapy' 'within' '14' 'days' 'or' 'five' 'half-lives' 'of' 'the'
 'compound' 'or' 'active' 'metabolites' ',' 'whichever' 'is' 'longer' ','
 'before' 'the' 'first' 'dose' 'of' 'study' 'treatment' ';' 'subjects'
 'receiving' 'gonadotropin-releasing' 'hormone' '(' 'GnRH' ')' 'agonists'
 'and' 'antagonists' 'are' 'allowed' 'to' 'participate']","[0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0.]"
NCT02495935,"15:24:treatment,80:97:chronic_disease,108:127:chronic_disease,129:142:chronic_disease","Presence of a pacemaker, any metal artifacts in head and trunk, any history of epileptic seizure or severe psychiatric disease (schizophrenia, etc.)","['Presence' 'of' 'a' 'pacemaker' ',' 'any' 'metal' 'artifacts' 'in' 'head'
 'and' 'trunk' ',' 'any' 'history' 'of' 'epileptic' 'seizure' 'or'
 'severe' 'psychiatric' 'disease' '(' 'schizophrenia' ',' 'etc' '.' ')']","[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 0. 2.
 0. 0. 0. 0.]"
NCT02495415,"18:23:cancer,87:105:treatment,113:119:treatment",Bone marrow with tumor cells seen on routine morphology (not by NSE staining only) of bilateral aspirate and/or biopsy on one bone marrow sample,"['Bone' 'marrow' 'with' 'tumor' 'cells' 'seen' 'on' 'routine' 'morphology'
 '(' 'not' 'by' 'NSE' 'staining' 'only' ')' 'of' 'bilateral' 'aspirate'
 'and/or' 'biopsy' 'on' 'one' 'bone' 'marrow' 'sample']","[0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 0. 0.
 0. 0.]"
NCT02495415,"34:56:cancer,60:76:cancer,107:112:cancer,116:119:treatment,121:129:treatment","Patients with previously treated leptomeningeal disease or brain metastases without evidence of remaining tumor by PET, MRI scan, or spinal fluid","['Patients' 'with' 'previously' 'treated' 'leptomeningeal' 'disease' 'or'
 'brain' 'metastases' 'without' 'evidence' 'of' 'remaining' 'tumor' 'by'
 'PET' ',' 'MRI' 'scan' ',' 'or' 'spinal' 'fluid']",[0. 0. 0. 0. 3. 3. 0. 3. 3. 0. 0. 0. 0. 3. 0. 1. 0. 1. 1. 0. 0. 0. 0.]
NCT02495168,"1:22:treatment,23:38:treatment,70:76:chronic_disease,86:97:treatment,99:109:treatment,111:123:treatment","Monoclonal antibodies/Biologic agents which may affect the course of asthma (such as mepolizumab, reslizumab, lebrikizumab, and others)","['Monoclonal' 'antibodies/Biologic' 'agents' 'which' 'may' 'affect' 'the'
 'course' 'of' 'asthma' '(' 'such' 'as' 'mepolizumab' ',' 'reslizumab' ','
 'lebrikizumab' ',' 'and' 'others' ')']",[1. 1. 1. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0.]
NCT02495168,"1:6:chronic_disease,10:19:chronic_disease,21:63:chronic_disease,67:72:chronic_disease,","Viral or bacterial, upper or lower respiratory tract infection or sinus or middle ear infection","['Viral' 'or' 'bacterial' ',' 'upper' 'or' 'lower' 'respiratory' 'tract'
 'infection' 'or' 'sinus' 'or' 'middle' 'ear' 'infection']",[2. 0. 2. 0. 2. 2. 2. 2. 2. 2. 0. 2. 0. 0. 0. 0.]
NCT02495168,",,,,90:99:treatment,109:119:treatment,121:138:treatment",≥15% and ≥ 0.20 L reversibility of FEV1 within 30 minutes following 360 mcg (4 puffs) of albuterol (400 mcg salbutamol) inhalation (pMDI),"['≥15' '%' 'and' '≥' '0.20' 'L' 'reversibility' 'of' 'FEV1' 'within' '30'
 'minutes' 'following' '360' 'mcg' '(' '4' 'puffs' ')' 'of' 'albuterol'
 '(' '400' 'mcg' 'salbutamol' ')' 'inhalation' '(' 'pMDI' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.
 1. 0. 1. 1. 0. 0.]"
NCT02494258,"23:32:treatment,38:66:treatment,81:107:treatment",subject is tolerating treatment with oral azacitidine monotherapy and continued oral azacitidine treatment,"['subject' 'is' 'tolerating' 'treatment' 'with' 'oral' 'azacitidine'
 'monotherapy' 'and' 'continued' 'oral' 'azacitidine' 'treatment']",[0. 0. 0. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02493530,"12:38:chronic_disease,40:55:chronic_disease,57:78:chronic_disease,83:105:chronic_disease,","History of cerebral vascular accident, unstable angina, myocardial infarction, or ventricular arrhythmia within the last 6 months","['History' 'of' 'cerebral' 'vascular' 'accident' ',' 'unstable' 'angina'
 ',' 'myocardial' 'infarction' ',' 'or' 'ventricular' 'arrhythmia'
 'within' 'the' 'last' '6' 'months']",[0. 0. 2. 2. 2. 0. 2. 2. 0. 2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02493426,"91:101:cancer,121:134:chronic_disease,136:145:chronic_disease,147:158:chronic_disease,160:167:chronic_disease,169:183:chronic_disease,187:211:chronic_disease","This includes, but is not limited to impairment of renal function, evidence or history of malignancy or any significant hematological, endocrine, respiratory, hepatic, cardiovascular or gastrointestinal disease","['This' 'includes' ',' 'but' 'is' 'not' 'limited' 'to' 'impairment' 'of'
 'renal' 'function' ',' 'evidence' 'or' 'history' 'of' 'malignancy' 'or'
 'any' 'significant' 'hematological' ',' 'endocrine' ',' 'respiratory' ','
 'hepatic' ',' 'cardiovascular' 'or' 'gastrointestinal' 'disease']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 2. 0. 2.
 0. 2. 0. 2. 0. 2. 0. 2. 2.]"
NCT02489045,"28:48:chronic_disease,52:56:allergy_name,60:72:allergy_name,247:272:chronic_disease","Patients with a history of anaphylactic allergy to eggs or egg products, manifested by one or more of the following symptoms: generalized urticaria, difficulty in breathing, swelling of the mouth and throat, hypotension, or shock. (Subjects with nonanaphylactic allergies to eggs or egg products may be enrolled in the study, but must be watched carefully for 1 h following the administration of SONAZOID)","['Patients' 'with' 'a' 'history' 'of' 'anaphylactic' 'allergy' 'to' 'eggs'
 'or' 'egg' 'products' ',' 'manifested' 'by' 'one' 'or' 'more' 'of' 'the'
 'following' 'symptoms' ':' 'generalized' 'urticaria' ',' 'difficulty'
 'in' 'breathing' ',' 'swelling' 'of' 'the' 'mouth' 'and' 'throat' ','
 'hypotension' ',' 'or' 'shock' '.' '(' 'Subjects' 'with'
 'nonanaphylactic' 'allergies' 'to' 'eggs' 'or' 'egg' 'products' 'may'
 'be' 'enrolled' 'in' 'the' 'study' ',' 'but' 'must' 'be' 'watched'
 'carefully' 'for' '1' 'h' 'following' 'the' 'administration' 'of'
 'SONAZOID' ')']","[0. 0. 0. 0. 0. 2. 2. 0. 4. 0. 4. 4. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02488967,"1:45:treatment,,74:92:treatment,115:131:treatment",Chronic daily treatment with corticosteroids with a dose of >= 10 mg/day methylprednisolone equivalent (excluding inhaled steroids),"['Chronic' 'daily' 'treatment' 'with' 'corticosteroids' 'with' 'a' 'dose'
 'of' '>' '=' '10' 'mg/day' 'methylprednisolone' 'equivalent' '('
 'excluding' 'inhaled' 'steroids' ')']",[1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 1. 1. 0.]
NCT02488967,",,107:131:treatment,133:165:treatment,167:204:treatment,209:217:treatment,,288:306:cancer","Patients with AST or alkaline phosphatase > ULN are eligible for inclusion in the study if liver imaging (computed tomography [CT], magnetic resonance imaging [MRI], positron emission tomography [PET]-CT, or PET scan) performed within 90 days prior to randomization does not demonstrate metastatic disease and the requirements above are met","['Patients' 'with' 'AST' 'or' 'alkaline' 'phosphatase' '>' 'ULN' 'are'
 'eligible' 'for' 'inclusion' 'in' 'the' 'study' 'if' 'liver' 'imaging'
 '(' 'computed' 'tomography' '[' 'CT' ']' ',' 'magnetic' 'resonance'
 'imaging' '[' 'MRI' ']' ',' 'positron' 'emission' 'tomography' '[' 'PET'
 ']' '-CT' ',' 'or' 'PET' 'scan' ')' 'performed' 'within' '90' 'days'
 'prior' 'to' 'randomization' 'does' 'not' 'demonstrate' 'metastatic'
 'disease' 'and' 'the' 'requirements' 'above' 'are' 'met']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0.
 0. 1. 1. 1. 1. 0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0.]"
NCT02487095,"1:4:chronic_disease,38:60:treatment,105:145:treatment,200:217:chronic_disease,236:262:treatment","HIV-positive subjects on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with VX-970. In addition, these subjects are at increased risk of lethal infections when treated with marrow-suppressive therapy","['HIV-positive' 'subjects' 'on' 'combination' 'antiretroviral' 'therapy'
 'are' 'ineligible' 'because' 'of' 'the' 'potential' 'for'
 'pharmacokinetic' 'interactions' 'with' 'VX-970' '.' 'In' 'addition' ','
 'these' 'subjects' 'are' 'at' 'increased' 'risk' 'of' 'lethal'
 'infections' 'when' 'treated' 'with' 'marrow-suppressive' 'therapy']","[2. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 2. 2. 0. 0. 0. 1. 1.]"
NCT02487095,"37:66:chronic_disease,213:232:chronic_disease,234:245:chronic_disease,247:258:chronic_disease,260:281:chronic_disease,283:308:chronic_disease,310:346:chronic_disease,348:372:chronic_disease,374:395:chronic_disease,,422:453:chronic_disease,455:486:chronic_disease,516:553:chronic_disease","Subjects with evidence of severe or uncontrolled systemic disease, or any concurrent condition, which could compromise participation in the study, including, but not limited to, active or uncontrolled infection, immune deficiencies, Hepatitis B, Hepatitis C, uncontrolled diabetes, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, uncontrolled cardiac arrhythmia, stroke/cerebrovascular accident within the past 6 months, or psychiatric illness/social situations which would jeopardize compliance with the protocol","['Subjects' 'with' 'evidence' 'of' 'severe' 'or' 'uncontrolled' 'systemic'
 'disease' ',' 'or' 'any' 'concurrent' 'condition' ',' 'which' 'could'
 'compromise' 'participation' 'in' 'the' 'study' ',' 'including' ',' 'but'
 'not' 'limited' 'to' ',' 'active' 'or' 'uncontrolled' 'infection' ','
 'immune' 'deficiencies' ',' 'Hepatitis' 'B' ',' 'Hepatitis' 'C' ','
 'uncontrolled' 'diabetes' ',' 'uncontrolled' 'hypertension' ','
 'symptomatic' 'congestive' 'heart' 'failure' ',' 'unstable' 'angina'
 'pectoris' ',' 'myocardial' 'infarction' 'within' 'the' 'past' '6'
 'months' ',' 'uncontrolled' 'cardiac' 'arrhythmia' ','
 'stroke/cerebrovascular' 'accident' 'within' 'the' 'past' '6' 'months'
 ',' 'or' 'psychiatric' 'illness/social' 'situations' 'which' 'would'
 'jeopardize' 'compliance' 'with' 'the' 'protocol']","[0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 2. 2. 2. 2. 0. 2. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.
 2. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT02487082,"60:77:treatment,79:95:treatment,97:121:treatment,123:136:treatment,138:151:treatment,153:166:treatment,194:205:chronic_disease","Use of any of the following drugs that might interact with study medications (anticholinergics, systemic corticosteroids, phenobarbital, peginterferon, beta-blockers or any drug that may cause arrhythmias)","['Use' 'of' 'any' 'of' 'the' 'following' 'drugs' 'that' 'might' 'interact'
 'with' 'study' 'medications' '(' 'anticholinergics' ',' 'systemic'
 'corticosteroids' ',' 'phenobarbital' ',' 'peginterferon' ','
 'beta-blockers' 'or' 'any' 'drug' 'that' 'may' 'cause' 'arrhythmias' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 1. 0. 1. 0. 1. 0. 1.
 0. 0. 0. 0. 0. 0. 2. 0.]"
NCT02485418,"8:28:treatment,,47:55:treatment,67:74:treatment,76:91:treatment,93:105:treatment","Use of sedative medications within 6 hours of infusion, including opioids, benzodiazepines, barbiturates","['Use' 'of' 'sedative' 'medications' 'within' '6' 'hours' 'of' 'infusion'
 ',' 'including' 'opioids' ',' 'benzodiazepines' ',' 'barbiturates']",[0. 0. 1. 1. 0. 0. 0. 0. 1. 0. 0. 1. 0. 1. 0. 1.]
NCT02484404,"45:50:treatment,59:84:treatment,114:125:treatment,127:138:treatment,140:149:treatment,151:160:treatment,171:187:treatment","Patients are allowed to have received prior PARPi, and/or anti-angiogenesis therapy including but not limited to thalidomide, bevacizumab, sunitinib, sorafenib, or other anti-angiogenics","['Patients' 'are' 'allowed' 'to' 'have' 'received' 'prior' 'PARPi' ','
 'and/or' 'anti-angiogenesis' 'therapy' 'including' 'but' 'not' 'limited'
 'to' 'thalidomide' ',' 'bevacizumab' ',' 'sunitinib' ',' 'sorafenib' ','
 'or' 'other' 'anti-angiogenics']","[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1.
 0. 0. 0. 1.]"
NCT02484404,"27:47:cancer,100:109:treatment,113:143:treatment","Patients who have a known KRAS wild type tumor must have progressed, been intolerant of or refused cetuximab or panitumumab-based chemotherapy","['Patients' 'who' 'have' 'a' 'known' 'KRAS' 'wild' 'type' 'tumor' 'must'
 'have' 'progressed' ',' 'been' 'intolerant' 'of' 'or' 'refused'
 'cetuximab' 'or' 'panitumumab-based' 'chemotherapy']",[0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1.]
NCT02484404,"28:47:chronic_disease,58:65:treatment,93:117:chronic_disease","Patients with a history of auto-immune disease requiring steroid maintenance, or history of primary immunodeficiency are not eligible","['Patients' 'with' 'a' 'history' 'of' 'auto-immune' 'disease' 'requiring'
 'steroid' 'maintenance' ',' 'or' 'history' 'of' 'primary'
 'immunodeficiency' 'are' 'not' 'eligible']",[0. 0. 0. 0. 0. 2. 2. 0. 1. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0.]
NCT02484300,"11:18:chronic_disease,39:51:chronic_disease,87:96:chronic_disease,108:114:chronic_disease,117:122:chronic_disease,124:134:chronic_disease,146:154:chronic_disease,157:170:chronic_disease,172:187:chronic_disease,206:214:chronic_disease","Any known cardiac (apart from treated hypertension with acceptable drugs, see below), pulmonary (including asthma), renal, neurologic (including epilepsy), neuromuscular, hepatic disease, or patients with diabetes","['Any' 'known' 'cardiac' '(' 'apart' 'from' 'treated' 'hypertension'
 'with' 'acceptable' 'drugs' ',' 'see' 'below' ')' ',' 'pulmonary' '('
 'including' 'asthma' ')' ',' 'renal' ',' 'neurologic' '(' 'including'
 'epilepsy' ')' ',' 'neuromuscular' ',' 'hepatic' 'disease' ',' 'or'
 'patients' 'with' 'diabetes']","[0. 0. 2. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 2. 0. 0. 2. 0.
 2. 0. 0. 2. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 2.]"
NCT02484248,"1:19:treatment,25:47:treatment,52:63:treatment",previous treatment with acid-reduction therapy and montelukast with a level 3 (as defined below)or lesser response,"['previous' 'treatment' 'with' 'acid-reduction' 'therapy' 'and'
 'montelukast' 'with' 'a' 'level' '3' '(' 'as' 'defined' 'below' ')' 'or'
 'lesser' 'response']",[1. 1. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02483728,"18:47:treatment,,66:79:treatment,83:106:treatment,",Patients on oral immunosuppressant medications within 4 weeks of patch testing or topical corticosteroids to the back within 1 week of patch testing,"['Patients' 'on' 'oral' 'immunosuppressant' 'medications' 'within' '4'
 'weeks' 'of' 'patch' 'testing' 'or' 'topical' 'corticosteroids' 'to'
 'the' 'back' 'within' '1' 'week' 'of' 'patch' 'testing']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02481765,"1:8:chronic_disease,10:21:chronic_disease,23:46:chronic_disease","Cardiac, hematologic, oncologic comorbidities that require intensive medical treatment","['Cardiac' ',' 'hematologic' ',' 'oncologic' 'comorbidities' 'that'
 'require' 'intensive' 'medical' 'treatment']",[2. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02481245,"19:33:treatment,35:42:treatment,48:62:treatment","Current use of of MAO Inhibitors, statins, and anticoagulants","['Current' 'use' 'of' 'of' 'MAO' 'Inhibitors' ',' 'statins' ',' 'and'
 'anticoagulants']",[0. 0. 0. 0. 1. 1. 0. 1. 0. 0. 1.]
NCT02480036,"22:38:chronic_disease,49:68:treatment,72:89:chronic_disease,160:171:treatment","Patients with severe spinal deformity requiring open reconstruction or extreme adiposity, in which determining placement of metal sleeve would be difficult by fluoroscopy (limited bone margin)","['Patients' 'with' 'severe' 'spinal' 'deformity' 'requiring' 'open'
 'reconstruction' 'or' 'extreme' 'adiposity' ',' 'in' 'which'
 'determining' 'placement' 'of' 'metal' 'sleeve' 'would' 'be' 'difficult'
 'by' 'fluoroscopy' '(' 'limited' 'bone' 'margin' ')']","[0. 0. 0. 2. 2. 0. 1. 1. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 0. 0. 0. 0. 0.]"
NCT02479698,"5:25:chronic_disease,15:24:chronic_disease,54:72:treatment,","For bacterial infections, patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment","['For' 'bacterial' 'infections' ',' 'patients' 'must' 'be' 'receiving'
 'definitive' 'therapy' 'and' 'have' 'no' 'signs' 'of' 'progressing'
 'infection' 'for' '72' 'hours' 'prior' 'to' 'enrollment']",[0. 2. 2. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT02479620,"8:27:treatment,34:51:treatment,68:90:treatment,106:131:treatment,135:200:treatment,","Use of alternative therapy, e.g. radiation therapy, as part of the index lesion treatment, or use of any drug eluting stents (DES) or drug-eluting balloon/drug-coated balloons (DEB/DCB) for treatment of any infra-inguinal lesions during the study procedure or during the initial six-month follow up period","['Use' 'of' 'alternative' 'therapy' ',' 'e.g' '.' 'radiation' 'therapy'
 ',' 'as' 'part' 'of' 'the' 'index' 'lesion' 'treatment' ',' 'or' 'use'
 'of' 'any' 'drug' 'eluting' 'stents' '(' 'DES' ')' 'or' 'drug-eluting'
 'balloon/drug-coated' 'balloons' '(' 'DEB/DCB' ')' 'for' 'treatment' 'of'
 'any' 'infra-inguinal' 'lesions' 'during' 'the' 'study' 'procedure' 'or'
 'during' 'the' 'initial' 'six-month' 'follow' 'up' 'period']","[0. 0. 1. 1. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 1. 1.
 1. 1. 0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02477839,"36:59:chronic_disease,61:89:chronic_disease,91:119:chronic_disease,121:136:chronic_disease,141:149:chronic_disease","Subject has a current diagnosis of Lennox-Gastaut syndrome, epilepsia partialis continua, primary generalized epilepsy, Dravet Syndorme, or seizures that are not of partial-onset origin","['Subject' 'has' 'a' 'current' 'diagnosis' 'of' 'Lennox-Gastaut'
 'syndrome' ',' 'epilepsia' 'partialis' 'continua' ',' 'primary'
 'generalized' 'epilepsy' ',' 'Dravet' 'Syndorme' ',' 'or' 'seizures'
 'that' 'are' 'not' 'of' 'partial-onset' 'origin']","[0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 2. 0. 2. 2. 2. 0. 2. 2. 0. 0. 2. 0. 0.
 0. 0. 0. 0.]"
NCT02477839,"57:70:chronic_disease,72:87:chronic_disease,99:108:treatment","has experienced any serious toxicity issues (defined as liver failure, aplastic anemia) with this treatment","['has' 'experienced' 'any' 'serious' 'toxicity' 'issues' '(' 'defined'
 'as' 'liver' 'failure' ',' 'aplastic' 'anemia' ')' 'with' 'this'
 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 0. 1.]
NCT02477124,"21:34:treatment,38:48:treatment,52:55:chronic_disease,79:83:treatment,92:101:treatment,105:120:cancer",Patients undergoing cervicography OR colposcopy OR VIA OR patients undergoing LEEP for the treatment of cervical cancer,"['Patients' 'undergoing' 'cervicography' 'OR' 'colposcopy' 'OR' 'VIA' 'OR'
 'patients' 'undergoing' 'LEEP' 'for' 'the' 'treatment' 'of' 'cervical'
 'cancer']",[0. 0. 1. 0. 1. 0. 2. 0. 0. 0. 1. 0. 0. 1. 0. 3. 3.]
NCT02476409,"54:90:chronic_disease,203:216:chronic_disease,252:267:chronic_disease","Patients with the following predisposing factors for osmotic demyelinating syndrome (ODS), assessed by the study investigator judgment, will be excluded: chronic alcoholism at the time of study, severe liver disease, marked malnutrition, and risk for chronic hypoxia","['Patients' 'with' 'the' 'following' 'predisposing' 'factors' 'for'
 'osmotic' 'demyelinating' 'syndrome' '(' 'ODS' ')' ',' 'assessed' 'by'
 'the' 'study' 'investigator' 'judgment' ',' 'will' 'be' 'excluded' ':'
 'chronic' 'alcoholism' 'at' 'the' 'time' 'of' 'study' ',' 'severe'
 'liver' 'disease' ',' 'marked' 'malnutrition' ',' 'and' 'risk' 'for'
 'chronic' 'hypoxia']","[0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02474667,"8:25:cancer,40:45:cancer,47:57:cancer,61:83:cancer,106:111:cancer,115:158:cancer","Has an active malignancy or history of solid, metastatic or hematologic malignancy with the exception of basal or squamous cell carcinoma in situ of the skin that has been adequately treated","['Has' 'an' 'active' 'malignancy' 'or' 'history' 'of' 'solid' ','
 'metastatic' 'or' 'hematologic' 'malignancy' 'with' 'the' 'exception'
 'of' 'basal' 'or' 'squamous' 'cell' 'carcinoma' 'in' 'situ' 'of' 'the'
 'skin' 'that' 'has' 'been' 'adequately' 'treated']","[0. 0. 3. 3. 0. 0. 0. 3. 0. 3. 0. 3. 3. 0. 0. 0. 0. 3. 0. 3. 3. 3. 3. 3.
 3. 3. 3. 0. 0. 0. 0. 0.]"
NCT02474667,"10:46:treatment,48:61:treatment,69:80:treatment","Requires treatment with the CYP1A2 inhibitors, ciprofloxacin and/or fluvoxamine","['Requires' 'treatment' 'with' 'the' 'CYP1A2' 'inhibitors' ','
 'ciprofloxacin' 'and/or' 'fluvoxamine']",[0. 1. 1. 1. 1. 1. 0. 1. 0. 1.]
NCT02474199,"31:57:cancer,65:76:cancer,78:83:cancer,87:100:cancer",History of adequately treated in-situ cervical carcinoma and/or skin cancer (basal or squamous cell) will be permitted,"['History' 'of' 'adequately' 'treated' 'in-situ' 'cervical' 'carcinoma'
 'and/or' 'skin' 'cancer' '(' 'basal' 'or' 'squamous' 'cell' ')' 'will'
 'be' 'permitted']",[0. 0. 0. 0. 3. 3. 3. 0. 3. 3. 0. 3. 0. 3. 3. 0. 0. 0. 0.]
NCT02474199,"1:11:treatment,16:29:chronic_disease,43:61:chronic_disease",Transplant for liver disease secondary to autoimmune disease,"['Transplant' 'for' 'liver' 'disease' 'secondary' 'to' 'autoimmune'
 'disease']",[1. 0. 2. 2. 0. 0. 2. 2.]
NCT02474173,"21:37:cancer,145:179:chronic_disease,378:386:treatment,398:415:treatment,,487:495:chronic_disease","Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events; however, patients with previously treated and stable brain metastases are eligible as long as they are no longer requiring steroids, completed radiation therapy more than 2 weeks prior to the first dose of study regimen and have no seizures or worsening neurologic symptoms","['Patients' 'with' 'known' 'brain' 'metastases' 'should' 'be' 'excluded'
 'from' 'this' 'clinical' 'trial' 'because' 'of' 'their' 'poor'
 'prognosis' 'and' 'because' 'they' 'often' 'develop' 'progressive'
 'neurologic' 'dysfunction' 'that' 'would' 'confound' 'the' 'evaluation'
 'of' 'neurologic' 'and' 'other' 'adverse' 'events' ';' 'however' ','
 'patients' 'with' 'previously' 'treated' 'and' 'stable' 'brain'
 'metastases' 'are' 'eligible' 'as' 'long' 'as' 'they' 'are' 'no' 'longer'
 'requiring' 'steroids' ',' 'completed' 'radiation' 'therapy' 'more'
 'than' '2' 'weeks' 'prior' 'to' 'the' 'first' 'dose' 'of' 'study'
 'regimen' 'and' 'have' 'no' 'seizures' 'or' 'worsening' 'neurologic'
 'symptoms']","[0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.
 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 2. 0. 0. 0. 0.]"
NCT02473276,"84:122:treatment,143:163:treatment,167:184:treatment","who are known to have had accidental dural puncture with an epidural needle during placement of neuraxial labor analgesia, and have either an intrathecal catheter or epidural catheter in place","['who' 'are' 'known' 'to' 'have' 'had' 'accidental' 'dural' 'puncture'
 'with' 'an' 'epidural' 'needle' 'during' 'placement' 'of' 'neuraxial'
 'labor' 'analgesia' ',' 'and' 'have' 'either' 'an' 'intrathecal'
 'catheter' 'or' 'epidural' 'catheter' 'in' 'place']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0.
 1. 1. 0. 0. 0. 0. 0.]"
NCT02473250,"1:15:treatment,17:26:treatment,28:44:treatment,46:74:treatment,78:86:treatment","Metal implants, pacemaker, metal prostheses, metal orthodontic appliances or shrapnel in the body","['Metal' 'implants' ',' 'pacemaker' ',' 'metal' 'prostheses' ',' 'metal'
 'orthodontic' 'appliances' 'or' 'shrapnel' 'in' 'the' 'body']",[1. 1. 0. 1. 0. 1. 1. 1. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02471911,"29:48:treatment,41:48:treatment,60:69:treatment,73:90:treatment,","Patients who have had other anti-cancer therapy, including radiation or experimental drug or therapy, within 28 days of enrollment","['Patients' 'who' 'have' 'had' 'other' 'anti-cancer' 'therapy' ','
 'including' 'radiation' 'or' 'experimental' 'drug' 'or' 'therapy' ','
 'within' '28' 'days' 'of' 'enrollment']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02471430,"65:83:allergy_name,84:102:allergy_name,106:118:allergy_name","History of anaphylaxis, allergy or serious adverse reactions to Interferon-alpha2a/Interferon-alpha2b or panobinostat","['History' 'of' 'anaphylaxis' ',' 'allergy' 'or' 'serious' 'adverse'
 'reactions' 'to' 'Interferon-alpha2a/Interferon-alpha2b' 'or'
 'panobinostat']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 0. 4.]
NCT02470897,",19:22:cancer,101:113:treatment,126:128:cancer,132:134:cancer",Clinical stage =< T2b (American Joint Committee on Cancer [AJCC] 7th Edition Staging Manual) and no radiographic evidence of T3 or T4 disease,"['Clinical' 'stage' '=' '<' 'T2b' '(' 'American' 'Joint' 'Committee' 'on'
 'Cancer' '[' 'AJCC' ']' '7th' 'Edition' 'Staging' 'Manual' ')' 'and' 'no'
 'radiographic' 'evidence' 'of' 'T3' 'or' 'T4' 'disease']","[0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.
 3. 0. 3. 0.]"
NCT02469857,"43:57:treatment,64:101:treatment,107:131:chronic_disease,168:178:treatment","Patients that are treated with continuous hemofiltration (e.g. Continuous Veno-Venous Hemofiltration) for acute kidney dysfunction, not due to NSTI, starting prior to study drug administration","['Patients' 'that' 'are' 'treated' 'with' 'continuous' 'hemofiltration'
 '(' 'e.g' '.' 'Continuous' 'Veno-Venous' 'Hemofiltration' ')' 'for'
 'acute' 'kidney' 'dysfunction' ',' 'not' 'due' 'to' 'NSTI' ',' 'starting'
 'prior' 'to' 'study' 'drug' 'administration']","[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 1. 1. 1. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 1. 0.]"
NCT02469129,"39:65:chronic_disease,80:89:treatment,93:113:treatment",Healthy volunteers without history of cardiopulmonary conditions requiring any treatment or medical intervention and who are not current smokers (Dosimetry Studies Arm only),"['Healthy' 'volunteers' 'without' 'history' 'of' 'cardiopulmonary'
 'conditions' 'requiring' 'any' 'treatment' 'or' 'medical' 'intervention'
 'and' 'who' 'are' 'not' 'current' 'smokers' '(' 'Dosimetry' 'Studies'
 'Arm' 'only' ')']","[0. 0. 0. 0. 0. 2. 2. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02468778,"1:15:chronic_disease,,55:90:treatment,94:108:treatment",Cardiac arrest within 24 hours of procedure requiring cardiopulmonary resuscitation (CPR) or defibrillation,"['Cardiac' 'arrest' 'within' '24' 'hours' 'of' 'procedure' 'requiring'
 'cardiopulmonary' 'resuscitation' '(' 'CPR' ')' 'or' 'defibrillation']",[2. 2. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 1.]
NCT02468453,"16:31:chronic_disease,35:59:chronic_disease,70:97:treatment,,131:140:treatment","Having a known anticoagulative or thromboembolic condition or taking anticoagulation medications one week prior to and during the treatment course (to allow inclusion, temporary cessation of use as per the subject's physician discretion)","['Having' 'a' 'known' 'anticoagulative' 'or' 'thromboembolic' 'condition'
 'or' 'taking' 'anticoagulation' 'medications' 'one' 'week' 'prior' 'to'
 'and' 'during' 'the' 'treatment' 'course' '(' 'to' 'allow' 'inclusion'
 ',' 'temporary' 'cessation' 'of' 'use' 'as' 'per' 'the' 'subject' ""'s""
 'physician' 'discretion' ')']","[0. 0. 0. 2. 0. 2. 2. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02468453,"26:71:chronic_disease,83:96:chronic_disease,100:104:chronic_disease,125:154:treatment",Subject has a history of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications,"['Subject' 'has' 'a' 'history' 'of' 'immunosuppression/immune'
 'deficiency' 'disorders' '(' 'including' 'HIV' 'infection' 'or' 'AIDS'
 ')' 'or' 'currently' 'using' 'immunosuppressive' 'medications']",[0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 2. 2. 0. 2. 0. 0. 0. 0. 1. 1.]
NCT02468453,"16:25:chronic_disease,126:154:chronic_disease,187:202:chronic_disease,204:215:chronic_disease,217:239:chronic_disease,241:250:chronic_disease,252:258:chronic_disease,260:264:chronic_disease,266:273:chronic_disease,314:329:chronic_disease,365:382:chronic_disease,386:398:chronic_disease,399:417:treatment","Subject has an infection or is suffering from current or has a history of significant skin conditions in the treated area or inflammatory skin conditions, including, but not limited to: photodermatoses, active acne, excessive skin dryness, psoriasis, eczema, rash, rosacea (particularly severe open wound stage), varicella scars, open lacerations or abrasions and active cold sores or herpes sores prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course","['Subject' 'has' 'an' 'infection' 'or' 'is' 'suffering' 'from' 'current'
 'or' 'has' 'a' 'history' 'of' 'significant' 'skin' 'conditions' 'in'
 'the' 'treated' 'area' 'or' 'inflammatory' 'skin' 'conditions' ','
 'including' ',' 'but' 'not' 'limited' 'to' ':' 'photodermatoses' ','
 'active' 'acne' ',' 'excessive' 'skin' 'dryness' ',' 'psoriasis' ','
 'eczema' ',' 'rash' ',' 'rosacea' '(' 'particularly' 'severe' 'open'
 'wound' 'stage' ')' ',' 'varicella' 'scars' ',' 'open' 'lacerations' 'or'
 'abrasions' 'and' 'active' 'cold' 'sores' 'or' 'herpes' 'sores' 'prior'
 'to' 'treatment' '(' 'duration' 'of' 'resolution' 'as' 'per' 'the'
 'Investigator' ""'s"" 'discretion' ')' 'or' 'during' 'the' 'treatment'
 'course']","[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.
 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 2. 2. 2. 2. 0. 2. 0. 2. 0. 2. 0.
 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 1.
 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02468453,"27:35:treatment,37:56:treatment,60:73:treatment,81:90:treatment,","Subject has undergone any surgical, light-based therapy or RF procedures in the treatment area within 3 months of treatment or during the study","['Subject' 'has' 'undergone' 'any' 'surgical' ',' 'light-based' 'therapy'
 'or' 'RF' 'procedures' 'in' 'the' 'treatment' 'area' 'within' '3'
 'months' 'of' 'treatment' 'or' 'during' 'the' 'study']",[0. 0. 0. 0. 1. 0. 1. 1. 0. 1. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02467478,"16:20:treatment,24:59:treatment,71:80:treatment,85:92:treatment",Current use of oral or injectable anti-diabetic medication other than Metformin and insulin,"['Current' 'use' 'of' 'oral' 'or' 'injectable' 'anti-diabetic'
 'medication' 'other' 'than' 'Metformin' 'and' 'insulin']",[0. 0. 0. 1. 0. 1. 1. 1. 0. 0. 1. 0. 1.]
NCT02466971,"90:114:chronic_disease,116:140:chronic_disease,142:163:chronic_disease,,206:224:chronic_disease,297:309:chronic_disease,334:351:chronic_disease,362:369:chronic_disease,449:460:chronic_disease,487:512:chronic_disease,,,555:574:chronic_disease","Patient has uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within six months of protocol initiation, cardiac arrhythmia within six months of protocol initiation; known inadequately controlled hypertension; clinically significant pulmonary disease including dyspnea at rest, or patients requiring supplemental oxygen, or poor pulmonary reserve; proteinuria or clinically significant renal function impairment (baseline serum creatinine > 2 mg/dL); or psychiatric illness/social situations that would limit compliance with study requirements","['Patient' 'has' 'uncontrolled' 'intercurrent' 'illness' 'including' ','
 'but' 'not' 'limited' 'to' ',' 'symptomatic' 'congestive' 'heart'
 'failure' ',' 'unstable' 'angina' 'pectoris' ',' 'myocardial'
 'infarction' 'within' 'six' 'months' 'of' 'protocol' 'initiation' ','
 'cardiac' 'arrhythmia' 'within' 'six' 'months' 'of' 'protocol'
 'initiation' ';' 'known' 'inadequately' 'controlled' 'hypertension' ';'
 'clinically' 'significant' 'pulmonary' 'disease' 'including' 'dyspnea'
 'at' 'rest' ',' 'or' 'patients' 'requiring' 'supplemental' 'oxygen' ','
 'or' 'poor' 'pulmonary' 'reserve' ';' 'proteinuria' 'or' 'clinically'
 'significant' 'renal' 'function' 'impairment' '(' 'baseline' 'serum'
 'creatinine' '>' '2' 'mg/dL' ')' ';' 'or' 'psychiatric' 'illness/social'
 'situations' 'that' 'would' 'limit' 'compliance' 'with' 'study'
 'requirements']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 2. 2. 2. 0. 2. 2. 0.
 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 2. 2.
 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 2. 2. 2. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02466750,"31:47:chronic_disease,60:106:treatment,142:157:treatment,163:173:treatment,,227:234:treatment","Have a personal history of an immunodeficiency or received treatment with an immunosuppressive medication, such as systemically administered glucocorticoids (eg, prednisone) within 1 month before planned administration of the vaccine","['Have' 'a' 'personal' 'history' 'of' 'an' 'immunodeficiency' 'or'
 'received' 'treatment' 'with' 'an' 'immunosuppressive' 'medication' ','
 'such' 'as' 'systemically' 'administered' 'glucocorticoids' '(' 'eg' ','
 'prednisone' ')' 'within' '1' 'month' 'before' 'planned' 'administration'
 'of' 'the' 'vaccine']","[0. 0. 0. 0. 0. 0. 2. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 1. 0. 0. 0. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02466685,"12:18:chronic_disease,20:32:cancer,33:71:chronic_disease,105:127:chronic_disease,","History of stroke, brain tumor, head trauma with loss of consciousness, or other clinically significant neurological condition within 12 months before screening","['History' 'of' 'stroke' ',' 'brain' 'tumor' ',' 'head' 'trauma' 'with'
 'loss' 'of' 'consciousness' ',' 'or' 'other' 'clinically' 'significant'
 'neurological' 'condition' 'within' '12' 'months' 'before' 'screening']","[0. 0. 2. 0. 3. 3. 0. 2. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0.
 0.]"
NCT02466126,"13:20:chronic_disease,22:31:chronic_disease,35:60:chronic_disease","presence of bipolar, psychotic or substance-abuse disorders","['presence' 'of' 'bipolar' ',' 'psychotic' 'or' 'substance-abuse'
 'disorders']",[0. 0. 2. 0. 2. 0. 2. 2.]
NCT02465541,"1:21:chronic_disease,29:42:chronic_disease,44:69:chronic_disease","Major mental illness (e.g., schizophrenia, major depressive disorder)","['Major' 'mental' 'illness' '(' 'e.g.' ',' 'schizophrenia' ',' 'major'
 'depressive' 'disorder' ')']",[2. 2. 2. 0. 0. 0. 2. 0. 2. 2. 2. 0.]
NCT02465268,"21:23:treatment,,,,93:96:treatment,,140:147:treatment,",Must have completed RT (targeted total dose of 59.4-60.0 Gy over ≤ 7 weeks) and concomitant TMZ (targeted dose of 75mg/m2/d for ≤ 49 days) therapy without significant toxicity that persisted over 4 weeks,"['Must' 'have' 'completed' 'RT' '(' 'targeted' 'total' 'dose' 'of'
 '59.4-60.0' 'Gy' 'over' '≤' '7' 'weeks' ')' 'and' 'concomitant' 'TMZ' '('
 'targeted' 'dose' 'of' '75mg/m2/d' 'for' '≤' '49' 'days' ')' 'therapy'
 'without' 'significant' 'toxicity' 'that' 'persisted' 'over' '4' 'weeks']","[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02465060,"5:18:treatment,20:32:treatment,41:69:treatment,,99:112:treatment,,167:176:treatment","Any prior therapy, radiotherapy (except palliative radiation therapy of 30 gray [Gy] or less), or major surgery must have been completed >= 4 weeks prior to start of treatment","['Any' 'prior' 'therapy' ',' 'radiotherapy' '(' 'except' 'palliative'
 'radiation' 'therapy' 'of' '30' 'gray' '[' 'Gy' ']' 'or' 'less' ')' ','
 'or' 'major' 'surgery' 'must' 'have' 'been' 'completed' '>' '=' '4'
 'weeks' 'prior' 'to' 'start' 'of' 'treatment']","[0. 1. 1. 0. 1. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02465060,"1:25:chronic_disease,29:49:treatment,54:62:treatment","Unstable angina pectoris or coronary angioplasty, or stenting","['Unstable' 'angina' 'pectoris' 'or' 'coronary' 'angioplasty' ',' 'or'
 'stenting']",[2. 2. 2. 0. 1. 1. 0. 0. 1.]
NCT02464904,"1:15:treatment,24:35:treatment,37:44:treatment,46:74:treatment,76:84:treatment,94:114:treatment","Anticoagulants such as clopidogrel, heparin, low-molecular weight heparin, warfarin or other novel anticoagulants have not been held for the standard time period published","['Anticoagulants' 'such' 'as' 'clopidogrel' ',' 'heparin' ','
 'low-molecular' 'weight' 'heparin' ',' 'warfarin' 'or' 'other' 'novel'
 'anticoagulants' 'have' 'not' 'been' 'held' 'for' 'the' 'standard' 'time'
 'period' 'published']","[1. 0. 0. 1. 0. 1. 0. 1. 1. 1. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02464878,"1:21:chronic_disease,23:37:chronic_disease,43:70:chronic_disease","Invasive aspergillus, histoplasmosis, and coccidoidomycosis infection within the last year","['Invasive' 'aspergillus' ',' 'histoplasmosis' ',' 'and'
 'coccidoidomycosis' 'infection' 'within' 'the' 'last' 'year']",[2. 2. 0. 2. 0. 0. 2. 2. 0. 0. 0. 0.]
NCT02464696,"8:27:chronic_disease,35:47:chronic_disease,51:70:chronic_disease",Active myocardial ischemia (acute ST elevation or non ST elevation MI,"['Active' 'myocardial' 'ischemia' '(' 'acute' 'ST' 'elevation' 'or' 'non'
 'ST' 'elevation' 'MI']",[0. 2. 2. 0. 0. 2. 2. 0. 2. 2. 2. 2.]
NCT02464436,"1:24:chronic_disease,28:40:chronic_disease,60:84:chronic_disease,140:147:treatment","Active ocular infection or inflammation, or any history of intraocular inflammation, that would expose subject to risk during or following surgery","['Active' 'ocular' 'infection' 'or' 'inflammation' ',' 'or' 'any'
 'history' 'of' 'intraocular' 'inflammation' ',' 'that' 'would' 'expose'
 'subject' 'to' 'risk' 'during' 'or' 'following' 'surgery']",[2. 2. 2. 0. 2. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02464436,"23:57:chronic_disease,59:76:chronic_disease,78:95:chronic_disease","Negative serology for human immunodeficiency virus (HIV), hepatitis B (HBV), hepatitis C (HCV)","['Negative' 'serology' 'for' 'human' 'immunodeficiency' 'virus' '(' 'HIV'
 ')' ',' 'hepatitis' 'B' '(' 'HBV' ')' ',' 'hepatitis' 'C' '(' 'HCV' ')']",[0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02463305,"9:32:treatment,46:66:treatment,,,150:161:treatment,163:175:treatment,177:193:treatment,","Allowed concomitant medications will include mesalamine compounds if used for at least 8 weeks and at a stable dose for at least 4 weeks, as well as thiopurines (azathioprine, 6-mercaptopurine) if used at a stable dose for at least 3 months","['Allowed' 'concomitant' 'medications' 'will' 'include' 'mesalamine'
 'compounds' 'if' 'used' 'for' 'at' 'least' '8' 'weeks' 'and' 'at' 'a'
 'stable' 'dose' 'for' 'at' 'least' '4' 'weeks' ',' 'as' 'well' 'as'
 'thiopurines' '(' 'azathioprine' ',' '6-mercaptopurine' ')' 'if' 'used'
 'at' 'a' 'stable' 'dose' 'for' 'at' 'least' '3' 'months']","[0. 1. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02462590,"41:71:chronic_disease,134:151:chronic_disease,165:168:chronic_disease,,212:241:treatment,249:261:treatment,263:275:treatment,277:293:treatment,295:305:treatment,307:319:treatment,321:333:treatment,335:343:treatment,346:370:treatment,382:391:treatment,406:416:cancer,427:439:treatment,,462:473:chronic_disease,,,538:553:treatment","Patients at potential increased risk of iatrogenic probiotic infection (see Section 2.6 for detailed explanation) including specific immunocompromised populations (HIV <200 CD4 cells/μL, those receiving chronic immunosuppressive medications (e.g., azathioprine, cyclosporine, cyclophosphamide, tacrolimus, methotrexate, mycofenolate, Anti-IL2), previous transplantation (including stem cell) at any time, malignancy requiring chemotherapy in the last 3 months, neutropenia [absolute neutrophil count < 500]). However, patients receiving corticosteroids previously or presently or projected to receive corticosteroids are not excluded","['Patients' 'at' 'potential' 'increased' 'risk' 'of' 'iatrogenic'
 'probiotic' 'infection' '(' 'see' 'Section' '2.6' 'for' 'detailed'
 'explanation' ')' 'including' 'specific' 'immunocompromised'
 'populations' '(' 'HIV' '<' '200' 'CD4' 'cells/μL' ',' 'those'
 'receiving' 'chronic' 'immunosuppressive' 'medications' '(' 'e.g.' ','
 'azathioprine' ',' 'cyclosporine' ',' 'cyclophosphamide' ',' 'tacrolimus'
 ',' 'methotrexate' ',' 'mycofenolate' ',' 'Anti-IL2' ')' ',' 'previous'
 'transplantation' '(' 'including' 'stem' 'cell' ')' 'at' 'any' 'time' ','
 'malignancy' 'requiring' 'chemotherapy' 'in' 'the' 'last' '3' 'months'
 ',' 'neutropenia' '[' 'absolute' 'neutrophil' 'count' '<' '500' ']' ')'
 '.' 'However' ',' 'patients' 'receiving' 'corticosteroids' 'previously'
 'or' 'presently' 'or' 'projected' 'to' 'receive' 'corticosteroids' 'are'
 'not' 'excluded']","[0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 2. 0.
 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0.
 1. 0. 0. 1. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 3. 0. 1. 0. 0. 0. 0. 0. 0. 2.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02461927,"1:7:treatment,,54:75:treatment,90:96:treatment",Opioid use within 10 days prior to study medication (injectable naltrexone) or risks for opioid use during the study,"['Opioid' 'use' 'within' '10' 'days' 'prior' 'to' 'study' 'medication' '('
 'injectable' 'naltrexone' ')' 'or' 'risks' 'for' 'opioid' 'use' 'during'
 'the' 'study']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02460783,"23:26:treatment,28:38:treatment,40:62:treatment","Contraindications for MRI (pacemakers, ferrous metal implants or shrapnel in or around the head, etc.)","['Contraindications' 'for' 'MRI' '(' 'pacemakers' ',' 'ferrous' 'metal'
 'implants' 'or' 'shrapnel' 'in' 'or' 'around' 'the' 'head' ',' 'etc' '.'
 ')']",[0. 0. 1. 0. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02460692,"30:44:chronic_disease,46:53:chronic_disease,57:70:chronic_disease,72:97:chronic_disease,103:128:chronic_disease,134:140:chronic_disease,142:146:chronic_disease","Individuals with significant cardiovascular, hepatic or renal disease, uncontrolled hypertension, and chronic pulmonary disease (eg, asthma, COPD)","['Individuals' 'with' 'significant' 'cardiovascular' ',' 'hepatic' 'or'
 'renal' 'disease' ',' 'uncontrolled' 'hypertension' ',' 'and' 'chronic'
 'pulmonary' 'disease' '(' 'eg' ',' 'asthma' ',' 'COPD' ')']",[0. 0. 0. 2. 0. 2. 0. 2. 2. 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 2. 0. 2. 0.]
NCT02459119,"15:25:cancer,49:59:cancer,115:142:cancer","Patients with metastatic (lymph node or distant metastasis, i.e. N+ or M1) or locally advanced unresectable (T4b) transitional cell carcinoma","['Patients' 'with' 'metastatic' '(' 'lymph' 'node' 'or' 'distant'
 'metastasis' ',' 'i.e' '.' 'N+' 'or' 'M1' ')' 'or' 'locally' 'advanced'
 'unresectable' '(' 'T4b' ')' 'transitional' 'cell' 'carcinoma']","[0. 0. 3. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.
 3. 3.]"
NCT02459119,"15:25:chronic_disease,27:34:chronic_disease,36:42:chronic_disease,47:62:chronic_disease,72:96:chronic_disease,108:134:chronic_disease,136:156:chronic_disease,160:178:chronic_disease,,213:222:treatment","Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of start of study treatment within 6 months of informed consent","['Subjects' 'with' 'thrombotic' ',' 'embolic' ',' 'venous' ',' 'or'
 'arterial' 'events' ',' 'such' 'as' 'cerebrovascular' 'accident' '('
 'including' 'transient' 'ischemic' 'attacks' ')' 'deep' 'vein'
 'thrombosis' 'or' 'pulmonary' 'embolism' 'within' '6' 'months' 'of'
 'start' 'of' 'study' 'treatment' 'within' '6' 'months' 'of' 'informed'
 'consent']","[0. 0. 2. 0. 2. 0. 2. 0. 0. 2. 2. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2.
 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]"
NCT02458482,"28:52:chronic_disease,61:67:treatment,69:73:treatment,77:90:treatment,110:128:treatment,206:221:chronic_disease,223:232:chronic_disease,241:251:chronic_disease","Patients with a history of spontaneous pneumothorax, recent facial, oral or skull surgery/trauma, history of esophageal surgery, known or suspected tympanic membrane rupture or other middle ear pathology, acute sinusitis, epistaxis, active hemoptysis or nausea will be excluded as these are contraindications for AccuPAP use","['Patients' 'with' 'a' 'history' 'of' 'spontaneous' 'pneumothorax' ','
 'recent' 'facial' ',' 'oral' 'or' 'skull' 'surgery/trauma' ',' 'history'
 'of' 'esophageal' 'surgery' ',' 'known' 'or' 'suspected' 'tympanic'
 'membrane' 'rupture' 'or' 'other' 'middle' 'ear' 'pathology' ',' 'acute'
 'sinusitis' ',' 'epistaxis' ',' 'active' 'hemoptysis' 'or' 'nausea'
 'will' 'be' 'excluded' 'as' 'these' 'are' 'contraindications' 'for'
 'AccuPAP' 'use']","[0. 0. 0. 0. 0. 2. 2. 0. 0. 1. 0. 1. 0. 1. 1. 0. 0. 0. 1. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02458014,"1:37:treatment,90:133:treatment,135:149:treatment,151:163:treatment,165:173:treatment,182:202:treatment,","Radiotherapy and cancer chemotherapy (except for intrathecal prophylaxis and/or low-dose maintenance therapy such as vinca alkaloids, mercaptopurine, methotrexate, steroids) or any investigational drug within 2 weeks before study entry","['Radiotherapy' 'and' 'cancer' 'chemotherapy' '(' 'except' 'for'
 'intrathecal' 'prophylaxis' 'and/or' 'low-dose' 'maintenance' 'therapy'
 'such' 'as' 'vinca' 'alkaloids' ',' 'mercaptopurine' ',' 'methotrexate'
 ',' 'steroids' ')' 'or' 'any' 'investigational' 'drug' 'within' '2'
 'weeks' 'before' 'study' 'entry']","[1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 1. 0. 1. 0. 1. 0.
 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]"
NCT02457845,"48:59:cancer,54:59:cancer,71:94:cancer,96:119:cancer,121:143:cancer,145:176:cancer,178:188:cancer,190:222:cancer,224:239:cancer,344:351:treatment,353:365:treatment,374:386:treatment","Pathologically proven malignant supratentorial brain tumor (including glioblastoma multiforme, giant cell glioblastoma, anaplastic astrocytoma, primitive neuroectodermal tumor, ependymoma, atypical teratoid/rhabdoid tumor, germ cell tumor, or other high-grade malignant tumor) which is progressive or recurrent despite standard care including surgery, radiotherapy, and/or chemotherapy","['Pathologically' 'proven' 'malignant' 'supratentorial' 'brain' 'tumor'
 '(' 'including' 'glioblastoma' 'multiforme' ',' 'giant' 'cell'
 'glioblastoma' ',' 'anaplastic' 'astrocytoma' ',' 'primitive'
 'neuroectodermal' 'tumor' ',' 'ependymoma' ',' 'atypical'
 'teratoid/rhabdoid' 'tumor' ',' 'germ' 'cell' 'tumor' ',' 'or' 'other'
 'high-grade' 'malignant' 'tumor' ')' 'which' 'is' 'progressive' 'or'
 'recurrent' 'despite' 'standard' 'care' 'including' 'surgery' ','
 'radiotherapy' ',' 'and/or' 'chemotherapy']","[0. 0. 0. 0. 3. 3. 0. 0. 3. 3. 0. 3. 3. 3. 0. 3. 3. 0. 3. 3. 3. 0. 3. 0.
 3. 3. 3. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 0. 1. 0. 0. 1.]"
NCT02456857,"7:42:chronic_disease,55:65:chronic_disease,113:128:treatment",Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus,"['Known' 'impairment' 'of' 'gastrointestinal' '(' 'GI' ')' 'function' 'or'
 'GI' 'disease' 'that' 'may' 'significantly' 'alter' 'the' 'absorption'
 'of' 'oral' 'everolimus']",[0. 2. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02456857,"1:24:treatment,32:56:cancer,60:80:cancer",Prior radiation therapy of the primary breast carcinoma or axillary lymph nodes,"['Prior' 'radiation' 'therapy' 'of' 'the' 'primary' 'breast' 'carcinoma'
 'or' 'axillary' 'lymph' 'nodes']",[1. 1. 1. 0. 0. 3. 3. 3. 0. 3. 3. 3.]
NCT02455193,"29:39:treatment,41:52:treatment,54:63:treatment,68:79:treatment,121:144:treatment","Currently prescribed either olanzapine, risperidone, clozapine, or haloperidol, OR not currently being treated with any neuroleptic medications","['Currently' 'prescribed' 'either' 'olanzapine' ',' 'risperidone' ','
 'clozapine' ',' 'or' 'haloperidol' ',' 'OR' 'not' 'currently' 'being'
 'treated' 'with' 'any' 'neuroleptic' 'medications']",[0. 0. 0. 1. 0. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02454517,"13:35:chronic_disease,,103:124:chronic_disease,128:134:chronic_disease,136:151:chronic_disease,153:164:chronic_disease,166:178:chronic_disease,180:195:chronic_disease,262:274:chronic_disease,,,,,365:375:chronic_disease,377:390:chronic_disease","Significant cardiovascular disease precluding an exercise program, including recent (within 6 months) myocardial infarction or stroke, pulmonary edema, myocarditis, pericarditis, unstable angina, pulmonary embolism/deep venous thrombosis (PE/DVT), uncontrolled hypertension (systolic blood pressure [SBP] > 200; diastolic blood pressure [DBP] > 110), uncontrolled arrhythmia, heart failure","['Significant' 'cardiovascular' 'disease' 'precluding' 'an' 'exercise'
 'program' ',' 'including' 'recent' '(' 'within' '6' 'months' ')'
 'myocardial' 'infarction' 'or' 'stroke' ',' 'pulmonary' 'edema' ','
 'myocarditis' ',' 'pericarditis' ',' 'unstable' 'angina' ',' 'pulmonary'
 'embolism/deep' 'venous' 'thrombosis' '(' 'PE/DVT' ')' ',' 'uncontrolled'
 'hypertension' '(' 'systolic' 'blood' 'pressure' '[' 'SBP' ']' '>' '200'
 ';' 'diastolic' 'blood' 'pressure' '[' 'DBP' ']' '>' '110' ')' ','
 'uncontrolled' 'arrhythmia' ',' 'heart' 'failure']","[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 0. 2. 2. 0. 2.
 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2.]"
NCT02454010,"14:48:chronic_disease,50:91:chronic_disease,95:118:chronic_disease","positive for human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV)","['positive' 'for' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')' ','
 'hepatitis' 'B' 'virus' 'surface' 'antigen' '(' 'HBsAg' ')' 'or'
 'hepatitis' 'C' 'virus' '(' 'HCV' ')']",[0. 0. 2. 2. 2. 2. 0. 0. 0. 2. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02453373,"14:37:chronic_disease,41:53:treatment,83:95:treatment","Suspicion of subarachnoid hemorrhage on pretreatment evaluation, even with normal neuroimaging","['Suspicion' 'of' 'subarachnoid' 'hemorrhage' 'on' 'pretreatment'
 'evaluation' ',' 'even' 'with' 'normal' 'neuroimaging']",[0. 0. 2. 2. 0. 1. 0. 0. 0. 0. 0. 1.]
NCT02452697,"15:35:chronic_disease,55:88:treatment,92:131:treatment","Patients with hematologic diseases who have undergone T-cell depleted reduced intensity or non-ablative allogeneic transplantation, using a 7-8/8 HLA-matched related or unrelated donor or 4-6/8 HLA-matched related donor","['Patients' 'with' 'hematologic' 'diseases' 'who' 'have' 'undergone'
 'T-cell' 'depleted' 'reduced' 'intensity' 'or' 'non-ablative'
 'allogeneic' 'transplantation' ',' 'using' 'a' '7-8/8' 'HLA-matched'
 'related' 'or' 'unrelated' 'donor' 'or' '4-6/8' 'HLA-matched' 'related'
 'donor']","[0. 0. 2. 2. 0. 0. 0. 1. 1. 1. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02452268,"26:37:cancer,38:48:cancer,57:67:cancer,,124:131:treatment",Histologically confirmed solid tumor malignancy that is metastatic or unresectable and have progressed on at least 1 prior therapy and for whom standard curative or palliative measures do not exist or are associated with minimal subject survival benefit,"['Histologically' 'confirmed' 'solid' 'tumor' 'malignancy' 'that' 'is'
 'metastatic' 'or' 'unresectable' 'and' 'have' 'progressed' 'on' 'at'
 'least' '1' 'prior' 'therapy' 'and' 'for' 'whom' 'standard' 'curative'
 'or' 'palliative' 'measures' 'do' 'not' 'exist' 'or' 'are' 'associated'
 'with' 'minimal' 'subject' 'survival' 'benefit']","[0. 0. 3. 3. 3. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02452203,"18:29:treatment,74:92:treatment,100:115:treatment,117:124:treatment,126:165:treatment,167:184:treatment,186:198:treatment,200:204:treatment,206:209:treatment,211:221:treatment,223:229:treatment,231:244:treatment,246:254:treatment","Certain drugs or medications consumed within the past week including any psychoactive drugs (e.g., benzodiazepines, opiates, selective serotonin reuptake inhibitors, dopamine agonists, barbiturates, MDMA, LSD, psilocybin, peyote, phencyclidine, ketamine)","['Certain' 'drugs' 'or' 'medications' 'consumed' 'within' 'the' 'past'
 'week' 'including' 'any' 'psychoactive' 'drugs' '(' 'e.g.' ','
 'benzodiazepines' ',' 'opiates' ',' 'selective' 'serotonin' 'reuptake'
 'inhibitors' ',' 'dopamine' 'agonists' ',' 'barbiturates' ',' 'MDMA' ','
 'LSD' ',' 'psilocybin' ',' 'peyote' ',' 'phencyclidine' ',' 'ketamine'
 ')']","[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 0. 1. 0. 1. 1. 1. 1.
 0. 1. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0.]"
NCT02452008,"5:14:treatment,16:26:treatment,37:67:treatment,,110:120:treatment","Had radiation, biological, or other investigational cancer therapy within 2 weeks prior to the first dose of study drug","['Had' 'radiation' ',' 'biological' ',' 'or' 'other' 'investigational'
 'cancer' 'therapy' 'within' '2' 'weeks' 'prior' 'to' 'the' 'first' 'dose'
 'of' 'study' 'drug']",[0. 1. 0. 1. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02452008,"31:36:cancer,37:43:treatment,87:96:treatment,118:126:treatment",Patients acceptance to have a tumor biopsy of an accessible lesion at baseline and on treatment if the lesion can be biopsied with acceptable clinical risk (as judged by the investigator),"['Patients' 'acceptance' 'to' 'have' 'a' 'tumor' 'biopsy' 'of' 'an'
 'accessible' 'lesion' 'at' 'baseline' 'and' 'on' 'treatment' 'if' 'the'
 'lesion' 'can' 'be' 'biopsied' 'with' 'acceptable' 'clinical' 'risk' '('
 'as' 'judged' 'by' 'the' 'investigator' ')']","[0. 0. 0. 0. 0. 3. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 1. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02451553,",84:99:chronic_disease,101:122:chronic_disease,137:155:chronic_disease,157:181:chronic_disease,183:207:chronic_disease,211:236:chronic_disease","Diagnosis with any of the following in the 12 months prior to registration: severe/unstable angina, myocardial infarction, uncontrolled cardiac arrhythmia, congestive heart failure, cerebrovascular accident or transient ischemic attack","['Diagnosis' 'with' 'any' 'of' 'the' 'following' 'in' 'the' '12' 'months'
 'prior' 'to' 'registration' ':' 'severe/unstable' 'angina' ','
 'myocardial' 'infarction' ',' 'uncontrolled' 'cardiac' 'arrhythmia' ','
 'congestive' 'heart' 'failure' ',' 'cerebrovascular' 'accident' 'or'
 'transient' 'ischemic' 'attack']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 2. 2. 0.
 2. 2. 2. 0. 2. 2. 0. 2. 2. 2.]"
NCT02451553,"1:31:treatment,33:42:treatment,46:81:treatment,83:92:treatment,97:108:treatment","Prior treatment with erlotinib, gefitinib or EGFR-blocking monoclonal antibodies (cetuximab and panitumumab)","['Prior' 'treatment' 'with' 'erlotinib' ',' 'gefitinib' 'or'
 'EGFR-blocking' 'monoclonal' 'antibodies' '(' 'cetuximab' 'and'
 'panitumumab' ')']",[1. 1. 1. 1. 0. 1. 0. 1. 1. 1. 0. 1. 0. 1. 0.]
NCT02451553,"27:35:treatment,56:77:treatment,147:165:treatment,153:165:treatment","patients who already have OncoPlex or other equivalent gene sequencing assay (eg Foundation One, Perthera, Caris etc) test results available from prior tumor biopsy are eligible to participate, without the needed of a repeat tumor biopsy, but the test results need to be available to the study principal investigator","['patients' 'who' 'already' 'have' 'OncoPlex' 'or' 'other' 'equivalent'
 'gene' 'sequencing' 'assay' '(' 'eg' 'Foundation' 'One' ',' 'Perthera'
 ',' 'Caris' 'etc' ')' 'test' 'results' 'available' 'from' 'prior' 'tumor'
 'biopsy' 'are' 'eligible' 'to' 'participate' ',' 'without' 'the' 'needed'
 'of' 'a' 'repeat' 'tumor' 'biopsy' ',' 'but' 'the' 'test' 'results'
 'need' 'to' 'be' 'available' 'to' 'the' 'study' 'principal'
 'investigator']","[0. 0. 0. 0. 1. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02451488,"1:29:treatment,31:39:treatment,41:79:treatment,81:93:treatment,","Immunosuppressive mediations (steroids, tumor necrosis factor (TNF)-inhibitors, azathioprine, etc.) within the past 6 weeks","['Immunosuppressive' 'mediations' '(' 'steroids' ',' 'tumor' 'necrosis'
 'factor' '(' 'TNF' ')' '-inhibitors' ',' 'azathioprine' ',' 'etc' '.' ')'
 'within' 'the' 'past' '6' 'weeks']",[1. 1. 0. 1. 0. 1. 1. 1. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02451423,"12:41:chronic_disease,43:63:chronic_disease,71:95:chronic_disease,111:122:chronic_disease,124:146:chronic_disease,195:208:treatment","History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan","['History' 'of' 'idiopathic' 'pulmonary' 'fibrosis' ',' 'organizing'
 'pneumonia' '(' 'e.g.' ',' 'bronchiolitis' 'obliterans' ')' ','
 'drug-induced' 'pneumonitis' ',' 'idiopathic' 'pneumonitis' ',' 'or'
 'evidence' 'of' 'active' 'pneumonitis' 'on' 'screening' 'chest' 'CT'
 'scan']","[0. 0. 2. 2. 2. 0. 2. 2. 0. 0. 0. 2. 2. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 1. 1.]"
NCT02451423,"1:13:cancer,25:27:chronic_disease,,115:125:treatment","Malignancies other than UC within 5 years prior to Cycle 1, Day 1, with the exception of those with a low risk of metastasis","['Malignancies' 'other' 'than' 'UC' 'within' '5' 'years' 'prior' 'to'
 'Cycle' '1' ',' 'Day' '1' ',' 'with' 'the' 'exception' 'of' 'those'
 'with' 'a' 'low' 'risk' 'of' 'metastasis']","[3. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1.]"
NCT02451423,"1:76:treatment,88:99:treatment,101:147:treatment","Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti CTLA-4, anti-PD1 and anti-PD-L1 therapeutic antibodies","['Prior' 'treatment' 'with' 'CD137' 'agonists' 'or' 'immune' 'checkpoint'
 'blockade' 'therapies' ',' 'including' 'anti' 'CTLA-4' ',' 'anti-PD1'
 'and' 'anti-PD-L1' 'therapeutic' 'antibodies']",[1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 1. 1. 0. 1. 1. 1. 1. 1.]
NCT02451423,"15:40:treatment,93:111:treatment,116:130:treatment",Subjects with malignant lymphadenectomy in the abdomen or pelvis considered appropriate for radical cystectomy and lymphadnectomy with the goal of complete resection of all malignant disease are allowed,"['Subjects' 'with' 'malignant' 'lymphadenectomy' 'in' 'the' 'abdomen' 'or'
 'pelvis' 'considered' 'appropriate' 'for' 'radical' 'cystectomy' 'and'
 'lymphadnectomy' 'with' 'the' 'goal' 'of' 'complete' 'resection' 'of'
 'all' 'malignant' 'disease' 'are' 'allowed']","[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02451423,"1:7:cancer,,50:57:treatment,104:127:treatment",cancer recurrence within 1 year of initiation of therapy for patients who have received induction plus maintenance BCG therapy,"['cancer' 'recurrence' 'within' '1' 'year' 'of' 'initiation' 'of'
 'therapy' 'for' 'patients' 'who' 'have' 'received' 'induction' 'plus'
 'maintenance' 'BCG' 'therapy']",[3. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02451215,"17:36:cancer,27:36:cancer,157:192:treatment",Newly diagnosed low-grade CNS tumor located in a site that is difficult to access surgically or recurrent/persistent low-grade CNS tumor (any site) despite treatment with conventional therapy,"['Newly' 'diagnosed' 'low-grade' 'CNS' 'tumor' 'located' 'in' 'a' 'site'
 'that' 'is' 'difficult' 'to' 'access' 'surgically' 'or'
 'recurrent/persistent' 'low-grade' 'CNS' 'tumor' '(' 'any' 'site' ')'
 'despite' 'treatment' 'with' 'conventional' 'therapy']","[0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 1. 1. 1.]"
NCT02448381,"38:64:chronic_disease,96:99:chronic_disease,103:109:chronic_disease",Subjects with significant history of systemic immunosuppression due to drugs or infection with HIV or HTLV 1,"['Subjects' 'with' 'significant' 'history' 'of' 'systemic'
 'immunosuppression' 'due' 'to' 'drugs' 'or' 'infection' 'with' 'HIV' 'or'
 'HTLV' '1']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2.]
NCT02446886,"29:40:treatment,42:51:treatment,57:73:treatment","Patients being treated with Natalizumab, Rituximab, and Cyclophosphamide","['Patients' 'being' 'treated' 'with' 'Natalizumab' ',' 'Rituximab' ','
 'and' 'Cyclophosphamide']",[0. 0. 0. 0. 1. 0. 1. 0. 0. 1.]
NCT02446457,"17:42:chronic_disease,46:52:chronic_disease,54:80:chronic_disease,95:103:treatment,107:126:chronic_disease","Has evidence of interstitial lung disease or active, non-infectious pneumonitis that required steroids or current pneumonitis","['Has' 'evidence' 'of' 'interstitial' 'lung' 'disease' 'or' 'active' ','
 'non-infectious' 'pneumonitis' 'that' 'required' 'steroids' 'or'
 'current' 'pneumonitis']",[0. 0. 0. 2. 2. 2. 0. 2. 0. 2. 2. 0. 0. 1. 0. 2. 2.]
NCT02446457,"39:52:treatment,90:111:treatment,125:135:treatment,148:168:treatment,,191:214:treatment",currently participating and receiving study therapy or has participated in a study of an investigational agent and received study drug or using an investigation device within 4 weeks of the first dose of treatment,"['currently' 'participating' 'and' 'receiving' 'study' 'therapy' 'or'
 'has' 'participated' 'in' 'a' 'study' 'of' 'an' 'investigational' 'agent'
 'and' 'received' 'study' 'drug' 'or' 'using' 'an' 'investigation'
 'device' 'within' '4' 'weeks' 'of' 'the' 'first' 'dose' 'of' 'treatment']","[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1.
 1. 0. 0. 0. 0. 0. 1. 1. 1. 1.]"
NCT02446457,"15:23:chronic_disease,36:52:chronic_disease,53:58:chronic_disease",subjects with vitiligo or resolved childhood asthma/atopy,['subjects' 'with' 'vitiligo' 'or' 'resolved' 'childhood' 'asthma/atopy'],[0. 0. 2. 0. 0. 2. 2.]
NCT02446236,"10:20:cancer,33:65:cancer,72:100:cancer,119:124:cancer,","A second malignancy, other than basal cell carcinoma of the skin or in situ carcinoma of the cervix (unless for other tumor type patient was treated with curative intent at least 2 years previously.)","['A' 'second' 'malignancy' ',' 'other' 'than' 'basal' 'cell' 'carcinoma'
 'of' 'the' 'skin' 'or' 'in' 'situ' 'carcinoma' 'of' 'the' 'cervix' '('
 'unless' 'for' 'other' 'tumor' 'type' 'patient' 'was' 'treated' 'with'
 'curative' 'intent' 'at' 'least' '2' 'years' 'previously' '.' ')']","[0. 0. 3. 0. 0. 0. 3. 3. 3. 3. 3. 3. 0. 0. 3. 3. 3. 3. 3. 0. 0. 0. 0. 3.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02446210,"106:121:chronic_disease,123:135:chronic_disease,139:162:chronic_disease","Ongoing cord compression or a syrinx in the spinal cord or who suffer from a spinal cord disease such as spinal stenosis, spina bifida or herniated cervical disk","['Ongoing' 'cord' 'compression' 'or' 'a' 'syrinx' 'in' 'the' 'spinal'
 'cord' 'or' 'who' 'suffer' 'from' 'a' 'spinal' 'cord' 'disease' 'such'
 'as' 'spinal' 'stenosis' ',' 'spina' 'bifida' 'or' 'herniated' 'cervical'
 'disk']","[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.
 2. 0. 2. 2. 2.]"
NCT02445768,"1:12:chronic_disease,16:32:chronic_disease,48:51:treatment",subcortical or cortical infarct confirmed with MRI,['subcortical' 'or' 'cortical' 'infarct' 'confirmed' 'with' 'MRI'],[2. 0. 2. 2. 0. 0. 1.]
NCT02442297,"25:81:cancer,71:74:cancer,85:115:cancer",Recurrent or refractory HER2 positive primary central nervous system (CNS) tumor or HER2 positive tumor metastatic to the CNS,"['Recurrent' 'or' 'refractory' 'HER2' 'positive' 'primary' 'central'
 'nervous' 'system' '(' 'CNS' ')' 'tumor' 'or' 'HER2' 'positive' 'tumor'
 'metastatic' 'to' 'the' 'CNS']",[0. 0. 0. 3. 3. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02442102,"1:29:treatment,37:47:treatment,49:60:treatment","Prior major thoracic surgery (e.g., sternotomy, thoracotomy)","['Prior' 'major' 'thoracic' 'surgery' '(' 'e.g.' ',' 'sternotomy' ','
 'thoracotomy' ')']",[1. 1. 1. 1. 0. 0. 0. 1. 0. 1. 0.]
NCT02441101,"23:32:treatment,33:46:treatment,64:93:treatment",Prior implantation of pacemaker/defibrillator with at least an atrial and RV mid septal lead,"['Prior' 'implantation' 'of' 'pacemaker/defibrillator' 'with' 'at' 'least'
 'an' 'atrial' 'and' 'RV' 'mid' 'septal' 'lead']",[0. 0. 0. 1. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1.]
NCT02440581,"1:19:chronic_disease,23:37:chronic_disease,67:101:chronic_disease",Systemic illnesses or organ diseases that may affect bone (except type 1 or type 2 diabetes mellitus),"['Systemic' 'illnesses' 'or' 'organ' 'diseases' 'that' 'may' 'affect'
 'bone' '(' 'except' 'type' '1' 'or' 'type' '2' 'diabetes' 'mellitus' ')']",[2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 2. 2. 2. 0.]
NCT02439450,"89:102:treatment,125:138:treatment,141:151:treatment","radiographically per RECIST 1.1 at first imaging assessment, and will begin maintenance immunotherapy with standard of care pembrolizumab ± pemetrexed","['radiographically' 'per' 'RECIST' '1.1' 'at' 'first' 'imaging'
 'assessment' ',' 'and' 'will' 'begin' 'maintenance' 'immunotherapy'
 'with' 'standard' 'of' 'care' 'pembrolizumab' '±' 'pemetrexed']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 1. 0. 1.]
NCT02438995,",57:62:cancer,149:151:treatment,152:155:treatment,156:164:treatment",Patients must have at least one confirmed and evaluable tumor site.* The recurrence must have bidimensional measurements by clinical examination or CT/MRI/PET scan. A confirmed recurrence site may also be biopsy-proven,"['Patients' 'must' 'have' 'at' 'least' 'one' 'confirmed' 'and' 'evaluable'
 'tumor' 'site' '.' '*' 'The' 'recurrence' 'must' 'have' 'bidimensional'
 'measurements' 'by' 'clinical' 'examination' 'or' 'CT/MRI/PET' 'scan' '.'
 'A' 'confirmed' 'recurrence' 'site' 'may' 'also' 'be' 'biopsy-proven']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02437851,"7:16:treatment,24:33:chronic_disease,45:73:chronic_disease,78:109:chronic_disease,",Acute treatment for an infection (excluding fungal infection of the skin and sexually transmitted infections) or other serious medical illness within 2 weeks before enrollment,"['Acute' 'treatment' 'for' 'an' 'infection' '(' 'excluding' 'fungal'
 'infection' 'of' 'the' 'skin' 'and' 'sexually' 'transmitted' 'infections'
 ')' 'or' 'other' 'serious' 'medical' 'illness' 'within' '2' 'weeks'
 'before' 'enrollment']","[0. 1. 0. 0. 2. 0. 0. 2. 2. 2. 2. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02437851,"20:37:cancer,41:59:cancer,77:111:treatment,112:144:treatment,",No evidence of any lymph node spread or distant metastases as determined by positron emission tomography (PET) computed tomography (CT) imaging within 8 weeks of enrollment,"['No' 'evidence' 'of' 'any' 'lymph' 'node' 'spread' 'or' 'distant'
 'metastases' 'as' 'determined' 'by' 'positron' 'emission' 'tomography'
 '(' 'PET' ')' 'computed' 'tomography' '(' 'CT' ')' 'imaging' 'within' '8'
 'weeks' 'of' 'enrollment']","[0. 0. 0. 0. 3. 3. 3. 0. 3. 3. 0. 0. 0. 1. 1. 1. 1. 0. 0. 1. 1. 1. 1. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02437851,"33:50:treatment,54:86:treatment,90:118:treatment,125:136:treatment,163:181:cancer","alternatively for those without PET CT capability, a magnetic resonance imaging (MRI) or CT of the abdomen and pelvis and a chest x-ray confirming no evidence of metastatic disease is acceptable","['alternatively' 'for' 'those' 'without' 'PET' 'CT' 'capability' ',' 'a'
 'magnetic' 'resonance' 'imaging' '(' 'MRI' ')' 'or' 'CT' 'of' 'the'
 'abdomen' 'and' 'pelvis' 'and' 'a' 'chest' 'x-ray' 'confirming' 'no'
 'evidence' 'of' 'metastatic' 'disease' 'is' 'acceptable']","[0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 1. 0. 0. 0. 0. 3. 3. 0. 0.]"
NCT02437370,"20:36:chronic_disease,53:77:treatment,99:124:treatment,,152:181:treatment",Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment,"['Has' 'a' 'diagnosis' 'of' 'immunodeficiency' 'or' 'is' 'receiving'
 'systemic' 'steroid' 'therapy' 'or' 'any' 'other' 'form' 'of'
 'immunosuppressive' 'therapy' 'within' '7' 'days' 'prior' 'to' 'the'
 'first' 'dose' 'of' 'trial' 'treatment']","[0. 0. 0. 0. 2. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.
 1. 1. 1. 1. 1.]"
NCT02437370,"18:57:cancer,65:89:cancer,124:140:cancer,218:225:treatment,,277:292:treatment,422:430:treatment,","Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis; subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment","['Has' 'known' 'active' 'central' 'nervous' 'system' '(' 'CNS' ')'
 'metastases' 'and/or' 'carcinomatous' 'meningitis' ';' 'subjects' 'with'
 'previously' 'treated' 'brain' 'metastases' 'may' 'participate'
 'provided' 'they' 'are' 'stable' '(' 'without' 'evidence' 'of'
 'progression' 'by' 'imaging' 'for' 'at' 'least' 'four' 'weeks' 'prior'
 'to' 'the' 'first' 'dose' 'of' 'trial' 'treatment' 'and' 'any'
 'neurologic' 'symptoms' 'have' 'returned' 'to' 'baseline' ')' ',' 'have'
 'no' 'evidence' 'of' 'new' 'or' 'enlarging' 'brain' 'metastases' ','
 'and' 'are' 'not' 'using' 'steroids' 'for' 'at' 'least' '7' 'days'
 'prior' 'to' 'trial' 'treatment']","[0. 0. 0. 3. 3. 3. 3. 3. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02437110,"10:25:chronic_disease,35:50:chronic_disease,54:91:chronic_disease,97:122:chronic_disease,132:143:chronic_disease,147:159:chronic_disease,173:183:cancer","Unstable medical disease (such as unstable angina or chronic obstructive pulmonary disease), or active infectious disease (such as Hepatitis C or tuberculosis), or current malignancy","['Unstable' 'medical' 'disease' '(' 'such' 'as' 'unstable' 'angina' 'or'
 'chronic' 'obstructive' 'pulmonary' 'disease' ')' ',' 'or' 'active'
 'infectious' 'disease' '(' 'such' 'as' 'Hepatitis' 'C' 'or'
 'tuberculosis' ')' ',' 'or' 'current' 'malignancy']","[0. 2. 2. 0. 0. 0. 2. 2. 0. 2. 2. 2. 2. 0. 0. 0. 2. 2. 2. 0. 0. 0. 2. 2.
 0. 2. 0. 0. 0. 0. 3.]"
NCT02436070,"61:67:chronic_disease,110:130:chronic_disease,132:140:chronic_disease","Presentation to the ED with a chief complaint related to an asthma exacerbation such as shortness of breath, respiratory distress, wheezing, etc","['Presentation' 'to' 'the' 'ED' 'with' 'a' 'chief' 'complaint' 'related'
 'to' 'an' 'asthma' 'exacerbation' 'such' 'as' 'shortness' 'of' 'breath'
 ',' 'respiratory' 'distress' ',' 'wheezing' ',' 'etc']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 0.
 0.]"
NCT02435992,"14:16:chronic_disease,18:39:chronic_disease,60:67:chronic_disease,90:109:chronic_disease,111:128:chronic_disease,133:149:chronic_disease","Diagnosis of CD, indeterminate colitis, or the presence of fistula consistent with CD or microscopic colitis, radiation colitis, or ischemic colitis","['Diagnosis' 'of' 'CD' ',' 'indeterminate' 'colitis' ',' 'or' 'the'
 'presence' 'of' 'fistula' 'consistent' 'with' 'CD' 'or' 'microscopic'
 'colitis' ',' 'radiation' 'colitis' ',' 'or' 'ischemic' 'colitis']","[0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 2.
 2.]"
NCT02433977,"88:101:chronic_disease,103:109:cancer,111:119:chronic_disease","Significant or uncontrolled concomitant medical illness including (but not limited to) heart disease, cancer, diabetes","['Significant' 'or' 'uncontrolled' 'concomitant' 'medical' 'illness'
 'including' '(' 'but' 'not' 'limited' 'to' ')' 'heart' 'disease' ','
 'cancer' ',' 'diabetes']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 3. 0. 2.]
NCT02433626,"1:14:treatment,26:101:treatment,,140:146:treatment","Major surgery, excluding skin biopsies and procedures for insertion of central venous access devices, within 28 days prior to the start of COTI-2","['Major' 'surgery' ',' 'excluding' 'skin' 'biopsies' 'and' 'procedures'
 'for' 'insertion' 'of' 'central' 'venous' 'access' 'devices' ',' 'within'
 '28' 'days' 'prior' 'to' 'the' 'start' 'of' 'COTI-2']","[1. 1. 0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1.]"
NCT02433210,"1:19:chronic_disease,56:63:chronic_disease,65:78:chronic_disease,80:89:chronic_disease","Medical conditions which may interfere with the study (cardiac, liver disease, Hepatitis)","['Medical' 'conditions' 'which' 'may' 'interfere' 'with' 'the' 'study' '('
 'cardiac' ',' 'liver' 'disease' ',' 'Hepatitis' ')']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 2. 0.]
NCT02431806,"46:61:allergy_name,50:61:allergy_name,76:86:allergy_name,111:146:allergy_name,150:201:allergy_name","Allergy, intolerance, or hypersensitivity to levomilnacipran, milnacipran, fluoxetine, or any other selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitors (SNRI)","['Allergy' ',' 'intolerance' ',' 'or' 'hypersensitivity' 'to'
 'levomilnacipran' ',' 'milnacipran' ',' 'fluoxetine' ',' 'or' 'any'
 'other' 'selective' 'serotonin' 'reuptake' 'inhibitor' '(' 'SSRI' ')'
 'or' 'serotonin-norepinephrine' 'reuptake' 'inhibitors' '(' 'SNRI' ')']","[0. 0. 0. 0. 0. 0. 0. 4. 0. 4. 0. 4. 0. 0. 0. 0. 0. 4. 4. 4. 4. 0. 0. 0.
 4. 4. 4. 4. 0. 0.]"
NCT02430077,"13:37:cancer,,,94:104:chronic_disease,136:148:cancer",Evidence of hepatocellular carcinoma: alpha-fetoprotein levels greater than 200 ng/ml and/or liver mass on imaging study suggestive of liver cancer,"['Evidence' 'of' 'hepatocellular' 'carcinoma' ':' 'alpha-fetoprotein'
 'levels' 'greater' 'than' '200' 'ng/ml' 'and/or' 'liver' 'mass' 'on'
 'imaging' 'study' 'suggestive' 'of' 'liver' 'cancer']",[0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT02430077,"1:21:treatment,38:53:chronic_disease,61:76:treatment,88:97:treatment,99:111:treatment,113:123:treatment,125:134:treatment,136:149:treatment,151:164:treatment,169:178:treatment,","Treatment with drugs associated with steatohepatitis, e.g., corticosteroids, high dose estrogens, methotrexate, amiodarone, tamoxifen, valproic acid, sulfasalazine, or oxacillin for more than 2 weeks in the 6 months prior to the study","['Treatment' 'with' 'drugs' 'associated' 'with' 'steatohepatitis' ','
 'e.g.' ',' 'corticosteroids' ',' 'high' 'dose' 'estrogens' ','
 'methotrexate' ',' 'amiodarone' ',' 'tamoxifen' ',' 'valproic' 'acid' ','
 'sulfasalazine' ',' 'or' 'oxacillin' 'for' 'more' 'than' '2' 'weeks' 'in'
 'the' '6' 'months' 'prior' 'to' 'the' 'study']","[1. 1. 1. 0. 0. 2. 0. 0. 0. 1. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 1. 0.
 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02429934,"28:34:cancer,,74:104:cancer,114:129:treatment",Subjects with a history of cancer within the last five years (other than non-melanoma skin cell cancers cured by local resection),"['Subjects' 'with' 'a' 'history' 'of' 'cancer' 'within' 'the' 'last'
 'five' 'years' '(' 'other' 'than' 'non-melanoma' 'skin' 'cell' 'cancers'
 'cured' 'by' 'local' 'resection' ')']",[0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 1. 1. 0.]
NCT02429934,"1:25:treatment,,111:120:treatment,143:152:treatment,,179:195:treatment,","Treatment with rituximab within the past 6 months (B cells must be detectable in peripheral blood at onset of treatment with study biologic), belimumab within the past 5 months, cyclophosphamide within the past 3 months","['Treatment' 'with' 'rituximab' 'within' 'the' 'past' '6' 'months' '(' 'B'
 'cells' 'must' 'be' 'detectable' 'in' 'peripheral' 'blood' 'at' 'onset'
 'of' 'treatment' 'with' 'study' 'biologic' ')' ',' 'belimumab' 'within'
 'the' 'past' '5' 'months' ',' 'cyclophosphamide' 'within' 'the' 'past'
 '3' 'months']","[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.
 0. 0. 1. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]"
NCT02429830,"16:34:treatment,38:46:treatment,48:66:treatment","Subject has an electrical implant or metallic, abdominal implants","['Subject' 'has' 'an' 'electrical' 'implant' 'or' 'metallic' ','
 'abdominal' 'implants']",[0. 0. 0. 1. 1. 0. 1. 0. 1. 1.]
NCT02429557,"6:40:chronic_disease,57:82:chronic_disease,84:101:chronic_disease,103:126:chronic_disease,131:153:chronic_disease","with neurogenic orthostatic hypotension associated with primary autonomic failure (Parkinson Disease, Multiple System Atrophy and Pure Autonomic Failure)","['with' 'neurogenic' 'orthostatic' 'hypotension' 'associated' 'with'
 'primary' 'autonomic' 'failure' '(' 'Parkinson' 'Disease' ',' 'Multiple'
 'System' 'Atrophy' 'and' 'Pure' 'Autonomic' 'Failure' ')']",[0. 2. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 0. 2. 2. 2. 0. 2. 2. 2. 0.]
NCT02427997,"14:35:chronic_disease,46:68:chronic_disease,70:78:chronic_disease,80:100:chronic_disease,144:165:chronic_disease,167:176:chronic_disease,187:207:chronic_disease,259:279:chronic_disease","have another neurological disorder, unstable cardiovascular disease, diabetes, lower limb arthritis, acute lower back or lower extremity pain, peripheral neuropathy, rheumatic or severe orthopaedic problems that may interfere with walking, or have diagnosed psychiatric problems","['have' 'another' 'neurological' 'disorder' ',' 'unstable'
 'cardiovascular' 'disease' ',' 'diabetes' ',' 'lower' 'limb' 'arthritis'
 ',' 'acute' 'lower' 'back' 'or' 'lower' 'extremity' 'pain' ','
 'peripheral' 'neuropathy' ',' 'rheumatic' 'or' 'severe' 'orthopaedic'
 'problems' 'that' 'may' 'interfere' 'with' 'walking' ',' 'or' 'have'
 'diagnosed' 'psychiatric' 'problems']","[0. 0. 2. 2. 0. 0. 2. 2. 0. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.
 2. 0. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]"
NCT02427841,"4:17:treatment,22:39:cancer,51:63:treatment,65:82:treatment,95:102:treatment,106:129:treatment","No prior therapy for pancreatic cancer, including chemotherapy, radiation therapy, definitive surgery or investigational therapy","['No' 'prior' 'therapy' 'for' 'pancreatic' 'cancer' ',' 'including'
 'chemotherapy' ',' 'radiation' 'therapy' ',' 'definitive' 'surgery' 'or'
 'investigational' 'therapy']",[0. 1. 1. 0. 3. 3. 0. 0. 1. 0. 1. 1. 0. 0. 1. 0. 1. 1.]
NCT02426476,"14:21:chronic_disease,23:32:chronic_disease,34:39:chronic_disease,43:72:chronic_disease,80:90:chronic_disease","a history of bipolar, psychotic, panic or obsessive-compulsive disorder (note: depression is an exclusion)","['a' 'history' 'of' 'bipolar' ',' 'psychotic' ',' 'panic' 'or'
 'obsessive-compulsive' 'disorder' '(' 'note' ':' 'depression' 'is' 'an'
 'exclusion' ')']",[0. 0. 0. 2. 0. 2. 0. 2. 0. 2. 2. 0. 0. 0. 2. 0. 0. 0. 0.]
NCT02425904,"1:12:treatment,99:109:treatment,111:125:treatment,127:136:treatment,138:149:treatment,151:163:treatment,165:175:treatment,,239:260:treatment","Clofarabine is excreted primarily by the kidneys. Therefore, drugs with known renal toxicity (e.g.vancomycin, amphotericin B, acyclovir, cyclosporin, methotrexate, tacrolimus) should be avoided to the extent possible during the 5 days of clofarabine treatment in each cycle or, if required, administered cautiously and with close monitoring","['Clofarabine' 'is' 'excreted' 'primarily' 'by' 'the' 'kidneys' '.'
 'Therefore' ',' 'drugs' 'with' 'known' 'renal' 'toxicity' '('
 'e.g.vancomycin' ',' 'amphotericin' 'B' ',' 'acyclovir' ',' 'cyclosporin'
 ',' 'methotrexate' ',' 'tacrolimus' ')' 'should' 'be' 'avoided' 'to'
 'the' 'extent' 'possible' 'during' 'the' '5' 'days' 'of' 'clofarabine'
 'treatment' 'in' 'each' 'cycle' 'or' ',' 'if' 'required' ','
 'administered' 'cautiously' 'and' 'with' 'close' 'monitoring']","[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 1. 0. 1.
 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02425904,"27:39:treatment,43:55:treatment,,84:96:treatment,100:111:treatment,247:271:treatment",Participants who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier. Corticosteroid treatment is allowed,"['Participants' 'who' 'have' 'had' 'chemotherapy' 'or' 'radiotherapy'
 'within' '2' 'weeks' '(' '6' 'weeks' 'for' 'nitrosoureas' 'or'
 'mitomycin' 'C' ')' 'prior' 'to' 'entering' 'the' 'study' 'or' 'those'
 'who' 'have' 'not' 'recovered' 'from' 'adverse' 'events' 'due' 'to'
 'agents' 'administered' 'more' 'than' '2' 'weeks' 'earlier' '.'
 'Corticosteroid' 'treatment' 'is' 'allowed']","[0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.]"
NCT02424968,"24:42:cancer,72:75:treatment,80:83:treatment,119:140:treatment,163:166:cancer,168:198:cancer,200:232:cancer,234:237:cancer,239:254:cancer,252:254:cancer","Must have a myeloid or lymphoid malignant disease that is treated with TLI and ATG reduced intensity conditioning for allogeneic transplant (any of the following AML, myelodysplastic syndrome [MDS], myeloproliferative disease [MPD], CLL, B or T-cell NHL, HL)","['Must' 'have' 'a' 'myeloid' 'or' 'lymphoid' 'malignant' 'disease' 'that'
 'is' 'treated' 'with' 'TLI' 'and' 'ATG' 'reduced' 'intensity'
 'conditioning' 'for' 'allogeneic' 'transplant' '(' 'any' 'of' 'the'
 'following' 'AML' ',' 'myelodysplastic' 'syndrome' '[' 'MDS' ']' ','
 'myeloproliferative' 'disease' '[' 'MPD' ']' ',' 'CLL' ',' 'B' 'or'
 'T-cell' 'NHL' ',' 'HL' ')']","[0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 1. 1. 0. 0. 0.
 0. 0. 3. 0. 3. 3. 3. 0. 0. 0. 3. 3. 3. 0. 0. 0. 3. 0. 3. 3. 3. 3. 0. 3.
 0.]"
NCT02424968,"31:42:chronic_disease,80:111:treatment,138:159:chronic_disease",donors with prior evidence of hepatitis B core antibody positivity will have a polymerase chain reaction (PCR) test done to evaluate for hepatitis B infection,"['donors' 'with' 'prior' 'evidence' 'of' 'hepatitis' 'B' 'core' 'antibody'
 'positivity' 'will' 'have' 'a' 'polymerase' 'chain' 'reaction' '(' 'PCR'
 ')' 'test' 'done' 'to' 'evaluate' 'for' 'hepatitis' 'B' 'infection']","[0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02423863,"1:38:cancer,87:103:cancer,122:129:treatment",Bulky intracranial metastatic disease with shift of midline structures or progressive brain metastasis such that ongoing therapy for these brain metastasis is required at the time of enrollment,"['Bulky' 'intracranial' 'metastatic' 'disease' 'with' 'shift' 'of'
 'midline' 'structures' 'or' 'progressive' 'brain' 'metastasis' 'such'
 'that' 'ongoing' 'therapy' 'for' 'these' 'brain' 'metastasis' 'is'
 'required' 'at' 'the' 'time' 'of' 'enrollment']","[3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02423772,"65:78:chronic_disease,80:99:chronic_disease,101:110:chronic_disease,114:136:chronic_disease","Meet diagnostic criteria for a current or past DSM diagnosis of schizophrenia, delusional disorder, psychotic or dissociative disorders","['Meet' 'diagnostic' 'criteria' 'for' 'a' 'current' 'or' 'past' 'DSM'
 'diagnosis' 'of' 'schizophrenia' ',' 'delusional' 'disorder' ','
 'psychotic' 'or' 'dissociative' 'disorders']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 2. 0. 2. 2.]
NCT02423525,"12:76:treatment,112:118:cancer,126:143:treatment,197:213:treatment","Has failed prior standard therapy including maximal safe surgical resection (when appropriate for the specific cancer type), radiation therapy (when appropriate for the specific cancer type), and systemic therapy (when appropriate for the specific cancer type)","['Has' 'failed' 'prior' 'standard' 'therapy' 'including' 'maximal' 'safe'
 'surgical' 'resection' '(' 'when' 'appropriate' 'for' 'the' 'specific'
 'cancer' 'type' ')' ',' 'radiation' 'therapy' '(' 'when' 'appropriate'
 'for' 'the' 'specific' 'cancer' 'type' ')' ',' 'and' 'systemic' 'therapy'
 '(' 'when' 'appropriate' 'for' 'the' 'specific' 'cancer' 'type' ')']","[0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 1. 1. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02423525,"21:46:cancer,48:79:cancer,81:105:cancer,129:139:cancer,157:166:treatment,","effectively treated non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured","['effectively' 'treated' 'non-melanoma' 'skin' 'cancers' ',' 'carcinoma'
 'in' 'situ' 'of' 'the' 'cervix' ',' 'ductal' 'carcinoma' 'in' 'situ' 'or'
 'effectively' 'treated' 'malignancy' 'that' 'has' 'been' 'in' 'remission'
 'for' 'more' 'than' '3' 'years' 'and' 'is' 'considered' 'to' 'be' 'cured']","[0. 0. 3. 3. 3. 0. 3. 3. 3. 3. 3. 3. 0. 3. 3. 3. 3. 0. 0. 0. 3. 0. 0. 0.
 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02422641,"1:16:treatment,26:38:treatment,50:66:treatment,",Prior treatment with any methotrexate containing systemic regimen within 1 year,"['Prior' 'treatment' 'with' 'any' 'methotrexate' 'containing' 'systemic'
 'regimen' 'within' '1' 'year']",[1. 1. 0. 0. 1. 0. 1. 1. 0. 0. 0.]
NCT02421380,"48:60:chronic_disease,85:93:cancer,100:103:treatment",Patients identified by a radiologist to have a brain lesion with high suspicion for neoplasm given MRI features,"['Patients' 'identified' 'by' 'a' 'radiologist' 'to' 'have' 'a' 'brain'
 'lesion' 'with' 'high' 'suspicion' 'for' 'neoplasm' 'given' 'MRI'
 'features']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 3. 0. 1. 0.]
NCT02419495,"1:13:treatment,18:31:treatment,45:72:treatment,,93:103:treatment,144:163:treatment,154:163:treatment,226:235:treatment,290:311:treatment,335:359:treatment","Chemotherapy, or immunotherapy or any other systemic anticancer therapy =< 3 weeks prior to study drug administration date; patients receiving anti-PD-1 treatment, and continue to receiving this treatment in combination with selinexor (Arms L and M), can start receiving the selinexor and anti-PD-1 combination without washout of the prior anti-PD-1 antibody","['Chemotherapy' ',' 'or' 'immunotherapy' 'or' 'any' 'other' 'systemic'
 'anticancer' 'therapy' '=' '<' '3' 'weeks' 'prior' 'to' 'study' 'drug'
 'administration' 'date' ';' 'patients' 'receiving' 'anti-PD-1'
 'treatment' ',' 'and' 'continue' 'to' 'receiving' 'this' 'treatment' 'in'
 'combination' 'with' 'selinexor' '(' 'Arms' 'L' 'and' 'M' ')' ',' 'can'
 'start' 'receiving' 'the' 'selinexor' 'and' 'anti-PD-1' 'combination'
 'without' 'washout' 'of' 'the' 'prior' 'anti-PD-1' 'antibody']","[1. 0. 0. 1. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 1.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02419495,"1:30:chronic_disease,52:63:treatment,65:75:treatment,80:91:treatment,","Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to the first dose","['Uncontrolled' 'active' 'infection' 'requiring' 'parenteral'
 'antibiotics' ',' 'antivirals' ',' 'or' 'antifungals' 'within' 'one'
 'week' 'prior' 'to' 'the' 'first' 'dose']",[2. 2. 2. 0. 0. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02419495,",,157:171:treatment,173:185:treatment,187:199:treatment,201:217:treatment,228:246:treatment,270:278:chronic_disease","recovered to grade =< 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03 (NCI-CTCAE v4.03) from the effects of recent surgery, radiotherapy, chemotherapy, hormonal therapy, or other targeted therapies, with the exception of alopecia","['recovered' 'to' 'grade' '=' '<' '1' 'by' 'the' 'National' 'Cancer'
 'Institute' 'Common' 'Terminology' 'Criteria' 'for' 'Adverse' 'Events'
 ',' 'version' '4.03' '(' 'NCI-CTCAE' 'v4.03' ')' 'from' 'the' 'effects'
 'of' 'recent' 'surgery' ',' 'radiotherapy' ',' 'chemotherapy' ','
 'hormonal' 'therapy' ',' 'or' 'other' 'targeted' 'therapies' ',' 'with'
 'the' 'exception' 'of' 'alopecia']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 0. 1. 1. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 2.]"
NCT02418195,"1:4:chronic_disease,26:41:chronic_disease,48:65:chronic_disease","MDD Participants without Suicide Attempt, with Suicidal Ideation","['MDD' 'Participants' 'without' 'Suicide' 'Attempt' ',' 'with' 'Suicidal'
 'Ideation']",[2. 0. 0. 2. 2. 0. 0. 2. 2.]
NCT02417701,"42:62:treatment,58:61:treatment,117:128:treatment,,209:220:treatment",Concomitant administration of any proton pump inhibitor (PPI) is not permitted during the study; patients receiving PPI therapy before enrollment must stop using the PPI for 7 days before their first dose of study drugs,"['Concomitant' 'administration' 'of' 'any' 'proton' 'pump' 'inhibitor' '('
 'PPI' ')' 'is' 'not' 'permitted' 'during' 'the' 'study' ';' 'patients'
 'receiving' 'PPI' 'therapy' 'before' 'enrollment' 'must' 'stop' 'using'
 'the' 'PPI' 'for' '7' 'days' 'before' 'their' 'first' 'dose' 'of' 'study'
 'drugs']","[0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02416206,"19:37:chronic_disease,46:62:chronic_disease,63:78:chronic_disease,89:123:chronic_disease","Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive","['Ongoing' 'or' 'active' 'systemic' 'infection' ',' 'active' 'hepatitis'
 'B' 'or' 'C' 'virus' 'infection' ',' 'or' 'known' 'human'
 'immunodeficiency' 'virus' '(' 'HIV' ')' 'positive']",[0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 2. 2. 2. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0.]
NCT02415660,"16:33:chronic_disease,43:70:treatment,75:78:treatment,110:122:chronic_disease,124:142:chronic_disease,146:170:treatment","History of any systemic disorder in which thoracic spine manipulation and TDN would be contraindicated (i.e. osteoporosis, bleeding disorders or anticoagulant medication use)","['History' 'of' 'any' 'systemic' 'disorder' 'in' 'which' 'thoracic'
 'spine' 'manipulation' 'and' 'TDN' 'would' 'be' 'contraindicated' '('
 'i.e' '.' 'osteoporosis' ',' 'bleeding' 'disorders' 'or' 'anticoagulant'
 'medication' 'use' ')']","[0. 0. 0. 2. 2. 0. 0. 1. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 1.
 1. 0. 0.]"
NCT02415556,"1:6:chronic_disease,10:23:chronic_disease,27:37:treatment",Liver or renal failure or transplant,['Liver' 'or' 'renal' 'failure' 'or' 'transplant'],[2. 0. 2. 2. 0. 1.]
NCT02415387,"1:11:treatment,36:44:treatment,56:63:treatment,74:85:treatment,91:108:treatment",Medication exclusions will include steroids as well as statins and other medications with anti-inflammatory actions,"['Medication' 'exclusions' 'will' 'include' 'steroids' 'as' 'well' 'as'
 'statins' 'and' 'other' 'medications' 'with' 'anti-inflammatory'
 'actions']",[1. 0. 0. 0. 1. 0. 0. 0. 1. 0. 0. 1. 0. 1. 0.]
NCT02414269,"25:49:treatment,92:109:treatment,113:136:treatment",A requirement for daily systemic corticosteroids for any reason or a requirement for other immunosuppressive or immunomodulatory agents,"['A' 'requirement' 'for' 'daily' 'systemic' 'corticosteroids' 'for' 'any'
 'reason' 'or' 'a' 'requirement' 'for' 'other' 'immunosuppressive' 'or'
 'immunomodulatory' 'agents']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1.]
NCT02414269,"1:14:cancer,15:25:cancer,95:102:treatment",Breast cancer metastatic to the pleura that extends outside of the pleura requiring immediate therapy,"['Breast' 'cancer' 'metastatic' 'to' 'the' 'pleura' 'that' 'extends'
 'outside' 'of' 'the' 'pleura' 'requiring' 'immediate' 'therapy']",[3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02414269,"21:35:cancer,62:77:treatment,81:96:treatment",Untreated or active CNS metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control),"['Untreated' 'or' 'active' 'CNS' 'metastases' '(' 'progressing' 'or'
 'requiring' 'anticonvulsants' 'or' 'corticosteroids' 'for' 'symptomatic'
 'control' ')']",[0. 0. 0. 3. 3. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0.]
NCT02413970,"8:27:chronic_disease,29:46:chronic_disease,48:64:chronic_disease,69:90:chronic_disease","Active psychiatric disease (psychotic illness, major depression, or acute anxiety attacks) which prevents subject compliance with the requirements of the investigational study testing","['Active' 'psychiatric' 'disease' '(' 'psychotic' 'illness' ',' 'major'
 'depression' ',' 'or' 'acute' 'anxiety' 'attacks' ')' 'which' 'prevents'
 'subject' 'compliance' 'with' 'the' 'requirements' 'of' 'the'
 'investigational' 'study' 'testing']","[0. 2. 2. 0. 2. 2. 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02413047,"15:41:chronic_disease,69:79:treatment,83:93:treatment,,167:177:treatment",Patients with inflammatory bowel disease who on are stable doses of infliximab or adalimumab for at least 3 months who experience a secondary loss of response to the medication based on clinical symptoms,"['Patients' 'with' 'inflammatory' 'bowel' 'disease' 'who' 'on' 'are'
 'stable' 'doses' 'of' 'infliximab' 'or' 'adalimumab' 'for' 'at' 'least'
 '3' 'months' 'who' 'experience' 'a' 'secondary' 'loss' 'of' 'response'
 'to' 'the' 'medication' 'based' 'on' 'clinical' 'symptoms']","[0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 0. 0. 0. 0.]"
NCT02412540,"8:19:treatment,35:46:chronic_disease,,92:116:treatment,118:130:treatment,132:149:treatment,151:164:treatment","use of medications known to cause fatty liver for > 2 consecutive weeks in past year (i.e. systemic glucocorticoids, tetracycline, anabolic steroids, valproic acid)","['use' 'of' 'medications' 'known' 'to' 'cause' 'fatty' 'liver' 'for' '>'
 '2' 'consecutive' 'weeks' 'in' 'past' 'year' '(' 'i.e' '.' 'systemic'
 'glucocorticoids' ',' 'tetracycline' ',' 'anabolic' 'steroids' ','
 'valproic' 'acid' ')']","[0. 0. 1. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0.
 1. 1. 0. 1. 1. 0.]"
NCT02411656,"34:62:cancer,92:95:cancer,180:188:chronic_disease,193:198:chronic_disease,200:213:chronic_disease,335:360:cancer,414:440:cancer,546:578:cancer,,","Has histological confirmation of HER2 normal breast carcinoma with a clinical diagnosis of IBC based on presence of inflammatory changes in the involved breast, including diffuse erythema and edema (peau d'orange), with or without an underlying palpable mass involving the majority of the skin of the breast; pathological evidence of dermal lymphatic invasion should be noted but is not required for diagnosis of inflammatory breast cancer regardless estrogen receptor (ER)/progesterone receptor (PR) status; OR has histological confirmation of triple negative breast carcinoma (HER2 normal, ER/PR < 10%) without clinical diagnosis of IBC","['Has' 'histological' 'confirmation' 'of' 'HER2' 'normal' 'breast'
 'carcinoma' 'with' 'a' 'clinical' 'diagnosis' 'of' 'IBC' 'based' 'on'
 'presence' 'of' 'inflammatory' 'changes' 'in' 'the' 'involved' 'breast'
 ',' 'including' 'diffuse' 'erythema' 'and' 'edema' '(' 'peau' ""d'orange""
 ')' ',' 'with' 'or' 'without' 'an' 'underlying' 'palpable' 'mass'
 'involving' 'the' 'majority' 'of' 'the' 'skin' 'of' 'the' 'breast' ';'
 'pathological' 'evidence' 'of' 'dermal' 'lymphatic' 'invasion' 'should'
 'be' 'noted' 'but' 'is' 'not' 'required' 'for' 'diagnosis' 'of'
 'inflammatory' 'breast' 'cancer' 'regardless' 'estrogen' 'receptor' '('
 'ER' ')' '/progesterone' 'receptor' '(' 'PR' ')' 'status' ';' 'OR' 'has'
 'histological' 'confirmation' 'of' 'triple' 'negative' 'breast'
 'carcinoma' '(' 'HER2' 'normal' ',' 'ER/PR' '<' '10' '%' ')' 'without'
 'clinical' 'diagnosis' 'of' 'IBC']","[0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 3. 3. 3. 0. 0. 0.
 0. 0. 0. 2. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02411656,"44:70:treatment,66:69:treatment,87:128:treatment,123:127:treatment,189:202:cancer","Is HER2 normal, defined as HER2 0 or 1+ by immunohistochemistry (IHC) and negative by fluorescence in situ hybridization (FISH) if performed; or HER2 is 2+ by IHC and negative by FISH; or HER2 negative by FISH if IHC is not performed","['Is' 'HER2' 'normal' ',' 'defined' 'as' 'HER2' '0' 'or' '1+' 'by'
 'immunohistochemistry' '(' 'IHC' ')' 'and' 'negative' 'by' 'fluorescence'
 'in' 'situ' 'hybridization' '(' 'FISH' ')' 'if' 'performed' ';' 'or'
 'HER2' 'is' '2+' 'by' 'IHC' 'and' 'negative' 'by' 'FISH' ';' 'or' 'HER2'
 'negative' 'by' 'FISH' 'if' 'IHC' 'is' 'not' 'performed']","[0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02409316,",90:92:treatment,94:103:treatment,105:108:treatment,110:120:treatment","At least one site of disease outside of the liver that is seen on standard imaging (e.g. CT, bone scan, MRI, FDG PET/CT)","['At' 'least' 'one' 'site' 'of' 'disease' 'outside' 'of' 'the' 'liver'
 'that' 'is' 'seen' 'on' 'standard' 'imaging' '(' 'e.g' '.' 'CT' ','
 'bone' 'scan' ',' 'MRI' ',' 'FDG' 'PET/CT' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0.
 1. 0. 1. 1. 0.]"
NCT02408861,"40:51:cancer,120:129:treatment,139:147:cancer,149:157:cancer,163:208:cancer","For participants in the 24 participant solid tumor cohort, only those histologies not known to respond to single agent nivolumab (such as pancreas, prostate, and microsatellite stable [MSS] colorectal cancer)","['For' 'participants' 'in' 'the' '24' 'participant' 'solid' 'tumor'
 'cohort' ',' 'only' 'those' 'histologies' 'not' 'known' 'to' 'respond'
 'to' 'single' 'agent' 'nivolumab' '(' 'such' 'as' 'pancreas' ','
 'prostate' ',' 'and' 'microsatellite' 'stable' '[' 'MSS' ']' 'colorectal'
 'cancer' ')']","[0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.
 3. 0. 3. 0. 0. 3. 3. 3. 3. 3. 0. 0. 0.]"
NCT02408861,"16:25:treatment,30:40:treatment,118:136:treatment,172:183:treatment,,,,,,,,489:509:treatment","The effects of nivolumab and ipilimumab on the developing human fetus are unknown; for this reason and because other therapeutic agents used in this trial are known to be teratogenic, women of childbearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; WOCBP should use an adequate method to avoid pregnancy for 6 months after the last dose of investigational drug","['The' 'effects' 'of' 'nivolumab' 'and' 'ipilimumab' 'on' 'the'
 'developing' 'human' 'fetus' 'are' 'unknown' ';' 'for' 'this' 'reason'
 'and' 'because' 'other' 'therapeutic' 'agents' 'used' 'in' 'this' 'trial'
 'are' 'known' 'to' 'be' 'teratogenic' ',' 'women' 'of' 'childbearing'
 'potential' '(' 'WOCBP' ')' 'and' 'men' 'must' 'agree' 'to' 'use'
 'adequate' 'contraception' '(' 'hormonal' 'or' 'barrier' 'method' 'of'
 'birth' 'control' ';' 'abstinence' ')' 'prior' 'to' 'study' 'entry' 'and'
 'for' 'the' 'duration' 'of' 'study' 'participation' ';' 'WOCBP' 'should'
 'use' 'an' 'adequate' 'method' 'to' 'avoid' 'pregnancy' 'for' '6'
 'months' 'after' 'the' 'last' 'dose' 'of' 'investigational' 'drug']","[0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]"
NCT02408861,"19:50:treatment,67:78:allergy_name,87:96:treatment,","a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen)","['a' 'brief' 'course' 'of' 'corticosteroids' 'for' 'prophylaxis' '('
 'e.g.' ',' 'contrast' 'dye' 'allergy' ')' 'or' 'for' 'treatment' 'of'
 'non-autoimmune' 'conditions' '(' 'e.g.' ',' 'delayed-type'
 'hypersensitivity' 'reaction' 'caused' 'by' 'contact' 'allergen' ')']","[0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 4. 4. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02408406,"1:10:cancer,24:30:cancer,32:49:cancer,51:76:cancer","Malignant diagnosis in breast, gynecologic (GYN), genitourinary (GU) cancer at any stage","['Malignant' 'diagnosis' 'in' 'breast' ',' 'gynecologic' '(' 'GYN' ')' ','
 'genitourinary' '(' 'GU' ')' 'cancer' 'at' 'any' 'stage']",[3. 0. 0. 3. 0. 3. 3. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0.]
NCT02407171,"14:30:chronic_disease,47:71:treatment,93:118:treatment,,147:165:treatment",diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 2 weeks of the first protocol treatment,"['diagnosis' 'of' 'immunodeficiency' 'or' 'is' 'receiving' 'systemic'
 'steroid' 'therapy' 'or' 'any' 'other' 'form' 'of' 'immunosuppressive'
 'therapy' 'within' '2' 'weeks' 'of' 'the' 'first' 'protocol' 'treatment']",[0. 0. 2. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02407028,"25:58:treatment,,112:122:treatment,123:134:treatment,138:162:treatment",Ability to initiate the first hyperbaric oxygen treatment within 14 hours of admission in patients requiring a craniotomy/craniectomy or major surgical procedure,"['Ability' 'to' 'initiate' 'the' 'first' 'hyperbaric' 'oxygen' 'treatment'
 'within' '14' 'hours' 'of' 'admission' 'in' 'patients' 'requiring' 'a'
 'craniotomy/craniectomy' 'or' 'major' 'surgical' 'procedure']",[0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 1.]
NCT02406885,"46:61:treatment,65:91:treatment,103:110:treatment,112:141:treatment,143:149:treatment,151:158:treatment,160:166:treatment","Participants currently receiving any type of anticoagulation or blood thinning medications, including heparin, low molecular weight heparins, Plavix, aspirin, NSAIDS","['Participants' 'currently' 'receiving' 'any' 'type' 'of'
 'anticoagulation' 'or' 'blood' 'thinning' 'medications' ',' 'including'
 'heparin' ',' 'low' 'molecular' 'weight' 'heparins' ',' 'Plavix' ','
 'aspirin' ',' 'NSAIDS']","[0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 1. 0. 0. 1. 0. 1. 1. 1. 1. 0. 1. 0. 1. 0.
 1.]"
NCT02405078,"24:31:treatment,46:66:treatment,71:109:treatment",Suitable candidate for therapy with standard salvage chemotherapy and autologous stem cell transplant (ASCT) as determined by the treating physician,"['Suitable' 'candidate' 'for' 'therapy' 'with' 'standard' 'salvage'
 'chemotherapy' 'and' 'autologous' 'stem' 'cell' 'transplant' '(' 'ASCT'
 ')' 'as' 'determined' 'by' 'the' 'treating' 'physician']",[0. 0. 0. 1. 0. 0. 1. 1. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02404194,"21:44:chronic_disease,59:72:chronic_disease,82:88:chronic_disease,92:108:chronic_disease",clear evidence that psychosis-risk syndrome is due to non-schizophrenia-spectrum Axis I or Axis II disorder,"['clear' 'evidence' 'that' 'psychosis-risk' 'syndrome' 'is' 'due' 'to'
 'non-schizophrenia-spectrum' 'Axis' 'I' 'or' 'Axis' 'II' 'disorder']",[0. 0. 0. 2. 2. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0.]
NCT02403193,"1:20:treatment,33:70:treatment,72:83:treatment,85:94:treatment,96:106:treatment","Prior immunotherapy is allowed (previous immune checkpoint inhibitors; anti-CTLA-4, anti-PD-1, anti-PD-L1 and/or combinations)","['Prior' 'immunotherapy' 'is' 'allowed' '(' 'previous' 'immune'
 'checkpoint' 'inhibitors' ';' 'anti-CTLA-4' ',' 'anti-PD-1' ','
 'anti-PD-L1' 'and/or' 'combinations' ')']",[1. 1. 0. 0. 0. 1. 1. 1. 1. 0. 1. 0. 1. 0. 1. 0. 0. 0.]
NCT02403128,"1:21:chronic_disease,23:41:chronic_disease,43:66:chronic_disease","pre-retinal fibrosis, retinal detachment, vitreo-macular traction","['pre-retinal' 'fibrosis' ',' 'retinal' 'detachment' ',' 'vitreo-macular'
 'traction']",[2. 2. 0. 0. 0. 0. 2. 2.]
NCT02402088,"5:23:chronic_disease,105:128:treatment,141:157:chronic_disease,162:179:chronic_disease","Any psychotic disorder or current psychiatric symptoms requiring specific attention, including need for psychiatric medications for current major depression and anxiety disorders","['Any' 'psychotic' 'disorder' 'or' 'current' 'psychiatric' 'symptoms'
 'requiring' 'specific' 'attention' ',' 'including' 'need' 'for'
 'psychiatric' 'medications' 'for' 'current' 'major' 'depression' 'and'
 'anxiety' 'disorders']",[0. 2. 2. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2.]
NCT02401347,"54:68:cancer,,102:120:treatment,155:171:cancer",A repeated CT or MRI following the identification of CNS metastases (obtained at least 2 weeks after definitive therapy) must document adequately treated brain metastases,"['A' 'repeated' 'CT' 'or' 'MRI' 'following' 'the' 'identification' 'of'
 'CNS' 'metastases' '(' 'obtained' 'at' 'least' '2' 'weeks' 'after'
 'definitive' 'therapy' ')' 'must' 'document' 'adequately' 'treated'
 'brain' 'metastases']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0.
 0. 3. 3.]"
NCT02401074,"45:57:treatment,97:104:treatment,106:117:treatment,128:142:treatment,152:160:treatment,162:169:treatment,171:179:treatment,","It is required that the subjects undergoing bronchoscopy are not on any anti-platelets (such as aspirin, clopidogrel, etc.) or anticoagulants (such as coumadin, heparin, Xarelto®, etc.) at least 5 days prior to the bronchoscopy","['It' 'is' 'required' 'that' 'the' 'subjects' 'undergoing' 'bronchoscopy'
 'are' 'not' 'on' 'any' 'anti-platelets' '(' 'such' 'as' 'aspirin' ','
 'clopidogrel' ',' 'etc' '.' ')' 'or' 'anticoagulants' '(' 'such' 'as'
 'coumadin' ',' 'heparin' ',' 'Xarelto®' ',' 'etc' '.' ')' 'at' 'least'
 '5' 'days' 'prior' 'to' 'the' 'bronchoscopy']","[1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.
 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.]"
NCT02401035,",,,88:120:treatment,164:168:chronic_disease,314:328:treatment,","Subjects aged 1 to 16 years who in the judgment of the investigator are candidates for gastric acid suppression therapy (ie, those with a presumptive diagnosis of GERD, a clinical diagnosis of suspected GERD, symptomatic GERD, or endoscopically proven GERD) and whom the investigator judges would need to receive IV PPI therapy for at least 4 days","['Subjects' 'aged' '1' 'to' '16' 'years' 'who' 'in' 'the' 'judgment' 'of'
 'the' 'investigator' 'are' 'candidates' 'for' 'gastric' 'acid'
 'suppression' 'therapy' '(' 'ie' ',' 'those' 'with' 'a' 'presumptive'
 'diagnosis' 'of' 'GERD' ',' 'a' 'clinical' 'diagnosis' 'of' 'suspected'
 'GERD' ',' 'symptomatic' 'GERD' ',' 'or' 'endoscopically' 'proven' 'GERD'
 ')' 'and' 'whom' 'the' 'investigator' 'judges' 'would' 'need' 'to'
 'receive' 'IV' 'PPI' 'therapy' 'for' 'at' 'least' '4' 'days']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0.]"
NCT02400463,"11:21:cancer,56:80:cancer,84:101:cancer","No active malignancy at the time of enrollment, except nonmelanoma skin cancers or carcinoma in situ","['No' 'active' 'malignancy' 'at' 'the' 'time' 'of' 'enrollment' ','
 'except' 'nonmelanoma' 'skin' 'cancers' 'or' 'carcinoma' 'in' 'situ']",[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 3. 3. 3.]
NCT02400255,"1:24:treatment,29:36:treatment,40:43:cancer",Chemotherapeutic agents for therapy of AML,['Chemotherapeutic' 'agents' 'for' 'therapy' 'of' 'AML'],[1. 1. 0. 1. 0. 3.]
NCT02400255,"1:16:treatment,,,76:94:treatment,105:120:treatment,",Post-transplant bone marrow blast count ≤ 5% confirmed by standard of care bone marrow biopsy performed post-transplant (at least 30 days post-transplant),"['Post-transplant' 'bone' 'marrow' 'blast' 'count' '≤' '5' '%' 'confirmed'
 'by' 'standard' 'of' 'care' 'bone' 'marrow' 'biopsy' 'performed'
 'post-transplant' '(' 'at' 'least' '30' 'days' 'post-transplant' ')']","[1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02398773,"41:67:treatment,77:87:treatment,91:102:treatment,108:129:treatment,145:162:treatment",Patient must NOT be planning to receive molecular targeted therapy (such as everolimus or palbociclib) nor HER2 directed therapy in addition to endocrine therapy,"['Patient' 'must' 'NOT' 'be' 'planning' 'to' 'receive' 'molecular'
 'targeted' 'therapy' '(' 'such' 'as' 'everolimus' 'or' 'palbociclib' ')'
 'nor' 'HER2' 'directed' 'therapy' 'in' 'addition' 'to' 'endocrine'
 'therapy']","[0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 1. 0. 1. 0. 0. 1. 1. 1. 0. 0. 0.
 1. 1.]"
NCT02398773,"24:42:chronic_disease,65:91:treatment,134:149:treatment,159:198:treatment",patients who developed metastatic disease while still receiving adjuvant endocrine therapy must have a planned change in the type of endocrine agent used for subsequent metastatic disease treatment,"['patients' 'who' 'developed' 'metastatic' 'disease' 'while' 'still'
 'receiving' 'adjuvant' 'endocrine' 'therapy' 'must' 'have' 'a' 'planned'
 'change' 'in' 'the' 'type' 'of' 'endocrine' 'agent' 'used' 'for'
 'subsequent' 'metastatic' 'disease' 'treatment']","[0. 0. 0. 2. 2. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 1. 1. 1.]"
NCT02397889,"46:60:treatment,65:82:treatment,89:104:treatment,114:127:treatment,131:138:treatment,","Patients who report current treatment with a benzodiazepine, an opioid medication, or a mood stabilizer (such as valproic acid or lithium) within 2 weeks prior to randomization","['Patients' 'who' 'report' 'current' 'treatment' 'with' 'a'
 'benzodiazepine' ',' 'an' 'opioid' 'medication' ',' 'or' 'a' 'mood'
 'stabilizer' '(' 'such' 'as' 'valproic' 'acid' 'or' 'lithium' ')'
 'within' '2' 'weeks' 'prior' 'to' 'randomization']","[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 1. 0. 0. 0. 1. 1. 0. 0. 0. 1. 1. 0. 1.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02397083,"42:62:cancer,67:87:cancer,91:119:cancer,137:174:cancer,178:196:treatment,200:230:treatment,","All patients with a diagnosis of complex atypical hyperplasia OR, grade 1 endometrioid OR focal grade 2 adenocarcinoma in predominately grade 1 disease endometrial carcinoma on endometrial biopsy or dilation and curettage (D & C) within three months of study enrollment","['All' 'patients' 'with' 'a' 'diagnosis' 'of' 'complex' 'atypical'
 'hyperplasia' 'OR' ',' 'grade' '1' 'endometrioid' 'OR' 'focal' 'grade'
 '2' 'adenocarcinoma' 'in' 'predominately' 'grade' '1' 'disease'
 'endometrial' 'carcinoma' 'on' 'endometrial' 'biopsy' 'or' 'dilation'
 'and' 'curettage' '(' 'D' '&' 'C' ')' 'within' 'three' 'months' 'of'
 'study' 'enrollment']","[0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 3. 3. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0.
 1. 1. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02397083,"30:50:treatment,62:74:treatment,76:93:treatment,95:103:treatment,108:130:treatment","Patients currently receiving anticancer therapies (including chemotherapy, radiation therapy, hormonal, or antibody-based therapy)","['Patients' 'currently' 'receiving' 'anticancer' 'therapies' '('
 'including' 'chemotherapy' ',' 'radiation' 'therapy' ',' 'hormonal' ','
 'or' 'antibody-based' 'therapy' ')']",[0. 0. 0. 1. 1. 0. 0. 1. 0. 1. 1. 0. 1. 0. 0. 1. 1. 0.]
NCT02397083,"14:31:chronic_disease,,,91:98:treatment,133:183:chronic_disease,227:249:treatment","Uncontrolled diabetes mellitus as defined by hemoglobin A1c (HbA1c) > 8% despite adequate therapy; patients with a known history of impaired fasting glucose or diabetes mellitus (DM) may be included, however blood glucose and antidiabetic treatment must be monitored closely throughout the trial and adjusted as necessary","['Uncontrolled' 'diabetes' 'mellitus' 'as' 'defined' 'by' 'hemoglobin'
 'A1c' '(' 'HbA1c' ')' '>' '8' '%' 'despite' 'adequate' 'therapy' ';'
 'patients' 'with' 'a' 'known' 'history' 'of' 'impaired' 'fasting'
 'glucose' 'or' 'diabetes' 'mellitus' '(' 'DM' ')' 'may' 'be' 'included'
 ',' 'however' 'blood' 'glucose' 'and' 'antidiabetic' 'treatment' 'must'
 'be' 'monitored' 'closely' 'throughout' 'the' 'trial' 'and' 'adjusted'
 'as' 'necessary']","[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 2. 2. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02394704,"1:23:chronic_disease,25:31:chronic_disease,33:44:chronic_disease,46:57:chronic_disease,59:67:chronic_disease","Neurological disorders (stroke, Alzheimer's, Parkinson's, epilepsy, etc.)","['Neurological' 'disorders' '(' 'stroke' ',' 'Alzheimer' ""'s"" ','
 'Parkinson' ""'s"" ',' 'epilepsy' ',' 'etc' '.' ')']",[2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2.]
NCT02394535,"33:45:chronic_disease,47:54:chronic_disease,56:65:chronic_disease,73:84:chronic_disease,91:105:treatment","Prior severe infusion reaction (bronchospasm, stridor, urticaria and/or hypotension) to a taxane therapy","['Prior' 'severe' 'infusion' 'reaction' '(' 'bronchospasm' ',' 'stridor'
 ',' 'urticaria' 'and/or' 'hypotension' ')' 'to' 'a' 'taxane' 'therapy']",[0. 0. 0. 0. 0. 2. 0. 2. 0. 2. 0. 2. 0. 0. 0. 1. 1.]
NCT02394028,"1:49:treatment,54:56:chronic_disease,86:95:chronic_disease",Treatment with antibiotics as adjunctive therapy for CD in the absence of documented infection,"['Treatment' 'with' 'antibiotics' 'as' 'adjunctive' 'therapy' 'for' 'CD'
 'in' 'the' 'absence' 'of' 'documented' 'infection']",[1. 1. 1. 1. 1. 1. 0. 2. 0. 0. 0. 0. 0. 2.]
NCT02393885,"23:66:treatment,79:91:chronic_disease,93:113:chronic_disease,118:127:chronic_disease","Documented history of previous catheter ablation with perforation, history of pericarditis, pericardial effusion, or tamponade","['Documented' 'history' 'of' 'previous' 'catheter' 'ablation' 'with'
 'perforation' ',' 'history' 'of' 'pericarditis' ',' 'pericardial'
 'effusion' ',' 'or' 'tamponade']",[0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 2. 0. 2. 2. 0. 0. 2.]
NCT02393885,"1:43:chronic_disease,47:101:chronic_disease,143:147:treatment",Symptomatic Persistent Atrial Fibrillation or Longstanding Persistent Atrial Fibrillation refractory to a minimum of one Class I or Class III AADs,"['Symptomatic' 'Persistent' 'Atrial' 'Fibrillation' 'or' 'Longstanding'
 'Persistent' 'Atrial' 'Fibrillation' 'refractory' 'to' 'a' 'minimum' 'of'
 'one' 'Class' 'I' 'or' 'Class' 'III' 'AADs']",[2. 2. 2. 2. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02393794,"1:14:cancer,30:47:chronic_disease,64:80:treatment",Breast cancer that is either stage III disease not amenable to curative therapy or stage IV,"['Breast' 'cancer' 'that' 'is' 'either' 'stage' 'III' 'disease' 'not'
 'amenable' 'to' 'curative' 'therapy' 'or' 'stage' 'IV']",[3. 3. 0. 0. 0. 2. 2. 2. 0. 0. 0. 1. 1. 0. 0. 0.]
NCT02393794,"19:36:chronic_disease,47:94:chronic_disease,96:115:chronic_disease,120:131:chronic_disease","Other significant ECG abnormalities including 2nd degree atrio-ventricular (AV) block type II, 3rd degree AV block, or bradycardia","['Other' 'significant' 'ECG' 'abnormalities' 'including' '2nd' 'degree'
 'atrio-ventricular' '(' 'AV' ')' 'block' 'type' 'II' ',' '3rd' 'degree'
 'AV' 'block' ',' 'or' 'bradycardia']",[0. 0. 2. 2. 0. 2. 2. 2. 2. 2. 2. 2. 0. 0. 0. 2. 2. 2. 2. 0. 0. 2.]
NCT02393794,"44:81:treatment,83:97:treatment,99:114:treatment,116:131:treatment,133:149:treatment","Subject has previously been treated with a Histone deacetylases (HDAC) inhibitor, PD-1 inhibitor, PD-L1 inhibitor, PD-L2 inhibitor, CTLA-4 inhibitor","['Subject' 'has' 'previously' 'been' 'treated' 'with' 'a' 'Histone'
 'deacetylases' '(' 'HDAC' ')' 'inhibitor' ',' 'PD-1' 'inhibitor' ','
 'PD-L1' 'inhibitor' ',' 'PD-L2' 'inhibitor' ',' 'CTLA-4' 'inhibitor']","[0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 1. 1. 0. 1. 1. 0. 1. 1. 0. 1.
 1.]"
NCT02393794,"1:20:treatment,22:57:treatment,59:68:treatment,72:84:treatment","herapy with heparin, low molecular weight heparin (LMWH), Factor Xa or fondaparinux is allowed","['herapy' 'with' 'heparin' ',' 'low' 'molecular' 'weight' 'heparin' '('
 'LMWH' ')' ',' 'Factor' 'Xa' 'or' 'fondaparinux' 'is' 'allowed']",[1. 1. 1. 0. 1. 1. 1. 1. 1. 0. 0. 0. 1. 1. 0. 1. 0. 0.]
NCT02393690,"19:22:treatment,31:57:treatment,73:85:treatment,",It is noted to be RAI-avid on radioactive iodine imaging (diagnostic or post-therapy whole body scans acceptable) and it measures >= 1 cm in the long axis,"['It' 'is' 'noted' 'to' 'be' 'RAI-avid' 'on' 'radioactive' 'iodine'
 'imaging' '(' 'diagnostic' 'or' 'post-therapy' 'whole' 'body' 'scans'
 'acceptable' ')' 'and' 'it' 'measures' '>' '=' '1' 'cm' 'in' 'the' 'long'
 'axis']","[0. 0. 0. 0. 0. 1. 0. 1. 1. 1. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02393690,"77:93:chronic_disease,95:116:chronic_disease,118:139:chronic_disease,153:177:chronic_disease,179:203:chronic_disease,205:223:chronic_disease,228:265:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, hepatitis B infection, hepatitis C infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' ',' 'ongoing' 'or' 'active' 'infection' ',' 'hepatitis'
 'B' 'infection' ',' 'hepatitis' 'C' 'infection' ',' 'symptomatic'
 'congestive' 'heart' 'failure' ',' 'unstable' 'angina' 'pectoris' ','
 'cardiac' 'arrhythmia' ',' 'or' 'psychiatric' 'illness/social'
 'situations' 'that' 'would' 'limit' 'compliance' 'with' 'study'
 'requirements']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0.
 2. 2. 2. 0. 2. 2. 2. 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT02392897,"84:106:chronic_disease,110:127:chronic_disease,188:234:treatment","Presence of diseases requiring dietary modification, including physician diagnosed cardiovascular disease or diabetes mellitus, use of medications that may impact study results including non-steroidal anti-inflammatory drugs (NSAIDS)","['Presence' 'of' 'diseases' 'requiring' 'dietary' 'modification' ','
 'including' 'physician' 'diagnosed' 'cardiovascular' 'disease' 'or'
 'diabetes' 'mellitus' ',' 'use' 'of' 'medications' 'that' 'may' 'impact'
 'study' 'results' 'including' 'non-steroidal' 'anti-inflammatory' 'drugs'
 '(' 'NSAIDS' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 1. 1. 1. 0. 0.]"
NCT02392572,"4:13:treatment,29:37:treatment,42:46:chronic_disease,,64:76:treatment",No treatment with high dose steroids for GVHD (up to >/= 20 mg Prednisolone or equivalent per day),"['No' 'treatment' 'with' 'high' 'dose' 'steroids' 'for' 'GVHD' '(' 'up'
 'to' '>' '/=' '20' 'mg' 'Prednisolone' 'or' 'equivalent' 'per' 'day' ')']",[0. 1. 0. 0. 0. 1. 0. 2. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02392572,"19:34:treatment,,103:119:treatment,,149:168:treatment",The interval from prior treatment to time of study drug administration should be at least 2 weeks for cytotoxic agents or at least 5 half-lives for noncytotoxic agents,"['The' 'interval' 'from' 'prior' 'treatment' 'to' 'time' 'of' 'study'
 'drug' 'administration' 'should' 'be' 'at' 'least' '2' 'weeks' 'for'
 'cytotoxic' 'agents' 'or' 'at' 'least' '5' 'half-lives' 'for'
 'noncytotoxic' 'agents']","[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0.
 0. 0. 1. 1.]"
NCT02392286,"1:18:chronic_disease,27:33:cancer,37:49:treatment,53:72:treatment",immunocompromised (active cancer on chemotherapy or radiation treatment),"['immunocompromised' '(' 'active' 'cancer' 'on' 'chemotherapy' 'or'
 'radiation' 'treatment' ')']",[2. 0. 0. 3. 0. 1. 0. 1. 1. 0.]
NCT02391987,"1:20:chronic_disease,22:31:chronic_disease,35:40:chronic_disease","shortness of breath, orthopnea or edema","['shortness' 'of' 'breath' ',' 'orthopnea' 'or' 'edema']",[2. 2. 2. 0. 2. 0. 2.]
NCT02390752,"5:9:cancer,18:21:treatment,84:103:treatment,121:126:treatment,130:149:treatment","For DIPG typical MRI findings must be present which include hypo- or isointense on T1-weighted imaging, hyperintense on FLAIR or T2-weighted imaging, epicenter in the pons in the face of a typical clinical presentation","['For' 'DIPG' 'typical' 'MRI' 'findings' 'must' 'be' 'present' 'which'
 'include' 'hypo-' 'or' 'isointense' 'on' 'T1-weighted' 'imaging' ','
 'hyperintense' 'on' 'FLAIR' 'or' 'T2-weighted' 'imaging' ',' 'epicenter'
 'in' 'the' 'pons' 'in' 'the' 'face' 'of' 'a' 'typical' 'clinical'
 'presentation']","[0. 3. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 0. 1. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02390752,"9:18:treatment,34:48:treatment,52:73:treatment,100:112:treatment,117:125:cancer","Ongoing treatment with any other cancer therapy or investigational agent, with the exception of IT chemotherapy for leukemia, when indicated","['Ongoing' 'treatment' 'with' 'any' 'other' 'cancer' 'therapy' 'or'
 'investigational' 'agent' ',' 'with' 'the' 'exception' 'of' 'IT'
 'chemotherapy' 'for' 'leukemia' ',' 'when' 'indicated']",[0. 1. 0. 0. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1. 0. 3. 0. 0. 0.]
NCT02390752,"22:24:chronic_disease,73:77:cancer,82:94:cancer,146:154:cancer,158:179:cancer,289:304:cancer,321:338:chronic_disease,376:392:chronic_disease,451:454:chronic_disease","Phase II: inoperable PN causing morbidity, such as (but not limited to) head and neck lesions that could compromise the airway or great vessels, brachial or lumbar plexus lesions that could cause nerve compression and loss of function, lesions that could result in major deformity (e.g., orbital lesions) or significant cosmetic problems, lesions of the extremity that cause limb hypertrophy or loss of function, and painful lesions in patients with NF1","['Phase' 'II' ':' 'inoperable' 'PN' 'causing' 'morbidity' ',' 'such' 'as'
 '(' 'but' 'not' 'limited' 'to' ')' 'head' 'and' 'neck' 'lesions' 'that'
 'could' 'compromise' 'the' 'airway' 'or' 'great' 'vessels' ',' 'brachial'
 'or' 'lumbar' 'plexus' 'lesions' 'that' 'could' 'cause' 'nerve'
 'compression' 'and' 'loss' 'of' 'function' ',' 'lesions' 'that' 'could'
 'result' 'in' 'major' 'deformity' '(' 'e.g.' ',' 'orbital' 'lesions' ')'
 'or' 'significant' 'cosmetic' 'problems' ',' 'lesions' 'of' 'the'
 'extremity' 'that' 'cause' 'limb' 'hypertrophy' 'or' 'loss' 'of'
 'function' ',' 'and' 'painful' 'lesions' 'in' 'patients' 'with' 'NF1']","[0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 3. 3. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 3. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]"
NCT02389517,"34:59:treatment,84:102:treatment,111:123:treatment,128:147:chronic_disease,,,,196:220:chronic_disease,225:240:chronic_disease,244:265:chronic_disease,","Evidence of current uncontrolled cardiovascular conditions, including uncontrolled cardiac conditions such as hypertension, or cardiac arrhythmias, or New York Heart Association stage III and IV congestive heart failure, or unstable angina or myocardial infarction within the past 6 months","['Evidence' 'of' 'current' 'uncontrolled' 'cardiovascular' 'conditions'
 ',' 'including' 'uncontrolled' 'cardiac' 'conditions' 'such' 'as'
 'hypertension' ',' 'or' 'cardiac' 'arrhythmias' ',' 'or' 'New' 'York'
 'Heart' 'Association' 'stage' 'III' 'and' 'IV' 'congestive' 'heart'
 'failure' ',' 'or' 'unstable' 'angina' 'or' 'myocardial' 'infarction'
 'within' 'the' 'past' '6' 'months']","[0. 0. 0. 0. 1. 1. 0. 0. 0. 2. 2. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 2. 2. 2. 0. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0.]"
NCT02389517,"15:38:cancer,42:59:cancer,121:130:treatment",patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection,"['patients' 'with' 'nonmelanoma' 'skin' 'cancer' 'or' 'carcinoma' 'in'
 'situ' 'of' 'any' 'type' 'are' 'not' 'excluded' 'if' 'they' 'have'
 'undergone' 'complete' 'resection']",[0. 0. 3. 3. 3. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02389465,"1:4:allergy_name,30:55:allergy_name,57:66:allergy_name","MRI contraindications (e.g., foreign metallic implants, pacemaker)","['MRI' 'contraindications' '(' 'e.g.' ',' 'foreign' 'metallic' 'implants'
 ',' 'pacemaker' ')']",[4. 0. 0. 0. 0. 4. 4. 4. 0. 4. 0.]
NCT02389309,"1:15:treatment,16:30:treatment,44:90:treatment,97:105:treatment,107:135:treatment","Anticoagulants/anti-platelets: patients on therapeutic (treatment) dose of anticoagulants (e.g. warfarin, low molecular-weight heparin)","['Anticoagulants/anti-platelets' ':' 'patients' 'on' 'therapeutic' '('
 'treatment' ')' 'dose' 'of' 'anticoagulants' '(' 'e.g' '.' 'warfarin' ','
 'low' 'molecular-weight' 'heparin' ')']",[1. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 1. 0. 1. 1. 1. 0.]
NCT02389309,",28:40:treatment,42:56:treatment,58:69:treatment,71:82:treatment,84:95:treatment,101:110:treatment","Drugs prolong QT interval; erythromycin, clarithromycin, pentamidine, ondansetron, granisetron, and methadone","['Drugs' 'prolong' 'QT' 'interval' ';' 'erythromycin' ',' 'clarithromycin'
 ',' 'pentamidine' ',' 'ondansetron' ',' 'granisetron' ',' 'and'
 'methadone']",[0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 1.]
NCT02389309,"38:60:chronic_disease,73:81:chronic_disease,85:103:chronic_disease,,126:151:chronic_disease,,,230:251:chronic_disease,255:270:chronic_disease,,,341:365:chronic_disease,375:393:chronic_disease,404:414:treatment,416:440:chronic_disease,486:513:chronic_disease,536:554:chronic_disease,556:582:chronic_disease,593:613:chronic_disease,646:673:chronic_disease,713:736:chronic_disease,746:769:chronic_disease,771:795:chronic_disease,800:819:chronic_disease,,848:875:treatment,","Patients with clinically significant cardiovascular disease: history of ischemic or hemorrhagic stroke within past 6 months; uncontrolled hypertension, on at least 2 repeated determinations on separate days within past 3 months; myocardial infarction or unstable angina within past 6 months; New York Heart Association grade III or greater congestive heart failure, serious cardiac arrhythmia requiring medication, unstable angina pectoris within past 6 months; clinically significant peripheral vascular disease within past 6 months; pulmonary embolism, deep vein thrombosis (DVT), or other thromboembolic event within past 6 months; diagnosed congenital long QT syndrome; any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes); prolonged QTc interval on pre-entry electrocardiogram (> 450 msec)","['Patients' 'with' 'clinically' 'significant' 'cardiovascular' 'disease'
 ':' 'history' 'of' 'ischemic' 'or' 'hemorrhagic' 'stroke' 'within' 'past'
 '6' 'months' ';' 'uncontrolled' 'hypertension' ',' 'on' 'at' 'least' '2'
 'repeated' 'determinations' 'on' 'separate' 'days' 'within' 'past' '3'
 'months' ';' 'myocardial' 'infarction' 'or' 'unstable' 'angina' 'within'
 'past' '6' 'months' ';' 'New' 'York' 'Heart' 'Association' 'grade' 'III'
 'or' 'greater' 'congestive' 'heart' 'failure' ',' 'serious' 'cardiac'
 'arrhythmia' 'requiring' 'medication' ',' 'unstable' 'angina' 'pectoris'
 'within' 'past' '6' 'months' ';' 'clinically' 'significant' 'peripheral'
 'vascular' 'disease' 'within' 'past' '6' 'months' ';' 'pulmonary'
 'embolism' ',' 'deep' 'vein' 'thrombosis' '(' 'DVT' ')' ',' 'or' 'other'
 'thromboembolic' 'event' 'within' 'past' '6' 'months' ';' 'diagnosed'
 'congenital' 'long' 'QT' 'syndrome' ';' 'any' 'history' 'of' 'clinically'
 'significant' 'ventricular' 'arrhythmias' '(' 'such' 'as' 'ventricular'
 'tachycardia' ',' 'ventricular' 'fibrillation' ',' 'or' 'torsades' 'de'
 'pointes' ')' ';' 'prolonged' 'QTc' 'interval' 'on' 'pre-entry'
 'electrocardiogram' '(' '>' '450' 'msec' ')']","[0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 2. 2. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 2. 2. 2. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 2. 2. 0.
 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]"
NCT02389309,"1:27:treatment,,56:70:treatment,,88:102:treatment",Stem cell transplant (SCT): at least 8 weeks following autologous SCT and 12 weeks for allogeneic SCT,"['Stem' 'cell' 'transplant' '(' 'SCT' ')' ':' 'at' 'least' '8' 'weeks'
 'following' 'autologous' 'SCT' 'and' '12' 'weeks' 'for' 'allogeneic'
 'SCT']",[1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 1.]
NCT02389309,"36:51:treatment,55:75:treatment,127:139:chronic_disease",patients must not be receiving any anti-thrombotic or anti-platelet agents; patient cannot be on drugs that cause significant prolonged QT (category I drug),"['patients' 'must' 'not' 'be' 'receiving' 'any' 'anti-thrombotic' 'or'
 'anti-platelet' 'agents' ';' 'patient' 'can' 'not' 'be' 'on' 'drugs'
 'that' 'cause' 'significant' 'prolonged' 'QT' '(' 'category' 'I' 'drug'
 ')']","[0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0.
 0. 0. 0.]"
NCT02389023,"1:23:treatment,40:57:treatment,79:93:treatment,101:109:treatment,117:144:treatment,484:502:treatment,504:544:treatment,546:580:treatment","femoral endarterectomy with or without patch angioplasty involving the common femoral artery and/or profunda and/or proximal superficial artery. The index groin may have undergone prior procedures (may be inflow or outflow for existing grafts), but the patient must have fully healed from the prior operation. May include patients with concomitant proximal and/or distal peripheral vascular intervention. The patch may be autogenous venous or arterial or prosthetic material such as bovine pericardium, dacron or polytetrafluoroethylene (PTFE). Bilateral femoral endarterectomies are eligible for enrollment. The right and left groin incision would be randomized to the same dressing which is consistent with routine clinical practice","['femoral' 'endarterectomy' 'with' 'or' 'without' 'patch' 'angioplasty'
 'involving' 'the' 'common' 'femoral' 'artery' 'and/or' 'profunda'
 'and/or' 'proximal' 'superficial' 'artery' '.' 'The' 'index' 'groin'
 'may' 'have' 'undergone' 'prior' 'procedures' '(' 'may' 'be' 'inflow'
 'or' 'outflow' 'for' 'existing' 'grafts' ')' ',' 'but' 'the' 'patient'
 'must' 'have' 'fully' 'healed' 'from' 'the' 'prior' 'operation' '.' 'May'
 'include' 'patients' 'with' 'concomitant' 'proximal' 'and/or' 'distal'
 'peripheral' 'vascular' 'intervention' '.' 'The' 'patch' 'may' 'be'
 'autogenous' 'venous' 'or' 'arterial' 'or' 'prosthetic' 'material' 'such'
 'as' 'bovine' 'pericardium' ',' 'dacron' 'or' 'polytetrafluoroethylene'
 '(' 'PTFE' ')' '.' 'Bilateral' 'femoral' 'endarterectomies' 'are'
 'eligible' 'for' 'enrollment' '.' 'The' 'right' 'and' 'left' 'groin'
 'incision' 'would' 'be' 'randomized' 'to' 'the' 'same' 'dressing' 'which'
 'is' 'consistent' 'with' 'routine' 'clinical' 'practice']","[1. 1. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 1. 0. 1. 1. 1. 1. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02387905,"30:38:cancer,40:47:cancer,52:74:cancer","Patients with a histology of lymphoma, myeloma and small cell lung cancer histologies","['Patients' 'with' 'a' 'histology' 'of' 'lymphoma' ',' 'myeloma' 'and'
 'small' 'cell' 'lung' 'cancer' 'histologies']",[0. 0. 0. 0. 0. 3. 0. 3. 0. 3. 3. 3. 3. 0.]
NCT02384954,"1:33:chronic_disease,99:124:treatment,,260:267:treatment",Anti-CD20 mAb-refractory disease is defined as progressive disease while on rituximab (or another treatment of an anti-CD20 monoclonal antibody) or progression within 6 months of rituximab-containing (or another treatment of an anti-CD20 antibody-containing) therapy,"['Anti-CD20' 'mAb-refractory' 'disease' 'is' 'defined' 'as' 'progressive'
 'disease' 'while' 'on' 'rituximab' '(' 'or' 'another' 'treatment' 'of'
 'an' 'anti-CD20' 'monoclonal' 'antibody' ')' 'or' 'progression' 'within'
 '6' 'months' 'of' 'rituximab-containing' '(' 'or' 'another' 'treatment'
 'of' 'an' 'anti-CD20' 'antibody-containing' ')' 'therapy']","[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02383979,"34:48:treatment,41:48:treatment,61:70:chronic_disease",possessing a contraindication to mirror therapy for example blindness or inability to position properly for the therapy,"['possessing' 'a' 'contraindication' 'to' 'mirror' 'therapy' 'for'
 'example' 'blindness' 'or' 'inability' 'to' 'position' 'properly' 'for'
 'the' 'therapy']",[0. 0. 0. 0. 1. 1. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02382549,"6:22:cancer,60:67:treatment,132:157:treatment",Each brain metastasis must have been completely removed by surgery or each unresected brain metastasis must have been treated with stereotactic radiosurgery,"['Each' 'brain' 'metastasis' 'must' 'have' 'been' 'completely' 'removed'
 'by' 'surgery' 'or' 'each' 'unresected' 'brain' 'metastasis' 'must'
 'have' 'been' 'treated' 'with' 'stereotactic' 'radiosurgery']",[0. 3. 3. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02382549,"17:36:treatment,40:59:treatment,64:82:cancer,,",The most recent surgical resections or gamma-knife therapy for malignant melanoma must have been completed ≥ 1 week and ≤ 6 months prior to registration,"['The' 'most' 'recent' 'surgical' 'resections' 'or' 'gamma-knife'
 'therapy' 'for' 'malignant' 'melanoma' 'must' 'have' 'been' 'completed'
 '≥' '1' 'week' 'and' '≤' '6' 'months' 'prior' 'to' 'registration']","[0. 0. 0. 1. 1. 0. 1. 1. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02382419,"12:56:chronic_disease,58:71:chronic_disease,73:82:chronic_disease,87:114:chronic_disease,143:152:treatment","Documented human immunodeficiency virus (HIV) infection, genital warts, chancroid, or pelvic inflammatory disease that will require long term treatment","['Documented' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')' 'infection'
 ',' 'genital' 'warts' ',' 'chancroid' ',' 'or' 'pelvic' 'inflammatory'
 'disease' 'that' 'will' 'require' 'long' 'term' 'treatment']",[0. 2. 2. 2. 2. 2. 0. 0. 0. 2. 2. 0. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 1.]
NCT02382419,",14:21:treatment,,111:126:treatment,111:114:chronic_disease,115:126:treatment,,342:352:treatment,,,478:486:treatment,,","Women in the vaccine-eligible age range cannot have received vaccine prior to enrollment, but will be offered HPV vaccination at the end of the study; in brief, we are interested in the efficacy of intervention in preventing HPV in the absence of HPV vaccination, since most women worldwide who might utilize intervention will not have been vaccinated; this includes United States (US) women in the vaccine catch-up 19-26 year old age group (beyond the age groups eligible for Vaccines for Children- funded vaccination) who have so far had very low (< 10%) vaccine uptake; it also includes the entire group of US women > 26 years of age; moreover, it includes women of all ages in developing countries, who most need an HPV prevention strategy, but may never be vaccinated; it should be noted that delaying vaccination in women 19-26 years of age by one year is safe and reasonable, since there is insufficient data to establish a recommendation for or against universal vaccination in this age group as concluded by an American Cancer Society expert panel, which includes the Principal Investigator (PI) of this protocol, Dr. Mark Einstein; it is anticipated that if the intervention gel is efficacious, HPV vaccinated women would need to be studied in a similar future trial with power analysis taking into account vaccine effectiveness as well","['Women' 'in' 'the' 'vaccine-eligible' 'age' 'range' 'can' 'not' 'have'
 'received' 'vaccine' 'prior' 'to' 'enrollment' ',' 'but' 'will' 'be'
 'offered' 'HPV' 'vaccination' 'at' 'the' 'end' 'of' 'the' 'study' ';'
 'in' 'brief' ',' 'we' 'are' 'interested' 'in' 'the' 'efficacy' 'of'
 'intervention' 'in' 'preventing' 'HPV' 'in' 'the' 'absence' 'of' 'HPV'
 'vaccination' ',' 'since' 'most' 'women' 'worldwide' 'who' 'might'
 'utilize' 'intervention' 'will' 'not' 'have' 'been' 'vaccinated' ';'
 'this' 'includes' 'United' 'States' '(' 'US' ')' 'women' 'in' 'the'
 'vaccine' 'catch-up' '19-26' 'year' 'old' 'age' 'group' '(' 'beyond'
 'the' 'age' 'groups' 'eligible' 'for' 'Vaccines' 'for' 'Children-'
 'funded' 'vaccination' ')' 'who' 'have' 'so' 'far' 'had' 'very' 'low' '('
 '<' '10' '%' ')' 'vaccine' 'uptake' ';' 'it' 'also' 'includes' 'the'
 'entire' 'group' 'of' 'US' 'women' '>' '26' 'years' 'of' 'age' ';'
 'moreover' ',' 'it' 'includes' 'women' 'of' 'all' 'ages' 'in'
 'developing' 'countries' ',' 'who' 'most' 'need' 'an' 'HPV' 'prevention'
 'strategy' ',' 'but' 'may' 'never' 'be' 'vaccinated' ';' 'it' 'should'
 'be' 'noted' 'that' 'delaying' 'vaccination' 'in' 'women' '19-26' 'years'
 'of' 'age' 'by' 'one' 'year' 'is' 'safe' 'and' 'reasonable' ',' 'since'
 'there' 'is' 'insufficient' 'data' 'to' 'establish' 'a' 'recommendation'
 'for' 'or' 'against' 'universal' 'vaccination' 'in' 'this' 'age' 'group'
 'as' 'concluded' 'by' 'an' 'American' 'Cancer' 'Society' 'expert' 'panel'
 ',' 'which' 'includes' 'the' 'Principal' 'Investigator' '(' 'PI' ')' 'of'
 'this' 'protocol' ',' 'Dr.' 'Mark' 'Einstein' ';' 'it' 'is' 'anticipated'
 'that' 'if' 'the' 'intervention' 'gel' 'is' 'efficacious' ',' 'HPV'
 'vaccinated' 'women' 'would' 'need' 'to' 'be' 'studied' 'in' 'a'
 'similar' 'future' 'trial' 'with' 'power' 'analysis' 'taking' 'into'
 'account' 'vaccine' 'effectiveness' 'as' 'well']","[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02377089,"23:37:treatment,39:50:treatment,52:65:treatment,70:96:treatment,","evidence of receiving antidepressant, antianxiety, antipsychotic, or mood-stabilizer medication where the dose has not been stable for a minimum of six weeks prior to entering the randomization","['evidence' 'of' 'receiving' 'antidepressant' ',' 'antianxiety' ','
 'antipsychotic' ',' 'or' 'mood-stabilizer' 'medication' 'where' 'the'
 'dose' 'has' 'not' 'been' 'stable' 'for' 'a' 'minimum' 'of' 'six' 'weeks'
 'prior' 'to' 'entering' 'the' 'randomization']","[0. 0. 0. 1. 0. 1. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02374333,"1:4:cancer,34:41:treatment,76:90:treatment","ALL without curative options for therapy, including those not eligible for allogeneic SCT","['ALL' 'without' 'curative' 'options' 'for' 'therapy' ',' 'including'
 'those' 'not' 'eligible' 'for' 'allogeneic' 'SCT']",[3. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02374021,"4:22:treatment,,60:63:treatment,68:71:treatment",No non-biologic DMARDs in preceding two months (other than MTX and HCQ),"['No' 'non-biologic' 'DMARDs' 'in' 'preceding' 'two' 'months' '(' 'other'
 'than' 'MTX' 'and' 'HCQ' ')']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0.]
NCT02372006,"14:17:cancer,19:23:cancer,25:46:cancer,48:63:cancer,64:68:cancer,70:80:cancer,82:95:cancer,97:100:cancer,105:112:cancer","diagnosis of HGG, DIPG, low grade astrocytoma, medulloblastoma/PNET, ependymoma, neuroblastoma, RMS and tumours with ErbB deregulation","['diagnosis' 'of' 'HGG' ',' 'DIPG' ',' 'low' 'grade' 'astrocytoma' ','
 'medulloblastoma/PNET' ',' 'ependymoma' ',' 'neuroblastoma' ',' 'RMS'
 'and' 'tumours' 'with' 'ErbB' 'deregulation']",[0. 0. 3. 0. 3. 0. 3. 3. 3. 0. 3. 0. 3. 0. 3. 0. 3. 0. 3. 0. 0. 0.]
NCT02369653,"1:14:treatment,26:73:treatment,78:100:treatment,105:120:treatment,",Major surgery [excluding Central Venous Access Device (CVAD) replacement and bone marrow aspiration and non-open biopsy] within the last 7 days prior to enrollment that may be associated with a risk of bleeding,"['Major' 'surgery' '[' 'excluding' 'Central' 'Venous' 'Access' 'Device'
 '(' 'CVAD' ')' 'replacement' 'and' 'bone' 'marrow' 'aspiration' 'and'
 'non-open' 'biopsy' ']' 'within' 'the' 'last' '7' 'days' 'prior' 'to'
 'enrollment' 'that' 'may' 'be' 'associated' 'with' 'a' 'risk' 'of'
 'bleeding']","[1. 1. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0. 1. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02369458,"7:10:chronic_disease,25:59:treatment,127:138:treatment,229:255:treatment","Known HIV-positivity on combination antiretroviral therapy because of the potential for pharmacokinetic interactions with the study drugs. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated","['Known' 'HIV-positivity' 'on' 'combination' 'antiretroviral' 'therapy'
 'because' 'of' 'the' 'potential' 'for' 'pharmacokinetic' 'interactions'
 'with' 'the' 'study' 'drugs' '.' 'In' 'addition' ',' 'these' 'patients'
 'are' 'at' 'increased' 'risk' 'of' 'lethal' 'infections' 'when' 'treated'
 'with' 'marrow-suppressive' 'therapy' '.' 'Appropriate' 'studies' 'will'
 'be' 'undertaken' 'in' 'patients' 'receiving' 'combination'
 'antiretroviral' 'therapy' 'when' 'indicated']","[0. 2. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02367196,"1:21:cancer,23:31:cancer,35:48:cancer,51:71:cancer","High grade lymphomas (Burkitts or lymphoblastic), plasma cell leukemia","['High' 'grade' 'lymphomas' '(' 'Burkitts' 'or' 'lymphoblastic' ')' ','
 'plasma' 'cell' 'leukemia']",[3. 3. 3. 0. 3. 0. 3. 0. 0. 3. 3. 3.]
NCT02367040,"1:18:chronic_disease,14:17:chronic_disease,22:39:chronic_disease,35:38:chronic_disease,159:189:treatment","Hepatitis B (HBV) or hepatitis C (HCV). Patients positive for HBsAg or HBcAb will be eligible if they are negative for HBV-DNA, these patients should receive prophylactic antiviral therapy. Patients positive for anti- HCV antibody will be eligible if they are negative for HCV-RNA","['Hepatitis' 'B' '(' 'HBV' ')' 'or' 'hepatitis' 'C' '(' 'HCV' ')' '.'
 'Patients' 'positive' 'for' 'HBsAg' 'or' 'HBcAb' 'will' 'be' 'eligible'
 'if' 'they' 'are' 'negative' 'for' 'HBV-DNA' ',' 'these' 'patients'
 'should' 'receive' 'prophylactic' 'antiviral' 'therapy' '.' 'Patients'
 'positive' 'for' 'anti-' 'HCV' 'antibody' 'will' 'be' 'eligible' 'if'
 'they' 'are' 'negative' 'for' 'HCV-RNA']","[2. 2. 2. 2. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02367040,"32:44:treatment,,118:137:treatment,127:136:treatment,,312:342:treatment","be considered unfit to receive chemotherapy on reason of age, concomitant morbidities, and/or residual toxicity from previous treatments, or unwillingness to receive chemotherapy. These patients must also have had a progression-free and treatment-free interval of at least 6 months after completion of the last rituximab-containing treatment. Patients in whom chemotherapy is contraindicated are defined by one of the following features","['be' 'considered' 'unfit' 'to' 'receive' 'chemotherapy' 'on' 'reason'
 'of' 'age' ',' 'concomitant' 'morbidities' ',' 'and/or' 'residual'
 'toxicity' 'from' 'previous' 'treatments' ',' 'or' 'unwillingness' 'to'
 'receive' 'chemotherapy' '.' 'These' 'patients' 'must' 'also' 'have'
 'had' 'a' 'progression-free' 'and' 'treatment-free' 'interval' 'of' 'at'
 'least' '6' 'months' 'after' 'completion' 'of' 'the' 'last'
 'rituximab-containing' 'treatment' '.' 'Patients' 'in' 'whom'
 'chemotherapy' 'is' 'contraindicated' 'are' 'defined' 'by' 'one' 'of'
 'the' 'following' 'features']","[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02366871,"1:6:treatment,11:16:treatment,25:50:treatment",SSRIs and SNRIs (common anti-depressant therapies),['SSRIs' 'and' 'SNRIs' '(' 'common' 'anti-depressant' 'therapies' ')'],[1. 0. 1. 0. 0. 1. 1. 0.]
NCT02366819,"43:70:treatment,79:92:cancer,146:164:cancer","Locally advanced disease as determined by endoscopic ultrasound (EUS) stage > primary tumor (T) 3 and/or any T, lymph nodes (N)+ disease without metastatic disease (Mx)","['Locally' 'advanced' 'disease' 'as' 'determined' 'by' 'endoscopic'
 'ultrasound' '(' 'EUS' ')' 'stage' '>' 'primary' 'tumor' '(' 'T' ')' '3'
 'and/or' 'any' 'T' ',' 'lymph' 'nodes' '(' 'N' ')' '+' 'disease'
 'without' 'metastatic' 'disease' '(' 'Mx' ')']","[0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0.]"
NCT02366754,"6:9:treatment,13:16:treatment,54:68:chronic_disease","Have MRI or TMS contraindications such as pre-injury claustrophobia, metal in eyes/face or brain","['Have' 'MRI' 'or' 'TMS' 'contraindications' 'such' 'as' 'pre-injury'
 'claustrophobia' ',' 'metal' 'in' 'eyes/face' 'or' 'brain']",[0. 1. 0. 1. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT02366611,"41:45:treatment,56:73:chronic_disease,75:90:treatment,92:119:treatment,121:137:chronic_disease,139:159:chronic_disease","Any condition that would prevent use of tDCS including skull abnormality, implanted metal, implanted electronic device, seizure disorder, neurologic condition","['Any' 'condition' 'that' 'would' 'prevent' 'use' 'of' 'tDCS' 'including'
 'skull' 'abnormality' ',' 'implanted' 'metal' ',' 'implanted'
 'electronic' 'device' ',' 'seizure' 'disorder' ',' 'neurologic'
 'condition']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 2. 2. 0. 1. 1. 1. 0. 0. 0. 0. 2. 2. 0. 2. 2.]
NCT02365766,"23:37:treatment,69:77:treatment,81:116:treatment,",Subjects on full dose anticoagulants must be on a stable regimen of warfarin or low molecular weight heparin (LMWH) for at least two weeks,"['Subjects' 'on' 'full' 'dose' 'anticoagulants' 'must' 'be' 'on' 'a'
 'stable' 'regimen' 'of' 'warfarin' 'or' 'low' 'molecular' 'weight'
 'heparin' '(' 'LMWH' ')' 'for' 'at' 'least' 'two' 'weeks']","[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02365467,"16:26:chronic_disease,28:36:chronic_disease,41:56:chronic_disease","Subject has an aneurysmal, tortuous, or atherosclerotic LSA","['Subject' 'has' 'an' 'aneurysmal' ',' 'tortuous' ',' 'or'
 'atherosclerotic' 'LSA']",[0. 0. 0. 2. 0. 2. 0. 0. 2. 0.]
NCT02365467,"18:27:treatment,45:53:chronic_disease,73:85:treatment",Subject requires treatment of an infrarenal aneurysm at the time of the implantation,"['Subject' 'requires' 'treatment' 'of' 'an' 'infrarenal' 'aneurysm' 'at'
 'the' 'time' 'of' 'the' 'implantation']",[0. 0. 1. 0. 0. 0. 2. 0. 0. 0. 0. 0. 1.]
NCT02362997,",24:61:treatment,54:61:treatment,62:75:treatment,","No more than 1 line of anthracycline-containing chemotherapy prior to ASCT, and no more than 3 lines of therapy total prior to ASCT for arms A and B; no more than 1 line of therapy prior to ASCT for arm C","['No' 'more' 'than' '1' 'line' 'of' 'anthracycline-containing'
 'chemotherapy' 'prior' 'to' 'ASCT' ',' 'and' 'no' 'more' 'than' '3'
 'lines' 'of' 'therapy' 'total' 'prior' 'to' 'ASCT' 'for' 'arms' 'A' 'and'
 'B' ';' 'no' 'more' 'than' '1' 'line' 'of' 'therapy' 'prior' 'to' 'ASCT'
 'for' 'arm' 'C']","[0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02362997,"19:41:chronic_disease,52:56:chronic_disease,127:131:chronic_disease","Participants with active viral hepatitis (positive HepB sAg, positive HepB core Ab with positive HepB viral load, or positive HepC antibody with positive HepC viral load)","['Participants' 'with' 'active' 'viral' 'hepatitis' '(' 'positive' 'HepB'
 'sAg' ',' 'positive' 'HepB' 'core' 'Ab' 'with' 'positive' 'HepB' 'viral'
 'load' ',' 'or' 'positive' 'HepC' 'antibody' 'with' 'positive' 'HepC'
 'viral' 'load' ')']","[0. 0. 2. 2. 2. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02362308,"20:38:chronic_disease,47:66:chronic_disease,68:74:chronic_disease,76:83:chronic_disease,88:113:chronic_disease","History of serious neurologic disease such as cerebral hemorrhage, stroke, seizure, or transient ischemic attack","['History' 'of' 'serious' 'neurologic' 'disease' 'such' 'as' 'cerebral'
 'hemorrhage' ',' 'stroke' ',' 'seizure' ',' 'or' 'transient' 'ischemic'
 'attack']",[0. 0. 0. 2. 2. 0. 0. 2. 2. 0. 2. 0. 2. 0. 0. 2. 2. 2.]
NCT02361944,"1:8:treatment,45:55:treatment,59:70:treatment",surgery on the heart or aorta that requires sternotomy or thoracotomy,"['surgery' 'on' 'the' 'heart' 'or' 'aorta' 'that' 'requires' 'sternotomy'
 'or' 'thoracotomy']",[1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1.]
NCT02361554,"12:34:chronic_disease,,,92:104:chronic_disease,105:113:chronic_disease,114:131:chronic_disease",history of traumatic brain injury associated with loss of consciousness of > 1 hour and/or intracranial/epidural/subdural bleeding,"['history' 'of' 'traumatic' 'brain' 'injury' 'associated' 'with' 'loss'
 'of' 'consciousness' 'of' '>' '1' 'hour' 'and/or'
 'intracranial/epidural/subdural' 'bleeding']",[0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02360579,"1:31:treatment,33:49:treatment,51:56:treatment,62:73:treatment","NMA-LD preconditioning regimen (cyclophosphamide, mesna, and fludarabine)","['NMA-LD' 'preconditioning' 'regimen' '(' 'cyclophosphamide' ',' 'mesna'
 ',' 'and' 'fludarabine' ')']",[1. 1. 1. 0. 1. 0. 1. 0. 0. 1. 0.]
NCT02360579,"113:139:chronic_disease,150:162:treatment,164:185:chronic_disease","Patients who have active medical illness(es) that would pose increased risk for study participation, including: active systemic infections requiring systemic ABX, coagulation disorders, or other active major medical illnesses of the cardiovascular, respiratory, or immune system","['Patients' 'who' 'have' 'active' 'medical' 'illness' '(' 'es' ')' 'that'
 'would' 'pose' 'increased' 'risk' 'for' 'study' 'participation' ','
 'including' ':' 'active' 'systemic' 'infections' 'requiring' 'systemic'
 'ABX' ',' 'coagulation' 'disorders' ',' 'or' 'other' 'active' 'major'
 'medical' 'illnesses' 'of' 'the' 'cardiovascular' ',' 'respiratory' ','
 'or' 'immune' 'system']","[0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.
 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02360579,",,54:76:chronic_disease,78:88:chronic_disease,130:153:chronic_disease","Patients ≥ 60 years of age and who have a history of ischemic heart disease, chest pain, or clinically significant atrial and/or ventricular arrhythmias must have a cardiac stress test. Patients with any irreversible wall movement abnormalities","['Patients' '≥' '60' 'years' 'of' 'age' 'and' 'who' 'have' 'a' 'history'
 'of' 'ischemic' 'heart' 'disease' ',' 'chest' 'pain' ',' 'or'
 'clinically' 'significant' 'atrial' 'and/or' 'ventricular' 'arrhythmias'
 'must' 'have' 'a' 'cardiac' 'stress' 'test' '.' 'Patients' 'with' 'any'
 'irreversible' 'wall' 'movement' 'abnormalities']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0.
 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02359825,"6:31:chronic_disease,68:76:chronic_disease,80:97:chronic_disease",have peripheral nerve injuries that are complicated by significant vascular or orthopedic damage,"['have' 'peripheral' 'nerve' 'injuries' 'that' 'are' 'complicated' 'by'
 'significant' 'vascular' 'or' 'orthopedic' 'damage']",[0. 2. 2. 2. 0. 0. 0. 0. 0. 2. 0. 2. 2.]
NCT02358850,"35:46:treatment,48:55:treatment,57:62:treatment,64:72:treatment,74:82:treatment","Contraindications to pain regimen medications (Tylenol, Norco, Percocet, Dilaudid)","['Contraindications' 'to' 'pain' 'regimen' 'medications' '(' 'Tylenol' ','
 'Norco' ',' 'Percocet' ',' 'Dilaudid' ')']",[0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0.]
NCT02358187,"4:17:chronic_disease,19:35:chronic_disease,37:46:chronic_disease,50:69:chronic_disease","No overt cardiac, gastrointestinal, pulmonary or psychiatric disease","['No' 'overt' 'cardiac' ',' 'gastrointestinal' ',' 'pulmonary' 'or'
 'psychiatric' 'disease']",[0. 2. 2. 0. 2. 0. 2. 0. 2. 2.]
NCT02357849,"26:51:chronic_disease,64:89:chronic_disease,91:104:chronic_disease,106:130:chronic_disease,132:148:chronic_disease,153:169:chronic_disease","lifetime diagnosis of an Axis I psychotic disorder, including: schizophreniform disorder, schizophrenia, schizoaffective disorder, bipolar disorder, or major depression with psychotic features","['lifetime' 'diagnosis' 'of' 'an' 'Axis' 'I' 'psychotic' 'disorder' ','
 'including' ':' 'schizophreniform' 'disorder' ',' 'schizophrenia' ','
 'schizoaffective' 'disorder' ',' 'bipolar' 'disorder' ',' 'or' 'major'
 'depression' 'with' 'psychotic' 'features']","[0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 2. 2. 0. 2. 0. 2. 2. 0. 2. 2. 0. 0. 2.
 2. 0. 0. 0.]"
NCT02355535,"18:49:treatment,119:133:chronic_disease,135:159:chronic_disease,161:184:chronic_disease,,,","Abnormalities on 12-lead electrocardiogram (ECG) considered by the investigator to be clinically significant (such as acute ischemia, left bundle branch block, ventricular arrhythmias) or baseline prolongation of the rate-corrected QT interval (e.g., repeated demonstration of QTc interval > 480 milliseconds)","['Abnormalities' 'on' '12-lead' 'electrocardiogram' '(' 'ECG' ')'
 'considered' 'by' 'the' 'investigator' 'to' 'be' 'clinically'
 'significant' '(' 'such' 'as' 'acute' 'ischemia' ',' 'left' 'bundle'
 'branch' 'block' ',' 'ventricular' 'arrhythmias' ')' 'or' 'baseline'
 'prolongation' 'of' 'the' 'rate-corrected' 'QT' 'interval' '(' 'e.g.' ','
 'repeated' 'demonstration' 'of' 'QTc' 'interval' '>' '480' 'milliseconds'
 ')']","[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 2.
 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02355535,"18:29:chronic_disease,31:49:chronic_disease,54:57:chronic_disease,79:102:treatment","Has a history of blood clots, pulmonary embolism, or DVT unless controlled by anticoagulant treatment","['Has' 'a' 'history' 'of' 'blood' 'clots' ',' 'pulmonary' 'embolism' ','
 'or' 'DVT' 'unless' 'controlled' 'by' 'anticoagulant' 'treatment']",[0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 2. 0. 0. 0. 1. 1.]
NCT02355002,"23:33:chronic_disease,37:56:chronic_disease,64:82:chronic_disease,84:92:chronic_disease,94:106:chronic_disease,117:137:chronic_disease,186:189:treatment","Current or history of neurologic or psychiatric disease (e.g., mental retardation, dementia, brain damage, or other cognitive impairment) that would interfere with ability to engage in TMS","['Current' 'or' 'history' 'of' 'neurologic' 'or' 'psychiatric' 'disease'
 '(' 'e.g.' ',' 'mental' 'retardation' ',' 'dementia' ',' 'brain' 'damage'
 ',' 'or' 'other' 'cognitive' 'impairment' ')' 'that' 'would' 'interfere'
 'with' 'ability' 'to' 'engage' 'in' 'TMS']","[0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 0. 2. 2. 0. 2. 0. 2. 2. 0. 0. 0. 2. 2. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02355002,"8:23:treatment,27:42:treatment,,95:112:treatment",Use of benzodiazepines or anticonvulsants within 2 weeks prior to study (to be ruled out by a urine drug screen),"['Use' 'of' 'benzodiazepines' 'or' 'anticonvulsants' 'within' '2' 'weeks'
 'prior' 'to' 'study' '(' 'to' 'be' 'ruled' 'out' 'by' 'a' 'urine' 'drug'
 'screen' ')']",[0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0.]
NCT02354703,",60:89:treatment,97:107:treatment,132:143:treatment","Current or recent (within 4 weeks prior to Baseline Visit) treatment with antipsychotics or any medication likely to interact with ondansetron to produce an adverse effect, as judged by a study physician","['Current' 'or' 'recent' '(' 'within' '4' 'weeks' 'prior' 'to' 'Baseline'
 'Visit' ')' 'treatment' 'with' 'antipsychotics' 'or' 'any' 'medication'
 'likely' 'to' 'interact' 'with' 'ondansetron' 'to' 'produce' 'an'
 'adverse' 'effect' ',' 'as' 'judged' 'by' 'a' 'study' 'physician']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 1. 0. 0. 0. 0. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02353819,"25:48:treatment,55:63:treatment,65:73:treatment","Clinically eligible for rectal spacer insertion (e.g. Duraseal, SpaceOAR, or equivalent product) per physician evaluation","['Clinically' 'eligible' 'for' 'rectal' 'spacer' 'insertion' '(' 'e.g' '.'
 'Duraseal' ',' 'SpaceOAR' ',' 'or' 'equivalent' 'product' ')' 'per'
 'physician' 'evaluation']",[0. 0. 0. 1. 1. 1. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02353819,"10:17:treatment,21:33:treatment,38:53:cancer",Previous surgery or chemotherapy for prostate cancer,['Previous' 'surgery' 'or' 'chemotherapy' 'for' 'prostate' 'cancer'],[0. 1. 0. 1. 0. 3. 3.]
NCT02353728,"1:19:treatment,35:60:treatment,,89:98:treatment",Previous treatment with any other tyrosine kinase inhibitor except for up to 2 weeks of nilotinib,"['Previous' 'treatment' 'with' 'any' 'other' 'tyrosine' 'kinase'
 'inhibitor' 'except' 'for' 'up' 'to' '2' 'weeks' 'of' 'nilotinib']",[1. 1. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02352454,"1:6:chronic_disease,46:54:chronic_disease,56:66:chronic_disease,79:89:chronic_disease,91:116:chronic_disease","Ulcer not of VLU pathophysiology (e.g., pure diabetic, vasculitic, radiation, rheumatoid, collagen vascular disease, pressure, or arterial etiology)","['Ulcer' 'not' 'of' 'VLU' 'pathophysiology' '(' 'e.g.' ',' 'pure'
 'diabetic' ',' 'vasculitic' ',' 'radiation' ',' 'rheumatoid' ','
 'collagen' 'vascular' 'disease' ',' 'pressure' ',' 'or' 'arterial'
 'etiology' ')']","[2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 0. 0. 2. 0. 2. 2. 2. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02351544,"70:77:treatment,79:102:chronic_disease,117:134:chronic_disease","Patients with systemic conditions that make them poor candidates for surgery (coronary artery disease, uncontrolled diabetes mellitus, etc…)","['Patients' 'with' 'systemic' 'conditions' 'that' 'make' 'them' 'poor'
 'candidates' 'for' 'surgery' '(' 'coronary' 'artery' 'disease' ','
 'uncontrolled' 'diabetes' 'mellitus' ',' 'etc…' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 2. 2. 2. 0. 0. 2. 2. 0. 0. 0.]
NCT02350764,"1:8:treatment,10:16:treatment,18:33:treatment,35:45:treatment,51:74:treatment,59:74:treatment,110:128:chronic_disease","Inhaled, ocular, intra-articular, intranasal, and topical corticosteroids are permitted in absence of active autoimmune disease","['Inhaled' ',' 'ocular' ',' 'intra-articular' ',' 'intranasal' ',' 'and'
 'topical' 'corticosteroids' 'are' 'permitted' 'in' 'absence' 'of'
 'active' 'autoimmune' 'disease']",[1. 0. 1. 0. 1. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02350764,"15:38:chronic_disease,40:54:chronic_disease,70:89:treatment,110:116:chronic_disease,117:122:chronic_disease,155:190:treatment,192:206:chronic_disease,216:224:chronic_disease,226:235:chronic_disease,240:248:chronic_disease,264:282:treatment","Subjects with type I diabetes melitis, hypothyroidism only requiring hormone replacement, resolved childhood asthma/atopy, patients with asthma requiring intermittent bronchodilator therapy, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger","['Subjects' 'with' 'type' 'I' 'diabetes' 'melitis' ',' 'hypothyroidism'
 'only' 'requiring' 'hormone' 'replacement' ',' 'resolved' 'childhood'
 'asthma/atopy' ',' 'patients' 'with' 'asthma' 'requiring' 'intermittent'
 'bronchodilator' 'therapy' ',' 'skin' 'disorders' '(' 'such' 'as'
 'vitiligo' ',' 'psoriasis' ',' 'or' 'alopecia' ')' 'not' 'requiring'
 'systemic' 'treatment' ',' 'or' 'conditions' 'not' 'expected' 'to'
 'recur' 'in' 'the' 'absence' 'of' 'an' 'external' 'trigger']","[0. 0. 2. 2. 2. 2. 0. 2. 0. 0. 1. 1. 0. 0. 0. 2. 0. 0. 0. 0. 0. 1. 1. 1.
 0. 2. 2. 0. 0. 0. 2. 0. 2. 0. 0. 2. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02349958,"1:29:cancer,74:105:cancer,106:120:cancer,141:172:treatment",Primary ovarian cancer (POC) with Stage IC or greater stage Recurrent or persistent ovarian cancer (ROC) Ovarian cancer patients who desire Consolidation Chemotherapy (CC),"['Primary' 'ovarian' 'cancer' '(' 'POC' ')' 'with' 'Stage' 'IC' 'or'
 'greater' 'stage' 'Recurrent' 'or' 'persistent' 'ovarian' 'cancer' '('
 'ROC' ')' 'Ovarian' 'cancer' 'patients' 'who' 'desire' 'Consolidation'
 'Chemotherapy' '(' 'CC' ')']","[3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 3. 3. 0. 0.
 0. 1. 1. 1. 0. 0.]"
NCT02349867,"24:39:chronic_disease,57:76:chronic_disease,86:105:chronic_disease,116:140:chronic_disease,,,,197:220:chronic_disease,231:254:treatment,,281:302:chronic_disease,315:338:chronic_disease","Clinically significant cardiac disease, including major cardiac dysfunction, such as uncontrolled angina, clinical congestive heart failure with New York Heart Association (NYHA) class III or IV, ventricular arrhythmias requiring anti-arrhythmic therapy, recent (within 6 months) myocardial infarction or unstable coronary artery disease","['Clinically' 'significant' 'cardiac' 'disease' ',' 'including' 'major'
 'cardiac' 'dysfunction' ',' 'such' 'as' 'uncontrolled' 'angina' ','
 'clinical' 'congestive' 'heart' 'failure' 'with' 'New' 'York' 'Heart'
 'Association' '(' 'NYHA' ')' 'class' 'III' 'or' 'IV' ',' 'ventricular'
 'arrhythmias' 'requiring' 'anti-arrhythmic' 'therapy' ',' 'recent' '('
 'within' '6' 'months' ')' 'myocardial' 'infarction' 'or' 'unstable'
 'coronary' 'artery' 'disease']","[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0.
 2. 2. 2.]"
NCT02349867,"34:45:treatment,47:57:treatment,61:70:treatment","Known or presumed intolerance of gemcitabine, vorinostat or sorafenib","['Known' 'or' 'presumed' 'intolerance' 'of' 'gemcitabine' ',' 'vorinostat'
 'or' 'sorafenib']",[0. 0. 0. 0. 0. 1. 0. 1. 0. 1.]
NCT02349867,",39:60:treatment,107:113:chronic_disease,118:129:chronic_disease","Recovery from ≥ grade 2 toxicities of prior therapy regimen to grade 1 or baseline, with the exception of anemia and lymphopenia and chronic residual toxicities","['Recovery' 'from' '≥' 'grade' '2' 'toxicities' 'of' 'prior' 'therapy'
 'regimen' 'to' 'grade' '1' 'or' 'baseline' ',' 'with' 'the' 'exception'
 'of' 'anemia' 'and' 'lymphopenia' 'and' 'chronic' 'residual' 'toxicities']","[0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0.
 0. 0. 0.]"
NCT02347891,"12:30:cancer,,86:105:cancer,107:112:cancer,116:129:cancer","History of malignant neoplasm within the last 5 years, except for adequately treated cancers of the skin (basal or squamous cell)","['History' 'of' 'malignant' 'neoplasm' 'within' 'the' 'last' '5' 'years'
 ',' 'except' 'for' 'adequately' 'treated' 'cancers' 'of' 'the' 'skin' '('
 'basal' 'or' 'squamous' 'cell' ')']",[0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 3. 0. 3. 3. 0.]
NCT02347202,"17:23:chronic_disease,27:43:chronic_disease,66:85:chronic_disease","apparent severe mental or physical illness (e.g., self report of clinical depression)","['apparent' 'severe' 'mental' 'or' 'physical' 'illness' '(' 'e.g.' ','
 'self' 'report' 'of' 'clinical' 'depression' ')']",[0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 2. 2. 0.]
NCT02346526,"1:20:cancer,36:45:treatment,49:80:treatment",Visceral metastases as assessed by abdominal or pelvic computed tomography (CT) or other imaging modality,"['Visceral' 'metastases' 'as' 'assessed' 'by' 'abdominal' 'or' 'pelvic'
 'computed' 'tomography' '(' 'CT' ')' 'or' 'other' 'imaging' 'modality']",[3. 3. 0. 0. 0. 1. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02346201,"22:41:treatment,46:59:treatment,61:70:treatment,79:89:treatment,137:152:treatment,183:211:treatment,216:241:treatment,,","Currently taking any amphetamine product, an antipsychotic, bupropion, or any medication that would prohibit the safe concurrent use of methylphenidate, including but not limited to monoamine oxidase inhibitors and tricyclic antidepressants within the 30 days preceding randomization or a period of time equal to 5 half-lives of drug, whichever period of time is longer","['Currently' 'taking' 'any' 'amphetamine' 'product' ',' 'an'
 'antipsychotic' ',' 'bupropion' ',' 'or' 'any' 'medication' 'that'
 'would' 'prohibit' 'the' 'safe' 'concurrent' 'use' 'of' 'methylphenidate'
 ',' 'including' 'but' 'not' 'limited' 'to' 'monoamine' 'oxidase'
 'inhibitors' 'and' 'tricyclic' 'antidepressants' 'within' 'the' '30'
 'days' 'preceding' 'randomization' 'or' 'a' 'period' 'of' 'time' 'equal'
 'to' '5' 'half-lives' 'of' 'drug' ',' 'whichever' 'period' 'of' 'time'
 'is' 'longer']","[0. 0. 0. 1. 1. 0. 0. 1. 0. 1. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.
 0. 0. 0. 0. 0. 1. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02344355,"28:46:treatment,58:72:treatment,90:96:cancer",Patients who have received prior chemotherapy (including Gliadel wafers) for the current glioma,"['Patients' 'who' 'have' 'received' 'prior' 'chemotherapy' '(' 'including'
 'Gliadel' 'wafers' ')' 'for' 'the' 'current' 'glioma']",[0. 0. 0. 0. 1. 1. 0. 0. 1. 1. 0. 0. 0. 0. 3.]
NCT02343549,"18:39:treatment,41:86:treatment,91:122:treatment","Currently taking cytotoxic medications, non-steroidal ant-inflammatory drugs (NSAIDS), or enzyme inducing anticonvulsants","['Currently' 'taking' 'cytotoxic' 'medications' ',' 'non-steroidal'
 'ant-inflammatory' 'drugs' '(' 'NSAIDS' ')' ',' 'or' 'enzyme' 'inducing'
 'anticonvulsants']",[0. 0. 1. 1. 0. 1. 1. 1. 1. 0. 0. 0. 0. 1. 1. 1.]
NCT02343042,",46:67:chronic_disease,140:150:treatment,154:179:treatment,",Any non-hematological toxicities (except for peripheral neuropathy as described in exclusion criterion #24) that patients experienced from treatments in previous clinical studies must have resolved to ≤ Grade 2 by Cycle 1 Day 1,"['Any' 'non-hematological' 'toxicities' '(' 'except' 'for' 'peripheral'
 'neuropathy' 'as' 'described' 'in' 'exclusion' 'criterion' '#' '24' ')'
 'that' 'patients' 'experienced' 'from' 'treatments' 'in' 'previous'
 'clinical' 'studies' 'must' 'have' 'resolved' 'to' '≤' 'Grade' '2' 'by'
 'Cycle' '1' 'Day' '1']","[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02343042,"20:39:cancer,89:96:cancer,122:138:treatment",Patients must have symptomatic myeloma per IMWG guidelines with either CRAB criteria or Myeloma Defining Events and need systemic therapy,"['Patients' 'must' 'have' 'symptomatic' 'myeloma' 'per' 'IMWG'
 'guidelines' 'with' 'either' 'CRAB' 'criteria' 'or' 'Myeloma' 'Defining'
 'Events' 'and' 'need' 'systemic' 'therapy']",[0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 1. 1.]
NCT02343042,"1:10:treatment,12:24:treatment,29:42:treatment,56:74:treatment,,94:98:treatment,104:123:treatment,","Radiation, chemotherapy, or immunotherapy or any other anticancer therapy ≤ 2 weeks prior to C1D1, and radio-immunotherapy within 6 weeks prior to C1D1","['Radiation' ',' 'chemotherapy' ',' 'or' 'immunotherapy' 'or' 'any'
 'other' 'anticancer' 'therapy' '≤' '2' 'weeks' 'prior' 'to' 'C1D1' ','
 'and' 'radio-immunotherapy' 'within' '6' 'weeks' 'prior' 'to' 'C1D1']","[1. 0. 1. 0. 0. 1. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 0. 0. 1. 0. 0. 0. 0.
 0. 0.]"
NCT02342808,"8:30:chronic_disease,32:55:chronic_disease,71:79:chronic_disease,",Severe ischemic heart disease (CCS Class 3 or 4 angina or evidence of ischemia at <85% heart rate reserve on treadmill testing),"['Severe' 'ischemic' 'heart' 'disease' '(' 'CCS' 'Class' '3' 'or' '4'
 'angina' 'or' 'evidence' 'of' 'ischemia' 'at' '<' '85' '%' 'heart' 'rate'
 'reserve' 'on' 'treadmill' 'testing' ')']","[0. 2. 2. 2. 0. 2. 2. 2. 2. 2. 2. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02342782,"13:56:treatment,100:125:treatment,192:215:treatment,,,",Significant prior external beam dose-limiting radiation to a critical organ based on review of the prior radiation treatment records by the Radiation Oncology PI; patients who have had prior external beam radiation > 2000 cGy (at 180 to 200 cGy per day) to the lung will be ineligible,"['Significant' 'prior' 'external' 'beam' 'dose-limiting' 'radiation' 'to'
 'a' 'critical' 'organ' 'based' 'on' 'review' 'of' 'the' 'prior'
 'radiation' 'treatment' 'records' 'by' 'the' 'Radiation' 'Oncology' 'PI'
 ';' 'patients' 'who' 'have' 'had' 'prior' 'external' 'beam' 'radiation'
 '>' '2000' 'cGy' '(' 'at' '180' 'to' '200' 'cGy' 'per' 'day' ')' 'to'
 'the' 'lung' 'will' 'be' 'ineligible']","[0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02342782,"55:88:cancer,181:190:cancer,225:242:treatment,247:251:treatment","pathologically confirmed diagnosis of systemic mature T-cell non-Hodgkin lymphoma (NHL) with City of Hope pathology review as per World Health Organization (WHO) classification of lymphomas 2008, who are deemed eligible for high dose therapy and AHCT","['pathologically' 'confirmed' 'diagnosis' 'of' 'systemic' 'mature'
 'T-cell' 'non-Hodgkin' 'lymphoma' '(' 'NHL' ')' 'with' 'City' 'of' 'Hope'
 'pathology' 'review' 'as' 'per' 'World' 'Health' 'Organization' '(' 'WHO'
 ')' 'classification' 'of' 'lymphomas' '2008' ',' 'who' 'are' 'deemed'
 'eligible' 'for' 'high' 'dose' 'therapy' 'and' 'AHCT']","[0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 1.]"
NCT02341209,",88:189:treatment,193:226:treatment,271:279:cancer","Measurable disease in at least one target lesion in the skin or able to be assessed by radiographic examination with FDG-PET fluorodeoxyglucose possitron emission tomography (FDG-PET) scan or computarized tomography (CT) scan, or peripheral blood showing involvement of lymphoma","['Measurable' 'disease' 'in' 'at' 'least' 'one' 'target' 'lesion' 'in'
 'the' 'skin' 'or' 'able' 'to' 'be' 'assessed' 'by' 'radiographic'
 'examination' 'with' 'FDG-PET' 'fluorodeoxyglucose' 'possitron'
 'emission' 'tomography' '(' 'FDG-PET' ')' 'scan' 'or' 'computarized'
 'tomography' '(' 'CT' ')' 'scan' ',' 'or' 'peripheral' 'blood' 'showing'
 'involvement' 'of' 'lymphoma']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1.
 1. 1. 1. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.]"
NCT02340156,"1:18:treatment,9:18:treatment,42:62:treatment,","Planned treatment, or treatment with any investigational drug within 4 weeks prior to screening","['Planned' 'treatment' ',' 'or' 'treatment' 'with' 'any' 'investigational'
 'drug' 'within' '4' 'weeks' 'prior' 'to' 'screening']",[1. 1. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02339922,"34:59:chronic_disease,84:96:chronic_disease,98:117:chronic_disease,122:146:chronic_disease,152:167:chronic_disease,171:192:chronic_disease,","Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, cardiac arrhythmias, or congestive heart failure, and unstable angina or myocardial infarction within the past 6 months","['Evidence' 'of' 'current' 'uncontrolled' 'cardiovascular' 'conditions'
 ',' 'including' 'uncontrolled' 'hypertension' ',' 'cardiac' 'arrhythmias'
 ',' 'or' 'congestive' 'heart' 'failure' ',' 'and' 'unstable' 'angina'
 'or' 'myocardial' 'infarction' 'within' 'the' 'past' '6' 'months']","[0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 2. 2. 0. 2.
 2. 0. 0. 0. 0. 0.]"
NCT02339233,"1:4:chronic_disease,8:12:chronic_disease,21:28:chronic_disease",HIV or AIDS related illness,['HIV' 'or' 'AIDS' 'related' 'illness'],[2. 0. 2. 0. 2.]
NCT02338999,"22:37:chronic_disease,48:51:chronic_disease,48:57:chronic_disease,,,137:150:chronic_disease,164:192:treatment,201:212:chronic_disease,366:381:treatment","Patients with active lupus nephritis or active CNS lupus at baseline even if SLEDAI-2K <20. Active disease will be considered as CNS or renal disease that require aggressive immunosuppression. Active CNS disease will be diagnosed based on clinical presentation and physical exam, exclusion of other conditions that could explain symptomatology and, when warranted, ancillary tests (imaging) that support the diagnosis","['Patients' 'with' 'active' 'lupus' 'nephritis' 'or' 'active' 'CNS'
 'lupus' 'at' 'baseline' 'even' 'if' 'SLEDAI-2K' '<' '20' '.' 'Active'
 'disease' 'will' 'be' 'considered' 'as' 'CNS' 'or' 'renal' 'disease'
 'that' 'require' 'aggressive' 'immunosuppression' '.' 'Active' 'CNS'
 'disease' 'will' 'be' 'diagnosed' 'based' 'on' 'clinical' 'presentation'
 'and' 'physical' 'exam' ',' 'exclusion' 'of' 'other' 'conditions' 'that'
 'could' 'explain' 'symptomatology' 'and' ',' 'when' 'warranted' ','
 'ancillary' 'tests' '(' 'imaging' ')' 'that' 'support' 'the' 'diagnosis']","[0. 0. 0. 2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 2. 2. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]"
NCT02338999,"18:38:chronic_disease,42:51:chronic_disease,68:84:treatment",Prior history of hemorrhagic cystitis or hematuria while receiving cyclophosphamide that could not be explained by other causes,"['Prior' 'history' 'of' 'hemorrhagic' 'cystitis' 'or' 'hematuria' 'while'
 'receiving' 'cyclophosphamide' 'that' 'could' 'not' 'be' 'explained' 'by'
 'other' 'causes']",[0. 0. 0. 2. 2. 0. 2. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02338232,"17:31:treatment,33:54:treatment,59:73:treatment,88:115:treatment,200:219:treatment","Subjects taking ACE inhibitors, potassium supplements, or spironolactone (or any other potassium-sparing diuretics) who cannot discontinue use prior to initiation of study treatment OR who require a high-potassium diet","['Subjects' 'taking' 'ACE' 'inhibitors' ',' 'potassium' 'supplements' ','
 'or' 'spironolactone' '(' 'or' 'any' 'other' 'potassium-sparing'
 'diuretics' ')' 'who' 'can' 'not' 'discontinue' 'use' 'prior' 'to'
 'initiation' 'of' 'study' 'treatment' 'OR' 'who' 'require' 'a'
 'high-potassium' 'diet']","[0. 0. 1. 1. 0. 1. 1. 0. 0. 1. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]"
NCT02337465,"1:16:cancer,20:26:treatment,74:91:treatment","prostate cancer by biopsy, with the intent of undergoing definitive dose radiation therapy to targets within the liver, or prostate","['prostate' 'cancer' 'by' 'biopsy' ',' 'with' 'the' 'intent' 'of'
 'undergoing' 'definitive' 'dose' 'radiation' 'therapy' 'to' 'targets'
 'within' 'the' 'liver' ',' 'or' 'prostate']",[3. 3. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02336451,"28:46:treatment,48:58:treatment,66:80:treatment,99:115:treatment,125:147:treatment","Patients may have received prior chemotherapy, crizotinib (other ALK inhibitors are not allowed), biologic therapy or other investigational agents","['Patients' 'may' 'have' 'received' 'prior' 'chemotherapy' ','
 'crizotinib' '(' 'other' 'ALK' 'inhibitors' 'are' 'not' 'allowed' ')' ','
 'biologic' 'therapy' 'or' 'other' 'investigational' 'agents']",[0. 0. 0. 0. 1. 1. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 1. 0. 0. 1. 1.]
NCT02336217,"1:7:chronic_disease,11:26:chronic_disease,30:51:treatment",Type 1 or type 2 diabetes on therapeutic treatment other than just lifestyle changes,"['Type' '1' 'or' 'type' '2' 'diabetes' 'on' 'therapeutic' 'treatment'
 'other' 'than' 'just' 'lifestyle' 'changes']",[2. 2. 0. 2. 2. 2. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02335242,"19:32:treatment,36:49:treatment,59:61:chronic_disease,115:124:treatment,135:145:treatment",Has had extensive prior surgery or sclerotherapy to treat LM such that scarring may interfere with evaluation and treatment effect of sildenafil,"['Has' 'had' 'extensive' 'prior' 'surgery' 'or' 'sclerotherapy' 'to'
 'treat' 'LM' 'such' 'that' 'scarring' 'may' 'interfere' 'with'
 'evaluation' 'and' 'treatment' 'effect' 'of' 'sildenafil']",[0. 0. 0. 1. 1. 0. 1. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1.]
NCT02335242,"29:66:treatment,76:88:treatment,90:102:treatment,104:116:treatment,118:128:treatment,153:162:treatment","Requires concomitant use of potent cytochrome P450 3A4 inhibitors (such as ketoconazole, itraconazole, erythromycin, saquinavir), or concomitant use of ritonavir","['Requires' 'concomitant' 'use' 'of' 'potent' 'cytochrome' 'P450' '3A4'
 'inhibitors' '(' 'such' 'as' 'ketoconazole' ',' 'itraconazole' ','
 'erythromycin' ',' 'saquinavir' ')' ',' 'or' 'concomitant' 'use' 'of'
 'ritonavir']","[0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0.
 0. 1.]"
NCT02334865,"23:35:cancer,,86:106:cancer,108:143:cancer,148:189:cancer","Disease free of prior malignancies for > 2 years with exception of currently treated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast","['Disease' 'free' 'of' 'prior' 'malignancies' 'for' '>' '2' 'years' 'with'
 'exception' 'of' 'currently' 'treated' 'basal' 'cell' 'carcinoma' ','
 'squamous' 'cell' 'carcinoma' 'of' 'the' 'skin' ',' 'or' 'carcinoma' 'in'
 'situ' 'of' 'the' 'cervix' 'or' 'breast']","[0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02334579,"1:16:treatment,27:40:treatment,47:57:treatment,59:68:treatment,70:81:treatment,84:95:treatment,102:111:treatment,114:133:treatment,140:149:treatment,151:163:treatment,165:175:treatment,178:187:treatment,194:197:treatment,203:224:treatment","Hormone therapy: includes LHRH agonists (e.g. leuprolide, goserelin, triptorelin), antagonists (e.g. degarelix), peripheral blockers (e.g. flutamide, bicalutamide, nilutamide), estrogens (e.g. DES) and bilateral orchiectomy","['Hormone' 'therapy' ':' 'includes' 'LHRH' 'agonists' '(' 'e.g' '.'
 'leuprolide' ',' 'goserelin' ',' 'triptorelin' ')' ',' 'antagonists' '('
 'e.g' '.' 'degarelix' ')' ',' 'peripheral' 'blockers' '(' 'e.g' '.'
 'flutamide' ',' 'bicalutamide' ',' 'nilutamide' ')' ',' 'estrogens' '('
 'e.g' '.' 'DES' ')' 'and' 'bilateral' 'orchiectomy']","[1. 1. 0. 0. 1. 1. 0. 0. 0. 1. 0. 1. 0. 1. 0. 0. 1. 0. 0. 0. 1. 0. 0. 1.
 1. 0. 0. 0. 1. 0. 1. 0. 1. 0. 0. 1. 0. 0. 0. 1. 0. 0. 1. 1.]"
NCT02332850,"1:7:treatment,15:27:cancer,,80:101:treatment",Biopsy proven plasmacytoma (should be measured within 28 days prior to initial investigational agent dosing),"['Biopsy' 'proven' 'plasmacytoma' '(' 'should' 'be' 'measured' 'within'
 '28' 'days' 'prior' 'to' 'initial' 'investigational' 'agent' 'dosing' ')']",[1. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.]
NCT02332850,"1:19:treatment,23:43:cancer,47:82:cancer,87:105:cancer,95:105:cancer,116:131:cancer,138:154:treatment","complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, low-risk prostate cancer after curative therapy or complete resection of other advanced malignancy with the expectation that the patient has received curative therapy","['complete' 'resection' 'of' 'basal' 'cell' 'carcinoma' 'or' 'squamous'
 'cell' 'carcinoma' 'of' 'the' 'skin' ',' 'an' 'in' 'situ' 'malignancy'
 ',' 'low-risk' 'prostate' 'cancer' 'after' 'curative' 'therapy' 'or'
 'complete' 'resection' 'of' 'other' 'advanced' 'malignancy' 'with' 'the'
 'expectation' 'that' 'the' 'patient' 'has' 'received' 'curative'
 'therapy']","[1. 1. 0. 3. 3. 3. 0. 3. 3. 3. 3. 3. 3. 0. 0. 3. 3. 3. 0. 0. 3. 3. 0. 1.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02332668,"18:37:chronic_disease,39:41:chronic_disease,43:64:chronic_disease",Known history of active tuberculosis (TB; Bacillus tuberculosis),"['Known' 'history' 'of' 'active' 'tuberculosis' '(' 'TB' ';' 'Bacillus'
 'tuberculosis' ')']",[0. 0. 0. 2. 2. 0. 2. 0. 2. 2. 0.]
NCT02332291,"8:22:treatment,44:68:treatment,,,114:124:treatment",Use of antidepressant medications or other psychotropic medications in the last 4 weeks (or the last 6 weeks for fluoxetine),"['Use' 'of' 'antidepressant' 'medications' 'or' 'other' 'psychotropic'
 'medications' 'in' 'the' 'last' '4' 'weeks' '(' 'or' 'the' 'last' '6'
 'weeks' 'for' 'fluoxetine' ')']",[0. 0. 1. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02329327,"27:30:treatment,32:57:treatment,61:67:treatment,,126:144:treatment","Planned administration of PCC, fresh frozen plasma (FFP) or rfVIIa from Screening until within 12 hours after the end of the andexanet infusion","['Planned' 'administration' 'of' 'PCC' ',' 'fresh' 'frozen' 'plasma' '('
 'FFP' ')' 'or' 'rfVIIa' 'from' 'Screening' 'until' 'within' '12' 'hours'
 'after' 'the' 'end' 'of' 'the' 'andexanet' 'infusion']","[0. 0. 0. 1. 0. 1. 1. 1. 1. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 1.]"
NCT02327403,"17:20:chronic_disease,22:34:treatment,38:48:treatment,54:62:treatment",patient only on CNI (cyclosporine or tacrolimus) and steroids,"['patient' 'only' 'on' 'CNI' '(' 'cyclosporine' 'or' 'tacrolimus' ')'
 'and' 'steroids']",[0. 0. 0. 2. 0. 1. 0. 1. 0. 0. 1.]
NCT02324582,"10:23:treatment,32:41:treatment,43:53:treatment,55:65:treatment,67:77:treatment,82:148:treatment,160:170:treatment,280:289:treatment,294:314:treatment","received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways) including anti-CD40 and anti-OX40 antibodies","['received' 'prior' 'therapy' 'with' 'an' 'anti-PD-1' ',' 'anti-PD-L1' ','
 'anti-PD-L2' ',' 'anti-CD137' ',' 'or' 'anti-Cytotoxic'
 'T-lymphocyte-associated' 'antigen-4' '(' 'CTLA-4' ')' 'antibody' '('
 'including' 'ipilimumab' 'or' 'any' 'other' 'antibody' 'or' 'drug'
 'specifically' 'targeting' 'T-cell' 'co-stimulation' 'or' 'checkpoint'
 'pathways' ')' 'including' 'anti-CD40' 'and' 'anti-OX40' 'antibodies']","[0. 1. 1. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1.]"
NCT02324439,"30:32:cancer,43:71:cancer,73:98:cancer,102:123:cancer,145:163:treatment,,237:253:treatment","Patients with a diagnosis of OC including epithelial ovarian carcinoma, primary peritoneal cancer or fallopian tube cancer who are currently in clinical remission as determined by the PI or co-I and are within 4 months of completion of cancer treatment","['Patients' 'with' 'a' 'diagnosis' 'of' 'OC' 'including' 'epithelial'
 'ovarian' 'carcinoma' ',' 'primary' 'peritoneal' 'cancer' 'or'
 'fallopian' 'tube' 'cancer' 'who' 'are' 'currently' 'in' 'clinical'
 'remission' 'as' 'determined' 'by' 'the' 'PI' 'or' 'co-I' 'and' 'are'
 'within' '4' 'months' 'of' 'completion' 'of' 'cancer' 'treatment']","[0. 0. 0. 0. 0. 3. 0. 3. 3. 3. 0. 3. 3. 1. 1. 3. 3. 3. 0. 0. 0. 0. 1. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02323945,"42:51:chronic_disease,53:75:chronic_disease,101:122:chronic_disease,133:141:chronic_disease,158:181:chronic_disease","Concurrent severe medical illness (i.e., infection, cardiovascular disease, ossification, recurrent autonomic dysreflexia, unhealed decubiti, and history of pulmonary complications)","['Concurrent' 'severe' 'medical' 'illness' '(' 'i.e.' ',' 'infection' ','
 'cardiovascular' 'disease' ',' 'ossification' ',' 'recurrent' 'autonomic'
 'dysreflexia' ',' 'unhealed' 'decubiti' ',' 'and' 'history' 'of'
 'pulmonary' 'complications' ')']","[0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 2. 2. 0. 0. 2. 0. 0. 0. 0.
 2. 2. 0.]"
NCT02323880,"58:64:cancer,98:116:treatment,128:132:cancer,137:156:cancer,,,,,271:280:treatment,300:307:treatment","Part C: Patients with recurrent or refractory high grade glioma (WHO grade III/IV) and requiring surgical resection (excluding DIPG and disseminated tumors), who in the opinion of treating physicians, are medically stable to receive 3-4 doses of selinexor (8-10 days of treatment) before undergoing surgery without compromising the success of the procedure","['Part' 'C' ':' 'Patients' 'with' 'recurrent' 'or' 'refractory' 'high'
 'grade' 'glioma' '(' 'WHO' 'grade' 'III/IV' ')' 'and' 'requiring'
 'surgical' 'resection' '(' 'excluding' 'DIPG' 'and' 'disseminated'
 'tumors' ')' ',' 'who' 'in' 'the' 'opinion' 'of' 'treating' 'physicians'
 ',' 'are' 'medically' 'stable' 'to' 'receive' '3-4' 'doses' 'of'
 'selinexor' '(' '8-10' 'days' 'of' 'treatment' ')' 'before' 'undergoing'
 'surgery' 'without' 'compromising' 'the' 'success' 'of' 'the' 'procedure']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 3. 0.
 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]"
NCT02323880,",40:74:treatment,59:68:treatment,76:92:treatment,","at least 150 days must have elapsed if prior total body irradiation (TBI), craniospinal XRT or if >= 50% radiation of pelvis","['at' 'least' '150' 'days' 'must' 'have' 'elapsed' 'if' 'prior' 'total'
 'body' 'irradiation' '(' 'TBI' ')' ',' 'craniospinal' 'XRT' 'or' 'if' '>'
 '=' '50' '%' 'radiation' 'of' 'pelvis']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.
 1. 0. 0.]"
NCT02323581,",120:136:treatment,,,,,346:365:treatment,,,,,,,745:760:treatment","Iliac artery access: i) ≥ 6mm diameter, and absence of severe calcification and tortuosity ii) Or, planned creation of surgical conduit for TAAA device delivery f. For patients with associated common iliac artery aneurysms (>20mm diameter), adequate internal and external iliac artery landing zones and common iliac artery luminal diameter (for iliac branch device use): i. ≥ 10mm long segment of healthy internal iliac artery for branch attachment ii. Internal iliac diameter ≥ 5mm and ≤ 12mm iii. External iliac diameter ≥ 6mm diameter, and absence of severe calcification and tortuosity iv. Minimum common iliac artery luminal diameter ≥ 14mm v. Or, in patients with bilateral common iliac artery aneurysms without suitable anatomy, planned surgical bypass to maintain patency of at least one internal iliac artery","['Iliac' 'artery' 'access' ':' 'i' ')' '≥' '6mm' 'diameter' ',' 'and'
 'absence' 'of' 'severe' 'calcification' 'and' 'tortuosity' 'ii' ')' 'Or'
 ',' 'planned' 'creation' 'of' 'surgical' 'conduit' 'for' 'TAAA' 'device'
 'delivery' 'f.' 'For' 'patients' 'with' 'associated' 'common' 'iliac'
 'artery' 'aneurysms' '(' '>' '20mm' 'diameter' ')' ',' 'adequate'
 'internal' 'and' 'external' 'iliac' 'artery' 'landing' 'zones' 'and'
 'common' 'iliac' 'artery' 'luminal' 'diameter' '(' 'for' 'iliac' 'branch'
 'device' 'use' ')' ':' 'i' '.' '≥' '10mm' 'long' 'segment' 'of' 'healthy'
 'internal' 'iliac' 'artery' 'for' 'branch' 'attachment' 'ii' '.'
 'Internal' 'iliac' 'diameter' '≥' '5mm' 'and' '≤' '12mm' 'iii' '.'
 'External' 'iliac' 'diameter' '≥' '6mm' 'diameter' ',' 'and' 'absence'
 'of' 'severe' 'calcification' 'and' 'tortuosity' 'iv' '.' 'Minimum'
 'common' 'iliac' 'artery' 'luminal' 'diameter' '≥' '14mm' 'v.' 'Or' ','
 'in' 'patients' 'with' 'bilateral' 'common' 'iliac' 'artery' 'aneurysms'
 'without' 'suitable' 'anatomy' ',' 'planned' 'surgical' 'bypass' 'to'
 'maintain' 'patency' 'of' 'at' 'least' 'one' 'internal' 'iliac' 'artery']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02323191,"14:33:treatment,45:57:treatment,61:77:treatment,","Any approved anti-cancer therapy, including chemotherapy or hormonal therapy, within 3 weeks prior to initiation of study treatment, with the exceptions provided in the protocol","['Any' 'approved' 'anti-cancer' 'therapy' ',' 'including' 'chemotherapy'
 'or' 'hormonal' 'therapy' ',' 'within' '3' 'weeks' 'prior' 'to'
 'initiation' 'of' 'study' 'treatment' ',' 'with' 'the' 'exceptions'
 'provided' 'in' 'the' 'protocol']","[0. 0. 1. 1. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02323191,"1:22:treatment,26:45:treatment,,94:104:treatment",Prior corticosteroids as anti-cancer therapy within a minimum of 14 days of first receipt of study drug,"['Prior' 'corticosteroids' 'as' 'anti-cancer' 'therapy' 'within' 'a'
 'minimum' 'of' '14' 'days' 'of' 'first' 'receipt' 'of' 'study' 'drug']",[1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02323126,"19:36:chronic_disease,40:57:chronic_disease,78:95:chronic_disease",positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infection,"['positive' 'test' 'for' 'hepatitis' 'B' 'virus' 'or' 'hepatitis' 'C'
 'virus' 'indicating' 'acute' 'or' 'chronic' 'infection']",[0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02323100,"24:31:chronic_disease,33:38:chronic_disease,42:56:chronic_disease","Clinically significant cardiac, liver or kidney disease","['Clinically' 'significant' 'cardiac' ',' 'liver' 'or' 'kidney' 'disease']",[0. 0. 2. 0. 2. 0. 2. 2.]
NCT02322047,"25:45:chronic_disease,82:98:treatment,117:127:treatment,129:140:treatment,145:155:treatment,","Psychiatric/behavioral: psychiatric disorder requiring any medication other than anti-depressants; currently taking disulfiram, acamprosate, or naltrexone or planning to take any of these medications during the 8-week medication phase of the study","['Psychiatric/behavioral' ':' 'psychiatric' 'disorder' 'requiring' 'any'
 'medication' 'other' 'than' 'anti-depressants' ';' 'currently' 'taking'
 'disulfiram' ',' 'acamprosate' ',' 'or' 'naltrexone' 'or' 'planning' 'to'
 'take' 'any' 'of' 'these' 'medications' 'during' 'the' '8-week'
 'medication' 'phase' 'of' 'the' 'study']","[0. 0. 2. 2. 0. 0. 0. 0. 0. 1. 0. 0. 0. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02321501,"1:19:chronic_disease,58:73:cancer,127:145:cancer","Measurable disease by RECIST or evaluable disease (e.g., bone metastasis, or lesions which do not fulfill RECIST criteria for metastatic disease)","['Measurable' 'disease' 'by' 'RECIST' 'or' 'evaluable' 'disease' '('
 'e.g.' ',' 'bone' 'metastasis' ',' 'or' 'lesions' 'which' 'do' 'not'
 'fulfill' 'RECIST' 'criteria' 'for' 'metastatic' 'disease' ')']","[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3.
 0.]"
NCT02321501,"21:26:cancer,45:67:treatment,71:82:treatment,,116:120:treatment",Patient will have a tumor suitable for fine needle aspirates (FNA) or core biopsy for research purposes (2 or more FNAs if core is not feasible),"['Patient' 'will' 'have' 'a' 'tumor' 'suitable' 'for' 'fine' 'needle'
 'aspirates' '(' 'FNA' ')' 'or' 'core' 'biopsy' 'for' 'research'
 'purposes' '(' '2' 'or' 'more' 'FNAs' 'if' 'core' 'is' 'not' 'feasible'
 ')']","[0. 0. 0. 0. 3. 0. 0. 0. 1. 1. 1. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1.
 0. 0. 0. 0. 0. 0.]"
NCT02321501,"22:30:treatment,22:48:treatment,79:93:treatment,95:109:treatment,153:163:treatment,165:176:treatment,178:186:treatment","Therapeutic doses of warfarin sodium (Coumadin) or any other coumadin-derived anti-coagulant. Anticoagulants not derived from warfarin are allowed (eg, dabigatran, rivaroxaban, apixaban)","['Therapeutic' 'doses' 'of' 'warfarin' 'sodium' '(' 'Coumadin' ')' 'or'
 'any' 'other' 'coumadin-derived' 'anti-coagulant' '.' 'Anticoagulants'
 'not' 'derived' 'from' 'warfarin' 'are' 'allowed' '(' 'eg' ','
 'dabigatran' ',' 'rivaroxaban' ',' 'apixaban' ')']","[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 0. 1. 0. 1. 0.]"
NCT02321501,"1:24:chronic_disease,13:24:chronic_disease,26:42:chronic_disease,85:95:treatment",ventricular arrhythmias; supraventricular and nodal arrhythmias not controlled with medication,"['ventricular' 'arrhythmias' ';' 'supraventricular' 'and' 'nodal'
 'arrhythmias' 'not' 'controlled' 'with' 'medication']",[2. 2. 0. 2. 0. 0. 0. 0. 0. 0. 1.]
NCT02320292,"21:42:treatment,73:82:treatment,91:99:cancer",Receiving any other investigational agent that would be considered as a treatment for the lymphoma,"['Receiving' 'any' 'other' 'investigational' 'agent' 'that' 'would' 'be'
 'considered' 'as' 'a' 'treatment' 'for' 'the' 'lymphoma']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1. 0. 0. 3.]
NCT02319369,"8:30:chronic_disease,41:55:treatment,57:67:treatment,72:83:treatment,91:129:chronic_disease,141:167:chronic_disease","Has an uncontrolled infection requiring IV antibiotics, antivirals, or antifungals, known human immunodeficiency virus infection, or active hepatitis B or C infection","['Has' 'an' 'uncontrolled' 'infection' 'requiring' 'IV' 'antibiotics' ','
 'antivirals' ',' 'or' 'antifungals' ',' 'known' 'human'
 'immunodeficiency' 'virus' 'infection' ',' 'or' 'active' 'hepatitis' 'B'
 'or' 'C' 'infection']","[0. 0. 2. 2. 0. 1. 1. 0. 1. 0. 0. 1. 0. 0. 2. 2. 2. 2. 0. 0. 0. 2. 2. 2.
 2. 2.]"
NCT02319369,"19:45:treatment,160:174:treatment,230:268:treatment","Participated in a therapeutic clinical study within a washout time of 2 weeks or 5 half-lives of the drug/biologic (whichever is longer) before starting study drug treatment under this protocol, or current participation in other therapeutic investigational procedures","['Participated' 'in' 'a' 'therapeutic' 'clinical' 'study' 'within' 'a'
 'washout' 'time' 'of' '2' 'weeks' 'or' '5' 'half-lives' 'of' 'the'
 'drug/biologic' '(' 'whichever' 'is' 'longer' ')' 'before' 'starting'
 'study' 'drug' 'treatment' 'under' 'this' 'protocol' ',' 'or' 'current'
 'participation' 'in' 'other' 'therapeutic' 'investigational' 'procedures']","[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02317991,"38:60:treatment,62:74:treatment,76:92:treatment,97:114:treatment,","Patients who have received any other investigational agents, chemotherapy, biologic therapy, or radiation therapy within the 28 days prior to Day 1 of the study","['Patients' 'who' 'have' 'received' 'any' 'other' 'investigational'
 'agents' ',' 'chemotherapy' ',' 'biologic' 'therapy' ',' 'or' 'radiation'
 'therapy' 'within' 'the' '28' 'days' 'prior' 'to' 'Day' '1' 'of' 'the'
 'study']","[0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02315612,"47:51:treatment,86:93:chronic_disease,150:177:treatment","(For children who are unable to cooperate for PFTs, the criterion is: No evidence of dyspnea at rest, no exercise intolerance and no requirement for supplemental oxygen therapy. )","['(' 'For' 'children' 'who' 'are' 'unable' 'to' 'cooperate' 'for' 'PFTs'
 ',' 'the' 'criterion' 'is' ':' 'No' 'evidence' 'of' 'dyspnea' 'at' 'rest'
 ',' 'no' 'exercise' 'intolerance' 'and' 'no' 'requirement' 'for'
 'supplemental' 'oxygen' 'therapy' '.' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 1. 1. 0. 0.]"
NCT02315612,"131:155:cancer,168:182:treatment,184:196:treatment,201:232:treatment","Patients must have measurable or evaluable disease at the time of enrollment, which may include any evidence of disease including minimal residual disease detected by flow cytometry, cytogenetics, or polymerase chain reaction (PCR) analysis","['Patients' 'must' 'have' 'measurable' 'or' 'evaluable' 'disease' 'at'
 'the' 'time' 'of' 'enrollment' ',' 'which' 'may' 'include' 'any'
 'evidence' 'of' 'disease' 'including' 'minimal' 'residual' 'disease'
 'detected' 'by' 'flow' 'cytometry' ',' 'cytogenetics' ',' 'or'
 'polymerase' 'chain' 'reaction' '(' 'PCR' ')' 'analysis']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3.
 0. 0. 1. 1. 0. 1. 0. 0. 1. 1. 1. 1. 0. 0. 0.]"
NCT02315612,"1:18:cancer,33:61:cancer,74:79:cancer,","Second malignancy other than in situ carcinoma of the cervix, unless the tumor was treated with curative intent at least two years previously and subject is in remission","['Second' 'malignancy' 'other' 'than' 'in' 'situ' 'carcinoma' 'of' 'the'
 'cervix' ',' 'unless' 'the' 'tumor' 'was' 'treated' 'with' 'curative'
 'intent' 'at' 'least' 'two' 'years' 'previously' 'and' 'subject' 'is'
 'in' 'remission']","[3. 3. 0. 0. 0. 3. 3. 3. 3. 3. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02315612,"1:21:treatment,39:58:treatment,60:74:treatment","immunohistochemistry will be used for lymph node biopsies, flow cytometry will be used for peripheral blood and bone marrow samples and CSF when feasible","['immunohistochemistry' 'will' 'be' 'used' 'for' 'lymph' 'node' 'biopsies'
 ',' 'flow' 'cytometry' 'will' 'be' 'used' 'for' 'peripheral' 'blood'
 'and' 'bone' 'marrow' 'samples' 'and' 'CSF' 'when' 'feasible']","[1. 0. 0. 0. 0. 1. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02315196,"1:19:chronic_disease,23:38:chronic_disease,32:38:chronic_disease,,,,128:141:chronic_disease,184:207:chronic_disease,232:251:chronic_disease,253:269:chronic_disease,321:341:treatment,354:368:chronic_disease,372:410:chronic_disease","Myocardial infarct or unstable angina within 6 months before enrollment, New York Heart Association (NYHA) class II or greater heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, clinically significant pericardial disease, valvular disease with documented compromise in cardiac function, or electrocardiographic evidence of acute ischemic or active conduction system abnormalities","['Myocardial' 'infarct' 'or' 'unstable' 'angina' 'within' '6' 'months'
 'before' 'enrollment' ',' 'New' 'York' 'Heart' 'Association' '(' 'NYHA'
 ')' 'class' 'II' 'or' 'greater' 'heart' 'failure' ',' 'uncontrolled'
 'angina' ',' 'severe' 'uncontrolled' 'ventricular' 'arrhythmias' ','
 'clinically' 'significant' 'pericardial' 'disease' ',' 'valvular'
 'disease' 'with' 'documented' 'compromise' 'in' 'cardiac' 'function' ','
 'or' 'electrocardiographic' 'evidence' 'of' 'acute' 'ischemic' 'or'
 'active' 'conduction' 'system' 'abnormalities']","[2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.
 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 0. 0. 2. 2. 0. 2. 2. 2. 2.]"
NCT02315196,"7:20:treatment,40:46:treatment,55:65:cancer","Prior anthracycline, platinum salt, or taxane for any malignancy","['Prior' 'anthracycline' ',' 'platinum' 'salt' ',' 'or' 'taxane' 'for'
 'any' 'malignancy']",[0. 1. 0. 0. 0. 0. 0. 1. 0. 0. 3.]
NCT02315196,",,,58:71:cancer,,,,,,,129:155:treatment,159:200:treatment,,246:251:cancer,,318:328:treatment","Women with previously untreated, unilateral stage II-III breast cancer, ER/PgR/HER2 negative (ER =< 5%, PgR =< 5%, HER2 0-1+ by immunohistochemistry [IHC] or fluorescence in situ hybridization [FISH] =< 2.0); if clinically negative lymph nodes, tumor size should be minimum 1.0 cm and identifiable under office-based ultrasound guidance","['Women' 'with' 'previously' 'untreated' ',' 'unilateral' 'stage' 'II-III'
 'breast' 'cancer' ',' 'ER/PgR/HER2' 'negative' '(' 'ER' '=' '<' '5' '%'
 ',' 'PgR' '=' '<' '5' '%' ',' 'HER2' '0-1+' 'by' 'immunohistochemistry'
 '[' 'IHC' ']' 'or' 'fluorescence' 'in' 'situ' 'hybridization' '[' 'FISH'
 ']' '=' '<' '2.0' ')' ';' 'if' 'clinically' 'negative' 'lymph' 'nodes'
 ',' 'tumor' 'size' 'should' 'be' 'minimum' '1.0' 'cm' 'and'
 'identifiable' 'under' 'office-based' 'ultrasound' 'guidance']","[0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]"
NCT02314377,"25:29:chronic_disease,26:29:chronic_disease,77:110:chronic_disease,137:145:chronic_disease,151:154:chronic_disease,310:319:chronic_disease,321:332:chronic_disease","In the case of sporadic bAVM, these would be referable to the lesion, e.g., progressive neurological deficits, refractory headaches and seizures; for HHT patients, bAVM may be asymptomatic, but patient must have one progressively symptomatic manifestation of HHT that is referable to a vascular lesion, e.g., epistaxis, GI bleeding; or another solid organ AVM","['In' 'the' 'case' 'of' 'sporadic' 'bAVM' ',' 'these' 'would' 'be'
 'referable' 'to' 'the' 'lesion' ',' 'e.g.' ',' 'progressive'
 'neurological' 'deficits' ',' 'refractory' 'headaches' 'and' 'seizures'
 ';' 'for' 'HHT' 'patients' ',' 'bAVM' 'may' 'be' 'asymptomatic' ',' 'but'
 'patient' 'must' 'have' 'one' 'progressively' 'symptomatic'
 'manifestation' 'of' 'HHT' 'that' 'is' 'referable' 'to' 'a' 'vascular'
 'lesion' ',' 'e.g.' ',' 'epistaxis' ',' 'GI' 'bleeding' ';' 'or'
 'another' 'solid' 'organ' 'AVM']","[0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0.
 2. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 2.]"
NCT02314221,"1:16:chronic_disease,18:42:chronic_disease,58:79:chronic_disease","Atherosclerosis, congestive heart failure, or history of myocardial infarction","['Atherosclerosis' ',' 'congestive' 'heart' 'failure' ',' 'or' 'history'
 'of' 'myocardial' 'infarction']",[2. 0. 2. 2. 2. 0. 0. 0. 0. 2. 2.]
NCT02313428,"11:20:chronic_disease,32:37:chronic_disease,44:54:chronic_disease,58:71:chronic_disease",Untreated infection at site of ulcer (i.e. cellulitis or osteomyelitis),"['Untreated' 'infection' 'at' 'site' 'of' 'ulcer' '(' 'i.e' '.'
 'cellulitis' 'or' 'osteomyelitis' ')']",[0. 2. 0. 0. 0. 2. 0. 0. 0. 2. 0. 2. 0.]
NCT02312596,"8:21:chronic_disease,61:70:chronic_disease,74:83:chronic_disease,,,,,,","Severe liver disease is defined as known history of chronic hepatitis or cirrhosis &/or the following abnormal Liver Function Tests: ALT & AST >35, ALP >120, PT >12 seconds","['Severe' 'liver' 'disease' 'is' 'defined' 'as' 'known' 'history' 'of'
 'chronic' 'hepatitis' 'or' 'cirrhosis' '&' '/or' 'the' 'following'
 'abnormal' 'Liver' 'Function' 'Tests' ':' 'ALT' '&' 'AST' '>' '35' ','
 'ALP' '>' '120' ',' 'PT' '>' '12' 'seconds']","[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02312570,"1:21:chronic_disease,33:58:chronic_disease,61:71:chronic_disease,73:92:chronic_disease,94:97:chronic_disease,105:118:chronic_disease","Rheumatoid arthritis (and other collagen vascular disease), vasculitis, sickle cell disease, HIV Severe liver disease","['Rheumatoid' 'arthritis' '(' 'and' 'other' 'collagen' 'vascular'
 'disease' ')' ',' 'vasculitis' ',' 'sickle' 'cell' 'disease' ',' 'HIV'
 'Severe' 'liver' 'disease']",[2. 2. 0. 0. 0. 2. 2. 2. 0. 0. 2. 0. 2. 2. 2. 0. 2. 0. 2. 2.]
NCT02312518,"18:48:treatment,,87:96:treatment,98:107:treatment,111:120:treatment","Received another investigational device or drug within 30 days of enrollment Received allograft, autograft or xenograft within 30 days of enrollment","['Received' 'another' 'investigational' 'device' 'or' 'drug' 'within' '30'
 'days' 'of' 'enrollment' 'Received' 'allograft' ',' 'autograft' 'or'
 'xenograft' 'within' '30' 'days' 'of' 'enrollment']",[0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0.]
NCT02312245,"14:24:cancer,,71:96:cancer,100:131:cancer",Other active malignancy =< 3 years prior to registration; EXCEPTIONS: non-melanotic skin cancer or carcinoma-in-situ of the cervix,"['Other' 'active' 'malignancy' '=' '<' '3' 'years' 'prior' 'to'
 'registration' ';' 'EXCEPTIONS' ':' 'non-melanotic' 'skin' 'cancer' 'or'
 'carcinoma-in-situ' 'of' 'the' 'cervix']",[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 3. 3. 3. 3.]
NCT02311621,",16:37:treatment,42:73:treatment,86:104:treatment",≥ 6 weeks from myeloablative therapy and autologous stem cell transplant (timed from stem cell infusion),"['≥' '6' 'weeks' 'from' 'myeloablative' 'therapy' 'and' 'autologous'
 'stem' 'cell' 'transplant' '(' 'timed' 'from' 'stem' 'cell' 'infusion'
 ')']",[0. 0. 0. 0. 1. 1. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02311361,"1:4:chronic_disease,33:56:treatment,149:175:treatment,180:204:treatment",HIV-positive patients receiving anti-retroviral therapy are excluded from this study due to the possibility of pharmacokinetic interactions between antiretroviral medications and Tremelimumab or MEDI4736,"['HIV-positive' 'patients' 'receiving' 'anti-retroviral' 'therapy' 'are'
 'excluded' 'from' 'this' 'study' 'due' 'to' 'the' 'possibility' 'of'
 'pharmacokinetic' 'interactions' 'between' 'antiretroviral' 'medications'
 'and' 'Tremelimumab' 'or' 'MEDI4736']",[2. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 1.]
NCT02310633,"41:69:chronic_disease,82:86:chronic_disease,91:101:chronic_disease",no current or past history of disabling Axis I psychiatric disorders (except for PTSD and depression),"['no' 'current' 'or' 'past' 'history' 'of' 'disabling' 'Axis' 'I'
 'psychiatric' 'disorders' '(' 'except' 'for' 'PTSD' 'and' 'depression'
 ')']",[0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 2. 0. 2. 0.]
NCT02310464,"1:14:treatment,16:20:treatment,22:33:treatment,35:44:treatment,53:57:treatment","Immunotherapy [mAbs, Interferons, Cytokines (except GCSF)]","['Immunotherapy' '[' 'mAbs' ',' 'Interferons' ',' 'Cytokines' '(' 'except'
 'GCSF' ')' ']']",[1. 0. 1. 0. 1. 0. 1. 0. 0. 1. 0. 0.]
NCT02310464,"38:59:chronic_disease,81:98:chronic_disease,112:136:chronic_disease,,,147:171:chronic_disease,173:191:chronic_disease,196:215:chronic_disease,216:233:chronic_disease","Subjects with any known uncontrolled inter-current illness including ongoing or active infections, symptomatic congestive heart failure (NYHA>2), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Subjects' 'with' 'any' 'known' 'uncontrolled' 'inter-current' 'illness'
 'including' 'ongoing' 'or' 'active' 'infections' ',' 'symptomatic'
 'congestive' 'heart' 'failure' '(' 'NYHA' '>' '2' ')' ',' 'unstable'
 'angina' 'pectoris' ',' 'cardiac' 'arrhythmia' ',' 'or' 'psychiatric'
 'illness/social' 'situations' 'that' 'would' 'limit' 'compliance' 'with'
 'study' 'requirements']","[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 2.
 2. 2. 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT02309580,"12:46:treatment,52:66:treatment,68:78:treatment,,122:132:treatment","Concurrent systemic immunosuppressant therapy (eg, cyclosporine A, tacrolimus, etc.) within 28 days of the first dose of study drug","['Concurrent' 'systemic' 'immunosuppressant' 'therapy' '(' 'eg' ','
 'cyclosporine' 'A' ',' 'tacrolimus' ',' 'etc' '.' ')' 'within' '28'
 'days' 'of' 'the' 'first' 'dose' 'of' 'study' 'drug']","[0. 1. 1. 1. 0. 0. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 1.]"
NCT02309580,"1:19:treatment,21:37:treatment,43:50:treatment,,105:114:treatment","Previous radiation, hormonal therapy, and surgery must have been discontinued at least 2 weeks prior to treatment in this study and adverse effects must have resolved","['Previous' 'radiation' ',' 'hormonal' 'therapy' ',' 'and' 'surgery'
 'must' 'have' 'been' 'discontinued' 'at' 'least' '2' 'weeks' 'prior' 'to'
 'treatment' 'in' 'this' 'study' 'and' 'adverse' 'effects' 'must' 'have'
 'resolved']","[1. 1. 0. 1. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02309580,"12:33:chronic_disease,35:50:chronic_disease,55:78:chronic_disease,","history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to enrollment","['history' 'of' 'myocardial' 'infarction' ',' 'unstable' 'angina' ',' 'or'
 'acute' 'coronary' 'syndrome' 'within' '6' 'months' 'prior' 'to'
 'enrollment']",[0. 0. 2. 2. 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02308709,"1:19:treatment,7:19:treatment,24:39:cancer,49:59:cancer",Prior radiotherapy for thoracic cancer or other malignancy leading to any overlap of planned radiotherapy fields,"['Prior' 'radiotherapy' 'for' 'thoracic' 'cancer' 'or' 'other'
 'malignancy' 'leading' 'to' 'any' 'overlap' 'of' 'planned' 'radiotherapy'
 'fields']",[1. 1. 0. 3. 3. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02307565,"16:36:chronic_disease,45:75:chronic_disease,77:90:chronic_disease,94:110:chronic_disease","Diagnosis of a psychiatric disorder such as post-traumatic stress disorder, schizophrenia or bipolar disorder","['Diagnosis' 'of' 'a' 'psychiatric' 'disorder' 'such' 'as'
 'post-traumatic' 'stress' 'disorder' ',' 'schizophrenia' 'or' 'bipolar'
 'disorder']",[0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 0. 2. 2.]
NCT02306954,"13:21:chronic_disease,25:43:treatment,50:71:treatment,76:88:treatment","Evidence of ischemia on exercise tolerance test, stress thallium study, or baseline EKG","['Evidence' 'of' 'ischemia' 'on' 'exercise' 'tolerance' 'test' ','
 'stress' 'thallium' 'study' ',' 'or' 'baseline' 'EKG']",[0. 0. 2. 0. 1. 1. 0. 0. 1. 1. 1. 0. 0. 1. 1.]
NCT02304458,"1:38:treatment,34:37:treatment,39:64:treatment,,,130:158:treatment,160:176:treatment,","External beam radiation therapy (XRT)/external beam irradiation including protons: >= 14 days after local XRT; >= 150 days after total body irradiation (TBI), craniospinal XRT or if radiation to >= 50% of the pelvis","['External' 'beam' 'radiation' 'therapy' '(' 'XRT' ')' '/external' 'beam'
 'irradiation' 'including' 'protons' ':' '>' '=' '14' 'days' 'after'
 'local' 'XRT' ';' '>' '=' '150' 'days' 'after' 'total' 'body'
 'irradiation' '(' 'TBI' ')' ',' 'craniospinal' 'XRT' 'or' 'if'
 'radiation' 'to' '>' '=' '50' '%' 'of' 'the' 'pelvis']","[1. 1. 1. 1. 1. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 1. 1. 1. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02304458,"51:60:treatment,137:152:treatment,156:166:treatment","Patients must not have received prior exposure to nivolumab; for patients enrolled in parts C, D and E, patients must not have received prior nivolumab or ipilimumab","['Patients' 'must' 'not' 'have' 'received' 'prior' 'exposure' 'to'
 'nivolumab' ';' 'for' 'patients' 'enrolled' 'in' 'parts' 'C' ',' 'D'
 'and' 'E' ',' 'patients' 'must' 'not' 'have' 'received' 'prior'
 'nivolumab' 'or' 'ipilimumab']","[0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1.]"
NCT02303977,"1:21:treatment,38:67:treatment,77:88:treatment,92:101:treatment,173:183:treatment,185:194:treatment,196:207:treatment,209:220:treatment,222:232:treatment,237:246:treatment","First-line treatment with a standard platinum doublet chemotherapy regimen (carboplatin or cisplatin at standard dosing plus one of the following drugs at standard dosing: paclitaxel, docetaxel, vinblastine, vinorelbine, pemetrexed, or etoposide)","['First-line' 'treatment' 'with' 'a' 'standard' 'platinum' 'doublet'
 'chemotherapy' 'regimen' '(' 'carboplatin' 'or' 'cisplatin' 'at'
 'standard' 'dosing' 'plus' 'one' 'of' 'the' 'following' 'drugs' 'at'
 'standard' 'dosing' ':' 'paclitaxel' ',' 'docetaxel' ',' 'vinblastine'
 ',' 'vinorelbine' ',' 'pemetrexed' ',' 'or' 'etoposide' ')']","[1. 1. 0. 0. 0. 1. 1. 1. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 1. 0.]"
NCT02302976,"35:49:chronic_disease,54:74:chronic_disease,79:106:chronic_disease,135:157:chronic_disease,160:166:chronic_disease,180:219:chronic_disease,221:238:chronic_disease,251:279:treatment,281:301:chronic_disease,310:336:chronic_disease,338:344:chronic_disease,353:361:chronic_disease","a history of significant medical (cardiovascular) or neurological illness, ie prior myocardial infarction, current active symptoms of cardiovascular disease / angina, evidence of cocaine-related cardiovascular symptoms, prior arrhythmias or need for cardiovascular resuscitation, neurovascular events such as transient ischemic attacks, stroke, and/or seizures Parameters re: elevations in vital signs are now explicitly specified under Safety features built into our one-day self-administration paradigm)","['a' 'history' 'of' 'significant' 'medical' '(' 'cardiovascular' ')' 'or'
 'neurological' 'illness' ',' 'ie' 'prior' 'myocardial' 'infarction' ','
 'current' 'active' 'symptoms' 'of' 'cardiovascular' 'disease' '/'
 'angina' ',' 'evidence' 'of' 'cocaine-related' 'cardiovascular'
 'symptoms' ',' 'prior' 'arrhythmias' 'or' 'need' 'for' 'cardiovascular'
 'resuscitation' ',' 'neurovascular' 'events' 'such' 'as' 'transient'
 'ischemic' 'attacks' ',' 'stroke' ',' 'and/or' 'seizures' 'Parameters'
 're' ':' 'elevations' 'in' 'vital' 'signs' 'are' 'now' 'explicitly'
 'specified' 'under' 'Safety' 'features' 'built' 'into' 'our' 'one-day'
 'self-administration' 'paradigm' ')']","[0. 0. 0. 0. 0. 0. 1. 1. 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 2. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0.
 2. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02301611,"12:32:treatment,64:76:treatment,78:95:treatment","Completing SoC adjuvant therapy per NCCN guidelines to include chemotherapy, radiation therapy","['Completing' 'SoC' 'adjuvant' 'therapy' 'per' 'NCCN' 'guidelines' 'to'
 'include' 'chemotherapy' ',' 'radiation' 'therapy']",[0. 1. 1. 1. 0. 0. 0. 0. 0. 1. 0. 1. 1.]
NCT02301546,"17:42:chronic_disease,50:63:chronic_disease,65:91:chronic_disease","Current or past major psychiatric illness (e.g., schizophrenia, bipolar affective disorder)","['Current' 'or' 'past' 'major' 'psychiatric' 'illness' '(' 'e.g.' ','
 'schizophrenia' ',' 'bipolar' 'affective' 'disorder' ')']",[0. 0. 0. 2. 2. 2. 0. 0. 0. 2. 0. 2. 2. 2. 0.]
NCT02299414,"1:18:chronic_disease,20:34:chronic_disease,36:42:chronic_disease,44:47:chronic_disease","Cardiac disorders: cardiomyopathy, angina, CAD","['Cardiac' 'disorders' ':' 'cardiomyopathy' ',' 'angina' ',' 'CAD']",[2. 2. 0. 2. 0. 2. 0. 2.]
NCT02296684,"31:52:treatment,31:53:treatment,125:147:treatment,,184:191:treatment",Currently receiving any other investigational agents or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of MK-3475,"['Currently' 'receiving' 'any' 'other' 'investigational' 'agents' 'or'
 'has' 'participated' 'in' 'a' 'study' 'of' 'an' 'investigational' 'agent'
 'or' 'using' 'an' 'investigational' 'device' 'within' '4' 'weeks' 'of'
 'the' 'first' 'dose' 'of' 'MK-3475']","[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1.]"
NCT02296684,"18:29:chronic_disease,42:77:treatment,104:115:chronic_disease,128:135:treatment,163:172:chronic_disease",Known history of hepatitis B (defined as hepatitis B survace antigen [HBsAg] reactive) or known active hepatitis C (defined as HCV RNA [qualitative] is detected) infection,"['Known' 'history' 'of' 'hepatitis' 'B' '(' 'defined' 'as' 'hepatitis' 'B'
 'survace' 'antigen' '[' 'HBsAg' ']' 'reactive' ')' 'or' 'known' 'active'
 'hepatitis' 'C' '(' 'defined' 'as' 'HCV' 'RNA' '[' 'qualitative' ']' 'is'
 'detected' ')' 'infection']","[0. 0. 0. 2. 2. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 1. 0. 0. 0. 0. 0. 0. 2.]"
NCT02296684,"1:30:treatment,37:44:treatment,50:73:treatment",intranasal influenza vaccines (e.g. FluMist) are live attenuated viruses,"['intranasal' 'influenza' 'vaccines' '(' 'e.g' '.' 'FluMist' ')' 'are'
 'live' 'attenuated' 'viruses']",[1. 1. 1. 0. 0. 0. 1. 0. 0. 1. 1. 1.]
NCT02293109,"1:16:chronic_disease,20:41:chronic_disease,,,,,100:113:chronic_disease,115:134:chronic_disease,154:177:chronic_disease,199:222:chronic_disease,224:243:chronic_disease,287:295:chronic_disease,299:338:chronic_disease","Unstable angina or myocardial infarction within 6 months prior to enrollment, NYHA class III or IV heart failure, uncontrolled angina, history of severe coronary artery disease, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or electrocardiographic evidence of acute ischemia or grade 3 conduction system abnormalities unless subject has a pacemaker","['Unstable' 'angina' 'or' 'myocardial' 'infarction' 'within' '6' 'months'
 'prior' 'to' 'enrollment' ',' 'NYHA' 'class' 'III' 'or' 'IV' 'heart'
 'failure' ',' 'uncontrolled' 'angina' ',' 'history' 'of' 'severe'
 'coronary' 'artery' 'disease' ',' 'severe' 'uncontrolled' 'ventricular'
 'arrhythmias' ',' 'sick' 'sinus' 'syndrome' ',' 'or'
 'electrocardiographic' 'evidence' 'of' 'acute' 'ischemia' 'or' 'grade'
 '3' 'conduction' 'system' 'abnormalities' 'unless' 'subject' 'has' 'a'
 'pacemaker']","[2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0.
 0. 0. 2. 2. 2. 0. 0. 0. 2. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2.
 2. 2. 2. 0. 0. 0. 0. 0.]"
NCT02291978,"36:46:treatment,95:98:treatment,123:137:chronic_disease","Patients with contraindication for MR imaging such as implanted metallic devices that are not MRI-safe, size limitations, claustrophobia. etc","['Patients' 'with' 'contraindication' 'for' 'MR' 'imaging' 'such' 'as'
 'implanted' 'metallic' 'devices' 'that' 'are' 'not' 'MRI-safe' ',' 'size'
 'limitations' ',' 'claustrophobia' '.' 'etc']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 2. 0. 0.]
NCT02291978,"8:31:chronic_disease,33:46:chronic_disease,42:45:chronic_disease,",Severe cerebrovascular disease (multiple CVAs or CVA within 6 months),"['Severe' 'cerebrovascular' 'disease' '(' 'multiple' 'CVAs' 'or' 'CVA'
 'within' '6' 'months' ')']",[0. 2. 2. 0. 2. 2. 0. 2. 0. 0. 0. 0.]
NCT02291523,"37:46:treatment,,65:70:treatment,72:80:treatment,84:100:treatment","Children with recent dose change of biologics (within 4 weeks), 5-ASA, steroids or immunomodulators (within 4 weeks)","['Children' 'with' 'recent' 'dose' 'change' 'of' 'biologics' '(' 'within'
 '4' 'weeks' ')' ',' '5-ASA' ',' 'steroids' 'or' 'immunomodulators' '('
 'within' '4' 'weeks' ')']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0.]
NCT02290951,"16:50:chronic_disease,54:71:chronic_disease,77:100:chronic_disease,104:127:chronic_disease",Infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV),"['Infection' 'with' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')' 'or'
 'chronic' 'infection' 'with' 'hepatitis' 'B' 'virus' '(' 'HBV' ')' 'or'
 'hepatitis' 'C' 'virus' '(' 'HCV' ')']","[0. 0. 2. 2. 2. 2. 0. 0. 0. 2. 2. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02287558,"9:16:treatment,18:31:treatment,33:56:treatment,60:79:treatment","Chronic aspirin, NSAID therapy, anticoagulation therapy or antiplatelet agents","['Chronic' 'aspirin' ',' 'NSAID' 'therapy' ',' 'anticoagulation' 'therapy'
 'or' 'antiplatelet' 'agents']",[0. 1. 0. 1. 1. 0. 1. 1. 0. 1. 1.]
NCT02286687,"1:17:chronic_disease,28:56:treatment,79:99:chronic_disease,110:125:treatment",Active infection requiring intravenous (IV) antibiotics or other uncontrolled intercurrent illness requiring hospitalization,"['Active' 'infection' 'requiring' 'intravenous' '(' 'IV' ')' 'antibiotics'
 'or' 'other' 'uncontrolled' 'intercurrent' 'illness' 'requiring'
 'hospitalization']",[2. 2. 0. 1. 1. 1. 0. 0. 0. 0. 0. 2. 2. 0. 1.]
NCT02286687,"18:57:cancer,65:89:cancer,124:140:cancer,,263:292:treatment,277:292:treatment,422:430:treatment,","Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis; subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment; this exception does not include carcinomatous meningitis which is excluded regardless or clinical stability","['Has' 'known' 'active' 'central' 'nervous' 'system' '(' 'CNS' ')'
 'metastases' 'and/or' 'carcinomatous' 'meningitis' ';' 'subjects' 'with'
 'previously' 'treated' 'brain' 'metastases' 'may' 'participate'
 'provided' 'they' 'are' 'stable' '(' 'without' 'evidence' 'of'
 'progression' 'by' 'imaging' 'for' 'at' 'least' 'four' 'weeks' 'prior'
 'to' 'the' 'first' 'dose' 'of' 'trial' 'treatment' 'and' 'any'
 'neurologic' 'symptoms' 'have' 'returned' 'to' 'baseline' ')' ',' 'have'
 'no' 'evidence' 'of' 'new' 'or' 'enlarging' 'brain' 'metastases' ','
 'and' 'are' 'not' 'using' 'steroids' 'for' 'at' 'least' '7' 'days'
 'prior' 'to' 'trial' 'treatment' ';' 'this' 'exception' 'does' 'not'
 'include' 'carcinomatous' 'meningitis' 'which' 'is' 'excluded'
 'regardless' 'or' 'clinical' 'stability']","[0. 0. 0. 3. 3. 3. 3. 3. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02286687,",36:45:treatment,36:152:treatment,112:120:treatment,122:132:treatment,137:152:treatment,","Patients must be >= 4 weeks beyond treatment with any chemotherapy or other investigational therapy to include hormonal, biological, or targeted agents; or at least 5 half-lives from hormonal, biological, or targeted agents, whichever is shorter at the time of treatment initiation","['Patients' 'must' 'be' '>' '=' '4' 'weeks' 'beyond' 'treatment' 'with'
 'any' 'chemotherapy' 'or' 'other' 'investigational' 'therapy' 'to'
 'include' 'hormonal' ',' 'biological' ',' 'or' 'targeted' 'agents' ';'
 'or' 'at' 'least' '5' 'half-lives' 'from' 'hormonal' ',' 'biological' ','
 'or' 'targeted' 'agents' ',' 'whichever' 'is' 'shorter' 'at' 'the' 'time'
 'of' 'treatment' 'initiation']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02285101,"13:20:chronic_disease,24:41:chronic_disease,,,,,208:212:treatment,216:220:treatment,233:254:chronic_disease,,302:312:chronic_disease,328:336:chronic_disease,340:343:treatment","Significant cardiac or pulmonary disease defined by New York Heart Association (NYHA) Class III or IV (see Appendix 13.5), left ventricular ejection fraction (LVEF) lower than institutional normal limits by echo or MUGA, history of myocardial infarction within the past 6 months, significant unstable arrhythmia or evidence of ischemia on ECG","['Significant' 'cardiac' 'or' 'pulmonary' 'disease' 'defined' 'by' 'New'
 'York' 'Heart' 'Association' '(' 'NYHA' ')' 'Class' 'III' 'or' 'IV' '('
 'see' 'Appendix' '13.5' ')' ',' 'left' 'ventricular' 'ejection'
 'fraction' '(' 'LVEF' ')' 'lower' 'than' 'institutional' 'normal'
 'limits' 'by' 'echo' 'or' 'MUGA' ',' 'history' 'of' 'myocardial'
 'infarction' 'within' 'the' 'past' '6' 'months' ',' 'significant'
 'unstable' 'arrhythmia' 'or' 'evidence' 'of' 'ischemia' 'on' 'ECG']","[0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 2. 2. 0. 0. 0.
 0. 0. 0. 0. 0. 2. 0. 0. 0. 2. 0. 1.]"
NCT02282462,"12:35:treatment,40:55:chronic_disease,57:69:chronic_disease,73:87:chronic_disease","undergoing anatomic lung resection for bullous disease, lung abscess or bronchiectasis","['undergoing' 'anatomic' 'lung' 'resection' 'for' 'bullous' 'disease' ','
 'lung' 'abscess' 'or' 'bronchiectasis']",[0. 1. 2. 2. 0. 2. 2. 0. 0. 0. 0. 2.]
NCT02278315,"1:16:treatment,40:60:treatment,65:80:treatment",Prior treatment with or intolerance to proteasome inhibitor and immunomodulator,"['Prior' 'treatment' 'with' 'or' 'intolerance' 'to' 'proteasome'
 'inhibitor' 'and' 'immunomodulator']",[1. 1. 0. 0. 0. 0. 1. 1. 0. 1.]
NCT02278250,"59:69:cancer,113:145:cancer,208:227:cancer,264:280:treatment,285:303:cancer,",Participants with advanced (locally advanced incurable or metastatic) histologically or cytologically confirmed high-grade serous ovarian cancer (high nuclear Grades 2 or 3). Participants should have either platinum-refractory (disease progression during initial platinum therapy) or platinum-resistant (disease progression <6 months after completion of platinum therapy) disease,"['Participants' 'with' 'advanced' '(' 'locally' 'advanced' 'incurable'
 'or' 'metastatic' ')' 'histologically' 'or' 'cytologically' 'confirmed'
 'high-grade' 'serous' 'ovarian' 'cancer' '(' 'high' 'nuclear' 'Grades'
 '2' 'or' '3' ')' '.' 'Participants' 'should' 'have' 'either'
 'platinum-refractory' '(' 'disease' 'progression' 'during' 'initial'
 'platinum' 'therapy' ')' 'or' 'platinum-resistant' '(' 'disease'
 'progression' '<' '6' 'months' 'after' 'completion' 'of' 'platinum'
 'therapy' ')' 'disease']","[0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02278198,"18:37:treatment,57:71:cancer,86:104:cancer,145:187:treatment",status post near total thyroidectomy for differentiated thyroid cancer without known distant metastases and who are planning to undergo routine remnant thyroid tissue ablation with I-131,"['status' 'post' 'near' 'total' 'thyroidectomy' 'for' 'differentiated'
 'thyroid' 'cancer' 'without' 'known' 'distant' 'metastases' 'and' 'who'
 'are' 'planning' 'to' 'undergo' 'routine' 'remnant' 'thyroid' 'tissue'
 'ablation' 'with' 'I-131']","[0. 0. 0. 1. 1. 0. 0. 3. 3. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1.
 1. 1.]"
NCT02277548,"1:10:treatment,40:61:chronic_disease,80:96:treatment","Treatment entails significant risk for symptomatic mucositis likely to require opioid analgesia, as per the discretion of treating physician/NP","['Treatment' 'entails' 'significant' 'risk' 'for' 'symptomatic'
 'mucositis' 'likely' 'to' 'require' 'opioid' 'analgesia' ',' 'as' 'per'
 'the' 'discretion' 'of' 'treating' 'physician/NP']",[1. 0. 0. 0. 0. 2. 2. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02276443,",,71:106:treatment,110:131:treatment,,166:176:treatment",Patients must have left ventricular ejection fraction (LVEF) > 50% by multi gated acquisition scan (MUGA) or echocardiogram (ECHO) within 12 weeks prior to starting adriamycin,"['Patients' 'must' 'have' 'left' 'ventricular' 'ejection' 'fraction' '('
 'LVEF' ')' '>' '50' '%' 'by' 'multi' 'gated' 'acquisition' 'scan' '('
 'MUGA' ')' 'or' 'echocardiogram' '(' 'ECHO' ')' 'within' '12' 'weeks'
 'prior' 'to' 'starting' 'adriamycin']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 1. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02276443,"18:33:cancer,,78:95:cancer,151:156:cancer,161:196:cancer","Prior history of invasive cancer within 5 years of study entry or history of metastatic cancer; exceptions include non-metastatic, curatively treated basal and squamous cell carcinoma of the skin","['Prior' 'history' 'of' 'invasive' 'cancer' 'within' '5' 'years' 'of'
 'study' 'entry' 'or' 'history' 'of' 'metastatic' 'cancer' ';'
 'exceptions' 'include' 'non-metastatic' ',' 'curatively' 'treated'
 'basal' 'and' 'squamous' 'cell' 'carcinoma' 'of' 'the' 'skin']","[0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 3.
 0. 3. 3. 3. 3. 3. 3.]"
NCT02273375,"18:28:cancer,33:59:cancer,61:87:cancer,91:134:cancer","A combination of small cell and non-small cell lung cancer, pulmonary carcinoid tumour or large-cell neuroendocrine carcinoma (LCNEC)","['A' 'combination' 'of' 'small' 'cell' 'and' 'non-small' 'cell' 'lung'
 'cancer' ',' 'pulmonary' 'carcinoid' 'tumour' 'or' 'large-cell'
 'neuroendocrine' 'carcinoma' '(' 'LCNEC' ')']",[0. 0. 0. 3. 3. 0. 3. 3. 3. 3. 0. 3. 3. 3. 0. 3. 3. 3. 3. 0. 0.]
NCT02273375,"10:28:treatment,33:42:treatment,46:51:cancer,96:108:treatment",No prior anticancer therapy for treatment of NSCLC other than standard post-operative adjuvant chemotherapy is permissible,"['No' 'prior' 'anticancer' 'therapy' 'for' 'treatment' 'of' 'NSCLC'
 'other' 'than' 'standard' 'post-operative' 'adjuvant' 'chemotherapy' 'is'
 'permissible']",[0. 0. 1. 1. 0. 1. 0. 3. 0. 0. 0. 0. 0. 1. 0. 0.]
NCT02273375,"82:86:cancer,88:94:cancer,96:102:cancer,107:112:cancer","according to WHO Classification of Tumours (WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. WHO/IARC Classification of Tumours, 4th Edition, Volume 7)","['according' 'to' 'WHO' 'Classification' 'of' 'Tumours' '(' 'WHO'
 'Classification' 'of' 'Tumours' 'of' 'the' 'Lung' ',' 'Pleura' ','
 'Thymus' 'and' 'Heart' '.' 'WHO/IARC' 'Classification' 'of' 'Tumours' ','
 '4th' 'Edition' ',' 'Volume' '7' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 3. 0. 3. 0. 3. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02273362,"1:13:treatment,17:36:treatment,40:55:chronic_disease,,81:96:treatment,98:113:treatment",Percutaneous or transjugular biopsy of cirrhotic liver at least 7 days prior to liver resection (surgical cohort),"['Percutaneous' 'or' 'transjugular' 'biopsy' 'of' 'cirrhotic' 'liver' 'at'
 'least' '7' 'days' 'prior' 'to' 'liver' 'resection' '(' 'surgical'
 'cohort' ')']",[1. 0. 1. 1. 0. 2. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.]
NCT02273362,"34:38:treatment,181:195:treatment,207:245:chronic_disease,246:272:chronic_disease",individuals who use prescription PPIs and have approval from their primary health care provider to discontinue for the duration of clinical trial participation may be enrolled; an alternate drug to control gastroesophageal reflux disease (GERD)/peptic ulcer disease (PUD) symptoms will be suggested,"['individuals' 'who' 'use' 'prescription' 'PPIs' 'and' 'have' 'approval'
 'from' 'their' 'primary' 'health' 'care' 'provider' 'to' 'discontinue'
 'for' 'the' 'duration' 'of' 'clinical' 'trial' 'participation' 'may' 'be'
 'enrolled' ';' 'an' 'alternate' 'drug' 'to' 'control' 'gastroesophageal'
 'reflux' 'disease' '(' 'GERD' ')' '/peptic' 'ulcer' 'disease' '(' 'PUD'
 ')' 'symptoms' 'will' 'be' 'suggested']","[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 1. 0. 0. 2. 2. 2. 2. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0.]"
NCT02272998,"20:25:cancer,39:45:treatment,152:170:treatment",Patients must have tumor suitable for biopsy (as assessed by trained specialists in interventional radiology) and medically fit to undergo a biopsy or surgical procedure,"['Patients' 'must' 'have' 'tumor' 'suitable' 'for' 'biopsy' '(' 'as'
 'assessed' 'by' 'trained' 'specialists' 'in' 'interventional' 'radiology'
 ')' 'and' 'medically' 'fit' 'to' 'undergo' 'a' 'biopsy' 'or' 'surgical'
 'procedure']","[0. 0. 0. 3. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 1.]"
NCT02272998,"15:28:chronic_disease,30:52:chronic_disease,56:74:chronic_disease","Patients with macular edema, retinal vein occlusion or retinal hemorrhage are excluded","['Patients' 'with' 'macular' 'edema' ',' 'retinal' 'vein' 'occlusion' 'or'
 'retinal' 'hemorrhage' 'are' 'excluded']",[0. 0. 2. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT02272218,"72:96:chronic_disease,105:116:chronic_disease,118:125:chronic_disease,129:144:chronic_disease,146:156:cancer,160:175:chronic_disease,177:203:chronic_disease,211:220:chronic_disease,222:242:chronic_disease,282:299:treatment,304:321:chronic_disease","comorbidities that would make lap band surgery contraindicated (severe cardiopulmonary diseases, severe esophagitis, stomach or duodenal ulcers, esophageal or gastric varices, inflammatory bowel disease, liver cirrhosis, chronic pancreatitis, alcohol or drug addiction, on chronic steroid treatment, or active infections)","['comorbidities' 'that' 'would' 'make' 'lap' 'band' 'surgery'
 'contraindicated' '(' 'severe' 'cardiopulmonary' 'diseases' ',' 'severe'
 'esophagitis' ',' 'stomach' 'or' 'duodenal' 'ulcers' ',' 'esophageal'
 'or' 'gastric' 'varices' ',' 'inflammatory' 'bowel' 'disease' ',' 'liver'
 'cirrhosis' ',' 'chronic' 'pancreatitis' ',' 'alcohol' 'or' 'drug'
 'addiction' ',' 'on' 'chronic' 'steroid' 'treatment' ',' 'or' 'active'
 'infections' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 0. 2. 0. 2. 2. 0. 3. 0. 2.
 2. 0. 2. 2. 2. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 2.
 2. 0.]"
NCT02271919,"5:12:chronic_disease,16:37:chronic_disease,39:46:chronic_disease,48:56:chronic_disease,61:83:treatment,128:137:treatment","Any medical or psychiatric condition, illness, disorder, or concomitant medication that could compromise participant safety or treatment, as determined by the principal investigator and/or study physician","['Any' 'medical' 'or' 'psychiatric' 'condition' ',' 'illness' ','
 'disorder' ',' 'or' 'concomitant' 'medication' 'that' 'could'
 'compromise' 'participant' 'safety' 'or' 'treatment' ',' 'as'
 'determined' 'by' 'the' 'principal' 'investigator' 'and/or' 'study'
 'physician']","[0. 2. 0. 2. 2. 0. 2. 0. 2. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02271919,"19:39:treatment,47:69:treatment,73:96:treatment,141:151:treatment,","Plan to use other nicotine substitutes (i.e., over-the-counter [OTC] or prescription medication for smoking cessation) or smoking cessation treatments in the next 12 months","['Plan' 'to' 'use' 'other' 'nicotine' 'substitutes' '(' 'i.e.' ','
 'over-the-counter' '[' 'OTC' ']' 'or' 'prescription' 'medication' 'for'
 'smoking' 'cessation' ')' 'or' 'smoking' 'cessation' 'treatments' 'in'
 'the' 'next' '12' 'months']","[0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 1. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1.
 0. 0. 0. 0. 0.]"
NCT02270970,"1:7:cancer,,54:80:cancer,92:116:cancer",Cancer within 5 years (except for completely excised cervical carcinoma in situ or excised non-melanoma skin cancer),"['Cancer' 'within' '5' 'years' '(' 'except' 'for' 'completely' 'excised'
 'cervical' 'carcinoma' 'in' 'situ' 'or' 'excised' 'non-melanoma' 'skin'
 'cancer' ')']",[3. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 3. 3. 3. 0.]
NCT02270450,"20:47:chronic_disease,58:88:cancer,95:102:cancer,104:115:cancer,138:146:cancer,148:153:cancer,155:161:cancer,163:174:cancer,176:183:cancer,185:192:cancer,194:202:cancer,204:210:cancer,212:219:cancer,221:229:cancer,231:268:cancer,286:293:cancer","Patients must have malignant bowel obstruction due to an intra-abdominal primary cancer (i.e. stomach, small bowel [including duodenum], pancreas, colon, rectum, appendiceal, ovarian, uterine, cervical, kidney, bladder, prostate, gastrointestinal stromal tumor [GIST] [all sites], and sarcoma)","['Patients' 'must' 'have' 'malignant' 'bowel' 'obstruction' 'due' 'to'
 'an' 'intra-abdominal' 'primary' 'cancer' '(' 'i.e' '.' 'stomach' ','
 'small' 'bowel' '[' 'including' 'duodenum' ']' ',' 'pancreas' ',' 'colon'
 ',' 'rectum' ',' 'appendiceal' ',' 'ovarian' ',' 'uterine' ',' 'cervical'
 ',' 'kidney' ',' 'bladder' ',' 'prostate' ',' 'gastrointestinal'
 'stromal' 'tumor' '[' 'GIST' ']' '[' 'all' 'sites' ']' ',' 'and'
 'sarcoma' ')']","[0. 0. 0. 2. 2. 2. 0. 0. 0. 3. 3. 3. 0. 0. 0. 3. 0. 3. 3. 0. 0. 0. 0. 0.
 3. 0. 3. 0. 3. 0. 3. 0. 3. 0. 3. 0. 3. 0. 3. 0. 3. 0. 3. 0. 3. 3. 3. 3.
 0. 0. 0. 0. 0. 0. 0. 0. 3. 0.]"
NCT02269293,"11:24:treatment,41:56:cancer,68:80:treatment,82:107:treatment,112:131:treatment,,186:195:treatment","Any other prior therapy directed at the malignant tumor, including chemotherapy, biologic/targeted therapy and immunologic therapy, must be discontinued at least 3 weeks prior to study treatment initiation","['Any' 'other' 'prior' 'therapy' 'directed' 'at' 'the' 'malignant' 'tumor'
 ',' 'including' 'chemotherapy' ',' 'biologic/targeted' 'therapy' 'and'
 'immunologic' 'therapy' ',' 'must' 'be' 'discontinued' 'at' 'least' '3'
 'weeks' 'prior' 'to' 'study' 'treatment' 'initiation']","[0. 0. 1. 1. 0. 0. 0. 3. 3. 0. 0. 1. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 0.]"
NCT02269293,"15:33:cancer,37:63:cancer,78:90:treatment,78:96:treatment,113:139:treatment,257:281:treatment,369:389:treatment,448:457:cancer",Patients with endometrial cancer or endometrial carcinosarcoma may either be chemotherapy naive OR have had one prior line of chemotherapy that must have been a platinum-based chemotherapy regimen in the adjuvant or advanced/recurrent setting. The initial platinum-based treatment may have included consolidation/maintenance and/or biologic/targeted agents as part of first-line treatment. Patients entering the trial chemotherapy naive MUST have Stage IVB or recurrent disease AND have disease that is not amenable to curative intent,"['Patients' 'with' 'endometrial' 'cancer' 'or' 'endometrial'
 'carcinosarcoma' 'may' 'either' 'be' 'chemotherapy' 'naive' 'OR' 'have'
 'had' 'one' 'prior' 'line' 'of' 'chemotherapy' 'that' 'must' 'have'
 'been' 'a' 'platinum-based' 'chemotherapy' 'regimen' 'in' 'the'
 'adjuvant' 'or' 'advanced/recurrent' 'setting' '.' 'The' 'initial'
 'platinum-based' 'treatment' 'may' 'have' 'included'
 'consolidation/maintenance' 'and/or' 'biologic/targeted' 'agents' 'as'
 'part' 'of' 'first-line' 'treatment' '.' 'Patients' 'entering' 'the'
 'trial' 'chemotherapy' 'naive' 'MUST' 'have' 'Stage' 'IVB' 'or'
 'recurrent' 'disease' 'AND' 'have' 'disease' 'that' 'is' 'not' 'amenable'
 'to' 'curative' 'intent']","[0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0.
 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02269280,"1:14:treatment,20:30:treatment,34:45:treatment",Prior therapy with decitabine or azacitidine,['Prior' 'therapy' 'with' 'decitabine' 'or' 'azacitidine'],[1. 1. 0. 1. 0. 1.]
NCT02268253,"15:25:cancer,33:39:cancer,59:87:chronic_disease,104:124:cancer",has an active malignancy and/or cancer history (excluding myeloproliferative disorders and concomitant myeloid malignancies as specified in the inclusion criteria) that can confound the assessment of the study endpoints,"['has' 'an' 'active' 'malignancy' 'and/or' 'cancer' 'history' '('
 'excluding' 'myeloproliferative' 'disorders' 'and' 'concomitant'
 'myeloid' 'malignancies' 'as' 'specified' 'in' 'the' 'inclusion'
 'criteria' ')' 'that' 'can' 'confound' 'the' 'assessment' 'of' 'the'
 'study' 'endpoints']","[0. 0. 0. 3. 0. 3. 0. 0. 0. 2. 2. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02268253,"42:59:chronic_disease,67:104:chronic_disease,106:128:chronic_disease","has uncontrolled, clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease, pulmonary hypertension) that, in the Investigator's opinion, would put the patient at significant risk for pulmonary complications during the study","['has' 'uncontrolled' ',' 'clinically' 'significant' 'pulmonary' 'disease'
 '(' 'e.g.' ',' 'chronic' 'obstructive' 'pulmonary' 'disease' ','
 'pulmonary' 'hypertension' ')' 'that' ',' 'in' 'the' 'Investigator' ""'s""
 'opinion' ',' 'would' 'put' 'the' 'patient' 'at' 'significant' 'risk'
 'for' 'pulmonary' 'complications' 'during' 'the' 'study']","[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02267863,"14:36:chronic_disease,38:66:chronic_disease,125:143:chronic_disease","Uncontrolled leptomeningeal disease, auto-immune hemolytic anemia and uncontrolled and clinical significant disease related metabolic disorder","['Uncontrolled' 'leptomeningeal' 'disease' ',' 'auto-immune' 'hemolytic'
 'anemia' 'and' 'uncontrolled' 'and' 'clinical' 'significant' 'disease'
 'related' 'metabolic' 'disorder']",[0. 2. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02266745,"1:17:chronic_disease,19:24:chronic_disease,29:45:chronic_disease,56:72:treatment","Active bacterial, viral, or fungal infection requiring systemic therapy","['Active' 'bacterial' ',' 'viral' ',' 'or' 'fungal' 'infection'
 'requiring' 'systemic' 'therapy']",[2. 2. 0. 2. 0. 0. 2. 2. 0. 1. 1.]
NCT02266719,",218:285:treatment,276:285:chronic_disease,379:428:treatment,525:535:chronic_disease,539:556:chronic_disease","Prior surgical or interventional procedure within 30 days of the anticipated date of the fenestrated procedure, with the exception of planned staged procedures to provide access for repair (e.g. staged iliac conduit, thoracic endovascular aortic aneurysm repair for proximal aneurysms), to facilitate the procedure by allowing open reparation of a target artery not amenable to revascularization with the investigational device, such us an internal iliac artery, subclavian artery or visceral artery with early bifurcation, tortuosity or occlusive disease preventing successful placement and alignment side stents, or to treat proximal aortic aneurysms","['Prior' 'surgical' 'or' 'interventional' 'procedure' 'within' '30' 'days'
 'of' 'the' 'anticipated' 'date' 'of' 'the' 'fenestrated' 'procedure' ','
 'with' 'the' 'exception' 'of' 'planned' 'staged' 'procedures' 'to'
 'provide' 'access' 'for' 'repair' '(' 'e.g' '.' 'staged' 'iliac'
 'conduit' ',' 'thoracic' 'endovascular' 'aortic' 'aneurysm' 'repair'
 'for' 'proximal' 'aneurysms' ')' ',' 'to' 'facilitate' 'the' 'procedure'
 'by' 'allowing' 'open' 'reparation' 'of' 'a' 'target' 'artery' 'not'
 'amenable' 'to' 'revascularization' 'with' 'the' 'investigational'
 'device' ',' 'such' 'us' 'an' 'internal' 'iliac' 'artery' ','
 'subclavian' 'artery' 'or' 'visceral' 'artery' 'with' 'early'
 'bifurcation' ',' 'tortuosity' 'or' 'occlusive' 'disease' 'preventing'
 'successful' 'placement' 'and' 'alignment' 'side' 'stents' ',' 'or' 'to'
 'treat' 'proximal' 'aortic' 'aneurysms']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 2. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02266329,"52:62:treatment,52:63:treatment,64:74:treatment,,213:231:treatment,245:260:treatment,262:277:treatment,279:294:treatment,296:304:treatment,305:314:treatment,316:332:treatment,356:369:treatment,371:395:treatment,397:437:treatment,443:472:treatment","Subjects must be on a stable dose of the following medications/treatments for at least 4 weeks prior to the preliminary screening period, and must intend to continue the medication for the duration of the trial: psychoactive drugs, for example anticonvulsants, benzodiazepines, antidepressants, sedative/hypnotics; antihypertensive medications, including beta blockers, calcium channel blockers, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers; magnesium prescribed specifically for headache","['Subjects' 'must' 'be' 'on' 'a' 'stable' 'dose' 'of' 'the' 'following'
 'medications/treatments' 'for' 'at' 'least' '4' 'weeks' 'prior' 'to'
 'the' 'preliminary' 'screening' 'period' ',' 'and' 'must' 'intend' 'to'
 'continue' 'the' 'medication' 'for' 'the' 'duration' 'of' 'the' 'trial'
 ':' 'psychoactive' 'drugs' ',' 'for' 'example' 'anticonvulsants' ','
 'benzodiazepines' ',' 'antidepressants' ',' 'sedative/hypnotics' ';'
 'antihypertensive' 'medications' ',' 'including' 'beta' 'blockers' ','
 'calcium' 'channel' 'blockers' ',' 'angiotensin' 'converting' 'enzyme'
 'inhibitors' ',' 'and' 'angiotensin' 'receptor' 'blockers' ';'
 'magnesium' 'prescribed' 'specifically' 'for' 'headache']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 0. 1. 0. 1. 0.
 1. 0. 1. 0. 0. 0. 1. 1. 0. 1. 1. 1. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02265874,",60:70:treatment,125:143:treatment,145:157:treatment,159:171:treatment,173:184:treatment,","Patients must have been treated with at least 10 mg/day of prednisone or equivalent or one or more immunomodulating agents (hydroxychloroquine, methotrexate, azathioprine, leflunomide) for >3 months before screening","['Patients' 'must' 'have' 'been' 'treated' 'with' 'at' 'least' '10'
 'mg/day' 'of' 'prednisone' 'or' 'equivalent' 'or' 'one' 'or' 'more'
 'immunomodulating' 'agents' '(' 'hydroxychloroquine' ',' 'methotrexate'
 ',' 'azathioprine' ',' 'leflunomide' ')' 'for' '>' '3' 'months' 'before'
 'screening']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1.
 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0.]"
NCT02264678,"22:28:cancer,,80:82:treatment,86:94:treatment",patients must have a tumour at least 1 cm in size that can be measured using a CT or MRI scan,"['patients' 'must' 'have' 'a' 'tumour' 'at' 'least' '1' 'cm' 'in' 'size'
 'that' 'can' 'be' 'measured' 'using' 'a' 'CT' 'or' 'MRI' 'scan']",[0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1.]
NCT02263729,"27:35:allergy_name,27:43:treatment,75:94:allergy_name","Has contraindications for Losartan therapy (hypersensitivity to Losartan, hepatic involvement)","['Has' 'contraindications' 'for' 'Losartan' 'therapy' '('
 'hypersensitivity' 'to' 'Losartan' ',' 'hepatic' 'involvement' ')']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 4. 4. 0.]
NCT02263274,"17:39:chronic_disease,50:61:cancer,63:88:chronic_disease,90:112:chronic_disease,114:138:treatment,154:169:chronic_disease","Space occupying intracranial pathology including brain tumor, ateriovenous malformation, cavernous malformation, prior surgical resection or significant encephalomalcia that would create unknown tissue inhomogeneity that cannot be accurately modeled","['Space' 'occupying' 'intracranial' 'pathology' 'including' 'brain'
 'tumor' ',' 'ateriovenous' 'malformation' ',' 'cavernous' 'malformation'
 ',' 'prior' 'surgical' 'resection' 'or' 'significant' 'encephalomalcia'
 'that' 'would' 'create' 'unknown' 'tissue' 'inhomogeneity' 'that' 'can'
 'not' 'be' 'accurately' 'modeled']","[0. 0. 2. 2. 0. 3. 3. 0. 2. 2. 0. 2. 2. 0. 1. 1. 1. 0. 0. 2. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02261519,"12:18:cancer,,68:88:cancer,93:116:cancer",History of cancer not in remission for the last 3 years except for basal cell carcinoma and squamous cell carcinoma,"['History' 'of' 'cancer' 'not' 'in' 'remission' 'for' 'the' 'last' '3'
 'years' 'except' 'for' 'basal' 'cell' 'carcinoma' 'and' 'squamous' 'cell'
 'carcinoma']",[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 3. 3. 3.]
NCT02261519,"49:72:chronic_disease,74:95:chronic_disease,97:113:chronic_disease,115:140:chronic_disease,142:166:chronic_disease,168:193:chronic_disease,195:212:chronic_disease,214:258:chronic_disease,260:268:chronic_disease,292:308:chronic_disease","Meets the DSM-IV or V criteria at screening for intellectual disability, dissociative disorder, bipolar disorder, major depressive disorder, schizoaffective disorder, schizophreniform disorder, autistic disorder, primary substance-induced psychotic disorder, dementia, or any other comorbid mental disorders that in the opinion of the Investigator may interfere with study conduct and results interpretation","['Meets' 'the' 'DSM-IV' 'or' 'V' 'criteria' 'at' 'screening' 'for'
 'intellectual' 'disability' ',' 'dissociative' 'disorder' ',' 'bipolar'
 'disorder' ',' 'major' 'depressive' 'disorder' ',' 'schizoaffective'
 'disorder' ',' 'schizophreniform' 'disorder' ',' 'autistic' 'disorder'
 ',' 'primary' 'substance-induced' 'psychotic' 'disorder' ',' 'dementia'
 ',' 'or' 'any' 'other' 'comorbid' 'mental' 'disorders' 'that' 'in' 'the'
 'opinion' 'of' 'the' 'Investigator' 'may' 'interfere' 'with' 'study'
 'conduct' 'and' 'results' 'interpretation']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 2. 2. 0. 2. 2. 2. 0. 2. 2.
 0. 2. 2. 0. 2. 2. 0. 2. 2. 2. 2. 0. 2. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02259621,"49:58:treatment,72:95:treatment,194:222:treatment","As there is potential for hepatic toxicity with nivolumab or nivolumab/ipilimumab combinations, drugs with a predisposition to hepatoxicity should be used with caution in patients treated with nivolumab-containing regimen","['As' 'there' 'is' 'potential' 'for' 'hepatic' 'toxicity' 'with'
 'nivolumab' 'or' 'nivolumab/ipilimumab' 'combinations' ',' 'drugs' 'with'
 'a' 'predisposition' 'to' 'hepatoxicity' 'should' 'be' 'used' 'with'
 'caution' 'in' 'patients' 'treated' 'with' 'nivolumab-containing'
 'regimen']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 1.]"
NCT02259621,"1:26:cancer,28:43:cancer,45:52:cancer,54:60:cancer,62:67:cancer,71:97:cancer","non melanoma skin cancers, in situ bladder, gastric, breast, colon or cervical cancers/dysplasia","['non' 'melanoma' 'skin' 'cancers' ',' 'in' 'situ' 'bladder' ',' 'gastric'
 ',' 'breast' ',' 'colon' 'or' 'cervical' 'cancers/dysplasia']",[3. 3. 3. 3. 0. 3. 3. 3. 0. 3. 0. 3. 0. 3. 0. 3. 3.]
NCT02257424,"5:32:treatment,23:32:treatment,60:68:chronic_disease","All prior anti-cancer treatment-related toxicities (except alopecia and laboratory values as listed in Eligibility Criteria #4) must be Grade 1 according to the Common Terminology Criteria for Adverse Events version 4 (CTCAE version 4.03, 2009) at the time of starting treatment","['All' 'prior' 'anti-cancer' 'treatment-related' 'toxicities' '(' 'except'
 'alopecia' 'and' 'laboratory' 'values' 'as' 'listed' 'in' 'Eligibility'
 'Criteria' '#' '4' ')' 'must' 'be' 'Grade' '1' 'according' 'to' 'the'
 'Common' 'Terminology' 'Criteria' 'for' 'Adverse' 'Events' 'version' '4'
 '(' 'CTCAE' 'version' '4.03' ',' '2009' ')' 'at' 'the' 'time' 'of'
 'starting' 'treatment']","[0. 1. 1. 1. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02257424,"20:38:treatment,49:54:cancer,61:78:treatment,82:104:treatment",Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents),"['Patients' 'receiving' 'concurrent' 'therapy' 'for' 'their' 'tumor' '('
 'i.e' '.' 'chemotherapeutics' 'or' 'investigational' 'agents' ')']",[0. 0. 1. 1. 0. 0. 3. 0. 0. 0. 1. 0. 1. 1. 0.]
NCT02257424,"15:31:cancer,45:56:treatment,60:67:treatment,,250:261:treatment",patients with brain metastases treated with gamma knife or surgery are allowed to participate after 3 weeks have elapsed since their procedure . Demonstration of brain stability by an imaging study after the procedure is required for gamma knife or CNS surgery patients,"['patients' 'with' 'brain' 'metastases' 'treated' 'with' 'gamma' 'knife'
 'or' 'surgery' 'are' 'allowed' 'to' 'participate' 'after' '3' 'weeks'
 'have' 'elapsed' 'since' 'their' 'procedure' '.' 'Demonstration' 'of'
 'brain' 'stability' 'by' 'an' 'imaging' 'study' 'after' 'the' 'procedure'
 'is' 'required' 'for' 'gamma' 'knife' 'or' 'CNS' 'surgery' 'patients']","[0. 0. 3. 3. 0. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.]"
NCT02257138,"26:38:chronic_disease,40:74:chronic_disease,78:95:chronic_disease","patients with history of tuberculosis, human immunodeficiency virus (HIV) or hepatitis B and C","['patients' 'with' 'history' 'of' 'tuberculosis' ',' 'human'
 'immunodeficiency' 'virus' '(' 'HIV' ')' 'or' 'hepatitis' 'B' 'and' 'C']",[0. 0. 0. 0. 2. 0. 2. 2. 2. 2. 0. 0. 0. 2. 2. 2. 2.]
NCT02256631,"52:66:treatment,71:96:treatment,132:165:treatment,220:239:treatment","Receipt of or anticipated need for blood products, immunoglobulin, or immunosuppressive therapy. This includes infants who require hepatitis B immunoglobulin (HBIG) but does not require exclusion of infants who receive hepatitis B vaccine in the newborn period","['Receipt' 'of' 'or' 'anticipated' 'need' 'for' 'blood' 'products' ','
 'immunoglobulin' ',' 'or' 'immunosuppressive' 'therapy' '.' 'This'
 'includes' 'infants' 'who' 'require' 'hepatitis' 'B' 'immunoglobulin' '('
 'HBIG' ')' 'but' 'does' 'not' 'require' 'exclusion' 'of' 'infants' 'who'
 'receive' 'hepatitis' 'B' 'vaccine' 'in' 'the' 'newborn' 'period']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02254863,"14:23:chronic_disease,25:30:chronic_disease,35:51:chronic_disease,67:89:treatment","Uncontrolled bacterial, viral, or fungal infection at the time of pre-UCBT cytoreduction","['Uncontrolled' 'bacterial' ',' 'viral' ',' 'or' 'fungal' 'infection' 'at'
 'the' 'time' 'of' 'pre-UCBT' 'cytoreduction']",[0. 2. 0. 2. 0. 0. 2. 2. 0. 0. 0. 0. 1. 1.]
NCT02253316,"12:23:cancer,27:53:cancer,64:73:treatment",Concurrent hematologic or non-hematologic malignancy requiring treatment,"['Concurrent' 'hematologic' 'or' 'non-hematologic' 'malignancy'
 'requiring' 'treatment']",[0. 3. 0. 3. 3. 0. 1.]
NCT02253316,"20:35:treatment,85:101:cancer,109:130:chronic_disease,132:152:chronic_disease","Patients may be on corticosteroids if they are being given for disorders other than multiple myeloma (e.g., adrenal insufficiency, rheumatoid arthritis, etc.)","['Patients' 'may' 'be' 'on' 'corticosteroids' 'if' 'they' 'are' 'being'
 'given' 'for' 'disorders' 'other' 'than' 'multiple' 'myeloma' '(' 'e.g.'
 ',' 'adrenal' 'insufficiency' ',' 'rheumatoid' 'arthritis' ',' 'etc' '.'
 ')']","[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 2. 2. 0. 2. 2.
 0. 0. 0. 0.]"
NCT02252588,"23:29:chronic_disease,31:45:chronic_disease,47:62:chronic_disease,67:104:chronic_disease","Clinical diagnosis of asthma, bronchiectasis, cystic fibrosis, or severe alpha-1 antitrypsin deficiency","['Clinical' 'diagnosis' 'of' 'asthma' ',' 'bronchiectasis' ',' 'cystic'
 'fibrosis' ',' 'or' 'severe' 'alpha-1' 'antitrypsin' 'deficiency']",[0. 0. 0. 2. 0. 2. 0. 2. 2. 0. 0. 2. 2. 2. 2.]
NCT02252432,"30:53:chronic_disease,65:78:chronic_disease,80:85:chronic_disease,87:103:chronic_disease,107:116:chronic_disease","Individuals with significant psychological disorders including: schizophrenia, mania, bipolar disorder or psychosis","['Individuals' 'with' 'significant' 'psychological' 'disorders'
 'including' ':' 'schizophrenia' ',' 'mania' ',' 'bipolar' 'disorder' 'or'
 'psychosis']",[0. 0. 0. 2. 2. 0. 0. 2. 0. 2. 0. 2. 2. 0. 2.]
NCT02252081,"16:26:cancer,30:36:cancer,,77:118:cancer",Current active malignancy or cancer history in the prior 5 years (excluding squamous cell and basal cell skin cancers),"['Current' 'active' 'malignancy' 'or' 'cancer' 'history' 'in' 'the'
 'prior' '5' 'years' '(' 'excluding' 'squamous' 'cell' 'and' 'basal'
 'cell' 'skin' 'cancers' ')']",[0. 0. 3. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 3. 3. 0.]
NCT02251431,"1:28:treatment,30:43:treatment,45:58:treatment,69:94:treatment","Implanted cardiac pacemaker, defibrillator, loop recorder, or other implanted metallic device","['Implanted' 'cardiac' 'pacemaker' ',' 'defibrillator' ',' 'loop'
 'recorder' ',' 'or' 'other' 'implanted' 'metallic' 'device']",[1. 1. 1. 0. 1. 0. 1. 1. 0. 0. 0. 1. 1. 1.]
NCT02250664,"36:51:chronic_disease,101:110:treatment,114:127:treatment,",Be in good physical health without serious illness or change in health or medication (not including methadone or buprenorphine dose) in the past three months as determined by the license medical professional at each site,"['Be' 'in' 'good' 'physical' 'health' 'without' 'serious' 'illness' 'or'
 'change' 'in' 'health' 'or' 'medication' '(' 'not' 'including'
 'methadone' 'or' 'buprenorphine' 'dose' ')' 'in' 'the' 'past' 'three'
 'months' 'as' 'determined' 'by' 'the' 'license' 'medical' 'professional'
 'at' 'each' 'site']","[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02250534,"6:26:treatment,28:37:treatment,41:64:treatment","used nicotine replacement, bupropion or other pharmacotherapies as cessation aids in the past month","['used' 'nicotine' 'replacement' ',' 'bupropion' 'or' 'other'
 'pharmacotherapies' 'as' 'cessation' 'aids' 'in' 'the' 'past' 'month']",[0. 1. 1. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02245841,"8:27:treatment,32:41:treatment,123:140:chronic_disease",Use of topical medications and sunscreen currently and in past will be noted but not weighed for assessment of refractory cutaneous disease,"['Use' 'of' 'topical' 'medications' 'and' 'sunscreen' 'currently' 'and'
 'in' 'past' 'will' 'be' 'noted' 'but' 'not' 'weighed' 'for' 'assessment'
 'of' 'refractory' 'cutaneous' 'disease']",[0. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02243813,"55:66:treatment,127:136:treatment,169:204:treatment","Currently taking on a regular (e.g., daily) basis any medications having a primary centrally-acting pharmacological effect on serotonin neurons or medications that are Mono amine Oxidase (MAO) inhibitors","['Currently' 'taking' 'on' 'a' 'regular' '(' 'e.g.' ',' 'daily' ')'
 'basis' 'any' 'medications' 'having' 'a' 'primary' 'centrally-acting'
 'pharmacological' 'effect' 'on' 'serotonin' 'neurons' 'or' 'medications'
 'that' 'are' 'Mono' 'amine' 'Oxidase' '(' 'MAO' ')' 'inhibitors']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.
 0. 0. 1. 1. 1. 1. 1. 0. 0.]"
NCT02239913,"64:87:chronic_disease,101:138:chronic_disease,151:158:chronic_disease,199:219:chronic_disease","History of serious physical disease, current physical disease, impaired cardiovascular functioning, chronic obstructive pulmonary disease, history of seizure or current or past histories of serious psychiatric disorder that in the opinion of the study physician would interfere with study","['History' 'of' 'serious' 'physical' 'disease' ',' 'current' 'physical'
 'disease' ',' 'impaired' 'cardiovascular' 'functioning' ',' 'chronic'
 'obstructive' 'pulmonary' 'disease' ',' 'history' 'of' 'seizure' 'or'
 'current' 'or' 'past' 'histories' 'of' 'serious' 'psychiatric' 'disorder'
 'that' 'in' 'the' 'opinion' 'of' 'the' 'study' 'physician' 'would'
 'interfere' 'with' 'study']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 2. 0. 0. 0. 2. 0. 0.
 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02237183,"29:43:treatment,67:74:treatment,84:127:treatment","patients must not be taking anticoagulants, with the exception of aspirin or other non-steroidal anti-inflammatory medications","['patients' 'must' 'not' 'be' 'taking' 'anticoagulants' ',' 'with' 'the'
 'exception' 'of' 'aspirin' 'or' 'other' 'non-steroidal'
 'anti-inflammatory' 'medications']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 1. 0. 0. 1. 1. 1.]
NCT02236000,"1:17:chronic_disease,21:38:chronic_disease,57:80:treatment",Active infection or chronic infection requiring chronic suppressive antibiotics,"['Active' 'infection' 'or' 'chronic' 'infection' 'requiring' 'chronic'
 'suppressive' 'antibiotics']",[2. 2. 0. 2. 2. 0. 0. 1. 1.]
NCT02235857,"10:25:treatment,52:69:chronic_disease,78:98:chronic_disease,107:130:chronic_disease,153:185:treatment","Adequate anticoagulation cannot be achieved due to severe hemophilia, severe hemorrhage diathesis, severe gastrointestinal ulcers, or are recipients of vitamin K antagonist medications","['Adequate' 'anticoagulation' 'can' 'not' 'be' 'achieved' 'due' 'to'
 'severe' 'hemophilia' ',' 'severe' 'hemorrhage' 'diathesis' ',' 'severe'
 'gastrointestinal' 'ulcers' ',' 'or' 'are' 'recipients' 'of' 'vitamin'
 'K' 'antagonist' 'medications']","[0. 1. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 1.
 1. 1. 1.]"
NCT02235857,"1:65:treatment,100:121:chronic_disease,123:150:chronic_disease,159:177:chronic_disease,185:193:chronic_disease,202:229:chronic_disease,241:267:chronic_disease","Extracorporeal circulation therapy with Liposorber® LA-15 System cannot be tolerated due to severe cardiac insufficiency, acute myocardial infarction, severe cardiac arrhythmia, acute apoplexy, severe uncontrollable hypertension, or severe uncontrollable hypotension","['Extracorporeal' 'circulation' 'therapy' 'with' 'Liposorber®' 'LA-15'
 'System' 'can' 'not' 'be' 'tolerated' 'due' 'to' 'severe' 'cardiac'
 'insufficiency' ',' 'acute' 'myocardial' 'infarction' ',' 'severe'
 'cardiac' 'arrhythmia' ',' 'acute' 'apoplexy' ',' 'severe'
 'uncontrollable' 'hypertension' ',' 'or' 'severe' 'uncontrollable'
 'hypotension']","[1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 2. 0. 0. 0. 0.
 0. 0. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0.]"
NCT02235857,"1:30:chronic_disease,40:58:treatment,118:141:treatment,149:178:treatment,,232:240:treatment,244:261:treatment","Refractory nephrotic syndrome in which standard treatment options are unsuccessful (i.e., patient is unresponsive to standard corticosteroid and/or calcineurin inhibitor therapy for at least 8 weeks resulting in failure to achieve complete or partial remission)","['Refractory' 'nephrotic' 'syndrome' 'in' 'which' 'standard' 'treatment'
 'options' 'are' 'unsuccessful' '(' 'i.e.' ',' 'patient' 'is'
 'unresponsive' 'to' 'standard' 'corticosteroid' 'and/or' 'calcineurin'
 'inhibitor' 'therapy' 'for' 'at' 'least' '8' 'weeks' 'resulting' 'in'
 'failure' 'to' 'achieve' 'complete' 'or' 'partial' 'remission' ')']","[2. 2. 2. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0.]"
NCT02234934,"20:40:chronic_disease,42:53:chronic_disease,55:66:chronic_disease,68:71:chronic_disease,73:83:chronic_disease,85:99:chronic_disease,103:116:chronic_disease,,,165:173:treatment","Evidence of active infection with HIV-1, hepatitis B, Hepatitis C, CMV, adenovirus, parvovirus B19 or toxoplasmosis by DNA PCR within 8 weeks prior to mobilization/pheresis or bone marrow harvest","['Evidence' 'of' 'active' 'infection' 'with' 'HIV-1' ',' 'hepatitis' 'B'
 ',' 'Hepatitis' 'C' ',' 'CMV' ',' 'adenovirus' ',' 'parvovirus' 'B19'
 'or' 'toxoplasmosis' 'by' 'DNA' 'PCR' 'within' '8' 'weeks' 'prior' 'to'
 'mobilization/pheresis' 'or' 'bone' 'marrow' 'harvest']","[0. 0. 0. 2. 2. 2. 0. 2. 2. 0. 2. 2. 0. 2. 0. 2. 0. 2. 2. 0. 2. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]"
NCT02234557,"14:37:chronic_disease,39:70:chronic_disease,72:90:chronic_disease,95:101:chronic_disease","diagnosis of Intellectual Disability, Developmental Language Disorder, Reading Disability, or Autism (screened for using the Social Competence Questionnaire (SCQ)","['diagnosis' 'of' 'Intellectual' 'Disability' ',' 'Developmental'
 'Language' 'Disorder' ',' 'Reading' 'Disability' ',' 'or' 'Autism' '('
 'screened' 'for' 'using' 'the' 'Social' 'Competence' 'Questionnaire' '('
 'SCQ' ')']","[0. 0. 2. 2. 0. 2. 2. 2. 0. 2. 2. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02234193,"24:32:treatment,76:90:treatment,110:116:treatment","Willingness to undergo biopsies of full-thickness skin tissue from the pre-abdominoplasty skin, and have the biopsy sites marked by tattoos","['Willingness' 'to' 'undergo' 'biopsies' 'of' 'full-thickness' 'skin'
 'tissue' 'from' 'the' 'pre-abdominoplasty' 'skin' ',' 'and' 'have' 'the'
 'biopsy' 'sites' 'marked' 'by' 'tattoos']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02233868,"1:11:treatment,24:33:treatment,37:40:chronic_disease,61:64:treatment,80:89:treatment,91:102:treatment,104:115:treatment,117:129:treatment,132:143:treatment,170:186:treatment,201:216:treatment,241:268:treatment,270:289:treatment,295:323:treatment,326:333:treatment,335:342:treatment,344:360:treatment,362:380:treatment,493:502:treatment,504:517:treatment","antivirals (except for treatment of HSV with agents without CNS activity, e.g. acyclovir, ganciclovir, famciclovir, valacyclovir); anxiolytics; cough/cold preparations (dextromethorphan preparations, pseudoephedrine); hormones (exceptions: thyroid hormone replacement, oral contraceptives, and estrogen replacement therapy); insulin; lithium; muscle relaxants; psychotropic drugs not otherwise specified (nos) including herbal products (no drugs with psychomotor effects or with anxiolytics, stimulant, antipsychotic, or sedative properties); sedatives/hypnotics","['antivirals' '(' 'except' 'for' 'treatment' 'of' 'HSV' 'with' 'agents'
 'without' 'CNS' 'activity' ',' 'e.g' '.' 'acyclovir' ',' 'ganciclovir'
 ',' 'famciclovir' ',' 'valacyclovir' ')' ';' 'anxiolytics' ';'
 'cough/cold' 'preparations' '(' 'dextromethorphan' 'preparations' ','
 'pseudoephedrine' ')' ';' 'hormones' '(' 'exceptions' ':' 'thyroid'
 'hormone' 'replacement' ',' 'oral' 'contraceptives' ',' 'and' 'estrogen'
 'replacement' 'therapy' ')' ';' 'insulin' ';' 'lithium' ';' 'muscle'
 'relaxants' ';' 'psychotropic' 'drugs' 'not' 'otherwise' 'specified' '('
 'nos' ')' 'including' 'herbal' 'products' '(' 'no' 'drugs' 'with'
 'psychomotor' 'effects' 'or' 'with' 'anxiolytics' ',' 'stimulant' ','
 'antipsychotic' ',' 'or' 'sedative' 'properties' ')' ';'
 'sedatives/hypnotics']","[1. 0. 0. 0. 1. 0. 2. 0. 0. 0. 1. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0.
 1. 0. 0. 0. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 1. 1. 0. 0. 1.
 1. 1. 0. 0. 1. 0. 1. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0.]"
NCT02233322,"1:25:chronic_disease,32:46:chronic_disease,48:57:chronic_disease","severe end-organ disease, e.g. cardiovascular, pulmonary, etc, which may limit ability to complete study","['severe' 'end-organ' 'disease' ',' 'e.g' '.' 'cardiovascular' ','
 'pulmonary' ',' 'etc' ',' 'which' 'may' 'limit' 'ability' 'to' 'complete'
 'study']",[2. 2. 2. 0. 0. 0. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02232516,"1:18:chronic_disease,62:80:cancer,112:116:cancer",topical treatment may have been given for prior existence of cutaneous lymphoma that has since become systemic PTCL,"['topical' 'treatment' 'may' 'have' 'been' 'given' 'for' 'prior'
 'existence' 'of' 'cutaneous' 'lymphoma' 'that' 'has' 'since' 'become'
 'systemic' 'PTCL']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 3.]
NCT02231073,"1:13:chronic_disease,24:56:chronic_disease,65:95:chronic_disease,97:120:chronic_disease,122:143:chronic_disease,148:165:chronic_disease","Parkinsonism subjects: iPD and Parkinson plus syndromes such as Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Syndrome, or Cerebellar Ataxia","['Parkinsonism' 'subjects' ':' 'iPD' 'and' 'Parkinson' 'plus' 'syndromes'
 'such' 'as' 'Progressive' 'Supranuclear' 'Palsy' ',' 'Multiple' 'System'
 'Atrophy' ',' 'Corticobasal' 'Syndrome' ',' 'or' 'Cerebellar' 'Ataxia']",[2. 0. 0. 2. 2. 2. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 2. 0. 2. 2. 0. 0. 2. 2.]
NCT02229565,"15:37:treatment,79:88:treatment,92:97:treatment,101:114:treatment","Patients with prior systemic therapy will not be eligible for the study, i.e. radiation or chemo or immunotherapy","['Patients' 'with' 'prior' 'systemic' 'therapy' 'will' 'not' 'be'
 'eligible' 'for' 'the' 'study' ',' 'i.e' '.' 'radiation' 'or' 'chemo'
 'or' 'immunotherapy']",[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1.]
NCT02226341,"38:43:chronic_disease,45:52:chronic_disease,54:67:chronic_disease,69:85:chronic_disease,87:96:chronic_disease,98:105:chronic_disease,110:130:chronic_disease,338:341:chronic_disease","Severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, or neurological disease (or, in the investigator's opinion, any other concomitant medical condition that places the participant at risk by participating in this study) with the exception of diseases or conditions related to active SLE","['Severe' ',' 'progressive' ',' 'or' 'uncontrolled' 'renal' ',' 'hepatic'
 ',' 'hematological' ',' 'gastrointestinal' ',' 'pulmonary' ',' 'cardiac'
 ',' 'or' 'neurological' 'disease' '(' 'or' ',' 'in' 'the' 'investigator'
 ""'s"" 'opinion' ',' 'any' 'other' 'concomitant' 'medical' 'condition'
 'that' 'places' 'the' 'participant' 'at' 'risk' 'by' 'participating' 'in'
 'this' 'study' ')' 'with' 'the' 'exception' 'of' 'diseases' 'or'
 'conditions' 'related' 'to' 'active' 'SLE']","[0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 2. 0. 2. 0. 2. 0. 2. 0. 0. 2. 2. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]"
NCT02225548,"27:37:cancer,,74:82:cancer,86:108:cancer",Subject with a history of malignancy within the past 5 years (other than squamous or basal cell skin cancer),"['Subject' 'with' 'a' 'history' 'of' 'malignancy' 'within' 'the' 'past'
 '5' 'years' '(' 'other' 'than' 'squamous' 'or' 'basal' 'cell' 'skin'
 'cancer' ')']",[0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 3. 3. 3. 3. 0.]
NCT02225548,"23:53:chronic_disease,76:88:chronic_disease,102:114:chronic_disease,116:134:chronic_disease","Subject with a severe chronic or acute liver disease, history of moderate (Child-Pugh B), or severe (Child-Pugh C) hepatic impairment","['Subject' 'with' 'a' 'severe' 'chronic' 'or' 'acute' 'liver' 'disease'
 ',' 'history' 'of' 'moderate' '(' 'Child-Pugh' 'B' ')' ',' 'or' 'severe'
 '(' 'Child-Pugh' 'C' ')' 'hepatic' 'impairment']","[0. 0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 2. 2.]"
NCT02225548,"31:40:treatment,45:65:chronic_disease,94:109:treatment,111:125:treatment,127:147:treatment,149:159:treatment,161:183:treatment,185:189:treatment,195:242:treatment","unwilling to cease use of any treatment for erectile dysfunction during the study, including oral medication, vacuum devices, constrictive devices, injections, urethral suppositories, gels, any over-the-counter or nonprescription medications, and products purchased via the internet","['unwilling' 'to' 'cease' 'use' 'of' 'any' 'treatment' 'for' 'erectile'
 'dysfunction' 'during' 'the' 'study' ',' 'including' 'oral' 'medication'
 ',' 'vacuum' 'devices' ',' 'constrictive' 'devices' ',' 'injections' ','
 'urethral' 'suppositories' ',' 'gels' ',' 'any' 'over-the-counter' 'or'
 'nonprescription' 'medications' ',' 'and' 'products' 'purchased' 'via'
 'the' 'internet']","[0. 0. 0. 0. 0. 0. 1. 0. 2. 2. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 1. 1. 0.
 1. 0. 1. 1. 0. 1. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]"
NCT02219555,"1:21:chronic_disease,31:53:chronic_disease,65:69:chronic_disease","rheumatoid arthritis or other inflammatory arthritis, including gout","['rheumatoid' 'arthritis' 'or' 'other' 'inflammatory' 'arthritis' ','
 'including' 'gout']",[2. 2. 0. 0. 2. 2. 0. 0. 2.]
NCT02217345,"1:5:chronic_disease,34:51:chronic_disease,55:62:treatment,66:72:treatment",AFLD defined as demonstration of hepatic steatosis by imaging or biopsy in absence of significant alcohol consumption and other causes of hepatic steatosis,"['AFLD' 'defined' 'as' 'demonstration' 'of' 'hepatic' 'steatosis' 'by'
 'imaging' 'or' 'biopsy' 'in' 'absence' 'of' 'significant' 'alcohol'
 'consumption' 'and' 'other' 'causes' 'of' 'hepatic' 'steatosis']",[2. 0. 0. 0. 0. 2. 2. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02215096,"7:23:chronic_disease,34:50:treatment,54:83:treatment",Known active infection requiring intravenous (IV) or oral anti-infective treatment,"['Known' 'active' 'infection' 'requiring' 'intravenous' '(' 'IV' ')' 'or'
 'oral' 'anti-infective' 'treatment']",[0. 2. 2. 0. 1. 1. 0. 0. 0. 1. 1. 1.]
NCT02215096,"20:48:treatment,54:58:treatment,60:63:treatment,67:114:treatment","Subjects must have prior enzalutamide treatment; Any PI3K, AKT or mammalian target of rapamycin (mTOR) inhibitors","['Subjects' 'must' 'have' 'prior' 'enzalutamide' 'treatment' ';' 'Any'
 'PI3K' ',' 'AKT' 'or' 'mammalian' 'target' 'of' 'rapamycin' '(' 'mTOR'
 ')' 'inhibitors']",[0. 0. 0. 1. 1. 1. 0. 0. 1. 0. 1. 0. 1. 1. 1. 1. 1. 1. 0. 0.]
NCT02213913,"12:22:cancer,,129:153:cancer,179:196:cancer","No current malignancy. Subjects who have been free of malignancy for at least 2 years, or have a history of completely resected non-melanoma skin cancer, or successfully treated in situ carcinoma (any site) are eligible","['No' 'current' 'malignancy' '.' 'Subjects' 'who' 'have' 'been' 'free'
 'of' 'malignancy' 'for' 'at' 'least' '2' 'years' ',' 'or' 'have' 'a'
 'history' 'of' 'completely' 'resected' 'non-melanoma' 'skin' 'cancer' ','
 'or' 'successfully' 'treated' 'in' 'situ' 'carcinoma' '(' 'any' 'site'
 ')' 'are' 'eligible']","[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 3. 3. 3. 0. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0.]"
NCT02213575,"12:30:treatment,32:58:chronic_disease,60:74:chronic_disease,76:95:chronic_disease,97:117:chronic_disease,127:149:chronic_disease","history of intestinal surgery, inflammatory bowel disease, celiac disease, lactose intolerance, chronic pancreatitis or other malabsorption disorder","['history' 'of' 'intestinal' 'surgery' ',' 'inflammatory' 'bowel'
 'disease' ',' 'celiac' 'disease' ',' 'lactose' 'intolerance' ','
 'chronic' 'pancreatitis' 'or' 'other' 'malabsorption' 'disorder']",[0. 0. 1. 1. 0. 2. 2. 2. 0. 2. 2. 0. 2. 2. 0. 2. 2. 0. 0. 2. 2.]
NCT02213289,",31:47:treatment,59:71:treatment,79:91:treatment",>6 months after completion of adjuvant therapy (including chemotherapy and/or radiotherapy),"['>' '6' 'months' 'after' 'completion' 'of' 'adjuvant' 'therapy' '('
 'including' 'chemotherapy' 'and/or' 'radiotherapy' ')']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 1. 0. 1. 0.]
NCT02213289,"21:31:treatment,35:51:treatment,59:76:cancer",Must be amenable to ultrasound or CT-guided biopsy of one metastatic lesion,"['Must' 'be' 'amenable' 'to' 'ultrasound' 'or' 'CT-guided' 'biopsy' 'of'
 'one' 'metastatic' 'lesion']",[0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 3. 3.]
NCT02209636,"8:17:treatment,37:47:treatment,49:61:treatment,63:78:treatment","Active vitamin D analogue use (i.e. calcitriol, paricalcitol, doxercalciferol)","['Active' 'vitamin' 'D' 'analogue' 'use' '(' 'i.e' '.' 'calcitriol' ','
 'paricalcitol' ',' 'doxercalciferol' ')']",[0. 1. 1. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0.]
NCT02208362,"65:87:cancer,144:159:cancer,215:252:cancer,270:286:treatment","Participant has a prior histologically-confirmed diagnosis of a grade III or IV glioma, or has a prior histologically-confirmed diagnosis of a grade II glioma and now has radiographic progression consistent with a grade III or IV malignant glioma (MG) after completing standard therapy","['Participant' 'has' 'a' 'prior' 'histologically-confirmed' 'diagnosis'
 'of' 'a' 'grade' 'III' 'or' 'IV' 'glioma' ',' 'or' 'has' 'a' 'prior'
 'histologically-confirmed' 'diagnosis' 'of' 'a' 'grade' 'II' 'glioma'
 'and' 'now' 'has' 'radiographic' 'progression' 'consistent' 'with' 'a'
 'grade' 'III' 'or' 'IV' 'malignant' 'glioma' '(' 'MG' ')' 'after'
 'completing' 'standard' 'therapy']","[0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]"
NCT02207465,"15:31:chronic_disease,54:68:cancer,128:142:treatment,143:151:treatment",Short-segment venous occlusion resulting from either tumor thrombus or encasement with suitable proximal and distal vessel for reconstruction/grafting,"['Short-segment' 'venous' 'occlusion' 'resulting' 'from' 'either' 'tumor'
 'thrombus' 'or' 'encasement' 'with' 'suitable' 'proximal' 'and' 'distal'
 'vessel' 'for' 'reconstruction/grafting']",[0. 2. 2. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02207439,"10:17:treatment,25:59:chronic_disease,60:78:treatment",Previous therapy with a human immunodeficiency virus (HIV) protease inhibitor,"['Previous' 'therapy' 'with' 'a' 'human' 'immunodeficiency' 'virus' '('
 'HIV' ')' 'protease' 'inhibitor']",[0. 1. 0. 0. 2. 2. 2. 2. 0. 0. 1. 1.]
NCT02204098,",,,125:138:cancer,197:204:treatment,230:235:cancer","Clinical T2-T4c, any N, M0 invasive ER+ (Allred Score of 6-8) and HER2- (0 or 1+ by IHC or FISH negative for amplification) breast cancer by AJCC 7th edition clinical staging, with the goal being surgery to completely excise the tumor in the breast and the lymph node","['Clinical' 'T2-T4c' ',' 'any' 'N' ',' 'M0' 'invasive' 'ER+' '(' 'Allred'
 'Score' 'of' '6-8' ')' 'and' 'HER2-' '(' '0' 'or' '1+' 'by' 'IHC' 'or'
 'FISH' 'negative' 'for' 'amplification' ')' 'breast' 'cancer' 'by' 'AJCC'
 '7th' 'edition' 'clinical' 'staging' ',' 'with' 'the' 'goal' 'being'
 'surgery' 'to' 'completely' 'excise' 'the' 'tumor' 'in' 'the' 'breast'
 'and' 'the' 'lymph' 'node']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 3.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02203903,"13:15:chronic_disease,31:37:treatment,154:157:cancer,162:165:cancer,187:194:treatment","Evidence of HD by morphology, PET/CT uptake in a site of previous disease in the absence of other etiologies ARM C only includes patients with high risk AML and MDS who have received an alloBMT and have not had hematologic relapse of disease","['Evidence' 'of' 'HD' 'by' 'morphology' ',' 'PET/CT' 'uptake' 'in' 'a'
 'site' 'of' 'previous' 'disease' 'in' 'the' 'absence' 'of' 'other'
 'etiologies' 'ARM' 'C' 'only' 'includes' 'patients' 'with' 'high' 'risk'
 'AML' 'and' 'MDS' 'who' 'have' 'received' 'an' 'alloBMT' 'and' 'have'
 'not' 'had' 'hematologic' 'relapse' 'of' 'disease']","[0. 0. 2. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 3. 0. 3. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02203695,"20:37:chronic_disease,68:75:chronic_disease,77:86:chronic_disease,88:106:chronic_disease,110:130:chronic_disease,148:158:chronic_disease,170:173:chronic_disease,175:188:chronic_disease","Serious concurrent medical illnesses (including uncontrolled major cardiac, pulmonary, Child-Pugh C liver or psychiatric diseases) or active major infections (including HIV, Hepatitis A-C)","['Serious' 'concurrent' 'medical' 'illnesses' '(' 'including'
 'uncontrolled' 'major' 'cardiac' ',' 'pulmonary' ',' 'Child-Pugh' 'C'
 'liver' 'or' 'psychiatric' 'diseases' ')' 'or' 'active' 'major'
 'infections' '(' 'including' 'HIV' ',' 'Hepatitis' 'A-C' ')']","[0. 0. 2. 2. 0. 0. 0. 0. 2. 0. 2. 0. 2. 2. 2. 0. 2. 2. 0. 0. 0. 0. 2. 0.
 0. 2. 0. 2. 2. 0.]"
NCT02203552,"12:29:chronic_disease,31:44:chronic_disease,48:54:chronic_disease","History of diabetes mellitus, heart disease or stroke","['History' 'of' 'diabetes' 'mellitus' ',' 'heart' 'disease' 'or' 'stroke']",[0. 0. 2. 2. 0. 2. 2. 0. 2.]
NCT02203513,"38:48:cancer,,115:142:cancer,156:183:cancer,189:225:cancer","Another previous or current invasive malignancy within the last 2 years, with the exception of curatively treated stage Ia cervical carcinoma, or resected stage Ia endometrial cancer, and noninvasive nonmelanoma skin cancers","['Another' 'previous' 'or' 'current' 'invasive' 'malignancy' 'within'
 'the' 'last' '2' 'years' ',' 'with' 'the' 'exception' 'of' 'curatively'
 'treated' 'stage' 'Ia' 'cervical' 'carcinoma' ',' 'or' 'resected' 'stage'
 'Ia' 'endometrial' 'cancer' ',' 'and' 'noninvasive' 'nonmelanoma' 'skin'
 'cancers']","[0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3.]"
NCT02203513,"27:56:cancer,,,,129:133:cancer,156:165:treatment","Patients enrolling in the triple negative breast cancer (ER-/PR-/Her2-) group, Cohort 3, must have a negative family history of HBOC syndrome, or negative gBRCA1/2m test","['Patients' 'enrolling' 'in' 'the' 'triple' 'negative' 'breast' 'cancer'
 '(' 'ER-/PR-/Her2-' ')' 'group' ',' 'Cohort' '3' ',' 'must' 'have' 'a'
 'negative' 'family' 'history' 'of' 'HBOC' 'syndrome' ',' 'or' 'negative'
 'gBRCA1/2m' 'test']","[0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.
 0. 0. 0. 0. 1. 0.]"
NCT02203513,"12:22:treatment,24:33:treatment,38:53:treatment","The use of raloxifene, denosumab, or bisphosphonates for bone health","['The' 'use' 'of' 'raloxifene' ',' 'denosumab' ',' 'or' 'bisphosphonates'
 'for' 'bone' 'health']",[0. 0. 0. 1. 0. 1. 0. 0. 1. 0. 0. 0.]
NCT02201992,"10:19:treatment,25:35:treatment,47:60:treatment",No prior treatment with crizotinib or another ALK inhibitor,"['No' 'prior' 'treatment' 'with' 'crizotinib' 'or' 'another' 'ALK'
 'inhibitor']",[0. 0. 1. 0. 1. 0. 0. 1. 1.]
NCT02201589,"21:54:treatment,56:100:treatment,102:121:treatment,123:140:chronic_disease,144:158:chronic_disease","Patient must have a Type A thoracic aortic dissection, retrograde Type A thoracic aortic dissection, intramural hematoma, penetrating ulcer or pseudoaneurysm of the ascending thoracic aorta affecting the area between the Sinus of Valsalva and the innominate artery orifice (with no involvement of the aortic valve) and be considered candidates for endovascular repair;","['Patient' 'must' 'have' 'a' 'Type' 'A' 'thoracic' 'aortic' 'dissection'
 ',' 'retrograde' 'Type' 'A' 'thoracic' 'aortic' 'dissection' ','
 'intramural' 'hematoma' ',' 'penetrating' 'ulcer' 'or' 'pseudoaneurysm'
 'of' 'the' 'ascending' 'thoracic' 'aorta' 'affecting' 'the' 'area'
 'between' 'the' 'Sinus' 'of' 'Valsalva' 'and' 'the' 'innominate' 'artery'
 'orifice' '(' 'with' 'no' 'involvement' 'of' 'the' 'aortic' 'valve' ')'
 'and' 'be' 'considered' 'candidates' 'for' 'endovascular' 'repair' ';']","[0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 1. 1. 1. 1. 1. 1. 0. 1. 1. 0. 2. 2. 0. 2.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02200445,"10:18:treatment,23:26:chronic_disease,28:51:chronic_disease,55:58:chronic_disease","Positive serology for HIV, hepatitis B virus (HBV) or HCV","['Positive' 'serology' 'for' 'HIV' ',' 'hepatitis' 'B' 'virus' '(' 'HBV'
 ')' 'or' 'HCV']",[0. 1. 0. 2. 0. 2. 2. 2. 2. 0. 0. 0. 2.]
NCT02195232,"22:29:treatment,,45:65:treatment,67:86:treatment,88:119:treatment,,189:227:treatment,273:282:treatment,","Current daily use of aspirin (>81mg daily), Clopidogrel (Plavix), cilostazol (Pletal), aspirin-dipyridamole (Aggrenox) (within 10 days) or considered to use regular use of higher doses of non-steroidal anti-inflammatory agents as determined by the treating physician (e.g ibuprofen > 800 mg daily or equivalent)","['Current' 'daily' 'use' 'of' 'aspirin' '(' '>' '81mg' 'daily' ')' ','
 'Clopidogrel' '(' 'Plavix' ')' ',' 'cilostazol' '(' 'Pletal' ')' ','
 'aspirin-dipyridamole' '(' 'Aggrenox' ')' '(' 'within' '10' 'days' ')'
 'or' 'considered' 'to' 'use' 'regular' 'use' 'of' 'higher' 'doses' 'of'
 'non-steroidal' 'anti-inflammatory' 'agents' 'as' 'determined' 'by' 'the'
 'treating' 'physician' '(' 'e.g' 'ibuprofen' '>' '800' 'mg' 'daily' 'or'
 'equivalent' ')']","[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 1. 0. 0. 0. 1. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]"
NCT02194738,"4:20:cancer,24:41:cancer,52:68:treatment,",No locally advanced or metastatic cancer requiring systemic therapy within 5 years prior to registration,"['No' 'locally' 'advanced' 'or' 'metastatic' 'cancer' 'requiring'
 'systemic' 'therapy' 'within' '5' 'years' 'prior' 'to' 'registration']",[0. 3. 3. 0. 3. 3. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02193191,"1:8:chronic_disease,9:28:chronic_disease,29:46:chronic_disease",Medical/psychiatric illness/social situations that would limit compliance with study requirements as determined by the treating physician,"['Medical/psychiatric' 'illness/social' 'situations' 'that' 'would'
 'limit' 'compliance' 'with' 'study' 'requirements' 'as' 'determined' 'by'
 'the' 'treating' 'physician']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02192398,"16:33:treatment,16:25:treatment,77:86:treatment,90:103:treatment,110:118:treatment,120:127:treatment,170:191:treatment,209:213:chronic_disease","Currently in a treatment program for alcohol or drug abuse, or currently on methadone or buprenorphine (i.e. suboxone, subutex) for treatment of addiction, or currently prescribed stimulants for treatment of ADHD","['Currently' 'in' 'a' 'treatment' 'program' 'for' 'alcohol' 'or' 'drug'
 'abuse' ',' 'or' 'currently' 'on' 'methadone' 'or' 'buprenorphine' '('
 'i.e' '.' 'suboxone' ',' 'subutex' ')' 'for' 'treatment' 'of' 'addiction'
 ',' 'or' 'currently' 'prescribed' 'stimulants' 'for' 'treatment' 'of'
 'ADHD']","[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 1. 0. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 2.]"
NCT02192398,"7:28:chronic_disease,,89:105:chronic_disease,107:123:chronic_disease,125:138:chronic_disease,140:156:chronic_disease,161:180:chronic_disease","Major psychiatric disorders that required hospitalization in the past 6 months such as: major depression, bipolar disorder, schizophrenia, anxiety disorder, or psychotic disorders","['Major' 'psychiatric' 'disorders' 'that' 'required' 'hospitalization'
 'in' 'the' 'past' '6' 'months' 'such' 'as' ':' 'major' 'depression' ','
 'bipolar' 'disorder' ',' 'schizophrenia' ',' 'anxiety' 'disorder' ','
 'or' 'psychotic' 'disorders']","[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 2. 0. 2. 2.
 0. 0. 2. 2.]"
NCT02192359,"1:18:chronic_disease,52:67:treatment,73:88:treatment,93:105:treatment",High-grade glioma has recurred or progressed after prior treatment with brain radiation and temozolomide,"['High-grade' 'glioma' 'has' 'recurred' 'or' 'progressed' 'after' 'prior'
 'treatment' 'with' 'brain' 'radiation' 'and' 'temozolomide']",[2. 2. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 1.]
NCT02192359,"8:23:treatment,25:33:treatment,35:46:treatment,48:79:treatment,90:129:treatment,131:140:treatment,142:154:treatment,156:169:treatment,171:184:treatment,186:195:treatment,197:210:treatment,,251:260:treatment","Use of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inducers including hepatic enzyme-inducing anticonvulsants (phenytoin, fosphenytoin, carbamazepine, phenobarbital, primidone, oxcarbazepine) within 2 weeks prior to start of study treatment","['Use' 'of' 'cytochrome' 'P450' ',' 'family' '3' ',' 'subfamily' 'A' ','
 'polypeptide' '4' '(' 'CYP3A4' ')' 'inducers' 'including' 'hepatic'
 'enzyme-inducing' 'anticonvulsants' '(' 'phenytoin' ',' 'fosphenytoin'
 ',' 'carbamazepine' ',' 'phenobarbital' ',' 'primidone' ','
 'oxcarbazepine' ')' 'within' '2' 'weeks' 'prior' 'to' 'start' 'of'
 'study' 'treatment']","[0. 0. 1. 1. 0. 1. 1. 0. 1. 1. 0. 1. 1. 1. 1. 0. 0. 0. 1. 1. 1. 0. 1. 0.
 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02191488,"22:38:chronic_disease,40:49:chronic_disease,71:81:allergy_name,83:98:allergy_name,100:122:allergy_name","History of cutaneous photosensitivity, porphyria, hypersensitivity to porphyrins, photodermatosis, exfoliative dermatitis","['History' 'of' 'cutaneous' 'photosensitivity' ',' 'porphyria' ','
 'hypersensitivity' 'to' 'porphyrins' ',' 'photodermatosis' ','
 'exfoliative' 'dermatitis']",[0. 0. 0. 2. 0. 2. 0. 0. 0. 4. 0. 4. 0. 4. 4.]
NCT02191098,"21:63:chronic_disease,74:83:treatment,88:107:treatment",Active or recurrent herpes or varicella-zoster virus infection requiring treatment (or chronic suppression),"['Active' 'or' 'recurrent' 'herpes' 'or' 'varicella-zoster' 'virus'
 'infection' 'requiring' 'treatment' '(' 'or' 'chronic' 'suppression' ')']",[0. 0. 0. 2. 2. 2. 2. 2. 0. 1. 0. 0. 1. 1. 0.]
NCT02189889,"1:7:chronic_disease,11:21:chronic_disease,42:55:treatment",sepsis or bacteremia defined by positive blood culture,['sepsis' 'or' 'bacteremia' 'defined' 'by' 'positive' 'blood' 'culture'],[2. 0. 2. 0. 0. 0. 1. 1.]
NCT02188745,"62:68:treatment,73:81:treatment,86:95:treatment","Baseline radiographic staging, including specifically either PET/CT, or CT (CAP) and bone scan","['Baseline' 'radiographic' 'staging' ',' 'including' 'specifically'
 'either' 'PET/CT' ',' 'or' 'CT' '(' 'CAP' ')' 'and' 'bone' 'scan']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02188745,"13:31:treatment,36:44:cancer,45:63:cancer",One line of prior chemotherapy for advanced/metastatic disease is permissible,"['One' 'line' 'of' 'prior' 'chemotherapy' 'for' 'advanced/metastatic'
 'disease' 'is' 'permissible']",[0. 0. 0. 1. 1. 0. 3. 3. 0. 0.]
NCT02188745,"1:16:treatment,,34:44:cancer,48:72:cancer,",surgical biopsy of ≥1 site(s) of metastatic or locally advanced disease performed as standard of care within the past 4 months for assessment of eligibility for study participation (except as noted below in c/d/e),"['surgical' 'biopsy' 'of' '≥1' 'site' '(' 's' ')' 'of' 'metastatic' 'or'
 'locally' 'advanced' 'disease' 'performed' 'as' 'standard' 'of' 'care'
 'within' 'the' 'past' '4' 'months' 'for' 'assessment' 'of' 'eligibility'
 'for' 'study' 'participation' '(' 'except' 'as' 'noted' 'below' 'in'
 'c/d/e' ')']","[1. 1. 0. 0. 0. 0. 0. 0. 0. 3. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02188121,"1:14:chronic_disease,16:29:chronic_disease,39:45:treatment,50:67:treatment","renal failure, liver failure, or both statin and angiotension drug contraindications","['renal' 'failure' ',' 'liver' 'failure' ',' 'or' 'both' 'statin' 'and'
 'angiotension' 'drug' 'contraindications']",[2. 2. 0. 2. 2. 0. 0. 0. 1. 0. 1. 1. 0.]
NCT02187848,"1:19:chronic_disease,60:71:treatment,77:102:treatment,","Medical conditions requiring concomitant administration of medications with narrow therapeutic window, metabolized by cytochrome P450 (CYPs) enzymes and for which a dose reduction cannot be considered","['Medical' 'conditions' 'requiring' 'concomitant' 'administration' 'of'
 'medications' 'with' 'narrow' 'therapeutic' 'window' ',' 'metabolized'
 'by' 'cytochrome' 'P450' '(' 'CYPs' ')' 'enzymes' 'and' 'for' 'which' 'a'
 'dose' 'reduction' 'can' 'not' 'be' 'considered']","[2. 2. 0. 0. 0. 0. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02187198,"1:28:chronic_disease,39:48:chronic_disease,50:81:chronic_disease","serious psychiatric illness including psychosis, bipolar disorder with psychosis","['serious' 'psychiatric' 'illness' 'including' 'psychosis' ',' 'bipolar'
 'disorder' 'with' 'psychosis']",[2. 2. 2. 0. 2. 0. 2. 2. 2. 2.]
NCT02186418,"49:69:chronic_disease,55:69:chronic_disease,80:98:treatment,285:294:treatment,300:327:treatment","Minimum of two episodes of clinically diagnosed acute chest syndrome requiring hospital admission, or one life threatening episode of acute chest syndrome requiring ICU admission for exchange transfusion and or intubation, or frequent acute chest syndrome episodes, which necessitate treatment with chronic transfusion therapy","['Minimum' 'of' 'two' 'episodes' 'of' 'clinically' 'diagnosed' 'acute'
 'chest' 'syndrome' 'requiring' 'hospital' 'admission' ',' 'or' 'one'
 'life' 'threatening' 'episode' 'of' 'acute' 'chest' 'syndrome'
 'requiring' 'ICU' 'admission' 'for' 'exchange' 'transfusion' 'and' 'or'
 'intubation' ',' 'or' 'frequent' 'acute' 'chest' 'syndrome' 'episodes'
 ',' 'which' 'necessitate' 'treatment' 'with' 'chronic' 'transfusion'
 'therapy']","[0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 1.]"
NCT02186418,"20:23:treatment,43:63:treatment,67:78:treatment,134:146:treatment,213:219:chronic_disease","Patients with high TCD do equally well on chronic transfusions or hydroxyurea, as per a subsequent TWITCH study, where patients with elevated TCD were randomized to hydroxyurea or chronic transfusions to prevent stroke","['Patients' 'with' 'high' 'TCD' 'do' 'equally' 'well' 'on' 'chronic'
 'transfusions' 'or' 'hydroxyurea' ',' 'as' 'per' 'a' 'subsequent'
 'TWITCH' 'study' ',' 'where' 'patients' 'with' 'elevated' 'TCD' 'were'
 'randomized' 'to' 'hydroxyurea' 'or' 'chronic' 'transfusions' 'to'
 'prevent' 'stroke']","[0. 0. 0. 1. 0. 0. 0. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]"
NCT02184520,"1:24:chronic_disease,33:51:chronic_disease,53:76:chronic_disease,78:107:chronic_disease","Neuromuscular disorders such as muscular dystrophy, spinal muscular atrophy, amyotrophic lateral sclerosis, etc","['Neuromuscular' 'disorders' 'such' 'as' 'muscular' 'dystrophy' ','
 'spinal' 'muscular' 'atrophy' ',' 'amyotrophic' 'lateral' 'sclerosis' ','
 'etc']",[2. 2. 0. 0. 2. 2. 0. 2. 2. 2. 0. 2. 2. 2. 0. 0.]
NCT02181478,"1:19:treatment,24:47:cancer,51:88:cancer",Concurrent therapy for extramedullary leukemia or central nervous system (CNS) lymphoma,"['Concurrent' 'therapy' 'for' 'extramedullary' 'leukemia' 'or' 'central'
 'nervous' 'system' '(' 'CNS' ')' 'lymphoma']",[1. 1. 0. 3. 3. 0. 3. 3. 3. 3. 3. 0. 0.]
NCT02181257,"34:37:chronic_disease,114:129:treatment,131:158:chronic_disease,164:196:chronic_disease","Inherent to the diagnosis of new BOS is the exclusion of other potential causes of allograft dysfunction such as acute rejection, respiratory tract infection, and airway anastomotic complications","['Inherent' 'to' 'the' 'diagnosis' 'of' 'new' 'BOS' 'is' 'the' 'exclusion'
 'of' 'other' 'potential' 'causes' 'of' 'allograft' 'dysfunction' 'such'
 'as' 'acute' 'rejection' ',' 'respiratory' 'tract' 'infection' ',' 'and'
 'airway' 'anastomotic' 'complications']","[0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 2. 2.
 2. 0. 0. 2. 2. 2.]"
NCT02181257,"15:34:chronic_disease,36:59:chronic_disease,61:90:chronic_disease,92:111:chronic_disease,113:134:chronic_disease,136:144:chronic_disease,155:167:chronic_disease,171:187:chronic_disease,220:231:treatment","patients with lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum, albinism, or other dermatologic or ocular condition that contraindicates the use of methoxsalen or markedly enhances photosensitivity in the investigator's judgment","['patients' 'with' 'lupus' 'erythematosus' ',' 'porphyria' 'cutanea'
 'tarda' ',' 'erythropoietic' 'protoporphyria' ',' 'variegate' 'porphyria'
 ',' 'xeroderma' 'pigmentosum' ',' 'albinism' ',' 'or' 'other'
 'dermatologic' 'or' 'ocular' 'condition' 'that' 'contraindicates' 'the'
 'use' 'of' 'methoxsalen' 'or' 'markedly' 'enhances' 'photosensitivity'
 'in' 'the' 'investigator' ""'s"" 'judgment']","[0. 0. 2. 2. 0. 2. 2. 2. 0. 2. 2. 0. 2. 2. 0. 2. 2. 0. 2. 0. 0. 0. 2. 0.
 2. 2. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02179359,"14:33:chronic_disease,35:46:chronic_disease,48:71:chronic_disease,95:116:chronic_disease,129:149:treatment","Diagnosis of Sickle Cell Disease, Thalassemia, Diamond Blackfan Anemia or other non-malignant hematologic disorders for which a stem cell transplant is indicated","['Diagnosis' 'of' 'Sickle' 'Cell' 'Disease' ',' 'Thalassemia' ','
 'Diamond' 'Blackfan' 'Anemia' 'or' 'other' 'non-malignant' 'hematologic'
 'disorders' 'for' 'which' 'a' 'stem' 'cell' 'transplant' 'is' 'indicated']",[0. 0. 2. 2. 2. 0. 2. 0. 2. 2. 2. 0. 0. 0. 2. 2. 0. 0. 0. 1. 1. 1. 0. 0.]
NCT02178709,"43:55:treatment,59:73:treatment,82:91:treatment,93:106:treatment,108:121:treatment,123:131:treatment,136:145:treatment","Unable or unwilling to discontinue use of ketoconazole or St John's wort. Use of phenytoin, carbamazepine, phenobarbital, rifampin and rifabutin is discouraged, but not contraindicated","['Unable' 'or' 'unwilling' 'to' 'discontinue' 'use' 'of' 'ketoconazole'
 'or' 'St' 'John' ""'s"" 'wort' '.' 'Use' 'of' 'phenytoin' ','
 'carbamazepine' ',' 'phenobarbital' ',' 'rifampin' 'and' 'rifabutin' 'is'
 'discouraged' ',' 'but' 'not' 'contraindicated']","[0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 1. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0.
 1. 0. 0. 0. 0. 0. 0.]"
NCT02177838,"23:64:cancer,66:77:cancer,81:87:cancer","Histologically proven squamous cell carcinoma of the oropharynx, hypopharynx or larynx","['Histologically' 'proven' 'squamous' 'cell' 'carcinoma' 'of' 'the'
 'oropharynx' ',' 'hypopharynx' 'or' 'larynx']",[0. 0. 3. 3. 3. 3. 3. 3. 0. 3. 0. 3.]
NCT02177695,"37:39:treatment,43:51:treatment,56:63:treatment,67:72:treatment,",Staging scans with abdominal/pelvic CT or MRI scan and CT scan or x-ray of the chest within 56 days prior to registration,"['Staging' 'scans' 'with' 'abdominal/pelvic' 'CT' 'or' 'MRI' 'scan' 'and'
 'CT' 'scan' 'or' 'x-ray' 'of' 'the' 'chest' 'within' '56' 'days' 'prior'
 'to' 'registration']",[0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02176967,"4:22:treatment,26:38:treatment,62:75:treatment","No prior radiotherapy or chemotherapy, with the exception of dexamethasone, which is allowed","['No' 'prior' 'radiotherapy' 'or' 'chemotherapy' ',' 'with' 'the'
 'exception' 'of' 'dexamethasone' ',' 'which' 'is' 'allowed']",[0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02176161,"28:51:treatment,53:71:treatment,73:82:treatment,84:116:treatment","Current or previous use of 5α-reductase inhibitors, antiandrogen drugs, metformin, oral or injectable diabetes drug","['Current' 'or' 'previous' 'use' 'of' '5α-reductase' 'inhibitors' ','
 'antiandrogen' 'drugs' ',' 'metformin' ',' 'oral' 'or' 'injectable'
 'diabetes' 'drug']",[0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 1. 0. 1. 1. 1. 1. 1.]
NCT02174549,"48:51:cancer,88:106:treatment,110:113:treatment,127:132:cancer,,,262:302:cancer,314:334:cancer","Patients with single or multiple (2-4 nodules) HCC who are unsuitable or unwilling for surgical resection or RFA. The largest tumor nodule should be less than 10 cm in the largest diameter. The total volume of tumor cannot exceed 50% of liver; or patients with liver metastatic gastrointestinal cancer, including neuroendocrine tumor","['Patients' 'with' 'single' 'or' 'multiple' '(' '2-4' 'nodules' ')' 'HCC'
 'who' 'are' 'unsuitable' 'or' 'unwilling' 'for' 'surgical' 'resection'
 'or' 'RFA' '.' 'The' 'largest' 'tumor' 'nodule' 'should' 'be' 'less'
 'than' '10' 'cm' 'in' 'the' 'largest' 'diameter' '.' 'The' 'total'
 'volume' 'of' 'tumor' 'can' 'not' 'exceed' '50' '%' 'of' 'liver' ';' 'or'
 'patients' 'with' 'liver' 'metastatic' 'gastrointestinal' 'cancer' ','
 'including' 'neuroendocrine' 'tumor']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 0. 0. 3.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.
 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 3. 3.]"
NCT02172651,"18:38:chronic_disease,81:97:chronic_disease,111:135:chronic_disease,137:161:chronic_disease,163:181:chronic_disease,186:205:chronic_disease,206:223:chronic_disease,334:343:treatment","Any uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, may increase the risks associated with study participation or study treatment, limit compliance with study requirements, or interfere with the interpretation of study results","['Any' 'uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' ',' 'ongoing' 'or' 'active' 'infection' ',' 'symptomatic'
 'congestive' 'heart' 'failure' ',' 'unstable' 'angina' 'pectoris' ','
 'cardiac' 'arrhythmia' ',' 'or' 'psychiatric' 'illness/social'
 'situations' 'that' ',' 'in' 'the' 'opinion' 'of' 'the' 'investigator'
 ',' 'may' 'increase' 'the' 'risks' 'associated' 'with' 'study'
 'participation' 'or' 'study' 'treatment' ',' 'limit' 'compliance' 'with'
 'study' 'requirements' ',' 'or' 'interfere' 'with' 'the' 'interpretation'
 'of' 'study' 'results']","[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 2.
 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02172651,"25:59:chronic_disease,61:78:chronic_disease,92:121:chronic_disease","Known positive test for human immunodeficiency virus (HIV), hepatitis C virus, or acute or chronic hepatitis B infection","['Known' 'positive' 'test' 'for' 'human' 'immunodeficiency' 'virus' '('
 'HIV' ')' ',' 'hepatitis' 'C' 'virus' ',' 'or' 'acute' 'or' 'chronic'
 'hepatitis' 'B' 'infection']",[0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 2. 2. 2. 2.]
NCT02172651,"27:39:treatment,43:55:treatment,,,84:95:treatment,100:115:treatment",Participants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for bevacizumab) of liver resection,"['Participants' 'who' 'have' 'had' 'chemotherapy' 'or' 'radiotherapy'
 'within' '4' 'weeks' '(' '6' 'weeks' 'for' 'bevacizumab' ')' 'of' 'liver'
 'resection']",[0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 1.]
NCT02172651,"16:25:treatment,29:46:treatment,87:103:cancer",Prior systemic treatment or radiation therapy is allowed for patients with resectable liver metastases,"['Prior' 'systemic' 'treatment' 'or' 'radiation' 'therapy' 'is' 'allowed'
 'for' 'patients' 'with' 'resectable' 'liver' 'metastases']",[0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT02171429,"88:109:chronic_disease,124:132:chronic_disease,134:143:chronic_disease,147:166:chronic_disease,185:193:chronic_disease,197:216:chronic_disease,218:243:chronic_disease,245:278:chronic_disease,280:295:chronic_disease,310:336:chronic_disease","A history of or current conditions and diseases affecting the digestive tract, such as indeterminate colitis, suspicion of ischemic, radiation or microscopic colitis, Crohn's disease, fistulas or abdominal abscesses, colonic mucosal dysplasia, stricture (stenosis) of the colon, toxic megacolon, or unremoved adenomatous colonic polyps","['A' 'history' 'of' 'or' 'current' 'conditions' 'and' 'diseases'
 'affecting' 'the' 'digestive' 'tract' ',' 'such' 'as' 'indeterminate'
 'colitis' ',' 'suspicion' 'of' 'ischemic' ',' 'radiation' 'or'
 'microscopic' 'colitis' ',' 'Crohn' ""'s"" 'disease' ',' 'fistulas' 'or'
 'abdominal' 'abscesses' ',' 'colonic' 'mucosal' 'dysplasia' ','
 'stricture' '(' 'stenosis' ')' 'of' 'the' 'colon' ',' 'toxic' 'megacolon'
 ',' 'or' 'unremoved' 'adenomatous' 'colonic' 'polyps']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 0. 2. 0.
 2. 2. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 2. 2. 2. 0. 2. 2. 2. 2. 2. 0. 0. 0.
 2. 2. 0. 0. 0. 2. 2. 2.]"
NCT02171429,"22:46:chronic_disease,72:82:chronic_disease,104:120:chronic_disease,125:141:treatment","History of active or latent tuberculosis (TB), recurrent opportunistic infections, severe disseminated viral infections and organ transplant","['History' 'of' 'active' 'or' 'latent' 'tuberculosis' '(' 'TB' ')' ','
 'recurrent' 'opportunistic' 'infections' ',' 'severe' 'disseminated'
 'viral' 'infections' 'and' 'organ' 'transplant']",[0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 2. 0. 0. 0. 2. 2. 0. 1. 1.]
NCT02169830,"1:14:treatment,16:50:treatment,59:69:treatment",Nortriptyline: monoamine oxidase inhibitors (MAO) such as phenelzine,"['Nortriptyline' ':' 'monoamine' 'oxidase' 'inhibitors' '(' 'MAO' ')'
 'such' 'as' 'phenelzine']",[1. 0. 1. 1. 1. 1. 0. 0. 0. 0. 1.]
NCT02169739,"23:39:chronic_disease,46:69:treatment,79:101:chronic_disease","Known history of limb vascular disease, limb vascular bypass surgery, or limb deep venous thrombosis","['Known' 'history' 'of' 'limb' 'vascular' 'disease' ',' 'limb' 'vascular'
 'bypass' 'surgery' ',' 'or' 'limb' 'deep' 'venous' 'thrombosis']",[0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT02169739,"7:15:chronic_disease,19:33:chronic_disease,69:81:treatment",Prior cortical or retinal stroke (diagnosed either clinically or by neuroimaging),"['Prior' 'cortical' 'or' 'retinal' 'stroke' '(' 'diagnosed' 'either'
 'clinically' 'or' 'by' 'neuroimaging' ')']",[0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02169089,"18:28:cancer,39:47:cancer,52:60:cancer",History of prior malignancy including leukemia and lymphoma,"['History' 'of' 'prior' 'malignancy' 'including' 'leukemia' 'and'
 'lymphoma']",[0. 0. 0. 3. 0. 3. 0. 3.]
NCT02169037,"1:19:treatment,21:39:treatment,41:77:treatment","ASD closure device, LAA closure device, prosthetic mitral or tricuspid valve","['ASD' 'closure' 'device' ',' 'LAA' 'closure' 'device' ',' 'prosthetic'
 'mitral' 'or' 'tricuspid' 'valve']",[1. 1. 1. 0. 1. 1. 1. 0. 1. 1. 1. 1. 1.]
NCT02169037,"19:42:chronic_disease,44:50:chronic_disease,54:57:chronic_disease,,",history of recent cerebrovascular disease (stroke or TIA) or systemic thromboembolism within < 6 months,"['history' 'of' 'recent' 'cerebrovascular' 'disease' '(' 'stroke' 'or'
 'TIA' ')' 'or' 'systemic' 'thromboembolism' 'within' '<' '6' 'months']",[0. 0. 0. 2. 2. 0. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02169037,",71:106:chronic_disease,,,187:198:treatment,202:218:treatment",reported incidence of at least two documented episodes of symptomatic paroxysmal atrial fibrillation (AF) during the three months preceding trial entry (at least 1 episode documented by 12-lead ECG or ECG rhythm strip),"['reported' 'incidence' 'of' 'at' 'least' 'two' 'documented' 'episodes'
 'of' 'symptomatic' 'paroxysmal' 'atrial' 'fibrillation' '(' 'AF' ')'
 'during' 'the' 'three' 'months' 'preceding' 'trial' 'entry' '(' 'at'
 'least' '1' 'episode' 'documented' 'by' '12-lead' 'ECG' 'or' 'ECG'
 'rhythm' 'strip' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0.]"
NCT02167022,"1:19:chronic_disease,59:83:treatment,177:186:chronic_disease,255:261:cancer,263:278:chronic_disease","Medical conditions that may prevent the administration of rehabilitation therapies at the intensity required by the study, or that may compromise the study ability to maintain blindness, or that have a co-morbidity not typically associated with CP (i.e. cancer, cystic fibrosis)","['Medical' 'conditions' 'that' 'may' 'prevent' 'the' 'administration' 'of'
 'rehabilitation' 'therapies' 'at' 'the' 'intensity' 'required' 'by' 'the'
 'study' ',' 'or' 'that' 'may' 'compromise' 'the' 'study' 'ability' 'to'
 'maintain' 'blindness' ',' 'or' 'that' 'have' 'a' 'co-morbidity' 'not'
 'typically' 'associated' 'with' 'CP' '(' 'i.e' '.' 'cancer' ',' 'cystic'
 'fibrosis' ')']","[2. 2. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 2. 2. 0.]"
NCT02166905,"1:13:treatment,15:32:treatment,37:50:treatment,,91:101:treatment,,115:127:treatment","Chemotherapy, radiation therapy, or immunotherapy within 4 weeks prior to first dosing of study drug (6 weeks for nitrosoureas)","['Chemotherapy' ',' 'radiation' 'therapy' ',' 'or' 'immunotherapy'
 'within' '4' 'weeks' 'prior' 'to' 'first' 'dosing' 'of' 'study' 'drug'
 '(' '6' 'weeks' 'for' 'nitrosoureas' ')']",[1. 0. 1. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 0.]
NCT02166905,"7:24:chronic_disease,32:50:chronic_disease,61:72:treatment,74:92:chronic_disease","Other serious illnesses (e.g., serious infections requiring antibiotics, bleeding disorders)","['Other' 'serious' 'illnesses' '(' 'e.g.' ',' 'serious' 'infections'
 'requiring' 'antibiotics' ',' 'bleeding' 'disorders' ')']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 1. 0. 2. 2. 0.]
NCT02166905,"8:35:treatment,46:79:treatment,91:101:treatment,103:113:treatment,119:131:treatment","Use of UDP glucuronosyltransferase 1 family, polypeptide A9 (UGT1A9) inhibitor including: diclofenac, imipramine, and ketoconazole","['Use' 'of' 'UDP' 'glucuronosyltransferase' '1' 'family' ',' 'polypeptide'
 'A9' '(' 'UGT1A9' ')' 'inhibitor' 'including' ':' 'diclofenac' ','
 'imipramine' ',' 'and' 'ketoconazole']",[0. 0. 1. 1. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 1. 0. 1. 0. 0. 1.]
NCT02165007,"10:18:chronic_disease,22:31:chronic_disease,35:47:treatment,41:47:treatment,81:108:treatment,,,",bridging fibrosis or cirrhosis on liver biopsy (biopsy required for patients on chronic transfusion therapy for > 1 year and evidence of iron overload with ferritin >1000 ng/mL),"['bridging' 'fibrosis' 'or' 'cirrhosis' 'on' 'liver' 'biopsy' '(' 'biopsy'
 'required' 'for' 'patients' 'on' 'chronic' 'transfusion' 'therapy' 'for'
 '>' '1' 'year' 'and' 'evidence' 'of' 'iron' 'overload' 'with' 'ferritin'
 '>' '1000' 'ng/mL' ')']","[0. 2. 0. 2. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02163434,"35:57:treatment,69:83:treatment,85:91:treatment,,104:114:treatment,116:125:treatment,129:149:treatment,151:167:treatment,169:180:treatment,182:190:treatment,195:206:treatment,","Agrees to discontinue any current anti-emetic treatments (including antihistamines, ginger, > 10mg/day vitamin B6, serotonin or dopamine antagonists, anticholinergics, acupuncture, hypnosis, or wrist bands) for the next 4 weeks","['Agrees' 'to' 'discontinue' 'any' 'current' 'anti-emetic' 'treatments'
 '(' 'including' 'antihistamines' ',' 'ginger' ',' '>' '10mg/day'
 'vitamin' 'B6' ',' 'serotonin' 'or' 'dopamine' 'antagonists' ','
 'anticholinergics' ',' 'acupuncture' ',' 'hypnosis' ',' 'or' 'wrist'
 'bands' ')' 'for' 'the' 'next' '4' 'weeks']","[0. 0. 0. 0. 0. 1. 1. 0. 0. 1. 0. 1. 0. 0. 0. 1. 1. 0. 1. 0. 1. 1. 0. 1.
 0. 1. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]"
NCT02163317,"1:25:treatment,27:40:treatment,43:54:treatment,59:99:treatment,104:119:cancer","Previous radical surgery (prostatectomy), cryosurgery, or high intensity focused ultrasound (HIFU) for prostate cancer","['Previous' 'radical' 'surgery' '(' 'prostatectomy' ')' ',' 'cryosurgery'
 ',' 'or' 'high' 'intensity' 'focused' 'ultrasound' '(' 'HIFU' ')' 'for'
 'prostate' 'cancer']",[1. 1. 1. 0. 1. 0. 0. 1. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 3. 3.]
NCT02162511,"49:75:treatment,163:179:treatment,184:209:treatment",Participant's medical screening clears s/he for allogeneic transplantation as per current institutional SOP based on standards of foundation for accreditation of cellular therapy and stem cell transplantation (FACT),"['Participant' ""'s"" 'medical' 'screening' 'clears' 's/he' 'for'
 'allogeneic' 'transplantation' 'as' 'per' 'current' 'institutional' 'SOP'
 'based' 'on' 'standards' 'of' 'foundation' 'for' 'accreditation' 'of'
 'cellular' 'therapy' 'and' 'stem' 'cell' 'transplantation' '(' 'FACT' ')']","[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.
 0. 1. 1. 1. 0. 0. 0.]"
NCT02159703,"39:62:cancer,70:80:cancer,93:105:cancer,","Histologically confirmed diagnosis of squamous cell carcinoma of the oropharynx, stage IVa, p16-positive on immunohistochemistry","['Histologically' 'confirmed' 'diagnosis' 'of' 'squamous' 'cell'
 'carcinoma' 'of' 'the' 'oropharynx' ',' 'stage' 'IVa' ',' 'p16-positive'
 'on' 'immunohistochemistry']",[0. 0. 0. 0. 3. 3. 3. 0. 0. 3. 0. 0. 0. 0. 3. 0. 0.]
NCT02159495,"22:40:treatment,42:55:treatment,59:68:treatment,","His/her last dose of prior chemotherapy, immunotherapy or radiation is at least 2 weeks out from PBMC collection","['His/her' 'last' 'dose' 'of' 'prior' 'chemotherapy' ',' 'immunotherapy'
 'or' 'radiation' 'is' 'at' 'least' '2' 'weeks' 'out' 'from' 'PBMC'
 'collection']",[0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02159495,"19:22:cancer,37:61:cancer,,112:134:treatment","for patients with AML evolving from myelodysplastic syndrome, they should have completed at least one cycle of induction chemotherapy","['for' 'patients' 'with' 'AML' 'evolving' 'from' 'myelodysplastic'
 'syndrome' ',' 'they' 'should' 'have' 'completed' 'at' 'least' 'one'
 'cycle' 'of' 'induction' 'chemotherapy']",[0. 0. 0. 3. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02159027,"1:18:chronic_disease,29:40:chronic_disease,42:51:chronic_disease,57:76:chronic_disease,81:97:chronic_disease,128:136:chronic_disease,140:162:chronic_disease,206:218:treatment,222:240:treatment","Chronic illnesses including hematologic, pulmonary, and autoimmune diseases and endocrinopathies, except for stable controlled diabetes or cardiovascular disease in the view of the investigator and stable testosterone or thyroid medication use","['Chronic' 'illnesses' 'including' 'hematologic' ',' 'pulmonary' ',' 'and'
 'autoimmune' 'diseases' 'and' 'endocrinopathies' ',' 'except' 'for'
 'stable' 'controlled' 'diabetes' 'or' 'cardiovascular' 'disease' 'in'
 'the' 'view' 'of' 'the' 'investigator' 'and' 'stable' 'testosterone' 'or'
 'thyroid' 'medication' 'use']","[2. 2. 0. 2. 0. 2. 0. 0. 2. 2. 0. 2. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 0. 1. 1. 0.]"
NCT02158793,"19:37:chronic_disease,51:79:chronic_disease,91:121:chronic_disease",Subjects with any cognitive deficits related to a TBI (traumatic brain injury) and or any organic neurological disorders will not be considered for this protocol,"['Subjects' 'with' 'any' 'cognitive' 'deficits' 'related' 'to' 'a' 'TBI'
 '(' 'traumatic' 'brain' 'injury' ')' 'and' 'or' 'any' 'organic'
 'neurological' 'disorders' 'will' 'not' 'be' 'considered' 'for' 'this'
 'protocol']","[0. 0. 0. 2. 2. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02153229,"22:38:cancer,51:54:cancer,80:89:treatment,98:126:cancer,128:147:cancer,151:166:cancer,184:199:cancer","Patients with active invasive cancers, other than MPM, that require additional treatment, except non-melanomatous skin cancer, superficial bladder or cervical cancer, and early-stage prostate cancer","['Patients' 'with' 'active' 'invasive' 'cancers' ',' 'other' 'than' 'MPM'
 ',' 'that' 'require' 'additional' 'treatment' ',' 'except'
 'non-melanomatous' 'skin' 'cancer' ',' 'superficial' 'bladder' 'or'
 'cervical' 'cancer' ',' 'and' 'early-stage' 'prostate' 'cancer']","[0. 0. 0. 3. 3. 0. 0. 0. 3. 0. 0. 0. 0. 1. 0. 0. 3. 3. 3. 0. 3. 3. 0. 3.
 3. 0. 0. 0. 3. 3.]"
NCT02152995,"26:31:cancer,48:62:cancer,74:84:cancer",Availability of archival tumor tissue from the thyroid cancer primary or metastasis (a tissue block or a minimum of 30 unstained slides would be required; patients with less archival tissue available may still be eligible for the study after discussion with the MSK principal investigator),"['Availability' 'of' 'archival' 'tumor' 'tissue' 'from' 'the' 'thyroid'
 'cancer' 'primary' 'or' 'metastasis' '(' 'a' 'tissue' 'block' 'or' 'a'
 'minimum' 'of' '30' 'unstained' 'slides' 'would' 'be' 'required' ';'
 'patients' 'with' 'less' 'archival' 'tissue' 'available' 'may' 'still'
 'be' 'eligible' 'for' 'the' 'study' 'after' 'discussion' 'with' 'the'
 'MSK' 'principal' 'investigator' ')']","[0. 0. 0. 3. 0. 0. 0. 3. 3. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02152995,"4:16:treatment,9:16:treatment,20:36:treatment,44:69:treatment,","No chemotherapy or targeted therapy (e.g., tyrosine kinase inhibitor) is allowed < 4 weeks prior to the initiation of therapy on this protocol","['No' 'chemotherapy' 'or' 'targeted' 'therapy' '(' 'e.g.' ',' 'tyrosine'
 'kinase' 'inhibitor' ')' 'is' 'allowed' '<' '4' 'weeks' 'prior' 'to'
 'the' 'initiation' 'of' 'therapy' 'on' 'this' 'protocol']","[0. 1. 0. 1. 1. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02152995,"20:23:chronic_disease,28:31:chronic_disease,32:41:chronic_disease",chronic or cleared HBV and HCV infection,['chronic' 'or' 'cleared' 'HBV' 'and' 'HCV' 'infection'],[0. 0. 0. 2. 0. 2. 2.]
NCT02152254,"26:38:treatment,40:47:treatment,52:64:treatment,,127:136:treatment,150:161:treatment,165:186:treatment","The patient has received chemotherapy, surgery, or radiotherapy (for therapeutic purposes) within 3 weeks of initiating study treatment (4 weeks for bevacizumab or investigational drugs)","['The' 'patient' 'has' 'received' 'chemotherapy' ',' 'surgery' ',' 'or'
 'radiotherapy' '(' 'for' 'therapeutic' 'purposes' ')' 'within' '3'
 'weeks' 'of' 'initiating' 'study' 'treatment' '(' '4' 'weeks' 'for'
 'bevacizumab' 'or' 'investigational' 'drugs' ')']","[0. 0. 0. 0. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.
 0. 0. 1. 0. 1. 1. 0.]"
NCT02151175,"34:86:treatment,90:99:treatment,104:114:treatment,115:134:chronic_disease",Subjects who have been offered a non-dominant anterior-mesial temporal lobe resection as treatment for medication refractory epilepsy,"['Subjects' 'who' 'have' 'been' 'offered' 'a' 'non-dominant'
 'anterior-mesial' 'temporal' 'lobe' 'resection' 'as' 'treatment' 'for'
 'medication' 'refractory' 'epilepsy']",[0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 1. 0. 1. 2. 2.]
NCT02150967,",67:78:treatment,95:104:treatment,119:129:cancer",Patients must have received at least one prior regimen containing gemcitabine with or without cisplatin for advanced/ metastatic disease,"['Patients' 'must' 'have' 'received' 'at' 'least' 'one' 'prior' 'regimen'
 'containing' 'gemcitabine' 'with' 'or' 'without' 'cisplatin' 'for'
 'advanced/' 'metastatic' 'disease']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 1. 0. 0. 3. 0.]
NCT02148003,"27:37:chronic_disease,39:51:chronic_disease,55:73:chronic_disease","Psychopathology including depression, somatization or poor coping skills","['Psychopathology' 'including' 'depression' ',' 'somatization' 'or' 'poor'
 'coping' 'skills']",[0. 0. 2. 0. 2. 0. 2. 2. 2.]
NCT02146924,"39:52:treatment,146:177:treatment,189:229:treatment","If research participant is undergoing leukapheresis and the research participant has undergone prior alloSCT, two months must have elapsed since allogeneic stem cell transplant to undergo PBMC collection for T cell manufacturing","['If' 'research' 'participant' 'is' 'undergoing' 'leukapheresis' 'and'
 'the' 'research' 'participant' 'has' 'undergone' 'prior' 'alloSCT' ','
 'two' 'months' 'must' 'have' 'elapsed' 'since' 'allogeneic' 'stem' 'cell'
 'transplant' 'to' 'undergo' 'PBMC' 'collection' 'for' 'T' 'cell'
 'manufacturing']","[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.
 1. 0. 0. 1. 1. 1. 1. 1. 1.]"
NCT02146924,"43:65:treatment,70:91:treatment,93:105:treatment,110:127:treatment","Research participants receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy","['Research' 'participants' 'receiving' 'any' 'other' 'investigational'
 'agents' ',' 'or' 'concurrent' 'biological' ',' 'chemotherapy' ',' 'or'
 'radiation' 'therapy']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 1. 1. 0. 1. 0. 0. 1. 1.]
NCT02145351,"1:16:treatment,21:23:chronic_disease,29:54:treatment,58:72:treatment",Acute treatment for HF with intravenous loop diuretic or hemofiltration,"['Acute' 'treatment' 'for' 'HF' 'with' 'intravenous' 'loop' 'diuretic'
 'or' 'hemofiltration']",[1. 1. 0. 2. 0. 1. 1. 1. 0. 1.]
NCT02143726,"17:26:treatment,33:69:treatment,81:113:treatment,117:150:treatment,159:168:treatment,172:186:cancer",No prior use of sorafenib or an mammalian target of rapamycin (mTOR) (including phosphoinositide 3-kinase [PI3k] or protein kinase B [AKT]) inhibitor for the treatment of thyroid cancer,"['No' 'prior' 'use' 'of' 'sorafenib' 'or' 'an' 'mammalian' 'target' 'of'
 'rapamycin' '(' 'mTOR' ')' '(' 'including' 'phosphoinositide' '3-kinase'
 '[' 'PI3k' ']' 'or' 'protein' 'kinase' 'B' '[' 'AKT' ']' ')' 'inhibitor'
 'for' 'the' 'treatment' 'of' 'thyroid' 'cancer']","[0. 0. 0. 0. 1. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 1. 1.
 1. 1. 1. 0. 0. 0. 0. 0. 1. 0. 3. 3.]"
NCT02143050,"10:22:treatment,27:42:chronic_disease,,88:97:treatment",Received radiotherapy for non CNS disease within the 2 weeks prior to commencing study treatment,"['Received' 'radiotherapy' 'for' 'non' 'CNS' 'disease' 'within' 'the' '2'
 'weeks' 'prior' 'to' 'commencing' 'study' 'treatment']",[0. 1. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02140554,"26:66:chronic_disease,68:73:chronic_disease,78:83:chronic_disease,86:109:chronic_disease,114:131:chronic_disease","Positive for presence of human immunodeficiency virus type 1 or 2 (HIV-1 and HIV-2), hepatitis B virus (HBV), or hepatitis C (HCV)","['Positive' 'for' 'presence' 'of' 'human' 'immunodeficiency' 'virus'
 'type' '1' 'or' '2' '(' 'HIV-1' 'and' 'HIV-2' ')' ',' 'hepatitis' 'B'
 'virus' '(' 'HBV' ')' ',' 'or' 'hepatitis' 'C' '(' 'HCV' ')']","[0. 0. 0. 0. 2. 2. 2. 2. 2. 2. 2. 0. 2. 0. 2. 0. 0. 2. 2. 2. 2. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02139280,"1:16:treatment,21:52:treatment,45:52:treatment,",Prior Treatment: No previous cytotoxic chemotherapy within 4 weeks prior to initiation of therapy,"['Prior' 'Treatment' ':' 'No' 'previous' 'cytotoxic' 'chemotherapy'
 'within' '4' 'weeks' 'prior' 'to' 'initiation' 'of' 'therapy']",[1. 1. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02138617,"1:25:treatment,27:38:treatment,55:71:chronic_disease,,105:137:treatment,166:190:treatment","Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 of FOLFIRI + bevacizumab initiation or anticipation of need for major surgical procedure during the course of the study","['Major' 'surgical' 'procedure' ',' 'open' 'biopsy' ',' 'or' 'significant'
 'traumatic' 'injury' 'within' '28' 'days' 'prior' 'to' 'Day' '1' 'of'
 'FOLFIRI' '+' 'bevacizumab' 'initiation' 'or' 'anticipation' 'of' 'need'
 'for' 'major' 'surgical' 'procedure' 'during' 'the' 'course' 'of' 'the'
 'study']","[1. 1. 1. 0. 1. 1. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0.
 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0.]"
NCT02138617,"16:38:treatment,,72:79:treatment,82:93:treatment","placement of a vascular access device, within 7 days prior to Day 1 of FOLFIRI + bevacizumab initiation","['placement' 'of' 'a' 'vascular' 'access' 'device' ',' 'within' '7' 'days'
 'prior' 'to' 'Day' '1' 'of' 'FOLFIRI' '+' 'bevacizumab' 'initiation']",[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0.]
NCT02135588,"1:17:chronic_disease,32:38:chronic_disease,43:55:chronic_disease","Major hemorrhage, coincidental stroke, or major trauma","['Major' 'hemorrhage' ',' 'coincidental' 'stroke' ',' 'or' 'major'
 'trauma']",[2. 2. 0. 0. 2. 0. 0. 2. 2.]
NCT02134392,"15:51:treatment,53:75:treatment,77:102:treatment,104:121:treatment","Recent use of potent immunosuppressive medications (calcineurin inhibitors, exogenous glucocorticoids, biological agents, etc..)","['Recent' 'use' 'of' 'potent' 'immunosuppressive' 'medications' '('
 'calcineurin' 'inhibitors' ',' 'exogenous' 'glucocorticoids' ','
 'biological' 'agents' ',' 'etc' '..' ')']",[0. 0. 0. 1. 1. 1. 0. 1. 1. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0.]
NCT02133573,"30:41:treatment,65:77:treatment,84:97:treatment,99:108:treatment,110:122:treatment,126:137:treatment","Prescription or ingestion of medications known to interact with progesterone (e.g. Bromocriptine, Rifamycin, Ketoconazole or Cyclosporin)","['Prescription' 'or' 'ingestion' 'of' 'medications' 'known' 'to'
 'interact' 'with' 'progesterone' '(' 'e.g' '.' 'Bromocriptine' ','
 'Rifamycin' ',' 'Ketoconazole' 'or' 'Cyclosporin' ')']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 1. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0.]
NCT02132598,"1:27:chronic_disease,78:89:chronic_disease,93:110:chronic_disease",Gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation,"['Gastrointestinal' 'disorders' 'particularly' 'those' 'associated' 'with'
 'a' 'high' 'risk' 'of' 'perforation' 'or' 'fistula' 'formation']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2.]
NCT02132598,"54:70:chronic_disease,84:93:treatment,97:135:treatment",Patients must have received at least one regimen for systemic disease which may be cytotoxic or oral tyrosine kinase inhibitor therapy,"['Patients' 'must' 'have' 'received' 'at' 'least' 'one' 'regimen' 'for'
 'systemic' 'disease' 'which' 'may' 'be' 'cytotoxic' 'or' 'oral'
 'tyrosine' 'kinase' 'inhibitor' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 1. 0. 1. 1. 1. 1. 1.]
NCT02132598,"1:26:chronic_disease,27:32:chronic_disease,,93:102:treatment",Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment,"['Serious' 'non-healing' 'wound/ulcer/bone' 'fracture' 'within' '28'
 'days' 'before' 'the' 'first' 'dose' 'of' 'study' 'treatment']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02132598,",67:76:treatment,88:98:cancer,114:132:treatment",The subject has had evidence within 2 years of the start of study treatment of another malignancy which required systemic treatment,"['The' 'subject' 'has' 'had' 'evidence' 'within' '2' 'years' 'of' 'the'
 'start' 'of' 'study' 'treatment' 'of' 'another' 'malignancy' 'which'
 'required' 'systemic' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 3. 0. 0. 1. 1.]
NCT02132598,"38:61:treatment,63:86:treatment,91:126:treatment,121:125:treatment,176:193:treatment,","The subject is receiving concomitant treatment with warfarin, warfarin-related agents, or low molecular weight heparin (LMWH) at the time of study entry at therapeutic doses. Low-dose warfarin (≤ 1 mg/day) or LMWH at prophylactic doses","['The' 'subject' 'is' 'receiving' 'concomitant' 'treatment' 'with'
 'warfarin' ',' 'warfarin-related' 'agents' ',' 'or' 'low' 'molecular'
 'weight' 'heparin' '(' 'LMWH' ')' 'at' 'the' 'time' 'of' 'study' 'entry'
 'at' 'therapeutic' 'doses' '.' 'Low-dose' 'warfarin' '(' '≤' '1' 'mg/day'
 ')' 'or' 'LMWH' 'at' 'prophylactic' 'doses']","[0. 0. 0. 0. 0. 1. 1. 1. 0. 1. 1. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02132130,"33:47:chronic_disease,49:62:chronic_disease,64:93:chronic_disease,128:144:treatment,148:165:treatment","Any otological history, such as chronic otitis, cholesteatoma, tympanic membrane perforation, that suggests poor candidacy for cochlear implant or inner ear surgery or suggests potential interference with study auditory or vestibular function tests","['Any' 'otological' 'history' ',' 'such' 'as' 'chronic' 'otitis' ','
 'cholesteatoma' ',' 'tympanic' 'membrane' 'perforation' ',' 'that'
 'suggests' 'poor' 'candidacy' 'for' 'cochlear' 'implant' 'or' 'inner'
 'ear' 'surgery' 'or' 'suggests' 'potential' 'interference' 'with' 'study'
 'auditory' 'or' 'vestibular' 'function' 'tests']","[0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1.
 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02131805,"55:64:treatment,66:81:treatment,85:99:treatment",Receipt of drug that will affect biologic response to radiation (radiosensitizer or radioprotector),"['Receipt' 'of' 'drug' 'that' 'will' 'affect' 'biologic' 'response' 'to'
 'radiation' '(' 'radiosensitizer' 'or' 'radioprotector' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0.]
NCT02131597,"16:31:cancer,169:185:treatment,210:231:treatment",organ-confined prostate cancer with no evidence of recurrent or progressive disease based on prostate-specific antigen (PSA) values are also eligible for this study if hormonal therapy has been initiated or a radical prostatectomy has been performed,"['organ-confined' 'prostate' 'cancer' 'with' 'no' 'evidence' 'of'
 'recurrent' 'or' 'progressive' 'disease' 'based' 'on' 'prostate-specific'
 'antigen' '(' 'PSA' ')' 'values' 'are' 'also' 'eligible' 'for' 'this'
 'study' 'if' 'hormonal' 'therapy' 'has' 'been' 'initiated' 'or' 'a'
 'radical' 'prostatectomy' 'has' 'been' 'performed']","[0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.]"
NCT02131467,"27:50:treatment,,86:102:treatment,104:112:treatment,118:129:treatment,140:155:treatment","Subjects may be on stable anti-dystonia treatment (for at least one month) including anticholinergics, baclofen, and anxiolytics including benzodiazepines","['Subjects' 'may' 'be' 'on' 'stable' 'anti-dystonia' 'treatment' '(' 'for'
 'at' 'least' 'one' 'month' ')' 'including' 'anticholinergics' ','
 'baclofen' ',' 'and' 'anxiolytics' 'including' 'benzodiazepines']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 1. 0. 1.]
NCT02131389,"15:38:treatment,51:55:treatment,57:89:treatment",Has undergone partial hip replacement or previous ORIF (open reduction internal fixation of femur or acetabulum),"['Has' 'undergone' 'partial' 'hip' 'replacement' 'or' 'previous' 'ORIF'
 '(' 'open' 'reduction' 'internal' 'fixation' 'of' 'femur' 'or'
 'acetabulum' ')']",[0. 0. 1. 1. 1. 0. 0. 1. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02129348,"22:29:treatment,76:97:chronic_disease,145:160:chronic_disease","Contraindications to lithium in this study include: resting tremor causing functional impairment, history of falls in the last month, untreated thyroid disease or any abnormal thyroid function test (T3, T4, or TSH)","['Contraindications' 'to' 'lithium' 'in' 'this' 'study' 'include' ':'
 'resting' 'tremor' 'causing' 'functional' 'impairment' ',' 'history' 'of'
 'falls' 'in' 'the' 'last' 'month' ',' 'untreated' 'thyroid' 'disease'
 'or' 'any' 'abnormal' 'thyroid' 'function' 'test' '(' 'T3' ',' 'T4' ','
 'or' 'TSH' ')']","[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.
 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02128906,"48:64:chronic_disease,66:87:chronic_disease,89:114:chronic_disease","No uncontrolled intercurrent illness including active infection, uncontrolled diabetes, uncontrolled hypertension","['No' 'uncontrolled' 'intercurrent' 'illness' 'including' 'active'
 'infection' ',' 'uncontrolled' 'diabetes' ',' 'uncontrolled'
 'hypertension']",[0. 2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02128906,"15:19:cancer,21:23:cancer,25:27:cancer,52:69:cancer","patients with T1-2, N0, M0 resected differentiated thyroid carcinoma, who are eligible","['patients' 'with' 'T1-2' ',' 'N0' ',' 'M0' 'resected' 'differentiated'
 'thyroid' 'carcinoma' ',' 'who' 'are' 'eligible']",[0. 0. 3. 0. 3. 0. 3. 0. 0. 3. 3. 0. 0. 0. 0.]
NCT02124902,",,42:55:cancer,70:87:treatment,115:139:treatment,147:156:treatment",Newly diagnosed clinical stage II or III breast cancer with complete surgical excision of the breast cancer after neoadjuvant chemotherapy as the treatment goal,"['Newly' 'diagnosed' 'clinical' 'stage' 'II' 'or' 'III' 'breast' 'cancer'
 'with' 'complete' 'surgical' 'excision' 'of' 'the' 'breast' 'cancer'
 'after' 'neoadjuvant' 'chemotherapy' 'as' 'the' 'treatment' 'goal']",[0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 1. 0. 0. 1. 0.]
NCT02124772,"19:31:cancer,53:88:cancer,108:131:cancer,171:185:cancer,189:205:cancer,209:232:chronic_disease",For subjects with solid tumors that are not primary central nervous system (CNS) tumors or NF-1 associated plexiform neurofibromas subjects with symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression,"['For' 'subjects' 'with' 'solid' 'tumors' 'that' 'are' 'not' 'primary'
 'central' 'nervous' 'system' '(' 'CNS' ')' 'tumors' 'or' 'NF-1'
 'associated' 'plexiform' 'neurofibromas' 'subjects' 'with' 'symptomatic'
 'or' 'untreated' 'leptomeningeal' 'or' 'brain' 'metastases' 'or' 'spinal'
 'cord' 'compression']","[0. 0. 0. 3. 3. 0. 0. 0. 0. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0.
 0. 0. 3. 0. 3. 3. 0. 2. 2. 2.]"
NCT02124772,"33:67:treatment,75:89:treatment,91:101:treatment,113:126:treatment,135:182:treatment","Part B, Part C and Part D only: Previous treatment with dabrafenib or any BRAF inhibitor, trametinib or another MEK inhibitor, or and Extracellular signal-regulated kinase inhibitor","['Part' 'B' ',' 'Part' 'C' 'and' 'Part' 'D' 'only' ':' 'Previous'
 'treatment' 'with' 'dabrafenib' 'or' 'any' 'BRAF' 'inhibitor' ','
 'trametinib' 'or' 'another' 'MEK' 'inhibitor' ',' 'or' 'and'
 'Extracellular' 'signal-regulated' 'kinase' 'inhibitor']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 1. 1. 0. 1. 0. 0. 1. 1.
 0. 0. 0. 1. 1. 1. 1.]"
NCT02124772,"15:28:cancer,54:75:treatment,75:81:treatment,94:111:treatment,114:135:treatment",Subjects with neuroblastoma that is only detected by bone marrow aspirate/biopsy or elevated homovanillic acid / vanillylmandelic acid (HVA/VMA),"['Subjects' 'with' 'neuroblastoma' 'that' 'is' 'only' 'detected' 'by'
 'bone' 'marrow' 'aspirate/biopsy' 'or' 'elevated' 'homovanillic' 'acid'
 '/' 'vanillylmandelic' 'acid' '(' 'HVA/VMA' ')']",[0. 0. 3. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 1. 1. 0. 1. 1. 0. 0. 0.]
NCT02122185,"26:35:cancer,52:59:cancer,61:75:cancer,80:108:cancer","Histologically confirmed carcinoma consistent with ovarian, fallopian tube, or primary peritoneal carcinoma","['Histologically' 'confirmed' 'carcinoma' 'consistent' 'with' 'ovarian'
 ',' 'fallopian' 'tube' ',' 'or' 'primary' 'peritoneal' 'carcinoma']",[0. 0. 3. 0. 0. 3. 0. 3. 3. 0. 0. 3. 3. 3.]
NCT02122185,"14:38:cancer,40:54:cancer,56:73:chronic_disease","evidenced by abdominal carcinomatosis, omental caking, pleural effusions","['evidenced' 'by' 'abdominal' 'carcinomatosis' ',' 'omental' 'caking' ','
 'pleural' 'effusions']",[0. 0. 3. 3. 0. 3. 3. 0. 2. 2.]
NCT02122185,"71:95:cancer,113:130:chronic_disease,134:141:chronic_disease","they should have presumed stage III or IV disease, generally based on abdominal carcinomatosis, omental caking, pleural effusions or ascites","['they' 'should' 'have' 'presumed' 'stage' 'III' 'or' 'IV' 'disease' ','
 'generally' 'based' 'on' 'abdominal' 'carcinomatosis' ',' 'omental'
 'caking' ',' 'pleural' 'effusions' 'or' 'ascites']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 2. 2. 0. 2.]
NCT02122172,"14:34:chronic_disease,77:93:chronic_disease,107:131:chronic_disease,142:157:treatment,162:181:treatment","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' ',' 'ongoing' 'or' 'active' 'infection' ',' 'symptomatic'
 'congestive' 'heart' 'failure' ',' 'unstable' 'angina' 'pectoris' ','
 'or' 'psychiatric' 'illness/social' 'situations' 'that' 'would' 'limit'
 'compliance' 'with' 'study' 'requirements']","[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 1. 1. 0.
 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02121184,"17:33:chronic_disease,39:56:chronic_disease,58:70:chronic_disease,72:84:chronic_disease","Presence of any systemic disease (ex: diabetes mellitus, hypertension, preeclampsia","['Presence' 'of' 'any' 'systemic' 'disease' '(' 'ex' ':' 'diabetes'
 'mellitus' ',' 'hypertension' ',' 'preeclampsia']",[0. 0. 0. 2. 2. 0. 0. 0. 2. 2. 0. 2. 0. 2.]
NCT02120222,"69:92:chronic_disease,96:111:treatment,129:167:chronic_disease,184:221:chronic_disease,222:254:chronic_disease",Uncontrolled clinically significant conduction abnormalities (e.g.: ventricular tachycardia on antiarrhythmics are excluded and 1st degree atrioventricular (AV) block or asymptomatic left anterior fascicular block [LAFB]/right bundle branch block [RBBB],"['Uncontrolled' 'clinically' 'significant' 'conduction' 'abnormalities'
 '(' 'e.g' '.' ':' 'ventricular' 'tachycardia' 'on' 'antiarrhythmics'
 'are' 'excluded' 'and' '1st' 'degree' 'atrioventricular' '(' 'AV' ')'
 'block' 'or' 'asymptomatic' 'left' 'anterior' 'fascicular' 'block' '['
 'LAFB' ']' '/right' 'bundle' 'branch' 'block' '[' 'RBBB' ']']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 1. 0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0.
 0. 2. 2. 2. 2. 2. 0. 0. 2. 2. 2. 2. 2. 0. 0.]"
NCT02115295,"26:60:treatment,65:73:treatment,75:88:treatment,94:105:treatment,107:135:treatment,137:148:treatment,150:160:treatment,162:166:treatment,,,271:284:cancer,316:343:cancer,379:392:cancer","For Frontline cohort: No prior potentially-curative therapy for leukemia. Prior therapy with hydroxyurea, hematopoietic growth factors, azacytidine, decitabine, ATRA, or a total dose of cytarabine up to 2g (for emergency use for stabilization) is allowed. Patients with secondary AMLwho have been treated for their antecedent myeloid neoplasm will be enrolled into the separate Secondary AML cohort","['For' 'Frontline' 'cohort' ':' 'No' 'prior' 'potentially-curative'
 'therapy' 'for' 'leukemia' '.' 'Prior' 'therapy' 'with' 'hydroxyurea' ','
 'hematopoietic' 'growth' 'factors' ',' 'azacytidine' ',' 'decitabine' ','
 'ATRA' ',' 'or' 'a' 'total' 'dose' 'of' 'cytarabine' 'up' 'to' '2g' '('
 'for' 'emergency' 'use' 'for' 'stabilization' ')' 'is' 'allowed' '.'
 'Patients' 'with' 'secondary' 'AMLwho' 'have' 'been' 'treated' 'for'
 'their' 'antecedent' 'myeloid' 'neoplasm' 'will' 'be' 'enrolled' 'into'
 'the' 'separate' 'Secondary' 'AML' 'cohort']","[0. 0. 0. 0. 0. 1. 1. 1. 0. 1. 0. 1. 1. 0. 1. 0. 1. 1. 1. 0. 1. 0. 1. 0.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.
 3. 0. 0. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 3. 3. 0.]"
NCT02114229,"73:75:cancer,76:78:cancer,82:85:cancer","For Stratum A participants, histologic confirmation of the diagnosis of AT/RT or MRT may be from the original diagnosis or at the time of recurrence/progression","['For' 'Stratum' 'A' 'participants' ',' 'histologic' 'confirmation' 'of'
 'the' 'diagnosis' 'of' 'AT/RT' 'or' 'MRT' 'may' 'be' 'from' 'the'
 'original' 'diagnosis' 'or' 'at' 'the' 'time' 'of'
 'recurrence/progression']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02114229,"1:22:chronic_disease,,,,,105:118:chronic_disease,120:139:chronic_disease,161:184:chronic_disease,189:209:treatment,228:236:chronic_disease","Myocardial infarction within 6 months prior to enrollment or New York Heart Association Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities","['Myocardial' 'infarction' 'within' '6' 'months' 'prior' 'to' 'enrollment'
 'or' 'New' 'York' 'Heart' 'Association' 'Class' 'III' 'or' 'IV' 'heart'
 'failure' ',' 'uncontrolled' 'angina' ',' 'severe' 'uncontrolled'
 'ventricular' 'arrhythmias' ',' 'or' 'electrocardiographic' 'evidence'
 'of' 'acute' 'ischemia' 'or' 'active' 'conduction' 'system'
 'abnormalities']","[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0.
 0. 2. 2. 0. 0. 1. 0. 0. 0. 2. 0. 0. 0. 0. 0.]"
NCT02114229,"21:30:treatment,,49:67:treatment,60:67:treatment,129:138:treatment,149:163:cancer",Patients must begin treatment within 42 days of definitive surgery (day of surgery is day 0; definitive surgery includes repeat surgeries to resect residual tumor),"['Patients' 'must' 'begin' 'treatment' 'within' '42' 'days' 'of'
 'definitive' 'surgery' '(' 'day' 'of' 'surgery' 'is' 'day' '0' ';'
 'definitive' 'surgery' 'includes' 'repeat' 'surgeries' 'to' 'resect'
 'residual' 'tumor' ')']","[0. 0. 0. 1. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.
 0. 3. 3. 0.]"
NCT02112617,"20:23:treatment,31:33:treatment,,82:91:treatment,102:120:treatment,125:134:treatment,141:160:treatment,164:173:treatment,175:184:treatment,188:197:treatment",Diagnostic Imaging MRI and/or CT of the area to be treated within 8 weeks of any treatment. Baseline bone marrow biopsy and bone scan (with 99mTc-diphosphonate or MIBG scan (131I-MIBG or 123I-MIBG) from time of original diagnosis is required,"['Diagnostic' 'Imaging' 'MRI' 'and/or' 'CT' 'of' 'the' 'area' 'to' 'be'
 'treated' 'within' '8' 'weeks' 'of' 'any' 'treatment' '.' 'Baseline'
 'bone' 'marrow' 'biopsy' 'and' 'bone' 'scan' '(' 'with'
 '99mTc-diphosphonate' 'or' 'MIBG' 'scan' '(' '131I-MIBG' 'or' '123I-MIBG'
 ')' 'from' 'time' 'of' 'original' 'diagnosis' 'is' 'required']","[0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 1. 1. 0. 0.
 0. 0. 0. 1. 0. 1. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02111850,"8:27:chronic_disease,46:70:treatment,73:94:chronic_disease","Active systemic infections, (e.g.: requiring anti-infective treatment), coagulation disorders or any other active major medical illnesses","['Active' 'systemic' 'infections' ',' '(' 'e.g' '.' ':' 'requiring'
 'anti-infective' 'treatment' ')' ',' 'coagulation' 'disorders' 'or' 'any'
 'other' 'active' 'major' 'medical' 'illnesses']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02111850,",50:72:treatment,110:129:treatment,,228:236:chronic_disease,240:248:chronic_disease","More than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients' toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo)","['More' 'than' 'four' 'weeks' 'must' 'have' 'elapsed' 'since' 'any'
 'prior' 'systemic' 'therapy' 'at' 'the' 'time' 'the' 'patient' 'receives'
 'the' 'preparative' 'regimen' ',' 'and' 'patients' ""'"" 'toxicities'
 'must' 'have' 'recovered' 'to' 'a' 'grade' '1' 'or' 'less' '(' 'except'
 'for' 'toxicities' 'such' 'as' 'alopecia' 'or' 'vitiligo' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0.]"
NCT02110069,"22:33:treatment,70:83:treatment,104:119:treatment","Patients who require medications that are strong inhibitors/inducers CYP3A4 enzyme activity, including anticonvulsants, (Appendix II) to control concurrent medical conditions","['Patients' 'who' 'require' 'medications' 'that' 'are' 'strong'
 'inhibitors/inducers' 'CYP3A4' 'enzyme' 'activity' ',' 'including'
 'anticonvulsants' ',' '(' 'Appendix' 'II' ')' 'to' 'control' 'concurrent'
 'medical' 'conditions']",[0. 0. 0. 1. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02109627,",,28:56:treatment,60:87:treatment,94:103:treatment","Ejection fraction >=40% by transthoracic echocardiogram or radionuclide ventriculogram, i.e. MUGA scan","['Ejection' 'fraction' '>' '=40' '%' 'by' 'transthoracic' 'echocardiogram'
 'or' 'radionuclide' 'ventriculogram' ',' 'i.e' '.' 'MUGA' 'scan']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 0. 0. 1. 1.]
NCT02109627,",,67:79:treatment,129:139:treatment,,187:198:treatment",Pregnant women are excluded from this study because the effect of ficlatuzumab on the developing fetus remains unknown and that cytarabine is a pregnancy risk category D drug with known teratogenic or abortifacient effects,"['Pregnant' 'women' 'are' 'excluded' 'from' 'this' 'study' 'because' 'the'
 'effect' 'of' 'ficlatuzumab' 'on' 'the' 'developing' 'fetus' 'remains'
 'unknown' 'and' 'that' 'cytarabine' 'is' 'a' 'pregnancy' 'risk'
 'category' 'D' 'drug' 'with' 'known' 'teratogenic' 'or' 'abortifacient'
 'effects']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]"
NCT02108860,"12:22:cancer,,113:123:cancer,127:163:cancer,168:194:cancer,234:252:treatment","History of malignancy within the past five years or any evidence of persistent malignancy, except fully excised basal cell or squamous cell carcinomas of the skin, or cervical carcinoma in situ which has been treated or excised in a curative procedure","['History' 'of' 'malignancy' 'within' 'the' 'past' 'five' 'years' 'or'
 'any' 'evidence' 'of' 'persistent' 'malignancy' ',' 'except' 'fully'
 'excised' 'basal' 'cell' 'or' 'squamous' 'cell' 'carcinomas' 'of' 'the'
 'skin' ',' 'or' 'cervical' 'carcinoma' 'in' 'situ' 'which' 'has' 'been'
 'treated' 'or' 'excised' 'in' 'a' 'curative' 'procedure']","[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 3. 3. 3.
 3. 3. 3. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]"
NCT02108860,"10:53:treatment,72:84:treatment,88:103:treatment,116:141:treatment",Positive anti-neutrophil cytoplasmic antibody (ANCA) test specific for proteinase-3 or myeloperoxidase measured by enzyme-linked immunoassay,"['Positive' 'anti-neutrophil' 'cytoplasmic' 'antibody' '(' 'ANCA' ')'
 'test' 'specific' 'for' 'proteinase-3' 'or' 'myeloperoxidase' 'measured'
 'by' 'enzyme-linked' 'immunoassay']",[0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 1. 1.]
NCT02107703,",98:121:chronic_disease,123:146:chronic_disease,148:172:chronic_disease","Have a personal history within the last 12 months of any of the following conditions: syncope of cardiovascular etiology, ventricular tachycardia, ventricular fibrillation, or sudden cardiac arrest","['Have' 'a' 'personal' 'history' 'within' 'the' 'last' '12' 'months' 'of'
 'any' 'of' 'the' 'following' 'conditions' ':' 'syncope' 'of'
 'cardiovascular' 'etiology' ',' 'ventricular' 'tachycardia' ','
 'ventricular' 'fibrillation' ',' 'or' 'sudden' 'cardiac' 'arrest']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02107703,"14:30:cancer,47:65:treatment,69:76:treatment,80:98:cancer",Have locally advanced disease not amenable to curative treatment by surgery or metastatic disease,"['Have' 'locally' 'advanced' 'disease' 'not' 'amenable' 'to' 'curative'
 'treatment' 'by' 'surgery' 'or' 'metastatic' 'disease']",[0. 0. 3. 3. 0. 0. 0. 1. 1. 0. 1. 0. 3. 3.]
NCT02107703,",56:73:treatment,81:99:treatment,104:122:cancer",Participants may not have received more than 1 line of endocrine therapy or any prior chemotherapy for metastatic disease,"['Participants' 'may' 'not' 'have' 'received' 'more' 'than' '1' 'line'
 'of' 'endocrine' 'therapy' 'or' 'any' 'prior' 'chemotherapy' 'for'
 'metastatic' 'disease']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 1. 1. 0. 3. 3.]
NCT02106988,"1:16:treatment,7:16:treatment,60:72:treatment","Prior radiation to the site of current primary disease, if re-treatment would lead to violation of known radiation dose tolerance limits for that site","['Prior' 'radiation' 'to' 'the' 'site' 'of' 'current' 'primary' 'disease'
 ',' 'if' 're-treatment' 'would' 'lead' 'to' 'violation' 'of' 'known'
 'radiation' 'dose' 'tolerance' 'limits' 'for' 'that' 'site']","[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02106650,"1:30:chronic_disease,43:60:chronic_disease,71:86:chronic_disease,152:161:treatment","active uncontrolled infection, underlying medical condition, or other serious illness that would impair the ability of the patient to receive protocol treatment","['active' 'uncontrolled' 'infection' ',' 'underlying' 'medical'
 'condition' ',' 'or' 'other' 'serious' 'illness' 'that' 'would' 'impair'
 'the' 'ability' 'of' 'the' 'patient' 'to' 'receive' 'protocol'
 'treatment']",[2. 2. 2. 0. 0. 2. 2. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02106598,"1:24:treatment,26:38:treatment,43:50:treatment","Prior radiation therapy, chemotherapy, or surgery in patients requiring flap reconstruction in the head and neck region","['Prior' 'radiation' 'therapy' ',' 'chemotherapy' ',' 'or' 'surgery' 'in'
 'patients' 'requiring' 'flap' 'reconstruction' 'in' 'the' 'head' 'and'
 'neck' 'region']",[1. 1. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02106312,"1:7:treatment,15:18:chronic_disease,34:70:treatment,96:111:cancer,123:145:cancer,233:248:cancer,310:315:treatment,363:384:treatment","Biopsy proven MLS (including the reciprocal chromosomal translocation t(12;16)(q13;p11); A the primary sarcoma in case of non-metastatic disease for management is with curative intent (regimen to be chosen = 18 x 2 GY) B in case of oligometastatic patients, the metastasis may also be irradiated to a dose of 36 GY in order to postpone the time interval to next systemic chemotherapy. These patients are usually not operated upon and the total dose may also be reached in 12 times 3 Gy, for convenience purposes (see paragraph 10 for radiobiological considerations)","['Biopsy' 'proven' 'MLS' '(' 'including' 'the' 'reciprocal' 'chromosomal'
 'translocation' 't' '(' '12' ';' '16' ')' '(' 'q13' ';' 'p11' ')' ';' 'A'
 'the' 'primary' 'sarcoma' 'in' 'case' 'of' 'non-metastatic' 'disease'
 'for' 'management' 'is' 'with' 'curative' 'intent' '(' 'regimen' 'to'
 'be' 'chosen' '=' '18' 'x' '2' 'GY' ')' 'B' 'in' 'case' 'of'
 'oligometastatic' 'patients' ',' 'the' 'metastasis' 'may' 'also' 'be'
 'irradiated' 'to' 'a' 'dose' 'of' '36' 'GY' 'in' 'order' 'to' 'postpone'
 'the' 'time' 'interval' 'to' 'next' 'systemic' 'chemotherapy' '.' 'These'
 'patients' 'are' 'usually' 'not' 'operated' 'upon' 'and' 'the' 'total'
 'dose' 'may' 'also' 'be' 'reached' 'in' '12' 'times' '3' 'Gy' ',' 'for'
 'convenience' 'purposes' '(' 'see' 'paragraph' '10' 'for'
 'radiobiological' 'considerations' ')']","[1. 0. 2. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.
 3. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02105766,"1:21:chronic_disease,31:34:chronic_disease,53:64:treatment,",Acute chest syndrome/ 2 prior ACS/ any ACS while on hydroxyurea (at MTD for at least 6 months),"['Acute' 'chest' 'syndrome/' '2' 'prior' 'ACS/' 'any' 'ACS' 'while' 'on'
 'hydroxyurea' '(' 'at' 'MTD' 'for' 'at' 'least' '6' 'months' ')']",[2. 2. 2. 0. 0. 2. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02105766,"1:7:chronic_disease,114:135:chronic_disease,146:173:treatment",Stroke defined as a clinically significant neurologic event that is accompanied by an infarct on cerebral MRI or cerebral arteriopathy requiring chronic transfusion therapy,"['Stroke' 'defined' 'as' 'a' 'clinically' 'significant' 'neurologic'
 'event' 'that' 'is' 'accompanied' 'by' 'an' 'infarct' 'on' 'cerebral'
 'MRI' 'or' 'cerebral' 'arteriopathy' 'requiring' 'chronic' 'transfusion'
 'therapy']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 1. 1. 1.]
NCT02101944,"52:80:treatment,85:105:treatment,129:140:treatment,,191:221:treatment","Patients must have been previously treated with an immunomodulatory drug (IMiD) and proteasome inhibitor, must be refractory to carfilzomib defined as progression on or within 2 months of a carfilzomib-containing therapy, and must be progressing","['Patients' 'must' 'have' 'been' 'previously' 'treated' 'with' 'an'
 'immunomodulatory' 'drug' '(' 'IMiD' ')' 'and' 'proteasome' 'inhibitor'
 ',' 'must' 'be' 'refractory' 'to' 'carfilzomib' 'defined' 'as'
 'progression' 'on' 'or' 'within' '2' 'months' 'of' 'a'
 'carfilzomib-containing' 'therapy' ',' 'and' 'must' 'be' 'progressing']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]"
NCT02101853,"1:18:treatment,11:18:treatment,,61:78:treatment,101:112:chronic_disease,,191:215:treatment,220:244:treatment,246:258:treatment","Cytotoxic therapy: at least 14 days since the completion of cytotoxic therapy with the exception of hydroxyurea, which is permitted up to 24 hours prior to the start of protocol therapy, or maintenance chemotherapy, or intrathecal chemotherapy (methotrexate strongly preferred) administered at the time of the required diagnostic lumbar puncture to establish baseline CNS status","['Cytotoxic' 'therapy' ':' 'at' 'least' '14' 'days' 'since' 'the'
 'completion' 'of' 'cytotoxic' 'therapy' 'with' 'the' 'exception' 'of'
 'hydroxyurea' ',' 'which' 'is' 'permitted' 'up' 'to' '24' 'hours' 'prior'
 'to' 'the' 'start' 'of' 'protocol' 'therapy' ',' 'or' 'maintenance'
 'chemotherapy' ',' 'or' 'intrathecal' 'chemotherapy' '(' 'methotrexate'
 'strongly' 'preferred' ')' 'administered' 'at' 'the' 'time' 'of' 'the'
 'required' 'diagnostic' 'lumbar' 'puncture' 'to' 'establish' 'baseline'
 'CNS' 'status']","[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02101853,"15:47:cancer,48:87:cancer,88:143:cancer",Patients with Philadelphia chromosome positive/breakpoint cluster region protein (BCR)-Abelson murine leukemia viral oncogene homolog 1 (ABL1)+ ALL,"['Patients' 'with' 'Philadelphia' 'chromosome' 'positive/breakpoint'
 'cluster' 'region' 'protein' '(' 'BCR' ')' '-Abelson' 'murine' 'leukemia'
 'viral' 'oncogene' 'homolog' '1' '(' 'ABL1' ')' '+' 'ALL']",[0. 0. 3. 3. 3. 3. 3. 3. 3. 0. 0. 3. 3. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0.]
NCT02101736,"1:17:chronic_disease,39:48:treatment,,89:104:treatment",Active infection requiring systematic treatment within 28 days before the first dose of study treatment,"['Active' 'infection' 'requiring' 'systematic' 'treatment' 'within' '28'
 'days' 'before' 'the' 'first' 'dose' 'of' 'study' 'treatment']",[2. 2. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02101736,"1:39:treatment,94:113:chronic_disease,203:217:treatment","Concomitant treatment with medications that prolong the QT interval and have a known risk of Torsades de Pointes is not contraindicated, but should be avoided if possible and will require more frequent EKG monitoring","['Concomitant' 'treatment' 'with' 'medications' 'that' 'prolong' 'the'
 'QT' 'interval' 'and' 'have' 'a' 'known' 'risk' 'of' 'Torsades' 'de'
 'Pointes' 'is' 'not' 'contraindicated' ',' 'but' 'should' 'be' 'avoided'
 'if' 'possible' 'and' 'will' 'require' 'more' 'frequent' 'EKG'
 'monitoring']","[1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]"
NCT02101736,"10:17:treatment,28:36:treatment,42:83:treatment","Low dose aspirin, low-dose warfarin, and prophylactic low molecular weight heparin","['Low' 'dose' 'aspirin' ',' 'low-dose' 'warfarin' ',' 'and' 'prophylactic'
 'low' 'molecular' 'weight' 'heparin']",[0. 0. 1. 0. 0. 1. 0. 0. 1. 1. 1. 1. 1.]
NCT02101034,",,71:81:cancer,85:120:cancer,145:160:treatment,167:198:cancer","A history of other malignancy ≤ 1 year previous with the exception of basal cell or squamous cell carcinoma of the skin which were treated with local resection only, carcinoma in situ of the cervix, or synchronous H&N primaries","['A' 'history' 'of' 'other' 'malignancy' '≤' '1' 'year' 'previous' 'with'
 'the' 'exception' 'of' 'basal' 'cell' 'or' 'squamous' 'cell' 'carcinoma'
 'of' 'the' 'skin' 'which' 'were' 'treated' 'with' 'local' 'resection'
 'only' ',' 'carcinoma' 'in' 'situ' 'of' 'the' 'cervix' ',' 'or'
 'synchronous' 'H' '&' 'N' 'primaries']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 3. 3. 3. 3. 3. 3. 3. 3.
 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02101034,"38:41:chronic_disease,72:94:treatment,124:168:treatment",Phase I and Arm 1 of Phase II: Known HIV-positivity and on combination antiretroviral therapy because of the potential for pharmacokinetic interactions with PD 0332991,"['Phase' 'I' 'and' 'Arm' '1' 'of' 'Phase' 'II' ':' 'Known'
 'HIV-positivity' 'and' 'on' 'combination' 'antiretroviral' 'therapy'
 'because' 'of' 'the' 'potential' 'for' 'pharmacokinetic' 'interactions'
 'with' 'PD' '0332991']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 1. 1.
 1. 1.]"
NCT02101034,"45:59:cancer,111:119:treatment,123:147:treatment,171:177:treatment,,214:224:treatment","individuals who have had previously-treated CNS metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medications (with the exception of Keppra) for 1 month prior to first dose of PD 0332991","['individuals' 'who' 'have' 'had' 'previously-treated' 'CNS' 'metastases'
 ',' 'are' 'asymptomatic' ',' 'and' 'have' 'had' 'no' 'requirement' 'for'
 'steroids' 'or' 'anti-seizure' 'medications' '(' 'with' 'the' 'exception'
 'of' 'Keppra' ')' 'for' '1' 'month' 'prior' 'to' 'first' 'dose' 'of' 'PD'
 '0332991']","[0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0.
 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]"
NCT02100891,"11:29:cancer,82:99:treatment,110:124:treatment","High Risk Neuroblastoma (NB): Must have progressed on or recurred after standard frontline therapy including autologous HCT, or be ineligible for autologous HCT","['High' 'Risk' 'Neuroblastoma' '(' 'NB' ')' ':' 'Must' 'have' 'progressed'
 'on' 'or' 'recurred' 'after' 'standard' 'frontline' 'therapy' 'including'
 'autologous' 'HCT' ',' 'or' 'be' 'ineligible' 'for' 'autologous' 'HCT']","[0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02100722,",,206:223:treatment,232:235:treatment,240:244:treatment","Three vessel CAD, defined as ≥ 50% diameter stenosis by visual estimation in each of the three major epicardial vessels or major side branches, but not involving left main coronary artery, and amenable to revascularization by both PCI and CABG as determined by the Heart Team","['Three' 'vessel' 'CAD' ',' 'defined' 'as' '≥' '50' '%' 'diameter'
 'stenosis' 'by' 'visual' 'estimation' 'in' 'each' 'of' 'the' 'three'
 'major' 'epicardial' 'vessels' 'or' 'major' 'side' 'branches' ',' 'but'
 'not' 'involving' 'left' 'main' 'coronary' 'artery' ',' 'and' 'amenable'
 'to' 'revascularization' 'by' 'both' 'PCI' 'and' 'CABG' 'as' 'determined'
 'by' 'the' 'Heart' 'Team']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 0. 1. 0. 0. 0. 0.
 0. 0.]"
NCT02099058,"24:55:chronic_disease,51:54:chronic_disease,59:70:chronic_disease,85:117:treatment","Subject has history of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD or pneumonitis","['Subject' 'has' 'history' 'of' 'interstitial' 'lung' 'disease' '(' 'ILD'
 ')' 'or' 'pneumonitis' 'that' 'required' 'treatment' 'with' 'systemic'
 'steroids' ',' 'or' 'any' 'evidence' 'of' 'active' 'ILD' 'or'
 'pneumonitis']","[0. 0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 2. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02099058,"19:35:cancer,129:140:allergy_name,152:157:allergy_name,159:164:allergy_name,166:171:allergy_name,175:180:allergy_name","Subject must have metastatic NSCLC with documented Epidermal Growth Factor Receptor (EGFR) mutation(s) known to be sensitive to osimertinib, including del19, L858R, G719X or L861Q","['Subject' 'must' 'have' 'metastatic' 'NSCLC' 'with' 'documented'
 'Epidermal' 'Growth' 'Factor' 'Receptor' '(' 'EGFR' ')' 'mutation' '('
 's' ')' 'known' 'to' 'be' 'sensitive' 'to' 'osimertinib' ',' 'including'
 'del19' ',' 'L858R' ',' 'G719X' 'or' 'L861Q']","[0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4.
 0. 0. 4. 0. 4. 0. 4. 0. 4.]"
NCT02098876,"13:32:chronic_disease,50:65:chronic_disease,59:65:chronic_disease,90:105:chronic_disease","Evidence of myocardial ischemia (e.g., stable or unstable angina, post-infarct angina or silent ischemia) suitable for PCI","['Evidence' 'of' 'myocardial' 'ischemia' '(' 'e.g.' ',' 'stable' 'or'
 'unstable' 'angina' ',' 'post-infarct' 'angina' 'or' 'silent' 'ischemia'
 ')' 'suitable' 'for' 'PCI']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0.]
NCT02098161,",58:88:treatment,,111:121:treatment,130:144:treatment,179:214:treatment,261:271:treatment","Patients who are currently receiving chronic (> 14 days) treatment with corticosteroids at a dose >= 10 mg of prednisone (or its glucocorticoid equivalent) per day, or any other chronic immunosuppressive treatment that cannot be discontinued prior to starting study drug","['Patients' 'who' 'are' 'currently' 'receiving' 'chronic' '(' '>' '14'
 'days' ')' 'treatment' 'with' 'corticosteroids' 'at' 'a' 'dose' '>' '='
 '10' 'mg' 'of' 'prednisone' '(' 'or' 'its' 'glucocorticoid' 'equivalent'
 ')' 'per' 'day' ',' 'or' 'any' 'other' 'chronic' 'immunosuppressive'
 'treatment' 'that' 'can' 'not' 'be' 'discontinued' 'prior' 'to'
 'starting' 'study' 'drug']","[0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.
 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]"
NCT02095184,"37:55:treatment,57:74:treatment,79:96:treatment,115:128:cancer","Patients must not have received any prior chemotherapy, radiation therapy, or endocrine therapy for their current breast cancer","['Patients' 'must' 'not' 'have' 'received' 'any' 'prior' 'chemotherapy'
 ',' 'radiation' 'therapy' ',' 'or' 'endocrine' 'therapy' 'for' 'their'
 'current' 'breast' 'cancer']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 0. 1. 1. 0. 0. 0. 3. 3.]
NCT02094794,"57:79:treatment,107:119:treatment,124:141:treatment","Plans during the trial to receive any other (non-trial) investigational agents, or concurrent biological, chemotherapy, or radiation therapy","['Plans' 'during' 'the' 'trial' 'to' 'receive' 'any' 'other' '('
 'non-trial' ')' 'investigational' 'agents' ',' 'or' 'concurrent'
 'biological' ',' 'chemotherapy' ',' 'or' 'radiation' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 0. 0. 1. 1.]
NCT02094625,"1:37:chronic_disease,154:173:chronic_disease,195:205:treatment,223:238:treatment,",Moderate or Severe Persistent Asthma as defined by the latest recommendations from the National Heart Lung and Blood Institute definition includes daily asthma exacerbation with need for rescue medication) or an overnight hospitalization for asthma exacerbation within the previous 28 days,"['Moderate' 'or' 'Severe' 'Persistent' 'Asthma' 'as' 'defined' 'by' 'the'
 'latest' 'recommendations' 'from' 'the' 'National' 'Heart' 'Lung' 'and'
 'Blood' 'Institute' 'definition' 'includes' 'daily' 'asthma'
 'exacerbation' 'with' 'need' 'for' 'rescue' 'medication' ')' 'or' 'an'
 'overnight' 'hospitalization' 'for' 'asthma' 'exacerbation' 'within'
 'the' 'previous' '28' 'days']","[2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.
 0. 0. 0. 0. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02092324,"24:34:cancer,,88:110:cancer,148:171:cancer,197:214:cancer,219:245:cancer","Subjects with invasive malignancy over the previous 2 years except treated early stage carcinomas of the skin, completely resected intraepithelial carcinoma of the cervix, and completely resected papillary thyroid and follicular thyroid cancers","['Subjects' 'with' 'invasive' 'malignancy' 'over' 'the' 'previous' '2'
 'years' 'except' 'treated' 'early' 'stage' 'carcinomas' 'of' 'the' 'skin'
 ',' 'completely' 'resected' 'intraepithelial' 'carcinoma' 'of' 'the'
 'cervix' ',' 'and' 'completely' 'resected' 'papillary' 'thyroid' 'and'
 'follicular' 'thyroid' 'cancers']","[0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 3. 3. 3.
 3. 0. 0. 0. 0. 3. 3. 0. 3. 3. 3.]"
NCT02091999,"1:17:chronic_disease,21:34:chronic_disease,41:50:chronic_disease",Active infection or corneal ulcer (e.g. keratitis),['Active' 'infection' 'or' 'corneal' 'ulcer' '(' 'e.g' '.' 'keratitis' ')'],[2. 2. 0. 2. 2. 0. 0. 0. 2. 0.]
NCT02091999,"18:37:chronic_disease,39:44:cancer,49:52:treatment","Dose Escalation, Renal insufficiency, NSCLC and CPI-Treated Expansion Cohorts","['Dose' 'Escalation' ',' 'Renal' 'insufficiency' ',' 'NSCLC' 'and'
 'CPI-Treated' 'Expansion' 'Cohorts']",[0. 0. 0. 2. 2. 0. 3. 0. 1. 0. 0.]
NCT02091999,"15:38:cancer,40:65:cancer,186:205:treatment,251:268:cancer","Subjects with nonmelanoma skin cancer, localized prostate cancer treated with curative intent with no evidence of progression, low-risk or very low risk localized prostate cancer under active surveillance/watchful waiting without intent to treat, or carcinoma in situ of any time","['Subjects' 'with' 'nonmelanoma' 'skin' 'cancer' ',' 'localized'
 'prostate' 'cancer' 'treated' 'with' 'curative' 'intent' 'with' 'no'
 'evidence' 'of' 'progression' ',' 'low-risk' 'or' 'very' 'low' 'risk'
 'localized' 'prostate' 'cancer' 'under' 'active' 'surveillance/watchful'
 'waiting' 'without' 'intent' 'to' 'treat' ',' 'or' 'carcinoma' 'in'
 'situ' 'of' 'any' 'time']","[0. 0. 3. 3. 3. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 0. 0.]"
NCT02091999,"26:37:chronic_disease,39:63:chronic_disease,65:72:chronic_disease,74:85:chronic_disease,90:109:chronic_disease","Uncontrolled or evolving retinopathy, wet macular degeneration, uveitis, papilledema, or optic disc disorder","['Uncontrolled' 'or' 'evolving' 'retinopathy' ',' 'wet' 'macular'
 'degeneration' ',' 'uveitis' ',' 'papilledema' ',' 'or' 'optic' 'disc'
 'disorder']",[0. 0. 0. 2. 0. 2. 2. 2. 0. 2. 0. 2. 0. 0. 2. 2. 2.]
NCT02091141,"33:68:treatment,,123:138:treatment,152:176:treatment",Administration of strong/potent cytochrome P3A4 (CYP3A4) inhibitors or inducers within 14 days prior to the first dose of study treatment and while on treatment with alectinib,"['Administration' 'of' 'strong/potent' 'cytochrome' 'P3A4' '(' 'CYP3A4'
 ')' 'inhibitors' 'or' 'inducers' 'within' '14' 'days' 'prior' 'to' 'the'
 'first' 'dose' 'of' 'study' 'treatment' 'and' 'while' 'on' 'treatment'
 'with' 'alectinib']","[0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1.
 0. 0. 0. 0.]"
NCT02091141,"40:59:treatment,,91:106:cancer,117:134:treatment,137:152:treatment,157:166:treatment,,277:285:chronic_disease,287:304:treatment,","Concurrent administration of any other anti-cancer therapy (except male participants with prostate cancer receiving androgen blockade): Bisphosphonates and denosumab are allowed; Most recent anti-cancer therapy ≤28 days and have not recovered from the side effects, excluding alopecia; Radiation therapy within ≤14 days","['Concurrent' 'administration' 'of' 'any' 'other' 'anti-cancer' 'therapy'
 '(' 'except' 'male' 'participants' 'with' 'prostate' 'cancer' 'receiving'
 'androgen' 'blockade' ')' ':' 'Bisphosphonates' 'and' 'denosumab' 'are'
 'allowed' ';' 'Most' 'recent' 'anti-cancer' 'therapy' '≤28' 'days' 'and'
 'have' 'not' 'recovered' 'from' 'the' 'side' 'effects' ',' 'excluding'
 'alopecia' ';' 'Radiation' 'therapy' 'within' '≤14' 'days']","[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 3. 3. 0. 1. 1. 0. 0. 1. 0. 1. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 1. 1. 0. 0. 0.]"
NCT02091141,"18:28:cancer,,118:128:cancer,166:197:cancer,199:226:cancer,228:253:cancer,255:279:cancer,284:306:cancer","History of other malignancy within 5 years prior to screening, with the exception of those with a negligible risk of metastasis or death, such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer","['History' 'of' 'other' 'malignancy' 'within' '5' 'years' 'prior' 'to'
 'screening' ',' 'with' 'the' 'exception' 'of' 'those' 'with' 'a'
 'negligible' 'risk' 'of' 'metastasis' 'or' 'death' ',' 'such' 'as'
 'adequately' 'treated' 'carcinoma' 'in' 'situ' 'of' 'the' 'cervix' ','
 'non-melanoma' 'skin' 'carcinoma' ',' 'localized' 'prostate' 'cancer' ','
 'ductal' 'carcinoma' 'in' 'situ' ',' 'or' 'Stage' 'I' 'uterine' 'cancer']","[0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0.
 0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 3. 0. 3. 3. 3. 0. 3. 3. 3. 0. 3. 3. 3. 3.
 0. 0. 3. 3. 3. 3.]"
NCT02091141,"32:59:treatment,41:59:treatment,52:59:treatment,75:81:cancer,98:104:cancer,218:227:treatment,284:293:treatment",Participants who have received standard first-line therapy for metastatic cancer (except for the tumors for which no first-line therapy exists) and in whom a trial of targeted therapy is considered the best available treatment option. Eligible participants should not have available therapies that will convey clinical benefit and/or are not suitable options per the treating physician's judgment,"['Participants' 'who' 'have' 'received' 'standard' 'first-line' 'therapy'
 'for' 'metastatic' 'cancer' '(' 'except' 'for' 'the' 'tumors' 'for'
 'which' 'no' 'first-line' 'therapy' 'exists' ')' 'and' 'in' 'whom' 'a'
 'trial' 'of' 'targeted' 'therapy' 'is' 'considered' 'the' 'best'
 'available' 'treatment' 'option' '.' 'Eligible' 'participants' 'should'
 'not' 'have' 'available' 'therapies' 'that' 'will' 'convey' 'clinical'
 'benefit' 'and/or' 'are' 'not' 'suitable' 'options' 'per' 'the'
 'treating' 'physician' ""'s"" 'judgment']","[0. 0. 0. 0. 1. 1. 1. 0. 0. 3. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02091141,"1:19:treatment,25:36:treatment,50:64:treatment,66:81:treatment",Previous treatment with vemurafenib or any other BRAF inhibitor (prior sorafenib is allowed),"['Previous' 'treatment' 'with' 'vemurafenib' 'or' 'any' 'other' 'BRAF'
 'inhibitor' '(' 'prior' 'sorafenib' 'is' 'allowed' ')']",[1. 1. 0. 1. 0. 0. 0. 1. 1. 0. 1. 1. 0. 0. 0.]
NCT02091141,"33:46:chronic_disease,75:102:treatment,137:148:treatment","Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude absorption of vemurafenib","['Refractory' 'nausea' 'and' 'vomiting' ',' 'malabsorption' ',' 'external'
 'biliary' 'shunt' ',' 'or' 'significant' 'bowel' 'resection' 'that'
 'would' 'preclude' 'absorption' 'of' 'vemurafenib']",[0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 1.]
NCT02091141,"1:10:treatment,25:53:treatment,,98:107:treatment","Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during the course of the study","['Treatment' 'with' 'systemic' 'immunosuppressive' 'medication' 'within'
 '2' 'weeks' 'prior' 'to' 'initiation' 'of' 'study' 'treatment' ',' 'or'
 'anticipation' 'of' 'need' 'for' 'systemic' 'immunosuppressive'
 'medication' 'during' 'the' 'course' 'of' 'the' 'study']","[1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02089607,"37:52:allergy_name,54:61:allergy_name,56:59:allergy_name,63:72:allergy_name,74:80:allergy_name,87:93:allergy_name,96:109:allergy_name,111:115:allergy_name,117:125:allergy_name,129:133:allergy_name","Known sensitivities or allergies to stainless steel, nitinol, polyester, solder (tin, silver), polypropylene, PTFE, urethane or gold","['Known' 'sensitivities' 'or' 'allergies' 'to' 'stainless' 'steel' ','
 'nitinol' ',' 'polyester' ',' 'solder' '(' 'tin' ',' 'silver' ')' ','
 'polypropylene' ',' 'PTFE' ',' 'urethane' 'or' 'gold']","[0. 0. 0. 0. 0. 4. 4. 0. 4. 0. 4. 0. 4. 0. 4. 0. 4. 0. 0. 4. 0. 4. 0. 4.
 0. 4.]"
NCT02088554,"30:42:chronic_disease,44:62:chronic_disease,72:90:chronic_disease","Patient presents with active endocarditis, active myocarditis or other systemic infection","['Patient' 'presents' 'with' 'active' 'endocarditis' ',' 'active'
 'myocarditis' 'or' 'other' 'systemic' 'infection']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 2. 2.]
NCT02085941,"1:7:cancer,37:40:treatment,56:59:treatment,60:62:treatment",Tumors that are not clearly seen by MRI but showing on PET/CT will be ablated with PET/CT guidance,"['Tumors' 'that' 'are' 'not' 'clearly' 'seen' 'by' 'MRI' 'but' 'showing'
 'on' 'PET/CT' 'will' 'be' 'ablated' 'with' 'PET/CT' 'guidance']",[3. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT02080221,"13:24:treatment,66:70:chronic_disease,74:88:chronic_disease",patients on antibiotics for infection or patients getting over a cold or seasonal virus,"['patients' 'on' 'antibiotics' 'for' 'infection' 'or' 'patients' 'getting'
 'over' 'a' 'cold' 'or' 'seasonal' 'virus']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2.]
NCT02078102,",45:67:treatment,79:89:treatment,91:105:treatment,107:125:treatment,131:145:treatment,151:173:treatment,185:197:treatment,201:213:treatment,250:259:treatment","Patients must be at least 4 weeks from last cytotoxic chemotherapy (including alkylating, anthracyclines, epipodophylatoxins, and platinum drugs), or immunomodulatory drugs (including lenalidomide or pomalidomide, or related derivatives) at time of treatment on this protocol","['Patients' 'must' 'be' 'at' 'least' '4' 'weeks' 'from' 'last' 'cytotoxic'
 'chemotherapy' '(' 'including' 'alkylating' ',' 'anthracyclines' ','
 'epipodophylatoxins' ',' 'and' 'platinum' 'drugs' ')' ',' 'or'
 'immunomodulatory' 'drugs' '(' 'including' 'lenalidomide' 'or'
 'pomalidomide' ',' 'or' 'related' 'derivatives' ')' 'at' 'time' 'of'
 'treatment' 'on' 'this' 'protocol']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 1. 0. 1. 0. 1. 0. 0. 1. 1. 0. 0.
 0. 1. 1. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]"
NCT02076906,"1:8:treatment,12:22:treatment,61:70:treatment",Implant or prosthesis or scar tissue within the path of the HIFU beam,"['Implant' 'or' 'prosthesis' 'or' 'scar' 'tissue' 'within' 'the' 'path'
 'of' 'the' 'HIFU' 'beam']",[1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02076906,"18:31:treatment,33:52:treatment,56:63:treatment",The last dose of immunotherapy (monoclonal antibody or vaccine),"['The' 'last' 'dose' 'of' 'immunotherapy' '(' 'monoclonal' 'antibody' 'or'
 'vaccine' ')']",[0. 0. 0. 0. 1. 0. 1. 1. 0. 1. 0.]
NCT02075671,",33:55:treatment,46:55:treatment,60:67:chronic_disease,69:82:treatment,84:104:treatment,106:118:treatment,120:132:treatment","History of failing at least one conventional treatment for rosacea (metronidazole, sodium sulfacetamide, tetracycline, azelaic acid) or not interested in continuous treatment with these agents","['History' 'of' 'failing' 'at' 'least' 'one' 'conventional' 'treatment'
 'for' 'rosacea' '(' 'metronidazole' ',' 'sodium' 'sulfacetamide' ','
 'tetracycline' ',' 'azelaic' 'acid' ')' 'or' 'not' 'interested' 'in'
 'continuous' 'treatment' 'with' 'these' 'agents']","[0. 0. 0. 0. 0. 0. 1. 1. 0. 2. 0. 1. 0. 1. 1. 0. 1. 0. 1. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02074631,"1:23:chronic_disease,34:73:chronic_disease,84:113:chronic_disease,115:133:chronic_disease,135:155:chronic_disease,157:176:chronic_disease,177:200:chronic_disease,223:236:treatment","Non-malignant diseases including idiopathic severe aplastic anemia (SAA) and other bone marrow failure disorders, hemoglobinopathies, adrenoleukodystrophy, immune deficiencies/dysregulation disorders who will be receiving myeloablative or reduced toxicity preparative regimens that meet the following criteria","['Non-malignant' 'diseases' 'including' 'idiopathic' 'severe' 'aplastic'
 'anemia' '(' 'SAA' ')' 'and' 'other' 'bone' 'marrow' 'failure'
 'disorders' ',' 'hemoglobinopathies' ',' 'adrenoleukodystrophy' ','
 'immune' 'deficiencies/dysregulation' 'disorders' 'who' 'will' 'be'
 'receiving' 'myeloablative' 'or' 'reduced' 'toxicity' 'preparative'
 'regimens' 'that' 'meet' 'the' 'following' 'criteria']","[2. 2. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 2. 2. 2. 2. 0. 2. 0. 2. 0. 2. 2. 2.
 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02074436,"10:34:chronic_disease,52:66:cancer,68:80:cancer,84:97:cancer,109:147:treatment,",Acute or chronic thrombocytopenia in patients with acute leukemia (myeloblastic or lymphoblastic) receiving induction or re-induction chemotherapy that is expected to induce marrow aplasia for at least 2 weeks,"['Acute' 'or' 'chronic' 'thrombocytopenia' 'in' 'patients' 'with' 'acute'
 'leukemia' '(' 'myeloblastic' 'or' 'lymphoblastic' ')' 'receiving'
 'induction' 'or' 're-induction' 'chemotherapy' 'that' 'is' 'expected'
 'to' 'induce' 'marrow' 'aplasia' 'for' 'at' 'least' '2' 'weeks']","[0. 0. 2. 2. 0. 0. 0. 3. 3. 0. 3. 0. 3. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02074436,"1:35:treatment,60:76:chronic_disease,119:123:chronic_disease",Hematopoietic stem cell transplant recipients with chronic thrombocytopenia due to chronic graft-versus-host disease (GVHD) or other causes,"['Hematopoietic' 'stem' 'cell' 'transplant' 'recipients' 'with' 'chronic'
 'thrombocytopenia' 'due' 'to' 'chronic' 'graft-versus-host' 'disease' '('
 'GVHD' ')' 'or' 'other' 'causes']",[1. 1. 1. 1. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0.]
NCT02073097,"8:32:chronic_disease,,,,91:99:chronic_disease,174:195:chronic_disease,","Active congestive heart failure (New York heart Association Class III or IV), symptomatic ischemia, or conduction abnormalities uncontrolled by conventional intervention or myocardial infarction within four months prior to enrollment","['Active' 'congestive' 'heart' 'failure' '(' 'New' 'York' 'heart'
 'Association' 'Class' 'III' 'or' 'IV' ')' ',' 'symptomatic' 'ischemia'
 ',' 'or' 'conduction' 'abnormalities' 'uncontrolled' 'by' 'conventional'
 'intervention' 'or' 'myocardial' 'infarction' 'within' 'four' 'months'
 'prior' 'to' 'enrollment']","[0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]"
NCT02073097,"16:27:treatment,99:122:treatment,,,,,,,339:348:treatment,,,,,,,699:710:treatment","The effects of Carfilzomib on the developing human fetus are unknown. For this reason and because chemotherapeutic agents used in this study are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (double barrier method of birth control or abstinence) 2 weeks prior to initiation of treatment, for the duration of study participation and for 3 months after completing treatment. Should a woman become pregnant or suspect that she is pregnant while she or her partner is participating in this study, she should inform the treating physician immediately. Men must agree to refrain from sperm donation for at least 90 days after the last dose of carfilzomib","['The' 'effects' 'of' 'Carfilzomib' 'on' 'the' 'developing' 'human'
 'fetus' 'are' 'unknown' '.' 'For' 'this' 'reason' 'and' 'because'
 'chemotherapeutic' 'agents' 'used' 'in' 'this' 'study' 'are' 'known' 'to'
 'be' 'teratogenic' ',' 'women' 'of' 'child-bearing' 'potential' 'and'
 'men' 'must' 'agree' 'to' 'use' 'adequate' 'contraception' '(' 'double'
 'barrier' 'method' 'of' 'birth' 'control' 'or' 'abstinence' ')' '2'
 'weeks' 'prior' 'to' 'initiation' 'of' 'treatment' ',' 'for' 'the'
 'duration' 'of' 'study' 'participation' 'and' 'for' '3' 'months' 'after'
 'completing' 'treatment' '.' 'Should' 'a' 'woman' 'become' 'pregnant'
 'or' 'suspect' 'that' 'she' 'is' 'pregnant' 'while' 'she' 'or' 'her'
 'partner' 'is' 'participating' 'in' 'this' 'study' ',' 'she' 'should'
 'inform' 'the' 'treating' 'physician' 'immediately' '.' 'Men' 'must'
 'agree' 'to' 'refrain' 'from' 'sperm' 'donation' 'for' 'at' 'least' '90'
 'days' 'after' 'the' 'last' 'dose' 'of' 'carfilzomib']","[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1.]"
NCT02072148,"1:4:chronic_disease,14:19:cancer,51:54:treatment",HPV negative OPSCC as determined by determined by PCR,['HPV' 'negative' 'OPSCC' 'as' 'determined' 'by' 'determined' 'by' 'PCR'],[2. 0. 3. 0. 0. 0. 0. 0. 1.]
NCT02072148,"21:33:cancer,91:122:cancer,124:129:cancer,133:168:cancer,170:184:cancer,178:184:cancer,224:231:treatment,","Previous or current malignancies at other sites, with the exception of adequately treated in situ carcinoma of the cervix, basal or squamous cell carcinoma of the skin, thyroid cancer, or other cancer curatively treated by surgery and with no current evidence of disease for at least 5 years","['Previous' 'or' 'current' 'malignancies' 'at' 'other' 'sites' ',' 'with'
 'the' 'exception' 'of' 'adequately' 'treated' 'in' 'situ' 'carcinoma'
 'of' 'the' 'cervix' ',' 'basal' 'or' 'squamous' 'cell' 'carcinoma' 'of'
 'the' 'skin' ',' 'thyroid' 'cancer' ',' 'or' 'other' 'cancer'
 'curatively' 'treated' 'by' 'surgery' 'and' 'with' 'no' 'current'
 'evidence' 'of' 'disease' 'for' 'at' 'least' '5' 'years']","[0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 3. 0. 3. 0. 3.
 3. 3. 3. 3. 3. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02070549,"5:18:treatment,30:42:treatment,44:56:treatment,44:78:treatment,80:96:treatment,101:114:treatment,,","Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within 28 days prior to enrollment and/or daily or weekly chemotherapy without the potential for delayed toxicity within 14 days prior to enrollment","['Any' 'major' 'surgery' ',' 'extensive' 'radiotherapy' ',' 'chemotherapy'
 'with' 'delayed' 'toxicity' ',' 'biologic' 'therapy' ',' 'or'
 'immunotherapy' 'within' '28' 'days' 'prior' 'to' 'enrollment' 'and/or'
 'daily' 'or' 'weekly' 'chemotherapy' 'without' 'the' 'potential' 'for'
 'delayed' 'toxicity' 'within' '14' 'days' 'prior' 'to' 'enrollment']","[0. 1. 1. 0. 0. 1. 0. 1. 1. 1. 1. 0. 1. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02070549,"1:31:cancer,108:118:cancer,162:167:cancer","Hepatocellular carcinoma (HCC) patients are not required to have histologically or cytologically confirmed malignancy, patients are considered eligible based on tumor markers and/or imaging assessment","['Hepatocellular' 'carcinoma' '(' 'HCC' ')' 'patients' 'are' 'not'
 'required' 'to' 'have' 'histologically' 'or' 'cytologically' 'confirmed'
 'malignancy' ',' 'patients' 'are' 'considered' 'eligible' 'based' 'on'
 'tumor' 'markers' 'and/or' 'imaging' 'assessment']","[3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 3.
 0. 0. 0. 0.]"
NCT02070549,"1:11:treatment,,,,,155:163:chronic_disease,,,,,,,487:496:treatment,,","Trametinib can cause fetal harm when administered to a pregnant woman; women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, during the study participation, and for four months after the last dose of the drug; women of child-bearing potential must have a negative serum pregnancy test within 14 days prior to registration and agree to use effective contraception throughout the treatment period and for 4 months after the last dose of study treatment; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately","['Trametinib' 'can' 'cause' 'fetal' 'harm' 'when' 'administered' 'to' 'a'
 'pregnant' 'woman' ';' 'women' 'of' 'child-bearing' 'potential' 'and'
 'men' 'must' 'agree' 'to' 'use' 'adequate' 'contraception' '(' 'hormonal'
 'or' 'barrier' 'method' 'of' 'birth' 'control' ';' 'abstinence' ')'
 'prior' 'to' 'study' 'entry' ',' 'during' 'the' 'study' 'participation'
 ',' 'and' 'for' 'four' 'months' 'after' 'the' 'last' 'dose' 'of' 'the'
 'drug' ';' 'women' 'of' 'child-bearing' 'potential' 'must' 'have' 'a'
 'negative' 'serum' 'pregnancy' 'test' 'within' '14' 'days' 'prior' 'to'
 'registration' 'and' 'agree' 'to' 'use' 'effective' 'contraception'
 'throughout' 'the' 'treatment' 'period' 'and' 'for' '4' 'months' 'after'
 'the' 'last' 'dose' 'of' 'study' 'treatment' ';' 'should' 'a' 'woman'
 'become' 'pregnant' 'or' 'suspect' 'she' 'is' 'pregnant' 'while' 'she'
 'or' 'her' 'partner' 'is' 'participating' 'in' 'this' 'study' ',' 'she'
 'should' 'inform' 'her' 'treating' 'physician' 'immediately']","[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02068612,"39:59:chronic_disease,71:90:chronic_disease,92:103:chronic_disease,108:116:chronic_disease","Are currently under treatment for any psychiatric disorder, including clinical depression, Alzheimer's, or dementia","['Are' 'currently' 'under' 'treatment' 'for' 'any' 'psychiatric'
 'disorder' ',' 'including' 'clinical' 'depression' ',' 'Alzheimer' ""'s""
 ',' 'or' 'dementia']",[2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2.]
NCT02068092,"29:49:treatment,58:67:treatment,85:91:cancer",Must not participate in any other clinical trial for the treatment or prevention of cancer unless they are no longer receiving the intervention and are in the follow-up phase only. Participants must also agree not to join such a trial while participating in this study,"['Must' 'not' 'participate' 'in' 'any' 'other' 'clinical' 'trial' 'for'
 'the' 'treatment' 'or' 'prevention' 'of' 'cancer' 'unless' 'they' 'are'
 'no' 'longer' 'receiving' 'the' 'intervention' 'and' 'are' 'in' 'the'
 'follow-up' 'phase' 'only' '.' 'Participants' 'must' 'also' 'agree' 'not'
 'to' 'join' 'such' 'a' 'trial' 'while' 'participating' 'in' 'this'
 'study']","[0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 1. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02067975,"38:51:chronic_disease,53:77:chronic_disease,81:106:chronic_disease","Has met DSM-IV-TR/DSM-5 Criteria for schizophrenia, schizoaffective disorder or schizophreniform disorder","['Has' 'met' 'DSM-IV-TR/DSM-5' 'Criteria' 'for' 'schizophrenia' ','
 'schizoaffective' 'disorder' 'or' 'schizophreniform' 'disorder']",[0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 2. 2.]
NCT02067819,"7:27:chronic_disease,110:119:chronic_disease,121:126:chronic_disease,128:138:chronic_disease,164:168:chronic_disease,170:176:chronic_disease,181:214:chronic_disease","Major psychiatric disorder at screening that would preclude full participation in study procedures including psychosis, mania, depression, untreated combined type ADHD, autism and pervasive developmental disorders","['Major' 'psychiatric' 'disorder' 'at' 'screening' 'that' 'would'
 'preclude' 'full' 'participation' 'in' 'study' 'procedures' 'including'
 'psychosis' ',' 'mania' ',' 'depression' ',' 'untreated' 'combined'
 'type' 'ADHD' ',' 'autism' 'and' 'pervasive' 'developmental' 'disorders']","[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 2. 0. 0. 0. 0. 2.
 0. 2. 0. 2. 2. 2.]"
NCT02064673,"1:18:treatment,30:39:treatment,46:53:treatment",radiation therapy as primary treatment after surgery,['radiation' 'therapy' 'as' 'primary' 'treatment' 'after' 'surgery'],[1. 1. 0. 0. 1. 0. 1.]
NCT02064296,"21:44:chronic_disease,46:62:chronic_disease,67:85:chronic_disease","Presence of a known coagulation abnormality, thrombocytopenia, or bleeding diathesis that may preclude the safe use of acupuncture","['Presence' 'of' 'a' 'known' 'coagulation' 'abnormality' ','
 'thrombocytopenia' ',' 'or' 'bleeding' 'diathesis' 'that' 'may'
 'preclude' 'the' 'safe' 'use' 'of' 'acupuncture']",[0. 0. 0. 0. 2. 2. 0. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02064296,"8:41:treatment,43:49:treatment,71:79:treatment","Use of over the counter pain medications (NSAIDs, etc.) on the day of MRI scan","['Use' 'of' 'over' 'the' 'counter' 'pain' 'medications' '(' 'NSAIDs' ','
 'etc' '.' ')' 'on' 'the' 'day' 'of' 'MRI' 'scan']",[0. 0. 1. 1. 1. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02064036,"10:28:treatment,30:52:treatment,57:78:treatment","Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy","['Previous' 'pelvic' 'irradiation' ',' 'prostate' 'brachytherapy' ',' 'or'
 'bilateral' 'orchiectomy']",[0. 1. 1. 0. 1. 1. 0. 0. 1. 1.]
NCT02064036,"39:51:chronic_disease,53:62:chronic_disease,67:81:chronic_disease","Severe, active co-morbidity including heart issues, infection and liver problems","['Severe' ',' 'active' 'co-morbidity' 'including' 'heart' 'issues' ','
 'infection' 'and' 'liver' 'problems']",[0. 0. 0. 0. 0. 2. 2. 0. 2. 0. 2. 2.]
NCT02061761,"20:31:treatment,33:36:cancer,38:40:cancer,42:45:cancer","For dose expansion monotherapy: CLL, HL, NHL","['For' 'dose' 'expansion' 'monotherapy' ':' 'CLL' ',' 'HL' ',' 'NHL']",[0. 0. 0. 1. 0. 3. 0. 3. 0. 3.]
NCT02061293,"21:34:chronic_disease,38:62:chronic_disease,102:125:chronic_disease","A family history of schizophrenia or schizoaffective disorder (first or second degree relatives), or bipolar disorder type 1 (first degree relatives)","['A' 'family' 'history' 'of' 'schizophrenia' 'or' 'schizoaffective'
 'disorder' '(' 'first' 'or' 'second' 'degree' 'relatives' ')' ',' 'or'
 'bipolar' 'disorder' 'type' '1' '(' 'first' 'degree' 'relatives' ')']","[0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0.
 0. 0.]"
NCT02061293,"79:95:chronic_disease,111:134:chronic_disease,136:159:chronic_disease,161:174:chronic_disease,176:201:chronic_disease,,247:271:chronic_disease,273:279:chronic_disease,281:296:chronic_disease,298:319:chronic_disease,321:343:chronic_disease,345:371:chronic_disease,373:406:chronic_disease,411:435:chronic_disease","Medical conditions that would preclude safe participation in the trial (e.g., seizure disorder, significantly impaired liver function, coronary artery disease, heart failure, uncontrolled hypertension (above 165/95 mmHg at screening), history of cerebrovascular accident, asthma, hyperthyroidism, narrow-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, or bladder-neck obstruction)","['Medical' 'conditions' 'that' 'would' 'preclude' 'safe' 'participation'
 'in' 'the' 'trial' '(' 'e.g.' ',' 'seizure' 'disorder' ','
 'significantly' 'impaired' 'liver' 'function' ',' 'coronary' 'artery'
 'disease' ',' 'heart' 'failure' ',' 'uncontrolled' 'hypertension' '('
 'above' '165/95' 'mmHg' 'at' 'screening' ')' ',' 'history' 'of'
 'cerebrovascular' 'accident' ',' 'asthma' ',' 'hyperthyroidism' ','
 'narrow-angle' 'glaucoma' ',' 'stenosing' 'peptic' 'ulcer' ','
 'pyloroduodenal' 'obstruction' ',' 'symptomatic' 'prostatic'
 'hypertrophy' ',' 'or' 'bladder-neck' 'obstruction' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 2.
 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 0. 2. 0. 2.
 2. 0. 2. 2. 2. 0. 2. 2. 0. 2. 2. 2. 0. 0. 2. 2. 0.]"
NCT02058095,"1:11:treatment,15:27:treatment,19:27:treatment,,76:91:treatment",Peritoneal or hemodialysis within 90 days or anticipation that dialysis or ultrafiltration of any form will be required during the study period,"['Peritoneal' 'or' 'hemodialysis' 'within' '90' 'days' 'or' 'anticipation'
 'that' 'dialysis' 'or' 'ultrafiltration' 'of' 'any' 'form' 'will' 'be'
 'required' 'during' 'the' 'study' 'period']",[1. 0. 1. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02057133,"13:35:treatment,73:105:treatment,,124:156:treatment,158:169:treatment,171:180:treatment,186:204:cancer,234:257:treatment","For Part D (LY2835219 + exemestane): The participant must have received prior systemic endocrine therapy with at least one nonsteroidal aromatase inhibitor (anastrozole, letrozole) for metastatic disease and may be receiving ongoing therapy with exemestane","['For' 'Part' 'D' '(' 'LY2835219' '+' 'exemestane' ')' ':' 'The'
 'participant' 'must' 'have' 'received' 'prior' 'systemic' 'endocrine'
 'therapy' 'with' 'at' 'least' 'one' 'nonsteroidal' 'aromatase'
 'inhibitor' '(' 'anastrozole' ',' 'letrozole' ')' 'for' 'metastatic'
 'disease' 'and' 'may' 'be' 'receiving' 'ongoing' 'therapy' 'with'
 'exemestane']","[0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 1. 1.
 1. 0. 1. 0. 1. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02057133,"29:46:treatment,126:148:chronic_disease,168:187:chronic_disease,189:200:chronic_disease,,","For Part G: Have a baseline electrocardiogram (obtained from Day -14 to Day -1) with any of the following abnormal findings: ventricular arrhythmia, evidence of acute myocardial ischemia, heart block (of any degree), or QTc prolongation (defined as QTcB ≥450 milliseconds)","['For' 'Part' 'G' ':' 'Have' 'a' 'baseline' 'electrocardiogram' '('
 'obtained' 'from' 'Day' '-14' 'to' 'Day' '-1' ')' 'with' 'any' 'of' 'the'
 'following' 'abnormal' 'findings' ':' 'ventricular' 'arrhythmia' ','
 'evidence' 'of' 'acute' 'myocardial' 'ischemia' ',' 'heart' 'block' '('
 'of' 'any' 'degree' ')' ',' 'or' 'QTc' 'prolongation' '(' 'defined' 'as'
 'QTcB' '≥450' 'milliseconds' ')']","[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 2. 2. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02057133,"21:52:cancer,54:101:cancer,111:135:cancer","Have a diagnosis of hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2) negative metastatic breast cancer for Parts A to E, G, and I","['Have' 'a' 'diagnosis' 'of' 'hormone' 'receptor' 'positive' '(' 'HR+' ')'
 ',' 'human' 'epidermal' 'growth' 'factor' 'receptor' '2' '(' 'HER2' ')'
 'negative' 'metastatic' 'breast' 'cancer' 'for' 'Parts' 'A' 'to' 'E' ','
 'G' ',' 'and' 'I']","[0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 3. 3. 3. 3. 3. 3. 3. 0. 0. 0. 3. 3. 3.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02056873,"10:53:treatment,65:79:chronic_disease,81:94:chronic_disease,96:102:chronic_disease,104:122:chronic_disease,124:145:chronic_disease,150:168:chronic_disease,230:237:treatment","Abnormal brain magnetic resonance imaging (MRI) scan, including severe atrophy, hydrocephalus, stroke, structural lesions, demyelinating lesions, or infectious lesions that would potentially confound the outcome or safety of the surgery as judged by the study neurosurgeon","['Abnormal' 'brain' 'magnetic' 'resonance' 'imaging' '(' 'MRI' ')' 'scan'
 ',' 'including' 'severe' 'atrophy' ',' 'hydrocephalus' ',' 'stroke' ','
 'structural' 'lesions' ',' 'demyelinating' 'lesions' ',' 'or'
 'infectious' 'lesions' 'that' 'would' 'potentially' 'confound' 'the'
 'outcome' 'or' 'safety' 'of' 'the' 'surgery' 'as' 'judged' 'by' 'the'
 'study' 'neurosurgeon']","[0. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 2. 2. 0. 2. 0. 2. 0. 2. 2. 0. 2. 2. 0.
 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]"
NCT02056873,"24:46:treatment,47:88:treatment,90:93:treatment",Must have been offered habit reversal therapy/cognitive behavioral intervention therapy (HRT) if subject did not have it prior to enrollment,"['Must' 'have' 'been' 'offered' 'habit' 'reversal' 'therapy/cognitive'
 'behavioral' 'intervention' 'therapy' '(' 'HRT' ')' 'if' 'subject' 'did'
 'not' 'have' 'it' 'prior' 'to' 'enrollment']",[0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02056873,"23:30:chronic_disease,32:42:chronic_disease,44:60:chronic_disease,71:98:chronic_disease","Untreated or unstable anxiety, depression, bipolar disorder, or other Axis I psychiatric disorder","['Untreated' 'or' 'unstable' 'anxiety' ',' 'depression' ',' 'bipolar'
 'disorder' ',' 'or' 'other' 'Axis' 'I' 'psychiatric' 'disorder']",[0. 0. 0. 2. 0. 2. 0. 2. 2. 0. 0. 0. 2. 2. 2. 2.]
NCT02053766,"32:55:treatment,59:80:treatment,116:134:treatment,",Subject is scheduled to have a non-emergent diagnostic or therapeutic procedure for routine medical care requiring general anesthesia estimated to last at least one hour,"['Subject' 'is' 'scheduled' 'to' 'have' 'a' 'non-emergent' 'diagnostic'
 'or' 'therapeutic' 'procedure' 'for' 'routine' 'medical' 'care'
 'requiring' 'general' 'anesthesia' 'estimated' 'to' 'last' 'at' 'least'
 'one' 'hour']","[0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02050347,"5:13:cancer,102:116:treatment,122:148:treatment",Any leukemia specific marker (such as t(9:22) or t(4:11)) documented in the patient's leukemia cells pre transplant on a post transplant evaluation,"['Any' 'leukemia' 'specific' 'marker' '(' 'such' 'as' 't' '(' '9:22' ')'
 'or' 't' '(' '4:11' ')' ')' 'documented' 'in' 'the' 'patient' ""'s""
 'leukemia' 'cells' 'pre' 'transplant' 'on' 'a' 'post' 'transplant'
 'evaluation']","[0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 1. 0. 0. 1. 1. 1.]"
NCT02050113,"27:42:allergy_name,44:53:allergy_name,55:68:allergy_name,70:76:allergy_name,92:96:allergy_name,101:108:allergy_name","Allergy or sensitivity to stainless steel, polyester, polypropylene, solder (tin, silver), gold, or nitinol","['Allergy' 'or' 'sensitivity' 'to' 'stainless' 'steel' ',' 'polyester' ','
 'polypropylene' ',' 'solder' '(' 'tin' ',' 'silver' ')' ',' 'gold' ','
 'or' 'nitinol']",[0. 0. 0. 0. 4. 4. 0. 4. 0. 4. 0. 4. 0. 0. 0. 0. 0. 0. 4. 0. 0. 4.]
NCT02050113,"1:32:treatment,50:61:treatment,76:108:treatment",Previous left-sided thoracotomy (if the proposed open repair would require dissection of the thoracic aorta),"['Previous' 'left-sided' 'thoracotomy' '(' 'if' 'the' 'proposed' 'open'
 'repair' 'would' 'require' 'dissection' 'of' 'the' 'thoracic' 'aorta' ')']",[1. 1. 1. 0. 0. 0. 0. 1. 1. 0. 0. 1. 1. 1. 1. 1. 0.]
NCT02048852,"54:66:treatment,68:76:treatment,78:92:treatment,97:112:treatment,121:128:treatment,132:141:treatment","not using an acceptable form of birthcontrol such as Depo-provera, Norplant, tubal ligation and barrier methods such as condoms or diaphragm","['not' 'using' 'an' 'acceptable' 'form' 'of' 'birthcontrol' 'such' 'as'
 'Depo-provera' ',' 'Norplant' ',' 'tubal' 'ligation' 'and' 'barrier'
 'methods' 'such' 'as' 'condoms' 'or' 'diaphragm']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 1. 0. 1. 1. 0. 0. 1. 0. 1.]
NCT02048722,"25:55:chronic_disease,66:82:chronic_disease,105:133:cancer,137:153:cancer","Evidence of significant central nervous system disease including seizure disorder requiring medication, symptomatic metastatic brain or meningeal tumors","['Evidence' 'of' 'significant' 'central' 'nervous' 'system' 'disease'
 'including' 'seizure' 'disorder' 'requiring' 'medication' ','
 'symptomatic' 'metastatic' 'brain' 'or' 'meningeal' 'tumors']",[0. 0. 0. 2. 2. 2. 2. 0. 2. 2. 0. 0. 0. 3. 3. 3. 0. 3. 3.]
NCT02048722,"15:32:chronic_disease,34:51:chronic_disease,56:69:chronic_disease","Presence of a non-healing wound, non-healing ulcer, or bone fracture","['Presence' 'of' 'a' 'non-healing' 'wound' ',' 'non-healing' 'ulcer' ','
 'or' 'bone' 'fracture']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 2. 2.]
NCT02048722,"1:25:chronic_disease,37:63:chronic_disease,66:86:chronic_disease,90:108:chronic_disease,","cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months of informed consent","['cerebrovascular' 'accident' '(' 'including' 'transient' 'ischemic'
 'attacks' ')' ',' 'deep' 'vein' 'thrombosis' 'or' 'pulmonary' 'embolism'
 'within' '6' 'months' 'of' 'informed' 'consent']",[2. 2. 0. 0. 2. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02048371,",,19:30:cancer,32:44:cancer,50:63:cancer","Age ≥ 10 year for Liposarcoma, Osteosarcoma, and Ewing sarcoma","['Age' '≥' '10' 'year' 'for' 'Liposarcoma' ',' 'Osteosarcoma' ',' 'and'
 'Ewing' 'sarcoma']",[0. 0. 0. 0. 0. 3. 0. 3. 0. 0. 3. 3.]
NCT02048371,"82:93:cancer,95:113:chronic_disease,115:120:cancer,121:139:cancer,180:205:cancer,209:235:cancer","Patients must have histologically or cytologically confirmed advanced/metastatic liposarcoma, osteogenic sarcoma, Ewing/Ewing-like sarcoma of soft tissue or bone, fusion-positive alveolar rhabdomyosarcoma or embryonal rhabdomyosarcoma/fusion-negative alveolar rhabdomyosarcoma","['Patients' 'must' 'have' 'histologically' 'or' 'cytologically'
 'confirmed' 'advanced/metastatic' 'liposarcoma' ',' 'osteogenic'
 'sarcoma' ',' 'Ewing/Ewing-like' 'sarcoma' 'of' 'soft' 'tissue' 'or'
 'bone' ',' 'fusion-positive' 'alveolar' 'rhabdomyosarcoma' 'or'
 'embryonal' 'rhabdomyosarcoma/fusion-negative' 'alveolar'
 'rhabdomyosarcoma']","[0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 2. 2. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 3. 3.
 0. 3. 3. 0. 0.]"
NCT02048371,"1:23:treatment,46:67:treatment,99:108:treatment,110:119:treatment,121:130:treatment,132:142:treatment,144:153:treatment,155:166:treatment,168:177:treatment,182:192:treatment","Prior systemic therapy with a small molecule oral kinase inhibitor, including but not limited to: pazopanib, sunitinib, sorafenib, everolimus, sirolimus, vemurafenib, dasatinib and trametinib","['Prior' 'systemic' 'therapy' 'with' 'a' 'small' 'molecule' 'oral'
 'kinase' 'inhibitor' ',' 'including' 'but' 'not' 'limited' 'to' ':'
 'pazopanib' ',' 'sunitinib' ',' 'sorafenib' ',' 'everolimus' ','
 'sirolimus' ',' 'vemurafenib' ',' 'dasatinib' 'and' 'trametinib']","[1. 1. 1. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1.
 0. 1. 0. 1. 0. 1. 0. 1.]"
NCT02047474,"16:39:chronic_disease,43:66:treatment,68:76:treatment,81:92:treatment,171:181:cancer","No evidence of extrapancreatic disease by cross sectional imaging, PET scan, or laparoscopy, including nodal involvement beyond the peripancreatic tissues and/or distant metastases","['No' 'evidence' 'of' 'extrapancreatic' 'disease' 'by' 'cross' 'sectional'
 'imaging' ',' 'PET' 'scan' ',' 'or' 'laparoscopy' ',' 'including' 'nodal'
 'involvement' 'beyond' 'the' 'peripancreatic' 'tissues' 'and/or'
 'distant' 'metastases']","[0. 0. 0. 2. 2. 0. 1. 1. 1. 0. 1. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 3.]"
NCT02047474,"17:33:chronic_disease,42:62:chronic_disease,73:109:chronic_disease","No uncontrolled seizure disorder, active neurological disease, or known central nervous system (CNS) disease","['No' 'uncontrolled' 'seizure' 'disorder' ',' 'active' 'neurological'
 'disease' ',' 'or' 'known' 'central' 'nervous' 'system' '(' 'CNS' ')'
 'disease']",[0. 0. 2. 2. 0. 0. 2. 2. 0. 0. 0. 2. 2. 2. 2. 2. 0. 0.]
NCT02046330,"31:49:chronic_disease,51:67:chronic_disease,69:82:chronic_disease,87:111:chronic_disease","Current or past non-affective psychotic disorder, Bipolar Disorder, Schizophrenia, or Schizoaffective disorder","['Current' 'or' 'past' 'non-affective' 'psychotic' 'disorder' ','
 'Bipolar' 'Disorder' ',' 'Schizophrenia' ',' 'or' 'Schizoaffective'
 'disorder']",[0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 2. 0. 0. 2. 2.]
NCT02044120,"30:47:cancer,,97:132:cancer,136:160:cancer","Other clinically significant malignant disease diagnosed within the previous 5 years, excluding intra-epithelial cervical neoplasia or non-melanoma skin cancer","['Other' 'clinically' 'significant' 'malignant' 'disease' 'diagnosed'
 'within' 'the' 'previous' '5' 'years' ',' 'excluding' 'intra-epithelial'
 'cervical' 'neoplasia' 'or' 'non-melanoma' 'skin' 'cancer']",[0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 3. 3. 3.]
NCT02044120,"28:35:treatment,,58:74:treatment,,90:107:treatment,111:124:treatment","Time elapsed from previous therapy must be ≥ 3 weeks for systemic therapy, ≥ 2 weeks for radiation therapy or major surgery","['Time' 'elapsed' 'from' 'previous' 'therapy' 'must' 'be' '≥' '3' 'weeks'
 'for' 'systemic' 'therapy' ',' '≥' '2' 'weeks' 'for' 'radiation'
 'therapy' 'or' 'major' 'surgery']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1.]
NCT02043548,"1:27:treatment,46:58:treatment,60:72:treatment,74:86:treatment,88:109:treatment,115:125:treatment","Concomitant IS medications permitted include methotrexate, azathioprine, cyclosporine, mycophenolate mofetil, and tacrolimus","['Concomitant' 'IS' 'medications' 'permitted' 'include' 'methotrexate' ','
 'azathioprine' ',' 'cyclosporine' ',' 'mycophenolate' 'mofetil' ',' 'and'
 'tacrolimus']",[1. 1. 1. 0. 0. 1. 0. 1. 0. 1. 0. 1. 1. 0. 0. 1.]
NCT02043548,"36:55:chronic_disease,57:62:chronic_disease,64:70:chronic_disease,72:85:chronic_disease,95:105:chronic_disease,136:148:chronic_disease,153:183:chronic_disease,185:202:chronic_disease,208:221:chronic_disease","Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections (including but not limited to tuberculosis and atypical mycobacterial disease, Hepatitis B and C, and herpes zoster","['Known' 'active' 'current' 'or' 'history' 'of' 'recurrent' 'bacterial'
 ',' 'viral' ',' 'fungal' ',' 'mycobacterial' 'or' 'other' 'infections'
 '(' 'including' 'but' 'not' 'limited' 'to' 'tuberculosis' 'and'
 'atypical' 'mycobacterial' 'disease' ',' 'Hepatitis' 'B' 'and' 'C' ','
 'and' 'herpes' 'zoster']","[0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 0. 2. 0. 2. 0. 0. 2. 0. 0. 0. 0. 0. 0. 2.
 0. 2. 2. 2. 0. 2. 2. 2. 2. 0. 0. 2. 2.]"
NCT02043548,"12:20:chronic_disease,131:146:treatment,,203:225:treatment,229:251:treatment,258:270:treatment,272:284:treatment,286:298:treatment,300:310:treatment,312:333:treatment,335:351:treatment,353:357:treatment,359:374:treatment,380:389:treatment","Refractory myositis patients are defined (see Section 3.1.1) as having failed (or considered intolerant to) an adequate course of glucocorticoids or having failed glucocorticoids and at least one other immunosuppressive (IS) or immunomodulatory agent (e.g. methotrexate, azathioprine, cyclosporine, tacrolimus, mycophenolate mofetil, cyclophosphamide, IVIg, anti-TNF agents, and rituximab)","['Refractory' 'myositis' 'patients' 'are' 'defined' '(' 'see' 'Section'
 '3.1.1' ')' 'as' 'having' 'failed' '(' 'or' 'considered' 'intolerant'
 'to' ')' 'an' 'adequate' 'course' 'of' 'glucocorticoids' 'or' 'having'
 'failed' 'glucocorticoids' 'and' 'at' 'least' 'one' 'other'
 'immunosuppressive' '(' 'IS' ')' 'or' 'immunomodulatory' 'agent' '('
 'e.g' '.' 'methotrexate' ',' 'azathioprine' ',' 'cyclosporine' ','
 'tacrolimus' ',' 'mycophenolate' 'mofetil' ',' 'cyclophosphamide' ','
 'IVIg' ',' 'anti-TNF' 'agents' ',' 'and' 'rituximab' ')']","[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 1. 0. 0. 0. 1. 0. 1. 0. 1.
 0. 1. 0. 1. 1. 0. 1. 0. 1. 0. 1. 1. 0. 0. 1. 0.]"
NCT02041936,"19:27:chronic_disease,31:49:chronic_disease,51:57:chronic_disease,61:85:chronic_disease",Have a history of epilepsy or cardiac arrhythmia (atrial or ventricular fibrillation),"['Have' 'a' 'history' 'of' 'epilepsy' 'or' 'cardiac' 'arrhythmia' '('
 'atrial' 'or' 'ventricular' 'fibrillation' ')']",[0. 0. 0. 0. 2. 0. 2. 2. 0. 2. 0. 2. 2. 0.]
NCT02040610,"1:30:treatment,40:53:treatment,55:66:treatment,71:83:chronic_disease","Prior prostate cancer therapy such as: prostatectomy, cryotherapy, or hyperthermia","['Prior' 'prostate' 'cancer' 'therapy' 'such' 'as' ':' 'prostatectomy' ','
 'cryotherapy' ',' 'or' 'hyperthermia']",[1. 1. 1. 1. 0. 0. 0. 1. 0. 1. 0. 0. 2.]
NCT02037048,"34:43:chronic_disease,49:60:chronic_disease,64:81:chronic_disease,170:184:chronic_disease,224:245:treatment","Patients with a known history of infection with hepatitis B or hepatitis C virus (active, previously treated, or both) will not be eligible due to the increased risk of hepatotoxicity and viral reactivation associated with systemic chemotherapy","['Patients' 'with' 'a' 'known' 'history' 'of' 'infection' 'with'
 'hepatitis' 'B' 'or' 'hepatitis' 'C' 'virus' '(' 'active' ','
 'previously' 'treated' ',' 'or' 'both' ')' 'will' 'not' 'be' 'eligible'
 'due' 'to' 'the' 'increased' 'risk' 'of' 'hepatotoxicity' 'and' 'viral'
 'reactivation' 'associated' 'with' 'systemic' 'chemotherapy']","[0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 1. 1.]"
NCT02037048,"24:66:treatment,73:129:treatment,130:159:treatment,177:187:treatment,188:194:treatment",staging should include upper endoscopy with endoscopic ultrasound and a fludeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) scan (with diagnostic CT abdomen/pelvis preferred),"['staging' 'should' 'include' 'upper' 'endoscopy' 'with' 'endoscopic'
 'ultrasound' 'and' 'a' 'fludeoxyglucose' '(' 'FDG' ')' '-positron'
 'emission' 'tomography' '(' 'PET' ')' '/computed' 'tomography' '(' 'CT'
 ')' 'scan' '(' 'with' 'diagnostic' 'CT' 'abdomen/pelvis' 'preferred' ')']","[0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 1. 1. 1. 1.
 1. 0. 0. 0. 0. 0. 1. 0. 0.]"
NCT02035085,"1:11:treatment,16:33:treatment,38:54:cancer",Lumpectomy and radiation therapy for breast carcinoma,['Lumpectomy' 'and' 'radiation' 'therapy' 'for' 'breast' 'carcinoma'],[1. 0. 1. 1. 0. 3. 3.]
NCT02033616,"18:33:chronic_disease,50:72:chronic_disease,87:111:treatment",Known underlying cardiac disease associated with myocardial dysfunction that requires active medical treatment,"['Known' 'underlying' 'cardiac' 'disease' 'associated' 'with' 'myocardial'
 'dysfunction' 'that' 'requires' 'active' 'medical' 'treatment']",[0. 0. 2. 2. 0. 0. 2. 2. 0. 0. 1. 1. 1.]
NCT02030990,"13:24:chronic_disease,26:46:chronic_disease,60:77:treatment","Evidence of keratoconus, corneal irregularity, or abnormal videokeratography in either eye","['Evidence' 'of' 'keratoconus' ',' 'corneal' 'irregularity' ',' 'or'
 'abnormal' 'videokeratography' 'in' 'either' 'eye']",[0. 0. 2. 0. 2. 2. 0. 0. 0. 1. 0. 0. 0.]
NCT02025465,"1:14:chronic_disease,32:45:chronic_disease,,,,,143:197:chronic_disease,201:222:chronic_disease",Heart failure and a history of heart failure with an ejection fraction of 40-50% may occur with a normal ejection fraction now referred to as Heart Failure With Preserved Ejection Fraction (HFpEF) or diastolic dysfunction,"['Heart' 'failure' 'and' 'a' 'history' 'of' 'heart' 'failure' 'with' 'an'
 'ejection' 'fraction' 'of' '40-50' '%' 'may' 'occur' 'with' 'a' 'normal'
 'ejection' 'fraction' 'now' 'referred' 'to' 'as' 'Heart' 'Failure' 'With'
 'Preserved' 'Ejection' 'Fraction' '(' 'HFpEF' ')' 'or' 'diastolic'
 'dysfunction']","[2. 2. 2. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]"
NCT02021279,"86:104:chronic_disease,106:124:chronic_disease,129:135:chronic_disease","Subject has a known neurologic or medical condition affecting bladder function (e.g. multiple sclerosis, spinal cord injury, or stroke with residual neurologic deficit)","['Subject' 'has' 'a' 'known' 'neurologic' 'or' 'medical' 'condition'
 'affecting' 'bladder' 'function' '(' 'e.g' '.' 'multiple' 'sclerosis' ','
 'spinal' 'cord' 'injury' ',' 'or' 'stroke' 'with' 'residual' 'neurologic'
 'deficit' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 2. 0. 0. 2. 0.
 0. 0. 0. 0.]"
NCT02021279,"50:59:treatment,61:74:treatment,79:91:treatment","Subject has had prior or is currently undergoing radiation, laser therapy, or chemotherapy in the pelvic area","['Subject' 'has' 'had' 'prior' 'or' 'is' 'currently' 'undergoing'
 'radiation' ',' 'laser' 'therapy' ',' 'or' 'chemotherapy' 'in' 'the'
 'pelvic' 'area']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 1. 0. 0. 0. 0.]
NCT02020707,"1:25:chronic_disease,51:70:treatment,92:115:chronic_disease",Congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias,"['Congestive' 'heart' 'failure' 'requiring' 'use' 'of' 'ongoing'
 'maintenance' 'therapy' 'for' 'life-threatening' 'ventricular'
 'arrhythmias']",[2. 2. 2. 0. 0. 0. 0. 1. 1. 0. 0. 2. 2.]
NCT02020707,"12:48:chronic_disease,56:75:cancer,77:99:chronic_disease","History of central nervous system (CNS) disease (e.g., primary brain tumor, vascular abnormalities, etc.)","['History' 'of' 'central' 'nervous' 'system' '(' 'CNS' ')' 'disease' '('
 'e.g.' ',' 'primary' 'brain' 'tumor' ',' 'vascular' 'abnormalities' ','
 'etc' '.' ')']",[0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 3. 3. 3. 0. 2. 2. 0. 0. 0. 0.]
NCT02020707,"27:42:cancer,51:74:cancer,76:90:cancer,102:125:cancer","allowable histologies for cervical cancer include squamous cell carcinoma, adenocarcinoma, and mixed/adenosquamous carcinoma","['allowable' 'histologies' 'for' 'cervical' 'cancer' 'include' 'squamous'
 'cell' 'carcinoma' ',' 'adenocarcinoma' ',' 'and' 'mixed/adenosquamous'
 'carcinoma']",[0. 0. 0. 3. 3. 0. 3. 3. 3. 0. 3. 0. 0. 3. 3.]
NCT02020707,"85:97:treatment,116:127:treatment,131:140:treatment,169:175:cancer,,,,","platinum-resistant, defined as =< 183 days from the date of the most recent dose of chemotherapy containing either carboplatin or cisplatin until the first evidence of cancer recurrence or progression either symptoms directly attributable to cancer, radiographic recurrence of cancer, or cancer antigen 125 (CA-125) > 70, confirmed >= 7 days later (confirmation of elevated CA-125 may be beyond 183 days and still count as platinum-resistant)","['platinum-resistant' ',' 'defined' 'as' '=' '<' '183' 'days' 'from' 'the'
 'date' 'of' 'the' 'most' 'recent' 'dose' 'of' 'chemotherapy' 'containing'
 'either' 'carboplatin' 'or' 'cisplatin' 'until' 'the' 'first' 'evidence'
 'of' 'cancer' 'recurrence' 'or' 'progression' 'either' 'symptoms'
 'directly' 'attributable' 'to' 'cancer' ',' 'radiographic' 'recurrence'
 'of' 'cancer' ',' 'or' 'cancer' 'antigen' '125' '(' 'CA-125' ')' '>' '70'
 ',' 'confirmed' '>' '=' '7' 'days' 'later' '(' 'confirmation' 'of'
 'elevated' 'CA-125' 'may' 'be' 'beyond' '183' 'days' 'and' 'still'
 'count' 'as' 'platinum-resistant' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 0. 1. 0.
 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02019641,"16:41:chronic_disease,53:88:chronic_disease,90:134:chronic_disease,136:147:chronic_disease,166:187:chronic_disease","A diagnosis of interstitial lung disease, including idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonitis (NSIP), sarcoidosis, or other form of chronic lung fibrosis based on clinical context via clinic note from a pulmonologist","['A' 'diagnosis' 'of' 'interstitial' 'lung' 'disease' ',' 'including'
 'idiopathic' 'pulmonary' 'fibrosis' '(' 'IPF' ')' ',' 'non-specific'
 'interstitial' 'pneumonitis' '(' 'NSIP' ')' ',' 'sarcoidosis' ',' 'or'
 'other' 'form' 'of' 'chronic' 'lung' 'fibrosis' 'based' 'on' 'clinical'
 'context' 'via' 'clinic' 'note' 'from' 'a' 'pulmonologist']","[0. 0. 0. 2. 2. 2. 0. 0. 2. 2. 2. 2. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 2. 0.
 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02016924,"8:17:treatment,26:36:treatment,58:67:treatment,",either ritonavir-boosted atazanavir or ritonavir-boosted darunavir once or twice daily as per product label for a minimum of 3 months prior to the screening visit,"['either' 'ritonavir-boosted' 'atazanavir' 'or' 'ritonavir-boosted'
 'darunavir' 'once' 'or' 'twice' 'daily' 'as' 'per' 'product' 'label'
 'for' 'a' 'minimum' 'of' '3' 'months' 'prior' 'to' 'the' 'screening'
 'visit']","[0. 1. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02016781,"1:20:treatment,17:20:cancer,89:101:treatment,109:118:treatment,123:133:cancer",Therapy-related MDS (defined as the occurrence of MDS due to prior exposure to systemic chemotherapy and/or radiation for malignancy),"['Therapy-related' 'MDS' '(' 'defined' 'as' 'the' 'occurrence' 'of' 'MDS'
 'due' 'to' 'prior' 'exposure' 'to' 'systemic' 'chemotherapy' 'and/or'
 'radiation' 'for' 'malignancy' ')']",[1. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 3. 0.]
NCT02016235,"55:95:chronic_disease,97:112:chronic_disease,,,146:162:chronic_disease,181:199:treatment,201:216:treatment,221:230:treatment,","Exclusion criteria for calcium stone formers include: primary or secondary hyperparathyroidism, hyperthyroidism, estimated GFR <40 ml/mn/1.73m2, chronic diarrhea states; intake of thiazide diuretics, glucocorticoids, or estrogens within one month of the study","['Exclusion' 'criteria' 'for' 'calcium' 'stone' 'formers' 'include' ':'
 'primary' 'or' 'secondary' 'hyperparathyroidism' ',' 'hyperthyroidism'
 ',' 'estimated' 'GFR' '<' '40' 'ml/mn/1.73m2' ',' 'chronic' 'diarrhea'
 'states' ';' 'intake' 'of' 'thiazide' 'diuretics' ',' 'glucocorticoids'
 ',' 'or' 'estrogens' 'within' 'one' 'month' 'of' 'the' 'study']","[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0.
 0. 0. 0. 1. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0.]"
NCT02013778,"24:48:cancer,134:137:cancer,141:147:treatment,,300:303:treatment,307:309:treatment,,400:409:chronic_disease,417:436:chronic_disease,,",Patient diagnosed with hepatocellular carcinoma in both lobes of the liver by one of the following methods (Pathologically confirmed HCC by biopsy or HCC 2 cm with classic radiographic findings of arterial phase enhancement with venous phase washout and pseudocapsule formation on contrast enhanced MRI or CT or Lesion greater than 2 cm with probable imaging features of HCC and imaging findings of cirrhosis and/or portal hypertension or a serum alphafetoprotein (AFP) greater than 200 mg/mL,"['Patient' 'diagnosed' 'with' 'hepatocellular' 'carcinoma' 'in' 'both'
 'lobes' 'of' 'the' 'liver' 'by' 'one' 'of' 'the' 'following' 'methods'
 '(' 'Pathologically' 'confirmed' 'HCC' 'by' 'biopsy' 'or' 'HCC' '2' 'cm'
 'with' 'classic' 'radiographic' 'findings' 'of' 'arterial' 'phase'
 'enhancement' 'with' 'venous' 'phase' 'washout' 'and' 'pseudocapsule'
 'formation' 'on' 'contrast' 'enhanced' 'MRI' 'or' 'CT' 'or' 'Lesion'
 'greater' 'than' '2' 'cm' 'with' 'probable' 'imaging' 'features' 'of'
 'HCC' 'and' 'imaging' 'findings' 'of' 'cirrhosis' 'and/or' 'portal'
 'hypertension' 'or' 'a' 'serum' 'alphafetoprotein' '(' 'AFP' ')'
 'greater' 'than' '200' 'mg/mL']","[0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02013492,"43:68:cancer,70:83:cancer,89:107:cancer,118:130:cancer","preference will be given to patients with metastatic ovarian cancer, breast cancer, and malignant melanoma, as these malignancies have been shown to be sensitive to manipulation of the beta-adrenergic receptor","['preference' 'will' 'be' 'given' 'to' 'patients' 'with' 'metastatic'
 'ovarian' 'cancer' ',' 'breast' 'cancer' ',' 'and' 'malignant' 'melanoma'
 ',' 'as' 'these' 'malignancies' 'have' 'been' 'shown' 'to' 'be'
 'sensitive' 'to' 'manipulation' 'of' 'the' 'beta-adrenergic' 'receptor']","[0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 3. 3. 0. 0. 3. 3. 0. 0. 0. 3. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02013154,"50:62:cancer,,132:142:cancer,144:167:cancer,184:201:cancer","Disease-free of active second/secondary or prior malignancies for equal to or over 2 years with the exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix or breast","['Disease-free' 'of' 'active' 'second/secondary' 'or' 'prior'
 'malignancies' 'for' 'equal' 'to' 'or' 'over' '2' 'years' 'with' 'the'
 'exception' 'of' 'currently' 'treated' 'basal' 'cell' ',' 'squamous'
 'cell' 'carcinoma' 'of' 'the' 'skin' ',' 'or' 'carcinoma' 'in-situ' 'of'
 'the' 'cervix' 'or' 'breast']","[0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 3.
 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02013154,"57:78:cancer,82:108:cancer,109:122:cancer,126:140:cancer,144:166:cancer",Participants with histologically confirmed recurrent or metastatic esophageal or gastro-esophageal junction squamous cell or adenocarcinoma or gastric adenocarcinoma with Wnt Signaling Alterations,"['Participants' 'with' 'histologically' 'confirmed' 'recurrent' 'or'
 'metastatic' 'esophageal' 'or' 'gastro-esophageal' 'junction' 'squamous'
 'cell' 'or' 'adenocarcinoma' 'or' 'gastric' 'adenocarcinoma' 'with' 'Wnt'
 'Signaling' 'Alterations']",[0. 0. 0. 0. 0. 0. 3. 3. 0. 3. 3. 3. 3. 0. 3. 0. 3. 3. 0. 0. 0. 0.]
NCT02013154,"1:10:treatment,16:31:treatment,,84:108:treatment,",Treatment with corticosteroids (≥ 10 mg per day prednisone or equivalent) or other immune suppressive drugs within the 14 days prior to study entry,"['Treatment' 'with' 'corticosteroids' '(' '≥' '10' 'mg' 'per' 'day'
 'prednisone' 'or' 'equivalent' ')' 'or' 'other' 'immune' 'suppressive'
 'drugs' 'within' 'the' '14' 'days' 'prior' 'to' 'study' 'entry']","[1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02012296,"5:18:treatment,61:121:treatment,128:147:treatment,149:158:treatment,163:201:treatment,208:220:treatment,224:230:treatment","Any prior therapy for castrate disease is acceptable except prior specific cytochrome P450 family 17 (CYP17) antagonists (e.g. abiraterone acetate, orteronel) or prior second generation AR antagonists (e.g. enzalutamide or ARN509) which are excluded other than enzalutamide as specified for phase II portion","['Any' 'prior' 'therapy' 'for' 'castrate' 'disease' 'is' 'acceptable'
 'except' 'prior' 'specific' 'cytochrome' 'P450' 'family' '17' '(' 'CYP17'
 ')' 'antagonists' '(' 'e.g' '.' 'abiraterone' 'acetate' ',' 'orteronel'
 ')' 'or' 'prior' 'second' 'generation' 'AR' 'antagonists' '(' 'e.g' '.'
 'enzalutamide' 'or' 'ARN509' ')' 'which' 'are' 'excluded' 'other' 'than'
 'enzalutamide' 'as' 'specified' 'for' 'phase' 'II' 'portion']","[0. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.
 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02011971,"1:22:chronic_disease,30:38:chronic_disease,40:53:chronic_disease,62:68:cancer,70:80:chronic_disease","Major medical disease (e.g., diabetes, heart disease, active cancer, depression)","['Major' 'medical' 'disease' '(' 'e.g.' ',' 'diabetes' ',' 'heart'
 'disease' ',' 'active' 'cancer' ',' 'depression' ')']",[2. 2. 2. 0. 0. 0. 2. 0. 2. 2. 0. 0. 3. 0. 2. 0.]
NCT02008656,"4:21:chronic_disease,32:61:treatment,63:79:treatment",No active infections requiring systemic antibiotic treatment (oral antibiotics are acceptable at the discretion of the treating physician),"['No' 'active' 'infections' 'requiring' 'systemic' 'antibiotic'
 'treatment' '(' 'oral' 'antibiotics' 'are' 'acceptable' 'at' 'the'
 'discretion' 'of' 'the' 'treating' 'physician' ')']",[0. 2. 2. 0. 1. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02008656,"31:41:cancer,45:70:cancer,82:97:cancer",except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer,"['except' 'for' 'adequately' 'treated' 'basal' 'cell' 'or' 'squamous'
 'cell' 'skin' 'cancer' 'or' 'in' 'situ' 'cervical' 'cancer']",[0. 0. 0. 0. 3. 3. 0. 3. 3. 3. 3. 0. 0. 0. 3. 3.]
NCT02007239,"1:26:chronic_disease,,83:96:treatment,,250:269:chronic_disease","Respiratory insufficiency requiring oxygen supplementation of at least 2 Liter by nasal cannula for at least 12 hours (also including invasive, noninvasive, continuous positive airway pressure or biphasic airway pressure for the purpose of treating respiratory failure)","['Respiratory' 'insufficiency' 'requiring' 'oxygen' 'supplementation' 'of'
 'at' 'least' '2' 'Liter' 'by' 'nasal' 'cannula' 'for' 'at' 'least' '12'
 'hours' '(' 'also' 'including' 'invasive' ',' 'noninvasive' ','
 'continuous' 'positive' 'airway' 'pressure' 'or' 'biphasic' 'airway'
 'pressure' 'for' 'the' 'purpose' 'of' 'treating' 'respiratory' 'failure'
 ')']","[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0.]"
NCT02004275,",17:33:treatment,26:33:treatment,38:54:cancer,47:54:cancer,134:146:treatment,150:169:treatment,202:220:treatment,263:275:treatment,277:287:treatment,292:323:treatment,349:385:treatment,395:427:treatment,458:471:treatment","1 prior line of systemic therapy for multiple myeloma, where a line of therapy for myeloma is defined as 1 or more planned cycles of single agent or combination therapy, as well as a planned series of treatment regimens administered in a sequential manner (e.g. lenalidomide, bortezomib and dexamethasone induction therapy for 4 cycles followed by autologous stem cell transplantation and then lenalidomide maintenance therapy would be considered 1 line of prior therapy)","['1' 'prior' 'line' 'of' 'systemic' 'therapy' 'for' 'multiple' 'myeloma'
 ',' 'where' 'a' 'line' 'of' 'therapy' 'for' 'myeloma' 'is' 'defined' 'as'
 '1' 'or' 'more' 'planned' 'cycles' 'of' 'single' 'agent' 'or'
 'combination' 'therapy' ',' 'as' 'well' 'as' 'a' 'planned' 'series' 'of'
 'treatment' 'regimens' 'administered' 'in' 'a' 'sequential' 'manner' '('
 'e.g' '.' 'lenalidomide' ',' 'bortezomib' 'and' 'dexamethasone'
 'induction' 'therapy' 'for' '4' 'cycles' 'followed' 'by' 'autologous'
 'stem' 'cell' 'transplantation' 'and' 'then' 'lenalidomide' 'maintenance'
 'therapy' 'would' 'be' 'considered' '1' 'line' 'of' 'prior' 'therapy' ')']","[0. 1. 1. 0. 1. 1. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 1. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02004275,"1:9:treatment,15:34:treatment,39:45:treatment",Ixazomib is a substrate of CYP3A4 and CYP1A2,['Ixazomib' 'is' 'a' 'substrate' 'of' 'CYP3A4' 'and' 'CYP1A2'],[1. 0. 0. 1. 1. 1. 0. 1.]
NCT02004275,"23:48:treatment,52:58:treatment,83:89:treatment",No strong inducers of cytochrome P450 (CYP) 3A4 or CYP1A2 or strong inhibitors of CYP3A4 or CYP1A2,"['No' 'strong' 'inducers' 'of' 'cytochrome' 'P450' '(' 'CYP' ')' '3A4'
 'or' 'CYP1A2' 'or' 'strong' 'inhibitors' 'of' 'CYP3A4' 'or' 'CYP1A2']",[0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 1. 0. 0. 0. 0. 1. 0. 0.]
NCT02004275,"56:68:treatment,69:82:treatment,87:97:treatment,101:112:treatment",initial response followed by progression on continuous lenalidomide-dexamethasone +/- elotuzumab or daratumumab,"['initial' 'response' 'followed' 'by' 'progression' 'on' 'continuous'
 'lenalidomide-dexamethasone' '+/-' 'elotuzumab' 'or' 'daratumumab']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1.]
NCT02004028,"24:34:cancer,106:130:treatment,134:165:treatment",Localized disease. The malignancy is confined to one affected hemithorax. Mediastinal N2 lymph nodes via cervical mediastinoscopy or EBUS (endobronchial ultrasound) must be negative in order to be eligible,"['Localized' 'disease' '.' 'The' 'malignancy' 'is' 'confined' 'to' 'one'
 'affected' 'hemithorax' '.' 'Mediastinal' 'N2' 'lymph' 'nodes' 'via'
 'cervical' 'mediastinoscopy' 'or' 'EBUS' '(' 'endobronchial' 'ultrasound'
 ')' 'must' 'be' 'negative' 'in' 'order' 'to' 'be' 'eligible']","[0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02004028,"57:81:chronic_disease,83:101:chronic_disease,106:143:chronic_disease","Uncontrolled intercurrent illness including symptomatic congestive heart failure, cardiac arrhythmia, or psychiatric illness/social situations which in the opinion of the study investigators would be associated with undue risk of participation in the study","['Uncontrolled' 'intercurrent' 'illness' 'including' 'symptomatic'
 'congestive' 'heart' 'failure' ',' 'cardiac' 'arrhythmia' ',' 'or'
 'psychiatric' 'illness/social' 'situations' 'which' 'in' 'the' 'opinion'
 'of' 'the' 'study' 'investigators' 'would' 'be' 'associated' 'with'
 'undue' 'risk' 'of' 'participation' 'in' 'the' 'study']","[0. 0. 0. 0. 0. 2. 2. 2. 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02003222,"47:66:treatment,68:80:treatment,103:122:treatment,123:136:treatment,167:188:treatment","It is recommended to utilize a regimen of the integrase inhibitor, dolutegravir, combined with either disoproxil fumarate/emtricitabine or dolutegravir combined with tenofovir alafenamide/emtricitabine","['It' 'is' 'recommended' 'to' 'utilize' 'a' 'regimen' 'of' 'the'
 'integrase' 'inhibitor' ',' 'dolutegravir' ',' 'combined' 'with' 'either'
 'disoproxil' 'fumarate/emtricitabine' 'or' 'dolutegravir' 'combined'
 'with' 'tenofovir' 'alafenamide/emtricitabine']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 1.
 1.]"
NCT02003222,"31:50:treatment,89:99:treatment,101:110:treatment,118:126:treatment","Patient must not be receiving protease inhibitors or once daily formulations containing cobicistat, stavudine, or on regimens containing stavudine or zidovudine","['Patient' 'must' 'not' 'be' 'receiving' 'protease' 'inhibitors' 'or'
 'once' 'daily' 'formulations' 'containing' 'cobicistat' ',' 'stavudine'
 ',' 'or' 'on' 'regimens' 'containing' 'stavudine' 'or' 'zidovudine']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02002260,"12:20:treatment,24:36:treatment,70:74:treatment,78:85:treatment",History of ablation or hysterectomy or have any contraindications to COCs or LNG-IUS,"['History' 'of' 'ablation' 'or' 'hysterectomy' 'or' 'have' 'any'
 'contraindications' 'to' 'COCs' 'or' 'LNG-IUS']",[0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 1. 0. 1.]
NCT02000115,"1:17:chronic_disease,30:40:cancer,,,63:69:chronic_disease,,,86:102:chronic_disease,,","Blood dyscrasias as defined: leukopenia (WBC<3000 mm3), acute anemia (Hb < 9 mg/dL), thrombocytopenia (platelet count <50,000 cells/mm³)","['Blood' 'dyscrasias' 'as' 'defined' ':' 'leukopenia' '(' 'WBC' '<' '3000'
 'mm3' ')' ',' 'acute' 'anemia' '(' 'Hb' '<' '9' 'mg/dL' ')' ','
 'thrombocytopenia' '(' 'platelet' 'count' '<' '50,000' 'cells/mm³' ')']","[2. 2. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 2. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02000115,"14:36:treatment,77:92:treatment,117:151:treatment,223:243:chronic_disease,255:270:chronic_disease","Pre-existing prosthetic heart valve or other implant in any valve position, prosthetic ring, severe circumferential mitral annular calcification (MAC) which is continuous with calcium in the LVOT, severe (greater than 3+) mitral insufficiency, or severe mitral stenosis with pulmonary compromise","['Pre-existing' 'prosthetic' 'heart' 'valve' 'or' 'other' 'implant' 'in'
 'any' 'valve' 'position' ',' 'prosthetic' 'ring' ',' 'severe'
 'circumferential' 'mitral' 'annular' 'calcification' '(' 'MAC' ')'
 'which' 'is' 'continuous' 'with' 'calcium' 'in' 'the' 'LVOT' ',' 'severe'
 '(' 'greater' 'than' '3+' ')' 'mitral' 'insufficiency' ',' 'or' 'severe'
 'mitral' 'stenosis' 'with' 'pulmonary' 'compromise']","[0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 1. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01999179,"17:34:chronic_disease,88:98:treatment,100:102:treatment,106:116:treatment","Upper extremity venous thrombosis associated with an indwelling catheter documented by ultrasound, CT or venography","['Upper' 'extremity' 'venous' 'thrombosis' 'associated' 'with' 'an'
 'indwelling' 'catheter' 'documented' 'by' 'ultrasound' ',' 'CT' 'or'
 'venography']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1.]
NCT01996865,"27:49:chronic_disease,55:78:chronic_disease,80:103:chronic_disease,105:139:chronic_disease","Known seropositive for or active viral infection with hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV)","['Known' 'seropositive' 'for' 'or' 'active' 'viral' 'infection' 'with'
 'hepatitis' 'B' 'virus' '(' 'HBV' ')' ',' 'hepatitis' 'C' 'virus' '('
 'HCV' ')' ',' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')']","[0. 0. 0. 0. 2. 2. 2. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.
 2. 2. 0. 0.]"
NCT01994538,"7:28:treatment,67:70:chronic_disease,88:98:chronic_disease,100:109:chronic_disease","Other antimicrobial therapy (new or ongoing) prescribed for a non-UTI diagnosis (e.g., cellulitis, pneumonia, etc.)","['Other' 'antimicrobial' 'therapy' '(' 'new' 'or' 'ongoing' ')'
 'prescribed' 'for' 'a' 'non-UTI' 'diagnosis' '(' 'e.g.' ',' 'cellulitis'
 ',' 'pneumonia' ',' 'etc' '.' ')']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 2. 0. 2. 0. 0. 0. 0.]
NCT01994382,"24:42:cancer,38:42:cancer,39:42:cancer,95:98:cancer,99:101:cancer,103:106:cancer,109:113:cancer,126:131:cancer,133:144:cancer,146:149:cancer,194:197:cancer,198:201:cancer,203:207:cancer,212:216:cancer,223:225:cancer,226:228:cancer","Histological evidence: FL Grade 1-3A/iNHL, with relapsed or refractory disease (iNHL includes LPL/WM, MZL); aNHL, defined as DLBCL, FL Grade 3B, MCL, and transformed NHL with relapsed disease; CLL/SLL, PTCL, or CTCL (with MF/SS) with relapsed or refractory","['Histological' 'evidence' ':' 'FL' 'Grade' '1-3A/iNHL' ',' 'with'
 'relapsed' 'or' 'refractory' 'disease' '(' 'iNHL' 'includes' 'LPL/WM' ','
 'MZL' ')' ';' 'aNHL' ',' 'defined' 'as' 'DLBCL' ',' 'FL' 'Grade' '3B' ','
 'MCL' ',' 'and' 'transformed' 'NHL' 'with' 'relapsed' 'disease' ';'
 'CLL/SLL' ',' 'PTCL' ',' 'or' 'CTCL' '(' 'with' 'MF/SS' ')' 'with'
 'relapsed' 'or' 'refractory']","[0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 3. 0. 0. 3. 0. 0. 0.
 3. 0. 0. 0. 0. 0. 3. 0. 0. 0. 3. 0. 0. 0. 0. 3. 0. 3. 0. 0. 3. 0. 0. 3.
 0. 0. 0. 0. 0.]"
NCT01994382,"13:23:chronic_disease,34:61:treatment,63:84:chronic_disease,88:110:chronic_disease","Significant GI disease, previous major gastric/bowel surgery, difficulty swallowing or malabsorption syndrome","['Significant' 'GI' 'disease' ',' 'previous' 'major' 'gastric/bowel'
 'surgery' ',' 'difficulty' 'swallowing' 'or' 'malabsorption' 'syndrome']",[0. 2. 2. 0. 0. 1. 1. 1. 0. 2. 2. 0. 2. 2.]
NCT01993810,"1:38:chronic_disease,61:80:chronic_disease,106:117:cancer,158:171:treatment,",Chronic obstructive pulmonary disease exacerbation or other respiratory illness other than the diagnosed lung cancer requiring hospitalization or precluding study therapy within 30 days before registration,"['Chronic' 'obstructive' 'pulmonary' 'disease' 'exacerbation' 'or' 'other'
 'respiratory' 'illness' 'other' 'than' 'the' 'diagnosed' 'lung' 'cancer'
 'requiring' 'hospitalization' 'or' 'precluding' 'study' 'therapy'
 'within' '30' 'days' 'before' 'registration']","[2. 2. 2. 2. 0. 0. 0. 2. 2. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 1. 1. 0. 0. 0.
 0. 0.]"
NCT01993810,"39:61:cancer,65:70:cancer,89:98:treatment",Patients with prior history of either small cell lung cancer or NSCLC regardless of the treatment received,"['Patients' 'with' 'prior' 'history' 'of' 'either' 'small' 'cell' 'lung'
 'cancer' 'or' 'NSCLC' 'regardless' 'of' 'the' 'treatment' 'received']",[0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 3. 0. 0. 0. 1. 0.]
NCT01993719,",50:72:treatment,110:129:treatment,,227:235:chronic_disease,239:247:chronic_disease,295:310:treatment","More than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo). Patients must have progressive disease after prior treatment","['More' 'than' 'four' 'weeks' 'must' 'have' 'elapsed' 'since' 'any'
 'prior' 'systemic' 'therapy' 'at' 'the' 'time' 'the' 'patient' 'receives'
 'the' 'preparative' 'regimen' ',' 'and' 'patients' 'toxicities' 'must'
 'have' 'recovered' 'to' 'a' 'grade' '1' 'or' 'less' '(' 'except' 'for'
 'toxicities' 'such' 'as' 'alopecia' 'or' 'vitiligo' ')' '.' 'Patients'
 'must' 'have' 'progressive' 'disease' 'after' 'prior' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT01992861,"32:62:treatment,38:54:treatment,82:87:cancer",Patients who have received any prior pelvic radiation therapy in the area of the tumor that precludes the delivery of a curative dose of pelvic radiation,"['Patients' 'who' 'have' 'received' 'any' 'prior' 'pelvic' 'radiation'
 'therapy' 'in' 'the' 'area' 'of' 'the' 'tumor' 'that' 'precludes' 'the'
 'delivery' 'of' 'a' 'curative' 'dose' 'of' 'pelvic' 'radiation']","[0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT01990209,"1:22:cancer,30:44:treatment,48:58:cancer",Archived tumor tissue from a primary biopsy or metastatic lesion for centralized determination of AR expression is mandatory,"['Archived' 'tumor' 'tissue' 'from' 'a' 'primary' 'biopsy' 'or'
 'metastatic' 'lesion' 'for' 'centralized' 'determination' 'of' 'AR'
 'expression' 'is' 'mandatory']",[3. 3. 3. 0. 0. 1. 1. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01990209,"36:55:treatment,87:96:treatment,100:103:treatment",LHRH agonists maybe used to render ovarian suppression with post-menopausal ranges of estradiol or FSH per institutional guidelines,"['LHRH' 'agonists' 'maybe' 'used' 'to' 'render' 'ovarian' 'suppression'
 'with' 'post-menopausal' 'ranges' 'of' 'estradiol' 'or' 'FSH' 'per'
 'institutional' 'guidelines']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0.]
NCT01990209,"20:49:chronic_disease,166:178:treatment,184:202:chronic_disease,,,259:281:chronic_disease","Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy (eg, ulcerative disease, uncontrolled nausea, vomiting, diarrhea ≥ Grade 2, and malabsorption syndrome)","['Presence' 'of' 'active' 'gastrointestinal' '(' 'GI' ')' 'disease' 'or'
 'other' 'condition' 'that' 'will' 'interfere' 'significantly' 'with'
 'the' 'absorption' ',' 'distribution' ',' 'metabolism' ',' 'or'
 'excretion' 'of' 'oral' 'therapy' '(' 'eg' ',' 'ulcerative' 'disease' ','
 'uncontrolled' 'nausea' ',' 'vomiting' ',' 'diarrhea' '≥' 'Grade' '2' ','
 'and' 'malabsorption' 'syndrome' ')']","[0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 1. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0.]"
NCT01989585,"28:43:treatment,89:119:chronic_disease,154:176:chronic_disease,180:195:treatment",Able to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels,"['Able' 'to' 'swallow' 'and' 'retain' 'oral' 'medication' 'and' 'must'
 'not' 'have' 'any' 'clinically' 'significant' 'gastrointestinal'
 'abnormalities' 'that' 'may' 'alter' 'absorption' 'such' 'as'
 'malabsorption' 'syndrome' 'or' 'major' 'resection' 'of' 'the' 'stomach'
 'or' 'bowels']","[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 2. 2.
 0. 1. 1. 0. 0. 0. 0. 0.]"
NCT01989585,"1:15:treatment,19:38:treatment,66:73:treatment","Anticoagulants or antiplatelet agents except for low-dose, 81 mg aspirin","['Anticoagulants' 'or' 'antiplatelet' 'agents' 'except' 'for' 'low-dose'
 ',' '81' 'mg' 'aspirin']",[1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1.]
NCT01989585,"12:21:treatment,12:42:treatment,27:42:treatment,127:134:treatment,136:148:treatment,238:263:treatment","Concurrent treatment with bisphosphonates is permitted; however, treatment must be initiated prior to the first dose of study therapy; prophylactic use of bisphosphonates in patients without bone disease is not permitted, except for the treatment of osteoporosis","['Concurrent' 'treatment' 'with' 'bisphosphonates' 'is' 'permitted' ';'
 'however' ',' 'treatment' 'must' 'be' 'initiated' 'prior' 'to' 'the'
 'first' 'dose' 'of' 'study' 'therapy' ';' 'prophylactic' 'use' 'of'
 'bisphosphonates' 'in' 'patients' 'without' 'bone' 'disease' 'is' 'not'
 'permitted' ',' 'except' 'for' 'the' 'treatment' 'of' 'osteoporosis']","[0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01989585,"12:36:chronic_disease,48:69:chronic_disease,74:89:chronic_disease,92:112:treatment,117:125:treatment,,151:164:treatment","History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization","['History' 'of' 'acute' 'coronary' 'syndromes' '(' 'including'
 'myocardial' 'infarction' 'and' 'unstable' 'angina' ')' ',' 'coronary'
 'angioplasty' ',' 'or' 'stenting' 'within' '6' 'months' 'prior' 'to'
 'randomization']","[0. 0. 2. 1. 1. 0. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.
 1.]"
NCT01989585,"18:41:chronic_disease,37:40:chronic_disease,46:69:chronic_disease,65:68:chronic_disease","Known history of hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection are eligible); it is not necessary to conduct HBV and HCV testing at screening","['Known' 'history' 'of' 'hepatitis' 'B' 'virus' '(' 'HBV' ')' ',' 'or'
 'hepatitis' 'C' 'virus' '(' 'HCV' ')' 'infection' '(' 'patients' 'with'
 'chronic' 'or' 'cleared' 'HBV' 'and' 'HCV' 'infection' 'are' 'eligible'
 ')' ';' 'it' 'is' 'not' 'necessary' 'to' 'conduct' 'HBV' 'and' 'HCV'
 'testing' 'at' 'screening']","[0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01989585,"38:60:treatment,85:106:treatment,,,245:254:treatment","Patients who are receiving any other investigational agents have received any other investigational drugs within 28 days (or five half-lives, whichever is shorter; with a minimum of 14 days from the last dose) preceding the first dose of study treatment and during the study","['Patients' 'who' 'are' 'receiving' 'any' 'other' 'investigational'
 'agents' 'have' 'received' 'any' 'other' 'investigational' 'drugs'
 'within' '28' 'days' '(' 'or' 'five' 'half-lives' ',' 'whichever' 'is'
 'shorter' ';' 'with' 'a' 'minimum' 'of' '14' 'days' 'from' 'the' 'last'
 'dose' ')' 'preceding' 'the' 'first' 'dose' 'of' 'study' 'treatment'
 'and' 'during' 'the' 'study']","[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]"
NCT01989585,"1:17:treatment,19:33:treatment,39:52:treatment","Prior navitoclax, BRAF inhibitor, and MEK inhibitor is prohibited; (exceptions for Phase I are described above)","['Prior' 'navitoclax' ',' 'BRAF' 'inhibitor' ',' 'and' 'MEK' 'inhibitor'
 'is' 'prohibited' ';' '(' 'exceptions' 'for' 'Phase' 'I' 'are'
 'described' 'above' ')']",[1. 1. 0. 1. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01989585,"14:34:chronic_disease,77:101:chronic_disease,115:139:chronic_disease,141:165:chronic_disease,167:185:chronic_disease,187:208:chronic_disease,213:232:chronic_disease,233:250:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active serious infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled diabetes, or psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' ',' 'ongoing' 'or' 'active' 'serious' 'infection' ','
 'symptomatic' 'congestive' 'heart' 'failure' ',' 'unstable' 'angina'
 'pectoris' ',' 'cardiac' 'arrhythmia' ',' 'uncontrolled' 'diabetes' ','
 'or' 'psychiatric' 'illness/social' 'situations' 'that' 'would' 'limit'
 'compliance' 'with' 'study' 'requirements']","[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 2.
 0. 2. 2. 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT01989507,"105:119:treatment,121:129:treatment,131:143:treatment,148:155:treatment","medication contraindications for smoking cessation (smoking cessation may change the bioavailability of antipsychotics, warfarin, theophylline and insulin)","['medication' 'contraindications' 'for' 'smoking' 'cessation' '('
 'smoking' 'cessation' 'may' 'change' 'the' 'bioavailability' 'of'
 'antipsychotics' ',' 'warfarin' ',' 'theophylline' 'and' 'insulin' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0.]
NCT01988246,"43:49:allergy_name,53:61:allergy_name,92:102:treatment",Patients with a known hypersensitivity to NSAIDs or steroids or any component of the study medication,"['Patients' 'with' 'a' 'known' 'hypersensitivity' 'to' 'NSAIDs' 'or'
 'steroids' 'or' 'any' 'component' 'of' 'the' 'study' 'medication']",[0. 0. 0. 0. 0. 0. 4. 0. 4. 0. 0. 0. 0. 0. 0. 1.]
NCT01988246,"8:19:treatment,58:90:treatment,95:109:treatment,117:140:treatment,142:169:treatment,187:193:treatment,","Use of medications known to affect the macula, including hydroxychloroquinine (Plaquenil) and phenothiozines (e.g., thioridazine [Mellaril], chloropromazine [Thorazine]) or supplemental niacin ≥3 grams/day","['Use' 'of' 'medications' 'known' 'to' 'affect' 'the' 'macula' ','
 'including' 'hydroxychloroquinine' '(' 'Plaquenil' ')' 'and'
 'phenothiozines' '(' 'e.g.' ',' 'thioridazine' '[' 'Mellaril' ']' ','
 'chloropromazine' '[' 'Thorazine' ']' ')' 'or' 'supplemental' 'niacin'
 '≥3' 'grams/day']","[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 0. 0. 0. 1. 1. 0. 0. 0.
 1. 1. 0. 0. 0. 0. 0. 1. 0. 0.]"
NCT01986205,"8:18:cancer,48:68:cancer,,104:140:treatment,142:187:treatment,220:236:treatment","Active malignancy, previous malignancy (except basal cell carcinoma) in the last 5 years, or any prior treatment with bleomycin (Blenoxane). Prior treatment with doxorubicin (Adriamycin) is acceptable as long follow-up echocardiography is normal","['Active' 'malignancy' ',' 'previous' 'malignancy' '(' 'except' 'basal'
 'cell' 'carcinoma' ')' 'in' 'the' 'last' '5' 'years' ',' 'or' 'any'
 'prior' 'treatment' 'with' 'bleomycin' '(' 'Blenoxane' ')' '.' 'Prior'
 'treatment' 'with' 'doxorubicin' '(' 'Adriamycin' ')' 'is' 'acceptable'
 'as' 'long' 'follow-up' 'echocardiography' 'is' 'normal']","[0. 3. 0. 0. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1.
 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.]"
NCT01986205,"1:13:chronic_disease,23:32:chronic_disease,34:52:chronic_disease,54:60:chronic_disease,93:113:chronic_disease,139:159:chronic_disease","Lung disease, such as emphysema, chronic bronchitis, asthma that is not well-controlled, or bullous lung disease that raises the risk for pulmonary barotrauma due to air trapping","['Lung' 'disease' ',' 'such' 'as' 'emphysema' ',' 'chronic' 'bronchitis'
 ',' 'asthma' 'that' 'is' 'not' 'well-controlled' ',' 'or' 'bullous'
 'lung' 'disease' 'that' 'raises' 'the' 'risk' 'for' 'pulmonary'
 'barotrauma' 'due' 'to' 'air' 'trapping']","[2. 2. 0. 0. 0. 2. 0. 2. 2. 0. 2. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0.
 0. 2. 2. 0. 0. 0. 0.]"
NCT01986075,"19:22:chronic_disease,,105:132:chronic_disease,302:317:treatment,321:334:treatment","Participants with MDD, with symptom severity that exceeds a HAM-D score of 20, and/or any other current Axis I psychiatric disorder as defined by DSM-V supported by the MINI that in the investigator's judgment are unstable, would be disrupted by study medication, or are likely to require specialized pharmacotherapy or psychotherapy during the study period","['Participants' 'with' 'MDD' ',' 'with' 'symptom' 'severity' 'that'
 'exceeds' 'a' 'HAM-D' 'score' 'of' '20' ',' 'and/or' 'any' 'other'
 'current' 'Axis' 'I' 'psychiatric' 'disorder' 'as' 'defined' 'by' 'DSM-V'
 'supported' 'by' 'the' 'MINI' 'that' 'in' 'the' 'investigator' ""'s""
 'judgment' 'are' 'unstable' ',' 'would' 'be' 'disrupted' 'by' 'study'
 'medication' ',' 'or' 'are' 'likely' 'to' 'require' 'specialized'
 'pharmacotherapy' 'or' 'psychotherapy' 'during' 'the' 'study' 'period']","[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0.]"
NCT01985087,"36:49:treatment,54:77:cancer,88:97:treatment,101:113:treatment",Participants must not have had any prior therapy for glioblastoma multiforme including radiation or chemotherapy,"['Participants' 'must' 'not' 'have' 'had' 'any' 'prior' 'therapy' 'for'
 'glioblastoma' 'multiforme' 'including' 'radiation' 'or' 'chemotherapy']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 3. 3. 0. 1. 0. 1.]
NCT01983462,"12:34:chronic_disease,43:60:treatment,61:84:treatment,86:107:chronic_disease,109:115:chronic_disease,117:130:chronic_disease,,,188:202:chronic_disease,204:226:chronic_disease,244:265:treatment,267:293:chronic_disease","History of cardiovascular disease such as heart angioplasty/stent or bypass surgery, myocardial infarction, stroke, heart failure with or without left ventricular ejection fraction <40%, cardiomyopathy, valvular heart disease, cardiomyopathy, heart transplantation, Type 2 and Type 1 diabetes","['History' 'of' 'cardiovascular' 'disease' 'such' 'as' 'heart'
 'angioplasty/stent' 'or' 'bypass' 'surgery' ',' 'myocardial' 'infarction'
 ',' 'stroke' ',' 'heart' 'failure' 'with' 'or' 'without' 'left'
 'ventricular' 'ejection' 'fraction' '<' '40' '%' ',' 'cardiomyopathy' ','
 'valvular' 'heart' 'disease' ',' 'cardiomyopathy' ',' 'heart'
 'transplantation' ',' 'Type' '2' 'and' 'Type' '1' 'diabetes']","[0. 0. 2. 2. 0. 0. 1. 1. 1. 1. 1. 0. 2. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 2. 2.]"
NCT01983462,"4:21:treatment,29:36:treatment,38:46:treatment,49:56:treatment,58:69:treatment,72:79:treatment,81:101:treatment,115:143:treatment,","On weight loss drugs (e.g., Xenical (orlistat), Meridia (sibutramine), Acutrim (phenylpropanol-amine), or similar over-the-counter medications) within 3 months of screening","['On' 'weight' 'loss' 'drugs' '(' 'e.g.' ',' 'Xenical' '(' 'orlistat' ')'
 ',' 'Meridia' '(' 'sibutramine' ')' ',' 'Acutrim' '('
 'phenylpropanol-amine' ')' ',' 'or' 'similar' 'over-the-counter'
 'medications' ')' 'within' '3' 'months' 'of' 'screening']","[0. 1. 1. 1. 0. 0. 0. 1. 0. 1. 0. 0. 1. 0. 1. 0. 0. 1. 0. 1. 0. 0. 0. 0.
 1. 1. 0. 0. 0. 0. 0. 0.]"
NCT01983462,"8:24:treatment,26:34:treatment,36:41:treatment,51:62:treatment,64:72:treatment,74:81:treatment,83:92:treatment","Taking cox-2 inhibitors (Celebrex, Vioxx, etc) or allopurinol (Zyloprim, Lopurin, Allopurin)","['Taking' 'cox-2' 'inhibitors' '(' 'Celebrex' ',' 'Vioxx' ',' 'etc' ')'
 'or' 'allopurinol' '(' 'Zyloprim' ',' 'Lopurin' ',' 'Allopurin' ')']",[0. 1. 1. 0. 1. 0. 1. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0.]
NCT01983462,"8:27:treatment,36:49:treatment,51:58:treatment,60:69:treatment,80:89:treatment,92:100:treatment","Taking thyroid medications such as levothyroxine (Levoxyl, Synthroid, Levoxyl, Unithroid); Levodopa","['Taking' 'thyroid' 'medications' 'such' 'as' 'levothyroxine' '('
 'Levoxyl' ',' 'Synthroid' ',' 'Levoxyl' ',' 'Unithroid' ')' ';'
 'Levodopa']",[0. 1. 1. 0. 0. 1. 0. 1. 0. 1. 0. 0. 0. 1. 0. 0. 1.]
NCT01980823,"10:22:treatment,24:41:treatment,46:62:treatment,","No prior chemotherapy, radiation therapy, or breast resection within 6 months of study entry","['No' 'prior' 'chemotherapy' ',' 'radiation' 'therapy' ',' 'or' 'breast'
 'resection' 'within' '6' 'months' 'of' 'study' 'entry']",[0. 0. 1. 0. 1. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT01976585,"13:35:chronic_disease,,55:79:chronic_disease,81:102:chronic_disease,,127:142:chronic_disease,144:164:treatment,189:208:chronic_disease,212:243:chronic_disease",Significant cardiovascular disease (i.e. NYHA class 3 congestive heart failure; myocardial infarction with the past 6 months; unstable angina; coronary angioplasty with the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias),"['Significant' 'cardiovascular' 'disease' '(' 'i.e' '.' 'NYHA' 'class' '3'
 'congestive' 'heart' 'failure' ';' 'myocardial' 'infarction' 'with' 'the'
 'past' '6' 'months' ';' 'unstable' 'angina' ';' 'coronary' 'angioplasty'
 'with' 'the' 'past' '6' 'months' ';' 'uncontrolled' 'atrial' 'or'
 'ventricular' 'cardiac' 'arrhythmias' ')']","[0. 2. 2. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 2. 2. 0.
 1. 1. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 2. 0.]"
NCT01976169,"13:37:chronic_disease,39:63:chronic_disease,65:96:chronic_disease,","Symptomatic congestive heart failure, unstable angina pectoris, stroke or myocardial infarction within 3 months","['Symptomatic' 'congestive' 'heart' 'failure' ',' 'unstable' 'angina'
 'pectoris' ',' 'stroke' 'or' 'myocardial' 'infarction' 'within' '3'
 'months']",[0. 2. 2. 2. 0. 2. 2. 2. 0. 2. 2. 2. 2. 0. 0. 0.]
NCT01974609,"41:52:allergy_name,54:67:allergy_name,72:81:allergy_name","reported allergy or adverse reaction to hydrocodone, acetaminophen, or ibuprofen","['reported' 'allergy' 'or' 'adverse' 'reaction' 'to' 'hydrocodone' ','
 'acetaminophen' ',' 'or' 'ibuprofen']",[0. 0. 0. 0. 0. 0. 4. 0. 4. 0. 0. 4.]
NCT01973283,"86:100:treatment,122:131:treatment,178:196:treatment,202:205:treatment","Subject is considered based on history to be unlikely to respond to the single agent antidepressant (i.e., subjects with treatment resistant depression, including subjects with previous treatment with ECT)","['Subject' 'is' 'considered' 'based' 'on' 'history' 'to' 'be' 'unlikely'
 'to' 'respond' 'to' 'the' 'single' 'agent' 'antidepressant' '(' 'i.e.'
 ',' 'subjects' 'with' 'treatment' 'resistant' 'depression' ','
 'including' 'subjects' 'with' 'previous' 'treatment' 'with' 'ECT' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 1. 0. 0.
 0. 0. 0. 0. 1. 1. 0. 1. 0.]"
NCT01972919,"1:27:cancer,29:46:cancer,50:68:chronic_disease","Distant metastatic disease, second malignancy or peritoneal seeding","['Distant' 'metastatic' 'disease' ',' 'second' 'malignancy' 'or'
 'peritoneal' 'seeding']",[3. 3. 3. 0. 3. 3. 0. 2. 2.]
NCT01970176,"1:13:chronic_disease,17:48:chronic_disease,50:57:chronic_disease,59:66:chronic_disease","Infiltrative or inflammatory myocardial disease (amyloid, sarcoid)","['Infiltrative' 'or' 'inflammatory' 'myocardial' 'disease' '(' 'amyloid'
 ',' 'sarcoid' ')']",[2. 0. 2. 2. 2. 0. 2. 0. 2. 0.]
NCT01969643,"1:24:cancer,,71:95:treatment,330:346:treatment","Triple-negative disease (ER/PR/HER2-negative) and received at least 2 prior cytotoxic regimens in the incurable, unresectable, LA/MBC setting; or ER-positive and/or PR-positive/HER2-negative disease and received at least 2 prior cytotoxic regimens in the incurable, unresectable, LA/MBC setting and are no longer a candidate for hormonal therapy (not enrolling new patients)","['Triple-negative' 'disease' '(' 'ER/PR/HER2-negative' ')' 'and'
 'received' 'at' 'least' '2' 'prior' 'cytotoxic' 'regimens' 'in' 'the'
 'incurable' ',' 'unresectable' ',' 'LA/MBC' 'setting' ';' 'or'
 'ER-positive' 'and/or' 'PR-positive/HER2-negative' 'disease' 'and'
 'received' 'at' 'least' '2' 'prior' 'cytotoxic' 'regimens' 'in' 'the'
 'incurable' ',' 'unresectable' ',' 'LA/MBC' 'setting' 'and' 'are' 'no'
 'longer' 'a' 'candidate' 'for' 'hormonal' 'therapy' '(' 'not' 'enrolling'
 'new' 'patients' ')']","[3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]"
NCT01968109,"36:44:cancer,46:53:cancer,55:62:cancer,67:90:cancer,92:105:cancer,107:114:cancer,119:140:cancer,150:172:treatment,174:191:cancer,183:191:cancer,214:219:cancer,221:241:cancer,251:253:treatment,285:323:treatment,369:439:treatment","For Dose escalation: subjects with cervical, ovarian, bladder and colorectal cancer (CRC), head and neck, gastric and hepatocellular cancer naive to immuno-oncology agents; 1st line melanoma and 1st line/2nd line NSCLC; Renal Cell Carcinoma naive to IO; NSCLC progressing while on or after therapy with anti-PD1/anti-PDL-1 and melanoma subjects progressed while-on or after treatment with anti-PD1 or anti-PDL1 with or without anti-CTLA-4","['For' 'Dose' 'escalation' ':' 'subjects' 'with' 'cervical' ',' 'ovarian'
 ',' 'bladder' 'and' 'colorectal' 'cancer' '(' 'CRC' ')' ',' 'head' 'and'
 'neck' ',' 'gastric' 'and' 'hepatocellular' 'cancer' 'naive' 'to'
 'immuno-oncology' 'agents' ';' '1st' 'line' 'melanoma' 'and' '1st'
 'line/2nd' 'line' 'NSCLC' ';' 'Renal' 'Cell' 'Carcinoma' 'naive' 'to'
 'IO' ';' 'NSCLC' 'progressing' 'while' 'on' 'or' 'after' 'therapy' 'with'
 'anti-PD1/anti-PDL-1' 'and' 'melanoma' 'subjects' 'progressed' 'while-on'
 'or' 'after' 'treatment' 'with' 'anti-PD1' 'or' 'anti-PDL1' 'with' 'or'
 'without' 'anti-CTLA-4']","[0. 0. 0. 0. 0. 0. 3. 0. 3. 0. 3. 0. 3. 3. 3. 0. 0. 0. 3. 3. 3. 0. 3. 0.
 3. 3. 0. 0. 1. 1. 0. 3. 3. 3. 0. 0. 0. 0. 3. 0. 3. 3. 3. 0. 0. 1. 0. 0.
 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01967823,"113:123:cancer,158:175:treatment,184:190:treatment,207:216:treatment","Confirmation of ESO expression and pathology is not required in patients with definitive radiologic evidence of meningioma who are unresectable, and in whom radiation therapy without biopsy is the standard treatment","['Confirmation' 'of' 'ESO' 'expression' 'and' 'pathology' 'is' 'not'
 'required' 'in' 'patients' 'with' 'definitive' 'radiologic' 'evidence'
 'of' 'meningioma' 'who' 'are' 'unresectable' ',' 'and' 'in' 'whom'
 'radiation' 'therapy' 'without' 'biopsy' 'is' 'the' 'standard'
 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0.
 1. 1. 0. 1. 0. 0. 0. 1.]"
NCT01967823,"51:67:treatment,82:111:treatment,117:135:cancer","Patients must have previously received first-line standard therapy (or effective salvage chemotherapy regimens) for metastatic disease, if known to be effective for that disease, and have been either non-responders (progressive disease) or have recurred","['Patients' 'must' 'have' 'previously' 'received' 'first-line' 'standard'
 'therapy' '(' 'or' 'effective' 'salvage' 'chemotherapy' 'regimens' ')'
 'for' 'metastatic' 'disease' ',' 'if' 'known' 'to' 'be' 'effective' 'for'
 'that' 'disease' ',' 'and' 'have' 'been' 'either' 'non-responders' '('
 'progressive' 'disease' ')' 'or' 'have' 'recurred']","[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 1. 1. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01967238,"13:28:chronic_disease,30:42:treatment,46:67:treatment","(either the influenza virus, pneumococcal or meningococcal vaccine)","['(' 'either' 'the' 'influenza' 'virus' ',' 'pneumococcal' 'or'
 'meningococcal' 'vaccine' ')']",[0. 0. 0. 2. 2. 0. 1. 0. 1. 1. 0.]
NCT01967238,"36:42:chronic_disease,44:48:chronic_disease,52:69:chronic_disease,103:124:chronic_disease","Documented previous infection with dengue, zika or chikungunya virus or no history of dengue, zika or chikungunya infection","['Documented' 'previous' 'infection' 'with' 'dengue' ',' 'zika' 'or'
 'chikungunya' 'virus' 'or' 'no' 'history' 'of' 'dengue' ',' 'zika' 'or'
 'chikungunya' 'infection']",[0. 0. 0. 0. 2. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01964859,"130:151:chronic_disease,153:170:cancer,172:191:chronic_disease,200:203:chronic_disease,205:214:chronic_disease,216:227:chronic_disease,229:240:chronic_disease","Having a significant medical history that the investigator feels is not safe for study participation (for example, some forms of autoimmune conditions, metastatic cancer, infectious diseases such as HIV, HTLV I/II, Hepatitis B, Hepatitis C)","['Having' 'a' 'significant' 'medical' 'history' 'that' 'the'
 'investigator' 'feels' 'is' 'not' 'safe' 'for' 'study' 'participation'
 '(' 'for' 'example' ',' 'some' 'forms' 'of' 'autoimmune' 'conditions' ','
 'metastatic' 'cancer' ',' 'infectious' 'diseases' 'such' 'as' 'HIV' ','
 'HTLV' 'I/II' ',' 'Hepatitis' 'B' ',' 'Hepatitis' 'C' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.
 0. 3. 3. 0. 2. 2. 0. 0. 2. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0.]"
NCT01964261,"11:32:treatment,34:43:treatment,45:67:treatment,72:94:treatment","Implanted Cardiac Defibrillator, Pacemaker, vagal nerve stimulator, or spinal cord stimulator","['Implanted' 'Cardiac' 'Defibrillator' ',' 'Pacemaker' ',' 'vagal' 'nerve'
 'stimulator' ',' 'or' 'spinal' 'cord' 'stimulator']",[0. 1. 1. 0. 1. 0. 1. 1. 1. 0. 0. 1. 1. 1.]
NCT01959698,"8:44:chronic_disease,68:86:chronic_disease,100:120:chronic_disease,154:159:cancer",Active central nervous system (CNS) disease defined as symptomatic meningeal lymphoma or known CNS parenchymal lymphoma; a lumbar puncture demonstrating DLBCL at the time of registration to this study is not exclusion for study enrollment,"['Active' 'central' 'nervous' 'system' '(' 'CNS' ')' 'disease' 'defined'
 'as' 'symptomatic' 'meningeal' 'lymphoma' 'or' 'known' 'CNS'
 'parenchymal' 'lymphoma' ';' 'a' 'lumbar' 'puncture' 'demonstrating'
 'DLBCL' 'at' 'the' 'time' 'of' 'registration' 'to' 'this' 'study' 'is'
 'not' 'exclusion' 'for' 'study' 'enrollment']","[0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 3.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01959698,",,142:171:treatment,179:197:treatment,206:219:treatment","Measurable or assessable disease is required; measurable tumor size (at least one node measuring 2.25 cm^2 in bidimensional measurement) per computed tomography (CT) scan, other radiological study, and/or physical exam","['Measurable' 'or' 'assessable' 'disease' 'is' 'required' ';' 'measurable'
 'tumor' 'size' '(' 'at' 'least' 'one' 'node' 'measuring' '2.25' 'cm^2'
 'in' 'bidimensional' 'measurement' ')' 'per' 'computed' 'tomography' '('
 'CT' ')' 'scan' ',' 'other' 'radiological' 'study' ',' 'and/or'
 'physical' 'exam']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 1. 1. 1. 0. 0. 0. 0. 1. 1. 0. 0. 1. 1.]"
NCT01959698,"65:78:treatment,80:97:treatment,99:111:treatment,116:129:treatment","Patients must not have any significant toxicity associated with prior surgery, radiation therapy, chemotherapy, or immunotherapy, per principal investigator (PI) discretion","['Patients' 'must' 'not' 'have' 'any' 'significant' 'toxicity'
 'associated' 'with' 'prior' 'surgery' ',' 'radiation' 'therapy' ','
 'chemotherapy' ',' 'or' 'immunotherapy' ',' 'per' 'principal'
 'investigator' '(' 'PI' ')' 'discretion']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT01959425,"1:14:chronic_disease,25:43:chronic_disease,47:53:chronic_disease",Acute illness or active systemic infection or sepsis,['Acute' 'illness' 'or' 'active' 'systemic' 'infection' 'or' 'sepsis'],[2. 2. 0. 0. 2. 2. 0. 2.]
NCT01959425,"1:4:treatment,51:67:treatment,69:80:chronic_disease,91:109:chronic_disease,123:154:chronic_disease,","OAT required for reasons not related to AF (i.e., prosthetic valve, PV stenosis, previous pulmonary embolism, presence of spontaneous echo contrast [SEC] at standard echo performed at 3-months follow-up)","['OAT' 'required' 'for' 'reasons' 'not' 'related' 'to' 'AF' '(' 'i.e.' ','
 'prosthetic' 'valve' ',' 'PV' 'stenosis' ',' 'previous' 'pulmonary'
 'embolism' ',' 'presence' 'of' 'spontaneous' 'echo' 'contrast' '[' 'SEC'
 ']' 'at' 'standard' 'echo' 'performed' 'at' '3-months' 'follow-up' ')']","[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 2. 2. 0. 0. 2. 2. 0. 0. 0. 2.
 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01959204,"11:20:treatment,24:35:treatment,,87:97:treatment",Has taken oxycodone or oxymorphone within the 48 hours before anticipated dosing with study drug,"['Has' 'taken' 'oxycodone' 'or' 'oxymorphone' 'within' 'the' '48' 'hours'
 'before' 'anticipated' 'dosing' 'with' 'study' 'drug']",[0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01959204,"10:20:treatment,60:66:treatment,,110:133:treatment,134:146:treatment,151:163:treatment,165:186:treatment,195:207:treatment,213:232:treatment,241:250:treatment,285:293:treatment,295:308:treatment,314:323:treatment","Uses any medication known to be an inhibitor or inducer of CYP3A4 within 14 days (for inhibitors such as the azole-antifungal agents voriconazole and ketoconazole, macrolide antibiotics such as erythromycin, and protease inhibitors such as ritonavir) or 28 days (for inducers such as rifampin, carbamazepine, and phenytoin) of dosing with study drug","['Uses' 'any' 'medication' 'known' 'to' 'be' 'an' 'inhibitor' 'or'
 'inducer' 'of' 'CYP3A4' 'within' '14' 'days' '(' 'for' 'inhibitors'
 'such' 'as' 'the' 'azole-antifungal' 'agents' 'voriconazole' 'and'
 'ketoconazole' ',' 'macrolide' 'antibiotics' 'such' 'as' 'erythromycin'
 ',' 'and' 'protease' 'inhibitors' 'such' 'as' 'ritonavir' ')' 'or' '28'
 'days' '(' 'for' 'inducers' 'such' 'as' 'rifampin' ',' 'carbamazepine'
 ',' 'and' 'phenytoin' ')' 'of' 'dosing' 'with' 'study' 'drug']","[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.
 0. 1. 0. 1. 1. 0. 0. 1. 0. 0. 1. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0.]"
NCT01954966,"16:39:treatment,41:56:treatment,58:72:treatment,77:88:treatment,124:135:chronic_disease,150:159:treatment,164:180:chronic_disease,191:207:chronic_disease,209:235:chronic_disease,237:265:chronic_disease,267:297:chronic_disease,302:316:chronic_disease","Regular use of psychotropic medication (antidepressants, antipsychotics, or anxiolytics) and recent (within previous year) psychiatric diagnosis and treatment for Axis I disorders including major depression, bipolar affective disorder, generalized anxiety disorder, post-traumatic stress disorder and panic disorder","['Regular' 'use' 'of' 'psychotropic' 'medication' '(' 'antidepressants'
 ',' 'antipsychotics' ',' 'or' 'anxiolytics' ')' 'and' 'recent' '('
 'within' 'previous' 'year' ')' 'psychiatric' 'diagnosis' 'and'
 'treatment' 'for' 'Axis' 'I' 'disorders' 'including' 'major' 'depression'
 ',' 'bipolar' 'affective' 'disorder' ',' 'generalized' 'anxiety'
 'disorder' ',' 'post-traumatic' 'stress' 'disorder' 'and' 'panic'
 'disorder']","[0. 0. 0. 1. 1. 0. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 1.
 0. 2. 2. 2. 0. 2. 2. 0. 2. 2. 2. 0. 2. 2. 2. 0. 2. 2. 2. 0. 2. 2.]"
NCT01954576,"31:53:treatment,75:85:treatment,99:102:cancer",Currently receiving any other investigational agents that are intended as treatments of recurrent GBM,"['Currently' 'receiving' 'any' 'other' 'investigational' 'agents' 'that'
 'are' 'intended' 'as' 'treatments' 'of' 'recurrent' 'GBM']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 0. 0. 3.]
NCT01954576,"9:15:treatment,19:28:treatment,42:47:cancer,175:192:treatment","Planned biopsy or resection of recurrent tumor for therapeutic and/or diagnostic purpose, and with adequate bone marrow, hepatic, cardiac, and renal function to undergo this planned procedure","['Planned' 'biopsy' 'or' 'resection' 'of' 'recurrent' 'tumor' 'for'
 'therapeutic' 'and/or' 'diagnostic' 'purpose' ',' 'and' 'with' 'adequate'
 'bone' 'marrow' ',' 'hepatic' ',' 'cardiac' ',' 'and' 'renal' 'function'
 'to' 'undergo' 'this' 'planned' 'procedure']","[0. 1. 0. 1. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 1.]"
NCT01954576,"50:53:cancer,70:91:treatment,182:188:treatment,192:201:treatment",Unequivocal evidence of recurrent or progressive GBM before or after bevacizumab treatment first based on radiographic appearances then confirmed by histologic confirmation through biopsy or resection,"['Unequivocal' 'evidence' 'of' 'recurrent' 'or' 'progressive' 'GBM'
 'before' 'or' 'after' 'bevacizumab' 'treatment' 'first' 'based' 'on'
 'radiographic' 'appearances' 'then' 'confirmed' 'by' 'histologic'
 'confirmation' 'through' 'biopsy' 'or' 'resection']","[0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 0. 1.]"
NCT01954173,"30:40:treatment,42:58:treatment,60:78:treatment,83:111:treatment","Patients must have undergone cystectomy (total cystectomy, radical cystectomy +/- pelvic lymph node dissection) with no evidence of macroscopic residual disease","['Patients' 'must' 'have' 'undergone' 'cystectomy' '(' 'total'
 'cystectomy' ',' 'radical' 'cystectomy' '+/-' 'pelvic' 'lymph' 'node'
 'dissection' ')' 'with' 'no' 'evidence' 'of' 'macroscopic' 'residual'
 'disease']",[0. 0. 0. 0. 1. 0. 1. 1. 0. 1. 1. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01953588,"1:6:cancer,,,,58:62:cancer,75:78:treatment,,",Tumor estrogen receptor (ER) Allred score between 0-5 or HER2 positive by IHC (3+) or amplified by FISH > 2.0,"['Tumor' 'estrogen' 'receptor' '(' 'ER' ')' 'Allred' 'score' 'between'
 '0-5' 'or' 'HER2' 'positive' 'by' 'IHC' '(' '3+' ')' 'or' 'amplified'
 'by' 'FISH' '>' '2.0']",[3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01953263,"78:81:chronic_disease,83:91:chronic_disease,96:117:chronic_disease,129:145:chronic_disease","Patients with a history of systemic conditions, including but not limited to HIV, diabetes and chronic liver disease (including Hepatitis B or C), that the Investigator believes may jeopardize the safety of the patient to participate in the study","['Patients' 'with' 'a' 'history' 'of' 'systemic' 'conditions' ','
 'including' 'but' 'not' 'limited' 'to' 'HIV' ',' 'diabetes' 'and'
 'chronic' 'liver' 'disease' '(' 'including' 'Hepatitis' 'B' 'or' 'C' ')'
 ',' 'that' 'the' 'Investigator' 'believes' 'may' 'jeopardize' 'the'
 'safety' 'of' 'the' 'patient' 'to' 'participate' 'in' 'the' 'study']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 2. 2. 2. 0. 0. 2. 2.
 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01952730,",37:49:treatment,51:63:treatment,65:78:treatment,89:111:treatment","At least 4 weeks since last dose of chemotherapy, radiotherapy, immunotherapy, systemic glucocorticoid therapy or operation in order to receive vaccine","['At' 'least' '4' 'weeks' 'since' 'last' 'dose' 'of' 'chemotherapy' ','
 'radiotherapy' ',' 'immunotherapy' ',' 'systemic' 'glucocorticoid'
 'therapy' 'or' 'operation' 'in' 'order' 'to' 'receive' 'vaccine']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT01950351,"1:16:chronic_disease,20:36:chronic_disease,47:70:treatment",acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration,"['acute' 'bacterial' 'or' 'fungal' 'infection' 'requiring' 'intravenous'
 'antibiotics' 'at' 'the' 'time' 'of' 'registration']",[2. 2. 0. 2. 2. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT01950234,"1:5:chronic_disease,7:11:chronic_disease,16:20:chronic_disease","SPMS, PPMS, or PRMS phenotype, according to Lublin and Reingold criteria","['SPMS' ',' 'PPMS' ',' 'or' 'PRMS' 'phenotype' ',' 'according' 'to'
 'Lublin' 'and' 'Reingold' 'criteria']",[2. 0. 2. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01950234,"1:10:treatment,16:29:treatment,44:66:treatment,96:105:treatment,",Treatment with dalfampridine or compounded 4-aminopyridine (4-AP) will be permitted as long as treatment has been ongoing and stable for at least 3 months prior to randomization,"['Treatment' 'with' 'dalfampridine' 'or' 'compounded' '4-aminopyridine'
 '(' '4-AP' ')' 'will' 'be' 'permitted' 'as' 'long' 'as' 'treatment' 'has'
 'been' 'ongoing' 'and' 'stable' 'for' 'at' 'least' '3' 'months' 'prior'
 'to' 'randomization']","[1. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT01947140,"8:19:chronic_disease,21:32:chronic_disease,37:48:chronic_disease","Active Hepatitis A, Hepatitis B, or Hepatitis C infection","['Active' 'Hepatitis' 'A' ',' 'Hepatitis' 'B' ',' 'or' 'Hepatitis' 'C'
 'infection']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01946074,"17:36:treatment,111:121:treatment,125:132:treatment","Subjects in the combination therapy cohorts must meet the above inclusion criteria and be eligible to receive paclitaxel or FOLFIRI per most current prescribing information, or at the discretion of the Investigator","['Subjects' 'in' 'the' 'combination' 'therapy' 'cohorts' 'must' 'meet'
 'the' 'above' 'inclusion' 'criteria' 'and' 'be' 'eligible' 'to' 'receive'
 'paclitaxel' 'or' 'FOLFIRI' 'per' 'most' 'current' 'prescribing'
 'information' ',' 'or' 'at' 'the' 'discretion' 'of' 'the' 'Investigator']","[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01945814,"1:39:treatment,44:47:chronic_disease,49:52:chronic_disease,57:67:chronic_disease","Treatment of reactivation or infection for EBV, CMV, or Adenovirus","['Treatment' 'of' 'reactivation' 'or' 'infection' 'for' 'EBV' ',' 'CMV'
 ',' 'or' 'Adenovirus']",[1. 1. 1. 1. 1. 0. 2. 0. 2. 0. 0. 2.]
NCT01943851,"1:12:treatment,17:38:cancer,40:55:treatment","Hydroxyurea for proliferative disease, Corticosteroids, Use of hematopoetic growth factors is permitted at the discretion of the investigator according to published guidelines (e.g., National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH), etc.)","['Hydroxyurea' 'for' 'proliferative' 'disease' ',' 'Corticosteroids' ','
 'Use' 'of' 'hematopoetic' 'growth' 'factors' 'is' 'permitted' 'at' 'the'
 'discretion' 'of' 'the' 'investigator' 'according' 'to' 'published'
 'guidelines' '(' 'e.g.' ',' 'National' 'Comprehensive' 'Cancer' 'Network'
 '(' 'NCCN' ')' ',' 'American' 'Society' 'of' 'Clinical' 'Oncology' '('
 'ASCO' ')' ',' 'American' 'Society' 'of' 'Hematology' '(' 'ASH' ')' ','
 'etc' '.' ')']","[1. 0. 3. 3. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT01943851,"34:54:treatment,56:66:treatment,74:84:treatment",Subjects with a prior history of stem cell transplant (autologous and/or allogeneic) are allowed,"['Subjects' 'with' 'a' 'prior' 'history' 'of' 'stem' 'cell' 'transplant'
 '(' 'autologous' 'and/or' 'allogeneic' ')' 'are' 'allowed']",[0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 1. 0. 1. 0. 0. 0.]
NCT01941316,"86:96:treatment,132:147:allergy_name,152:172:allergy_name,174:189:allergy_name,238:247:chronic_disease,251:269:chronic_disease","Must have no contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment","['Must' 'have' 'no' 'contraindication' 'to' 'any' 'of' 'the' 'required'
 'concomitant' 'drugs' 'or' 'supportive' 'treatments' ',' 'including'
 'hypersensitivity' 'to' 'all' 'anticoagulation' 'and' 'antiplatelet'
 'options' ',' 'antiviral' 'drugs' ',' 'or' 'intolerance' 'to' 'hydration'
 'due' 'to' 'preexisting' 'pulmonary' 'or' 'cardiac' 'impairment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 4. 0. 4. 4. 0.
 4. 4. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2.]"
NCT01941316,"40:62:treatment,117:122:cancer,163:181:cancer","Patients who received primary curative chemoradiation therapy for limited disease, but who recur within the primary tumor site, previously radiated field or with distant metastases","['Patients' 'who' 'received' 'primary' 'curative' 'chemoradiation'
 'therapy' 'for' 'limited' 'disease' ',' 'but' 'who' 'recur' 'within'
 'the' 'primary' 'tumor' 'site' ',' 'previously' 'radiated' 'field' 'or'
 'with' 'distant' 'metastases']","[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0.
 0. 3. 3.]"
NCT01940094,"39:51:treatment,53:64:treatment,66:82:treatment,84:96:treatment,98:119:treatment,121:141:treatment,146:155:treatment,176:215:treatment,207:214:treatment,261:272:treatment","Acceptable maintenance agents include azathioprine, leflunomide, 6-mercaptopurine, methotrexate, mycophenolate mofetil, mycophenolate sodium, or rituximab. Patients may be on trimethoprim/sulfamethoxazole (TMP/SMX) for use as either a maintenance agent or for prophylaxis for infection. TMP/SMX may be used in combination with other drugs","['Acceptable' 'maintenance' 'agents' 'include' 'azathioprine' ','
 'leflunomide' ',' '6-mercaptopurine' ',' 'methotrexate' ','
 'mycophenolate' 'mofetil' ',' 'mycophenolate' 'sodium' ',' 'or'
 'rituximab' '.' 'Patients' 'may' 'be' 'on'
 'trimethoprim/sulfamethoxazole' '(' 'TMP/SMX' ')' 'for' 'use' 'as'
 'either' 'a' 'maintenance' 'agent' 'or' 'for' 'prophylaxis' 'for'
 'infection' '.' 'TMP/SMX' 'may' 'be' 'used' 'in' 'combination' 'with'
 'other' 'drugs']","[0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.
 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT01928589,"28:52:treatment,56:84:treatment,101:107:cancer",Patients who have received neoadjuvant chemotherapy or neoadjuvant hormonal therapy for the current cancer,"['Patients' 'who' 'have' 'received' 'neoadjuvant' 'chemotherapy' 'or'
 'neoadjuvant' 'hormonal' 'therapy' 'for' 'the' 'current' 'cancer']",[0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 3.]
NCT01928576,"1:8:treatment,12:28:treatment,41:60:treatment,,81:91:treatment,143:161:chronic_disease","Inhaled or topical steroids and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease","['Inhaled' 'or' 'topical' 'steroids' 'and' 'adrenal' 'replacement'
 'steroid' 'doses' '>' '10' 'mg' 'daily' 'prednisone' 'equivalent' ','
 'are' 'permitted' 'in' 'the' 'absence' 'of' 'active' 'autoimmune'
 'disease']","[1. 0. 1. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.
 2.]"
NCT01928576,",57:69:treatment,,102:111:treatment,116:137:cancer","Patients must have received at least one platinum based chemotherapy, and not more than three, prior therapies for stage IIIB/IV disease","['Patients' 'must' 'have' 'received' 'at' 'least' 'one' 'platinum' 'based'
 'chemotherapy' ',' 'and' 'not' 'more' 'than' 'three' ',' 'prior'
 'therapies' 'for' 'stage' 'IIIB/IV' 'disease']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 3. 3. 3.]
NCT01928576,",,53:63:treatment,65:76:treatment,82:91:treatment,126:137:treatment,141:154:treatment","Pregnant women are excluded from this study because entinostat, azacitidine, and Nivolumab are agents with the potential for teratogenic or abortifacient effects","['Pregnant' 'women' 'are' 'excluded' 'from' 'this' 'study' 'because'
 'entinostat' ',' 'azacitidine' ',' 'and' 'Nivolumab' 'are' 'agents'
 'with' 'the' 'potential' 'for' 'teratogenic' 'or' 'abortifacient'
 'effects']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0.]
NCT01928576,"15:23:chronic_disease,25:49:chronic_disease,60:74:chronic_disease,85:104:treatment","Subjects with vitiligo, type 1 diabetes mellitus, residual hypothyroidism requiring hormone replacement, or conditions not expected to recur in the absence of an external trigger are permitted to enroll","['Subjects' 'with' 'vitiligo' ',' 'type' '1' 'diabetes' 'mellitus' ','
 'residual' 'hypothyroidism' 'requiring' 'hormone' 'replacement' ',' 'or'
 'conditions' 'not' 'expected' 'to' 'recur' 'in' 'the' 'absence' 'of' 'an'
 'external' 'trigger' 'are' 'permitted' 'to' 'enroll']","[0. 0. 2. 0. 2. 2. 2. 2. 0. 0. 2. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01925573,"57:75:chronic_disease,82:114:chronic_disease,116:137:chronic_disease,,","Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g. active or uncontrolled infection, uncontrolled diabetes) that could cause unacceptable safety risks or compromise compliance with the protocol 12 Pregnant or breast-feeding women. 13 Patients unwilling or unable to comply with the protocol","['Other' 'concurrent' 'severe' 'and/or' 'uncontrolled' 'concomitant'
 'medical' 'conditions' '(' 'e.g' '.' 'active' 'or' 'uncontrolled'
 'infection' ',' 'uncontrolled' 'diabetes' ')' 'that' 'could' 'cause'
 'unacceptable' 'safety' 'risks' 'or' 'compromise' 'compliance' 'with'
 'the' 'protocol' '12' 'Pregnant' 'or' 'breast-feeding' 'women' '.' '13'
 'Patients' 'unwilling' 'or' 'unable' 'to' 'comply' 'with' 'the'
 'protocol']","[0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01925573,"40:52:cancer,62:87:cancer,108:119:cancer,121:144:cancer","Patients with recurrent or progressive glioblastoma or other grade IV malignant glioma (i.e. glioblastoma, gliosarcoma, giant cell glioblastoma, etc.)","['Patients' 'with' 'recurrent' 'or' 'progressive' 'glioblastoma' 'or'
 'other' 'grade' 'IV' 'malignant' 'glioma' '(' 'i.e' '.' 'glioblastoma'
 ',' 'gliosarcoma' ',' 'giant' 'cell' 'glioblastoma' ',' 'etc' '.' ')']","[0. 0. 0. 0. 0. 3. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 3. 0. 3. 3. 3. 0. 0.
 0. 0.]"
NCT01925378,"28:39:chronic_disease,44:60:chronic_disease,76:93:chronic_disease","Patients with a chronic or acute renal, or hepatic disorder, a significant bleeding disorder, or any other condition which in the Investigator's opinion might preclude study participation for the duration of the trial","['Patients' 'with' 'a' 'chronic' 'or' 'acute' 'renal' ',' 'or' 'hepatic'
 'disorder' ',' 'a' 'significant' 'bleeding' 'disorder' ',' 'or' 'any'
 'other' 'condition' 'which' 'in' 'the' 'Investigator' ""'s"" 'opinion'
 'might' 'preclude' 'study' 'participation' 'for' 'the' 'duration' 'of'
 'the' 'trial']","[0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01925131,"4:14:treatment,18:27:treatment,61:64:chronic_disease",No zidovudine or stavudine as part of cART Patients who are HIV+ and do not meet all of these criteria are not eligible for this study,"['No' 'zidovudine' 'or' 'stavudine' 'as' 'part' 'of' 'cART' 'Patients'
 'who' 'are' 'HIV+' 'and' 'do' 'not' 'meet' 'all' 'of' 'these' 'criteria'
 'are' 'not' 'eligible' 'for' 'this' 'study']","[0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT01925131,"26:44:chronic_disease,46:52:chronic_disease,57:72:chronic_disease,63:72:chronic_disease,211:222:treatment,232:241:treatment","Patients must not have a systemic bacterial, fungal, or viral infection that is not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement despite appropriate antibiotics or other treatment)","['Patients' 'must' 'not' 'have' 'a' 'systemic' 'bacterial' ',' 'fungal'
 ',' 'or' 'viral' 'infection' 'that' 'is' 'not' 'controlled' '(' 'defined'
 'as' 'exhibiting' 'ongoing' 'signs/symptoms' 'related' 'to' 'the'
 'infection' 'and' 'without' 'improvement' 'despite' 'appropriate'
 'antibiotics' 'or' 'other' 'treatment' ')']","[0. 0. 0. 0. 0. 2. 2. 0. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 0.]"
NCT01925131,"3:29:treatment,59:68:treatment,83:94:treatment,99:109:treatment,113:126:treatment,128:138:treatment,139:152:treatment,157:177:treatment","a standard induction regimen is defined as any program of treatment that includes vincristine and prednisone or dexamethasone, cytarabine/anthracycline, or high dose cytarabine","['a' 'standard' 'induction' 'regimen' 'is' 'defined' 'as' 'any' 'program'
 'of' 'treatment' 'that' 'includes' 'vincristine' 'and' 'prednisone' 'or'
 'dexamethasone' ',' 'cytarabine/anthracycline' ',' 'or' 'high' 'dose'
 'cytarabine']","[0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 1. 1.
 1.]"
NCT01923662,"1:10:chronic_disease,26:47:chronic_disease,60:68:chronic_disease,69:98:chronic_disease",Paralysis resulting from neurological disorder such as low cervical/thoracic spinal cord injuries (C6-T12,"['Paralysis' 'resulting' 'from' 'neurological' 'disorder' 'such' 'as'
 'low' 'cervical/thoracic' 'spinal' 'cord' 'injuries' '(' 'C6-T12']",[2. 0. 0. 2. 2. 0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT01920737,"15:54:cancer,81:91:treatment,96:114:treatment",Patients with T-cell or B cell lymphoblastic lymphoma confirmed by conventional immature T- or pre B cell markers even if the bone marrow is not involved are also eligible,"['Patients' 'with' 'T-cell' 'or' 'B' 'cell' 'lymphoblastic' 'lymphoma'
 'confirmed' 'by' 'conventional' 'immature' 'T-' 'or' 'pre' 'B' 'cell'
 'markers' 'even' 'if' 'the' 'bone' 'marrow' 'is' 'not' 'involved' 'are'
 'also' 'eligible']","[0. 0. 3. 3. 3. 3. 3. 3. 0. 0. 0. 1. 1. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT01920061,"15:19:cancer,,,41:60:treatment,68:78:cancer",Patients with TNBC and one or two prior cytotoxic therapies in the metastatic setting,"['Patients' 'with' 'TNBC' 'and' 'one' 'or' 'two' 'prior' 'cytotoxic'
 'therapies' 'in' 'the' 'metastatic' 'setting']",[0. 0. 3. 0. 0. 0. 0. 0. 1. 1. 0. 0. 3. 0.]
NCT01920061,"1:35:cancer,37:59:cancer,64:91:cancer,116:160:treatment","castrate resistant prostate cancer, advanced breast cancer, or non-small cell lunch cancer that are candidates for treatment with a docetaxel-based combination","['castrate' 'resistant' 'prostate' 'cancer' ',' 'advanced' 'breast'
 'cancer' ',' 'or' 'non-small' 'cell' 'lunch' 'cancer' 'that' 'are'
 'candidates' 'for' 'treatment' 'with' 'a' 'docetaxel-based' 'combination']",[3. 3. 3. 3. 0. 3. 3. 3. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 1. 1. 1. 1. 1.]
NCT01918683,"45:49:treatment,64:70:cancer,75:99:treatment",Meets clinical criteria for eligibility for TACE to the target lesion per Interventional Radiology,"['Meets' 'clinical' 'criteria' 'for' 'eligibility' 'for' 'TACE' 'to' 'the'
 'target' 'lesion' 'per' 'Interventional' 'Radiology']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 3. 0. 1. 1.]
NCT01918644,"64:66:allergy_name,68:71:allergy_name,121:147:treatment,199:225:treatment",History of prior allergic reactions attributed to compounds of CT/ MRI contrast that cannot be managed with appropriate pre-medication prophylaxis and thereby preclude use of baseline/ follow-up or radiation planning imaging,"['History' 'of' 'prior' 'allergic' 'reactions' 'attributed' 'to'
 'compounds' 'of' 'CT/' 'MRI' 'contrast' 'that' 'can' 'not' 'be' 'managed'
 'with' 'appropriate' 'pre-medication' 'prophylaxis' 'and' 'thereby'
 'preclude' 'use' 'of' 'baseline/' 'follow-up' 'or' 'radiation' 'planning'
 'imaging']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 4. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 1. 1.]"
NCT01915095,"20:36:chronic_disease,40:49:chronic_disease,51:75:chronic_disease","Premorbid, ongoing major depression or psychosis, altered cognitive status","['Premorbid' ',' 'ongoing' 'major' 'depression' 'or' 'psychosis' ','
 'altered' 'cognitive' 'status']",[0. 0. 0. 2. 2. 0. 2. 0. 2. 2. 2.]
NCT01912651,",39:46:treatment,48:67:treatment,93:104:treatment,109:119:treatment,147:167:cancer,208:232:treatment","current or recent (within one week of surgery) systemic antibiotic use, intolerance to both clindamycin and cephalexin, discovery of a persistent cutaneous malignancy at the site of the defect following the reconstructive procedure and previous reconstruction at the site of the skin/soft-tissue defect","['current' 'or' 'recent' '(' 'within' 'one' 'week' 'of' 'surgery' ')'
 'systemic' 'antibiotic' 'use' ',' 'intolerance' 'to' 'both' 'clindamycin'
 'and' 'cephalexin' ',' 'discovery' 'of' 'a' 'persistent' 'cutaneous'
 'malignancy' 'at' 'the' 'site' 'of' 'the' 'defect' 'following' 'the'
 'reconstructive' 'procedure' 'and' 'previous' 'reconstruction' 'at' 'the'
 'site' 'of' 'the' 'skin/soft-tissue' 'defect']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0.
 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01912612,"26:65:treatment,70:95:treatment,105:114:treatment",Willing to withdraw from selective serotonin reuptake inhibitors and tricyclic antidepressants prior to treatment initiation,"['Willing' 'to' 'withdraw' 'from' 'selective' 'serotonin' 'reuptake'
 'inhibitors' 'and' 'tricyclic' 'antidepressants' 'prior' 'to' 'treatment'
 'initiation']",[0. 0. 0. 0. 1. 1. 1. 1. 0. 1. 1. 0. 0. 1. 0.]
NCT01910818,"41:62:chronic_disease,,,192:202:treatment,204:213:treatment,236:256:chronic_disease","Significant concurrent illness, such as uncontrolled diabetes (with a hemoglobin A1C of more than 8) (i.e., any disease state that in the opinion of the Investigator would interfere with the anesthesia, treatment, or healing process); Mentally incompetent, prisoner or evidence of active substance or alcohol abuse","['Significant' 'concurrent' 'illness' ',' 'such' 'as' 'uncontrolled'
 'diabetes' '(' 'with' 'a' 'hemoglobin' 'A1C' 'of' 'more' 'than' '8' ')'
 '(' 'i.e.' ',' 'any' 'disease' 'state' 'that' 'in' 'the' 'opinion' 'of'
 'the' 'Investigator' 'would' 'interfere' 'with' 'the' 'anesthesia' ','
 'treatment' ',' 'or' 'healing' 'process' ')' ';' 'Mentally' 'incompetent'
 ',' 'prisoner' 'or' 'evidence' 'of' 'active' 'substance' 'or' 'alcohol'
 'abuse']","[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01908777,"1:31:chronic_disease,,,,,,154:163:treatment,,175:189:treatment,197:200:treatment",Congestive heart failure (CHF) that meets New York Heart Association (NYHA) Class II to IV definitions (see Appendix 2) and/or ejection fraction <40% by MUGA scan or <50% by echocardiogram and/or MRI,"['Congestive' 'heart' 'failure' '(' 'CHF' ')' 'that' 'meets' 'New' 'York'
 'Heart' 'Association' '(' 'NYHA' ')' 'Class' 'II' 'to' 'IV' 'definitions'
 '(' 'see' 'Appendix' '2' ')' 'and/or' 'ejection' 'fraction' '<' '40' '%'
 'by' 'MUGA' 'scan' 'or' '<' '50' '%' 'by' 'echocardiogram' 'and/or' 'MRI']","[2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 0. 1.]"
NCT01906385,"1:22:chronic_disease,24:30:chronic_disease,32:57:chronic_disease,","Myocardial infarction, stroke, transient ischemic attack within 6 months","['Myocardial' 'infarction' ',' 'stroke' ',' 'transient' 'ischemic'
 'attack' 'within' '6' 'months']",[2. 2. 0. 2. 0. 2. 2. 2. 0. 0. 0.]
NCT01905709,",,,,86:96:treatment,128:138:treatment,146:155:treatment,157:169:treatment,171:182:treatment","At least three episodes of mild-to-moderate CDI and failure of a 6-8 week taper with vancomycin with or without an alternative antibiotic (e.g., rifaximin, nitazoxanide, fidaxomicin)","['At' 'least' 'three' 'episodes' 'of' 'mild-to-moderate' 'CDI' 'and'
 'failure' 'of' 'a' '6-8' 'week' 'taper' 'with' 'vancomycin' 'with' 'or'
 'without' 'an' 'alternative' 'antibiotic' '(' 'e.g.' ',' 'rifaximin' ','
 'nitazoxanide' ',' 'fidaxomicin' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 1. 0. 0.
 0. 1. 0. 1. 0. 1. 0.]"
NCT01905046,",18:29:treatment,33:50:treatment,62:77:cancer",Women who have a core biopsy or excisional biopsy containing invasive cancer,"['Women' 'who' 'have' 'a' 'core' 'biopsy' 'or' 'excisional' 'biopsy'
 'containing' 'invasive' 'cancer']",[0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 3. 3.]
NCT01904136,"1:29:cancer,25:28:cancer,,123:140:treatment,133:140:treatment,187:217:cancer,237:251:cancer,,,,,,589:610:cancer,825:847:treatment","acute myeloid leukemia (AML): a. first complete remission with high-risk features defined as: (i) greater than 1 cycle of induction therapy required to achieve remission; (ii) preceding myelodysplastic syndrome (MDS); (iii) presence of FLT3 mutations or internal tandem duplication or other mutations associated with poor-risk AML (e.g. DNMT3A, TET2); (iv) French-American-British Classification (FAB) M6 or M7 classification; (v) adverse cytogenetics: -5, deletion (del) 5q, -7, del7q, abnormalities involving 3q, 9q, 11q, 20q, 21q, 17, +8 or complex karyotype (> 3 abnormalities); (vi) treatment-related AML, or b. second or greater remission; patients beyond second remission have to be in complete remission (CR) at transplant to be eligible, or c. primary induction failure with partial response to therapy who achieve adequate cytoreduction","['acute' 'myeloid' 'leukemia' '(' 'AML' ')' ':' 'a.' 'first' 'complete'
 'remission' 'with' 'high-risk' 'features' 'defined' 'as' ':' '(' 'i' ')'
 'greater' 'than' '1' 'cycle' 'of' 'induction' 'therapy' 'required' 'to'
 'achieve' 'remission' ';' '(' 'ii' ')' 'preceding' 'myelodysplastic'
 'syndrome' '(' 'MDS' ')' ';' '(' 'iii' ')' 'presence' 'of' 'FLT3'
 'mutations' 'or' 'internal' 'tandem' 'duplication' 'or' 'other'
 'mutations' 'associated' 'with' 'poor-risk' 'AML' '(' 'e.g' '.' 'DNMT3A'
 ',' 'TET2' ')' ';' '(' 'iv' ')' 'French-American-British'
 'Classification' '(' 'FAB' ')' 'M6' 'or' 'M7' 'classification' ';' '('
 'v' ')' 'adverse' 'cytogenetics' ':' '-5' ',' 'deletion' '(' 'del' ')'
 '5q' ',' '-7' ',' 'del7q' ',' 'abnormalities' 'involving' '3q' ',' '9q'
 ',' '11q' ',' '20q' ',' '21q' ',' '17' ',' '+8' 'or' 'complex'
 'karyotype' '(' '>' '3' 'abnormalities' ')' ';' '(' 'vi' ')'
 'treatment-related' 'AML' ',' 'or' 'b.' 'second' 'or' 'greater'
 'remission' ';' 'patients' 'beyond' 'second' 'remission' 'have' 'to' 'be'
 'in' 'complete' 'remission' '(' 'CR' ')' 'at' 'transplant' 'to' 'be'
 'eligible' ',' 'or' 'c.' 'primary' 'induction' 'failure' 'with' 'partial'
 'response' 'to' 'therapy' 'who' 'achieve' 'adequate' 'cytoreduction']","[3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 3.
 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 1.]"
NCT01903330,",86:101:treatment,,131:148:treatment,131:140:treatment,215:244:treatment","MRI record must be obtained showing the MRI was conducted at least 4 weeks after any salvage surgery, and at least 12 weeks after radiation therapy, or at least 4 weeks after radiation for a new lesion outside the prior primary radiation field","['MRI' 'record' 'must' 'be' 'obtained' 'showing' 'the' 'MRI' 'was'
 'conducted' 'at' 'least' '4' 'weeks' 'after' 'any' 'salvage' 'surgery'
 ',' 'and' 'at' 'least' '12' 'weeks' 'after' 'radiation' 'therapy' ','
 'or' 'at' 'least' '4' 'weeks' 'after' 'radiation' 'for' 'a' 'new'
 'lesion' 'outside' 'the' 'prior' 'primary' 'radiation' 'field']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.
 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1.]"
NCT01903330,"18:29:treatment,39:43:treatment,48:77:treatment",Prior receipt of bevacizumab or other VEGF- or VEGF receptor-targeted agents,"['Prior' 'receipt' 'of' 'bevacizumab' 'or' 'other' 'VEGF-' 'or' 'VEGF'
 'receptor-targeted' 'agents']",[0. 0. 0. 1. 0. 0. 1. 1. 1. 0. 0.]
NCT01902810,"23:67:chronic_disease,69:75:chronic_disease,85:113:chronic_disease","Currently treated for Chronic Obstructive Pulmonary Disease (COPD), asthma or other chronic pulmonary conditions","['Currently' 'treated' 'for' 'Chronic' 'Obstructive' 'Pulmonary' 'Disease'
 '(' 'COPD' ')' ',' 'asthma' 'or' 'other' 'chronic' 'pulmonary'
 'conditions']",[0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 2. 0. 0. 2. 2. 2.]
NCT01901055,"7:14:chronic_disease,18:37:chronic_disease,41:56:treatment,",Acute medical or surgical conditions or hospitalization ≤ 3 months,"['Acute' 'medical' 'or' 'surgical' 'conditions' 'or' 'hospitalization' '≤'
 '3' 'months']",[0. 2. 0. 2. 2. 0. 1. 0. 0. 0.]
NCT01900093,"14:25:chronic_disease,27:53:chronic_disease,55:76:chronic_disease,78:102:chronic_disease,124:136:chronic_disease","Diagnosis of scleroderma, systemic fungal infections, ocular herpes simplex, congestive heart failure, and/or uncontrolled hypertension, and/or any clinically relevant medical disease that would put the patient at risk by participating in the study","['Diagnosis' 'of' 'scleroderma' ',' 'systemic' 'fungal' 'infections' ','
 'ocular' 'herpes' 'simplex' ',' 'congestive' 'heart' 'failure' ','
 'and/or' 'uncontrolled' 'hypertension' ',' 'and/or' 'any' 'clinically'
 'relevant' 'medical' 'disease' 'that' 'would' 'put' 'the' 'patient' 'at'
 'risk' 'by' 'participating' 'in' 'the' 'study']","[0. 0. 2. 0. 2. 2. 2. 0. 2. 2. 2. 0. 2. 2. 2. 0. 0. 0. 2. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01898793,"27:36:chronic_disease,,91:98:treatment,131:148:chronic_disease",Infiltrates attributed to infection must be stable/ improving after 1 week of appropriate therapy (4 weeks for presumed or proven fungal infections),"['Infiltrates' 'attributed' 'to' 'infection' 'must' 'be' 'stable/'
 'improving' 'after' '1' 'week' 'of' 'appropriate' 'therapy' '(' '4'
 'weeks' 'for' 'presumed' 'or' 'proven' 'fungal' 'infections' ')']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0.]
NCT01898793,"102:141:treatment,339:363:cancer,377:389:treatment,391:408:treatment,417:431:treatment","OR High-risk AML (by ELN criteria; See Appendix C) in complete remission (CR) and has either refused hematopoietic stem cell transplantation OR is currently not eligible for hematopoietic stem cell transplantation OR for whom hematopoietic stem cell transplantation is being reserved for later relapse. This is inclusive of patients with minimal residual disease evidenced by cytogenetics, molecular testing, and/or flow cytometry","['OR' 'High-risk' 'AML' '(' 'by' 'ELN' 'criteria' ';' 'See' 'Appendix' 'C'
 ')' 'in' 'complete' 'remission' '(' 'CR' ')' 'and' 'has' 'either'
 'refused' 'hematopoietic' 'stem' 'cell' 'transplantation' 'OR' 'is'
 'currently' 'not' 'eligible' 'for' 'hematopoietic' 'stem' 'cell'
 'transplantation' 'OR' 'for' 'whom' 'hematopoietic' 'stem' 'cell'
 'transplantation' 'is' 'being' 'reserved' 'for' 'later' 'relapse' '.'
 'This' 'is' 'inclusive' 'of' 'patients' 'with' 'minimal' 'residual'
 'disease' 'evidenced' 'by' 'cytogenetics' ',' 'molecular' 'testing' ','
 'and/or' 'flow' 'cytometry']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.
 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 0. 1. 0. 1. 1. 0. 0. 1. 1.]"
NCT01898793,"1:24:treatment,35:48:treatment,52:63:treatment",cytoreductive therapies including leukapheresis or hydroxyurea,"['cytoreductive' 'therapies' 'including' 'leukapheresis' 'or'
 'hydroxyurea']",[1. 1. 0. 1. 0. 1.]
NCT01896921,"1:15:treatment,25:33:treatment,35:48:treatment,50:63:treatment,68:77:treatment","CYP3A inducers (such as rifampin, carbamazepine, phenobarbital and phenytoin)","['CYP3A' 'inducers' '(' 'such' 'as' 'rifampin' ',' 'carbamazepine' ','
 'phenobarbital' 'and' 'phenytoin' ')']",[1. 1. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0.]
NCT01895777,"43:46:chronic_disease,53:56:chronic_disease,58:60:chronic_disease,62:85:chronic_disease,87:108:chronic_disease","Documented diagnosis of clinically stable VTE (e.g. DVT, PE, central line thrombosis, sinus vein thrombosis) per investigator judgment","['Documented' 'diagnosis' 'of' 'clinically' 'stable' 'VTE' '(' 'e.g' '.'
 'DVT' ',' 'PE' ',' 'central' 'line' 'thrombosis' ',' 'sinus' 'vein'
 'thrombosis' ')' 'per' 'investigator' 'judgment']",[0. 0. 0. 0. 0. 2. 0. 0. 0. 2. 0. 2. 0. 2. 2. 2. 0. 2. 2. 2. 0. 0. 0. 0.]
NCT01894061,"20:54:chronic_disease,50:53:chronic_disease,55:64:chronic_disease",Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not mandatory),"['Known' 'diagnosis' 'of' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')'
 'infection' '(' 'HIV' 'testing' 'is' 'not' 'mandatory' ')']",[0. 0. 0. 2. 2. 2. 2. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT01893554,"14:25:treatment,41:62:treatment,67:80:chronic_disease,,117:128:treatment,165:184:treatment",Has received antibiotics or systemic or nasal steroid therapy for acute illness within the previous 3 days prior to vaccination (steroid skin creams or lotions and topical antibiotics or antifungal preparations are permitted),"['Has' 'received' 'antibiotics' 'or' 'systemic' 'or' 'nasal' 'steroid'
 'therapy' 'for' 'acute' 'illness' 'within' 'the' 'previous' '3' 'days'
 'prior' 'to' 'vaccination' '(' 'steroid' 'skin' 'creams' 'or' 'lotions'
 'and' 'topical' 'antibiotics' 'or' 'antifungal' 'preparations' 'are'
 'permitted' ')']","[0. 0. 1. 0. 0. 0. 1. 1. 1. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.
 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]"
NCT01893554,"20:57:chronic_disease,98:101:chronic_disease,118:178:treatment,183:217:treatment,230:246:treatment,248:267:treatment,273:303:treatment","Known or suspected impairment of immunological functions, including maternal history of positive HIV test, receiving immunosuppressive therapy including systemic corticosteroids, or bone marrow/solid organ transplant recipients (topical steroids, topical antibiotics, and topical antifungal medications are acceptable)","['Known' 'or' 'suspected' 'impairment' 'of' 'immunological' 'functions'
 ',' 'including' 'maternal' 'history' 'of' 'positive' 'HIV' 'test' ','
 'receiving' 'immunosuppressive' 'therapy' 'including' 'systemic'
 'corticosteroids' ',' 'or' 'bone' 'marrow/solid' 'organ' 'transplant'
 'recipients' '(' 'topical' 'steroids' ',' 'topical' 'antibiotics' ','
 'and' 'topical' 'antifungal' 'medications' 'are' 'acceptable' ')']","[0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0.
 1. 1. 1. 1. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01893554,"23:34:treatment,43:66:treatment,84:107:chronic_disease,109:118:treatment,124:143:treatment,155:171:treatment,173:192:treatment,198:223:treatment","Permitted concomitant medications include nutritional supplements, medications for gastroesophageal reflux, eye drops, and topical medications, including topical steroids, topical antibiotics, and topical antifungal agents","['Permitted' 'concomitant' 'medications' 'include' 'nutritional'
 'supplements' ',' 'medications' 'for' 'gastroesophageal' 'reflux' ','
 'eye' 'drops' ',' 'and' 'topical' 'medications' ',' 'including' 'topical'
 'steroids' ',' 'topical' 'antibiotics' ',' 'and' 'topical' 'antifungal'
 'agents']","[0. 0. 1. 0. 1. 1. 0. 0. 0. 2. 2. 0. 1. 1. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT01893307,"1:6:cancer,26:45:cancer,61:88:chronic_disease",Tumor tissue (primary or cervical metastasis) available for human papilloma virus (HPV),"['Tumor' 'tissue' '(' 'primary' 'or' 'cervical' 'metastasis' ')'
 'available' 'for' 'human' 'papilloma' 'virus' '(' 'HPV' ')']",[3. 0. 0. 0. 0. 3. 3. 0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT01890590,"67:104:cancer,,,171:174:treatment,178:185:treatment",Participants must have histologically or radiological evidence of Stage I (T1N0M0) renal cell carcinoma with a size no larger than 8 cm in greatest dimension measured by MRI or CT Scan,"['Participants' 'must' 'have' 'histologically' 'or' 'radiological'
 'evidence' 'of' 'Stage' 'I' '(' 'T1N0M0' ')' 'renal' 'cell' 'carcinoma'
 'with' 'a' 'size' 'no' 'larger' 'than' '8' 'cm' 'in' 'greatest'
 'dimension' 'measured' 'by' 'MRI' 'or' 'CT' 'Scan']","[0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 0. 1. 1.]"
NCT01884740,"49:71:treatment,162:171:treatment,175:189:treatment",Patients with significant concurrent medical or psychiatric conditions that would place them at increased risk or affect their ability to receive or comply with treatment or post-treatment clinical monitoring,"['Patients' 'with' 'significant' 'concurrent' 'medical' 'or' 'psychiatric'
 'conditions' 'that' 'would' 'place' 'them' 'at' 'increased' 'risk' 'or'
 'affect' 'their' 'ability' 'to' 'receive' 'or' 'comply' 'with'
 'treatment' 'or' 'post-treatment' 'clinical' 'monitoring']","[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 0. 1. 0. 0.]"
NCT01884740,"1:11:treatment,42:51:treatment,,114:124:treatment",craniotomy patients are eligible for the treatment if they have had a craniotomy greater than two weeks prior to IA therapy,"['craniotomy' 'patients' 'are' 'eligible' 'for' 'the' 'treatment' 'if'
 'they' 'have' 'had' 'a' 'craniotomy' 'greater' 'than' 'two' 'weeks'
 'prior' 'to' 'IA' 'therapy']",[1. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01880567,"17:20:cancer,44:56:cancer,,130:140:cancer,142:177:cancer,179:210:cancer,214:220:cancer,268:283:cancer,311:328:treatment,330:337:treatment,341:354:treatment,,","Newly diagnosed MCL: Disease free of prior malignancies of equal to or greater than 6 months with exception of currently treated basal cell, squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast, or other malignancies in remission (including prostate cancer patients in remission from radiation therapy, surgery or brachytherapy), not actively being treated, with a life expectancy > 3 years","['Newly' 'diagnosed' 'MCL' ':' 'Disease' 'free' 'of' 'prior'
 'malignancies' 'of' 'equal' 'to' 'or' 'greater' 'than' '6' 'months'
 'with' 'exception' 'of' 'currently' 'treated' 'basal' 'cell' ','
 'squamous' 'cell' 'carcinoma' 'of' 'the' 'skin' ',' 'carcinoma' 'in'
 'situ' 'of' 'the' 'cervix' 'or' 'breast' ',' 'or' 'other' 'malignancies'
 'in' 'remission' '(' 'including' 'prostate' 'cancer' 'patients' 'in'
 'remission' 'from' 'radiation' 'therapy' ',' 'surgery' 'or'
 'brachytherapy' ')' ',' 'not' 'actively' 'being' 'treated' ',' 'with' 'a'
 'life' 'expectancy' '>' '3' 'years']","[0. 0. 3. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3.
 0. 3. 3. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0.
 3. 3. 0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT01880567,"17:20:cancer,36:44:cancer,49:69:cancer",Newly diagnosed MCL: Patients with blastoid and pleomorphic variants,"['Newly' 'diagnosed' 'MCL' ':' 'Patients' 'with' 'blastoid' 'and'
 'pleomorphic' 'variants']",[0. 0. 3. 0. 0. 0. 3. 0. 3. 3.]
NCT01880567,"21:24:cancer,49:69:cancer,162:168:treatment",Relapsed/refractory MCL: Confirmed diagnosis of mantle cell lymphoma with cluster of differentiation (CD)20 and cyclin D1 through cyclin D3 positivity in tissue biopsy,"['Relapsed/refractory' 'MCL' ':' 'Confirmed' 'diagnosis' 'of' 'mantle'
 'cell' 'lymphoma' 'with' 'cluster' 'of' 'differentiation' '(' 'CD' ')'
 '20' 'and' 'cyclin' 'D1' 'through' 'cyclin' 'D3' 'positivity' 'in'
 'tissue' 'biopsy']","[0. 3. 0. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1.]"
NCT01880567,"10:24:chronic_disease,35:64:treatment,79:99:treatment",Relapsed/refractory MCL: Requires anticoagulation with warfarin or equivalent vitamin K antagonist,"['Relapsed/refractory' 'MCL' ':' 'Requires' 'anticoagulation' 'with'
 'warfarin' 'or' 'equivalent' 'vitamin' 'K' 'antagonist']",[2. 2. 0. 0. 1. 1. 1. 0. 0. 1. 1. 1.]
NCT01880567,"14:26:chronic_disease,41:58:chronic_disease,67:102:chronic_disease,104:120:chronic_disease,131:140:treatment,146:166:treatment,168:177:treatment,181:198:treatment,200:217:chronic_disease,222:241:chronic_disease","uncontrolled hypertension, uncontrolled diabetes mellitus, active/symptomatic coronary artery disease, active infection requiring treatment with systemic antibiotics, antiviral or antifungal agents, active hemorrhage, or psychiatric illness","['uncontrolled' 'hypertension' ',' 'uncontrolled' 'diabetes' 'mellitus'
 ',' 'active/symptomatic' 'coronary' 'artery' 'disease' ',' 'active'
 'infection' 'requiring' 'treatment' 'with' 'systemic' 'antibiotics' ','
 'antiviral' 'or' 'antifungal' 'agents' ',' 'active' 'hemorrhage' ',' 'or'
 'psychiatric' 'illness']","[0. 2. 0. 0. 2. 2. 0. 2. 2. 2. 2. 0. 0. 0. 0. 1. 0. 1. 1. 0. 1. 0. 1. 1.
 0. 0. 0. 0. 0. 2. 2.]"
NCT01878617,"10:37:chronic_disease,100:124:chronic_disease,126:135:chronic_disease,155:163:chronic_disease,164:187:chronic_disease,189:198:chronic_disease,211:234:chronic_disease,322:346:chronic_disease,355:362:chronic_disease,366:385:chronic_disease","No major sensory or motor impairment that would preclude valid cognitive testing (e.g., unresolved posterior fossa syndrome, blindness, poorly controlled seizures/photosensitive epilepsy, psychosis) or a major psychological condition that would preclude completion of the intervention (e.g., significant oppositionality, autism spectrum disorder, severe anxiety or depressive symptoms)","['No' 'major' 'sensory' 'or' 'motor' 'impairment' 'that' 'would'
 'preclude' 'valid' 'cognitive' 'testing' '(' 'e.g.' ',' 'unresolved'
 'posterior' 'fossa' 'syndrome' ',' 'blindness' ',' 'poorly' 'controlled'
 'seizures/photosensitive' 'epilepsy' ',' 'psychosis' ')' 'or' 'a' 'major'
 'psychological' 'condition' 'that' 'would' 'preclude' 'completion' 'of'
 'the' 'intervention' '(' 'e.g.' ',' 'significant' 'oppositionality' ','
 'autism' 'spectrum' 'disorder' ',' 'severe' 'anxiety' 'or' 'depressive'
 'symptoms' ')']","[0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 2. 0. 0. 0.
 2. 2. 0. 2. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.
 2. 2. 0. 0. 2. 0. 2. 2. 0.]"
NCT01877382,"5:34:treatment,38:51:treatment,,74:94:treatment",Had therapeutic radiation therapy or major surgery within 4 weeks before study drug treatment,"['Had' 'therapeutic' 'radiation' 'therapy' 'or' 'major' 'surgery' 'within'
 '4' 'weeks' 'before' 'study' 'drug' 'treatment']",[0. 1. 1. 1. 0. 1. 1. 0. 0. 0. 0. 1. 1. 1.]
NCT01877382,"1:28:treatment,32:43:treatment,,72:86:treatment",treatment with nitrosoureas or mitomycin C within 6 weeks before study drug treatment,"['treatment' 'with' 'nitrosoureas' 'or' 'mitomycin' 'C' 'within' '6'
 'weeks' 'before' 'study' 'drug' 'treatment']",[1. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 1. 1.]
NCT01876511,"12:24:treatment,,70:77:treatment,90:114:treatment",received a live vaccine within 4 weeks prior to or after any dose of MK-3475 (exception: inactivated flu vaccines),"['received' 'a' 'live' 'vaccine' 'within' '4' 'weeks' 'prior' 'to' 'or'
 'after' 'any' 'dose' 'of' 'MK-3475' '(' 'exception' ':' 'inactivated'
 'flu' 'vaccines' ')']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 1. 1. 1. 0.]
NCT01873131,"15:21:chronic_disease,46:83:chronic_disease,87:109:chronic_disease,121:138:chronic_disease,140:185:chronic_disease,187:208:chronic_disease,214:231:chronic_disease,270:277:allergy_name,338:351:allergy_name,355:369:allergy_name","Patients with asthma or a history of asthma, chronic obstructive pulmonary disease or cardiovascular disease, including sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, and cardiogenic shock; hypersensitivity to any component of timolol; and in those patients receiving systemic administration of beta-blockers or ace inhibitors","['Patients' 'with' 'asthma' 'or' 'a' 'history' 'of' 'asthma' ',' 'chronic'
 'obstructive' 'pulmonary' 'disease' 'or' 'cardiovascular' 'disease' ','
 'including' 'sinus' 'bradycardia' ',' 'second' 'or' 'third' 'degree'
 'atrioventricular' 'block' ',' 'overt' 'cardiac' 'failure' ',' 'and'
 'cardiogenic' 'shock' ';' 'hypersensitivity' 'to' 'any' 'component' 'of'
 'timolol' ';' 'and' 'in' 'those' 'patients' 'receiving' 'systemic'
 'administration' 'of' 'beta-blockers' 'or' 'ace' 'inhibitors']","[0. 0. 2. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 2. 2. 0. 0. 2. 2. 0. 2. 2. 2.
 2. 2. 2. 0. 2. 2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 4. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 4. 0. 4. 4.]"
NCT01872975,"26:36:treatment,121:135:cancer,140:144:cancer","For patients who undergo lumpectomy, the margins of the resected specimen or re-excision must be histologically free of invasive tumor and DCIS as determined by the local pathologist","['For' 'patients' 'who' 'undergo' 'lumpectomy' ',' 'the' 'margins' 'of'
 'the' 'resected' 'specimen' 'or' 're-excision' 'must' 'be'
 'histologically' 'free' 'of' 'invasive' 'tumor' 'and' 'DCIS' 'as'
 'determined' 'by' 'the' 'local' 'pathologist']","[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 3. 0.
 0. 0. 0. 0. 0.]"
NCT01872975,"101:120:treatment,149:175:treatment,211:238:treatment,263:277:cancer",Patient must have had pathologic confirmation of axillary nodal involvement at presentation (before neoadjuvant therapy) based on either a positive fine needle aspirate (FNA) (demonstrating malignant cells) or positive core needle biopsy (demonstrating invasive adenocarcinoma),"['Patient' 'must' 'have' 'had' 'pathologic' 'confirmation' 'of' 'axillary'
 'nodal' 'involvement' 'at' 'presentation' '(' 'before' 'neoadjuvant'
 'therapy' ')' 'based' 'on' 'either' 'a' 'positive' 'fine' 'needle'
 'aspirate' '(' 'FNA' ')' '(' 'demonstrating' 'malignant' 'cells' ')' 'or'
 'positive' 'core' 'needle' 'biopsy' '(' 'demonstrating' 'invasive'
 'adenocarcinoma' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 1. 1.
 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0.]"
NCT01872975,"21:34:cancer,50:63:cancer,67:80:cancer",patients who have a primary tumor that is either HER2-positive or HER2-negative,"['patients' 'who' 'have' 'a' 'primary' 'tumor' 'that' 'is' 'either'
 'HER2-positive' 'or' 'HER2-negative']",[0. 0. 0. 0. 3. 3. 0. 0. 0. 3. 0. 3.]
NCT01871766,"29:47:treatment,51:84:treatment,96:104:treatment,151:156:cancer,157:166:treatment",Participant has received no prior radiotherapy or chemotherapy for rhabdomyosarcoma (excluding steroids) unless an emergency situation requires local tumor treatment,"['Participant' 'has' 'received' 'no' 'prior' 'radiotherapy' 'or'
 'chemotherapy' 'for' 'rhabdomyosarcoma' '(' 'excluding' 'steroids' ')'
 'unless' 'an' 'emergency' 'situation' 'requires' 'local' 'tumor'
 'treatment']",[0. 0. 0. 0. 1. 1. 0. 1. 1. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 3. 1.]
NCT01871727,"12:27:treatment,32:36:cancer,63:76:treatment","History of prior therapies for CTCL as follows: must have had prior therapy, any number of prior therapies allowed","['History' 'of' 'prior' 'therapies' 'for' 'CTCL' 'as' 'follows' ':' 'must'
 'have' 'had' 'prior' 'therapy' ',' 'any' 'number' 'of' 'prior'
 'therapies' 'allowed']",[0. 0. 1. 1. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01871727,"1:19:treatment,28:48:treatment,54:62:treatment,85:100:treatment",Topical treatments (except topical chemotherapy) and steroids are not considered as prior therapies,"['Topical' 'treatments' '(' 'except' 'topical' 'chemotherapy' ')' 'and'
 'steroids' 'are' 'not' 'considered' 'as' 'prior' 'therapies']",[1. 1. 0. 0. 1. 1. 0. 0. 1. 0. 0. 0. 0. 1. 1.]
NCT01869114,"1:4:cancer,8:11:cancer,30:60:treatment,49:60:treatment",MDS or AML as above BUT with prior therapy with Azacitibine (Arm C): Patients who meet criteria for either Arm A or Arm B but have been treated or are currently treated with Azacitibine,"['MDS' 'or' 'AML' 'as' 'above' 'BUT' 'with' 'prior' 'therapy' 'with'
 'Azacitibine' '(' 'Arm' 'C' ')' ':' 'Patients' 'who' 'meet' 'criteria'
 'for' 'either' 'Arm' 'A' 'or' 'Arm' 'B' 'but' 'have' 'been' 'treated'
 'or' 'are' 'currently' 'treated' 'with' 'Azacitibine']","[3. 0. 3. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01869114,"15:47:chronic_disease,49:64:chronic_disease,78:102:chronic_disease,104:125:chronic_disease,,175:193:chronic_disease","Patients with uncontrolled high blood pressure, unstable angina, symptomatic congestive heart failure, myocardial infarction within the past 6 months or serious uncontrolled cardiac arrhythmia","['Patients' 'with' 'uncontrolled' 'high' 'blood' 'pressure' ',' 'unstable'
 'angina' ',' 'symptomatic' 'congestive' 'heart' 'failure' ','
 'myocardial' 'infarction' 'within' 'the' 'past' '6' 'months' 'or'
 'serious' 'uncontrolled' 'cardiac' 'arrhythmia']","[0. 0. 2. 2. 2. 2. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.
 0. 2. 2.]"
NCT01865162,"96:103:chronic_disease,127:149:chronic_disease,151:156:chronic_disease,160:173:chronic_disease,191:204:chronic_disease,206:219:chronic_disease,221:234:chronic_disease,236:257:chronic_disease,265:298:chronic_disease,300:309:chronic_disease,311:331:chronic_disease,336:348:chronic_disease","Any systemic illness or unstable medical condition that might pose additional risk, including: cardiac, unstable metabolic or endocrine disturbances, renal or liver disease, past history of renal calculi, hyperuricemia, hypercalcemia, mitochondrial disease, known disorder of fatty acid metabolism, porphyria, carnitine deficiency and pancreatitis","['Any' 'systemic' 'illness' 'or' 'unstable' 'medical' 'condition' 'that'
 'might' 'pose' 'additional' 'risk' ',' 'including' ':' 'cardiac' ','
 'unstable' 'metabolic' 'or' 'endocrine' 'disturbances' ',' 'renal' 'or'
 'liver' 'disease' ',' 'past' 'history' 'of' 'renal' 'calculi' ','
 'hyperuricemia' ',' 'hypercalcemia' ',' 'mitochondrial' 'disease' ','
 'known' 'disorder' 'of' 'fatty' 'acid' 'metabolism' ',' 'porphyria' ','
 'carnitine' 'deficiency' 'and' 'pancreatitis']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 2. 2. 0. 2.
 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 2. 2. 0. 0. 2. 2. 2. 2. 2. 0.
 2. 0. 2. 2. 0. 2.]"
NCT01864265,"18:32:chronic_disease,60:83:treatment,85:92:treatment,","Individuals with claustrophobia, tattoos containing metal, magnetic endoprostheses, surgery on bone in between a time interval < 3 months","['Individuals' 'with' 'claustrophobia' ',' 'tattoos' 'containing' 'metal'
 ',' 'magnetic' 'endoprostheses' ',' 'surgery' 'on' 'bone' 'in' 'between'
 'a' 'time' 'interval' '<' '3' 'months']",[0. 0. 2. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01861106,"18:28:cancer,39:45:cancer,96:103:treatment","History of prior malignancy. However, cancer survivors who have undergone potentially curative therapy may be considered for stem cell donation on a case-by-case basis","['History' 'of' 'prior' 'malignancy' '.' 'However' ',' 'cancer'
 'survivors' 'who' 'have' 'undergone' 'potentially' 'curative' 'therapy'
 'may' 'be' 'considered' 'for' 'stem' 'cell' 'donation' 'on' 'a'
 'case-by-case' 'basis']","[0. 0. 0. 3. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT01859819,"49:74:chronic_disease,94:118:chronic_disease,206:213:treatment","These patients are excluded due to the expected intense immunosuppression, increased risk of opportunistic infections, and higher expected septic death rate in this subgroup of patients with this proposed therapy","['These' 'patients' 'are' 'excluded' 'due' 'to' 'the' 'expected' 'intense'
 'immunosuppression' ',' 'increased' 'risk' 'of' 'opportunistic'
 'infections' ',' 'and' 'higher' 'expected' 'septic' 'death' 'rate' 'in'
 'this' 'subgroup' 'of' 'patients' 'with' 'this' 'proposed' 'therapy']","[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT01858168,"36:60:cancer,115:118:cancer,123:145:cancer",Previously documented diagnosis of myelodysplastic syndrome (or any dysplastic leukocyte morphology suggestive of MDS) or acute myeloid leukemia,"['Previously' 'documented' 'diagnosis' 'of' 'myelodysplastic' 'syndrome'
 '(' 'or' 'any' 'dysplastic' 'leukocyte' 'morphology' 'suggestive' 'of'
 'MDS' ')' 'or' 'acute' 'myeloid' 'leukemia']",[0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 3. 3. 3.]
NCT01851369,"1:4:chronic_disease,26:60:treatment,117:123:treatment",HIV-positive patients on combination antiretroviral therapy are ineligible because of possible PK interactions with TRC102,"['HIV-positive' 'patients' 'on' 'combination' 'antiretroviral' 'therapy'
 'are' 'ineligible' 'because' 'of' 'possible' 'PK' 'interactions' 'with'
 'TRC102']",[2. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01851369,"30:47:cancer,59:75:chronic_disease,118:131:treatment,152:180:treatment",Phase II only: patients with colorectal cancer with known MSI-high disease who have not previously been treated with immunotherapy or who have refused treatment with immunotherapy,"['Phase' 'II' 'only' ':' 'patients' 'with' 'colorectal' 'cancer' 'with'
 'known' 'MSI-high' 'disease' 'who' 'have' 'not' 'previously' 'been'
 'treated' 'with' 'immunotherapy' 'or' 'who' 'have' 'refused' 'treatment'
 'with' 'immunotherapy']","[0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.
 1. 1. 1.]"
NCT01850758,"35:49:chronic_disease,92:112:chronic_disease,114:142:chronic_disease,144:163:chronic_disease,165:176:chronic_disease,178:190:chronic_disease,192:207:chronic_disease","Inflammatory or auto-immune based joint diseases or other lower extremity pathology (e.g., rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, polymyalgia, polymyositis, gout pseudogout)","['Inflammatory' 'or' 'auto-immune' 'based' 'joint' 'diseases' 'or' 'other'
 'lower' 'extremity' 'pathology' '(' 'e.g.' ',' 'rheumatoid' 'arthritis'
 ',' 'systemic' 'lupus' 'erythematosus' ',' 'psoriatic' 'arthritis' ','
 'polymyalgia' ',' 'polymyositis' ',' 'gout' 'pseudogout' ')']","[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 2. 0. 2. 2. 0.
 2. 0. 2. 0. 2. 2. 0.]"
NCT01850758,"43:53:cancer,132:141:treatment,145:167:treatment","Tested positive or has been treated for a malignancy in the past or is suspected of having a malignancy or is currently undergoing radiation or chemotherapy treatment for a malignancy anywhere in the body, whether adjacent to or distant from the proposed injection site","['Tested' 'positive' 'or' 'has' 'been' 'treated' 'for' 'a' 'malignancy'
 'in' 'the' 'past' 'or' 'is' 'suspected' 'of' 'having' 'a' 'malignancy'
 'or' 'is' 'currently' 'undergoing' 'radiation' 'or' 'chemotherapy'
 'treatment' 'for' 'a' 'malignancy' 'anywhere' 'in' 'the' 'body' ','
 'whether' 'adjacent' 'to' 'or' 'distant' 'from' 'the' 'proposed'
 'injection' 'site']","[0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01849146,",34:47:treatment,49:67:treatment,75:82:treatment,84:102:treatment,104:115:treatment","2 weeks from administration of a non-cytotoxic, FDA-approved agent (e.g., Tarceva, hydroxychloroquine, bevacizumab, etc.)","['2' 'weeks' 'from' 'administration' 'of' 'a' 'non-cytotoxic' ','
 'FDA-approved' 'agent' '(' 'e.g.' ',' 'Tarceva' ',' 'hydroxychloroquine'
 ',' 'bevacizumab' ',' 'etc' '.' ')']",[0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0.]
NCT01849146,"20:30:cancer,57:62:cancer,66:101:cancer,105:136:cancer,138:144:cancer,149:156:cancer","have no concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or bladder","['have' 'no' 'concurrent' 'malignancy' 'except' 'curatively' 'treated'
 'basal' 'or' 'squamous' 'cell' 'carcinoma' 'of' 'the' 'skin' 'or'
 'carcinoma' 'in' 'situ' 'of' 'the' 'cervix' ',' 'breast' ',' 'or'
 'bladder']","[0. 0. 0. 3. 0. 0. 0. 3. 0. 3. 3. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 3.
 0. 0. 3.]"
NCT01849146,"56:68:cancer,72:75:treatment,,103:112:treatment",measurable contrast-enhancing progressive or recurrent glioblastoma by MRI within 21 days of starting treatment,"['measurable' 'contrast-enhancing' 'progressive' 'or' 'recurrent'
 'glioblastoma' 'by' 'MRI' 'within' '21' 'days' 'of' 'starting'
 'treatment']",[0. 0. 0. 0. 0. 3. 0. 1. 0. 0. 0. 0. 0. 1.]
NCT01842399,"8:17:treatment,65:84:treatment,86:106:treatment,108:129:treatment,131:150:treatment,152:170:treatment,174:210:treatment,251:262:treatment,308:321:treatment","Taking medicines that may increase the risk of bleeding such as Coumadin (warfarin), Plavix (clopidogrel), Xarelto (rivaroxaban), Pradaxa (dabgatran), Eliquis (apixaban) or Heparin (blood thinning medications) due to their potential interaction with resveratrol and the increased risk for bleeding with the muscle biopsy","['Taking' 'medicines' 'that' 'may' 'increase' 'the' 'risk' 'of' 'bleeding'
 'such' 'as' 'Coumadin' '(' 'warfarin' ')' ',' 'Plavix' '(' 'clopidogrel'
 ')' ',' 'Xarelto' '(' 'rivaroxaban' ')' ',' 'Pradaxa' '(' 'dabgatran' ')'
 ',' 'Eliquis' '(' 'apixaban' ')' 'or' 'Heparin' '(' 'blood' 'thinning'
 'medications' ')' 'due' 'to' 'their' 'potential' 'interaction' 'with'
 'resveratrol' 'and' 'the' 'increased' 'risk' 'for' 'bleeding' 'with'
 'the' 'muscle' 'biopsy']","[0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 1. 0. 0. 0. 1. 1. 0.
 0. 0. 1. 1. 0. 0. 0. 1. 1. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]"
NCT01841333,"21:33:chronic_disease,35:44:chronic_disease,55:64:chronic_disease,89:96:treatment","Active uncontrolled acute fungal, bacterial, or other infection that is unresponsive to therapy at time of study drug dosing","['Active' 'uncontrolled' 'acute' 'fungal' ',' 'bacterial' ',' 'or' 'other'
 'infection' 'that' 'is' 'unresponsive' 'to' 'therapy' 'at' 'time' 'of'
 'study' 'drug' 'dosing']",[0. 0. 2. 2. 0. 2. 0. 0. 0. 2. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT01835626,"19:42:cancer,38:42:cancer,118:127:treatment,158:165:treatment,227:258:treatment","For patients with multiple cutaneous BCCs at baseline that are not designated by the investigator as target lesions, treatment of these non-target BCCs with surgery may be permitted but must be discussed with Data Coordinator prior to any surgical procedure","['For' 'patients' 'with' 'multiple' 'cutaneous' 'BCCs' 'at' 'baseline'
 'that' 'are' 'not' 'designated' 'by' 'the' 'investigator' 'as' 'target'
 'lesions' ',' 'treatment' 'of' 'these' 'non-target' 'BCCs' 'with'
 'surgery' 'may' 'be' 'permitted' 'but' 'must' 'be' 'discussed' 'with'
 'Data' 'Coordinator' 'prior' 'to' 'any' 'surgical' 'procedure']","[0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.
 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1.]"
NCT01835626,",,59:68:treatment,,,171:180:treatment,186:196:treatment","Male patients must use condoms at all times, even after a vasectomy, during sexual intercourse with pregnant partners or female partners of reproductive potential during treatment with vismodegib","['Male' 'patients' 'must' 'use' 'condoms' 'at' 'all' 'times' ',' 'even'
 'after' 'a' 'vasectomy' ',' 'during' 'sexual' 'intercourse' 'with'
 'pregnant' 'partners' 'or' 'female' 'partners' 'of' 'reproductive'
 'potential' 'during' 'treatment' 'with' 'vismodegib']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 0. 1.]"
NCT01829958,"20:31:chronic_disease,20:41:chronic_disease,118:130:treatment",Evidence of active hepatitis B infection (i.e. patients testing positive hepatitis B surface antigen or viral DNA by PCR analysis),"['Evidence' 'of' 'active' 'hepatitis' 'B' 'infection' '(' 'i.e' '.'
 'patients' 'testing' 'positive' 'hepatitis' 'B' 'surface' 'antigen' 'or'
 'viral' 'DNA' 'by' 'PCR' 'analysis' ')']",[0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.]
NCT01829958,"1:16:chronic_disease,18:33:chronic_disease,37:55:chronic_disease",Serous effusion (plural effusion or peritoneal ascites),"['Serous' 'effusion' '(' 'plural' 'effusion' 'or' 'peritoneal' 'ascites'
 ')']",[2. 2. 0. 2. 2. 0. 2. 2. 0.]
NCT01827384,"29:38:treatment,48:62:treatment,83:95:treatment",Patients who have had prior treatment with any PARP inhibitor in combination with temozolomide,"['Patients' 'who' 'have' 'had' 'prior' 'treatment' 'with' 'any' 'PARP'
 'inhibitor' 'in' 'combination' 'with' 'temozolomide']",[0. 0. 0. 0. 0. 1. 0. 0. 1. 1. 0. 0. 0. 1.]
NCT01827384,"15:42:chronic_disease,138:153:treatment,192:217:treatment,240:262:chronic_disease,268:295:chronic_disease","Patients with gastrointestinal conditions that might predispose for drug intolerability or poor drug absorption (e.g., inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, malabsorption syndrome, and active peptic ulcer disease)","['Patients' 'with' 'gastrointestinal' 'conditions' 'that' 'might'
 'predispose' 'for' 'drug' 'intolerability' 'or' 'poor' 'drug'
 'absorption' '(' 'e.g.' ',' 'inability' 'to' 'take' 'oral' 'medication'
 'or' 'a' 'requirement' 'for' 'IV' 'alimentation' ',' 'prior' 'surgical'
 'procedures' 'affecting' 'absorption' ',' 'malabsorption' 'syndrome' ','
 'and' 'active' 'peptic' 'ulcer' 'disease' ')']","[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.
 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 2. 0.]"
NCT01827384,"15:24:treatment,33:69:cancer,57:60:cancer,70:100:cancer,96:99:cancer,158:197:treatment,201:244:treatment","Patients with treatment-related acute myeloid leukemia (AML) (t-AML)/myelodysplastic syndrome (MDS), or with features suggestive of AML/MDS, or who have had prior allogeneic bone marrow transplant or double umbilical cord blood transplantation","['Patients' 'with' 'treatment-related' 'acute' 'myeloid' 'leukemia' '('
 'AML' ')' '(' 't-AML' ')' '/myelodysplastic' 'syndrome' '(' 'MDS' ')' ','
 'or' 'with' 'features' 'suggestive' 'of' 'AML/MDS' ',' 'or' 'who' 'have'
 'had' 'prior' 'allogeneic' 'bone' 'marrow' 'transplant' 'or' 'double'
 'umbilical' 'cord' 'blood' 'transplantation']","[0. 0. 1. 3. 3. 3. 3. 3. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 1. 1. 1. 1. 1.]"
NCT01827384,"15:30:cancer,44:57:treatment,61:72:treatment",patients with prostate cancer may continue LHRH agonists or antagonists,"['patients' 'with' 'prostate' 'cancer' 'may' 'continue' 'LHRH' 'agonists'
 'or' 'antagonists']",[0. 0. 3. 3. 0. 0. 1. 1. 0. 1.]
NCT01823198,"1:23:chronic_disease,55:75:treatment,,96:103:treatment","Uncontrolled infection, not responding to appropriate antimicrobial agents after seven days of therapy; the protocol principal investigator (PI) is the final arbiter of eligibility","['Uncontrolled' 'infection' ',' 'not' 'responding' 'to' 'appropriate'
 'antimicrobial' 'agents' 'after' 'seven' 'days' 'of' 'therapy' ';' 'the'
 'protocol' 'principal' 'investigator' '(' 'PI' ')' 'is' 'the' 'final'
 'arbiter' 'of' 'eligibility']","[2. 2. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT01822522,"28:41:chronic_disease,28:31:chronic_disease,101:142:treatment,144:165:treatment,359:387:treatment","Serologic documentation of HIV infection at any time prior to study entry, as evidenced by positive enzyme-linked immunosorbent assay (ELISA), positive western blot, or any other federally approved licensed HIV test; alternatively, this documentation may include a record that another physician has documented that the participant has HIV infection based on prior ELISA and western blot, or other approved diagnostic tests","['Serologic' 'documentation' 'of' 'HIV' 'infection' 'at' 'any' 'time'
 'prior' 'to' 'study' 'entry' ',' 'as' 'evidenced' 'by' 'positive'
 'enzyme-linked' 'immunosorbent' 'assay' '(' 'ELISA' ')' ',' 'positive'
 'western' 'blot' ',' 'or' 'any' 'other' 'federally' 'approved' 'licensed'
 'HIV' 'test' ';' 'alternatively' ',' 'this' 'documentation' 'may'
 'include' 'a' 'record' 'that' 'another' 'physician' 'has' 'documented'
 'that' 'the' 'participant' 'has' 'HIV' 'infection' 'based' 'on' 'prior'
 'ELISA' 'and' 'western' 'blot' ',' 'or' 'other' 'approved' 'diagnostic'
 'tests']","[0. 0. 0. 2. 2. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01822522,"1:13:treatment,43:47:cancer,51:67:cancer,",radiotherapy to any other site (including bone or brain metastases) must be completed at least 28 days prior to registration,"['radiotherapy' 'to' 'any' 'other' 'site' '(' 'including' 'bone' 'or'
 'brain' 'metastases' ')' 'must' 'be' 'completed' 'at' 'least' '28' 'days'
 'prior' 'to' 'registration']",[1. 0. 0. 0. 0. 0. 0. 3. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01817751,"1:24:chronic_disease,51:72:chronic_disease,74:98:chronic_disease,110:136:chronic_disease,,161:176:treatment","Arterial thromboembolic or embolic events such as myocardial infarction, cerebrovascular accident, including transient ischemic attacks 6 months prior to first study treatment","['Arterial' 'thromboembolic' 'or' 'embolic' 'events' 'such' 'as'
 'myocardial' 'infarction' ',' 'cerebrovascular' 'accident' ','
 'including' 'transient' 'ischemic' 'attacks' '6' 'months' 'prior' 'to'
 'first' 'study' 'treatment']",[2. 2. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 1. 1.]
NCT01817751,"37:43:cancer,,,80:104:treatment,108:140:treatment","Pathologically confirmed high-grade glioma (WHO grade 3 or 4), with documented computed tomography (CT) or magnetic resonance imaging (MRI) progression or recurrence","['Pathologically' 'confirmed' 'high-grade' 'glioma' '(' 'WHO' 'grade' '3'
 'or' '4' ')' ',' 'with' 'documented' 'computed' 'tomography' '(' 'CT' ')'
 'or' 'magnetic' 'resonance' 'imaging' '(' 'MRI' ')' 'progression' 'or'
 'recurrence']","[0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 1. 1. 1. 1.
 0. 0. 0. 0. 0.]"
NCT01815359,"13:25:cancer,44:68:cancer,92:120:cancer,,","Other prior malignancies, except for cured non-melanoma skin cancer, curatively treated in situ carcinoma of the cervix, adequately treated malignancies for which there has been no evidence of activity for more than 3 years or indolent tumors for which observation over three years is a reasonable option","['Other' 'prior' 'malignancies' ',' 'except' 'for' 'cured' 'non-melanoma'
 'skin' 'cancer' ',' 'curatively' 'treated' 'in' 'situ' 'carcinoma' 'of'
 'the' 'cervix' ',' 'adequately' 'treated' 'malignancies' 'for' 'which'
 'there' 'has' 'been' 'no' 'evidence' 'of' 'activity' 'for' 'more' 'than'
 '3' 'years' 'or' 'indolent' 'tumors' 'for' 'which' 'observation' 'over'
 'three' 'years' 'is' 'a' 'reasonable' 'option']","[0. 0. 3. 0. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT01811368,"1:10:chronic_disease,28:47:chronic_disease,51:68:chronic_disease",Cirrhosis with evidence of portal hypertension or bridging fibrosis,"['Cirrhosis' 'with' 'evidence' 'of' 'portal' 'hypertension' 'or'
 'bridging' 'fibrosis']",[2. 0. 0. 0. 2. 2. 0. 2. 2.]
NCT01809002,"13:28:allergy_name,37:52:allergy_name,53:63:allergy_name",Allergic to Bovine products such as Bovine Collagen Nerve Cuff,"['Allergic' 'to' 'Bovine' 'products' 'such' 'as' 'Bovine' 'Collagen'
 'Nerve' 'Cuff']",[0. 0. 4. 4. 0. 0. 0. 0. 4. 4.]
NCT01807091,"51:63:chronic_disease,65:74:chronic_disease,76:92:chronic_disease","Afebrile with clear chest imaging and no signs of active viral, bacterial, fungal infection unless determined to be, at the discretion of the investigator, not clinically significant in the context of this study","['Afebrile' 'with' 'clear' 'chest' 'imaging' 'and' 'no' 'signs' 'of'
 'active' 'viral' ',' 'bacterial' ',' 'fungal' 'infection' 'unless'
 'determined' 'to' 'be' ',' 'at' 'the' 'discretion' 'of' 'the'
 'investigator' ',' 'not' 'clinically' 'significant' 'in' 'the' 'context'
 'of' 'this' 'study']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01804634,",,51:60:treatment,62:74:treatment,78:99:treatment,101:110:treatment",Patients with >5 identified lesions on the end of induction (COG ANBL0532 or standard chemotherapy) MIBG scan,"['Patients' 'with' '>' '5' 'identified' 'lesions' 'on' 'the' 'end' 'of'
 'induction' '(' 'COG' 'ANBL0532' 'or' 'standard' 'chemotherapy' ')'
 'MIBG' 'scan']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 1. 1. 0. 1. 1.]
NCT01804465,"27:61:cancer,63:81:treatment,111:118:treatment,126:155:treatment","Histologically confirmed, metastatic prostate adenocarcinoma (positive bone scan and/or measurable disease on CT scan and/or MRI of the abdomen and pelvis)","['Histologically' 'confirmed' ',' 'metastatic' 'prostate' 'adenocarcinoma'
 '(' 'positive' 'bone' 'scan' 'and/or' 'measurable' 'disease' 'on' 'CT'
 'scan' 'and/or' 'MRI' 'of' 'the' 'abdomen' 'and' 'pelvis' ')']",[0. 0. 0. 3. 3. 3. 0. 1. 1. 1. 0. 0. 0. 0. 1. 1. 0. 1. 1. 1. 1. 1. 1. 0.]
NCT01802346,"1:14:cancer,52:64:treatment,88:116:treatment,","Breast cancer subjects may not have received prior chemotherapy, with the exception of curative-intent chemotherapy for a separate malignancy more than 3 years ago","['Breast' 'cancer' 'subjects' 'may' 'not' 'have' 'received' 'prior'
 'chemotherapy' ',' 'with' 'the' 'exception' 'of' 'curative-intent'
 'chemotherapy' 'for' 'a' 'separate' 'malignancy' 'more' 'than' '3'
 'years' 'ago']","[3. 3. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT01802346,"44:61:cancer,63:75:treatment,103:114:treatment,106:114:treatment,129:147:treatment","Subjects do not need to have measurable or evaluable disease; chemotherapy may be administered in the neoadjuvant, adjuvant, or metastatic setting","['Subjects' 'do' 'not' 'need' 'to' 'have' 'measurable' 'or' 'evaluable'
 'disease' ';' 'chemotherapy' 'may' 'be' 'administered' 'in' 'the'
 'neoadjuvant' ',' 'adjuvant' ',' 'or' 'metastatic' 'setting']",[0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 1. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 1. 1.]
NCT01799538,"1:42:treatment,44:69:treatment,73:109:treatment,113:156:treatment,","Treatment with monoaminoxidase inhibitors, tricyclic antidepressants or Beta-adrenergic receptor antagonists or long acting anticholinergic bronchodilators who are unable to be discontinued for at least seven days before enrollment","['Treatment' 'with' 'monoaminoxidase' 'inhibitors' ',' 'tricyclic'
 'antidepressants' 'or' 'Beta-adrenergic' 'receptor' 'antagonists' 'or'
 'long' 'acting' 'anticholinergic' 'bronchodilators' 'who' 'are' 'unable'
 'to' 'be' 'discontinued' 'for' 'at' 'least' 'seven' 'days' 'before'
 'enrollment']","[1. 1. 1. 1. 0. 1. 1. 0. 1. 1. 1. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT01795573,"1:4:cancer,,,,100:119:treatment,,,,,298:315:treatment,349:359:cancer,364:378:treatment,386:406:treatment","CLL: Absence of constitutional symptoms attributable to CLL; No lymph nodes >1.5 cm in diameter on computed tomography; No hepatomegaly or splenomegaly by computed tomography; Absolute neutrophil count >1500/microL; Platelet count >100,000/microL; No clonal lymphocytes in the peripheral blood by immunophenotyping; Bone marrow with no evidence of clonal CLL (by flow cytometry and/or immunohistochemistry","['CLL' ':' 'Absence' 'of' 'constitutional' 'symptoms' 'attributable' 'to'
 'CLL' ';' 'No' 'lymph' 'nodes' '>' '1.5' 'cm' 'in' 'diameter' 'on'
 'computed' 'tomography' ';' 'No' 'hepatomegaly' 'or' 'splenomegaly' 'by'
 'computed' 'tomography' ';' 'Absolute' 'neutrophil' 'count' '>'
 '1500/microL' ';' 'Platelet' 'count' '>' '100,000/microL' ';' 'No'
 'clonal' 'lymphocytes' 'in' 'the' 'peripheral' 'blood' 'by'
 'immunophenotyping' ';' 'Bone' 'marrow' 'with' 'no' 'evidence' 'of'
 'clonal' 'CLL' '(' 'by' 'flow' 'cytometry' 'and/or'
 'immunohistochemistry']","[3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0.
 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1.]"
NCT01795573,"1:18:chronic_disease,31:39:treatment,43:49:treatment",Hepatitis B and C negative by serology or RT-PCR,['Hepatitis' 'B' 'and' 'C' 'negative' 'by' 'serology' 'or' 'RT-PCR'],[2. 2. 2. 2. 0. 0. 1. 0. 1.]
NCT01795573,"77:80:treatment,77:94:cancer,77:95:cancer,104:113:treatment,263:265:treatment,321:352:treatment,334:352:treatment,445:465:treatment","NHL: No clinical evidence of disease or disease-related symptoms; Typically FDG-avid lymphomas: a post-treatment residual mass of any size is permitted as long as it is PET negative; Variably FDG-avid lymphoma/FDG avidity unknown: all lymph nodes normal size by CT; Spleen and liver non-palpable and without nodules; If pretreatment bone marrow biopsy was positive, repeat bone marrow biopsy must be negative; if morphologically indeterminate, immunohistochemistry should be negative If pretreatment bone marrow biopsy was positive, repeat bone marrow biopsy must be negative; if morphologically indeterminate, immunohistochemistry should be negative","['NHL' ':' 'No' 'clinical' 'evidence' 'of' 'disease' 'or'
 'disease-related' 'symptoms' ';' 'Typically' 'FDG-avid' 'lymphomas' ':'
 'a' 'post-treatment' 'residual' 'mass' 'of' 'any' 'size' 'is' 'permitted'
 'as' 'long' 'as' 'it' 'is' 'PET' 'negative' ';' 'Variably' 'FDG-avid'
 'lymphoma/FDG' 'avidity' 'unknown' ':' 'all' 'lymph' 'nodes' 'normal'
 'size' 'by' 'CT' ';' 'Spleen' 'and' 'liver' 'non-palpable' 'and'
 'without' 'nodules' ';' 'If' 'pretreatment' 'bone' 'marrow' 'biopsy'
 'was' 'positive' ',' 'repeat' 'bone' 'marrow' 'biopsy' 'must' 'be'
 'negative' ';' 'if' 'morphologically' 'indeterminate' ','
 'immunohistochemistry' 'should' 'be' 'negative' 'If' 'pretreatment'
 'bone' 'marrow' 'biopsy' 'was' 'positive' ',' 'repeat' 'bone' 'marrow'
 'biopsy' 'must' 'be' 'negative' ';' 'if' 'morphologically'
 'indeterminate' ',' 'immunohistochemistry' 'should' 'be' 'negative']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT01794793,",8:21:treatment,32:92:treatment,97:111:treatment,,145:160:treatment",Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment,"['Female' 'sterilization' '(' 'have' 'had' 'surgical' 'bilateral'
 'oophorectomy' 'with' 'or' 'without' 'hysterectomy' ')' 'or' 'tubal'
 'ligation' 'at' 'least' 'six' 'weeks' 'before' 'taking' 'study'
 'treatment']",[0. 1. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01794559,"12:22:treatment,24:43:cancer,45:69:chronic_disease,92:108:chronic_disease,110:126:chronic_disease,128:141:chronic_disease,143:168:chronic_disease,170:178:chronic_disease,180:198:chronic_disease,203:243:chronic_disease,255:273:treatment,","History of craniotomy, cerebral metastases, cerebrovascular accident, current diagnosis of seizure disorder, bipolar disorder, schizophrenia, schizo-affective disorder, dementia, mental retardation, or major depression with psychotic features, or use of depot neuroleptics in the last 12 months","['History' 'of' 'craniotomy' ',' 'cerebral' 'metastases' ','
 'cerebrovascular' 'accident' ',' 'current' 'diagnosis' 'of' 'seizure'
 'disorder' ',' 'bipolar' 'disorder' ',' 'schizophrenia' ','
 'schizo-affective' 'disorder' ',' 'dementia' ',' 'mental' 'retardation'
 ',' 'or' 'major' 'depression' 'with' 'psychotic' 'features' ',' 'or'
 'use' 'of' 'depot' 'neuroleptics' 'in' 'the' 'last' '12' 'months']","[0. 0. 1. 0. 3. 3. 0. 2. 2. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 2. 0. 2. 2. 0.
 2. 0. 2. 2. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]"
NCT01793519,",,,71:80:treatment,93:103:treatment,105:115:treatment,120:130:treatment,,170:182:treatment,184:202:treatment,204:217:treatment,219:230:treatment,232:243:treatment,245:257:treatment,259:271:treatment,279:292:treatment,,,,,,,","In sustained clinical remission for the last 6 months while receiving treatment with either etanercept, infliximab, or adalimumab, and greater than or equal to 1 DMARD (methotrexate, hydroxychloroquine, sulfasalazine, leflunomide, minocycline, cyclosporine, azathioprine, gold, penicillamine). DAS28 should be less than 2.6 on each visit over the preceding 6 months, with at least one visit 2-4 months before enrollment. If there is no visit 6 months before enrollment, the nearest visit in the 6-12 month period before enrollment should be considered and have a DAS28 less than 2.6","['In' 'sustained' 'clinical' 'remission' 'for' 'the' 'last' '6' 'months'
 'while' 'receiving' 'treatment' 'with' 'either' 'etanercept' ','
 'infliximab' ',' 'or' 'adalimumab' ',' 'and' 'greater' 'than' 'or'
 'equal' 'to' '1' 'DMARD' '(' 'methotrexate' ',' 'hydroxychloroquine' ','
 'sulfasalazine' ',' 'leflunomide' ',' 'minocycline' ',' 'cyclosporine'
 ',' 'azathioprine' ',' 'gold' ',' 'penicillamine' ')' '.' 'DAS28'
 'should' 'be' 'less' 'than' '2.6' 'on' 'each' 'visit' 'over' 'the'
 'preceding' '6' 'months' ',' 'with' 'at' 'least' 'one' 'visit' '2-4'
 'months' 'before' 'enrollment' '.' 'If' 'there' 'is' 'no' 'visit' '6'
 'months' 'before' 'enrollment' ',' 'the' 'nearest' 'visit' 'in' 'the'
 '6-12' 'month' 'period' 'before' 'enrollment' 'should' 'be' 'considered'
 'and' 'have' 'a' 'DAS28' 'less' 'than' '2.6']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 0. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01791543,"10:46:chronic_disease,50:79:treatment,85:96:treatment",Definite protruding left ventricular thrombus on pre-ablation echocardiography when LV ablation is required,"['Definite' 'protruding' 'left' 'ventricular' 'thrombus' 'on'
 'pre-ablation' 'echocardiography' 'when' 'LV' 'ablation' 'is' 'required']",[0. 2. 2. 2. 2. 0. 1. 1. 0. 1. 1. 0. 0.]
NCT01791543,"7:34:treatment,63:84:chronic_disease,86:94:chronic_disease","prior antiarrhythmic drug therapy has failed due to recurrent ventricular arrythmia, toxicity, or intolerance","['prior' 'antiarrhythmic' 'drug' 'therapy' 'has' 'failed' 'due' 'to'
 'recurrent' 'ventricular' 'arrythmia' ',' 'toxicity' ',' 'or'
 'intolerance']",[0. 1. 1. 1. 0. 0. 0. 0. 0. 2. 2. 0. 2. 0. 0. 0.]
NCT01787487,"30:56:chronic_disease,58:103:chronic_disease,108:161:chronic_disease,172:179:treatment","Patients with a diagnosis of primary myelofibrosis (PM), post polycythemia vera myelofibrosis (PPV MF), or post essential thrombocythemia myelofibrosis (PET MF) requiring therapy, including those previously treated and relapsed or refractory, or if newly diagnosed, with intermediate or high risk according to International Working Group (IWG-MRT) criteria","['Patients' 'with' 'a' 'diagnosis' 'of' 'primary' 'myelofibrosis' '(' 'PM'
 ')' ',' 'post' 'polycythemia' 'vera' 'myelofibrosis' '(' 'PPV' 'MF' ')'
 ',' 'or' 'post' 'essential' 'thrombocythemia' 'myelofibrosis' '(' 'PET'
 'MF' ')' 'requiring' 'therapy' ',' 'including' 'those' 'previously'
 'treated' 'and' 'relapsed' 'or' 'refractory' ',' 'or' 'if' 'newly'
 'diagnosed' ',' 'with' 'intermediate' 'or' 'high' 'risk' 'according' 'to'
 'International' 'Working' 'Group' '(' 'IWG-MRT' ')' 'criteria']","[0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 2. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01787409,"25:30:cancer,34:69:cancer,99:131:treatment,133:142:treatment,143:159:treatment,161:186:treatment,188:207:treatment","Newly diagnosed de-novo DLBCL or primary mediastinal B-cell lymphoma that will be treated with an anthracycline-containing regimen (rituximab-cyclophosphamide, doxorubicin hydrochloride, prednisone [R-CHOP] or equivalent)","['Newly' 'diagnosed' 'de-novo' 'DLBCL' 'or' 'primary' 'mediastinal'
 'B-cell' 'lymphoma' 'that' 'will' 'be' 'treated' 'with' 'an'
 'anthracycline-containing' 'regimen' '(' 'rituximab-cyclophosphamide' ','
 'doxorubicin' 'hydrochloride' ',' 'prednisone' '[' 'R-CHOP' ']' 'or'
 'equivalent' ')']","[0. 0. 0. 3. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 1. 0. 1.
 1. 0. 0. 0. 0. 0.]"
NCT01782599,"30:53:chronic_disease,55:68:chronic_disease,70:94:chronic_disease,96:112:chronic_disease,114:133:chronic_disease","lifetime DSM-IV diagnosis of organic mental disorder, schizophrenia, schizoaffective disorder, bipolar disorder, delusional disorder","['lifetime' 'DSM-IV' 'diagnosis' 'of' 'organic' 'mental' 'disorder' ','
 'schizophrenia' ',' 'schizoaffective' 'disorder' ',' 'bipolar' 'disorder'
 ',' 'delusional' 'disorder']",[0. 0. 0. 0. 2. 2. 2. 0. 2. 0. 2. 2. 0. 2. 2. 0. 2. 2.]
NCT01774019,"30:42:cancer,54:71:cancer,73:102:cancer,113:134:cancer","Biliary strictures caused by malignancies other than pancreatic cancer, distal CBD cholangiocarcinoma and other periampullary cancers","['Biliary' 'strictures' 'caused' 'by' 'malignancies' 'other' 'than'
 'pancreatic' 'cancer' ',' 'distal' 'CBD' 'cholangiocarcinoma' 'and'
 'other' 'periampullary' 'cancers']",[0. 0. 0. 0. 3. 0. 0. 3. 3. 0. 3. 3. 3. 0. 0. 3. 3.]
NCT01773707,"28:43:chronic_disease,45:49:chronic_disease,51:63:chronic_disease,68:93:chronic_disease,103:114:cancer,116:126:cancer,131:147:chronic_disease","These include pre-existing cardiac disease, COPD, neurological, or blood count abnormalities (such as lymphopenia, leukopenia, or thrombocytopenia)","['These' 'include' 'pre-existing' 'cardiac' 'disease' ',' 'COPD' ','
 'neurological' ',' 'or' 'blood' 'count' 'abnormalities' '(' 'such' 'as'
 'lymphopenia' ',' 'leukopenia' ',' 'or' 'thrombocytopenia' ')']",[0. 0. 0. 2. 2. 0. 2. 0. 2. 0. 0. 2. 2. 2. 0. 0. 0. 3. 0. 3. 0. 0. 2. 0.]
NCT01772329,"21:32:treatment,34:37:treatment,41:57:treatment",undergoing standard primary TKR; THR or Shoulder Surgery,"['undergoing' 'standard' 'primary' 'TKR' ';' 'THR' 'or' 'Shoulder'
 'Surgery']",[0. 0. 1. 1. 0. 1. 0. 1. 1.]
NCT01760863,"27:75:treatment,187:210:treatment,246:262:treatment",Adult patients undergoing 2-stage revision arthroplasty of the knee or hip with the causative organism(s) identified using tissue culture and/or joint fluid analysis that is amenable to oral antibiotic therapy. Patients must be able to tolerate oral antibiotics and agree to participate in the study,"['Adult' 'patients' 'undergoing' '2-stage' 'revision' 'arthroplasty' 'of'
 'the' 'knee' 'or' 'hip' 'with' 'the' 'causative' 'organism' '(' 's' ')'
 'identified' 'using' 'tissue' 'culture' 'and/or' 'joint' 'fluid'
 'analysis' 'that' 'is' 'amenable' 'to' 'oral' 'antibiotic' 'therapy' '.'
 'Patients' 'must' 'be' 'able' 'to' 'tolerate' 'oral' 'antibiotics' 'and'
 'agree' 'to' 'participate' 'in' 'the' 'study']","[0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT01760655,"28:69:treatment,81:84:chronic_disease,107:128:treatment,147:168:treatment","Examples are patients with previous treatment with radiation therapy precluding TBI, or a past history of myeloablative therapy, precluding a 2nd myeloablative regimen","['Examples' 'are' 'patients' 'with' 'previous' 'treatment' 'with'
 'radiation' 'therapy' 'precluding' 'TBI' ',' 'or' 'a' 'past' 'history'
 'of' 'myeloablative' 'therapy' ',' 'precluding' 'a' '2nd' 'myeloablative'
 'regimen']","[0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 2. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.
 0.]"
NCT01760655,"35:45:cancer,62:73:cancer,93:108:treatment","Patients with evidence of another malignancy, exclusive of a skin cancer that requires only local treatment, should not be enrolled on this protocol","['Patients' 'with' 'evidence' 'of' 'another' 'malignancy' ',' 'exclusive'
 'of' 'a' 'skin' 'cancer' 'that' 'requires' 'only' 'local' 'treatment' ','
 'should' 'not' 'be' 'enrolled' 'on' 'this' 'protocol']","[0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 3. 3. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT01760005,"13:23:treatment,25:39:treatment,41:64:treatment","Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, or foreign metal objects in the eyes, skin or body which would preclude MRI scan","['Presence' 'of' 'pacemakers' ',' 'aneurysm' 'clips' ',' 'artificial'
 'heart' 'valves' ',' 'ear' 'implants' ',' 'or' 'foreign' 'metal'
 'objects' 'in' 'the' 'eyes' ',' 'skin' 'or' 'body' 'which' 'would'
 'preclude' 'MRI' 'scan']","[0. 0. 1. 0. 1. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT01757418,"25:44:chronic_disease,46:48:chronic_disease,52:76:chronic_disease",Documented diagnosis of sickle cell disease (SS or S-β thalassemia genotype),"['Documented' 'diagnosis' 'of' 'sickle' 'cell' 'disease' '(' 'SS' 'or'
 'S-β' 'thalassemia' 'genotype' ')']",[0. 0. 0. 2. 2. 2. 0. 2. 0. 2. 2. 2. 0.]
NCT01754857,"7:14:treatment,20:29:treatment,67:95:chronic_disease","Prior therapy with rituximab is permitted, even in the setting of rituximab-refractory disease","['Prior' 'therapy' 'with' 'rituximab' 'is' 'permitted' ',' 'even' 'in'
 'the' 'setting' 'of' 'rituximab-refractory' 'disease']",[0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT01750567,"12:28:chronic_disease,44:50:chronic_disease,54:58:chronic_disease",Ongoing or active infection concerning for sepsis or SIRS,"['Ongoing' 'or' 'active' 'infection' 'concerning' 'for' 'sepsis' 'or'
 'SIRS']",[0. 0. 2. 2. 0. 0. 2. 0. 2.]
NCT01743950,"1:25:cancer,33:57:cancer,61:84:cancer",active second malignancy unless non-melanoma skin cancer or cervical cancer in situ,"['active' 'second' 'malignancy' 'unless' 'non-melanoma' 'skin' 'cancer'
 'or' 'cervical' 'cancer' 'in' 'situ']",[3. 3. 3. 0. 3. 3. 3. 0. 3. 3. 3. 3.]
NCT01742299,",32:63:treatment,80:92:treatment,,151:160:treatment",Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment,"['Female' 'sterilization' '(' 'have' 'had' 'surgical' 'bilateral'
 'oophorectomy' 'with' 'or' 'without' 'hysterectomy' ')' 'or' 'tubal'
 'ligation' 'at' 'least' 'six' 'weeks' 'before' 'taking' 'study'
 'treatment']",[0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01737502,"41:52:cancer,54:62:cancer,64:90:cancer,94:116:cancer","Histologic or cytologic confirmation of lung cancer (squamous, ras-mutated adenocarcinoma or small cell lung cancer)","['Histologic' 'or' 'cytologic' 'confirmation' 'of' 'lung' 'cancer' '('
 'squamous' ',' 'ras-mutated' 'adenocarcinoma' 'or' 'small' 'cell' 'lung'
 'cancer' ')']",[0. 0. 0. 0. 0. 3. 3. 0. 3. 0. 3. 3. 0. 3. 3. 3. 3. 0.]
NCT01734512,",,12:27:treatment,79:87:treatment,111:122:treatment,",INR ≤1.5. (Anticoagulation is allowed if target INR ≤ 1.5 on a stable dose of warfarin or on a stable dose of LMW heparin for >2 weeks at time of randomization),"['INR' '≤1.5' '.' '(' 'Anticoagulation' 'is' 'allowed' 'if' 'target' 'INR'
 '≤' '1.5' 'on' 'a' 'stable' 'dose' 'of' 'warfarin' 'or' 'on' 'a' 'stable'
 'dose' 'of' 'LMW' 'heparin' 'for' '>' '2' 'weeks' 'at' 'time' 'of'
 'randomization' ')']","[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.
 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01734512,"43:53:allergy_name,63:73:allergy_name,80:89:allergy_name,91:103:allergy_name","Patients with a known hypersensitivity to everolimus or other rapamycins (e.g. sirolimus, temsirolimus)","['Patients' 'with' 'a' 'known' 'hypersensitivity' 'to' 'everolimus' 'or'
 'other' 'rapamycins' '(' 'e.g' '.' 'sirolimus' ',' 'temsirolimus' ')']",[0. 0. 0. 0. 0. 0. 4. 0. 0. 4. 0. 0. 0. 4. 0. 4. 0.]
NCT01730937,"64:83:chronic_disease,210:212:treatment,216:219:treatment,244:247:cancer,","For patients whose CURRENT disease is vascular only: enhancing vascular thrombosis (involving portal vein, IVC and/or hepatic vein) demonstrating early arterial enhancement and delayed washout on multi-phasic CT or MRI in a patient with known HCC (diagnosed previously <720 days) using the above criteria","['For' 'patients' 'whose' 'CURRENT' 'disease' 'is' 'vascular' 'only' ':'
 'enhancing' 'vascular' 'thrombosis' '(' 'involving' 'portal' 'vein' ','
 'IVC' 'and/or' 'hepatic' 'vein' ')' 'demonstrating' 'early' 'arterial'
 'enhancement' 'and' 'delayed' 'washout' 'on' 'multi-phasic' 'CT' 'or'
 'MRI' 'in' 'a' 'patient' 'with' 'known' 'HCC' '(' 'diagnosed'
 'previously' '<' '720' 'days' ')' 'using' 'the' 'above' 'criteria']","[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT01730937,"18:21:chronic_disease,69:78:treatment,84:128:treatment,,","patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count ≥ (350) cells/microliter, and no known detectable viral load, at the time of study entry","['patients' 'who' 'are' 'HIV' 'positive' 'are' 'eligible' ',' 'provided'
 'they' 'are' 'under' 'treatment' 'with' 'highly' 'active'
 'antiretroviral' 'therapy' '(' 'HAART' ')' 'and' 'have' 'a' 'CD4' 'count'
 '≥' '(' '350' ')' 'cells/microliter' ',' 'and' 'no' 'known' 'detectable'
 'viral' 'load' ',' 'at' 'the' 'time' 'of' 'study' 'entry']","[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01730118,"8:22:chronic_disease,24:33:chronic_disease,37:53:chronic_disease,64:73:treatment","Active systemic viral, bacterial or fungal infection requiring treatment","['Active' 'systemic' 'viral' ',' 'bacterial' 'or' 'fungal' 'infection'
 'requiring' 'treatment']",[0. 2. 2. 0. 2. 0. 2. 2. 0. 1.]
NCT01730118,"10:36:treatment,39:62:treatment,68:89:treatment,92:130:treatment,141:164:treatment","Naive to trastuzumab (Herceptin(TM)), pertuzumab (Perjeta(TM)) and lapatinib (Tykerb(TM)), ado-trastuzumab emtansine (Kadcyla(TM)) or other HER2-directed therapies","['Naive' 'to' 'trastuzumab' '(' 'Herceptin' '(' 'TM' ')' ')' ','
 'pertuzumab' '(' 'Perjeta' '(' 'TM' ')' ')' 'and' 'lapatinib' '('
 'Tykerb' '(' 'TM' ')' ')' ',' 'ado-trastuzumab' 'emtansine' '(' 'Kadcyla'
 '(' 'TM' ')' ')' 'or' 'other' 'HER2-directed' 'therapies']","[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0.
 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1.]"
NCT01730118,"26:53:chronic_disease,105:114:treatment,142:170:treatment",Patients with inadequate bilateral peripheral venous or central venous catheter access for the required apheresis to allow generation of the autologous AdHER2 DC vaccine product,"['Patients' 'with' 'inadequate' 'bilateral' 'peripheral' 'venous' 'or'
 'central' 'venous' 'catheter' 'access' 'for' 'the' 'required' 'apheresis'
 'to' 'allow' 'generation' 'of' 'the' 'autologous' 'AdHER2' 'DC' 'vaccine'
 'product']","[0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 1. 1. 1. 1.
 0.]"
NCT01730118,"27:36:treatment,40:60:treatment,91:104:cancer","Stable, concurrent use of tamoxifen or aromatase inhibitors for hormone receptor positive breast cancer are allowed","['Stable' ',' 'concurrent' 'use' 'of' 'tamoxifen' 'or' 'aromatase'
 'inhibitors' 'for' 'hormone' 'receptor' 'positive' 'breast' 'cancer'
 'are' 'allowed']",[0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 3. 3. 0. 0.]
NCT01722240,"1:16:chronic_disease,44:60:treatment,82:94:treatment",Type 1 Diabetes on continuous subcutaneous insulin infusion (CSII; also known as insulin pump),"['Type' '1' 'Diabetes' 'on' 'continuous' 'subcutaneous' 'insulin'
 'infusion' '(' 'CSII' ';' 'also' 'known' 'as' 'insulin' 'pump' ')']",[2. 2. 2. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01720147,"14:16:chronic_disease,27:35:treatment,39:56:treatment",Diagnosis of FA proven by DEB test or molecular testing,"['Diagnosis' 'of' 'FA' 'proven' 'by' 'DEB' 'test' 'or' 'molecular'
 'testing']",[0. 0. 2. 0. 0. 1. 1. 0. 1. 1.]
NCT01715220,"15:54:chronic_disease,67:78:chronic_disease,,136:141:chronic_disease,162:172:chronic_disease,174:204:chronic_disease,248:269:chronic_disease,271:288:chronic_disease,349:377:treatment,,417:430:allergy_name","Patients with obstructive hypertrophic cardiomyopathy, pronounced hypovolemia, alcohol use in the last 8 hours, clinical intoxication, STEMI or presumed cardiac chest pain, inferior myocardial infarction with right ventricular involvement, raised intracranial pressure, cardiac tamponade and patients taking certain drugs for erectile dysfunction (phosphodiesterase inhibitors), pregnancy or with a known allergy to nitroglycerin will be excluded from the study","['Patients' 'with' 'obstructive' 'hypertrophic' 'cardiomyopathy' ','
 'pronounced' 'hypovolemia' ',' 'alcohol' 'use' 'in' 'the' 'last' '8'
 'hours' ',' 'clinical' 'intoxication' ',' 'STEMI' 'or' 'presumed'
 'cardiac' 'chest' 'pain' ',' 'inferior' 'myocardial' 'infarction' 'with'
 'right' 'ventricular' 'involvement' ',' 'raised' 'intracranial'
 'pressure' ',' 'cardiac' 'tamponade' 'and' 'patients' 'taking' 'certain'
 'drugs' 'for' 'erectile' 'dysfunction' '(' 'phosphodiesterase'
 'inhibitors' ')' ',' 'pregnancy' 'or' 'with' 'a' 'known' 'allergy' 'to'
 'nitroglycerin' 'will' 'be' 'excluded' 'from' 'the' 'study']","[0. 0. 2. 2. 2. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 2.
 2. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 0. 0. 0. 0. 0. 0.]"
NCT01712308,"20:58:chronic_disease,63:79:chronic_disease,85:102:chronic_disease","Known positive for human immunodeficiency virus-1 (HIV-1), or active infection with hepatitis-B or -C","['Known' 'positive' 'for' 'human' 'immunodeficiency' 'virus-1' '(' 'HIV-1'
 ')' ',' 'or' 'active' 'infection' 'with' 'hepatitis-B' 'or' '-C']",[0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 2. 2. 0. 2. 2. 2.]
NCT01703949,"7:41:chronic_disease,45:56:chronic_disease,77:125:chronic_disease",Known human immunodeficiency virus (HIV) or hepatitis B positivity or prior progressive multifocal leukoencephalopathy (PML),"['Known' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')' 'or' 'hepatitis'
 'B' 'positivity' 'or' 'prior' 'progressive' 'multifocal'
 'leukoencephalopathy' '(' 'PML' ')']",[0. 2. 2. 2. 2. 0. 0. 0. 2. 2. 0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT01703117,"18:29:treatment,89:101:treatment,184:193:treatment,195:206:treatment,208:215:treatment,217:224:treatment,226:235:treatment,237:253:treatment,262:274:treatment,279:294:treatment,296:321:treatment,323:338:treatment","Currently taking medications that either have evidence of glutamatergic activity or has previous MRS evidence of effects on brain glutamate levels at the discretion of the PI such as memantine, lamotrigine, lithium, opiates, bupropion, psychostimulants such as amphetamines and methylphenidate, tricyclic antidepressants, benzodiazepines and any other drug that the investigators judge might interfere with the study","['Currently' 'taking' 'medications' 'that' 'either' 'have' 'evidence' 'of'
 'glutamatergic' 'activity' 'or' 'has' 'previous' 'MRS' 'evidence' 'of'
 'effects' 'on' 'brain' 'glutamate' 'levels' 'at' 'the' 'discretion' 'of'
 'the' 'PI' 'such' 'as' 'memantine' ',' 'lamotrigine' ',' 'lithium' ','
 'opiates' ',' 'bupropion' ',' 'psychostimulants' 'such' 'as'
 'amphetamines' 'and' 'methylphenidate' ',' 'tricyclic' 'antidepressants'
 ',' 'benzodiazepines' 'and' 'any' 'other' 'drug' 'that' 'the'
 'investigators' 'judge' 'might' 'interfere' 'with' 'the' 'study']","[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 1. 0. 1. 0. 1. 1.
 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01703117,"13:39:chronic_disease,48:64:chronic_disease,66:79:chronic_disease,81:104:chronic_disease,106:123:chronic_disease,115:123:chronic_disease,125:151:chronic_disease,153:165:chronic_disease","Significant neuropsychiatric illnesses such as bipolar disorder, schizophrenia, moderate-severe anxiety, vascular dementia, Creutzfeldt-Jakob dementia, HIV dementia, and dementia in other specified diseases","['Significant' 'neuropsychiatric' 'illnesses' 'such' 'as' 'bipolar'
 'disorder' ',' 'schizophrenia' ',' 'moderate-severe' 'anxiety' ','
 'vascular' 'dementia' ',' 'Creutzfeldt-Jakob' 'dementia' ',' 'HIV'
 'dementia' ',' 'and' 'dementia' 'in' 'other' 'specified' 'diseases']","[0. 2. 2. 0. 0. 2. 2. 0. 2. 0. 2. 2. 0. 2. 2. 0. 2. 2. 0. 2. 2. 0. 0. 0.
 0. 0. 0. 0.]"
NCT01698658,"15:24:treatment,26:43:treatment,51:61:treatment","Scheduled for mammogram, breast ultrasound and/or breast MRI","['Scheduled' 'for' 'mammogram' ',' 'breast' 'ultrasound' 'and/or' 'breast'
 'MRI']",[0. 0. 1. 0. 1. 1. 0. 0. 0.]
NCT01697371,"1:13:treatment,30:43:treatment,,88:97:treatment,,,,",Chemotherapy and/or targeted agent therapy must be completed at least 2 weeks prior to radiation and started at least 14 days after completion of SBPT Women of childbearing potential and male participants must practice adequate contraception,"['Chemotherapy' 'and/or' 'targeted' 'agent' 'therapy' 'must' 'be'
 'completed' 'at' 'least' '2' 'weeks' 'prior' 'to' 'radiation' 'and'
 'started' 'at' 'least' '14' 'days' 'after' 'completion' 'of' 'SBPT'
 'Women' 'of' 'childbearing' 'potential' 'and' 'male' 'participants'
 'must' 'practice' 'adequate' 'contraception']","[1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01697293,"102:109:allergy_name,151:161:allergy_name,163:173:allergy_name","History of allergic reactions attributed to compounds of similar chemical or biologic composition to PTX-200 or other agents used in the study (e.g., imidazoles, quinolones)","['History' 'of' 'allergic' 'reactions' 'attributed' 'to' 'compounds' 'of'
 'similar' 'chemical' 'or' 'biologic' 'composition' 'to' 'PTX-200' 'or'
 'other' 'agents' 'used' 'in' 'the' 'study' '(' 'e.g.' ',' 'imidazoles'
 ',' 'quinolones' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 4. 0. 4. 0.]"
NCT01697293,",39:55:treatment,61:72:treatment,77:94:treatment,,111:123:treatment,134:144:treatment","at least 3 weeks for the last dose of biologic therapy (eg, bevacizumab) or cytotoxic therapy (or 2 weeks for capecitabine or weekly paclitaxel","['at' 'least' '3' 'weeks' 'for' 'the' 'last' 'dose' 'of' 'biologic'
 'therapy' '(' 'eg' ',' 'bevacizumab' ')' 'or' 'cytotoxic' 'therapy' '('
 'or' '2' 'weeks' 'for' 'capecitabine' 'or' 'weekly' 'paclitaxel']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0.
 1. 0. 0. 1.]"
NCT01697293,"18:43:cancer,96:105:treatment,109:122:cancer,130:141:treatment","patients who are hormone-receptor positive and who have received other hormonal agents for the treatment of breast cancer (e.g., Fulvestrant) are also eligible","['patients' 'who' 'are' 'hormone-receptor' 'positive' 'and' 'who' 'have'
 'received' 'other' 'hormonal' 'agents' 'for' 'the' 'treatment' 'of'
 'breast' 'cancer' '(' 'e.g.' ',' 'Fulvestrant' ')' 'are' 'also'
 'eligible']","[0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 3. 3. 0. 0. 0. 1. 0. 0.
 0. 0.]"
NCT01696734,"12:50:chronic_disease,72:83:chronic_disease,85:105:chronic_disease,107:132:chronic_disease","refractory gastroesophageal reflux disease (GERD) including persistent esophagitis, refractory heartburn, reflux-related laryngitis, and respiratory symptoms","['refractory' 'gastroesophageal' 'reflux' 'disease' '(' 'GERD' ')'
 'including' 'persistent' 'esophagitis' ',' 'refractory' 'heartburn' ','
 'reflux-related' 'laryngitis' ',' 'and' 'respiratory' 'symptoms']",[2. 2. 2. 2. 2. 0. 0. 0. 0. 2. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0.]
NCT01690468,"1:27:chronic_disease,,98:137:treatment,176:198:treatment","platinum-resistant disease is defined by a disease-free interval of less than 6 months following treatment with a platinum-based regimen, or the progression of disease during platinum-based therapy","['platinum-resistant' 'disease' 'is' 'defined' 'by' 'a' 'disease-free'
 'interval' 'of' 'less' 'than' '6' 'months' 'following' 'treatment' 'with'
 'a' 'platinum-based' 'regimen' ',' 'or' 'the' 'progression' 'of'
 'disease' 'during' 'platinum-based' 'therapy']","[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT01684904,"16:26:cancer,35:63:cancer,,118:145:cancer,147:158:cancer,163:169:cancer","Prior invasive malignancy (except non-melanomatous skin cancer), unless disease free for a minimum of 2 years ( e.g. carcinoma in situ of breast, oral cavity, or cervix are permissible)","['Prior' 'invasive' 'malignancy' '(' 'except' 'non-melanomatous' 'skin'
 'cancer' ')' ',' 'unless' 'disease' 'free' 'for' 'a' 'minimum' 'of' '2'
 'years' '(' 'e.g' '.' 'carcinoma' 'in' 'situ' 'of' 'breast' ',' 'oral'
 'cavity' ',' 'or' 'cervix' 'are' 'permissible' ')']","[0. 0. 3. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3.
 3. 3. 3. 0. 3. 3. 0. 0. 3. 0. 0. 0.]"
NCT01684397,"1:30:treatment,35:61:cancer,72:80:treatment,84:106:treatment",Prior VEGF targeted therapies for renal cell carcinoma (RCC) including adjuvant or neoadjuvant treatments,"['Prior' 'VEGF' 'targeted' 'therapies' 'for' 'renal' 'cell' 'carcinoma'
 '(' 'RCC' ')' 'including' 'adjuvant' 'or' 'neoadjuvant' 'treatments']",[1. 1. 1. 1. 0. 3. 3. 3. 3. 0. 0. 0. 1. 0. 1. 1.]
NCT01681589,"39:64:chronic_disease,66:99:chronic_disease,114:134:chronic_disease,143:154:chronic_disease,162:168:chronic_disease,170:178:chronic_disease,182:203:chronic_disease","Complicating medical problems such as uncontrolled hypertension, diabetes with signs of neuropathy, and previous neurological illness such as head trauma, prior stroke, epilepsy or demyelinating disease, implanted neuromodulatory or electronic device, metal in head","['Complicating' 'medical' 'problems' 'such' 'as' 'uncontrolled'
 'hypertension' ',' 'diabetes' 'with' 'signs' 'of' 'neuropathy' ',' 'and'
 'previous' 'neurological' 'illness' 'such' 'as' 'head' 'trauma' ','
 'prior' 'stroke' ',' 'epilepsy' 'or' 'demyelinating' 'disease' ','
 'implanted' 'neuromodulatory' 'or' 'electronic' 'device' ',' 'metal' 'in'
 'head']","[0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 2. 2. 2. 0. 0. 0. 2. 2. 0. 0. 2. 2. 0. 0.
 2. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01681264,"16:25:treatment,16:33:treatment,77:86:treatment,90:103:treatment,110:118:treatment,120:127:treatment,188:192:chronic_disease","Currently in a treatment program for alcohol or drug abuse, or currently on methadone or buprenorphine (i.e. suboxone, subutex) for treatment of addiction, or stimulants for treatment of ADHD","['Currently' 'in' 'a' 'treatment' 'program' 'for' 'alcohol' 'or' 'drug'
 'abuse' ',' 'or' 'currently' 'on' 'methadone' 'or' 'buprenorphine' '('
 'i.e' '.' 'suboxone' ',' 'subutex' ')' 'for' 'treatment' 'of' 'addiction'
 ',' 'or' 'stimulants' 'for' 'treatment' 'of' 'ADHD']","[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 1. 0. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]"
NCT01676753,"28:44:chronic_disease,69:94:treatment,106:141:treatment,153:189:treatment,218:233:treatment,238:244:chronic_disease,246:283:chronic_disease,285:302:chronic_disease,325:341:treatment,,426:441:treatment","Patient has a diagnosis of immunodeficiency or is receiving ongoing immunosuppressive therapy, including systemic or enteric corticosteroids except for non-systemically absorbed treatments (such as inhaled or topical steroid therapy for asthma, chronic obstructive pulmonary disease, allergic rhinitis). Patient must be off systemic steroid or any other form of immunosuppressive therapy within 7 days prior to first dose of trial treatment","['Patient' 'has' 'a' 'diagnosis' 'of' 'immunodeficiency' 'or' 'is'
 'receiving' 'ongoing' 'immunosuppressive' 'therapy' ',' 'including'
 'systemic' 'or' 'enteric' 'corticosteroids' 'except' 'for'
 'non-systemically' 'absorbed' 'treatments' '(' 'such' 'as' 'inhaled' 'or'
 'topical' 'steroid' 'therapy' 'for' 'asthma' ',' 'chronic' 'obstructive'
 'pulmonary' 'disease' ',' 'allergic' 'rhinitis' ')' '.' 'Patient' 'must'
 'be' 'off' 'systemic' 'steroid' 'or' 'any' 'other' 'form' 'of'
 'immunosuppressive' 'therapy' 'within' '7' 'days' 'prior' 'to' 'first'
 'dose' 'of' 'trial' 'treatment']","[0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 1. 1. 0. 0. 1. 1. 1. 1. 0. 0. 1. 1. 1. 0.
 0. 0. 0. 0. 0. 1. 1. 0. 2. 0. 2. 2. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]"
NCT01676753,",28:57:treatment,33:57:treatment,214:232:treatment","Patients less than 2 weeks post major surgical procedure (all surgical wounds must be fully healed). For the purpose of this criterion, a major surgical procedure is defined as one requiring the administration of general anesthesia","['Patients' 'less' 'than' '2' 'weeks' 'post' 'major' 'surgical'
 'procedure' '(' 'all' 'surgical' 'wounds' 'must' 'be' 'fully' 'healed'
 ')' '.' 'For' 'the' 'purpose' 'of' 'this' 'criterion' ',' 'a' 'major'
 'surgical' 'procedure' 'is' 'defined' 'as' 'one' 'requiring' 'the'
 'administration' 'of' 'general' 'anesthesia']","[0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]"
NCT01676259,"15:20:cancer,75:102:treatment,179:192:treatment",Have a target tumor that is accessible for intratumoral administration by EUS (Endoscopic Ultrasound) guidance as determined by the radiologist/gastroenterologist performing the EUS insertion,"['Have' 'a' 'target' 'tumor' 'that' 'is' 'accessible' 'for' 'intratumoral'
 'administration' 'by' 'EUS' '(' 'Endoscopic' 'Ultrasound' ')' 'guidance'
 'as' 'determined' 'by' 'the' 'radiologist/gastroenterologist'
 'performing' 'the' 'EUS' 'insertion']","[0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT01672138,"22:39:chronic_disease,48:63:chronic_disease,65:76:chronic_disease,78:96:chronic_disease","Reversible causes of atrial arrhythmia such as hyperthyroidism, sarcoidosis, pulmonary embolism etc","['Reversible' 'causes' 'of' 'atrial' 'arrhythmia' 'such' 'as'
 'hyperthyroidism' ',' 'sarcoidosis' ',' 'pulmonary' 'embolism' 'etc']",[0. 0. 0. 2. 2. 0. 0. 2. 0. 2. 0. 2. 2. 0.]
NCT01670877,"33:50:treatment,,88:109:treatment,201:210:treatment","The patient must have completed radiation therapy and be at least 1 week from the last systemic chemotherapy administration, with adequate recovery of bone marrow and organ functions, before starting neratinib","['The' 'patient' 'must' 'have' 'completed' 'radiation' 'therapy' 'and'
 'be' 'at' 'least' '1' 'week' 'from' 'the' 'last' 'systemic'
 'chemotherapy' 'administration' ',' 'with' 'adequate' 'recovery' 'of'
 'bone' 'marrow' 'and' 'organ' 'functions' ',' 'before' 'starting'
 'neratinib']","[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT01668563,"17:25:chronic_disease,64:72:treatment,76:98:treatment",The patient and aneurysm are considered appropriate for either surgical or endovascular treatment by the treating team,"['The' 'patient' 'and' 'aneurysm' 'are' 'considered' 'appropriate' 'for'
 'either' 'surgical' 'or' 'endovascular' 'treatment' 'by' 'the' 'treating'
 'team']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0.]
NCT01662466,"7:11:treatment,16:25:treatment,29:32:chronic_disease,33:36:chronic_disease",Using DHEA for treatment of DOR/POA,['Using' 'DHEA' 'for' 'treatment' 'of' 'DOR/POA'],[0. 1. 0. 1. 0. 2.]
NCT01660607,"14:19:chronic_disease,24:35:chronic_disease,,84:93:treatment",negative for HIV 1 and hepatitis C by nucleic acid testing (NAT) within 30 days of apheresis collection,"['negative' 'for' 'HIV' '1' 'and' 'hepatitis' 'C' 'by' 'nucleic' 'acid'
 'testing' '(' 'NAT' ')' 'within' '30' 'days' 'of' 'apheresis'
 'collection']",[0. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT01653093,"27:92:treatment,100:117:treatment,119:129:treatment,131:147:treatment,149:163:treatment,165:190:treatment","Patients with any type of bioimplant activated by mechanical, electronic, or magnetic means (e.g., cochlear implants, pacemakers, neurostimulators, biostimulators, electronic infusion pumps, etc.)","['Patients' 'with' 'any' 'type' 'of' 'bioimplant' 'activated' 'by'
 'mechanical' ',' 'electronic' ',' 'or' 'magnetic' 'means' '(' 'e.g.' ','
 'cochlear' 'implants' ',' 'pacemakers' ',' 'neurostimulators' ','
 'biostimulators' ',' 'electronic' 'infusion' 'pumps' ',' 'etc' '.' ')']","[0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 1.
 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01652092,"1:16:chronic_disease,44:66:chronic_disease,70:79:chronic_disease,83:89:treatment",acute hepatitis or evidence of moderate or severe portal fibrosis or cirrhosis on biopsy,"['acute' 'hepatitis' 'or' 'evidence' 'of' 'moderate' 'or' 'severe'
 'portal' 'fibrosis' 'or' 'cirrhosis' 'on' 'biopsy']",[2. 2. 0. 0. 0. 0. 0. 2. 2. 2. 0. 2. 0. 1.]
NCT01648751,"31:39:chronic_disease,46:53:treatment,55:59:treatment","Other prior interventions for prolapse (e.g. pessary, PFPT)","['Other' 'prior' 'interventions' 'for' 'prolapse' '(' 'e.g' '.' 'pessary'
 ',' 'PFPT' ')']",[0. 0. 0. 0. 2. 0. 0. 0. 1. 0. 1. 0.]
NCT01648023,"28:50:treatment,63:73:treatment,75:86:treatment,91:100:treatment","Patients who have received prior systemic therapy with either irinotecan, gemcitabine, or cisplatin","['Patients' 'who' 'have' 'received' 'prior' 'systemic' 'therapy' 'with'
 'either' 'irinotecan' ',' 'gemcitabine' ',' 'or' 'cisplatin']",[0. 0. 0. 0. 1. 1. 1. 0. 0. 1. 0. 1. 0. 0. 1.]
NCT01643473,"6:31:chronic_disease,,,,,144:152:chronic_disease,156:170:chronic_disease,,,,227:230:chronic_disease,253:267:chronic_disease",Have uncontrolled hypertension defined as BP>140/90 mmHg on at least two consecutive visits in the past year (or BP>130/80 mmHg for those with diabetes or kidney disease) and Framingham Risk Scores (FRS) >20% (or at least one CVD risk factor including hyperlipidemia or diabetes),"['Have' 'uncontrolled' 'hypertension' 'defined' 'as' 'BP' '>' '140/90'
 'mmHg' 'on' 'at' 'least' 'two' 'consecutive' 'visits' 'in' 'the' 'past'
 'year' '(' 'or' 'BP' '>' '130/80' 'mmHg' 'for' 'those' 'with' 'diabetes'
 'or' 'kidney' 'disease' ')' 'and' 'Framingham' 'Risk' 'Scores' '(' 'FRS'
 ')' '>' '20' '%' '(' 'or' 'at' 'least' 'one' 'CVD' 'risk' 'factor'
 'including' 'hyperlipidemia' 'or' 'diabetes' ')']","[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 2. 0. 0. 0. 2. 0. 0. 0.]"
NCT01639508,"1:18:treatment,23:27:cancer,31:47:cancer,,74:100:treatment,,145:182:treatment,,259:282:treatment","Radiation therapy for bone or brain metastasis within 2 weeks, any other external radiation therapy within 4 weeks of first dose of study drug. Systemic treatment with radionuclides within 4weeks. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible","['Radiation' 'therapy' 'for' 'bone' 'or' 'brain' 'metastasis' 'within' '2'
 'weeks' ',' 'any' 'other' 'external' 'radiation' 'therapy' 'within' '4'
 'weeks' 'of' 'first' 'dose' 'of' 'study' 'drug' '.' 'Systemic'
 'treatment' 'with' 'radionuclides' 'within' '4weeks' '.' 'Subjects'
 'with' 'clinically' 'relevant' 'ongoing' 'complications' 'from' 'prior'
 'radiation' 'therapy' 'are' 'not' 'eligible']","[1. 1. 0. 3. 0. 3. 3. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0.]"
NCT01639508,"1:17:chronic_disease,28:46:treatment,,87:102:treatment",active infection requiring systemic treatment within 28 days before the first dose of study treatment,"['active' 'infection' 'requiring' 'systemic' 'treatment' 'within' '28'
 'days' 'before' 'the' 'first' 'dose' 'of' 'study' 'treatment']",[2. 2. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01631617,"28:33:allergy_name,35:46:allergy_name,51:75:allergy_name,80:89:allergy_name,93:104:allergy_name","Known allergic reaction to sulfa, beta-lactam, or tetracycline class drugs; or lidocaine or epinephrine","['Known' 'allergic' 'reaction' 'to' 'sulfa' ',' 'beta-lactam' ',' 'or'
 'tetracycline' 'class' 'drugs' ';' 'or' 'lidocaine' 'or' 'epinephrine']",[0. 0. 0. 0. 4. 0. 4. 0. 0. 4. 4. 4. 0. 0. 4. 0. 4.]
NCT01631617,"40:58:chronic_disease,78:93:treatment,166:175:treatment,",Subjects with unstable or uncontrolled medical conditions that could require hospitalization during the initial month of the study or who have been hospitalized for treatment of these conditions in the one month prior to baseline sampling,"['Subjects' 'with' 'unstable' 'or' 'uncontrolled' 'medical' 'conditions'
 'that' 'could' 'require' 'hospitalization' 'during' 'the' 'initial'
 'month' 'of' 'the' 'study' 'or' 'who' 'have' 'been' 'hospitalized' 'for'
 'treatment' 'of' 'these' 'conditions' 'in' 'the' 'one' 'month' 'prior'
 'to' 'baseline' 'sampling']","[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01627821,"88:126:treatment,,,194:224:treatment,255:267:treatment","Patients on Optimal Medical Management (OMM) as defined in Section 9.2 OR dependent on intra-aortic balloon counter-pulsation for 7 days OR other temporary (indicated for 30 days use, or less) mechanical circulatory support for 7 days, OR supported with IV inotropes for 7 days and failing to respond","['Patients' 'on' 'Optimal' 'Medical' 'Management' '(' 'OMM' ')' 'as'
 'defined' 'in' 'Section' '9.2' 'OR' 'dependent' 'on' 'intra-aortic'
 'balloon' 'counter-pulsation' 'for' '7' 'days' 'OR' 'other' 'temporary'
 '(' 'indicated' 'for' '30' 'days' 'use' ',' 'or' 'less' ')' 'mechanical'
 'circulatory' 'support' 'for' '7' 'days' ',' 'OR' 'supported' 'with' 'IV'
 'inotropes' 'for' '7' 'days' 'and' 'failing' 'to' 'respond']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.
 0. 0. 0. 0. 0. 0.]"
NCT01626079,"1:4:treatment,8:17:treatment,76:80:treatment,",BNP or NT-proBNP must be obtained after the subject has been stabilized on GDMT and at least 30 days after,"['BNP' 'or' 'NT-proBNP' 'must' 'be' 'obtained' 'after' 'the' 'subject'
 'has' 'been' 'stabilized' 'on' 'GDMT' 'and' 'at' 'least' '30' 'days'
 'after']",[1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT01626079,"1:24:chronic_disease,35:44:treatment,56:83:treatment",Hemodynamic instability requiring inotropic support or mechanical heart assistance,"['Hemodynamic' 'instability' 'requiring' 'inotropic' 'support' 'or'
 'mechanical' 'heart' 'assistance']",[2. 2. 0. 1. 0. 0. 1. 1. 1.]
NCT01626079,"1:30:chronic_disease,38:49:chronic_disease,51:66:chronic_disease,68:79:chronic_disease","Infiltrative cardiomyopathies (e.g., amyloidosis, hemochromatosis, sarcoidosis)","['Infiltrative' 'cardiomyopathies' '(' 'e.g.' ',' 'amyloidosis' ','
 'hemochromatosis' ',' 'sarcoidosis' ')']",[2. 2. 0. 0. 0. 2. 0. 2. 0. 2. 0.]
NCT01626079,"155:170:treatment,207:214:treatment,231:240:treatment","The subject or the subject's legal representative understands and agrees that should he/she be assigned to the Control group, he/she will be treated with medical therapy and conservative management without surgery and without the MitraClip, either domestically or abroad","['The' 'subject' 'or' 'the' 'subject' ""'s"" 'legal' 'representative'
 'understands' 'and' 'agrees' 'that' 'should' 'he/she' 'be' 'assigned'
 'to' 'the' 'Control' 'group' ',' 'he/she' 'will' 'be' 'treated' 'with'
 'medical' 'therapy' 'and' 'conservative' 'management' 'without' 'surgery'
 'and' 'without' 'the' 'MitraClip' ',' 'either' 'domestically' 'or'
 'abroad']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 1. 0. 0. 0. 0. 1. 0. 0. 0. 1. 0. 0. 0. 0. 0.]"
NCT01626079,"37:92:treatment,79:82:treatment,86:91:treatment,",revascularization and/or implant of Cardiac Resynchronization Therapy device (CRT or CRT-D) or reprogramming of an implanted CRT or CRT-D that results in increased biventricular pacing (from <92% to ≥92%),"['revascularization' 'and/or' 'implant' 'of' 'Cardiac' 'Resynchronization'
 'Therapy' 'device' '(' 'CRT' 'or' 'CRT-D' ')' 'or' 'reprogramming' 'of'
 'an' 'implanted' 'CRT' 'or' 'CRT-D' 'that' 'results' 'in' 'increased'
 'biventricular' 'pacing' '(' 'from' '<' '92' '%' 'to' '≥92' '%' ')']","[0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01625923,"25:36:treatment,42:74:treatment,94:125:treatment,","Subject has never had a gastrectomy, nor major gastric surgical procedure or any evidence of bowel obstruction or strictures within the previous 12 months","['Subject' 'has' 'never' 'had' 'a' 'gastrectomy' ',' 'nor' 'major'
 'gastric' 'surgical' 'procedure' 'or' 'any' 'evidence' 'of' 'bowel'
 'obstruction' 'or' 'strictures' 'within' 'the' 'previous' '12' 'months']","[0. 0. 0. 0. 0. 1. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0.
 0.]"
NCT01625234,"5:18:treatment,20:32:treatment,37:50:treatment,,76:91:treatment,,140:144:treatment","Any major surgery, radiotherapy, or immunotherapy within the last 21 days (focal radiation does not require a washout period; ≥4 weeks for WBRT)","['Any' 'major' 'surgery' ',' 'radiotherapy' ',' 'or' 'immunotherapy'
 'within' 'the' 'last' '21' 'days' '(' 'focal' 'radiation' 'does' 'not'
 'require' 'a' 'washout' 'period' ';' '≥4' 'weeks' 'for' 'WBRT' ')']","[0. 1. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 0.]"
NCT01625234,"71:104:allergy_name,112:122:allergy_name,134:160:allergy_name","Patients with a known allergy or delayed hypersensitivity reaction to drugs chemically related to X-396 (e.g., crizotinib) or to the active ingredient of X-396","['Patients' 'with' 'a' 'known' 'allergy' 'or' 'delayed' 'hypersensitivity'
 'reaction' 'to' 'drugs' 'chemically' 'related' 'to' 'X-396' '(' 'e.g.'
 ',' 'crizotinib' ')' 'or' 'to' 'the' 'active' 'ingredient' 'of' 'X-396']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 4. 4. 4. 4. 0. 0. 0. 4. 0. 0. 0. 0. 4.
 4. 4. 4.]"
NCT01624090,"21:44:treatment,63:92:treatment,101:113:treatment,115:127:treatment,129:140:treatment,145:157:treatment","Disease amenable to biopsy via percutaneous approach or other minimally invasive procedures such as thoracoscopy, bronchoscopy, laparoscopy, or GI endoscopy","['Disease' 'amenable' 'to' 'biopsy' 'via' 'percutaneous' 'approach' 'or'
 'other' 'minimally' 'invasive' 'procedures' 'such' 'as' 'thoracoscopy'
 ',' 'bronchoscopy' ',' 'laparoscopy' ',' 'or' 'GI' 'endoscopy']",[0. 0. 0. 1. 1. 1. 0. 0. 0. 1. 1. 1. 0. 0. 1. 0. 1. 0. 1. 0. 0. 1. 1.]
NCT01624090,"27:42:chronic_disease,44:67:chronic_disease,82:100:chronic_disease","Patients with evidence of active bleeding, intratumoral hemorrhage or history of bleeding diatheses","['Patients' 'with' 'evidence' 'of' 'active' 'bleeding' ',' 'intratumoral'
 'hemorrhage' 'or' 'history' 'of' 'bleeding' 'diatheses']",[0. 0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT01623167,"1:32:treatment,42:45:treatment,47:58:treatment,73:89:treatment","Prior immunosuppressive therapy with any ATG, alemtuzumab, or high dose cyclophosphamide","['Prior' 'immunosuppressive' 'therapy' 'with' 'any' 'ATG' ','
 'alemtuzumab' ',' 'or' 'high' 'dose' 'cyclophosphamide']",[1. 1. 1. 0. 0. 1. 0. 1. 0. 0. 0. 0. 1.]
NCT01622868,"7:26:cancer,35:63:cancer,85:112:cancer,144:151:cancer,167:180:cancer,","Prior invasive malignancy (except non-melanomatous skin cancer, curatively resected thyroid papillary carcinoma, and invasive and non-invasive cancers related to the breast cancer) unless disease free for a minimum of 3 years","['Prior' 'invasive' 'malignancy' '(' 'except' 'non-melanomatous' 'skin'
 'cancer' ',' 'curatively' 'resected' 'thyroid' 'papillary' 'carcinoma'
 ',' 'and' 'invasive' 'and' 'non-invasive' 'cancers' 'related' 'to' 'the'
 'breast' 'cancer' ')' 'unless' 'disease' 'free' 'for' 'a' 'minimum' 'of'
 '3' 'years']","[0. 3. 3. 0. 0. 3. 3. 3. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 3. 0. 0. 0. 3.
 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01620216,"1:11:chronic_disease,15:29:chronic_disease,104:120:chronic_disease,122:141:chronic_disease,143:163:chronic_disease,168:186:chronic_disease","Thrombotic or embolic venous or arterial events, such as cerebrovascular accident, including transient ischemic attacks, arterial thrombosis, deep vein thrombosis and pulmonary embolism","['Thrombotic' 'or' 'embolic' 'venous' 'or' 'arterial' 'events' ',' 'such'
 'as' 'cerebrovascular' 'accident' ',' 'including' 'transient' 'ischemic'
 'attacks' ',' 'arterial' 'thrombosis' ',' 'deep' 'vein' 'thrombosis'
 'and' 'pulmonary' 'embolism']","[2. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 2. 2. 2.
 0. 2. 2.]"
NCT01620216,"26:34:cancer,65:97:cancer,101:135:cancer",with relapsed/refractory leukemia with a confirmed diagnosis of acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL),"['with' 'relapsed/refractory' 'leukemia' 'with' 'a' 'confirmed'
 'diagnosis' 'of' 'acute' 'myelogenous' 'leukemia' '(' 'AML' ')' 'or'
 'acute' 'lymphoblastic' 'leukemia' '(' 'ALL' ')']",[0. 0. 3. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01618357,"1:19:treatment,21:39:treatment,,91:95:treatment",Anti-cancer Agents: Anti-cancer agents are not permitted within 21 days prior to start of POPI,"['Anti-cancer' 'Agents' ':' 'Anti-cancer' 'agents' 'are' 'not' 'permitted'
 'within' '21' 'days' 'prior' 'to' 'start' 'of' 'POPI']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01618357,"14:26:treatment,19:26:treatment,28:41:treatment,43:59:treatment,64:87:treatment,,138:147:treatment,152:161:treatment","Last dose of chemotherapy, immunotherapy, biologic therapy, or investigational therapy, was less than 14 days prior to protocol therapy (radiation and veliparib)","['Last' 'dose' 'of' 'chemotherapy' ',' 'immunotherapy' ',' 'biologic'
 'therapy' ',' 'or' 'investigational' 'therapy' ',' 'was' 'less' 'than'
 '14' 'days' 'prior' 'to' 'protocol' 'therapy' '(' 'radiation' 'and'
 'veliparib' ')']","[0. 0. 0. 1. 0. 1. 0. 1. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 0. 1. 0.]"
NCT01618357,"1:8:treatment,19:34:treatment,59:63:treatment,98:101:treatment",Surgery: Incident breast biopsies only permitted prior to POPI to confirm residual disease after NAC,"['Surgery' ':' 'Incident' 'breast' 'biopsies' 'only' 'permitted' 'prior'
 'to' 'POPI' 'to' 'confirm' 'residual' 'disease' 'after' 'NAC']",[1. 0. 0. 1. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 1.]
NCT01617161,"1:15:treatment,17:43:chronic_disease,47:73:chronic_disease,89:100:chronic_disease,104:109:chronic_disease","Hip prosthesis, inflammatory bowel disease or connective tissue disorder such as active scleroderma or lupus","['Hip' 'prosthesis' ',' 'inflammatory' 'bowel' 'disease' 'or' 'connective'
 'tissue' 'disorder' 'such' 'as' 'active' 'scleroderma' 'or' 'lupus']",[1. 1. 0. 2. 2. 2. 0. 2. 2. 2. 0. 0. 0. 2. 0. 2.]
NCT01614990,",,14:17:chronic_disease,19:23:chronic_disease,32:36:chronic_disease,54:61:treatment","class III-IV CHF, AIDS, severe COPD requiring use of home O2","['class' 'III-IV' 'CHF' ',' 'AIDS' ',' 'severe' 'COPD' 'requiring' 'use'
 'of' 'home' 'O2']",[0. 0. 2. 0. 2. 0. 0. 2. 0. 0. 0. 1. 1.]
NCT01614197,"1:10:chronic_disease,32:63:treatment,92:104:treatment,106:116:treatment,151:176:chronic_disease,177:204:treatment,208:239:treatment","Anti-GVHD or agents to prevent organ rejection post-transplant: Patients who are receiving cyclosporine, tacrolimus or other agents to prevent either graft-versus-host disease post bone marrow transplant or organ rejection post transplant are not eligible for this trial","['Anti-GVHD' 'or' 'agents' 'to' 'prevent' 'organ' 'rejection'
 'post-transplant' ':' 'Patients' 'who' 'are' 'receiving' 'cyclosporine'
 ',' 'tacrolimus' 'or' 'other' 'agents' 'to' 'prevent' 'either'
 'graft-versus-host' 'disease' 'post' 'bone' 'marrow' 'transplant' 'or'
 'organ' 'rejection' 'post' 'transplant' 'are' 'not' 'eligible' 'for'
 'this' 'trial']","[2. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 2. 2.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01614197,"1:33:treatment,72:103:treatment,108:117:treatment,119:132:treatment,137:150:treatment","Enzyme inducing Anti-convulsants: Patients who are currently receiving enzyme inducing anticonvulsants (ie phenytoin, phenobarbitol, or carbamazepine) are not eligible","['Enzyme' 'inducing' 'Anti-convulsants' ':' 'Patients' 'who' 'are'
 'currently' 'receiving' 'enzyme' 'inducing' 'anticonvulsants' '(' 'ie'
 'phenytoin' ',' 'phenobarbitol' ',' 'or' 'carbamazepine' ')' 'are' 'not'
 'eligible']",[1. 1. 1. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0.]
NCT01614197,"15:23:cancer,27:35:cancer,76:88:treatment",Patients with leukemia or lymphoma who relapse while receiving maintenance chemotherapy will not be required to have a waiting period before enrollment onto this study,"['Patients' 'with' 'leukemia' 'or' 'lymphoma' 'who' 'relapse' 'while'
 'receiving' 'maintenance' 'chemotherapy' 'will' 'not' 'be' 'required'
 'to' 'have' 'a' 'waiting' 'period' 'before' 'enrollment' 'onto' 'this'
 'study']","[0. 0. 3. 0. 3. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT01608438,"1:16:chronic_disease,18:32:chronic_disease,36:46:chronic_disease,","Skull fractures, skull deficits or concussion within the last 6 months","['Skull' 'fractures' ',' 'skull' 'deficits' 'or' 'concussion' 'within'
 'the' 'last' '6' 'months']",[2. 2. 0. 2. 2. 0. 2. 0. 0. 0. 0. 0.]
NCT01604512,"28:43:chronic_disease,89:112:treatment,152:169:cancer,174:190:chronic_disease","New or increased enhancing brain lesion(s) OR nonenhancing brain lesion(s) if receiving anti-angiogenic therapy, which is considered indeterminate for tumor progression vs. radiation injury by the neuroradiologist or clinician","['New' 'or' 'increased' 'enhancing' 'brain' 'lesion' '(' 's' ')' 'OR'
 'nonenhancing' 'brain' 'lesion' '(' 's' ')' 'if' 'receiving'
 'anti-angiogenic' 'therapy' ',' 'which' 'is' 'considered' 'indeterminate'
 'for' 'tumor' 'progression' 'vs.' 'radiation' 'injury' 'by' 'the'
 'neuroradiologist' 'or' 'clinician']","[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0.
 0. 0. 3. 3. 0. 2. 2. 0. 0. 0. 0. 0.]"
NCT01599559,"13:22:treatment,24:32:treatment,34:43:treatment,,59:66:treatment,70:77:treatment","6 cycles of CHOP14-21, DA-EPOCH, Mega-CHOP or 12 weeks of VACOP-B or MACOP-B","['6' 'cycles' 'of' 'CHOP14-21' ',' 'DA-EPOCH' ',' 'Mega-CHOP' 'or' '12'
 'weeks' 'of' 'VACOP-B' 'or' 'MACOP-B']",[0. 0. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0. 1. 0. 1.]
NCT01597518,"1:18:cancer,33:52:cancer,,103:135:cancer,139:174:cancer","Active malignancy or history of invasive malignancy within the last five years, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitely treated","['Active' 'malignancy' 'or' 'history' 'of' 'invasive' 'malignancy'
 'within' 'the' 'last' 'five' 'years' ',' 'with' 'the' 'exception' 'of'
 'superficial' 'basal' 'cell' 'carcinoma' 'or' 'squamous' 'cell'
 'carcinoma' 'of' 'the' 'skin' 'that' 'has' 'been' 'definitely' 'treated']","[3. 3. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 3. 3.
 3. 3. 3. 3. 0. 0. 0. 0. 0.]"
NCT01595529,"24:33:chronic_disease,,,90:111:treatment,115:123:treatment,","A urine culture proven infection with a second uropathogen > 10,000 CFU/mL collected via suprapubic aspiration or catheter or > 50,000 CFU/mL collected via clean void","['A' 'urine' 'culture' 'proven' 'infection' 'with' 'a' 'second'
 'uropathogen' '>' '10,000' 'CFU/mL' 'collected' 'via' 'suprapubic'
 'aspiration' 'or' 'catheter' 'or' '>' '50,000' 'CFU/mL' 'collected' 'via'
 'clean' 'void']","[0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT01595061,"34:44:chronic_disease,53:62:chronic_disease,64:89:chronic_disease,100:125:chronic_disease,136:163:treatment","Patients with evidence of active septicemia, severe infection, gastrointestinal bleeding or severe gastrointestinal symptoms requiring medical or surgical therapy","['Patients' 'with' 'evidence' 'of' 'active' 'septicemia' ',' 'severe'
 'infection' ',' 'gastrointestinal' 'bleeding' 'or' 'severe'
 'gastrointestinal' 'symptoms' 'requiring' 'medical' 'or' 'surgical'
 'therapy']",[0. 0. 0. 0. 0. 2. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 1. 1. 1. 1.]
NCT01591356,"34:55:chronic_disease,106:123:chronic_disease,125:137:chronic_disease,142:147:cancer","Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as a known bleeding disorder, coagulopathy, or tumor involving major vessels","['Patients' 'with' 'active' 'bleeding' 'or' 'pathologic' 'conditions'
 'that' 'carry' 'high' 'risk' 'of' 'bleeding' ',' 'such' 'as' 'a' 'known'
 'bleeding' 'disorder' ',' 'coagulopathy' ',' 'or' 'tumor' 'involving'
 'major' 'vessels']","[0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0.
 3. 0. 0. 0.]"
NCT01591356,"20:36:treatment,46:61:cancer,68:78:treatment,82:127:treatment","stable regimens of hormonal therapy i.e. for prostate cancer (e.g. leuprolide, a gonadotropin-releasing hormone [GnRH] agonist)","['stable' 'regimens' 'of' 'hormonal' 'therapy' 'i.e' '.' 'for' 'prostate'
 'cancer' '(' 'e.g' '.' 'leuprolide' ',' 'a' 'gonadotropin-releasing'
 'hormone' '[' 'GnRH' ']' 'agonist' ')']",[0. 0. 0. 1. 1. 0. 0. 0. 3. 3. 0. 0. 0. 1. 0. 0. 1. 1. 1. 1. 0. 0. 0.]
NCT01589263,"22:50:chronic_disease,68:72:chronic_disease,84:87:chronic_disease",Current diagnosis of acute or chronic prostatitis (which may cause LUTS that mimic BPH),"['Current' 'diagnosis' 'of' 'acute' 'or' 'chronic' 'prostatitis' '('
 'which' 'may' 'cause' 'LUTS' 'that' 'mimic' 'BPH' ')']",[0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 2. 0. 0. 2. 0.]
NCT01589263,"11:24:treatment,26:41:treatment,43:53:treatment,58:73:treatment,78:100:treatment,","Has taken phenylephrine, pseudoephedrine, imipramine, an anticholinergic, or cholinergic medication within the past 2 weeks","['Has' 'taken' 'phenylephrine' ',' 'pseudoephedrine' ',' 'imipramine' ','
 'an' 'anticholinergic' ',' 'or' 'cholinergic' 'medication' 'within' 'the'
 'past' '2' 'weeks']",[0. 0. 1. 0. 1. 0. 1. 0. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT01584076,"1:10:chronic_disease,27:37:chronic_disease,45:58:chronic_disease",Amblyopia associated with strabismus and/or anisometropia,['Amblyopia' 'associated' 'with' 'strabismus' 'and/or' 'anisometropia'],[2. 0. 0. 2. 0. 2.]
NCT01582191,"32:42:allergy_name,44:51:allergy_name,53:68:allergy_name,77:105:allergy_name","History of hypersensitivity to vandetanib, lactose, murine products, or any component of the formulation","['History' 'of' 'hypersensitivity' 'to' 'vandetanib' ',' 'lactose' ','
 'murine' 'products' ',' 'or' 'any' 'component' 'of' 'the' 'formulation']",[0. 0. 0. 0. 4. 0. 4. 0. 4. 4. 0. 0. 0. 4. 4. 4. 4.]
NCT01581749,"15:34:cancer,52:67:cancer,71:101:cancer,","history of an invasive malignancy (other than this prostate cancer,or basal or squamous skin cancers) within prior 5 years","['history' 'of' 'an' 'invasive' 'malignancy' '(' 'other' 'than' 'this'
 'prostate' 'cancer' ',' 'or' 'basal' 'or' 'squamous' 'skin' 'cancers' ')'
 'within' 'prior' '5' 'years']",[0. 0. 0. 3. 3. 0. 0. 0. 0. 3. 3. 0. 0. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0.]
NCT01581580,"42:61:chronic_disease,71:90:chronic_disease,94:98:chronic_disease","current or pre-existing life-threatening respiratory disease, such as respiratory failure or ARDS","['current' 'or' 'pre-existing' 'life-threatening' 'respiratory' 'disease'
 ',' 'such' 'as' 'respiratory' 'failure' 'or' 'ARDS']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 2.]
NCT01572480,"37:47:treatment,59:69:treatment,71:98:treatment,100:123:treatment,128:137:treatment,153:160:treatment","Contraindication to any concomitant medication, including antivirals, anticoagulation prophylaxis, tumor lysis prophylaxis, or hydration given prior to therapy","['Contraindication' 'to' 'any' 'concomitant' 'medication' ',' 'including'
 'antivirals' ',' 'anticoagulation' 'prophylaxis' ',' 'tumor' 'lysis'
 'prophylaxis' ',' 'or' 'hydration' 'given' 'prior' 'to' 'therapy']",[0. 0. 0. 0. 1. 0. 0. 1. 0. 1. 1. 0. 1. 1. 1. 0. 0. 1. 0. 0. 0. 1.]
NCT01572480,"14:34:chronic_disease,77:93:chronic_disease,107:131:chronic_disease,133:148:chronic_disease,159:177:chronic_disease,182:201:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' ',' 'ongoing' 'or' 'active' 'infection' ',' 'symptomatic'
 'congestive' 'heart' 'failure' ',' 'unstable' 'angina' 'pectoris' ','
 'cardiac' 'arrhythmia' ',' 'or' 'psychiatric' 'illness/social'
 'situations']","[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 0. 0.
 2. 2. 0. 0. 2. 2. 0.]"
NCT01568255,"23:49:chronic_disease,51:63:chronic_disease,65:72:chronic_disease,74:86:chronic_disease,88:104:chronic_disease","Clinical diagnosis of overt vitamin D deficiency: osteomalacia, rickets, hypocalcemia, hypophosphatemia","['Clinical' 'diagnosis' 'of' 'overt' 'vitamin' 'D' 'deficiency' ':'
 'osteomalacia' ',' 'rickets' ',' 'hypocalcemia' ',' 'hypophosphatemia']",[0. 0. 0. 2. 2. 2. 2. 0. 2. 0. 2. 0. 2. 0. 2.]
NCT01562626,"51:60:treatment,96:107:treatment,109:119:treatment,121:132:treatment,137:149:treatment,150:164:treatment","Patient's medical history does not contraindicate treatment with at least one of the following antibiotics: ampicillin, clindamycin and erythromycin/clarithromycin","['Patient' ""'s"" 'medical' 'history' 'does' 'not' 'contraindicate'
 'treatment' 'with' 'at' 'least' 'one' 'of' 'the' 'following'
 'antibiotics' ':' 'ampicillin' ',' 'clindamycin' 'and'
 'erythromycin/clarithromycin']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1.]
NCT01562626,"13:31:chronic_disease,46:61:treatment,69:93:treatment",Presence of autoimmune disease that requires corticosteroids and/or immunosuppressive agents,"['Presence' 'of' 'autoimmune' 'disease' 'that' 'requires'
 'corticosteroids' 'and/or' 'immunosuppressive' 'agents']",[0. 0. 2. 2. 0. 0. 1. 0. 1. 1.]
NCT01558544,"1:8:treatment,81:106:treatment,110:114:cancer","Surgery that requires removal of ovaries for medical condition or disease, e.g. Prophylactic oophorectomy in BRCA patients","['Surgery' 'that' 'requires' 'removal' 'of' 'ovaries' 'for' 'medical'
 'condition' 'or' 'disease' ',' 'e.g' '.' 'Prophylactic' 'oophorectomy'
 'in' 'BRCA' 'patients']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 3. 0.]
NCT01554410,",,15:30:cancer,47:53:treatment,61:83:cancer","Stage IB2-IVA cervical cancer or stage I with biopsy-proven pelvic node metastases, positive surgical margins, or parametrial extension based upon standard diagnostic workup","['Stage' 'IB2-IVA' 'cervical' 'cancer' 'or' 'stage' 'I' 'with'
 'biopsy-proven' 'pelvic' 'node' 'metastases' ',' 'positive' 'surgical'
 'margins' ',' 'or' 'parametrial' 'extension' 'based' 'upon' 'standard'
 'diagnostic' 'workup']","[0. 0. 3. 3. 0. 0. 0. 0. 1. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT01554371,"37:57:cancer,70:87:cancer,105:129:cancer","Patients with other active, current primary malignancies, other than carcinoma in situ of the cervix or non-melanoma skin cancer","['Patients' 'with' 'other' 'active' ',' 'current' 'primary' 'malignancies'
 ',' 'other' 'than' 'carcinoma' 'in' 'situ' 'of' 'the' 'cervix' 'or'
 'non-melanoma' 'skin' 'cancer']",[0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 3. 3. 3.]
NCT01553071,"1:14:treatment,,65:76:treatment,81:89:treatment",Major surgery in the last three weeks due to unknown effects of fenretinide and safingol on wound healing,"['Major' 'surgery' 'in' 'the' 'last' 'three' 'weeks' 'due' 'to' 'unknown'
 'effects' 'of' 'fenretinide' 'and' 'safingol' 'on' 'wound' 'healing']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0.]
NCT01553071,"36:52:cancer,64:75:chronic_disease,77:86:chronic_disease,90:113:chronic_disease","Patients with previously untreated brain metastases (including parenchymal, meningeal or dural-based CNS lesions)","['Patients' 'with' 'previously' 'untreated' 'brain' 'metastases' '('
 'including' 'parenchymal' ',' 'meningeal' 'or' 'dural-based' 'CNS'
 'lesions' ')']",[0. 0. 0. 0. 3. 3. 0. 0. 2. 0. 2. 0. 2. 2. 2. 0.]
NCT01553071,"7:30:chronic_disease,79:98:chronic_disease,99:116:chronic_disease",other major medical illnesses of the cardiovascular or respiratory systems or psychiatric illness/social situations that would limit compliance with study requirements,"['other' 'major' 'medical' 'illnesses' 'of' 'the' 'cardiovascular' 'or'
 'respiratory' 'systems' 'or' 'psychiatric' 'illness/social' 'situations'
 'that' 'would' 'limit' 'compliance' 'with' 'study' 'requirements']",[0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT01542879,"1:14:chronic_disease,15:30:chronic_disease,85:96:treatment",Hemosiderosis/hemochromatosis (patients can still be included in 2nd branch without ferumoxytol),"['Hemosiderosis/hemochromatosis' '(' 'patients' 'can' 'still' 'be'
 'included' 'in' '2nd' 'branch' 'without' 'ferumoxytol' ')']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT01538966,"1:11:chronic_disease,39:42:treatment,47:71:treatment,","Acromegaly patients who have received SRL and dopamine agonist therapy, after a 6 week washout period of the dopamine agonist","['Acromegaly' 'patients' 'who' 'have' 'received' 'SRL' 'and' 'dopamine'
 'agonist' 'therapy' ',' 'after' 'a' '6' 'week' 'washout' 'period' 'of'
 'the' 'dopamine' 'agonist']",[2. 0. 0. 0. 0. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01532687,"5:35:treatment,,84:152:treatment,158:167:treatment,169:178:treatment,184:195:treatment","Any prior treatment with pazopanib or vascular endothelial growth factor (VEGF) or vascular endothelial growth factor receptor (VEGFR)-targeting agents (eg. sorafenib, sunitinib, and bevacizumab)","['Any' 'prior' 'treatment' 'with' 'pazopanib' 'or' 'vascular'
 'endothelial' 'growth' 'factor' '(' 'VEGF' ')' 'or' 'vascular'
 'endothelial' 'growth' 'factor' 'receptor' '(' 'VEGFR' ')' '-targeting'
 'agents' '(' 'eg' '.' 'sorafenib' ',' 'sunitinib' ',' 'and' 'bevacizumab'
 ')']","[0. 1. 1. 1. 1. 0. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 0. 1. 0. 0. 1. 0.]"
NCT01532687,"33:72:cancer,76:105:cancer,158:172:cancer","History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS metastases, are asymptomatic","['History' 'or' 'clinical' 'evidence' 'of' 'central' 'nervous' 'system'
 '(' 'CNS' ')' 'metastases' 'or' 'leptomeningeal' 'carcinomatosis' ','
 'except' 'for' 'individuals' 'who' 'have' 'previously-treated' 'CNS'
 'metastases' ',' 'are' 'asymptomatic']","[0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 3. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT01532687,"1:18:treatment,20:27:treatment,31:49:treatment","Radiation therapy, surgery or tumor embolization","['Radiation' 'therapy' ',' 'surgery' 'or' 'tumor' 'embolization']",[1. 1. 0. 1. 0. 1. 1.]
NCT01522768,"25:46:treatment,37:46:treatment,71:84:treatment,86:103:treatment,127:144:treatment,150:173:treatment,289:305:treatment,,363:371:treatment,,548:563:treatment","Additional experimental anti-cancer treatment and/or standard chemo-, immunotherapy, hormone treatment (with the exception of megestrol acetate), or concurrent radiotherapy is not allowed concomitantly with the administration of study treatment (with the exception listed in section 9.0) 89Zr-trastuzumab use as imaging agent for 89Zr-trastuzumab PET permitted. Afatinib is a substrate of P-gp and its plasma concentrations can be affected by the use of P-gp inhibitors (data on file) and it is also likely that P-gp inducers could also influence afatinib plasma concentrations","['Additional' 'experimental' 'anti-cancer' 'treatment' 'and/or' 'standard'
 'chemo-' ',' 'immunotherapy' ',' 'hormone' 'treatment' '(' 'with' 'the'
 'exception' 'of' 'megestrol' 'acetate' ')' ',' 'or' 'concurrent'
 'radiotherapy' 'is' 'not' 'allowed' 'concomitantly' 'with' 'the'
 'administration' 'of' 'study' 'treatment' '(' 'with' 'the' 'exception'
 'listed' 'in' 'section' '9.0' ')' '89Zr-trastuzumab' 'use' 'as' 'imaging'
 'agent' 'for' '89Zr-trastuzumab' 'PET' 'permitted' '.' 'Afatinib' 'is'
 'a' 'substrate' 'of' 'P-gp' 'and' 'its' 'plasma' 'concentrations' 'can'
 'be' 'affected' 'by' 'the' 'use' 'of' 'P-gp' 'inhibitors' '(' 'data' 'on'
 'file' ')' 'and' 'it' 'is' 'also' 'likely' 'that' 'P-gp' 'inducers'
 'could' 'also' 'influence' 'afatinib' 'plasma' 'concentrations']","[0. 0. 1. 1. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.]"
NCT01522768,"12:30:chronic_disease,93:109:chronic_disease,134:151:chronic_disease,165:171:cancer,173:202:chronic_disease,184:202:chronic_disease,,250:253:chronic_disease","Concurrent medical conditions which may increase the risk of toxicity, including ongoing or active infection, history of significant bleeding disorder unrelated to cancer (congenital bleeding disorders, acquired bleeding disorders within one year), HIV-positive","['Concurrent' 'medical' 'conditions' 'which' 'may' 'increase' 'the' 'risk'
 'of' 'toxicity' ',' 'including' 'ongoing' 'or' 'active' 'infection' ','
 'history' 'of' 'significant' 'bleeding' 'disorder' 'unrelated' 'to'
 'cancer' '(' 'congenital' 'bleeding' 'disorders' ',' 'acquired'
 'bleeding' 'disorders' 'within' 'one' 'year' ')' ',' 'HIV-positive']","[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 2. 2. 0. 0.
 3. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]"
NCT01522768,"65:76:treatment,108:114:treatment,131:138:treatment",Patients who have previously provided samples at any time after trastuzumab resistance will be exempt from biopsy at the start of therapy,"['Patients' 'who' 'have' 'previously' 'provided' 'samples' 'at' 'any'
 'time' 'after' 'trastuzumab' 'resistance' 'will' 'be' 'exempt' 'from'
 'biopsy' 'at' 'the' 'start' 'of' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 1.]
NCT01522768,"19:34:treatment,46:58:treatment,60:72:treatment,74:86:treatment,88:100:treatment,102:111:treatment,113:146:treatment,148:157:treatment,159:168:treatment,170:179:treatment,192:205:treatment,217:231:treatment,233:243:treatment,270:293:treatment","The use of potent P-gp inhibitors (including cyclosporine, erythromycin, ketoconazole, itraconazole, quinidine, Phenobarbital salt with quinidine, ritonavir, valspodar, verapamil) and potent P-gp inducers (including St John's wort, rifampicin) has to be avoided during treatment with afatinib","['The' 'use' 'of' 'potent' 'P-gp' 'inhibitors' '(' 'including'
 'cyclosporine' ',' 'erythromycin' ',' 'ketoconazole' ',' 'itraconazole'
 ',' 'quinidine' ',' 'Phenobarbital' 'salt' 'with' 'quinidine' ','
 'ritonavir' ',' 'valspodar' ',' 'verapamil' ')' 'and' 'potent' 'P-gp'
 'inducers' '(' 'including' 'St' 'John' ""'s"" 'wort' ',' 'rifampicin' ')'
 'has' 'to' 'be' 'avoided' 'during' 'treatment' 'with' 'afatinib']","[0. 0. 0. 0. 1. 1. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 1. 1. 1. 0. 1.
 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 1.
 1. 1.]"
NCT01512888,",,36:45:treatment,71:91:treatment,108:138:treatment",Less than 300 CD3+ T-cells by flow cytometry or higher if evidence of maternal engraftment as supported by peripheral blood FISH analysis for XY and XX,"['Less' 'than' '300' 'CD3+' 'T-cells' 'by' 'flow' 'cytometry' 'or'
 'higher' 'if' 'evidence' 'of' 'maternal' 'engraftment' 'as' 'supported'
 'by' 'peripheral' 'blood' 'FISH' 'analysis' 'for' 'XY' 'and' 'XX']","[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 1. 1. 1. 0. 0.
 0. 0.]"
NCT01505569,"1:41:cancer,,,74:83:cancer,101:119:cancer",Atypical Teratoid/Rhabdoid Tumor (AT/RT): less than 70 years of age with CNS AT/RT (with or without metastatic disease),"['Atypical' 'Teratoid/Rhabdoid' 'Tumor' '(' 'AT/RT' ')' ':' 'less' 'than'
 '70' 'years' 'of' 'age' 'with' 'CNS' 'AT/RT' '(' 'with' 'or' 'without'
 'metastatic' 'disease' ')']",[3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 3. 3. 0.]
NCT01505569,"8:23:cancer,,,75:93:treatment,188:197:treatment","Infant Medulloblastoma: Children less than 8 months of age at the time of definitive surgery (for histopathologic diagnosis), any histology, any metastatic state, with total or sub-total resection","['Infant' 'Medulloblastoma' ':' 'Children' 'less' 'than' '8' 'months' 'of'
 'age' 'at' 'the' 'time' 'of' 'definitive' 'surgery' '(' 'for'
 'histopathologic' 'diagnosis' ')' ',' 'any' 'histology' ',' 'any'
 'metastatic' 'state' ',' 'with' 'total' 'or' 'sub-total' 'resection']","[0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT01505062,"13:30:chronic_disease,141:153:cancer,155:163:chronic_disease,165:194:chronic_disease,198:217:chronic_disease","Concomitant systemic diseases including those in which the disease itself, or the treatment for the disease, can alter ocular function (eg, malignancies, diabetes, juvenile rheumatoid arthritis or sickle cell disease)","['Concomitant' 'systemic' 'diseases' 'including' 'those' 'in' 'which'
 'the' 'disease' 'itself' ',' 'or' 'the' 'treatment' 'for' 'the' 'disease'
 ',' 'can' 'alter' 'ocular' 'function' '(' 'eg' ',' 'malignancies' ','
 'diabetes' ',' 'juvenile' 'rheumatoid' 'arthritis' 'or' 'sickle' 'cell'
 'disease' ')']","[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 3. 0. 2. 0. 2. 2. 2. 0. 2. 2. 2. 0.]"
NCT01505062,"1:18:treatment,46:57:treatment,59:73:treatment,175:199:treatment","diagnostic agents used during the study (eg, fluorescein, dilation drops), or medications planned for use during the peri-operative period, particularly topical, injected or systemic corticosteroids","['diagnostic' 'agents' 'used' 'during' 'the' 'study' '(' 'eg' ','
 'fluorescein' ',' 'dilation' 'drops' ')' ',' 'or' 'medications' 'planned'
 'for' 'use' 'during' 'the' 'peri-operative' 'period' ',' 'particularly'
 'topical' ',' 'injected' 'or' 'systemic' 'corticosteroids']","[1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 1.]"
NCT01495819,"36:59:treatment,61:76:treatment,78:92:treatment,97:108:treatment,139:148:treatment,153:174:chronic_disease,185:201:chronic_disease,203:219:chronic_disease,221:234:chronic_disease","requirement of any form of regular psychotropic medication (antidepressants, antipsychotics, or anxiolytics) or psychiatric diagnosis and treatment for psychiatric disorders including major depression, bipolar disorder, schizophrenia in the past 6 months","['requirement' 'of' 'any' 'form' 'of' 'regular' 'psychotropic'
 'medication' '(' 'antidepressants' ',' 'antipsychotics' ',' 'or'
 'anxiolytics' ')' 'or' 'psychiatric' 'diagnosis' 'and' 'treatment' 'for'
 'psychiatric' 'disorders' 'including' 'major' 'depression' ',' 'bipolar'
 'disorder' ',' 'schizophrenia' 'in' 'the' 'past' '6' 'months']","[0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 0. 0. 1. 0. 0. 2. 2. 0. 1. 0. 0. 0.
 0. 2. 2. 0. 2. 2. 0. 2. 0. 0. 0. 0. 0.]"
NCT01494662,"1:21:chronic_disease,27:47:chronic_disease,51:73:chronic_disease",Active liver disease from autoimmune disorders or sclerosing cholangitis,"['Active' 'liver' 'disease' 'from' 'autoimmune' 'disorders' 'or'
 'sclerosing' 'cholangitis']",[2. 2. 2. 0. 2. 2. 0. 2. 2.]
NCT01494662,"1:8:treatment,46:49:treatment,133:144:chronic_disease,175:182:treatment",Head CT with contrast is allowed in place of MRI at baseline and throughout the study if MRI is contraindicated and a participant's CNS lesions are clearly measurable on the head CT,"['Head' 'CT' 'with' 'contrast' 'is' 'allowed' 'in' 'place' 'of' 'MRI' 'at'
 'baseline' 'and' 'throughout' 'the' 'study' 'if' 'MRI' 'is'
 'contraindicated' 'and' 'a' 'participant' ""'s"" 'CNS' 'lesions' 'are'
 'clearly' 'measurable' 'on' 'the' 'head' 'CT']","[1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 2. 2. 0. 0. 0. 0. 0. 1. 1.]"
NCT01494662,"1:13:chronic_disease,39:63:cancer,77:84:chronic_disease",Lung disease from etiology other than metastatic breast cancer resulting in dyspnea at rest (4A-4C),"['Lung' 'disease' 'from' 'etiology' 'other' 'than' 'metastatic' 'breast'
 'cancer' 'resulting' 'in' 'dyspnea' 'at' 'rest' '(' '4A-4C' ')']",[2. 2. 0. 0. 0. 0. 3. 3. 3. 0. 0. 2. 0. 0. 0. 0. 0.]
NCT01494662,"23:33:treatment,41:44:treatment,74:81:cancer",Patients who have had prior WBRT and/or SRS and then whose prior treated lesions have progressed thereafter,"['Patients' 'who' 'have' 'had' 'prior' 'WBRT' 'and/or' 'SRS' 'and' 'then'
 'whose' 'prior' 'treated' 'lesions' 'have' 'progressed' 'thereafter']",[0. 0. 0. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 3. 0. 0. 0.]
NCT01494324,"19:26:treatment,42:63:treatment,82:91:treatment",refuse to undergo surgery and choose any percutaneous ablation as an alternative treatment option,"['refuse' 'to' 'undergo' 'surgery' 'and' 'choose' 'any' 'percutaneous'
 'ablation' 'as' 'an' 'alternative' 'treatment' 'option']",[0. 0. 0. 1. 0. 0. 0. 1. 1. 0. 0. 0. 1. 0.]
NCT01481974,"36:50:allergy_name,52:64:allergy_name,68:80:allergy_name","Have any known hypersensitivity to prostaglandins, prostacyclin or treprostinil","['Have' 'any' 'known' 'hypersensitivity' 'to' 'prostaglandins' ','
 'prostacyclin' 'or' 'treprostinil']",[0. 0. 0. 0. 0. 4. 0. 4. 0. 4.]
NCT01465100,"13:19:chronic_disease,21:30:chronic_disease,38:54:chronic_disease","Subject has sepsis, pneumonia, other active infection","['Subject' 'has' 'sepsis' ',' 'pneumonia' ',' 'other' 'active' 'infection']",[0. 0. 2. 0. 2. 0. 0. 2. 2.]
NCT01464034,"17:35:treatment,37:44:treatment,59:76:treatment,,140:148:treatment,213:236:chronic_disease","Exposure to any prior chemotherapy, steroid use, or other myeloma treatment within 14 days prior to first dose. Pts currently on long term steroids do not require any washout period. in addition, steroid use for spinal cord compression is permitted and does not require a washout period","['Exposure' 'to' 'any' 'prior' 'chemotherapy' ',' 'steroid' 'use' ',' 'or'
 'other' 'myeloma' 'treatment' 'within' '14' 'days' 'prior' 'to' 'first'
 'dose' '.' 'Pts' 'currently' 'on' 'long' 'term' 'steroids' 'do' 'not'
 'require' 'any' 'washout' 'period' '.' 'in' 'addition' ',' 'steroid'
 'use' 'for' 'spinal' 'cord' 'compression' 'is' 'permitted' 'and' 'does'
 'not' 'require' 'a' 'washout' 'period']","[0. 0. 0. 1. 1. 0. 1. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT01464034,"13:23:chronic_disease,25:32:chronic_disease,34:41:chronic_disease,46:53:chronic_disease,","Significant neuropathy (Grade 3, Grade 4, or Grade 2 with pain) at the time of the first dose and/or within 14 days before enrollment","['Significant' 'neuropathy' '(' 'Grade' '3' ',' 'Grade' '4' ',' 'or'
 'Grade' '2' 'with' 'pain' ')' 'at' 'the' 'time' 'of' 'the' 'first' 'dose'
 'and/or' 'within' '14' 'days' 'before' 'enrollment']","[0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT01459107,"7:33:chronic_disease,38:55:chronic_disease,95:102:treatment",Mixed connective tissue diseases and collagen diseases can result in poor wound healing after surgery,"['Mixed' 'connective' 'tissue' 'diseases' 'and' 'collagen' 'diseases'
 'can' 'result' 'in' 'poor' 'wound' 'healing' 'after' 'surgery']",[0. 2. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01445821,"10:13:treatment,69:86:treatment,259:279:chronic_disease,283:313:treatment","Abnormal EKG [non-specific ST-segment and T-wave (ST-T) (pattern in electrocardiogram) wave abnormalities, low QRS (a pattern seen in an electrocardiogram that indicates the pulses in a heart beat and their duration) voltage, or ventricular hypertrophy], or pericardial effusion or pericardial enhancement on MRI","['Abnormal' 'EKG' '[' 'non-specific' 'ST-segment' 'and' 'T-wave' '('
 'ST-T' ')' '(' 'pattern' 'in' 'electrocardiogram' ')' 'wave'
 'abnormalities' ',' 'low' 'QRS' '(' 'a' 'pattern' 'seen' 'in' 'an'
 'electrocardiogram' 'that' 'indicates' 'the' 'pulses' 'in' 'a' 'heart'
 'beat' 'and' 'their' 'duration' ')' 'voltage' ',' 'or' 'ventricular'
 'hypertrophy' ']' ',' 'or' 'pericardial' 'effusion' 'or' 'pericardial'
 'enhancement' 'on' 'MRI']","[0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 1. 1. 1. 0. 0. 0.]"
NCT01445821,"1:19:chronic_disease,23:33:chronic_disease,37:44:treatment,48:65:treatment",Pulmonary fibrosis or alveolitis on CT scan or chest X-ray (CXR) (ground glass appearance of alveolitis),"['Pulmonary' 'fibrosis' 'or' 'alveolitis' 'on' 'CT' 'scan' 'or' 'chest'
 'X-ray' '(' 'CXR' ')' '(' 'ground' 'glass' 'appearance' 'of' 'alveolitis'
 ')']",[2. 2. 0. 2. 0. 1. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01436968,"1:14:chronic_disease,32:41:chronic_disease,52:61:chronic_disease","Liver disease, including known cirrhosis or active hepatitis","['Liver' 'disease' ',' 'including' 'known' 'cirrhosis' 'or' 'active'
 'hepatitis']",[2. 2. 0. 0. 0. 2. 0. 0. 2.]
NCT01434472,"1:18:chronic_disease,45:71:treatment,115:148:chronic_disease,150:159:chronic_disease","Medical condition that would contraindicate allogeneic transplantation as per standard practice guidelines (e.g., impaired cardiopulmonary function, hepatitis, etc)","['Medical' 'condition' 'that' 'would' 'contraindicate' 'allogeneic'
 'transplantation' 'as' 'per' 'standard' 'practice' 'guidelines' '('
 'e.g.' ',' 'impaired' 'cardiopulmonary' 'function' ',' 'hepatitis' ','
 'etc' ')']",[2. 2. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 2. 0. 0. 0.]
NCT01434316,"76:84:treatment,130:144:treatment,130:135:cancer,160:166:treatment,288:297:allergy_name,392:407:treatment,429:437:treatment,441:469:treatment,510:533:treatment,,,,,653:675:treatment","Eligible patients in the dose escalation phases of the trial must agree to biopsies of normal skin, unless they undergo optional tumor biopsies; the mandatory biopsy requirement can be waived at the discretion of principal investigator in the event of any medical contraindication (e.g. lidocaine allergy); patients enrolled to the expanded cohorts must agree to tumor sampling; patients on anticoagulation must be able to hold warfarin or low molecular weight heparin for a sufficient amount of time to make skin and tumor biopsies safe to perform; PT/INR and PTT should be =< 1.5 times the institutional upper limit of normal prior to performance of skin or tumor biopsies, with values re-checked after the eligibility screen as medically indicated","['Eligible' 'patients' 'in' 'the' 'dose' 'escalation' 'phases' 'of' 'the'
 'trial' 'must' 'agree' 'to' 'biopsies' 'of' 'normal' 'skin' ',' 'unless'
 'they' 'undergo' 'optional' 'tumor' 'biopsies' ';' 'the' 'mandatory'
 'biopsy' 'requirement' 'can' 'be' 'waived' 'at' 'the' 'discretion' 'of'
 'principal' 'investigator' 'in' 'the' 'event' 'of' 'any' 'medical'
 'contraindication' '(' 'e.g' '.' 'lidocaine' 'allergy' ')' ';' 'patients'
 'enrolled' 'to' 'the' 'expanded' 'cohorts' 'must' 'agree' 'to' 'tumor'
 'sampling' ';' 'patients' 'on' 'anticoagulation' 'must' 'be' 'able' 'to'
 'hold' 'warfarin' 'or' 'low' 'molecular' 'weight' 'heparin' 'for' 'a'
 'sufficient' 'amount' 'of' 'time' 'to' 'make' 'skin' 'and' 'tumor'
 'biopsies' 'safe' 'to' 'perform' ';' 'PT/INR' 'and' 'PTT' 'should' 'be'
 '=' '<' '1.5' 'times' 'the' 'institutional' 'upper' 'limit' 'of' 'normal'
 'prior' 'to' 'performance' 'of' 'skin' 'or' 'tumor' 'biopsies' ',' 'with'
 'values' 're-checked' 'after' 'the' 'eligibility' 'screen' 'as'
 'medically' 'indicated']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 1. 1. 1. 0. 0. 3. 1.
 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 4. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.
 1. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01434316,"22:38:treatment,42:56:treatment,90:100:treatment",Subjects on a potent CYP3A4 inhibitor or CPY3A4 inducer who cannot be changed to another medication,"['Subjects' 'on' 'a' 'potent' 'CYP3A4' 'inhibitor' 'or' 'CPY3A4' 'inducer'
 'who' 'can' 'not' 'be' 'changed' 'to' 'another' 'medication']",[0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01434316,"33:45:treatment,,91:100:treatment,159:177:treatment",patients must not have received chemotherapy for 3 weeks prior to the initiation of study treatment and must have full recovery from any acute effects of any prior chemotherapy,"['patients' 'must' 'not' 'have' 'received' 'chemotherapy' 'for' '3'
 'weeks' 'prior' 'to' 'the' 'initiation' 'of' 'study' 'treatment' 'and'
 'must' 'have' 'full' 'recovery' 'from' 'any' 'acute' 'effects' 'of' 'any'
 'prior' 'chemotherapy']","[0. 0. 0. 0. 0. 1. 0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT01433965,"32:47:chronic_disease,57:80:chronic_disease,84:107:chronic_disease","Known sero-positive for active viral infection with HI, hepatitis B virus (HBV) or hepatitis C virus (HCV)","['Known' 'sero-positive' 'for' 'active' 'viral' 'infection' 'with' 'HI'
 ',' 'hepatitis' 'B' 'virus' '(' 'HBV' ')' 'or' 'hepatitis' 'C' 'virus'
 '(' 'HCV' ')']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01430390,"35:57:chronic_disease,61:80:chronic_disease,101:110:chronic_disease,131:142:chronic_disease","History of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration","['History' 'of' 'clinically' 'significant' 'ventricular' 'arrhythmia' 'or'
 'unexplained' 'syncope' ',' 'not' 'believed' 'to' 'be' 'vasovagal' 'in'
 'nature' 'or' 'due' 'to' 'dehydration']",[0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 2.]
NCT01430390,"26:43:chronic_disease,95:117:chronic_disease,190:215:chronic_disease",Preceding and/or ongoing organ dysfunction or other co-morbidity including but not limited to uncontrolled infection that would impair the patient's ability to endure known side effects of cytokine release syndrome or neurological toxicity,"['Preceding' 'and/or' 'ongoing' 'organ' 'dysfunction' 'or' 'other'
 'co-morbidity' 'including' 'but' 'not' 'limited' 'to' 'uncontrolled'
 'infection' 'that' 'would' 'impair' 'the' 'patient' ""'s"" 'ability' 'to'
 'endure' 'known' 'side' 'effects' 'of' 'cytokine' 'release' 'syndrome'
 'or' 'neurological' 'toxicity']","[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 2. 2. 2. 0. 0. 0.]"
NCT01430390,"20:35:treatment,39:64:treatment,,179:188:treatment,192:201:treatment",Subjects receiving steroid therapy at physiological replacement doses only are allowed provided there has been no increase in dose for at least 2 weeks prior to subject starting apheresis or treatment,"['Subjects' 'receiving' 'steroid' 'therapy' 'at' 'physiological'
 'replacement' 'doses' 'only' 'are' 'allowed' 'provided' 'there' 'has'
 'been' 'no' 'increase' 'in' 'dose' 'for' 'at' 'least' '2' 'weeks' 'prior'
 'to' 'subject' 'starting' 'apheresis' 'or' 'treatment']","[0. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 0. 1.]"
NCT01422746,"9:17:treatment,,42:58:chronic_disease,62:83:chronic_disease",Morning cortisol < 3 µg/dL or history of Cushing syndrome or adrenal insufficiency,"['Morning' 'cortisol' '<' '3' 'µg/dL' 'or' 'history' 'of' 'Cushing'
 'syndrome' 'or' 'adrenal' 'insufficiency']",[0. 1. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2.]
NCT01422005,"10:30:chronic_disease,39:50:chronic_disease,58:64:chronic_disease,66:74:chronic_disease,79:100:chronic_disease","Previous neurological illness such as head trauma, prior stroke, epilepsy, or demyelinating disease","['Previous' 'neurological' 'illness' 'such' 'as' 'head' 'trauma' ','
 'prior' 'stroke' ',' 'epilepsy' ',' 'or' 'demyelinating' 'disease']",[0. 2. 2. 0. 0. 2. 2. 0. 0. 2. 0. 2. 0. 0. 2. 2.]
NCT01420887,"28:31:treatment,35:65:treatment,75:93:chronic_disease,102:116:treatment","Contraindication to use of CPM or regional brachial plexus block, such as bleeding diathesis, use of anticoagulants or severe restriction in shoulder range of movement","['Contraindication' 'to' 'use' 'of' 'CPM' 'or' 'regional' 'brachial'
 'plexus' 'block' ',' 'such' 'as' 'bleeding' 'diathesis' ',' 'use' 'of'
 'anticoagulants' 'or' 'severe' 'restriction' 'in' 'shoulder' 'range' 'of'
 'movement']","[0. 0. 0. 0. 1. 0. 1. 1. 1. 1. 0. 0. 0. 2. 2. 0. 0. 0. 1. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT01419561,"37:62:cancer,67:84:chronic_disease,105:127:chronic_disease",Body cavity effusions not caused by primary effusion lymphoma nor chylous effusions directly related to lymphatic infiltration by KS,"['Body' 'cavity' 'effusions' 'not' 'caused' 'by' 'primary' 'effusion'
 'lymphoma' 'nor' 'chylous' 'effusions' 'directly' 'related' 'to'
 'lymphatic' 'infiltration' 'by' 'KS']",[0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 2. 2. 0. 0. 0. 2. 2. 0. 0.]
NCT01415882,"1:11:treatment,18:27:treatment,29:45:treatment,","Alkylators (e.g. melphalan, cyclophosphamide) =< 14 days prior to registration","['Alkylators' '(' 'e.g' '.' 'melphalan' ',' 'cyclophosphamide' ')' '=' '<'
 '14' 'days' 'prior' 'to' 'registration']",[1. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01415882,"20:40:treatment,58:68:treatment,73:84:treatment,,125:132:treatment,,",Patients should be proteasome inhibitor naïve (including bortezomib and carfilzomib) OR have received less than 6 cycles of therapy with a bortezomib or carfilzomib containing regimen and were not refractory to the bortezomib or carfilzomib based regimen (less than a PR or progression on or within 60 days of discontinuation),"['Patients' 'should' 'be' 'proteasome' 'inhibitor' 'naïve' '(' 'including'
 'bortezomib' 'and' 'carfilzomib' ')' 'OR' 'have' 'received' 'less' 'than'
 '6' 'cycles' 'of' 'therapy' 'with' 'a' 'bortezomib' 'or' 'carfilzomib'
 'containing' 'regimen' 'and' 'were' 'not' 'refractory' 'to' 'the'
 'bortezomib' 'or' 'carfilzomib' 'based' 'regimen' '(' 'less' 'than' 'a'
 'PR' 'or' 'progression' 'on' 'or' 'within' '60' 'days' 'of'
 'discontinuation' ')']","[0. 0. 0. 1. 1. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT01415752,"36:62:cancer,93:119:treatment,155:196:treatment","Histologically confirmed untreated mantle cell lymphoma (MCL), with documented cyclin D1 by immunohistochemical stains and/or t(11;14) by cytogenetics or fluorescence in situ hybridization (FISH)","['Histologically' 'confirmed' 'untreated' 'mantle' 'cell' 'lymphoma' '('
 'MCL' ')' ',' 'with' 'documented' 'cyclin' 'D1' 'by'
 'immunohistochemical' 'stains' 'and/or' 't' '(' '11' ';' '14' ')' 'by'
 'cytogenetics' 'or' 'fluorescence' 'in' 'situ' 'hybridization' '(' 'FISH'
 ')']","[0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 1. 1. 1. 1. 0. 0.]"
NCT01415752,",,,45:58:chronic_disease,60:79:chronic_disease,101:124:chronic_disease,129:149:treatment,168:176:chronic_disease","Patients must not have NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia","['Patients' 'must' 'not' 'have' 'NYHA' 'Class' 'III' 'or' 'IV' 'heart'
 'failure' ',' 'uncontrolled' 'angina' ',' 'severe' 'uncontrolled'
 'ventricular' 'arrhythmias' ',' 'or' 'electrocardiographic' 'evidence'
 'of' 'acute' 'ischemia']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 0. 2. 2. 0. 0. 1. 0. 0.
 0. 2.]"
NCT01409161,"16:19:cancer,49:90:treatment,92:123:treatment,128:136:treatment","A diagnosis of APL based on the presence of the PML-RAR-alpha fusion gene by cytogenetics, polymerase chain reaction (PCR), or POD test","['A' 'diagnosis' 'of' 'APL' 'based' 'on' 'the' 'presence' 'of' 'the'
 'PML-RAR-alpha' 'fusion' 'gene' 'by' 'cytogenetics' ',' 'polymerase'
 'chain' 'reaction' '(' 'PCR' ')' ',' 'or' 'POD' 'test']","[0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 1. 1. 1. 1. 0. 0. 0. 0.
 1. 1.]"
NCT01407809,"1:36:treatment,40:76:treatment,91:126:chronic_disease,130:166:chronic_disease,172:213:chronic_disease,217:224:chronic_disease",Magnetic Resonance Venography (MRV) or Computed Tomography Venography (CTV) demonstrating bilateral transverse sinus stenosis or unilateral transverse sinus stenosis with contralateral transverse sinus hypoplasia or atresia,"['Magnetic' 'Resonance' 'Venography' '(' 'MRV' ')' 'or' 'Computed'
 'Tomography' 'Venography' '(' 'CTV' ')' 'demonstrating' 'bilateral'
 'transverse' 'sinus' 'stenosis' 'or' 'unilateral' 'transverse' 'sinus'
 'stenosis' 'with' 'contralateral' 'transverse' 'sinus' 'hypoplasia' 'or'
 'atresia']","[1. 1. 1. 1. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 2. 2. 2. 2. 0. 2. 2. 2. 2. 0.
 2. 2. 2. 2. 0. 2.]"
NCT01389024,",24:27:treatment,24:35:treatment,,,72:93:treatment,","History of two or more TCD studies with a velocity ≥ 200 cm/sec by the non-imaging technique, or ≥185 cm/sec for the imaging technique or a indeterminate TCD","['History' 'of' 'two' 'or' 'more' 'TCD' 'studies' 'with' 'a' 'velocity'
 '≥' '200' 'cm/sec' 'by' 'the' 'non-imaging' 'technique' ',' 'or' '≥185'
 'cm/sec' 'for' 'the' 'imaging' 'technique' 'or' 'a' 'indeterminate' 'TCD']","[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT01389024,"23:41:chronic_disease,43:56:chronic_disease,61:96:chronic_disease,98:113:chronic_disease,,",Participant must have sickle cell anemia (hemoglobin SS) or sickle Beta-zero (null) thalassemia (hemoglobin S-B0) as confirmed at the local institution by hemoglobin analysis after six months of age,"['Participant' 'must' 'have' 'sickle' 'cell' 'anemia' '(' 'hemoglobin'
 'SS' ')' 'or' 'sickle' 'Beta-zero' '(' 'null' ')' 'thalassemia' '('
 'hemoglobin' 'S-B0' ')' 'as' 'confirmed' 'at' 'the' 'local' 'institution'
 'by' 'hemoglobin' 'analysis' 'after' 'six' 'months' 'of' 'age']","[0. 0. 0. 2. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01384513,"1:8:cancer,12:43:cancer,49:71:cancer",Hodgkin or Indolent Non-Hodgkin's lymphoma with chemosensitive disease,"['Hodgkin' 'or' 'Indolent' 'Non-Hodgkin' ""'s"" 'lymphoma' 'with'
 'chemosensitive' 'disease']",[3. 0. 3. 3. 3. 0. 0. 3. 3.]
NCT01379573,"22:37:treatment,88:96:treatment,242:245:treatment,,278:281:chronic_disease","Mother is taking any glucocorticoids. Although unlikely to be preventative, the use of steroids may confound the interpretation of results. The final point of intense discussion centered around whether another exclusion should be the use of HCQ in the first pregnancy in which CHB occurred. While one could argue that in these mothers HCQ was not effective and perhaps will not be again, this assumption remains speculative and thus prior absence of efficacy of HCQ will not constitute an exclusion criteria","['Mother' 'is' 'taking' 'any' 'glucocorticoids' '.' 'Although' 'unlikely'
 'to' 'be' 'preventative' ',' 'the' 'use' 'of' 'steroids' 'may' 'confound'
 'the' 'interpretation' 'of' 'results' '.' 'The' 'final' 'point' 'of'
 'intense' 'discussion' 'centered' 'around' 'whether' 'another'
 'exclusion' 'should' 'be' 'the' 'use' 'of' 'HCQ' 'in' 'the' 'first'
 'pregnancy' 'in' 'which' 'CHB' 'occurred' '.' 'While' 'one' 'could'
 'argue' 'that' 'in' 'these' 'mothers' 'HCQ' 'was' 'not' 'effective' 'and'
 'perhaps' 'will' 'not' 'be' 'again' ',' 'this' 'assumption' 'remains'
 'speculative' 'and' 'thus' 'prior' 'absence' 'of' 'efficacy' 'of' 'HCQ'
 'will' 'not' 'constitute' 'an' 'exclusion' 'criteria']","[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 2. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01372631,"23:33:treatment,34:44:treatment,53:62:treatment,69:77:cancer,81:111:cancer",Patients undergoing a lumpectomy mastectomy for the treatment of an invasive or non-invasive breast malignancy,"['Patients' 'undergoing' 'a' 'lumpectomy' 'mastectomy' 'for' 'the'
 'treatment' 'of' 'an' 'invasive' 'or' 'non-invasive' 'breast'
 'malignancy']",[0. 0. 0. 1. 1. 0. 0. 1. 0. 0. 3. 0. 3. 3. 3.]
NCT01367444,"34:54:chronic_disease,56:66:chronic_disease,68:81:chronic_disease,86:106:treatment","History or signs consistent with unilateral amblyopia (strabismic, anisometropic, or stimulus deprivation)","['History' 'or' 'signs' 'consistent' 'with' 'unilateral' 'amblyopia' '('
 'strabismic' ',' 'anisometropic' ',' 'or' 'stimulus' 'deprivation' ')']",[0. 0. 0. 0. 0. 2. 2. 0. 2. 0. 2. 0. 0. 1. 1. 0.]
NCT01366612,"32:43:allergy_name,47:56:allergy_name,63:73:allergy_name,75:80:allergy_name,84:92:allergy_name","Documented hypersensitivity to fludarabine or melphalan or to bortezomib, boron or mannitol or any components of the formulation","['Documented' 'hypersensitivity' 'to' 'fludarabine' 'or' 'melphalan' 'or'
 'to' 'bortezomib' ',' 'boron' 'or' 'mannitol' 'or' 'any' 'components'
 'of' 'the' 'formulation']",[0. 0. 0. 4. 0. 4. 0. 0. 4. 0. 4. 0. 4. 0. 0. 0. 0. 0. 0.]
NCT01365169,"21:30:treatment,37:43:cancer,176:200:cancer",Currently receiving treatment for a cancer other than those listed in the arm-specific inclusion criteria (exception: the study does not exclude those receiving treatment for non-melanoma skin cancer) (Arms 2 and 3),"['Currently' 'receiving' 'treatment' 'for' 'a' 'cancer' 'other' 'than'
 'those' 'listed' 'in' 'the' 'arm-specific' 'inclusion' 'criteria' '('
 'exception' ':' 'the' 'study' 'does' 'not' 'exclude' 'those' 'receiving'
 'treatment' 'for' 'non-melanoma' 'skin' 'cancer' ')' '(' 'Arms' '2' 'and'
 '3' ')']","[0. 0. 1. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0.]"
NCT01365169,"27:50:treatment,55:80:cancer,82:114:cancer,119:135:chronic_disease","Patients who will undergo curative pancreatectomy for pancreatic adenocarcinoma, pancreatic neuroendocrine tumors, or pancreatic cysts (malignant or benign) (PCS study)","['Patients' 'who' 'will' 'undergo' 'curative' 'pancreatectomy' 'for'
 'pancreatic' 'adenocarcinoma' ',' 'pancreatic' 'neuroendocrine' 'tumors'
 ',' 'or' 'pancreatic' 'cysts' '(' 'malignant' 'or' 'benign' ')' '(' 'PCS'
 'study' ')']","[0. 0. 0. 0. 1. 1. 0. 2. 2. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT01360606,"1:31:treatment,35:62:treatment,72:79:treatment,81:105:treatment,107:124:treatment,126:149:treatment,151:181:treatment,185:197:treatment,287:300:treatment,,390:399:treatment,461:465:treatment,521:537:treatment,","Previous systemic chemotherapy or non-radiation local therapy (such as surgery, hepatic arterial therapy, chemoembolization, radiofrequency ablation, percutaneous ethanol injection or cryoablation) is allowed. The lesion must however have shown criteria of progression based on RECIST. Local therapy must be completed at least 4 weeks prior to the baseline scan. This is to create a safer treatment environment and to help determine the effect of treatment by SBRT alone. Patients will be allowed to go onto appropriate systemic therapy, as determined by their medical oncologist, 2 weeks following delivery of SBRT","['Previous' 'systemic' 'chemotherapy' 'or' 'non-radiation' 'local'
 'therapy' '(' 'such' 'as' 'surgery' ',' 'hepatic' 'arterial' 'therapy'
 ',' 'chemoembolization' ',' 'radiofrequency' 'ablation' ','
 'percutaneous' 'ethanol' 'injection' 'or' 'cryoablation' ')' 'is'
 'allowed' '.' 'The' 'lesion' 'must' 'however' 'have' 'shown' 'criteria'
 'of' 'progression' 'based' 'on' 'RECIST' '.' 'Local' 'therapy' 'must'
 'be' 'completed' 'at' 'least' '4' 'weeks' 'prior' 'to' 'the' 'baseline'
 'scan' '.' 'This' 'is' 'to' 'create' 'a' 'safer' 'treatment'
 'environment' 'and' 'to' 'help' 'determine' 'the' 'effect' 'of'
 'treatment' 'by' 'SBRT' 'alone' '.' 'Patients' 'will' 'be' 'allowed' 'to'
 'go' 'onto' 'appropriate' 'systemic' 'therapy' ',' 'as' 'determined' 'by'
 'their' 'medical' 'oncologist' ',' '2' 'weeks' 'following' 'delivery'
 'of' 'SBRT']","[1. 1. 1. 0. 1. 1. 1. 0. 0. 0. 1. 0. 1. 1. 1. 0. 1. 0. 1. 1. 0. 1. 1. 1.
 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT01356290,",,,,,,,,,,304:313:treatment,319:328:treatment,333:349:treatment","Participants must have normal organ and bone marrow function (ALT <5x institutional upper limit of normal, creatinine <1.5x institutional upper limit of normal for age, WBC >1000/mm3, platelets > 20,000/mm3. Patients with values less than WBC 2000/mm3 or platelets 50,000/mm3 will require initiation of treatment with etoposide and cyclophosphamide at a lower starting dose as defined within the protocol","['Participants' 'must' 'have' 'normal' 'organ' 'and' 'bone' 'marrow'
 'function' '(' 'ALT' '<' '5x' 'institutional' 'upper' 'limit' 'of'
 'normal' ',' 'creatinine' '<' '1.5x' 'institutional' 'upper' 'limit' 'of'
 'normal' 'for' 'age' ',' 'WBC' '>' '1000/mm3' ',' 'platelets' '>'
 '20,000/mm3' '.' 'Patients' 'with' 'values' 'less' 'than' 'WBC'
 '2000/mm3' 'or' 'platelets' '50,000/mm3' 'will' 'require' 'initiation'
 'of' 'treatment' 'with' 'etoposide' 'and' 'cyclophosphamide' 'at' 'a'
 'lower' 'starting' 'dose' 'as' 'defined' 'within' 'the' 'protocol']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01349101,"19:23:cancer,27:33:chronic_disease,56:76:treatment",For patients with CMML or RAEB-2 they must demonstrate chemo-responsiveness,"['For' 'patients' 'with' 'CMML' 'or' 'RAEB-2' 'they' 'must' 'demonstrate'
 'chemo-responsiveness']",[0. 0. 0. 3. 0. 2. 0. 0. 0. 1.]
NCT01345344,"16:33:treatment,37:58:treatment,90:101:chronic_disease,123:132:treatment","current use of opioid analgesics or stimulant medications or the fatigue associated with sleep apnea or shift work (e.g., modafinil)","['current' 'use' 'of' 'opioid' 'analgesics' 'or' 'stimulant' 'medications'
 'or' 'the' 'fatigue' 'associated' 'with' 'sleep' 'apnea' 'or' 'shift'
 'work' '(' 'e.g.' ',' 'modafinil' ')']",[0. 0. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT01341080,"1:16:chronic_disease,28:46:treatment,102:109:treatment,","Serious illness (requiring systemic treatment/or hospitalization) until the subject either completes therapy or is clinically stable on therapy, in the opinion of the site investigator, for at least 60 days prior to study entry","['Serious' 'illness' '(' 'requiring' 'systemic' 'treatment/or'
 'hospitalization' ')' 'until' 'the' 'subject' 'either' 'completes'
 'therapy' 'or' 'is' 'clinically' 'stable' 'on' 'therapy' ',' 'in' 'the'
 'opinion' 'of' 'the' 'site' 'investigator' ',' 'for' 'at' 'least' '60'
 'days' 'prior' 'to' 'study' 'entry']","[2. 2. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01333046,",54:64:treatment,68:81:treatment,86:102:treatment",Patients greater than or equal to 18 years old after autologous or syngeneic SCT (as adjuvant therapy),"['Patients' 'greater' 'than' 'or' 'equal' 'to' '18' 'years' 'old' 'after'
 'autologous' 'or' 'syngeneic' 'SCT' '(' 'as' 'adjuvant' 'therapy' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 1. 1. 0.]
NCT01326715,"44:61:chronic_disease,71:76:chronic_disease,80:94:chronic_disease","Reported history of clinically significant medical disorders, such as liver or kidney disease, that could potentially increase the risk of CNS damage due to manganese exposure","['Reported' 'history' 'of' 'clinically' 'significant' 'medical'
 'disorders' ',' 'such' 'as' 'liver' 'or' 'kidney' 'disease' ',' 'that'
 'could' 'potentially' 'increase' 'the' 'risk' 'of' 'CNS' 'damage' 'due'
 'to' 'manganese' 'exposure']","[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT01313533,"1:22:chronic_disease,57:89:treatment,91:157:treatment,161:177:treatment","cute traumatic injury, vasculitis or planned concurrent ventricular surgical restoration, automatic implantable cardioverter defibrillators (AICD) placement or valvular surgery","['cute' 'traumatic' 'injury' ',' 'vasculitis' 'or' 'planned' 'concurrent'
 'ventricular' 'surgical' 'restoration' ',' 'automatic' 'implantable'
 'cardioverter' 'defibrillators' '(' 'AICD' ')' 'placement' 'or'
 'valvular' 'surgery']",[2. 2. 2. 0. 0. 0. 0. 0. 1. 1. 1. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0. 1. 1.]
NCT01312857,"23:38:treatment,39:55:treatment,102:111:treatment",Patients who have had prior anti EGFR antibody therapy inhibitors and who have not responded to this treatment will be excluded,"['Patients' 'who' 'have' 'had' 'prior' 'anti' 'EGFR' 'antibody' 'therapy'
 'inhibitors' 'and' 'who' 'have' 'not' 'responded' 'to' 'this' 'treatment'
 'will' 'be' 'excluded']",[0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT01306045,"5:33:chronic_disease,79:109:treatment,129:186:treatment",Any uncontrolled medical illness that precludes the patient from undergoing a biopsy for molecular profiling and / or receiving treatment under one of the experimental arms of the study,"['Any' 'uncontrolled' 'medical' 'illness' 'that' 'precludes' 'the'
 'patient' 'from' 'undergoing' 'a' 'biopsy' 'for' 'molecular' 'profiling'
 'and' '/' 'or' 'receiving' 'treatment' 'under' 'one' 'of' 'the'
 'experimental' 'arms' 'of' 'the' 'study']","[0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 1. 1. 1. 1. 1.
 1. 1. 1. 1. 1.]"
NCT01306045,"15:43:cancer,27:43:cancer,110:119:chronic_disease,163:173:chronic_disease,163:185:chronic_disease,292:301:treatment,339:363:cancer,,428:443:treatment,","Patients with symptomatic brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. However, patients who have had treatment for their brain metastases and whose brain metastatic disease status has remained stable for at least 1 week after the end of brain radiation may be enrolled to undergo molecular profiling at the discretion of the principal investigator. In addition, brain metastatic disease should be stable for at least 4 weeks, before the patients can be enrolled in any of the experimental treatment arms","['Patients' 'with' 'symptomatic' 'brain' 'metastases' 'should' 'be'
 'excluded' 'from' 'this' 'clinical' 'trial' 'because' 'of' 'their' 'poor'
 'prognosis' 'and' 'because' 'they' 'often' 'develop' 'progressive'
 'neurologic' 'dysfunction' 'that' 'would' 'confound' 'the' 'evaluation'
 'of' 'neurologic' 'and' 'other' 'adverse' 'events' '.' 'However' ','
 'patients' 'who' 'have' 'had' 'treatment' 'for' 'their' 'brain'
 'metastases' 'and' 'whose' 'brain' 'metastatic' 'disease' 'status' 'has'
 'remained' 'stable' 'for' 'at' 'least' '1' 'week' 'after' 'the' 'end'
 'of' 'brain' 'radiation' 'may' 'be' 'enrolled' 'to' 'undergo' 'molecular'
 'profiling' 'at' 'the' 'discretion' 'of' 'the' 'principal' 'investigator'
 '.' 'In' 'addition' ',' 'brain' 'metastatic' 'disease' 'should' 'be'
 'stable' 'for' 'at' 'least' '4' 'weeks' ',' 'before' 'the' 'patients'
 'can' 'be' 'enrolled' 'in' 'any' 'of' 'the' 'experimental' 'treatment'
 'arms']","[0. 0. 3. 1. 1. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 2.
 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01306019,"48:54:treatment,56:67:chronic_disease,76:89:treatment,91:103:treatment,169:178:chronic_disease","Isolation of a bacteria, fungus, or virus from biopsy, skin lesion, blood, nasal washing, bronchoscopy, cerebrospinal fluid or stool likely to be an etiologic agent of infection","['Isolation' 'of' 'a' 'bacteria' ',' 'fungus' ',' 'or' 'virus' 'from'
 'biopsy' ',' 'skin' 'lesion' ',' 'blood' ',' 'nasal' 'washing' ','
 'bronchoscopy' ',' 'cerebrospinal' 'fluid' 'or' 'stool' 'likely' 'to'
 'be' 'an' 'etiologic' 'agent' 'of' 'infection']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 2. 2. 0. 0. 0. 1. 1. 0. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]"
NCT01293214,"29:41:treatment,55:65:treatment,75:84:chronic_disease,89:100:chronic_disease","Willing to receive standard vaccinations prior to the transplant, such as influenza and hepatitis B","['Willing' 'to' 'receive' 'standard' 'vaccinations' 'prior' 'to' 'the'
 'transplant' ',' 'such' 'as' 'influenza' 'and' 'hepatitis' 'B']",[0. 0. 0. 0. 1. 0. 0. 0. 1. 0. 0. 0. 2. 0. 2. 2.]
NCT01280669,"15:32:chronic_disease,25:32:chronic_disease,51:85:treatment,93:105:treatment,107:119:treatment,121:137:treatment,139:151:treatment,153:166:treatment,167:174:treatment,176:186:treatment,191:203:treatment,216:226:treatment,236:251:treatment,260:269:treatment,378:402:treatment","Patients with bilateral uveitis who are receiving systemic immunosuppressive therapy (e.g., methotrexate, cyclosporine, cyclophosphamide, chlorambucil, mycophenolate mofetil, tacrolimus, or azathioprine) other than prednisone or other corticosteroids for the treatment of uveitis and the uveitis in the fellow eye, in the opinion of the Investigator, cannot be controlled with standard local therapies alone","['Patients' 'with' 'bilateral' 'uveitis' 'who' 'are' 'receiving'
 'systemic' 'immunosuppressive' 'therapy' '(' 'e.g.' ',' 'methotrexate'
 ',' 'cyclosporine' ',' 'cyclophosphamide' ',' 'chlorambucil' ','
 'mycophenolate' 'mofetil' ',' 'tacrolimus' ',' 'or' 'azathioprine' ')'
 'other' 'than' 'prednisone' 'or' 'other' 'corticosteroids' 'for' 'the'
 'treatment' 'of' 'uveitis' 'and' 'the' 'uveitis' 'in' 'the' 'fellow'
 'eye' ',' 'in' 'the' 'opinion' 'of' 'the' 'Investigator' ',' 'can' 'not'
 'be' 'controlled' 'with' 'standard' 'local' 'therapies' 'alone']","[0. 0. 2. 2. 0. 0. 0. 1. 1. 1. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 1. 0.
 1. 0. 0. 1. 0. 0. 0. 1. 0. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0.]"
NCT01270724,"28:39:treatment,41:52:treatment,60:70:treatment","Patients who have received gemcitabine, oxaliplatin and/or paclitaxel","['Patients' 'who' 'have' 'received' 'gemcitabine' ',' 'oxaliplatin'
 'and/or' 'paclitaxel']",[0. 0. 0. 0. 1. 0. 1. 0. 1.]
NCT01261728,"43:76:cancer,142:147:cancer,201:217:treatment",Histologically confirmed high-grade upper tract transitional cell carcinoma at MSKCC or a participating site and/or radiographically visible tumor stage T2-T4a N0/X M0 disease with positive selective urinary cytology or high-grade concomitant bladder tumor,"['Histologically' 'confirmed' 'high-grade' 'upper' 'tract' 'transitional'
 'cell' 'carcinoma' 'at' 'MSKCC' 'or' 'a' 'participating' 'site' 'and/or'
 'radiographically' 'visible' 'tumor' 'stage' 'T2-T4a' 'N0/X' 'M0'
 'disease' 'with' 'positive' 'selective' 'urinary' 'cytology' 'or'
 'high-grade' 'concomitant' 'bladder' 'tumor']","[0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 1. 0. 0. 0. 0. 0.]"
NCT01261728,"22:29:chronic_disease,33:52:chronic_disease,72:88:chronic_disease","Serious intercurrent medical or psychiatric illness, including serious active infection","['Serious' 'intercurrent' 'medical' 'or' 'psychiatric' 'illness' ','
 'including' 'serious' 'active' 'infection']",[0. 0. 2. 0. 2. 2. 0. 0. 0. 2. 2.]
NCT01245712,"1:35:cancer,44:51:cancer,55:63:cancer",Non-epithelial breast malignancies such as sarcoma or lymphoma,"['Non-epithelial' 'breast' 'malignancies' 'such' 'as' 'sarcoma' 'or'
 'lymphoma']",[3. 3. 3. 0. 0. 3. 0. 3.]
NCT01245712,"8:30:cancer,32:47:cancer,51:55:cancer,,",Proven multicentric carcinoma (invasive cancer or DCIS) in more than one quadrant or separated by 4 or more centimeters,"['Proven' 'multicentric' 'carcinoma' '(' 'invasive' 'cancer' 'or' 'DCIS'
 ')' 'in' 'more' 'than' 'one' 'quadrant' 'or' 'separated' 'by' '4' 'or'
 'more' 'centimeters']",[0. 3. 3. 0. 3. 3. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01243931,"1:10:chronic_disease,12:27:chronic_disease,29:37:chronic_disease,103:110:treatment","Cataracts, retinal disease, glaucoma, or other eye conditions that may limit the visual outcome after surgery","['Cataracts' ',' 'retinal' 'disease' ',' 'glaucoma' ',' 'or' 'other' 'eye'
 'conditions' 'that' 'may' 'limit' 'the' 'visual' 'outcome' 'after'
 'surgery']",[2. 0. 2. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01228448,"28:32:cancer,37:41:cancer,47:64:cancer,96:108:treatment","Adult subjects with brain, head and neck, and skull base tumors receiving external beam proton radiotherapy at the Francis H. Burr Proton Therapy Center at MGH","['Adult' 'subjects' 'with' 'brain' ',' 'head' 'and' 'neck' ',' 'and'
 'skull' 'base' 'tumors' 'receiving' 'external' 'beam' 'proton'
 'radiotherapy' 'at' 'the' 'Francis' 'H.' 'Burr' 'Proton' 'Therapy'
 'Center' 'at' 'MGH']","[0. 0. 0. 0. 0. 3. 0. 3. 0. 0. 3. 3. 3. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT01220583,"4:31:treatment,35:52:treatment,57:82:cancer",No prior systemic chemotherapy or radiation therapy for salivary gland malignancy,"['No' 'prior' 'systemic' 'chemotherapy' 'or' 'radiation' 'therapy' 'for'
 'salivary' 'gland' 'malignancy']",[0. 1. 1. 1. 0. 1. 1. 0. 3. 3. 3.]
NCT01200940,"61:71:allergy_name,75:79:allergy_name,87:94:allergy_name","Known allergy, sensitivity or other contraindication to any study food or drug or its vehicle","['Known' 'allergy' ',' 'sensitivity' 'or' 'other' 'contraindication' 'to'
 'any' 'study' 'food' 'or' 'drug' 'or' 'its' 'vehicle']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 4. 0. 4. 0. 0. 4.]
NCT01185210,"17:24:treatment,26:35:treatment,37:46:treatment,48:54:treatment","Medication use: opioids, Tegaserod, laxatives, enemas","['Medication' 'use' ':' 'opioids' ',' 'Tegaserod' ',' 'laxatives' ','
 'enemas']",[0. 0. 0. 1. 0. 1. 0. 1. 0. 1.]
NCT01184547,"1:19:chronic_disease,23:29:chronic_disease,43:58:chronic_disease","Mental retardation or autism or any other mental disorder, which makes it impossible to participate in an exercise program","['Mental' 'retardation' 'or' 'autism' 'or' 'any' 'other' 'mental'
 'disorder' ',' 'which' 'makes' 'it' 'impossible' 'to' 'participate' 'in'
 'an' 'exercise' 'program']",[2. 2. 0. 2. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01174121,"40:57:cancer,89:94:cancer,98:120:cancer,122:135:cancer,137:150:cancer,152:158:cancer,160:179:cancer,184:196:cancer","Measurable (per RECIST v1.0 criteria), metastatic cancer of one of the following types: upper or lower gastrointestinal, hepatobiliary, genitourinary, breast, ovarian/endometrial, or glioblastoma","['Measurable' '(' 'per' 'RECIST' 'v1.0' 'criteria' ')' ',' 'metastatic'
 'cancer' 'of' 'one' 'of' 'the' 'following' 'types' ':' 'upper' 'or'
 'lower' 'gastrointestinal' ',' 'hepatobiliary' ',' 'genitourinary' ','
 'breast' ',' 'ovarian/endometrial' ',' 'or' 'glioblastoma']","[0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 3. 0. 3. 3. 0. 3. 0.
 3. 0. 3. 0. 3. 0. 0. 3.]"
NCT01174108,"1:4:chronic_disease,43:46:chronic_disease,48:51:chronic_disease,55:64:chronic_disease,66:82:chronic_disease","HIV positive (donors who are positive for HBV, HCV or HTLV-I/II, T.cruzi [Chagas] may be used at the discretion of the investigator following counseling and approval from the recipient)","['HIV' 'positive' '(' 'donors' 'who' 'are' 'positive' 'for' 'HBV' ','
 'HCV' 'or' 'HTLV-I/II' ',' 'T.cruzi' '[' 'Chagas' ']' 'may' 'be' 'used'
 'at' 'the' 'discretion' 'of' 'the' 'investigator' 'following'
 'counseling' 'and' 'approval' 'from' 'the' 'recipient' ')']","[2. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01174108,"1:23:chronic_disease,27:35:chronic_disease,65:76:treatment,95:106:chronic_disease",Refractory anemia (RA) or RARS MDS patients who have associated transfusion dependence and/or neutropenia,"['Refractory' 'anemia' '(' 'RA' ')' 'or' 'RARS' 'MDS' 'patients' 'who'
 'have' 'associated' 'transfusion' 'dependence' 'and/or' 'neutropenia']",[2. 2. 2. 0. 0. 0. 2. 2. 0. 0. 0. 0. 1. 0. 0. 2.]
NCT01174108,"18:36:treatment,48:57:treatment,70:76:chronic_disease,78:80:chronic_disease,82:97:chronic_disease,99:124:chronic_disease,133:146:chronic_disease,150:165:chronic_disease","Unfit to receive filgrastim (G-CSF) or undergo apheresis (history of stroke, MI, unstable angina, uncontrolled hypertension, severe heart disease or palpable spleen)","['Unfit' 'to' 'receive' 'filgrastim' '(' 'G-CSF' ')' 'or' 'undergo'
 'apheresis' '(' 'history' 'of' 'stroke' ',' 'MI' ',' 'unstable' 'angina'
 ',' 'uncontrolled' 'hypertension' ',' 'severe' 'heart' 'disease' 'or'
 'palpable' 'spleen' ')']","[0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 0. 0. 0. 2. 0. 2. 0. 2. 2. 0. 2. 2. 0. 0.
 2. 2. 0. 2. 2. 0.]"
NCT01130077,"28:35:cancer,41:59:cancer,85:115:treatment,98:107:treatment,108:115:treatment,155:167:treatment","Newly diagnosed high-grade gliomas with metastatic disease within the CNS requiring craniospinal radiation therapy. Patients may or may not have received chemotherapy during radiation, but cannot have received chemotherapy after radiation therapy was completed","['Newly' 'diagnosed' 'high-grade' 'gliomas' 'with' 'metastatic' 'disease'
 'within' 'the' 'CNS' 'requiring' 'craniospinal' 'radiation' 'therapy' '.'
 'Patients' 'may' 'or' 'may' 'not' 'have' 'received' 'chemotherapy'
 'during' 'radiation' ',' 'but' 'can' 'not' 'have' 'received'
 'chemotherapy' 'after' 'radiation' 'therapy' 'was' 'completed']","[0. 0. 0. 3. 0. 3. 3. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01130077,",64:82:treatment,70:82:treatment,86:111:treatment,,,272:289:treatment","Patients enrolled on stratum C must have received at least two prior chemotherapy or biologic therapy regimens and may not have received radiation to the index lesion within 1 year of enrollment. Patients on Strata A, B, E, and F can not have received chemotherapy after radiation therapy was completed","['Patients' 'enrolled' 'on' 'stratum' 'C' 'must' 'have' 'received' 'at'
 'least' 'two' 'prior' 'chemotherapy' 'or' 'biologic' 'therapy' 'regimens'
 'and' 'may' 'not' 'have' 'received' 'radiation' 'to' 'the' 'index'
 'lesion' 'within' '1' 'year' 'of' 'enrollment' '.' 'Patients' 'on'
 'Strata' 'A' ',' 'B' ',' 'E' ',' 'and' 'F' 'can' 'not' 'have' 'received'
 'chemotherapy' 'after' 'radiation' 'therapy' 'was' 'completed']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 1. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT01128816,"1:51:chronic_disease,59:67:chronic_disease,69:79:chronic_disease,83:95:chronic_disease,","American Heart Association Stage B-D Heart failure due to ischemic, idiopathic or hypertensive causes, present for at least 3 months","['American' 'Heart' 'Association' 'Stage' 'B-D' 'Heart' 'failure' 'due'
 'to' 'ischemic' ',' 'idiopathic' 'or' 'hypertensive' 'causes' ','
 'present' 'for' 'at' 'least' '3' 'months']",[2. 2. 2. 2. 2. 2. 2. 0. 0. 2. 0. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01101451,"31:46:cancer,,,58:81:cancer,83:106:cancer,110:124:cancer,167:179:treatment,185:207:treatment","Pathologically proven primary cervical cancer I-IIA with squamous cell carcinoma, adenosquamous carcinoma or adenocarcinoma initially treated with a standard radical hysterectomy with pelvic lymphadenectomy","['Pathologically' 'proven' 'primary' 'cervical' 'cancer' 'I-IIA' 'with'
 'squamous' 'cell' 'carcinoma' ',' 'adenosquamous' 'carcinoma' 'or'
 'adenocarcinoma' 'initially' 'treated' 'with' 'a' 'standard' 'radical'
 'hysterectomy' 'with' 'pelvic' 'lymphadenectomy']","[0. 0. 0. 3. 3. 0. 0. 3. 3. 3. 0. 3. 3. 0. 3. 0. 0. 0. 0. 0. 0. 1. 0. 1.
 1.]"
NCT01099644,"5:11:cancer,23:28:cancer,30:38:treatment","For tumors other than DSRCT, Burtomab reactivity must be confirmed by immunohistochemistry","['For' 'tumors' 'other' 'than' 'DSRCT' ',' 'Burtomab' 'reactivity' 'must'
 'be' 'confirmed' 'by' 'immunohistochemistry']",[0. 3. 0. 0. 3. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT01096368,"54:64:cancer,76:95:chronic_disease,117:122:cancer,313:320:treatment","There is no minimum performance level; children with ependymoma may suffer neurologic sequelae as a result of their tumor or surgical measures taken to establish a diagnosis and resect the tumor; in the majority of cases, there is neurologic recovery; neurologic recovery is not likely to be impeded by protocol therapy","['There' 'is' 'no' 'minimum' 'performance' 'level' ';' 'children' 'with'
 'ependymoma' 'may' 'suffer' 'neurologic' 'sequelae' 'as' 'a' 'result'
 'of' 'their' 'tumor' 'or' 'surgical' 'measures' 'taken' 'to' 'establish'
 'a' 'diagnosis' 'and' 'resect' 'the' 'tumor' ';' 'in' 'the' 'majority'
 'of' 'cases' ',' 'there' 'is' 'neurologic' 'recovery' ';' 'neurologic'
 'recovery' 'is' 'not' 'likely' 'to' 'be' 'impeded' 'by' 'protocol'
 'therapy']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 2. 2. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1.]"
NCT01087294,"12:24:chronic_disease,51:61:treatment,63:69:chronic_disease,81:94:chronic_disease,120:126:chronic_disease","History of hypertension that is not controlled by medication, stroke, or severe heart disease (donors with symptomatic angina will be excluded)","['History' 'of' 'hypertension' 'that' 'is' 'not' 'controlled' 'by'
 'medication' ',' 'stroke' ',' 'or' 'severe' 'heart' 'disease' '('
 'donors' 'with' 'symptomatic' 'angina' 'will' 'be' 'excluded' ')']","[0. 0. 2. 0. 0. 0. 0. 0. 1. 0. 2. 0. 0. 0. 2. 2. 0. 0. 0. 0. 2. 0. 0. 0.
 0.]"
NCT01061515,"30:47:treatment,53:66:treatment,,136:148:treatment",Patients must have undergone debulking surgery with peritonectomy and have been allowed at least 4 weeks to recover prior to receiving chemotherapy,"['Patients' 'must' 'have' 'undergone' 'debulking' 'surgery' 'with'
 'peritonectomy' 'and' 'have' 'been' 'allowed' 'at' 'least' '4' 'weeks'
 'to' 'recover' 'prior' 'to' 'receiving' 'chemotherapy']",[0. 0. 0. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01059786,"10:17:treatment,24:36:treatment,38:48:treatment,","No other therapy (i.e. chemotherapy, interferon) for 4 weeks prior to study entry","['No' 'other' 'therapy' '(' 'i.e' '.' 'chemotherapy' ',' 'interferon' ')'
 'for' '4' 'weeks' 'prior' 'to' 'study' 'entry']",[0. 0. 1. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01059786,"35:46:treatment,47:54:treatment,,112:127:treatment",The patient may have any required vaccination/booster administered at least 4 weeks prior to the initiation of study treatment,"['The' 'patient' 'may' 'have' 'any' 'required' 'vaccination/booster'
 'administered' 'at' 'least' '4' 'weeks' 'prior' 'to' 'the' 'initiation'
 'of' 'study' 'treatment']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01054196,"62:70:cancer,72:90:cancer,95:135:cancer","Patients must have histologically or cytologically confirmed relapsed, primary refractory, or relapsed and refractory multiple myeloma","['Patients' 'must' 'have' 'histologically' 'or' 'cytologically'
 'confirmed' 'relapsed' ',' 'primary' 'refractory' ',' 'or' 'relapsed'
 'and' 'refractory' 'multiple' 'myeloma']",[0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0.]
NCT01045148,"24:31:cancer,43:48:cancer,50:57:cancer,62:88:cancer,","Previous or concurrent cancers other than basal, in situ, or squamous cell skin cancers unless disease-free for ≥ 5 years","['Previous' 'or' 'concurrent' 'cancers' 'other' 'than' 'basal' ',' 'in'
 'situ' ',' 'or' 'squamous' 'cell' 'skin' 'cancers' 'unless'
 'disease-free' 'for' '≥' '5' 'years']",[0. 0. 0. 3. 0. 0. 3. 0. 3. 3. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0.]
NCT01042522,"58:76:allergy_name,103:109:cancer,212:223:chronic_disease,240:255:treatment","Patients with a history of hypersensitivity reactions to prior chemotherapy administered for previous cancer diagnoses are eligible to participate in the study, unless the hypersensitivity reaction consisted of anaphylaxis not amenable to desensitization","['Patients' 'with' 'a' 'history' 'of' 'hypersensitivity' 'reactions' 'to'
 'prior' 'chemotherapy' 'administered' 'for' 'previous' 'cancer'
 'diagnoses' 'are' 'eligible' 'to' 'participate' 'in' 'the' 'study' ','
 'unless' 'the' 'hypersensitivity' 'reaction' 'consisted' 'of'
 'anaphylaxis' 'not' 'amenable' 'to' 'desensitization']","[0. 0. 0. 0. 0. 0. 0. 0. 4. 4. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 2. 0. 0. 0. 1.]"
NCT01037790,"1:25:cancer,,,,155:166:treatment,171:188:treatment,","Metastatic breast cancer (7 triple negative, 23 ER+ after the first 15 patients are enrolled on the non-CCND1cohort; in addition 10 HER2+ for combination trastuzumab and PD0332991 therapy) up to 55 total enrollment slots B","['Metastatic' 'breast' 'cancer' '(' '7' 'triple' 'negative' ',' '23' 'ER+'
 'after' 'the' 'first' '15' 'patients' 'are' 'enrolled' 'on' 'the'
 'non-CCND1cohort' ';' 'in' 'addition' '10' 'HER2+' 'for' 'combination'
 'trastuzumab' 'and' 'PD0332991' 'therapy' ')' 'up' 'to' '55' 'total'
 'enrollment' 'slots' 'B']","[3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01037790,"13:37:chronic_disease,39:63:chronic_disease,65:71:chronic_disease,75:96:chronic_disease,","symptomatic congestive heart failure, unstable angina pectoris, stroke or myocardial infarction within 3 months","['symptomatic' 'congestive' 'heart' 'failure' ',' 'unstable' 'angina'
 'pectoris' ',' 'stroke' 'or' 'myocardial' 'infarction' 'within' '3'
 'months']",[0. 2. 2. 2. 0. 2. 2. 2. 0. 2. 0. 2. 2. 0. 0. 0.]
NCT01011777,"74:78:treatment,82:105:treatment,138:165:chronic_disease",Any degree of renal scarring at the time of screening as demonstrated by DMSA or MAG3 renal scintigraphy in the presence of any grade of vesicoureteral reflux (VUR),"['Any' 'degree' 'of' 'renal' 'scarring' 'at' 'the' 'time' 'of' 'screening'
 'as' 'demonstrated' 'by' 'DMSA' 'or' 'MAG3' 'renal' 'scintigraphy' 'in'
 'the' 'presence' 'of' 'any' 'grade' 'of' 'vesicoureteral' 'reflux' '('
 'VUR' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0.
 0. 2. 2. 2. 0. 0.]"
NCT00980538,"50:62:chronic_disease,64:83:chronic_disease,238:247:treatment,253:256:treatment","Any active clinically significant disease (e.g., pancreatitis, cardiac dysfunction) or findings of medical history, laboratory or physical examination that, in the investigator's opinion, would compromise the participant's safety during treatment with ETR","['Any' 'active' 'clinically' 'significant' 'disease' '(' 'e.g.' ','
 'pancreatitis' ',' 'cardiac' 'dysfunction' ')' 'or' 'findings' 'of'
 'medical' 'history' ',' 'laboratory' 'or' 'physical' 'examination' 'that'
 ',' 'in' 'the' 'investigator' ""'s"" 'opinion' ',' 'would' 'compromise'
 'the' 'participant' ""'s"" 'safety' 'during' 'treatment' 'with' 'ETR']","[0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1.]"
NCT00977977,"1:30:treatment,34:58:treatment,,121:130:treatment,135:147:treatment",Immunosuppressive medications or experimental medications of any type during the three month period prior to initiating Rituximab and cyclosporine,"['Immunosuppressive' 'medications' 'or' 'experimental' 'medications' 'of'
 'any' 'type' 'during' 'the' 'three' 'month' 'period' 'prior' 'to'
 'initiating' 'Rituximab' 'and' 'cyclosporine']",[1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1.]
NCT00977977,"53:75:treatment,115:123:chronic_disease,125:142:chronic_disease,146:158:chronic_disease","evidence of intolerance or toxicity associated with cyclosporine treatment of any duration including irreversible azotemia, liver dysfunction or hypertension","['evidence' 'of' 'intolerance' 'or' 'toxicity' 'associated' 'with'
 'cyclosporine' 'treatment' 'of' 'any' 'duration' 'including'
 'irreversible' 'azotemia' ',' 'liver' 'dysfunction' 'or' 'hypertension']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 2.]
NCT00975520,"21:28:cancer,,,184:211:cancer,,230:254:cancer,259:268:cancer","Patients with prior cancers, except: those diagnosed ≥ 5 years ago with no evidence of disease relapse and clinical expectation of relapse of less than 5%; prior successfully treated Level 1 cutaneous melanomas ≥ 2 years ago; or non-melanoma skin cancer; or carcinoma in situ of the cervix","['Patients' 'with' 'prior' 'cancers' ',' 'except' ':' 'those' 'diagnosed'
 '≥' '5' 'years' 'ago' 'with' 'no' 'evidence' 'of' 'disease' 'relapse'
 'and' 'clinical' 'expectation' 'of' 'relapse' 'of' 'less' 'than' '5' '%'
 ';' 'prior' 'successfully' 'treated' 'Level' '1' 'cutaneous' 'melanomas'
 '≥' '2' 'years' 'ago' ';' 'or' 'non-melanoma' 'skin' 'cancer' ';' 'or'
 'carcinoma' 'in' 'situ' 'of' 'the' 'cervix']","[0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 0.
 3. 0. 0. 0. 0. 0.]"
NCT00969111,"1:16:cancer,40:44:treatment,46:58:treatment,62:96:treatment","Prostate cancer treated primarily with open, laparoscopic or robotically assisted prostatectomy","['Prostate' 'cancer' 'treated' 'primarily' 'with' 'open' ','
 'laparoscopic' 'or' 'robotically' 'assisted' 'prostatectomy']",[3. 3. 0. 0. 0. 1. 0. 1. 0. 1. 1. 1.]
NCT00967577,"7:29:treatment,37:54:treatment,,73:82:treatment",Prior cytotoxic chemotherapy and/or radiation therapy within 4 weeks of treatment,"['Prior' 'cytotoxic' 'chemotherapy' 'and/or' 'radiation' 'therapy'
 'within' '4' 'weeks' 'of' 'treatment']",[0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 1.]
NCT00967577,"13:35:treatment,28:35:treatment,39:48:treatment,,123:139:treatment",Subjects on bisphosphonate therapy or denosumab must be on a stable dose and must have started therapy > 4 weeks prior to protocol therapy,"['Subjects' 'on' 'bisphosphonate' 'therapy' 'or' 'denosumab' 'must' 'be'
 'on' 'a' 'stable' 'dose' 'and' 'must' 'have' 'started' 'therapy' '>' '4'
 'weeks' 'prior' 'to' 'protocol' 'therapy']",[0. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT00959140,"1:4:cancer,20:29:treatment,34:49:treatment",ALL: Refractory to Induction and salvage therapy,['ALL' ':' 'Refractory' 'to' 'Induction' 'and' 'salvage' 'therapy'],[3. 0. 0. 0. 1. 0. 1. 1.]
NCT00948285,"15:34:chronic_disease,,,73:103:chronic_disease,131:141:treatment",Patients with renal insufficiency (serum Cr > 1.5) due to the danger of nephrogenic systemic sclerosis with the administration of Gadolinium,"['Patients' 'with' 'renal' 'insufficiency' '(' 'serum' 'Cr' '>' '1.5' ')'
 'due' 'to' 'the' 'danger' 'of' 'nephrogenic' 'systemic' 'sclerosis'
 'with' 'the' 'administration' 'of' 'Gadolinium']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 1.]
NCT00930228,"15:19:chronic_disease,30:46:chronic_disease,78:87:chronic_disease","subjects with PCOS will have hyperandrogenism, whether it is clinical (e.g., hirsutism) or biochemical (i.e., elevated plasma T)","['subjects' 'with' 'PCOS' 'will' 'have' 'hyperandrogenism' ',' 'whether'
 'it' 'is' 'clinical' '(' 'e.g.' ',' 'hirsutism' ')' 'or' 'biochemical'
 '(' 'i.e.' ',' 'elevated' 'plasma' 'T' ')']","[0. 0. 2. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT00929006,"1:8:chronic_disease,39:53:chronic_disease,57:73:chronic_disease",Obesity resulting from a well-defined endocrinopathy or genetic syndrome,"['Obesity' 'resulting' 'from' 'a' 'well-defined' 'endocrinopathy' 'or'
 'genetic' 'syndrome']",[2. 0. 0. 0. 0. 2. 0. 2. 2.]
NCT00926237,"17:23:treatment,36:63:treatment,52:62:treatment,68:83:treatment,96:120:treatment,126:136:chronic_disease,159:167:chronic_disease,",Subjects taking SSRI's (a class of anti-depressant medications)and benzodiazepines (a class of anti-anxiety medications) for depression or anxiety related to tinnitus must be stable on their current dose for at least 3 months and must not alter their dose or medication during their involvement with this study,"['Subjects' 'taking' 'SSRI' ""'s"" '(' 'a' 'class' 'of' 'anti-depressant'
 'medications' ')' 'and' 'benzodiazepines' '(' 'a' 'class' 'of'
 'anti-anxiety' 'medications' ')' 'for' 'depression' 'or' 'anxiety'
 'related' 'to' 'tinnitus' 'must' 'be' 'stable' 'on' 'their' 'current'
 'dose' 'for' 'at' 'least' '3' 'months' 'and' 'must' 'not' 'alter' 'their'
 'dose' 'or' 'medication' 'during' 'their' 'involvement' 'with' 'this'
 'study']","[1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 2. 1. 1.
 1. 1. 2. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.
 1. 1. 1. 1. 1.]"
NCT00924027,"36:43:treatment,58:67:treatment,86:109:cancer",Patients who are unable to undergo surgery and must have treatment for an inoperable primary cervical cancer,"['Patients' 'who' 'are' 'unable' 'to' 'undergo' 'surgery' 'and' 'must'
 'have' 'treatment' 'for' 'an' 'inoperable' 'primary' 'cervical' 'cancer']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 1. 0. 0. 0. 3. 3. 3.]
NCT00924027,"1:21:chronic_disease,33:36:chronic_disease,38:49:chronic_disease","autoimmune disorders, including SLE, Scleroderma, etc","['autoimmune' 'disorders' ',' 'including' 'SLE' ',' 'Scleroderma' ','
 'etc']",[2. 2. 0. 0. 2. 0. 2. 0. 0.]
NCT00914628,"1:4:cancer,9:12:cancer,34:36:treatment",AML and ALL in 2nd or subsequent CR,['AML' 'and' 'ALL' 'in' '2nd' 'or' 'subsequent' 'CR'],[3. 0. 3. 0. 0. 0. 0. 1.]
NCT00911560,",33:45:treatment,49:62:treatment,67:82:treatment",≥ 3 weeks between completion of chemotherapy or immunotherapy and 1st vaccination,"['≥' '3' 'weeks' 'between' 'completion' 'of' 'chemotherapy' 'or'
 'immunotherapy' 'and' '1st' 'vaccination']",[0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 1.]
NCT00909909,"15:25:treatment,29:39:treatment,51:71:treatment,75:94:treatment,99:117:cancer",Has undergone lumpectomy or mastectomy and either sentinel node biopsy or axillary dissection (if invasive carcinoma is present),"['Has' 'undergone' 'lumpectomy' 'or' 'mastectomy' 'and' 'either'
 'sentinel' 'node' 'biopsy' 'or' 'axillary' 'dissection' '(' 'if'
 'invasive' 'carcinoma' 'is' 'present' ')']",[0. 0. 1. 0. 1. 0. 0. 1. 1. 1. 0. 1. 1. 0. 0. 3. 3. 0. 0. 0.]
NCT00909909,"24:33:cancer,35:41:cancer,35:40:cancer,,175:193:cancer,230:240:cancer,244:250:treatment",No proven multicentric carcinoma (tumors in different quadrants of the breast or tumor separated by ≥ 4 cm) with other clinically or radiographically suspicious areas in the ipsilateral breast unless confirmed to be negative for malignancy by biopsy,"['No' 'proven' 'multicentric' 'carcinoma' '(' 'tumors' 'in' 'different'
 'quadrants' 'of' 'the' 'breast' 'or' 'tumor' 'separated' 'by' '≥' '4'
 'cm' ')' 'with' 'other' 'clinically' 'or' 'radiographically' 'suspicious'
 'areas' 'in' 'the' 'ipsilateral' 'breast' 'unless' 'confirmed' 'to' 'be'
 'negative' 'for' 'malignancy' 'by' 'biopsy']","[0. 0. 0. 3. 0. 3. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 3. 0. 1.]"
NCT00902720,"1:10:treatment,19:28:treatment,69:79:cancer",radiation for the treatment or prevention of a medical condition or malignancy expected to result in permanent and complete loss of subsequent ovarian function or have a medical condition or malignancy that requires removal of all or part of one or both ovaries,"['radiation' 'for' 'the' 'treatment' 'or' 'prevention' 'of' 'a' 'medical'
 'condition' 'or' 'malignancy' 'expected' 'to' 'result' 'in' 'permanent'
 'and' 'complete' 'loss' 'of' 'subsequent' 'ovarian' 'function' 'or'
 'have' 'a' 'medical' 'condition' 'or' 'malignancy' 'that' 'requires'
 'removal' 'of' 'all' 'or' 'part' 'of' 'one' 'or' 'both' 'ovaries']","[1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT00887146,"22:65:chronic_disease,22:56:chronic_disease,90:108:treatment",Patients known to be human immunodeficiency virus (HIV) positive and currently receiving retroviral therapy,"['Patients' 'known' 'to' 'be' 'human' 'immunodeficiency' 'virus' '(' 'HIV'
 ')' 'positive' 'and' 'currently' 'receiving' 'retroviral' 'therapy']",[0. 0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 1. 1.]
NCT00887146,"38:47:treatment,71:87:treatment,91:107:treatment,119:125:cancer,151:179:treatment",if they are receiving other specific treatment (with the exclusion of hormonal therapy or Her-2 inhibitors) for their cancer or if they have received prior total body irradiation which included the brain,"['if' 'they' 'are' 'receiving' 'other' 'specific' 'treatment' '(' 'with'
 'the' 'exclusion' 'of' 'hormonal' 'therapy' 'or' 'Her-2' 'inhibitors' ')'
 'for' 'their' 'cancer' 'or' 'if' 'they' 'have' 'received' 'prior' 'total'
 'body' 'irradiation' 'which' 'included' 'the' 'brain']","[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 0. 0. 3. 0. 0. 0.
 0. 0. 1. 1. 1. 1. 0. 0. 0. 0.]"
NCT00887146,"21:28:treatment,50:65:treatment,67:79:treatment,72:79:treatment","patients with prior surgery cannot have received prior radiation, chemotherapy or targeted therapy","['patients' 'with' 'prior' 'surgery' 'can' 'not' 'have' 'received' 'prior'
 'radiation' ',' 'chemotherapy' 'or' 'targeted' 'therapy']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1.]
NCT00875342,"8:26:treatment,39:64:treatment,66:81:treatment,86:112:treatment","Taking oral anticoagulant medication, ethionamide (Trecator-SC), isoniazid (INH), or anti-depressant medication","['Taking' 'oral' 'anticoagulant' 'medication' ',' 'ethionamide' '('
 'Trecator-SC' ')' ',' 'isoniazid' '(' 'INH' ')' ',' 'or'
 'anti-depressant' 'medication']",[0. 1. 1. 0. 0. 1. 1. 0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 1.]
NCT00862433,"18:21:allergy_name,25:28:allergy_name,30:51:allergy_name,56:61:allergy_name,62:68:allergy_name","Food allergy, to soy or egg, milk protein (casein), or wheat/gluten","['Food' 'allergy' ',' 'to' 'soy' 'or' 'egg' ',' 'milk' 'protein' '('
 'casein' ')' ',' 'or' 'wheat/gluten']",[0. 0. 0. 0. 4. 0. 4. 0. 4. 4. 4. 0. 0. 0. 0. 4.]
NCT00862433,"8:19:treatment,32:56:treatment,58:81:treatment","Use of medications (other than oral hypoglycemic agents, hormonal contraceptives and medications taken only on an as-needed basis)","['Use' 'of' 'medications' '(' 'other' 'than' 'oral' 'hypoglycemic'
 'agents' ',' 'hormonal' 'contraceptives' 'and' 'medications' 'taken'
 'only' 'on' 'an' 'as-needed' 'basis' ')']",[0. 0. 1. 0. 0. 0. 1. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00840047,"101:104:treatment,105:108:treatment,109:111:treatment,123:126:treatment,","Participants will have had, or are scheduled to have clinical imaging evaluations which may include FDG PET CT, or CT, or MRI within 4 weeks of entry","['Participants' 'will' 'have' 'had' ',' 'or' 'are' 'scheduled' 'to' 'have'
 'clinical' 'imaging' 'evaluations' 'which' 'may' 'include' 'FDG' 'PET'
 'CT' ',' 'or' 'CT' ',' 'or' 'MRI' 'within' '4' 'weeks' 'of' 'entry']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0.
 1. 0. 0. 0. 0. 0.]"
NCT00819208,"15:24:treatment,41:53:treatment,57:66:treatment",No concurrent treatment with additional chemotherapy or radiation,"['No' 'concurrent' 'treatment' 'with' 'additional' 'chemotherapy' 'or'
 'radiation']",[0. 0. 1. 0. 0. 1. 0. 1.]
NCT00801489,"30:33:cancer,38:79:cancer,81:98:chronic_disease,120:124:chronic_disease","Patients must have untreated AML, or high-risk myelodysplastic syndromes (MDS) (refractory anemia with excess blasts, [RAEB], or RAEB in transformation [RAEB-t]) characterized by t(8;21), inv(16), or t(16;16); the presence of additional abnormalities is irrelevant","['Patients' 'must' 'have' 'untreated' 'AML' ',' 'or' 'high-risk'
 'myelodysplastic' 'syndromes' '(' 'MDS' ')' '(' 'refractory' 'anemia'
 'with' 'excess' 'blasts' ',' '[' 'RAEB' ']' ',' 'or' 'RAEB' 'in'
 'transformation' '[' 'RAEB-t' ']' ')' 'characterized' 'by' 't' '(' '8'
 ';' '21' ')' ',' 'inv' '(' '16' ')' ',' 'or' 't' '(' '16' ';' '16' ')'
 ';' 'the' 'presence' 'of' 'additional' 'abnormalities' 'is' 'irrelevant']","[0. 0. 0. 0. 3. 0. 0. 3. 3. 3. 3. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 2. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT00788164,"1:16:treatment,21:27:treatment,38:80:chronic_disease",Colposcopically and biopsy confirmed grade 3 cervical intraepithelial neoplasia,"['Colposcopically' 'and' 'biopsy' 'confirmed' 'grade' '3' 'cervical'
 'intraepithelial' 'neoplasia']",[1. 0. 1. 0. 2. 2. 2. 2. 2.]
NCT00739362,"1:31:chronic_disease,33:58:chronic_disease,60:68:chronic_disease,70:97:chronic_disease,99:107:chronic_disease,122:133:chronic_disease","Central nervous system disease (cerebrovascular accidents, dementia, neurodegenerative disorders, epilepsy or history of head injury)","['Central' 'nervous' 'system' 'disease' '(' 'cerebrovascular' 'accidents'
 ',' 'dementia' ',' 'neurodegenerative' 'disorders' ',' 'epilepsy' 'or'
 'history' 'of' 'head' 'injury' ')']",[2. 2. 2. 2. 0. 2. 2. 0. 2. 0. 2. 2. 0. 2. 0. 0. 0. 2. 2. 0.]
NCT00739362,"12:25:chronic_disease,37:54:chronic_disease,64:76:chronic_disease",History of HIV infection or ongoing chronic infection (such as tuberculosis),"['History' 'of' 'HIV' 'infection' 'or' 'ongoing' 'chronic' 'infection' '('
 'such' 'as' 'tuberculosis' ')']",[0. 0. 2. 2. 0. 0. 2. 2. 0. 0. 0. 2. 0.]
NCT00737893,"31:44:treatment,54:87:treatment,94:131:treatment","Scheduled to undergo curative prostatectomy applying bilateral nerve-sparing procedure, with intact pre-surgical erectile function","['Scheduled' 'to' 'undergo' 'curative' 'prostatectomy' 'applying'
 'bilateral' 'nerve-sparing' 'procedure' ',' 'with' 'intact'
 'pre-surgical' 'erectile' 'function']",[0. 0. 0. 0. 1. 0. 1. 1. 1. 0. 0. 1. 1. 1. 1.]
NCT00734877,"24:34:cancer,38:63:cancer,57:63:cancer,68:88:cancer,","for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease free for at least three years","['for' 'adequately' 'treated' 'basal' 'cell' 'or' 'squamous' 'cell' 'skin'
 'cancer' ',' 'in' 'situ' 'cervical' 'cancer' ',' 'or' 'other' 'cancer'
 'for' 'which' 'the' 'patient' 'has' 'been' 'disease' 'free' 'for' 'at'
 'least' 'three' 'years']","[0. 0. 0. 3. 3. 0. 3. 3. 3. 3. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT00720785,",43:65:treatment,96:109:cancer,118:125:treatment",Disease involving greater than 25% of the liver radiographically (estimated based on review of liver lesions seen on CT scan),"['Disease' 'involving' 'greater' 'than' '25' '%' 'of' 'the' 'liver'
 'radiographically' '(' 'estimated' 'based' 'on' 'review' 'of' 'liver'
 'lesions' 'seen' 'on' 'CT' 'scan' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.]
NCT00720785,"1:19:cancer,21:31:cancer,35:49:cancer",cancer of the lung (small cell or non small cell),"['cancer' 'of' 'the' 'lung' '(' 'small' 'cell' 'or' 'non' 'small' 'cell'
 ')']",[3. 3. 3. 3. 0. 3. 3. 0. 3. 3. 3. 0.]
NCT00719888,"1:13:treatment,14:35:cancer,40:54:cancer,,92:108:treatment","Chemotherapy refractory large cell and high grade NHL (i.e., progressive disease after > 2 salvage regimens)","['Chemotherapy' 'refractory' 'large' 'cell' 'and' 'high' 'grade' 'NHL' '('
 'i.e.' ',' 'progressive' 'disease' 'after' '>' '2' 'salvage' 'regimens'
 ')']",[1. 3. 3. 3. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.]
NCT00719888,"28:54:treatment,58:83:treatment,102:117:treatment","Patients who have received Y-90 ibritumomab (Zevalin) or I-131 tostumomab (Bexxar), as part of their salvage therapy are not eligible for Regimen A","['Patients' 'who' 'have' 'received' 'Y-90' 'ibritumomab' '(' 'Zevalin' ')'
 'or' 'I-131' 'tostumomab' '(' 'Bexxar' ')' ',' 'as' 'part' 'of' 'their'
 'salvage' 'therapy' 'are' 'not' 'eligible' 'for' 'Regimen' 'A']","[0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.
 0. 0. 0. 0.]"
NCT00716066,"8:18:cancer,40:53:cancer,57:89:cancer",Active malignancy (excluding localized squamous cell or basal cell carcinoma of the skin),"['Active' 'malignancy' '(' 'excluding' 'localized' 'squamous' 'cell' 'or'
 'basal' 'cell' 'carcinoma' 'of' 'the' 'skin' ')']",[0. 3. 0. 0. 0. 3. 3. 0. 3. 3. 3. 3. 3. 3. 0.]
NCT00715611,"28:45:cancer,54:62:cancer,66:98:cancer",Patients with a concurrent active malignancy (except squamous or basal cell carcinoma of the skin),"['Patients' 'with' 'a' 'concurrent' 'active' 'malignancy' '(' 'except'
 'squamous' 'or' 'basal' 'cell' 'carcinoma' 'of' 'the' 'skin' ')']",[0. 0. 0. 0. 3. 3. 0. 0. 3. 0. 3. 3. 3. 3. 3. 3. 0.]
NCT00713492,"37:52:chronic_disease,64:67:chronic_disease,69:83:chronic_disease,85:96:chronic_disease,98:114:chronic_disease,116:123:chronic_disease,125:130:chronic_disease,132:141:chronic_disease,146:168:chronic_disease","Current or prior history of serious medical illness, including CNS, cardiovascular, respiratory, gastrointestinal, hepatic, renal, endocrine, or reproductive disorders","['Current' 'or' 'prior' 'history' 'of' 'serious' 'medical' 'illness' ','
 'including' 'CNS' ',' 'cardiovascular' ',' 'respiratory' ','
 'gastrointestinal' ',' 'hepatic' ',' 'renal' ',' 'endocrine' ',' 'or'
 'reproductive' 'disorders']","[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 0. 2. 0. 2. 0. 2. 0. 2. 0. 2. 0. 2. 0.
 0. 2. 2.]"
NCT00703105,"37:64:treatment,68:81:treatment,,111:116:cancer",Patients must not have received any antineoplastic chemotherapy or immunotherapy for the four weeks preceding tumor excision,"['Patients' 'must' 'not' 'have' 'received' 'any' 'antineoplastic'
 'chemotherapy' 'or' 'immunotherapy' 'for' 'the' 'four' 'weeks'
 'preceding' 'tumor' 'excision']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 3. 0.]
NCT00695214,"12:20:allergy_name,22:33:allergy_name,35:47:allergy_name,51:59:allergy_name","Allergy to propofol, soybean oil, egg lecithin or glycerol","['Allergy' 'to' 'propofol' ',' 'soybean' 'oil' ',' 'egg' 'lecithin' 'or'
 'glycerol']",[0. 0. 4. 0. 4. 4. 0. 4. 4. 0. 4.]
NCT00673842,"1:27:treatment,35:59:chronic_disease,68:74:chronic_disease","mechanical tricuspid valve, known vascular access problems, active sepsis, etc","['mechanical' 'tricuspid' 'valve' ',' 'known' 'vascular' 'access'
 'problems' ',' 'active' 'sepsis' ',' 'etc']",[1. 1. 1. 0. 0. 2. 2. 2. 0. 0. 2. 0. 0.]
NCT00670358,"15:43:treatment,51:58:treatment,60:67:treatment","No concurrent erythroid-stimulating agents (e.g., Procrit, Aranesp)","['No' 'concurrent' 'erythroid-stimulating' 'agents' '(' 'e.g.' ','
 'Procrit' ',' 'Aranesp' ')']",[0. 0. 1. 1. 0. 0. 0. 1. 0. 1. 0.]
NCT00670358,"10:27:cancer,46:70:cancer,64:70:cancer","No other active malignancy, except localized nonmelanotic skin cancer or any cancer that, in the judgment of the investigator, has been treated with curative intent and will not interfere with the study treatment plan and response assessment","['No' 'other' 'active' 'malignancy' ',' 'except' 'localized'
 'nonmelanotic' 'skin' 'cancer' 'or' 'any' 'cancer' 'that' ',' 'in' 'the'
 'judgment' 'of' 'the' 'investigator' ',' 'has' 'been' 'treated' 'with'
 'curative' 'intent' 'and' 'will' 'not' 'interfere' 'with' 'the' 'study'
 'treatment' 'plan' 'and' 'response' 'assessment']","[0. 0. 3. 3. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT00630565,"29:57:treatment,82:105:treatment,129:147:treatment",Patients who cannot receive total body irradiation (TBI) (for example those with prior radiation therapy) will also receive the Bu/CY conditioning,"['Patients' 'who' 'can' 'not' 'receive' 'total' 'body' 'irradiation' '('
 'TBI' ')' '(' 'for' 'example' 'those' 'with' 'prior' 'radiation'
 'therapy' ')' 'will' 'also' 'receive' 'the' 'Bu/CY' 'conditioning']","[0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0.
 1. 1.]"
NCT00630253,"1:22:cancer,29:76:cancer,,96:99:treatment",Malignant solid tumor (e.g. squamous cell carcinoma of the head/neck/cervix) within 2 years of HCT,"['Malignant' 'solid' 'tumor' '(' 'e.g' '.' 'squamous' 'cell' 'carcinoma'
 'of' 'the' 'head/neck/cervix' ')' 'within' '2' 'years' 'of' 'HCT']",[3. 3. 3. 0. 0. 0. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 1.]
NCT00594217,",37:44:chronic_disease,48:69:chronic_disease,96:120:chronic_disease,141:165:chronic_disease,167:173:chronic_disease,184:205:treatment","Women with a significant history of cardiac or pulmonary dysfunction (e.g., known or suspected congestive heart failure; known or suspected coronary atherosclerosis; asthma requiring systemic intermittent corticosteroids; etc.)","['Women' 'with' 'a' 'significant' 'history' 'of' 'cardiac' 'or'
 'pulmonary' 'dysfunction' '(' 'e.g.' ',' 'known' 'or' 'suspected'
 'congestive' 'heart' 'failure' ';' 'known' 'or' 'suspected' 'coronary'
 'atherosclerosis' ';' 'asthma' 'requiring' 'systemic' 'intermittent'
 'corticosteroids' ';' 'etc' '.' ')']","[0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 2.
 2. 0. 2. 0. 1. 1. 0. 0. 0. 0. 0.]"
NCT00584649,"26:43:chronic_disease,61:76:chronic_disease,80:96:chronic_disease",An alternative cause for sinus tachycardia identified (e.g. hyperthyroidism or pheochromocytoma),"['An' 'alternative' 'cause' 'for' 'sinus' 'tachycardia' 'identified' '('
 'e.g' '.' 'hyperthyroidism' 'or' 'pheochromocytoma' ')']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 2. 0. 2. 0.]
NCT00573027,"1:11:chronic_disease,19:40:chronic_disease,47:59:chronic_disease,61:70:chronic_disease,72:88:chronic_disease","Chest pain with a non-ischemic etiology (e.g.,pericarditis, pneumonia, esophageal spasm)","['Chest' 'pain' 'with' 'a' 'non-ischemic' 'etiology' '(' 'e.g.' ','
 'pericarditis' ',' 'pneumonia' ',' 'esophageal' 'spasm' ')']",[2. 2. 0. 0. 2. 2. 0. 0. 0. 2. 0. 2. 0. 2. 2. 0.]
NCT00542373,"43:56:chronic_disease,58:72:chronic_disease,129:140:cancer","Persons with any other condition (such as lichen planus, Fanconi anemia, heavy tobacco use, etc) making them at higher risk for oral cancer development","['Persons' 'with' 'any' 'other' 'condition' '(' 'such' 'as' 'lichen'
 'planus' ',' 'Fanconi' 'anemia' ',' 'heavy' 'tobacco' 'use' ',' 'etc' ')'
 'making' 'them' 'at' 'higher' 'risk' 'for' 'oral' 'cancer' 'development']","[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 3. 3. 0.]"
NCT00492778,"34:55:treatment,60:91:treatment,116:123:treatment,134:151:cancer",All patients must have undergone complete hysterectomy and bilateral salpingo-oophorectomy at the time of original therapy for their uterine carcinoma,"['All' 'patients' 'must' 'have' 'undergone' 'complete' 'hysterectomy'
 'and' 'bilateral' 'salpingo-oophorectomy' 'at' 'the' 'time' 'of'
 'original' 'therapy' 'for' 'their' 'uterine' 'carcinoma']",[0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 1. 0. 0. 3. 3.]
NCT00492778,"28:44:treatment,46:52:treatment,57:78:treatment","Patients who have received previous vaginal, pelvic, or abdominal irradiation","['Patients' 'who' 'have' 'received' 'previous' 'vaginal' ',' 'pelvic' ','
 'or' 'abdominal' 'irradiation']",[0. 0. 0. 0. 1. 1. 0. 1. 0. 0. 1. 1.]
NCT00467987,"13:31:treatment,33:40:treatment,42:56:treatment,58:87:treatment,91:103:treatment","Subjects on thiazolidinediones, statins, ACE inhibitors, angiotensin receptor blockers or antioxidants will be allowed as long as they are on stable doses of these compounds and the dosage in not changed during the study","['Subjects' 'on' 'thiazolidinediones' ',' 'statins' ',' 'ACE' 'inhibitors'
 ',' 'angiotensin' 'receptor' 'blockers' 'or' 'antioxidants' 'will' 'be'
 'allowed' 'as' 'long' 'as' 'they' 'are' 'on' 'stable' 'doses' 'of'
 'these' 'compounds' 'and' 'the' 'dosage' 'in' 'not' 'changed' 'during'
 'the' 'study']","[0. 0. 1. 0. 1. 0. 1. 1. 0. 1. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT00383656,",23:38:chronic_disease,42:88:chronic_disease,112:130:chronic_disease",Women and minors with GnRH deficiency or idiopathic hypogonadotropic hypogonadism (IHH) will have a history of primary amenorrhea,"['Women' 'and' 'minors' 'with' 'GnRH' 'deficiency' 'or' 'idiopathic'
 'hypogonadotropic' 'hypogonadism' '(' 'IHH' ')' 'will' 'have' 'a'
 'history' 'of' 'primary' 'amenorrhea']",[0. 0. 0. 0. 2. 2. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT00368355,"17:33:chronic_disease,93:114:treatment,129:144:treatment",Patients with a severe infection that on evaluation by the Principal Investigator precludes ablative chemotherapy or successful transplantation,"['Patients' 'with' 'a' 'severe' 'infection' 'that' 'on' 'evaluation' 'by'
 'the' 'Principal' 'Investigator' 'precludes' 'ablative' 'chemotherapy'
 'or' 'successful' 'transplantation']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 1.]
NCT00358657,"4:42:treatment,46:75:treatment,89:112:chronic_disease,123:138:chronic_disease,149:156:treatment,197:212:chronic_disease","on multiple-gated acquisition (MUGA) scan or cardiac echocardiogram (echo), symptomatic coronary artery disease, or other cardiac failure requiring therapy; patients with a history of, or current cardiac disease should be evaluated with appropriate cardiac studies and/or cardiology consult","['on' 'multiple-gated' 'acquisition' '(' 'MUGA' ')' 'scan' 'or' 'cardiac'
 'echocardiogram' '(' 'echo' ')' ',' 'symptomatic' 'coronary' 'artery'
 'disease' ',' 'or' 'other' 'cardiac' 'failure' 'requiring' 'therapy' ';'
 'patients' 'with' 'a' 'history' 'of' ',' 'or' 'current' 'cardiac'
 'disease' 'should' 'be' 'evaluated' 'with' 'appropriate' 'cardiac'
 'studies' 'and/or' 'cardiology' 'consult']","[0. 1. 1. 1. 1. 0. 0. 0. 2. 2. 1. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT00357565,"27:51:cancer,73:80:treatment,103:106:cancer,155:169:treatment",Patients with evidence of minimal residual disease at the completion of therapy or evidence of rising MRD while on therapy. MRD will be defined by either flow cytometry,"['Patients' 'with' 'evidence' 'of' 'minimal' 'residual' 'disease' 'at'
 'the' 'completion' 'of' 'therapy' 'or' 'evidence' 'of' 'rising' 'MRD'
 'while' 'on' 'therapy' '.' 'MRD' 'will' 'be' 'defined' 'by' 'either'
 'flow' 'cytometry']","[0. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 1. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 1.]"
NCT00338377,"9:20:treatment,24:44:treatment,,85:108:treatment",Has had prior B-RAF or MEK targeted therapy within 7 days prior to the start of the lymphodepletion regimen (Cohort A and Cohort B),"['Has' 'had' 'prior' 'B-RAF' 'or' 'MEK' 'targeted' 'therapy' 'within' '7'
 'days' 'prior' 'to' 'the' 'start' 'of' 'the' 'lymphodepletion' 'regimen'
 '(' 'Cohort' 'A' 'and' 'Cohort' 'B' ')']","[0. 0. 1. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.
 0. 0.]"
NCT00338377,"31:50:cancer,68:80:treatment,81:94:treatment",Patients must have measurable metastatic melanoma. (Turnstile II - Chemotherapy/Cell Infusion -Inclusion Criteria),"['Patients' 'must' 'have' 'measurable' 'metastatic' 'melanoma' '.' '('
 'Turnstile' 'II' '-' 'Chemotherapy/Cell' 'Infusion' '-Inclusion'
 'Criteria' ')']",[0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.]
NCT00338377,"15:18:treatment,31:34:cancer,64:86:cancer","Patients with MRI evidence of LMD, with or without evidence of malignant cells in CSF (positive cytology)","['Patients' 'with' 'MRI' 'evidence' 'of' 'LMD' ',' 'with' 'or' 'without'
 'evidence' 'of' 'malignant' 'cells' 'in' 'CSF' '(' 'positive' 'cytology'
 ')']",[0. 0. 1. 0. 0. 3. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0.]
NCT00338377,"9:16:treatment,9:56:treatment,71:88:treatment,,123:155:treatment,,176:200:treatment,269:281:treatment,282:295:treatment","Require steroid therapy or steroid-containing compounds, or have used systemic steroids in the past 30 days, or have used topical or inhalational steroids in the past 2 weeks prior to lymphodepletion. Exception: Patients on physiologic dose of steroid (Turnstile II - Chemotherapy/Cell Infusion Exclusion Criteria)","['Require' 'steroid' 'therapy' 'or' 'steroid-containing' 'compounds' ','
 'or' 'have' 'used' 'systemic' 'steroids' 'in' 'the' 'past' '30' 'days'
 ',' 'or' 'have' 'used' 'topical' 'or' 'inhalational' 'steroids' 'in'
 'the' 'past' '2' 'weeks' 'prior' 'to' 'lymphodepletion' '.' 'Exception'
 ':' 'Patients' 'on' 'physiologic' 'dose' 'of' 'steroid' '(' 'Turnstile'
 'II' '-' 'Chemotherapy/Cell' 'Infusion' 'Exclusion' 'Criteria' ')']","[0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.
 1. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.
 0. 0. 0.]"
NCT00285935,"28:53:chronic_disease,55:63:chronic_disease,70:83:chronic_disease","Current DSM-5 diagnosis of Major Depressive Disorder, unipolar, with non-psychotic features","['Current' 'DSM-5' 'diagnosis' 'of' 'Major' 'Depressive' 'Disorder' ','
 'unipolar' ',' 'with' 'non-psychotic' 'features']",[0. 0. 0. 0. 2. 2. 2. 0. 2. 0. 0. 2. 0.]
NCT00186927,"12:24:chronic_disease,26:32:chronic_disease,58:77:chronic_disease,79:95:chronic_disease,97:116:chronic_disease","History of lung disease, asthma, and hospitalization for respiratory illness, immunodeficiency, sickle cell disease, or any other serious underlying condition","['History' 'of' 'lung' 'disease' ',' 'asthma' ',' 'and' 'hospitalization'
 'for' 'respiratory' 'illness' ',' 'immunodeficiency' ',' 'sickle' 'cell'
 'disease' ',' 'or' 'any' 'other' 'serious' 'underlying' 'condition']","[0. 0. 2. 2. 0. 2. 0. 0. 0. 0. 2. 2. 0. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0.
 0.]"
NCT00147056,"46:63:cancer,73:80:treatment,82:91:treatment,96:108:treatment","Subjects with (newly diagnosed or recurrent) metastatic cancer for whom surgery, radiation, or radiosurgery has not been advised by the treating physician","['Subjects' 'with' '(' 'newly' 'diagnosed' 'or' 'recurrent' ')'
 'metastatic' 'cancer' 'for' 'whom' 'surgery' ',' 'radiation' ',' 'or'
 'radiosurgery' 'has' 'not' 'been' 'advised' 'by' 'the' 'treating'
 'physician']","[0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT00107289,"1:5:treatment,11:13:cancer,39:48:treatment",MIBG-avid NB and evaluable disease on MIBG scan at time of enrollment on protocol,"['MIBG-avid' 'NB' 'and' 'evaluable' 'disease' 'on' 'MIBG' 'scan' 'at'
 'time' 'of' 'enrollment' 'on' 'protocol']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00107289,"27:29:cancer,157:171:cancer,186:208:chronic_disease","ust have the diagnosis of NB in accordance with the International Criteria, i.e., either histopathology (confirmed by the MSKCC Department of Pathology) or BM involvement plus elevated urinary catecholamines","['ust' 'have' 'the' 'diagnosis' 'of' 'NB' 'in' 'accordance' 'with' 'the'
 'International' 'Criteria' ',' 'i.e.' ',' 'either' 'histopathology' '('
 'confirmed' 'by' 'the' 'MSKCC' 'Department' 'of' 'Pathology' ')' 'or'
 'BM' 'involvement' 'plus' 'elevated' 'urinary' 'catecholamines']","[0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 3. 3. 0. 0. 2. 2.]"
NCT00075387,"40:51:treatment,53:69:treatment,71:90:treatment,95:113:treatment","Subjects who have contraindications to carboplatin, cyclophosphamide, etoposide phosphate, or sodium thiosulfate","['Subjects' 'who' 'have' 'contraindications' 'to' 'carboplatin' ','
 'cyclophosphamide' ',' 'etoposide' 'phosphate' ',' 'or' 'sodium'
 'thiosulfate']",[0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 1. 0. 0. 1. 1.]
NCT00001337,"23:45:chronic_disease,47:68:chronic_disease,72:96:chronic_disease","No active symptomatic ischemic heart disease, myocardial infarction or congestive heart failure within the past year","['No' 'active' 'symptomatic' 'ischemic' 'heart' 'disease' ',' 'myocardial'
 'infarction' 'or' 'congestive' 'heart' 'failure' 'within' 'the' 'past'
 'year']",[0. 0. 0. 2. 2. 2. 0. 2. 2. 0. 2. 2. 2. 0. 0. 0. 0.]
